<SEC-DOCUMENT>0001104659-21-120633.txt : 20210929
<SEC-HEADER>0001104659-21-120633.hdr.sgml : 20210929
<ACCEPTANCE-DATETIME>20210929122744
ACCESSION NUMBER:		0001104659-21-120633
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		21
FILED AS OF DATE:		20210929
DATE AS OF CHANGE:		20210929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		211290488

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(215) 921-7600

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2128671d2_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&#160;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B>UNITED
STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B>WASHINGTON,
D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B>FORM
8-K</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B>CURRENT
REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B>PURSUANT
TO SECTION 13 OR 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B>OF
THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt">Date
of Report (Date of earliest event reported):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B>September 28, 2021</B></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>


<P STYLE="font: 18pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><B>AMICUS THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt">(Exact
Name of Registrant as Specified in  Charter)</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%; border-collapse: collapse; text-align: left">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 2px; text-align: center; width: 32%"><B><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Delaware</B></FONT></B></TD>
    <TD STYLE="padding: 2px; text-align: left; width: 1%"><B>&#160;</B></TD>
    <TD STYLE="padding: 2px; text-align: center; width: 34%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>001-33497</B></FONT></TD>
    <TD STYLE="padding: 2px; text-align: left; width: 1%"><B>&#160;</B></TD>
    <TD STYLE="padding: 2px; text-align: center; width: 32%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>71-0869350</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 2px; text-align: center"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal; font-weight: normal">(State
                                            or Other Jurisdiction</FONT></P>
        <P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal; font-weight: normal">of Incorporation)</FONT></P></TD>
    <TD STYLE="padding: 2px; text-align: center"><FONT STYLE="font-style: normal; font-weight: normal">&#160;</FONT></TD>
    <TD STYLE="padding: 2px; text-align: center"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal; font-weight: normal">(Commission</FONT></P>
        <P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal; font-weight: normal">File
        Number)</FONT></P></TD>
    <TD STYLE="padding: 2px; text-align: center"><FONT STYLE="font-style: normal; font-weight: normal">&#160;</FONT></TD>
    <TD STYLE="padding: 2px; text-align: center"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal; font-weight: normal">(IRS
                                            Employer</FONT></P>
        <P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-style: normal; font-weight: normal">Identification
        No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 192px; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 192px; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3675 Market Street,
Philadelphia, PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>(Address of Principal
Executive Offices, and Zip Code)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">215-921-7600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Registrant&#8217;s
telephone number, including Area Code</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>(Former Name or Former
Address, if Changed Since Last Report)</B></P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; text-align: justify; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):</P>

<P STYLE="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.2in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant
to Section 12(b) of the Act:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%; border-collapse: collapse; text-align: left">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Trading
    <BR>
Symbol(s)</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name of each exchange</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>on which registered</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 2px; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common Stock Par Value $0.01</FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="padding: 2px; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FOLD</FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="padding: 2px; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NASDAQ</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item&#160;1.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-indent: 2.1pt"><FONT STYLE="font-size: 10pt"><B>Entry Into A Material Definitive Agreement</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business Combination Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 29, 2021, Amicus Therapeutics, Inc.,
a Delaware corporation (the &#8220;<I>Company</I>&#8221;), ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (&#8220;<I>ARYA</I>&#8221;),
Amicus GT Holdings, LLC, a Delaware limited liability company and wholly-owned subsidiary of Amicus (&#8220;<I>Amicus GT</I>&#8221;) and
Caritas Therapeutics, LLC, a Delaware limited liability company and wholly-owned subsidiary of Amicus GT (&#8220;<I>Caritas</I>&#8221;)
entered into a Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the &#8220;<I>Business
Combination Agreement</I>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Business Combination Agreement and the transactions
contemplated thereby were unanimously approved by the boards of directors of each of the Company and ARYA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The Business Combination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Business Combination Agreement provides for,
among other things, the following transactions: (i) a pre-closing reorganization of the Company pursuant to which the entities and assets
constituting the Company&#8217;s gene therapy business (such entities, the &#8220;<I>Amicus GT Entities</I>&#8221;) will be transferred
to Caritas (the <I>&#8220;Pre-Closing Reorganization</I>&#8221;), (ii) ARYA will change its jurisdiction of incorporation by deregistering
as an exempted company in the Cayman Islands and continuing and domesticating as a corporation incorporated under the laws of the State
of Delaware (the &#8220;<I>Domestication</I>&#8221;) and, in connection with the Domestication, (A) ARYA&#8217;s name will be changed
to &#8220;Caritas Therapeutics, Inc.&#8221; (&#8220;<I>New Caritas</I>&#8221;) (unless such name is not available in Delaware or ARYA
is otherwise unable to change its name to &#8220;Caritas Therapeutics, Inc.,&#8221; in which case ARYA shall cause its name to change
to such other name mutually agreed to by ARYA and the Company (such agreement not to be unreasonably withheld, conditioned or delayed
by either ARYA or the Company), (B) each outstanding Class A ordinary share of ARYA and each outstanding Class B ordinary share of ARYA
will become one share of Class A Common Stock of New Caritas (the &#8220;<I>Caritas Common Stock</I>&#8221;), and (C) ARYA will amend
and restate its certificate of incorporation and bylaws in connection with the Domestication and (iii) (A) the Company will cause the
existing limited liability company agreement of Caritas to be amended and restated, (B)&#160;the Company will cause all of the limited
liability company interests of Caritas existing immediately prior to the Closing (as defined in the Business Combination Agreement) to
be re-classified into a number of common units (&#8220;<I>Units</I>&#8221;) equal to the Transaction Equity Security Amount (as defined
in the Business Combination Agreement) based on a pre-transaction equity value for Caritas of $175,000,000, (C)&#160;Amicus will make
an additional cash contribution of $50 million (the &#8220;<I>Amicus Contribution Amount</I>&#8221;) in exchange for a number of Units
equal to the Amicus Contribution Equity Amount (as defined in the Business Combination Agreement), (D) ARYA will contribute the Closing
Date Contribution Amount (as defined in the Business Combination Agreement) to Caritas in exchange for a number of Units equal to the
Net Outstanding ARYA Class A Shares (as defined in the Business Combination Agreement) and (E) New Caritas will issue to Amicus GT a number
of Class B Shares, par value $0.0001 per share of New Caritas (the &#8220;<I>Class B Shares</I>&#8221;) (which will have no economic value
but will entitle the holder thereof to one vote per share), equal to the number of Units held by Amicus GT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Pre-Closing Reorganization,
the Domestication and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the &#8220;<I>Business
Combination</I>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Business Combination, the combined
company will be organized in an &#8220;Up-C&#8221; structure, in which substantially all of the assets and business of New Caritas will
be held by Caritas and will operate through Caritas and the subsidiaries of Caritas, and New Caritas will be a publicly listed holding
company that will hold equity interests in Caritas. At the Closing, Caritas and Amicus GT, its sole equity holder will amend and restate
the limited liability company agreement of Caritas (the &#8220;<I>Amended and Restated Limited Liability Company Agreement</I>&#8221;)
in its entirety to, among other things, provide Amicus GT the right to redeem its Units for cash or, at New Caritas&#8217;s option, Caritas
Common Stock, in each case subject to certain restrictions set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrent with the closing of the
transactions contemplated by the Business Combination Agreement, New Caritas will enter into the tax receivable agreement (the
 &#8220;<I>Tax Receivable Agreement</I>&#8221;) with Caritas, Amicus GT, New Caritas and the other persons from time to time that
become a party thereto (such other persons and Amicus GT, collectively, the &#8220;<I>TRA Participants</I>&#8221;). Pursuant to the
Tax Receivable Agreement, New Caritas will be required to pay the TRA Participants 85% of the amount of savings, if any, in U.S.
federal, state and local income tax that New Caritas actually realizes (computed using certain simplifying assumptions) as a result
of the increases in tax basis related to any exchanges of Units for Caritas Common Stock. All such payments to the TRA Participants
will be New Caritas&#8217;s obligation, and not that of Caritas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Business Combination is expected to close in
late 2021 or early 2022, following the receipt of the required approval by ARYA&#8217;s shareholders and the fulfillment of other customary
closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Representations and Warranties; Covenants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Business Combination Agreement contains representations,
warranties and covenants of each of the parties thereto that are customary for transactions of this type, subject to a mutual indemnity
for specified matters. The Company and ARYA have also agreed to take all action within their respective power as may be necessary or appropriate
such that, immediately after the Closing, the New Caritas board of directors will consist of seven directors, which shall be divided into
three classes and be comprised of seven individuals determined by the Company, ARYA Sciences Holdings IV (&#8220;<I>ARYA Sponsor</I>&#8221;)
and ARYA prior to the effectiveness of the Registration Statement as follows: two directors that will be designated by the Company; one
director that will be designated by ARYA Sponsor; and four directors that the Company and ARYA will mutually agree to designate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Conditions to Each Party&#8217;s Obligations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The obligation of the Company, Amicus GT, Caritas
and ARYA to consummate the Business Combination is subject to certain customary closing conditions, including, but not limited to, (i)
the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
(ii) the absence of any order, law or other legal restraint or prohibition issued by any court of competent jurisdiction or other governmental
entity of competent jurisdiction prohibiting or preventing the consummation of the transactions contemplated by the Business Combination
Agreement, (iii) the effectiveness of the Registration Statement on Form S-4 (the &#8220;<I>Registration Statement</I>&#8221;) in accordance
with the provisions of the Securities Act registering the ARYA Class A Common Stock to be issued in the Business Combination, (iv) the
required approvals of ARYA&#8217;s shareholders, (v) ARYA having at least $5,000,001 of net tangible assets (as determined in accordance
with Rule 3a51-1(g)(1) of the Securities Exchange Act of 1934, as amended) remaining after the closing of the Business Combination, (vi)
the approval by Nasdaq of ARYA&#8217;s initial listing application in connection with the Business Combination and (vii) the aggregate
cash proceeds from ARYA&#8217;s trust account, together with the proceeds from the Caritas PIPE Investment (as defined below) and the
Amicus Contribution Amount, equaling no less than $300,000,000 (after deducting any amounts paid to ARYA shareholders that exercise their
redemption rights in connection with the Business Combination).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Termination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Business Combination
Agreement may be terminated under certain customary and limited circumstances prior to the closing of the Business Combination,
including, but not limited to, (i) by mutual written consent of ARYA and the Company, (ii) by ARYA if the representations and
warranties of the Amicus GT Entities are not true and correct or if the Company, Amicus GT or Caritas fails to perform any covenant
or agreement set forth in the Business Combination Agreement, in each case such that certain conditions to closing cannot be
satisfied and the breach or breaches of such representations or warranties or the failure to perform such covenant or agreement, as
applicable, are not cured or cannot be cured within certain specified time periods, (iii) by the Company if the representations and
warranties of ARYA are not true and correct or if ARYA fails to perform any covenant or agreement set forth in the Business
Combination Agreement, in each case such that certain conditions to closing cannot be satisfied and the breach or breaches of such
representations or warranties or the failure to perform such covenant or agreement, as applicable, are not cured or cannot be cured
within certain specified time periods, (iv) subject to certain limited exceptions, by either ARYA or the Company if the Closing has
not occurred by March 29, 2022, (v) by either ARYA or the Company if certain required approvals are not obtained from ARYA
shareholders after the conclusion of a meeting of ARYA&#8217;s shareholders held for such purpose at which such shareholders voted
on such approvals and (vi) by either ARYA or the Company, if any governmental entity of competent jurisdiction shall have issued an
order permanently enjoining or prohibiting the transactions contemplated under the Business Combination Agreement and such order
shall have become final and nonappealable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Business Combination Agreement is validly
terminated, none of the parties to the Business Combination Agreement will have any liability or any further obligation under the Business
Combination Agreement, except in the case of a willful and material breach or Fraud (as defined in the Business Combination Agreement)
and for customary obligations that survive the termination thereof (such as confidentiality obligations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Business Combination Agreement is
filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference, and the foregoing description of the
Business Combination Agreement is qualified in its entirety by reference thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sponsor Letter Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently with the execution of the Business
Combination Agreement, (i)&#160;ARYA, (ii)&#160;ARYA Sponsor, (iii)&#160;each other holder of Class B ordinary shares of ARYA (the &#8220;<I>Other
Class B Shareholders</I>&#8221; and with ARYA Sponsor, the &#8220;<I>Class B Shareholders</I>&#8221;), (iv)&#160;each of Joseph Edelman,
Adam Stone, Michael Altman and Konstantin Poukalov (with the Class B Shareholders, the &#8220;<I>Insiders</I>&#8221;) and (v)&#160;Amicus
GT entered into the Sponsor Letter Agreement (the &#8220;<I>Sponsor Letter Agreement</I>&#8221;), pursuant to which, among other things,
(i) each Class B Shareholder agreed to vote in favor of each of the transaction proposals to be voted upon at the meeting of ARYA shareholders,
including approval of the Business Combination Agreement and the transactions contemplated thereby, (ii) each Class B Shareholder agreed
to waive any adjustment to the conversion ratio set forth in the governing documents of ARYA or any other anti-dilution or similar protection
with respect to the Class B ordinary shares (whether resulting from the transactions contemplated by the Subscription Agreements (as defined
below) or otherwise), (iii) each of the Insiders and ARYA agreed to terminate certain existing agreements or arrangements and (iv) each
Class B Shareholder agreed to be bound by certain transfer restrictions with respect to his, her or its shares in ARYA prior to the Closing,
in each case, on the terms and subject to the conditions set forth in the Sponsor Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Sponsor Letter Agreement is filed
with this Current Report on Form 8-K as Exhibit 10.2 and is incorporated herein by reference, and the foregoing description of the Sponsor
Letter Agreement is qualified in its entirety by reference thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amicus PIPE Investment (Private Placement)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 29, 2021,
the Company entered into a securities purchase agreement (the &#8220;<I>Redmile Purchase Agreement</I>&#8221;) with certain entities
affiliated with Redmile Group LLC (the &#8220;<I>Redmile Purchasers</I>&#8221;), a securities purchase agreement (the
 &#8220;<I>Perceptive Purchase Agreement</I>&#8221;) with Perceptive Life Sciences Master Fund, Ltd. (the &#8220;<I>Perceptive PIPE
Investor</I>&#8221;) and a securities purchase agreement (the &#8220;<I>Third Party Purchase Agreemen</I>t&#8221;, together with the
Redmile Purchase Agreement and the Perceptive Purchase Agreement, the &#8220;<I>Purchase Agreements</I>&#8221;) with the purchasers
set forth on Schedule A&#160;attached thereto (together with the Redmile Purchasers and the Perceptive PIPE Investor, the
 &#8220;<I>Purchasers</I>&#8221;) for the private placement (the &#8220;<I>Amicus Private Placement</I>&#8221;) of an aggregate of
(a) 11,296,660&#160;shares of the Company&#8217;s common stock, at a purchase price of $10.18 per share (the &#8220;<I>Common
Stock</I>&#8221;) and (b) pre-funded warrants to purchase an aggregate of 8,349,705 shares of Common Stock (the &#8220;<I>Pre-Funded
Warrants</I>&#8221;), at a purchase price of $10.17 per Pre-Funded Warrant. The Purchase Agreements are substantially similar, with
the principal differences between the three Purchase Agreements being that the Redmile Purchase Agreement provides for the sale of
Pre-Funded Warrants, and the Redmile Purchase Agreement and the Perceptive Purchase Agreement each provide for a lock-up period of
nine (9) months while the Third Party Purchase Agreement provides for a lock-up period of 60 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Gross proceeds from the Amicus Private Placement
are expected to be approximately $199,916,502.13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Pre-Funded Warrant has an initial exercise
price of $0.01 per share and is exercisable at any time after its original issuance at the option of each holder, in such holder&#8217;s
discretion, by (i) payment in full in immediately available funds of the initial exercise price for the number of shares of Common Stock
purchased upon such exercise or (ii) a cashless exercise, in which case the holder would receive upon such exercise the net number of
shares of Common Stock determined according to the formula set forth in the Pre-Funded Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Pre-Funded Warrants may not be exercised if,
upon giving effect to such exercise, (i) the aggregate number of shares of Common Stock beneficially owned by the holder together with
such holder&#8217;s affiliates, any person having beneficial ownership of shares of Common Stock owned by the holder as calculated in
accordance with Section 13(d) of the Exchange Act, or any persons acting as a Section 13(d) group together with such holder or any of
such holder&#8217;s affiliates (any such person other than holder, including any group of which Holder is a member, an &#8220;<I>Additional
Restricted Ownership Person</I>&#8221;) would exceed 9.99% of the number of shares of Common Stock outstanding immediately after giving
effect to the exercise, or (ii) the combined voting power of the Company&#8217;s securities beneficially owned by the holder any Additional
Restricted Ownership Person would exceed 9.99% of the combined voting power of all of the Company&#8217;s securities then outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded
Warrants. However, any holder may increase or decrease such percentage, but not in excess of 19.99%, upon at least 61 days&#8217; prior
notice from the holder to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of certain fundamental transactions,
the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind and amount of securities,
cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental
transaction without regard to any limitations on exercise contained in the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Agreements
contain customary indemnification provisions, representations, warranties and covenants made by the Company. In addition, pursuant
to the terms of the Purchase Agreements, each Purchaser has agreed to a &#8220;lock-up&#8221; period that generally prohibits,
without the prior written consent of the Company, the sale, transfer, pledge or other disposition of securities of the Company
through the period ending nine (9) months (in the case of the Redmile Purchase Agreement and the Perceptive Purchase Agreement) or
sixty (60) days (in the case of the Third Party Purchase Agreement) from the date of the applicable Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Amicus Private Placement,
the Company has agreed to file a registration statement within 50 days after the closing (the &#8220;<I>Initial Registration Statement</I>&#8221;)
for purposes of registering the shares of Common Stock and shares of Common Stock underlying the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing description of the Purchase Agreements
and the Pre-Funded Warrants does not purport to be complete and is qualified in its entirety by reference to the copies of the Securities
Purchase Agreements, which are filed as Exhibit 10.3, Exhibit 10.4 and Exhibit 10.5 to this Current Report on Form 8-K, and the copy of
the form of Pre-Funded Warrant that was purchased by each Redmile Purchaser, which is filed as Exhibit 4.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The representations, warranties and covenants contained
in the Purchase Agreements were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the
parties to the Purchase Agreements, and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Purchase
Agreements are incorporated herein by reference only to provide investors with information regarding the terms of the Purchase Agreements,
and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction
with the disclosures in the Company&#8217;s periodic reports and other filings with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>New Caritas PIPE Investment (Private Placement)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently with the execution
of the Business Combination Agreement, ARYA entered into subscription agreements (the &#8220;<I>Subscription Agreements</I>&#8221;) with
certain investors, including, among others, the Perceptive PIPE Investor, a fund managed by Perceptive Advisors, an affiliate
of ARYA Sponsor and certain additional third party investors. Pursuant to the Subscription Agreements, investors agreed to subscribe
for and purchase, and ARYA agreed to issue and sell to such investors, on the Closing Date (as defined in the Business Combination Agreement)
immediately prior to the Closing (as defined in the Business Combination Agreement), an aggregate of 20,150,000 shares of ARYA Common
Stock for a purchase price of $10.00 per share, for aggregate gross proceeds of $201,500,000 (the &#8220;<I>Caritas PIPE Investment</I>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of the Caritas PIPE Investment is contingent
upon, among other things, the substantially concurrent consummation of the Business Combination. The Subscription Agreements provide that
ARYA will grant the investors in the Caritas PIPE Investment certain customary registration rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Rights Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently with the execution of the Business
Combination Agreement, ARYA, Caritas, the Perceptive PIPE Investor, ARYA Sponsor, the Other Class B Shareholders and Amicus GT entered
into an investor rights agreement (the &#8220;<I>Investor Rights Agreement</I>&#8221;) pursuant to which, among other things, the Perceptive
PIPE Investor, ARYA Sponsor, the Company and the Other Class B Shareholders (i) each agreed not to effect any sale or distribution of
any equity securities of New Caritas (and, in the case of the Amicus GT, the Units) held by any of them during the one-year lock-up period
described therein and (ii) were granted certain registration rights with respect to their Registrable Securities (as defined in the Investor
Rights Agreement), in each case, on the terms and subject to the conditions set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Investor Rights Agreement is filed
with this Current Report on Form 8-K as Exhibit 10.6 and is incorporated herein by reference, and the foregoing description of the Investor
Rights Agreement is qualified in its entirety by reference thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Nomination Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently with the Closing, ARYA, ARYA Sponsor
and the Company will enter into a director nomination agreement (the &#8220;<I>Director Nomination Agreement</I>&#8221;), pursuant to
which, among other things, (i)&#160;the Company will be entitled to ongoing director designation rights with respect to the two director
positions for which the Company initially designated directors in connection with the Closing, subject to customary fall-away thresholds
based on the Company&#8217;s continued ownership of New Caritas and (ii)&#160;ARYA Sponsor will be entitled to ongoing director designation
rights with respect to the one director position for which ARYA Sponsor initially designated a director in connection with the Closing,
subject to customary fall-away thresholds based on ARYA Sponsor&#8217;s continued ownership of New Caritas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Co-Development and Collaboration Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently with the Closing, the Company and
Caritas will enter into a co-development and commercialization agreement (the &#8220;<I>Co-Development and Collaboration Agreement</I>&#8221;)
pursuant to which, among other things, (i) the Company and Caritas will collaborate in the research and development of gene therapy product
candidates for the treatment of Fabry disease and Pompe diseases, (ii) Caritas will grant the Company an exclusive license under Caritas&#8217;
intellectual property to clinically develop and commercialize certain existing and future gene therapy candidates and (iii) Caritas will
grant the Company a right of first negotiation for the Company to negotiate an exclusive license to develop and commercialize therapeutic
products incorporating gene therapy technologies being developed by Caritas for certain muscular dystrophy indications, in each case,
subject to the terms and conditions therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transition Services Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently with the Closing, the Company and
Caritas will enter into a transition services agreement pursuant to which, among other things, (i)&#160;the Company and/or one or more
of its affiliates will provide certain transitional services to to Caritas and/or one or more of its affiliates and (ii)&#160;Caritas
and/or one or more its affiliates will provide certain transitional services to the Company and/or one or more of its affiliates, in each
case, in order to facilitate the orderly transition of the Company&#8217;s gene therapy business to Caritas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amended Hayfin Loan Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the execution of the Business
Combination Agreement, Hayfin Capital Management (&#8220;<I>Hayfin</I>&#8221;) and the Company amended the existing loan agreement governing
the Company&#8217;s $400 million Senior Secured Term Loan due 2026, dated as of July 17, 2020, <FONT STYLE="background-color: white">by
and among the Company, </FONT>Hayfin and the other parties there<FONT STYLE="background-color: white">to, </FONT>for the purpose of permitting
the transactions contemplated by the Business Combination Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Limited Consent and Amendment No.
1 to Loan Agreement is filed with this Current Report on Form 8-K as Exhibit 10.7 and is incorporated herein by reference, and the foregoing
description of the Limited Consent and Amendment No. 1 to Loan Agreement is qualified in its entirety by reference thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item&#160;3.02</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt; text-indent: 2.1pt"><FONT STYLE="font-size: 10pt"><B>Unregistered Sales of Equity Securities.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The issuance of the 11,296,660 shares of Common Stock and the Pre-Funded
Warrants to purchase 8,349,705 shares of Common stock constituting the Amicus Private Offering was exempt from registration under Section&#160;4(2)&#160;of
the Securities Act of 1933, as amended, or Regulation D thereunder, as a transaction by an issuer not involving a public offering. Each
Purchaser has represented that it is an &#8220;accredited investor,&#8221; as that term is defined in Rule 501(a) of Regulation D under
the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"> Item 1.01 of this Current Report on Form&#160;8-K contains a more detailed description of the issuance of shares of Common Stock and Pre-Funded Warrants to purchase shares of Common Stock and is incorporated into this Item 3.02 by reference.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item&#160;5.02</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt; text-indent: 2.1pt"><FONT STYLE="font-size: 10pt"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>John F. Crowley</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In connection with the
Business Combination, John F. Crowley, who has served as a Director, Chairman and Chief Executive Officer of the Company since February
2010 and Chief Executive Officer since January 2005 (except for a period from April 2011 through August 2011 during which time he served
as Executive Chairman), will resign as Chief Executive Officer and Director of the Company and is expected to enter into an employment
agreement with New Caritas pursuant to which he will become the Chief Executive Officer of New Caritas effective as of, and contingent
upon, the Closing. Mr. Crowley is also expected to be nominated to serve as a director of New Caritas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Bradley L. Campbell to become Company Chief Executive Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the
Business Combination and the expected departure of John F. Crowley as the Chief Executive Officer of the Company, Bradley L.
Campbell, who has served as a member of the Company&#8217;s board of directors since June&#160;2018 and as President and Chief
Operating Officer since January&#160;2015, and Chief Operating Officer since December&#160;2013, has agreed to enter into an
employment agreement with the Company (the &#8220;<I>CEO Employment Agreement</I>&#8221;) at the Closing pursuant to which Mr.
Campbell will become the Chief Executive Officer of the Company for a term that will commence at the Closing and continue until Mr.
Campbell&#8217;s employment is terminated by either Mr. Campbell or the Company. Upon its execution in connection with the Closing,
the CEO Employment Agreement will supersede Mr. Campbell&#8217;s prior employment agreement with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Under the terms of the
CEO Employment Agreement, Mr. Campbell will be (i) entitled to an initial annual base salary of $625,000; (ii) eligible to receive an
annual cash bonus with a target opportunity of 100% of base salary, with the actual amount determined by the compensation committee of
the Company&#8217;s board of directors. Mr. Campbell will also receive a one-time promotion grant of Company equity valued at $2 million,
comprised of 50% Company stock options and 50% restricted stock units, which will vest (subject to continued employment) in accordance
with the terms and conditions of the applicable Company equity plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The CEO Employment
Agreement provides that if Mr. Campbell&#8217;s employment is terminated for any reason, Mr. Campbell will be entitled to (1) all
accrued but unpaid base salary, (2) unreimbursed expenses and (3) other accrued obligations under the Company&#8217;s employee plans
((1)-(3), collectively, &#8220;<I>CEO Accrued Amounts</I>&#8221;). If Mr. Campbell&#8217;s employment is terminated by the Company
without Cause (as defined in the CEO Employment Agreement) and not within 12 months after a &#8220;Change in Control Event&#8221;
(as defined in the CEO Employment Agreement), Mr. Campbell will be entitled to (1) the CEO Accrued Amounts, (2) payment of an amount
equal to his then current base salary (generally payable over 18 months following termination), (3) payment of a bonus equal to 150%
of the target bonus for the calendar year in which such termination occurs pro-rated for the number of days actually worked in the
year of termination (generally payable within 75 days following termination), (4) the accelerated vesting of any Company stock
options and restricted Company stock units held by Mr. Campbell that were scheduled to vest within 12 months following such
termination and (5) the continuation of employee benefits plans for a period of 18 months after the date of termination ((2)-(5),
collectively, the &#8220;<I>CEO Severance Benefits</I>&#8221;). Under the terms of the CEO Employment Agreement, if Mr.
Campbell&#8217;s employment is terminated by the Company without Cause or by Mr. Campbell for Good Reason (as defined in the
agreement) within 12 months of a Change in Control Event (as defined in the agreement), Mr. Campbell will be entitled to (1) the CEO
Accrued Amounts and (2) payment of an amount equal to 2 times his then current base salary (generally payable over 24 months
following termination), (3) a lump sum payment of an amount equal to 200% of the target bonus for the calendar year in which such
termination occurs (generally payable within 75 days following termination), (4) the accelerated vesting of any Amicus stock
options and restricted stock grants held by Mr. <FONT STYLE="font-size: 10pt">Campbell; and (5) the continuation of employee
benefits plans for a period of 24 months after the date of termination ((2)-(5), collectively, the &#8220;<I>CEO Change in Control
Severance Benefits</I>&#8221;). The payment of CEO Severance Benefits or CEO Change in Control Severance Benefits are contingent on
Mr. Campbell signing and not revoking a release of claims in favor of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Strategic Advisor Agreement with John F. Crowley</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has also agreed
to enter into a Strategic Advisor Agreement with John F. Crowley (the &#8220;<I>Strategic Advisor Agreement</I>&#8221;) in connection
with the consummation of the Business Combination, pursuant to which, following the Closing, Mr. Crowley will provide services to the
Company as Chairman Emeritus and Chief Strategic Advisor (or in such other position as may be mutually agreed upon by the parties) for
an initial term of two years (which term may be extended for an additional year by mutual agreement). Upon its execution in connection
with the Closing, the Strategic Advisor Agreement will supersede Mr. Crowley&#8217;s prior employment agreement with the Company. As consideration
for the services to be provided under the Strategic Advisor Agreement, the Company will pay Mr. Crowley an annual base salary of $300,000
(subject to increase). Mr. Crowley will not be eligible to participate in the Company&#8217;s bonus program. Under the Strategic Advisor
Agreement, Mr. Crowley will be eligible to receive a grant of restricted stock units with respect to Amicus common stock with a value
of $1.4 million at grant, vesting as to 50% of the units on each of the first two anniversaries of the date of grant, generally subject
to continued service with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Strategic Advisor Agreement
provides that in the event of a termination of Mr. Crowley&#8217;s employment by the Company during the term without &#8220;Cause&#8221;
(as defined in the Strategic Advisor Agreement), Mr. Crowley will be entitled to accrued payments and benefits under the agreement as
well as a severance payment equal to 1.5 times his then-current annual base salary, plus accelerated vesting of unvested equity compensation
from the Company and certain continued medical benefits for thirty-six months following termination. If such termination (or a resignation
for &#8220;Good Reason&#8221; (as defined in the Strategic Advisor Agreement)) occurs during the twelve month period following a Change
in Control Event (as defined in the Strategic Advisor Agreement), then the severance payment will be 2 times his then current annual base
salary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Strategic Advisor Agreement
also provides that if the agreement is not extended for an additional year beyond the initial two year term, Mr. Crowley and his eligible
dependents will remain eligible to continue their participation in any Company group health plan in which they are then participating
for a period of twelve additional months, and that the Company will pay the full premiums otherwise payable for such coverage during such
twelve month period. The Company will also allow Mr. Crowley and his dependents to continue to participate in those plans at his expense
under COBRA for a period of twenty-nine months following the end of his employment or the twelve month period described above, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Samantha Prout </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the
Business Combination, Samantha Prout, who has served as Vice President and Global Controller since March of 2020, and Principal
Accounting Officer of the Company since June of 2018, will resign as Vice President and Global Controller and has agreed to enter
into an employment agreement with New Caritas at the Closing pursuant to which Ms. Prout will become the SVP Finance, Principal
Accounting Officer &amp; Principal Financial Officer of New Caritas effective as of, and contingent upon, the Closing. Effective
September 29, 2021, Ms. Prout will no longer serve as Principal Accounting Officer of the Company as Daphne Quimi, Chief Financial
Officer, will serve as both Principal Financial Officer and Principal Accounting Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><B>Hung Do Amendment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective September 28, 2021, Hung Do, who
has served as Chief Science Officer of the Company since July 2015, entered into amendment (the &#8220;<I>Do Amendment</I>&#8221;) to
his employment agreement, dated February 18, 2020. Under the terms of the Do Amendment, Dr. Do will no longer serve as the Company&#8217;s
Chief Scientific Officer but will be named Chief Scientific Advisor (&#8220;<I>CSA</I>&#8221;). As CSA, Dr. Do will continue to support
the Company as described in Exhibit C-1 to the Do Amendment and may pursue other opportunities, including with M6P Therapeutics, provided
they do not constitute &#8220;Competitive Activities&#8221; as described in the Do Amendment. In light of these reduced duties and responsibilities
as CSA and a part-time employee, as of the effective date Dr. Do will receive one-half of his current base salary, and, as an employee,
continue to be eligible to participate in the Company&#8217;s benefit plans and remain eligible for equity grants under the Company&#8217;s
Amended and Restated 2007 Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Do Amendment is filed with this Current Report on Form
8-K as Exhibit 10.8 and is incorporated herein by reference, and the foregoing description of the Do Amendment is qualified in its entirety
by reference thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item&#160;7.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-indent: 2.1pt"><FONT STYLE="font-size: 10pt"><B>Regulation FD Disclosure.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 29, 2021, ARYA and the Company issued
a press release announcing their entry into the Business Combination Agreement. The press release is attached hereto as Exhibit 99.1 and
incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furnished as Exhibits 99.2 and 99.3 hereto and
incorporated into this Item 7.01 by reference is the investor presentation that ARYA and the Company have prepared for use in connection
with the announcement of the Business Combination and a transcript <FONT STYLE="background-color: white">of the investor presentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing (including Exhibits 99.1, 99.2 and
99.3) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange
Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise be subject to the liabilities of that section, nor will it be deemed
to be incorporated by reference in any filing under the Securities Act or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529; text-align: justify; background-color: white"><FONT STYLE="background-color: white">This
Form 8-K contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995
relating to the business combination, development of Caritas&#8217; product candidates, preclinical and clinical development of our product
candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential
regulatory approval of our product candidates, commercialization plans, manufacturing plans and financing plans. The inclusion of forward-looking
statements should not be regarded as a representation by us that any of our plans or Caritas&#8217; plans will be achieved. Any or all
of the forward-looking statements in this Form 8-K may turn out to be wrong and can be affected by inaccurate assumptions we might make
or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes
of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies
and clinical trials, and revenue goals, including as they are impacted by COVID-19 related disruption, are based on current information.
The potential impact on operations and/or revenue from the COVID-19 pandemic is inherently unknown and cannot be predicted with confidence
and may cause actual results and performance to differ materially from the statements in this release, including without limitation, because
of the impact on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19,
such as travel bans, shelter in place orders and third-party business closures and resource allocations, manufacturing and supply chain
disruptions and limitations on patient access to commercial or clinical product or to treatment sites. In addition to the impact of the
COVID-19 pandemic, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent
in our business, including, without limitation: the potential that the transaction may not be completed in a timely manner or at all,
which may adversely affect the price of our securities; the potential that the proposed transaction disrupts our current plans and operations
and potential difficulties in our employee retention as a result of the transaction; the potential that results of clinical or preclinical
studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in clinical
trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product
candidates; the potential that Caritas may not be successful in maintaining or establishing collaborations, which could adversely affect
its ability to develop products; substantial competition in the rapidly evolving field of gene therapy, which may result in others discovering,
developing or commercializing products before or more successfully than Caritas; the potential that regulatory authorities approve biosimilar
products with claims that compete with any of Caritas&#8217; product candidates; the potential that preclinical and clinical studies could
be delayed due to the identification of serious side effects or other safety issues; the potential that we or Caritas may not be able
to manufacture or supply sufficient clinical or commercial products; the potential that Caritas may become involved in product liability
lawsuits and in lawsuits to protect or enforce intellectual property rights, which could be expensive and time-consuming, and could result
in substantial liabilities and the impairment of commercialization efforts of product candidates; and the potential that we or Caritas
will need additional funding to complete all of our respective studies, commercialization and manufacturing. In addition, all forward-looking
statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Report
10-Q for the quarter ended June 30, 2021. You are cautioned not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake
no obligation to revise or update this news release to reflect events or circumstances after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529; text-align: justify; background-color: white">&#160;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><B>Participants
in the Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529; text-align: justify; background-color: white"><FONT STYLE="background-color: white">The
Company and its respective directors and executive officers under SEC rules, may be deemed to be participants in the solicitation of
proxies of ARYA&#8217;s shareholders in connection with the Business Combination. Investors and </FONT>security holders may obtain
more detailed information regarding the names and interests in the Business Combination of ARYA&#8217;s directors and officers in
ARYA&#8217;s filings with the SEC, including the Registration Statement to be filed with the SEC by ARYA, which will include the
proxy statement of ARYA for the Business Combination, and such information and names of such directors and executive officers and
their interests in the Business Combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529; text-align: justify; background-color: white">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><B>Item 8.01</B></TD><TD><B>Other Events.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 29, 2021, the Company issued a press release announcing
that the U.S. Food and Drug Administration (FDA) has accepted the Company&#8217;s Biologics License Application (BLA) for cipaglucosidase
alfa and the New Drug Application (NDA) for miglustat for AT-GAA, the Company&#8217;s investigational two-component therapy for the treatment
of Pompe disease. A copy of the press release is attached hereto as Exhibit 99.4 and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529; text-align: justify; background-color: white">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"><B>Item&#160;9.01.</B></TD><TD><B>Financial Statements and Exhibits.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;(d)&#160;Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Exhibit No.</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
<TD>Form of Pre-Funded Warrant</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD>&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">10.1* </FONT></TD>
<TD>Business Combination Agreement, dated as of September 29, 2021, by and among ARYA Sciences Acquisition Corp IV, Amicus Therapeutics, Inc., Amicus GT Holdings, Inc. and Caritas Therapeutics, LLC</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD>&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
<TD STYLE="text-align: justify">Sponsor Letter Agreement, dated as of
September 29, 2021, by and among ARYA Sciences Acquisition Corp IV, <FONT STYLE="background-color: white">ARYA Sciences Holdings IV,
Amicus GT Holdings, Inc. and the other parties thereto</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
<TD STYLE="text-align: justify">Securities Purchase Agreement, dated September 29, 2021, by and between Amicus Therapeutics, Inc. and Redmile Group LLC</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
<TD STYLE="text-align: justify">Securities Purchase Agreement, dated September 29, 2021, by and between Amicus Therapeutics, Inc. and Perceptive Life Sciences Master
Fund, Ltd. </TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">10.5</FONT></TD>
<TD STYLE="text-align: justify">Securities Purchase Agreement, dated September 29, 2021, by and among Amicus Therapeutics, Inc. and the Purchasers identified on the signature
pages thereto</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">10.6</FONT></TD>
<TD STYLE="text-align: justify">Investor Rights Agreement, dated September 29, 2021, <FONT STYLE="background-color: white">by and among </FONT>ARYA Sciences Acquisition Corp IV, <FONT>Caritas Therapeutics, LLC, </FONT>Perceptive Life Sciences Master Fund, Ltd.<FONT STYLE="background-color: white">, ARYA Sciences Holdings IV, Amicus GT Holdings, Inc. and the other parties thereto</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">10.7</FONT></TD>
<TD STYLE="text-align: justify">Limited Consent and Amendment No. 1 to Loan Agreement</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">10.8</TD>
<TD STYLE="text-align: justify">Amendment to Employment and Confidentiality Agreements, dated September 28, 2021, by and between Amicus Therapeutics, Inc. and Hung Do</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
<TD STYLE="text-align: justify">Press Release of ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. dated September 29, 2021</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
<TD STYLE="text-align: justify">Investor Presentation of Caritas Therapeutics, Inc., dated September <FONT STYLE="background-color: white">29, </FONT>2021</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">99.3</FONT></TD>
<TD STYLE="text-align: justify">Transcript of Conference Call, dated September 29, 2021</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">99.4</TD>
<TD STYLE="text-align: justify">Press Release of Amicus Therapeutics, Inc. dated September 29, 2021</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&#160;</TD>
<TD STYLE="text-align: justify">&#160;</TD></TR>
<TR>
<TD STYLE="width: 10%; font-size: 10pt">&#160;</TD>
<TD STYLE="vertical-align: top; width: 3%; font-size: 10pt"><FONT STYLE="font-size: 10pt">*</FONT></TD>
<TD STYLE="text-align: justify; vertical-align: top; width: 87%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">Dated: September 29, 2021</FONT></TD>
<TD STYLE="vertical-align: bottom; font-size: 10pt; width: 55%"><FONT STYLE="font-size: 10pt">AMICUS THERAPEUTICS, INC.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; width: 50%">&#160;</TD>
<TD STYLE="vertical-align: top; font-size: 10pt; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; width: 45%">/s/ Ellen S. Rosenberg &#160;</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&#160;</TD>
<TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
<TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Ellen S. Rosenberg </FONT></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&#160;</TD>
<TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
<TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Chief Legal Officer and Corporate Secretary </FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE
SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE
ACT AND ANY APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM OR UNLESS THE COMPANY HAS RECEIVED AN OPINION
OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMICUS THERAPEUTICS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON
STOCK</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Number of Shares: [&#8226;]<BR>
(subject to adjustment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 30%; padding: 0.25pt 0.25pt 0.25pt 10pt; font-size: 10pt; text-indent: -10pt">Warrant No. [&#8226;]</TD>
    <TD STYLE="vertical-align: bottom; width: 70%; padding: 0.25pt; font-size: 10pt; text-align: right">Original Issue Date: [&#8226;]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amicus Therapeutics, Inc.,
a Delaware corporation (the &#8220;<B>Company</B>&#8221;), hereby certifies that, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, [&#8226;] or its registered assigns (the &#8220;<B>Holder</B>&#8221;), is entitled, subject
to the terms set forth below, to purchase from the Company up to a total of [&#8226;] shares of common stock, $0.01 par value per share
(the &#8220;<B>Common Stock</B>&#8221;), of the Company (each such share, a &#8220;<B>Warrant Share</B>&#8221; and all such shares, the
 &#8220;<B>Warrant Shares</B>&#8221;) at an exercise price per share equal to $0.01 per share (as adjusted from time to time as provided
in <U>Section 10</U> herein, the &#8220;<B>Exercise Price</B>&#8221;) upon surrender of this Warrant to Purchase Common Stock (including
any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#8220;<B>Warrant</B>&#8221;) at any time
and from time to time on or after the date hereof (the &#8220;<B>Original Issue Date</B>&#8221;), subject to the following terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Definitions</I>. For purposes of this Warrant, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<B>Affiliate</B>&#8221; means any Person directly or indirectly controlled by, controlling or under common control with,
a Holder, as such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall
continue. For purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, &#8220;controlled by,&#8221; &#8220;controlling&#8221;
and &#8220;under common control with&#8221;) means, with respect to a Person, possession, direct or indirect, of (a) the power to direct
or cause direction of the management and policies of such Person (whether through ownership of securities or partnership or other ownership
interests, by contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant
or other similar arrangement) or other comparable equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &#8220;<B>Commission</B>&#8221; means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<B>Closing Sale Price</B>&#8221; means, for any security as of any date, the last trade price for such security on the Principal
Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended
hours basis and does not designate the last trade price, then the last trade price of such security immediately prior to 4:00 P.M., New
York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other
trading market on the relevant date, the last quoted bid price for the security in the over-the-counter market on the relevant date as
reported by OTC Markets Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing
Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security
on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable
to agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to
determine the fair market value. The Board of Directors&#8217; determination shall be binding upon all parties absent demonstrable error.
All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction
during the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<B>Principal Trading Market</B>&#8221; means the national securities exchange or other trading market on which the Common
Stock is primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<B>Securities Act</B>&#8221; means the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<B>Trading Day</B>&#8221; means any weekday on which the Principal Trading Market is open for trading. If the Common Stock
is not listed or admitted for trading, &#8220;Trading Day&#8221; means any day except any Saturday, any Sunday, any day which is a federal
legal holiday in the United States or any day on which banking institutions in New York City are authorized or required by law or other
governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&#8220;<B>Transfer Agent</B>&#8221; means American Stock Transfer &amp; Trust Company, LLC, the Company&#8217;s transfer agent
and registrar for the Common Stock, and any successor appointed in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Warrant Register</I>. The Company shall register ownership of this Warrant, upon records to be maintained by the Company for
that purpose (the &#8220;<B>Warrant Register</B>&#8221;), in the name of the record Holder (which shall include the initial Holder or,
as the case may be, any assignee to which this Warrant is assigned hereunder) from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for
all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><I>Registration
of Transfers</I>. Subject to compliance with all applicable securities laws and the rules of the Principal Trading Market, the
Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant
Register, upon surrender of this Warrant and delivery of a written assignment of this Warrant substantially in the form attached
hereto as <U>Exhibit A</U>, and payment for all applicable transfer taxes (if any) by the Holder or any subsequent holder. Upon any
such transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a
 &#8220;<B>New Warrant</B>&#8221;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New
Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The
acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and
obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its
Transfer Agent to, prepare, issue and deliver at the Company&#8217;s own expense any New Warrant under this <U>Section 3</U>. Until
due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all
purposes, and the Company shall not be affected by any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Transfer Restrictions. </I>If this Warrant is not registered pursuant to an effective registration statement under the Securities
Act and under applicable state securities or blue sky laws at the time of the surrender of this Warrant in connection with any transfer
of this Warrant, the Company may require, as a condition of allowing such transfer, that (i) the Holder or transferee of this Warrant,
as the case may be, furnish to the Company a written opinion of counsel (which opinion shall be in form, substance and scope customary
for opinions of counsel in comparable transactions) to the effect that such transfer may be made without registration under the Securities
Act and under applicable state securities or blue sky laws, and (ii) the Holder or transferee execute and deliver to the Company an investment
letter in form and substance acceptable to the Company, and (iii) the transferee be an &#8220;accredited investor&#8221; as defined in
Rule 501(a)(1), (a)(2), (a)(3), (a)(7), or (a)(8) promulgated under the Securities Act or a &#8220;qualified institutional buyer&#8221;
as defined in Rule 144A(a) promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Exercise and Duration of Warrants</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time
and from time to time on or after the Original Issue Date, subject to <U>Section 12</U> below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as <U>Exhibit B</U>
hereto (the &#8220;<B>Exercise Notice</B>&#8221;), completed and duly signed, and (ii) payment of the Exercise Price for the number of
Warrant Shares as to which this Warrant is being exercised (which may take the form of a &#8220;cashless exercise&#8221; if so indicated
in the Exercise Notice pursuant to <U>Section 11</U> below). The date on which such exercise notice is delivered to the Company (as determined
in accordance with the notice provisions hereof) is an <B>&#8220;Exercise Date</B>.&#8221; The Holder shall not be required to deliver
the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect
as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant
Shares, if any. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions
of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Delivery of Warrant Shares</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon exercise of this Warrant, the Company shall promptly (but in no event later than three (3) Trading Days after the Exercise
Date), upon the request of the Holder, cause the Transfer Agent to credit such aggregate number of shares of Common Stock to which the
Holder is entitled pursuant to such exercise to the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company
(&#8220;<B>DTC</B>&#8221;) through its Deposit Withdrawal Agent Commission system or if the Transfer Agent is not participating in the
Fast Automated Securities Transfer Program (the &#8220;<B>FAST Program</B>&#8221;) or if the certificates are required to bear a legend
regarding restriction on transferability, a certificate, registered in the Company&#8217;s share register in the name of the Holder or
its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise in electronic book entry
form to the account of such Holder or, upon request of the Holder, by physical delivery to the address specified in the Exercise Notice.
The Holder, or any natural person or legal entity (each, a &#8220;<B>Person</B>&#8221;) so designated by the Holder to receive Warrant
Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such
Warrant Shares are credited to the Holder&#8217;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If by the close of the third (3rd) Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate
representing the required number of Warrant Shares in the manner required pursuant to <U>Section 6(a)</U> or fails to cause the Transfer
Agent to credit the Holder&#8217;s DTC account for such number of Warrant Shares to which the Holder is entitled, and if after such third
(3rd) Trading Day and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &#8220;<B>Buy-In</B>&#8221;), then the Company shall, within three (3) Trading Days after the Holder&#8217;s written request
and in the Holder&#8217;s sole discretion, either (i) pay in cash to the Holder an amount equal to the Holder&#8217;s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company&#8217;s obligation to
deliver such certificate (and to issue such Warrant Shares) or to cause the Holder&#8217;s DTC account to be credited for such Warrant
Shares shall terminate or (ii) promptly deliver to the Holder a certificate or certificates representing such Warrant Shares and pay cash
to the Holder in an amount equal to the excess (if any) of Holder&#8217;s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased in the Buy-In over the product of (A) the number of shares of Common Stock purchased in the
Buy-In, times (B) the Closing Sale Price of a share of Common Stock on the Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>To
the extent permitted by law and subject to <U>Section 6(b)</U>, the Company&#8217;s obligations to cause the Transfer Agent to issue
and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in <U>Section
12</U> below) are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver
or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same,
or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other
Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and
irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with
the issuance of Warrant Shares. Subject to <U>Section 6(b)</U>, nothing herein shall limit the Holder&#8217;s right to pursue any
other remedies available to it hereunder, at law or in equity including, a decree of specific performance and/or injunctive relief
with respect to the Company&#8217;s failure to timely deliver certificates representing shares of Common Stock upon exercise of the
Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Charges, Taxes and Expenses</I>. Issuance and delivery of certificates for shares of Common Stock, if any, upon exercise of
this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense
(excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid
by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect
of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder
or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring
this Warrant or receiving Warrant Shares upon exercise hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be
issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant,
but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each
case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances
shall also comply with such other reasonable regulations and procedures and pay such other reasonable third-party costs as the Company
may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated
Warrant to the Company as a condition precedent to the Company&#8217;s obligation to issue the New Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Reservation of Warrant Shares</I>. The Company covenants that it will, at all times while this Warrant is outstanding, reserve
and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of
enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially
issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights
of persons other than the Holder (taking into account the adjustments and restrictions of <U>Section 10</U>). The Company covenants that
all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with
the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may
be reasonably necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be
listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase
the par value of the Common Stock at any time while this Warrant is outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject
to adjustment from time to time as set forth in this <U>Section 10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on
its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and
in accordance with the terms of such stock on the Original Issue Date that is payable in shares of Common Stock, (ii) subdivides its outstanding
shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common Stock into a smaller
number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares of Common Stock of
the Company, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of
shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common
Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that
if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be
recomputed accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to
this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall
become effective immediately after the effective date of such subdivision or combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pro Rata Distributions</U>. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common
Stock for no consideration (i) evidences of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by
the preceding paragraph) (iii) rights or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each
case, a &#8220;<B>Distribution</B>&#8221;), other than a reclassification as to which <U>Section 10(c)</U> applies, then in each such
case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including the ownership limitation set forth in <U>Section 12(a)</U> hereof) immediately before the date of which
a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to
be determined for the participation in such Distribution (provided, however, to the extent that the Holder&#8217;s right to participate
in any such Distribution would result in the Holder exceeding the ownership limitation set forth in <U>Section 12(a)</U> hereof, then
the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock
as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the
Holder until the earlier of (i) such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding
the ownership limitation set forth in <U>Section 12(a)</U> hereof and (ii) such time as the Holder has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Fundamental
Transactions</U>. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation of the
Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company
immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the
surviving entity immediately after such merger or consolidation, (ii) the Company effects any sale to another Person of all or
substantially all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or
exchange offer (whether by the Company or another Person) that is accepted by holders of capital stock tender shares representing
more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, (iv) the
Company consummates a stock purchase agreement or other business combination (including, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the voting power of
the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such
transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the transaction) or
(v) the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock
is effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or
combination of shares of Common Stock covered by <U>Section 10(a)</U> above) (in any such case, a &#8220;<B>Fundamental
Transaction</B>&#8221;), then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of
this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence
of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of
Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein
(the &#8220;<B>Alternate Consideration</B>&#8221;), and the Warrant will be deemed automatically exercised in full in exchange for
such Alternate Consideration pursuant to the &#8220;cashless exercise&#8221; provisions in <U>Section 11</U> below upon the
consummation of the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Number of Warrant Shares</U>. Simultaneously with any adjustment to the Exercise Price pursuant to <U>Section 10</U> (including
any adjustment to the Exercise Price that would have been effected but for the final sentence in this paragraph 10(d)), the number of
Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such
adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as
the aggregate Exercise Price in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise
Price be adjusted below the par value of the Common Stock then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculations</U>. All calculations under this <U>Section 10</U> shall be made to the nearest one-hundredth of one cent or the
nearest share, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this <U>Section 10</U>, the Company at its expense
will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant
and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type
of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise
to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly
deliver a copy of each such certificate to the Holder and to the Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution
of cash, securities or other property in respect of its Common Stock, including, any granting of rights or warrants to subscribe for or
purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating or solicits
stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs
of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the
Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable record or effective date
on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however,
that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described
in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating
or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section 10(c)</U>, other than a Fundamental Transaction
under clause (iii) of <U>Section 10(c)</U>, then, except if such notice and the contents thereof shall be deemed to constitute material
non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior
to the date such Fundamental Transaction is consummated. Holder agrees to maintain any information disclosed pursuant to this <U>Section
10(g)</U> in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in
the Company&#8217;s securities following receipt any such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Payment of Cashless Exercise Price</I>. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole
discretion, satisfy its obligation to pay the Exercise Price through a &#8220;cashless exercise,&#8221; in which event the Company shall
issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act
as determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">X = Y [(A-B)/A]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-indent: -0.5in">&#8220;X&#8221; equals the number
of Warrant Shares to be issued to the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-indent: -0.5in">&#8220;Y&#8221; equals the total number
of Warrant Shares with respect to which this Warrant is then being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-indent: -0.5in">&#8220;A&#8221; equals the Closing
Sale Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-indent: -0.5in">&#8220;B&#8221; equals the Exercise
Price per Warrant Share then in effect on the Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of Rule 144 promulgated under
the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in such a &#8220;cashless
exercise&#8221; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall
be deemed to have commenced, on the Original Issue Date (provided that the Commission continues to take the position that such
treatment is proper at the time of such exercise). In the event that a registration statement registering the issuance of Warrant
Shares is, for any reason, not effective at the time of exercise of this Warrant, then this Warrant may only be exercised through a
cashless exercise, as set forth in this <U>Section 10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In no event will the exercise
of this Warrant be settled in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Limitations on Exercise</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Notwithstanding
anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall not be
entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving
effect or immediately prior to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by
the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the
Holder&#8217;s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the &#8220;<B>Exchange
Act</B>&#8221;), to exceed 9.99% (the &#8220;<B>Maximum Percentage</B>&#8221;) of the total number of issued and outstanding shares
of Common Stock of the Company following such exercise, or (ii) the combined voting power of the securities of the Company
beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder&#8217;s for purposes of Section 13(d) of the Exchange Act to exceed 9.99% of the combined voting power of
all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the
number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected
in (x) the Company&#8217;s most recent Form 10-Q or Form 10-K, as the case may be, filed with the Commission prior to the Exercise
Date, (y) a more recent public announcement by the Company or (z) any other notice by the Company or the Transfer Agent setting
forth the number of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3)
Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any
case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of
Common Stock was reported. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum
Percentage to any other percentage not in excess of 19.99% specified in such notice; provided that any such increase or decrease
will not be effective until at least the sixty-first (61st) day after such notice is delivered to the Company. For purposes of this <U>Section
12(a)</U>, the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates
and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section
13(d) of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which
such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x) exercise
of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the
unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including
any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including any debt,
preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for,
or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation on conversion or exercise analogous
to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose
beneficial ownership of Common Stock would be aggregated with the Holder&#8217;s for purposes of Section 13(d) of the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This <U>Section 12</U> shall not restrict the number of shares of Common Stock which a Holder may receive or beneficially own in
order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction
as contemplated in <U>Section 10(c)</U> of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu
of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next
whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Notices</I>. Any and all notices or other communications or deliveries hereunder (including any Exercise Notice) shall be in
writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered
via facsimile or confirmed e-mail prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of
transmission, if such notice or communication is delivered via facsimile or confirmed e-mail on a day that is not a Trading Day or later
than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally recognized
overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required
to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Amicus Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attention: Ellen Rosenberg, General Counsel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">3675 Market Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Philadelphia, PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: erosenberg@amicusrx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">With a copy to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Troutman Pepper Hamilton Sanders LLP<BR>
Attention: Scott R. Jones, Esq.<BR>
400 Berwyn Park<BR>
899 Cassatt Road<BR>
Berwyn, PA 19312<BR>
Email: scott.jones@troutman.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If to the Holder, to its address or e-mail address
set forth herein or on the books and records of the Company. Or, in each of the above instances, to such other address or e-mail address
as the recipient party has specified by written notice given to each other party at least five (5) days prior to the effectiveness of
such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days&#8217; notice
to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged
or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any corporation
to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall
be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice
of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#8217;s last address
as shown on the Warrant Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><I>Miscellaneous</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Rights as a Stockholder</U>. The Holder, solely in such Person&#8217;s capacity as a holder of this Warrant, shall not be
entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained
in this Warrant be construed to confer upon the Holder, solely in such Person&#8217;s capacity as the Holder of this Warrant, any of the
rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization,
issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings,
receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is
then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing
any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company,
whether such liabilities are asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Shares</U>. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,
including, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting
the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (c)
use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof as may be necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Successors
and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may
not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental
Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors
and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the
Company and the Holder any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only
in writing signed by the Company and the Holder, or their successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment and Waiver</U>. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company
may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained
the written consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS
WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES
OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE
AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF THE WARRANT OR
ANY OF THE DOCUMENTS DELIVERED HEREUNDER), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING,
ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY
WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF
VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES
TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN
SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY
WAIVES ALL RIGHTS TO A TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed
to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect,
the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby,
and the Company and the Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially
reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Interpretation</U>. For purposes of this Warrant, (a) the words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221;
are deemed to be followed by the words &#8220;without limitation&#8221;; (b) the word &#8220;or&#8221; is not exclusive; and (c) the words
 &#8220;herein,&#8221; &#8220;hereof, &#8220;hereby,&#8221; &#8220;hereto&#8221; and &#8220;hereunder&#8221; refer to this Warrant as a
whole. Unless the context otherwise requires, references herein: (x) to sections and schedules mean the sections of, and schedules attached
to, this Warrant; (y) to an agreement, instrument, or other document means such agreement, instrument, or other document (as amended,
supplemented and modified from time to time to the extent permitted by the provisions thereof/without regard to subsequent amendments,
supplements, and modifications thereto); and (z) to a statute means such statute (as amended from time to time and includes/enforced at
the time and date of this Warrant becoming effective) and does not include any successor legislation thereto and any regulations promulgated
thereunder. This Warrant shall be construed without regard to any presumption or rule requiring construction or interpretation against
the party drafting an instrument or causing any instrument to be drafted. The schedules referred to herein shall be construed with, and
as an integral part of, this Warrant to the same extent as if they were set forth verbatim herein. All references to &#8220;$&#8221; or
 &#8220;dollars&#8221; mean the lawful currency of the United States of America. Whenever the singular is used in this Warrant, the same
shall include the plural, and whenever the plural is used herein, the same shall include the singular, where appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT>-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AMICUS THERAPEUTICS, INC.&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">Name: &nbsp;Daphne Quimi</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">Title: &nbsp;&nbsp;Chief Financial Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page to Warrant]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF ASSIGNMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: justify">Name:</TD>
    <TD STYLE="width: 52%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Address:</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>&nbsp;&mdash;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;&mdash;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: _______________ __, ______</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holder&#8217;s Signature:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holder&#8217;s Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE: The signature to this Form of Assignment must correspond with
the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatever. Officers of corporations
and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT B</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF EXERCISE NOTICE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[To be executed by the Holder to purchase Warrant
Shares under the Warrant]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned is the Holder of Warrant No.<U>[ ] </U>(the &#8220;Warrant&#8221;) issued by Amicus Therapeutics, Inc., a Delaware corporation
(the &#8220;Company&#8221;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in
the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Holder intends that payment of the Exercise Price shall be made as (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash Exercise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&#8220;Cashless Exercise&#8221; under Section 11 of the
Warrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Holder has elected a Cash Exercise, the Holder shall pay the sum of $__________ in immediately available funds to the Company in accordance
with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms of the Warrant.
The Warrant Shares shall be delivered to the following DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced
hereby the Holder, its Affiliates and any other Person whose beneficial ownership of Common Stock would be aggregated with the Holder&#8217;s
for purposes of Section 13(d) of the Exchange Act will not beneficially own in excess of the number of shares of Common Stock (as determined
in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a) of the
Warrant to which this notice relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 3%">Dated:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 52%">&nbsp;</TD>
  <TD STYLE="width: 45%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="white-space: nowrap; width: 5%">Name of Holder:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 2%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 53%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Name:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Title:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Signature must conform in all respects to name
of Holder as specified on the face of the Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Execution Version</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BUSINESS COMBINATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SEPTEMBER 29, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BY AND AMONG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARYA SCIENCES ACQUISITION CORP IV,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMICUS THERAPEUTICS,&nbsp;INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMICUS GT HOLDINGS, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARITAS THERAPEUTICS, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><B><U>Page</U></B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;I DEFINITIONS</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>4</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;II BUSINESS COMBINATION</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>29</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 10%"><FONT STYLE="font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Closing Transactions</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 10%"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">2.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Closing; Closing Date</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">2.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Withholding</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;III REPRESENTATIONS AND WARRANTIES RELATING TO THE AMBER ENTITIES</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>31</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Existence and Power</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Authorization</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consents and Requisite Governmental Approvals; Non-Contravention</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Finders&rsquo; Fees</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Information Supplied</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">3.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Investigation; No Other Representations</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt; text-transform: uppercase">3.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase">Exclusivity of Representations and Warranties</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;IV REPRESENTATIONS AND WARRANTIES RELATING TO THE BUSINESS</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>34</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Existence and Power</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Capitalization</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Assumed Names</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Financial Statements; No Undisclosed Liabilities</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Business Activities</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Internal Controls</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Absence of Certain Changes</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Tangible Personal Property; Sufficiency and Title to Assets</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Litigation</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Contracts</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Licenses and Permits</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Compliance with Laws</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Information Technology and Data Matters</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Employees</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.16</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Employment Benefit Plans</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">46</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Real Property</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.18</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Tax Matters</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.19</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Environmental Laws</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.20</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.21</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Affiliate Arrangements</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">52</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 29; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS<BR>
</B></FONT>(cont&rsquo;d)</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><B><U>Page</U></B></TD></TR>

<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 10%"><FONT STYLE="font-size: 10pt">4.22</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Certain Business Practices</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 10%"><FONT STYLE="font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.23</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Trade Controls</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.24</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Material Suppliers</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">4.25</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Regulatory Compliance</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;V REPRESENTATIONS AND WARRANTIES OF ARYA</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>55</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Existence and Power</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Authority</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Governmental Authorization</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Non-Contravention</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Finders&rsquo; Fees</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Capitalization</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Investment Company Act</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Trust Account</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">ARYA SEC Documents and Financial Statements; Internal Controls</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Litigation</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Business Activities</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Employee Benefit Plans</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Compliance with Laws</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Tax Matters</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Absence of Certain Changes</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.16</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">PIPE Investments</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Transactions with Affiliates</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.18</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Information Supplied</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.19</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Certain Business Practices</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.20</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Trade Controls</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">5.21</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Investigation; No Other Representation</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">65</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt; text-transform: uppercase">5.22</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; text-transform: uppercase">Exclusivity of Representations and Warranties</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;VI COVENANTS OF THE PARTIES</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>66</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conduct of the Business Entities and the Business</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">66</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conduct of the Business of ARYA</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">71</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Efforts to Consummate</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Exclusive Dealing</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Confidentiality; Access to Information</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">75</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Preparation of Registration Statement / Proxy Statement</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">80</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">ARYA Shareholder Approval</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">81</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Nasdaq Listing</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">82</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Trust Account</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">82</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Directors&rsquo; and Officers&rsquo; Indemnification and Insurance</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">83</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Post-Closing Directors and Officers</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">84</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Tax Matters</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">85</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS<BR>
</B>(cont&rsquo;d)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Page</U></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 10%"><FONT STYLE="font-size: 10pt">6.13</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Post-Closing Incentive Equity Plan; Post-Closing Employee Stock Purchase Plan</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 10%"><FONT STYLE="font-size: 10pt">87</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Pre-Closing Reorganization; Excluded Assets and Liabilities</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">88</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Limitation on Assignment of Contributed Business Assets; Third-Party Consents</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">90</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.16</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Misallocated Assets</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">92</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Shared Contracts</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">92</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.18</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Restrictive Covenants</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">93</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.19</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Related Party Transactions</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.20</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Insurance Coverage</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.21</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Lien Releases</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">97</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.22</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Litigation Support</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">97</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.23</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Cooperation Regarding Financial Statements and Related Information</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">98</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.24</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Transition Committee</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">99</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.25</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Intellectual Property License</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">99</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">6.26</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Philadelphia Facility Sublease</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">6.27</TD>
    <TD>Co-Development and Commercialization Agreement</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">100</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;VII EMPLOYEE MATTER COVENANTS</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>100</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">7.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Employee Matters Covenant.</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">100</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">7.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Third-Party Beneficiaries</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">103</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;VIII CONDITIONS TO CLOSING</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>104</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">8.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conditions to the Obligations of the Parties</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">104</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">8.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conditions to Obligations of ARYA</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">104</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">8.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conditions to Obligations of the Amber Entities</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">106</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">8.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Frustration of Closing Conditions</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">107</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;IX TERMINATION</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>107</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Termination</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">107</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">9.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Effect of Termination</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">108</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;X INDEMNIFICATION</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>108</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Survival</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">108</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">10.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Indemnification by Amber GT Parent and Amber GT</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">10.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Indemnification by ARYA</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">10.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Indemnification Procedures</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">110</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">10.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Exclusive Remedy</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">112</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">10.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Additional Indemnification Provisions</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">112</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">10.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Limitation of Liability</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">113</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">10.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Manner of Payments</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">113</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS<BR>
</B>(cont&rsquo;d)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><U>Page </U></B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>Article&nbsp;XI MISCELLANEOUS</B></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>113</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; width: 10%"><FONT STYLE="font-size: 10pt">11.1</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 10%"><FONT STYLE="font-size: 10pt">113</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amendments; Waivers</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">115</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Arm&rsquo;s-Length Bargaining; No Presumption against Drafter</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">115</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Publicity</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">116</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Expenses</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">117</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Assignment or Delegation</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">117</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Governing Law</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">117</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Counterparts; Electronic Signatures</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">117</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Knowledge of Amber GT Parent; Knowledge of ARYA</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">118</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Entire Agreement</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">118</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Exhibits and Schedules</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">118</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">118</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Construction; Interpretation</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">119</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Third-Party Beneficiaries</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">119</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Trust Account Waiver</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">120</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.16</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Submission to Jurisdiction</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">120</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Remedies</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">121</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.18</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Waiver of Jury Trial</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">121</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in"><FONT STYLE="font-size: 10pt">11.19</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Non-Recourse</FONT></TD>
    <TD STYLE="text-align: right; vertical-align: bottom"><FONT STYLE="font-size: 10pt">122</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Annexes&nbsp;&amp; Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;A</U></FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of PIPE Subscription Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;B</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of A&amp;R Company LLC Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;C</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Tax Receivables Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;D</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of </FONT><FONT STYLE="font-size: 10pt">Director Nomination Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;E</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of </FONT><FONT STYLE="font-size: 10pt">Co-Development and Commercialization Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;F</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of </FONT><FONT STYLE="font-size: 10pt">Transition Services Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;G</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of ARYA Post-Closing Certificate of Incorporation</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;H</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of ARYA Post-Closing Bylaws</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;I-1</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Post-Closing Incentive Equity Plan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exhibit&nbsp;I-2</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Post-Closing Employee Stock Purchase Plan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Annex&nbsp;A</U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PIPE Investors</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BUSINESS COMBINATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This BUSINESS COMBINATION
AGREEMENT (the &ldquo;<U>Agreement</U>&rdquo;), dated as of September&nbsp;29, 2021 (the &ldquo;<U>Effective Date</U>&rdquo;), is made
by and among ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company, Amicus,&nbsp;Inc. a Delaware corporation (&ldquo;<U>Amber
GT Parent</U>&rdquo;), Amicus GT Holdings, LLC, a Delaware limited liability company (&ldquo;<U>Amber GT</U>&rdquo;), and Caritas Therapeutics,
LLC, a Delaware limited liability company (the &ldquo;<U>Company</U>&rdquo;). ARYA, Amber GT Parent, Amber GT and the Company shall be
referred to herein from time to time collectively as the &ldquo;<U>Parties</U>&rdquo; or individually as a &ldquo;<U>Party.</U>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>W I T N E S E T H:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
ARYA is a blank check company incorporated as a Cayman Islands exempted company on August&nbsp;24, 2020, and incorporated for the purpose
of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination
with one or more businesses or entities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
pursuant to the Governing Documents of ARYA, ARYA is required to provide an opportunity for its shareholders to have their outstanding
ARYA Class&nbsp;A Shares redeemed on the terms and subject to the conditions set forth therein in connection with obtaining the ARYA Shareholder
Approval;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
as of the date of this Agreement, ARYA Sciences Holdings IV, a Cayman Islands exempted limited company (the &ldquo;<U>ARYA Sponsor</U>&rdquo;),
and the Other Class&nbsp;B Shareholders collectively own 3,737,500 ARYA Class&nbsp;B Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
(a)&nbsp;Amber GT is a direct and wholly owned Subsidiary of Amber GT Parent formed for purposes of consummating the transactions contemplated
by this Agreement and the applicable Additional Agreements and, from and after the Closing, holding Equity Securities in the Company and
ARYA and (b)&nbsp;the Company is, as of the date hereof, a direct and wholly owned Subsidiary of Amber GT formed for purposes of consummating
the transactions contemplated by this Agreement and the applicable Additional Agreements and, from and after the Closing, operating the
Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
concurrently with the execution of this Agreement, the ARYA Sponsor, the Other Class&nbsp;B Shareholders, ARYA and Amber GT are entering
into the Sponsor Letter Agreement (the &ldquo;<U>Sponsor Letter Agreement</U>&rdquo;), pursuant to which the ARYA Sponsor and each Other
Class&nbsp;B Shareholder have agreed to (a)&nbsp;vote in favor of this Agreement and the transactions contemplated hereby, (b)&nbsp;waive
any adjustment to the conversion ratio set forth in the Governing Documents of ARYA or any other anti-dilution or similar protection with
respect to the ARYA Class&nbsp;B Shares held by him, her or it (whether resulting from the transactions contemplated by the PIPE Subscription
Agreements or otherwise) and (c)&nbsp;subject to, and conditioned upon the occurrence of and effective as of, the Closing terminate certain
existing agreements or arrangements, in each case, on the terms and subject to the conditions set forth in the Sponsor Letter Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
prior to the Closing, Amber GT Parent shall cause the Pre-Closing Reorganization to occur on the terms and subject to the conditions set
forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
on the Closing Date, prior to the Closing, ARYA shall transfer by way of continuation from the Cayman Islands to the State of Delaware
and domesticate as a Delaware corporation in accordance with Section&nbsp;388 of the DGCL and Part&nbsp;XII of the Cayman Islands Companies
Act (2021 Revision) (the &ldquo;<U>Domestication</U>&rdquo;), on the terms and subject to the conditions set forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
concurrently with the execution of this Agreement, each of Perceptive Life Sciences Master Fund Ltd., a Cayman Islands exempted company
(the &ldquo;<U>Perceptive PIPE Investor</U>&rdquo;) and each of the investors set forth on <U>Annex&nbsp;A</U> hereto (collectively with
the Perceptive PIPE Investor, the &ldquo;<U>PIPE Investors</U>&rdquo;) are entering into a Subscription Agreement, substantially in the
form attached hereto as <U>Exhibit&nbsp;A</U> (collectively, the &ldquo;<U>PIPE Subscription Agreements</U>&rdquo;), pursuant to which,
among other things, each PIPE Investor has agreed to subscribe for and purchase on the Closing Date immediately prior to the Closing,
and ARYA has agreed to issue and sell to each such PIPE Investor on the Closing Date immediately prior to the Closing, the number of ARYA
Class&nbsp;A Shares set forth in the applicable PIPE Subscription Agreement in exchange for the purchase price set forth therein (the
equity financing under all PIPE Subscription Agreements, collectively, the &ldquo;<U>PIPE Investment</U>&rdquo;), in each case, on the
terms and subject to the conditions set forth therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
at the Closing, (a)&nbsp;ARYA shall contribute the Closing Date Contribution Amount to the Company and, in exchange therefor, the Company
shall issue to ARYA the number of Company Units determined pursuant to this Agreement, (b)&nbsp;Amber GT Parent shall contribute, or cause
to be contributed, the Amber GT Parent Contribution Amount and, in exchange therefor, the Company shall issue to Amber GT the number of
Company Units determined pursuant to this Agreement with respect thereto, and (c)&nbsp;in connection with the contribution and issuance
described above, (i)&nbsp;ARYA shall issue to Amber GT the number of shares of ARYA Class&nbsp;B Shares determined pursuant to this Agreement,
(ii)&nbsp;Amber GT, Amber GT Parent, ARYA and the Company shall enter into the Amended and Restated Limited Liability Company Agreement
of the Company, substantially in the form attached hereto as <U>Exhibit&nbsp;B</U> (the &ldquo;<U>A&amp;R Company LLC Agreement</U>&rdquo;),
to, among other things, (A)&nbsp;recapitalize the authorized Equity Securities of the Company such that, from and after the Closing, the
authorized classes of Equity Securities of the Company will consist of Company Units, with the applicable, rights, preferences and obligations
set forth in the A&amp;R Company LLC Agreement, and (B)&nbsp;appoint the individuals that are members of the ARYA Board immediately after
the Closing to the board of managers of the Company and (iii)&nbsp;the Existing Company LLC Interests held by Amber GT (which, for the
avoidance of doubt, constitute as of the date hereof, and will constitute at all times prior to the Closing, all of the issued and outstanding
Equity Securities of the Company) shall be reclassified into the number of Company Units determined pursuant to this Agreement, in the
case of each of clause&nbsp;(a), (b)&nbsp;and (c), on the terms and subject to the conditions set forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
concurrently with the execution of this Agreement, each of ARYA, the Company, the Perceptive PIPE Investor, the ARYA Sponsor, the Other
Class&nbsp;B Shareholders and Amber GT Parent are each entering into the Investor Rights Agreement (the &ldquo;<U>Investor Rights Agreement</U>&rdquo;),
pursuant to which, among other things, the Perceptive PIPE Investor, the ARYA Sponsor, Amber GT and the Other Class&nbsp;B Shareholders
will each, subject to, and conditioned upon the occurrence of, the Closing, (a)&nbsp;agree not to effect any sale or distribution of any
Equity Securities of ARYA and, in the case of Amber GT, the Company held by any of them during the lock-up period described therein and
(b)&nbsp;will be granted certain registration rights with respect to their respective ARYA Shares, in each case, on the terms and subject
to the conditions set forth therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
at the Closing, Amber GT, the Company and ARYA will enter into the Tax Receivable Agreement, substantially in the form attached hereto
as <U>Exhibit&nbsp;C</U> (the &ldquo;<U>Tax Receivable Agreement</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">L.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
at the Closing, ARYA, ARYA Sponsor and Amber GT Parent will enter into a director nomination agreement, substantially in the form attached
hereto as <U>Exhibit&nbsp;D</U> (the &ldquo;<U>Director Nomination Agreement</U>&rdquo;), pursuant to which, among other things, each
of Amber GT Parent and the ARYA Sponsor will have the right to nominate individuals to the director seats held by the Amber GT Parent
Designees or the ARYA Sponsor Designees, as applicable, in each case, on the terms and subject to the conditions therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">M.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
the board of directors of ARYA (the &ldquo;<U>ARYA Board</U>&rdquo;) has (a)&nbsp;approved this Agreement, the Additional Agreements to
which ARYA is or will be a party and the transactions contemplated hereby and thereby (including the Domestication) and (b)&nbsp;recommended,
among other things, approval of this Agreement and the transactions contemplated by this Agreement (including the Domestication) by the
holders of ARYA Shares entitled to vote thereon; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B>WHEREAS</B>,
(a)&nbsp;the board of directors of Amber GT Parent has approved this Agreement, the Additional Agreements to which it is or will be a
party and the transactions contemplated hereby and thereby (including the Pre-Closing Reorganization), (b)&nbsp;the board of directors
of Amber GT has approved this Agreement, the Additional Agreements to which Amber GT is or will be a party and the transactions contemplated
hereby and thereby (including the Pre-Closing Reorganization) and (c)&nbsp;Amber GT, as the sole member of the Company, has approved this
Agreement, the Additional Agreements to which the Company is or will be a party and the transactions contemplated hereby and thereby (including
the Pre-Closing Reorganization) (the &ldquo;<U>Company Sole Member Consent</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE</B></FONT>, in consideration of the premises set forth above, which are incorporated in this Agreement as if fully set forth
below, and the representations, warranties, covenants and agreements set forth in this Agreement, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Parties accordingly agree
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;I<BR>
DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following terms, as used
herein, have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>A&amp;R
Company LLC Agreement</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
means any lawsuit, litigation, action, inquiry, audit, examination or investigation, claim, complaint, charge, proceeding, suit or arbitration
(in each case, whether civil, criminal or administrative and whether public or private) by or before or otherwise involving any Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Additional
Agreements</U>&rdquo; means the Transition Services Agreement, the Co-Development and Commercialization Agreement, the A&amp;R Company
LLC Agreement, the Tax Receivable Agreement, the Investor Rights Agreement, the Sponsor Letter Agreement, the PIPE Subscription Agreements,
the Director Nomination Agreement, the Philadelphia Facility Sublease and each other agreement, document, instrument or certificate contemplated
by this Agreement executed or to be executed in connection with the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means, with respect to any Person, any other Person directly or indirectly Controlling, Controlled by, or under common Control with such
Person. Notwithstanding the foregoing or anything to the contrary herein, (a)&nbsp;for the avoidance of doubt, (i)&nbsp;prior to the Closing,
each Business Entity shall be deemed to be an Affiliate of each of Amber GT Parent and Amber GT and (ii)&nbsp;from and after the Closing,
each Business Entity shall be deemed to be an Affiliate of ARYA (and, for the avoidance of doubt, not an Affiliate of Amber GT Parent
or Amber GT), and (b)&nbsp;the Affiliates of the ARYA Sponsor shall be deemed to include Perceptive Advisors LLC, a Delaware limited liability
company, and its Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Aggregate
Closing PIPE Proceeds</U>&rdquo; means the aggregate cash proceeds received (or deemed received) by ARYA (or one or more of its designees)
in respect of the PIPE Investment (whether prior to or on the Closing Date and without, for the avoidance of doubt, giving effect to,
or otherwise taking into account the use of any such proceeds). For the avoidance of doubt, any cash proceeds received (or deemed received)
by ARYA in respect of any amounts funded under a PIPE Subscription Agreement prior to the Closing Date shall constitute, and be taken
into account for purposes of determining, the Aggregate Closing PIPE Proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Aggregate
Closing Transaction Proceeds</U>&rdquo; means an amount equal to (a)&nbsp;the amount of cash in the Trust Account as of immediately prior
to the Closing (and before, for the avoidance of doubt, giving effect to any ARYA Share Redemptions and the payment of the Deferred Underwriting
Commission payable to Goldman Sachs&nbsp;&amp; Co. LLC and Jefferies LLC), <I>minus</I> (b)&nbsp;the aggregate amount of cash required
to fund ARYA Share Redemptions from the Trust Account, <I>plus</I> (c)&nbsp;the Aggregate Closing PIPE Proceeds, <I>plus</I> (d)&nbsp;the
aggregate cash proceeds received (or deemed received) by the Company in respect of Amber GT Parent Contribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Agreed
Designee</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.11(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Agreement</U>&rdquo;
has the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
Biologics</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.1(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
Confidential Information</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.5(j)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
Disclosure Schedules</U>&rdquo; means the disclosure schedules to this Agreement delivered to ARYA by the Amber Entities on the date of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
Entities</U>&rdquo; means, collectively, Amber GT Parent, Amber GT and, prior to the Closing, the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
Entity Expenses</U>&rdquo; means, as of any determination time, the aggregate amount of fees, expenses, commissions or other amounts incurred
by or on behalf of, and that are due and payable (and not otherwise expressly allocated to ARYA pursuant to the terms this Agreement or
any Additional Agreement) by any Amber Entity in connection with the negotiation, preparation or execution of this Agreement or any Additional
Agreements, the performance of its covenants or agreements in this Agreement or any Additional Agreements or the consummation of the transactions
contemplated hereby or thereby, including (a)&nbsp;the fees and expenses of outside legal counsel, accountants, advisors, brokers, investment
bankers, consultants, or other agents or service providers of any Amber Entity or any of its Affiliates and (b)&nbsp;any other fees, expenses,
commissions or other amounts that are expressly allocated to any Amber Entity pursuant to this Agreement or any Additional Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
Fundamental Representations</U>&rdquo; means the representations and warranties set forth in <U>Section&nbsp;3.1</U> (Existence and Power),
<U>Section&nbsp;3.2</U> (Authorization), <U>Section&nbsp;3.4</U> (Finders&rsquo; Fees), <U>Section&nbsp;4.1</U> (Existence and Power),
<U>Section&nbsp;4.2</U> (Capitalization), <U>Section&nbsp;4.5</U> (Business Activities), <U>Section&nbsp;4.7</U> (Absence of Certain Changes),
<U>Section&nbsp;4.8(a)</U>&nbsp;and <U>Section&nbsp;4.8(c)</U>&nbsp;(Tangible Personal Property; Sufficiency and Title to Assets) and
<U>Section&nbsp;4.13(b)</U>&nbsp;(Intellectual Property).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
GT</U>&rdquo; has the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
GT Parent</U>&rdquo; has the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
GT Parent Contribution Amount</U>&rdquo; means an amount in cash equal to $50,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
GT Parent Contribution Equity Amount</U>&rdquo; means a number of Company Units or ARYA Class&nbsp;B Shares, as applicable, equal to (a)&nbsp;the
Amber GT Parent Contribution Amount, <I>divided by</I> (b)&nbsp;$10.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
GT Parent Designee</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.11(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
Indemnified Parties</U>&rdquo; has the meaning set forth in <U>Section&nbsp;10.3(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
Material Adverse Effect</U>&rdquo; means any change, event, effect or occurrence that, individually or in the aggregate with any other
change, event, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on (a)&nbsp;the results
of operations, assets, Liabilities or condition (financial or otherwise) of the Business, or (b)&nbsp;the ability of any Amber Entity
to consummate the transactions contemplated by this Agreement in accordance with the terms hereof; <U>provided</U>, <U>however</U>, that,
in the case of clause&nbsp;(a), none of the following shall be taken into account in determining whether an Amber Material Adverse Effect
has occurred or is reasonably likely to occur: any adverse change, event, effect or occurrence arising after the date of this Agreement
from or related to (i)&nbsp;general business or economic conditions in or affecting the United States, or changes therein, or the global
economy generally, (ii)&nbsp;any national or international political or social conditions in the United States or any other country, including
the engagement by the United States or any other country in hostilities, whether or not pursuant to the declaration of a national emergency
or war, or the occurrence in any place of any military or terrorist attack, sabotage or cyberterrorism, (iii)&nbsp;changes in conditions
of the financial, banking, capital or securities markets generally in the United States or any other country or region in the world, or
changes therein, including changes in interest rates in the United States or any other country and changes in exchange rates for the currencies
of any countries, (iv)&nbsp;any change, event, effect or occurrence that is generally applicable to the industries or markets in which
the Business operates, (v)&nbsp;the execution or public announcement of this Agreement or the pendency or consummation of the transactions
contemplated by this Agreement, including the impact thereof on the relationships of the Business, contractual or otherwise, with employees,
customers, investors, contractors, lenders, suppliers, vendors, partners, licensors, licensees, payors or other third parties related
thereto (<U>provided </U>that the exception in this clause&nbsp;(v)&nbsp;shall not apply to the representations and warranties set forth
in <U>Section&nbsp;3.3(a)</U>&nbsp;to the extent that its purpose is to address the consequences resulting from the public announcement
or pendency or consummation of the transactions contemplated by this Agreement or the condition set forth in <U>Section&nbsp;8.2(b)</U>&nbsp;to
the extent it relates to such representations and warranties), (vi)&nbsp;any failure by the Business to meet, or changes to, any internal
or published budgets, projections, forecasts, estimates or predictions (although the underlying facts and circumstances resulting in such
failure may be taken into account to the extent not otherwise excluded from this definition pursuant to clauses&nbsp;(i)&nbsp;through
(iv)&nbsp;or (vii)), or (vii)&nbsp;any hurricane, tornado, flood, earthquake, tsunami, natural disaster, mudslides, wild fires, epidemics,
pandemics (including COVID-19) or quarantines, acts of God or other natural disasters or comparable events in the United States or any
other country or region in the world, or any escalation of the foregoing; <U>provided</U>, <U>however</U>, that any change, event, effect
or occurrence resulting from a matter described in any of the foregoing clauses&nbsp;(i)&nbsp;through (iv)&nbsp;or (vii)&nbsp;may be taken
into account in determining whether an Amber Material Adverse Effect has occurred or is reasonably likely to occur to the extent such
change, event, effect or occurrence has had or would reasonably be expected to have a disproportionate adverse effect on the Business
relative to other participants operating in the industries or markets in which the Business operates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
Related Party</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.21</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Amber
Related Party Transactions</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.21</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Anti-Corruption
Laws</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.22</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA</U>&rdquo;
means (a)&nbsp;prior to the consummation of the Domestication, ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company,
and (b)&nbsp;from and after the consummation of the Domestication, ARYA as domesticated in Delaware, and anticipated to be named &ldquo;<U>Caritas
Therapeutics,&nbsp;Inc.,</U>&rdquo; a Delaware corporation. Any reference to ARYA in this Agreement or any Additional Agreement shall
be deemed to refer to clause&nbsp;(a)&nbsp;or (b), as the context so requires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Acquisition Proposal</U>&rdquo; means any transaction or series of related transactions constituting a &ldquo;<U>Business Combination</U>&rdquo;
(as defined in ARYA&rsquo;s Governing Documents as in effect as of the date hereof). Notwithstanding the foregoing or anything to the
contrary herein, none of this Agreement, the Additional Agreements or the transactions contemplated hereby or thereby shall constitute
an ARYA Acquisition Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Board</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Board Recommendation</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Class&nbsp;A Shares</U>&rdquo; means (a)&nbsp;prior to the consummation of the Domestication, ARYA&rsquo;s Class&nbsp;A ordinary shares
and (b)&nbsp;from and after the consummation of the Domestication, shares of Class&nbsp;A common stock, par value $0.0001 per share, of
ARYA as contemplated pursuant to the ARYA Post-Closing Certificate of Incorporation. Any reference to the ARYA Class&nbsp;A Shares or
the ARYA Shares in this Agreement or any Additional Agreement shall be deemed to refer to clause&nbsp;(a)&nbsp;or clause&nbsp;(b)&nbsp;of
this definition, as the context so requires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.30</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Class&nbsp;B Shares</U>&rdquo; means (a)&nbsp;prior to the consummation of the Domestication, ARYA&rsquo;s Class&nbsp;B ordinary shares
and (b)&nbsp;from and after the consummation of the Domestication, shares of Class&nbsp;B common stock, par value $0.0001 per share, of
ARYA as contemplated pursuant to the ARYA Post-Closing Certificate of Incorporation. Any reference to the ARYA Class&nbsp;B Shares or
the ARYA Shares in this Agreement or any Additional Agreement shall be deemed to refer to clause&nbsp;(a)&nbsp;or clause&nbsp;(b)&nbsp;of
this definition, as the context so requires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
D&amp;O Persons</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.10(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Designee</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.11(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Disclosure Schedules</U>&rdquo; means the disclosure schedules to this Agreement delivered to the Amber Entities by ARYA on the date of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.34</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Expenses</U>&rdquo; means, as of any determination time, the aggregate amount of fees, expenses, commissions or other amounts incurred
by or on behalf of, and that are due and payable (and not otherwise expressly allocated to an Amber Entity pursuant to the terms of this
Agreement or any Additional Agreement) by ARYA in connection with the negotiation, preparation or execution of this Agreement or any Additional
Agreement, the performance of its covenants or agreements in this Agreement or any Additional Agreement or the consummation of the transactions
contemplated hereby or thereby, including (a)&nbsp;the fees and expenses of outside legal counsel, accountants, advisors, brokers, investment
bankers, consultants, or other agents or service providers of ARYA and (b)&nbsp;any other fees, expenses, commissions or other amounts
that are expressly allocated to ARYA pursuant to this Agreement or any Additional Agreement. Notwithstanding the foregoing or anything
to the contrary herein, ARYA Expenses shall not include any Amber Entity Expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.35</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Financial Statements</U>&rdquo; has the meaning set forth in <U>Section&nbsp;5.9(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.36</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Fundamental Representations</U>&rdquo; means the representations and warranties set forth in <U>Section&nbsp;5.1</U> (Existence and Power),
<U>Section&nbsp;5.2</U> (Authority), <U>Section&nbsp;5.5</U> (Finders&rsquo; Fees) and <U>Section&nbsp;5.6</U> (Capitalization).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Indemnified Parties</U>&rdquo; has the meaning set forth in <U>Section&nbsp;10.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.38</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Material Adverse Effect</U>&rdquo; means any change, event, effect or occurrence that, individually or in the aggregate with any other
change, event, effect or occurrence, has had or would reasonably be expected to have a material adverse effect on the ability of ARYA
to consummate the transactions contemplated by this Agreement in accordance with the terms hereof. Notwithstanding the foregoing or anything
to the contrary herein, (a)&nbsp;in no event shall (i)&nbsp;any change, event, effect or occurrence to the extent relating to any of the
Amber Entities, the Business Entities or the Business, (ii)&nbsp;any ARYA Share Redemption, in and of itself, or (iii)&nbsp;any breach
of any covenants, agreements or obligations of a PIPE Investor under a PIPE Subscription Agreement (including any breach of a PIPE Investor&rsquo;s
obligations to fund its commitment thereunder when required), in and of itself, constitute an ARYA Material Adverse Effect and (b)&nbsp;no
change, event, effect or occurrence that is generally applicable to &ldquo;<U>SPACs</U>&rdquo; shall be taken into account in determining
whether an ARYA Material Adverse Effect has occurred or is reasonably likely to occur, except to the extent any such change, event, effect
or occurrence has had or would reasonably be expected to have a disproportionate adverse effect on ARYA relative to other similarly situated
 &ldquo;SPACs&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Post-Closing Bylaws</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Post-Closing Certificate of Incorporation</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Related Party</U>&rdquo; has the meaning set forth in <U>Section&nbsp;5.17</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.42</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Related Party Transactions</U>&rdquo; has the meaning set forth in <U>Section&nbsp;5.17</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.43</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
SEC Documents</U>&rdquo; has the meaning set forth in <U>Section&nbsp;5.9(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Share Redemption</U>&rdquo; means the election of an eligible holder of ARYA Class&nbsp;A Shares (as determined in accordance with ARYA&rsquo;s
Governing Documents and the Investment Management Trust Agreement) to redeem all or a portion of such holder&rsquo;s ARYA Class&nbsp;A
Shares, at the per-share price, payable in cash, equal to such holder&rsquo;s pro rata share of the cash in the Trust Account (as determined
in accordance with ARYA&rsquo;s Governing Documents and the Investment Management Trust Agreement) in connection with the transactions
contemplated by this Agreement and the Additional Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.45</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Shareholder Approval</U>&rdquo; means, collectively, the Required ARYA Shareholder Approval and the Other ARYA Shareholder Approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Shareholders Meeting</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.47</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Shares</U>&rdquo; means, collectively, the ARYA Class&nbsp;A Shares and the ARYA Class&nbsp;B Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.48</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Sponsor</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.49</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ARYA
Sponsor Consent</U>&rdquo; means the consent of the ARYA Sponsor with respect to the entry by ARYA into this Agreement, as required pursuant
to that certain letter agreement, dated February&nbsp;25, 2021, by and among ARYA, the ARYA Sponsor and the other Persons party thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.50</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Assumed
Business Liabilities</U>&rdquo; means, subject to <U>Section&nbsp;6.14(c)</U>&nbsp;and subject to, and without limitation of, any covenants,
agreements or obligations of Amber GT Parent or any of its Affiliates under any Additional Agreement, all of the following Liabilities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">all
Post-Closing Taxes;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">all
Liabilities under, or otherwise to the extent related to or arising out of, the Contributed Business Contracts after the Closing (including,
for the avoidance of doubt, all Liabilities specifically allocated to ARYA pursuant to <U>Section&nbsp;6.17</U>), except for any such
Liabilities to the extent related to or arising out of any breach or other violation of any Contributed Business Contract prior to the
Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(i)&nbsp;except
for any Liabilities retained by Amber GT Parent or any of its Affiliates pursuant to <U>Article&nbsp;VII</U>, all Liabilities related
to or arising out of the employment of any Transferred Employees by the Company or its Affiliates after the Closing and (ii)&nbsp;all
other Liabilities related to Transferred Employees specifically assumed by ARYA or any of its Affiliates pursuant to <U>Article&nbsp;VII</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">all
Liabilities to the extent related to or arising out of the matters listed on <U>Section&nbsp;1.50</U> of the Amber Disclosure Schedules;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">all
other Liabilities that are not the subject of clause&nbsp;(a)&nbsp;through clause&nbsp;(d)&nbsp;of this <U>Section&nbsp;1.50</U> to the
extent related to or arising out of the conduct of the Business or the operation of the Contributed Business Assets, in each case, by
ARYA or its Affiliates after the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.51</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Authority</U>&rdquo;
means any United States or non-United States (a)&nbsp;federal, state, local, municipal or other government, (b)&nbsp;governmental or
quasi-governmental entity of any nature (including any governmental agency, branch, department, official, or entity and any court or
other tribunal) or (c)&nbsp;body exercising or entitled to exercise any administrative, executive, judicial, legislative, police, regulatory,
or taxing authority or power of any nature, including any arbitrator or arbitral tribunal (public or private).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.52</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Books
and Records</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(f)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.53</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business</U>&rdquo;
means the business of investigating, manufacturing, researching, developing, testing, seeking, applying for, obtaining and maintaining
Regulatory Permits, commercializing, selling and marketing products, product candidates, platforms or services arising out of the Gene
Therapy Portfolio (including the Gene Therapy Products). Unless the context requires otherwise or as expressly set forth herein, any reference
to the Business in this Agreement or any Additional Agreement shall be deemed to refer to the Business as conducted or operated by the
Amber Entities and their Affiliates (prior to the Closing) or the Business as conducted or operated by the Business Entities and their
Affiliates (after the Closing), as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Acquisition Proposal</U>&rdquo; means: (a)&nbsp;any direct or indirect acquisition or similar transaction, in one or a series of transactions,
(i)&nbsp;of or with any of the Business Entities or of all or a material portion of the Equity Securities, either individually or in the
aggregate, of any of the Business Entities or (ii)&nbsp;of all or a material portion of the assets, properties or rights related to or
arising out of the Business or any material assets, properties or rights, either individually or in the aggregate, related to or arising
out of the Business (in the case of each of clause&nbsp;(i)&nbsp;and (ii), whether by merger, consolidation, recapitalization, sale, transfer
or license of assets, properties or rights, purchase or issuance of Equity Securities, tender offer or otherwise), or (b)&nbsp;any equity
or similar investment in any of the Business Entities. Notwithstanding the foregoing or anything to the contrary herein, none of this
Agreement, the Additional Agreements or the transactions contemplated hereby or thereby shall constitute a Business Acquisition Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.55</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Combination</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.26</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.56</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Combination Proposal</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.57</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Confidential Information</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.5(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.58</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Contractor</U>&rdquo; means any individual natural Person independent contractor or agency worker of the Amber Entities or any Affiliate
of the Amber Entities who is primarily dedicated to the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.59</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than a Saturday, Sunday or a legal holiday on which commercial banking institutions in New York, New
York are authorized to close for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.60</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Employee</U>&rdquo; means each individual who is employed by the Amber Entities or any of their Affiliates and who either (a)&nbsp;is
set forth on <U>Section&nbsp;1.60</U> of the Amber Disclosure Schedules, or (b)&nbsp;has been reasonably and in good faith determined
by Amber GT Parent to be necessary to the operation of the Business prior to the Closing Date; <U>provided</U>, that, in the case of clause
(b), and without otherwise limiting or affecting the obligations (or the standard of determination) of Amber GT Parent in clause (b),
Amber GT Parent shall: (x)&nbsp;provide prior written notice to ARYA of any such proposed determination, including the identity of each
such individual, (y)&nbsp;provide ARYA a reasonable opportunity to comment and consult on such proposed determination, and (z)&nbsp;consider
in good faith and take into account the comments and view of ARYA with respect to each such individual prior to making any such determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.61</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Employees List</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.15(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.62</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Entities</U>&rdquo; means, collectively, the Company and the Other Business Entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.63</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Insurance Policies</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.20</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.64</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Permits</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.11</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.65</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Business
Product</U>&rdquo; means each existing platform, program or product candidate that has been or is being researched, tested, developed,
manufactured or commercialized by or on behalf of the Business, including all Gene Therapy Products set forth on <U>Section&nbsp;1.65</U>
of the Amber Disclosure Schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.66</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>CARES
Act</U>&rdquo; means the Coronavirus Aid, Relief, and Economic Security Act (Pub. L. 116-136) and any regulations or administrative or
other guidance published with respect thereto by any Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.67</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>CBA</U>&rdquo;
means any collective bargaining agreement or other Contract with any labor union or labor organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.68</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Celenex</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.1(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.69</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Change
of Control Payment</U>&rdquo; means any success, change of control, retention, transaction bonus or other similar payment or amount that
(a)&nbsp;is payable to or may become payable to any Business Employee or Business Contractor (in each case, regardless of whether paid
or payable prior to, at or after the Closing or in connection with or otherwise related to this Agreement or any Additional Agreement)
and (b)&nbsp;with respect to which, following the Closing, any Business Entity or any Affiliate thereof has or may have any Liability
(without, for the avoidance of doubt, taking into account any indemnities (or similar arrangements) hereunder or under any Additional
Agreements).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.70</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Change
of Control Transaction</U>&rdquo; means any transaction or series of related transactions that results, directly or indirectly, in the
shareholders of a Person as of immediately prior to such transaction(s)&nbsp;holding, in the aggregate, less than fifty percent (50%)
of the voting shares of such Person (or any successor or parent company of such Person) immediately after the consummation thereof (whether
by merger, consolidation, tender offer, recapitalization, purchase or issuance of equity securities, tender offer or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.71</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.72</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing
Company Financial Statements</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.4(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.73</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.74</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing
Date Contribution Amount</U>&rdquo; means an amount equal to (a)&nbsp;the amount of cash in the Trust Account as of immediately prior
to the Closing (and before, for the avoidance of doubt, giving effect to the ARYA Share Redemptions and the payment of the Deferred Underwriting
Commission payable to Goldman Sachs&nbsp;&amp; Co. LLC and Jefferies LLC), <I>less</I> (b)&nbsp;the aggregate amount of cash required
to fund ARYA Share Redemptions from the Trust Account and the Deferred Underwriting Commission payable to Goldman Sachs&nbsp;&amp; Co.
LLC and Jefferies LLC, <I>plus</I> (c)&nbsp;the Aggregate Closing PIPE Proceeds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.75</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing
Filing</U>&rdquo; has the meaning set forth in <U>Section&nbsp;11.4(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.76</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Closing
Press Release</U>&rdquo; has the meaning set forth in <U>Section&nbsp;11.4(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.77</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Co-Development
and Commercialization Agreement</U>&rdquo; means the Co-Development and Commercialization Agreement, substantially in the form attached
as <U>Exhibit&nbsp;E</U> hereto and with such modifications, amendments or supplements as may be mutually agreed to in writing by each
of ARYA and Amber GT Parent, to be entered into by Amber GT Parent, Amber GT and certain of their Affiliates identified therein, on the
one hand, and ARYA, the Company and certain of their Affiliates identified therein, on the other hand, at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.78</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Code</U>&rdquo;
means the Internal Revenue Code of 1986.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.79</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Commingled
Books and Records</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.5(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.80</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Commingled
Employee Records</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.5(f)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.81</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Company</U>&rdquo;
has the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.82</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Company
401(k)&nbsp;Plan</U>&rdquo; has the meaning set forth in <U>Section&nbsp;7.1(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.83</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Sole Member Consent</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.84</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Company
Units</U>&rdquo; means the &ldquo;<U>Common Units</U>&rdquo; of the Company (as defined in the A&amp;R Company LLC Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.85</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Competing
Business</U>&rdquo; means, (i)&nbsp;with respect to Amber GT Parent and its Affiliates, a business that competes directly or indirectly
with the Restricted Business and (ii)&nbsp;with respect to ARYA and its Affiliates, a business that competes directly or indirectly with
the Retained Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.86</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Computer
Systems</U>&rdquo; means the computer hardware, Software, systems and information technology infrastructure (including telecommunications)
controlled, owned, licensed or leased by the Amber Entities or their Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.87</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Confidentiality
Agreement</U>&rdquo; means the Mutual Confidentiality Agreement, dated as of July&nbsp;19, 2021, by and between Amber GT Parent and ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.88</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Confidentiality
Period</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.5(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.89</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Consent</U>&rdquo;
means any notice, authorization, qualification, registration, filing, notification, waiver, order, consent or approval to be obtained
from, filed with or delivered to, an Authority or other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.90</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contracts</U>&rdquo;
means all legally-binding contracts, agreements, notes, indentures, leases, licenses and sublicenses, commitments, undertakings or other
arrangements, in each case, whether oral or written, but not including any Employee Benefit Plan (other than any Contracts with respect
to a Change of Control Payment).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.91</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Books and Records</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(f)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.92</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Business Assets</U>&rdquo; means, subject to <U>Section&nbsp;6.14(b)</U>, the following assets, properties, claims and rights (whether
tangible, intangible or otherwise and wherever located) of Amber GT Parent or any of its Affiliates:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
of the following Intellectual Property to the extent owned by Amber GT Parent or any of its Affiliates: (i)&nbsp;all Patents filed prior
to the Closing Date that are Related to the Business, including those Patents set forth on <U>Section&nbsp;1.92(a)(i)</U>&nbsp;of the
Amber Disclosure Schedules, together with any extensions, supplemental protection certificates, reexaminations, reissues, renewals, divisionals,
continuations, continuations-in-part, revisions and foreign counterparts that claim priority to any of the foregoing or to which any of
the foregoing claim priority (the &ldquo;<U>Contributed Patents</U>&rdquo;); (ii)&nbsp;all Trademarks that are Related to the Business,
including those Trademarks set forth on <U>Section&nbsp;1.92(a)(ii)</U>&nbsp;of the Amber Disclosure Schedules, including all translations,
adaptations, and combinations thereof, and all common law rights, registrations, applications for registration thereof, together with
any extensions and renewals thereof, and together with the goodwill associated with any of the foregoing (the &ldquo;<U>Contributed Trademarks</U>&rdquo;);
(iii)&nbsp;all Copyrights that are Related to the Business, including those Copyrights set forth on <U>Section&nbsp;1.92(a)(iii)</U>&nbsp;of
the Amber Disclosure Schedules (the &ldquo;<U>Contributed Copyrights</U>&rdquo;); (iv)&nbsp;all Internet domain name registrations that
are Related to the Business, including those Internet domain name registrations set forth on <U>Section&nbsp;1.92(a)(iv)</U>&nbsp;of the
Amber Disclosure Schedules (the &ldquo;<U>Contributed Domain Names</U>&rdquo;); (v)&nbsp;all Trade Secrets that are Related to the Business,
including those Trade Secrets set forth on <U>Section&nbsp;1.92(a)(v)</U>&nbsp;of the Amber Disclosure Schedules (the &ldquo;<U>Contributed
Trade Secrets</U>&rdquo;); and (vi)&nbsp;all other Intellectual Property that is Related to the Business (irrespective of whether within
or outside of any of clauses (i)&nbsp;through (v)) (all such Intellectual Property, together with the Contributed Patents, Contributed
Trademarks, Contributed Copyrights, Contributed Trade Secrets and Contributed Domain Names, collectively, the &ldquo;<U>Contributed Business
IP</U>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Regulatory Permits Related to the Business, including the Regulatory Permits set forth on <U>Section&nbsp;1.92(b)</U>&nbsp;of the Amber
Disclosure Schedules (the &ldquo;<U>Contributed Regulatory Permits</U>&rdquo;), all other Business Permits and all rights or claims related
to or arising under any of the foregoing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Gene Therapy Portfolio Contracts, all other Contracts Related to the Business, including the Contracts set forth on <U>Section&nbsp;1.92(c)</U>&nbsp;of
the Amber Disclosure Schedules (the &ldquo;<U>Contributed Business Contracts</U>&rdquo;), and all rights or claims related to or arising
under any of the foregoing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
machinery, equipment, office equipment and supplies and all other items of tangible personal property (including any furniture, furnishings,
fixtures, vehicles, tools, components, laptops, tablets and smartphones) that are Related to the Business or otherwise primarily utilized
by a Business Employee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
Contributed Real Property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">subject
to <U>Section&nbsp;6.5(d)</U>&nbsp;and <U>Section&nbsp;6.5(e)</U>, all books and records (financial, laboratory and otherwise), customer
and supplier lists, advertising, marketing or other promotional materials, billing records, distribution lists, manuals, safety data,
clinical trial (or similar) data and patient data and related programs (including patient support and market research programs and related
databases), records, files and documents related to the preparation, filing prosecution, granting, maintenance or defense of any Contributed
Business IP, any specifications, data and other documentation constituting or concerning the Business Products (or any &ldquo;know how&rdquo;
or similar items with respect thereto), and all Business or Business Product complaint files and adverse event files (collectively, the
 &ldquo;<U>Books and Records</U>&rdquo;), in each case, owned, in possession of or controlled by Amber GT Parent or any of its Affiliates
and to the extent relating to, held for use with or used in connection with the Business or the other Contributed Business Assets (the
 &ldquo;<U>Contributed Books and Records</U>&rdquo;); <U>provided</U> that (i)&nbsp;the Contributed Books and Records shall not include
(A)&nbsp;the Contributed Business Employee Records (the treatment of which is set forth in <U>Section&nbsp;1.92(g)</U>&nbsp;below), and
(B)&nbsp;any Books and Records the transfer of which would be prohibited by applicable Law, and (ii)&nbsp;the Amber Entities may redact
any information, documents or materials in Contributed Books and Records to the extent relating to or constituting Excluded Assets or
Excluded Liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">subject
to <U>Section&nbsp;6.5(d)</U>&nbsp;and <U>Section&nbsp;6.5(f)</U>, all employee or personnel files, in each case, owned, in possession
of or controlled by Amber GT Parent or any of its Affiliates and to the extent related to any Business Employee (collectively, the &ldquo;<U>Contributed
Business Employee Records</U>&rdquo;); <U>provided</U> that the Contributed Business Employee Records shall not include any files the
transfer of which would be prohibited by applicable Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
inventory, biological drug substances and biological drug products, finished goods, raw materials, works in progress, packaging and labeling
materials, supplies and parts Related to the Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
credits, prepaid expenses or assets, deferred charges, securities deposits or other prepaid items Related to the Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">the
goodwill and other intangible assets Related to the Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Actions available to or being pursued by Amber GT Parent or any of its Affiliates to the extent related to or arising out of the conduct
of the Business or the operation of the other Contributed Business Assets, whether arising by way of counterclaim or otherwise;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
proceeds received from and after the date hereof under Amber GT Parent&rsquo;s or any of its Affiliates insurance policies or programs
to the extent related to the damage or destruction of any assets, properties or rights prior to the Closing that are, or would have been
but for such damage or destruction, included in the other Contributed Business Assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
assets, properties and rights described on <U>Section&nbsp;1.92(m)</U>&nbsp;of the Amber Disclosure Schedules; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">without
expanding or otherwise modifying any of the assets, properties or rights contemplated by clauses (a)&nbsp;through (n)&nbsp;of this definition,
all other assets, properties and rights (including any tangible embodiments of any Contributed Business IP) that are Related to the Business
(other than, for the avoidance of doubt, any such other assets, properties or rights that constitute Excluded Assets).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.93</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Business Contracts</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.94</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Business Employee Records</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(g)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.95</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Business IP</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.96</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Copyrights</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.97</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Domain Names</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.98</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Leased Real Property</U>&rdquo; means all leasehold or subleasehold estates and other rights to use or occupy any land, buildings, structures,
improvements, fixtures or other interest in real property held by any of the Amber Entities or any of their Affiliates set forth on <U>Section&nbsp;4.17(b)</U>&nbsp;of
the Amber Disclosure Schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.99</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Owned Real Property</U>&rdquo; means all land, together with all buildings, structures, improvements and fixtures located thereon, and
all easements and other rights and interests appurtenant thereto, owned by any of the Amber Entities or any of their Affiliates set forth
on <U>Section&nbsp;4.17(a)</U>&nbsp;of the Amber Disclosure Schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.100</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Patents</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.101</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Real Property</U>&rdquo; means, collectively, the Contributed Leased Real Property and the Contributed Owned Real Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.102</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Regulatory Permits</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.103</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Trademarks</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.104</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Contributed
Trade Secrets</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.92(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.105</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Control</U>&rdquo;
means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, by Contract or otherwise; and the terms &ldquo;<U>Controlled</U>&rdquo; and &ldquo;<U>Controlling</U>&rdquo;
have meanings correlative to the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.106</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Copyrights</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;1.143</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.107</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>COVID-19</U>&rdquo;
means SARS-CoV-2 or COVID-19, and any evolutions or mutations thereof or related or associated epidemics, pandemic or disease outbreaks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.108</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Data
Security Requirements</U>&rdquo; means the following, in each case to the extent applicable to the conduct of the Business: (a)&nbsp;all
Privacy Laws; (b)&nbsp;the rules, policies, and procedures of the Amber Entities and their Affiliates regarding any Personal Information
that is accessed, collected, stored, shared, secured, distributed, transferred, destroyed, processed or used by the Amber Entities or
any of their Affiliates; (c)&nbsp;industry standards to the extent binding; and (d)&nbsp;Contracts that any of the Amber Entities or any
of their Affiliates has entered or by which is otherwise bound regarding any Personal Information accessed, collected, stored, shared,
secured, distributed, transferred, destroyed, processed or used by the Amber Entities or their Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.109</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Deferred
Underwriting Commission</U>&rdquo; has the meaning ascribed to such term in the Underwriting Agreement, dated February&nbsp;25, 2021,
by and among ARYA, Goldman Sachs&nbsp;&amp; Co. LLC and Jefferies LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.110</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>DGCL</U>&rdquo;
means the Delaware General Corporate Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.111</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Director
Nomination Agreement</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.112</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Disabling
Code</U>&rdquo; means computer code or other mechanism of any kind designed to disrupt, disable or harm in any manner the operation of
any Software or hardware or Computer System or to misuse, gain unauthorized access to or misappropriate any business or personal information,
including worms, bombs, backdoors, clocks, timers or other disabling device code, or designs or routines that cause Software or information
to be erased, inoperable, or otherwise incapable of being used, either automatically, with passage of time or upon command.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.113</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Domestication</U>&rdquo;
has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.114</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Domestication
Proposal</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.115</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Effective
Date</U>&rdquo; has the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.116</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Employee
Benefit Plan</U>&rdquo; means each &ldquo;employee benefit plan&rdquo; (as such term is defined in Section&nbsp;3(3)&nbsp;of the United
States Employee Retirement Security Act of 1974 (&ldquo;<U>ERISA</U>&rdquo;), whether or not subject to ERISA), each pension, retirement,
profit-sharing, savings, health, welfare, post-employment welfare, bonus, incentive, commission, stock option, stock appreciation right,
phantom stock, restricted stock unit, performance stock unit, other equity or equity-based, deferred compensation, severance, retention,
accident, disability, employment, change of control, deal bonus, stock purchase, restricted stock, separation, consulting, vacation paid
time off, fringe benefit and each other benefit or compensatory plan, program, policy, Contract or arrangement, in each case that is sponsored,
maintained, contributed or entered into by, or for which there is any liability to, any Amber Entity or any of its Affiliates, in each
case, for the benefit of any Business Employee or any Business Contractor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.117</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Environmental
Laws</U>&rdquo; means all Laws relating to pollution, public or worker health or safety, the protection of the environment, or the use,
storage, handling, release or disposal of, or exposure to any Hazardous Materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.118</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Equity
Securities</U>&rdquo; means any share, share capital, capital stock, partnership, membership, joint venture or similar interest in any
Person (including any stock appreciation right, phantom stock, restricted stock unit, performance stock unit, restricted stock, profit
participation or similar rights) and any option, warrant, right or security (including debt securities) convertible, exchangeable or
exercisable therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.119</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>ERISA</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;1.116</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.120</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the U.S. Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.121</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Excluded
Assets</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.14(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.122</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Excluded
Liabilities</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.14(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.123</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Existing
Company LLC Interests</U>&rdquo; means the &ldquo;<U>Common Units</U>&rdquo; of the Company (as defined in the Existing Company LLCA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.124</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Existing
Company LLCA</U>&rdquo; means the Limited Liability Company Agreement of the Company, dated as of September&nbsp;24, 2021, by and between
the Company and Amber GT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.125</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;4.22</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.126</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
means the U.S. Food and Drug Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.127</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Financial
Statements</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.4(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.128</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>FL
RE Holdings, LLC</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.1(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.129</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Fraud</U>&rdquo;
means common law fraud under the Laws of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.130</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
means U.S. generally accepted accounting principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.131</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Gene
Therapy</U>&rdquo; means <I>in vivo</I> gene therapy for the delivery of DNA or RNA for the treatment of a specific disease or condition
and all associated signs, symptoms, stages or progression (including precursor conditions), including, <I>in vivo </I>and <I>ex vivo</I>
gene therapy via adenoviruses, adeno-associated viruses, lentiviruses and other viral or non-viral vectors, gene editing and other technologies
related to inducing breaks in a DNA or RNA sequence, or substituting, replacing, activating or deleting a particular base or set of bases
of a DNA or RNA sequence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.132</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Gene
Therapy Portfolio</U>&rdquo; means (a)&nbsp;the Intellectual Property assets, properties and rights licensed under, and intangible assets
and other assets, properties and rights of any of Amber GT Parent or one or more of its Affiliates related to or arising out of, the
Gene Therapy Portfolio Contracts and (b)&nbsp;the Contributed Business IP (including, in respect of the foregoing (a)&nbsp;and (b), for
the avoidance of doubt, any platform or product candidates developed under or utilizing any such assets, properties or rights).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.133</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Gene
Therapy Portfolio Contracts</U>&rdquo; means the Contracts set forth on <U>Section&nbsp;1.133</U> of the Amber Disclosure Schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.134</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Gene
Therapy Products</U>&rdquo; means all products that primarily utilize Gene Therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.135</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Governing
Documents</U>&rdquo; means the legal document(s)&nbsp;by which any Person (other than an individual) establishes its legal existence
or that govern its internal affairs. For example, the &ldquo;Governing Documents&rdquo; of a U.S. corporation are its certificate or
articles of incorporation and bylaws, the &ldquo;Governing Documents&rdquo; of a U.S. limited partnership are its limited partnership
agreement and certificate of limited partnership, the &ldquo;Governing Documents&rdquo; of a U.S. limited liability company are its operating
or limited liability company agreement and certificate of formation, and the &ldquo;Governing Documents&rdquo; of a Cayman Islands exempted
company are its memorandum and articles of association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.136</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Hazardous
Material</U>&rdquo; means any pollutants, contaminants, or other materials, substances or wastes that are regulated by or for which Liability
or standards of conduct may be imposed under any Environmental Law, including oil, petroleum, petroleum-derived substances, radiation
and radioactive materials, noise, odors, mold and microbial matter, polychlorinated biphenyls, radon, urea formaldehyde, perfluoroalkyl
and polyfluoroalkyl substances, and asbestos or any materials containing asbestos.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.137</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>HSR
Act</U>&rdquo; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.138</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Inactive
Business Employee</U>&rdquo; has the meaning set forth in <U>Section&nbsp;7.1(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.139</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Incentive
Equity Plan Proposal</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.140</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
means, as of any time, with respect to any Person: (a)&nbsp;all obligations of such Person for borrowed money (including amounts by reason
of overdrafts and amounts owed by reason of letter of credit reimbursement agreements), including with respect thereto, all interests,
fees, costs and prepayment and other penalties, (b)&nbsp;all obligations of such Person evidenced by bonds, debentures, notes or similar
instruments, (c)&nbsp;all obligations of such Person under conditional sale or other title retention agreements relating to property
purchased by such Person, (d)&nbsp;all obligations of such Person for the deferred purchase price of property, assets or services, including
 &ldquo;earn-outs&rdquo; and &ldquo;seller notes&rdquo; (other than, for the avoidance of doubt, trade accounts payable incurred in the
ordinary course), (e)&nbsp;all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right,
contingent or otherwise, to be secured by) any lien or security interest on property owned or acquired by such Person, whether or not
the obligations secured thereby have been assumed, (f)&nbsp;all liabilities for capitalized leases, (g)&nbsp;reimbursement and other
obligations with respect to letters of credit, bank guarantees, bankers&rsquo; acceptances or other similar instruments, (h)&nbsp;derivative,
hedging, swap, foreign exchange or similar arrangements, including swaps, caps, collars, hedges or similar arrangements, and (i)&nbsp;any
of the obligations of any other Person of the type referred to in clauses&nbsp;(a)&nbsp;through (h)&nbsp;above directly or indirectly
guaranteed by such Person or secured by any assets of such Person, whether or not such Indebtedness has been assumed by such Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.141</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Indemnified
Party</U>&rdquo; has the meaning set forth in <U>Section&nbsp;10.4(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.142</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Indemnifying
Party</U>&rdquo; has the meaning set forth in <U>Section&nbsp;10.4(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.143</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Intellectual
Property</U>&rdquo; means (together with all rights in or to) all of the following, anywhere in the world: any (a)&nbsp;trademarks, service
marks, trade names, domain names, trade dress, URLs, social media accounts, logos and other source identifiers, including registration
thereof or application for registration therefor, together with the goodwill symbolized by any of the foregoing (clause&nbsp;(a), collectively,
 &ldquo;<U>Trademarks</U>&rdquo;), (b)&nbsp;patents, patent applications (including provisional applications) and all improvements thereto,
and statutory invention registrations, including all divisionals, continuations, continuations-in-part, renewals, reissues, extensions,
certificates of reexamination, utility models and supplementary protection certificates, (clause&nbsp;(b), collectively, &ldquo;<U>Patents</U>&rdquo;),
(c)&nbsp;trade secrets, know-how, and other confidential, proprietary or sensitive information, including unpatented technology, inventions
(whether or not patentable or reduced to practice), data and databases, ideas, processes, methods, techniques, research and development,
source code, drawings, specifications, layouts, designs, formulae, algorithms, compositions, industrial models, architectures, plans,
proposals, technical data, financial, business and marketing plans and proposals, customer and supplier lists, and price and cost information
(clause&nbsp;(c), collectively, &ldquo;<U>Trade Secrets</U>&rdquo;), (d)&nbsp;formulae, methods, processes, protocols, specifications,
techniques, and other forms of technology (whether or not embodied in any tangible form and including all tangible embodiments of the
foregoing, such as laboratory notebooks, samples, studies and summaries), (e)&nbsp;rights in Software, (f)&nbsp;published and unpublished
works of authorship, whether copyrightable or not, moral rights and mask works, copyright, copyright registration, application for copyright
registration (clause&nbsp;(f), collectively, &ldquo;<U>Copyrights</U>&rdquo;), (g)&nbsp;any other type of proprietary intellectual property
right, (h)&nbsp;all registrations and applications for registration of any of the foregoing clauses&nbsp;(a)&nbsp;through (g)&nbsp;and
(h)&nbsp;all copies and tangible embodiments of any of the foregoing clauses&nbsp;(a)&nbsp;through (g)&nbsp;(in whatever form or medium).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.144</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Intellectual
Property License</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.25(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.145</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Intended
Tax Treatment</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.12(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.146</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Intermediate
HoldCo</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.1(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.147</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Internal
Controls</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.6(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.148</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Investment
Company Act</U>&rdquo; means the Investment Company Act of 1940.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.149</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Investment
Management Trust Agreement</U>&rdquo; means the investment management trust agreement, dated March&nbsp;2, 2021, by and between ARYA and
the Trustee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.150</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Investor
Rights Agreement</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.151</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>IPO</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;11.15</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.152</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>JOBS
Act</U>&rdquo; means the Jumpstart Our Business Startups Act of 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.153</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Latest
Balance Sheet</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.4(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.154</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Law</U>&rdquo;
means any federal, national, state, local, foreign, national, multinational or supranational statute, law (including common law and, if
applicable, fiduciary or similar duties), act, statute, ordinance, treaty, Order, rule, code, regulation or other binding directive, guidance
issued, promulgated or enforced by an Authority having jurisdiction over a given matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.155</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Leases</U>&rdquo;
means all leases, subleases, licenses, concessions and other agreements pursuant to which any of the Amber Entities or any of their Affiliates
holds any Contributed Leased Real Property, including the right to all security deposits and other amounts and instruments deposited
by or on behalf of any of the Amber Entities or their Affiliates thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.156</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Liability</U>&rdquo;
or &ldquo;<U>liability</U>&rdquo; means any and all debts, liabilities and obligations, whether accrued or fixed, absolute or contingent,
known or unknown, matured or unmatured or determined or determinable, including those arising under any Law (including any Environmental
Law), Action or Order and those arising under any Contract, agreement, arrangement, commitment or undertaking.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.157</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Licensed
Intellectual Property</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.25(d)(i)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.158</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Lien</U>&rdquo;
means any mortgage, lien, license or sub-license, pledge, charge, security interest or other similar encumbrance or interest of any kind
in respect of such asset, and any conditional sale or voting agreement or proxy, including any agreement to give any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.159</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Losses</U>&rdquo;
means all losses, costs, interest, Taxes, charges, expenses (including reasonable and out-of-pocket attorneys&rsquo; fees), obligations,
Liabilities, damages, settlement payments, awards, judgments, fines and penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.160</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Material
Business Contract</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.10(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.161</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Material
Supplier</U>&rdquo; has the meaning set forth in <U>Section&nbsp;4.24</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.162</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>MiaMed</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.1(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.163</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Nasdaq</U>&rdquo;
means The Nasdaq Capital Market LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.164</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Nasdaq
Proposal</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.165</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Net
Outstanding ARYA Class&nbsp;A Shares</U>&rdquo; means a number equal to (a)&nbsp;the sum of (i)&nbsp;the number of ARYA Class&nbsp;A Shares
outstanding as of immediately prior to the Closing (and after, for the avoidance of doubt, the consummation of the Domestication and the
conversion of ARYA Class&nbsp;B Shares into ARYA Class&nbsp;A Shares as contemplated hereby) and (ii)&nbsp;the number of ARYA Class&nbsp;A
Shares to be issued pursuant to the PIPE Subscription Agreements, <I>minus</I> (b)&nbsp;the number of ARYA Class&nbsp;A Shares redeemed
and cancelled in connection with the ARYA Share Redemptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.166</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Non-Assignable
Assets</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.15(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.167</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Notice
of Claim</U>&rdquo; means a written notice that specifies with reasonable specificity and detail the circumstances (then known) giving
rise to the Losses (or potential Losses) that are being claimed by an Indemnified Party (including (a)&nbsp;if applicable, the breach
of any Specified Representations or any covenant or agreement set forth in this Agreement, (b)&nbsp;the applicable subsection of <U>Section&nbsp;10.2
</U>or <U>Section&nbsp;10.3(a)</U>&nbsp;under which the Indemnified Party is claiming Losses and (c)&nbsp;whether such claim is a Third-Party
Claim) and, to the extent then quantifiable, an estimate as to the amount of Losses that are indemnifiable hereunder or reasonably expected
to be indemnifiable hereunder (<U>provided</U> that any such estimate shall not affect any Indemnified Party&rsquo;s rights to, or an
Indemnified Party&rsquo;s obligations with respect to, any indemnity under <U>Article&nbsp;X)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.168</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Notice
of Dispute</U>&rdquo; has the meaning set forth in <U>Section&nbsp;10.4(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.169</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>OFAC</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;1.221</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.170</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Officers</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;6.11(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.171</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Order</U>&rdquo;
means any decree, order, judgment, ruling, writ, judicial or arbitral award, injunction, subpoena, verdict, determination or decision
entered, issued or rendered by an Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.172</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Ordinary
Course Tax Sharing Agreement</U>&rdquo; means any written commercial agreement entered into in the ordinary course of business the principal
subject matter of which is not Tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.173</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Other
ARYA Shareholder Approval</U>&rdquo; means the approval of each Other Transaction Proposal by the affirmative vote of the holders of the
requisite number of ARYA Shares entitled to vote thereon, whether in person or by proxy at the ARYA Shareholders Meeting (or any adjournment
thereof), in accordance with the Governing Documents of ARYA and applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.174</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Other
Business Entities</U>&rdquo; means, collectively, MiaMed, Celenex and Amber Biologics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.175</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Other
Class&nbsp;B Shareholders</U>&rdquo; means Todd Wider, Leslie Trigg and Michael Henderson.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.176</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Other
Governing Document Proposals</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.177</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Other
Transaction Proposals</U>&rdquo; means each Transaction Proposal, other than the Required Transaction Proposals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.178</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Owned
Intellectual Property</U>&rdquo; means all Intellectual Property owned or purported to be owned by any Amber Entities or any of their
Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.179</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Parent
401(k)&nbsp;Plan</U>&rdquo; has the meaning set forth in <U>Section&nbsp;7.1(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.180</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Party</U>&rdquo;
or &ldquo;<U>Parties</U>&rdquo; has the meaning set forth in the preamble.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.181</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Patents</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;1.143</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.182</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Payroll
Tax Executive Order</U>&rdquo; means the Presidential Memorandum on Deferring Payroll Tax Obligations in Light of the Ongoing COVID-19
Disaster, as issued on August&nbsp;8, 2020, and including any administrative or other guidance published with respect thereto by any Authority
(including IRS Notice 2020-65).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.183</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>PCAOB</U>&rdquo;
means the Public Company Accounting Oversight Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.184</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Perceptive
PIPE Investor</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.185</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Perceptive
Shareholders</U>&rdquo; means, collectively, the ARYA Sponsor and the Perceptive PIPE Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.186</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Permits</U>&rdquo;
means any approvals, authorizations, clearances, licenses, registrations, permits or certificates of an Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.187</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Permitted
Liens</U>&rdquo; means the following Liens: (a)&nbsp;all covenants, conditions, restrictions, easements, rights of way encumbrances and
other similar matters of record affecting title to any Contributed Real Property which, in each case, do not materially impair or interfere
with the value, use or occupancy of such Contributed Real Property or the operation of the Business thereon; (b)&nbsp;mechanics&rsquo;,
carriers&rsquo;, workers&rsquo;, repairers&rsquo; and similar statutory Liens arising or incurred in the ordinary course of business
(i)&nbsp;that are not yet due or payable, (ii)&nbsp;that are not material in amount or effect on the Business, and (iii)&nbsp;that have
not resulted, directly or indirectly, from a breach, default or violation by any Amber Entity or any of its Affiliates of any Contract,
Law or Order; (c)&nbsp;Liens for Taxes, assessments or governmental charges or levies that are not yet due and payable or that are being
contested in good faith by appropriate proceedings (<U>provided</U> that, in each case, appropriate reserves required pursuant to GAAP
have been made in respect thereof); (d)&nbsp;zoning, building codes and other land-use Laws regulating the use or occupancy of any Contributed
Real Property or the activities conducted thereon that are imposed by any Authority having jurisdiction over any Contributed Real Property
and that are not violated by the current use or occupancy of such Contributed Real Property and that, in each case, do not materially
impair or interfere with the use or occupancy of such Contributed Real Property or the operation of the Business thereon; and (e)&nbsp;non-exclusive
licenses to Intellectual Property granted in the ordinary course of business and that do not adversely affect the use of such Intellectual
Property by the Business or are otherwise <I>de minimis</I> in amount or effect to the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.188</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual, corporation, partnership (including a general partnership, limited partnership or limited liability partnership),
limited liability company, association, trust or other entity or organization, including an Authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.189</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Personal
Information</U>&rdquo; means all data or other information that, alone or in combination with other data or information, can be reasonably
used to identify (directly or indirectly) an individual, household, computer or device, including any personally identifiable data (e.g.,
name, address, phone number, email address, financial account number, payment card data, government issued identifier, and health or
medical information), or that is otherwise considered personally identifiable information under applicable laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.190</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Philadelphia
Facility Sublease</U>&rdquo; means the sublease agreement to be entered into between Amber GT Parent and the Company at the Closing with
respect to the property leased by Amber GT pursuant to that certain Lease, dated as of February&nbsp;23, 2019, by and between Amber GT
Parent and Wexford-SCEC 3675 Market Street, LLC, with commercial and other terms substantially consistent with the terms of the most
recent drafts of such sublease agreement shared between Amber GT Parent and ARYA prior to the date hereof and with such changes or modifications
thereto as mutually agreed to by Amber GT Parent and ARYA (such agreement not to be unreasonably withheld, conditioned or delayed by
either Amber GT Parent or ARYA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.191</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>PIPE
Investment</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.192</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>PIPE
Investors</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.193</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>PIPE
Subscription Agreements</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.194</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Post-Closing
Employee Stock Purchase Plan</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.13.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.195</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Post-Closing
Incentive Equity Plan</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.13</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.196</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Post-Closing
Tax Period</U>&rdquo; means each taxable period beginning after the Closing Date and the portion of any Straddle Period beginning on the
day after the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.197</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Post-Closing
Taxes</U>&rdquo; means (a)&nbsp;all non-income Taxes imposed on Amber GT Parent or any of its Affiliates (other than the Business Entities)
with respect to the Business Entities, the Contributed Business Assets, or the Business, in each case that are attributable to any Post-Closing
Tax Period (such Taxes for a Straddle Period to be apportioned in accordance with <U>Section&nbsp;6.12(d)</U>) and (b)&nbsp;all Liabilities
for Transfer Taxes, other than Pre-Closing Reorganization Transfer Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.198</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Pre-Closing
Reorganization</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.1(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.199</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Pre-Closing
Reorganization Transfer Taxes</U>&rdquo; means any Transfer Taxes to the extent related to, incurred in connection with or arising from
the Pre-Closing Reorganization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.200</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Pre-Closing
Tax Period</U>&rdquo; means each taxable period ending on or before the Closing Date and the portion of any Straddle Period ending on
and including the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.201</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Pre-Closing
Taxes</U>&rdquo; means, without duplication, (a)&nbsp;all Taxes imposed on or with respect to the Business Entities, the Contributed Business
Assets or the Business, in each case that are attributable to any Pre-Closing Tax Period (such Taxes for a Straddle Period to be apportioned
in accordance with <U>Section&nbsp;6.12(d)</U>), (b)&nbsp;all Taxes (other than Post-Closing Taxes) of Amber GT Parent or any of its Affiliates
(other than the Business Entities), (c)&nbsp;Taxes imposed on any Business Entity as a result of having been a member of any &ldquo;affiliated
group&rdquo; (as defined in Section&nbsp;1504 of the Code) (or any similar provision of Law) of which such Business Entity is or was a
member on or prior to the Closing under or by reason of Treasury Regulation Section&nbsp;1.1502-6(a)&nbsp;(or any similar provision of
Law) and (d)&nbsp;all Pre-Closing Reorganization Transfer Taxes; <U>provided</U> that this clause&nbsp;(d)&nbsp;is the only clause of
this definition that includes Transfer Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.202</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Pre-Transaction
Equity Value</U>&rdquo; means $175,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.203</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Privacy
Laws</U>&rdquo; means HIPAA, the HITECH Act, the European Union&rsquo;s General Data Protection Regulation (EU) 2016/679, the California
Consumer Privacy Act of 2018, and any similar or analogous federal, state or foreign Laws relating to the access, collection, storage,
sharing, securing, distribution, transfer, destruction, processing and use of Personal Information (including any security breach notification
requirements and Laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.204</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;11.15</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.205</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Public
Health Laws</U>&rdquo; means all applicable Laws relating to the development, pre-clinical testing, nonclinical testing, manufacture,
production, analysis, distribution, importation, exportation, use, handling, quality, sale or promotion of any drug, including any biologic,
or medical device, placebo, or other article (including any ingredient or component of the foregoing products) subject to regulation
under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &sect;&nbsp;301 <I>et seq</I>.), the Public Health Service Act (42 U.S.C. &sect;&nbsp;262
<I>et seq</I>.), or similar federal, state or foreign Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.206</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Public
Shareholders</U>&rdquo; has the meaning set forth in <U>Section&nbsp;11.15</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.207</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Registration
Statement / Proxy Statement</U>&rdquo; means a registration statement on Form&nbsp;S-4 relating to the transactions contemplated by this
Agreement and the Additional Agreements and containing a prospectus and proxy statement of ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.208</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Regulatory
Permits</U>&rdquo; means all Permits granted by the FDA or any comparable Authority (whether U.S. or non-U.S.), or an institutional review
board or independent ethics committee, including biomarker qualification determinations, drug development tool qualifications, investigational
new drug applications, new drug applications, abbreviated new drug applications, biologics license applications, device premarket approval
applications, device premarket notifications, investigational device exemptions, and other comparable national or foreign manufacturing
approvals and authorizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.209</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Reimbursement
Remainder</U>&rdquo; means an amount equal to (a)&nbsp;$25,000,000, <I>minus</I> (b)&nbsp;the Unpaid ARYA Transaction Expenses. For the
avoidance of doubt, if the Unpaid ARYA Transaction Expenses are equal to or in excess of $25,000,000, then the Reimbursement Remainder
shall be $0.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.210</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Related
to the Business</U>&rdquo; means exclusively relating to, exclusively held for use with, or exclusively in connection with the Business,
in each case, as the context requires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.211</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Remedies
Exception</U>&rdquo; means bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability
relating to or affecting creditors&rsquo; rights generally, and subject, as to enforceability to general equity principles (whether considered
in a proceeding in equity or at Law).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.212</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Representatives</U>&rdquo;
means, with respect to a Person, such Person&rsquo;s Affiliates and its and such Affiliates&rsquo; respective directors, officers, employees,
advisors, agents, consultants, attorneys, accountants, investment bankers or other representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.213</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Required
ARYA Shareholder Approval</U>&rdquo; means the approval of each Required Transaction Proposal by the affirmative vote of the holders of
the requisite number of ARYA Shares entitled to vote thereon, whether in person or by proxy at the ARYA Shareholders Meeting (or any adjournment
thereof), in accordance with the Governing Documents of ARYA and applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.214</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Required
Governing Document Proposal</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.215</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Required
Transaction Proposals</U>&rdquo; means, collectively, the Business Combination Proposal, the Domestication Proposal, the Nasdaq Proposal,
the Required Governing Document Proposal and the Incentive Equity Plan Proposal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.216</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Restricted
Business</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.18(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.217</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Restrictive
Covenant Period</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.18(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.218</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Retained
Business</U>&rdquo; means Amber GT Parent&rsquo;s business of investigating, manufacturing, researching, developing, testing, seeking,
applying for, obtaining and maintaining Regulatory Permits for, commercializing, selling and marketing non-gene therapy medicines for
Fabry disease and Pompe disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.219</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Retained
Employee</U>&rdquo; means any employee who is (i)&nbsp;actively employed by Amber GT Parent or any of its Affiliates immediately prior
to the Closing and who continues to be so employed as of immediately following the Closing and (ii)&nbsp;is not a Transferred Employee
or, for the purposes of <U>Section&nbsp;6.18(g)</U>, an Inactive Business Employee pursuant to the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.220</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Retained
Names</U>&rdquo; means the Trademarks set forth in <U>Section&nbsp;1.219</U> of the Amber Disclosure Schedules, and any Trademarks related
thereto or containing or comprising any of the foregoing, including any Trademarks derivative thereof or confusingly similar thereto,
or any telephone numbers or other alphanumeric addresses or mnemonics containing any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.221</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Sanctioned
Country</U>&rdquo; means any country or region that is, or has been in the last five (5)&nbsp;years prior to the date of this Agreement,
the subject or target of a comprehensive embargo under Trade Controls (including Cuba,&nbsp;Iran, North Korea, Sudan, Syria, Venezuela
and the Crimea region of Ukraine).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.222</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Sanctioned
Person</U>&rdquo; means any Person that is the subject or target of sanctions or restrictions under Trade Controls, including: (a)&nbsp;any
Person listed on any applicable U.S. or non-U.S. sanctions- or export-related restricted party list, including the U.S. Department of
the Treasury Office of Foreign Assets Control&rsquo;s (&ldquo;<U>OFAC</U>&rdquo;) Specially Designated Nationals and Blocked Persons
List; (b)&nbsp;any Person that is, in the aggregate, fifty percent (50%) or greater owned, directly or indirectly, or otherwise controlled
by a Person or Persons described in clause&nbsp;(a); or (c)&nbsp;any national of a Sanctioned Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.223</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Sarbanes-Oxley
Act</U>&rdquo; means the Sarbanes-Oxley Act of 2002.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.224</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Schedules</U>&rdquo;
means, collectively, the Amber Disclosure Schedules and the ARYA Disclosure Schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.225</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>SEC</U>&rdquo;
means the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.226</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.227</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Shared
Contracts</U>&rdquo; means each Contract to which an Amber Entity or any of its Affiliates is a party to or bound materially relating
to the Business or that is otherwise material to the operation or conduct of the Business, but not exclusively relating to, exclusively
held for use with, or exclusively used in connection with the Business, and not otherwise a Contributed Business Contract, a Contract
for which services will be provided pursuant to the Transition Services Agreement or an Employee Benefit Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Options: NewSection; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.228</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Shared
Contractual Liabilities</U>&rdquo; means all Liabilities in respect of Specified Shared Contracts from and after the later of (a)&nbsp;the
Closing and (b)&nbsp;the time at which the Company or one of its Affiliates obtains all of the claims, rights and benefits under a Specified
Shared Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.229</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Signing
Filing</U>&rdquo; has the meaning set forth in <U>Section&nbsp;11.4(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.230</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Signing
Press Release</U>&rdquo; has the meaning set forth in <U>Section&nbsp;11.4(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.231</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Software</U>&rdquo;
means all computer software, including all source code, object or executable code, firmware, software compilations, software implementations
of algorithms, software tool sets, compilers, application programming interfaces, data, databases, software models and methodologies,
development tools, files, records, technical drawings and programmer comments and annotations and data relating to the foregoing and
any and all modifications, enhancements, updates, upgrades, releases, improvement and derivate works thereof and any documentation related
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.232</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Specified
Representations</U>&rdquo; has the meaning set forth in <U>Section&nbsp;10.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.233</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Specified
Shared Contract</U>&rdquo; means each Shared Contract set forth on <U>Section&nbsp;6.17</U> of the Amber Disclosure Schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.234</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Sponsor
Letter Agreement</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.235</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Straddle
Period</U>&rdquo; means any taxable period that begins on or before the Closing Date and ends after the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.236</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
or &ldquo;<U>Subsidiaries</U>&rdquo; means (a)&nbsp;one or more entities of which at least fifty percent (50%) of the capital stock or
share capital or other equity or voting securities are Controlled or owned, directly or indirectly, by the respective Person and (b)&nbsp;any
partnership, limited liability company, joint venture or other entity of which the respective Person or any Subsidiary is a general partner,
manager, managing member or the equivalent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.237</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Tax
Action</U>&rdquo; means any Action in respect of Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.238</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Tax
Claim</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.12(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.239</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Tax
Receivable Agreement</U>&rdquo; has the meaning set forth in the recitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.240</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Tax
Return</U>&rdquo; means any return, information return, declaration, or any similar statement, and any amendment thereto, including any
attached Schedule and supporting information that is filed with or supplied to, or required to be filed with or supplied to, any Taxing
Authority in connection with the determination, assessment, collection or payment of a Tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.241</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Tax
Sharing Agreement</U>&rdquo; means any agreement or arrangement pursuant to which any Amber Entity, any Business Entity or any Affiliate
of the foregoing is or may be obligated to indemnify any Person for, or otherwise pay, any Tax of or imposed on another Person, or pay
over to any other Person any amount determined by reference to actual or deemed Tax benefits, Tax assets or attributes or Tax savings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.242</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Tax(es)</U>&rdquo;
means all U.S. federal, state, local, or non-U.S. net or gross income, net or gross receipts, net or gross proceeds, payroll, employment,
excise, stamp, occupation, windfall or excess profits, profits, customs, capital stock, withholding, social security, unemployment, real
property, personal property (tangible and intangible), sales, use, transfer, value added, alternative or add-on minimum, capital gains,
ad valorem, franchise, capital, estimated, goods and services, premium, environmental or other taxes, assessments, duties or similar
charges of any kind whatsoever in the nature of tax, including all interest, penalties and additions to tax imposed by or otherwise payable
to any Taxing Authority with respect to the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.243</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Taxing
Authority</U>&rdquo; means the U.S. Internal Revenue Service and any other Authority responsible for the collection, assessment or imposition
of any Tax or the administration of any Law relating to any Tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.244</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Termination
Date</U>&rdquo; has the meaning set forth in <U>Section&nbsp;9.1(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.245</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Third-Party
Claim</U>&rdquo; has the meaning set forth in <U>Section&nbsp;10.4(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.246</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Trade
Controls</U>&rdquo; means all U.S. and non-U.S. Laws relating to: (a)&nbsp;economic, trade, and financial sanctions, including those
administered and enforced by OFAC, the U.S. Department of State, and the United Nations; (b)&nbsp;export, import, reexport, transfer,
and retransfer controls, including those administered and enforced by the U.S. Department of Commerce Bureau of Industry and Security,
U.S. Customs and Border Protection, and the United Nations; (c)&nbsp;antiboycott requirements; or (d)&nbsp;the prevention of money laundering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.247</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Trade
Secrets</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.143</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.248</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Trademarks</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;1.143</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.249</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Transaction
Equity Security Amount</U>&rdquo; means a number of Company Units or ARYA Class&nbsp;B Shares, as applicable, equal to (a)&nbsp;the Pre-Transaction
Equity Value, <I>divided by</I> (b)&nbsp;$10.00.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.250</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Transaction
Proposals</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.251</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Transfer
Taxes</U>&rdquo; means any and all transfer, documentary, sales, use, gross receipts, stamp, registration, value added, recording, escrow
and other similar Taxes and fees (including any penalties and interest) incurred in connection with the transactions contemplated by
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.252</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Transferred
Employee</U>&rdquo; has the meaning set forth in <U>Section&nbsp;7.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.253</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Transition
Committee</U>&rdquo; has the meaning set forth in <U>Section&nbsp;6.24</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.254</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Transition
Services Agreement</U>&rdquo; means the Transition Services Agreement, substantially in the form attached as <U>Exhibit&nbsp;H</U> hereto
and with such modifications, amendments or supplements in writing as may be mutually agreed to in writing by each of ARYA and Amber GT
Parent, to be entered into by Amber GT Parent, Amber GT and certain of their Affiliates identified therein, on the one hand, and ARYA,
the Company and certain of their Affiliates identified therein, on the other hand, at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.255</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Treasury
Regulations</U>&rdquo; means the United States Treasury Regulations promulgated under the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.256</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Trust
Account</U>&rdquo; has the meaning set forth in <U>Section&nbsp;5.8(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.257</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Trust
Account Released Claims</U>&rdquo; has the meaning set forth in <U>Section&nbsp;11.15</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.258</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Trustee</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;5.8(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.259</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Unpaid
Amber Entity Transaction Expenses</U>&rdquo; means the Amber Entity Expenses that are unpaid as of immediately prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.260</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>Unpaid
ARYA Transaction Expenses</U>&rdquo; means the ARYA Expenses that are unpaid as of immediately prior to the Closing. Notwithstanding
the foregoing or anything to the contrary in this Agreement, in no event shall the Unpaid ARYA Transaction Expenses include any Excluded
Liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.261</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt">&ldquo;<U>WARN
Act</U>&rdquo; means the Worker Adjustment and Retraining Notification Act of 1988 or any similar Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;II<BR>
BUSINESS COMBINATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing
Transactions</U>. On the terms and subject to the conditions set forth in this Agreement, the following transactions shall occur in the
order set forth in this <U>Section&nbsp;2.1</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Pre-Closing
Reorganization</U>. Prior to the Closing, each of Amber GT Parent and Amber GT shall cause the following transactions to occur: (i)&nbsp;Amber
GT Parent shall cause the cancellation of the intercompany receivables that it holds from MiaMed,&nbsp;Inc., a Delaware corporation (&ldquo;<U>MiaMed</U>&rdquo;),
Amber Biologics Inc., a Delaware corporation (&ldquo;<U>Amber Biologics</U>&rdquo;), and Celenex Inc., a Delaware corporation (&ldquo;<U>Celenex</U>&rdquo;),
<U>provided</U> that, in each case, following the Closing, no Business Entity, ARYA or any of their respective Affiliates shall have
any further liability with respect to such intercompany receivables or the cancellation thereof; (ii)&nbsp;MiaMed shall be converted
into a Delaware limited liability company in accordance with the DGCL and the Delaware Limited Liability Company Act and become a disregarded
entity for U.S. federal income Tax purposes; (iii)&nbsp;Amber GT Parent shall form Amicus GT Intermediate Holdings, LLC a Delaware limited
liability company (&ldquo;<U>Intermediate HoldCo</U>&rdquo;) that will elect to be treated as an association taxable as a corporation
for U.S. federal income Tax purposes effective as of its formation, as a direct and wholly owned Subsidiary; (iv)&nbsp;Amber GT Parent
shall make a capital contribution of all of the issued and outstanding Equity Securities of Amber Biologics to Intermediate HoldCo; (v)&nbsp;Amber
Biologics shall be converted into a Delaware limited liability company in accordance with the DGCL and the Delaware Limited Liability
Company Act and become a disregarded entity for U.S. federal income Tax purposes, and, in connection therewith, Amber Biologics&rsquo;s
name shall be changed to a name to be mutually agreed by ARYA and Amber GT Parent (such agreement not to be unreasonably withheld, conditioned
or delayed by either ARYA or Amber GT Parent) (&ldquo;<U>FL RE Holdings, LLC</U>&rdquo;); (vi)&nbsp;Amber GT Parent shall make a capital
contribution of all of the issued and outstanding Equity Securities of Celenex to Amber GT; (vii)&nbsp;Celenex shall be converted into
a Delaware limited liability company in accordance with the DGCL and the Delaware Limited Liability Company Act and become a disregarded
entity for U.S. federal income Tax purposes; (viii)&nbsp;Amber GT Parent shall make a capital contribution of all of the issued and outstanding
Equity Securities of MiaMed to Amber GT; (ix)&nbsp;Intermediate HoldCo shall make a capital contribution of all of the issued and outstanding
Equity Securities of FL RE Holdings, LLC to Amber GT; (x)&nbsp;Amber GT shall make a capital contribution of all of the issued and outstanding
Equity Securities of Celenex, MiaMed and FL RE Holdings, LLC to the Company, with each such company becoming a direct and wholly owned
Subsidiary of the Company; (xi)&nbsp;subject to <U>Section&nbsp;6.15</U>, Amber GT Parent shall, and shall cause its Affiliates (other
than, for the avoidance of doubt, the Business Entities) to, transfer, convey, assign and deliver to the Company all of Amber GT Parent&rsquo;s
and such Affiliates&rsquo; respective right, title and interest, free and clear of any Liens (other than Permitted Liens), in and to
the Contributed Business Assets, and the Company shall assume, and thereafter satisfy, discharge and perform when due, the Assumed Business
Liabilities; and (xii)&nbsp;in accordance with <U>Section&nbsp;7.1</U>, transfer the employment of each Business Employee (other than
any Inactive Business Employee) to a Business Entity (the transactions described in the foregoing clauses (i)&nbsp;through (xii), collectively,
the &ldquo;<U>Pre-Closing Reorganization</U>&rdquo;). Notwithstanding anything to the contrary in the foregoing, Amber GT Parent shall
be permitted to amend or modify the foregoing transactions with the prior written consent of ARYA (such consent not to be unreasonably
withheld conditioned or delayed in the case of clauses (i)&nbsp;through (x)), <U>provided</U> that, without limiting the generality of
the foregoing, it shall be deemed to be reasonable for ARYA to withhold, condition or delay its consent to any such amendment or modification
that, individually or in the aggregate together with any other amendments or modifications, would reasonably be expected to (A)&nbsp;materially
delay the transactions contemplated by this Agreement or by the Additional Agreements, (B)&nbsp;adversely affect, directly or indirectly,
ARYA or any of its shareholders, the Business Entities following the Closing, the conduct or operations of the Contributed Business Assets
following the Closing, the other rights or remedies of ARYA or the Business Entities following the Closing, or the obligations of any
Amber Entity under this Agreement or the Additional Agreements (including, for the avoidance of doubt, the performance of, or compliance
with, any covenants or agreements to the extent such covenants or agreements apply or require performance following the Closing) in each
case, in any material respect or (C)&nbsp;result in the ARYA or any of the Business Entities being liable for, or having any obligations
with respect to, any Excluded Liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Domestication</U>.
On the Closing Date, prior to the Closing, ARYA shall cause the Domestication to occur in accordance with Section&nbsp;388 of the DGCL
and Part&nbsp;XII of the Cayman Islands Companies Act (2021 Revision), including by filing (i)&nbsp;with the Delaware Secretary of State
a Certificate of Domestication with respect to the Domestication, in form and substance reasonably acceptable to ARYA and the Company,
together with the ARYA Post-Closing Certificate of Incorporation and (ii)&nbsp;making all filings required to be made with the Registrar
of Companies in the Cayman Islands in connection with the Domestication. In connection with (and as part of) the Domestication, ARYA
shall cause (i)&nbsp;each ARYA Class&nbsp;A Share and each ARYA Class&nbsp;B Share that is issued and outstanding immediately prior to
the Domestication to be converted into one share of Class&nbsp;A common stock, par value $0.0001 per share, of ARYA, (ii)&nbsp;the Governing
Documents of ARYA to become the certificate of incorporation, substantially in the form attached hereto as <U>Exhibit&nbsp;G</U> (with
such changes as may be agreed in writing by ARYA and Amber GT Parent, the &ldquo;<U>ARYA Post-Closing Certificate of Incorporation</U>&rdquo;),
and the bylaws, substantially in the form attached hereto as <U>Exhibit&nbsp;H</U> (with such changes as may be agreed in writing by
ARYA and Amber GT Parent, the &ldquo;<U>ARYA Post-Closing Bylaws</U>&rdquo;), and (iii)&nbsp;ARYA&rsquo;s name to be changed to &ldquo;Caritas
Therapeutics,&nbsp;Inc.&rdquo;; <U>provided</U> that, if such name is not available in Delaware or ARYA is otherwise unable to change
its name to &ldquo;Caritas Therapeutics,&nbsp;Inc.,&rdquo; it shall cause its name to change to such other name mutually agreed to by
ARYA and Amber GT Parent (such agreement not to be unreasonably withheld, conditioned or delayed by either ARYA or Amber GT Parent).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Existing
Company LLC Interests Re-classification; Purchase of Company Units; Issuance of ARYA Class&nbsp;B Shares</U>. At the Closing, (i)&nbsp;Amber
GT and the Company shall cause the Existing Company LLCA to be amended and restated to be in the form of the A&amp;R Company LLC Agreement
and, in connection therewith, all of the Existing Company LLC Interests held by Amber GT Parent shall be re-classified into a number
of Company Units equal to the Transaction Equity Security Amount, and (ii)&nbsp;substantially concurrently with clause&nbsp;(i), (x)&nbsp;Amber
GT Parent shall contribute, or cause to be contributed, to the Company the Amber GT Parent Contribution Amount in exchange for a number
of Company Units equal to the Amber GT Parent Contribution Equity Amount, free and clear of all Liens (other than restrictions on transfer
under applicable securities Laws, the A&amp;R Company LLC Agreement and the Investor Rights Agreement), (y)&nbsp;ARYA shall contribute,
or cause to be contributed, to the Company the Closing Date Contribution Amount in exchange for a number of Company Units equal to the
Net Outstanding ARYA Class&nbsp;A Shares, free and clear of all Liens (other than restrictions on transfer under applicable securities
Laws, the A&amp;R Company LLC Agreement and the Investor Rights Agreement) and (z)&nbsp;ARYA shall issue a number of ARYA Class&nbsp;B
Shares equal to the sum of (A)&nbsp;the Transaction Equity Security Amount and (B)&nbsp;the Amber GT Parent Contribution Equity Amount
to Amber GT, free and clear of all Liens (other than restrictions on transfer under applicable securities Laws, the Governing Documents
of ARYA and the Investor Rights Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing;
Closing Date</U>. Unless this Agreement is earlier terminated in accordance with <U>Article&nbsp;IX</U>, the closing of the transactions
contemplated by this Agreement (the &ldquo;<U>Closing</U>&rdquo;) shall take place electronically by exchange of the closing deliverables
by the means provided in <U>Section&nbsp;11.8</U> on a date no later than three (3)&nbsp;Business Days after the satisfaction or, to
the extent permitted by applicable Law, waiver of all the conditions set forth in <U>Article&nbsp;VIII</U> (other than those conditions
that by their nature are to be satisfied at the Closing, but subject to satisfaction or waiver of such conditions), or at such other
place, date or time as Amber GT Parent and ARYA may mutually agree upon in writing. The date on which the Closing actually occurs is
hereinafter referred to as the &ldquo;<U>Closing Date.</U>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Withholding</U>.
ARYA and the Company shall be entitled to deduct and withhold (or cause to be deducted and withheld) from any amount otherwise payable
under this Agreement such amounts as are required to be deducted and withheld with respect to the making of such payment under the Code
or any other provision of applicable Tax Laws. To the extent that such withheld amounts are paid over to or deposited with the applicable
Authority, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the Person in respect of
which such deduction and withholding were made. Prior to undertaking any such deduction or withholding pursuant to this <U>Section&nbsp;2.3</U>,
ARYA and the Company shall use commercially reasonable efforts to provide notice to the Person in respect of whom any such deduction
or withholding is required and cooperate in good faith with such Person to obtain any reduction or relief from any such deduction or
withholding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;III<BR>
REPRESENTATIONS AND WARRANTIES RELATING TO THE AMBER ENTITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to <U>Section&nbsp;11.11</U>,
except as set forth in the Amber Disclosure Schedules, each of the Amber Entities hereby represents and warrants to ARYA, in each case,
as of the date of this Agreement and as of the Closing, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Existence
and Power</U>. Each Amber Entity is a corporation, limited liability company, limited partnership or other applicable business entity
duly incorporated, organized or formed, as applicable, validly existing in good standing (or the equivalent thereof, if applicable, with
respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction
of incorporation, organization or formation, as applicable. Each Amber Entity has all requisite power, authority and capacity, corporate
and otherwise, and all Permits and Consents necessary and required to carry on the Business as presently conducted, except as has not
resulted in and would not reasonably be expected to result in, individually or in the aggregate, an Amber Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization</U>.
Each Amber Entity has the requisite corporate, limited liability company or other similar power and authority to execute and deliver
this Agreement, to perform its covenants, agreements and obligations hereunder and to consummate the transaction contemplated hereby.
Each Amber Entity and each of its applicable Affiliates has the requisite corporate, limited liability company or other similar power
and authority to execute and deliver each Additional Agreement to which it is or will be a party, to perform its covenants, agreements
and obligations thereunder and to consummate the transactions contemplated thereby. The execution and delivery by each Amber Entity of
this Agreement, the execution and delivery by each Amber Entity and each of their respective Affiliates of the Additional Agreements
to which it is, or will be, a party, the performance by each Amber Entity and each of their respective Affiliates of its covenants, agreements
and obligations under this Agreement or any Additional Agreements, as applicable, and the consummation by each Amber Entity and each
of their respective Affiliates of the transactions contemplated hereby or thereby, as applicable, are within the respective corporate,
limited liability company, or other similar powers and authority of each Amber Entity or each such Affiliate thereof, as applicable,
and have been duly authorized by all necessary corporate (or similar) action on the part of each Amber Entity and each of such Affiliate.
This Agreement constitutes, and, upon their execution and delivery, each of the Additional Agreements to which an Amber Entity or any
of its Affiliates, is, or will be, a party, will constitute, a valid and legally binding agreement of each Amber Entity or each Affiliate
thereof, as applicable, enforceable against each such Amber Entity or Affiliate (assuming that this Agreement and the Additional Agreements
to which each Amber Entity or each Affiliate thereof is or is contemplated to be a party are or will be upon execution thereof, as applicable,
duly authorized, executed and delivered by the non-Affiliated Persons party thereto), as applicable, in accordance with their respective
terms, subject to the Remedies Exception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Consents
and Requisite Governmental Approvals; Non-Contravention</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">None
of the execution or delivery by any Amber Entity of this Agreement, the execution or delivery by any Amber Entity or any of their respective
Affiliates of any Additional Agreement to which it is or will be a party, the performance by any Amber Entity or any of their respective
Affiliates of any covenants, agreements or obligations under this Agreement or any Additional Agreements, as applicable, or the consummation
of the transactions contemplated hereby or thereby, as applicable, does or will, directly or indirectly (with or without due notice or
lapse of time or both): (i)&nbsp;contravene or conflict with any Governing Documents of an Amber Entity or any of its Affiliates, (ii)&nbsp;violate,
or constitute a breach under, any Law or Order to which an Amber Entity or any of its Affiliates or any of its properties or assets are
subject or bound (including, for the avoidance of doubt, any of the Contributed Business Assets), (iii)&nbsp;result in a violation or
breach of, or constitute a default or give rise to any right of termination, cancellation, amendment, modification, suspension, revocation
or acceleration or Consent under, any of the terms, conditions or provisions of (A)&nbsp;any Contract to which any Amber Entity or any
of its Affiliates is a party or bound (including, for the avoidance of doubt, any Contributed Business Contract or any Leases) or (B)&nbsp;any
Business Permit (including, for the avoidance of doubt, any Contributed Regulatory Permit) or (iv)&nbsp;result in the creation or imposition
of any Lien (other than Permitted Liens) (A)&nbsp;on any of the Contributed Business Assets (other than any Permitted Liens) or (B)&nbsp;on
any Equity Securities of any of the Business Entities, except, in the case of clauses&nbsp;(ii)&nbsp;through (iii), as has not resulted
in and would not reasonably be expected to result in, individually or in the aggregate, an Amber Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Consent of any Authority is required on the part of any Amber Entity with respect to its execution or delivery of, or performance of
its covenants, agreements or obligations under, this Agreement or the transactions contemplated hereby or on the part of any Amber Entity
or any Affiliate thereof with respect to its execution or delivery of, or performance of its covenants, agreements or obligations under,
any Additional Agreement to which it is or will be party or the consummation of the transactions contemplated thereby, except for (i)&nbsp;compliance
with and filings under the HSR Act, or (ii)&nbsp;any other Consents the absence of which has not resulted in and would not reasonably
be expected to result in, individually or in the aggregate, an Amber Material Adverse Effect. There are no votes or other Consents of
any class or series of Equity Securities of any Amber Entity or any Affiliate thereof required to adopt or approve this Agreement, the
Additional Agreements, the performance of any of the covenants, agreements or obligations of any such Person hereunder or thereunder
or the consummation of the transactions contemplated hereby or thereby, other than the Company Sole Member Consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Finders&rsquo;
Fees</U>. Except as set forth on <U>Section&nbsp;3.4</U> of the Amber Disclosure Schedules, there is no investment banker, broker, finder
or other intermediary that has been retained by or on behalf of any Amber Entity or any of its Affiliates who is or may be entitled to
any fee, commission or other payment or consideration in connection with the consummation of the transactions contemplated by this Agreement
or the Additional Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Information
Supplied</U>. None of the information supplied or to be supplied by or on behalf of any Amber Entity or any of its Affiliates expressly
for inclusion or incorporation by reference in the Registration Statement / Proxy Statement will, when the Registration Statement / Proxy
Statement is declared effective or when the Registration Statement / Proxy Statement is mailed to the ARYA shareholders or at the time
of the ARYA Shareholders Meeting, and in the case of any post-effective amendment thereto, at the time of such post-effective amendment,
contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order
to make the statements therein, in light of the circumstances under which they are made, not misleading; <U>provided</U>, <U>however</U>,
notwithstanding the foregoing provisions of this <U>Section&nbsp;3.5</U>, no representation or warranty is made by the Amber Entities
or any of their Affiliates with respect to information or statements made or incorporated by reference in the Registration Statement
/ Proxy Statement that were not supplied by or on behalf of the Amber Entities for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investigation;
No Other Representations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Amber Entity, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees that (i)&nbsp;it
has conducted its own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business,
assets, condition, operations and prospects of, ARYA and (ii)&nbsp;it has been furnished with or given access to such documents and information
about ARYA and its businesses and operations as it and its Representatives have deemed necessary to enable it to make an informed decision
with respect to the execution, delivery and performance of this Agreement, the Additional Agreements and the transactions contemplated
hereby and thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
entering into this Agreement and the Additional Agreements to which it is or will be a party, each Amber Entity has relied solely on
its own investigation and analysis and the representations and warranties expressly set forth in <U>Article&nbsp;V</U> and in the Additional
Agreements to which it is or will be a party and no other representations or warranties of ARYA or any other Person, either express or
implied, and each Amber Entity, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees
that, except for the representations and warranties expressly set forth in <U>Article&nbsp;V</U> and in the Additional Agreements to
which ARYA is a party and to which it is or will be a party, ARYA has not made any representation or warranty, either express or implied,
in connection with or related to this Agreement, the Additional Agreements or the transactions contemplated hereby or thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">3.7</FONT><FONT STYLE="text-transform: uppercase">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exclusivity
of Representations and Warranties</U></FONT></FONT><FONT STYLE="font-size: 10pt">. NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO ARYA
OR ANY OF ITS REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA),
EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS <U>ARTICLE&nbsp;III</U>, <U>ARTICLE&nbsp;IV</U> OR THE ADDITIONAL AGREEMENTS, NONE OF
THE AMBER ENTITIES NOR ANY OTHER PERSON MAKES, AND EACH AMBER ENTITY EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND
OR NATURE, EXPRESS OR IMPLIED,&nbsp;IN CONNECTION WITH THIS AGREEMENT, THE ADDITIONAL AGREEMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED
HEREBY OR THEREBY,&nbsp;INCLUDING AS TO THE MATERIALS RELATING TO THE BUSINESS OR THE CONTRIBUTED BUSINESS ASSETS THAT HAVE BEEN MADE
AVAILABLE TO ARYA OR ANY OF ITS REPRESENTATIVES OR IN ANY PRESENTATION RELATED TO THE BUSINESS OR THE CONTRIBUTED BUSINESS ASSETS BY
OR ON BEHALF OF THE MANAGEMENT OF ANY OF THE AMBER ENTITIES OR ANY OF THEIR AFFILIATES OR OTHERS IN CONNECTION WITH THE TRANSACTIONS
CONTEMPLATED HEREBY OR BY THE ADDITIONAL AGREEMENTS, AND NO STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR MADE IN ANY SUCH PRESENTATION
SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY ARYA IN EXECUTING, DELIVERING OR PERFORMING
THIS AGREEMENT, THE ADDITIONAL AGREEMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES
EXPRESSLY SET FORTH IN <U>ARTICLE&nbsp;III</U>, <U>ARTICLE&nbsp;IV</U> OR THE ADDITIONAL AGREEMENTS,&nbsp;IT IS UNDERSTOOD THAT ANY COST
ESTIMATES, PROJECTIONS OR OTHER PREDICTIONS, ANY DATA, ANY FINANCIAL INFORMATION OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS,&nbsp;INCLUDING
ANY OFFERING MEMORANDUM OR SIMILAR MATERIALS MADE AVAILABLE BY OR ON BEHALF OF ANY AMBER ENTITY ARE NOT AND SHALL NOT BE DEEMED TO BE
OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF ANY AMBER ENTITY OR THE COMPANY OR ANY OTHER PERSON, AND, EXCEPT FOR THE REPRESENTATIONS
AND WARRANTIES EXPRESSLY SET FORTH IN <U>ARTICLE&nbsp;III</U>, <U>ARTICLE&nbsp;IV</U> OR THE ADDITIONAL AGREEMENTS, EACH AMBER ENTITY
EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED,&nbsp;IN CONNECTION THEREWITH. NOTWITHSTANDING
ANYTHING SET FORTH IN THIS AGREEMENT TO THE CONTRARY, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN <U>ARTICLE&nbsp;III</U>,
<U>ARTICLE&nbsp;IV</U> OR THE ADDITIONAL AGREEMENTS, NONE OF THE AMBER ENTITIES NOR ANY OTHER PERSON MAKES ANY REPRESENTATIONS OR WARRANTIES
TO ARYA REGARDING ANY PROJECTIONS OR THE FUTURE OR PROBABLE PROFITABILITY, SUCCESS, BUSINESS, OPPORTUNITIES, RELATIONSHIPS AND OPERATIONS
OF THE COMPANY.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;IV<BR>
REPRESENTATIONS AND WARRANTIES RELATING TO THE BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to <U>Section&nbsp;11.11</U>,
except as set forth in the Amber Disclosure Schedules, each of the Amber Entities hereby represents and warrants to ARYA, in each case,
as of the date of this Agreement and as of the Closing, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Existence
and Power</U>. Each Business Entity: (a)&nbsp;is a corporation, limited liability company, limited partnership or other applicable business
entity duly incorporated, organized or formed, as applicable, validly existing and in good standing (or the equivalent thereof, if applicable,
in each case, with respect to the jurisdictions that recognize the concept of good standing or any equivalent thereof) under the Laws
of its jurisdiction of incorporation, organization or formation, as applicable, (b)&nbsp;has all requisite corporate, limited liability
company or other applicable business entity power and authority to own, lease and operate its properties and assets and to carry on the
Business as presently conducted, and (c)&nbsp;is duly licensed or qualified to do business and is in good standing in each jurisdiction
in which the ownership or operation of the Contributed Business Assets or the conduct of the Business requires such licensing or qualification,
except, in the case of this clause&nbsp;(c), as has not resulted in and would not reasonably be expected to result in, individually or
in the aggregate, an Amber Material Adverse Effect. <U>Section&nbsp;4.1</U> of the Amber Disclosure Schedules lists all jurisdictions
in which each Business Entity is duly licensed or qualified to do business as of the date hereof. True, correct and complete copies of
the Governing Documents of each Business Entity have been made available to ARYA, in each case, as amended and in effect as of the date
of this Agreement. The Governing Documents of each Business Entity are in full force and effect, and none of the Business Entities is
in breach or violation of any provision set forth in its Governing Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;4.2(a)</U>&nbsp;of
the Amber Disclosure Schedules sets forth a true, correct and complete statement of (i)&nbsp;the number and class or series (as applicable)
of all of the Equity Securities of the Business Entities issued and outstanding, and (ii)&nbsp;the identity of the Persons that are the
record and beneficial owners thereof. All of the outstanding Equity Securities of each Business Entity have been or will be, in the case
of the Company Units to be issued on the Closing Date on the terms and subject to the conditions herein, duly authorized and validly
issued, and are, or will be, as applicable, fully paid and nonassessable. The Equity Securities of each Business Entity: (i)&nbsp;were
not issued in violation of such Business Entity&rsquo;s Governing Documents or any other Contract to which such Business Entity is bound,
in each case, in any material respect; (ii)&nbsp;were not issued in violation of any preemptive rights, call option, right of first refusal
or first offer, subscription rights, transfer restrictions or similar rights of any Person, in each case, in any material respect; (iii)&nbsp;have
been offered, sold and issued in compliance in all material respects with applicable Law, including securities Laws, in each case, in
any material respect; and (iv)&nbsp;are free and clear of all Liens (other than transfer restrictions under applicable Law or under such
Business Entity&rsquo;s Governing Documents). The Business Entities do not have outstanding (x)&nbsp;equity appreciation, phantom equity
or profit participation rights or (y)&nbsp;options, stock appreciation rights, restricted stock, restricted stock units, phantom stock,
warrants, purchase rights, subscription rights, conversion rights, exchange rights, calls, puts, rights of first refusal or first offer
or other Contracts that could require such Business Entity to issue, sell or otherwise cause to become outstanding or to acquire, repurchase
or redeem any Equity Securities or securities convertible into or exchangeable for Equity Securities of such Business Entity. There are
no voting trusts, proxies or other Contracts with respect to the voting or transfer of the Business Entities&rsquo; Equity Securities.
No other class of Equity Securities of the Business Entities is authorized or issued or outstanding and, other than as set forth in <U>Section&nbsp;4.2(a)</U>&nbsp;of
the Amber Disclosure Schedules, there are no outstanding Equity Securities of any Business Entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amber
GT will have, immediately prior to the Closing, valid, good and marketable title to all of the Existing Company Units, free and clear
of all Liens (other than transfer restrictions under applicable securities Laws or under the Governing Documents of the Company), and
all of the outstanding Equity Securities of Amber GT are owned directly by Amber GT Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as set forth on <U>Section&nbsp;4.2(c)</U>&nbsp;of the Amber Disclosure Schedules, none of the Business Entities owns or holds (of record,
beneficially, legally or otherwise), directly or indirectly, any Equity Securities in any other Person or the right to acquire any such
Equity Securities, and none of the Business Entities are a partner or member of any partnership, limited liability company or joint venture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Options: NewSection; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;4.2(d)</U>&nbsp;of
the Amber Disclosure Schedules sets forth a list of all Change of Control Payments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Assumed
Names</U>. Since January&nbsp;1, 2019, none of the Amber Entities or any of their respective Affiliates has used the Retained Names to
conduct the Business other than those set forth in <U>Section&nbsp;4.3</U> of the Amber Disclosure Schedules. Each Amber Entity and each
Affiliate thereof (including the Business Entities) has filed appropriate &ldquo;doing business as&rdquo; certificates or similar filings
in all applicable jurisdictions in which the operation or conduct of the Business would require such certificate or other filing, with
respect to itself, except as has not resulted in and would not reasonably be expected to result in, individually or in the aggregate,
an Amber Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Financial
Statements; No Undisclosed Liabilities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Amber Entities have made available to ARYA true, correct and complete copies of (i)&nbsp;the unaudited combined balance sheets of the
Business as of June&nbsp;30, 2021 (the &ldquo;<U>Latest Balance Sheet</U>&rdquo;) and June&nbsp;30, 2020, and the related unaudited combined
statements of operations and comprehensive loss and cash flows of the Business for each of the six-month periods then ended and (ii)&nbsp;the
unaudited combined balance sheets of the Business as of December&nbsp;31, 2020 and December&nbsp;31, 2019, and the related unaudited
combined statements of operations and comprehensive loss, and cash flows of the Business for each year then ended (the financial statements
described in clause&nbsp;(a)&nbsp;and clause&nbsp;(b), collectively, the &ldquo;<U>Financial Statements</U>&rdquo;), each of which are
attached to <U>Section&nbsp;4.4(a)</U>&nbsp;of the Amber Disclosure Schedules. The Financial Statements (including the notes thereto)
(A)&nbsp;were prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated (except as may be specifically
indicated in the notes thereto and subject to, in the case of any unaudited financial statements, normal year end audit adjustments (none
of which are individually or in the aggregate material) and the absence of notes thereto), (B)&nbsp;fairly present, in all material respects,
the financial position, results of operations and cash flows of the Business as at the date thereof and for the period indicated therein
(subject to, in the case of any unaudited financial statements, normal year end audit adjustments (none of which are, individually or
in the aggregate, material)), and (C)&nbsp;comply in all material respects with the applicable accounting requirements and with the rules&nbsp;and
regulations of the SEC, the Exchange Act and the Securities Act (including Regulation S-X or Regulation S-K, as applicable) in effect
as of the date of this Agreement, at the time of filing the Registration Statement / Proxy Statement and at the time of effectiveness
of the Registration Statement / Proxy Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(i)&nbsp;The
audited combined balance sheets of the Business as of December&nbsp;31, 2020 and December&nbsp;31, 2019, and the related audited combined
statements of operations and comprehensive loss, and cash flows of the Business for each year then ended, and (ii)&nbsp;each of the other
financial statements or similar reports of the Business, the Amber Entities or any of their respective Affiliates required to be included
in the Registration Statement / Proxy Statement or any other filings to be made by ARYA or any of the Amber Entities with the SEC in
connection with the transactions contemplated by this Agreement or any other Additional Agreement (clause (i)&nbsp;and (ii), collectively,
the &ldquo;<U>Closing Company Financial Statements</U>&rdquo;), when delivered following the date of this Agreement in accordance with
<U>Section&nbsp;6.23</U>, (i)&nbsp;will be prepared in accordance with GAAP applied on a consistent basis throughout the periods indicated
(except, in the case of any audited financial statements, as may be specifically indicated in the notes thereto and subject to, in the
case of any unaudited financial statements, normal year end audit adjustments (none of which are individually or in the aggregate material)
and the absence of notes thereto), (ii)&nbsp;will fairly present, in all material respects, the financial position, results of operations
and cash flows of the Business as at the date thereof and for the period indicated therein (subject to, in the case of any unaudited
financial statements, normal year end audit adjustments (none of which are, individually or in the aggregate, material)), (iii)&nbsp;in
the case of any audited financial statements, will be audited in accordance with the standards of the PCAOB and will contain an unqualified
report of the Business&rsquo; auditors and (iv)&nbsp;will comply in all material respects with the applicable accounting requirements
and with the rules&nbsp;and regulations of the SEC, the Exchange Act and the Securities Act (including Regulation S-X or Regulation S-K,
as applicable) in effect as of the date of such delivery, at the time of filing the Registration Statement / Proxy Statement and at the
time of effectiveness of the Registration Statement / Proxy Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
(i)&nbsp;as set forth on the face of the Latest Balance Sheet, (ii)&nbsp;for Liabilities incurred in the ordinary course of business
since the date of the Latest Balance Sheet (none of which are Liabilities directly or indirectly related to a breach of Contract, breach
of warranty, tort, infringement, Action or violation of, or non-compliance with, Law), (iii)&nbsp;for Liabilities incurred in connection
with the negotiation, preparation or execution of this Agreement or any Additional Agreements, the performance by the Business Entities
of their respective covenants or agreements in this Agreement or any Additional Agreement to which it is or will be a party or the consummation
of the transactions contemplated hereby or thereby and (iv)&nbsp;for Liabilities that are not and would not reasonably be expected to
be, individually or in the aggregate, material to the Business, none of the Business Entities or the Amber Entities (as it relates to
the operation or conduct of the Business) have any Liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Business
Activities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Company was organized solely for the purposes of holding Equity Securities of the other Business Entities and the Contributed Business
Assets and, from and after the Closing, conducting the Business and operating the Contributed Business Assets and has not conducted any
activities or businesses other than the activities (i)&nbsp;in connection with or incidental or related to its organization or continuing
corporate (or similar) existence, (ii)&nbsp;those incidental or related to or incurred in connection with the negotiation, preparation
or execution of this Agreement or any Additional Agreements, the performance of its covenants or agreements in this Agreement or any
Additional Agreement or the consummation of the transactions contemplated hereby or thereby, (iii)&nbsp;those that are administrative,
ministerial or otherwise immaterial in nature or (iv)&nbsp;those set forth on <U>Section&nbsp;4.5(a)</U>&nbsp;of the Amber Disclosure
Schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as set forth on <U>Section&nbsp;4.5(b)</U>&nbsp;of the Amber Disclosure Schedules, (i)&nbsp;none of the Business Entities are party to
or bound by any Contract or have any rights, properties or assets, other than those rights, properties or assets that constitute Contributed
Business Assets or are otherwise related to conducting the Business or operating the Contributed Business Assets or rights under any
Additional Agreement and (ii)&nbsp;none of the Business Entities have any Liabilities, other than those Liabilities related to conducting
the Business or operating the Contributed Business Assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 69; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Internal
Controls</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Amber Entities and their applicable Affiliates have devised and maintain a system of internal accounting controls that are designed to
provide reasonable assurances regarding the reliability of financial reporting and the preparation of the Financial Statements in accordance
with GAAP (&ldquo;<U>Internal Controls</U>&rdquo;). The Internal Controls that are designed to provide, in all material respects, reasonable
assurance that (i)&nbsp;transactions are executed only in accordance with management&rsquo;s authorization and (ii)&nbsp;all transactions
are recorded as necessary to permit preparation of proper and accurate financial statements in accordance with GAAP and to maintain accountability
for the Business&rsquo; assets. None of the Amber Entities or any of their Affiliates nor an independent auditor of the Business has
identified or been made aware of (A)&nbsp;any significant deficiency or material weakness in the system of Internal Controls utilized
by the Amber Entities or any of their Affiliates, (B)&nbsp;any fraud that involves management or other employees who have a role in the
preparation of the Financial Statements or the Internal Controls utilized by the Amber Entities or any of their Affiliates or (C)&nbsp;any
claim or allegation regarding any of the foregoing. To the knowledge of Amber GT Parent, (i)&nbsp;there are no significant deficiencies
or material weaknesses in the design or operation of the Internal Controls over financial reporting that would reasonably be expected
to adversely affect, in a material manner, the Amber Entities or their Affiliates&rsquo; ability to record, process, summarize and report
financial information and (ii)&nbsp;there is no Fraud that involves the management of an Amber Entity or any of its Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
Contracts, documents, and other papers or copies thereof delivered to ARYA by or on behalf of the Amber Entities and their Affiliates
are true, correct and complete in all material respects. The Books and Records accurately and fairly, in all material respects, reflect
the transactions by the Business. All accounts, books and ledgers of the Business that form the basis of the Financial Statements have
been properly and accurately kept and completed in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Certain Changes</U>. During the period beginning June&nbsp;30, 2021, and ending on the date of this Agreement, (a)&nbsp;no Amber Material
Adverse Effect has occurred and (b)&nbsp;except as expressly contemplated by this Agreement, any Additional Agreement or in connection
with the transactions contemplated hereby and thereby, (i)&nbsp;the Amber Entities and their Affiliates have conducted the Business and
operated the Contributed Business Assets in the ordinary course in all material respects and (ii)&nbsp;none of the Amber Entities or
any of their Affiliates have taken any action that would require the consent of ARYA if taken during the period from the date of this
Agreement until the Closing pursuant to <U>Section&nbsp;6.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
<U>Tangible Personal Property; Sufficiency and Title to Assets</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Contributed Business Assets, together with any rights, materials, goods and services provided by an Amber Entity or any of its Affiliates
following the Closing pursuant to this Agreement, the Co-Development and Commercialization Agreement, the Transition Services Agreement
and the Philadelphia Facility Sublease, (i)&nbsp;constitute all of the assets (tangible or intangible), rights, materials, goods and
services that are necessary for or used in the conduct of the Business as it is conducted immediately prior to the Closing and (ii)&nbsp;will
be sufficient for the conduct of the Business in all material respects immediately following the Closing in the manner in which it is
conducted immediately prior the Closing; <U>provided</U>, <U>however</U>, that the representation and warranty set forth in this <U>Section&nbsp;4.8(a)</U>&nbsp;is
not made with respect to Intellectual Property or Computer Systems, which is the subject of <U>Section&nbsp;4.13(b)</U>&nbsp;to the extent
set forth therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
material tangible personal property Related to the Business have no defects, are in good operating condition and repair and function
in accordance with their intended uses (ordinary wear and tear excepted) and have been properly maintained, and are suitable for their
present uses and meet all specifications and warranty requirements with respect thereto, in each case, except as is not and would not
be reasonably expected to be, individually or in the aggregate, material to the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Amber Entities and their Affiliates collectively have, or as of immediately prior to the Closing will have, good and valid title to,
or a valid leasehold or other interest in, all of the tangible Contributed Business Assets, in each case free and clear of all Liens
(other than Permitted Liens).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Litigation</U>.
There is no, and since January&nbsp;1, 2019, there has been no, Actions pending against, or to the knowledge of Amber GT Parent, threatened
against, any Amber Entity or any of their respective Affiliates that relates to the Contributed Business Assets, the Assumed Business
Liabilities or the operation or conduct of the Business or otherwise against any Business Entity that, if adversely decided or resolved,
would or would reasonably be expected to be, individually or in the aggregate, material to the Business, taken as a whole. None of the
Amber Entities or any of their Affiliates is subject to or bound by any material Order that relates to the Contributed Business Assets,
the Assumed Business Liabilities or the operation or conduct of the Business, and none of the Business Entities is otherwise subject
to or bound by any material Order. As of the date of this Agreement, there are no material Actions by an Amber Entity or any of its Affiliates
that relates to the Contributed Business Assets, the Assumed Business Liabilities or the operation or conduct of the Business pending
against any other Person, and there are no other material Actions by a Business Entity pending against any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Contracts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;4.10(a)</U>&nbsp;of
the Amber Disclosure Schedules sets forth, as of the date of this Agreement, a list of the following Contracts, to which an Amber Entity
or any of its Affiliates is a party to or bound by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Gene Therapy Portfolio Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract relating to Indebtedness of any Business Entity or to the placing of a Lien (other than a Permitted Lien) on any material assets
or properties of any Business Entity or the Contributed Business Assets;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract under which any Amber Entity or any of its Affiliates is lessee of or holds or operates, in each case, any tangible property
(other than real property) related to or arising out of the Business, owned by any other Person, except for any lease or agreement under
which the aggregate annual rental payments do not exceed $250,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract under which any Amber Entity or any of its Affiliates is lessor of or permits any third party to hold or operate, in each case,
any tangible property (other than real property) related to or arising out of the Business, except for any lease or agreement under which
the aggregate annual rental payments do not exceed $250,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
(A)&nbsp;joint venture, profit-sharing, partnership, collaboration, co-promotion, commercialization, co-development, research and development
or other similar Contract related to or arising out of the Business, in each case, that requires, or would reasonably be expected to require
(based on any occurrence, development, activity or event contemplated by such Contract), aggregate payments to or from any Business Entity
in excess of $1,000,000 over the life of the Contract, (B)&nbsp;Contract Related to the Business pursuant to which Intellectual Property
owned by any Person is licensed to an Amber Entity or any of its Affiliates, (C)&nbsp;Contract related to or arising out of the Business
granting to any Person a license to Contributed Business IP (except, with respect to (A)-(C)&nbsp;of the foregoing, any material transfer
agreements, clinical trial agreements, nondisclosure agreements, services agreements, commercially available Software or technology licenses
or other Contract in which the grant of rights is incidental and not material to performance under such Contract) for any non-exclusive
licenses granted to customers of the Business in the ordinary course of business) or (D)&nbsp;Contract that provides for any sale, assignment
or transfer of ownership to or from a Third Party of Contributed Business IP that exists as of the Closing (other than assignments of
Intellectual Property created or developed by employees or contractors on behalf of the Business and any other Contact in which the grant
of rights is incidental or not material to performance under such Contract);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract that (A)&nbsp;limits or purports to limit, in any material respect, the freedom of the Business or any Business Entity to engage
or compete in any line of business or with any Person or in any area or that would so limit or purport to limit, in any material respect,
the operations of ARYA or any of its Affiliates after the Closing, (B)&nbsp;contains any exclusivity, &ldquo;most favored nation&rdquo;
or similar provisions, obligations or restrictions related to the Business or (C)&nbsp;contains any other provisions restricting or purporting
to restrict the ability of the Business or any Business Entity to sell, manufacture, develop, commercialize, test or research products,
directly or indirectly through third parties, or to solicit any potential employee or customer in any material respect or that would so
limit or purports to limit, in any material respect, ARYA or any of its Affiliates after the Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract requiring any future capital commitment or capital expenditure (or series of capital expenditures) by the Business or any Business
Entity in an amount in excess of (A)&nbsp;$250,000 annually or (B)&nbsp;$500,000 over the life of the Contract;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract requiring the Business or any Business Entity to guarantee the Liabilities of any Person (other than the Business Entities to
the extent related to the Business) or pursuant to which any Person (other than another Business Entity) has guaranteed the Liabilities
of a Business Entity, in each case in excess of $500,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract under which the Business or any Business Entity has, directly or indirectly, made or agreed to make any loan, advance, or assignment
of payment to any Person or made any capital contribution to, or other investment in, any Person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract required to be disclosed on <U>Section&nbsp;4.21</U> of the Amber Disclosure Schedules;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract with any Person (A)&nbsp;pursuant to which the Business or any Business Entity (or ARYA or any of its Affiliates after the Closing)
may be required to pay milestones, royalties or other contingent payments based on any investigation, manufacture, research, testing,
development, regulatory filings or approval, sale, distribution, commercial manufacture or other similar occurrences, developments, activities
or events or (B)&nbsp;under which any Amber Entity or any of its Affiliates granted to any Person any right of first refusal, right of
first negotiation, option to purchase, option to license or any other similar rights with respect to any Contributed Business Assets,
Business Products or any Intellectual Property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract providing for any Change of Control Payment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract for the disposition of any material assets or properties of the Business or for the acquisition of any material properties or
assets that would constitute Contributed Business Assets if held by an Amber Entity or any of its Affiliates immediately prior to the
Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
settlement, conciliation or similar Contract related to the Business or the Contributed Business Assets (A)&nbsp;the performance of which
would be reasonably likely to involve any payments after the date of this Agreement, (B)&nbsp;with an Authority or (C)&nbsp;that imposes
or is reasonably likely to impose, at any time in the future, any material, non-monetary obligations on any Business Entity (or ARYA or
any of its Affiliates after the Closing);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract with an Authority related to the Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Contract with a Material Supplier;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
other Contract that constitutes a Contributed Business Contract or a Shared Contract; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
other Contract Related to the Business, the performance of which requires either (A)&nbsp;annual payments to or from any Amber Entity
or any of its Affiliates in excess of $1,000,000 or (B)&nbsp;aggregate payments to or from any Amber Entity or any of its Affiliates in
excess of $1,000,000 over the life of the Contract and, in each case, is not terminable by the applicable Amber Entity or Affiliate thereof
without penalty upon less than thirty (30) days&rsquo; prior written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Contract disclosed or required to be disclosed pursuant to <U>Section&nbsp;4.10(a)</U>&nbsp;(each, a &ldquo;<U>Material Business Contract</U>&rdquo;)
represents the valid and binding obligation of an Amber Entity or an Affiliates thereof and, to the knowledge of Amber GT Parent, represents
the valid and binding obligations of the other parties thereto, and is in full force and effect, and none of the Amber Entities, any of
their Affiliates or, to the knowledge of Amber GT Parent, any other party thereto, is in material breach or default (whether with or without
the passage of time or the giving of notice or both) under the terms of any such Material Business Contract. None of the Amber Entities
or any of their Affiliates has assigned, delegated, or otherwise transferred any of their material rights or obligations with respect
to any Material Business Contracts, or granted a power of attorney with respect thereto. The Amber Entities have made available to ARYA
true, correct and complete copies of each Material Business Contract as of the date of this Agreement. As of the date hereof, none of
the Amber Entities or any of their Affiliates has received any written, or to the knowledge of Amber GT Parent, oral notice to terminate
any Material Business Contracts or to amend in any material respect, or not renew any Material Business Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.11</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Licenses
and Permits</U>. <U>Section&nbsp;4.11</U> of the Amber Disclosure Schedules contains a true, correct and complete list of each material
Permit that is required for the ownership or use of the Contributed Business Assets or the operation or conduct of the Business, in each
case as conducted or owned by an Amber Entity or any of its Affiliates on the date hereof (collectively, the &ldquo;<U>Business Permits</U>&rdquo;),
together with the name of the Authority issuing the same and the holder of the Business Permit. The Business Permits are valid and in
full force and effect, and none of the Business Permits will be terminated or become terminable as a result of the transactions contemplated
hereby, except, in each case, as has not resulted in and would not reasonably be expected to result in, individually or in the aggregate,
an Amber Material Adverse Effect. The Amber Entities and their Affiliates have all Business Permits necessary to operate the Business
in the manner in which it is now operated, except where the absence of such permit has not resulted in and would not reasonably be expected
to result in, individually or in the aggregate, an Amber Material Adverse Effect. None of the Amber Entities or any of their Affiliates
is in default or violation of any term, condition or provision of any Business Permit, except as has not resulted in and would not reasonably
be expected to result in, individually or in the aggregate, an Amber Material Adverse Effect. Since January&nbsp;1, 2019, none of the
Amber Entities or their Affiliates has received any written notice of any Action or investigation relating to the revocation, nonrenewal,
suspension or modification of any Business Permit, except as has not resulted in and would not reasonably be expected to result in, individually
or in the aggregate, an Amber Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Laws</U>. Subject to <U>Section&nbsp;4.14</U>, the Amber Entities and their Affiliates are, and since January&nbsp;1, 2019, have
been, in compliance in all material respects with all applicable Laws and Orders (to the extent applicable or related to their ownership
of the Contributed Business Assets or the operation or conduct of the Business). Since January&nbsp;1, 2019, to the extent applicable
to its ownership of the Contributed Business Assets or the operation or conduct of the Business, none of the Amber Entities or their
Affiliates has received any notice of or, to the knowledge of Amber GT Parent, been charged with any violation of any Laws, except as
is not and would not reasonably be expected to be, individually or in the aggregate, material to the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.13</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;4.13</U>
of the Amber Disclosure Schedules sets forth a true, correct and complete list, as of the date hereof, of all registered, patented or
applied for Intellectual Property (including domain names) that are Contributed Business IP and owned by any Amber Entity or its Affiliates
(whether exclusively or jointly with another Person) specifying as to each, as applicable: (A)&nbsp;the nature of such Intellectual Property
(e.g., whether a Patent, Trademark, Copyright, or domain name); (B)&nbsp;the owner of such Intellectual Property; (C)&nbsp;the jurisdictions
by or in which such Intellectual Property has been issued or registered or in which an application for such issuance or registration has
been filed; (D)&nbsp;the applicable registration or serial number of such Intellectual Property; and (E)&nbsp;where such Intellectual
Property is jointly owned with any other Person, the applicable joint owner. Since January&nbsp;1, 2019, none of the Amber Entities or
their Affiliates (to the extent applicable to their ownership of the Contributed Business IP or the operation or conduct of the Business)
have received any written claims or been a party to any Action contesting the validity, use, ownership, enforceability or registrability
of any of the Contributed Business IP. All of the registered Contributed Business IP is subsisting and, to the knowledge of Amber GT Parent,
enforceable, valid and in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Business, the Amber Entities and
their Affiliates exclusively own and possess, and the Company or another Business Entity will (i)&nbsp;exclusively own and possess at
Closing, all right, title and interest to and in all Owned Intellectual Property that is Contributed Business IP, and (ii)&nbsp;at Closing
have the right to use pursuant to the Co-Development and Commercialization Agreement, the Intellectual Property License, the Transition
Services Agreement or a valid and enforceable written Contract set forth in <U>Section&nbsp;4.13(b)</U>&nbsp;of the Amber Disclosure Schedules
all other Intellectual Property used in or held for use by the Amber Entities in the Business, all of which Intellectual Property in clauses&nbsp;(i)&nbsp;and
(ii)&nbsp;includes all Intellectual Property necessary for or material to the operation or conduct of the Business as currently conducted
and as currently proposed to be conducted by the Amber Entities and their Affiliates, in the case of clause (i), free and clear of all
Liens (other than Permitted Liens; <U>provided</U> that this <U>Section&nbsp;4.13(b)</U>&nbsp;is not a representation or warranty with
respect to infringement, misappropriation or other violation of Intellectual Property).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(i)&nbsp;Since
January&nbsp;1, 2019, none of the Amber Entities or their Affiliates (to the extent applicable to their ownership of the Contributed Business
IP or the operation or conduct of the Business) has been charged in, or been a defendant, in any Action, or received any written notice,
relating to any actual, alleged or suspected infringement, misappropriation or violation of any Intellectual Property of any third party
by an Amber Entity or its Affiliates; (ii)&nbsp;there is no other material claim currently pending against any Amber Entity or its Affiliates
of infringement of any Intellectual Property of a third party by any Amber Entity or its Affiliates related to or arising out of the Business;
and (iii)&nbsp;to the knowledge of Amber GT Parent, as of the date hereof, there is currently no continuing, and since January&nbsp;1,
2019 there has not been any, infringement, misappropriation, or violation by any other Person of any Owned Intellectual Property used
or held for use in the Business or other Contributed Business IP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">To
the knowledge of Amber GT Parent, as of the date hereof, neither the current operation or current conduct of the Business nor the current
use by the Amber Entities or their Affiliates of any Owned Intellectual Property that is Contributed Business IP infringes, misappropriates,
or violates, and has not since January&nbsp;1, 2019 infringed, misappropriated, or violated, the Intellectual Property of any third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2019, all employees, agents, consultants or contractors of the Amber Entities or their Affiliates who have contributed
to or participated in the creation or development of any material Owned Intellectual Property exclusively used or held for use in the
Business either: (i)&nbsp;is a party to a written, valid and enforceable &ldquo;work-for-hire&rdquo; agreement under which an Amber Entity
or one of its Affiliates is deemed to be the owner or author of all Intellectual Property rights created or developed by such Person;
or (ii)&nbsp;has executed a written assignment, or by operation of law has assigned, to an Amber Entity or one of its Affiliates all right,
title and interest in and to all Intellectual Property created or developed by such Person. All employees, agents, consultants, contractors
or other Persons to whom the Amber Entities or their Affiliates have granted access to any material Trade Secrets or confidential information
included in the Contributed Business Assets are subject to obligations regarding non-disclosure and confidentiality. To the knowledge
of Amber GT Parent, no Person is in material breach of any such agreement or obligation referenced in this <U>Section&nbsp;4.13(e)</U>&nbsp;with
respect to any Intellectual Property, Trade Secrets or confidential information that is material to the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Amber Entities and their Affiliates have taken reasonable measures to safeguard and maintain the confidentiality of all Trade Secrets
and other Owned Intellectual Property that are confidential and material to the operation or conduct of the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.14</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Information
Technology and Data Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as is not and would not reasonably be expected to be, individually or in the aggregate, material to the Business, to the extent applicable
to the operations of the Contributed Business Assets in the operation or conduct of the Business, (i)&nbsp;all Computer Systems are in
good operating condition and operate in accordance with their applicable documentation in all material respects, and (ii)&nbsp;to the
knowledge of Amber GT Parent, none of the Computer Systems contains any Disabling Code. The Amber Entities and their Affiliates (to the
extent applicable to their ownership of the Contributed Business Assets in the operation or conduct of the Business) employ commercially
reasonable protection and security measures (including commercially reasonable physical, organizational and technological measures) designed
to protect the confidentiality, integrity and security of the Computer Systems and designed to detect and safeguard against Disabling
Code. The Amber Entities and their Affiliates have in place business continuity and disaster recovery plans that are designed to minimize
and mitigate the occurrence, duration and effect of any unscheduled unavailability of the Computer Systems to the extent related to the
operation or conduct of the Business. Except as is not and would not reasonably be expected to be, individually or in the aggregate, material
to the Business, to the knowledge of Amber GT Parent, to the extent related to the operation or conduct of the Business, there have been
no (i)&nbsp;successful unauthorized intrusions or breaches of the security of the Computer Systems, (ii)&nbsp;prolonged periods of unscheduled
unavailability of the Computer Systems, or (iii)&nbsp;failures, breakdowns or continued substandard performance of the Computer Systems,
in each case that have caused any substantial disruption or interruption in or to the use of the Computer Systems, taken as a whole.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2019, the Amber Entities and their Affiliates comply with, and have complied with, all Data Security Requirements in all
material respects in the operation or conduct of the Business. Except as is not and would not reasonably be expected to be, individually
or in the aggregate, material to the Business and to the extent applicable or related to the ownership of the Contributed Business Assets
in the operation or conduct of the Business, none of the Amber Entities or any of their Affiliates has experienced any breach of security,
phishing incident, ransomware or malware attack, or other incident in which confidential information, Trade Secrets or Personal Information,
was, or to the knowledge of Amber GT Parent, may have been, accessed, disclosed, or exfiltrated in an unauthorized manner, and none of
the Amber Entities or any of their Affiliates has received any written notices or complaints from any Person or been the subject of any
material Action with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.15</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Employees</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;4.15(a)(i)</U>&nbsp;of
the Amber Disclosure Schedules provides a true, correct and complete list of all Business Employees as of the date hereof (as such Schedule
may be updated prior to the Closing by Amber GT Parent in accordance with <U>Section&nbsp;7.1(a)</U>, the &ldquo;<U>Business Employees
List</U>&rdquo;), and <U>Section&nbsp;4.15(a)(ii)</U>&nbsp;of the Amber Disclosure Schedules provides a true, correct and complete list
of each other employee of the Amber Entities or any of their Affiliates as of the date hereof who primarily provides services to the Business.
The Business Employees List also sets forth a true, correct and complete list, in all material respects, of the following information
for each such Business Employee as of the date hereof (and without, for the avoidance of doubt, giving effect to any updates pursuant
to <U>Section&nbsp;7.1(a)</U>&nbsp;after the date hereof): (i)&nbsp;employee identification number, (ii)&nbsp;current job title, (iii)&nbsp;current
annual salary or hourly rate of pay, as applicable, (iv)&nbsp;annual target incentive compensation opportunity, (v)&nbsp;primary work
location, (vi)&nbsp;hire date, (vii)&nbsp;leave status (including type of leave, start date and anticipated return date (if known)), (viii)&nbsp;work
visa details (including type of work visa, dates of validity and sponsoring entity), and (ix)&nbsp;accrued, unused vacation, in each case
to the extent permitted by applicable Law. To the knowledge of Amber GT Parent, no Business Employee with annualized compensation at or
above $250,000 intends to terminate his or her employment or at any time within twelve (12) months of the date hereof or has provided
notice of any such termination of employment. <U>Section&nbsp;4.15(a)(ii)</U>&nbsp;of the Amber Disclosure Schedules provides a true,
correct and complete list of all Business Contractors as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Business Employees are sufficient in number and skill to operate the Business as of immediately following the Closing in the same manner
as the Business was operated immediately prior to Closing, taking into account the services that will be provided to the Business Entities
under the Transition Services Agreement following the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">None
of the Amber Entities or any of their Affiliates (with respect to the Business Employees or to the extent applicable to their ownership
of the Contributed Business Assets or related to the operation or conduct of the Business) is a party to, bound by, or subject to any
CBA, and no Business Employees are represented by any labor union or other labor organization with respect to their employment. There
are no, and since January&nbsp;1, 2019, there have not been any actual, or, to the knowledge of Amber GT Parent, threatened unfair labor
practice charges, material labor grievances, material labor arbitrations, strikes, lockouts, work stoppages, slowdowns, picketing, hand
billing or other material labor disputes against or affecting the Amber Entities or any of their Affiliates (with respect to the Business)
or any union organizing activities with respect to the Business or any Business Employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">To
the knowledge of Amber GT Parent, no Business Employee, Business Contractor or former employee or independent contractor of the Business
is in any material respect in violation of any term of any employment agreement, nondisclosure agreement, non-competition agreement, non-solicitation
agreement, restrictive covenant or similar obligation owed to (i)&nbsp;the Amber Entities or their Affiliates (to the extent applicable
to their ownership of the Contributed Business Assets or related to the operation or conduct of the Business) or (ii)&nbsp;any third party
with respect to such Person&rsquo;s right to be employed or engaged by the Amber Entities or their Affiliates (to the extent applicable
to their ownership of the Contributed Business Assets or related to the operation or conduct of the Business).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Amber Entities and their Affiliates (with respect to the Business Employees or to the extent applicable to their ownership of the Contributed
Business Assets or related to the operation or conduct of the Business) are, and since January&nbsp;1, 2019 have been, in compliance in
all material respects with all applicable Laws respecting labor, employment and employment practices, including all Laws respecting terms
and conditions of employment, health and safety, wages and hours (including the classification of independent contractors and exempt and
non-exempt employees), immigration (including the completion of Forms I-9 for all U.S. employees), employment harassment, discrimination
or retaliation, whistleblowing, disability rights or benefits, equal opportunity, plant closures and layoffs (including the WARN Act),
employee trainings and notices, workers&rsquo; compensation, labor relations, employee leave issues, COVID-19, affirmative action and
unemployment insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not result in a material Liability, the Amber Entities and their Affiliates (with respect to the Business) have fully and timely
paid all wages, salaries, wage premiums, commissions, bonuses, fees, or other compensation that has come due and payable to all Business
Employees, Business Contractors and former employees and independent contractors of the Business under applicable Law, Contract or policy,
and each individual who is providing, or since January&nbsp;1, 2019, has provided, services for the Business and is, or was, classified
and treated as an independent contractor, consultant, leased employee, or other non-employee service provider, or exempt employee, in
each case, is, and has been, properly classified and treated as such for all applicable purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
mass layoffs, facility closures or shutdowns (whether voluntary or by Order), reductions-in-force, furloughs, temporary layoffs, material
reductions in salary or wages or other material workforce changes affecting employees or independent contractors of the Business has occurred
since March&nbsp;1, 2020, or is currently, planned or announced, as a result of COVID-19 or any Law, Order, directive, guidelines or recommendations
by any Authority in connection with or in response to COVID-19. None of the Amber Entities or any of their Affiliates (with respect to
the Business) have otherwise experienced any material employment-related liability with respect to COVID-19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.16</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Employment
Benefit Plans</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;4.16(a)</U>&nbsp;of
the Amber Disclosure Schedules sets forth a true, correct and complete list of each material Employee Benefit Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Amber Entities have provided ARYA with, to the extent applicable, (i)&nbsp;true, correct and complete copies of each material Employee
Benefit Plan, (ii)&nbsp;any related trust agreement or other funding instrument, (iii)&nbsp;the most recent IRS determination or opinion
letter, (iv)&nbsp;any summary plan description, (v)&nbsp;any non-routine correspondence with any Authority since January&nbsp;1, 2020,
relating to any Employee Benefit Plan and (vi)&nbsp;the most recent financial statements and Form&nbsp;5500 annual report (including attached
schedules).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Employee Benefit Plan (and each related trust, insurance contract or fund) has in all material respects, been funded, administered and
maintained, in form and operation, in accordance with its terms and with the applicable requirements of all applicable Law, including,
without limitation (and where applicable) ERISA and the Code. None of the Business Entities has incurred any material penalty or Tax (whether
or not assessed) under Sections 4980B, 4980D, 4980H, 6721 or 6722 of the Code and, to the knowledge of Amber GT Parent, no circumstances
or events have occurred that could reasonably be expected to result in the imposition of any such penalties or Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
contributions, premiums or other payments that are due have been paid in all material respects on a timely basis with respect to each
Employee Benefit Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Employee Benefit Plan that is intended to meet the requirements of a &ldquo;qualified plan&rdquo; under Section&nbsp;401(a)&nbsp;of the
Code has received a favorable determination letter or is entitled to rely on a favorable opinion letter from the Internal Revenue Service
to the effect that such Employee Benefit Plan meets the requirements of Section&nbsp;401(a)&nbsp;of the Code and no event has occurred
and no condition exists with respect to the form or operation of such Employee Benefit Plan which could reasonably be expected to cause
the loss of such qualified status of any such Employee Benefit Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
member of the Business Entities maintains, sponsors, contributes to or has any Liability with respect to (i)&nbsp;any pension plan that
is subject to Title IV of ERISA or (ii)&nbsp;any &ldquo;multiemployer plan&rdquo; (as such term is defined under Section&nbsp;4001(a)(3)&nbsp;of
ERISA), including as a consequence of at any time being considered a single employer under Section&nbsp;414 of the Code or Section&nbsp;4001(b)&nbsp;of
ERISA with any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Employee Benefit Plan provides nor do any Business Entities have any current or potential obligation to provide post-termination or post-ownership
health, life or other welfare benefits to Business Employees other than as required under Section&nbsp;4980B of the Code or any similar
applicable law for which the covered individual pays the full cost of coverage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as would not result in a Liability to the Business Entities, there do not exist any pending or, to the knowledge of Amber GT Parent, threatened
claims (other than routine claims for benefits), suits, actions, disputes, audits or investigations with respect to any Employee Benefit
Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the execution and delivery of this Agreement nor the consummation of the transactions contemplated by this Agreement could (alone or in
combination with any other event) (i)&nbsp;result in the forgiveness of any indebtedness of any current or former Business Employees,
(ii)&nbsp;increase the amount or value of any compensation or benefits payable to any current or former Business Employees, (iii)&nbsp;result
in the acceleration of the time of payment or vesting, or trigger any payment or funding or forfeiture of any compensation or benefits
to any current or former Business Employee under any Employee Benefit Plan or otherwise, or (iv)&nbsp;result in severance pay or any increase
in severance pay upon any termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
the execution and delivery of this Agreement nor the approval or consummation of the transactions contemplated by this Agreement could
(either alone or in connection with any event) result in any payment or benefit (whether in cash or property or the vesting of property)
to any &ldquo;disqualified individual&rdquo; (within the meaning of Section&nbsp;280G of the Code) that could, individually or in combination
with any other such payment, constitute an &ldquo;excess parachute payment&rdquo; (within the meaning of Section&nbsp;280G(b)(1)&nbsp;of
the Code).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Employee Benefit Plan that is a &ldquo;non-qualified deferred compensation plan&rdquo; (as such term is defined in Section&nbsp;409A(d)(1)&nbsp;of
the Code) has been maintained, in all material respects in form and operation in compliance with the requirements of Section&nbsp;409A
of the Code and applicable guidance issued thereunder and, to the knowledge of Amber GT Parent, no amount under any such Employee Benefit
Plan is or has been subject to the interest and additional Tax set forth under Section&nbsp;409A(a)(1)(B)&nbsp;of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Business Entity has any obligation to make a &ldquo;gross-up&rdquo; or similar payment in respect of any Taxes or related interest or
penalties that may become payable under Section&nbsp;4999 or 409A of the Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.17</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Real
Property.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;4.17(a)</U>&nbsp;of
the Amber Disclosure Schedules sets forth the address of each Contributed Owned Real Property. With respect to each Contributed Owned
Real Property: (i)&nbsp;an Amber Entity or one of its Affiliates (as the case may be) has good and marketable indefeasible fee simple
title to such Contributed Owned Real Property, free and clear of all liens and encumbrances, except Permitted Liens: (ii)&nbsp;except
as set forth in <U>Section&nbsp;4.17(a)</U>&nbsp;of the Amber Disclosure Schedules, none of the Amber Entities or their Affiliates has
leased or otherwise granted to any Person the right to use or occupy such Contributed Owned Real Property or any portion thereof; and
(iii)&nbsp;other than the right of the Company pursuant to this Agreement, there are no outstanding options, rights of first offer or
rights of first refusal to purchase such Contributed Owned Real Property or any portion thereof or interest therein. None of the Amber
Entities or their Affiliates is a party to any agreement or option to purchase any real property or interest therein related to or arising
out of the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;4.17(b)</U>&nbsp;of
the Amber Disclosure Schedules sets forth the address of each Contributed Leased Real Property and a true, correct and complete list of
all Leases (including the date and name of the parties to such Lease). The Amber Entities have delivered to ARYA a true, correct and complete
copy of each such Lease document (including all amendments, extensions, renewals, guaranties and other agreements with respect thereto).
With respect to each Lease: (i)&nbsp;such Lease is valid, binding and in full force and effect, subject to the Remedies Exception and
Permitted Liens; (ii)&nbsp;there exists no breach, default or event of default thereunder by any of the Amber Entities or any of their
Affiliates party thereto; (iii)&nbsp;none of the parties to such Lease is in breach or default under such Lease and no party to such Lease
has received notice of default or termination thereunder, and no event has occurred or circumstance exists which, with the delivery of
notice, the passage of time or both, would constitute a breach or default, or permit the termination, modification or acceleration of
rent under such Lease; (iv)&nbsp;none of the Amber Entities or their Affiliates has subleased, licensed or otherwise granted any Person
the right to use or occupy the Contributed Leased Real Property or any portion thereof; and (v)&nbsp;none of the Amber Entities or any
of their respective Affiliates has collaterally assigned or granted any other security interest in such Lease or any interest therein.
The Contributed Leased Real Property is in a state of maintenance and repair in all material respects adequate and suitable for the purposes
for which it is presently being used in all material respects, and there are no material repair or restoration works likely to be required
in connection with any of the Contributed Leased Real Property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Contributed Real Property comprises all of the real property used or intended to be used in, or otherwise related to, the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.18</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Tax
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
material Tax Returns required to be filed by or in respect of the Business have been duly and timely filed and all such Tax Returns are
true, correct and complete in all material respects. All material amounts of Taxes due and owing by or in respect of Amber GT Parent or
any of its Affiliates related to the Business have been duly and timely paid in full to the appropriate Taxing Authority (or are being
contested in good faith by appropriate proceedings, in each case for which adequate reserves have been established with respect to such
Taxes in the Financial Statements in accordance with GAAP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of Amber GT Parent and its Affiliates has (i)&nbsp;complied in all material respects with all applicable Laws relating to the reporting,
payment, collection and withholding of Taxes and (ii)&nbsp;duly and timely withheld or collected and paid over to the appropriate Taxing
Authority all material Taxes required to be withheld or collected by them, in each case, to the extent related to the operation or conduct
of the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
is no Action with respect to a material amount of Taxes of Amber GT Parent or any of its Affiliates, in each case which Taxes relate to
or arise out of the Business, that is currently pending or ongoing, or that has been threatened in writing, and has not been fully resolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
statute of limitations in respect of the assessment or collection of any material Taxes of Amber GT Parent or any of its Affiliates related
to the Business has been waived or extended, which waiver or extension is in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
is no Lien (other than Liens for Taxes not yet due and payable or that may be paid without penalty or other Permitted Liens) for Taxes
related to or arising out of the Business upon any of the assets of Amber GT Parent or any of its Affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
claim or Action has been made in writing or commenced by a Taxing Authority in a jurisdiction where Amber GT Parent or any of its Affiliates
has not paid any Tax or filed Tax Returns, in each case related to or arising out of the Business, asserting that Amber GT Parent or such
Affiliate is or may be subject to Tax or required to file Tax Returns in such jurisdiction related to or arising out of the Business.
None of the Business Entities currently has a permanent establishment (as defined in an applicable Tax treaty) or other fixed place of
business in a country other than the country in which it is organized. None of the Business Entities is required to pay Taxes on its net
income in any country other than its country of organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Business Entity is a party to any Tax Sharing Agreement (other than an Ordinary Course Tax Sharing Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
election under Treasury Regulation Section&nbsp;301.9100-22 (or any similar provision of state, local, or non-U.S. Laws) has been made
with respect to the Business Entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">None
of the Business Entities will be required to include any material item of income in, or exclude any material item of deduction from, taxable
income for any taxable period (or portion thereof) ending after the Closing Date as a result of any (i)&nbsp;change in method of accounting
made prior to the Closing or use of an improper method of accounting for a taxable period (or portion thereof) ending on or prior to the
Closing Date, (ii)&nbsp;&ldquo;closing agreement&rdquo; as described in Section&nbsp;7121 of the Code (or any similar provision of state,
local or non-U.S. Law) executed prior to the Closing, (iii)&nbsp;intercompany transactions occurring, or any excess loss account existing,
prior to the Closing, in each case as described in Treasury Regulations under Section&nbsp;1502 of the Code (or any similar provision
of state, local or non-U.S. Law), (iv)&nbsp;installment sale or open transaction disposition made prior to the Closing or (v)&nbsp;prepaid
amount or advanced payment received outside of the ordinary course of business, or deferred revenue accrued, prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of the Business Entities is registered for the purposes of sales Tax, use Tax, value-added Taxes, or any similar Tax in all jurisdictions
where it is required by Law to be so registered, and has complied in all material respects with all Laws relating to such Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">None
of the Business Entities (i)&nbsp;has engaged or participated in any &ldquo;listed transaction&rdquo; within the meaning of Section&nbsp;6707A(c)(2)&nbsp;of
the Code and applicable Treasury Regulations thereunder, (ii)&nbsp;has any Liability for material Taxes of any Person (other than Amber
GT Parent or any of its Affiliates) under Treasury Regulation Section&nbsp;1.1502-6 (or any similar provision of state, local or non-U.S.
Law), as a result of being (or having been) a member of an affiliated, consolidated, unitary, or other group for applicable Tax purposes,
as a transferee or successor, by Contract or otherwise, or (iii)&nbsp;is subject to or has requested any private letter ruling (or similar
ruling) from any Taxing Authority that is still in effect (or pending if requested).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the two (2)&nbsp;years prior to the date of this Agreement, no Business Entity has been a &ldquo;distributing corporation&rdquo; or a
 &ldquo;controlled corporation&rdquo; (as such terms are used in Section&nbsp;355 of the Code) in a distribution intended or purported
to qualify in whole or in part for Tax-deferred treatment under Section&nbsp;355 of the Code (or so much of Section&nbsp;356 of the Code
as relates to Section&nbsp;355 of the Code).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(i)&nbsp;None
of the Business Entities has deferred any &ldquo;applicable employment taxes&rdquo; (as defined in Section&nbsp;2302(d)(1)&nbsp;of the
CARES Act) that may be deferred pursuant to Section&nbsp;2302 of the CARES Act; (ii)&nbsp;none of the Business Entities has deferred any
payroll Tax obligations (including those imposed by Sections 3101(a)&nbsp;and 3201 of the Code) pursuant to or in connection with the
Payroll Tax Executive Order; and (iii)&nbsp;none of the Business Entities nor any Affiliate that would be aggregated with such Business
Entity and treated as one employer for purposes of Section&nbsp;2301 of the CARES Act, has sought or obtained, or intends to seek or obtain
a covered loan under paragraph (36) of Section&nbsp;7(a)&nbsp;of the Small Business Act (15 U.S.C. 636(a)), as added by Section&nbsp;1102
of the CARES Act. To the extent applicable, each Business Entity has properly complied in all material respects with all Laws and duly
accounted for any available Tax credits under Sections 7001 through 7005 of the FFCRA and Section&nbsp;2301 of the CARES Act or any similar
provision of state or local Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">None
of the Business Entities (nor any predecessor thereof) was in existence prior to January&nbsp;1, 1994.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.19</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Environmental
Laws</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as has not resulted in and would not reasonably be expected to result in, individually or in the aggregate, an Amber Material Adverse
Effect, to the extent applicable to their ownership or operation of the Contributed Business Assets or the operation or conduct of the
Business: (i)&nbsp;the Amber Entities and their Affiliates are currently and since January&nbsp;1, 2019, have been in compliance with
all Environmental Laws; (ii)&nbsp;without limiting the generality of the foregoing, the Amber Entities and their Affiliates have, since
January&nbsp;1, 2019, obtained, maintained and complied with, and are currently in compliance with, all Permits required pursuant to Environmental
Laws for the ownership or use of the Contributed Business Assets or the operation or conduct of the Business; (iii)&nbsp;none of the Amber
Entities or any of their respective Affiliates has received any notice, report or other information regarding any actual or alleged violation
of or Liabilities under any Environmental Laws; (iv)&nbsp;there are no Actions pending or, to the knowledge of Amber GT Parent, threatened
against any Amber Entity or any of its Affiliates with respect to violations of or Liabilities under Environmental Laws; (v)&nbsp;none
of the Amber Entities, nor any of their predecessors or Affiliates, has treated, stored, disposed of, arranged for or permitted the disposal
of, transported, handled or released, owned or operated any property or facility contaminated by, or exposed any Person to any Hazardous
Material so as to give rise to Liabilities under any Environmental Laws; and (vi)&nbsp;none of the Amber Entities or any of their respective
Affiliates has assumed, undertaken, become subject to or provided an indemnity with respect to any Liability of any other Person relating
to Environmental Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Amber Entities have delivered to ARYA all environmental and occupational safety and health related audits, assessments, reports and other
material documents relating to the Business, the Contributed Business Assets or the current or former facilities or operations of the
Business Entities that are in their possession or reasonable control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.20</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Insurance</U>.
<U>Section&nbsp;4.20</U> of the Amber Disclosure Schedules sets forth a true, correct and complete list of all material insurance policies
owned or held by a Business Entity or that otherwise provides for coverage of the Business or any of the Contributed Business Assets (the
 &ldquo;<U>Business Insurance Policies</U>&rdquo;). All such policies are in full force and effect, all premiums due and payable thereon
have been paid in full in all material respects as of the date hereof, and copies of all such policies have been made available to ARYA.
As of the date hereof, no claim by any Amber Entity or its Affiliates related to the Business or the Contributed Business Assets under
a Business Insurance Policy is pending as to which coverage has been denied or disputed, or rights reserved to do so, by the underwriters
thereof, except as is not or would not reasonably be expected to be, individually or in the aggregate, material to the Business. None
of the Amber Entities or any of their respective Affiliates is in material breach or default under the terms of any such insurance policy
(including any such breach or default with respect to the giving of notice of claims) and, to the knowledge of Amber GT Parent, no event
has occurred that (with or without notice or the lapse of time or both) would constitute a material breach or material default. As of
the date hereof, no written notice of pending material premium increase, cancellation, termination or non-renewal has been received by
any Amber Entity or any of its Affiliates with respect to any such policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.21</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Affiliate
Arrangements</U>. <U>Section&nbsp;4.21(a)</U>&nbsp;of the Amber Disclosure Schedules sets forth all Contracts between (a)&nbsp;any Business
Entity, on the one hand, and (b)&nbsp;(i)&nbsp;any Amber Entity or any of their respective Affiliates (other than, for the avoidance of
doubt any other Business Entity or the Company), (ii)&nbsp;any officer, director, employee, partner, member, manager or direct or indirect
equityholder of any such Amber Entity or Affiliate or (iii)&nbsp;any family member of the foregoing Persons, on the other hand (each Person
identified in sub-clause&nbsp;(ii)&nbsp;and (iii)&nbsp;of this clause&nbsp;(b), a &ldquo;<U>Amber Related Party</U>&rdquo;), other than
Contracts entered into after the date of this Agreement that are either permitted pursuant to <U>Section&nbsp;6.1(b)</U>&nbsp;or entered
into in accordance with <U>Section&nbsp;6.1(b)</U>. Except as set forth on <U>Section&nbsp;4.21(b)</U>&nbsp;of the Amber Disclosure Schedules,
no Amber Related Party: (A)&nbsp;owns any material interest in any material asset or property used in the Business; (B)&nbsp;possesses,
directly or indirectly, any material financial interest in, or is a director or executive officer of, any Person that is a Material Supplier,
vendor, partner, customer, lessor or other material business relation of the Business, (C)&nbsp;is a supplier, vendor, partner, customer,
lessor, or other material business relation of the Business or (D)&nbsp;owes any material amount to, or is owed any material amount by,
any Business Entity or the Business (other than accrued compensation, employee benefits, employee or director expense reimbursement, in
each case, in the ordinary course of business or pursuant to any transaction entered into after the date of this Agreement that is either
permitted pursuant to <U>Section&nbsp;6.1(b)</U>&nbsp;or entered into in accordance with <U>Section&nbsp;6.1(b)</U>). All Contracts, arrangements,
understandings, interests and other matters that are required to be disclosed pursuant to this <U>Section&nbsp;4.21</U> (including, for
the avoidance of doubt, pursuant to the second sentence of this <U>Section&nbsp;4.21</U>) are referred to herein as &ldquo;<U>Amber Related
Party Transactions.</U>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.22</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Certain
Business Practices</U>. To the extent applicable or related to the ownership of the Contributed Business Assets or the operation or conduct
of the Business, none of the Amber Entities or their Affiliates, nor, to the knowledge of Amber GT Parent, any director, officer, agent
or employee of such Persons (in their capacities as such) has, since January&nbsp;1, 2019, (a)&nbsp;used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses relating to political activity, (b)&nbsp;made any unlawful payment to foreign or domestic
government officials or employees, to foreign or domestic political parties or campaigns or violated any provision of the Foreign Corrupt
Practices Act of 1977 (&ldquo;<U>FCPA</U>&rdquo;), UK Bribery Act, or similar applicable Law prohibiting bribery or corruption (together
with the FCPA, &ldquo;<U>Anti-Corruption Laws</U>&rdquo;) or (c)&nbsp;made any other unlawful payment. To the extent applicable or related
to the ownership of the Contributed Business Assets or the operation or conduct of the Business, none of the Amber Entities or any of
their Affiliates, nor, to the knowledge of Amber GT Parent, any director, officer, agent or employee of the Amber Entities or their Affiliates
(nor any Person acting on behalf of any of the foregoing, but solely in his or her capacity as a director, officer, employee or agent
of the Amber Entities or their Affiliates) has, since January&nbsp;1, 2019, directly or indirectly, given or agreed to give any gift or
similar benefit to any customer, supplier, governmental employee or other Person who is or may be in a position to help or hinder the
Amber Entities or their Affiliates in connection with any actual or proposed transaction related to or arising out of the Business, in
each case in violation of any Anti-Corruption Law in any material respect. No material Action involving the Amber Entities or their Affiliates
with respect to any Anti-Corruption Law is pending or, to the knowledge of Amber GT Parent, threatened with respect to the ownership,
operation or conduct of the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.23</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Trade
Controls</U>. To the extent applicable or related to their ownership of the Contributed Business Assets or the operation or conduct of
the Business, none of the Amber Entities or their Affiliates, nor to the knowledge of Amber GT Parent, any director, officer, agent or
employee of the Amber Entities or their Affiliates (in their capacities as such) has, since January&nbsp;1, 2019, (i)&nbsp;been a Sanctioned
Person, (ii)&nbsp;been organized, resident or located in a Sanctioned Country, (iii)&nbsp;engaged in any dealings or transactions with
any Sanctioned Person or in any Sanctioned Country, or (iv)&nbsp;otherwise been in violation of Trade Controls in any material respect.
Neither the Amber Entities nor their Affiliates have received, to the extent applicable or related to their ownership of the Contributed
Business Assets or the operation or conduct of the Business, from any Authority or any other Person any notice, inquiry, or internal or
external allegation; made any voluntary or involuntary disclosure to an Authority; or conducted any internal investigation or audit, in
each case concerning any actual or potential material violation or wrongdoing related to Trade Controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.24</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Material
Suppliers</U>. <U>Section&nbsp;4.24</U> of the Amber Disclosure Schedules sets forth a true, correct and complete list of the top ten
(10)&nbsp;largest suppliers of products or services related to or arising out of the Business to any of the Amber Entities or any of their
Affiliates, based on amounts paid or payable with respect to (x)&nbsp;the twelve (12)-month period ending December&nbsp;31, 2020, and
(y)&nbsp;for the six (6)-month period ending June&nbsp;30, 2021 (each, a &ldquo;<U>Material Supplier</U>&rdquo;). None of the Amber Entities
or their Affiliates (i)&nbsp;is, or has been since December&nbsp;31, 2019, engaged in any material dispute with any Material Supplier,
or (ii)&nbsp;has received any written notice from any Material Supplier indicating that it intends to cancel, terminate, materially reduce
or otherwise adversely modify in any material respect its relationship in respect to the Business or the Business Entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.25</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt"><U>Regulatory
Compliance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
Regulatory Permits and applications for Regulatory Permits submitted by or in respect of the Business have been duly and timely submitted
and are true, correct and complete in all respects, and all materials made available to ARYA with respect to the Regulatory Permits, including
the plans, status, and results of development, investigation, manufacture, analysis, and other activities intended to support any Regulatory
Permit are true, correct and complete in all respects, except, in each case, as has not resulted in and would not reasonably be expected
to result in, individually or in the aggregate, an Amber Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Amber Entities and all Affiliates and, to the knowledge of Amber GT Parent, each third party that is a manufacturer, contractor or agent
for any Business Product are in compliance in all material respects with all necessary Regulatory Permits (to the extent applicable to
their ownership of the Contributed Business Assets or related to the operation or conduct of the Business), and no event, circumstance
or state of facts has occurred which (with or without due notice or lapse of time or both) would reasonably be expected to result in the
failure to be in compliance in all material respects with the terms of any such Regulatory Permit required by the FDA or any other Authority
under the Public Health Laws or any other comparable Laws. To the knowledge of Amber GT Parent, as of the date hereof, neither FDA nor
any other Authority is considering limiting, suspending or revoking any Regulatory Permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
Gene Therapy Products are being and have been developed, investigated, manufactured, prepared, packaged, tested, labeled and distributed
in compliance in all material respects with the Public Health Laws or any other applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
is (and since January&nbsp;1, 2019, there has been) no material Action or, to the knowledge of Amber GT Parent threatened against the
Amber Entities and their Affiliates related to compliance with Public Health Laws, to the extent applicable to their ownership of the
Contributed Business Assets or related to the operation or conduct of the Business. None of the Amber Entities or any of their Affiliates
has, and since January&nbsp;1, 2019, has not had, any material Liabilities for failure to comply with any Public Health Laws (to the extent
applicable to their ownership of the Contributed Business Assets or related to the operation or conduct of the Business).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2019, none of the Amber Entities or any of their respective Affiliates or any third party that is a manufacturer, contractor
or agent for any Business Product or any component thereof has undergone, or to the knowledge of Amber GT Parent, is currently undergoing,
any inspection related to any Business Product&nbsp;or any other Authority investigation under any Public Health Law (to the extent applicable
to their ownership of the Contributed Business Assets or related to the operation or conduct of the Business).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2019, no clinical trial site conducting a clinical trial sponsored by or on behalf of any Amber Entity or any Affiliate
thereof has undergone, or is undergoing any inspection related to any Business Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
January&nbsp;1, 2019, no Business Products have been distributed that were upon their shipment by any Amber Entity adulterated or misbranded
in violation of 21 U.S.C. &sect;&nbsp;331 or any other Authority&rsquo;s jurisdiction. No Business Products have been seized, withdrawn
or recalled, and no Business Products have been detained or subject to a suspension of research, manufacturing or distribution (other
than in the ordinary course of business), and to the knowledge of Amber GT Parent, there are no facts or circumstances reasonably likely
to cause (i)&nbsp;the seizure, denial, withdrawal, recall, detention, public health notification, safety alert or suspension of manufacturing
or other activity relating to any Business Product or (ii)&nbsp;a termination, seizure or suspension of researching, clinical investigation,
manufacturing or distributing of any Business Product, in either case, except as has not resulted in and would not reasonably be expected
to result in, individually or in the aggregate, an Amber Material Adverse Effect. As of the date of this Agreement, no proceedings in
the United States or any other jurisdiction seeking the withdrawal, recall, revocation, suspension, import detention or seizure of any
Business Product are pending or, to the knowledge of Amber GT Parent, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 5 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
Amber Entity or, to the knowledge of Amber GT Parent, any of its directors, officers, employees, individual independent contractors or
other service providers, including clinical trial investigators, coordinators, monitors, Business Products or services, (i)&nbsp;have
been excluded, disqualified, or debarred from any federal healthcare program (including Medicare or Medicaid) or any other federal program
or any other healthcare program or reimbursement regulation or agreement or (ii)&nbsp;have received notice from the FDA, any other Authority
or any health insurance institution with respect to debarment, disqualification (to the extent applicable to their ownership of the Contributed
Business Assets or related to the operation or conduct of the Business). None of the Amber Entities or, to the knowledge of Amber GT Parent,
any of their officers, directors, employees, agents or contractors has been convicted of any crime or engaged in any conduct for which
(A)&nbsp;debarment is mandated or permitted by 21 U.S.C. &sect;&nbsp;335a or (B)&nbsp;such Person could be excluded from participating
in the federal healthcare programs under Section&nbsp;1128 of the Social Security Act or any similar law (to the extent applicable to
their ownership of the Contributed Business Assets or related to the operation or conduct of the Business). To the knowledge of Amber
GT Parent, no officer or other employee or agent of any Amber Entity has (x)&nbsp;made any untrue statement of material fact or fraudulent
statement to the FDA or any other Authority; (y)&nbsp;failed to disclose a material fact required to be disclosed to the FDA or any other
Authority; or (z)&nbsp;committed an act, made a statement or failed to make a statement that would reasonably be expected to provide the
basis for the FDA or any other Authority to refuse to grant a Regulatory Permit for any Business Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="sp5-a_001"></A><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;V<BR>
REPRESENTATIONS AND WARRANTIES OF ARYA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to (a)&nbsp;<U>Section&nbsp;11.11</U>,
except as set forth in the ARYA Disclosure Schedules, or (b)&nbsp;except as set forth in any ARYA SEC Document (excluding any disclosures
in any &ldquo;risk factors&rdquo; section that do not constitute statements of fact, disclosures in any forward-looking statements disclaimers
and other disclosures that are generally cautionary, predictive or forward-looking in nature), ARYA hereby represents and warrants to
the Amber Entities, in each case, as of the date of this Agreement and as of the Closing, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_002"></A>5.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Existence
and Power</U>. ARYA is a corporation, limited liability company, limited partnership or other applicable business entity duly incorporated,
organized or formed, as applicable, validly existing in good standing (or the equivalent thereof, if applicable, with respect to the jurisdictions
that recognize the concept of good standing or any equivalent thereof) under the Laws of its jurisdiction of incorporation, organization
or formation, as applicable. ARYA has all power and authority, corporate and otherwise, and all material Permits and Consents required
to own and operate its properties and assets and to carry on its business as presently conducted, except as has not resulted in and would
not reasonably be expected to result in, individually or in the aggregate, an ARYA Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_003"></A>5.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authority</U>.
ARYA has the requisite corporate, limited liability company or other similar power and authority to execute and deliver this Agreement
and each Additional Agreement to which it is or will be a party, to perform its covenants, agreements and obligations hereunder and thereunder
and to consummate the transaction contemplated hereby and thereby. Subject to the receipt of the ARYA Shareholder Approval, the execution
and delivery by ARYA of this Agreement, the execution and delivery by ARYA of the Additional Agreements to which it is, or will be, a
party, the performance by ARYA under this Agreement or any Additional Agreements, and the consummation by ARYA of the transactions contemplated
hereby or thereby, are within the respective corporate, limited liability company or other similar powers and authority of ARYA and have
been duly authorized by all necessary corporate (or similar) action on the part of ARYA. This Agreement constitutes, and, upon their execution
and delivery, each of the Additional Agreements to which ARYA, is, or will be, a party, will constitute, a valid and legally binding agreement
of ARYA (assuming that this Agreement and the Additional Agreements to which ARYA or any of its Affiliates is or is contemplated to be
a party are or will be upon execution thereof, as applicable, duly authorized, executed and delivered by the other Persons party thereto),
enforceable against ARYA, in accordance with their respective terms, subject to the Remedies Exception.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_004"></A>5.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governmental
Authorization</U>. Except as set forth on <U>Section&nbsp;5.3</U> of the ARYA Disclosure Schedules, no Consent of any Authority is required
on the part of ARYA with respect to ARYA&rsquo;s execution, delivery or performance of its covenants, agreements or obligations under
this Agreement or the Additional Agreements to which it is or will be party or the consummation of the transactions contemplated hereby
or thereby, except for (a)&nbsp;compliance with and filings under the HSR Act, (b)&nbsp;the filing with the SEC of (i)&nbsp;the Registration
Statement / Proxy Statement and the declaration of the effectiveness thereof by the SEC and (ii)&nbsp;such reports under Section&nbsp;13(a)&nbsp;or
15(d)&nbsp;of the Exchange Act as may be required in connection with this Agreement, the Additional Agreements or the transactions contemplated
hereby or thereby, (c)&nbsp;such filings with and approvals of Nasdaq to permit the ARYA Class&nbsp;A Shares to be issued in connection
with the transactions contemplated by this Agreement and the other Additional Agreements to be listed on Nasdaq, (d)&nbsp;such filings
and approvals required in connection with the Domestication, (e)&nbsp;the ARYA Shareholder Approval and the ARYA Sponsor Consent or (f)&nbsp;any
other consents, approvals, authorizations, designations, declarations, waivers or filings, the absence of which, in each of clauses&nbsp;(a)&nbsp;through
(f), has not resulted in and would not reasonably be expected to result in, individually or in the aggregate, an ARYA Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_005"></A>5.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Non-Contravention</U>.
Except as set forth on <U>Section&nbsp;5.4</U> of the ARYA Disclosure Schedules, none of the execution or delivery by ARYA of this Agreement,
the execution or delivery by ARYA of any Additional Agreement to which it is or will be a party, the performance by ARYA under this Agreement
or any Additional Agreements, as applicable, or the consummation of the transactions contemplated hereby or thereby, as applicable, does
or will, directly or indirectly (with or without due notice or lapse of time or both) (a)&nbsp;contravene or conflict with any Governing
Documents of ARYA, (b)&nbsp;violate, or constitute a breach under, any Law or Order to which ARYA or any of its properties or assets are
subject or bound, (c)&nbsp;result in a violation or breach of, or constitute a default or give rise to any right of termination, Consent,
cancellation, amendment, modification, suspension, revocation or acceleration under, any of the terms, conditions or provisions of any
Contract or Permits to which ARYA is a party or bound, as applicable, or (d)&nbsp;result in the creation or imposition of any Lien (other
than Permitted Liens) on any of ARYA&rsquo;s assets, except, in the case of clauses&nbsp;(b)&nbsp;through (d), as has not resulted in
and would not reasonably be expected to result in, individually or in the aggregate, an ARYA Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_006"></A>5.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Finders&rsquo;
Fees</U>. Except as set forth on <U>Section&nbsp;5.5</U> of the ARYA Disclosure Schedules, there is no investment banker, broker, finder
or other intermediary that has been retained by or on behalf of ARYA or any of its Affiliates who is or may be entitled to any fee, commission
or other payment or consideration in connection with the consummation of the transactions contemplated by this Agreement or the Additional
Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_007"></A>5.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Section&nbsp;5.6(a)</U>&nbsp;of
the ARYA Disclosure Schedules sets forth a true, correct and complete statement of the number and class or series (as applicable) of the
issued and outstanding prior to ARYA Shares prior to the consummation of the Domestication. As of the date hereof, no other shares of
capital stock or other Equity Securities of ARYA are issued, reserved for issuance or outstanding. All issued and outstanding ARYA Shares
(except to the extent such concepts are not applicable under the applicable Law of ARYA&rsquo;s jurisdiction of organization, incorporation
or formation, as applicable, or other applicable Law) prior to the consummation of the Domestication (i)&nbsp;have been duly authorized,
validly issued, fully paid and nonassessable, (ii)&nbsp;were not issued in violation of ARYA&rsquo;s Governing Documents or in material
violation of any other Contract to which ARYA is bound, (iii)&nbsp;were not issued in material violation of any preemptive rights, call
option, right of first refusal or first offer, subscription rights, transfer restrictions or similar rights of any Person, and (iv)&nbsp;have
been offered, sold and issued in compliance in all material respects with applicable Law, including securities Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Immediately
after the Closing, (i)&nbsp;the authorized capital stock of ARYA will consist of 250,000,000 Class&nbsp;A Shares, 70,000,000 Class&nbsp;B
Shares and 12,500,000 shares of preferred stock, par value $0.0001, and (ii)&nbsp;all of the issued and outstanding ARYA Shares (A)&nbsp;will
be duly authorized, validly issued, fully paid and nonassessable, (B)&nbsp;will have been issued in compliance in all material respects
with applicable Law and (C)&nbsp;will not have been issued in breach or violation of any preemptive rights or Contract to which ARYA is
a party or bound in any material respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as contemplated by this Agreement, the Additional Agreements or the transactions contemplated hereby or thereby or as otherwise either
permitted pursuant to <U>Section&nbsp;6.2</U> or issued, granted or entered into, as applicable, in accordance with <U>Section&nbsp;6.2</U>,
or as set forth on <U>Section&nbsp;5.6(c)</U>&nbsp;of the ARYA Disclosure Schedules, there are no outstanding (i)&nbsp;subscriptions,
calls, options, warrants, rights or other securities convertible into or exchangeable or exercisable for shares of ARYA Shares or the
equity interests of ARYA, or any other Contracts to which ARYA is a party or by which ARYA is bound obligating ARYA to issue or sell any
shares of capital stock of, other equity interests in, or debt securities of, ARYA and (ii)&nbsp;no equity equivalents, stock appreciation
rights, phantom stock ownership interests or similar rights in ARYA. Except as set forth in ARYA&rsquo;s Governing Documents or as contemplated
by this Agreement, the Additional Agreements or the transactions contemplated hereby or thereby or as otherwise either permitted pursuant
to <U>Section&nbsp;6.2</U> or entered into in accordance with <U>Section&nbsp;6.2</U>, there are no outstanding contractual obligations
of ARYA to repurchase, redeem or otherwise acquire any securities or equity interests of ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><A NAME="sp5-a_008"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Company Act</U>. ARYA is not an &ldquo;investment company&rdquo; or a Person directly or indirectly &ldquo;controlled&rdquo; by or acting
on behalf of an &ldquo;investment company,&rdquo; in each case within the meaning of the Investment Company Act. ARYA constitutes an &ldquo;emerging
growth company&rdquo; within the meaning of the JOBS Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_009"></A>5.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Trust
Account</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">As
of the date hereof, ARYA has at least $149,500,000 in the trust fund established by ARYA for the benefit of its public shareholders in
a trust account (the &ldquo;<U>Trust Account</U>&rdquo;), maintained by Continental Stock Transfer&nbsp;&amp; Trust Company (the &ldquo;<U>Trustee</U>&rdquo;)
acting as trustee. The funds held in the Trust are (a)&nbsp;invested in United States &ldquo;government securities&rdquo; within the meaning
of Section&nbsp;2(a)(16) of the Investment Company Act, having a maturity of 185 days or less or in money market funds meeting certain
conditions under Rule&nbsp;2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations
and (b)&nbsp;held in trust by the Trustee pursuant to the Investment Management Trust Agreement. There are no separate agreements, side
letters or other agreements or understandings (whether written or unwritten, express or implied) that would cause the description of the
Investment Management Trust Agreement in the ARYA SEC Documents to be inaccurate, or that would entitle any Person to any portion of the
funds in the Trust Account (other than (i)&nbsp;in respect of Deferred Underwriting Commissions or Taxes, (ii)&nbsp;the holders of Equity
Securities of ARYA prior to the Closing Date who shall have elected to redeem their ARYA Class&nbsp;A Shares pursuant to the Governing
Documents of ARYA or (iii)&nbsp;if ARYA fails to complete a Business Combination within the allotted time period set forth in the Governing
Documents of ARYA and liquidates the Trust Account, subject to the terms of the Trust Agreement, ARYA (in limited amounts to permit ARYA
to pay the expenses of the Trust Account&rsquo;s liquidation, dissolution and winding up of ARYA) and then the holders of Equity Securities
of ARYA prior to the Closing Date). Prior to the Closing, none of the funds held in the Trust Account are permitted to be released, except
in the circumstances described in the Governing Documents of ARYA and the Investment Management Trust Agreement. As of the date hereof,
ARYA has performed all material obligations required to be performed by it, and is not in material breach or default, or delinquent in
performance in any material respect or any other respect (claimed or actual) in any material respect, under the Investment Management
Trust Agreement, and, to the knowledge of ARYA, no event has occurred which (with due notice or lapse of time or both) would constitute
a material default under the Investment Management Trust Agreement. As of the date of this Agreement, there are no Actions pending, or
to the knowledge of ARYA, threatened with respect to the Trust Account. Since March&nbsp;2, 2021, ARYA has not released any money from
the Trust Account (other than interest income earned on the funds held in the Trust Account as permitted by the Investment Management
Trust Agreement). Upon the consummation of the transactions contemplated hereby (including the distribution of assets from the Trust Account
(A)&nbsp;in respect of Deferred Underwriting Commissions or Taxes or (B)&nbsp;to the holders of Equity Securities of ARYA prior to the
Closing Date who have elected to redeem their ARYA Class&nbsp;A Shares pursuant to the Governing Documents of ARYA, each in accordance
with the terms of and as set forth in the Investment Management Trust Agreement), ARYA shall have no further obligation under either the
Investment Management Trust Agreement or the Governing Documents of ARYA to liquidate or distribute any assets held in the Trust Account,
and the Investment Management Trust Agreement shall terminate in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_010"></A>5.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>ARYA
SEC Documents and Financial Statements; Internal Controls</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
has filed on a timely basis all forms, reports, schedules, statements and other documents, including any exhibits thereto, required to
be filed or furnished by ARYA with the SEC since ARYA&rsquo;s formation under the Exchange Act or the Securities Act, together with any
amendments, restatements or supplements thereto (the &ldquo;<U>ARYA SEC Documents</U>&rdquo;). The ARYA SEC Documents have been prepared
in all material respects in accordance with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley
Act, as the case may be, and the rules&nbsp;and regulations thereunder. The ARYA SEC Documents did not, at the time they were filed with
the SEC (except to the extent that information contained in any ARYA SEC Document has been or is revised or superseded by a later filed
ARYA SEC Document, then on the date of such filing), contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which
they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
financial statements and notes contained or incorporated by reference in the ARYA SEC Documents (collectively, the &ldquo;<U>ARYA Financial
Statements</U>&rdquo;) (i)&nbsp;fairly present in all material respects the financial position of ARYA as at the respective dates thereof,
and the results of its operations, shareholders&rsquo; equity and cash flows for the respective periods then ended (subject, in the case
of any unaudited interim financial statements, to normal year-end audit adjustments (none of which is expected to be material) and the
absence of notes thereto), (ii)&nbsp;were prepared in conformity with GAAP applied on a consistent basis during the periods indicated
(except, in the case of any audited financial statements, as may be indicated in the notes thereto and subject, in the case of any unaudited
financial statements, to normal year-end audit adjustments (none of which is expected to be material) and the absence of notes thereto),
(iii)&nbsp;in the case of the audited ARYA Financial Statements, were audited in accordance with the standards of the PCAOB and (iv)&nbsp;comply
in all material respects with the applicable accounting requirements and with the rules&nbsp;and regulations of the SEC, the Exchange
Act and the Securities Act in effect as of the respective dates thereof (including Regulation S-X or Regulation S-K, as applicable).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as is not required in reliance on exemptions from various reporting requirements by virtue of ARYA&rsquo;s status as an &ldquo;emerging
growth company&rdquo; within the meaning of the Securities Act, as modified by the JOBS Act, or &ldquo;smaller reporting company&rdquo;
within the meaning of the Exchange Act,&nbsp;since its IPO, ARYA has (i)&nbsp;established and maintained, a system of &ldquo;internal
controls&rdquo; over financial reporting (as defined in Rule&nbsp;13a-15 and Rule&nbsp;15d-15 under the Exchange Act) designed to provide
reasonable assurance regarding the reliability in all material respects of its financial reporting and the preparation of its financial
statements for external purposes in accordance with GAAP and (ii)&nbsp;established and maintained disclosure controls and procedures (as
defined in Rule&nbsp;13a-15 and Rule&nbsp;15d-15 under the Exchange Act) designed to ensure that material information relating to ARYA
is made known to the principal executive officer and principal financial officer by others within ARYA. ARYA maintains and, for all periods
covered by ARYA Financial Statements, has maintained Books and Records in the ordinary course of business that are true, correct and complete
and reflect the revenues, expenses, assets and liabilities of ARYA in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
has not taken any action prohibited by Section&nbsp;402 of the Sarbanes-Oxley Act. There are no outstanding loans or other extensions
of credit made by ARYA to any executive officer (as defined in Rule&nbsp;3b-7 under the Exchange Act) or director of ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
is, and since the IPO through the date of this Agreement has been, in compliance in all material respects with all applicable listing
and corporate governance rules&nbsp;and regulations of Nasdaq. The ARYA Class&nbsp;A Shares outstanding as of the date hereof are registered
pursuant to Section&nbsp;12(b)&nbsp;of the Exchange Act and are listed for trading on Nasdaq. As of the date of this Agreement, there
is no Action pending or, to the knowledge of ARYA, threatened against ARYA by Nasdaq or the SEC, respectively, with respect to any intention
to deregister ARYA Class&nbsp;A Shares or prohibit or terminate the listing of the ARYA Class&nbsp;A Shares on Nasdaq. None of ARYA nor
any of its Affiliates has, as of the date hereof, taken any action that is designed to terminate the registration of ARYA Class&nbsp;A
Shares under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Since
its incorporation and through the date of this Agreement, ARYA has not received any written report, complaint, allegation, assertion or
claim that there is (i)&nbsp;a &ldquo;significant deficiency&rdquo; in the internal controls over financial reporting of ARYA, (ii)&nbsp;a
 &ldquo;material weakness&rdquo; in the internal controls over financial reporting of ARYA or (iii)&nbsp;any fraud that involves management
or other employees of ARYA who have a significant role in the internal controls over financial reporting of ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
for the Liabilities (i)&nbsp;set forth in <U>Section&nbsp;5.9(g)</U>&nbsp;of the ARYA Disclosure Schedules, (ii)&nbsp;incurred in connection
with the negotiation, preparation or execution of this Agreement or any Additional Agreement, the performance of its covenants or agreements
in this Agreement or any Additional Agreement or the consummation of the transactions contemplated hereby or thereby (including, for the
avoidance of doubt, the ARYA Expenses and any Liabilities arising out of, or related to, any Action related to this Agreement, the Additional
Agreements or the transactions contemplated hereby or thereby, including any shareholder demand or other shareholder Actions (including
derivative claims) arising out of, or related to, any of the foregoing), (iii)&nbsp;set forth or disclosed in the ARYA Financial Statements,
(iv)&nbsp;that have arisen since the date of the most recent balance sheet included in the ARYA SEC Documents in the ordinary course of
business, (v)&nbsp;that are either permitted pursuant to <U>Section&nbsp;6.2</U> or incurred in accordance with <U>Section&nbsp;6.2</U>
or (vi)&nbsp;that are not, and would not reasonably be expected to be, individually or in the aggregate, material to ARYA, ARYA does not
have any Liabilities as of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_011"></A>5.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Litigation</U>.
There are (and since its organization, incorporation or formation, as applicable, there has been) no material Actions pending against
or, to the knowledge of ARYA, threatened against or involving ARYA that, if adversely decided or resolved, has been or would reasonably
be expected to be, individually or in the aggregate, material to ARYA. As of the date of this Agreement, ARYA is not subject to or bound
by any material Order. As of the date of this Agreement, there are no material Actions by ARYA pending against any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_012"></A>5.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Business
Activities</U>. Since its incorporation, ARYA has not conducted any business activities other than activities (a)&nbsp;in connection with
or incident or related to its incorporation, initial public offering, continuing corporate (or similar) existence or its registration
under Section&nbsp;12(b)&nbsp;of the Exchange Act and continued listing on Nasdaq, (b)&nbsp;directed toward the accomplishment of a business
combination, including those incident or related to or incurred in connection with the negotiation, preparation or execution of this Agreement
or any Additional Agreement to which ARYA is or will be a party, the performance of its covenants or agreements in this Agreement or any
Additional Agreement to which ARYA is or will be a party or the consummation of the transactions contemplated hereby or thereby, or (c)&nbsp;those
that are administrative, ministerial or otherwise immaterial in nature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_013"></A>5.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Employee
Benefit Plans</U>. ARYA has never had any employees, and other than reimbursement of any out-of-pocket expenses incurred by ARYA&rsquo;s officers
and directors in connection with activities on ARYA&rsquo;s behalf in an aggregate amount not in excess of the amount of cash held by
ARYA outside of the Trust Account, ARYA does not have any unsatisfied material liability with respect to any ARYA employee. ARYA does
not maintain or have any direct or indirect liability under any employee benefit plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_014"></A>5.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Laws</U>. ARYA is (and since its organization, incorporation or formation, as applicable, has been) in compliance in all material
respects with all applicable Laws. Since its formation, none of ARYA or any of its Affiliates has received any notice of or, to the knowledge
of ARYA, been charged with any violation of any Laws, except as is not and would not reasonably be expected to be, individually or in
the aggregate, material to ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_015"></A>5.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Tax
Matters.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">All
material Tax Returns required to be filed by ARYA have been duly and timely filed and all such Tax Returns are true, correct and complete
in all material respects. All material amounts of Taxes due and owing by ARYA have been duly and timely paid in full to the appropriate
Taxing Authority (or are being contested in good faith by appropriate proceedings, in each case for which adequate reserves have been
established with respect to such Taxes in ARYA&rsquo;s financial statements in accordance with GAAP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
has (i)&nbsp;complied in all material respects with all applicable Laws relating to the reporting, payment, collection and withholding
of Taxes and (ii)&nbsp;duly and timely withheld or collected and paid over to the appropriate Taxing Authority all material Taxes required
to be withheld or collected by ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
is no Action with respect to a material amount of Taxes of ARYA that is currently pending or ongoing, or that has been threatened in writing,
and has not been fully resolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
statute of limitations in respect of the assessment or collection of any material Taxes of ARYA has been waived or extended, which waiver
or extension is in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">There
is no Lien (other than Liens for Taxes not yet due and payable or that may be paid without penalty or other Permitted Liens) for Taxes
upon any of the assets of ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
claim or Action has been made in writing or commenced by a Taxing Authority in a jurisdiction where ARYA has not paid any Tax or filed
Tax Returns asserting that ARYA is or may be subject to Tax or required to file Tax Returns in such jurisdiction. ARYA does not currently
have a permanent establishment (as defined in an applicable Tax treaty) or other fixed place of business in a country other than the country
in which it is organized. ARYA is not required to pay Taxes on its net income in any country other than its country of organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
is not a party to any Tax Sharing Agreement (other than an Ordinary Course Tax Sharing Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 93; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
is not currently nor has it ever been included in any consolidated, combined or unitary Tax Return other than a Tax Return that includes
only ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
will not be required to include any material item of income in, or exclude any material item of deduction from, taxable income for any
taxable period (or portion thereof) ending after the Closing Date as a result of any (i)&nbsp;change in method of accounting made prior
to the Closing or use of an improper method of accounting for a taxable period (or portion thereof) ending on or prior to the Closing
Date, (ii)&nbsp;&ldquo;closing agreement&rdquo; as described in Section&nbsp;7121 of the Code (or any similar provision of state, local
or non-U.S. Law) executed prior to the Closing, (iii)&nbsp;intercompany transactions occurring, or any excess loss account existing, prior
to the Closing, in each case as described in Treasury Regulations under Section&nbsp;1502 of the Code (or any similar provision of state,
local or non-U.S. Law), (iv)&nbsp;installment sale or open transaction disposition made prior to the Closing or (v)&nbsp;prepaid amount
or advanced payment received outside of the ordinary course of business, or deferred revenue accrued, prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
is registered for the purposes of sales Tax, use Tax, value-added Taxes, or any similar Tax in all jurisdictions where it is required
by Law to be so registered, and has complied in all material respects with all Laws relating to such Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
(i)&nbsp;has not engaged or participated in any &ldquo;listed transaction&rdquo; within the meaning of Section&nbsp;6707A(c)(2)&nbsp;of
the Code and applicable Treasury Regulations thereunder, (ii)&nbsp;does not have any Liability for material Taxes of any Person under
Treasury Regulation Section&nbsp;1.1502-6 (or any similar provision of state, local or non-U.S. Law), as a result of being (or having
been) a member of an affiliated, consolidated, unitary, or other group for applicable Tax purposes, as a transferee or successor, by Contract
or otherwise, or (iii)&nbsp;is not subject to and has not requested any private letter ruling (or similar ruling) from any Taxing Authority
that is still in effect (or pending if requested).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the two (2)&nbsp;years prior to the date of this Agreement, ARYA has not been a &ldquo;distributing corporation&rdquo; or a &ldquo;controlled
corporation&rdquo; (as such terms are used in Section&nbsp;355 of the Code) in a distribution intended or purported to qualify in whole
or in part for Tax-deferred treatment under Section&nbsp;355 of the Code (or so much of Section&nbsp;356 of the Code as relates to Section&nbsp;355
of the Code).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
has not (i)&nbsp;deferred any &ldquo;applicable employment taxes&rdquo; (as defined in Section&nbsp;2302(d)(1)&nbsp;of the CARES Act)
that may be deferred pursuant to Section&nbsp;2302 of the CARES Act; (ii)&nbsp;deferred any payroll Tax obligations (including those imposed
by Sections 3101(a)&nbsp;and 3201 of the Code) pursuant to or in connection with the Payroll Tax Executive Order or (iii)&nbsp;sought
or obtained, nor does ARYA intend to seek or obtain, a covered loan under paragraph (36) of Section&nbsp;7(a)&nbsp;of the Small Business
Act (15 U.S.C. 636(a)), as added by Section&nbsp;1102 of the CARES Act. To the extent applicable, ARYA has properly complied in all material
respects with all Laws and duly accounted for any available Tax credits under Sections 7001 through 7005 of the FFCRA and Section&nbsp;2301
of the CARES Act or any similar provision of state or local Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="sp5-a_016"></A>5.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Certain Changes</U>. During the period beginning June&nbsp;30, 2021 and ending on the date of this Agreement, (a)&nbsp;no ARYA Material
Adverse Effect has occurred and (b)&nbsp;except (i)&nbsp;as expressly contemplated by this Agreement or any Additional Agreement, (ii)&nbsp;in
connection with the transactions contemplated hereby and thereby, or (iii)&nbsp;in connection with or related to its formation, initial
public offering or its evaluation or analysis of other potential business combinations prior to the date hereof, neither ARYA or any
of its Affiliates has taken any action that would require the consent of Amber GT Parent if taken during the period from the date of
this Agreement until the Closing pursuant to clauses (i)&nbsp;through (iv), (vii), (viii), (xiii)&nbsp;or (xiv)&nbsp;of <U>Section&nbsp;6.2(a)</U>&nbsp;or
clause (xvi)&nbsp;of <U>Section&nbsp;6.2(a)</U>&nbsp;(to the extent related to the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="sp5-a_017"></A>5.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>PIPE
Investments</U>. ARYA has made available to Amber GT Parent true, correct and complete copies of the PIPE Subscription Agreements (each
as in effect as of the date hereof). As of the date of this Agreement, the PIPE Subscription Agreements (a)&nbsp;are in full force and
effect without amendment or modification, (b)&nbsp;are the valid, binding and enforceable obligations of ARYA (or its applicable Affiliate)
and, to the knowledge of ARYA, each other party thereto (except, in any case, as may be limited by Remedies Exceptions) and (c)&nbsp;have
not been withdrawn, terminated or rescinded in any respect. There are no other Contracts between ARYA and any PIPE Investor relating
to any PIPE Subscription Agreement that would reasonably be expected to affect the obligations of the PIPE Investors to contribute to
ARYA the applicable portion of the PIPE Investment set forth in the PIPE Subscription Agreements. As of the date hereof, assuming (i)&nbsp;the
accuracy of the representations and warranties contained in <U>Article&nbsp;III</U> and <U>Article&nbsp;IV</U>, and with respect to each
PIPE Investor (other than the Perceptive PIPE Investor), the representations and warranties of each PIPE Investor in the applicable PIPE
Subscription Agreement, in each case, in all material respects, and (ii)&nbsp;the performance or compliance by the Amber Entities of
their respective covenants, agreements and obligations to be performed or complied with at or prior to the Closing hereunder and, with
respect to each PIPE Investor (other than the Perceptive PIPE Investor), the performance by each PIPE Investor of its covenants, agreements
and obligations under the applicable PIPE Subscription Agreement, in each case, in all material respects (x)&nbsp;to the knowledge of
ARYA, no facts or circumstances exist that would reasonably be expected to result in any of the conditions set forth in any PIPE Subscription
Agreement not being satisfied or the PIPE Investment not being available to ARYA, on the Closing Date, (y)&nbsp;no event has occurred
that, with or without notice, lapse of time or both, would constitute a default or breach on the part of ARYA under any material term
or condition of any PIPE Subscription Agreement and (y)&nbsp;ARYA has no reason to believe that it will be unable to satisfy in all material
respects on a timely basis any term or condition to be satisfied by it contained in any PIPE Subscription Agreement. The PIPE Subscription
Agreements contain all of the conditions precedent (other than the conditions contained in this Agreement or the Additional Agreements)
to the obligations of the PIPE Investors to contribute to ARYA the applicable portion of the PIPE Investment set forth in the PIPE Subscription
Agreements on the terms therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_018"></A>5.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transactions
with Affiliates</U>. <U>Section&nbsp;5.17</U> of the ARYA Disclosure Schedules sets forth all Contracts between (a)&nbsp;ARYA, on the
one hand, and (b)&nbsp;any officer, director, employee, partner, member, manager, direct or indirect equityholder or Affiliate of ARYA
or any family member of any such officer, director or employee, on the other hand (each Person identified in this&nbsp;clause&nbsp;(b),
a &ldquo;<U>ARYA Related Party</U>&rdquo;), other than (i)&nbsp;Contracts with respect to an ARYA Related Party&rsquo;s employment with,
or the provision of services to, ARYA or its Affiliates that were entered into in the ordinary course of business (including with regard
to benefit plans, indemnification arrangements and other ordinary course compensation matters), (ii)&nbsp;Contracts with respect to an
ARYA Related Party&rsquo;s status as a holder of ARYA Shares or (iii)&nbsp;Contracts entered into after the date of this Agreement that
are either permitted pursuant to <U>Section&nbsp;6.2</U> or entered into in accordance with <U>Section&nbsp;6.2</U>. Except as set forth
on <U>Section&nbsp;5.17</U> of the ARYA Disclosure Schedules, no ARYA Related Party: (A)&nbsp;owns any material interest in any material
asset or property used in the business of ARYA; (B)&nbsp;possesses, directly or indirectly, any material financial interest in, or is
a director or executive officer of, any Person which is a material supplier, vendor, partner, customer, lessor or other material business
relation of ARYA, (C)&nbsp;is a supplier, vendor, partner, customer, lessor, or other material business relation of ARYA or (D)&nbsp;owes
any material amount to, or is owed any material amount by, ARYA (other than accrued compensation, employee benefits, employee or director
expense reimbursement, in each case, in the ordinary course of business or pursuant to any transaction entered into after the date of
this Agreement that is either permitted pursuant to <U>Section&nbsp;6.2(a)</U>&nbsp;or entered into in accordance with <U>Section&nbsp;6.2(a)</U>).
All Contracts, arrangements, understandings, interests and other matters that are required to be disclosed pursuant to this <U>Section&nbsp;5.17</U>
(including, for the avoidance of doubt, pursuant to the second sentence of this <U>Section&nbsp;5.17</U>) are referred to herein as &ldquo;<U>ARYA
Related Party Transactions.</U>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="sp5-a_019"></A>5.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Information
Supplied</U>. None of the information supplied or to be supplied by or on behalf of ARYA or any of its Affiliates expressly for inclusion
or incorporation by reference in the Registration Statement / Proxy Statement will, when the Registration Statement / Proxy Statement
is declared effective or when the Registration Statement / Proxy Statement is mailed to the ARYA shareholders or at the time of the ARYA
Shareholders Meeting, and in the case of any post-effective amendment thereto, at the time of such post-effective amendment, contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they are made, not misleading; <U>provided</U>, <U>however</U>, that
notwithstanding the foregoing provisions of this <U>Section&nbsp;5.18</U>, no representation or warranty is made by ARYA or any of its
Affiliates with respect to information or statements made or incorporated by reference in the Registration Statement / Proxy Statement
that were not supplied by or on behalf of ARYA for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_020"></A>5.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Certain
Business Practices</U>. ARYA has not, nor, to the knowledge of ARYA, has any Affiliate, director, officer, agent or employee of ARYA (in their
capacities as such), since ARYA&rsquo;s formation, (a)&nbsp;used any funds for unlawful contributions, gifts, entertainment or other unlawful
expenses relating to political activity, (b)&nbsp;made any unlawful payment to foreign or domestic government officials or employees,
to foreign or domestic political parties or campaigns or violated any provision of Anti-Corruption Laws or (c)&nbsp;made any other unlawful
payment. ARYA has not, nor, to the knowledge of ARYA, has any Affiliate, director, officer, agent or employee of ARYA or its Affiliates
(nor any Person acting on behalf of any of the foregoing, but solely in his or her capacity as a director, officer, employee or agent
of ARYA or its Affiliates), since ARYA&rsquo;s formation, directly or indirectly, given or agreed to give any gift or similar benefit
to any customer, supplier, governmental employee or other Person in connection with any actual or proposed transaction, in each case in
violation of any Anti-Corruption Law in any material respect. No material Action involving ARYA or its Affiliates with respect to any
Anti-Corruption Law is pending or, to the knowledge of ARYA, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_021"></A>5.20</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Trade
Controls</U>. None of ARYA or its Affiliates, nor any director, officer, agent or employee of ARYA or its Affiliates (in their capacities
as such) has, since ARYA&rsquo;s formation, (a)&nbsp;been a Sanctioned Person, (b)&nbsp;been organized, resident or located in a Sanctioned
Country, (c)&nbsp;engaged in any dealings or transactions with any Sanctioned Person or in any Sanctioned Country, or (d)&nbsp;otherwise
been in violation of Trade Controls in any material respect. ARYA nor its Affiliates have: (i)&nbsp;received from any Authority or any
other Person any notice, inquiry, or internal or external allegation; (ii)&nbsp;made any voluntary or involuntary disclosure to an Authority;
or (iii)&nbsp;conducted any internal investigation or audit, in each case concerning any actual or potential material violation or wrongdoing
related to Trade Controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_022"></A>5.21</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investigation;
No Other Representation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA,
on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees that (i)&nbsp;it has conducted its
own independent review and analysis of, and, based thereon, has formed an independent judgment concerning, the business, assets, condition,
operations and prospects, of the Business and (ii)&nbsp;it has been furnished with or given access to such documents and information about
the Business as it and its Representatives have deemed necessary to enable it to make an informed decision with respect to the execution,
delivery and performance of this Agreement, the Additional Agreements and the transactions contemplated hereby and thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
entering into this Agreement and the Additional Agreements to which it is or will be a party, ARYA has relied solely on its own investigation
and analysis and the representations and warranties expressly set forth in <U>Article&nbsp;III</U>, <U>Article&nbsp;IV</U> and the Additional
Agreements to which it is or will be a party and no other representations or warranties of the Amber Entities or any other Person, either
express or implied, and ARYA, on its own behalf and on behalf of its Representatives, acknowledges, represents, warrants and agrees that,
except for the representations and warranties expressly set forth in <U>Article&nbsp;III</U>, <U>Article&nbsp;IV</U> and the Additional
Agreements to which it is or will be a party, none of the Amber Entities or any other Person makes or has made any representation or warranty,
either express or implied, in connection with or related to this Agreement, the Additional Agreements or the transactions contemplated
hereby or thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><A NAME="sp5-a_024"></A>5.22</FONT><FONT STYLE="text-transform: uppercase">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="font-size: 10pt; text-transform: uppercase"><U>Exclusivity
of Representations and Warranties</U></FONT><FONT STYLE="font-size: 10pt">. NOTWITHSTANDING THE DELIVERY OR DISCLOSURE TO THE AMBER ENTITIES
OR ANY OF THEIR REPRESENTATIVES OF ANY DOCUMENTATION OR OTHER INFORMATION (INCLUDING ANY FINANCIAL PROJECTIONS OR OTHER SUPPLEMENTAL DATA),
EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS <U>ARTICLE&nbsp;V</U> OR THE ADDITIONAL AGREEMENTS, NEITHER ARYA, NOR ANY OTHER PERSON
MAKES, AND ARYA EXPRESSLY DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED,&nbsp;IN CONNECTION WITH
THIS AGREEMENT, THE ADDITIONAL AGREEMENTS OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY,&nbsp;INCLUDING AS TO THE MATERIALS
RELATING TO THE BUSINESS AND AFFAIRS OR HOLDINGS OF ARYA THAT HAVE BEEN MADE AVAILABLE TO THE AMBER ENTITIES OR ANY OF THEIR RESPECTIVE
REPRESENTATIVES OR IN ANY PRESENTATION OF THE BUSINESS AND AFFAIRS OF ARYA BY OR ON BEHALF OF THE MANAGEMENT OF ARYA OR OTHERS IN CONNECTION
WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR BY THE ADDITIONAL AGREEMENTS, AND NO STATEMENT CONTAINED IN ANY OF SUCH MATERIALS OR MADE
IN ANY SUCH PRESENTATION SHALL BE DEEMED A REPRESENTATION OR WARRANTY HEREUNDER OR OTHERWISE OR DEEMED TO BE RELIED UPON BY ANY OF THE
AMBER ENTITIES OR ANY OF THEIR RESPECTIVE REPRESENTATIVES IN EXECUTING, DELIVERING OR PERFORMING THIS AGREEMENT, THE ADDITIONAL AGREEMENTS
OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS <U>ARTICLE&nbsp;V</U>
OR THE ADDITIONAL AGREEMENTS,&nbsp;IT IS UNDERSTOOD THAT ANY COST ESTIMATES, PROJECTIONS OR OTHER PREDICTIONS, ANY DATA, ANY FINANCIAL
INFORMATION OR ANY MEMORANDA OR OFFERING MATERIALS OR PRESENTATIONS,&nbsp;INCLUDING ANY OFFERING MEMORANDUM OR SIMILAR MATERIALS MADE
AVAILABLE BY OR ON BEHALF OF ARYA ARE NOT AND SHALL NOT BE DEEMED TO BE OR TO INCLUDE REPRESENTATIONS OR WARRANTIES OF ARYA, AND, EXCEPT
FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS <U>ARTICLE&nbsp;V</U> OR THE ADDITIONAL AGREEMENTS, ARYA EXPRESSLY
DISCLAIMS, ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND OR NATURE, EXPRESS OR IMPLIED,&nbsp;IN CONNECTION THEREWITH. NOTWITHSTANDING
ANYTHING SET FORTH IN THIS AGREEMENT TO THE CONTRARY, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS <U>ARTICLE&nbsp;V</U>
OR THE ADDITIONAL AGREEMENTS NEITHER ARYA NOR ANY OTHER PERSON MAKES ANY REPRESENTATIONS OR WARRANTIES TO THE AMBER ENTITIES REGARDING
ANY PROJECTIONS OR THE FUTURE OR PROBABLE PROFITABILITY, SUCCESS, BUSINESS, OPPORTUNITIES, RELATIONSHIPS AND OPERATIONS OF ARYA OR, FOLLOWING
THE CLOSING, THE BUSINESS ENTITIES OR THE BUSINESS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="sp5-a_023"></A><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VI<BR>
COVENANTS OF THE PARTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="sp5-a_025"></A>6.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conduct
of the Business Entities and the Business</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Effective Date through the earlier of the Closing or the termination of this Agreement in accordance with its terms, except
(x)&nbsp;as expressly contemplated by this Agreement or any Additional Agreement, (y)&nbsp;as required by applicable Law or (z)&nbsp;with
the prior written consent of ARYA (not to be unreasonably withheld, conditioned or delayed), each Amber Entity shall, and shall cause
its Affiliates to, conduct the Business in the ordinary course consistent with past practice in all material respects and use their commercially
reasonable efforts to preserve substantially intact their respective properties, assets, operations and relationships with Authorities,
employees, suppliers, and other material business relations, in each case, to the extent primarily related to the Business or otherwise
constituting or related to the Contributed Business Assets, the Business Employees or the Business Contractors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Without
limiting the generality of the foregoing, from and after the Effective Date through the earlier of the Closing or the termination of this
Agreement in accordance with its terms, except (w)&nbsp;as set forth on <U>Section&nbsp;6.1(b)</U>&nbsp;of the Amber Disclosure Schedules,
(x)&nbsp;as expressly contemplated by this Agreement or any Additional Agreement, (y)&nbsp;as required by applicable Law or (z)&nbsp;as
consented to in writing by ARYA (such consent not to be unreasonably withheld, conditioned or delayed in the case of clauses (i), (v),
(vi), (viii), (ix), (xi), (xiii), (xv), (xvi), (xviii), (xix), (xx), (xxiii)&nbsp;or (xxv)&nbsp;(to the extent related to any of the foregoing
clauses)), each Amber Entity shall not, and shall cause its Affiliates not to, do the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">amend,
modify, restate or supplement the Governing Documents of any Business Entity (other than, for the avoidance of doubt, as expressly contemplated
by this Agreement);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">transfer,
issue, sell, grant or otherwise dispose of, or subject to a Lien, (A)&nbsp;any Equity Securities of any Business Entity or (B)&nbsp;any
options, warrants, rights of conversion or other rights, agreements, arrangements or commitments obligating any Business Entity to issue,
deliver or sell any Equity Securities of any Business Entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">declare,
set aside, make or pay a dividend on, or make any other distribution or payment in respect of, any Equity Securities of any Business Entity
or repurchase or redeem any outstanding Equity Securities of any Business Entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">sell,
assign, abandon, dispose of, license or transfer, any Contributed Business Assets, or any other assets or properties related to or arising
out of the Business (other than Intellectual Property), other than dispositions or transfers of inventory in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">except
as required by the terms of any existing Employee Benefit Plan as in effect on the date hereof and listed on <U>Section&nbsp;4.16(a)</U>&nbsp;of
the Amber Disclosure Schedules, as set forth on <U>Section&nbsp;6.1(b)(v)</U>&nbsp;of the Amber Disclosure Schedules or for ordinary course
actions consistent with past practice which are applicable to employees of Amber GT Parent and its Affiliates generally and for which
Amber GT Parent and its Affiliates (excluding, for the avoidance of doubt, the Company) are solely obligated to pay (and do not disproportionately
affect any Business Employees or Business Contractors), (A)&nbsp;materially increase or decrease the amount of any bonus, salary or other
compensation or benefits payable or to become payable to any current or former employee, officer, director or other individual service
provider of the Business, including any Business Employee or Business Contractor, (B)&nbsp;take any action to accelerate the timing or
vesting of any payments or benefits, or the funding (other than ordinary course funding of the Parent 401(k)&nbsp;Plan benefits) of any
payments or benefits payable or to become payable to any current or former employee, officer, director or other individual service provider
of the Business, including any Business Employee or Business Contractor, (C)&nbsp;grant, or promise to grant, any bonuses, commission,
change in control payments, deferred compensation, severance, deal bonus, retention or equity or equity-based rights or other compensatory
payments or benefits to any current or former employee, officer, director or other individual service provider of the Business, including
any Business Employee or Business Contractor, (D)&nbsp;establish, adopt, enter into, commence participation in, fund, terminate, increase
the coverage or benefits available under, or materially amend any Employee Benefit Plan (or any plan or arrangement that would be an Employee
Benefit Plan if in effect on the date of this Agreement), or (E)&nbsp;hire or engage any Business Employee or Business Contractor with
total annualized compensation in excess of $250,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;enter
into any CBA related to the terms and conditions of one or more Business Employees&rsquo; employment or the Business or (B)&nbsp;recognize
or certify any labor union, labor organization, or group of employees as the bargaining representative for any Business Employees;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">implement
or announce any mass layoffs, furloughs, plant closings, or reductions in force affecting any group of Business Employees or Business
Contractors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;fail
to maintain the Contributed Real Property in substantially the same condition as of the date of this Agreement, ordinary wear and tear
casualty and condemnation excepted, or (B)&nbsp;amend, modify, extend, renew or terminate any Lease or enter into any new lease, sublease,
license or other agreement for the use or occupancy of any Contributed Real Property or to which any Business Entity is a party or bound
or that would adversely affect the rights of the Company, or the obligations of Amber GT Parent, under any Lease or the Philadelphia Sublease
following the Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;obtain,
create, assume or incur any loan or other Indebtedness primarily related to the Business or otherwise constituting or related to the Contributed
Business Assets, the Business Employees or the Business Contractors or to which any Business Entity or any Affiliates thereof could, directly
or indirectly, have any Liabilities following the Closing, (B)&nbsp;forgive, cancel or compromise any material debt or claim, or waive
or release any right of material value, in each case to the extent primarily related to the Business or that would otherwise constitute
or relate to a Contributed Business Asset, the Business Employees or the Business Contractors or (C)&nbsp;grant any indemnity, bond or
other guarantee for the benefit of any Person by any Business Entity, otherwise primarily related to the Business or otherwise constituting
or relating to the Contributed Business Assets, the Business Employees or the Business Contractors, or to which any Business Entity or
any Affiliates thereof could, directly or indirectly, have any Liabilities, in each case of sub clauses&nbsp;(A)-(C), other than in the
ordinary course of business in an aggregate amount not to exceed $1,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;merge,
consolidate, combine or amalgamate any Business Entity with any Person or otherwise have any Business Entity acquired or purchased acquired
by any other Person (whether by merger, consolidating with, purchase of Equity Securities or assets or otherwise) or (B)&nbsp;have any
Business Entity purchase or otherwise acquire (whether by merging or consolidating with, purchasing any Equity Security in or a substantial
portion of the assets of, or by any other manner) any corporation, partnership, association or other business entity or organization or
division thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;make
any loans, advances or capital contributions to, or guarantees for the benefit of, or any investments in, any Person by a Business Entity
or (B)&nbsp;otherwise make any loans, advances, or guarantees for the benefit of, any Business Employee or Business Contractor, other
than the reimbursement of expenses of Business Employees or Business Contractors in the ordinary course of business consistent with past
practice, in each case of sub clauses&nbsp;(A)&nbsp;and (B), other than in the ordinary course of business in an aggregate amount not
to exceed $1,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 100; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
respect to any Business Entity or to the extent otherwise primarily related to the Business, the Contributed Business Assets, the Business
Employees, the Business Contractors or Assumed Business Liabilities, (A)&nbsp;make, change, or revoke any material Tax election, (B)&nbsp;enter
into any settlement or compromise with any Taxing Authority relating to any material Tax matter, (C)&nbsp;abandon or fail to conduct any
material Tax Action in respect of a material amount of Taxes or a material Tax Return, (D)&nbsp;file any amended Tax Return in respect
of a material amount of Taxes, (E)&nbsp;consent to any extension or waiver of the statutory period of limitations applicable to a material
amount of Taxes or material Tax Return, (F)&nbsp;enter into any Tax Sharing Agreement</FONT><FONT STYLE="font-size: 10pt">, (G)&nbsp;adopt
or change a method of Tax accounting with respect to material Taxes of any Business Entity or to the extent otherwise related to the Business,
or (H)&nbsp;change an accounting period with respect to a material amount of Taxes of any Business Entity or to the extent otherwise related
to the Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">settle
or compromise, or enter into any settlement, conciliation or other similar Contract with respect to, any Action, or enter into any consent
decree or settlement agreement with any Authority, in each case, to the extent primarily related to the Business, or otherwise constituting
or related to any Contributed Business Asset, Business Employee or Business Contractor, or to which any Business Entity is subject or
would be party or bound, as applicable, in each case, other than settlements or compromises of any Action that (A)&nbsp;would involve
the payment of less than $1,000,000, in the aggregate, (B)&nbsp;that does not impose, or by its terms will not impose at any point in
the future, any material, non-monetary obligations on the Business or any Business Entity (or ARYA or any of its Affiliates following
the Closing) and (C)&nbsp;that is otherwise paid in full by the Amber Entities prior to the Closing or would constitute Excluded Liabilities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">assign,
sell, transfer, abandon, let lapse, license (except non-exclusive licenses granted in the ordinary course of business) or otherwise dispose
of, any Contributed Business IP, other than in the ordinary course of business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">not
commit or authorize any commitment to make any capital expenditures primarily related to the Business or otherwise constituting or related
to the Contributed Business Assets, the Business Employees or the Business Contractors in excess of $1,000,000 individually or $2,000,000
in the aggregate (except as set forth in the capital expenditure budget of the Business provided to ARYA as of the date hereof);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">disclose
any material Trade Secrets primarily used or held for use in the Business (other than pursuant to a written confidentiality agreement
or other confidentiality obligations entered into in the ordinary course of business with reasonable protections of, and preserving all
rights of the Business in or to, such Trade Secrets);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">make
any change in any Business Entity&rsquo;s accounting methodology, practice or policy other than changes required by GAAP or applicable
Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">waive
or release any noncompetition, non-solicitation, non-disclosure, non-interference, non-disparagement, or other restrictive covenant obligation
of any Business Employee, Business Contractor or former employee or independent contractor of the Business;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">except
as contemplated in <U>Section&nbsp;7.1(b)</U>, (A)&nbsp;transfer the employment of any (x)&nbsp;employee of the Amber Entities (other
than the Business Entities) who is not a Business Employee to a Business Entity or modify such individual&rsquo;s duties and responsibilities
such that they would become a Business Employee, or (y)&nbsp;Business Employee out of any Business Entity or change the job duties or
responsibilities of any Business Employee such that the individual no longer satisfies the definition of a Business Employee, other than
such actions that are taken in order to fill a vacancy for any position with total annualized compensation not greater than $300,000,
or (B)&nbsp;terminate the employment or engagement of (other than for cause), furlough or temporarily layoff any Business Employee or
Business Contractor;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 6 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;amend,
modify or terminate any Material Business Contract (excluding, for the avoidance of doubt, any expiration or automatic extension or renewal
of any such Material Business Contract pursuant to its terms), (B)&nbsp;waive any material benefit or right under any Material Business
Contract, (C)&nbsp;enter into any Contract that would constitute a Material Business Contract or (D)&nbsp;consummate any other transaction
or make (or agree to make) any other payments that, if reflected in a Contract and existing on the date hereof, would be required to
be disclosed on <U>Section&nbsp;4.21</U> of the Amber Disclosure Schedules;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">cause
the Business Entities to engage in any business or activities, or incur any Liabilities, that would be required to be disclosed on <U>Section&nbsp;4.5
</U>of the Amber Disclosure Schedules if engaged in or incurred prior to the date hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">authorize,
recommend, propose or announce an intention to adopt, or otherwise effect, a plan of complete or partial liquidation, dissolution, restructuring,
recapitalization, reorganization or similar transaction (other than, for the avoidance of doubt, the transactions expressly contemplated
by this Agreement) involving any Business Entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">enter
into any Contract with any broker, finder, investment banker or other Person under which such Person is or will be entitled to any brokerage
fee, finders&rsquo; fee or other commission in connection with the transactions contemplated by this Agreement or any Additional Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">make
or enter into any Contract providing for any Change of Control Payment, other than Change of Control Payments that do not exceed $25,000
individually or $100,000 in the aggregate with all other such Change of Control Payments under this <U>Section&nbsp;6.1(b)(xxiv)</U>;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">enter
into any Contract to take, or cause to be taken, any of the actions set forth in this <U>Section&nbsp;6.1(b)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything
in this <U>Section&nbsp;6.1(b)</U>&nbsp;to the contrary, nothing set forth in this Agreement shall give ARYA, directly or indirectly,
the right to control or direct the operations of the Business or the Business Entities prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Conduct
of the Business of ARYA</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Effective Date through the earlier of the Closing or the termination of this Agreement in accordance with its terms, ARYA
shall not, and shall cause its Subsidiaries not to, as applicable, except as expressly contemplated by this Agreement or any Additional
Agreement (including, for the avoidance of doubt, in connection with the Domestication or the PIPE Investment), as required by applicable
Law, as set forth on <U>Section&nbsp;6.2(a)</U>&nbsp;of the ARYA Disclosure Schedules or as consented to in writing by Amber GT Parent
(such consent not to be unreasonably withheld, conditioned or delayed), do any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">create
or form any Subsidiary;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">adopt
any amendments, supplements, restatements or modifications to the Investment Management Trust Agreement or the Governing Documents of
ARYA;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">acquire
(including, without limitation, by merger, consolidation, or acquisition of stock or assets or any other business combination) any corporation,
partnership, other business organization or enter into any strategic joint ventures, partnerships or alliances with any other person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">declare,
set aside, make or pay a dividend on, or make any other distribution or payment in respect of, its Equity Securities, or repurchase,
redeem or otherwise acquire, or offer to repurchase, redeem or otherwise acquire, any outstanding of its Equity Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">split,
combine or reclassify any of its capital stock or other Equity Securities or issue any other security in respect of, in lieu of or in
substitution for shares of its capital stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)&nbsp;make,
change, or revoke any material Tax election, (B)&nbsp;enter into any settlement or compromise with any Taxing Authority relating to any
material Tax matter, (C)&nbsp;abandon or fail to conduct any material Tax Action in respect of a material amount of Taxes or a material
Tax Return, (D)&nbsp;file any amended Tax Return in respect of a material amount of Taxes, (E)&nbsp;consent to any extension or waiver
of the statutory period of limitations applicable to a material amount of Taxes or material Tax Return, (F)&nbsp;enter into any Tax Sharing
Agreement</FONT><FONT STYLE="font-size: 10pt">, (G)&nbsp;adopt or change a method of Tax accounting with respect to material Taxes, or
(H)&nbsp;change an accounting period with respect to a material amount of Taxes;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">incur,
create or assume any Indebtedness or guarantee any Indebtedness of another Person, issue or sell any debt securities (or warrants or
other rights to acquire any debt securities), in each case of, other than in the ordinary course of business in an aggregate amount not
to exceed $1,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">make
any loans or advances to, or capital contributions in, any other Person, other than to, or in, ARYA or any of its Subsidiaries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">issue
any Equity Securities or&nbsp;grant any additional options, warrants or stock appreciation rights with respect to its Equity Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">(A)&nbsp;amend,
modify or renew any Contract that constitutes an ARYA Related Party Transaction, other than the entry into any Contract with an ARYA
Related Party with respect to the incurrence of Indebtedness permitted by <U>Section&nbsp;6.2(a)(vii)</U>&nbsp;or (B)&nbsp;enter into
any Contract that would constitute an ARYA Related Party Transaction;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">engage
in any activities or business, or incur any Liabilities, other than with respect to any activities or businesses that are or any Liabilities,
directly or indirectly, arising out of or related to any activities or businesses that are (A)&nbsp;either permitted under this <U>Section&nbsp;6.2
</U>(including, for the avoidance of doubt, any activities or businesses contemplated by, incurred in connection with or that are otherwise
incidental or attendant to this Agreement or any Additional Agreement, the performance of any covenants or agreements hereunder or thereunder
or the consummation of the transactions contemplated hereby or thereby) or in accordance with this <U>Section&nbsp;6.2</U>, (B)&nbsp;in
connection with or incident or related to its incorporation, continuing corporate (or similar) existence or it being (or continuing to
be) a U.S. public company listed on Nasdaq, or (C)&nbsp;administrative, ministerial or otherwise immaterial in nature;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">make
any change in accounting methodology, practice or policy other than changes required by GAAP or applicable Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">waive,
release, assign, settle or compromise any Action pending or threatened against ARYA or any of their respective directors or officers
that would materially and adversely affect ARYA after the Closing Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">authorize,
recommend, propose or announce an intention to adopt a plan of complete or partial liquidation, dissolution, restructuring, recapitalization,
reorganization or similar transaction (other than, for the avoidance of doubt, the transactions expressly contemplated by this Agreement
and the Additional Agreements);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">enter
into any Contract with any broker, finder, investment banker or other Person under which such Person is or will be entitled to any brokerage
fee, finders&rsquo; fee or other commission in connection with the transactions contemplated by this Agreement; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">enter
into any Contract to take, or cause to be taken, any of the actions set forth in this <U>Section&nbsp;6.2(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything in this <U>Section&nbsp;6.2</U> to the contrary, (i)&nbsp;nothing set forth in this Agreement shall give the Amber Entities,
directly or indirectly, the right to control or direct the operations of ARYA and (ii)&nbsp;nothing set forth in this Agreement shall
prohibit, or otherwise restrict the ability of, ARYA from using the funds held by ARYA outside the Trust Account from otherwise distributing
or paying over any funds held by ARYA outside the Trust Account to the ARYA Sponsor or any of its Affiliates, in each case, prior to
the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Efforts
to Consummate</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to the terms and conditions herein provided, each of the Parties shall use reasonable best efforts to take, or cause to be taken, all
actions and to do, or cause to be done, all things reasonably necessary or advisable to consummate and make effective as promptly as
reasonably practicable the transactions contemplated by this Agreement, including (i)&nbsp;the satisfaction, but not waiver, of the closing
conditions set forth in <U>Article&nbsp;VIII</U> and, in the case of any Additional Agreement to which such Party is contemplated to
be a party after the date of this Agreement, to execute and delivery such Additional Agreement when required pursuant to this Agreement,
and (ii)&nbsp;using reasonable best efforts to obtain the PIPE Investment on the terms and subject to the conditions set forth in the
PIPE Subscription Agreements. Without limiting the generality of the foregoing, each of the Parties shall use reasonable best efforts
to obtain, file with or deliver to, as applicable, any Consents of any Authority or other Persons necessary, proper or advisable to consummate
the transactions contemplated by this Agreement or the Additional Agreements; <U>provided</U>, <U>however</U>, that in the case of any
such Consents of any Person (other than an Authority), ARYA and its Affiliates (including, for the avoidance of doubt, from and after
the Closing, the Business Entities) shall not be required to make any payments to secure any such Consent and shall not be required to
amend, modify or supplement any Contract to which such Consent may relate, and Amber GT Parent, Amber GT and their respective Affiliates
(including, prior to the Closing, the Business Entities) shall not take any of the foregoing actions without ARYA&rsquo;s prior written
consent. Amber GT Parent shall bear the costs incurred in connection with obtaining, filing or delivering such Consents; <U>provided</U>,
<U>however</U>, that each Party shall bear its out-of-pocket costs and expenses in connection with the preparation of any such Consents.
Each Party shall (A)&nbsp;make any appropriate filings pursuant to the HSR Act with respect to the transactions contemplated by this
Agreement promptly (and in any event within ten (10)&nbsp;Business Days) following the date of this Agreement, and (B)&nbsp;respond as
promptly as reasonably practicable to any requests by any Authority for additional information and documentary material that may be requested
pursuant to the HSR Act. ARYA shall promptly inform Amber GT Parent of any communication between ARYA, on the one hand, and any Authority,
on the other hand, and Amber GT Parent shall promptly inform ARYA of any communication between any Amber Entity or any Affiliate thereof,
on the one hand, and any Authority, on the other hand, in either case, regarding any of the transactions contemplated by this Agreement
or any Additional Agreement; <U>provided</U> that, for the avoidance of doubt, the foregoing shall not apply with respect to communications
with any Taxing Authority following the Closing Date. Without limiting the foregoing, (x)&nbsp;to the extent available at the time of
filing thereof, the Parties agree to request early termination of the applicable waiting period under the HSR Act, and (y)&nbsp;each
Party and their respective Affiliates shall not extend any waiting period, review period or comparable period under the HSR Act or enter
into any agreement with any Authority not to consummate the transactions contemplated hereby or by the Additional Agreements, except
with the prior written consent of ARYA and Amber GT Parent. Nothing in this <U>Section&nbsp;6.3</U> obligates any Party or any of its
Affiliates to agree to (i)&nbsp;sell, license or otherwise dispose of, or hold separate and agree to sell, license or otherwise dispose
of, any entities, assets or facilities of any Business Entity or any entity, facility or asset of such Party or any of its Affiliates,
(ii)&nbsp;terminate, amend or assign existing relationships and contractual rights or obligations, (iii)&nbsp;amend, assign or terminate
existing licenses or other agreements, or (iv)&nbsp;enter into new licenses or other agreements. No Party shall agree to any of the measures
set forth in the immediately preceding sentence with respect to such Party or with respect to any other Party or any of its Affiliates,
except with ARYA&rsquo;s and Amber GT Parent&rsquo;s prior written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 105; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Effective Date through the earlier of the Closing or the termination of this Agreement in accordance with its terms, ARYA,
on the one hand, and the Amber Entities, on the other hand, shall give counsel for Amber GT Parent (in the case of ARYA) or ARYA (in
the case of any Amber Entity), a reasonable opportunity to review in advance, and consider in good faith the views of the other in connection
with, any proposed written communication to any Authority relating to the transactions contemplated by this Agreement or the Additional
Agreements. Each of the Parties agrees not to participate in any substantive meeting or discussion, either in person or by telephone
with any Authority in connection with the transactions contemplated by this Agreement unless it consults with, in the case of ARYA, Amber
GT Parent, or, in the case of any Amber Entity, ARYA in advance and, to the extent not prohibited by such Authority, gives, in the case
of ARYA, Amber GT Parent, or, in the case of any Amber Entity, ARYA, the opportunity to attend and participate in such meeting or discussion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything in this Agreement to the contrary, in the event that this <U>Section&nbsp;6.3</U> conflicts with any other covenant or agreement
in this <U>Article&nbsp;VI</U> that is intended to specifically address any subject matter, then such other covenant or agreement shall
govern and control solely to the extent of such conflict.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exclusive
Dealing</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Effective Date through the earlier of the Closing or the termination of this Agreement in accordance with its terms, each
Amber Entity shall not, and shall cause its Representatives not to, directly or indirectly: (i)&nbsp;solicit, initiate, knowingly encourage
(including by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any
inquiry, proposal or offer (written or oral) with respect to a Business Acquisition Proposal; (ii)&nbsp;furnish or disclose any non-public
information to any Person in connection with, or that could reasonably be expected to lead to, a Business Acquisition Proposal; (iii)&nbsp;enter
into any Contract or other arrangement or understanding regarding a Business Acquisition Proposal; (iv)&nbsp;make any filings with the
SEC in connection with a public offering of any Equity Securities of any Business Entity (or any Affiliate or successor of any Business
Entity) or any other Person for the purpose of a public offering with respect to the Business; or (v)&nbsp;otherwise cooperate in any
way with, or assist or participate in, or knowingly facilitate or knowingly encourage any effort or attempt by any Person to do or seek
to do any of the foregoing. Each Amber Entity agrees to (A)&nbsp;notify ARYA promptly upon receipt of any Business Acquisition Proposal
by any Person, and to describe the material terms and conditions of any such Business Acquisition Proposal in reasonable detail (including
the identity of the Persons making such Business Acquisition Proposal) and (B)&nbsp;keep ARYA reasonably informed on a current basis
of any modifications to such offer or information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Effective Date through the earlier of the Closing or the termination of this Agreement in accordance with its terms, ARYA
shall not, and shall cause its Representatives not to, directly or indirectly: (i)&nbsp;solicit, initiate, knowingly encourage (including
by means of furnishing or disclosing information), knowingly facilitate, discuss or negotiate, directly or indirectly, any inquiry, proposal
or offer (written or oral) with respect to an ARYA Acquisition Proposal; (ii)&nbsp;furnish or disclose any non-public information to
any Person in connection with, or that could reasonably be expected to lead to, an ARYA Acquisition Proposal; (iii)&nbsp;enter into any
Contract or other arrangement or understanding regarding an ARYA Acquisition Proposal; or (iv)&nbsp;otherwise cooperate in any way with,
or assist or participate in, or knowingly facilitate or knowingly encourage any effort or attempt by any Person to do or seek to do any
of the foregoing. ARYA agrees to (A)&nbsp;notify Amber GT Parent promptly upon receipt of any ARYA Acquisition Proposal by ARYA, and
to describe the material terms and conditions of any such ARYA Acquisition Proposal in reasonable detail (including the identity of any
person or entity making such ARYA Acquisition Proposal) and (B)&nbsp;keep Amber GT Parent reasonably informed on a current basis of any
modifications to such offer or information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
the avoidance of doubt, it is understood and agreed that the covenants and agreements set forth in this <U>Section&nbsp;6.4</U> shall
not prohibit the Amber Entities, ARYA or any of their respective Representatives from taking any actions in the ordinary course that
are not otherwise in violation of this <U>Section&nbsp;6.4</U> (such as answering phone calls) or informing any Person inquiring about
a possible Business Acquisition Proposal or ARYA Acquisition Proposal, as applicable, of the existence of the covenants and agreements
set forth in this <U>Section&nbsp;6.4</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Confidentiality;
Access to Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Parties hereby acknowledge and agree that the information being provided in connection with this Agreement and the consummation of the
transactions contemplated hereby is subject to the terms of the Confidentiality Agreement, the terms of which are incorporated herein
by reference. Notwithstanding the foregoing or anything to the contrary in this Agreement, in the event that this <U>Section&nbsp;6.5(a)</U>&nbsp;or
the Confidentiality Agreement conflicts with any other covenant or agreement set forth in this Agreement or any Additional Agreement
that contemplates the disclosure, use or provision of information or otherwise, then such other covenant or agreement set forth in this
Agreement or such Additional Agreement, as applicable, shall govern and control to the extent of such conflict. The Parties hereby acknowledge
and agree that, notwithstanding anything to the contrary therein, the Confidentiality Agreement shall be automatically terminated effective
as of the Closing without any further action by any Party or any other Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Effective Date through the earlier of the Closing or the termination of this Agreement in accordance with its terms, upon
reasonable advance written notice, the Amber Entities shall provide, or cause to be provided, to ARYA and its Representatives during
normal business hours reasonable access to the books, records, properties and employees (including, for the avoidance of doubt, the Business
Employees), in each case, to the extent Related to the Business (in a manner so as to not interfere with the normal business operations
of the Amber Entities); <U>provided</U> that, notwithstanding any provision of this Agreement to the contrary, Amber GT Parent shall
not be required to provide ARYA or its Representatives with access to or copies of any income Tax Returns or books and records (including
workpapers) related thereto except to the extent such income Tax Returns or books and records relate solely to the Business Entities
or the Business. Notwithstanding the foregoing, none of the Amber Entities shall be required to provide to ARYA or any of its Representatives
any information (i)&nbsp;if and to the extent doing so would (A)&nbsp;violate any Law to which any Amber Entity is subject, (B)&nbsp;violate
any legally-binding obligation of any Amber Entity with respect to confidentiality, non-disclosure or privacy (taking into account, for
the avoidance of doubt, the Confidentiality Agreement) or (C)&nbsp;based on the advice of outside legal counsel, jeopardize protections
afforded to any Amber Entity under the attorney-client privilege or the attorney work product doctrine (<U>provided</U> that, in case
of each of clauses&nbsp;(A)&nbsp;through (C), each Amber Entity shall, and shall cause its Affiliates to, use commercially reasonable
efforts to (x)&nbsp;provide such access as can be provided (or otherwise convey such information regarding the applicable matter as can
be conveyed) without violating such privilege, doctrine, Contract, obligation or Law and (y)&nbsp;provide such information in a manner
without violating such privilege, doctrine, Contract, obligation or Law), or (ii)&nbsp;if any Amber Entity or any of its Representatives,
on the one hand, and ARYA or any of its Representatives, on the other hand, are adverse parties in a litigation and such information
is reasonably pertinent thereto; <U>provided</U> that Amber GT Parent shall, in the case of clause&nbsp;(i)&nbsp;or (ii), provide prompt
written notice of the withholding of access or information on any such basis unless such written notice is prohibited by applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Effective Date through the earlier of the Closing or the termination of this Agreement in accordance with its terms, upon
reasonable advance written notice, ARYA shall provide, or cause to be provided, to Amber GT Parent and its Representatives during normal
business hours reasonable access to the books, records, properties and employees of ARYA, in each case, to the extent related to the
transactions contemplated by this Agreement (in a manner so as to not interfere with the normal business operations of ARYA or any of
its Affiliates); <U>provided</U> that, notwithstanding any provision of this Agreement to the contrary, ARYA shall not be required to
provide Amber GT Parent or its Representatives with access to or copies of any income Tax Returns or book and records (including workpapers)
related thereto. Notwithstanding the foregoing, ARYA shall not be required to provide, or cause to be provided to, Amber GT Parent or
any of its Representatives any information (i)&nbsp;if and to the extent doing so would (A)&nbsp;violate any Law to which ARYA is subject,
(B)&nbsp;violate any legally binding obligation of ARYA with respect to confidentiality, non-disclosure or privacy (taking into account,
for the avoidance of doubt, the Confidentiality Agreement) or (C)&nbsp;based on outside legal counsel, jeopardize protections afforded
to ARYA under the attorney-client privilege or the attorney work product doctrine (<U>provided</U> that, in case of each of clauses&nbsp;(A)&nbsp;through
(C), ARYA shall use commercially reasonable efforts to (x)&nbsp;provide such access as can be provided (or otherwise convey such information
regarding the applicable matter as can be conveyed) without violating such privilege, doctrine, Contract, obligation or Law and (y)&nbsp;provide
such information in a manner without violating such privilege, doctrine, Contract, obligation or Law), or (ii)&nbsp;if ARYA, the ARYA
Sponsor or any of their respective Representatives, on the one hand, and any Amber Entity or any of their respective Representatives,
on the other hand, are adverse parties in a litigation and such information is reasonably pertinent thereto; <U>provided</U> that ARYA
shall, in the case of clause&nbsp;(i)&nbsp;or (ii), provide prompt written notice of the withholding of access or information on any
such basis unless such written notice is prohibited by applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
a period of six (6)&nbsp;years after the Closing, upon reasonable advance notice, ARYA shall provide, or cause to be provided, to Amber
GT Parent and its Representatives, at Amber GT Parent&rsquo;s expense, during normal business hours reasonable access to the Contributed
Books and Records and the Contributed Business Employee Records in its possession or control as of such time, in each case, to the extent
related to the operation of the Business prior to the Closing and necessary in connection with any Action, preparation of financial statements
or SEC, stock exchange or bank regulatory reporting obligations. Any such access shall be in a manner so as to not interfere with the
normal business operations of ARYA or any of its Affiliates. Notwithstanding the foregoing, ARYA shall not be required to provide, or
cause to be provided to, Amber GT Parent or any of its Representatives any information (i)&nbsp;if and to the extent doing so would (A)&nbsp;violate
any Law to which ARYA is subject, (B)&nbsp;violate any legally-binding obligation of ARYA with respect to confidentiality, non-disclosure
or privacy (taking into account, for the avoidance of doubt, the Confidentiality Agreement) or (C)&nbsp;based on the advice of outside
counsel, jeopardize protections afforded to ARYA under the attorney-client privilege or the attorney work product doctrine (<U>provided
</U>that, in case of each of clauses&nbsp;(A)&nbsp;through (C), ARYA shall use commercially reasonable efforts to (x)&nbsp;provide such
access as can be provided (or otherwise convey such information regarding the applicable matter as can be conveyed) without violating
such privilege, doctrine, Contract, obligation or Law and (y)&nbsp;provide such information in a manner without violating such privilege,
doctrine, Contract, obligation or Law), or (ii)&nbsp;if ARYA, the ARYA Sponsor or any of their respective Representatives, on the one
hand, and any Amber Entity or any of its Representatives, on the other hand, are adverse parties in a litigation and such information
is reasonably pertinent thereto; <U>provided</U> that ARYA shall, in the case of clause&nbsp;(i)&nbsp;or (ii), provide prompt written
notice of the withholding of access or information on any such basis unless such written notice is prohibited by applicable Law. This
<U>Section&nbsp;6.5(d)</U>&nbsp;shall not apply with respect to Taxes, which shall be governed by <U>Section&nbsp;6.12(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Closing, Amber GT Parent shall, and shall cause its Representatives to, provide ARYA and its Representatives with copies
of or access to (as determined in the sole discretion of ARYA) the portion of any Books and Records, in each case, to the extent relating
to, held for use with or used in connection with the Business but are not Contributed Books and Records and owned by, in possession of
or controlled by Amber GT Parent or any of its Affiliates as of such time (such Books and Records, collectively, the &ldquo;<U>Commingled
Books and Records</U>&rdquo;); <U>provided</U> that (i)&nbsp;Amber GT Parent shall not be required to provide copies of or access to
any Commingled Books and Records to the extent prohibited by applicable Law (<U>provided</U> that, Amber GT Parent shall, and shall cause
its Representatives to, use commercially reasonable efforts to (x)&nbsp;provide such access as can be provided (or otherwise convey such
information regarding the applicable matter as can be conveyed) without violating such Law and (y)&nbsp;provide such access or information
in a manner without violating such Law), and (ii)&nbsp;for the avoidance of doubt, Amber GT Parent and any of its Representatives may
redact or remove any information in any Commingled Books and Records prior to providing copies or access to ARYA and its Representatives
under this <U>Section&nbsp;6.5(e)</U>&nbsp;to the extent not relating to, held for use with or used in connection with the Business.
This <U>Section&nbsp;6.5(e)</U>&nbsp;shall not apply with respect to Taxes, which shall be governed by <U>Section&nbsp;6.12(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Closing, Amber GT Parent shall, and shall cause its Affiliates to, provide ARYA and its Representatives with copies of
or access to (as determined in the sole discretion of ARYA) the portion of employee or personnel files, in each case, to the extent relating
to a Business Employee but are not Contributed Business Employee Records and owned by, or in possession of or controlled by Amber GT
Parent or any of its Affiliates as of such time (such employee or personnel files, collectively, the &ldquo;<U>Commingled Employee Records</U>&rdquo;);
<U>provided</U> that (i)&nbsp;Amber GT Parent shall not be required to provide copies of or access to any Commingled Employee Records
to the extent prohibited by applicable Law (<U>provided</U> that Amber GT Parent shall, and shall cause its Representatives to, use commercially
reasonable efforts to (x)&nbsp;provide such access as can be provided (or otherwise convey such information regarding the applicable
matter as can be conveyed) without violating such Law or Order and (y)&nbsp;provide such access or information in a manner without violating
such Law or Order), and (ii)&nbsp;for the avoidance of doubt, Amber GT Parent and any of its Affiliates may redact or remove any information
in any Commingled Employee Records prior to providing copies or access to under this <U>Section&nbsp;6.5(f)</U>&nbsp;to the extent not
related to or arising out of the Business or any Business Employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
a period of time equal to the shortest of (i)&nbsp;six (6)&nbsp;years from and after the Closing Date, (ii)&nbsp;Amber GT Parent&rsquo;s
standard record retention policy period or (iii)&nbsp;such period time as may be required by applicable Law, Amber GT Parent shall, and
shall cause its Affiliates to, hold all Commingled Books and Records and Commingled Employee Records existing on the Closing Date and
not to destroy or dispose of any thereof, and thereafter, if it desires to destroy or dispose of such books and records, to offer first
in writing at least thirty (30) days prior to such destruction or disposition to surrender them to ARYA; <U>provided</U> that, for the
avoidance of doubt, Amber GT Parent and any of its Affiliates may redact or remove any information in any Commingled Books and Records
or the Commingled Employee Records prior to surrendering them to the Company under this <U>Section&nbsp;6.5(g)</U>&nbsp;to the extent
not relating to, held for use with or used in connection with the Business or related to or arising out of any Business Employee. This
<U>Section&nbsp;6.5(g)</U>&nbsp;shall not apply with respect to Taxes, which shall be governed by <U>Section&nbsp;6.12(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
a period of time equal to the shortest of (i)&nbsp;six (6)&nbsp;years from and after the Closing Date, (ii)&nbsp;ARYA&rsquo;s standard
record retention policy period or (iii)&nbsp;such period of time as may be required by applicable Law, ARYA shall, and shall cause its
Affiliates to, hold all Contributed Books and Records delivered to the Company on the Closing Date and not to destroy or dispose of any
thereof, and thereafter, if it desires to destroy or dispose of such books and records, to offer first in writing at least thirty (30)
days prior to such destruction or disposition to surrender them to Amber GT Parent (at its sole cost) to the extent any such books and
records relate to Excluded Assets or Excluded Liabilities; <U>provided</U> that, for the avoidance of doubt, ARYA and any of its Affiliates
may redact or remove any information in any Contributed Books and Records prior to surrendering them to the Company under this <U>Section&nbsp;6.5(h)</U>&nbsp;to
the extent not relating to, held for use with or used in connection with the Excluded Assets or Excluded Liabilities. This <U>Section&nbsp;6.5(h)</U>&nbsp;shall
not apply with respect to Taxes, which shall be governed by <U>Section&nbsp;6.12(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
a period of eighteen (18) months from and after the Closing Date (such period of time, the &ldquo;<U>Confidentiality Period</U>&rdquo;),
Amber GT Parent shall, and shall cause each of its Representatives who have received Business Confidential Information, to, (i)&nbsp;treat
and hold as confidential all confidential or proprietary information of, or to the extent related to, the Business and either in existence
at or prior to the Closing or delivered to Amber GT Parent or any of its Representatives pursuant to this Agreement or any Additional
Agreement after the Closing (the &ldquo;<U>Business Confidential Information</U>&rdquo;) and (ii)&nbsp;refrain from using or disclosing
any of the Business Confidential Information except as provided or otherwise permitted under this Agreement or any Additional Agreement
to which it is a party, or in connection with any dispute or Action arising in connection with any of the foregoing; <U>provided</U>,
<U>however</U>, that none of the following shall be deemed to be Business Confidential Information: (A)&nbsp;information that is generally
available to or known by the public (other than through disclosure by Amber GT Parent or any of its Representatives in violation of this
<U>Section&nbsp;6.5(i)</U>); (B)&nbsp;information that is acquired by Amber GT Parent or any of its Representatives after the Closing
from a source which, to the actual knowledge of such Person, is not prohibited from disclosing such information by a legal, contractual,
fiduciary or similar obligation; (C)&nbsp;information that is independently derived, developed or acquired by Amber GT Parent or any
of its Representatives following the Closing without reference to or use of information subject to the confidentiality obligations of
this <U>Section&nbsp;6.5(i)</U>; or (D)&nbsp;information to the extent related to any Excluded Assets or Excluded Liabilities, which
shall, for the avoidance of doubt, be deemed to be Amber Confidential Information. Notwithstanding anything to the contrary in this <U>Section&nbsp;6.5(i)</U>,
in the event that Amber GT Parent or any of its Representatives is required or requested to disclose any Business Confidential Information
during the Confidentiality Period by Law or to an Authority or otherwise in connection with compliance, Tax or regulatory activity, then
any of the foregoing Persons shall notify ARYA as promptly as practicable and permissible of such request or requirement so that ARYA
may seek an appropriate protective order or waive compliance with the provisions of this <U>Section&nbsp;6.5(i)</U>. If, in the absence
of a protective order or the receipt of a waiver hereunder, such Person, on the advice of its outside legal counsel, is compelled to
disclose any Business Confidential Information, such Person may disclose only that portion of such Business Confidential Information
to which it is advised by its counsel to disclose and shall use commercially reasonable efforts to cause the recipient thereof to keep
such information confidential.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">During
the Confidentiality Period, ARYA shall, and shall cause any of its Representatives who have received Amber Confidential Information to,
(i)&nbsp;treat and hold as confidential all confidential or proprietary information related to Amber GT Parent or any of its Affiliates
delivered to ARYA or its Representatives whether before or after the date hereof (other than, for the avoidance of doubt, the Business
Confidential Information) (the &ldquo;<U>Amber Confidential Information</U>&rdquo;) and (ii)&nbsp;refrain from using or disclosing any
of the Amber Confidential Information except as provided or otherwise permitted under this Agreement or any Additional Agreement, or
in connection with any dispute or Action arising in connection with any of the foregoing; <U>provided</U>, <U>however</U>, that none
of the following shall be deemed to be Amber Confidential Information: (A)&nbsp;information that is generally available to or known by
the public (other than through disclosure by ARYA or its Representatives in violation of this <U>Section&nbsp;6.5(j)</U>); (B)&nbsp;information
that is acquired by ARYA or any of its Representatives after the Closing from a source which, to the actual knowledge of such Persons,
is not prohibited from disclosing such information by a legal, contractual, fiduciary or similar obligation; (C)&nbsp;information that
is independently derived, developed or acquired by ARYA or any of its Representatives after the Closing without reference to or use of
information subject to the confidentiality obligations of this <U>Section&nbsp;6.5(j)</U>; or (D)&nbsp;information to the extent Related
to the Business, the Contributed Business Assets or the Assumed Business Liabilities, which shall, for the avoidance of doubt, be deemed
to be Business Confidential Information. Notwithstanding anything to the contrary in this <U>Section&nbsp;6.5(j)</U>, in the event that
ARYA or any of its Representatives is required or requested to disclose any Amber Confidential Information during the Confidentiality
Period by Law or to an Authority or otherwise in connection with compliance, Tax or regulatory activity, then any of the foregoing Persons
shall notify Amber GT Parent as promptly as practicable and permissible of such request or requirement so that Amber GT Parent seek an
appropriate protective order or waive compliance with the provisions of this <U>Section&nbsp;6.5(j)</U>. If, in the absence of a protective
order or the receipt of a waiver hereunder, such Person, on the advice of its outside legal counsel, is compelled to disclose any Amber
Confidential Information, such Person may disclose only that portion of such Amber Confidential Information to which it is advised by
its counsel to disclose and shall use commercially reasonable efforts to cause the recipient thereof to keep such information confidential.
For the avoidance of doubt, the obligations set forth in this <U>Section&nbsp;6.5(j)</U>&nbsp;are in addition to any continuing obligations
under the Confidentiality Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing or anything to the contrary in this Agreement, in the event that <U>Section&nbsp;6.5(d)</U>&nbsp;through <U>Section&nbsp;6.5(j)</U>&nbsp;conflicts
with any other covenant or agreement set forth in any Additional Agreement that contemplates the disclosure, use or provision of information
or otherwise that is the subject of subsection, then such other covenant or agreement set forth in such Additional Agreement, as applicable,
shall govern and control to the extent of such conflict.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Preparation
of Registration Statement / Proxy Statement</U>. As promptly as reasonably practicable following the date of this Agreement, ARYA and
Amber GT Parent shall prepare and mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed by either
of ARYA or Amber GT Parent, as applicable), and ARYA shall file with the SEC, the Registration Statement / Proxy Statement (it being
understood that the Registration Statement / Proxy Statement shall include a proxy statement / prospectus of ARYA which will be included
therein and which will be used for the ARYA Shareholders Meeting to adopt and approve the Transaction Proposals and other matters reasonably
related to the Transaction Proposals, all in accordance with and as required by ARYA&rsquo;s Governing Documents, applicable Law, and
any applicable rules&nbsp;and regulations of the SEC and Nasdaq). ARYA and each Amber Entity shall use its reasonable best efforts to
(a)&nbsp;cause the Registration Statement / Proxy Statement to comply in all material respects with the applicable rules&nbsp;and regulations
promulgated by the SEC (including, in the case of the Amber Entities, with respect to the Business, the provision of financial statements
of, and any other information with respect to, the Business for all periods, and in the form, required to be included in the Registration
Statement / Proxy Statement under securities Laws (after giving effect to any waivers received) or in response to any comments from the
SEC); (b)&nbsp;promptly notify, in the case of an Amber Entity, ARYA or, in the case of ARYA, Amber GT Parent, reasonably cooperate with
each other with respect to and respond promptly to any comments of the SEC or its staff; (c)&nbsp;promptly prepare and, in the case of
ARYA and Amber GT Parent only, mutually agree upon (such agreement not to be unreasonably withheld, conditioned or delayed by either
ARYA or Amber GT Parent, as applicable) any amendments or supplements to the Registration Statement / Proxy Statement in order to address
comments or requests from the SEC or its staff (which amendments or supplements shall be promptly filed by the Company); (d)&nbsp;have
the Registration Statement / Proxy Statement declared effective under the Securities Act as promptly as reasonably practicable after
it is filed with the SEC; and (e)&nbsp;keep the Registration Statement / Proxy Statement effective through the Closing in order to permit
the consummation of the transactions contemplated by this Agreement. ARYA, on the one hand, and each Amber Entity, on the other hand,
shall promptly furnish, or cause to be furnished, to the other all information concerning such Party and its Representatives that may
be required or reasonably requested in connection with any action contemplated by this <U>Section&nbsp;6.6</U> or for inclusion in any
other statement, filing, notice or application made by or on behalf of ARYA to the SEC or Nasdaq in connection with the transactions
contemplated by this Agreement or the Additional Agreements. If any Party becomes aware of any information that should be disclosed in
an amendment or supplement to the Registration Statement / Proxy Statement, then: (i)&nbsp;such Party shall promptly inform, in the case
of ARYA, Amber GT Parent, or, in the case of any Amber Entity, ARYA, thereof; (ii)&nbsp;ARYA and Amber GT Parent shall prepare and mutually
agree upon (such agreement not to be unreasonably withheld, conditioned or delayed by either ARYA or Amber GT Parent, as applicable),
an amendment or supplement to the Registration Statement / Proxy Statement; (iii)&nbsp;ARYA shall as promptly as practicable file such
mutually agreed upon amendment or supplement with the SEC; and (iv)&nbsp;the Parties shall reasonably cooperate, if appropriate in the
discretion of ARYA, in mailing such amendment or supplement to the shareholders of ARYA. ARYA shall as promptly as reasonably practicable
advise Amber GT Parent of the time of effectiveness of the Registration Statement / Proxy Statement, the issuance of any stop order relating
thereto or the suspension of the qualification of ARYA Shares for offering or sale in any jurisdiction, and ARYA and the Amber Entities
shall each use its reasonable best efforts to have any such stop order or suspension lifted, reversed or otherwise terminated. Each of
the Parties shall use reasonable best efforts to ensure that none of the information related to him, her or it or any of his, her or
its Representatives, supplied by or on his, her or its behalf for inclusion or incorporation by reference in the Registration Statement
/ Proxy Statement will, at the time the Registration Statement / Proxy Statement is initially filed with the SEC, at each time at which
it is amended, or at the time it becomes effective under the Securities Act, contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under
which they are made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 112; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>ARYA
Shareholder Approval</U>. As promptly as reasonably practicable following the time at which the Registration Statement / Proxy Statement
is declared effective under the Securities Act, ARYA shall (a)&nbsp;cause the Registration Statement / Proxy Statement to be mailed to
the ARYA shareholders, (b)&nbsp;use reasonable best efforts to solicit proxies from the ARYA shareholders to vote in favor of each of
the Transaction Proposals and (c)&nbsp;duly give notice of, and use reasonable best efforts to duly convene and hold, a meeting of its
shareholders (the &ldquo;<U>ARYA Shareholders Meeting</U>&rdquo;), in each case, in accordance with the Governing Documents of ARYA and
applicable Law, for the purposes of obtaining the ARYA Shareholder Approval and, if applicable, any approvals related thereto and providing
its applicable shareholders with the opportunity to elect to effect an ARYA Share Redemption. Except as otherwise required by applicable
Law: (i)&nbsp;ARYA shall, through the ARYA Board, recommend to its shareholders (the &ldquo;<U>ARYA Board Recommendation</U>&rdquo;),
(A)&nbsp;the adoption and approval of this Agreement and the transactions contemplated hereby (the &ldquo;<U>Business Combination Proposal</U>&rdquo;);
(B)&nbsp;the adoption and the approval of the Domestication (the &ldquo;<U>Domestication Proposal</U>&rdquo;); (C)&nbsp;the adoption
and approval of the issuance of the ARYA Shares in connection with the transactions contemplated by this Agreement as required by Nasdaq
listing rules&nbsp;(the &ldquo;<U>Nasdaq Proposal</U>&rdquo;); (D)&nbsp;the adoption and approval of the ARYA Post-Closing Certificate
of Incorporation (the &ldquo;<U>Required Governing Document Proposal</U>&rdquo;); (E)&nbsp;the approval, on a non-binding advisory basis,
of certain differences between the Governing Documents of ARYA as in effect as of such time and the proposed ARYA Post-Closing Certificate
of Incorporation and the proposed ARYA Post-Closing Bylaws (collectively, the &ldquo;<U>Other Governing Document Proposals</U>&rdquo;);
(F)&nbsp;the adoption and approval of the Post-Closing Incentive Equity Plan (the &ldquo;<U>Incentive Equity Plan Proposal</U>&rdquo;);
(G)&nbsp;the adoption and approval of the Post-Closing Employee Stock Purchase Plan; (H)&nbsp;the adoption and approval of each other
proposal that either the SEC or Nasdaq (or the respective staff members thereof) indicates is necessary in its comments to the Registration
Statement / Proxy Statement or in correspondence related thereto; (I)&nbsp;the adoption and approval of each other proposal reasonably
agreed to by ARYA and Amber GT Parent as necessary or appropriate in connection with the consummation of the transactions contemplated
by this Agreement or the Additional Agreements; and (J)&nbsp;the adoption and approval of a proposal for the adjournment of the ARYA
Shareholders Meeting, if necessary, to permit further solicitation of proxies because there are not sufficient votes to approve and adopt
any of the foregoing (such proposals in (A)&nbsp;through (J), collectively, the &ldquo;<U>Transaction Proposals</U>&rdquo;), and (ii)&nbsp;ARYA
shall include such recommendation contemplated by clause (i)&nbsp;in the Registration Statement / Proxy Statement. Notwithstanding the
foregoing or anything to the contrary herein, ARYA may only adjourn the ARYA Shareholders Meeting (1)&nbsp;to solicit additional proxies
for the purpose of obtaining the ARYA Shareholder Approval, (2)&nbsp;for the absence of a quorum, (3)&nbsp;to allow reasonable additional
time for the filing or mailing of any supplemental or amended disclosures that ARYA (or Amber GT Parent) has reasonably determined in
good faith, based on the advice of outside legal counsel, is reasonably likely to be required under applicable Law and for such supplemental
or amended disclosure to be disseminated and reviewed by the shareholders of ARYA prior to the ARYA Shareholders Meeting or (4)&nbsp;if
the holders of ARYA Class&nbsp;A Shares have elected to redeem a number of ARYA Class&nbsp;A Shares as of such time that would reasonably
be expected to result in the condition set forth in <U>Section&nbsp;8.1(g)</U>&nbsp;not being satisfied; <U>provided</U> that, without
the consent of Amber GT Parent (such consent not to be unreasonably withheld, conditioned or delayed), in no event shall ARYA adjourn
the ARYA Shareholders Meeting for more than fifteen (15) Business Days later than the most recently adjourned meeting or to a date that
is beyond the date that is five (5)&nbsp;Business Days prior to the Termination Date. ARYA covenants that none of the ARYA Board, ARYA
or any committee of the ARYA Board shall (x)&nbsp;except as otherwise required by applicable Law, change, withdraw, withhold, qualify,
amend or modify, or publicly propose to change, withdraw, withhold, qualify, amend or modify, in a manner adverse to the Amber Entities,
any recommendation by the ARYA Board or ARYA of Transaction Proposals, (y)&nbsp;adopt, approve, recommend or declare advisable or publicly
propose to adopt, approve, recommend or declare advisable, any ARYA Acquisition Proposal or (z)&nbsp;except as otherwise required by
applicable Law, fail to include the ARYA Board Recommendation in the Registration Statement / Proxy Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Nasdaq
Listing</U>. ARYA shall use its reasonable best efforts to (a)&nbsp;cause the ARYA Class&nbsp;A Shares issuable in accordance with this
Agreement to be approved for listing on Nasdaq, subject to official notice of issuance thereof and (b)&nbsp;to satisfy any applicable
initial and continuing listing requirements of Nasdaq, in each case prior to the Closing. Each Amber Entity shall, and shall cause its
Representatives to, reasonably cooperate with ARYA and its Representatives in connection with the foregoing. From the date of this Agreement
through the Closing, (i)&nbsp;ARYA will use reasonable best efforts to keep current and timely file all of its required public filings
with the SEC and otherwise comply in all material respects with applicable securities Laws and (ii)&nbsp;if ARYA receives any written
or, to the knowledge of ARYA, oral notice from Nasdaq that ARYA has failed, or would reasonably be expected to fail, to meet the listing
requirements of the Nasdaq as of the Closing or within six (6)&nbsp;months thereafter for any reason, then ARYA shall, if not otherwise
prohibited by applicable Law or Order, give written notice of such Nasdaq notice to Amber GT Parent as promptly as practicable thereafter,
including, if applicable and not otherwise prohibited by applicable Law or Order, a copy of any written notice received from Nasdaq (<U>provided
</U>that a failure, in and of itself, to give any notice contemplated by this clause&nbsp;(ii)&nbsp;shall in no event cause the condition
to Closing set forth in <U>Section&nbsp;8.3(a)</U>&nbsp;to not be satisfied). Notwithstanding the foregoing or anything to the contrary
herein, in no event shall ARYA be deemed to be in breach or violation of this <U>Section&nbsp;6.8</U> to the extent such breach or violation
of this <U>Section&nbsp;6.8</U> directly or indirectly resulted from a breach by any Amber Entity of any of its applicable covenants,
agreements and obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Trust
Account</U>. Upon satisfaction or, to the extent permitted by applicable Law, waiver of the conditions set forth in <U>Article&nbsp;VIII
</U>and provision of notice thereof to the Trustee, (a)&nbsp;at the Closing, ARYA shall (i)&nbsp;cause the documents, certificates and
notices required to be delivered to the Trustee pursuant to the Investment Management Trust Agreement to be so delivered, and (ii)&nbsp;make
all appropriate arrangements to cause the Trustee to (A)&nbsp;pay as and when due all amounts, if any, payable to the ARYA shareholders
in respect of the ARYA Share Redemptions, (B)&nbsp;pay the amounts due to the underwriters of ARYA&rsquo;s initial public offering for
their Deferred Underwriting Commissions as set forth in the Investment Management Trust Agreement and (C)&nbsp;immediately thereafter,
pay all remaining amounts then available in the Trust Account to ARYA, or to such other recipients as ARYA designates (as approved by
Amber GT Parent), in accordance with the Investment Management Trust Agreement, and (b)&nbsp;thereafter, the Trust Account shall terminate,
except as otherwise provided therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 114; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Directors&rsquo;
and Officers&rsquo; Indemnification and Insurance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Party agrees that (i)&nbsp;all rights to indemnification or exculpation now existing in favor of the directors and officers of ARYA,
as provided in the Governing Documents of ARYA or otherwise in effect as of immediately prior to the Domestication, in either case, solely
with respect to any matters occurring on or prior to the Closing, shall survive the transactions contemplated by this Agreement and shall
continue in full force and effect from and after the Closing for a period of six (6)&nbsp;years and (ii)&nbsp;ARYA will perform and discharge,
or cause to be performed and discharged, all obligations to provide such indemnity and exculpation during such six (6)&nbsp;year period.
To the maximum extent permitted by applicable Law, during such six (6)&nbsp;year period, ARYA shall advance, or cause to be advanced,
expenses in connection with such indemnification as provided in the Governing Documents of ARYA or other applicable agreements as in
effect immediately prior to the Domestication. The indemnification and liability limitation or exculpation provisions of the Governing
Documents of ARYA shall not, during such six (6)&nbsp;year period, be amended, repealed or otherwise modified following the Closing in
any manner that would adversely affect the rights thereunder of individuals who, as of immediately prior to the Closing, or at any time
prior to such time, were directors or officers of ARYA (the &ldquo;<U>ARYA D&amp;O Persons</U>&rdquo;) entitled to be so indemnified,
have their liability limited or be exculpated with respect to any matters occurring on or prior to the Closing and relating to the fact
that such ARYA D&amp;O Person was a director or officer of ARYA on or prior to the Closing, unless such amendment, repeal or other modification
is required by applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
shall not have any obligation under this <U>Section&nbsp;6.10</U> to any ARYA D&amp;O Person when and if a court of competent jurisdiction
shall ultimately determine (and such determination shall have become final and non-appealable) that the indemnification of such ARYA
D&amp;O Person in the manner contemplated hereby is prohibited by applicable Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
shall purchase, at or prior to the Closing, and ARYA shall maintain, or cause to be maintained, in effect for a period of six (6)&nbsp;years
following the Closing, without any lapses in coverage, a &ldquo;tail&rdquo; policy providing directors&rsquo; and officers&rsquo; liability
insurance for the benefit of those Persons who are covered (whether directly, via endorsement or otherwise) by any comparable insurance
policies of ARYA in effect as of the date of this Agreement with respect to matters occurring on or prior to the Closing. Such insurance
policy shall provide coverage on terms (with respect to coverage and amount) that are substantially the same as (and no less favorable
in the aggregate to the Persons covered thereby than) the coverage provided under ARYA&rsquo;s directors&rsquo; and officers&rsquo; liability
insurance policies in effect as of the date of this Agreement; <U>provided</U> that ARYA shall not be obligated to pay annual premiums
in excess of three hundred-fifty percent (350%) of the most recent annual premium paid by ARYA prior to the date of this Agreement and,
in such event, ARYA shall purchase the maximum coverage available for three hundred-fifty percent (350%) of the most recent annual premium
paid by ARYA prior to the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 115; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
ARYA or any of its successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any other corporation or entity and shall
not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or substantially
all of their respective properties and assets as an entity in one or a series of related transactions to any Person, then in each such
case, proper provisions shall be made so that the successors or assigns of ARYA shall assume all of the obligations set forth in this
<U>Section&nbsp;6.10</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Persons entitled to the indemnification, liability limitation, exculpation or insurance coverage set forth in this <U>Section&nbsp;6.10
</U>are intended to be third-party beneficiaries of this <U>Section&nbsp;6.10</U>. This <U>Section&nbsp;6.10</U> shall survive the consummation
of the transactions contemplated by this Agreement and shall be binding on all successors and assigns of ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Post-Closing
Directors and Officers</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
of ARYA and the Amber Entities shall take all such action within their respective power as may be necessary or appropriate such that
effective immediately after the Closing: (i)&nbsp;the ARYA Board shall consist of seven (7)&nbsp;directors, which shall be divided into
three (3)&nbsp;classes, designated Class&nbsp;I,&nbsp;II and III, with Class&nbsp;I consisting of two (2)&nbsp;directors, Class&nbsp;II
consisting of two (2)&nbsp;directors and Class&nbsp;III consisting of three (3)&nbsp;directors; (ii)&nbsp;the members of the ARYA Board
are the individuals determined in accordance with <U>Section&nbsp;6.11(b)</U>; (iii)&nbsp;the members of the compensation committee,
audit committee and nominating committee of the ARYA Board are the individuals determined in accordance with <U>Section&nbsp;6.11(c)</U>;
and (iv)&nbsp;the officers of ARYA and the Company (collectively, the &ldquo;<U>Officers</U>&rdquo;) are the individuals determined in
accordance with <U>Section&nbsp;6.11(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to the time at which the Registration Statement / Proxy Statement is declared effective under the Securities Act and in accordance with
<U>Section&nbsp;6.11(a)</U>, ARYA Sponsor and Amber GT Parent shall designate the directors that will be on the ARYA Board immediately
after the Closing, as follows: (i)&nbsp;the ARYA Sponsor shall designate one (1)&nbsp;individual (the &ldquo;<U>ARYA Designee</U>&rdquo;)
as a Class&nbsp;III director; (ii)&nbsp;Amber GT Parent shall designate two (2)&nbsp;individuals (each, an &ldquo;<U>Amber GT Parent
Designee</U>&rdquo;), one of which shall be a Class&nbsp;II director and the other a Class&nbsp;I director; and (iii)&nbsp;ARYA and Amber
GT Parent shall mutually agree to designate four (4)&nbsp;individuals (each, an &ldquo;<U>Agreed Designee</U>&rdquo;), each of which
shall be designated to such other director class positions as mutually agreed by ARYA and Amber GT Parent (such agreement not to be unreasonably
withheld, conditioned or delayed by either ARYA or Amber GT Parent).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 7 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to the time at which the Registration Statement / Proxy Statement is declared effective under the Securities Act, (i)&nbsp;the ARYA Sponsor
may designate the ARYA Designee to serve as a member of the compensation committee, the audit committee or the nominating committee of
the ARYA Board immediately after the Closing, subject to applicable listing rules&nbsp;of Nasdaq and applicable securities Laws,&nbsp;(ii)&nbsp;Amber
GT Parent may designate up to one Amber GT Parent Designee to serve as a member of the compensation committee, the audit committee or
the nominating committee of the ARYA Board immediately after the Closing, subject to applicable listing rules&nbsp;of Nasdaq and applicable
securities Laws, and (iii)&nbsp;the ARYA Sponsor and Amber GT Parent shall mutually agree (such agreement not to be unreasonably withheld,
conditioned or delayed by either the ARYA Sponsor or Amber GT Parent) to the other members of the compensation committee, the audit committee
or the nominating committee of the ARYA Board immediately after the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
individuals identified on <U>Section&nbsp;6.11(d)</U>&nbsp;of the Amber Disclosure Schedules shall be Officers immediately after the
Closing, with each such individual holding the title set forth opposite his or her name. In the event that any such individual identified
on <U>Section&nbsp;6.11(d)</U>&nbsp;of the Amber Disclosure Schedules is unwilling or unable (whether due to death, disability or otherwise)
to serve as an Officer, then, prior to the time at which the Registration Statement / Proxy Statement is declared effective under the
Securities Act, Amber GT Parent and ARYA Sponsor shall mutually determine (such Agreement not to be unreasonably withheld, conditioned
or delayed by either Amber GT Parent or ARYA Sponsor) another individual to serve as such Officer and, upon such mutual agreement, <U>Section&nbsp;6.11(d)</U>&nbsp;of
the Amber Disclosure Schedules shall automatically be deemed amended to include such replacement individual as an Officer in lieu of,
and to serve with the same title as, the individual so replaced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Tax
Matters</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cooperation</U>.
Following the Closing Date, each Party shall reasonably cooperate (and cause its Affiliates to reasonably cooperate), as and to the extent
reasonably requested by each other Party, in connection with the preparation and filing of Tax Returns with respect to the Business and
any examination or other Tax Action with respect to Taxes or Tax Returns of or with respect to any of the Business Entities for any Pre-Closing
Tax Period or Straddle Period. Such cooperation shall include the provision of records and information which are reasonably relevant
to any such audit or other Tax Action, making employees available on a mutually convenient basis to provide additional information and
explanation of any material provided hereunder, and executing any powers of attorney required in connection with any such audit or other
Tax Action. Following the Closing, each of Amber GT Parent and ARYA shall (and shall cause its respective Affiliates to) retain all books
and records with respect to Tax matters pertinent to the Business Entities or the Business relating to any taxable period (or portion
of any taxable period) beginning before the Closing Date until the expiration of the statute of limitations (including any extensions
thereof) of the respective taxable periods, and to abide by all record retention agreements entered into with any Taxing Authority. Each
of Amber GT Parent and ARYA shall (and shall cause its respective Affiliates to) provide any information reasonably requested to allow
Amber GT Parent, ARYA or the Business Entities to comply with any information reporting or withholding requirements contained in the
Code or other applicable Laws or to compute the amount of payroll or other employment Taxes due with respect to any payment made in connection
with this Agreement. For the avoidance of doubt, this <U>Section&nbsp;6.12(a)</U>&nbsp;shall not apply to any dispute or threatened dispute
among the Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transfer
Taxes</U>. All Transfer Taxes, other than the Pre-Closing Reorganization Transfer Taxes, shall be borne by the Company. Unless otherwise
required by applicable Law, the Company shall prepare and file, or cause to be prepared and filed, all necessary Tax Returns in respect
of such Transfer Taxes and other documentation with respect to all Transfer Taxes, and, if required by applicable Law, Amber GT Parent,
the Business Entities and ARYA shall, and shall cause their respective Affiliates to, reasonably cooperate and join in the execution
of any such Tax Returns and other documentation. The Parties shall reasonably cooperate to establish any available exemption from (or
reduction in) any such Transfer Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 117; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intended
Tax Treatment</U>. The Parties acknowledge and agree that for U.S. federal and, as applicable, state and local Tax purposes, it is intended
that: (i)&nbsp;prior to the Pre-Closing Reorganization, the Company has been an entity disregarded as separate from Amber GT, and (ii)&nbsp;as
a result of the contribution of the Closing Date Contribution Amount by ARYA, the Company will become a partnership pursuant to the general
principles of Rev. Rul. 99-5, 1991-1 C.B. 434, Situation 2 (clauses&nbsp;(i)&nbsp;and (ii), the &ldquo;<U>Intended Tax Treatment</U>&rdquo;).
The Parties shall, and shall cause each of their respective applicable Affiliates to, in each case except as otherwise required by a
 &ldquo;determination&rdquo; within the meaning of Section&nbsp;1313(a)&nbsp;of the Code, (A)&nbsp;prepare and file all Tax Returns consistent
with the Intended Tax Treatment and (B)&nbsp;take no position in any Tax Action that is inconsistent with the Intended Tax Treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Straddle
Periods</U>. For purposes of this Agreement, whenever it is necessary to determine the liability for Taxes of or with respect to any
Business Entity or otherwise with respect to the Business for any Straddle Period, the determination of such Taxes for the portion of
the Straddle Period ending on and including, and the portion of the Straddle Period beginning after, the Closing Date shall be determined
by assuming that the Straddle Period consisted of two (2)&nbsp;taxable years or periods, one which ended on (and included) the Closing
Date and the other which began on the day following the Closing Date, and all taxable items of or with respect to such Business Entity
(or otherwise with respect to the Business) for the Straddle Period shall be allocated between such two (2)&nbsp;taxable years or periods
on a &ldquo;closing of the books basis&rdquo; by assuming that the books of the applicable Person were closed at the close of the Closing
Date; <U>provided</U>, <U>however</U>, (i)&nbsp;exemptions, allowances or deductions that are calculated on an annual basis, such as
the deduction for depreciation, and (ii)&nbsp;periodic Taxes (other than income, franchise/capital, sales, use, or withholding Taxes)
such as real and personal property Taxes, shall be apportioned ratably between such periods based on the number of days for the portion
of the Straddle Period ending on and including the Closing Date, on the one hand, and the number of days for the portion of the Straddle
Period beginning after the Closing Date, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Contests
Related to Taxes</U>. Each Party agrees to provide written notice to the other applicable Parties within fifteen (15) days of the receipt
of any written notice by such Party of any Tax Action involving Taxes payable by or with respect to any Business Entity or otherwise
with respect to the Business for any Pre-Closing Tax Period or Straddle Period (a &ldquo;<U>Tax Claim</U>&rdquo;). Amber GT Parent shall
have the responsibility for, and the right to control, any Tax Claims that relate to a Pre-Closing Tax Period it elects to control by
notice to the Company within fifteen (15) days after receipt of notice thereof from the Taxing Authority or pursuant to this <U>Section&nbsp;6.12(e)</U>;
<U>provided</U> that (i)&nbsp;Amber GT Parent shall not settle or compromise any such Tax Claim without the prior written consent of
the Company (such consent not to be unreasonably withheld, conditioned or delayed) and (ii)&nbsp;the Company may participate in (but
not control) any such defense and investigation at its sole cost and expense. The Company shall control all Tax Claims that relate to
a Pre-Closing Tax Period that Amber GT Parent does not elect to control pursuant to this <U>Section&nbsp;6.12(e)</U>&nbsp;and all Tax
Claims that relate to a Straddle Period; <U>provided</U> that (i)&nbsp;the Company shall not settle or compromise any such Tax Claim
that would reasonably be expected to materially increase Amber GT Parent&rsquo;s Tax liability or indemnification obligations pursuant
to this Agreement without the prior written consent of Amber GT Parent (such consent not to be unreasonably withheld, conditioned or
delayed) and (ii)&nbsp;Amber GT Parent may participate in (but not control) any such defense and investigation at its sole cost and expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 118; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Any
refund (or credit in lieu of a refund) received by ARYA, the Company or the Business Entities for Taxes (including any interest thereon
received from a Taxing Authority) with respect to the Business Entities or otherwise with respect to the Business for any Pre-Closing
Tax Period or the pre-Closing portion of any Straddle Period (such Taxes for a Straddle Period to be determined in accordance with <U>Section&nbsp;6.12(d)</U>)
shall be for the account of Amber GT Parent, and ARYA or the Company shall (or shall cause the applicable Business Entity to) promptly
(and in no event later than five (5)&nbsp;Business Days after receipt by ARYA, the Company or any Business Entity thereof) pay to Amber
GT Parent the amount of any such refund; <U>provided</U>, that ARYA, the Company and the Business Entities shall not be required to affirmatively
seek any such refund (or credit). A refund (or credit) of Taxes shall be treated for this purpose as received to the extent that any
amount otherwise refundable has instead been set off or otherwise applied to or against, or has otherwise reduced, any Tax payable by,
or liability of, (i)&nbsp;the Business Entities for any period other than a Pre-Closing Tax Period or the pre-Closing portion of any
Straddle Period, or (ii)&nbsp;ARYA or the Company. The amount of any refund (or credit) payable to Amber GT Parent pursuant to this <U>Section&nbsp;6.12(f)</U>&nbsp;shall
be net of all reasonable out-of-pocket costs and expenses (including Taxes) incurred by ARYA, the Company or the Business Entities in
connection with realizing such refund (or credit).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Tax
Covenants Survival</U>. Notwithstanding any provision of this Agreement to the contrary, the covenants and agreements set forth in this
<U>Section&nbsp;6.12</U> shall survive until sixty (60) days after the expiration of the applicable statute of limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Post-Closing
Incentive Equity Plan; Post-Closing Employee Stock Purchase Plan</U>. The ARYA Board shall approve and adopt an equity incentive plan,
substantially in the form attached hereto as <U>Exhibit&nbsp;I-1</U> and with any changes or modifications thereto as Amber GT Parent
and ARYA may mutually agree in writing (such agreement not to be unreasonably withheld, conditioned or delayed by either Amber GT Parent
or ARYA, as applicable) (the &ldquo;<U>Post-Closing Incentive Equity Plan</U>&rdquo;), in the manner prescribed under applicable Laws,
effective as of one (1)&nbsp;day prior to the Closing Date, reserving 9,000,000 ARYA Class&nbsp;A Shares for issuance thereunder and
providing for a ten (10)-year annual &ldquo;evergreen&rdquo; replenishment of the ARYA Class&nbsp;A Shares reserved for issuance thereunder,
in an amount, which when added to the ARYA Class&nbsp;A Shares reserved for issuance under the Post-Closing Incentive Equity Plan immediately
prior to each such replenishment, shall equal 5% of the then outstanding ARYA Shares. The ARYA Board shall approve and adopt an employee
stock purchase plan, substantially in the form attached hereto as <U>Exhibit&nbsp;I-2</U> and with any changes or modifications thereto
as Amber GT Parent and ARYA may mutually agree in writing (such agreement not to be unreasonably withheld, conditioned or delayed by
either Amber GT Parent or ARYA, as applicable) (the &ldquo;<U>Post-Closing Employee Stock Purchase Plan</U>&rdquo;), in the manner prescribed
under applicable Laws, effective as of one (1)&nbsp;day prior to the Closing Date, reserving the number of ARYA Class&nbsp;A Shares set
forth therein for issuance thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 119; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Pre-Closing
Reorganization; Excluded Assets and Liabilities</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Amber Entities shall, and shall cause their respective Representatives to (x)&nbsp;use reasonable best efforts to complete the Pre-Closing
Reorganization no later than immediately prior to the Closing, and (y)&nbsp;reasonably consult with and cooperate with ARYA and its Representatives
in connection with the Pre-Closing Reorganization and otherwise keep ARYA and its Representatives apprised, in reasonable detail, of
the status of the Pre-Closing Reorganization. Without limiting the generality of the foregoing, (i)&nbsp;as promptly as practicable following
the date hereof (and in any event fifteen (15) Business Days prior to the Closing Date), Amber GT Parent shall provide, or cause to be
provided, drafts of all agreements, documents and instruments related to the Pre-Closing Reorganization, and give ARYA and its Representatives
a reasonable amount of time to review and provide comments to all such agreements, documents and instruments and shall consider in good
faith all comments provided by ARYA and its Representatives, and (ii)&nbsp;none of the Amber Entities or any of their Affiliates shall
enter into any agreement, document or instrument related to the Pre-Closing Reorganization that is not in a form and substance reasonably
satisfactory to ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything in <U>Section&nbsp;2.1</U> or otherwise in this Agreement to the contrary, from and after the Pre-Closing Reorganization, Amber
GT Parent and its Affiliates shall retain all of their respective rights, titles and interests in and to, and there shall be excluded
from the transfer, conveyance, assignment and delivery to the Company, and the Contributed Business Assets shall not include, the following
assets, properties, claims and rights (whether tangible, intangible or otherwise and wherever located) (collectively, the &ldquo;<U>Excluded
Assets</U>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
cash, cash equivalents, credit cards and bank accounts of Amber GT Parent or any of its Affiliates (other than, for the avoidance of
doubt, the Business Entities);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">except
as provided in <U>Article&nbsp;VII</U>, the sponsorship of, and all assets or contracts maintained pursuant to or in connection with,
all Employee Benefit Plans;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Intellectual Property, other than the Contributed Intellectual Property;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
insurance policies and rights thereunder, other than to the extent provided in <U>Section&nbsp;1.92(l)</U>&nbsp;or <U>Section&nbsp;6.20</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
assets, properties and rights described on <U>Section&nbsp;6.14(b)(v)</U>&nbsp;of the Amber Disclosure Schedules; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
other assets, properties and rights of Amber GT Parent or any of its Affiliates, of whatever kind and nature, real, personal or mixed,
tangible or intangible, or otherwise, that are not specifically addressed by <U>Section&nbsp;1.92</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 120; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary in this Agreement, from and after the Pre-Closing Reorganization, Amber GT Parent shall retain and remain responsible
for and satisfy, discharge and perform when due, and ARYA and its Affiliates (including, from and after the Closing, the Business Entities)
shall have no obligation with respect to, all of the following Liabilities (collectively, the &ldquo;<U>Excluded Liabilities</U>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Pre-Closing Taxes provided, that for the avoidance of doubt, this clause&nbsp;(i)&nbsp;is the only clause of this <U>Section&nbsp;6.14(c)</U>&nbsp;that
includes Liabilities with respect to Taxes;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Liabilities to the extent related to or arising out of any Indebtedness of the Business Entities existing at or prior to the Closing
or of Amber GT Parent, Amber GT or any of their respective Affiliates (other than the Business Entities) existing at any time;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Liabilities to the extent related to or arising out of (A)&nbsp;any employee or independent contractor of the Amber Entities or any of
their Affiliates who is not a Transferred Employee at any time prior to, on or after the Closing Date, (B)&nbsp;any Transferred Employee
on or prior to the Closing (including, all Liabilities to the extent relating to or attributable to such employee&rsquo;s or contractor&rsquo;s
work, employment or engagement prior to the Closing or any claim relating to or attributable to facts that occurred prior to the Closing)
or (C)&nbsp;any incentive equity or similar awards of Amber GT Parent or any of its Affiliates held by any Transferred Employee;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Liabilities in respect of any Action, whether or not presently threatened, asserted or pending, to the extent related to or arising out
of the conduct of the Business or the operation of the Contributed Business Assets prior to the Closing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">except
as set forth in <U>Article&nbsp;VII</U>, all Liabilities to the extent related to or arising out of the matters listed on <U>Section&nbsp;6.14(c)(v)</U>&nbsp;of
the Amber Disclosure Schedules or any Employee Benefit Plans;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Liabilities related to or arising out of any noncompliance by Amber GT Parent or any of its Affiliates, employees or agents with any
applicable Law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">each
Change of Control Payment to the extent related to any Contracts or other arrangements in effect prior to the Closing and that are not
otherwise agreed in writing by ARYA;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Liabilities allocated to Amber GT Parent pursuant to <U>Section&nbsp;6.17</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
Amber Entity Expenses allocated to Amber GT Parent pursuant to <U>Section&nbsp;11.5</U>; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">all
other Liabilities of Amber GT Parent or any of its Affiliates or to the extent related to or arising out of the Contributed Business
Assets or the Business, in each case, that are not specifically addressed by <U>Section&nbsp;1.50</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Limitation
on Assignment of Contributed Business Assets; Third-Party Consents</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the contribution, grant, assignment, transfer, conveyance or delivery to any Business Entity of any asset that would be a Contributed
Business Asset or any claim or right or any benefit arising thereunder or resulting therefrom would be prohibited under applicable Law
or would require the Consent of any Person and such Consent has not been given or obtained, as applicable, at or prior to the Closing
(collectively, the &ldquo;<U>Non-Assignable Assets</U>&rdquo;), then, subject to the last sentence of this <U>Section&nbsp;6.15(a)</U>,
(i)&nbsp;the Closing shall proceed in accordance with this Agreement without the contribution, grant, assignment, transfer, conveyance
or delivery, as applicable, of the Non-Assignable Assets, and (ii)&nbsp;to the extent not inconsistent with the terms of any Non-Assignable
Asset or applicable Law, the Parties shall treat the Company as the owner thereof for Tax purposes from and after the Closing. Notwithstanding
the foregoing, (A)&nbsp;an asset shall not constitute a Non-Assignable Asset and the Closing shall not proceed as provided in the immediately
preceding sentence if the prohibition under applicable Law or the failure to give or obtain at or prior to the Closing was proximately
caused by any Amber Entity&rsquo;s breach of any covenant, agreement or obligation under this Agreement (including any of those set forth
in <U>Section&nbsp;6.1</U>), unless such breach is, for purposes of this <U>Section&nbsp;6.15(a)</U>&nbsp;and, if applicable, <U>Section&nbsp;8.3(a)</U>,
waived by ARYA, and (B)&nbsp;this <U>Section&nbsp;6.15(a)</U>&nbsp;shall not be construed as limiting, modifying or otherwise affecting
any of the other covenants or agreements of the Amber Entities under this Agreement to the extent such covenants or agreements require
performance at or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">With
respect to each Non-Assignable Asset, (i)&nbsp;from and after the Closing, Amber GT Parent and Amber GT shall, and shall cause their
Affiliates to, use reasonable best efforts to give, or cause to be given, or to obtain, or cause to be obtained, each Consent required
to contribute, grant, assign, transfer, convey or deliver, as applicable, such Non-Assignable Asset and (ii)&nbsp;upon obtaining or giving
any Consent of the type described in clause&nbsp;(i), the applicable Non-Assignable Asset shall be deemed to have been automatically
contributed, granted, assigned, transferred, conveyed or delivered, as applicable, to the Company (or, in the sole discretion of ARYA,
any Affiliate thereof) on the terms set forth in this Agreement for no additional consideration without the requirement of any further
action of ARYA or any of its Affiliates, as of the Closing, except to the extent the date of such Consent is deemed by applicable Law
to have occurred on another date or is otherwise consented to in writing by ARYA to have occurred as of another date, in which case,
as of such date. ARYA shall, and shall cause its pertinent Affiliates to, at the sole cost and expense of Amber GT Parent, reasonably
cooperate with Amber GT Parent and Amber GT in connection with the foregoing. Notwithstanding the foregoing, in no event shall (A)&nbsp;ARYA
or any its Affiliates be required to make any payments to secure any such Consent or amend, modify or supplement any Contract to which
such Consent may relate, or (B)&nbsp;Amber GT Parent, Amber GT or any of their respective Affiliates amend, modify or supplement any
Contract to which such Consent may relate without ARYA&rsquo;s prior written consent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 122; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Closing until a Non-Assignable Assets is contributed, granted, assigned, transferred, conveyed or delivered, as applicable,
as provided in <U>Section&nbsp;6.15(b)</U>, each of Amber GT Parent and Amber GT shall, and shall cause their respective Affiliates to,
(i)&nbsp;provide the Company and its Affiliates the maximum allowable use of the Non-Assignable Assets, including by establishing an
agency type or similar arrangement reasonably satisfactory to ARYA under which the Company and its Affiliates would obtain the claims,
rights and benefits and assume the corresponding liabilities and obligations with respect thereto (including by means of any subcontracting,
sublicensing or subleasing arrangement) and (ii)&nbsp;exercise, enforce and exploit, only at the direction of ARYA and for the benefit
of the Company and Affiliates, any and all claims, rights and benefits of Amber GT Parent, Amber GT or any of their respective Affiliates
under or with respect to, or arising in connection with, such Non-Assignable Asset to the extent permitted by applicable Law. Except
to the extent expressly prohibited by applicable Law, Amber GT Parent shall hold in trust for and pay to the Company (or, in the sole
discretion of ARYA, any Affiliate thereof) promptly upon receipt thereof, all income, proceeds and other monies received by Amber GT
Parent, Amber GT or any of their Affiliates in respect of any such Non-Assignable Asset, in each case, without any interest; <U>provided
</U>that ARYA shall reimburse Amber GT Parent for any and all reasonable, documented and out-of-pocket costs, fees, expenses and amounts,
other than to the extent constituting Excluded Liabilities, that are incurred by Amber GT solely as a result of any arrangement contemplated
by this <U>Section&nbsp;6.15(c)</U>. Each of the Parties intend that, as of Closing, for applicable tax purposes, the Company should
be treated as the beneficial owner of each Non-Assignable Asset (and shall have the benefits and burdens of such beneficial ownership).
and the Parties shall file all Tax Returns in a manner consistent with such intention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Prior
to the Closing, (i)&nbsp;ARYA and Amber GT Parent shall each use commercially reasonable efforts to, effective as of the Closing, have
Amber GT Parent and any of its Affiliates (other than, for the avoidance of doubt, the Business Entities) removed as guarantor of or
obligor of Liabilities arising after the Closing with respect to the matter set forth on <U>Section&nbsp;6.15(d)</U>&nbsp;of the Amber
Disclosure Schedules (the &ldquo;<U>Existing Amber Guaranty</U>&rdquo;) and (ii)&nbsp;to the extent required to obtain a release of Amber
GT Parent or any of its Affiliates (other than, for the avoidance of doubt, the Business Entities) as a guarantor of or obligor of Liabilities
arising after the Closing under the Existing Amber Guaranty, ARYA shall execute a guarantee agreement, in a form and substance reasonable
acceptable to ARYA and effective as of the Closing, with respect to ARYA being a guarantor of Liabilities in respect of the Existing
Amber Guaranty to the extent arising after the Closing. If the actions contemplated by the preceding sentence are not completed at or
prior to the Closing, then (x)&nbsp;ARYA and Amber GT Parent shall each use commercially reasonable efforts to, as promptly as practicable
after the Closing, have Amber GT Parent and any of its Affiliates (other than, for the avoidance of doubt, the Business Entities) removed
as guarantor of or obligor of Liabilities arising after the Closing with respect to the Existing Amber Guaranty and (ii)&nbsp;to the
extent required to obtain a release of Amber GT Parent or any of its Affiliates (other than, for the avoidance of doubt, the Business
Entities) as a guarantor or obligor of Liabilities arising after the Closing under the Existing Amber Guaranty, ARYA shall execute a
guarantee agreement, in a form and substance reasonably acceptable to ARYA, with respect to ARYA being a guarantor of Liabilities in
respect of the Existing Amber Guaranty to the extent arising after the Closing, and (y)&nbsp;ARYA shall, from and after the Closing,
indemnify, defend and hold harmless Amber GT Parent or its Affiliates, as applicable, against or from any Liability arising out of or
resulting from the Existing Amber Guaranty following the Closing to the extent provided in, and in accordance with, <U>Section&nbsp;10.3
</U>and the other applicable provisions in <U>Article&nbsp;X</U>. Notwithstanding the foregoing or anything to the contrary contained
in this Agreement, (A)&nbsp;in no event shall (i)&nbsp;ARYA or any its Affiliates be required to make any payments or other concessions,
or otherwise amend, modify or supplement any Contract related to the Existing Amber Guaranty, in order to remove Amber GT Parent or any
of its Affiliates as a guarantor or obligor with respect to the Existing Guaranty as contemplated by this <U>Section&nbsp;6.15(d)</U>&nbsp;or,
as applicable, otherwise in connection with ARYA becoming a guarantor in respect of the Existing Amber Guaranty as contemplated by this
<U>Section&nbsp;6.15(d)</U>, except, for the avoidance of doubt, for any amendments, modifications or supplements to any such Contract
solely to the extent that it removes Amber GT Parent or its Affiliates as a guarantor or obligor of, or substitutes ARYA in respect of,
the applicable Liabilities with respect to the Existing Amber Guaranty as expressly contemplated by this <U>Section&nbsp;6.15(d)</U>,
and (ii)&nbsp;Amber GT Parent or any of its Affiliates take any of the actions contemplated by clause (i), except for any payments that
are paid in full by Amber GT Parent or its Affiliates, and (B)&nbsp;for the avoidance of doubt, in no event shall ARYA or any of its
Affiliates have any obligations or Liabilities with respect to any Excluded Liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 123; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Misallocated
Assets</U>. Subject to <U>Section&nbsp;6.15</U> and <U>Section&nbsp;6.17</U>, following the Closing, in the event that any Party becomes
aware that (a)&nbsp;record or beneficial ownership or possession of any asset that is a Contributed Business Asset has not been contributed,
granted, assigned, transferred, conveyed or, as applicable, delivered by the applicable Amber Entity or its Affiliates to a Business
Entity or any of its Affiliates at or prior to the Closing, or that any Assumed Business Liability has not been assumed by a Business
Entity or any of its Affiliates at or prior to the Closing, or (b)&nbsp;record or beneficial ownership or possession of an asset that
is not a Contributed Business Asset has been contributed, granted, assigned, transferred, conveyed or delivered, as applicable, by Amber
GT Parent or any of its Affiliates to the Company or one of its Affiliates at or prior to the Closing, or that any Excluded Liability
has been erroneously assumed by the Company or any of its Affiliates at or prior to the Closing, then it shall promptly notify, in the
case of Amber GT Parent or Amber GT, ARYA or, in the case of ARYA or the Company, Amber GT Parent, and the Parties shall thereafter reasonably
cooperate to, as promptly as practicable, (i)&nbsp;contribute, grant, assign, transfer convey or deliver (or cause to be contributed,
granted, assigned, transferred, conveyed or delivered), as applicable, without consideration the relevant asset to the Company or an
Affiliate thereof designated by ARYA in writing or Amber GT Parent or an Affiliate thereof designated by Amber GT Parent in writing,
as applicable, or (ii)&nbsp;cause the relevant Liability to be assumed by the Company or an Affiliate thereof designated by ARYA in writing
or Amber GT Parent or an Affiliate thereof designated by Amber GT Parent in writing, as applicable, in each case pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Shared
Contracts</U>. Except as otherwise agreed by Amber GT Parent and ARYA in writing or as otherwise expressly provided in this Agreement
or any of the Additional Agreements, until the expiration date of any Specified Shared Contract, the Parties shall (and shall cause their
respective Affiliates to) use reasonable best efforts to obtain or structure an arrangement for the Company and its Affiliates to, from
and after the Closing, obtain the claims, rights and benefits, and assume the corresponding Liabilities and obligations thereunder (other
than to the extent related to or arising out of any breach or other violation of such Specified Shared Contract at or prior to the Closing),
of such portion of any such Specified Shared Contract that is related to or arising out of the Business with terms and conditions materially
similar to those terms and conditions applicable as of the date hereof or, if entered into after the date hereof, as of immediately prior
to the Closing, as reasonably determined by Amber GT Parent and ARYA in good faith. With respect to Shared Contractual Liabilities pursuant
to, under or relating to any Specified Shared Contract, such Shared Contractual Liabilities shall be allocated between Amber GT Parent
and the Company as follows: (a)&nbsp;if a liability is incurred solely in respect of either the Business or the other businesses of Amber
GT Parent or any of its Affiliates, such liability shall be allocated to the Company or an Affiliate thereof designated in writing by
ARYA (in respect of the Business) or Amber GT Parent (in respect of the other businesses of Amber GT Parent or any of its Affiliates);
and (b)&nbsp;if a liability cannot be so allocated under clause&nbsp;(a), such liability shall be allocated to Amber GT Parent or the
Company or an Affiliate thereof designated in writing by ARYA, as the case may be, based on the relative proportion of total benefit
received by the Company or any of its Affiliates in respect of the Business and Amber GT Parent or any of its Affiliates in respect of
its other businesses under the relevant Specified Shared Contract, as reasonably determined in good faith by Amber GT Parent and ARYA.
Notwithstanding the foregoing or anything to the contrary in this Agreement, (i)&nbsp;Amber GT Parent or ARYA, as applicable, shall be
responsible for any or all Liabilities arising from its (or its Affiliates&rsquo;) direct or indirect breach of any Specified Shared
Contract and (ii)&nbsp;from and after the Closing, except as required by applicable Law or with the prior written consent of ARYA (not
to be unreasonably withheld, condition or delayed), Amber GT Parent shall not, and shall cause its Affiliates not to, (A)&nbsp;amend
or modify in a manner that is adverse to ARYA, any of its Affiliates or the Business in any material respect or terminate any Specified
Shared Contract (excluding, for the avoidance of doubt, any expiration or automatic extension or renewal of any such Specified Shared
Contract pursuant to its terms), or (B)&nbsp;waive any material benefit or right under any Specified Shared Contract to the extent related
to the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Restrictive
Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amber
GT Parent covenants and agrees that, during the period beginning as of the Closing Date and ending on the twelve (12) month anniversary
thereof (the &ldquo;<U>Restrictive Covenant Period</U>&rdquo;), other than with respect to the arrangements set forth in the Co-Development
and Commercialization Agreement, it shall not, and shall cause its Affiliates not to, directly or indirectly, (i)&nbsp; acquire, finance,
own any interest in, manage, control, participate in, consult with, render services for, operate or in any manner engage in the Business
(collectively, the &ldquo;<U>Restricted Business</U>&rdquo;) anywhere in the world, (ii)&nbsp;conduct or engage in a Competing Business
or (iii)&nbsp;take any action that is designed or intended to have the effect of discouraging any licensor, client, supplier, vendor,
customer or other business relation of the Business from maintaining the same business relationships with the Company or any of its Affiliates
after the Closing as it maintained with such Person prior to the Closing or at any time during the Restrictive Covenant Period. Notwithstanding
the foregoing, (A)&nbsp;direct or indirect ownership of less than five percent (5%) of the outstanding Equity Securities of a publicly
traded corporation shall not, in and of itself, be deemed to be engaging in the Restricted Business or otherwise constitute a violation
of this <U>Section&nbsp;6.18(a)</U>&nbsp;and (B)&nbsp;this <U>Section&nbsp;6.18(a)</U>&nbsp;shall not prohibit or otherwise restrict
Amber GT Parent from entering into or consummating an Amber GT Parent Change of Control Transaction; <U>provided</U> that, from and after
the consummation of any such Amber GT Parent Change of Control Transaction and continuing until the end of the Restrictive Covenant Period,
the restrictions set forth in this <U>Section&nbsp;6.18(a)</U>&nbsp;shall continue to apply to Amber GT Parent and its controlled Affiliates
(but not, for the avoidance of doubt, the acquiring Person(s)&nbsp;or any of its or their Affiliates as of immediately prior to the consummation
of such Amber GT Parent Change of Control Transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 125; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
covenants and agrees that, during the Restrictive Covenant Period, other than with respect to the arrangements set forth in the Co-Development
and Commercialization Agreement, it shall not, and shall cause its Affiliates not to, directly or indirectly, (i)&nbsp; acquire, finance,
own any interest in, manage, control, participate in, consult with, render services for, operate or in any manner engage in the Retained
Business anywhere in the world, (ii)&nbsp;conduct or engage in a Competing Business or (iii)&nbsp;take any action that is designed or
intended to have the effect of discouraging any licensor, client, supplier, vendor, customer or other business relation of the Retained
Business from maintaining the same business relationships with Amber GT or any of its Affiliates after the Closing as it maintained with
such Person prior to the Closing or at any time during the Restrictive Covenant Period (it being understood and agreed, for the avoidance
of doubt, that this clause (iii)&nbsp;shall in no event limit or affect the ability of ARYA or any of its Affiliates from operating or
conducting the Business or otherwise having relationships, arrangements or agreements with any such licensor, client, supplier, vendor,
customer or other business relation related to the conduct or operation of the Business following the Closing). Notwithstanding the foregoing,
(A)&nbsp;direct or indirect ownership of less than five percent (5%) of the outstanding Equity Securities of a publicly traded corporation
shall not, in and of itself, be deemed to be engaging in the Retained Business or otherwise constitute a violation of this <U>Section&nbsp;6.18(b)</U>&nbsp;and
(B)&nbsp;this <U>Section&nbsp;6.18(b)</U>&nbsp;shall not prohibit or otherwise restrict ARYA from entering into or consummating an ARYA
Change of Control Transaction; <U>provided</U> that, from and after the consummation of an ARYA Change of Control Transaction and continuing
until the end of the Restrictive Covenant Period, the restrictions set forth in this <U>Section&nbsp;6.18(b)</U>&nbsp;shall continue
to apply to ARYA and its controlled Affiliates (but not, for the avoidance of doubt, the acquiring Person(s)&nbsp;or any of its or their
Affiliates as of immediately prior to the consummation of such ARYA Change of Control Transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
<U>Section&nbsp;6.18(a)</U>&nbsp;or <U>Section&nbsp;6.18(b)</U>&nbsp;shall be deemed breached as a result of the ownership by either
Amber GT Parent or any of its Affiliates, or ARYA or any of its Affiliates, as applicable, of any interest if such interest arises as
a result of the acquisition following the Closing Date of a Person that engages, directly or indirectly, in a Competing Business; <U>provided
</U>that (i)&nbsp;such acquisition is not undertaken for the purpose of evading the obligations under <U>Section&nbsp;6.18(a)</U>&nbsp;or
<U>Section&nbsp;6.18(b)</U>, as applicable, and (ii)&nbsp;the applicable Party complies with <U>Section&nbsp;6.18(d)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event that Amber GT Parent, ARYA or any of their Affiliates acquires during the Restricted Covenant Period any interest in a Person
that engages, directly or indirectly, in a Competing Business, then Amber GT Parent or ARYA, as applicable, shall, or shall cause any
such acquiring Affiliate to, divest the Competing Business so acquired as promptly as practicable (but in any event within twelve (12)
months of such acquisition).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amber
GT Parent covenants and agrees that, during the Restrictive Covenant Period, Amber GT Parent shall not, and shall cause its Affiliates
not to, directly or indirectly, (i)&nbsp;solicit, recruit, induce or encourage or attempt to solicit, recruit, induce or encourage any
Transferred Employee to leave the employ of the Company or any of its Affiliates, (ii)&nbsp;hire, employ or otherwise engage any Transferred
Employee or (iii)&nbsp;in any other way adversely interfere with the relationship between any Business Entity or any of its Affiliates,
on the one hand, and any Transferred Employee, on the other; <U>provided</U>, <U>however</U>, that the foregoing shall not prohibit (A)&nbsp;any
Person from making general employment solicitations, such as through advertisements in publicly available media, so long as such general
employment solicitations are not specifically targeted at any employee or other service provider of any Business Entity or its Affiliates
and no Transferred Employee is hired or engaged as a result thereof or (B)&nbsp;Amber GT Parent or any of its Affiliates from hiring
any Transferred Employee within six (6)&nbsp;months following the date of such individual&rsquo;s termination of employment with the
Company or any of its Affiliates following the Closing Date, so long as such individual was not solicited, recruited, induced or encouraged
in violation of this <U>Section&nbsp;6.18(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 126; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">ARYA
covenants and agrees that, during the Restrictive Covenant Period, ARYA shall not, and shall cause its Affiliates not to, directly or
indirectly, (i)&nbsp;solicit, recruit, induce or encourage or attempt to solicit, recruit, induce or encourage any Retained Employee
to leave the employ of Amber GT Parent or any of its Affiliates, (ii)&nbsp;hire, employ or otherwise engage any Retained Employee or
(iii)&nbsp;in any other way adversely interfere with the relationship between Amber GT Parent or any of its Affiliates, on the one hand,
and any Retained Employee, on the other; <U>provided</U>, <U>however</U>, that the foregoing shall not prohibit (A)&nbsp;any Person from
making general employment solicitations, such as through advertisements in publicly available media, so long as such general employment
solicitations are not specifically targeted at any employee or other service provider of any Business Entity or its Affiliates and no
Retained Employee is hired or engaged as a result thereof or (B)&nbsp;ARYA or any of its Affiliates from hiring any Retained Employee
within six (6)&nbsp;months following the date of such individual&rsquo;s termination of employment with Amber GT Parent or any of its
Affiliates following the Closing Date, so long as such individual was not solicited, recruited, induced or encouraged in violation of
this <U>Section&nbsp;6.18(f)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
anything to the contrary in this <U>Section&nbsp;6.18</U>, at any time after the date of this Agreement (i)&nbsp;to the extent that any
Transferred Employee submits a bona fide request for a transfer from the Company to Amber GT Parent or any of its Affiliates and such
request is not the result of a violation of <U>Section&nbsp;6.18(e)</U>, Amber GT Parent shall be permitted to engage with any such Transferred
Employee with respect to an offer of employment with the prior written consent of ARYA (not to be unreasonably withheld, conditioned
or delayed) and (ii)&nbsp;to the extent that any Retained Employee submits a bona fide request for a transfer from Amber GT Parent to
the Company or any of its Affiliates and such request is not the result of a violation of <U>Section&nbsp;6.18(f)</U>, ARYA shall be
permitted to engage with any such Retained Employee with respect to an offer of employment with the prior written consent of Amber GT
Parent (not to be unreasonably withheld, conditioned or delayed), and in each case, Amber GT Parent and ARYA shall cooperate in good
faith to facilitate any such requests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the final judgment of a court of competent jurisdiction declares that any term or provision set forth in this <U>Section&nbsp;6.18</U>
is invalid or unenforceable, the Parties agree that the court making the determination of invalidity or unenforceability shall have the
power to reduce the scope, duration or area of the term or provision, to delete specific words or phrases, or to replace any invalid
or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention
of the invalid or unenforceable term or provision, and this <U>Section&nbsp;6.18</U> shall be enforceable as so modified after the expiration
of the time within which the judgment may be appealed. The Parties intend that the agreements, covenants and obligations set forth in
this <U>Section&nbsp;6.18</U> shall be deemed to be a series of separate covenants, one for each county or province of each and every
state, commonwealth, territory or jurisdiction of each county or province anywhere in the world and one for each month of the Restrictive
Covenant Period or other applicable period of time (if any), as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
the event of a breach or violation of any of the covenants, agreements or obligations in this <U>Section&nbsp;6.18</U>, the Restrictive
Covenant Period shall be tolled until such breach or violation has been duly cured, to the extent such breach or violation is curable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 127; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Related
Party Transactions</U>. Except for the Contracts and other arrangements set forth on <U>Section&nbsp;6.19</U> of the Amber Disclosure
Schedules or as otherwise expressly provided for under any Additional Agreement, at or prior to the Closing, all Contracts, payables,
receivables, Liabilities, obligations and arrangements between any Business Entity, on the one hand, and Amber GT Parent or any of its
Affiliates (other than, for the avoidance of doubt, any Business Entity), on the other hand, and any other Amber Related Party Transactions
shall be terminated, settled, eliminated or cancelled, as applicable, in each case in a manner reasonably satisfactory to ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.20</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Insurance
Coverage</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Except
as otherwise expressly provided in this Agreement (including, for the avoidance of doubt, the immediately subsequent sentence) or any
Additional Agreement, from and after the Closing, the Company and its Affiliates shall be responsible for obtaining and maintaining replacement
insurance coverage for the Business, the Contributed Business Assets and the Business Entities. Notwithstanding the foregoing or anything
to the contrary in this Agreement, (i)&nbsp;with respect to any facts, events, circumstances or occurrences, known or unknown, related
to or arising out of the Business, the Contributed Business Assets or the Transferred Employees that occurred (in whole or in part) prior
to the Closing that are covered by or insured under any occurrence based policies (including self-insurance) or any workers&rsquo; compensation
insurance policies or comparable workers&rsquo; compensation self-insurance, state or country programs of Amber GT Parent or any of its
Affiliates, the Company and its Affiliates may make claims, to the extent such claims relate to or arise out of facts, events, circumstances
or occurrences occurring prior to the Closing, under any such policies and programs, and (ii)&nbsp;Amber GT Parent shall maintain, or
cause to be maintained, in effect for a period of six (6)&nbsp;years following the Closing, without any lapses in coverage, directors&rsquo;,
officers&rsquo;, employees&rsquo; or similar liability insurance for the benefit of those Transferred Employees who are covered (whether
directly, via endorsement or otherwise) by any such policies Amber GT Parent or any of its Affiliates in effect as of the date of this
Agreement with respect to matters occurring on or prior to the Closing (provided that Amber GT Parent or its Affiliates may substitute
any such existing polices with new policies that provide coverage on terms (with respect to coverage and amount) that are substantially
the same as (and no less favorable in the aggregate to the Transferred Employees covered thereby than) the coverage provided under such
insurance policies in effect as of the date of this Agreement and any such substitution will not result in any lapses in coverage), and
the Company, its Affiliates and any such Transferred Employees may make claims, relate to or arise out of facts, events, circumstances
or occurrences occurring at or prior to the Closing, under any such policies described in this clause (ii). Amber GT Parent shall, and
shall cause its Affiliates to, (A)&nbsp;take such actions as may be reasonably requested by ARYA or the Company or, in the case of clause
(ii), any applicable Transferred Employee in connection with the tendering of such claims to the applicable insurers under such policy
or program, the pursuit of such claims or the collection of any Losses, to the extent available under such policy or program and (B)&nbsp;provide
the Company or an Affiliate thereof or, in the case of clause (ii), any applicable Transferred Employee designated in writing by ARYA
with the proceeds it realizes with respect to such claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
Amber GT Parent or any of its successors or assigns (i)&nbsp;shall merge or consolidate with or merge into any other corporation or entity
and shall not be the surviving or continuing corporation or entity of such consolidation or merger or (ii)&nbsp;shall transfer all or
substantially all of their respective properties and assets as an entity in one or a series of related transactions to any Person, then
in each such case, proper provisions shall be made so that the successors or assigns of Amber GT Parent shall assume all of the obligations
set forth in this <U>Section&nbsp;6.20</U>. The Transferred Employees that are entitled to insurance coverage set forth in <U>Section&nbsp;6.20(a)(ii)</U>&nbsp;are
intended to be third-party beneficiaries of such subsection and the related provisions of this <U>Section&nbsp;6.20</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 128; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.21</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Lien
Releases</U>. Prior to the Closing Date, Amber GT Parent shall deliver, or cause to be delivered, to ARYA evidence of (i)&nbsp;the termination
and release, effective as of the Closing, of all Liens (other than Permitted Liens) relating to the Contributed Business Assets and the
Business Entities and (ii)&nbsp;the filing of all documents (including UCC-3 or equivalent termination statements) necessary to effectuate,
evidence or reflect in the public record the termination and release, effective as of the Closing, of all such Liens, in each case, in
form and substance reasonably satisfactory to ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.22</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Litigation
Support</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Closing, if and for so long as ARYA or any of its Affiliates is prosecuting, contesting or defending any Action by or against
a third party in connection with any fact, situation, circumstance or transaction relating to, in connection with or arising from any
Excluded Assets or Excluded Liabilities or the pre-Closing conduct of the Business or operation of the Contributed Business Assets, then
Amber GT Parent shall, and shall cause its Representatives to, reasonably cooperate with ARYA and its Representatives in such prosecution,
contest or defense, including using commercially reasonable efforts to make available its pertinent personnel, participate in meetings,
provide such testimony and access to their pertinent books and records and take such other actions as shall be reasonably necessary in
connection with such prosecution, contest or defense. From and after the Closing, Amber GT Parent hereby agrees to cause the Company
or one of its Affiliates to be substituted or take similar actions, to the extent permitted by applicable Law, for the Company or one
of its Affiliates to be substituted in any and all Actions of the type described in <U>Section&nbsp;1.92(k)</U>&nbsp;or any and all Actions
that primarily relate to or would constitute, as applicable, Assumed Business Liabilities (it being understood and agreed, for the avoidance
of doubt, that in no event shall the Company or any of its Affiliates have any obligations or liabilities with respect to any Excluded
Liabilities).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Closing, if and for so long as Amber GT Parent or any of its Affiliates is defending any Action by or against a third party
in connection with any fact, situation, circumstance or transaction relating to, in connection with or arising from any Contributed Business
Assets or Assumed Business Liabilities or the post-Closing conduct of the Business or operation of the Contributed Business Assets, then
ARYA shall, and shall cause its pertinent Representatives to, reasonably cooperate with Amber GT Parent and its Representatives, at Amber
GT Parent&rsquo;s sole expense, in such defense, including using commercially reasonable efforts to make available its pertinent personnel,
participate in meetings, provide such testimony and access to their books and records and take such other actions as shall be reasonably
necessary in connection with such prosecution, contest or defense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 129; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Notwithstanding
<U>Section&nbsp;6.22(a)</U>, <U>Section&nbsp;6.22(b)</U>&nbsp;or anything to the contrary in this Agreement, (i)&nbsp;this <U>Section&nbsp;6.22
</U>shall not be applicable (A)&nbsp;to any indemnification claim under <U>Article&nbsp;X</U> which shall be governed by the terms and
subject to the conditions set forth in <U>Article&nbsp;X</U> (and not this <U>Section&nbsp;6.22</U>), or any Action brought by any Party
or any of its Affiliates against any other Party or any of its Affiliates (whether under this Agreement, any Additional Agreement or
otherwise) or (B)&nbsp;to any third-party claim with respect to Taxes, which shall be governed by <U>Section&nbsp;6.12(a)</U>, (ii)&nbsp;in
no event shall ARYA be required to provide any cooperation pursuant to <U>Section&nbsp;6.22(b)</U>&nbsp;if such Action, directly or indirectly,
relates to or arises out of any breach or failure by Amber GT Parent or any its Affiliates to perform or comply with any of their respective
covenants or agreements set forth in this Agreement, any Additional Agreement or any Contract entered into by Amber GT Parent or any
of its Affiliates, on the one hand, and ARYA or any of its Affiliates, on the other hand, following the Closing and (iii)&nbsp;in the
event that ARYA or any of its Affiliates is also the subject of any Action described in <U>Section&nbsp;6.22(b)</U>, then Amber GT shall,
and shall cause its pertinent Representatives, to reasonably cooperate with ARYA and its Representatives in the same manner described
therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.23</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cooperation
Regarding Financial Statements and Related Information.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amber
GT Parent shall deliver, or cause to be delivered, to ARYA, as promptly as practicable following the date of the relevant financial statement
or other applicable period, the Closing Company Financial Statements. The Closing Company Financial Statements (i)&nbsp;will be prepared
in accordance with GAAP applied on a consistent basis throughout the periods indicated (except, in the case of any audited financial
statements, as may be specifically indicated in the notes thereto and subject, in the case of any unaudited financial statements, to
normal year-end audit adjustments (none of which are individually or in the aggregate material) and the absence of notes thereto), (ii)&nbsp;will
fairly present in all material respects the financial position, results of operation and cash flows of the Business for the period indicated
therein, (iii)&nbsp;in the case of any audited financial statements, will be audited in accordance with the standards of the PCAOB and
will contain an unqualified report of the Business&rsquo; auditor and (iv)&nbsp;will comply in all material respects with the applicable
accounting requirements and with the rules&nbsp;and regulations of the SEC, the Exchange Act and the Securities Act (including Regulation
S-X or Regulation S-K, as applicable) in effect as of the date of such delivery, at the time of filing the Registration Statement / Proxy
Statement and at the time of effectiveness of the Registration Statement / Proxy Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Amber Entity shall use its reasonable best efforts (i)&nbsp;to assist, upon advance written notice, during normal business hours and
in a manner such as to not unreasonably interfere with the normal operation of any Amber Entity, ARYA in causing to be prepared in a
timely manner any other financial information or statements (including customary pro forma financial statements) that are required to
be included in the Registration Statement / Proxy Statement and any other filings to be made by ARYA with the SEC in connection with
the transactions contemplated by this Agreement or any Additional Agreement and (ii)&nbsp;to obtain the consents of its auditors with
respect thereto as may be required by applicable Law or requested by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
and after the Closing, ARYA shall, as promptly as practicable following written request by Amber GT Parent, cooperate with Amber GT Parent
and use its commercially reasonable efforts to provide to Amber GT Parent, at Amber GT Parent&rsquo;s sole cost and expense, all reports,
documentation or other information in ARYA&rsquo;s possession or control that are reasonably requested in writing by Amber GT Parent
and (i)&nbsp;are necessary, to the extent required by U.S. securities laws or rules&nbsp;or regulations of the SEC, to consolidate the
financial statements of the Business Entities with those of Amber GT Parent, in each case to permit Amber GT Parent to include such information
in its periodic filings and other reports with the SEC or (ii)&nbsp;are otherwise necessary for Amber GT Parent to comply with any requirement
under the U.S. securities laws with respect to its interests in ARYA, including any financial statements required by Regulation S-X under
the rules&nbsp;and regulations of the SEC (as interpreted by the staff of the SEC).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 130; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.24</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Transition
Committee</U></FONT>. As promptly as practicable following the date hereof, ARYA and Amber GT Parent shall establish a transition planning
team (the &ldquo;<U>Transition Committee</U>&rdquo;), composed of (i)&nbsp;two (2)&nbsp;individuals designated by ARYA and (ii)&nbsp;two
(2)&nbsp;individuals designated by Amber GT Parent. Subject to applicable Law, the Transition Committee shall, beginning as promptly
as practicable following the date hereof and continuing until the Closing, discuss and plan for the transition concerning the operations
and conduct of the Business after the Closing (including with respect to information technology transition and migration) and in connection
therewith and without limiting the generality of the foregoing, shall meet from time to time as reasonably requested by any member thereof.
The Parties acknowledge and agree that (x)&nbsp;in no event shall the implementation of any transition plan (other than, for the avoidance
of doubt, the Pre-Closing Reorganization) affect the timing of, or be a condition to, the Closing or affect or otherwise modify any other
covenants, agreements or obligations under this Agreement or any Additional Agreement and (y)&nbsp;the Transition Committee shall be
terminated at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.25</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property License</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Effective
as of the Closing, Amber GT Parent hereby grants (on its own behalf and on behalf of each of its Affiliates) to the Company a non-exclusive,
royalty-free and fully paid-up (subject to the terms hereof), worldwide, perpetual, irrevocable and non-terminable, right and license
to use, practice and otherwise exploit any and all Licensed Intellectual Property solely in conduct of the Business and any natural evolutions
and extensions thereof within the field of Gene Therapy, or otherwise within the field of Gene Therapy (the &ldquo;<U>Intellectual Property
License</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Intellectual Property License includes have made rights (as applicable), and the Company shall have the right to grant sublicenses (through
multiple tiers) under the Intellectual Property License to (i)&nbsp;its Affiliates, and (ii)&nbsp;to any Person within the field of Gene
Therapy in connection with the operation of the Business by the Company or its Affiliate, provided that in the case of this item (ii)&nbsp;such
sublicense is in furtherance of the Business of the Company and its Affiliates and any natural evolutions or extensions thereof but not
for the independent use of any such third party. The Intellectual Property License shall be transferrable in whole or in part to its
Affiliates or in connection with the sale of transfer of substantially all of the assets related to the Business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Under
the Intellectual Property License, as between the Parties, Amber GT Parent shall have the exclusive right (but not the obligation) to
control the filing, prosecution, maintenance and enforcement, and to bring or elect not to bring any proceedings to enforce, the Licensed
Intellectual Property, at its own expense, and to recover any and all damages or other amounts with respect thereto. The Company shall
(and shall cause its Affiliates), at the Company&rsquo;s expense, to cooperate with the Company in connection with any such enforcement
or proceeding. Amber GT Parent shall obtain from its Affiliates the necessary rights to grant to the Company the Intellectual Property
License and the rights thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 131; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 8 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
purposes of this <U>Section&nbsp;6.25</U>, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;Licensed
Intellectual Property&rdquo; means any and all (a)&nbsp;Patents, (b)&nbsp;Copyrights (whether or not registered or applied for) and (c)&nbsp;Know-How,
in each case (in respect of the foregoing (a)&nbsp;through (c)) to the extent owned and Controlled by Amber GT Parent or any of its Affiliates
(other than Trademarks and Contributed Business IP) as of the Closing that is used or held for use in the conduct of the Business as currently
conducted and as currently proposed to be conducted by the Amber Entities and their Affiliates; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Controlled&rdquo; means, with respect to
any Intellectual Property, that Amber GT Parent or its applicable Affiliate has the legal right or authority as of the Closing, to grant
to the Company the license and rights set forth in this <U>Section&nbsp;6.25</U> without a need to make payments to a Third Party related
to such grant other than payments agreed by the Company for which the Company will reimburse Amber GT Parent, and without violating (i)&nbsp;the
terms of any agreement or other arrangements with any Third Party existing as of the Closing or misappropriating the proprietary or trade
secret information of a Third Party or (ii)&nbsp;any Law applicable to such license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.26</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Philadelphia
Facility Sublease</U>. As promptly as practicable after the date hereof (and in any event prior to the Closing), Amber GT Parent and ARYA
shall cooperate in good faith and shall each use their reasonable best efforts to finalize the Philadelphia Facility Sublease. Notwithstanding
the foregoing or anything to the contrary contained in this Agreement, in no event shall ARYA or any of its Affiliates (including, from
and after the Closing, any of the Business Entities) be required to make any payment or other concessions in connection with the Company
becoming the sublessee thereunder other than (i)&nbsp;any required ordinary course deposit payments and (ii)&nbsp;all rental payment obligations
due and owing with respect to the period from and after the Closing, in each case, payable by the Company pursuant to the terms of the
Philadelphia Facility Sublease, and in no event shall Amber GT Parent or any of its Affiliates agree to any of the foregoing, except for
any payments or concessions either paid or satisfied in full by Amber GT Parent prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.27</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Co-Development
and Commercialization Agreement</U>. As promptly as practicable after the date hereof (and in any event prior to the Closing), Amber GT
Parent and ARYA shall each negotiate in good faith and reasonably cooperate with the other to finalize the schedules to the Co-Development
and Commercialization Agreement, and, without limiting the generality of the foregoing, each of Amber GT and ARYA shall, as promptly as
practicable after the date hereof (and in any event prior to the Closing), mutually agree to the schedules to the Co-Development and Commercialization
Agreement (such agreement not to be unreasonably withheld, conditioned or delayed by either Amber GT Parent or ARYA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VII<BR>
EMPLOYEE MATTER COVENANTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Employee
Matters Covenant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Amber
GT Parent shall provide an updated Business Employees List upon reasonable request by ARYA (and, in any event, no later than five (5)&nbsp;days
prior to the Closing Date); <U>provided</U> that (i)&nbsp;any such update shall not (A)&nbsp;cause the aggregate number of individuals
on such list to exceed 120 without the prior written consent of ARYA, (B)&nbsp;without limiting, and subject to, the covenants and agreements
set forth in <U>Section&nbsp;6.1(b)(vii)</U>, <U>Section&nbsp;6.1(b)(xix)</U>&nbsp;and <U>Section&nbsp;6.11</U>, other than in the case
of a resignation of an executive officer or termination of employment for cause of an executive officer, add any individual who will serve
as an executive officer of the Company without the consent of ARYA (such consent not to be unreasonably withheld or delayed) or (C)&nbsp;remove
any Business Employees unless such removal is the result of a termination of employment for cause or, solely in the case of any employee
with total annualized compensation of less than $300,000 and that is not otherwise an Officer, performance related issues as determined
reasonably and in good faith by Amber GT Parent and (ii)&nbsp;in no event will this <U>Section&nbsp;7.1(a)</U>&nbsp;limit, modify or otherwise
affect any of the other covenants, agreements or obligations of the Amber Entities hereunder (including those set forth in <U>Section&nbsp;6.1</U>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 132; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">As
part of the Pre-Closing Reorganization, and subject to <U>Section&nbsp;7.1(e)</U>, the Amber Entities shall, and shall cause their respective
Affiliates, as applicable, to transfer the employment of each Business Employee who is not employed by a Business Entity (other than an
Inactive Business Employee) to the Company or another Business Entity designated in writing by ARYA prior to the Closing Date. Each Business
Employee who is actively employed by a Business Entity immediately prior to the Closing and who continues to be so employed as of immediately
following the Closing shall be referred to herein as a &ldquo;<U>Transferred Employee.</U>&rdquo; Prior to the Closing, the Company and
Amber GT Parent shall cause the Company to adopt employee welfare benefit plans that are substantially identical to those employee welfare
benefit plans covering the Business Employees prior to the Closing, which plans shall provide coverage to the Transferred Employees in
accordance with the requirements of this <U>Section&nbsp;7.1(b)</U>&nbsp;from and after the Closing Date (as such plans may be amended
or terminated from time to time by the Company following the Closing). For the one (1)-year period immediately following the Closing (or
the date of the termination of the relevant Transferred Employee, if sooner), the Company or an Affiliate shall cause each Transferred
Employee to be provided with (i)&nbsp;salary or wages and (ii)&nbsp;annual cash bonus opportunities and employee benefits (excluding equity-based
compensation, special or one-time bonuses (including retention, change in control or similar bonuses), pension and retiree welfare benefits,
and any deferral opportunity under any nonqualified deferred compensation plan), in each case, that are no less favorable in the aggregate
to those provided to such Transferred Employees immediately prior to the Closing. The Company shall cause each Transferred Employee to
receive credit for such Transferred Employee&rsquo;s service with Amber GT Parent or an Affiliate prior to the Closing for purposes of
eligibility, vesting and determination of the level of benefits under any plan providing 401(k)&nbsp;benefits, severance, vacation or
paid time off in which such Transferred Employee participates following the Closing to the same extent such service was recognized by
Amber GT Parent or an Affiliate immediately prior to the Closing for the same purpose under the analogous Employee Benefit Plan; <U>provided</U>,
<U>however</U>, that such service shall not be recognized to the extent that such recognition would result in a duplication of benefits
or compensation with respect to the same period of service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Business Employee who is not actively at work as of the Closing Date due to short or long term disability leave, workers&rsquo; compensation,
family or medical leave, military leave or another approved leave of absence, which such other approved leave of absence was either commenced
prior to the date hereof or is approved by ARYA (such approval not to be unreasonably withheld, conditioned or delayed) (excluding regularly
scheduled vacation or paid time off) (each, an &ldquo;<U>Inactive Business Employee</U>&rdquo;) shall become and remain an employee of
Amber GT Parent or one of its Affiliates until and unless the Inactive Business Employee becomes available for and able to return to active
work within the one hundred eighty (180) days following the Closing Date (or such longer period as required by applicable Law), at which
time a Business Entity shall offer employment to such Inactive Business Employee (meeting the standards set forth in <U>Section&nbsp;7.1(a)</U>)
effective upon the date such Inactive Business Employee is available for and able to return to active work, and any such Inactive Business
Employee who then returns to work and accepts and actually commences employment with the Company or its Affiliate shall be considered
a Transferred Employee for purposes of this Agreement; <U>provided</U> that, if any such Inactive Business Employee becomes a Transferred
Employee, then the Company shall reimburse Amber GT Parent and its Affiliates for all documented and out-of-pocket costs and amounts paid
by Amber GT Parent and its Affiliates in respect of the provision of benefits and compensation in respect of any Inactive Business Employee
with respect to the period from the Closing Date until the date that such Inactive Business Employee returns to work.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 133; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Prior
to the Closing, the Company and Amber GT Parent shall adopt or cause to be adopted a tax qualified defined contribution 401(k)&nbsp;plan
sponsored by the Company (the &ldquo;<U>Company 401(k)&nbsp;Plan</U>&rdquo;) and any trust agreements or other plan documents reasonably
necessary for the operation of such plan and shall cause trustees to be appointed for such plan. In accordance with applicable Law, the
Company and Amber GT Parent shall cause, in the manner described herein, the accounts under the tax qualified 401(k)&nbsp;plan of Amber
GT Parent (the &ldquo;<U>Parent 401(k)&nbsp;Plan</U>&rdquo;) of each Business Employee who is not an Inactive Business Employee to be
transferred to the Company 401(k)&nbsp;Plan prior to or as soon as practicable after the Closing Date. On such date of transfer, (i)&nbsp;Amber
GT Parent shall cause the accounts (including any outstanding loan balances) of each such Business Employee and in the Parent 401(k)&nbsp;Plan
to be transferred to the Company 401(k)&nbsp;Plan and its related trust, (ii)&nbsp;the Company 401(k)&nbsp;Plan shall assume and be solely
responsible for all Liabilities under the Parent 401(k)&nbsp;Plan relating to the accounts that are so transferred as of the time of such
transfer, and (iii)&nbsp;the Company shall cause such transferred accounts to be accepted by the Company 401(k)&nbsp;Plan and its related
trust and shall cause the Company 401(k)&nbsp;Plan to satisfy all protected benefit requirements under the Code and applicable Law with
respect to the transferred accounts. Prior to the Closing, Amber GT Parent shall have made to the Company 401(k)&nbsp;Plan all employer
contributions that would otherwise be made but for the transactions contemplated by this Agreement, pro-rated for the portion of the plan
year ending as of the Closing and shall have paid all associated costs incurred in connection with such contributions. In determining
whether a Business Employee is vested in his or her account under the Company 401(k)&nbsp;Plan, the Company 401(k)&nbsp;Plan shall credit
each applicable Business Employee with all the individual&rsquo;s service credited under the Parent 401(k)&nbsp;Plan. Participants in
the Parent 401(k)&nbsp;will not be treated as having experienced a termination of service for purposes of such plans as a result of the
transactions contemplated by this agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Except
for the Employee Benefit Plans listed on <U>Section&nbsp;7.1(e)</U>&nbsp;of the Amber Disclosure Schedules, Amber GT Parent and its Affiliates
(other than the Business Entities) shall assume and retain sponsorship of, and be solely responsible for all Liabilities relating to or
at any time arising under or in connection with or pursuant to any Employee Benefit Plans or any other benefit or compensation plan, program,
policy, agreement, contract or arrangement of any kind at any time maintained, sponsored, or contributed to or required to be contributed
to by Amber GT Parent or any of its Affiliates (including the Business Entities) or under or with respect to which Amber GT Parent or
any of its Affiliates (including the Business Entities) has any Liability. From and after the Closing Date, the Company shall credit each
Transferred Employee with the accrued and unused vacation time which the Business Employee had earned prior to the Closing with Amber
GT Parent or an Affiliate for one (1)&nbsp;year following the Closing, and permit such vacation time to be used in a manner consistent
with the current Amber GT Parent policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 134; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Amber
GT Parent and its Affiliates (other than the Business Entities) shall be solely responsible for any obligation arising under Section&nbsp;4980B
of the Code with respect to all &ldquo;M&amp;A qualified beneficiaries&rdquo; (as defined in Treasury Regulation Section&nbsp;54.4980B-9)
with respect to qualifying events occurring on or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Amber
GT Parent shall, and shall cause its Affiliates to, use its commercially reasonable efforts to ensure that any foreign national who has
work authorization pursuant to a non-immigrant visa status in order to work for the Amber Entities in his or her current position may
continue to work in such position as a Transferred Employee on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">During
the period prior to the Closing Date, Amber GT Parent shall, and shall cause its Affiliates to, use commercially reasonable efforts to
make Business Contractors available to ARYA for the purpose of allowing ARYA to interview each such Business Contractor and determine
the nature and extent of each such person&rsquo;s continuation with ARYA, if any. Amber GT Parent shall, and shall cause its Affiliates
to, provide to ARYA contact information for third-party service providers providing contingent personnel to the Business and reasonably
cooperate in identifying and transferring such contingent work force to the extent requested by ARYA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
provision of this Agreement shall (i)&nbsp;create any right in any individual to continued employment by any Party or preclude the ability
of any Party to terminate the employment of any employee for any reason, (ii)&nbsp;confer upon any employee any rights or remedies under
or by reason of this Agreement or (iii)&nbsp;be treated as an amendment to any particular employee benefit plan of any Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Third-Party Beneficiaries.</U> This <U>Article&nbsp;VII</U> is solely for the benefit of the Parties and is not intended to confer upon
any other Persons (including any Business Employee or any other employee, former employee, participant in any Employee Benefit Plan or
any spouse, dependent or other beneficiary thereof) any rights or remedies whatsoever, including any third-party beneficiary rights by
reason of this <U>Article&nbsp;VII</U>. Nothing in this <U>Article&nbsp;VII</U>, express or implied, shall: (a)&nbsp;limit the ability
of Amber GT Parent, the Company, ARYA or any of their respective Subsidiaries or Affiliates from terminating the employment of any employee
(including any Business Employee or Business Contractor) prior to or after the Closing; (b)&nbsp;be construed to establish, amend or
modify any Employee Benefit Plan or other benefit or compensation plan, program, agreement, policy, contract or arrangement; or (c)&nbsp;limit
the ability of Amber GT Parent or any of its Affiliates (including following the Closing any Business Entity) to amend, modify or terminate
any benefit or compensation plan, program, agreement, policy, contract or arrangement at any time assumed, established, sponsored or
maintained by any of them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 135; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VIII<BR>
CONDITIONS TO CLOSING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Conditions
to the Obligations of the Parties</U>. The obligations of all of the Parties to consummate the Closing are subject to the satisfaction
or, if permitted by applicable Law, the waiver of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
waiting period under the HSR Act relating to the transactions contemplated by this Agreement shall have expired, been terminated or obtained
(or deemed, by applicable Law, to have been obtained), as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">No
Law or Order of an Authority of competent jurisdiction or other legal restraint or prohibition shall be in effect that prohibits or prevents
the consummation of the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Required ARYA Shareholder Approval shall have been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Registration Statement / Proxy Statement shall have become effective in accordance with the provisions of the Securities Act, no stop
order shall have been issued by the SEC and shall remain in effect with respect to the Registration Statement / Proxy Statement, and
no proceeding seeking such a stop order shall have been threatened or initiated by the SEC and remain pending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">After
giving effect to the transactions contemplated hereby (including the funding of the PIPE Investment) ARYA shall have at least $5,000,001
of net tangible assets (as determined in accordance with Rule&nbsp;3a51-1(g)(1)&nbsp;of the Exchange Act) immediately after the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">ARYA&rsquo;s
initial listing application with Nasdaq in connection with the transactions contemplated by this Agreement shall have been conditionally
approved and, immediately following the Closing, ARYA shall satisfy any applicable initial and continuing listing requirements of Nasdaq,
and ARYA shall not have received any notice of non-compliance therewith that has not been cured prior to, or would not be cured at or
immediately following, the Closing, and the ARYA Class&nbsp;A Shares (including the ARYA Class&nbsp;A Shares to be issued hereunder)
shall have been approved for listing on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Aggregate Closing Transaction Proceeds shall be equal to or greater than $300,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Conditions
to Obligations of ARYA</U>. The obligation of ARYA to consummate the Closing is subject to the satisfaction, or, if permitted by applicable
Law, the waiver, of the following further conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Amber Entities shall have performed and complied in all material respects with all of their respective covenants and agreements hereunder
required to be performed by them at or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 136; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(i)&nbsp;All
of the representations and warranties of the Amber Entities (other than the Amber Fundamental Representations), in each case disregarding
all qualifications and exceptions set forth herein relating to materiality or Amber Material Adverse Effect, shall be true and correct
in all respects as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (<U>provided
</U>that to the extent that any such representation and warranty is made as of an earlier date, such representation and warranty shall
be true and correct as of such earlier date), except as has not resulted in and would not reasonably be expected to result in, individually
or in the aggregate, an Amber Material Adverse Effect; (ii)&nbsp;the representations and warranties set forth in <U>Sections&nbsp;4.2(a)</U>&nbsp;through
<U>Section&nbsp;4.2(c)</U>&nbsp;shall be true and correct in all respects (except for <I>de minimis </I>inaccuracies) as of the date
of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (<U>provided</U> that, to the extent that
any such representation and warranty is made as of an earlier date, such representation and warranty shall be true and correct in all
respects (except for <I>de minimis </I>inaccuracies) as of such earlier date); (iii)&nbsp;the representations and warranties set forth
in <U>Section&nbsp;4.7(a)</U>&nbsp;shall be true and correct in all respects as of the date of this Agreement and as of the Closing Date,
as though made on and as of the Closing Date (<U>provided</U>, <U>however</U>, that this clause&nbsp;(iii)&nbsp;shall be deemed to be
satisfied if no Amber Material Adverse Effect is continuing); and (iv)&nbsp;all of the Amber Fundamental Representations (other than
the representations and warranties in <U>Sections&nbsp;4.2(a)</U>&nbsp;through <U>Section&nbsp;4.2(c)</U>&nbsp;and <U>Section&nbsp;4.7(a)</U>),
in each case disregarding all qualifications and exceptions set forth herein relating to materiality or Amber Material Adverse Effect,
shall be true and correct in all material respects as of the date of this Agreement and as of the Closing Date, as though made on and
as of the Closing Date (<U>provided</U> that, to the extent that any such representation and warranty is made as of an earlier date,
such representation and warranty shall be true and correct in all material respects as of such earlier date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Since
the date of this Agreement, there shall have been no Amber Material Adverse Effect that is continuing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">At
or prior to the Closing, the Amber Entities shall have delivered, or cause to be delivered, the following documents or agreements to
ARYA:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
certificate duly executed by an authorized officer of Amber GT Parent to the effect that the conditions set forth in clauses&nbsp;(a)&nbsp;through
(c)&nbsp;of this <U>Section&nbsp;8.2 </U>are satisfied, in a form and substance reasonably satisfactory to ARYA;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Transition Services Agreement duly executed by Amber GT Parent, Amber GT and their Affiliates identified therein and the Company and
the other Business Entities identified therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Co-Development and Commercialization Agreement duly executed by Amber GT Parent and its Affiliates identified therein and the Company
and the other Business Entities identified therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Tax Receivables Agreement duly executed by Amber GT and its Affiliates identified therein and the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
A&amp;R Company LLC Agreement duly executed by the Company and Amber GT;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Philadelphia Facility Sublease duly executed by Amber GT Parent and the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Director Nomination Agreement duly executed by Amber GT Parent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 137; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Pre-Closing Reorganization shall have been consummated in accordance with the applicable terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Conditions
to Obligations of the Amber Entities</U>. The obligations of the Amber Entities to consummate the Closing are subject to the satisfaction,
or, if permitted by applicable Law, the waiver of all the following further conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">ARYA
shall have performed and complied in all material respects with all of its covenants and agreements hereunder required to be performed
by it at or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">(i)&nbsp;All
of the representations and warranties of ARYA (other than the ARYA Fundamental Representations), in each case disregarding all qualifications
and exceptions set forth herein relating to materiality or ARYA Material Adverse Effect, shall be true and correct in all respects of
the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (<U>provided</U> that, to the extent
that any such representation and warranty is made as of an earlier date, such representation and warranty shall be true and correct as
of such earlier date), except as has not resulted in and would not reasonably be expected to result in, individually or in the aggregate,
an ARYA Material Adverse Effect; (ii)&nbsp;the representations and warranties set forth in <U>Section&nbsp;5.16</U> shall be true and
correct in all respects as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (except
to the extent that any such representation and warranty is made as of an earlier date, in which case such representation and warranty
shall be true and correct in all respects as of such earlier date); <U>provided</U>, <U>however</U>, that this clause&nbsp;(ii)&nbsp;shall
be deemed to be satisfied if no ARYA Material Adverse Effect is continuing; and (iii)&nbsp;all of the ARYA Fundamental Representations
(other than the representations and warranties set forth in <U>Section&nbsp;5.16</U>), in each case disregarding all qualifications and
exceptions set forth herein relating to materiality or ARYA Material Adverse Effect, shall be true and correct in all material respects
as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date (<U>provided</U> that, to the
extent that any such representation and warranty is made as of an earlier date, such representation and warranty shall be true and correct
in all material respects as of such earlier date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">At
or prior to the Closing, ARYA shall have delivered, or cause to be delivered, the following documents or agreements to the Amber Entities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">a
certificate duly executed by an authorized officer of ARYA to the effect that the conditions set forth in clauses&nbsp;(a)&nbsp;through
(b)&nbsp;of this <U>Section&nbsp;8.3</U> are satisfied, in a form and substance reasonably satisfactory to Amber GT Parent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Transition Services Agreement duly executed by ARYA;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Co-Development and Commercialization Agreement duly executed by ARYA;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Tax Receivables Agreement duly executed by ARYA;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
A&amp;R Company LLC Agreement duly executed by ARYA; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 138; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
Director Nomination Agreement duly executed by ARYA and ARYA Sponsor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Frustration
of Closing Conditions</U>. None of the Amber Entities may rely on the failure of any condition set forth in this <U>Article&nbsp;VIII
</U>to be satisfied if such failure was, either individually or in the aggregate, proximately caused by an Amber Entity&rsquo;s breach
of its obligations under this Agreement, including a breach of its obligations to use reasonable best efforts to cause the Closing to
occur, as required by <U>Section&nbsp;6.3</U>, or any other breach of this Agreement. ARYA may not rely on the failure of any condition
set forth in this <U>Article&nbsp;VIII</U> to be satisfied if such failure was proximately caused by ARYA&rsquo;s breach of its obligations
under this Agreement, including a breach of its obligations to use reasonable best efforts to cause the Closing to occur, as required
by <U>Section&nbsp;6.3</U>, or any other breach of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;IX<BR>
TERMINATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
mutual written consent of ARYA and Amber GT Parent;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
ARYA, if any of the representations or warranties set forth in <U>Article&nbsp;III</U> or <U>Article&nbsp;IV</U> shall not be true and
correct or if the any of the Amber Entities has failed to perform or comply with any covenant or agreement on the part of such Amber
Entity set forth in this Agreement (including an obligation to consummate the Closing) such that the condition to Closing set forth in
either <U>Section&nbsp;8.2(a)</U>&nbsp;or <U>Section&nbsp;8.2(b)</U>&nbsp;would not (assuming the Closing occurred as of such date) be
satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure or failures
to perform such covenants or agreements, as applicable, is (or are) not cured or cannot be cured within the earlier of (i)&nbsp;thirty
(30) days after written notice thereof is delivered to Amber GT Parent by ARYA and (ii)&nbsp;the Termination Date; <U>provided</U><I>,
</I><U>however</U>, that ARYA is not then in breach of this Agreement so as to prevent the condition to Closing set forth in either <U>Section&nbsp;8.3(a)</U>&nbsp;or
<U>Section&nbsp;8.3(b)</U>&nbsp;from being satisfied (assuming the Closing occurred as of such date) and the Perceptive PIPE Investor
is not then in breach of its PIPE Subscription Agreement so as to prevent the condition to the Closing set forth in <U>Section&nbsp;8.1(g)</U>&nbsp;from
being satisfied;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
Amber GT Parent, if any of the representations or warranties set forth in <U>Article&nbsp;V</U> shall not be true and correct or if ARYA
has failed to perform or comply with any covenant or agreement set forth in this Agreement (including an obligation to consummate the
Closing) such that the condition to Closing set forth in either <U>Section&nbsp;8.3(a)</U>&nbsp;or <U>Section&nbsp;8.3(b)&nbsp;</U>would
not (assuming the Closing occurred as of such date) be satisfied and the breach or breaches causing such representations or warranties
not to be true and correct, or the failure or failures to perform such covenants or agreements, as applicable, is (or are) not cured
or cannot be cured within the earlier of (i)&nbsp;thirty (30) days after written notice thereof is delivered to ARYA by Amber GT Parent
and (ii)&nbsp;the Termination Date; <U>provided</U>, <U>however</U>, none of the Amber Entities is then in breach of this Agreement so
as to prevent the condition to Closing set forth in <U>Section&nbsp;8.2(a)</U>&nbsp;or <U>Section&nbsp;8.2(b)</U>&nbsp;from being satisfied
(assuming the Closing occurred as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 139; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
either ARYA or Amber GT Parent, if the Closing shall not have occurred on or prior to March&nbsp;29, 2022 (the &ldquo;<U>Termination
Date</U>&rdquo;); <U>provided</U> that (i)&nbsp;the right to terminate this Agreement pursuant to this <U>Section&nbsp;9.1(d)</U>&nbsp;shall
not be available to ARYA if ARYA&rsquo;s breach of any of its covenants or agreements under this Agreement shall have proximately caused
the failure of the Closing to occur on or before the Termination Date, and (ii)&nbsp;the right to terminate this Agreement pursuant to
this <U>Section&nbsp;9.1(d)</U>&nbsp;shall not be available to Amber GT Parent if any Amber Entity&rsquo;s breach of any of its covenants
or agreements under this Agreement shall have, either individually or in the aggregate, proximately caused the failure of the Closing
to occur on or before the Termination Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
either ARYA or Amber GT Parent, if any Authority shall have issued an Order or taken any other action permanently enjoining, restraining
or otherwise prohibiting the transactions contemplated by this Agreement and such Order or other action shall have become final and nonappealable;
or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">by
either ARYA or Amber GT Parent if the ARYA Shareholders Meeting has been held (including any adjournment thereof), has concluded, ARYA&rsquo;s
shareholders have duly voted and the Required ARYA Shareholder Approval was not obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Effect
of Termination</U>. In the event of the termination of this Agreement pursuant to <U>Section&nbsp;9.1</U> this entire Agreement shall
become void (and there shall be no Liability or obligation on the part of the Parties and their respective Representatives) with the
exception of (a)&nbsp;<U>Section&nbsp;6.5(a)</U>, this <U>Section&nbsp;9.2</U>, <U>Article&nbsp;XI</U> and <U>Article&nbsp;I</U> (to
the extent related to the foregoing), each of which shall survive such termination and remain valid and binding obligations of the Parties
in accordance with their terms and (b)&nbsp;the Confidentiality Agreement, which shall survive such termination and remain valid and
binding obligations of the parties thereto in accordance with its respective terms. Notwithstanding the foregoing or anything to the
contrary herein, but subject to <U>Section&nbsp;11.15</U> the termination of this Agreement pursuant to <U>Section&nbsp;9.1</U> shall
not affect any Liability on the part of any Party for a willful and material breach of any covenant or agreement set forth in this Agreement
prior to such termination or Fraud.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;X<BR>
INDEMNIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Survival</U>.
All representations and warranties set forth in this Agreement set forth in this Agreement shall terminate and be of no further force
and effect upon the Closing, except for the representations and warranties of the Amber Entities set forth in <U>Section&nbsp;4.8(a)</U>,
<U>Section&nbsp;4.13(b)</U>&nbsp;and <U>Section&nbsp;4.15(b)</U>&nbsp;(the &ldquo;<U>Specified Representations</U>&rdquo;). All covenants
and agreements set forth in this Agreement that (a)&nbsp;by their terms apply or contemplate performance on or prior to the Closing shall
survive the Closing through and until and including the first (1st) anniversary of the Closing Date and (b)&nbsp;by their terms apply
or contemplate performance, in whole or in part, following the Closing shall survive the Closing and remain in full force and effect
in accordance with their respective terms as provided in this Agreement, or, if no term as to survival, indefinitely or the longer period
of time permitted by applicable Law. The Specified Representations shall survive Closing from and after the Closing until the date that
is ninety (90) days following the completion of the final consolidated audited financial statements of ARYA for the fiscal year ended
2022. The obligations to indemnify and hold harmless pursuant to (i)&nbsp;<U>Section&nbsp;10.2(b)</U>&nbsp;(solely with respect to Pre-Closing
Taxes) and (ii)&nbsp;<U>Section&nbsp;10.3(a)(ii)</U>&nbsp;(solely with respect to Post-Closing Taxes) shall survive for sixty (60) days
after the expiration of the applicable statute of limitations. The obligations to indemnify and hold harmless pursuant to <U>Section&nbsp;10.2
</U>or <U>Section&nbsp;10.3(a)</U>, as applicable, shall survive the consummation of the transactions contemplated hereby for the applicable
period set forth in this <U>Section&nbsp;10.1</U>, and no claim for indemnification pursuant to <U>Section&nbsp;10.2</U> or <U>Section&nbsp;10.3(a)</U>,
as applicable, may be made after the expiration of the applicable survival period with respect to the representation, warranty, covenant
or agreement underlying such indemnification obligation (which, for the avoidance of doubt, in the case of a claim pursuant to <U>Sections&nbsp;10.2(b)</U>&nbsp;(other
than with respect to Pre-Closing Taxes) or <U>Section&nbsp;10.3(a)(ii)</U>&nbsp;(other than with respect to Post-Closing Taxes), as applicable,
shall be indefinitely); <U>provided</U>, <U>however</U>, that if a Notice of Claim is delivered by ARYA (on behalf of itself or another
ARYA Indemnified Party) or Amber GT Parent (on behalf of itself or another Amber Indemnified Party), as applicable, prior to the end
of the applicable survival period with respect to such indemnification obligation pursuant to <U>Section&nbsp;10.2</U> or <U>Section&nbsp;10.3(a)</U>,
as applicable, then the claim(s)&nbsp;specified therein shall survive until final resolution thereof in accordance with the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 140; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
by Amber GT Parent and Amber GT</U>. From and after the Closing, and subject to the applicable limitations set forth in this <U>Article&nbsp;X
</U>and elsewhere in this Agreement, Amber GT Parent and Amber GT shall, jointly and severally, indemnify, defend and hold harmless ARYA,
its Affiliates (including, for the avoidance of doubt, the Business Entities) and their respective directors, officers, agents, employees,
successors and assigns (collectively, the &ldquo;<U>ARYA Indemnified Parties</U>&rdquo;) against, and reimburse each ARYA Indemnified
Party for, all Losses (in each case, whether arising from a Third-Party Claim or otherwise) that such ARYA Indemnified Party may suffer
or incur, or become subject to, arising out of or resulting from:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
breach or failure by Amber GT Parent or Amber GT to perform or comply with any of their respective covenants or agreements set forth
in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">each
Excluded Liability; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">the
breach of any Specified Representation; <U>provided</U> that any qualifications as to materiality, &ldquo;Amber Material Adverse Effect&rdquo;
or other similar materiality qualifications included in any such representation or warranty shall be disregarded for purposes of the
determination of whether or not such breach has occurred and for purposes of calculating the amount of any Losses subject to indemnification
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
by ARYA</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">From
and after the Closing, and subject to the applicable limitations set forth in this <U>Article&nbsp;X</U> and elsewhere in this Agreement,
ARYA and the Business Entities (excluding, for the avoidance of doubt, the ARYA Sponsor) shall indemnify, defend and hold harmless Amber
GT Parent, its Affiliates and their respective directors, officers, agents, employees, successors and assigns (collectively, the &ldquo;<U>Amber
Indemnified Parties</U>&rdquo;) against, and reimburse any Amber Indemnified Party for, all Losses (in each case, whether arising from
a Third-Party Claim or otherwise) that such Amber Indemnified Party may suffer or incur, or become subject to, arising out of or resulting
from:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">any
breach or failure by ARYA to perform or comply with any of its covenants or agreements set forth in this Agreement to the extent such
covenants or agreements apply or require performance following the Closing; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">each
Assumed Business Liability.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 141; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Notwithstanding
anything in this Agreement to the contrary, ARYA shall not be required to indemnify the Amber Indemnified Parties, and the Amber Indemnified
Parties shall not be entitled to recover, in respect of any Losses for which indemnity is claimed under this <U>Section&nbsp;10.3</U>
to the extent that such Losses (when taken together with any other Losses recovered or recoverable under this <U>Section&nbsp;10.3</U>)
would, in the aggregate, exceed the Pre-Transaction Equity Value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification
Procedures</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
an ARYA Indemnified Party or an Amber Indemnified Party, as applicable, believes (in good faith) that he, she or it is entitled to indemnification
pursuant to <U>Section&nbsp;10.2</U> or <U>Section&nbsp;10.3(a)</U>, as applicable (an &ldquo;<U>Indemnified Party</U>&rdquo;), then
ARYA (on behalf of itself or any other ARYA Indemnified Party) or Amber GT Parent (on behalf of itself or any other Amber Indemnified
Party) shall provide a Notice of Claim to the Party obligated to indemnify such Indemnified Party pursuant to this <U>Article&nbsp;X
</U>(such notified Party, the &ldquo;<U>Indemnifying Party</U>&rdquo;) as soon as reasonably practicable, but in any event no more than
forty-five (45) days after the Indemnified Party becomes actually aware of the circumstances indicating that the Indemnified Party has
incurred or could reasonably be expected to incur Losses in respect of which it is entitled to indemnification hereunder; <U>provided</U>,
<U>however</U>, that the failure to give such Notice of Claim within such forty-five (45) day period shall not relieve the Indemnifying
Party of its obligations hereunder, except to the extent that the Indemnifying Party is actually prejudiced thereby. Any such claim for
indemnification shall be conclusive against the Indemnifying Party in all respects thirty (30) days after receipt by the Indemnifying
Party of such Notice of Claim, unless within such period the Indemnifying Party sends the Indemnified Party a notice disputing such claim
(a &ldquo;<U>Notice of Dispute</U>&rdquo;). Upon receipt of any Notice of Dispute, ARYA and Amber GT Parent shall use commercially reasonable
efforts to cooperate and arrive at a mutually acceptable resolution of such dispute within thirty (30) days of receipt, or ARYA (on behalf
of itself or the other ARYA Indemnified Parties if ARYA or any other ARYA Indemnified Parties are the Indemnified Parties) or Amber GT
Parent (on behalf of itself or the other Amber Indemnified Parties if Amber GT Parent or any other Amber Indemnified Parties are the
Indemnified Parties) receiving the Notice of Dispute from the Indemnifying Party. If a mutually acceptable resolution cannot be reached
between ARYA and Amber GT Parent within such thirty (30) day period, then ARYA (on behalf of itself or the other ARYA Indemnified Parties
if ARYA or any other ARYA Indemnified Parties are the Indemnified Parties) or Amber GT Parent (on behalf of itself or the other Amber
Indemnified Parties if Amber GT Parent or any other Amber Indemnified Parties are the Indemnified Parties) and the Indemnifying Party
may thereupon proceed to pursue any and all available remedies at Law. Notwithstanding anything to the contrary in this <U>Article&nbsp;X</U>,
ARYA shall act on behalf of all ARYA Indemnified Parties pursuant to this <U>Article&nbsp;X</U> and Amber GT Parent shall act on behalf
of all Amber Indemnified Parties pursuant to this <U>Article&nbsp;X</U> (including, in each case and for the avoidance of doubt, in connection
with the making or resolution of any claim for indemnification or any Third-Party Claim or any rights or obligations set forth in <U>Section&nbsp;10.4
</U>with respect thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 142; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Subject
to the provisions of <U>Section&nbsp;10.4(a)</U>, if an Action by a Person who is not a Party or an Affiliate thereof (a &ldquo;<U>Third-Party
Claim</U>&rdquo;) is commenced against any Indemnified Party and the Indemnified Party intends to seek indemnity with respect thereto
under this <U>Article&nbsp;X</U>, then ARYA (on behalf of itself or the other ARYA Indemnified Parties if ARYA or any other ARYA Indemnified
Parties are the Indemnified Parties) or Amber GT Parent (on behalf of itself or the other Amber Indemnified Parties if Amber GT Parent
or any other Amber Indemnified Parties are the Indemnified Parties) shall promptly deliver a Notice of Claim to the Indemnifying Party;
<U>provided</U>, <U>however</U>, that the failure to promptly give such Notice of Claim shall not relieve the Indemnifying Party of its
obligations hereunder, except to the extent that the Indemnifying Party is actually prejudiced thereby. The Indemnifying Party shall
have thirty (30) days after receipt of the Notice of Claim to which such Third-Party Claim relates to assume the conduct and control,
through counsel reasonably acceptable to ARYA or Amber GT Parent, as applicable (it being understood and agreed that, if the Indemnifying
Party is ARYA, then Kirkland&nbsp;&amp; Ellis LLP shall be deemed to be reasonably acceptable) and at the expense of the Indemnifying
Party, of the settlement or defense thereof, and ARYA or Amber GT Parent, as applicable, shall reasonably cooperate with the Indemnifying
Party in connection therewith (it being acknowledged and agreed that upon such assumption of conduct and control, the Indemnifying Party,
and not the Indemnified Party(ies), shall, subject to clauses&nbsp;(i)&nbsp;through (iv)&nbsp;below, have the exclusive right to settle
and defend such Third-Party Claim); <U>provided</U>, <U>however</U>, that the Indemnifying Party may not settle any such Third-Party
Claim without the prior written consent of ARYA or Amber GT Parent, as applicable, if any such settlement (i)&nbsp;results in non-monetary
damages, (ii)&nbsp;contains an admission of wrongdoing or liability on behalf of any Indemnified Party, (iii)&nbsp;provides that an Indemnified
Party is required to (A)&nbsp;take or refrain from taking any material action that would, in the absence of taking or refraining to take
such action, adversely affect such Indemnified Party, (B)&nbsp;acknowledge any material rights of the Person making the Third-Party Claim
that would adversely affect such Indemnified Party or (C)&nbsp;waive any material rights that such Indemnified Party may have against
such Person making the Third-Party Claim or (iv)&nbsp;does not include a legally binding, unconditional and irrevocable full release
of the Indemnified Party by the Person bringing such Third-Party Claim from any obligations or liabilities it may have with respect to
the Third-Party Claim; <U>provided</U>, <U>further</U>, that the Indemnifying Party shall permit ARYA or Amber GT Parent, as applicable,
to participate in such settlement or defense through counsel chosen by ARYA or Amber GT Parent, as applicable (and the fees and expenses
of such counsel shall be borne by such Indemnified Party). If the Indemnifying Party does not notify ARYA or Amber GT Parent, as applicable,
within thirty (30) days after the receipt of the Indemnified Party&rsquo;s Notice of Claim hereunder that it elects to undertake the
defense thereof, the Indemnified Party shall have the right to contest, settle or compromise the claim and shall not waive any right
to indemnity pursuant to this Agreement for any Losses related thereto. ARYA or Amber GT Parent, as applicable, shall in no event settle
or compromise (or consent to the settlement or compromise of) any Third-Party Claim without the prior written consent of the Indemnifying
Party (such consent not to be unreasonably withheld, conditioned or delayed), unless it, as a condition precedent to such payment or
settlement, waives any right to indemnity by the Indemnifying Party for all Losses related to such Third-Party Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 143; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Parties shall, and shall cause their pertinent Representatives to, reasonably cooperate in the defense or prosecution of any Third-Party
Claim in respect of which indemnity may be sought hereunder, and each of ARYA and Amber GT Parent shall (and shall cause their respective
pertinent Representatives to) furnish such books, records, information and testimony, and attend such conferences, discovery proceedings,
hearings, trials and appeals, as may be reasonably requested in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
the avoidance of doubt, this <U>Section&nbsp;10.4</U> shall not apply with respect to Tax matters, which shall be governed by <U>Section&nbsp;6.12(e)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Exclusive
Remedy</U></FONT>. Subject to the last sentence of this <U>Section&nbsp;10.5 </U>and <U>Section&nbsp;6.10</U>, following the Closing,
the indemnification provisions of this <U>Article&nbsp;X</U> shall be the sole and exclusive remedies of the ARYA Indemnified Parties,
on the one hand, and the Amber Indemnified Parties, on the other hand, for any Losses (including any Losses from claims for breach of
contract, warranty, tortious conduct (including negligence) or otherwise and whether predicated on common law, statute, strict liability
or otherwise) that any ARYA Indemnified Party or an Amber Indemnified Party may at any time suffer or incur, or become subject to, as
a result of, or in connection with the transactions contemplated by this Agreement, including any failure by any Party to perform or
comply with any covenant or agreement that, by its terms, was to have been performed, or complied with, under this Agreement. Notwithstanding
anything in this Agreement to the contrary, this <U>Section&nbsp;10.5</U> shall not (a)&nbsp;affect, restrict or limit the remedies of
specific performance and injunctive or other equitable relief pursuant to <U>Section&nbsp;11.17 </U>or (b)&nbsp;for the avoidance of
doubt, affect, restrict or limit any of the rights, covenants, agreements or obligations (including, if applicable, indemnity or similar
obligations) of any parties under the Transition Services Agreement, the Co-Development and Commercialization Agreement, the A&amp;R
Company LLC Agreement, the Tax Receivables Agreement, the Investors Rights Agreement, or the Philadelphia Facility Sublease or any claims
by any party thereto against any other party(ies) thereto, in each case, on the terms and subject to the conditions therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Additional
Indemnification Provisions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">With
respect to each indemnification obligation set forth in this Agreement, all Losses shall be net of any amounts that have been recovered
by the Indemnified Party pursuant to any indemnification by, or indemnification agreement with, any third party or any insurance policy
or other cash receipts or sources of reimbursement in respect of such Loss (after deducting therefrom (i)&nbsp;the amount of the reasonable,
documented and out-of-pocket expenses incurred in procuring such recovery and (ii)&nbsp;in the case of an insurance policy, any actual
increases in premiums of such policies as a result of such recovery).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">In
any case where the Indemnified Party (or their Affiliates) recovers pursuant to any indemnification by, or indemnification agreement
with, any third party or any insurance policy or other cash receipts or sources of reimbursement any amount not previously taken into
account in respect of a matter for which such Indemnified Party was indemnified pursuant to <U>Section&nbsp;10.2</U> or <U>Section&nbsp;10.3(a)</U>,
as applicable, such Indemnified Party shall promptly pay over to the Indemnifying Party the amount so recovered or realized (after deducting
therefrom the amount of the reasonable, documented and out-of-pocket expenses incurred in procuring such recovery or realization, including,
in the case of an insurance policy, any actual increases in premiums as a result of such recovery), but not in excess of the sum of (i)&nbsp;any
amount previously so paid pursuant to <U>Section&nbsp;10.2</U> or <U>Section&nbsp;10.3(a)</U>, as applicable, to or on behalf of such
Indemnified Party in respect of such matter and (ii)&nbsp;any amount expended by Indemnifying Party in pursuing or defending any claim
arising out of such matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 144; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Limitation
of Liability</U>. Notwithstanding anything in this Agreement to the contrary, in no event shall any Party have any liability under this
<U>Article&nbsp;X</U> for any punitive damages (other than those actually paid to a third party in connection with any Third-Party Claim).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Manner
of Payments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Any
indemnification of an ARYA Indemnified Party pursuant to this <U>Article&nbsp;X </U>shall be effected by wire transfer of immediately
available funds from or on behalf of Amber GT Parent to an account designated in writing by ARYA (on behalf of itself or any other ARYA
Indemnified Parties) within five (5)&nbsp;Business Days after the final determination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Any
indemnification of an Amber Indemnified Party pursuant to this <U>Article&nbsp;X</U> shall be effected by wire transfer of immediately
available funds from or on behalf of ARYA to an account designated in writing by Amber GT Parent (on behalf of itself or any other Amber
Indemnified Party) within five (5)&nbsp;Business Days after the final determination thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;XI<BR>
MISCELLANEOUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any notice, requests, claims, demands and other communications hereunder shall be sent in writing and shall be deemed to have been duly
given by delivery in person, by email (having obtained electronic delivery confirmation thereof (i.e., an electronic record of the sender
that the email was sent to the intended recipient thereof without an &ldquo;error&rdquo; or similar message that such email was not received
by such intended recipient)), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to
the other Parties as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">if to the Company (prior to the Closing), Amber GT or Amber
GT Parent, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">c/o&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Amicus Therapeutics,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">3675 Market Street,&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Philadelphia, PA 19104&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn: Chief Legal Officer&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: gcoffice@amcisurx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 145; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP<BR>
1440 New York Avenue, N.W.<BR>
Washington, D.C. 20005</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 88%; margin-left: 1in">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attn:</FONT></TD>
  <TD STYLE="width: 95%"><FONT STYLE="font-size: 10pt">Graham
Robinson</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Katherine
D. Ashley</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Email: </TD>
  <TD>graham.robinson@skadden.com</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>katherine.ashley@skadden.com</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">if to ARYA (prior to the Closing), to:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c/o
ARYA Science Acquisition Corp IV</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">51 Astor Place, 10th Floor</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">New York, NY 10003</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Attn:</TD>
  <TD>Adam Stone</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Michael Altman</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">Doug Giordano</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">Konstantin Poukalov</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Email: </TD>
  <TD>adam@perceptivelife.com</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">michael@perceptivelife.com</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">doug@perceptivelife.com</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><FONT STYLE="font-size: 10pt">konstantin@perceptivelife.com</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirkland&nbsp;&amp;
Ellis LLP<BR>
601 Lexington Avenue<BR>
New York, NY 10022</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 88%; margin-left: 1in">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Attn:</FONT></TD>
  <TD STYLE="width: 95%">Jonathan
L. Davis, P.C.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Ryan Brissette</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Email:</TD>
  <TD><FONT STYLE="font-size: 10pt">jonathan.davis@kirkland.com</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>ryan.brissette@kirkland.com</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">if to the Company or ARYA (following the Closing), to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3675
Market Street,<BR>
Philadelphia, PA 19104</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 88%; margin-left: 1in">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">Attn:</TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-size: 10pt">John
F. Crowley</FONT></TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
    <TD>Email:</TD>
    <TD><FONT STYLE="font-size: 10pt">[to
be provided at Closing]</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 146; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 9 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirkland&nbsp;&amp;
Ellis LLP<BR>
601 Lexington Avenue<BR>
New York, NY 10022</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 1in; width: 18%">Attn:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%">Jonathan L. Davis, P.C.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Ryan Brissette</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 1in">Email:&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">jonathan.davis@kirkland.com</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">ryan.brissette@kirkland.com</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendments;
Waivers</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">This
Agreement cannot be amended, supplemented or modified, except by a writing signed by (i)&nbsp;each of ARYA and Amber GT Parent prior
to the Closing and (ii)&nbsp;ARYA, ARYA Sponsor and Amber GT Parent following the Closing, and cannot be amended, supplemented or modified
orally or by course of conduct. No provision hereof may be waived, except by a writing signed by the Party against whom such waiver is
to be enforced, and any such waiver shall apply only in the particular instance in which such waiver shall have been given; <U>provided</U>,
<U>however</U>, that, following the Closing, any waiver of any provision applicable to Amber GT Parent or Amber GT shall also require
the prior written consent of ARYA Sponsor. This Agreement may not be modified or amended except as provided in the preceding sentences
and any purported amendment by any Party or Parties effected in a manner which does not comply with this <U>Section&nbsp;11.2</U> shall
be void, ab initio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Neither
any failure or delay in exercising any right or remedy hereunder or in requiring satisfaction of any condition herein nor any course
of dealing shall constitute a waiver of or prevent any Party from enforcing any right or remedy or from requiring satisfaction of any
condition. No notice to or demand on a Party waives or otherwise affects any obligation of that Party or impairs any right of the Party
giving such notice or making such demand, including any right to take any action without notice or demand not otherwise required by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Arm&rsquo;s-Length
Bargaining; No Presumption against Drafter</U>. This Agreement has been negotiated at arm&rsquo;s-length by parties of equal bargaining
strength, each represented by counsel in connection with this Agreement and the transactions contemplated hereby. This Agreement creates
no fiduciary or other special relationship between the Parties, and no such relationship otherwise exists. No presumption in favor of
or against any Party in the construction or interpretation of this Agreement or any provision hereof shall be made based upon which Person
might have drafted this Agreement or such provision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 147; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Publicity</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Subject
to <U>Section&nbsp;11.4(b)</U>, <U>Section&nbsp;6.6</U>, and <U>Section&nbsp;6.7</U>, none of the Parties or any of their respective
Representatives shall issue any press releases or make any public announcements with respect to this Agreement or the transactions contemplated
hereby without the prior written consent of, prior to the Closing, Amber GT Parent and ARYA or, following the Closing, Amber GT Parent,
ARYA and the ARYA Sponsor; <U>provided</U>, <U>however</U>, that each Party, the ARYA Sponsor and their respective Representatives may
issue or make, as applicable, any such press release, public announcement or other communication (i)&nbsp;if such press release, public
announcement or other communication is required by applicable Law, in which case (A)&nbsp;prior to the Closing, the disclosing Party
or its applicable Representatives shall, unless and to the extent prohibited by such applicable Law, (x)&nbsp;if the disclosing Person
is ARYA, the ARYA Sponsor or any of their Representatives, reasonably consult with Amber GT Parent in connection therewith and provide
Amber GT Parent with an opportunity to review and comment on such press release, public announcement or communication and shall consider
any such comments in good faith, or (y)&nbsp;if the disclosing Party is an Amber Entity or any Representative of an Amber Entity, reasonably
consult with ARYA in connection therewith and provide ARYA with an opportunity to review and comment on such press release, public announcement
or communication and shall consider any such comments in good faith, or (B)&nbsp;following the Closing, the disclosing Party or its applicable
Representatives shall, unless and to the extent prohibited by such applicable Law, (x)&nbsp;if the disclosing Person is the ARYA Sponsor
or a Representative of the ARYA Sponsor, reasonably consult with ARYA and Amber GT Parent in connection therewith and provide ARYA and
Amber GT Parent with an opportunity to review and comment on such press release, public announcement or communication and consider any
such comments in good faith, (y)&nbsp;if the disclosing Person is Amber GT Parent or a Representative of Amber GT Parent, reasonably
consult with ARYA and the ARYA Sponsor in connection therewith and provide ARYA and the ARYA Sponsor with an opportunity to review and
comment on such press release, public announcement or communication and consider any such comments in good faith, and (z)&nbsp;if the
disclosing Person is ARYA or a Representative of ARYA, reasonably consult with Amber GT Parent and the ARYA Sponsor in connection therewith
and provide Amber GT Parent and the ARYA Sponsor with an opportunity to review and comment on such press release, public announcement
or communication and consider any such comments in good faith, (ii)&nbsp;to the extent such press release, public announcements or other
communications contain only information previously disclosed in a press release, public announcement or other communication previously
made in accordance with this <U>Section&nbsp;11.4</U> and (iii)&nbsp;to governmental Authorities in connection with any Consents required
to be made under this Agreement, the Additional Agreements or in connection with the transactions contemplated hereby or thereby. Notwithstanding
anything to the contrary in this <U>Section&nbsp;11.4</U> or otherwise in this Agreement, the Parties agree that the Perceptive Shareholders
and their respective Representatives may provide general information about the subject matter of this Agreement and the transactions
contemplated hereby to any direct or indirect former, current or prospective investor or in connection with normal fund raising or related
marketing or informational or reporting activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
initial press release concerning this Agreement and the transactions contemplated hereby shall be a joint press release in the form agreed
by Amber GT Parent and ARYA prior to the execution of this Agreement and such initial press release (the &ldquo;<U>Signing Press Release</U>&rdquo;)
shall be released as promptly as reasonably practicable after the execution of this Agreement on the day thereof. Promptly after the
execution of this Agreement, ARYA shall file a current report on Form&nbsp;8-K (the &ldquo;<U>Signing Filing</U>&rdquo;) with the Signing
Press Release and a description of this Agreement as required by, and in compliance with, the securities Laws, which Amber GT Parent
shall have the opportunity to review and comment upon prior to filing and ARYA shall consider such comments in good faith. Amber GT Parent,
on the one hand, and ARYA, on the other hand, shall mutually agree upon (such agreement not to be unreasonably withheld, conditioned
or delayed by either Amber GT Parent or ARYA, as applicable) a press release announcing the consummation of the transactions contemplated
by this Agreement (the &ldquo;<U>Closing Press Release</U>&rdquo;) prior to the Closing, and, on the Closing Date (or such other date
as may be mutually agreed to in writing by Amber GT Parent and ARYA prior to the Closing (such agreement not to be unreasonably withheld,
conditioned or delayed by either Amber GT Parent or ARYA, as applicable)), the Parties shall cause the Closing Press Release to be released.
Promptly after the Closing (but in any event within four (4)&nbsp;Business Days after the Closing), ARYA shall file a current report
on Form&nbsp;8-K (the &ldquo;<U>Closing Filing</U>&rdquo;) with the Closing Press Release and a description of the Closing as required
by securities Laws, which Closing Filing shall be mutually agreed upon by Amber GT Parent and ARYA prior to the Closing (such agreement
not to be unreasonably withheld, conditioned or delayed by either Amber GT Parent or ARYA, as applicable). In connection with the preparation
of each of the Signing Press Release, the Signing Filing, the Closing Press Release and the Closing Filing, each Party, upon written
request by any other Party, shall furnish such other Party with all information concerning itself, its directors, officers and equityholders,
and such other matters as may be reasonably necessary for such press release or filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 148; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Expenses</U>.
Unless otherwise specified herein or in the applicable Additional Agreement, each Party shall bear its own costs and expenses incurred
in connection with this Agreement, the Additional Agreements and the transactions contemplated hereby and thereby; <U>provided</U> that
(a)&nbsp;for the avoidance of doubt, if this Agreement is terminated in accordance with its terms, Amber GT Parent shall pay, or cause
to be paid, all Amber Entity Expenses and ARYA shall pay, or cause to be paid, all ARYA Expenses and (b)&nbsp;if the Closing occurs,
then (i)&nbsp;the Company shall pay, or cause to be paid, (A)&nbsp;the Unpaid ARYA Transaction Expenses, up to a maximum amount of $25,000,000
and (B)&nbsp;any Unpaid Amber Entity Transaction Expenses in an amount not to exceed the Reimbursement Remainder, and (ii)&nbsp;Amber
GT Parent shall pay, or cause to be paid, all Unpaid Amber Entity Expenses in excess of the Reimbursement Remainder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Assignment or Delegation</U>. No Party may assign any right or delegate any obligation hereunder, including by merger, consolidation,
operation of Law, or otherwise, without the written consent (a)&nbsp;ARYA and Amber GT Parent prior to the Closing and (b)&nbsp;ARYA,
Amber GT Parent and the ARYA Sponsor following the Closing. Any purported assignment or delegation that does not comply with the immediately
preceding sentence shall be void, in addition to constituting a material breach of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. This Agreement, and all claims or causes of action (whether in contract, tort or statute) that may be based upon, arise out
of or relate to this Agreement or any Additional Agreement or any of the transactions contemplated hereby or thereby, or the negotiation,
execution or performance of this Agreement or any Additional Agreement or any of the transactions contemplated hereby or thereby (including
any claim or cause of action based upon, arising out of related to any representation or warranty made in or in connection with this
Agreement or any Additional Agreement or any of the transactions contemplated hereby or any of the transactions contemplated thereby
or as inducement to enter into this Agreement or any Additional Agreement or any of the transactions contemplated hereby or thereby),
shall be construed and enforced in accordance with and governed by the Laws (both substantive and procedural) of the State of Delaware,
without giving effect to the conflict of Laws principles thereof (except that the Laws of the Cayman Islands shall also apply to the
Domestication).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Counterparts;
Electronic Signatures</U>. This Agreement and each Additional Agreement (including any of the closing deliverables contemplated hereby)
may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and
the same agreement. Delivery of an executed counterpart of a signature page&nbsp;to this Agreement or any Additional Agreement (including
any of the closing deliverables contemplated hereby) by email or scanned pages&nbsp;shall be effective as delivery of a manually executed
counterpart to this Agreement or any such Additional Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 149; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Knowledge
of Amber GT Parent; Knowledge of ARYA</U>. For all purposes of this Agreement, the phrase &ldquo;to the knowledge of Amber GT Parent&rdquo;
and &ldquo;known by Amber GT Parent&rdquo; and any derivations thereof shall mean as of the applicable date, the actual knowledge of
the individuals set forth on <U>Section&nbsp;11.9(a)</U>&nbsp;of the Amber Disclosure Schedules, assuming reasonable due inquiry and
investigation of his or her direct reports. For all purposes of this Agreement, the phrase &ldquo;to ARYA&rsquo;s knowledge&rdquo; and
 &ldquo;to the knowledge of ARYA&rdquo; and any derivations thereof shall mean as of the applicable date, the actual knowledge of the
individuals set forth on <U>Section&nbsp;11.9(b)</U>&nbsp;of the ARYA Disclosure Schedules, assuming reasonable due inquiry and investigation
of his or her direct reports. For the avoidance of doubt, none of the individuals set forth on <U>Section&nbsp;11.9(a)</U>&nbsp;of the
Amber Disclosure Schedules or <U>Section&nbsp;11.9(b)</U>&nbsp;of the ARYA Disclosure Schedules shall have any personal Liability or
obligations regarding such knowledge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. This Agreement, together with the Additional Agreements, including any exhibits and schedules attached hereto or thereto,
sets forth the entire agreement of the Parties with respect to the subject matter hereof and thereof and supersedes all prior and contemporaneous
understandings and agreements related thereto (whether written or oral), all of which are merged herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Exhibits
and Schedules</U>. All Exhibits and Schedules, or documents expressly incorporated into this Agreement, are hereby incorporated into
this Agreement and are hereby made a part hereof as if set out in full in this Agreement. The Schedules shall be arranged in sections
and subsections corresponding to the numbered and lettered Sections and subsections set forth in this Agreement. Any item disclosed in
the Amber Disclosure Schedules or in the ARYA Disclosure Schedules corresponding to any Section&nbsp;or subsection of <U>Article&nbsp;III
</U>or <U>Article&nbsp;IV</U> (in the case of the Amber Disclosure Schedules) or <U>Article&nbsp;V</U> (in the case of the ARYA Disclosure
Schedules) shall be deemed to have been disclosed with respect to every other section and subsection of <U>Article&nbsp;III</U> or <U>Article&nbsp;IV
</U>(in the case of the Amber Disclosure Schedules) or <U>Article&nbsp;V</U> (in the case of the ARYA Disclosure Schedules), as applicable,
where the relevance of such disclosure to such other Section&nbsp;or subsection is reasonably apparent on the face of the disclosure.
The information and disclosures set forth in the Schedules that correspond to the section or subsections of <U>Article&nbsp;III</U>,
<U>Article&nbsp;IV</U> or <U>Article&nbsp;V</U> may not be limited to matters required to be disclosed in the Schedules, and any such
additional information or disclosure is for informational purposes only and does not necessarily include other matters of a similar nature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
Subject to <U>Section&nbsp;6.18(h)</U>, whenever possible, each provision of this Agreement will be interpreted in such a manner as to
be effective and valid under applicable Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable
under applicable Law, all other provisions of this Agreement shall remain in full force and effect so long as the economic or legal substance
of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Subject to <U>Section&nbsp;6.18(h)</U>,
upon such determination that any term or other provision of this Agreement is invalid, illegal or unenforceable under applicable Law,
the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible
in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest
extent possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 150; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Construction;
Interpretation</U>. The term &ldquo;this Agreement&rdquo; means this Business Combination Agreement together with the Schedules and Exhibits
hereto, as the same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. The headings
set forth in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement.
Unless otherwise indicated to the contrary herein by the context or use thereof: (a)&nbsp;the words, &ldquo;herein,&rdquo; &ldquo;hereto,&rdquo;
 &ldquo;hereof&rdquo; and words of similar import refer to this Agreement as a whole, including the Schedules and Exhibits, and not to
any particular section, subsection, paragraph, subparagraph or clause set forth in this Agreement; (b)&nbsp;masculine gender shall also
include the feminine and neutral genders, and vice versa; (c)&nbsp;words importing the singular shall also include the plural, and vice
versa; (d)&nbsp;the words &ldquo;include,&rdquo; &ldquo;includes&rdquo; or &ldquo;including&rdquo; shall be deemed to be followed by
the words &ldquo;without limitation&rdquo;; (e)&nbsp;references to &ldquo;$&rdquo; or &ldquo;dollar&rdquo; or &ldquo;U.S. $&rdquo; shall
be references to United States dollars; (f)&nbsp;the word &ldquo;or&rdquo; is disjunctive but not exclusive; (g)&nbsp;the words &ldquo;writing,&rdquo;
 &ldquo;written&rdquo; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media)
in a visible form; (h)&nbsp;the word &ldquo;day&rdquo; means calendar day unless Business Day is expressly specified; (i)&nbsp;the word
 &ldquo;extent&rdquo; in the phrase &ldquo;to the extent&rdquo; means the degree to which a subject or other thing extends, and such phrase
shall not mean simply &ldquo;if&rdquo;; (j)&nbsp;all references to Articles, Sections, Exhibits or Schedules are to Articles, Sections,
Exhibits and Schedules of this Agreement; (k)&nbsp;the words &ldquo;provided&rdquo; or &ldquo;made available&rdquo; or words of similar
import (regardless of whether capitalized or not) shall mean, when used with reference to documents or other materials required to be
provided or made available to ARYA, any documents or other materials posted to the electronic data room located at datasite.com under
the project name &ldquo;Apollo AT&rdquo; as of 5:00 p.m., Eastern Time, at least one (1)&nbsp;Business Day prior to the date of this
Agreement; (l)&nbsp;all references to any Law will be to such Law, as amended, supplemented or otherwise modified or re-enacted from
time to time; and (m)&nbsp;all references to any Contract are to that Contract as amended or modified from time to time in accordance
with the terms thereof (subject to any restrictions on amendments or modifications set forth in this Agreement). If any action under
this Agreement is required to be done or taken on a day that is not a Business Day, then such action shall be required to be done or
taken not on such day but on the first succeeding Business Day thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Third-Party
Beneficiaries</U>. This Agreement shall be binding upon and inure solely to the benefit of each Party and its successors and permitted
assigns and, except as provided in <U>Section&nbsp;6.10</U>, <U>Section&nbsp;6.20</U>, the last sentence of this <U>Section&nbsp;11.14
</U>and <U>Section&nbsp;11.19</U>, nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person
any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement. The ARYA Sponsor shall be an express
third-party beneficiary of <U>Section&nbsp;6.5(c)-(d)</U>, <U>Section&nbsp;6.10</U>, <U>Section&nbsp;6.11</U>, <U>Section&nbsp;10.2</U>,
<U>Section&nbsp;10.4</U>, <U>Section&nbsp;11.6</U> and this <U>Section&nbsp;11.14</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 151; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Trust
Account Waiver</U>. Reference is made to the final prospectus of ARYA, filed with the SEC on February&nbsp;25, 2021 (the &ldquo;<U>Prospectus</U>&rdquo;).
Each Amber Entity acknowledges and agrees and understands that ARYA has established the Trust Account, which contains the proceeds of
its initial public offering (the &ldquo;<U>IPO</U>&rdquo;) and from certain private placements occurring simultaneously with the IPO
(including interest accrued from time to time thereon) for the benefit of ARYA&rsquo;s public shareholders (including overallotment shares
acquired by ARYA&rsquo;s underwriters, the &ldquo;<U>Public Shareholders</U>&rdquo;), and ARYA may disburse monies from the Trust Account
only in the express circumstances described in the Prospectus. For and in consideration of ARYA entering into this Agreement, and for
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, each Amber Entity hereby agrees on
behalf of itself and its Representatives that, notwithstanding the foregoing or anything to the contrary in this Agreement, none of the
Amber Entities or any of their respective Representatives does now or shall at any time hereafter have any right, title, interest or
claim of any kind in or to any monies in the Trust Account or distributions therefrom, or make any claim against the Trust Account (including
any distributions therefrom), regardless of whether such claim arises as a result of, in connection with or relating in any way to, this
Agreement or any proposed or actual business relationship between ARYA or any of its Representatives, on the one hand, and, each Amber
Entity or any of their respective Representatives, on the other hand, or any other matter, and regardless of whether such claim arises
based on contract, tort, equity or any other theory of legal liability (any and all such claims are collectively referred to hereafter
as the &ldquo;<U>Trust Account Released Claims</U>&rdquo;). Each Amber Entity, on its own behalf and on behalf of its Representatives,
hereby irrevocably waives any Trust Account Released Claims that it or any of its Representatives may have against the Trust Account
(including any distributions therefrom) now or in the future as a result of, or arising out of, any negotiations, or Contracts with ARYA
or its Representatives and will not seek recourse against the Trust Account (including any distributions therefrom) for any reason whatsoever
(including for an alleged breach of any agreement with ARYA or its Affiliates).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Submission
to Jurisdiction</U>. Each of the Parties irrevocably and unconditionally submits to the exclusive jurisdiction of the Chancery Court
of the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept jurisdiction, any federal court within
the State of Delaware, and then, if such federal court declines to accept jurisdiction, any state or federal court within New York, New
York), for the purposes of any Action (a)&nbsp;arising under this Agreement or under any Additional Agreement or (b)&nbsp;in any way
connected with or related or incidental to the dealings of the Parties in respect of this Agreement or any Additional Agreement or any
of the transactions contemplated hereby or any of the transactions contemplated thereby, and irrevocably and unconditionally waives any
objection to the laying of venue of any such Action in any such court, and further irrevocably and unconditionally waives and agrees
not to plead or claim in any such court that any such Action has been brought in an inconvenient forum. Each Party hereby irrevocably
and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any Action or cause
thereof against such Party (x)&nbsp;arising under this Agreement or under any Additional Agreement or (y)&nbsp;in any way connected with
or related or incidental to the dealings of the Parties in respect of this Agreement or any Additional Agreement or any of the transactions
contemplated hereby or any of the transactions contemplated thereby, (i)&nbsp;any claim that such Party is not personally subject to
the jurisdiction of the courts as described in this <U>Section&nbsp;11.16</U> for any reason, (ii)&nbsp;that such Party or such Party&rsquo;s
property is exempt or immune from the jurisdiction of any such court or from any legal process commenced in such courts (whether through
service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and
(iii)&nbsp;that (x)&nbsp;the Action or cause thereof in any such court is brought against such Party in an inconvenient forum, (y)&nbsp;the
venue of such Action or cause thereof against such Party is improper; or (z)&nbsp;this Agreement, or the subject matter hereof, may not
be enforced against such Party in or by such courts. Each Party agrees that service of any process, summons, notice or document by registered
mail to such Party&rsquo;s respective address set forth in <U>Section&nbsp;11.1</U> shall be effective service of process for any such
Action, demand, or cause thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 152; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
Except as otherwise expressly provided herein, any and all remedies provided herein will be deemed cumulative with and not exclusive
of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude
the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not
be an adequate remedy, would occur in the event that the Parties do not perform their respective obligations under the provisions of
this Agreement (including failing to take such actions as are required of them hereunder to consummate the transactions contemplated
by this Agreement) in accordance with their specific terms or otherwise breach such provisions. It is accordingly agreed that the Parties
shall be entitled to seek an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement
and to enforce specifically the terms and provisions of this Agreement, in each case, without posting a bond or undertaking and without
proof of damages and this being in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees
that it will not oppose the granting of an injunction, specific performance and other equitable relief when expressly available pursuant
to the terms of this Agreement on the basis that the other Parties have an adequate remedy at law or an award of specific performance
is not an appropriate remedy for any reason at law or equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Waiver
of Jury Trial</U>. EACH OF THE PARTIES HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY PROCEEDING,
CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (I)&nbsp;ARISING UNDER THIS AGREEMENT OR UNDER ANY ADDITIONAL AGREEMENT OR (II)&nbsp;IN ANY
WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES IN RESPECT OF THIS AGREEMENT OR ANY ADDITIONAL AGREEMENT OR
ANY OF THE TRANSACTIONS RELATED HERETO OR THERETO OR ANY FINANCING IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY OR ANY OF
THE TRANSACTIONS CONTEMPLATED THEREBY,&nbsp;IN EACH CASE, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY,
OR OTHERWISE. THE PARTIES EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH PROCEEDING, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE
DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES MAY&nbsp;FILE AN ORIGINAL COUNTERPART&nbsp;OF A COPY OF THIS AGREEMENT WITH
ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH PARTY CERTIFIES
AND ACKNOWLEDGES THAT (A)&nbsp;NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT
SUCH OTHER PARTY WOULD NOT,&nbsp;IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B)&nbsp;EACH SUCH PARTY UNDERSTANDS
AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C)&nbsp;EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY AND (D)&nbsp;EACH SUCH PARTY
HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION&nbsp;11.18</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 153; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Non-Recourse</U>.
This Agreement may only be enforced against, and any action for breach of this Agreement may only be made against, the Parties, and without
limiting the generality of the foregoing, none of the Representatives of any Party shall have any Liability arising out of or relating
to this Agreement, the negotiation hereof or its subject matter or the transactions contemplated hereby or the transactions contemplated
hereby, including with respect to any claim (whether in tort, contract or otherwise) for breach of this Agreement or in respect of any
written or oral representations made or alleged to be made in connection herewith, except as expressly provided herein or, for the avoidance
of doubt, for claims pursuant to any Additional Agreement by any party(ies) thereto against any other party(ies) thereto on the terms
and subject to the conditions therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>The remainder of this page&nbsp;intentionally
left blank; signature pages&nbsp;to follow</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 154; Value: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have caused this Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">ARYA SCIENCES ACQUISITION CORP IV</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Michael Altman</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Michael Altman</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[Signature Page &ndash;
Business Combination Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 155 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Split-Segment; Name: 10 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have caused this Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">AMICUS
    THERAPEUTICS,&nbsp;INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ John F. Crowley</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">John F. Crowley</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[Signature Page&nbsp;&ndash; Business Combination
Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 156 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have caused this Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">AMICUS GT HOLDINGS, LLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Bradley L. Campbell</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Bradley L. Campbell</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">President</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[Signature Page&nbsp;&ndash; Business Combination
Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 157 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have caused this Agreement to be duly executed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">CARITAS THERAPEUTICS, LLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ John F. Crowley</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">John F. Crowley</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[Signature Page&nbsp;&ndash; Business Combination
Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 158 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of PIPE Subscription Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 159 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit A</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SUBSCRIPTION AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARYA Sciences Acquisition Corp IV<BR>
51 Astor Place, 10th Floor<BR>
New York, New York 10002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Subscription Agreement
(this &#8220;<U>Subscription Agreement</U>&#8221;) is being entered into as of the date set forth on the signature page hereto, by and
between ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (&#8220;<U>ARYA</U>&#8221;), which shall be domesticated
as a Delaware corporation prior to the closing of the Transaction (as defined herein), and the undersigned subscriber (the &#8220;<U>Investor</U>&#8221;),
in connection with the Business Combination Agreement, dated as of the date hereof (as may be amended, supplemented or otherwise modified
from time to time, the &#8220;<U>Transaction Agreement</U>&#8221;), by and among ARYA, Amicus Therapeutics, Inc., a Delaware corporation
(&#8220;<FONT STYLE="font-weight: normal"><U>Parent</U></FONT>&#8221;), Caritas GT Holdings, LLC, a Delaware limited liability company
(&#8220;<FONT STYLE="font-weight: normal"><U>Caritas GT</U></FONT>&#8221;), and Caritas Therapeutics, LLC, a Delaware limited liability
company (the &#8220;<FONT STYLE="font-weight: normal"><U>Company</U></FONT>&#8221;), pursuant to which, among other things, ARYA will
contribute a portion of the net proceeds from the Trust Account (as defined below) and this Subscription Agreement and the Other Subscription
Agreements (as defined below) in exchange for a majority of the equity securities in the Company and, in connection therewith, Caritas
GT will receive Class B common stock, par value $0.0001 per share, in ARYA, in each case, on the terms and subject to the conditions set
forth in the Transaction Agreement (the &#8220;<U>Transaction</U>&#8221;). <FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">In
connection with the Transaction, ARYA is seeking commitments from interested investors to purchase, following the Domestication (as defined
below) and prior to the closing of the Transaction, shares of ARYA&#8217;s Class A common stock, par value $0.0001 per share (the &#8220;<U>Shares</U>&#8221;),
in a private placement for a purchase price of $10.00 per share (the &#8220;<U>Per Share Purchase Price</U>&#8221;). On or about the date
of this Subscription Agreement, ARYA is, severally and not jointly, entering into subscription agreements (the &#8220;<U>Other Subscription
Agreements</U>&#8221;, and together with this Subscription Agreement, the &#8220;<U>Subscription Agreements</U>&#8221;) with certain other
investors (the &#8220;<U>Other Investors</U>&#8221;, and together with the Investor, the &#8220;<U>Investors</U>&#8221;), pursuant to
which the Investors, severally and not jointly, have agreed to purchase on the closing date of the Transaction, inclusive of the Shares
subscribed for by the Investor, an aggregate amount of up to 20,150,000 Shares, at the Per Share Purchase Price. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Prior
to the closing of the Transaction (and as more fully described in, and on the terms and subject to the conditions set forth in, the Transaction
Agreement), ARYA will domesticate as a Delaware corporation in accordance with Section&nbsp;388 of the General Corporation Law of the
State of Delaware </FONT>and Part XII of the Cayman Islands Companies Act (2020 Revision) <FONT STYLE="background-color: white">(the &#8220;<U>Domestication</U>&#8221;).
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
aggregate purchase price to be paid by the Investor for the subscribed Shares (as set forth on the signature page hereto) is referred
to herein as the &#8220;<U>Subscription Amount.</U>&#8221; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection therewith, and
in consideration of the foregoing and the mutual representations, warranties and covenants, and subject to the conditions, set forth herein,
and intending to be legally bound hereby, each of the Investor and ARYA acknowledges and agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subscription</U>. The Investor hereby irrevocably subscribes for and agrees to purchase from ARYA the number of Shares set forth
on the signature page of this Subscription Agreement on the terms and subject to the conditions set forth in this Subscription Agreement.
The Investor acknowledges and agrees that ARYA reserves the right to accept or reject the Investor&#8217;s subscription for the Shares
for any reason or for no reason, in whole or in part, at any time prior to its acceptance, and the same shall be deemed to be accepted
by ARYA only when this Subscription Agreement is signed by a duly authorized person by or on behalf of ARYA. <FONT STYLE="background-color: white">The
Investor </FONT>acknowledges and agrees <FONT STYLE="background-color: white">that, as a result of the Domestication, the Shares that
will be purchased by the Investor and issued by ARYA on the terms and subject to the conditions set forth in this Subscription Agreement
shall be shares of common stock in a Delaware corporation (and not, for the avoidance of doubt, ordinary shares in a Cayman Islands exempted
company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 160 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Closing</U>.
The closing of the sale, purchase and issuance of the Shares contemplated hereby (the &#8220;<FONT STYLE="font-weight: normal"><U>Closing</U></FONT>&#8221;)
is contingent upon the substantially concurrent consummation of the Transaction. The Closing shall occur on the date of, and
immediately prior to, the effectiveness of the Transaction (the date the Closing so occurs, the &#8220;<U>Closing Date</U>&#8221;).
Upon delivery of written notice from (or on behalf of) ARYA to the Investor (the &#8220;<FONT STYLE="font-weight: normal"><U>Closing
Notice</U></FONT>&#8221;), that ARYA reasonably expects all conditions to the closing of the Transaction under the Transaction
Agreement to be satisfied or waived on a date that is not less than five (5) business days from the date on which the Closing Notice
is delivered to the Investor, the Investor shall deliver to ARYA, three (3) business days prior to the anticipated closing date
specified in the Closing Notice, the Subscription Amount by wire transfer of United States dollars in immediately available funds to
the account(s) specified by ARYA in the Closing Notice (such funds to be held in an escrow by ARYA or in such account(s) specified
by ARYA). On the Closing Date, ARYA shall issue a number of Shares to the Investor set forth on the signature page to this
Subscription Agreement and subsequently cause such Shares to be registered in book entry form, free and clear of all liens (other
than those arising under applicable securities laws), in the name of the Investor on ARYA&#8217;s share register; <U>provided</U>, <U>however</U>,
that ARYA&#8217;s obligation to issue the Shares to the Investor is contingent upon ARYA having received the Subscription Amount in
full accordance with this Section 2. In the event the Closing does not occur within two (2) business days of the anticipated Closing
Date specified in the Closing Notice, ARYA shall promptly (but not later than three (3) business days thereafter) return the
Subscription Amount to the Investor; provided that, unless this Subscription Agreement has been terminated pursuant to Section 8
hereof, such return of funds shall not terminate this Subscription Agreement or relieve the Investor of its obligation to purchase
the Shares at the Closing upon the delivery by ARYA of a subsequent Closing Notice in accordance with this Section 2. For purposes
of this Subscription Agreement, &#8220;business day&#8221; shall mean any day other than a Saturday, Sunday or a day on which
commercial banking institutions in New York, New York are authorized or required to close for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The obligation of the parties hereto to consummate the sale, purchase and issuance of the Shares pursuant to this Subscription
Agreement is subject to the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>no applicable governmental authority shall have enacted, issued, promulgated, enforced or entered any judgment, order, law,
rule or regulation (whether temporary, preliminary or permanent) which is then in effect and has the effect of making consummation of
the transactions contemplated hereby illegal or otherwise enjoining, restraining or prohibiting consummation of the (i) the sale, purchase
and issuance of the Shares pursuant to this Subscription Agreement or (ii) the Transaction; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>(A) all conditions precedent to the closing of the Transaction set forth in the Transaction Agreement shall have been satisfied
(which shall be deemed satisfied if mutually determined by the applicable parties to the Transaction Agreement and other than those conditions
under the Transaction Agreement that, by their nature are to be satisfied in connection with the closing of the Transaction, including
to the extent that any such condition is dependent upon the consummation of the sale, purchase and issuance of the Shares pursuant to
this Subscription Agreement or the Other Subscription Agreements) or waived by the applicable parties to the Transaction Agreement as
provided therein and (B) the closing of the Transaction shall be scheduled to occur concurrently with or on the same date as the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The obligation of ARYA to consummate the sale and issuance of the Shares pursuant to this Subscription Agreement shall be
subject to the condition (which may be waived in writing by ARYA with the prior written consent of Parent (not to be unreasonably withheld,
conditioned or delayed)) that all representations and warranties of the Investor contained in this Subscription Agreement are true and
correct in all material respects at and as of the Closing Date (except for (i) those representations and warranties qualified by materiality,
which shall be true and correct in all respects as of the Closing Date and (ii) those representations and warranties that speak as of
a specified earlier date, which shall be so true and correct in all material respects (or, if qualified by materiality, in all respects)
as of such specified earlier date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>The
obligation of the Investor to consummate the purchase of the Shares pursuant to this Subscription Agreement shall be subject to the
condition (which may be waived in writing by the Investor) that (i) all representations and warranties of ARYA contained in this
Subscription Agreement shall be true and correct in all material respects at and as of the Closing Date (except for (x) those
representations and warranties qualified by materiality or Material Adverse Effect (as defined below), which shall be true and
correct in all respects as of the Closing Date and (y) those representations and warranties that speak as of a specified earlier
date, which shall be so true and correct in all material respects (or, if qualified by materiality or Material Adverse Effect, in
all respects) as of such specified earlier date), (ii) ARYA shall have performed, satisfied and complied in all material respects
with all covenants, agreements and conditions required by this Subscription Agreement to be performed, satisfied or complied with by
it at or prior to the Closing and (iii) the Shares acquired hereunder shall have been approved for listing by the Stock Exchange (as
defined below), subject to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 161 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Further Assurances</U>. At the Closing, the parties hereto shall execute and deliver such additional documents and take such
additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the subscription as contemplated
by this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>ARYA Representations and Warranties</U>. ARYA represents and warrants to the Investor that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>ARYA
is an exempted company duly incorporated, validly existing and in good standing under the laws of the Cayman Islands (to the extent such
concept exists in such jurisdiction). ARYA has all power (corporate or otherwise) and authority to own, lease and operate its properties
and conduct its business as presently conducted and to enter into, deliver and perform its obligations under this Subscription Agreement.
As of the Closing Date, following the Domestication, ARYA will be duly incorporated, validly existing as a corporation and in good standing
under the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>As of the Closing Date, the Shares will be duly authorized and, when issued and delivered to the Investor against full payment
therefor in accordance with the terms of this Subscription Agreement, the Shares will be validly issued, fully paid and non-assessable
and will not have been issued in violation of or subject to any preemptive or similar rights created under ARYA&#8217;s certificate of
incorporation or bylaws (each, as amended to the Closing Date) or under the General Corporation Law of the State of Delaware or under
any agreement or instrument to which ARYA is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>The
Subscription Agreement and the Transaction Agreement have been duly authorized, executed and delivered by ARYA and, with respect to the
Subscription Agreement, assuming that the Subscription Agreement constitutes the valid and binding agreement of the Investor, constitutes
a legal, valid and binding obligation of ARYA, enforceable against ARYA in accordance with its terms, except as may be limited or otherwise
affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the
rights of creditors generally, or (ii) principles of equity, whether considered at law or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The sale and issuance of the Shares and the compliance by ARYA with all of the provisions of this Subscription Agreement
and the consummation of the transactions contemplated herein will not conflict with or result in a breach or violation of any of the terms
or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of
the property or assets of ARYA or any of its subsidiaries pursuant to the terms of (i) any indenture, mortgage, deed of trust, loan agreement,
lease, license or other agreement or instrument to which ARYA or any of its subsidiaries is a party or by which ARYA or any of its subsidiaries
is bound or to which any of the property or assets of ARYA or any of its subsidiaries is subject that would reasonably be expected to
have a material adverse effect on the business, financial condition or results of operations of ARYA and its subsidiaries, taken as a
whole or materially affect the validity of the Shares or the legal authority of ARYA to comply in all material respects with the terms
of this Subscription Agreement (a &#8220;<FONT STYLE="font-weight: normal"><U>Material Adverse Effect</U></FONT>&#8221;); (ii) result
in any violation of the provisions of the organizational documents of ARYA; or (iii) result in any violation of any statute or any judgment,
order, rule or regulation of any court or governmental agency or body, domestic or foreign, having jurisdiction over ARYA or any of their
properties that would reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">e.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>As
of their respective filing dates, all reports, forms, statements, schedules, prospectuses, proxy statements, registration statements
and other documents (the &#8220;<U>SEC Reports</U>&#8221;) required to be filed, or actually filed, by ARYA with the U.S. Securities
and Exchange Commission (the &#8220;<U>SEC</U>&#8221;) complied in all material respects with the applicable requirements of the
Securities Act of 1933, as amended (the &#8220;<U>Securities Act</U>&#8221;) and the Securities Exchange Act of 1934, as amended
(the &#8220;<U>Exchange Act</U>&#8221;) and the rules and regulations of the SEC promulgated thereunder, and none of the SEC
Reports, when filed or, if amended, as of the date of such amendment with respect to those disclosures that are amended, contained
any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading. ARYA has filed with the
SEC each SEC Report that ARYA was required to file with the SEC. The financial statements of ARYA included in the SEC Reports comply
in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in
effect at the time of filing or, if amended, as of the time of such amendment, and fairly present in all material respects the
financial position of ARYA as of and for the dates thereof and the results of operations and cash flows for the periods presented,
subject to (i) in the case of interim unaudited statements, normal, year-end audit adjustments, and (ii) changes to historical
accounting policies of ARYA in connection with any order, directive, guideline, comment or recommendation from the SEC that is
applicable to ARYA. A copy of each SEC Report is available to the Investor via the SEC&#8217;s EDGAR system. There are no
outstanding or unresolved comments in comment letters received by ARYA from the staff of the Division of Corporation Finance of the
SEC with respect to any of the SEC Reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 162 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">f.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ARYA is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or
registration with, any court or other federal, state, local or other governmental authority, self-regulatory organization or other person
in connection with the execution, delivery and performance by ARYA of this Subscription Agreement (including, without limitation, the
issuance of the Shares), other than (i) filings with the SEC, (ii) filings required by applicable state securities laws, (iii) filings
required by Nasdaq, or such other applicable stock exchange on which ARYA&#8217;s common equity is then listed (the &#8220;<U>Stock Exchange</U>&#8221;),
and (iv) the failure of which to obtain would not be reasonably likely to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">g.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The issued and outstanding Class A ordinary shares of ARYA, $0.0001 par value (&#8220;<U>Class A Shares</U>&#8221;) are
registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Stock Exchange. There is no suit, action, proceeding
or investigation pending or, to the knowledge of ARYA, threatened against ARYA by the Stock Exchange or the SEC, respectively, to prohibit
or terminate the listing of the Class A Shares or, when issued, the shares of common stock, par value $0.0001 per share, expected to be
issued in the Delaware corporation in connection with the Domestication (the &#8220;<U>Delaware Common Shares</U>&#8221;), or to deregister
the Class A Shares or, when registered and issued in connection with the Domestication, the Delaware Common Shares, under the Exchange
Act. ARYA has taken no action that is designed to terminate the registration of the Class A Shares under the Exchange Act, other than
in connection with the Domestication and subsequent registration under the Exchange Act of the Delaware Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">h.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Assuming the accuracy of the Investor&#8217;s representations and warranties set forth in Section 6, no registration under
the Securities Act is required for the offer and sale of the Shares by ARYA to the Investor hereunder. The Shares (i) were not offered
to the Investor by any form of general solicitation or general advertising and (ii) are not being offered to the Investor in a manner
involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Other than the Placement Agent (as defined below), ARYA has not engaged any broker, finder, commission agent, placement
agent or arranger in connection with the sale of the Shares, and ARYA is not under any obligation to pay any broker&#8217;s fee or commission
in connection with the sale of the Shares other than to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">j.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Other than as disclosed in the SEC Reports, ARYA has not entered into any side letter or similar agreement with any Other
Investor relating to an investment in the Shares that is materially more advantageous to such Other Investor than the terms and conditions
hereunder are to the Investor. The Other Subscription Agreements reflect the same Per Share Purchase Price and other terms with respect
to the purchase of the Shares that are not materially more favorable to the investors thereunder than the terms of this Subscription Agreement,
other than representations, warranties and terms particular to the regulatory requirements of such investor or its affiliates or related
funds. The Other Subscription Agreements have not been amended in any material respect following the date of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">k.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>As
of the date of this Subscription Agreement, the authorized capital stock of ARYA consists of 1,000,000 preference shares (the
 &#8220;<U>Preferred Shares</U>&#8221;), 479,000,000 Class A Shares, and 20,000,000 Class B ordinary shares (the &#8220;<U>Class B
Shares</U>&#8221;), each par value $0.0001 per share. As of the date of this Subscription Agreement, (i) no Preferred Shares are
issued and outstanding, (ii) 15,449,000 Class A shares are issued and outstanding, and (iii) 3,737,500 Class B Shares are issued and
outstanding. All issued and outstanding Class A Shares and Class B Shares have been duly authorized and validly issued, are fully
paid and are non-assessable. As of the date hereof, ARYA has no subsidiaries and does not own, directly or indirectly, interests or
investments (whether equity or debt) in any person, whether incorporated or unincorporated. There are no shareholder agreements,
voting trusts or other agreements or understandings to which ARYA is a party or by which it is bound relating to the voting of any
securities of ARYA, other than (1) as set forth in the SEC Reports and (2) as contemplated by the Transaction Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 163 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">l.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ARYA is in compliance with applicable law, except where such noncompliance would not reasonably be expected to have a Material
Adverse Effect. ARYA has not received any written communication from a governmental authority that alleges that ARYA is not in compliance
with or is in default of any applicable law, except where such noncompliance or default has not had and would not reasonably be expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">m.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Except for such matters as have not had and would not be reasonably likely to have, individually or in the aggregate, a
Material Adverse Effect, there is no (i) action, suit, claim or other proceeding, in each case by or before any governmental authority
pending, or, to the knowledge of ARYA, threatened against ARYA or (ii) judgment, decree injunction, ruling or order of any governmental
entity or arbitrator outstanding against ARYA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">n.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ARYA acknowledges and agrees that, notwithstanding anything herein to the contrary, the Shares may be pledged by Investor
in connection with a bona fide margin agreement, provided such pledge shall be (i) pursuant to an available exemption from the registration
requirements of the Securities Act or (ii) pursuant to, and in accordance with, a registration statement that is effective under the Securities
Act at the time of such pledge, and the Investor effecting a pledge of Shares shall not be required to provide ARYA with any notice thereof;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that neither ARYA, the Company or their respective counsels shall be required to take any action (or refrain from taking any action) in
connection with any such pledge, other than providing any such lender of such margin agreement with an acknowledgment that the Shares
are not subject to any contractual prohibition on pledging or lock up, the form of such acknowledgment to be subject to review and comment
by ARYA in all respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">o.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>There has been no action taken by (1) to the knowledge of ARYA, ARYA or any officer, director, or to the knowledge of ARYA,
any equityholder, manager, employee, agent or representative of ARYA or (2) to the knowledge of ARYA, by the Company, any of its subsidiaries
(collectively, ARYA, the Company and the Company&#8217;s subsidiaries, the &#8220;<U>Entities</U>&#8221;), or any officer, director, equityholder,
manager, employee, agent or representative of any of the Company or any of its subsidiaries, in each case of (1) and (2), acting on behalf
of any of the Entities, in violation of any applicable Anti-Corruption Laws (as herein defined), and, to the knowledge of ARYA, none of
the Entities or any officer, director, equityholder, manager, employee, agent or representative of any of the Entities, in each case,
acting on behalf of any of the Entities, have (i) been convicted of violating any Anti-Corruption Laws or subjected to any investigation
by a governmental authority for violation of any applicable Anti-Corruption Laws, (ii) conducted or initiated any internal investigation
or made a voluntary, directed, or involuntary disclosure to any governmental authority regarding any alleged act or omission arising under
or relating to any noncompliance with any Anti-Corruption Laws or (iii) received any written notice or citation from a governmental authority
for any actual or potential noncompliance with any applicable Anti-Corruption Laws. As used herein, &#8220;Anti-Corruption Laws&#8221;
means any applicable laws relating to corruption and bribery, including the U.S. Foreign Corrupt Practices Act of 1977 (as amended), the
UK Bribery Act 2010, and any similar law that prohibits bribery or corruption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">p.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ARYA is, and will continue to be, including following the Domestication, classified as a Subchapter C corporation for U.S.
federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Investor Representations and Warranties</U>. The Investor represents and warrants to ARYA that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor (i) is a &#8220;qualified institutional buyer&#8221; (as defined in Rule 144A under the Securities Act) or
an institutional &#8220;accredited investor&#8221; (within the meaning of Rule 501(a) under the Securities Act), in each case, satisfying
the applicable requirements set forth on <U>Schedule A</U>, (ii) is acquiring the Shares only for its own account and not for the account
of others, or if the Investor is subscribing for the Shares as a fiduciary or agent for one or more investor accounts, the Investor has
full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements, representations
and agreements herein on behalf of each owner of each such account, and (iii) is not acquiring the Shares with a view to, or for offer
or sale in connection with, any distribution thereof in violation of the Securities Act (and shall provide the requested information set
forth on <U>Schedule A</U>). The Investor is not an entity formed for the specific purpose of acquiring the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 164 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT> The Investor acknowledges and agrees that the Shares are being offered in a transaction not involving any public offering
within the meaning of the Securities Act and that the offer and sale of the Shares have not been registered under the Securities Act.
The Investor acknowledges and agrees that the Shares may not be offered, resold, transferred, pledged or otherwise disposed of by the
Investor absent an effective registration statement under the Securities Act except (i) to ARYA or a subsidiary thereof, (ii) to non-U.S.
persons pursuant to offers and sales that occur outside the United States within the meaning of Regulation S under the Securities Act
or (iii) pursuant to another applicable exemption from the registration requirements of the Securities Act, and in each of clauses (i)
and (iii) in accordance with any applicable securities laws of the states and other jurisdictions of the United States, and that any book
entries representing the Shares shall contain a restrictive legend to such effect, which legend shall be subject to removal as set forth
herein, subject to applicable law. The Investor acknowledges and agrees that the Shares will be subject to the foregoing transfer restrictions
and, as a result of these transfer restrictions, the Investor may not be able to readily offer, resell, transfer, pledge or otherwise
dispose of the Shares and may be required to bear the financial risk of an investment in the Shares for an indefinite period of time.
The Investor acknowledges and agrees that the Shares will not be eligible for offer, resale, transfer or disposition pursuant to Rule
144 promulgated under the Securities Act until at least one year from the date that ARYA files a Current Report on Form 8-K following
the Closing Date that includes the &#8220;Form 10&#8221; information required under applicable SEC rules and regulations. The Investor
acknowledges and agrees that it has been advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition
of any of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor acknowledges and agrees that the Investor is purchasing the Shares from ARYA. The Investor further acknowledges
that there have been no representations, warranties, covenants and agreements made to the Investor by or on behalf of ARYA, the Company,
any of their respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any
of the foregoing or any other person or entity, expressly or by implication, other than those representations, warranties, covenants and
agreements of ARYA expressly set forth in Section 5 of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor&#8217;s acquisition and holding of the Shares will not constitute or result in a non-exempt prohibited transaction
under Section 406 of the Employee Retirement Income Security Act of 1974, as amended, Section 4975 of the Internal Revenue Code of 1986,
as amended, or any applicable similar law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">e.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor acknowledges and agrees that the Investor has received such information as the Investor deems necessary in
order to make an investment decision with respect to the Shares, including, without limitation, with respect to ARYA, the Transaction
and the business of the Company and its subsidiaries. Without limiting the generality of the foregoing, the Investor acknowledges that
it had an opportunity to review the SEC Reports. The Investor acknowledges and agrees that the Investor and the Investor&#8217;s professional
advisor(s), if any, have had the full opportunity to ask such questions, receive such answers and obtain such information as the Investor
and such Investor&#8217;s professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">f.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor became aware of this offering of the Shares solely by means of direct contact between the Investor and ARYA,
the Company or a representative of ARYA or the Company, and the Shares were offered to the Investor solely by direct contact between the
Investor and ARYA, the Company or a representative of ARYA or the Company. The Investor did not become aware of this offering of the Shares,
nor were the Shares offered to the Investor, by any other means. The Investor acknowledges that the Shares (i) were not offered to it
by any form of general solicitation or general advertising and (ii) to its knowledge are not being offered in a manner involving a public
offering under, or in a distribution in violation of, the Securities Act, or any state securities laws. The Investor acknowledges that
it is not relying upon, and has not relied upon, any statement, representation or warranty made by any person, firm or corporation (including,
without limitation, ARYA, the Company, the Placement Agent, any of their respective affiliates or any control persons, officers, directors,
employees, partners, agents or representatives of any of the foregoing), other than the representations and warranties of ARYA contained
in Section 5 of this Subscription Agreement, in making its investment or decision to invest in ARYA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">g.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>The
Investor acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the Shares,
including, without limitation, those set forth in ARYA&#8217;s SEC Reports. The Investor has such knowledge and experience in
financial and business matters as to be capable of evaluating the merits and risks of an investment in the Shares, and the Investor
has sought such accounting, legal and tax advice as the Investor has considered necessary to make an informed investment
decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 165 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">h.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks
of an investment in the Shares and determined that the Shares are a suitable investment for the Investor and that the Investor is able
at this time and in the foreseeable future to bear the economic risk of a total loss of the Investor&#8217;s investment in ARYA. The Investor
acknowledges specifically that a possibility of total loss exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>In making its decision to purchase the Shares, the Investor has relied solely upon independent investigation made by the
Investor; provided that neither such investigation nor any other inquiries or due diligence conducted by the Investor shall modify, limit
or otherwise affect the Investor&#8217;s right to rely on ARYA&#8217;s representations and warranties contained in this Agreement. Without
limiting the generality of the foregoing, the Investor has not relied on any statements or other information provided by or on behalf
of the Placement Agent or any of its affiliates or any control persons, officers, directors, employees, partners, agents or representatives
of any of the foregoing concerning ARYA, the Company, the Transaction, the Transaction Agreement, this Subscription Agreement or the transactions
contemplated hereby or thereby, the Shares or the offer and sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">j.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>The
Investor acknowledges and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the Shares
or made any findings or determination as to the fairness of this investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">k.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>The
Investor has been duly formed or incorporated and is validly existing and is in good standing under the laws of its jurisdiction of formation
or incorporation, with power and authority to enter into, deliver and perform its obligations under this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">l.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>The
execution, delivery and performance by the Investor of this Subscription Agreement are within the powers of the Investor, have been duly
authorized and will not constitute or result in a breach or default under or conflict with any order, ruling or regulation of any court
or other tribunal or of any governmental commission or agency, or any agreement or other undertaking, to which the Investor is a party
or by which the Investor is bound that would reasonably be expected to have a material adverse effect on the legal authority of the Investor
to comply with the terms of this Subscription Agreement, and, if the Investor is not an individual, will not conflict with or violate
any provisions of the Investor&#8217;s organizational documents, including, without limitation, its incorporation or formation papers,
bylaws, indenture of trust or partnership or operating agreement, as may be applicable. The signature on this Subscription Agreement
is genuine, and the signatory, if the Investor is an individual, has legal competence and capacity to execute the same or, if the Investor
is not an individual, the signatory has been duly authorized to execute the same. This Subscription Agreement has been duly executed
and delivered by the Investor or the investment advisor to which the Investor has delegated decision-making authority over investments
and, assuming that the Subscription Agreement constitutes the valid and binding agreement of ARYA, constitutes a legal, valid and binding
obligation of the Investor, enforceable against the Investor in accordance with its terms except as may be limited or otherwise affected
by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of
creditors generally, and (ii) principles of equity, whether considered at law or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">m.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>The
Investor is not (i) a person or entity named on the List of Specially Designated Nationals and Blocked Persons administered by the
U.S. Treasury Department&#8217;s Office of Foreign Assets Control (&#8220;<FONT STYLE="font-weight: normal"><U>OFAC</U></FONT>&#8221;)
or in any Executive Order issued by the President of the United States and administered by OFAC (&#8220;<FONT STYLE="font-weight: normal"><U>OFAC
List</U></FONT>&#8221;), or a person or entity prohibited by any OFAC sanctions program, (ii) a Designated National as defined in
the Cuban Assets Control Regulations, 31 C.F.R. Part 515, or (iii) a non-U.S. shell bank or providing banking services indirectly to
a non-U.S. shell bank (each, a &#8220;<FONT STYLE="font-weight: normal"><U>Prohibited Investor</U></FONT>&#8221;). The Investor
agrees to provide law enforcement agencies, if requested thereby, such records as required by applicable law, provided that the
Investor is permitted to do so under applicable law. If the Investor is a financial institution subject to the Bank Secrecy Act (31
U.S.C. Section 5311 et seq.) (the &#8220;<FONT STYLE="font-weight: normal"><U>BSA</U></FONT>&#8221;), as amended by the USA PATRIOT
Act of 2001 (the &#8220;<FONT STYLE="font-weight: normal"><U>PATRIOT Act</U></FONT>&#8221;), and its implementing regulations
(collectively, the &#8220;<FONT STYLE="font-weight: normal"><U>BSA/PATRIOT Act</U></FONT>&#8221;), the Investor maintains policies
and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. To the extent required, it
maintains policies and procedures reasonably designed for the screening of its investors against the OFAC sanctions programs,
including, without limitation, the OFAC List. To the extent required by applicable law, the Investor maintains policies and
procedures reasonably designed to ensure that the funds held by the Investor and used to purchase the Shares were legally
derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 166 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">n.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor acknowledges that no disclosure or offering document has been prepared by <FONT STYLE="background-color: white">Jefferies
LLC</FONT> or any of its affiliates (the &#8220;<FONT STYLE="font-weight: normal"><U>Placement Agent</U></FONT>&#8221;) in connection
with the offer and sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">o.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor acknowledges that none of the Placement Agent, any of its affiliates nor any control persons, officers, directors,
employees, partners, agents or representatives of any of the foregoing have made any independent investigation with respect to ARYA, the
Company or its subsidiaries or any of their respective businesses, or the Shares or the accuracy, completeness or adequacy of any information
supplied to the Investor by ARYA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">p.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor acknowledges that in connection with the issue and purchase of the Shares, the Placement Agent has not acted
as the Investor&#8217;s underwriter, initial purchaser, dealer, financial advisor, fiduciary or in any similar capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">q.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><FONT STYLE="background-color: white">The Investor has or has commitments to have and, when required to deliver payment
to ARYA pursuant to Section 2 above, will have, sufficient funds to pay the Subscription Amount and consummate the </FONT>sale, purchase
and issuance <FONT STYLE="background-color: white">of the Shares pursuant to this Subscription Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">r.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>The
Investor does not have, as of the date hereof, and during the 30-day period immediately prior to the date hereof such Investor has not
entered into, any &#8220;put equivalent position&#8221; as such term is defined in Rule 16a-1 under the Exchange Act or short sale positions
with respect to the securities of ARYA. Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment
vehicle whereby separate portfolio managers manage separate portions of such Investor&#8217;s assets and the portfolio managers have
no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Investor&#8217;s assets,
the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made
the investment decision to purchase the Shares covered by this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Rights.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>In
the event that the Shares are not registered in connection with the consummation of the Transaction, ARYA agrees that, within
fifteen (15) calendar days after the consummation of the Transaction (the &#8220;<U>Filing Date</U>&#8221;), it will file with the
SEC (at its sole cost and expense) a registration statement registering the resale of the Shares (the &#8220;<U>Registration
Statement</U>&#8221;), and it shall use its commercially reasonable efforts to have the Registration Statement declared effective as
soon as practicable after the filing thereof, but no later than the earlier of (i) sixty (60) calendar days (or ninety (90) calendar
days if the SEC notifies ARYA that it will &#8220;review&#8221; the Registration Statement) following the Filing Date and (ii) five
(5) Business Days after ARYA is notified (orally or in writing, whichever is earlier) by the SEC that the Registration Statement
will not be &#8220;reviewed&#8221; or will not be subject to further review (such earlier date, the &#8220;<U>Effectiveness
Date</U>&#8221;). ARYA agrees to cause such Registration Statement, or another shelf registration statement that includes the Shares
to be sold pursuant to this Subscription Agreement, to remain effective until the earliest of (i) the fourth anniversary of the
Closing, (ii) the date on which the Investor ceases to hold any Shares issued pursuant to this Subscription Agreement, or (iii) on
the first date on which the Investor is able to sell all of its Shares issued pursuant to this Subscription Agreement (or shares
received in exchange therefor) under Rule 144 of the Securities Act within 90 days without limitation as to the amount of such
securities that may be sold and without the requirement for ARYA to be in compliance with the current public information required
under Rule 144(i)(2) (the &#8220;<U>Effectiveness Period</U>&#8221;). The Investor agrees to disclose its beneficial ownership, as
determined in accordance with Rule 13d-3 of the Exchange Act, of Shares to ARYA (or its successor) upon reasonable request to assist
ARYA in making the determination described above In no event shall the Investor be identified as a statutory underwriter in the
Registration Statement unless requested by the SEC; provided, that if the SEC requests that the Investor be identified as a
statutory underwriter in the Registration Statement, the Investor will have an opportunity to withdraw its Shares from the
Registration Statement. Notwithstanding the foregoing, if the SEC prevents ARYA from including any or all of the shares proposed to
be registered under the Registration Statement due to limitations on the use of Rule 415 of the Securities Act for the resale of the
Shares by the applicable shareholders or otherwise, such Registration Statement shall register for resale such number of Shares
which is equal to the maximum number of Shares as is permitted by the SEC. In such event, the number of Shares to be registered for
each selling shareholder named in the Registration Statement shall be reduced pro rata among all such selling shareholders. For as
long as the Registration Statement shall remain effective pursuant to this Section 7(a), ARYA will use commercially reasonable
efforts to (1) qualify the Shares for listing on the Stock Exchange, and (2) update or amend the Registration Statement as necessary
to include the Shares sold hereby for resale. For as long as the Investor holds the Shares, ARYA will use commercially reasonable
efforts to file all reports, and provide all customary and reasonable cooperation, necessary to enable the undersigned to resell the
Shares pursuant to the Registration Statement or Rule 144 of the Securities Act (when Rule 144 of the Securities Act becomes
available to the Investor), as applicable, including providing any legal opinions to ARYA&#8217;s transfer agent. Notwithstanding
anything to the contrary contained herein, ARYA may delay or postpone filing of such Registration Statement, and from time to time
require the Investor not to sell under the Registration Statement or suspend the use or effectiveness of any such Registration
Statement, if the board of directors of ARYA determines, in good faith and upon the advice of counsel, that either in order for the
Registration Statement to not contain a material misstatement or omission, an amendment thereto would be needed, or if such filing
or use could materially affect a bona fide business or financing transaction of ARYA or would require premature disclosure of
information that could materially adversely affect ARYA (each such circumstance, a &#8220;<U>Suspension Event</U>&#8221;); provided,
that, (i) ARYA shall not so delay filing or so suspend the use of the Registration Statement for a period of more than sixty (60)
consecutive days or more than a total of ninety (90) calendar days, in each case in any three hundred sixty (360) day period and
(ii) ARYA shall use commercially reasonable efforts to make such Registration Statement available for the resale by the undersigned
of the Shares as soon as practicable thereafter. If so directed by ARYA, the Investor will destroy all copies of the prospectus
covering the Shares in the Investor&#8217;s possession; provided, however, that this obligation to destroy all copies of the
prospectus covering the Shares shall not apply (x) to the extent the Investor is required to retain a copy of such prospectus (A) in
order to comply with applicable legal or regulatory requirements or (B) in accordance with a bona fide pre-existing document
retention policy or (y) to copies stored electronically on archival servers as a result of automatic data back-up. ARYA&#8217;s
obligations to include the Shares issued pursuant to this Subscription Agreement (or shares issued in exchange therefor) for resale
in the Registration Statement are contingent upon the Investor furnishing in writing to ARYA such information regarding the
Investor, the securities of ARYA held by the Investor and the intended method of disposition of such Shares, which shall be limited
to non-underwritten public offerings, as shall be reasonably requested by ARYA to effect the registration of such Shares, and shall
execute such documents in connection with such registration as ARYA may reasonably request that are customary of a selling
stockholder in similar situations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 167 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>ARYA
shall advise the Investor within two (2) Business Days: (i) when a Registration Statement or any post-effective amendment thereto
has become effective; (ii) of any request by the SEC for amendments or supplements to any Registration Statement or the prospectus
included therein or for additional information; (iii) of the issuance by the SEC of any stop order suspending the effectiveness of
any Registration Statement or the initiation of any proceedings for such purpose; (iv) of the receipt by ARYA of any notification
with respect to the suspension of the qualification of the Shares included therein for sale in any jurisdiction or the initiation or
threatening of any proceeding for such purpose; and (v) subject to the provisions in this Subscription Agreement, of the occurrence
of any event that requires the making of any changes in any Registration Statement or prospectus so that, as of such date, the
statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to make
the statements therein (in the case of a prospectus, in the light of the circumstances under which they were made) not misleading.
Upon receipt of any written notice from ARYA (which notice shall not contain any material non-public information regarding ARYA) of
the happening of any event contemplated in clauses (ii) through (v) above or of a Suspension Event during the period that the
Registration Statement is effective , the Investor agrees that (1) it will immediately discontinue offers and sales of the Shares
under the Registration Statement (excluding, for the avoidance of doubt, sales conducted pursuant to Rule 144 or another applicable
exemption to registration under the Securities Act) until the undersigned receives copies of a supplemental or amended prospectus
(which ARYA agrees to promptly prepare) that corrects the misstatement(s) or omission(s) referred to above and receives notice that
any post-effective amendment has become effective or unless otherwise notified by ARYA that it may resume such offers and sales, and
(2) it will maintain the confidentiality of any information included in such written notice delivered by ARYA except (A) for
disclosure to the Investor&#8217;s employees, agents and professional advisers who need to know such information and are obligated
to keep it confidential, (B) for disclosures to the extent required in order to comply with reporting obligations to its limited
partners who have agreed to keep such information confidential and (C) as required by law or subpoena. ARYA shall use its
commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement as
soon as reasonably practicable. Upon the occurrence of any event contemplated in clauses (i) through (v) above, except for such
times as ARYA is permitted hereunder to suspend, and has suspended, the use of a prospectus forming part of a Registration
Statement, ARYA shall use its commercially reasonable efforts to as soon as reasonably practicable prepare a post-effective
amendment to such Registration Statement or a supplement to the related prospectus, or file any other required document so that, as
thereafter delivered to purchasers of the Shares included therein, such prospectus will not include any untrue statement of a
material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 168 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ARYA will use its commercially reasonable efforts to (A) at the reasonable request of Investor, deliver all the necessary
documentation to cause ARYA&#8217;s transfer agent to remove all restrictive legends from any Shares being sold under the Registration
Statement or pursuant to Rule 144 at the time of sale of the Shares, or that may be sold by Investor without restriction under Rule 144,
including without limitation, any volume and manner of sale restrictions, and (B) cause its legal counsel to deliver to the transfer agent
the necessary legal opinions required by the transfer agent, if any, in connection with the instruction under <U>clause (A)</U> upon the
receipt of Investor representation letters and such other customary supporting documentation as requested by (and in a form reasonably
acceptable to) such counsel, in each case within 2 business days of such request. The Investor agrees to disclose its beneficial ownership,
as determined in accordance with Rule 13d-3 of the Exchange Act, of Shares to ARYA (or its successor) upon reasonable request to assist
ARYA in making the determination described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Indemnification</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ARYA agrees to indemnify and hold harmless, to the extent permitted by law, the Investor, its directors, and officers, employees,
and agents, and each person who controls the Investor (within the meaning of the Securities Act or the Exchange Act) and each affiliate
of the Investor (within the meaning of Rule 405 under the Securities Act) from and against any and all losses, claims, damages, liabilities
and expenses (including, without limitation, any reasonable and documented attorneys&#8217; fees and expenses incurred in connection with
defending or investigating any such action or claim) caused by any untrue or alleged untrue statement of material fact contained in any
Registration Statement, prospectus included in any Registration Statement (&#8220;Prospectus&#8221;) or preliminary Prospectus or any
amendment thereof or supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein not misleading, except insofar as the same are caused by or contained in any information furnished in writing
to ARYA by or on behalf of the Investor expressly for use therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor agrees, severally and not jointly with any other person that is a party to the Other Subscription Agreements,
to indemnify and hold harmless ARYA, its directors and officers and agents and each person who controls ARYA (within the meaning of the
Securities Act) against any losses, claims, damages, liabilities and expenses (including, without limitation, any reasonable and documented
attorneys&#8217; fees) resulting from any untrue statement of material fact contained in the Registration Statement, Prospectus or preliminary
Prospectus or any amendment thereof or supplement thereto or any omission of a material fact required to be stated therein or necessary
to make the statements therein not misleading, but only to the extent that such untrue statement or omission is contained in any information
so furnished in writing by the or on behalf of Investor expressly for use therein. In no event shall the liability of the Investor be
greater in amount than the dollar amount of the net proceeds received by such Investor upon the sale of the Shares purchased pursuant
to this Subscription Agreement giving rise to such indemnification obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>Any
person entitled to indemnification herein shall (1) give prompt written notice to the indemnifying party of any claim with respect
to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person&#8217;s right to
indemnification hereunder to the extent such failure has not prejudiced the indemnifying party) and (2) permit such indemnifying
party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed,
the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent.
An indemnifying party who elects not to assume the defense of a claim shall not be obligated to pay the fees and expenses of more
than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable
judgment of legal counsel to any indemnified party a conflict of interest exists between such indemnified party and any other of
such indemnified parties with respect to such claim. No indemnifying party shall, without the consent of the indemnified party,
consent to the entry of any judgment or enter into any settlement that (1) cannot be settled in all respects by the payment of money
(and such money is so paid by the indemnifying party pursuant to the terms of such settlement), (2) does not include as an
unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in
respect to such claim or litigation or (3) contains any statement of fault or culpability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 169 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The indemnification provided for under this Subscription Agreement shall remain in full force and effect regardless of any
investigation made by or on behalf of the indemnified party or any officer, director, employee, agent, affiliate or controlling person
of such indemnified party and shall survive the transfer of the Shares purchased pursuant to this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: #010000">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>If the indemnification provided under this <U>Section 7(d)</U> from the indemnifying party is unavailable or insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the
indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such losses, claims, damages,
liabilities and expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying party and the indemnified
party, as well as any other relevant equitable considerations. The relative fault of the indemnifying party and indemnified party shall
be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of
a material fact or omission or alleged omission to state a material fact, was made by, or relates to information supplied by, such indemnifying
party or indemnified party, and the indemnifying party&#8217;s and indemnified party&#8217;s relative intent, knowledge, access to information
and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the losses or other liabilities
referred to above shall be deemed to include, subject to the limitations set forth above, any legal or other fees, charges or expenses
reasonably incurred by such party in connection with any investigation or proceeding. No person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution pursuant to this <U>Section 7(d)</U> from
any person who was not guilty of such fraudulent misrepresentation. In no event shall the liability of the Investor pursuant to this Section
7(d)(v) be greater in amount than the dollar amount of the net proceeds received by such Investor upon the sale of the Shares purchased
pursuant to this Subscription Agreement giving rise to such indemnification obligation, and such obligations of the Investor shall be
several and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights
and obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon
the earliest to occur of (a) such date and time as the Transaction Agreement is terminated in accordance with its terms, (b) upon the
mutual written agreement of each of the parties hereto and the Company to terminate this Subscription Agreement, and (c) the delivery
of a notice of termination of this Subscription Agreement by the Investor to ARYA following the date that is fifteen (15) calendar days
after the Termination Date (as defined in the Transaction Agreement currently in effect on the date hereof, and such fifteenth calendar
day, the &#8220;<U>Outside Date</U>&#8221;), if the Closing has not occurred by the Outside Date (provided, that the right to terminate
this Subscription Agreement pursuant to this clause (c) shall not be available to the Investor if the Investor&#8217;s breach of any of
its covenants or obligations under this Subscription Agreement (or if an affiliate of the Investor is one of the Investors under an Other
Subscription Agreement, and such other Investor&#8217;s breach of any of its covenants or obligations under the Other Subscription Agreement),
either individually or in the aggregate, shall have proximately caused the failure of the consummation of the Transaction on or before
the Outside Date) (the termination events described in clauses (a)&#8211;(c) above, collectively, the &#8220;<U>Termination Events</U>&#8221;);
<U>provided</U> that nothing herein will relieve any party from liability for any willful and material breach of any covenant, agreement,
obligation, representation or warranty hereunder prior to the time of termination, and each party will be entitled to any remedies at
law or in equity to recover losses, liabilities or damages arising from any such willful and material breach. ARYA shall notify the Investor
of the termination of the Transaction Agreement as promptly as practicable after the termination of the Transaction Agreement. Upon the
occurrence of any Termination Event, this Subscription Agreement shall be void and of no further effect and any monies paid by the Investor
to ARYA in connection herewith shall promptly (and in any event within one (1) business day) following the Termination Event be returned
to the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Trust
Account Waiver</U>. The Investor acknowledges that ARYA is a blank check company with the powers and privileges to effect a merger,
asset acquisition, reorganization or similar business combination involving ARYA and one or more businesses or assets. The Investor
further acknowledges that, as described in ARYA&#8217;s prospectus relating to its initial public offering dated February 25, 2021
(the &#8220;<U>Final <FONT STYLE="font-weight: normal">Prospectus</FONT></U>&#8221;) available at www.sec.gov, substantially all of
ARYA&#8217;s assets consist of the cash proceeds of ARYA&#8217;s initial public offering and private placement of its securities,
and substantially all of those proceeds have been deposited in a trust account (the &#8220;<FONT STYLE="font-weight: normal"><U>Trust
Account</U></FONT>&#8221;) for the benefit of ARYA, its public shareholders and the underwriters of ARYA&#8217;s initial public
offering. Except with respect to interest earned on the funds held in the Trust Account that may be released to ARYA to pay its tax
obligations, if any, the cash in the Trust Account may be disbursed only for the purposes set forth in the Final Prospectus. For and
in consideration of ARYA entering into this Subscription Agreement, the receipt and sufficiency of which are hereby acknowledged,
the Investor hereby irrevocably waives any and all right, title and interest, or any claim of any kind it has or may have in the
future, in or to any monies held in the Trust Account, and agrees not to seek recourse against the Trust Account as a result of, or
arising out of, this Subscription Agreement or the transactions contemplated hereby regardless of whether such claim arises based on
contract, tort, equity or any other theory of legal liability; provided, however, that nothing in this Section 9 shall be deemed to
limit the Investor&#8217;s right, title, interest or claim to any monies held in the Trust Account by virtue of its record or
beneficial ownership of Class A Shares outstanding on the date hereof (whether acquired by the Investor prior to, on or after the
date hereof), pursuant to a validly exercised redemption right with respect to any such Class A Shares, in accordance with
ARYA&#8217;s Amended and Restated Memorandum and Articles of Association and the Investment Management Trust Agreement between
Continental Stock Transfer &amp; Trust Company and ARYA, dated March 2, 2021, except to the extent that the Investor has otherwise
agreed in writing with ARYA, the Company or any of their respective affiliates to not exercise such redemption right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 170 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Neither this Subscription Agreement nor any rights that may accrue to the Investor hereunder (other than the Shares acquired
hereunder and the rights set forth in Section 7 solely in connection with a transfer of such Shares (other than a transfer in connection
with a sale pursuant to either an effective registration statement or under Rule 144), if any) may be transferred or assigned. Notwithstanding
the foregoing, after notifying ARYA, Investor may assign its rights and obligations under this Subscription Agreement to one or more of
its affiliates (including other investment funds or accounts managed or advised by the investment manager who acts on behalf of Investor)
or, with the Company&#8217;s prior written consent, to another person, provided that no such assignment shall relieve Investor of its
obligations hereunder if any such assignee fails to perform such obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ARYA may request from the Investor such additional information as ARYA may deem necessary to register the resale of the
Shares and evaluate the eligibility of the Investor to acquire the Shares, and the Investor shall provide such information as may be reasonably
requested. The Investor acknowledges that ARYA may file a form of this Subscription Agreement with the SEC as an exhibit to a periodic
report or a registration statement of ARYA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">c.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor acknowledges that ARYA, the Company, the Placement Agent and others will rely on the acknowledgments, understandings,
agreements, representations and warranties of the Investor contained in this Subscription Agreement. Prior to the Closing, the Investor
agrees to promptly notify ARYA, the Company and the Placement Agent if any of the acknowledgments, understandings, agreements, representations
or warranties set forth in Section 6 above are no longer accurate in any material respect (other than those acknowledgments, understandings,
agreements, representations and warranties qualified by materiality, in which case the Investor shall notify ARYA, the Company and the
Placement Agent if they are no longer accurate in any respect). The Investor acknowledges and agrees that the purchase by the Investor
of Shares from ARYA will constitute a reaffirmation of the acknowledgments, understandings, agreements, representations and warranties
herein (as modified by any notice previously provided pursuant to this Section 10 or otherwise) by the Investor as of the time of such
purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">d.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ARYA, the Company and the Placement Agent are each entitled to rely upon this Subscription Agreement and each is irrevocably
authorized to produce this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding or
official inquiry with respect to the matters covered hereby; <U>provided</U>, <U>however</U>, that the foregoing clause of this Section
10(d) shall not give the Company or the Placement Agent any rights other than those expressly set forth herein and, without limiting the
generality of the foregoing and for the avoidance of doubt, in no event shall the Company be entitled to rely on any of the representations
and warranties of ARYA set forth in this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">e.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>All of the agreements, representations and warranties made by each party hereto in this Subscription Agreement shall survive
the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 171 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">f.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT> This Subscription Agreement may not be terminated other than pursuant to the terms of Section 8 above. The provisions of
this Subscription Agreement may not be modified, amended or waived except by an instrument in writing, signed by each of ARYA and the
Investor hereto; <U>provided</U>, <U>however</U>, that no modification, amendment or waiver by ARYA of the provisions of this Subscription
Agreement shall be effective without the prior written consent of Parent (other than modifications, amendments or waivers that are solely
ministerial in nature or otherwise immaterial and, in each case, do not affect any economic or any other material term of this Subscription
Agreement). No failure or delay of either ARYA or the Investor in exercising any right or remedy hereunder shall operate as a waiver thereof,
nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right
or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or power. The rights
and remedies of the parties hereunder are cumulative and are not exclusive of any rights or remedies that they would otherwise have hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">g.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>This
Subscription Agreement (including, without limitation, the schedule hereto) constitutes the entire agreement, and supersedes all other
prior agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to the subject
matter hereof. Except as set forth in Section 3(b), Section 7, Section 8, Section 10(c), Section 10(d), Section 10(f) and this Section
10(g) with respect to the persons specifically referenced therein, this Subscription Agreement shall not confer any rights or remedies
upon any person other than the parties hereto, and their respective successor and assigns, and the parties hereto acknowledge that such
persons so referenced are third party beneficiaries of this Subscription Agreement with right of enforcement for the purposes of, and
to the extent of, the rights granted to them, if any, pursuant to the applicable provisions; provided, that, notwithstanding anything
to the contrary contained in this Subscription Agreement, the Company is an intended third party beneficiary of each of the provisions
of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">h.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Except as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the
parties hereto and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements,
representations, warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs,
executors, administrators, successors, legal representatives and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>If any provision of this Subscription Agreement shall be adjudicated by a court of competent jurisdiction to be invalid,
illegal or unenforceable, the validity, legality or enforceability of the remaining provisions of this Subscription Agreement shall not
in any way be affected or impaired thereby and shall continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">j.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>This
Subscription Agreement may be executed in one or more counterparts (including, without limitation, by facsimile or electronic mail or
in .pdf) and by different parties in separate counterparts, with the same effect as if all parties hereto had signed the same document.
All counterparts so executed and delivered shall be construed together and shall constitute one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">k.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>The
parties hereto acknowledge and agree that irreparable damage would occur if any of the provisions of this Subscription Agreement were
not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be
entitled to an injunction or injunctions to prevent breaches of this Subscription Agreement, without posting a bond or undertaking and
without proof of damages, to enforce specifically the terms and provisions of this Subscription Agreement, this being in addition to
any other remedy to which such party is entitled at law, in equity, in contract, in tort or otherwise. The parties hereto acknowledge
and agree that the Company shall be entitled to seek to specifically enforce the Investor&#8217;s obligations to fund the Subscription
Amount and the provisions of this Subscription Agreement of which the Company is an express third party beneficiary, in each case, on
the terms and subject to the conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">l.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></FONT>Any
notice or communication required or permitted hereunder to be given to the Investor shall be in writing and either delivered personally,
emailed or sent by overnight mail via a reputable overnight carrier, or sent by certified or registered mail, postage prepaid, to such
address(es) or email address(es) set forth on the signature page hereto, and shall be deemed to be given and received (i) when so delivered
personally, (ii) when sent, with no mail undeliverable or other rejection notice, if sent by email, or (iii) three (3) business days
after the date of mailing to the address below or to such other address or addresses as the Investor may hereafter designate by notice
to ARYA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 172 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">m.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT> THIS SUBSCRIPTION AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE (REGARDLESS
OF THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER APPLICABLE PRINCIPLES OF CONFLICTS OF LAWS THEREOF) AS TO ALL MATTERS (INCLUDING ANY ACTION,
SUIT, LITIGATION, ARBITRATION, MEDIATION, CLAIM, CHARGE, COMPLAINT, INQUIRY, PROCEEDING, HEARING, AUDIT, INVESTIGATION OR REVIEWS BY OR
BEFORE ANY GOVERNMENTAL ENTITY RELATED HERETO), INCLUDING MATTERS OF VALIDITY, CONSTRUCTION, EFFECT, PERFORMANCE AND REMEDIES. THE PARTIES
HERETO IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE CHANCERY COURT OF THE STATE OF DELAWARE (OR, IF THE CHANCERY COURT OF THE
STATE OF DELAWARE DECLINES TO ACCEPT JURISDICTION, THE SUPERIOR COURT OF THE STATE OF DELAWARE, OR THE UNITED STATES DISTRICT COURT FOR
THE DISTRICT OF DELAWARE) SOLELY IN RESPECT OF THE INTERPRETATION AND ENFORCEMENT OF THE PROVISIONS OF THIS SUBSCRIPTION AGREEMENT AND
THE DOCUMENTS REFERRED TO IN THIS SUBSCRIPTION AGREEMENT AND IN RESPECT OF THE TRANSACTIONS CONTEMPLATED HEREBY, AND HEREBY WAIVE, AND
AGREE NOT TO ASSERT, AS A DEFENSE IN ANY ACTION, SUIT OR PROCEEDING FOR INTERPRETATION OR ENFORCEMENT HEREOF OR ANY SUCH DOCUMENT THAT
IS NOT SUBJECT THERETO OR THAT SUCH ACTION, SUIT OR PROCEEDING MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SAID COURTS OR THAT VENUE
THEREOF MAY NOT BE APPROPRIATE OR THAT THIS SUBSCRIPTION AGREEMENT OR ANY SUCH DOCUMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS, AND
THE PARTIES HERETO IRREVOCABLY AGREE THAT ALL CLAIMS WITH RESPECT TO SUCH ACTION, SUIT OR PROCEEDING SHALL BE HEARD AND DETERMINED BY
SUCH COURT. THE PARTIES HEREBY CONSENT TO AND GRANT ANY SUCH COURT JURISDICTION OVER THE PERSON OF SUCH PARTIES AND OVER THE SUBJECT MATTER
OF SUCH DISPUTE AND AGREE THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH SUCH ACTION, SUIT OR PROCEEDING IN THE MANNER PROVIDED
IN SECTION 10(l) OF THIS SUBSCRIPTION AGREEMENT OR IN SUCH OTHER MANNER AS MAY BE PERMITTED BY LAW SHALL BE VALID AND SUFFICIENT SERVICE
THEREOF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">EACH PARTY ACKNOWLEDGES AND
AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED BY THIS SUBSCRIPTION AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT
OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK
TO ENFORCE THE FOREGOING WAIVER; (II) SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THE FOREGOING WAIVER; (III) SUCH PARTY
MAKES THE FOREGOING WAIVER VOLUNTARILY AND (IV) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS SUBSCRIPTION AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 10(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">n.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></FONT>The
Investor hereby acknowledges and agrees that it will not, nor will any person acting at the Investor's direction or pursuant to any
understanding with Investor (including Investor's controlled affiliates) engage in any &#8220;short sales&#8221; (as defined in Rule
200 of Regulation SHO under the Exchange Act) with respect to, any Shares or any securities of ARYA or any instrument exchangeable
for or convertible into any Shares or any securities of ARYA until the consummation of the Transaction (or such earlier termination
of this Subscription Agreement in accordance with its terms). For the avoidance of doubt, this Section 10(n) shall not apply to (x)
ordinary course, non speculative hedging transactions, or (y) any sale (including the exercise of any redemption right) of
securities of ARYA (i) held by the Investor, its controlled affiliates or any person or entity acting on behalf of the Investor or
any of its controlled affiliates prior to the execution of this Subscription Agreement or (ii) purchased by the Investor, its
controlled affiliates or any person or entity acting on behalf of the Investor or any of its controlled affiliates in open market
transactions after the execution of this Subscription Agreement. Notwithstanding the foregoing, (i) nothing herein shall prohibit
any entities under common management with the Investor (including the Investor's controlled affiliates and/or affiliates) from
entering into any short sales; (ii) in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio
managers or desks manage separate portions of such Investor's assets this Section 10(n) shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Subscription
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 173 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="color: #010000">o.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>The Investor hereby acknowledges that the Placement Agent and/or its affiliates may now or in the future own securities
of ARYA and/or purchase securities in the Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Reliance and Exculpation.</U> The Investor acknowledges that it is not relying upon, and has not relied upon, any statement,
representation or warranty made by any person, firm or corporation (including, without limitation, <FONT STYLE="background-color: white">the
Placement Agent</FONT>, any of its affiliates or any control persons, officers, directors, employees, partners, agents or representatives
of any of the foregoing), other than the statements, representations and warranties of ARYA expressly contained in Section 5 of this Subscription
Agreement, in making its investment or decision to invest in ARYA. The Investor acknowledges and agrees that none of (i) any other investor
pursuant to this Subscription Agreement or any other subscription agreement related to the private placement of the Shares (including
the investor&#8217;s respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives
of any of the foregoing), (ii) <FONT STYLE="background-color: white">the Placement Agent, its affiliates or any control persons, officers,
directors, employees, partners, agents or representatives of any of the foregoing</FONT>, or (iii) any other party to the Transaction
Agreement or any Non-Party Affiliate, shall have any liability to the Investor pursuant to, arising out of or relating to this Subscription
Agreement or any other subscription agreement related to the private placement of the Shares, the negotiation hereof or thereof or its
subject matter, or the transactions contemplated hereby or thereby, including, without limitation, with respect to any action heretofore
or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Shares or with respect to any claim (whether
in tort, contract or otherwise) for breach of this Subscription Agreement or in respect of any written or oral representations made or
alleged to be made in connection herewith, as expressly provided herein, or for any actual or alleged inaccuracies, misstatements or omissions
with respect to any information or materials of any kind furnished by ARYA, the Company, the Placement Agent or any Non-Party Affiliate
concerning ARYA, the Company, the Placement Agent, any of their respective controlled affiliates, this Subscription Agreement or the transactions
contemplated hereby. For purposes of this Subscription Agreement, &#8220;Non-Party Affiliates&#8221; means each former, current or future
officer, director, employee, partner, member, manager, direct or indirect equityholder or affiliate of ARYA, the Company, the Placement
Agent or any of ARYA&#8217;s, the Company&#8217;s or the Placement Agent&#8217;s controlled affiliates or any family member of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure.</U> ARYA shall, on the first (1<SUP>st</SUP>) business day following the date of this Subscription Agreement, issue
one or more press releases or file with the SEC a Current Report on Form 8-K (collectively, the &#8220;Disclosure Document&#8221;) disclosing
all material terms of the transactions contemplated hereby and by the Other Subscription Agreements, the Transaction and any other material,
nonpublic information that ARYA has provided to the Investor at any time prior to the filing of the Disclosure Document. From and after
the disclosure of the Disclosure Document, the Investor and, to the knowledge of ARYA, the Investor&#8217;s affiliates, attorneys, agents
or representatives shall not be in possession of any material, non-public information received from ARYA, the Company or any of their
officers, directors, employees, agents or representatives, and the Investor shall no longer be subject to any confidentiality or similar
obligations under any current agreement, whether written or oral with ARYA, the Placement Agent, the Company or any of their affiliates,
relating to the transactions contemplated by this Subscription Agreement, the Other Subscription Agreements, or the Transaction Agreement.
Notwithstanding anything this this Subscription Agreement to the contrary, ARYA shall not, and shall cause each of its officers, directors,
employees, attorneys, representatives and agents not to, provide the Investor with any material, non-public information regarding ARYA
or the Company from and after the filing of the Disclosure Document with the SEC without the express prior written consent of the Investor.
ARYA understands and confirms that the Investor and the Investor&#8217;s affiliates, attorneys, agents and representatives will rely on
the foregoing representations and covenants in effecting transactions of securities in ARYA. <FONT STYLE="background-color: white">Notwithstanding
anything in this Subscription Agreement to the contrary, ARYA shall not (i) publicly disclose the name of the Investor or any of its affiliates
or advisers or include the name of the Investor or any of its affiliates or advisers in any press release without the prior written consent
of the Investor or (ii) publicly disclose the name of the Investor or any of its affiliates or advisers, or include the name of the Investor
or any of its affiliates or advisers in any filing with the SEC or any regulatory agency or trading market, without the prior written
consent of the Investor except as required by the federal securities law or pursuant to other routine proceedings of regulatory authorities,
or to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations
of the Stock Exchange, in which case ARYA will provide Investor with prior written notice (including by e-mail, with no mail undeliverable
or rejection notice) of such disclosure under this clause (ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 174 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Several Obligations</U>. The obligations of the Investor and each Other Investor in connection with the private placement are
several and not joint, and Investor shall not be responsible in any way for the performance of the obligations of any Other Investor in
connection with the private placement. Nothing contained herein or in any Other Subscription Agreement, and no action taken by Investor
or any Other Investor pursuant hereto or thereto, shall be deemed to constitute the Investor and Other Investor as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Investor and Other Investors are in any way acting in concert
or as a group with respect to such obligations or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>SIGNATURE PAGES FOLLOW</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 175 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Investor has executed or caused this Subscription Agreement to be executed by its duly authorized representative as of the date set
forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">Name of Investor:</TD>
    <TD>State/Country of Formation or Domicile:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 41%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Name in which Shares are to be registered (if different):</TD>
    <TD STYLE="width: 50%">Date: ________, 2021</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Investor&#8217;s EIN:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Business Address-Street:</TD>
    <TD>Mailing Address-Street (if different):</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>City, State, Zip:</TD>
    <TD>City, State, Zip:</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">Attn:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">Attn:&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Telephone No.:</TD>
    <TD STYLE="width: 50%">Telephone No.:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Facsimile No.:</TD>
    <TD>Facsimile No.:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Number of Shares subscribed for:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Aggregate Subscription Amount: $</TD>
    <TD>Price Per Share: $10.00</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You must pay the Subscription
Amount by wire transfer of United States dollars in immediately available funds to the account specified by ARYA in the Closing Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 176 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, ARYA has
accepted this Subscription Agreement as of the date set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">ARYA SCIENCES ACQUISITION CORP IV</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 177 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="background-color: white"><B>ELIGIBILITY
REPRESENTATIONS OF THE INVESTOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 25px">A.</TD>
    <TD>QUALIFIED INSTITUTIONAL BUYER STATUS</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 25px">&nbsp;</TD>
    <TD>(Please check the applicable subparagraphs):</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="background-color: white">&nbsp;&nbsp;We
are a &#8220;qualified institutional buyer&#8221; (as defined in Rule 144A under the Securities Act (a &#8220;<U>QIB</U>&#8221;)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 25px">B.</TD>
    <TD>INSTITUTIONAL ACCREDITED INVESTOR STATUS</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 25px">&nbsp;</TD>
    <TD>(Please check the applicable subparagraphs):</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="width: 25px">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 25px">1.</TD>
    <TD STYLE="text-align: justify; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT>&nbsp;&nbsp;We are an &#8220;accredited investor&#8221; (within the meaning of Rule 501(a) under the Securities Act or an entity in which all of the equity holders are accredited investors within the meaning of Rule 501(a) under the Securities Act), and have marked and initialed the appropriate box on the following page indicating the provision under which we qualify as an &#8220;accredited investor.&#8221;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 25px">&nbsp;</TD>
    <TD>2.&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;We are not a natural person.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Rule
501(a), in relevant part, states that an &#8220;accredited investor&#8221; shall mean any person who comes within any of the below listed
categories, or who the issuer reasonably believes comes within any of the below listed categories, at the time of the sale of the securities
to that person. The Investor has indicated, by marking and initialing the appropriate box below, the provision(s) below which apply to
the Investor and under which the Investor accordingly qualifies as an &#8220;accredited investor.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="background-color: white">&nbsp;&nbsp;Any
bank, registered broker or dealer, insurance company, registered investment company, business development company, or small business
investment company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="background-color: white">&nbsp;&nbsp;Any
plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political
subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="background-color: white">&nbsp;&nbsp;Any
employee benefit plan, within the meaning of the Employee Retirement Income Security Act of 1974, if a bank, insurance company, or registered
investment adviser makes the investment decisions, or if the plan has total assets in excess of $5,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="background-color: white">&nbsp;&nbsp;Any
organization described in Section&nbsp;501(c)(3) of the Internal Revenue Code, corporation, similar business trust, or partnership, not
formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="background-color: white">&nbsp;&nbsp;Any
trust with assets in excess of $5,000,000, not formed to acquire the securities offered, whose purchase is directed by a sophisticated
person; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="background-color: white">&nbsp;&nbsp;Any
entity in which all of the equity owners are accredited investors meeting one or more of the above tests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="background-color: white"><B><I>This
page should be completed by the Investor</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="background-color: white"><B><I>and
constitutes a part of the Subscription Agreement.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white"></P>

<!-- Field: Page; Sequence: 178 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; background-color: white"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of A&amp;R Company LLC Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 179 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit B</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">LIMITED LIABILITY COMPANY AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OF</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CARITAS THERAPEUTICS, LLC</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">a Delaware limited liability company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE &ldquo;SECURITIES ACT&rdquo;), OR THE SECURITIES LAWS OF ANY STATE OR ANY OTHER APPLICABLE SECURITIES LAWS
AND ARE BEING SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH LAWS. SUCH SECURITIES
MUST BE ACQUIRED FOR INVESTMENT ONLY AND MAY&nbsp;NOT BE OFFERED FOR SALE, PLEDGED, HYPOTHECATED, SOLD, ASSIGNED OR TRANSFERRED AT ANY
TIME EXCEPT IN COMPLIANCE WITH (I)&nbsp;THE SECURITIES ACT, ANY APPLICABLE STATE SECURITIES LAWS AND ANY OTHER APPLICABLE SECURITIES LAWS
AND (II)&nbsp;THE TERMS AND CONDITIONS OF THIS AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated as of [<FONT STYLE="font-family: Symbol">&middot;</FONT>], 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 180 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 11%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 79%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%"><U>Page</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;I</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DEFINED TERMS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;1.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Definitions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;1.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Other Definitions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;1.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Interpretation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;II</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">GENERAL PROVISIONS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;2.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amendment and Restatement; Formation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;2.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;2.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Principal Place of Business; Other Places of Business</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;2.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Term</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;2.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Concerted Action; No State-Law Partnership</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;2.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Business Purpose</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;2.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Powers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;2.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Representations and Warranties by Additional or Substitute Members</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;2.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Additional Representations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;III</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">CAPITAL CONTRIBUTIONS; MEMBERSHIP INTERESTS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;3.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Capital Contributions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;3.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Membership Interests</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;3.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Capital Contributions of, or Loans by, the Members</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;3.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Common Unit to Class A Share Ratio</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;3.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Equity Plans</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;3.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Stock Incentive Plan or Other Plan</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;3.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Interest; No Return</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;3.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Conversion or Redemption of Class A Shares or Capital Shares</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;3.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Capital Accounts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;IV</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DISTRIBUTIONS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;4.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Requirement and Characterization of Distributions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;4.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Tax Distributions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 181 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->--<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%"><FONT STYLE="font-size: 10pt">Section&nbsp;4.3</FONT></TD>
    <TD STYLE="width: 79%"><FONT STYLE="font-size: 10pt">Distributions in Kind</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;4.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Distributions upon Liquidation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;4.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Distributions to Reflect Additional Membership Interests</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;4.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Restricted Distributions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;4.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rounding</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;4.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Special Distributions to Facilitate Acquisitions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;V</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">ALLOCATIONS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;5.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Allocations of Net Profits and Net Loss of the Company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;5.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Special Allocations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;5.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Curative Allocations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;5.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Tax Allocations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;5.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Compliance with Section 704(b) of the Code</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;5.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consent of Partners</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;5.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Change in Company Interest</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;5.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Modification of Allocations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;VI</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">OPERATIONS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;6.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Management</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;6.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Compensation and Reimbursement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;6.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Outside Activities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;6.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Duties; Limitation of Liability of the Board of Managers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;6.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Fiduciary Duties of the Members</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;6.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Liability; Exculpation and Indemnification</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;6.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Notice of Proceedings</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;6.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amendments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;VII</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">RIGHTS AND OBLIGATIONS OF MEMBERS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;7.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Information Rights of Members Relating to the Company</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;7.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Members&rsquo; Right to Act</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;7.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Various Capacities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;7.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Listing of Members</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;VIII</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">BOOKS AND RECORDS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;8.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Books and Records</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;8.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Inspection</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 182 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->--<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;IX</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">TAX MATTERS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 11%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 79%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;9.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Partnership Status and Tax Elections</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;9.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Tax Returns; Information</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;9.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Partnership Representative</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;9.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Tax Elections</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;9.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Withholding</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;9.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Survival</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;X</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">MEMBER TRANSFERS AND WITHDRAWALS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;10.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Transfer</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;10.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Transfer of Membership Interests Held by the Parent Corporation Group</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;10.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Members&rsquo; Rights to Transfer</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">55</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;10.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Substituted Members</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;10.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Assignees</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;10.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">General Provisions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;10.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Restrictions on a Termination Transaction of the Corporation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;XI</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">ADMISSION OF MEMBERS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;11.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Members; Admission of Additional Members</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;11.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Limit on Number of Members</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;11.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Admission</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;XII</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">DISSOLUTION, LIQUIDATION AND TERMINATION</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;12.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">No Dissolution</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;12.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Events Causing Dissolution</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;12.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Distribution upon Dissolution</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;12.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Rights of Members</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;12.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">63</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;12.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Reasonable Time for Winding-Up</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;XIII</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">REDEMPTION RIGHTS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;13.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Redemption Rights of Non-Corporation Members</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">64</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 183 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->--<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Article&nbsp;XIV</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-size: 10pt; text-transform: uppercase">MISCELLANEOUS</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 11%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 79%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Amendments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">71</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Governing Law; Jurisdiction; Waiver of Jury Trial</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">72</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Accounting and Fiscal Year</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">73</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Entire Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Further Assurances</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Binding Effect</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">74</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">75</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Confidentiality</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">75</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consent by Spouse</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.11</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.12</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Remedies</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">76</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.13</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Survival</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">77</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.14</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">77</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.15</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Assignability</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">77</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.16</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Waiver</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">77</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Section&nbsp;14.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Acknowledgement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">77</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>EXHIBIT&nbsp;A</U>: EXAMPLES REGARDING ADJUSTMENT FACTOR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>EXHIBIT&nbsp;B</U>: FORM NOTICE OF REDEMPTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>EXHIBIT&nbsp;C</U>: FORM CONSENT BY SPOUSE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>SCHEDULE I</U>: SCHEDULE OF MEMBERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>SCHEDULE II</U>: INITIAL OFFICERS OF THE COMPANY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 184 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->--<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED LIMITED LIABILITY COMPANY<BR>
AGREEMENT OF</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CARITAS THERAPEUTICS, LLC</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This AMENDED AND RESTATED LIMITED LIABILITY COMPANY
AGREEMENT OF CARITAS THERAPEUTICS, LLC, dated as of [&bull;], 2021 (this &ldquo;<U>Agreement</U>&rdquo;), is entered into by and among
Caritas Therapeutics, LLC, a Delaware limited liability company (the &ldquo;<U>Company</U>&rdquo;), Amber GT Holdings, a Delaware limited
liability company (&ldquo;<U>Amber GT</U>&rdquo;), [Caritas Therapeutics, Inc.]<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>,
a Delaware corporation (formerly known as ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company) (the &ldquo;<U>Corporation</U>&rdquo;)
and, solely for purposes of Section 14.17 and the other sections of Article XIV and Article I (to the extent related to Section 14.17),
Amicus Therapeutics, Inc., a Delaware corporation (&ldquo;<U>Amber GT Parent</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RECITALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, prior to the date hereof, the Company
was formed as a limited liability company pursuant to the Delaware Limited Liability Company Act (the &ldquo;<U>Act</U>&rdquo;), by the
filing of a Certificate of Formation with the Secretary of State of the State of Delaware on September 24, 2021 (the &ldquo;<U>Certificate</U>&rdquo;);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, Amber GT, the initial member of
the Company, entered into a Limited Liability Company Agreement with the Company, dated as of September 24, 2021 (the &ldquo;<U>Original
Agreement</U>&rdquo;);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, pursuant to the Business Combination
Agreement, dated as of September 29, 2021 (the &ldquo;<U>Business Combination Agreement</U>&rdquo;) by and among the Corporation, Amber
GT Parent, Amber GT, and the Company, the parties thereto have consummated the transactions contemplated thereby and, as of the date hereof
and in accordance with Article II thereof, the Corporation holds a number of Common Units set forth on <U>Schedule I</U> (as in effect
as of the date hereof) and Amber GT, a wholly-owned Subsidiary of Amber GT Parent, holds a number of Common Units set forth on <U>Schedule
I</U> (as in effect as of the date hereof);<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP>&nbsp;</TD><TD STYLE="text-align: justify">To be the name of ARYA Sciences Acquisition Corp IV following
the consummation of the Domestication, as determined pursuant to the Business Combination Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>2</SUP>&nbsp;</TD><TD STYLE="text-align: justify">Schedule I to reflect (a) a number of Common Units equal to
the Net Outstanding ARYA Class A Shares (as defined in the Business Combination Agreement) being owned by the Corporation, and (b) a
number of Common Units equal to the sum of (i) the Transaction Equity Security Amount (as defined in the Business Combination Agreement)
and (ii) the Amber GT Parent Contribution Equity Amount (as defined in the Business Combination Agreement) being owned by Amber GT, in
each case, as of the Closing Date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 185; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, Section 9.2 of the Original Agreement
provides that Amber GT, as the sole member of the Company, may amend the Original Agreement; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, Amber GT now desires to amend and
restate the Original Agreement in its entirety to be as set forth herein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in consideration of the
benefits to be derived hereunder and the transactions contemplated hereby, and the representations, warranties, covenants, agreements
and conditions set forth herein, the Company and each Member, hereby agrees to amend and restate the Original Agreement in its entirety
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>DEFINED
TERMS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. As used herein, each of the following underlined terms has the meaning specified in this <U>Section&nbsp;1.1</U>:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Additional Agreements</U>&rdquo; has
the meaning set forth in the Business Combination Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Additional Member</U>&rdquo; means any
Person that is admitted to the Company as a Member pursuant to <U>Section&nbsp;11.1</U> and has not ceased to be a Member pursuant to
the Act and this Agreement; <U>provided</U> that a Substituted Member shall not be deemed an Additional Member.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Adjusted Capital Account Deficit</U>&rdquo;
means, with respect to any Member, the deficit balance, if any, in such Member&rsquo;s Capital Account as of the end of the relevant Fiscal
Year after giving effect to the following adjustments: (a) credit to such Capital Account any amounts that such Member is obligated to
restore pursuant to the penultimate sentences of Regulations sections 1.704-2(g)(1) and 1.704-2(i)(5) and (b) debit to such Capital Account
such Member&rsquo;s share of the items described in Regulations sections 1.704-1(b)(2)(ii)(d)(4), (5) and (6). This definition of Adjusted
Capital Account Deficit is intended to comply with the provisions of Regulations section 1.704-1(b)(2)(ii)(d) and shall be interpreted
consistently therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 186; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Adjustment Factor</U>&rdquo; means 1.0;
<U>provided</U>, <U>however</U>, that in the event:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> the Corporation (i)&nbsp;pays a dividend on its outstanding Class&nbsp;A Shares wholly or partly in Class&nbsp;A Shares or makes
a distribution to all holders of its outstanding Class&nbsp;A Shares wholly or partly in Class&nbsp;A Shares, (ii)&nbsp;splits or subdivides
its outstanding Class&nbsp;A Shares or (iii)&nbsp;effects a reverse stock split or otherwise combines its outstanding Class&nbsp;A Shares
into a smaller number of Class&nbsp;A Shares, the Adjustment Factor shall be adjusted by multiplying the Adjustment Factor in effect as
of immediately prior to the record date for purposes of determining the holders of Class A Shares entitled to participate in such dividend,
distribution, split, subdivision, reverse split or combination (or, if there is no such record date, the number of Class A Shares that
are entitled to participate in such distribution, split, subdivision, reverse split or combination) (which, for the avoidance of doubt
shall be determined without taking into account such dividend, distribution, split, subdivision, reverse split or combination) by a fraction,
(1)&nbsp;the numerator of which shall be the number of Class&nbsp;A Shares issued and outstanding on the record date for purposes of determining
the holders of Class A Shares entitled to participate in such dividend, distribution, split, subdivision, reverse split or combination
(or, if there is no such record date, the number of Class A Shares that are entitled to participate in such distribution, split, subdivision,
reverse split or combination) (assuming for such purposes that such dividend, distribution, split, subdivision, reverse split or combination
has occurred as of such time) and (2)&nbsp;the denominator of which shall be the actual number of Class&nbsp;A Shares issued and outstanding
on the record date (or, if there is no such record date, as of immediately prior to such distribution, split, subdivision, reverse split
or combination, as applicable) (which, for the avoidance of doubt shall be determined without taking into account such dividend, distribution,
split, subdivision, reverse split or combination);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Corporation distributes any rights, options or warrants to all holders of its Class&nbsp;A Shares to subscribe for or to purchase
or to otherwise acquire Class&nbsp;A Shares, or other securities or rights convertible into, exchangeable for or exercisable for Class&nbsp;A
Shares, at a price per share less than the Value of a Class&nbsp;A Share on the record date for such distribution (each a &ldquo;<U>Distributed
Right</U>&rdquo;), then, as of the later of the distribution date of such Distributed Rights and the time such Distributed Rights become
exercisable, the Adjustment Factor shall be adjusted by multiplying the Adjustment Factor in effect as of immediately prior to the later
of the distribution date of such Distributed Rights and the time such Distributed Rights become exercisable, by a fraction (i)&nbsp;the
numerator of which shall be the number of Class&nbsp;A Shares issued and outstanding on the later of such record date and the date such
Distributed Rights become exercisable, <U>plus</U> the maximum number of Class&nbsp;A Shares purchasable under such Distributed Rights
that are exercisable and (ii)&nbsp;the denominator of which shall be the number of Class&nbsp;A Shares issued and outstanding on the
later of such record date and the date such Distributed Rights become exercisable, <U>plus</U> a fraction (1)&nbsp;the numerator of which
is the maximum number of Class&nbsp;A Shares purchasable under such Distributed Rights that are exercisable, <U>multiplied by</U> the
minimum purchase price per Class&nbsp;A Share under such Distributed Rights that are exercisable and (2)&nbsp;the denominator of which
is the greater of the Value of a Class A Share (A) as of such record date and (B) the date such Distributed Rights become exercisable;
<U>provided</U>, <U>however</U>, that, if any such Distributed Rights expire, are forfeited or become no longer exercisable, then the
Adjustment Factor shall be adjusted, effective retroactive to the date of distribution (or, if later, the time the Distributed Rights
initially became exercisable) of the Distributed Rights, to reflect a reduced maximum number of Class&nbsp;A Shares or any change in
the minimum purchase price for the purposes of the above fraction; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 187; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Corporation distributes, by dividend or otherwise, to all holders of its Class&nbsp;A Shares any assets (including securities
and evidences of the Corporation&rsquo;s indebtedness, but excluding any dividend or distribution referred to in the foregoing clauses&nbsp;(a)
or (b)), which assets were not received by the Corporation or its Controlled Entities pursuant to a distribution by the Company in accordance
with this Agreement, then the Adjustment Factor shall be adjusted to equal the amount determined by multiplying the Adjustment Factor
in effect immediately prior to the record date for purposes of determining the holders of Class A Shares entitled to participate in such
distribution (or, if there is no such record date, the number of Class A Shares that are entitled to participate in such distribution)
by a fraction (i)&nbsp;the numerator of which shall be such Value of one Class&nbsp;A Share on such record date and (ii)&nbsp;the denominator
of which shall be the Value of one Class&nbsp;A Share as of such record date less the then Fair Market Value (as determined by the Corporation,
whose determination shall be conclusive) of the portion of the non-cash assets so distributed applicable to one Class&nbsp;A Share;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>provided</U> that, notwithstanding the foregoing, if any of the
events in clauses&nbsp;(a), (b) or (c) above occur, no adjustments to the Adjustment Factor will be made for any class or series of Membership
Interests to the extent that the Company makes or effects a correlative distribution or payment to all of the Members holding Membership
Interests of such class or series, or effects a correlative split, subdivision, reverse split or combination in respect of the Membership
Interests of such class or series. If the Corporation effects a dividend that allows holders of Class&nbsp;A Shares to elect to receive
cash or additional Class&nbsp;A Shares, the Company may effect a correlative distribution by distributing to all Members holding Membership
Interests a combination of cash and additional Membership Interests in the same ratio as the ratio of cash and Class&nbsp;A Shares paid
and issued by the Corporation, without offering Members an opportunity to elect to receive cash or additional Membership Interests. Any
adjustment to the Adjustment Factor shall become effective immediately after the event expressly giving rise to such adjustment. For illustrative
purposes only, examples of adjustments to the Adjustment Factor are set forth on <U>Exhibit&nbsp;A</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo; means, with
respect to any Person, any Person directly or indirectly controlling or controlled by or under common control with such Person; <U>provided</U>
that, for the purposes of this definition, &ldquo;<U>control</U>&rdquo; when used with respect to any Person means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through
the ownership of voting securities, by contract or otherwise, and the terms &ldquo;<U>controlling</U>&rdquo; and
 &ldquo;<U>controlled</U>&rdquo; have meanings correlative to the foregoing, <U>provided</U>, <U>however</U>, that (a) no member of
the Parent Corporation Group shall be considered an Affiliate of any Non-Corporation Member for purposes hereof, (b) ARYA Sponsor
(or any successor in interest to its rights under the Director Nomination Agreement) shall not be considered an Affiliate of the
Parent Corporation Group and (c) no Non-Corporation Member shall be deemed to be an Affiliate of Amber for purposes of <U>Section
7.4</U> from and after the time that it ceases to be a Controlled Entity of Amber (including as a result of a &ldquo;spin out&rdquo;
or similar transaction or series of related transactions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 188; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>ARYA Sponsor</U>&rdquo; means, ARYA Sciences
Holdings IV, a Cayman Islands exempted limited company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Assignee</U>&rdquo; means (a) any lender
or lenders secured by a Pledge, or agents acting on their behalf, to whom Membership Interests are Transferred pursuant to the exercise
of remedies under a Pledge and that has not become a Substituted Member and (b) that has the rights set forth in <U>Section&nbsp;10.5</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Asset</U>&rdquo; means any assets or
property of the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Assumed Tax Liability</U>&rdquo; means,
in the case of the Parent Corporation Group, the sum of (a) all of the Parent Corporation Group&rsquo;s federal, state, local and non-U.S.
tax liabilities, <U>plus</U> (b) the amount necessary to satisfy the Corporation&rsquo;s payment obligations pursuant to Article III of
the Tax Receivable Agreement, in each case during the Fiscal Year to which the Tax Distribution under <U>Section&nbsp;4.2</U> relates.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Authority</U>&rdquo; means any United
States or non-United States (a) federal, state, local, municipal or other government, (b) governmental or quasi-governmental entity of
any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal) or (c) body exercising
or entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any
nature, including any arbitrator or arbitral tribunal (public or private).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Bankruptcy</U>&rdquo; means, with respect
to any Person, the occurrence of any event specified in Section&nbsp;17-402(a)(4)&nbsp;or (5)&nbsp;of the Act with respect to such Person,
and the term &ldquo;<U>Bankrupt</U>&rdquo; has a meaning correlative to the foregoing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Board of Directors</U>&rdquo; means the
Board of Directors of the Corporation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Board of Managers</U>&rdquo; means the
Board of Managers of the Company, which shall, unless otherwise determined by the Board of Directors in its sole discretion, at all times
to be composed of the same Persons who are then members of the Board of Directors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo; means any day
other than a Saturday, Sunday or a legal holiday on which commercial banking institutions in New York, New York are authorized to close
for business.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Capital Accounts</U>&rdquo; means the
capital accounts established and maintained on the books of the Company for each Member in accordance with <U>Article&nbsp;III</U> hereof
and which, as of the date hereof, are set forth on <U>Schedule&nbsp;I</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 189; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Capital Contribution</U>&rdquo; means,
with respect to any Member, the cash, cash equivalents and the Fair Market Value of any other property contributed (as determined when
such property is or was contributed) to the Company by or on behalf of such Member in respect of Common Units or any other equity securities
of the Company pursuant to the terms hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Capital Share</U>&rdquo; means any share
of any class or series of capital stock of the Corporation now or hereafter authorized (including any Preferred Share), other than a Common
Share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Cash Amount</U>&rdquo; means an amount
of cash equal to the product of (a)&nbsp;the Value of a Class&nbsp;A Share, <U>multiplied by</U> (b)&nbsp;the Class&nbsp;A Shares Amount,
in each case, determined as of the applicable Valuation Date; <U>provided</U>, that in the event the Corporation sells Class A Shares
to fund such payment, such cash amount shall be net of any underwriters&rsquo; discounts or commissions and brokers&rsquo; fees or commissions
(including, for the avoidance of doubt, any deferred discounts or commissions and brokers&rsquo; fees or commissions payable in connection
with or as a result of such offering) in connection with such sale (collectively, &ldquo;<U>Discounts</U>&rdquo;) and the Corporation&rsquo;s
Capital Account shall be increased by an amount equal to any such Discounts relating to such sale of shares of Class A Shares in accordance
with <U>Section 6.2(c)</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Charter</U>&rdquo; means the certificate
of incorporation of the Corporation, within the meaning of Section&nbsp;104 of the General Corporation Law of the State of Delaware.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Class A Shares</U>&rdquo; means, as applicable,
(a) the Class A common stock, par value $0.0001 per share, of the Corporation or (b) following any consolidation, merger, reclassification
or other similar event involving the Corporation, any shares or other securities of the Corporation or any other Person or cash or other
property that become payable in consideration for the Class A common stock, par value $0.0001 per share, of the Corporation or into which
the Class A common stock, par value $0.0001 per share, of the Corporation is exchanged or converted as a result of such consolidation,
merger, reclassification or other similar event.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Class A Shares Amount</U>&rdquo; means
a number of Class&nbsp;A Shares equal to the product of (a)&nbsp;the number of Tendered Units or Termination Transaction Units, as applicable,
<U>multiplied by</U> (b)&nbsp;the Adjustment Factor; <U>provided</U>, <U>however</U>, that, in the event that the Corporation issues
to all holders of Class&nbsp;A Shares as of a certain record date rights, options, warrants or convertible or exchangeable securities
entitling such holders to subscribe for or purchase Class&nbsp;A Shares, or any other securities or property (collectively, the &ldquo;<U>Rights</U>&rdquo;),
with the record date for such Rights issuance being within the period starting on the date of the Notice of Redemption and ending on
the day immediately preceding the Specified Redemption Date, which Rights will not be distributed before the relevant Specified Redemption
Date in which the Tendering Party or the Termination Non-Corporation Member is receiving the Class A Shares Amount, then such Tendering
Party or the Termination Non-Corporation Member shall also be entitled to such Rights equal to the applicable Class A Shares Amount that
a holder of that number of Class&nbsp;A Shares would have been entitled to receive (assuming, for this purpose, that the holder was a
holder of the Class A Shares Amount as of the record date) at the time that the underlying Rights are received by the record holders
of Class A Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 190; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Class B Shares</U>&rdquo; means, as applicable,
(a) the Class B common stock, par value $0.0001 per share, of the Corporation or (b) following any consolidation, merger, reclassification
or other similar event involving the Corporation, any shares or other securities of the Corporation or any other Person or cash or other
property that become payable in consideration for the Class B common stock, par value $0.0001 per share, of the Corporation or into which
the Class B common stock, par value $0.0001 per share, of the Corporation is exchanged or converted as a result of such consolidation,
merger, reclassification or other similar event.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo; has the meaning set
forth in the Business Combination Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Closing Date</U>&rdquo; has the meaning
set forth in the Business Combination Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Code</U>&rdquo; means the Internal Revenue
Code of 1986, as amended.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Common Shares</U>&rdquo; means, collectively,
the Class A Shares and Class B Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Common Unit</U>&rdquo; means a Membership
Interest designated as a &ldquo;Common Unit&rdquo; in accordance with <U>Section&nbsp;3.2</U> and having the rights, preferences and privileges
set forth herein.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Company Employee</U>&rdquo; means an
employee of the Company or an employee of a Controlled Entity of the Company, if any.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Company Minimum Gain</U>&rdquo; means
 &ldquo;partnership minimum gain&rdquo; as set forth in Regulations section 1.704-2(b)(2).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Company Record Date</U>&rdquo; means,
with respect to any meeting of the Members, consent to any matter, distribution, allotment or determination of the Members, the record
date established by the Board of Managers for the purpose of determining the Members entitled to notice of or to vote at any such meeting,
consent to any such matter, receive any such distribution or allotment or make any such determination, as applicable, which, in the case
of a record date fixed for the determination of Members entitled to receive any distribution, shall (unless otherwise determined by the
Board of Managers) generally be the same as the record date established by the Corporation for a dividend or distribution to its stockholders
of some or all of its portion of such dividend or distribution.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Company Property</U>&rdquo; means all
interests in properties, whether real or personal, tangible or intangible, and rights of any type owned thereon or held by the Company
or any Controlled Entity thereof, including all cash, securities and other property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 191; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Consent</U>&rdquo; means the consent
to, approval of, or vote in favor of a proposed action by a Member given in accordance with <U>Section&nbsp;7.2</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Consent of the Members</U>&rdquo; means
the Consent of a Majority in Interest of the Members, with all of the Members voting together as a single class, which Consent shall be
obtained before the taking of any action for which it is required hereby and, except as otherwise provided herein, may be given or withheld
by the Members in their discretion.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Consent of the Non-Corporation Members</U>&rdquo;
means the Consent of a Majority in Interest of the Non-Corporation Members, with all of the Non-Corporation Members voting together as
a single class, which Consent shall be obtained before the taking of any action for which it is required hereby and, except as otherwise
provided herein, may be given or withheld by the Non-Corporation Members in their discretion.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Controlled Entity</U>&rdquo; means, as
to any Person, (a)&nbsp;any corporation more than 50% of the outstanding voting stock of which is owned by such Person or such Person&rsquo;s
Family Members or Affiliates, (b)&nbsp;any trust, whether or not revocable, of which such Person or such Person&rsquo;s Family Members
or Affiliates are the sole beneficiaries, (c)&nbsp;any partnership, limited partnership or limited liability partnership of which such
Person or such Person&rsquo;s Family Members or Affiliates is the general or managing partner or in which such Person or such Person&rsquo;s
Family Members or Affiliates hold partnership interests representing at least 50% of such partnership&rsquo;s capital and profits and
(d)&nbsp;any limited liability company of which such Person or such Person&rsquo;s Family Members or Affiliates is the manager or managing
member or in which such Person or such Person&rsquo;s Family Members or Affiliates hold limited liability company or membership interests
representing at least 50% of such limited liability company&rsquo;s capital and profits.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Covered Person</U>&rdquo; means, as of
any time of determination, (a) any current or former officer, manager, employee or other agent of the Company, the Parent Corporation
Group or any of their respective Subsidiaries, each, to the extent that the context so requires, in his or her capacity as such, and (b)&nbsp;any
Person who is or was serving at the request of the Company or the Parent Corporation Group or any of their respective Subsidiaries as
a manager or director, officer, employee, fiduciary or agent of another limited liability company or of a corporation, partnership, joint
venture, trust or other enterprise.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Cut-Off Date</U>&rdquo; means the tenth
(10th) Business Day after the Company&rsquo;s receipt of a Notice of Redemption or the date of delivery of the Termination Transaction
Redemption Notice.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Debt</U>&rdquo; means, with respect to
any Person as of any date of determination, (a)&nbsp;all indebtedness of such Person for borrowed money or for the deferred purchase price
of property or services, (b)&nbsp;all amounts owed by such Person to banks or other Persons in respect of reimbursement obligations under
letters of credit, surety bonds and other similar instruments guaranteeing payment or other performance of obligations by such Person,
(c)&nbsp;all indebtedness for borrowed money or for the deferred purchase price of property or services secured by any lien on any property
owned by such Person, to the extent attributable to such Person&rsquo;s interest in such property, even though such Person has not assumed
or become liable for the payment thereof and (d)&nbsp;obligations of such Person as lessee under leases that are required by U.S. generally
accepted accounting principles, in effect from time to time, to be classified as capital leases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 192; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>De Minimis</U>&rdquo; shall mean an amount
small enough as to make not accounting for it commercially reasonable or accounting for it administratively impractical, in each case
as determined by the Board of Managers.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Depreciation</U>&rdquo; means, for each
Fiscal Year or other applicable period, an amount equal to the federal income tax depreciation, amortization or other cost recovery deduction
allowable under U.S. federal income tax principles with respect to an asset for such Fiscal Year or other period, except that, if the
Gross Asset Value of an asset differs from its adjusted basis for U.S. federal income tax purposes at the beginning of such Fiscal Year
or period, Depreciation shall be in an amount that bears the same ratio to such beginning Gross Asset Value as the U.S. federal income
tax depreciation, amortization or other cost recovery deduction for such year or other period bears to such beginning adjusted tax basis
(except as otherwise required by Regulations section 1.704-3(d)(2)); <U>provided</U>, <U>however</U>, that, if the federal income tax
depreciation, amortization or other cost recovery deduction for such year or period is zero ($0), Depreciation shall be determined with
reference to such beginning Gross Asset Value using any reasonable method selected by the Board of Managers.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Director Nomination Agreement</U>&rdquo;
means the Director Nomination Agreement, dated as of the date hereof, by and among the Corporation, Amber GT Parent and ARYA Sponsor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Distributed Right</U>&rdquo; has the
meaning set forth in the definition of &ldquo;Adjustment Factor.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Equity Plan</U>&rdquo; means any
plan, agreement or other arrangement that provides for the grant or issuance of equity or equity-based awards and that is now or is
hereafter adopted by the Company or the Corporation for the benefit of any of their respective employees or other service providers
(including directors, advisers and consultants), or the employees or other services providers (including directors, advisers and
consultants) of any of their respective Affiliates or Controlled Entities.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Equivalent Units</U>&rdquo; means, with
respect to any class or series of Capital Shares, Membership Interests with preferences, conversion and other rights (other than voting
rights), restrictions, limitations as to dividends and other distributions, qualifications and terms and conditions of redemption that
are substantially the same as (or correspond to) the preferences, conversion and other rights, restrictions, limitations as to distributions,
qualifications and terms and conditions of redemption of such Capital Shares as appropriate to reflect the relative rights and preferences
of such Capital Shares as to the Class A Shares and the other classes and series of Capital Shares as such Equivalent Units would have
as to Common Units and the other classes and series of Units corresponding to the other classes of Capital Shares, but not as to matters
such as voting for members of the Board of Directors that are not applicable to the Company. For the avoidance of doubt, the voting rights,
redemption rights and rights to Transfer Equivalent Units need not be similar to the rights of the corresponding class or series of Capital
Shares, <U>provided</U>, <U>however</U>, that with respect to redemption rights, the terms of Equivalent Units must be such so that the
Company complies with <U>Section&nbsp;3.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 193; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>ERISA</U>&rdquo; means the Employee Retirement
Income Security Act of 1974.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo; means the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Fair Market Value</U>&rdquo; means, with
respect to any asset or property, an amount equal to the price at which a willing buyer having all relevant knowledge would purchase,
and a willing seller would sell, such asset or property in an arm&rsquo;s-length transaction taking into account all relevant factors
determinative of value (but without regard to any compulsion to sell or the impact of an immediate sale), in each case, as reasonably
determined in good faith by the Board of Managers.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Family Members</U>&rdquo; means, with
respect to any Person, (a) the spouse, former spouse, child, step-child, sibling, niece, nephew, parent, grandparent or any lineal descendent
(whether by blood or adoption) of such Person or a parent, grandparent or any lineal descendent (whether by blood or adoption) of such
Person&rsquo;s spouse, (b) any corporation, partnership or limited liability company all or substantially all of the equity interests
in which are owned by any Person described in the foregoing clause&nbsp;(a) or (c) a trust, custodial account or guardianship administered
primarily for the benefit of any Person described in the foregoing clause&nbsp;(a).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Gross Asset Value</U>&rdquo; means,
with respect to any Company asset, the adjusted tax basis of the asset for United States federal income tax purposes, except that
(a) the initial Gross Asset Value of any property contributed by a Member to the Company (other than cash) shall be the Fair Market
Value of such property, (b) the Gross Asset Value of any asset distributed or deemed distributed to a Member by the Company shall be
the Fair Market Value of such asset at the time of such distribution, and (c) the Gross Asset Values of all Company assets shall be
adjusted to equal their respective gross Fair Market Value, in accordance with the rules set forth in Section 1.704-1(b)(2)(iv)(f)
of the Regulations, except as otherwise provided herein, immediately prior to: (i) the date of the acquisition of any additional
Membership Interests by any new or existing Member in exchange for more than a De Minimis Capital Contribution; (ii) the date of the
distribution of more than a De Minimis amount of Company property (other than a pro rata distribution) to a Member; (iii) the date
of the actual liquidation of the Company within the meaning of Regulations section 1.704-1(b)(2)(ii)(g); (iv) the date of the
acquisition of any additional Membership Interests (other than a De Minimis number of Membership Interests) by any new or existing
Member as consideration for the performance of services to or for the benefit of the Company; or (v) any other time at which
revaluations of property are permitted to be made under Regulations section 1.704-1(b)(2)(iv); <U>provided</U> that adjustments
pursuant to the foregoing clauses&nbsp;(i), (ii), (iii) and (v) shall be made only if the Board of Managers reasonably determines
that such adjustments are necessary or appropriate to reflect the relative economic interests of the Members. In the case of any
asset that has a Gross Asset Value determined pursuant to the foregoing clauses&nbsp;(i), (ii), (iv) or (v), Depreciation shall be
computed based on the asset&rsquo;s Gross Asset Value as so determined, and not on the asset&rsquo;s adjusted tax basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 194; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Incapacity</U>&rdquo; or &ldquo;<U>Incapacitated</U>&rdquo;
means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to any Member who is an individual, the death or total physical disability of such Member or the entry by a court
of competent jurisdiction adjudicating such Member incompetent to manage his or her person or his or her estate;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to any Member that is a corporation or limited liability company, the filing of a certificate of dissolution, or its
equivalent, for the corporation or the revocation of its certificate or articles of information or similar governing document;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to any Member that is a limited liability company, partnership, limited partnership or limited liability partnership,
the dissolution and commencement of winding up of such Member;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to any Member that is an estate, the distribution by the fiduciary of such estate&rsquo;s entire interest in the Company;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to any trustee of a trust that is a Member, the termination of such trust (but not the substitution of a new trustee);
or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>with respect to any Member, the Bankruptcy of such Member.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Indemnifiable Losses</U>&rdquo;
means all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements
of any kind or nature whatsoever (including any interest and penalties, reasonable out-of-pocket expenses and the reasonable fees
and disbursements of counsel for a Covered Person in connection with any investigative, administrative or judicial proceedings,
whether or not such Covered Person shall be designated a party thereto), whether absolute, accrued, conditional or otherwise and
whether or not resulting from bona fide third-party claims.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Investor Rights Agreement</U>&rdquo;
means the Investor Rights Agreement, dated as of September 29, 2021, by and among the Corporation, the ARYA Sponsor, Amicus GT and certain
other Persons identified as &ldquo;Holders&rdquo; on the signature pages thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 195; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>IRS</U>&rdquo; means the United States
Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Law</U>&rdquo; means any federal, national,
state, local, foreign, multi-national or supranational statute, law (including common law and, if applicable, fiduciary or similar duties),
act, statute, ordinance, treaty, Order, rule, code, regulation or other binding directive, guidance issued, promulgated or enforced by
an Authority having jurisdiction over a given matter.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Lock-up Period</U>&rdquo; means the period
commencing on the Closing Date and continuing through the date that is 365 days after the Closing Date; <U>provided</U>, <U>however</U>,
that the Board of Managers may, by written agreement with a Member, shorten or lengthen the Lock-Up Period applicable to such Member without
having any obligation to do so for any other Member.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Majority in Interest of the Members</U>&rdquo;
means Members entitled to vote on or consent to any matter holding more than 50% of all outstanding Membership Interests held by all Members
entitled to vote on or consent to such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Majority in Interest of the Non-Corporation
Members</U>&rdquo; means the Non-Corporation Members entitled to vote on or consent to any matter holding more than 50% of all outstanding
Membership Interests held by all Non-Corporation Members entitled to vote on or consent to such matter.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Member</U>&rdquo; means Amber GT, the
Corporation, each Substituted Member and each Additional Member and, in each case, that has not ceased to be a member of the Company pursuant
to the Act and this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Member Minimum Gain</U>&rdquo; means
 &ldquo;partner nonrecourse debt minimum gain,&rdquo; as determined under Regulations section 1.704-2(i)(3).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Member Nonrecourse Debt</U>&rdquo; means
 &ldquo;partner nonrecourse debt,&rdquo; as set forth in Regulations section 1.704-2(b)(4).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Member Nonrecourse Deductions</U>&rdquo;
means &ldquo;partner nonrecourse deductions,&rdquo; as set forth in Regulations section 1.704-2(i). The amount of Member Nonrecourse Deductions
shall be determined as set forth in Regulations section 1.704-2(i).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Membership Interest</U>&rdquo; means
a limited liability company interest in the Company having the rights, preferences and privileges, and being subject to the covenants
and agreements, set forth herein; <U>provided</U> that there may be one or more classes of Membership Interests, including Common Units
and Equivalent Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 196; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Net Profits</U>&rdquo; and &ldquo;<U>Net
Loss</U>&rdquo; mean, for each Fiscal Year or other period, an amount equal to the Company&rsquo;s net taxable income or loss for such
year or period, determined in accordance with Section 703(a) of the Code (for this purpose, all items of income, gain, loss or deduction
required to be stated separately pursuant to Section 703(a)(1) of the Code shall be included in taxable income or loss), with the following
adjustments (without duplication):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any income of the Company that is exempt from federal income tax not otherwise taken into account in computing Net Profits or Net
Loss shall be added to such taxable income or loss;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>any
expenditures of the Company described in Section 705(a)(2)(B) of the Code or treated as expenditures described in Section 705(a)(2)(B)
of the Code pursuant to Regulations section 1.704-1(b)(2)(iv)(i) and not otherwise taken into account in computing Net Profits or Net
Loss shall be subtracted from such taxable income or loss;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>income,
gain or loss resulting from any disposition of, distribution to a Member of, or depreciation, amortization or other cost recovery deductions
with respect to, Company property shall be computed by reference to the Gross Asset Value of the property disposed of, notwithstanding
that the adjusted tax basis of such property differs from its Gross Asset Value;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event the Gross Asset Value of any Company asset is adjusted pursuant to the definition of Gross Asset Value above, the
amount of such adjustment shall be taken into account as gain or loss from the disposition of such asset for purposes of computing Net
Profits and Net Losses; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>to
the extent an adjustment to the adjusted tax basis of any asset pursuant to Section 734(b) of the Code is required pursuant to
Regulations section 1.704-1(b)(2)(iv)(m)(4) to be taken into account in determining Capital Accounts as a result of a distribution
(other than in liquidation of a Member&rsquo;s interest in the Company), the amount of such adjustment shall be treated as an item
of gain (if the adjustment increases the basis of the asset) or loss (if the adjustment decreases the basis of the asset) from the
disposition of the asset and shall be taken into account for purposes of computing Net Profits or Net Losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>New Securities</U>&rdquo; means (a) any
right, option, warrant or convertible or exchangeable security that entitles the holder thereof to subscribe for or purchase, convert
such security into or exchange such securities for, Common Shares or Capital Shares, excluding Capital Shares and any grants or issuances
under any Equity Plans, or (b)&nbsp;any Debt that entitles the holder thereof to convert such Debt into or exchange such Debt for, Common
Shares or Capital Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 197; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Non-Corporation Member</U>&rdquo; means
any Person (other than any member of the Parent Corporation Group) that is, from time to time, admitted to the Company as a member pursuant
to the Act and this Agreement, including any Substituted Member or Additional Member and, in each case, that has not ceased to be a member
of the Company pursuant to the Act and this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Nonrecourse Debt</U>&rdquo; means a &ldquo;nonrecourse
liability&rdquo; as set forth in Regulations section 1.704-2(b)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Nonrecourse Deductions</U>&rdquo; means
 &ldquo;nonrecourse deductions,&rdquo; as set forth in Regulations sections 1.704-2(b) and 1.704-2(c). The amount of Nonrecourse Deductions
shall be determined as set forth in Regulations sections 1.704-2(b) and 1.704-2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Notice of Redemption</U>&rdquo; means
the Notice of Redemption substantially in the form of <U>Exhibit&nbsp;B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Optionee</U>&rdquo; means a Person to
whom a stock option is granted under any Equity Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Order</U>&rdquo; means any decree, order,
judgment, ruling, writ, judicial or arbitral award, injunction, subpoena, verdict, determination or decision entered, issued or rendered
by an Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Parent Corporation Group</U>&rdquo; means,
collectively, the Corporation, its Affiliates and any successors thereof (other than the Company, its Subsidiaries and any successors
thereof) and each Permitted Transferee of any Membership Interests initially held by any of the foregoing (other than, for the avoidance
of doubt, the Company, its Subsidiaries or any successors thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Partnership Audit Procedures</U>&rdquo;
means Sections&nbsp;6221 through 6241 of the Code and the Regulations promulgated thereunder or successor provisions and any similar provision
of state or local tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Percentage Interest</U>&rdquo; means,
with respect to each Member, as to any class, series or type of Membership Interests, the fraction, expressed as a percentage, (a) the
numerator of which is the aggregate number of such class, series or type of Membership Interests held by such Member and (b) the denominator
of which is the total number of such class, series or type of Membership Interests held by all Members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Permitted Lender Transferee</U>&rdquo;
any lender or lenders secured by a Pledge, or agents acting on their behalf, to whom Membership Interests are Transferred pursuant to
the exercise of remedies under a Pledge and any special purpose entities owned and used by such lenders or agents for the purpose of holding
any such Membership Interests and that agrees to be bound by the terms and conditions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 198; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Permitted Transfer</U>&rdquo; means (a)
any Pledge and any Transfer of Membership Interests, in whole or in part, to a Permitted Transferee pursuant to the exercise of remedies
under a Pledge; <U>provided</U> that the terms thereof require that any Membership Interest subject thereto be redeemed pursuant to <U>Section&nbsp;13.1</U>
upon realization of such security, and (b) any Transfer by a Member of Membership Interests (other than a Pledge), in whole or in part,
to a Permitted Transferee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Permitted Transferee</U>&rdquo; means,
with respect to any Member, (a) any Family Member, Controlled Entity or Affiliate of such Member, (b) a Permitted Lender Transferee, (c)
any Person, including any Third-Party Pledge Transferee designated by any lender or lenders secured by a Pledge, or agents acting on their
behalf, to which Membership Interests are Transferred pursuant to the exercise of remedies under a Pledge, whether before or after one
(1) or more Permitted Lender Transferees take title to such Membership Interests, and (d) any other Member (that is not a Family Member,
Controlled Entity or Affiliate of such Member) or Permitted Transferee of such other Member (solely to the extent such Transfer is not
taxable for U.S. federal income tax purposes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo; means an individual
or a corporation, partnership, limited partnership, limited liability partnership, trust, unincorporated organization, association, limited
liability company or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Pledge</U>&rdquo; means a pledge by a
Member of one (1) or more of its Membership Interests to one (1) or more banks or lending institutions, or agents acting on their behalf,
that are not Affiliates of such Member, as collateral or security for a bona fide loan or other extension of credit, in each case as approved
in advance by the Board of Managers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Preferred Share</U>&rdquo; means a share
of capital stock of the Corporation now or hereafter authorized or reclassified that has dividend rights, or rights upon liquidation,
winding up and dissolution, that are superior or senior to the Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Qualified Transferee</U>&rdquo; means
an &ldquo;accredited investor,&rdquo; as defined in Rule&nbsp;501 promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Regulations</U>&rdquo; means, except
where the context indicates otherwise, the final and temporary regulations of the Department of the Treasury under the Code, as such regulations
may be lawfully changed from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Remedies Exception</U>&rdquo; means bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability relating to or affecting creditors&rsquo;
rights generally, and subject, as to enforceability to general equity principles (whether considered in a proceeding in equity or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 199; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Representatives</U>&rdquo; means, with
respect to any Member, such Member&rsquo;s officers, directors, employees, equityholders, partners, members, Affiliates, accountants,
attorneys, consultants, co-investors, investors, potential partners, financing sources, bankers, advisors and other agents or representatives
who actually receive Confidential Information; <U>provided</U>, <U>however</U>, that (A) no Person shall be considered one of the Corporation&rsquo;s
Representatives or Affiliates unless such person receives Confidential Information from or on behalf of the Corporation, and (B) no portfolio
company of any Affiliate of the Corporation or of the ARYA Sponsor shall be deemed to have received Confidential Information solely due
to the fact that such entity&rsquo;s directors, officers or employees may serve as directors, officers or employees of such portfolio
company solely to the extent that any such individual does not provide any Confidential Information to such portfolio company and does
not use any Confidential Information in connection with his or her role at such company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>SEC</U>&rdquo; means the Securities and
Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Securities Act</U>&rdquo; means the Securities
Act of 1933.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Specified Redemption Date</U>&rdquo;
means a date set by the Board of Managers in accordance with <U>Section&nbsp;13.1(c)(vii)</U> or, with respect to a Termination Transaction
Redemption, the date as set forth in a Termination Transaction Redemption Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo; or &ldquo;<U>Subsidiaries</U>&rdquo;
means (a) one or more entities of which at least fifty percent (50%) of the capital stock or share capital or other equity or voting securities
are Controlled or owned, directly or indirectly, by the respective Person (b) any partnership, limited liability company, joint venture
or other entity of which the respective Person or any Subsidiary is a general partner, manager, managing member or the equivalent and
(c) in the case of the Company, any partnership (for U.S. federal and applicable state income tax purposes) resulting from the Co-Development
and Commercialization Agreement, dated as of [&#9679;], 2021, by and between the Company and Amber GT Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Substituted Member</U>&rdquo; means a
Person that is admitted as a Member to the Company pursuant to <U>Section&nbsp;10.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Tax Receivable Agreement</U>&rdquo; means
the Tax Receivable Agreement, dated as of the Closing Date, by and among Amber GT, the Company and the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Terminating Non-Corporation Member</U>&rdquo;
has the meaning in the definition of &ldquo;Termination Transaction of a Non-Corporation Member.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 200; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Termination Transaction of a Non-Corporation
Member</U>&rdquo; means, with respect to any Non-Corporation Member, the occurrence of (a)&nbsp;a merger, consolidation or other combination
involving the Non-Corporation Member, on the one hand, and any other Person, on the other hand, whether in a single transaction or series
of related transactions, (b)&nbsp;a sale, lease, exchange or other transfer of all or substantially all of the consolidated assets of
such Non-Corporation Member or, in the case of any Non-Corporation Member that is a Subsidiary or Affiliate of Amber GT Parent, of Amber
GT Parent (or any successor or parent company thereof) by any Person or group of Person(s) that are not Affiliated with such Non-Corporation
Member or Amber GT Parent, as applicable, in each case, whether in a single transaction or a series of related transactions and whether
by merger, consolidation, tender offer, recapitalization, purchase or issuance of securities or otherwise, (c)&nbsp;the Bankruptcy of,
or the adoption of any plan of liquidation or dissolution of, such Non-Corporation Member or, in the case of any Non-Corporation Member
that is a Subsidiary or Affiliate of Amber GT Parent, of Amber GT Parent (or any successor or parent company thereof), (d)&nbsp;any other
direct or indirect Transfer of all or any portion of such Non-Corporation Member&rsquo;s Membership Interests, other than, in the case
of the foregoing clause (c), a Transfer effected in accordance with <U>Section 10.3</U>, (e) any other transaction or series of related
transactions that results, directly or indirectly, in the shareholders of such Non-Corporation Member or, in the case of any Non-Corporation
Member that is a Subsidiary or Affiliate of Amber GT Parent, of Amber GT Parent immediately prior to such transaction(s) holding, in the
aggregate, less than fifty percent (50%) of the voting shares or equity securities (whether voting or non-voting) of such Non-Corporation
Member (or any successor or parent company thereof) or of Amber GT Parent (or any successor or parent company thereof), as applicable
or (f) without limiting the covenants or agreements of such Non-Corporation Member hereunder (or any rights or remedies of the Company
or the Parent Corporation Group with respect thereto), the breach of <U>Section 7.4</U>; <U>provided</U>, <U>however</U>, that any Transfer
of all or any portion of a Non-Corporation Member&rsquo;s Membership Interests (other than to such Non-Corporation Member&rsquo;s Family
Members, Controlled Entities or Affiliates) to a Permitted Lender Transferee or Third Party Pledge Transferee consistent with the terms
herein and pursuant to the exercise of remedies under a Pledge, in each case, shall constitute a Termination Transaction of such Non-Corporation
Member; <U>provided</U>, <U>further</U>, that any Transfer of a Non-Corporation Member&rsquo;s Membership Interests described in the foregoing
clause (d) shall constitute a Termination Transaction of a Non-Corporation Member solely with respect to and to the extent of such Membership
Interests Transferred and such Membership Interests Transferred shall be considered Termination Transaction Units hereunder and subject
to the terms and conditions of <U>Article&nbsp;XIII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Termination Transaction of the Corporation</U>&rdquo;
means the occurrence of (a)&nbsp;a merger, consolidation or other combination or transaction(s) involving the Corporation (or any successor
or Affiliate thereof), on the one hand, and any other Person, on the other hand, and immediately after the consummation of such merger,
consolidation or other combination or transaction(s), the holders of voting securities of the Corporation immediately prior to such merger,
consolidation or other combination or transaction(s) do not immediately following the consummation thereof directly or indirectly hold
more than 50% of the combined voting power of the then outstanding voting securities of the Person resulting from such merger, consolidation
or combination or, if the Corporation (or any successor or Affiliate thereof) is a Controlled Entity of such Person, the ultimate parent
thereof, or (b)&nbsp;a sale, lease, exchange or other transfer of all or substantially all of the assets of the Corporation, on a consolidated
basis, in the case of clause (a) or (b), whether in a single transaction or a series of related transactions; <U>provided</U> that, notwithstanding
the foregoing, a &ldquo;Termination Transaction of the Corporation&rdquo; shall not be deemed to have occurred by virtue of the consummation
of any transaction or series of integrated transactions immediately following which the record holders of the voting shares of the Corporation
immediately prior to such transaction or series of transactions continue to hold directly or indirectly at least fifty percent (50%) of
the voting shares of the Corporation (or any successor, resulting or parent company thereof) immediately after the consummation of such
transaction or series of related transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 201; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Third Party</U>&rdquo; means a Person
that, as of immediately prior to the consummation of an action or transaction involving such Person, is not a (a) Member, (b) Assignee,
(c) Affiliate of the Company or any of the Members, (d) a wholly owned Controlled Entity of the Company or any of the Members, or (e)
the ARYA Sponsor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Third-Party Pledge Transferee</U>&rdquo;
means a Qualified Transferee, other than a Permitted Lender Transferee, that acquires one (1) or more Membership Interests pursuant to
the exercise of remedies by Permitted Lender Transferees under a Pledge and that agrees to be bound by the terms and conditions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo; means a day on
which the Nasdaq Global Market or such other principal United States securities exchange on which the Class A Shares are listed, quoted
or admitted to trading and is open for the transaction of business (unless such trading shall have been suspended for the entire day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Transfer</U>&rdquo; means any sale, assignment,
bequest, conveyance, devise, gift (outright or in trust), pledge, encumbrance, hypothecation, mortgage, exchange, transfer or other disposition
or act of alienation, whether voluntary or involuntary or by operation of law; <U>provided</U>, <U>however</U>, that when the term is
used in <U>Article&nbsp;X</U> (other than in <U>Section&nbsp;10.6(b)(ix</U>)) and <U>Section&nbsp;12.6</U>, &ldquo;Transfer&rdquo; does
not include (a)&nbsp;any acquisition of Tendered Units or Termination Transaction Units by the Company or the Corporation pursuant to
<U>Section&nbsp;13.1</U> or (b)&nbsp;any redemption of Common Units pursuant to any Membership Interest Designation. The terms &ldquo;<U>Transferred</U>&rdquo;
and &ldquo;<U>Transferring</U>&rdquo; have correlative meanings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Valuation Date</U>&rdquo; means, as applicable,
(a) the date of receipt by the Company of a Notice of Redemption pursuant to <U>Section&nbsp;13.1</U> or (b) any other date on which the
Value of any Class A Shares is to be determined hereunder; <U>provided</U> that, in each case, if such date is not a Business Day, the
Valuation Date shall be the immediately preceding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Value</U>&rdquo; means, with respect
to any Class A Share on any Valuation Date, the volume-weighted average of the daily sale prices for the ten (10) consecutive Trading
Days immediately preceding such Valuation Date, as reported by Bloomberg, L.P. (or, if not reported by Bloomberg, L.P., by another authoritative
source) (except that, in lieu of such volume-weighted average of the daily sale prices, (a) for purposes of <U>Section&nbsp;3.5</U>, (i)
in the case of an exercise of a share option under any Equity Plan, the sale price for the Trading Day immediately preceding the date
of exercise shall be used, and (ii) in the case of delivery of Class A Shares pursuant to restricted share units or other equity compensation
plans, the sale price on the date of such delivery shall be used and (b) unless otherwise determined by the Board of Managers, for purposes
of a Termination Transaction of the Corporation, the price per one Class A Share implied by such Termination Transaction of the Corporation
shall be used (with such implied price being determined by the Board of Managers based on the underlying definitive transaction documents
with respect to such Termination Transaction of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 202; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Definitions</U>. Each of the capitalized terms listed below has the meaning given to such term in the Section set forth
opposite such term below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 65%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Acquired Percentage</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 33%; font: 10pt Times New Roman, Times, Serif">Section&nbsp;13.1(b)(i)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Acquired Units</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;13.1(b)(i)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Act</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Recitals</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Agreement</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Preamble</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Agreement Action</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;14.2(a)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Amber GT</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Preamble</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Amber GT Parent</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Preamble</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Amber Member</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;14.1</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Approved Transfer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;10.3(a)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Business Combination Agreement</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Recitals</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Capital Account</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;3.10</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Certificate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Recitals</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Company</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Preamble</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Confidential Information</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;14.9(b)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Corporation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Preamble</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Corporation Record Date</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">Exhibit A</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Corporation Unit Acquisition</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;13.1(b)(i)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Designated Individual</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;9.3(a)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Disclosing Person</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;14.9(a)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Discounts</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Distributed Right</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Election Notice</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;13.1(b)(i)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Fiscal Year</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;14.3</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Imputed Underpayment Amount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;10.3(d)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Liquidating Event</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;12.2</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Liquidator</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Section&nbsp;12.3(a)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">M&amp;A Distribution</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;4.8</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">M&amp;A Event</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;4.8</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Manager</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Section&nbsp;6.1(a)(i)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">No-Duty Persons</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;6.5(a)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Non-Corporation Member Fiduciary Duties</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;6.3(b)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Original Agreement</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Recitals</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Partnership Representative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;9.3(a)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Protected Person</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;14.9(a)</TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 65%">Redemption</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt; width: 33%">Section&nbsp;13.1(a)(i)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Regulatory Allocations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;5.3</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Rights</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt">Section&nbsp;1.1</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -12pt; padding-left: 12pt">Rule 144</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;2.8(f)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Securities Act</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">Cover Page</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Special Redemption</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;13.1(a)(i)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Surviving Company</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;10.6(a)(ii)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Tax Distribution</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;4.2(a)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Tendered Units</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;13.1(a)(i)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Tendering Party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;13.1(a)(i)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Termination Transaction Notice</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;13.1(a)(iv)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Termination Transaction Redemption</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;13.1(a)(iv)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Termination Transaction Units</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;13.1(a)(iv)</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Transaction Consideration</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">Section&nbsp;10.6(a)(i)</TD></TR>
  </TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 203; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Interpretation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>When calculating the period of time before which, within which or following which any act is to be done or step taken pursuant
hereto, (i) the date that is the reference date in calculating such period shall be excluded and (ii) if the last day of such period is
a not a Business Day, the period in question shall end on the next succeeding Business Day.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Unless otherwise specifically indicated, any reference herein to &ldquo;$&rdquo; means U.S. dollars.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any reference herein to gender shall include all genders, and words imparting the singular number only shall include the plural
and vice versa.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties hereto are sophisticated and have carefully negotiated the provisions hereof. As a consequence, the parties hereto
do not intend that the presumptions of Laws relating to the interpretation of contracts against the drafter of any particular clause should
be applied hereto or any agreement or instrument executed in connection herewith, and therefore waive their effects.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> When a reference is made herein to an Article, Section, Schedule or Exhibit, such reference shall be to an Article, a Section,
a Schedule or an Exhibit of or hereto unless otherwise indicated. The table of contents and headings herein are for reference purposes
only and shall not affect in any way the meaning or interpretation hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Whenever
the words &ldquo;include,&rdquo; &ldquo;includes&rdquo; or &ldquo;including&rdquo; are used herein, they shall be deemed to be followed
by the words &ldquo;without limitation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 204; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
words &ldquo;hereof,&rdquo; &ldquo;hereto,&rdquo; &ldquo;hereby,&rdquo; &ldquo;herein&rdquo;, &ldquo;herewith&rdquo; and &ldquo;hereunder&rdquo;
and words of similar import when used herein shall refer to this Agreement as a whole and not to any particular provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The word &ldquo;extent&rdquo; in the phrase &ldquo;to the extent&rdquo; means the degree to which a subject or other thing extends,
and such phrase shall not mean simply &ldquo;if.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Any
contract, agreement or Law defined or referred to herein means such contract or Law as from time to time amended, restated, modified
or supplemented, unless otherwise specifically indicated, and the reference to any Law includes any rules or regulations promulgated
thereunder by an Authority of competent jurisdiction and any successor statute to any such Law. Any reference herein to &ldquo;applicable
Law&rdquo; shall be deemed to include a reference to &ldquo;the Act.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>References to a Person are also to its successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Exhibits and Schedules hereto are incorporated and made a part hereof and are an integral part hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
headings set forth in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The words &ldquo;writing,&rdquo; &ldquo;written&rdquo; and comparable terms refer to printing, typing and other means of reproducing
words (including electronic media) in a visible form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>GENERAL
PROVISIONS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Amendment
and Restatement; Formation</U>. This Agreement amends and restates the Original Agreement in its entirety. The Company is a limited
liability company previously formed and continued pursuant to the provisions of the Act and upon the terms and subject to the
conditions set forth herein. To the extent that the rights, powers, duties, obligations and liabilities of any Member or the Company
are different by reason of any provision hereof than they would be under applicable Law in the absence of any such provision, this
Agreement shall, to the extent permitted by applicable Law, control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Name</U>. The name of the Company is &ldquo;<FONT STYLE="color: windowtext">Caritas Therapeutics, LLC</FONT>&rdquo;. The Company
may do business under such name or under any other name or names which the Board of Managers may select from time to time. The Board of
Managers may change the name of the Company, at any time and from time to time, in accordance with applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 205; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Principal Place of Business; Other Places of Business</U>. The principal office and principal place of business of the Company
shall be as determined by the Board of Managers. The name and address of the Company&rsquo;s registered agent in the State of Delaware
is as set forth in the Certificate and may be changed from time to time in the Board of Managers&rsquo; sole discretion.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Term</U>. The term of the Company commenced on September 24, 2021, and such term shall continue until the Company is dissolved
in accordance with the Act or this Agreement. Notwithstanding the dissolution of the Company, the existence of the Company shall continue
until termination pursuant hereto or as otherwise provided in the Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Concerted Action; No State-Law Partnership</U>. Except as expressly provided herein, in performing any Member&rsquo;s obligations
or exercising its rights hereunder, such Member is acting independently and is not acting in concert with, on behalf of, as agent for,
or as joint venturer of, any other Member. Other than with respect to the Company, nothing herein shall be construed as creating a corporation,
association, joint stock company, business trust, organized group of Persons, whether incorporated or not, among or involving any Member
or its Affiliates, and nothing herein shall be construed as creating or requiring any continuing relationship or commitment as between
such parties other than as specifically set forth herein. The Members intend that the Company shall not be a partnership (including a
limited partnership) or joint venture, and that no Member or Members shall be a partner or joint venturer of any other Member or Members,
for any purpose other than U.S. federal and applicable state and local tax purposes, and nothing herein shall be construed to the contrary.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Business Purpose</U>. The Company may carry on any lawful business, purpose or activity in which a limited liability company
may be engaged under applicable Law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Powers</U>. Subject to the limitations set forth herein, the Company shall possess and may exercise all of the powers and privileges
granted to it by applicable Law or this Agreement, together with all powers incidental thereto, so far as such powers are necessary or
convenient to the conduct, promotion or attainment of the purpose of the Company set forth in <U>Section&nbsp;2.6</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties by Additional or Substitute Members</U>. Each Additional Member or Substituted Member (solely
with respect to himself, itself or herself as a condition to becoming an Additional Member or Substituted Member, respectively) upon
becoming a Member in accordance with the terms hereof, hereby represents and warrants to the Company and each other Member as of the
date he, she or its becomes a Member, severally and not jointly, as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>such Member has full power and authority to execute and deliver this Agreement, to become a Member as provided herein and to perform
such Member&rsquo;s obligations hereunder as a Member, and the execution, delivery and performance by such Member hereof has been duly
authorized by all necessary action;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 206; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the applicable documents set forth in <U>Section&nbsp;10.4(a)</U>, in the case of a Substituted Member, or <U>Section&nbsp;11.1(a)</U>,
in the case of an Additional Member, have been duly and validly executed and delivered by such Member and, assuming the due and valid
authorization, execution and delivery by the other parties hereto, constitute the binding obligation of such Member, enforceable against
such Member in accordance with its terms, subject to the Remedies Exception;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the execution and delivery of the Member&rsquo;s applicable joinder and performance by such Member of its obligations hereunder
shall not, with or without the giving of notice or the lapse of time, or both, (i) violate any provision of Law to which such Member is
subject or (ii) conflict with, or result in a breach or default under, any term or condition of such Member&rsquo;s certificate of incorporation
or bylaws, certificate of limited partnership or partnership agreement, certificate of formation or limited liability company agreement
or trust documents, as applicable, or any agreement or other instrument to which such Member is a party, except for any conflict, breach
or default that would not reasonably be expected to, individually or in the aggregate, (a) materially and adversely affect the ability
of such Member to perform or otherwise comply with any of his, her or its covenants, agreements or obligations hereunder and (b) materially
and adversely affect the assets, business, condition or results of operations of the Company and its Subsidiaries (taken as a whole);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No consent of any Authority is required on the part of such Member with respect to its execution or delivery of the Member&rsquo;s
applicable joinder, or performance of such Member&rsquo;s covenants, agreements or obligations under this Agreement or the transactions
contemplated hereby except for any consents the absence of which has not resulted in and would not reasonably be expected to, individually
or in the aggregate, (i) materially and adversely affect the ability of such Member to perform or otherwise comply with any of his, her
or its covenants, agreements or obligations hereunder and (ii) materially and adversely affect the assets, business, condition or results
of operations of the Company and its Subsidiaries (taken as a whole).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>such
Member (i) is acquiring such Member&rsquo;s Membership Interests solely for such Member&rsquo;s own account for investment and not
with a view to resale in connection with any distribution thereof and (ii) may not, directly or indirectly, Transfer any of the
Membership Interests or any interest therein or any rights relating thereto or offer to Transfer, except in compliance with the
Securities Act, applicable state securities or &ldquo;blue sky&rdquo; Laws and this Agreement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>such
Member acknowledges that (i) all Membership Interests currently or ever owned by such Member were&nbsp;issued&nbsp;in a transaction (or
transactions) that was not required to be registered under the Securities Act, (ii) the Membership Interests have not been registered
under the Securities Act or qualified under any state securities or &ldquo;blue sky&rdquo; Laws; (iii) it is not anticipated that there
shall be any public market for the Membership Interest; (iv) the Membership Interest must be held indefinitely and such Member must continue
to bear the economic risk of the investment in the Membership Interest unless the Membership Interests are subsequently registered under
the Securities Act and such state Laws or an exemption from registration is available; (v) Rule 144 promulgated under the Securities
Act (&ldquo;<FONT STYLE="color: windowtext"><U>Rule 144</U></FONT>&rdquo;) is not presently available with respect to sales of any securities
of the Company and the Company has made no covenant to make Rule 144 available and Rule 144 is not anticipated to be available in the
foreseeable future; (vi) if and when the Membership Interests may be disposed of without registration in reliance upon Rule 144, such
disposition can be made, if at all, only in accordance with the terms and conditions of Rule 144 (which may include limitations in the
amount of Membership Interests that may be Transferred) and this Agreement; (vii) if the exemption afforded by Rule 144 is not available,
sale of the Membership Interests without registration shall require the availability of an exemption under the Securities Act; (viii)
restrictive legends shall be placed on any certificate representing the Membership Interests; and (ix) a notation shall be made in the
appropriate records of the Company indicating that the Membership Interests are subject to restrictions on Transfer and, if the Company
should in the future engage the services of a transfer agent, appropriate stop-transfer instructions shall be issued to such transfer
agent with respect to the Membership Interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 207; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>such Member&rsquo;s financial situation is such that such Member can afford to (i) bear the economic risk of holding the Membership
Interests for an indefinite period and (ii)&nbsp;suffer the complete loss of such Member&rsquo;s investment in the Membership Interests;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>such Member (i) is familiar with the business, plans, properties, operations, prospects and financial condition of the Company
and has been granted the opportunity to ask questions of, and receive answers from, representatives of the Company concerning the Company
and the terms and conditions of the acquisition of the Membership Interests and to obtain any additional information that such Member
deems necessary to evaluate whether or not to make an investment in the Company, (ii) has the knowledge and experience in financial and
business matters to be able to evaluate the merits and risk of the investment in the Membership Interests and (iii) has carefully reviewed
the terms hereof and has evaluated the restrictions and obligations herein and therein;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>such
Member (i) has relied upon such Member&rsquo;s own independent appraisal and investigation, and the advice of such Member&rsquo;s
own counsel, tax advisors and other advisors, regarding the risks of an investment in the Company and (ii) shall continue to bear
sole responsibility for making such Member&rsquo;s own independent evaluation and monitoring of the risks of such Member&rsquo;s
investment in the Company;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>such Member is an &ldquo;accredited investor,&rdquo; as such term is defined in Rule 501(a) of Regulation D promulgated under the
Securities Act, and, in connection with the execution hereof, agrees to deliver such certificates to that effect as the Board may request;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 208; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>such Member&rsquo;s place of business or principal residence is as set forth on <U>Schedule&nbsp;I</U>; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>there is no investment banker, broker, finder or other intermediary that has been retained by, or is authorized to act on behalf
of, such Member or any Affiliate of such Member who might be entitled to any fee or commission from the Company in connection with the
transactions contemplated hereby.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;2.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Additional
Representations</U>. Each Member (solely with respect to such Member and including each Additional Member or Substituted Member as a
condition to becoming an Additional Member or Substituted Member, respectively), upon becoming a Member as of the date hereof (in the
case of ARYA Sponsor and Amber GT) or upon becoming a Member in accordance with the terms hereof (in the case of each Additional Member
or Substituted Member), hereby represents and warrants to the Company and each other Member as of the date he, she or it becomes a Member,
severally and not jointly, as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>such Member has not obtained, nor will such Member transfer or assign, any of its Membership Interests (or any interest therein)
or cause any of its Membership Interests (or any interest therein) to be marketed on or through an &ldquo;established securities market&rdquo;
within the meaning of Section 7704(b)(1) of the Code and the Regulations thereunder, or a &ldquo;secondary market,&rdquo; or the substantial
equivalent thereof, within the meaning of Section 7704(b)(2) of the Code and the Regulations thereunder, including an over-the-counter
market or an interdealer quotation system that regularly disseminates firm buy or sell quotations; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the participation of such Member as a Member will not cause the Company to have more than 100 partners (within the meaning of Regulations
section 1.7704-1(h), including the look through rule in Regulations section 1.7704-1(h)(3)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;<U><BR>
CAPITAL CONTRIBUTIONS; MEMBERSHIP INTERESTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Capital Contributions</U>. Each of Amber GT and the Corporation shall, upon its execution and delivery hereof, be admitted as
a Member as of the Closing Date. As of the Closing Date, the Members have made Capital Contributions to the Company in the amounts set
forth on <U>Schedule I</U> (as in effect as of the date hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Membership Interests</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to <U>Section&nbsp;3.2(c)</U>, the Company is authorized to issue one (1) class of Membership Interests: Common Units,
each of which shall be identical. The name and address of, and the class and number of Membership Interests held by, each Member from
time to time shall be as set forth on <U>Schedule&nbsp;I</U>. Following the Closing Date, the Company shall amend <U>Schedule&nbsp;I</U>,
without any further action by the Board of Managers or the Members, to reflect changes in the information intended to be reflected therein
that occur pursuant to, and in accordance with, this Agreement (provided that the Company shall have no obligation to amend Schedule I
to reflect any such change in respect of any Assignee unless and to the extent that the Company receives written notice from the Transferring
Member or any such Assignee with respect to such change). To the fullest extent permitted by applicable Law, (i) except due to any failure
by the Company to amend <U>Schedule I</U> as provided in the immediately preceding sentence, <U>Schedule&nbsp;I</U> shall be the definitive
record of the outstanding Membership Interests, the ownership of each outstanding Membership Interest and all relevant information with
respect to each Member and each Assignee, (ii) any reference herein to <U>Schedule&nbsp;I</U> shall be deemed a reference to <U>Schedule&nbsp;I</U>,
as amended and as in effect from time to time, and (iii) except due to any failure by the Company to amend Schedule I as provided in the
immediately preceding sentence, the Company shall be entitled to recognize the exclusive right of a Person registered on <U>Schedule&nbsp;I</U>
as the owner of the outstanding Membership Interests shown thereon for all purposes and shall not be bound to recognize any equitable
or other claim to or interest in Membership Interests on the part of any other Person, whether or not it shall have express or other notice
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 209; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Initially, the Common Units will be uncertificated. If the Board of Managers determines that it is in the interest of the Company
to issue certificates representing the Common Units, certificates will be issued and the Common Units will be represented by those certificates,
and this Agreement shall be amended as the Board of Managers shall determine is necessary to reflect the issuance of certificated Common
Units. Nothing contained in this <U>Section&nbsp;3.2(b)</U> shall be deemed to authorize or permit any Member to Transfer its Common Units
except as otherwise permitted hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Without
the Consent of any Member but subject to <U>Section 3.2(d)</U> and <U>Section 3.4</U>, the Board of Managers may cause the Company to
issue to any Person, and to admit any such Person that is not a Member as an Additional Member, and for such consideration and on such
terms and conditions as shall be established by the Board of Managers, additional Membership Interests in one (1) or more classes, or
one (1) or more series of any of such classes, with such designations, preferences, conversion or other rights, voting powers, restrictions,
rights to distributions, qualifications and terms and conditions (including rights that may be senior or otherwise entitled to preference
over existing Membership Interests) as shall be determined by the Board of Managers and either set forth in a written document thereafter
attached to and made an exhibit hereto, which exhibit shall be an amendment hereto and shall be incorporated herein by this reference,
or by amending and restating this Agreement to give effect to such classes or series of Membership Interests (each, a &ldquo;<U>Membership
Interest Designation</U>&rdquo;); <U>provided</U>, <U>however</U>, that, if there are any Non-Corporation Members at such time, without
the prior Consent of a Majority in Interest of the Non-Corporation Members, no such new class or series of Membership Interests shall
deprive such Non-Corporation Members of, or dilute or reduce, the pro rata share of all Membership Interests such Non-Corporation Members
would have received or to which they would have been entitled if such new class or series of Membership Interests had not been created,
except to the extent that the Company actually receives cash or other property or assets with a Fair Market Value (net of fees and expenses
incurred in connection with such issuance) in an aggregate amount, equal to the pro rata share of Membership Interests allocated to such
new class or series of Membership Interests and the number thereof issued by the Company, in each case, as determined by the Board of
Managers; <U>provided</U>, that this proviso shall not apply to a new class or series of Membership Interests that will be issued only
to Persons providing services to the Parent Corporation Group, the Company or any of their Controlled Entities and that are intended
to be classified as &ldquo;profits interests&rdquo; pursuant to IRS Revenue Procedure 93-27 or any other new class or series of Membership
Interests issued to the Parent Corporation Group in respect of any equity securities of the Parent Corporation Group issued under any
Equity Plan. Without limiting the foregoing, the Board of Managers is expressly authorized to cause the Company to issue Membership Interests
(i) upon the conversion, redemption or exchange of any Debt, Membership Interests or other securities issued by the Company, (ii) for
less than Fair Market Value, (iii) in connection with any merger of any other Person into the Company or any similar transaction or (iv)
upon the contribution of property or assets to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 210; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary herein, the Company shall not issue Membership Interests to any member of the Parent Corporation
Group, except in connection with any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>subject
to any Membership Interest Designation, the issuance of Membership Interests to all Members then holding Common Units, pro rata in accordance
with their respective Percentage Interests;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the issuance of (A) Common Units in connection with a corresponding issuance of Class A Shares or (B) Equivalent Units (other than
Common Units) issued in connection with an issuance of Capital Shares or New Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the issuance of Common Units or other Membership Interests in accordance with <U>Section&nbsp;3.5</U>, <U>Section&nbsp;3.6</U>
or <U>Section&nbsp;3.8</U>; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the issuance of Membership Interests upon the conversion, redemption or exchange of Debt, Membership Interests or other securities
issued by the Company to such member of the Parent Corporation Group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as expressly provided herein or in any Membership Interest Designation, no Person, including any Member, shall have any
preemptive, preferential, participation or similar right or rights to subscribe for or acquire any Membership Interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Capital
Contributions of, or Loans by, the Members</U>. Other than in connection with the issuance of additional Membership Interests to any
Member and except as otherwise provided by applicable Law, the Members shall have no obligation or, except with the prior written consent
of the Board of Managers, right to make any other Capital Contributions or any loans to the Company; <U>provided</U> that any such loan
to the Company shall not be considered a Capital Contribution. No Member shall be entitled to withdraw any part of such Member&rsquo;s
Capital Contribution or Capital Account or, except as expressly provided herein, to receive any distribution from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 211; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Common Unit to Class A Share Ratio</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The parties hereto acknowledge and agree that this Agreement intends to maintain at all times a one (1)-to-one (1) ratio between
(i) the number of outstanding Common Units owned by members of the Parent Corporation Group (in the aggregate) and (ii) the number of
outstanding Class A Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Notwithstanding
anything to the contrary herein and without the Consent of any other Member, if the Corporation effects a reclassification, subdivision,
combination or cancellation of the outstanding Class A Shares (including a subdivision effected by the Corporation declaring and paying
a dividend of Class A Shares on outstanding Class A Shares), the number of outstanding Common Units shall automatically be reclassified,
subdivided, combined or cancelled in the same manner such that, after giving effect to such reclassification, subdivision, combination
or cancellation, the number of outstanding Common Units owned by the members of the Parent Corporation Group shall equal, on a one (1)-for-one
(1) basis, the number of outstanding Class A Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company shall not undertake any subdivision (by any Common Unit split, Common Unit distribution, reclassification, recapitalization or
similar event) or combination (by reverse Common Unit split, reclassification, recapitalization or similar event) of outstanding Common
Units owned by any member of the Parent Corporation Group that is not accompanied by an correlative reclassification, subdivision, combination
or cancellation of outstanding Class A Shares in order to maintain at all times a one (1)-to-one (1) ratio between (i) the number of
Common Units owned by members of the Parent Corporation Group (in the aggregate) and (ii) the number of outstanding Class A Shares, unless
such reclassification, subdivision, combination or cancellation is necessary to maintain at all times a one (1)-to-one (1) ratio between
the number of Common Units owned by members of the Parent Corporation Group (in the aggregate) and the number of outstanding Class A
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary herein and without the Consent of any other Member, if at any time, any Class A Shares
are redeemed, repurchased or otherwise acquired by the Corporation then, immediately prior to such redemption, repurchase or acquisition
of Class A Shares, the Company shall redeem a number of Common Units held by the Corporation equal to the quotient of (i)&nbsp;the number
of Class A Shares so redeemed, repurchased or acquired, <U>divided by</U> (ii)&nbsp;the Adjustment Factor then in effect, such redemption,
repurchase or acquisition to be (A) for the same price per Common Unit (after giving effect to application of the Adjustment Factor) as
such Class A Shares are redeemed, repurchased or acquired and (B) on substantially similar terms, in the aggregate, as the redemption,
repurchase or acquisition of such Class A Shares, unless, in the case of this clause (B), as determined by the Board of Managers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 212; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Corporation shall not issue any additional Common Shares, Capital Shares or New Securities unless the Corporation contributes the net
cash proceeds or other net consideration received (for the avoidance of doubt, after taking into account or otherwise deducting for any
Discounts) from the issuance of such additional Common Shares or Capital Shares, or in the case of New Securities, the exercise or settlement
thereof (as the case may be) as a Capital Contribution and in exchange for (i) in the case of an issuance of Class A Shares, a number
of Common Units equal to the quotient of (1) the number of such issued Class A Shares, <U>divided by</U> (2) the Adjustment Factor then
in effect and (ii) in the case of an issuance of Capital Shares or New Securities, a number of Equivalent Units that correspond to the
class or series of such issued Capital Shares or New Securities; <U>provided</U>, <U>however</U>, that, notwithstanding the foregoing,
the Corporation may issue Common Shares, Capital Shares or New Securities (1) pursuant to <U>Section&nbsp;3.5</U>, <U>Section&nbsp;3.6</U>,
<U>Section&nbsp;4.2(b)</U> or <U>Section&nbsp;13.1(b)</U>, (2) pursuant to a dividend or distribution (including any stock split) of
Common Shares, Capital Shares or New Securities to all of the holders of the applicable class or series of Common Shares, Capital Shares
or New Securities (as the case may be), (3) upon a conversion, redemption, exchange or exercise of Capital Shares or of New Securities
or (4) in connection with an acquisition of Common Units or a property or other asset to be owned, directly or indirectly, by a member
of the Parent Corporation Group, in each case, solely to the extent permitted hereby and in accordance herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Equity Plans</U>.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Options Granted to Persons other than Company Employees</U>. If at any time or from time to time, in connection with any
Equity Plan, an option to purchase Class&nbsp;A Shares granted to a Person other than a Company Employee is duly exercised, the following
events will be deemed to have occurred:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>as
soon as practicable after such exercise, the Corporation shall make a Capital Contribution to the Company in an amount equal to the net
exercise price received by the Corporation from such exercising party in connection with the exercise of such stock option;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>notwithstanding the amount of the Capital Contribution actually made pursuant to <U>Section&nbsp;3.5(a)(i)</U>, the Corporation
shall be deemed to have contributed to the Company as a Capital Contribution an amount equal to the Value of a Class&nbsp;A Share as of
the date of exercise, <U>multiplied by</U> the number of Class&nbsp;A Shares issued in connection with the exercise of such stock option;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in exchange for such Capital Contribution, the Company shall issue a number of Common Units to the Corporation equal to the quotient
of (1)&nbsp;the number of Class&nbsp;A Shares issued in connection with the exercise of such stock option, <U>divided by</U> (2)&nbsp;the
Adjustment Factor then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 213; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Options Granted to Company Employees</U>. If at any time or from time to time, in connection with any Equity Plan, an
option to purchase Class&nbsp;A Shares granted to a Company Employee is duly exercised, the following events will be deemed to have occurred:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Corporation shall sell to the Company, and the Company shall purchase from the Corporation, the number of Class&nbsp;A Shares as to which
such stock option is being exercised, with the purchase price per Class&nbsp;A Share for such sale of Class&nbsp;A Shares to the Company
being the Value of a Class&nbsp;A Share as of the date of exercise of such stock option;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Company shall sell to the Optionee (or if the Optionee is an employee of a Controlled Entity of the Company, the Company shall sell to
such Controlled Entity, which in turn shall sell to the Optionee), for a cash price per share equal to the Value of a Class A Share as
of the date of exercise, the number of Class A Shares so exercised equal to (1) the exercise price paid to the Corporation by the exercising
party in connection with the exercise of such stock option <U>divided by</U> (2) the Value of a Class A Share at the time of such exercise;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Company shall transfer to the Optionee (or if the Optionee is an employee of a Controlled Entity of the Company, the Company
shall transfer to such Controlled Entity, which in turn shall transfer to the Optionee) at no additional cost, as additional compensation,
the number of Class A Shares equal to the number of Class A Shares described in <U>Section&nbsp;3.5(b)(i)</U> less the number of Class
A Shares described in <U>Section&nbsp;3.5(b)(ii)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>as soon as practicable after such exercise, the Corporation shall make a Capital Contribution to the Company of an amount equal
to all net proceeds received (from whatever source, but excluding any payment in respect of payroll taxes or other withholdings) by the
Corporation in connection with the exercise of such stock option; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> in exchange for such Capital Contribution, the Company shall issue a number of Common Units to the Corporation equal to the quotient
of (1) the number of Class A Shares issued in connection with the exercise of such stock option, <U>divided by</U> (2) the Adjustment
Factor then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Class A Shares Issued to Company Employees Under Equity Plans</U>. If at any time or from time to time, in connection
with any Equity Plan (other than in respect of the exercise of a stock option), any Class A Shares are issued to a Company Employee (including
any Class A Shares that are subject to forfeiture in the event specified vesting conditions are not achieved and any Class A Shares issued
in settlement of a restricted stock unit or similar award) in consideration for services performed for the Company or a Controlled Entity
of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 214; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Corporation shall issue such number of Class A Shares as are to be issued to the Company Employee in accordance with the Equity
Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the following events will be deemed to have occurred: (1) the Corporation shall be deemed to have sold such shares to the Company
(or if the Company Employee is an employee of a Controlled Entity of the Company, to such Controlled Entity) for a purchase price equal
to the Value of such shares, (2) the Company (or such Controlled Entity) shall be deemed to have delivered the shares to the Company Employee,
(3) the Corporation shall be deemed to have contributed the purchase price to the Company as a Capital Contribution, and (4) in the case
where the Company Employee is an employee of a Controlled Entity of the Company, the Company shall be deemed to have contributed such
amount to the capital of such Controlled Entity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Company shall issue to the Corporation a number of Common Units equal to the number of newly issued Class A Shares <U>divided by</U>
the Adjustment Factor then in effect in consideration for the deemed Capital Contribution described in <U>Section&nbsp;3.5(c)(ii)(3)</U>;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to the extent such Class A Shares were issued to a Person subject to vesting or forfeiture in the event that the vesting conditions
are not achieved or are incapable of being achieved or such Class A Shares are forfeited or otherwise repurchased for no consideration
by the Parent Corporation Group, as applicable, the actions described in clauses <U>(i)</U>, <U>(ii)</U> and <U>(iii)</U> shall be reversed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Other
Class A Shares Issued to Persons other than Company Employees Under Equity Plans</U>. If at any time or from time to time, in
connection with any Equity Plan (other than in respect of the exercise of a stock option), any Class A Shares are issued to a Person
other than a Company Employee (including any Class A Shares that are subject to forfeiture in the event specified vesting conditions
are not achieved or are incapable of being achieved and any Class A Shares issued in settlement of a restricted stock unit or
similar award) in consideration for services performed for the Corporation, the Company or any Affiliates of any of the foregoing,
the following events will be deemed to occur:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Corporation shall issue such number of Class A Shares as are to be issued to such Person in accordance with the Equity Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
Corporation shall be deemed to have contributed the Value of such Class A Shares to the Company as a Capital Contribution, and the Company
shall issue to the Corporation a number of newly issued Common Units equal to the number of newly issued Class A Shares <U>divided by
</U>the Adjustment Factor then in effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 215; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to the extent such Class A Shares were issued to a Person subject to vesting or forfeiture in the event that the vesting conditions
are not achieved or are incapable of being achieved or such Class A Shares are forfeited or otherwise repurchased for no consideration
by the Parent Corporation Group, as applicable, the actions described in clauses <U>(i)</U> and <U>(ii)</U> shall be reversed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Future Stock Incentive Plans</U>. Nothing herein shall be construed or applied to preclude or restrain the Corporation or any
other member of the Parent Corporation Group from adopting, modifying or terminating any stock or equity incentive plan for the benefit
of employees, officers, directors of or other service providers to the Corporation, the Company or any of their Affiliates. The Members
acknowledge and agree that, in the event that any such plan is adopted, modified or terminated by the Corporation, the Board of Managers
shall have the power, without the Consent of the Members or any further act of the Members, to amend this <U>Section&nbsp;3.5</U> as it
deems necessary or advisable to implement the terms and conditions of any such plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Issuance of Common Units</U>. The Company is expressly authorized to issue Common Units in the numbers specified in this <U>Section&nbsp;3.5</U>
without any further act or Consent of any Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Incentive Plan or Other Plan</U>. Except as may otherwise be provided in this <U>Article&nbsp;III</U>, the net proceeds
received by the Corporation in respect of any stock incentive or other stock or subscription plan or agreement, either (a)&nbsp;shall
be utilized by the Corporation to effect open market purchases of Class&nbsp;A Shares or (b) if the Corporation elects instead to issue
new Class&nbsp;A Shares with respect to such amounts, shall be contributed to the capital of the Company in exchange for a number of additional
Common Units equal to the number of newly issued Class A Shares <U>divided by</U> the Adjustment Factor then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>No
Interest; No Return</U>. No Member shall be entitled to interest on its Capital Contribution or on such Member&rsquo;s Capital
Account. Except as provided herein or by law, no Member shall have any right to demand or receive the return of its Capital
Contribution from the Company.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Conversion or Redemption of Class A Shares or Capital Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If, at any time, any Capital Shares are converted into Class A Shares, in whole or in part, then an equal number of Equivalent
Units held by the applicable member of the Parent Corporation Group that correspond to the class or series of Capital Shares so converted
shall automatically be converted or exchanged into a number of Common Units equal to the quotient of (i) the number of Class A Shares
issued upon such conversion, <U>divided by</U> (ii) the Adjustment Factor then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 216; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If, at any time, any Capital Shares are redeemed, repurchased or otherwise acquired (whether by exercise of a put or call, automatically
or by means of another arrangement) by the Corporation for cash, then, immediately prior to such redemption, repurchase or acquisition
of Capital Shares, the Company shall redeem an equal number of Equivalent Units held by the Corporation that correspond to the class or
series of Capital Shares so redeemed, repurchased or acquired (A)&nbsp;for the same price per Equivalent Unit (after giving effect to
application of any adjustment factor thereof set forth in a Membership Interest Designation) as such Capital Shares are redeemed, repurchased
or acquired and (B)&nbsp;on substantially similar terms, in the aggregate, as the redemption, repurchase or acquisition of such Capital
Shares, unless, in the case of this clause (B), as determined by the Board of Managers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, at any time, any Class A Shares are redeemed, repurchased or otherwise
acquired by the Corporation (whether upon forfeiture of any award granted under any Equity Plan, automatically or by means of another
arrangement), then, immediately prior to such redemption, repurchase or acquisition of Class A Shares, the Company shall redeem a number
of Common Units held by the Corporation equal to the quotient of (i) the number of Class A Shares so redeemed, repurchased or acquired,
<U>divided by</U> (ii) the Adjustment Factor then in effect, such redemption, repurchase or acquisition to be (A)&nbsp;for the same price
per Common Unit (after giving effect to application of the Adjustment Factor) as such Class A Shares are redeemed, repurchased or acquired
and (B)&nbsp;on substantially similar terms, in the aggregate, as the redemption, repurchase or acquisition of such Class A Shares, unless,
in the case of this clause (B), as determined by the Board of Managers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;3.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Capital
Accounts</U>. <FONT STYLE="color: black">A separate capital account (a &ldquo;</FONT><FONT STYLE="color: windowtext"><U>Capital
Account</U></FONT><FONT STYLE="color: black">&rdquo;) shall be established and maintained for each Member in accordance with the
requirements of Treasury Regulations Section 1.704-1(b)(2)(iv). Each Member&rsquo;s Capital Account (a) shall be increased by (i)
the amount of money contributed by such Member to the Company, (ii) the initial Fair Market Value of property contributed by such
Member to the Company (net of liabilities secured by the contributed property that the Company is considered to assume or take
subject to under Code Section 752) and (iii) allocations to such Member of Net Profits pursuant to <U>Section&nbsp;6.1</U> and any
other items of income or gain allocated to such Member pursuant to <U>Section&nbsp;6.2</U> and (b) shall be decreased by (i) the
amount of money distributed to such Member by the Company, (ii) the Fair Market Value of property distributed to </FONT>such Member
by the Company (net of liabilities secured by the distributed property that such Member is considered to assume or take subject to
under Code Section 752), and (iii) allocations to such Member of Net Losses pursuant to <FONT STYLE="color: black"><U>Section&nbsp;6.1</U>
and any other items of loss or deduction allocated to such Member pursuant to <U>Section&nbsp;6.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 217; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;IV</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>DISTRIBUTIONS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Requirement
and Characterization of Distributions</U>. Subject to, for the avoidance of doubt, the terms of any Membership Interest Designation,
distributions shall be made at such times and in such amounts as the Board of Managers may determine to the Members in accordance with
their respective Percentage Interests on such Company Record Date. The Corporation shall not distribute any amounts in respect of Class
A Shares or Capital Shares in excess of the Corporation&rsquo;s share of distributions from the Company without the Consent of a Majority
in Interest of the Non-Corporation Members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Distributions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>To
enable the Members (or their direct or indirect beneficial owners) to pay taxes on income of the Company or its Subsidiaries that is
taxable to the Members (or such owners), the Company shall, at the Board of Manager&rsquo;s discretion, make, to the extent that
funds are legally available therefor and would not be prohibited under any credit facility to which the Company or any Subsidiary
thereof is a party, cash distributions to the Members, during each Fiscal Year, pro rata among the Members based on their Percentage
Interests (each, a &ldquo;<FONT STYLE="color: windowtext"><U>Tax Distribution</U></FONT>&rdquo;), in an aggregate amount equal to
the greater of (i) the minimum amount necessary so that the Parent Corporation Group receives, in the aggregate, at least an amount
equal to its Assumed Tax Liability for the Fiscal Year or (ii) the minimum amount necessary so that each Non-Corporation Member
receives at least an amount equal to the product of (1) the highest aggregate rate of federal, state, and local income tax imposed
on any Member with respect to the Company&rsquo;s income for that Fiscal Year (taking into account the deductibility of state and
local income taxes for federal income tax purposes), <U>multiplied by</U> (2) the amount of the taxable income of the Company
allocated to such Non-Corporation Member for that Fiscal Year (including income includible with respect to the Company or any of the
Company&rsquo;s Subsidiaries by such Member or any of its direct or indirect beneficial owners by reason of Section 951, 951A or 956
of the Code or otherwise pursuant to subpart F of Part III of the Code, but excluding income recognized by such Non-Corporation
Member (or any of its direct or indirect beneficial owners) with respect to the issuance or vesting of such Member&rsquo;s Units).
Tax Distributions shall be paid at least quarterly during each Fiscal Year at times that coincide with the corporate Members&rsquo;
payment of estimated taxes, and the amount of each distribution shall be based upon the anticipated taxable income of the Company
for the Fiscal Year of the distribution and the anticipated amount of payments under the Tax Receivable Agreement for the Fiscal
Year of the distribution. For purposes of determining whether sufficient Tax Distributions have been made pursuant to this <U>Section&nbsp;4.2</U>
with respect to a Fiscal Year, all distributions made by the Company with respect to such Fiscal Year shall be treated as Tax
Distributions until the full amount of Tax Distributions is paid with respect to such Fiscal Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 218; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the extent any Tax Distribution to a member of the Parent Corporation Group is not ultimately used by the Parent Corporation
Group to pay a Tax liability (or to the extent used by the Parent Corporation Group to pay a Tax liability but ultimately refunded to
the Parent Corporation Group by the applicable taxing authority) or to make a payment under the Tax Receivable Agreement, such member
of the Parent Corporation Group may, in its sole discretion, elect to (i) distribute such excess cash amounts to the Corporation (as applicable)
to be distributed by the Corporation to the shareholders of the Corporation, (ii) contribute such excess cash amounts to the Company in
exchange for a number of Common Units or other equity securities of the Company on a value-for-value basis, and cause the Corporation
to distribute Class A Shares to the holders of Class A Shares (if the Company issues Common Units to such member of the Parent Corporation
Group) or such other equity securities of the Corporation (if the Company issues equity securities of the Company other than Common Units)
corresponding to the equity securities issued by the Company and with substantially the same rights to dividends and distributions, or
(iii) retain such excess cash amount. Notwithstanding clause&nbsp;(a) of the definition of Adjustment Factor, no adjustment shall be made
to the Adjustment Factor solely by reason of a distribution by the Corporation of Class A Shares or other equity securities made pursuant
to this <U>Section&nbsp;4.2(b)</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Distributions in Kind</U>. No Member may demand to receive property in connection with any distribution or other payment in
respect of Membership Interests, except, in the case of the Non-Corporation Members, in the circumstances provided in, and otherwise on
the terms and subject to the conditions of, <U>Article&nbsp;XIII</U>. The Board of Managers may cause the Company to make a distribution
in kind of the Company&rsquo;s assets to the Members, and such assets shall be distributed to the Members in such a fashion as to ensure
that the Fair Market Value is distributed and allocated in accordance with <U>Article IV</U> and <U>Article V</U>. If the Company distributes
property in kind that was contributed to the Company by a Member (or deemed contributed by a Member, for tax purposes, or received in
a tax-deferred exchange for property contributed or so deemed contributed to the Company by a Member), the Company shall use commercially
reasonable efforts to cause such property to be distributed to the Member who contributed such property (or was deemed to contribute such
property), to the extent that such Member is otherwise entitled to receive such a distribution at such time, in accordance with the immediately
foregoing sentence and the other provisions herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Distributions upon Liquidation</U>. Notwithstanding the other provisions of this <U>Article&nbsp;IV</U>, upon the occurrence
of a Liquidating Event, the assets of the Company shall be distributed to the Members in accordance with <U>Section&nbsp;12.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Distributions
to Reflect Additional Membership Interests</U>. If the Company issues additional Membership Interests pursuant to the provisions of <U>Article&nbsp;III</U>,
subject to the rights of any Member set forth in a Membership Interest Designation, the Board of Managers is hereby authorized to
make such revisions to this <U>Article&nbsp;IV</U> and to <U>Article&nbsp;V</U> as it determines are necessary or desirable to
reflect the issuance of such additional Membership Interests, including making preferential distributions to certain classes of
Membership Interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 219; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restricted Distributions</U>. Notwithstanding anything to the contrary herein, neither the Company nor the Board of Managers,
on behalf of the Company, shall make a distribution to any Member if such distribution would violate applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rounding</U>. All distributions payable under this <U>Article&nbsp;IV</U> shall be rounded to the nearest cent, with one-half
cent rounded downward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;4.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Special
Distributions to Facilitate Acquisitions</U>. Notwithstanding any other provision herein to the contrary, the Board of Managers
shall be permitted to cause a distribution, loan or other transfer of cash by the Company or one or more of its Controlled Entities
to be made solely to one or more member(s) of the Parent Corporation Group (such distribution, loan or other transfer satisfying the
following proviso, an &ldquo;<FONT STYLE="color: windowtext"><U>M&amp;A Distribution</U></FONT>&rdquo;), <U>provided</U>, <U>however </U>that
(a) each such distribution, loan or other transfer is (i) made at or following such time as the Board of Managers reasonably
determines that a specific transaction or series of transactions providing for the direct or indirect acquisition or similar
transaction of any entity, business(es), assets, properties or rights (whether by merger, consolidation, recapitalization, sale,
transfer or license of assets, properties or rights, purchase or issuance of equity securities, tender offer or otherwise) (an
 &ldquo;<U>M&amp;A Event</U>&rdquo;) is reasonably likely to be consummated by the applicable member of the Parent Corporation Group
(including, for the avoidance of doubt, at any time at or after the signing of any definitive transaction agreement) and (ii) used
solely to facilitate the consummation of such M&amp;A Event or otherwise in connection with such M&amp;A Event (including for the
purpose of paying any consideration (whether at the closing thereof or otherwise (including any contingent or deferred consideration
paid or payable following the closing thereof)) , and (b) the applicable member of the Parent Corporation Group (i) contributes (in
the case of an M&amp;A Distribution that was a distribution), (ii) transfers in repayment of the applicable M&amp;A Distribution
that was a loan (with any interest accrued thereon for the benefit of the Company) or (iii) sells solely in exchange for the
applicable previously made M&amp;A Distribution that was not a distribution or a loan, or causes to be contributed (in the case of
an M&amp;A Distribution that was a distribution), transferred in repayment of the applicable M&amp;A Distribution that was a loan,
or sold solely in exchange for the applicable previously made M&amp;A Distribution that was not a distribution or a loan, as soon as
practicable thereafter, to the Company or the applicable Controlled Entities of the Company, the entity, business(es), assets,
properties or rights directly or indirectly acquired with such distribution, loan or other transfer, as directed by the Board of
Managers. If the M&amp;A Distribution is not used solely to facilitate the consummation of or otherwise in connection with such
M&amp;A Event in accordance with the foregoing clause&nbsp;(a) within the time specified therefor by the Board of Managers, the
applicable member of the Parent Corporation Group will contribute (in the case of an M&amp;A Distribution that was a distribution),
transfer in repayment of the applicable M&amp;A Distribution that was a loan, or retransfer (in the case of an M&amp;A Distribution
that was not a distribution or a loan) the amount of such M&amp;A Distribution unspent or not otherwise utilized in connection with
such M&amp;A Event and, in the case of an M&amp;A Distribution that was a loan, any interest accrued on the amount being transferred
to the Company pursuant to this sentence to the Company or the applicable Controlled Entities of the Company at or prior to 5:00 pm
New York time on the applicable date. During any time period between the time of the M&amp;A Distribution and the contribution,
repayment or sale contemplated by the foregoing clause&nbsp;(b) of the immediately foregoing sentence, the applicable member of the
Parent Corporation Group shall hold such cash, and operate any acquired assets, properties or rights, for the benefit of the Company
or the applicable Controlled Entity thereof. The number of Common Units held the Members shall not change as a result of any M&amp;A
Distribution or the re-contribution, repayment or retransfer of such M&amp;A Distribution (together with any interest accrued
thereon) or contribution, repayment or sale of any assets directly or indirectly acquired with such M&amp;A Distribution, in each
case as described in this <U>Section&nbsp;4.8</U>. For the avoidance of doubt, neither an M&amp;A Distribution nor the
re-contribution, repayment or retransfer of such M&amp;A Distribution (together with any interest accrued thereon) or contribution,
repayment or sale of any entity, business(es), assets, properties or rights directly or indirectly acquired with such M&amp;A
Distribution shall have any effect on the Adjustment Factor or any other distribution or payment contemplated by this Agreement. For
purposes of all computations required hereunder, the amount of any M&amp;A Distribution that has not been repaid to the Company or
the applicable Controlled Entities of the Company (including, to the extent an acquisition has been consummated with the proceeds of
such M&amp;A Distribution but the assets so acquired have not yet been contributed, repaid or sold to the Company or the applicable
Controlled Entities of the Company as required hereby, the value of the assets so acquired) shall be treated as an asset owned by
the Company or the applicable Controlled Entities of the Company and not by the applicable member of the Parent Corporation Group.
For the avoidance of doubt, to the extent that any fees, costs or expenses are incurred or otherwise payable by the Parent
Corporation Group in connection with or related to the evaluation, negotiation, performance or execution or consummation of an
M&amp;A Event described in this <U>Section&nbsp;4.8</U>, such fees, costs and expenses will be subject to the payment and
reimbursement provisions in <U>Section&nbsp;6.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 220; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;V</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>ALLOCATIONS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Allocations
of Net Profits and Net Loss of the Company</U>. Subject to <U>Section&nbsp;5.2</U> and <U>Section&nbsp;5.3</U>, the Net Profits and
Net Losses of the Company for each Fiscal Year or other applicable period, and in the event of a liquidation or dissolution of the
Company, shall be allocated among the Members in a manner such that the Capital Account of each such Member, immediately after
giving effect to such allocation, is, as nearly as possible, equal (proportionately) to the amount of the distributions that would
be made to such Member during such Fiscal Year or other applicable period if (a) the Company were dissolved and terminated; (b) its
affairs were wound up and each Company asset was sold for cash equal to its Gross Asset Value; (c) all Company liabilities were
satisfied (limited with respect to each nonrecourse liability to the Gross Asset Value of the assets securing such liability); and
(d) the net assets of the Company were distributed in accordance with <U>Section&nbsp;12.3</U> to such Members immediately after
giving effect to such allocation, minus such Member&rsquo;s share of Company Minimum Gain and Member Minimum Gain, computed
immediately prior to the hypothetical sale of the Company&rsquo;s assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Special Allocations</U>. The following special allocations shall be made in the following order prior to any allocations under
<U>Section&nbsp;5.1</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Minimum Gain Chargeback</U>. Except as otherwise provided in Regulations section 1.704-2(f), notwithstanding any other
provision of this <U>Article&nbsp;V</U>, if there is a net decrease in Company Minimum Gain during any Fiscal Year, each Member shall
be specially allocated items of Company income and gain for such Fiscal Year (and, if necessary, subsequent Fiscal Years) in an amount
equal to such Member&rsquo;s share of the net decrease in Company Minimum Gain, determined in accordance with Regulations section 1.704-2(g).
Allocations pursuant to the previous sentence shall be made in proportion to the respective amounts required to be allocated to each
Member pursuant thereto. The items to be so allocated shall be determined in accordance with Regulations sections 1.704-2(f)(6)&nbsp;and
1.704-2(j)(2). This <U>Section&nbsp;5.2(a)</U>&nbsp;is intended to comply with the partnership minimum gain chargeback requirement in
Regulations section 1.704-2(f)&nbsp;and shall be interpreted and applied consistently therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Member Minimum Gain Chargeback</U>. Except as otherwise provided in Regulations section 1.704-2(i)(4), notwithstanding any other
provision of this <U>Article&nbsp;V</U> if there is a net decrease in Member Minimum Gain attributable to a Member Nonrecourse Debt during
any Fiscal Year, any Member with a share of that Member Minimum Gain attributable to such a Member Nonrecourse Debt (as determined under
Regulations section 1.704-2(i)(5)) as of the beginning of the year shall be allocated items of Company income and gain for such Fiscal
Year (and, if necessary, subsequent Fiscal Years) in an amount equal to such Member&rsquo;s share of the net decrease in Member Minimum
Gain, determined in accordance with Regulations section 1.704-2(i)(4). Allocations pursuant to the previous sentence shall be made in
proportion to the respective amounts required to be allocated to each Member pursuant thereto. The items to be so allocated shall be determined
in accordance with Regulations sections 1.704-2(f)(6) and 1.704-2(j)(2). This <U>Section&nbsp;5.2(b)</U> is intended to comply with the
partner minimum gain chargeback requirements in the Regulations and shall be interpreted and applied consistently therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Qualified Income Offset</U>. In the event any Member unexpectedly receives any adjustments, allocations or distributions described
in Regulations sections 1.704-1(b)(2)(ii)(d)(4), (5), or (6), items of Company income and gain shall be specially allocated to such Member
in an amount and manner sufficient to eliminate, to the extent required by the Regulations, the Adjusted Capital Account Deficit as quickly
as possible; <U>provided</U>, <U>however</U>, that an allocation pursuant to this <U>Section&nbsp;5.2(c)</U> shall be made only if and
to the extent that such Member would have an Adjusted Capital Account Deficit after all other allocations provided in this <U>Article&nbsp;V</U>
have been tentatively made as if this <U>Section&nbsp;5.2(c)</U> were not in this Agreement. This <U>Section&nbsp;5.2(c)</U> is intended
to comply with the qualified income offset provision in Regulations section 1.704-1(b)(2)(ii)(d) and shall be interpreted and applied
consistently therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Gross Income Allocation</U>. In the event any Member has a deficit Capital Account at the end of any Fiscal Year that is in
excess of the amount that such Member is deemed to be obligated to restore pursuant to the penultimate sentences of Regulations sections
1.704-2(g)(1) and 1.704-2(i)(5), each such Member shall be specially allocated items of Company income and gain in an amount and manner
sufficient to eliminate such deficit as quickly as possible; <U>provided</U>, <U>however</U>, that an allocation pursuant to this <U>Section&nbsp;5.2(d)</U>
shall be made only if and to the extent that such Member would have a deficit Capital Account in excess of such sum after all other allocations
provided in this <U>Article&nbsp;V</U> have been tentatively made as if <U>Section&nbsp;5.2(c)</U> and this <U>Section&nbsp;5.2(d)</U>
were not herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 221; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonrecourse Deductions</U>. Nonrecourse Deductions for any Fiscal Year shall be specially allocated among the Members pro rata
in accordance with each Member&rsquo;s relative share of Net Profits or Net Loss, as applicable, for such Fiscal year and each Member&rsquo;s
share of excess Nonrecourse Debt shall be allocated in the same manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Member Nonrecourse Deductions</U>. Member Nonrecourse Deductions for any Fiscal Year shall be specially allocated to the Member
who bears the economic risk of loss with respect to the Member Nonrecourse Debt to which such Member Nonrecourse Deductions are attributable
in accordance with Regulations section 1.752-2. If more than one Member bears the economic risk of loss for a Member Nonrecourse Debt,
any Member Nonrecourse Deductions attributable to that Member Nonrecourse Debt shall be allocated among the Members according to the ratio
in which they bear the economic risk of loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Code Section&nbsp;754 Adjustments</U>. To the extent an adjustment to the adjusted tax basis of any Company asset pursuant to
Sections 734(b) or 743(b) of the Code is required, pursuant to Regulations sections 1.704-1(b)(2)(iv)(m)(2) or (4), to be taken into account
in determining Capital Accounts, the amount of such adjustment to the Capital Accounts shall be treated as an item of gain (if the adjustment
increases the basis of the asset) or loss (if the adjustment decreases such basis), and such gain or loss shall be specially allocated
to the Members in a manner consistent with the manner in which their Capital Accounts are required to be adjusted pursuant to such Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Curative
Allocations</U>. The allocations set forth in <U>Section&nbsp;5.2(a)</U>&ndash;<U>(f)</U> (the &ldquo;<FONT STYLE="color: windowtext"><U>Regulatory
Allocations</U></FONT>&rdquo;) are intended to comply with certain requirements of the Regulations. It is the intent of the Members that,
to the extent possible, all Regulatory Allocations shall be offset either with other Regulatory Allocations or with special allocations
of other items of Company income, gain, loss or deduction pursuant to this <U>Section&nbsp;5.3</U>. Therefore, notwithstanding any other
provision hereof, the Regulatory Allocations shall be taken into account in allocating items of Company income, gain, loss and deduction
among the Members so that, to the extent possible, the net amount of such allocations of other items and the Regulatory Allocations to
each Member shall be equal to the net amount that would have been allocated to each such Member pursuant to <U>Section&nbsp;5.1</U> if
the Regulatory Allocations had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Allocations</U>. The Members shall cause income, gain, loss and deductions (including any depreciation and/or cost recovery deductions)
attributable to property contributed by a Member or revalued by the Company to be allocated among the Members for income tax purposes
in accordance with Section 704(c) of the Code and Regulations promulgated thereunder using the traditional method as described in Regulations
section 1.704-3(b). The Company shall make curative allocations of the resulting tax gain or loss from the sale or disposition of any
property in a manner that is intended to offset the effect of the cumulative amount of any &ldquo;ceiling rule limitations&rdquo; with
respect to allocations of depreciation or amortization deductions in respect of such property in the current and all prior Fiscal Years,
as outlined in Treasury Regulations&nbsp;Section&nbsp;1.704-3(c)(3). Allocations pursuant to this <U>Section&nbsp;5.4</U> shall be made
in such manner and utilizing such permissible tax elections as reasonably determined by the Board of Managers. Allocations pursuant to
this <U>Section&nbsp;5.4</U> are solely for purposes of United States federal, state, and local tax purposes and shall not affect, or
in any way be taken into account in computing, any Member&rsquo;s Capital Account or share of items of income, gain, loss and deduction.
The Members are aware of the tax consequences of the allocations made by this <U>Section&nbsp;5.4</U> and agree to be bound by the provisions
of this <U>Section&nbsp;5.4</U> in reporting their shares of items of Company income, gain, loss and deduction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 222; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliance
with Section 704(b) of the Code</U>. The allocation provisions contained in this <U>Article&nbsp;V</U> are intended to comply with Section
704(b) of the Code and the Regulations promulgated thereunder, and shall be interpreted and applied in a manner consistent therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Consent
of Partners.</U> The allocation methods of items of income, gain, loss and deduction contained in this <U>Article&nbsp;V</U> are hereby
expressly consented to by each Member as a condition of becoming a Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Change
in Company Interest</U>. If there is a change in any Member&rsquo;s Membership Interests during any Fiscal Year, the principles of Section
706(d) of the Code shall apply in allocating Net Profits and Net Loss and items thereof for such Fiscal Year to account for the variation.
For purposes of applying Section 706(d) of the Code, the Board of Managers may adopt any method or convention permitted under applicable
Regulations; <U>provided</U>, that in the event of a Transfer of Common Units solely between a transferor Member and a transferee Member
such transferor Member and transferee Member shall be entitled to determine the allocation method and convention under Section 706(d)
of the Code applicable as between such Members with respect to any and all allocations under Section 706(d) of the Code that affect solely
such transferor Member and transferee Member; <U>provided</U>, <U>further</U>, that to the extent the Company incurs any out-of-pocket
costs or expenses (as reasonably determined by the Company) in connection with administering any method or convention selected by such
Members pursuant to the foregoing proviso that differs from the method or convention otherwise adopted by the Board of Managers pursuant
to this <U>Section 5.7</U>, the transferor Member shall reimburse the Company for such costs and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;5.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Modification
of Allocations</U>. The allocations set forth in this <U>Article&nbsp;V</U> are intended to comply with certain requirements of the
Regulations. Notwithstanding the other provisions herein (including <U>Section&nbsp;5.4</U>), the Board of Managers shall be
authorized to make, in its reasonable discretion, appropriate amendments to the allocations of Net Profits and Net Loss (and to
individual items of income, gain, loss, deduction and credit) pursuant hereto as are required (a) in order to comply with Section
704 of the Code or applicable Regulations, (b) to allocate properly Net Profits and Net Loss (and individual items of income, gain,
loss, deduction and credit) to those Members who bear the economic burden or benefit associated therewith and/or (c) to otherwise
cause the Members to achieve the economic objectives hereunder, in each case, as reasonably determined by the Board of Managers. If
there are any changes after the date hereof in applicable Tax Law, Regulations or interpretation, or any errors, ambiguities,
inconsistencies or omissions herein with respect to allocations to be made to Capital Accounts which would, individually or in the
aggregate, cause the Members not to achieve in any material respect the economic objectives underlying this Agreement, the Board of
Managers may in its reasonable discretion make appropriate adjustments to such allocations in order to achieve or approximate such
economic objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 223; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;VI</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>OPERATIONS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Management</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Board of Managers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All management powers over the business and affairs of the Company shall be exclusively vested in the Board of Managers, and the
Board of Managers shall conduct, direct and exercise full control over all activities of the Company. Each member of the Board of Managers
is referred to herein as a &ldquo;<FONT STYLE="color: windowtext"><U>Manager</U></FONT>.&rdquo; The Managers shall be the &ldquo;managers&rdquo;
of the Company for the purposes of the Act. The Board of Managers may (1) act by meetings or written consents pursuant to <U>Section&nbsp;6.1(a)(iii)</U>
and <U>Section 6.1(a)(iv)</U> and (2) through any Person or Persons to whom authority and duties have been delegated pursuant to <U>Section&nbsp;6.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Board of Managers shall at all times consist of the same number of Managers as the Board of Directors and the same individuals
as the Board of Directors. No Member has a right to appoint or elect a Manager to the Board of Managers, except in order to effectuate
the immediately preceding sentence, and each Manager shall serve until his or her successor has been duly elected and qualified in the
same, or until his or her earlier removal, resignation, death or disability. Any Manager may only be removed from the Board of Managers
at any time, with or without cause only if such Person is removed from the Board of Directors. A Manager may resign at any time upon
written notice to the Board of Managers, subject to such Manager&rsquo;s concurrent resignation as a director of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> The Board of Managers may hold meetings, both regular and special, either within or without the State of Delaware, or solely by
means of electronic communication in accordance with the Act. Regular meetings of the Board of Managers may be held without notice at
such time and place as shall from time to time be determined by the Board of Managers. At all meetings of the Board of Managers, a majority
of the entire Board of Managers shall constitute a quorum for the transaction of business. Unless a different vote is required by express
provision of an applicable Law or this Agreement, the vote of a majority of Managers present at a meeting at which a quorum is present
shall be the act of the Board of Managers. At any meeting of the Board of Managers, business shall be transacted in such order and manner
as the Board of Managers may from time to time determine. If a quorum shall not be present at any meeting of the Board of Managers, the
directors present thereat may, to the fullest extent permitted by law, adjourn the meeting from time to time, without notice other than
announcement at the meeting, until a quorum shall be present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Unless otherwise restricted hereby, any action required or permitted to be taken at any meeting of the Board of Managers or of
any committee thereof may be taken without a meeting, if all members of the Board of Managers or of such committee, as the case may be,
consent thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions are
filed with the minutes of proceedings of the Board of Managers or committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Non-Corporation Member or Assignee (other than any officer, director, manager, member, employee, partner, agent, representative
or trustee of the Corporation, the Company or any of their Affiliates, in their capacity as such) shall take part in the operations, management
or control (within the meaning of the Act) of the Company&rsquo;s business, transact any business in the Company&rsquo;s name or have
the power to sign documents for or otherwise bind the Company. The transaction of any such business by the Corporation or any officer,
director, manager, member, employee, partner, agent, representative or trustee of the Corporation, the Company or any of their Affiliates,
in their capacity as such, shall not affect, impair or eliminate the limitations on the liability of the Non-Corporation Members or Assignees
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary herein, to the fullest extent permitted by applicable Law, the Board of Managers shall
have the power and authority to effectuate the sale, lease, transfer, exchange or other disposition of any, all or substantially all
of the assets, properties or rights of the Company (including the exercise or grant of any conversion, option, privilege or subscription
right or any other right available in connection with any assets at any time held by the Company) or the merger, consolidation, reorganization
or other combination of the Company with or into another entity, all without further act or Consent of the Members or any other Person
(but without, for the avoidance of doubt, limiting the covenants and agreements of the Non-Corporation Members set forth in <U>Section
10.6(b)</U>); <U>provided</U>, <U>however</U>, that nothing herein shall alter in any respect any rights under the Corporation&rsquo;s
Charter or bylaws or applicable Law of any stockholder of the Corporation to approve or adopt, as applicable, such sale, lease, exchange
or other disposition or a Non-Corporation Member, solely in its capacity as a stockholder of the Corporation, to vote in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 224; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Board of Managers may also, from time to time, appoint such officers and establish such management and/or advisory boards or
committees of the Company as the Board of Managers deems necessary or advisable, each of which shall have such powers, authority and responsibilities
as are delegated in writing by the Board of Managers from time to time. Each such officer, board or committee member shall serve at the
pleasure of, and may be removed by, the Board of Managers, and any officer of the Company or any of its Controlled Entities, in such officer&rsquo;s
capacities as such, shall owe to the Corporation, the Company and such Controlled Entity, as applicable, duties of loyalty and due care
of the type owed by the officers of a corporation to such corporation and its stockholders under the Laws of the State of Delaware. The
officers of the Company as of the date hereof shall be the individuals set forth on <U>Schedule&nbsp;II</U> hereto.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><SUP>3</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Board of Managers may cause the Company to contract and deal with the Corporation or any Affiliate of the Corporation in accordance
with, and subject to, any applicable related party (or similar) policies then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation and Reimbursement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Board of Managers shall not receive any fees from the Company for its services in administering the Company, except as otherwise
provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Subject
to <U>Section&nbsp;6.2(c)</U>, the Company shall be liable for, and shall reimburse the Corporation (or the applicable member of the
Parent Corporation Group), on a monthly basis, or such other basis as the Board of Managers may determine, for all sums expended and
obligations incurred or otherwise payable by the members of the Parent Corporation Group in connection with or related to the
Company&rsquo;s or any of its Subsidiary&rsquo;s business or other activities or otherwise in connection with or related to it being
the direct or indirect parent company of the Company, including (i)&nbsp;all fees, costs and expenses relating to or arising out of
the ownership of interests in or management or operation of, or for the benefit of, the Company or any of its Subsidiaries
(including, for the avoidance of doubt, any fees, costs or expenses related to or arising out of an M&amp;A Event, any capital
markets activities or restructuring of the Corporation, the Company or its Subsidiaries or any Action (or settlement)),
(ii)&nbsp;all compensation of officers, directors, employees and other service providers of the members of the Parent Corporation
Group or the Company, including payments under existing or future compensation plans of the members of the Parent Corporation Group
or the Company (including those that may provide for stock units, or phantom stock, pursuant to which employees of the Parent
Corporation Group or the Company will receive payments based upon dividends on or the value of Class&nbsp;A Shares or any Capital
Shares), (iii)&nbsp;all director fees, costs and expenses, (iv)&nbsp;all costs and expenses of the members of the Parent Corporation
Group&rsquo;s related to or arising out of the maintenance of its corporate status or being a public company, including fees, costs
and expenses related to or arising out of filings with the SEC or any other Authority, reports or other distributions to its
stockholders, capital markets activities or any Action (or settlement thereof)<FONT STYLE="font-size: 10pt">, </FONT>(v)&nbsp;all
other fees, costs and expenses reasonably incurred by the Parent Corporation Group, and (vi)&nbsp;fees, costs and expenses incurred
by third-party advisors or representatives to the Parent Corporation Group or any Affiliates thereof in connection with any of the
foregoing. The Members acknowledge that all such fees, costs and expenses are deemed to be for the benefit of the Company. Such
reimbursements shall be made on an after-tax basis (i.e., grossed up basis) and be in addition to any reimbursement of any member of
the Parent Corporation Group as a result of indemnification pursuant to <U>Section&nbsp;6.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>3</SUP></TD><TD STYLE="text-align: justify">Unless otherwise mutually agreed to by Amber GT Parent and ARYA,
the initial officers will be the Officers (as defined and determined in accordance with the Business Combination Agreement).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 225; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the extent practicable (as determined by the Board of Managers), the fees, costs and expenses described in this <U>Section&nbsp;6.2</U>
shall be treated as fees, costs and expenses of the Company and shall be billed directly to and paid by the Company; <U>provided</U>,
<U>however</U>, that notwithstanding any provision of this Agreement to the contrary, to the extent any such fees, costs and expenses
are not billed directly to and paid by the Company, the Company may direct the Corporation to pay any such fees, costs or expenses with
all or any portion of any proceeds or other consideration (&ldquo;<U>Directed Proceeds</U>&rdquo;) received by the Corporation in respect
of (i) the issuance, exercise, or settlement, as applicable, of any Common Shares, Capital Shares, New Securities or stock options or
(ii) any stock incentive or other stock or subscription plan or agreement, in each case, which Directed Proceeds would otherwise be required
to be contributed to the Company pursuant to any provision of this Agreement. In the event that (x) any amount received by the Corporation
with respect to a sale of Class A Shares described in the definition of &ldquo;Cash Amount&rdquo; or the issuance of any additional Common
Shares, Capital Shares or New Securities in accordance with <U>Section 3.4(e)</U> is net of any Discounts or (y) the Corporation pays
any fees, costs or expenses with Directed Proceeds pursuant the immediately preceding sentence, (A) the Corporation&rsquo;s Capital Account
shall be increased by the amount of such Discounts or Directed Proceeds, as applicable and (B) the Company shall be deemed to have paid
the Discounts or the fees, costs or expenses paid with such Directed Proceeds, as applicable. If and to the extent reimbursements to the
Corporation (or the applicable Member of the Parent Corporation Group) by the Company pursuant to this <U>Section&nbsp;6.2</U> or pursuant
to <U>Section 6.6</U> constitute gross income to such Person (as opposed to the repayment of advances made by such Person on behalf of
the Company), the parties intend that such amounts shall be treated as payments described under Section 707 of the Code and shall not
be treated as distributions pursuant to <U>Article&nbsp;IV</U> or otherwise be deemed to be a payment or amounts received in respect of
its Membership Interests (if any).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Outside Activities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>No
member of the Parent Corporation Group shall, directly or indirectly, enter into or conduct any business, other than in connection
with or related to (i)&nbsp;the ownership, acquisition or disposition of Membership Interests, (ii)&nbsp;the business or activities
of the Company or its Subsidiaries (including the management or operation thereof), (iii)&nbsp;its operation as a reporting company
with a class (or classes) of securities registered under the Exchange Act, (iv)&nbsp;the offering, sale, syndication, private
placement or public offering of stock, bonds, securities or other interests, (v)&nbsp;financing or refinancing of any type related
to the Company or its assets or activities and (vi)&nbsp;such activities as are incidental or ancillary to any of the foregoing or
typical for entities of the nature and type of the entities comprising the Parent Corporation Group; <U>provided</U>, <U>however</U>,
a member of the Parent Corporation Group may, in its sole and absolute discretion, from time to time hold or acquire entities,
businesses, assets, properties or rights (whether by merger, consolidation, recapitalization, sale, transfer or license of assets,
properties or rights) in its own name or otherwise other than through the Company so long as the members of the Parent Corporation
Group take commercially reasonable measures to ensure that the economic benefits and burdens of such assets are otherwise vested in
the Company, whether through assignment, mortgage loan or otherwise or, if it is not commercially reasonable to vest such economic
interests in the Company, the Members shall negotiate in good faith to amend the provisions hereof, including the definition of
 &ldquo;Adjustment Factor,&rdquo; to reflect such activities and the direct ownership of assets by the applicable member of the
Parent Corporation Group. The members of the Parent Corporation Group and any of their respective Affiliates may acquire Membership
Interests and shall be entitled to exercise all rights of a Member relating to such Membership Interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 226; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Subject
to (i) any agreements entered into by a Non-Corporation Member, any of its Affiliates or any officer, director, employee, agent,
trustee, Affiliate or stockholder of any of the foregoing with any member of the Parent Corporation Group, the Company or any
Controlled Entity thereof (including any employment or similar agreement or arrangement) and (ii) the duties and obligations of any
individual in his or her capacity as an officer or director of any member of the Parent Corporation Group, the Company or any
Controlled Entity thereof (clauses (i) and (ii), collectively, &ldquo;<U>Non-Corporation Member Duties</U>&rdquo;<FONT STYLE="color: windowtext">)</FONT>,
any Non-Corporation Member, officer, director, employee, agent, trustee, Affiliate, member or stockholder of any Non-Corporation
Member, shall be entitled to and may engage, invest or otherwise have an interest in any other business, activity or opportunity of
any nature, independently or with others, including any business engagement, investment or interest that is in direct or indirect
competition with the Company or enhanced by the activities of the Company. Neither the Company nor any Non-Corporation Member shall
have any rights by virtue hereof in any business ventures of any Non-Corporation Member or Assignee. Subject to such agreements and
the foregoing, none of the Non-Corporation Members nor any other Person shall have any rights by virtue hereof or the relationship
established hereby in any business ventures of any other Person (other than any member of the Parent Corporation Group, to the
extent expressly provided herein), and such Person shall have no obligation pursuant hereto, subject to any Non-Corporation Member
Duties, to offer any interest in any such business ventures to the Company, any Non-Corporation Member, or any such other Person,
even if such opportunity is of a character that, if presented to the Company, any Non-Corporation Member or such other Person, could
be taken by such Person. No amendment or repeal of this <U>Section&nbsp;6.3(b)</U> shall apply to or have any effect on the
liability or alleged liability of any Member for or with respect to any opportunities of which any such Member becomes aware prior
to such amendment or repeal. Any Person purchasing or otherwise acquiring any interest in any Membership Interests shall be deemed
to have notice of and consented to the provisions of this <U>Section&nbsp;6.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Duties; Limitation of Liability of the Board of Managers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Board of Managers shall owe the same fiduciary duties to the Company as the fiduciary duties the Board of Directors owes to
the Corporation under <FONT STYLE="font-size: 10pt">Delaware General Corporation Law (the &ldquo;<U>DGCL</U>&rdquo;)</FONT> (it being
understood and agreed, for the avoidance of doubt, that for purposes of applying these duties to the Company the Board of Managers shall
be entitled to take into account, among other things, the interests of stockholders of the Corporation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Without limiting any of the Board of Managers&rsquo; covenants or agreements hereunder or any of the duties any Manager may owe
to the stockholders of the Corporation under applicable Law, (i) no Manager, acting in their capacity as such, shall have any duties directly
to any Member and (ii) no Manager, acting in their capacity as such, shall be directly liable to the Company for money damages by reason
of their service as such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In performing its duties hereunder and under applicable Law, the Board of Managers shall be entitled to rely on the provisions
hereof and on any information, opinion, report or statement, including any financial statement or other financial data or the records
or books of account of the Company or any Controlled Entity of the Company, prepared or presented by an officer, employee or agent of
the Company or any such Controlled Entity, or by a lawyer, certified public accountant, appraiser or other Person engaged by the Company
as to any matter within such Person&rsquo;s professional or expert competence, and any act taken or omitted to be taken in reliance upon
any such information, opinion, report or statement as to matters that the Board of Managers reasonably believes to be within such Person&rsquo;s
professional or expert competence shall be conclusively presumed to have been done or omitted in good faith and in accordance with such
opinion. The Board of Managers may rely and shall be protected in acting or refraining from acting upon any resolution, certificate, statement,
instrument, opinion, report, notice, request, consent, order, bond, debenture or other paper or document believed by it in good faith
to be genuine and to have been signed or presented by the proper party or parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any amendment, modification or repeal of this <U>Section&nbsp;6.4</U> or any provision hereof shall be prospective only and shall
not in any way affect the limitations on the liability of the Managers under this <U>Section&nbsp;6.4</U>, as in effect immediately prior
to such amendment, modification or repeal, with respect to claims arising from or relating to matters occurring, in whole or in part,
prior to such amendment, modification or repeal, regardless of when such claims may arise or be asserted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 227; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fiduciary Duties of the Members</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> To the fullest extent permitted under applicable Law, no Member, in their capacity as such, (such Persons, the &ldquo;<FONT STYLE="color: windowtext"><U>No-Duty
Persons</U></FONT>&rdquo;) shall owe any fiduciary duty to any Covered Person, the Company, or any of their respective Representatives
or any other Person. This Agreement is not intended to, and does not, create or impose any fiduciary duty on any No-Duty Person, and any
such fiduciary duty that would otherwise apply under applicable Law is hereby eliminated to the fullest extent permitted under applicable
Law. Furthermore, each of the Members and the Company hereby unconditionally and irrevocably waives, to the fullest extent permitted by
applicable Law, any and all fiduciary duties (including any fiduciary duty related to or associated with self-dealing, corporate or business
opportunities or otherwise) of any No-Duty Person that, absent such waiver, would otherwise apply under applicable Law and, in doing so,
acknowledges and agrees that the only duties and obligation of each No-Duty Person, in its capacity as a Member, to each other Covered
Person, the Company, any of their respective Representatives or any other Person are as expressly set forth herein or under applicable
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the fullest extent permitted under applicable Law, whenever a No-Duty Person is permitted or required to make a decision or
take an action or omit to do any of the foregoing (i) in its &ldquo;sole discretion&rdquo; or &ldquo;discretion&rdquo; or under a similar
grant of authority or latitude or without an express standard of behavior (including standards such as &ldquo;reasonable&rdquo; or &ldquo;good
faith&rdquo;), such No-Duty Person shall be entitled to consider any such interests and factors, including its own, as it desires, and
shall have no duty or obligation to consider any other interests or factors whatsoever or (ii)&nbsp;with an express standard of behavior
(including standards such as &ldquo;reasonable&rdquo; or &ldquo;good faith&rdquo;), then such No-Duty Person shall comply with such express
standard but, to the fullest extent permitted under Law, shall not be subject to any other or additional standard imposed by this Agreement
or Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>The
provisions hereof, to the extent that they restrict or eliminate the duties and liabilities of the No-Duty Persons otherwise
existing at law or in equity, are agreed by the Members and the Company to replace such other duties and liabilities of the No-Duty
Persons to the fullest extent permitted by applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any amendment, modification or repeal of this <U>Section&nbsp;6.5</U> or any provision hereof shall be prospective only and shall
not in any way affect the limitations on the liability of the Members under this <U>Section&nbsp;6.5</U>, as in effect immediately prior
to such amendment, modification or repeal, with respect to claims arising from or relating to matters occurring, in whole or in part,
prior to such amendment, modification or repeal, regardless of when such claims may arise or be asserted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Liability; Exculpation and Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Liability</U>.
Except as otherwise provided herein, to the fullest extent permitted by applicable Law, the debts, obligations and liabilities of
the Company and each Controlled Entity thereof, whether arising in contract, tort or otherwise, shall be solely the debts,
obligations and liabilities of the Company or such Controlled Entity, and no Member shall be obligated to any Person (including any
creditor of the Company) for the repayment, satisfaction or discharge of any such debt, obligation or liability of the Company or
such Controlled Entity solely by reason of being a Member. The failure of the Company to observe any formalities relating to the
exercise of its powers or management of its business or affairs hereunder or under applicable Law shall not be a ground for imposing
personal liability on any Member or Covered Person for the obligations and liabilities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 228; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exculpation</U>. To the fullest extent permitted by applicable Law, no Covered Person who serves on behalf of the Company shall
be liable to the Company, any Controlled Entity thereof or any other Person for any loss, liability, damage or claim arising out of any
act or omission performed or omitted by such Covered Person on behalf of the Company or any Controlled Entity thereof or in furtherance
of the interests of the Company or any Controlled Entity thereof or arising out of or in connection with the Company or any Controlled
Entity thereof taken or omitted by such Covered Person, so long as such act or omission did not constitute gross negligence, fraud or
willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the fullest extent permitted by the Delaware Limited Liability Act (the &ldquo;<U>DLLCA</U>&rdquo;) , as the same exists or
as may hereafter be amended, a person who serves as a Manager of the Company shall not be personally liable to the Company or its Members
for monetary damages for breach of fiduciary duty as a Manager. If the DLLCA is amended to authorize corporate action further eliminating
or limiting the personal liability of directors, then the liability of a Manager of the Company shall be eliminated or limited to the
fullest extent permitted by the DLLCA, as so amended. Any repeal or modification of this <U>Section 6.6</U> shall not adversely affect
any right or protection of a Manager of the Company with respect to events occurring prior to the time of such repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>To
the fullest extent permitted by the DLLCA, as the same exists or may hereafter be amended (but, in the case of any such amendment,
only to the extent that such amendment permits the Company to provide broader indemnification rights than such law permitted the
Company to provide prior to such amendment), the Company shall indemnify any Covered Person who was or is a party or is threatened
to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or
investigative by reason of the fact that he or she is or was a Covered Person (any person in such a position, an
 &ldquo;<U>Indemnified Person</U>&rdquo;), whether the basis of such action, suit or proceeding is alleged action in an official
capacity as a director, officer or agent of the Company or in any other capacity while serving as a Covered Person, against
Indemnifiable Losses if such Indemnified Person acted in good faith and in a manner such Indemnified Person reasonably believed to
be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable
cause to believe such Indemnified Person&rsquo;s conduct was unlawful; <U>provided</U>, <U>however</U>, that, except as provided in <U>Section
6.6(i)</U> with respect to proceedings to enforce rights to indemnification or advancement, the Company shall indemnify any such
Indemnified Person in connection with a proceeding (or part thereof) initiated by such Indemnified Person only if such proceeding
(or part thereof) was authorized by the Board of Managers. The termination of any action, suit or proceeding by judgment, order,
settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the
Indemnified Person did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best
interests of the Company, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his or her
conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Advancement of Expenses</U>. Expenses (including attorneys&rsquo; fees) incurred by an Indemnified Person in defending any civil,
criminal, administrative or investigative action, suit or proceeding referenced in <U>Section 6.6(c)</U> shall be paid by the Company
in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such Indemnified
Person to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified by the Company. The
rights to indemnification and advancement of expenses conferred by this <U>Section&nbsp;6.6(d)</U> shall be contract rights and such rights
shall continue as to an Indemnified Person who has ceased to be a Covered Person of the Company and shall inure to the benefit of his
or her heirs, executors and administrators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 229; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Good-Faith Reliance</U>. For purposes of any determination under this <U>Section 6.6</U>, a Covered Person shall be deemed to
have acted in good faith and in a manner such Covered Person reasonably believed to be in or not opposed to the best interests of the
Company, or, with respect to any criminal action or proceeding, to have had no reasonable cause to believe such person&rsquo;s conduct
was unlawful, if such person&rsquo;s action is based on the records or books of account of the Company or another enterprise, or on information
supplied to such person by the Board of Managers or another enterprise in the course of their duties, or on the advice of legal counsel
for the Company or another enterprise or on information or records given or reports made to the Company or another enterprise by an independent
certified public accountant or by an appraiser or other expert selected with reasonable care by the Company or another enterprise. The
provisions of this <U>Section 6.6(e)</U> shall not be deemed to be exclusive or to limit in any way the circumstances in which a person
may be deemed to have met the applicable standard of conduct set forth in this <U>Section 6.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Changes
in Law</U>. Any repeal or amendment of this <U>Section 6.6</U> or by changes in the DLLCA, or the adoption of any other provision of
this Agreement inconsistent with this <U>Section 6.6</U>, shall, unless otherwise required by the DLLCA, be prospective only (except
to the extent such amendment or change in law permits the Company to provide broader indemnification or advancement rights on a
retroactive basis than permitted prior thereto), and shall not in any way diminish or adversely affect any right or protection
existing at the time of such repeal or amendment or adoption of such inconsistent provision in respect of any proceeding (regardless
of when such proceeding is first threatened, commenced or completed) arising out of or related to any act or omission occurring
prior to such repeal or amendment or adoption of such inconsistent provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification Not Exclusive</U>. The indemnification and advancement of expenses provided by, or granted pursuant to this
<U>Section 6.6</U> shall not be deemed exclusive of any other rights to which a Covered Person seeking indemnification or advancement
of expenses may be entitled under any, agreement, consent of Members or disinterested Managers or otherwise, both as to action in his
or her official capacity and as to action in another capacity as a Covered Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Primacy of Indemnification</U>. The Company hereby acknowledges that an Indemnified Person may have certain rights to other
indemnification, advancement of expenses and/or insurance from persons other than the Company (collectively, the &ldquo;<U>Other Indemnitors</U>&rdquo;).
The Company hereby agrees that with respect to any Indemnifiable Losses paid in settlement arising by reason of the fact that such Indemnified
Person is or was an Indemnified Person, (a) that the Company is the indemnitor of first resort (i.e., its obligations to an Indemnified
Person are primary and any obligation of the Other Indemnitors to advance expenses, provide indemnification or otherwise pay for the Indemnifiable
Losses incurred by such Indemnified Person are secondary), (b) that the Company shall be required to advance the full amount of Indemnifiable
Losses incurred by an Indemnified Person in accordance with this <U>Section 6.6(h)</U> and shall be liable for the full amount of all
Indemnifiable Losses to the extent legally permitted and as required by the terms of this Agreement (or any other agreement between the
Company and an Indemnified Person), without regard to any rights an Indemnified Person may have against the Other Indemnitors, and (c)
that the Company irrevocably waives, relinquishes and releases the Other Indemnitors from any and all claims against the Other Indemnitors
for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or
payment by the Other Indemnitors on behalf of an Indemnified Person with respect to any claim for which such Indemnified Person has sought
indemnification or advancement from the Company shall affect the foregoing and the Other Indemnitors shall have a right of contribution
and/or to be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Indemnified Person against
the Company. The Company and each Indemnified Person agree that the Other Indemnitors are express third party beneficiaries of the terms
of this <U>Section 6.6(h).</U>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Maintenance of Insurance or Other Financial Arrangements</U> The Company shall have power to purchase and maintain insurance
on behalf of any Person who is or was an Indemnified Person against any liability asserted against him or her and incurred by him or her
in any such capacity, or arising out of his or her status as such, whether or not the Company would have the power to indemnify him or
her against such liability under the provisions of this <U>Section 6.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 230; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>If
a claim under <U>Section 6.6(c)(ii)</U> or <U>Section 6.6(d)</U> is not paid in full by the Company within sixty (60) days after a
written claim has been received by the Company, except in the case of a claim for an advancement of expenses, in which case the
applicable period shall be twenty (20) days, the Indemnified Person may at any time thereafter bring suit against the Company to
recover the unpaid amount of the claim. To the fullest extent permitted by the DGCL (as if it were applicable to the Company), if
successful in whole or in part in any such suit, or in a suit brought by the Company to recover an advancement of expenses, the
Indemnified Person shall be entitled to be paid also the expense of prosecuting or defending such suit. In (a) any suit brought by
the Indemnified Person to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnified Person to
enforce a right to an advancement of expenses) it shall be a defense that, and (b) in any suit brought by the Company to recover an
advancement of expenses, the Company shall be entitled to recover such expenses only upon a final adjudication that, the Indemnified
Person has not met any applicable standard for indemnification set forth in the DLLCA. Neither the failure of the Company (including
its Managers who are not parties to such action, a committee of such Managers, independent legal counsel, or its Members) to have
made a determination prior to the commencement of such suit that indemnification of the Indemnified Person is proper in the
circumstances because the Indemnified Person has met the applicable standard of conduct set forth in the DLLCA, nor an actual
determination by the Company (including its Managers who are not parties to such action, a committee of such Managers, independent
legal counsel, or its Members) that the Indemnified Person has not met such applicable standard of conduct, shall create a
presumption that the Indemnified Person has not met the applicable standard of conduct or, in the case of such a suit brought by the
Indemnified Person, be a defense to such suit. In any suit brought by the Indemnified Person to enforce a right to indemnification
or to an advancement of expenses hereunder, or brought by the Company to recover an advancement of expenses, the burden of proving
that the Indemnified Person is not entitled to be indemnified, or to such advancement of expenses, under this <U>Section 6.6</U> or
otherwise shall be on the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of this <U>Section 6.6</U>, references to &ldquo;other enterprises&rdquo; shall include employee benefit plans and
references to &ldquo;fines&rdquo; shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references
to &ldquo;serving at the request of the Company&rdquo; shall include any service which imposes duties on, or involves services by, the
Indemnified Person with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and
in a manner he or she reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall
be deemed to have acted in a manner &ldquo;not opposed to the best interests of the Company&rdquo; as referred to in this <U>Section 6.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The indemnification and advancement of expenses provided by, or granted pursuant to, this <U>Section 6.6</U> shall continue as
to a person who has ceased to be an Indemnified Person and shall inure to the benefit of the heirs, executors and administrators of such
a person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company may, to the extent authorized from time to time by the Board of Managers, grant rights to indemnification and to the
advancement of expenses to any Person to the fullest extent of the provisions of this <U>Section 6.6</U> with respect to the indemnification
and advancement of expenses of Indemnified Persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>No Duplication of Payments</U>. The Company shall not be liable under this <U>Section&nbsp;6.6</U> to make any payment to a
Covered Person in respect of any Indemnifiable Losses to the extent that the Covered Person has otherwise actually received payment (net
of any expenses incurred in connection therewith and any repayment by the Covered Person made with respect thereto) under any insurance
policy or from any other source in respect of such Indemnifiable Losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 231; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice of Proceedings</U>. Promptly after receipt by a Covered Person of notice of the commencement of any proceeding against
such Covered Person, such Covered Person shall, if a claim for indemnification in respect thereof is to be made against the Company, give
prompt written notice to the Company of the commencement of such proceeding; <U>provided</U> that the failure of a Covered Person to give
notice as provided herein shall not relieve the Company of its obligations under <U>Section&nbsp;6.6</U>, except to the extent that the
Company is actually and materially prejudiced by such failure to give notice. In case any such proceeding is brought against a Covered
Person (other than a proceeding by or in the right of the Company), after the Company has acknowledged in writing its obligation to indemnify
and hold harmless the Covered Person, the Company shall be entitled to assume the defense of such proceeding; <U>provided</U> that the
Covered Person shall be entitled to participate in such proceeding and to retain its own counsel at its own expense. After notice from
the Company to such Covered Person acknowledging the Company&rsquo;s obligation to indemnify and hold harmless the Covered Person and
electing to assume the defense of such proceeding, the Company shall not be liable for expenses subsequently incurred by such Covered
Person in connection with the defense thereof. Without the consent of such Covered Person (not to be unreasonably withheld, conditioned
or delayed), the Company shall not consent to the entry of any judgment or enter into any settlement that does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such Covered Person of a release from all liability arising out of the proceeding
and claims asserted therein and does not involve any statement, finding or admission of any fault, culpability, failure to act, violation
of Law or admission of any wrongdoing by or on behalf of such Covered Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;6.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendments</U>. Any repeal, amendment or modification of <U>Article&nbsp;VI</U> shall not adversely affect any rights of a Covered
Person pursuant to this <U>Article&nbsp;VI</U>, including the right to indemnification and to the advancement of expenses of a Covered
Person, existing at the time of such repeal or modification with respect to any acts or omissions occurring prior to such repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;VII</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>RIGHTS
AND OBLIGATIONS OF MEMBERS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Information Rights of Members Relating to the Company</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>In
addition to other rights provided hereby or under applicable Law, the Company shall deliver to each Member (who is not also a
stockholder of the Corporation) a copy of any information mailed to all stockholders of the Corporation as soon as practicable after
such mailing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall notify any Member, on its written request (x)&nbsp;in connection with a redemption or proposed redemption pursuant
to <U>Article&nbsp;XIII</U> or (y)&nbsp;following the occurrence of an event that would reasonably be expected to cause a change to the
Adjustment Factor, of the then-current Adjustment Factor or any change made to the Adjustment Factor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 232; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section&nbsp;18&#45;305 of the Act (entitled &ldquo;Access to and Confidentiality of Information; Records&rdquo;) shall not apply
or be incorporated into this Agreement except to the extent expressly provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding any other provision of this <U>Section&nbsp;7.1</U>, the Company may keep confidential from the Non-Corporation
Members (or any of them), for such period of time as the Board of Managers determines, any information that (i)&nbsp;the Board of Managers
believes to be in the nature of trade secrets or other information the disclosure of which the Board of Managers reasonably believes is
not in the best interests of the Company or any member of the Parent Corporation Group, or (ii)&nbsp;the Company, any member of the Parent
Corporation Group or any Controlled Entity of the foregoing and its Subsidiaries is required by Law or by agreement to keep confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Members&rsquo; Right to Act</U>. For matters that require the Consent of the Members or the Consent of the Non-Corporation Members,
the applicable Members shall act through meetings or written consents as described in this <U>Section&nbsp;7.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as otherwise expressly provided herein, acts by Consent of the Members or Consent of the Non-Corporation Members, voting
together as a single class, shall be the acts of the Members or the Non-Corporation Members, respectively. Any Member entitled to vote
at a meeting of Members, or to express consent or dissent to any Company action in a written transmission without a meeting, may authorize
another Person or Persons to act for such Member by proxy in accordance with applicable Law. If a proxy designates two (2) or more Persons
to act as proxies, unless that instrument shall provide to the contrary, a majority of such Persons shall have and may exercise all the
powers of voting or giving consents thereby conferred, or, if a majority do not agree on any particular issue, the Company shall not be
required to recognize such proxy with respect to such issue if such proxy does not specify how the votes that are the subject of such
proxy are to be voted with respect to such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Actions
by the Members or the Non-Corporation Members hereunder shall be taken at a meeting called by the a Majority in Interest of the
Members on at least forty-eight (48) hours&rsquo; prior written notice to the other Members entitled to vote thereat, which notice
shall state the purpose or purposes for which such meeting is being called unless such notice is waived by such Member; <U>provided</U>, <U>however</U>,
that any such action may be taken by written consent; <U>provided</U> that such consent is signed by Members having not less than
the minimum Percentage Interest that would be necessary to authorize or take such action at a meeting at which the applicable
Members entitled to vote thereon were present and voted. The actions taken by the Members entitled to vote or Consent at any meeting
(as opposed to by written consent), however called and noticed, shall be as valid as though taken at a meeting duly held after
regular call and notice if (but not until), either before, at or after the meeting, the Members entitled to vote or consent as to
whom it was improperly held execute a written waiver of notice or a consent to the holding of such meeting or an approval of the
minutes thereof. Prompt notice of the action so taken without a meeting, which shall state the action so taken and may be delivered
via email, shall be given to those Members entitled to vote or consent who have not consented in writing; <U>provided</U>, <U>however</U>,
that the failure to give any such notice shall not affect the validity of the action taken by such written consent. Any action taken
pursuant to such written consent of the applicable Members shall have the same force and effect as if taken by the Members at a
meeting thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Various Capacities</U>. The Members acknowledge and agree that the Members or their Affiliates will from time to time act
in various capacities hereunder, including as a Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 233; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Listing of Members</U>. Without the approval of the Board of Managers, no Non-Corporation Member all or substantially all
of whose assets (together with its Affiliates) consist of Membership Interests may have its or any of its Affiliates securities listed
(or take any action that would require it to be listed) on any securities exchange or automated quotation system on which securities are
traded at any time; <U>provided</U>, that for the avoidance of doubt, this <U>Section 7.4</U> shall not apply with respect to the securities
of Amber GT Parent unless Amber GT Parent transfers to a non-Affiliate all or substantially all of its assets other than the Membership
Interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;VIII</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>BOOKS
AND RECORDS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Books and Records</U>. The Company shall use commercially reasonable efforts to keep, or cause to be kept, separate, complete
and accurate books and records of the Company for financial reporting purposes, on an accrual basis, in accordance with the United States
generally accepted accounting principles, consistently applied, including all books and records necessary to provide any information,
lists and copies of documents required pursuant to applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Inspection</U>.
Subject to <U>Section 14.9</U>, the Company shall permit the Non-Corporation Members (personally or through an authorized
representative), to (a) visit and inspect, at their sole cost and expense, the properties of the Company and its Controlled Entities
during normal business hours upon reasonable prior notice in such a manner as to not unreasonably disrupt the normal operations of
the Company or any such Controlled Affiliate and solely for purposes reasonably related to their respective Membership Interests and
(b) review and, in the reasonable discretion of the Board of Managers, copy (at their own expense) the books and records, or
business and financial records, of the Company or any of its Controlled Entities during reasonable business hours upon reasonable
prior notice in such a manner as to not unreasonably disrupt the normal operations of the Company or such Controlled Entity and
solely for purposes reasonably related to their respective Membership Interests. Notwithstanding the foregoing or anything to the
contrary herein, (i) to the extent that any information is publicly available (whether with the SEC or otherwise) the Company may,
in lieu of providing such access and information as contemplated by the preceding sentence, direct such Non-Corporation Member to
the location of such information, (ii) the Company and the Non-Corporation Members acknowledge and agree that each member of the
Parent Corporation Group shall have, to the fullest extent permitted by Law, full access to all books, records, information,
properties and other business relations of the Company, its Controlled Entities and their respective businesses, except and to the
extent determined otherwise by the Board of Managers and (iii)&nbsp;the access and information rights of any Non-Corporation Member
under this <U>Section&nbsp;8.2</U> may be limited to the extent that the Board of Managers reasonably and in good faith determines
that such limitation is necessary or advisable in light of any competing activities of such Non-Corporation Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;IX</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>TAX
MATTERS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Partnership Status and Tax Elections</U>. It is the intent of the Members that the Company be taxed as a partnership for United
States federal, state and local income Tax purposes. The Members hereby agree not to elect (a) to be excluded from the application of
subchapter K of chapter&nbsp;1 of subtitle A of the Code or any similar state statute and (b) for the Company to be treated as a corporation,
or an association taxable as a corporation, under the Code or any similar state statute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 234; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Tax
Returns; Information</U>. The Board of Managers shall arrange for the preparation of all Tax returns of the Company or any of its
Subsidiaries; <U>provided</U>, that in the case of any such Tax return that is a U.S. federal income Tax return, the Board of
Managers shall arrange for the preparation of such Tax return by a nationally-recognized accounting firm. In the case of any Tax
return of the Company or any of its Subsidiaries that relates to a taxable year (or portion thereof) of the Company or its any of
its Subsidiaries beginning on or before the Closing Date and with respect to which Amber GT or any of its Affiliates has any
indemnity obligation under the Business Combination Agreement, the Company shall provide a draft copy of such Tax Return to Amber GT
for its review and comment not later than fifteen (15) days prior to filing and shall consider in good faith any comments provided
by Amber GT with respect to such Tax return. For any taxable year in which Amber GT (or any of its Affiliates) owns more than 10% of
the Membership Interests for at least six (6) months during the taxable year, the Company shall provide a draft of the Company's IRS
Form 1065 (including all accompanying schedules) to Amber GT for its review and comment and shall use commercially reasonable
efforts to provide such draft at least thirty (30) days prior to filing. The Company shall consider in good faith any comments
provided by Amber GT. The Company shall keep at its principal office copies of the Company&rsquo;s (and its Subsidiaries&rsquo;)
federal, state and local income Tax returns, if any, for all taxable years or periods for which Amber GT (or any of its Affiliates)
owns more than 10% of the outstanding Membership Interests for at least six (6) months of such taxable year, and shall retain such
returns for the period required under applicable Law. Prior to destroying any such returns, the Company shall provide Amber GT a
reasonable opportunity, at its own expense, to take possession of such returns. As soon as reasonably practicable following the
filing of such income Tax returns, the Company shall furnish to each Member a copy of each such income Tax return as filed, together
with any schedules or other information, in each case as such Member may reasonably require in connection with such Member&rsquo;s
own tax affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Partnership Representative</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Corporation is hereby designated as the &ldquo;partnership representative&rdquo; of the Company (as that term is defined in
Section 6223(a) of the Code, the &ldquo;<FONT STYLE="color: windowtext"><U>Partnership Representative</U></FONT>&rdquo;), with all of
the rights, duties and powers provided for in the Code and Regulations. The Company shall appoint the &ldquo;designated individual&rdquo;
identified by the Partnership Representative to act on behalf of the Partnership Representative (the &ldquo;<FONT STYLE="color: windowtext"><U>Designated
Individual</U></FONT>&rdquo;) in accordance with the applicable Regulations. Each Member expressly consents to such designations and agrees
that it will execute, acknowledge, deliver, file and record at the appropriate public offices such documents as may be necessary or appropriate
to evidence such consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Members agree to reasonably cooperate to timely provide information requested by the Partnership Representative as needed to
comply with the Partnership Audit Procedures, including to make any elections available to the Company under the Partnership Audit Procedures.
Each Member agrees that, upon request of the Company, such Member shall take such actions as may be necessary or desirable (as determined
by the Partnership Representative) to (i)&nbsp;allow the Company to comply with the provisions of Section 6226 of the Partnership Audit
Procedures so that any &ldquo;partnership adjustments&rdquo; (as defined in Section&nbsp;6241(2) of the Partnership Audit Procedures)
are taken into account by the Members and former Members rather than the Company; (ii) use the provisions of Section 6225(c) of the Partnership
Audit Procedures including, but not limited to, filing amended tax returns with respect to any &ldquo;reviewed year&rdquo; (within the
meaning of Section&nbsp;6225(d)(1) of the Partnership Audit Procedures) or using the alternative procedure to filing amended returns to
reduce the amount of any partnership adjustment otherwise required to be taken into account by the Company; or (iii)&nbsp;otherwise allow
the Company and its Members to address and respond to any matters arising under the Partnership Audit Procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>For
any taxable year in which Amber GT (or any of its Affiliates) owns at least 10% of the interests in the Company for at least six (6)
months during the taxable year, the Partnership Representative shall deliver to Amber GT a copy of all material notices,
communications, reports and writings received from the IRS by the Company or the Partnership Representative relating to or
potentially resulting in an adjustment of Company items (a &ldquo;<U>Proposed Adjustment</U>&rdquo;) and shall keep Amber GT
reasonably informed regarding all material developments with respect to such Proposed Adjustment. In addition, with respect to any
such taxable year, the Partnership Representative shall (i) provide Amber GT with a draft copy of any correspondence, filing or
other materials to be submitted by the Company, the Partnership Representative or any of their Affiliates in connection with any
administrative or judicial proceedings relating to such Proposed Adjustment reasonably in advance of such submission, (ii) consider
in good faith all reasonable changes or comments to such correspondence, filing or other materials requested by Amber GT (to the
extent such comments are provided in a timely manner such that it would allow the Company to comply with any deadline imposed under
applicable Law), and (iii) provide Amber GT with a final copy of such correspondence, filing or other materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 235; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Partnership Representative shall use its commercially reasonable efforts to (i) apply the rules and elections under the Partnership
Audit Procedures in a manner that minimizes the likelihood that any Member would bear any material tax, interest or penalties as a result
of any audit or proceeding that is attributable to another Member (other than a predecessor in interest) and (ii) cause the financial
burden of any &ldquo;imputed underpayment&rdquo; (as determined in accordance with Section&nbsp;6225 of the Partnership Audit Procedures)
or Proposed Adjustment that does not give rise to an imputed underpayment to be apportioned among the Members of the Company for the taxable
year in which the adjustment is finalized in such manner as may be necessary (as determined by the Partnership Representative in good
faith) so that, to the maximum extent possible, the tax and economic consequences of the imputed underpayment or other Proposed Adjustment
and any associated interest and penalties (any such amount, an &ldquo;<FONT STYLE="color: windowtext"><U>Imputed Underpayment Amount</U></FONT>&rdquo;)
are borne by the Members based upon their interests in the Company for the reviewed year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Member agrees to indemnify and hold harmless the Company from and against any liability with respect to such Member&rsquo;s
share of any Tax deficiency paid or payable by the Company that is apportionable to the Member as determined in accordance with clause
(ii) of <U>Section 9.3(d)</U> with respect to an audited or reviewed taxable year for which such Member was a partner in the Company.
Any obligation of a Member pursuant to this <U>Section 9.3(e)</U> shall be implemented through adjustments to distributions otherwise
payable to such Member as determined in accordance with <U>Section&nbsp;4.1</U>; <U>provided</U>, <U>however</U>, that at the written
request of the Partnership Representative, each Member or former Member may be required to contribute to the Company such Member&rsquo;s
Imputed Underpayment Amount imposed on and paid by the Company; <U>provided</U>, <U>further</U>, that if a Member or former Member individually
directly pays, pursuant to the Partnership Audit Procedures, any such Imputed Underpayment Amount, then such payment shall reduce any
offset to distribution or required capital contribution of such Member or former Member. Any amount withheld from distributions pursuant
to this <U>Section 9.3(e)</U> shall be treated as an amount distributed to such Member or former Member for all purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>All
expenses incurred by the Partnership Representative or Designated Individual in connection with its duties as partnership
representative or designated individual, as applicable, shall be expenses of the Company (including, for the avoidance of doubt, any
costs and expenses incurred in connection with any claims asserted against the Partnership Representative or Designated Individual,
as applicable, except to the extent the Partnership Representative or Designated Individual is determined to have performed its
duties in the manner described in the final sentence of this <U>Section 9.3(f</U>), and the Company shall reimburse and indemnify
the Partnership Representative or Designated Individual, as applicable, for all such expenses and costs. Nothing herein shall be
construed to restrict the Partnership Representative or Designated Individual from engaging lawyers, accountants, tax advisers, or
other professional advisers or experts to assist the Partnership Representative or Designated Individual in discharging its duties
hereunder. Neither the Partnership Representative nor Designated Individual shall be liable to the Company, any Member or any
Affiliate thereof for any costs or losses to any Persons, any diminution in value or any liability whatsoever arising as a result of
the performance of its duties pursuant to this <U>Section&nbsp;9.3</U> absent (i)&nbsp;willful breach of any provision of this <U>Section&nbsp;9.3</U>
or (ii)&nbsp;bad faith, fraud, gross negligence or willful misconduct on the part of the Partnership Representative or Designated
Individual, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Elections</U>. The Company shall file (or cause to be filed) an election pursuant to Section 754 of the Code for the Company
(and any Subsidiary of the Company that is treated as a partnership for U.S. federal income Tax purposes) for each Fiscal Year (to the
extent such an election is not already in force) and shall maintain and keep such election in effect at all times and, except as otherwise
provided herein, the Board of Managers shall determine whether to make any other available election pursuant to the Code</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 236; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: 4 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Withholding</U>. The Company is authorized to withhold from distributions, or with respect to allocations, to the Members and
to pay over to any U.S. federal, state, local or non-U.S. government any amounts required to be so withheld pursuant to the Code or any
provisions of any other U.S. federal, state, local or non-U.S. Law and shall apportion such amounts to the Members with respect to which
such amount was withheld. The Members shall, upon request by the Company promptly pay to the Company any amount otherwise required to
be so withheld with respect to such Member that is paid over by the Company to the appropriate taxing authority (and such payment shall
not be considered a Capital Contribution for purposes hereof). Any amounts so withheld (and not paid to the Company by the applicable
Member) and paid over by the Company to the appropriate taxing authority shall be offset against the current or next amounts otherwise
distributable to such Member (and, to the extent so withheld and paid over, shall be treated as amounts distributed to such Member for
all purposes hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;9.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. The obligations set forth in this <U>Article&nbsp;IX</U> shall survive the termination of any Member&rsquo;s interest
in the Company, the termination hereof and/or the termination, dissolution, liquidation or winding up of the Company, and shall remain
binding on each Member for the period of time necessary to resolve with the IRS (or any other applicable taxing authority) all Tax matters
relating to the Company and for Members to satisfy their indemnification obligations, if any, pursuant to this <U>Article&nbsp;IX</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;X</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>MEMBER TRANSFERS
AND WITHDRAWALS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Membership Interest, in whole or in part, shall be (i) subject to the claims of any creditor, to any spouse for alimony or support
or to legal process and (ii) except as may be specifically provided for herein, voluntarily or involuntarily alienated or encumbered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Membership Interest held by a Member shall be Transferred, directly or indirectly, in whole or in part, except in accordance
with the terms and conditions set forth in <U>Section&nbsp;13.1</U> or this <U>Article&nbsp;X</U>. Any Transfer or purported Transfer
of a Membership Interest not made in accordance with <U>Section&nbsp;13.1</U> or this <U>Article&nbsp;X</U> shall be null and void <U>ab
initio</U>. Any Person to which a Transfer is made or attempted in violation of this <U>Article&nbsp;X</U> shall not become a Member,
shall not be entitled to vote on any matters coming before the Members and shall not have any other rights in or with respect to any rights
of a Member of the Company, except as otherwise provided herein. The approval of any Transfer in any one or more instances shall not limit
or waive the requirement for such approval in any other or future instance. For the avoidance of doubt, the restrictions on Transfer contained
in this <U>Article&nbsp;X</U> shall not apply to the Transfer of any capital stock of the Corporation; <U>provided</U> that no Class B
Shares may be Transferred unless an equal number of Common Units are Transferred therewith in accordance with this Agreement (including
in respect of those Transfers to Permitted Transferees) and the Charter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 237; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Regardless of whether such Transfer constitutes a Permitted Transfer, no Transfer of any Membership Interest may be made to a lender
to the Company or any Person who is related (within the meaning of Regulations section 1.752-4(b)) to any lender to the Company whose
loan constitutes a Nonrecourse Liability, without the consent of the Board of Managers; <U>provided</U> that as a condition to such consent,
the lender will be required to enter into an arrangement with the Company and the Corporation to redeem or exchange for the Class&nbsp;A
Shares Amount any Common Units in which a security interest is held by such lender immediately before the time at which such lender would
be deemed to be a member in the Company for purposes of allocating liabilities to such lender under Section 752 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer of Membership Interests Held by the Parent Corporation Group</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Except
as provided in <U>Section&nbsp;10.2(b)</U>, no member of the Parent Corporation Group may Transfer, directly or indirectly, its
Membership Interests, in whole or in part, without the Consent of the Non-Corporation Members, other than (x)&nbsp;a Transfer to a
Permitted Lender Transferee or to any Person, including any Third-Party Pledge Transferee designated by any lender or lenders
secured by a Pledge, or agents acting on their behalf, to which Membership Interests are Transferred pursuant to the exercise of
remedies under a Pledge, whether before or after one (1) or more Permitted Lender Transferees take title to such Membership
Interests or (y)&nbsp;a Transfer in connection with a corporate restructuring, reorganization, recapitalization or comparable
transaction (other than, for the avoidance of doubt, a Termination Transaction of the Corporation) in which (I)&nbsp;all of the
Membership Interests held by a member of the Parent Corporation Group immediately prior to such corporate transaction are
transferred to a successor surviving Person that directly or indirectly owns all of the Membership Interests previously held by such
member of the Parent Corporation Group and (II)&nbsp;if applicable, proper provision is made for the continuation of the rights and
benefits of the Non-Corporation Members hereunder (including, for the avoidance of doubt, those pursuant to <U>Article XIII</U> as
it pertains to any resulting public company in such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to, in the case of clause (i) the applicable provisions of this <U>Article&nbsp;X</U> and, in the case of clause (ii),
any express limitations hereunder with respect to such Transfer to which the members of the Parent Corporation Group are otherwise subject,
any member of the Parent Corporation Group may, in each case without the Consent of the Non-Corporation Members or any consent or approval
of any other Members, (i) Transfer its Membership Interests, in whole or in part, to any Person that is, and remains, a direct or indirect
wholly owned Controlled Entity of the Corporation, or (ii)&nbsp;Transfer its Membership Interests in connection with the consummation
of a Termination Transaction of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 238; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Members&rsquo; Rights to Transfer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General Restrictions</U>. Except for any Permitted Transfer (subject to the applicable provisions of this <U>Article X</U>)
or any Transfer of Membership Interests pursuant to <U>Section&nbsp;13.1</U>, no Non-Corporation Member or Assignee shall Transfer, directly
or indirectly, its Membership Interests, in whole or in part, without the prior written consent of the Board of Managers and subject to
any terms and conditions imposed by the Board of Managers (any such Transfer approved by the Board of Managers, an &ldquo;<FONT STYLE="color: windowtext"><U>Approved
Transfer</U></FONT>&rdquo;). Any purported transfer not made in accordance with the terms of this Agreement shall be void <U>ab initio</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer Conditions</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Qualified Transferee</U>. Except for any Transfer pursuant to <U>Section&nbsp;13.1</U>, any Permitted Transfer of a Non-Corporation
Member and any Approved Transfer shall be made only to a single Qualified Transferee; <U>provided</U>, <U>however</U>, that all Qualified
Transferees that are Affiliates, or that comprise investment accounts or funds managed by a single Qualified Transferee and its Affiliates,
shall be considered together to be a single Qualified Transferee; <U>provided</U>, <U>further</U>, that each such Transfer meeting the
minimum Transfer restriction of <U>Section&nbsp;10.3(b)(iii)</U>&nbsp;may be to a separate Qualified Transferee.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Opinion
of Counsel</U>. In connection with any Approved Transfer, the Transferring Member shall deliver or cause to be delivered to the
Company an opinion of legal counsel reasonably satisfactory to the Board of Managers to the effect that the proposed Transfer may be
effected without registration under the Securities Act and will not otherwise violate the registration provisions of the Securities
Act and the regulations promulgated thereunder or violate any state securities Laws or regulations applicable to the Company or the
Membership Interests Transferred; <U>provided</U>, <U>however</U>, that the Board of Managers may waive this condition in its sole
discretion; <U>provided</U>, <U>further</U>, that, if the Board of Managers determines, based on the advice of counsel, that such
Transfer would (A) create a material risk of requiring the filing of a registration statement under the Securities Act, (B) cause
the Company to be treated as an association taxable as a corporation or a &ldquo;publicly traded partnership&rdquo; pursuant to
Section 7704 of the Code, or (C) otherwise violate any federal or state securities Laws or regulations applicable to the Company or
the Membership Interests, the Board of Managers may, in its sole discretion, prohibit any such Approved Transfer. The foregoing
provisions of this <U>Section&nbsp;10.3(b)(ii)</U> shall not apply to any Permitted Transfer or any Transfer pursuant to <U>Section&nbsp;13.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Minimum Transfer Restriction</U>. Any Transferring Member in an Approved Transfer shall not Transfer less than the lesser of
(i)&nbsp;10,000 Common Units (as adjusted for any unit split, unit distribution, reverse unit split, reclassification or similar event,
in each case with such adjustment being determined by the Board of Managers) or (ii)&nbsp;all of the remaining Membership Interests owned
by such Transferring Member; <U>provided</U>, <U>however</U>, that for purposes of determining compliance with the foregoing restriction,
all Membership Interests owned by Affiliates of a Member shall be considered to be owned by such Member; <U>provided</U>, <U>further</U>,
that the Board of Managers may waive these provisions of this clause (iii) in its sole discretion; <U>provided</U>, that any such waiver
shall apply equally to all Non-Transferring Members. The foregoing provisions of this <U>Section&nbsp;10.3(b)(iii)</U> shall not apply
to any Permitted Transfer or any Transfer pursuant to <U>Section&nbsp;13.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 239; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Incapacity</U>. If a Member is subject to Incapacity, the executor, administrator, trustee, committee, guardian, conservator
or receiver of such Member&rsquo;s estate shall have all the rights of a Member, but not more rights than those enjoyed by other Members,
for the purpose of settling or managing the estate, and such power as the Incapacitated Member possessed to Transfer all or any part of
its interest in the Company. The Incapacity of a Member, in and of itself, shall not dissolve or terminate the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Information</U>. In connection with any Transfer hereunder, the Member Transferring such Member&rsquo;s Interest (or part
thereof) or any rights therein shall provide such information as may be reasonably requested by the Board of Managers, including in connection
with an election made or to be made by the Company pursuant to Section 754 of the Code or the Company&rsquo;s potential withholding obligation
under Section 1446(f)(4) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Substituted Members</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>A
transferee of any Membership Interests pursuant to <U>Section 10.2</U> or <U>Section 10.3</U> shall be admitted as a Substituted
Member, subject to compliance with the last sentence of this <U>Section&nbsp;10.4(a)</U>. The failure or refusal by the Board of
Managers to permit a transferee of any such Membership Interests to become a Substituted Member shall not give rise to any cause of
action against the Company, the Board of Managers or any member of the Parent Corporation Group. Subject to the foregoing, a
transferee shall not be admitted as a Substituted Member until and unless, and such underlying transfer shall not be effective until
and unless, it furnishes to the Board of Managers (i)&nbsp;a joinder agreement, in a form and substance satisfactory to the Board of
Managers, under which such Person agrees to be bound by all of the terms and conditions of this Agreement, (ii)&nbsp;Consent by
Spouse, if applicable, and (iii)&nbsp;such other documents or instruments as may be required by the Board of Managers in order to
effect such Person&rsquo;s admission as a Substituted Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>A Substituted Member shall have the same rights, preferences and privileges, and shall be subject to the same covenants and agreements,
set forth herein as the applicable Members.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Assignees</U>. An Assignee shall be entitled to receive distributions from the Company and the share of Net Profits, Net Losses
and other items of income, gain, loss, deduction and credit of the Company attributable to the Membership Interests assigned to such
transferee and the rights to Transfer the Membership Interests as provided in, and subject to the terms and conditions of, this <U>Article
X</U> and <U>Article&nbsp;XIII</U> with respect to such Assignee&rsquo;s Membership Interests (as if such Assignee was a Member and <U>provided</U>,
that such Assignee shall only have such rights if he, she or it otherwise complies with all covenants, agreements or obligations of a
Member with respect thereto, other than the last sentence of Section 10.4(a)), but shall not be deemed to be a Member or holder of Membership
Interests for any other purpose hereunder; provided that an Assignee shall not be entitled to such items if it would cause the Company
to be treated as an association taxable as a corporation or a &ldquo;publicly traded partnership&rdquo; pursuant to Section 7704 of the
Code. Unless admitted as a Substituted Member, no Assignee shall have any rights hereunder, other than those of an Assignee as expressly
provided in this <U>Section&nbsp;10.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 240; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>No
Transfer of any Membership Interests shall relieve the Transferring Member of any of its covenants and agreements hereunder, except
and to the extent actually performed or otherwise determined by the Board of Managers, and no Non-Corporation Member may withdraw
from the Company, except (i) as a result of a Permitted Transfer or Approved Transfer of all of such Member&rsquo;s Membership
Interests in which the transferee becomes a Substituted Member in accordance with <U>Section&nbsp;10.4</U>, (ii) pursuant to the
Redemption, Termination Transaction Redemption or Corporation Unit Acquisition of all of its Membership Interests under <U>Section&nbsp;13.1</U>
or any redemption of all of its Membership Interests pursuant to any Membership Interest Designation or (iii) as a result of the
acquisition by the Corporation of all of such Member&rsquo;s Membership Interests, whether or not pursuant to <U>Section&nbsp;13.1(b)</U>.
For the avoidance of doubt, Any Non-Corporation Member that Transfers all of its Membership Interests in a transaction contemplated
by the foregoing clauses&nbsp;(i) &ndash;(iii) shall cease to be a Non-Corporation Member.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary herein, except as otherwise determined, in the case of clauses (iii) through (x), by the
Board of Managers in its discretion or in connection with a Termination Transaction of the Corporation that is approved by the Board of
Directors, in no event may any Transfer of Membership Interests, in whole or in part (including any Redemption, Termination Transaction
Redemption or Corporation Unit Acquisition, any other acquisition of Membership Interests by the Corporation, any acquisition of Membership
Interests by the Company, any Permitted Transfer or any direct or indirect Transfer of an interest in any Member), be made:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to any Person who lacks the legal right, power or capacity to own a Membership Interest;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in violation of applicable Law;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>of any component portion of a Membership Interest, such as the Capital Account, or rights to distributions, separate and apart
from all other components of a Membership Interest;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 241; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if the Board of Managers determines that such Transfer would create a material risk that the Company would become, with respect
to any employee benefit plan subject to Title I of ERISA, a &ldquo;party-in-interest&rdquo; (as defined in ERISA Section&nbsp;3(14)) or
a &ldquo;disqualified person&rdquo; (as defined in Section 4975(c) of the Code);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if the Board of Managers determines, based on the advice of counsel, that such Transfer would create a material risk that any portion
of the assets of the Company would constitute assets of any employee benefit plan pursuant to Department of Labor Regulations section
2510.2-101;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if such Transfer requires the registration of such Membership Interest pursuant to any applicable federal or state securities Laws;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if the Board of Managers determines, based on the advice of counsel, that such Transfer creates a material risk that the Company
would become a reporting company under the Exchange Act;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> if the Board of Managers determines, based on the advice of counsel, that such Transfer subjects the Company to regulation under
the Investment Company Act of 1940, the Investment Advisors Act of 1940 or ERISA; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if the Board of Managers determines, based on the advice of counsel that (1) there would be a non De Minimis risk that such Transfer
would result in the Company having more than 100 partners, within the meaning of Regulations section 1.7704-1(h) (determined taking into
account the rules of Regulations section 1.7704-1(h)(3)), (2) there would be a non De Minimis risk that such Transfer would be treated
as effectuated through an &ldquo;established securities market&rdquo; or a &ldquo;secondary market (or the substantial equivalent thereof)&rdquo;
within the meaning of Section 7704 of the Code, (3) such Transfer would create a non De Minimis risk of the Company being treated as an
association taxable as a corporation or a &ldquo;publicly traded partnership&rdquo; pursuant to Section 7704 of the Code or (4) such Transfer
would cause the Company to have a non De Minimis withholding obligation under Section 1446(f) of the Code or a successor provision for
which the Company is paid in advance by the transferor pursuant to this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In connection with any proposed Transfer, at the request of the Board of Managers, the applicable transferor shall furnish to the
Company evidence in form and substance reasonably satisfactory to the Board of Managers (which shall, if requested by the Board of Managers,
include a representation letter of the proposed transferee, to include representations substantially similar to those described in <U>Section
2.8</U> and <U>Section 2.9</U> hereof) that the Transfer would not have any of the results described in <U>Section&nbsp;10.6(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 242; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Transfers pursuant to this <U>Article&nbsp;X</U>, other than a Permitted Transfer to a Permitted Transferee pursuant to the exercise
of remedies under a Pledge or a Transfer by a member of the Parent Corporation Group, may only be made on the first day of any month,
unless the Board of Managers otherwise agrees.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;10.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions on a Termination Transaction of the Corporation</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>So long as Amber GT Parent continues have a right to nominate a director to the Board of Directors pursuant to the Director Nomination
Agreement, no member of the Parent Corporation Group shall engage in, or cause or permit, a Termination Transaction of the Corporation,
other than (x) with the Consent of the Non-Corporation Members (not to be unreasonably withheld, conditioned or delayed), or (y) either:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>in
connection with any such Termination Transaction of the Corporation, each Non-Corporation Member will receive, or will have the
right to elect to receive (to the extent an election is made available to the holders of Class A Shares), the amount of cash,
securities or other property which such holder of Common Units would have received if it received Class A Shares in exchange for all
of its Common Units pursuant to a Corporation Unit Acquisition occurring immediately prior to the time the Termination Transaction
of the Corporation (the &ldquo;<FONT STYLE="color: windowtext"><U>Transaction Consideration</U></FONT>&rdquo;); <U>provided</U>, <U>however</U>,
that this clause (i) will be deemed to be satisfied with respect to each Non-Corporation Member that is required to effect a
Corporation Unit Acquisition pursuant to <U>Section 10.7(b)(iv)</U>; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all of the following conditions are met: (1)&nbsp;substantially all of the assets directly or indirectly owned by the Company prior
to the announcement of the Termination Transaction of the Corporation are, immediately after the Termination Transaction of the Corporation,
owned directly or indirectly by the Company or another limited partnership or limited liability company which is the survivor of a merger,
consolidation, combination of assets or similar transaction involving the Company (in each case, the &ldquo;<FONT STYLE="color: windowtext"><U>Surviving
Company</U></FONT>&rdquo;); (2)&nbsp;the Surviving Company is classified as a partnership for U.S. federal income tax purposes; (3)&nbsp;the
Non-Corporation Members that held Common Units immediately prior to the consummation of such Termination Transaction of the Corporation
own a percentage interest of the Surviving Company based on the relative Fair Market Value of the net assets of the Company and the other
net assets of the Surviving Company immediately prior to the consummation of such transaction unless such Non-Corporation Members receive
cash compensation for such Common Units; (4)&nbsp;the rights of such Non-Corporation Members with respect to the Surviving Company are
no less favorable in the aggregate as those of the Non-Corporation Members holding Common Units immediately prior to the consummation
of such transaction (except to the extent that any such rights are consistent with clause&nbsp;(5)&nbsp;below) and as those applicable
to any other Non-Corporation Members of the Surviving Company; and (5)&nbsp;such rights include the right to redeem their interests in
the Surviving Company on the terms and conditions no less favorable in the aggregate as those set forth in <U>Article&nbsp;XIII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 243; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>In
the event of a Termination Transaction of the Corporation, each of the Non-Corporation Members (i) agrees not to demand or exercise
appraisal or dissenters rights under any applicable business corporation law or other law with respect to such Termination
Transaction of the Corporation, (ii) shall vote (and if applicable, cause each of its Affiliates to vote), and provide its consent
(and if applicable, cause each of its Affiliates to provide its consents) with respect to, their respective Capital Shares, Common
Shares and/or, if applicable, Membership Interests (1) in favor of the Termination Transaction of the Corporation and (2) in
opposition to any and all other proposals that could oppose, prevent, delay, or impair the ability to consummate the proposed
Termination Transaction of the Corporation, (iii) shall refrain from depositing (and if applicable cause each of its Affiliates to
refrain from depositing) any Capital Shares, Common Shares or Membership Interests in a voting trust or subjecting any such equity
interests to any arrangement or agreement with respect to voting any such shares, unless the Corporation specifically so requests in
connection with the proposed Termination Transaction of the Corporation, or (iv)&nbsp;at the request of the Board of Directors shall
either (A) effect a Corporate Unit Acquisition for the Class A Shares Amount in respect of all or any portion of its Common Units
immediately prior to the consummation of the Termination Transaction of the Corporation, with the applicable covenants and
agreements with respect to such Corporate Units Acquisition applying to this <U>Section 10.7</U>, <I>mutatis mutandis</I>, or (B)
sell or otherwise transfer its Membership Interests to the purchaser(s) in such Termination Transaction of the Corporation, <U>provided</U>
that each such Non-Corporation Member receives the consideration on substantially the same terms he, she or it would have been
entitled to if it received Class&nbsp;A Shares in exchange for all of its Common Units pursuant to a Corporation Unit Acquisition
immediately prior to consummation of the Termination Transaction of the Corporation, and in connection with any such sale or
transfer shall execute and deliver customary transaction or similar agreements, which shall include customary representations of the
type described in <U>Article XIII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article&nbsp;XI<BR></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><U>ADMISSION
OF MEMBERS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;11.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Members; Admission of Additional Members</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>A Person (other than a then-existing Member) who makes a Capital Contribution to the Company in exchange for Membership Interests
and in accordance herewith shall be admitted to the Company as an Additional Member only upon furnishing to the Company with (i) a joinder
agreement, in form and substance satisfactory to the Board of Managers, under which such Person agrees to be bound by all of the terms
and conditions of this Agreement, (ii)&nbsp;Consent by Spouse, if applicable, and (iii)&nbsp;such other documents or instruments as may
be required by the Board of Managers in order to effect such Person&rsquo;s admission as an Additional Member.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary in this <U>Section&nbsp;11.1</U>, no Person shall be admitted as an Additional Member
without the consent of the Board of Managers. The admission of any Person as an Additional Member shall become effective on the date upon
which the name of such Person is recorded on the books and records of the Company, following the consent of the Board of Managers to such
admission and the satisfaction of all the conditions set forth in <U>Section&nbsp;11.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 244; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If any Additional Member is admitted to the Company, all distributions with respect to which the Company Record Date is before
the date of such admission shall be made solely to Members and Assignees other than the Additional Member, and all distributions thereafter
shall be made to all the Members and Assignees including such Additional Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;11.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limit on Number of Members</U>. Unless otherwise permitted by the Board of Managers, no Person shall be admitted to the Company
as an Additional Member if the effect of such admission would be to cause the Company to have a number of Members (including as Members
for this purpose those Persons indirectly owning an interest in the Company through another partnership, a limited liability company,
a subchapter S corporation or a grantor trust) that would cause the Company to become a reporting company under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;11.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Admission</U>. A Person shall be admitted to the Company as a Non-Corporation Member of the Company or a Board of Managers
of the Company only upon strict compliance, and not upon substantial compliance, with the requirements set forth herein for admission
to the Company as a Non-Corporation Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article&nbsp;XII</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><U>DISSOLUTION,
LIQUIDATION AND TERMINATION</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;12.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Dissolution</U>. The Company shall not be dissolved upon (a) the admission of Additional Members or Substituted Members in
accordance with the terms hereof, or (b) the Incapacity of any Member, or the occurrence of any other event that terminates the continued
membership of any Member in the Company. The Company may be dissolved, liquidated and terminated only pursuant to the provisions of this
<U>Article&nbsp;XII</U>, and the Members hereby irrevocably waive any and all other rights they may have to cause a dissolution of the
Company or a sale or partition of any or all of the Company assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;12.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Events Causing Dissolution</U>. The Company shall be dissolved and its affairs shall be wound up upon the earliest to occurrence
of any of the following events (each, a &ldquo;<FONT STYLE="color: windowtext"><U>Liquidating Event</U></FONT>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Board of Managers&rsquo; determination, with the Consent of the Members, to dissolve the Company and wind up its affairs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the sale of all or substantially all of the Company&rsquo;s consolidated assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 245; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the termination of the legal existence of the last remaining Member of the Company or the occurrence of any other event which terminates
the continued membership of the last remaining Member of the Company in the Company unless the Company is continued without dissolution
in a manner permitted by this Agreement or the Act; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the entry of a decree of judicial dissolution under Section 18-802 of the Act requiring such dissolution and winding up pursuant
to Law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;12.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Distribution upon Dissolution</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Upon
the dissolution of the Company pursuant to <U>Section&nbsp;12.2</U>, unless the Company is continued pursuant to <U>Section&nbsp;12.2</U>,
the Board of Managers or any Person selected by the Board of Managers (the Board of Managers or such other Person being referred to
herein as the &ldquo;<FONT STYLE="color: windowtext"><U>Liquidator</U></FONT>&rdquo;)) shall be responsible for overseeing the
winding up and dissolution of the Company and shall take full account of the Company&rsquo;s liabilities and property, and the
Company property shall be liquidated as promptly as is consistent with obtaining the Fair Market Value thereof, and the proceeds
therefrom (which may, to the extent determined by the Board of Managers, include shares of stock in the Corporation) shall be
applied and distributed in the following order:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>first, to the satisfaction of all of the Company&rsquo;s debts and liabilities to creditors including Members who are creditors
(other than with respect to liabilities owed to Members in satisfaction of liabilities for distributions), whether by payment or the making
of reasonable provision for payment thereof;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>second, to the satisfaction of all of the Company&rsquo;s liabilities to the Members in satisfaction of liabilities for distributions,
whether by payment or the making of reasonable provision for payment thereof; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the balance, if any, to the Members in accordance with <U>Section&nbsp;4.1</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Managers shall not receive any additional compensation
for any services performed pursuant to this <U>Article&nbsp;XII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 246; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding the provisions of <U>Section&nbsp;12.3(a)</U>&nbsp;that require liquidation of the assets of the Company, but subject
to the order of priorities set forth therein, if prior to or upon dissolution of the Company, the Liquidator determines that an immediate
sale of part or all of the Company&rsquo;s assets would be impractical or would cause undue loss to the Members, the Liquidator may, in
its sole and absolute discretion, defer for a reasonable time the liquidation of any assets except those necessary to satisfy liabilities
of the Company (including to those Members as creditors) and/or distribute to the Members, in lieu of cash, as tenants in common and in
accordance with the provisions of <U>Section&nbsp;12.3(a)</U>, undivided interests in such Company assets as the Liquidator deems not
suitable for liquidation. Any such distributions in kind shall be made only if, in the reasonable judgment of the Liquidator, such distributions
in kind are in the best interest of the Members, and shall be subject to such conditions relating to the disposition and management of
such properties as the Liquidator deems reasonable and equitable and to any agreements governing the operation of such properties at such
time. The Liquidator shall determine the Fair Market Value in its reasonable judgment of any property distributed in kind using such reasonable
method of valuation as it may adopt.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If any Member has a deficit balance in its Capital Account (after giving effect to all contributions, distributions and allocations
for all taxable years, including the year during which such liquidation occurs), such Member shall have no obligation to make any contribution
to the capital of the Company with respect to such deficit, and such deficit shall not be considered a debt owed to the Company or to
any other Person for any purpose whatsoever. In the sole and absolute discretion of the Board of Managers or the Liquidator, a pro rata
portion of the distributions that would otherwise be made to the Members pursuant to this <U>Article&nbsp;XII</U> may be:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>distributed to a trust established for the benefit of the Members for the purpose of liquidating Company assets, collecting amounts
owed to the Company, and paying any contingent or unforeseen liabilities or obligations of the Company or of the Board of Managers arising
out of or in connection with the Company and/or Company activities. The assets of any such trust shall be distributed to the Members,
from time to time, in the reasonable discretion of the Board of Managers, in the same proportions and amounts as would otherwise have
been distributed to the Member pursuant hereto; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>withheld or escrowed to provide a reasonable reserve for Company liabilities (contingent or otherwise) and to reflect the unrealized
portion of any installment obligations owed to the Company; <U>provided</U> that such withheld or escrowed amounts shall be distributed
to the Member in the manner and order of priority set forth in <U>Section&nbsp;12.3(a)</U>&nbsp;as soon as practicable.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;12.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rights of Members</U>. Except as otherwise provided herein and subject to the rights of any Member set forth in a Membership
Interest Designation, (a) each Member shall look solely to the assets of the Company for the return of its Capital Contribution, (b) no
Member shall have the right or power to demand or receive property other than cash from the Company and (c) no Member shall have priority
over any other Member as to the return of its Capital Contributions, distributions or allocations.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;12.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. The Company shall terminate when all of the assets of the Company, after payment of or due provision for all
debts, liabilities and obligations of the Company, shall have been distributed to the Members in the manner provided for in this <U>Article&nbsp;XII</U>,
and the Certificate shall have been cancelled in the manner required by the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 247; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;12.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reasonable Time for Winding-Up</U>. A reasonable time shall be allowed for the orderly winding-up of the business and affairs
of the Company and the liquidation of its assets pursuant to <U>Section&nbsp;12.3</U>, in order to minimize any losses otherwise attendant
upon such winding-up, and the provisions hereof shall remain in effect between and among the Members during the period of liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;XIII</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>REDEMPTION
RIGHTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;13.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Redemption Rights of Non-Corporation Members</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Redemption</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>After
the expiration or earlier termination of the Lock-Up Period, a Non-Corporation Member shall have the right (subject to the terms and
conditions set forth herein, including, for the avoidance of doubt, <U>Section&nbsp;13.1(b)</U> and <U>Section&nbsp;13.1(c)</U>) to
redeem all or a portion of the Common Units held by such Non-Corporation Member (any such Common Units with respect to which a
Non-Corporation Member has exercised such right, &ldquo;<FONT STYLE="color: windowtext"><U>Tendered Units</U></FONT>&rdquo;) in
exchange for the Cash Amount payable on the Specified Redemption Date (in each case, a &ldquo;<FONT STYLE="color: windowtext"><U>Redemption</U></FONT>&rdquo;); <U>provided</U>, <U>however</U>,
that, subject to any rights of the Corporation or the ARYA Sponsor under the Investor Rights Agreement, the Company may, in the
Board of Managers&rsquo; sole discretion, redeem Tendered Units at the request of a Non-Corporation Member prior to the end of the
Lock-Up Period (such a Redemption, which shall, for the avoidance of doubt, constitute and be treated as a Redemption for all
purposes hereof, a &ldquo;<FONT STYLE="color: windowtext"><U>Special Redemption</U></FONT>&rdquo;); <U>provided</U>, <U>further</U>,
that the Board of Managers first receives an opinion of counsel for the Non-Corporation Member reasonably satisfactory to the Board
of Managers to the effect that the proposed Special Redemption will not cause the Company or the Corporation to violate any federal
or state securities Laws or regulations applicable to the Special Redemption or the issuance and sale of Class A Shares pursuant to
a Corporation Unit Acquisition. Any Redemption shall be exercised pursuant to a Notice of Redemption delivered to the Company and
the Corporation by the Non-Corporation Member (the &ldquo;<FONT STYLE="color: windowtext"><U>Tendering Party</U></FONT>&rdquo;) not
less than ten (10) and not more than twenty (20) Business Days prior to the Specified Redemption Date; <U>provided</U> that,
notwithstanding anything herein to the contrary, a Notice of Redemption may only be submitted up to two (2) times per quarter of the
Fiscal Year. The Company&rsquo;s obligation to effect a Redemption shall be subject to <U>Section&nbsp;13.1(b)</U> and shall not be
binding on the Company until the Business Day following the Cut-Off Date. On or prior to the Specified Redemption Date, the
Tendering Party shall execute and deliver to the Company a customary redemption or other agreement to effect the applicable
transactions contemplated by this <U>Section 13.1</U> in a form reasonably acceptable to the Board of Managers, which agreement
shall include customary representations and warranties from the Tendering Party with respect to (i) good title to his, her or its
Common Units, (ii) the absence of liens and encumbrances with respect to his, her or its Common Units, (iii) if an individual, his
or her legal capacity or, if any other Person, its valid existence and good standing (if applicable), (iv)&nbsp;the authority for,
and, to the extent it relates to such Tendering Party, the validity and binding effect of (as against such Tendering Party) any
agreement entered into by such Tendering Party in connection with the redemption or other transactions, (v) no litigation pending
or, to the knowledge of such party, threatened against or affecting such Tendering Party relating to his, her or its ownership of
Common Units or that could otherwise reasonably be expected to materially delay or prevent such redemption or other transaction(s),
(vi) such redemption or other transaction(s) not conflicting with such Tendering Party&rsquo;s governing documents (if applicable),
or any law, order or regulation applicable to such Tendering Party, or creating any lien or encumbrance on such Tendering
Party&rsquo;s Common Units and (vii)&nbsp;the fact that no broker&rsquo;s commission is payable by the Company as a result of such
Tendering Party&rsquo;s conduct in connection with such redemption or other transaction(s). The Company and the Tendering Party
shall consummate the Redemption on the Specified Redemption Date, upon which the Tendering Party will transfer to the Company the
Tendered Units (free and clear of all liens and encumbrances, except for restrictions on transfer arising under applicable federal
or state securities Laws) and the Company shall deliver to the Tendering Party the applicable Cash Amount as a certified or bank
check payable to the Tendering Party or, in the Board of Managers&rsquo; sole and absolute discretion, by wire transfer of funds to
a bank account specified on the Notice of Redemption on or before the Specified Redemption Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 248; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Unless the Corporation has elected to effect a Corporation Unit Acquisition pursuant to <U>Section&nbsp;13.1(b)</U>, the Tendering
Party shall transfer and surrender the Tendered Units to be redeemed to the Company, in each case free and clear of all liens and encumbrances,
except for restrictions on transfer arising under applicable federal or state securities Laws, and the Company shall cancel the redeemed
Tendered Units.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Common Units to be redeemed by the Tendering Party are represented by a certificate or certificates, prior to the Specified
Redemption Date, the Tendering Party shall also present and surrender such certificate or certificates representing such Common Units
during reasonable business hours at the principal executive offices of the Company. If required by the Board of Managers, the Tendering
Party shall also deliver, prior to the Specified Redemption Date, instruments of transfer, in forms reasonably satisfactory to the Board
of Managers, duly executed by the Tendering Party or the Tendering Party&rsquo;s duly authorized representative.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Notwithstanding
the foregoing, (A)&nbsp;if a Termination Transaction of a Non-Corporation Member occurs with respect to a Non-Corporation Member,
then such Non-Corporation Member shall deliver a written notice to the Company and the Corporation as promptly as practicable (and
in any event five (5) Business Days) prior to the occurrence of such Termination Transaction of the Non-Corporation Member and (B)
the Board of Managers may elect, pursuant to a notice delivered to such Terminating Non-Corporation Member, specifying a Specified
Redemption Date (the &ldquo;<U>Termination Transaction Notice</U>&rdquo;), to require the Non-Corporation Member or any Substituted
Member or Assignee that holds Common Units initially held by such Non-Corporation Member to effect an exchange for the applicable
Class A Shares Amount pursuant to the provisions of <U>Section&nbsp;13.1(b)</U> (a &ldquo;<U>Termination Transaction
Redemption</U>&rdquo;) with respect to (x)&nbsp;in the case of a Termination Transaction of a Non-Corporation Member as defined in
clauses (a), (b), (c), (e) or (f) of the definition of Termination Transaction of a Non-Corporation Member, all of such
Non-Corporation Member&rsquo;s Membership Interests or (y)&nbsp;in the case of a Termination Transaction of a Non-Corporation Member
as defined in clause (d) of the definition of Termination Transaction of a Non-Corporation Member, solely with respect to all or any
portion of the Membership Interests Transferred in such Termination Transaction of a Non-Corporation Member (the Membership
Interests described in clause (x) or (y), as applicable, the &ldquo;<U>Termination Transaction Units</U>&rdquo;), which shall be
effective immediately prior to the consummation of such Termination Transaction of a Non-Corporation Member (but, for the avoidance
of doubt, shall be conditioned on the occurrence of such Termination Transaction of a Non-Corporation Member, and shall not be
effective if such Termination Transaction of a Non-Corporation Member does not occur).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 249; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Acquisition by the Corporation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding the provisions of <U>Section&nbsp;13.1(a)</U>, the Corporation may, in the sole discretion of the Board of Directors,
elect to acquire some or all of the Tendered Units from the Tendering Party or Termination Transaction Units from the Terminating Non-Corporation
Member (the Tendered Units or Termination Transaction Units, as applicable, with respect to which the Corporation elects to acquire, the
 &ldquo;<FONT STYLE="color: windowtext"><U>Acquired Units</U></FONT>&rdquo; and the percentage of Tendered Units or Termination Transaction
Units, as applicable, the Corporation elects to acquire, the &ldquo;<FONT STYLE="color: windowtext"><U>Acquired Percentage</U></FONT>&rdquo;)
in exchange for the applicable portion of the Class A Shares Amount or the Cash Amount as set forth in this <U>Section&nbsp;13.1(b)</U>
(a &ldquo;<FONT STYLE="color: windowtext"><U>Corporation Unit Acquisition</U></FONT>&rdquo;), by delivering written notice of such election
to the Tendering Party or the Terminating Non-Corporation Member and the Company, specifying the Acquired Units, the Acquired Percentage
and the form of consideration (as contemplated by <U>Section&nbsp;13.1(b)</U>), prior to 5:00 p.m., New York City time, on the Cut-Off
Date (an &ldquo;<FONT STYLE="color: windowtext"><U>Election Notice</U></FONT>&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>If
the Corporation delivers an Election Notice pursuant to <U>Section&nbsp;13.1(b)(i)</U> to the Tendering Party or the Terminating
Non-Corporation Member and the Company prior to 5:00 p.m., New York City time, on the Cut-Off Date, then on the Specified Redemption
Date, the Tendering Party or the Terminating Non-Corporation Member, as applicable, shall sell to the Corporation, and the
Corporation shall purchase, the Acquired Units for, in the Corporation&rsquo;s sole discretion, (1) a number of Class A Shares equal
to the product of the Class A Shares Amount, <U>multiplied by</U> the Acquired Percentage, (2) cash in an amount equal to the
product of the Cash Amount, <U>multiplied by</U> the Acquired Percentage or (3) a combination of the consideration set forth in the
foregoing clauses&nbsp;(1) and (2) in an aggregate amount equal to the Value of the Tendered Units or the Termination Transaction
Units subject to the Corporation Unit Acquisition. The Corporation shall be treated for all purposes hereof as the owner of such
Acquired Units; <U>provided</U> that, if the Corporation funds the Cash Amount other than through the issuance of Class A Shares,
such Acquired Units will be reclassified into another Equivalent Units of the Company if the Board of Managers determines such
reclassification is necessary. On or prior to the Specified Redemption Date, the Tendering Party or the Terminating Non-Corporation
Member shall (x)&nbsp;enter into customary redemption or other agreements to effect the transactions contemplated by this <U>Section&nbsp;13.1(b)</U>
in a form reasonably acceptable to the Board of Managers, which agreement shall include customary representations from the Tendering
Party with respect to (i) good title to his, her or its Common Units, (ii) the absence of liens and encumbrances with respect to
his, her or its Common Units, (iii) if an individual, his or her legal capacity or, if any other Person, its valid existence and
good standing (if applicable), (iv)&nbsp;the authority for, and, to the extent it relates to such Tendering Party, the validity and
binding effect of (as against such Tendering Party) any agreement entered into by such Tendering Party in connection with the
redemption or other transactions, (v) no litigation pending or, to the knowledge of such party, threatened against or affecting such
Tendering Party relating to his, her or its ownership of Common Units or that could otherwise reasonably be expected to materially
delay or prevent such redemption or other transaction(s), (vi) such redemption or other transaction(s) not conflicting with such
Tendering Party&rsquo;s governing documents (if applicable), or any law, order or regulation applicable to such Tendering Party, or
creating any lien or encumbrance on such Tendering Party&rsquo;s Common Units and (vii)&nbsp;the fact that no broker&rsquo;s
commission is payable by as a result of such Tendering Party&rsquo;s conduct in connection with such redemption or other
transaction(s) and (y)&nbsp;submit such written representations, investment letters, legal opinions or other instruments that are
reasonably necessary, in the view of the Corporation, to effect compliance with the Securities Act. In the event of a purchase of
Acquired Units by the Corporation pursuant to this <U>Section&nbsp;13.1(b)</U>, the Tendering Party shall no longer have the right
to cause the Company to effect a Redemption of such Acquired Units, and upon consummation of such purchase on the Specified
Redemption Date, the Company shall not have any obligation to redeem the Acquired Units under <U>Section&nbsp;13.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 250; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>If
the Corporation elects to acquire Acquired Units for Class A Shares, in whole or in part, then the Corporation shall issue to the
Tendering Party or the Terminating Non-Corporation Member the applicable number of Class A Shares (as determined under <U>Section&nbsp;13.1(b)(ii)</U>)
as duly authorized, validly issued, fully paid and non-assessable Class A Shares (it being understood and agreed that such Class A
Shares shall, unless otherwise determined by the Board of Directors, be in book-entry form and reflected in Corporation&rsquo;s (or
its transfer agent&rsquo;s) books and records) and, if applicable and if and when entitled thereto as provided in the definition of
 &ldquo;Class A Shares Amount,&rdquo; Rights, free of any pledge, lien, encumbrance or restriction (other than restrictions provided
in the Charter, the Investor Rights Agreement, the Securities Act and relevant state securities or &ldquo;blue sky&rdquo; Laws or,
in the case of any Rights, any other liens, encumbrances or restrictions that are applicable to all other such Rights). Except as
expressly required by any other written agreement between the Corporation and such Tendering Party or such Termination
Non-Corporation Member, no Tendering Party or Terminating Non-Corporation Member whose Acquired Units are acquired by the
Corporation pursuant to this <U>Section&nbsp;13.1(b)</U>, any Member, any Assignee or any other interested Person shall have any
right to require or cause the Corporation to register, qualify or list any Class A Shares owned or held by such Person, whether or
not such Class A Shares are issued pursuant to this <U>Section&nbsp;13.1(b)</U>, with the SEC, with any state securities
commissioner, department or agency, under the Securities Act or the Exchange Act or with any securities exchange. Notwithstanding
any delay in such delivery, the Tendering Party or the Terminating Non-Corporation Member shall, subject to his, her or its
compliance with the other applicable covenants and agreements contained in this <U>Article XIII</U>, be deemed the owner of such
Class A Shares for all purposes, including rights to vote or consent, receive dividends, and exercise rights, as of the Specified
Redemption Date. and the Tendering Party or the Terminating Non-Corporation Member shall be deemed to be the owner of, if
applicable, such Rights as of the time he, she or it should have been entitled to such Rights as provided in the definition of
 &ldquo;Class A Shares Amount&rdquo; for all purposes, including, to the extent applicable to such Rights, the rights to vote or
consent, receive dividends, and exercise rights. Class A Shares or Rights issued upon an acquisition of Acquired Units by the
Corporation pursuant to this <U>Section&nbsp;13.1(b) </U>may contain such legends regarding restrictions under the Securities Act,
the Investor Rights Agreement, the Securities Act, relevant state securities or &ldquo;blue sky&rdquo; Laws as the Corporation in
reasonably determines to be necessary or advisable in order to ensure compliance with such agreements or Laws and, in the case of
any such Rights, such other legends regarding restrictions that are applicable to all other such Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 251; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Corporation elects to acquire the Acquired Units for cash, in whole or in part, the Corporation shall deliver to the Tendering
Party or the Terminating Non-Corporation Member the applicable amount of cash (as determined under <U>Section&nbsp;13.1(b)(ii)</U>) as
a certified or bank check payable to the Tendering Party or the Terminating Non-Corporation Member or, in the Corporation&rsquo;s sole
and absolute discretion, by wire transfer of funds to a bank account specified on the Notice of Redemption or as provided in writing by
the Terminating Non-Corporation Member on or before the Specified Redemption Date.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Corporation elects to acquire Acquired Units, the Corporation shall continue as a Member of the Company with respect to
any Common Units or other Equivalent Units in the Company it receives hereunder.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary herein, with respect to any Redemption, Termination Transaction Redemption or Corporation
Unit Acquisition pursuant to this <U>Section&nbsp;13.1</U>:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>without the consent of the Board of Managers, no Tendering Party or Non-Corporation Terminating Member may effect a Redemption
for less than the lesser of (1) 10,000 Common Units (as adjusted for any unit split, unit distribution, reverse unit split, reclassification
or similar event, in each case with such adjustment being determined by the Board of Managers) or (2) all of the remaining Common Units
held by such Tendering Party or Non-Corporation Terminating Member;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if the Company makes a distribution to Members following 5:00 p.m., New York City time on the Valuation Date and prior to the delivery
or payment of Class A Shares Amount or the Cash Amount, as applicable, which distribution was not publicly announced prior to such Valuation
Date, then the Class A Shares Amount or the Cash Amount to be received or paid, as applicable, shall be reduced by the amount received
by the Tendering Party or the Non-Corporation Terminating Member in respect of the Acquired Units in such distribution (provided that
if a Tendering Party or the Non-Corporation Terminating Member is receiving both Class A Shares Amount and Cash Amount in connection with
one or more transactions contemplated by this <U>Article XIII</U>, then such reduction will, unless otherwise determined by the Corporation,
be pro rata among the Class A Shares Amount and Cash Amount (based on each such amount immediately prior to giving effect to such reduction));</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 252; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>if
(1)&nbsp;a Tendering Party surrenders Tendered Units during the period after the Company Record Date with respect to a distribution
payable to Members holding Common Units, and before the record date established by Corporation for a dividend to its stockholders of
some or all of its portion of such Company distribution, and (2)&nbsp;the Board of Managers elects to redeem any of such Tendered
Units in exchange for Class&nbsp;A Shares pursuant to <U>Section&nbsp;13.1(b)</U>, then such Tendering Party shall pay to the
Company an amount in cash equal to the dividend from the Corporation that he, she or it will be entitled to receive with respect to
such distribution and record date in respect of the Class A Shares received in respect of such Tendered Units;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the consummation of such Redemption, Termination Transaction Redemption or such Corporation Unit Acquisition shall be subject to
the expiration or termination of the applicable waiting period, if any, under the Hart-Scott-Rodino Antitrust Improvements Act of 1976
or, as determined by the Board of Managers, satisfaction of any other required antitrust or competition Laws;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Tendering Party or the Terminating Non-Corporation Member shall continue to own (subject , in the case of an Assignee to the
provisions of <U>Section 10.5</U>) all Common Units subject to any Redemption or Corporation Unit Acquisition, and be treated as a Non-Corporation
Member or an Assignee, as applicable, with respect to such Common Units for all purposes hereof, until the Specified Redemption Date and
until such Tendered Units are redeemed, acquired or exchanged, as applicable, pursuant to this <U>Section 13.1</U>;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>until the Specified Redemption Date, the Tendering Party or the Terminating Non-Corporation Member shall have no rights as a stockholder
of Corporation with respect to the Class&nbsp;A Shares issuable in connection with any Corporation Unit Acquisition;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>following the expiration of the Lock-up Period, the Board of Managers shall establish a Specified Redemption Date in each quarter
of each Fiscal Year, <U>provided</U> that (1) the Board of Managers may postpone any such date one or more times, (2) the Board of Managers
shall provide notice to the Members of each Specified Redemption Date at least forty-five (45) days prior to such Specified Redemption
Date and (3) the Board of Managers may, in its sole discretion, establish additional or other Specified Redemption Dates on such terms
and conditions as determined by the Board of Managers in its sole discretion, if it determines that doing so would not create a non De
Minimis risk that the Company would become a &ldquo;publicly traded partnership,&rdquo; as such term is defined in Section&nbsp;469(k)(2)
or Section&nbsp;7704(b) of the Code;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 253; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>the
Tendering Party or the Terminating Non-Corporation Member shall deliver to the Corporation or the Company, as applicable, a
certificate, dated as of the date of the Redemption and sworn under penalties of perjury, in a form reasonably acceptable to the
Corporation or the Company, as applicable, certifying as to such Tendering Party&rsquo;s or the Terminating Non-Corporation
Member&rsquo;s taxpayer identification number and, to the extent applicable, that such Tendering Party or the Terminating
Non-Corporation Member is a not a &ldquo;foreign person&rdquo; for purposes of Section 1445 and Section 1446(f) of the Code (which
certificate may be an Internal Revenue Service Form W-9 if then sufficient for such purposes under applicable Law); <U>provided</U>
that if such Tendering Party or the Terminating Non-Corporation Member does not certify as to the foregoing, the sole remedy of the
Corporation or the Company, as applicable, shall be to withhold any required taxes with respect to such Tendering Party or the
Terminating Non-Corporation Member pursuant to <U>Section 13.1(e)</U>; <U>provided</U>, <U>further</U>, that if the amount required
to be withheld exceeds the Cash Amount to be paid to the Tendering Party or the Terminating Non-Corporation Member in connection
with such exchange, then, if requested by the Company or the Corporation, as applicable, the Tendering Party or the Non-Terminating
Member shall pay to the Company or the Corporation, as applicable, an amount of cash equal to any such excess amount as a condition
to the exchange (and such cash shall reduce the amount of taxes withheld by the Corporation or the Company, as applicable);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in connection with any Redemption, Termination Transaction Redemption or Corporation Unit Acquisition, a number of Class B Shares
shall automatically and without any further consideration be surrendered and cancelled in accordance with the Charter;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>for U.S. federal and applicable state and local income tax purposes, each of the Tendering Party or the Terminating Non-Corporation
Member, the Company and the Corporation agree to treat each Corporation Unit Acquisition as a sale by the Tendering Party or the Terminating
Non-Corporation Member of their respective Common Units (together with the Class B Shares) to the Corporation in exchange for the issuance
or payment by the Corporation of the Class A Shares Amount or the Cash Amount; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in connection with any Redemption, Termination Transaction Redemption or Corporation Unit Acquisition, upon the acceptance of the
Class A Shares Amount or the Cash Amount, the Tendering Party or the Terminating Non-Corporation Member shall represent and warrant that
the Tendering Party or the Terminating Non-Corporation Member, as applicable, is the owner of the number of Common Units and Class B Shares
the Tendering Party is electing to have the Company redeem or in the case of the Terminating Non-Corporation Member, for which the Company
has determined shall be redeemed, and that such Common Units and Class B Shares are not subject to any liens or restrictions to transfer
the securities (other than restrictions imposed hereby or by the Charter, as applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 254; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>The
Board of Managers may (i) impose additional limitations and restrictions on Redemptions (including limiting Redemptions or creating
priority procedures for Redemptions) or (ii) require any Member or group of Members to redeem all of their Common Units, in each
case to the extent it reasonably determines, based on written advice from a nationally-recognized law firm or accounting firm at a
 &ldquo;will&rdquo; level, and with the prior written consent of the Non-Corporation Members (such consent not to be unreasonably
withheld, conditioned or delayed), that such limitations and restrictions are, or such Redemption is, as applicable, necessary to
avoid the Company being classified as a &ldquo;publicly traded partnership&rdquo; within the meaning of Section 7704 of the Code.
Upon delivery of any notice by the Board of Managers to such Member or group of Members requiring such Redemption (which notice
shall, for the avoidance of doubt, be delivered after the Non-Corporation Member&rsquo;s written consent shall have been obtained
and which shall be accompanied by the written advice from a nationally-recognized law firm or accounting firm referred to above),
such Member or group of Members shall be treated as having exercised their rights pursuant to <U>Section 13.1(a)(i)</U> to redeem
all of their Common Units in a Redemption on such date (and such date shall be deemed to be a Specified Redemption Date for purposes
hereof).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each of the Company and the Corporation shall be entitled to deduct and withhold from any consideration payable or otherwise deliverable
upon a Redemption such amounts as may be required to be deducted or withheld therefrom under the Code or any provision of applicable Law,
and to the extent deduction and withholding is required, such deduction and withholding may be taken in Class A Shares in the sole discretion
of the Board of Managers. To the extent that amounts are so withheld and paid over to the appropriate taxing authority (or, if taken in
Class A Shares, cash in the amount of the fair market value of such shares is paid over to the appropriate taxing authority), such amounts
will be treated for purposes hereof as having been paid to the Tendering Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">Article&nbsp;XIV</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><U>MISCELLANEOUS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as otherwise expressly required or permitted hereby, amendments or modifications to this Agreement must be approved by the
Board of Managers and the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 255; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Notwithstanding
anything to the contrary herein, (w) this Agreement shall not be amended or modified without the prior written consent of a Majority
in Interest of the Non-Corporation Members if such amendment or modification would (i) materially and adversely affect the
Non-Corporation Members disproportionately to any other similarly situated Member or class of Members (except for any amendment or
modification otherwise expressly contemplated by this Agreement), (ii) adversely affect in any material respect the limited
liability of the Non-Corporation Members as described in <U>Section&nbsp;6.3</U> and <U>Section&nbsp;6.4</U>, (iii) adversely affect
in any material respect the rights and obligations set forth in <U>Sections&nbsp;6.6</U>, <U>6.7</U> and <U>6.8</U> with respect to
indemnification of Covered Persons, (iv)&nbsp;adversely affect the rights of any Non-Corporation Member to receive the distributions
to which such Non-Corporation Member is entitled pursuant to <U>Article&nbsp;IV</U> or <U>Section&nbsp;12.3(a)(iii)</U>, or alter
the allocations specified in <U>Article&nbsp;V</U>, in each case, in a manner that is disproportionate to the Corporation or any
other member of the Parent Corporation Group that is a Member (except, in any case, as permitted pursuant to <U>Sections&nbsp;3.2</U>
(including, for the avoidance of doubt, any amendment or modification that is a Membership Interest Designation), and <U>Section
4.5</U>), (v) adversely affect in any material respect the rights of the Non-Corporation Members under <U>Section 7.1</U> or <U>Section
8.2</U> or (vi)&nbsp;adversely affect in any material respect any Non-Corporation Member&rsquo;s rights or obligations under <U>Section&nbsp;13.1</U>,
(x) <U>Section 6.1(a)(i)</U> and <U>Section 6.3</U> may not be amended or modified without the prior written consent of a Majority
in Interest of the Non-Corporation Member if such amendment or modification would adversely affect in any material respect the
Non-Corporation Members, (y) this <U>Section 14.1(b)</U> may not be amended or modified without consent of a Majority in Interest of
the Non-Corporation Members and (z)&nbsp;the Company may not be converted into a corporation without the consent of a Majority in
Interest of the Non-Corporation Members (other than in connection with a Termination Transaction of the Corporation). Any such
amendment, modification or action requiring the consent of a Member or group of Members pursuant to the preceding sentence consented
to by any Member shall be effective as to that Member, notwithstanding, if applicable, the absence of the requisite Consent required
by the preceding sentence.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law; Jurisdiction; Waiver of Jury Trial</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement, and all claims or causes of action (whether in contract, tort or statute) that may be based
upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement (including any claim or
cause of action based upon, arising out of related to any representation or warranty made in or in connection with this Agreement or as
inducement to enter into this Agreement) (each, an &ldquo;<U>Agreement Action</U>&rdquo;), shall be construed and enforced in accordance
with and governed by the Laws (both substantive and procedural) of the State of Delaware, without giving effect to the conflict of Laws
principles thereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Submission
to Jurisdiction</U>. Each of the Members irrevocably and unconditionally submits to the exclusive jurisdiction of the Chancery Court
of the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept jurisdiction, any federal court
within the State of Delaware), for the purposes of any Agreement Action (a) arising under this Agreement or (b) in any way connected
with or related or incidental to the dealings of the Members in respect of this Agreement or any of the transactions contemplated
hereby, and irrevocably and unconditionally waives any objection to the laying of venue of any such Agreement Action in any such
court, and further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such Agreement
Action has been brought in an inconvenient forum. Each Member hereby irrevocably and unconditionally waives, and agrees not to
assert, by way of motion or as a defense, counterclaim or otherwise, in any Agreement Action or cause thereof against such Member
(i) arising under this Agreement or (ii) in any way connected with or related or incidental to the dealings of the Members in
respect of this Agreement or any of the transactions contemplated hereby, (i)&nbsp;any claim that such Member is not personally
subject to the jurisdiction of the courts as described in this <U>Section&nbsp;14.2</U> for any reason, (ii)&nbsp;that such Member
or such Member&rsquo;s property is exempt or immune from the jurisdiction of any such court or from any legal process commenced in
such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution
of judgment or otherwise) and (iii)&nbsp;that (x)&nbsp;the Agreement Action or cause thereof in any such court is brought against
such Member in an inconvenient forum, (y)&nbsp;the venue of such Agreement Action or cause thereof against such Member is improper
or (z)&nbsp;this Agreement, or the subject matter hereof, may not be enforced against such Member in or by such courts. Each Member
agrees that service of any process, summons, notice or document by registered mail to such Member&rsquo;s respective address set
forth in <U>Section&nbsp;14.6</U> shall be effective service of process for any such Agreement Action, demand, or cause thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 256; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver of Jury Trial</U>. EACH OF THE MEMBERS HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY
OF ANY PROCEEDING, CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (I) ARISING UNDER THIS AGREEMENT OR (II) IN ANY WAY CONNECTED WITH OR RELATED
OR INCIDENTAL TO THE DEALINGS OF THE MEMBERS IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS RELATED HERETO, IN EACH CASE, WHETHER
NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. THE MEMBERS EACH HEREBY AGREES AND CONSENTS THAT
ANY SUCH PROCEEDING, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE MEMBERS MAY
FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE MEMBERS HERETO TO THE
WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH MEMBER CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER
MEMBER HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER MEMBER WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING
WAIVER, (B) EACH SUCH MEMBER UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) EACH SUCH MEMBER MAKES THIS WAIVER VOLUNTARILY
AND (D) EACH SUCH MEMBER HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN
THIS <U>SECTION&nbsp;14.2(C)</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accounting and Fiscal Year</U>. Subject to Section 448 of the Code, the books of the Company shall be kept on such method of
accounting for tax and financial reporting purposes as may be determined by the Board of Managers. The fiscal year of the Company (the
 &ldquo;<FONT STYLE="color: windowtext"><U>Fiscal Year</U></FONT>&rdquo;) shall be the calendar year, or, in the case of the first and
last Fiscal Years of the Company, the fraction thereof commencing on the Closing Date or ending on the date on which the winding-up of
the Company is completed, as the case may be, unless otherwise determined by the Board of Managers and permitted under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 257; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement</U>. This Agreement, together with the Business Combination Agreement and the Additional Agreements constitute
the entire agreement between the parties hereto pertaining to the subject matter hereof and fully supersede any and all prior or contemporaneous
agreements or understandings between the parties hereto pertaining to the subject matter hereof, including the Original Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Further
Assurances</U>. Upon written request of the Board of Managers, each of the parties hereto does hereby covenant and agree on behalf
of itself, its successors and its permitted assigns, without further consideration, to prepare, execute, acknowledge, file, record,
publish and deliver such other instruments, documents and statements, and to take such other action as may be required by Law or
reasonably necessary to effectively carry out the purposes hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any notice, requests, claims, demands and other communications hereunder shall be sent in writing and shall be
deemed to have been duly given by delivery in person, by email (having obtained electronic delivery confirmation thereof (i.e.<I>,</I>
an electronic record of the sender that the email was sent to the intended recipient thereof without an &ldquo;error&rdquo; or similar
message that such email was not received by such intended recipient)), or by registered or certified mail (postage prepaid, return receipt
requested) (upon receipt thereof), in each case, (i) with respect to the Members, at the addresses and email addresses (or to such other
address or email address as a Member may have specified by notice given to the other parties hereto pursuant to this provision) set forth
in <U>Schedule&nbsp;I</U> and (ii) with respect to the Company, to:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in">c/o</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in">Caritas Therapeutics, Inc.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in">3675 Market Street</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in">Philadelphia, PA 19104<BR>
Attention: John Crowley<BR>
Email: [&#9679;]</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">with a copy to (which shall not constitute notice):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Kirkland&nbsp;&amp; Ellis LLP<BR>
601 Lexington Avenue<BR>
New York, NY 10022<BR></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; width: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Jonathan L. Davis, P.C.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Ryan Brissette</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Peter Seligson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">jonathan.davis@kirkland.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ryan.brissette@kirkland.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">peter.seligson@kirkland.com</FONT></TD></TR>
  </TABLE>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Binding Effect</U>. Except as otherwise expressly provided herein, this Agreement shall be binding on and inure to the benefit
of the Members, their heirs, executors, administrators, successors and permitted assigns and all other Persons hereafter holding, having
or receiving a Membership Interest in the Company, whether as Assignees, Substituted Members or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 258; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Severability</U>.
Whenever possible, each provision of this Agreement will be interpreted in such a manner as to be effective and valid under
applicable Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under
applicable Law, all other provisions of this Agreement shall remain in full force and effect so long as the economic or legal
substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Member. Upon such
determination that any term or other provision of this Agreement is invalid, illegal or unenforceable under applicable Law, the
Members shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Members as closely as
possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to
the greatest extent possible.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Non-Corporation Member shall not, and shall cause his, her or its Affiliates not to (each of the foregoing, in such capacity,
the &ldquo;<FONT STYLE="color: windowtext"><U>Disclosing Person</U></FONT>&rdquo;), from and after Closing Date use in any manner detrimental
to the business of the Company, any of its Controlled Entities or any Member or any of its Affiliates, or disclose, publish or divulge
to any Person, any Confidential Information of the Company, any of its Controlled Entities or any other Member (each a &ldquo;<FONT STYLE="color: windowtext"><U>Protected
Person</U></FONT>&rdquo;). Notwithstanding the foregoing, each Member shall be permitted to disclose Confidential Information of the Company
or any of its Controlled Entities (i) to any Representative of such Person so long as such Representative has a &ldquo;need to know&rdquo;
such Confidential Information for a valid business purpose related to such Member&rsquo;s investment in the Company (or, in the case of
the Corporation, related to the Corporation&rsquo;s business and operations) and has been advised of the confidential nature of such Confidential
Information and has agreed to comply with this <U>Section&nbsp;14.9</U> applicable to such Confidential Information; <U>provided</U>,
that such Disclosing Person shall be liable for any breach of this <U>Section&nbsp;14.9</U> by any such Representative (assuming for purposes
of this proviso that such Representative is a Disclosing Person subject to the restrictions set forth in this <U>Section&nbsp;14.9</U>)
or (ii) to the extent required to be disclosed by such Member or any of its Representatives pursuant to Law or the rules of any securities
exchange on which the securities of such Member or any of its Affiliates is listed.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>As
used herein, the &ldquo;<FONT STYLE="color: windowtext"><U>Confidential Information</U></FONT>&rdquo; means, with respect to each
Protected Person, all data, information, reports, interpretations, forecasts and records, financial or otherwise, of such Protected
Person that are not available to the general public; <U>provided</U> that Confidential Information shall not include information
that (i) is or becomes generally available to the public other than as a result of a disclosure by any Disclosing Person not
otherwise permitted pursuant to this <U>Section&nbsp;14.9</U>, (ii) was or becomes available to a Disclosing Person on a
nonconfidential basis from a source other than the Protected Person; <U>provided</U> that, to the knowledge of the Disclosing
Person, such source is not bound by a confidentiality agreement with or other contractual, legal or fiduciary obligation of
confidentiality to such Protected Person with respect to such information, (iii) is developed independently by the Disclosing Party
without the use of any Confidential Information (other than in such Person&rsquo;s capacity as an officer, manager, director,
employee or consultant of the Company or its Affiliates) or (iv) is required to be disclosed by applicable Law or by subpoena,
summons or any other administrative or legal process, or by applicable regulatory standards, it being understood that, so long as it
is permitted by applicable Law or such process or standards, the Disclosing Person shall provide written notice to the Protected
Person as far in advance as reasonably practicable of such requirement and cooperate with the Protected Person, at the Protected
Person&rsquo;s sole expense, in seeking a protective order with respect to the Confidential Information sought pursuant to such
requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 259; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary herein, (i) each Non-Corporation Member may disclose Confidential Information to any federal,
state, local or foreign regulatory or self-regulatory body, or any securities exchange or listing authority, as part of a routine audit
not targeted at such Confidential Information without providing notice to any other party hereto and (ii) nothing herein shall prohibit
a Non-Corporation Member from (1) filing and, as provided for under Section 21F of the Exchange Act, maintaining the confidentiality of,
a claim with the SEC, (2) providing Confidential Information to the SEC or providing the SEC with information that would otherwise violate
any part hereof to the extent permitted by Section 21F of the Exchange Act, (3) cooperating, participating or assisting in an SEC investigation
or proceeding without notifying the Company or any of its Affiliates or any other Member or (4) receiving a monetary award as set forth
in Section 21F of the Exchange Act.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Consent by Spouse</U>. Each Non-Corporation Member who is a natural person and is married (and not formally separated with an
agreed-upon division of assets) and is subject to the community property Laws of any state shall deliver a duly executed Consent by Spouse,
in the form prescribed in <U>Exhibit&nbsp;C</U>, and at the time of execution hereof. Each such Non-Corporation Member shall also have
such Consent by Spouse executed by any spouse married to him or her at any time subsequent thereto while such natural person is a Non-Corporation
Member. Each Non-Corporation Member agrees and acknowledges that compliance with the requirements of this <U>Section&nbsp;14.10</U> by
each other Non-Corporation Member constitutes an essential part of the consideration for his or her execution hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all
of which shall constitute one and the same instrument. Delivery of an executed counterpart hereof in .pdf format via email shall be effective
as delivery of an original counterpart hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp; </FONT><U>Remedies</U>.
Except as otherwise expressly provided herein, any and all remedies provided herein will be deemed cumulative with and not exclusive
of any other remedy conferred hereby, or by law or equity upon such Member, and the exercise by a Member of any one remedy will not
preclude the exercise of any other remedy. The Members agree that irreparable damage for which monetary damages, even if available,
would not be an adequate remedy, would occur in the event that the Members do not perform their respective obligations under the
provisions of this Agreement in accordance with their specific terms or otherwise breach such provisions. It is accordingly agreed
that the Members shall be entitled to seek an injunction or injunctions, specific performance and other equitable relief to prevent
breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case, without posting a
bond or undertaking and without proof of damages and this being in addition to any other remedy to which they are entitled at law or
in equity. Each of the Members agrees that it will not oppose the granting of an injunction, specific performance and other
equitable relief when expressly available pursuant to the terms of this Agreement on the basis that the other Members have an
adequate remedy at law or an award of specific performance is not an appropriate remedy for any reason at law or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 260; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Survival</U>. The provisions of <U>Section&nbsp;6.6</U> and this <U>Article&nbsp;XIV</U> (and any other provisions herein necessary
for the effectiveness of the foregoing sections) shall survive the termination of the Company and/or the termination hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses</U>. Except as contemplated by <U>Section&nbsp;6.2 or otherwise expressly provided for herein</U>, each party hereto
shall pay its own expenses incident to preparing for, entering into and carrying out this Agreement and the transactions contemplated
hereby.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Assignability</U>. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned or delegated,
in whole or in part, by operation of law or otherwise, by the Company or any Member without the prior written consent of the Board of
Managers, and any such assignment without such prior written consent shall be null and void.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver</U>. No failure on the part of any party hereto to exercise any power, right, privilege or remedy hereunder, and no delay
on the part of any party hereto in exercising any power, right, privilege or remedy hereunder, shall operate as a waiver of such power,
right, privilege or remedy, and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or
further exercise thereof or of any other power, right, privilege or remedy. No party hereto shall be deemed to have waived any claim arising
out hereof, or any power, right, privilege or remedy hereunder, unless the waiver of such claim, power, right, privilege or remedy is
expressly set forth in a written instrument duly executed and delivered on behalf of such party, and any such waiver shall not be applicable
or have any effect except in the specific instance in which it is given.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section&nbsp;14.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Acknowledgement</U>. Amber GT Parent hereby acknowledges and agrees that it shall cause Amber GT and any transferee of Membership
Interests initially held by Amber GT (collectively, the &ldquo;<U>Amber Member</U>&rdquo;<FONT STYLE="color: windowtext"><U>)</U></FONT>
to comply with the applicable covenants, agreements and obligations hereunder and Amber GT Parent hereby covenants and agrees that it
will not, directly or indirectly, by amendment of its certificate of incorporation, bylaws or similar organizational documents, or through
any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities, or any other voluntary action,
avoid or seek to avoid or cause another Person to avoid or seek to avoid the observance or performance of any Amber Member of any terms
of this Agreement applicable to an Amber Member and will at all times in good faith cause any Amber Member to carry out all the provisions
of this Agreement applicable to such Amber Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 261; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, this Agreement has been executed
as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CARITAS THERAPEUTICS, LLC,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">a Delaware limited liability company</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ACKNOWLEDGED AND AGREED:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">[MEMBER]</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">[MEMBER]</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 262 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>MEMBERS AS OF [<FONT STYLE="font-family: Symbol">&middot;</FONT>], 2021</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&ldquo;PRE-RECAPITALIZATION MEMBERSHIP INTERESTS&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Member</TD><TD STYLE="width: 2%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%; font-size: 10pt; font-weight: bold; text-align: left"><B>Units</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">[Amber GT] (Member)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 263; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&ldquo;POST-RECAPITALIZATION UNITS&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 19%; font-size: 10pt; font-weight: bold">Member</TD><TD STYLE="text-align: center; width: 2%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 19%; font-size: 10pt; font-weight: bold; text-align: center">Address (for Notices)</TD><TD STYLE="text-align: center; width: 2%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 18%; font-size: 10pt; font-weight: bold; text-align: center">Capital Account<BR>
 Balance as of Closing<BR>
 Date</TD><TD STYLE="text-align: center; width: 2%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 18%; font-size: 10pt; font-weight: bold; text-align: center">Additional Capital<BR>
 Contributions (and<BR>
 Date Thereof)</TD><TD STYLE="text-align: center; width: 2%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 18%; font-size: 10pt; font-weight: bold; text-align: center">Common <BR>
Units</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">[ARYA] (Member)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">$</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt; padding-bottom: 1pt">N/A</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">[Amber GT] (Member)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">$ </TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt; padding-bottom: 1pt">N/A</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">$</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt">N/A</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">TOTAL</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">N/A</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 264; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">I-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OFFICERS AS OF CLOSING</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 265; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXAMPLES REGARDING ADJUSTMENT FACTOR</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For purposes of the following examples, it is assumed
that (a)&nbsp;the Adjustment Factor in effect on December 31, 2022 is 1.0 and (b)&nbsp;on January&nbsp;1, 2023 (the &ldquo;<U>Corporation
Record Date</U>&rdquo; for purposes of these examples), prior to the events described in the examples, there are 100 Class&nbsp;A Shares
issued and outstanding.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Example 1</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On the Corporation Record Date, the Corporation
declares a dividend on its outstanding Class&nbsp;A Shares in Class&nbsp;A Shares with no correlative distribution to the Members. The
amount of the dividend is one Class&nbsp;A Share in respect of each Class&nbsp;A Share owned as of the Corporation Record Date. Pursuant
to Paragraph&nbsp;(a)&nbsp;of the definition of &ldquo;Adjustment Factor&rdquo; the Adjustment Factor shall be adjusted on the Corporation
Record Date, effective immediately after the stock dividend is made, as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><B>1.0 * 200/100 = 2.0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accordingly, the Adjustment Factor after the stock
dividend is made is 2.0.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Example 2</U></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">On the Corporation Record Date, the Corporation
distributes options to purchase Class&nbsp;A Shares to all holders of its Class&nbsp;A Shares with no correlative distribution to the
Members. The amount of the distribution is one option to acquire one Class&nbsp;A Share in respect of each Class&nbsp;A Share owned. The
strike price is $4.00 a share and the options are fully exercisable at the time of distribution. The Value of a Class&nbsp;A Share on
the Corporation Record Date is $5.00 per share. Pursuant to clause&nbsp;(b)&nbsp;of the definition of &ldquo;Adjustment Factor,&rdquo;
the Adjustment Factor shall be adjusted on the Corporation Record Date, effective immediately after the options are distributed, as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify"><B>1.0 * (100 + 100)/(100 + 100 * $4.00/$5.00)
= 1.1111</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Accordingly, the Adjustment Factor after the options
are distributed is 1.1111. If the options expire or become no longer exercisable, then the retroactive adjustment specified in Paragraph&nbsp;(b)&nbsp;of
the definition of &ldquo;Adjustment Factor&rdquo; shall apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 266; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT B</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>NOTICE OF REDEMPTION</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Caritas Therapeutics, LLC<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The undersigned Non-Corporation Member hereby irrevocably
tenders for Redemption Common Units in Caritas Therapeutics, LLC in accordance with the terms of the Amended and Restated Limited Liability
Company Agreement of Caritas Therapeutics, LLC, dated as of [&bull;], 2021 (the &ldquo;<U>Agreement</U>&rdquo;), and the Redemption rights
referred to therein. All capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in
the Agreement. The undersigned Non-Corporation Member:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>undertakes to surrender such Common Units at the closing of the Redemption;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>directs that the certified check representing or, at the Board of Managers&rsquo; discretion, a wire transfer of the Cash Amount,
and/or the Class&nbsp;A Shares Amount, as applicable, deliverable upon the closing of such Redemption be delivered to the address or bank
account, as applicable, specified below;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>represents, warrants, certifies and agrees that: (i)&nbsp;the undersigned Non-Corporation Member has, and at the closing of the
Redemption will have, good, marketable and unencumbered title to such Common Units, free and clear of the rights or interests of any other
Person or entity; (ii)&nbsp;the undersigned Non-Corporation Member has, and at the closing of the Redemption will have, the full right,
power and authority to tender and surrender such Common Units as provided herein; (iii)&nbsp;the undersigned Non-Corporation Member, and
the tender and surrender of such Common Units for Redemption as provided herein complies with all conditions and requirements for redemption
of Common Units set forth in the Agreement; and (iv)&nbsp;the undersigned Non-Corporation Member has obtained the consent or approval
of all Persons and entities, if any, having the right to consent to or approve such tender and surrender; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>acknowledges that the undersigned will continue to own such Common Units unless and until either (1)&nbsp;such Common Units are
acquired by the Corporation pursuant to <U>Section&nbsp;13.1(b)</U>&nbsp;of the Agreement or (2)&nbsp;such redemption transaction closes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 267; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%">Dated:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name of Non-Corporation Member:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Signature of Non-Corporation Member</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Street Address</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">City, State and Zip Code</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Social security or identifying number</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Signature Medallion Guaranteed by:*</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>Select One and Complete the Details Below:</U></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Check or
<FONT STYLE="font-family: Wingdings">&uml;</FONT> Wire Transfer</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Issue Check Payable to (or shares in the<BR>
 name of):__________________________
<BR>
and deliver to the address above.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Bank Account Details:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Required unless waived by the Board of Managers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 268; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT C</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CONSENT OF SPOUSE</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">I acknowledge that I have read that certain Amended
and Restated Limited Liability Company Agreement of Caritas Therapeutics, LLC (the &ldquo;<U>Company</U>&rdquo;), dated as of [&bull;],
2021 (the &ldquo;<U>LLC Agreement</U>&rdquo;), and that I know its contents. I am aware that by its provisions, my spouse agrees to sell,
convert, dispose of, or otherwise transfer his or her interest in the Company, including any property or other interest that I have or
acquire therein, under certain circumstances. I hereby consent to such sale, conversion, disposition or other transfer; and approve of
the provisions of the LLC Agreement and any action hereafter taken by my spouse thereunder with respect to his or her interest, and I
agree to be bound thereby.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">I further agree that in the event of my death or
a dissolution of marriage or legal separation, my spouse shall have the absolute right to have my interest, if any, in the Company set
apart to him or her, whether through a will, a trust, a property settlement agreement or by decree of court, or otherwise, and that if
he or she be required by the terms of such will, trust, settlement or decree, or otherwise, to compensate me for said interest, that the
price shall be an amount equal to: (i)&nbsp;the then-current balance of the Capital Account relating to said interest; <U>multiplied by</U>
(ii)&nbsp;my percentage of ownership in such interest (all without regard to the effect of any vesting provisions in the LLC Agreement
related thereto).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This consent, including its existence, validity,
construction, and operating effect, and the rights of each of the parties hereto, shall be governed by and construed in accordance with
the laws of the [&#9679;]* without regard to otherwise governing principles of choice of law or conflicts of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">NAME:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">* Insert jurisdiction of residence
of Member and Spouse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 269; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">C-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Tax Receivables Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 270 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit C&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TAX RECEIVABLE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">by and among</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[Amber GT Holdings], LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Caritas Therapeutics, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[[Caritas], Inc.]<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>And Future Members of Caritas Therapeutics,
LLC</B><BR>
<B>From Time to Time Party Hereto</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated as of [&#9679;], 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>1</SUP></FONT></TD><TD><B>Note to Draft</B>: To be the name of ARYA Sciences Acquisition Corp IV following the Domestication.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 271 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This TAX RECEIVABLE AGREEMENT (as amended from
time to time, this &ldquo;<U>Agreement</U>&rdquo;), dated as of [&#9679;], 2021, is hereby entered into by and among Caritas, Inc., (f/k/a
ARYA Sciences Acquisition Corp IV), a Delaware corporation (&ldquo;<U>PubCo</U>&rdquo;), Amicus GT Holdings, LLC, a Delaware limited liability
company (&ldquo;<U>Amber GT</U>&rdquo;), Caritas Therapeutics, LLC, a Delaware limited liability company (&ldquo;<U>GT LLC</U>&rdquo;)
(each, excluding PubCo and GT LLC, and each of the other persons from time to time that become a party hereto, a &ldquo;<U>TRA Party</U>&rdquo;
and together, the &ldquo;<U>TRA Parties</U>&rdquo; and each TRA Party and PubCo, a &ldquo;<U>Party</U>&rdquo; and together, the &ldquo;<U>Parties</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, GT LLC is treated as a partnership for
U.S. federal income tax purposes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, prior to the consummation of the Caritas-PubCo
Combination (as defined below), Amber GT formed GT LLC and contributed certain assets to GT LLC in exchange for GT LLC Units (the &ldquo;<U>Units</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, on the date hereof, PubCo acquired common
voting units in GT LLC in exchange for cash pursuant to the Business Combination Agreement, dated September [28], 2021 (as amended, supplemented
or otherwise modified from time to time in accordance with its terms, the &ldquo;<U>BCA</U>&rdquo;) by and among Amicus Therapeutics,
Inc., a Delaware corporation (&ldquo;<U>Amber GT Parent</U>&rdquo;), PubCo, Amber GT and GT LLC (the transactions taken pursuant to the
BCA, the &ldquo;<U>Caritas-PubCo Combination</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, PubCo and Amber GT are the only members
of GT LLC as of the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, Article XIII of the LLC Agreement (as
defined herein) provides each TRA Party a redemption right pursuant to which each TRA Party may cause GT LLC or PubCo (if PubCo so elects,
in its sole discretion) to redeem or acquire, as the case may be, all or a portion of its Units from time to time for cash or, at PubCo&rsquo;s
option (as determined in PubCo&rsquo;s sole discretion), shares of Class A Common Stock (each, a &ldquo;<U>Redemption</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, GT LLC and each of its Subsidiaries (as
defined herein) that is treated as a partnership for U.S. federal income tax purposes will have in effect an election under Section 754
of the Code (as defined herein) for the Taxable Year (as defined herein) in which any Basis Transaction (as defined herein) occurs; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the Parties desire to provide for certain
payments and make certain arrangements with respect to certain tax benefits that may be derived by PubCo as the result of Basis Transactions
and the making of payments under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 272 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW, THEREFORE, in consideration of the foregoing
and the respective covenants and agreements set forth herein, and intending to be legally bound hereby, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
I </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. As used in this Agreement, the terms set forth in this Article I shall have the following meanings (such meanings
to be equally applicable to both the singular and plural forms of the terms defined).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Actual Tax Liability</U>&rdquo; means,
with respect to any Taxable Year, the sum of (i) the actual liability for U.S. federal income taxes of PubCo as reported on its IRS Form
1120 (or any successor form) for such Taxable Year, and, without duplication, the portion of any liability for U.S. federal income taxes
imposed directly on GT LLC (and GT LLC&rsquo;s applicable Subsidiaries) under Section 6225 or any similar provision of the Code that is
allocable to PubCo under Section 704 of the Code and/or the Partnership Audit Rules (provided, that such amounts will be calculated excluding
deductions of (and other effects of) state and local income taxes) and (ii) the product of the amount of the U.S. federal taxable income
or gain for such Taxable Year reported on PubCo&rsquo;s IRS Form 1120 (or any successor form) and the Assumed State and Local Tax Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Advisory Firm</U>&rdquo; means any law
or accounting firm that is (i) nationally recognized as being an expert in tax matters and (ii) agreed to by PubCo and the TRA Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo; means, with respect
to any Person, any Person directly or indirectly controlling or controlled by or under common control with such Person; <U>provided</U>
that, for the purposes of this definition, &ldquo;<U>control</U>&rdquo; when used with respect to any Person means the possession, directly
or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership
of voting securities, by contract or otherwise, and the terms &ldquo;<U>controlling</U>&rdquo; and &ldquo;<U>controlled</U>&rdquo; have
meanings correlative to the foregoing, <U>provided</U>, <U>however</U>, that no member of the Parent Corporation Group (as defined in
the LLC Agreement) shall be considered an Affiliate of any Non-Corporation Member (as defined in the LLC Agreement) for purposes hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Agreed Rate</U>&rdquo; means LIBOR plus
100 basis points.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Agreement</U>&rdquo; is defined in the
preamble of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Amended Schedule</U>&rdquo; is defined
in Section 2.04(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Amber GT Parent</U>&rdquo; is defined
in the recitals to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Assumed State and Local Tax
Rate</U>&rdquo; means, the tax rate equal to the sum of the product of (i) GT LLC&rsquo;s income and franchise tax apportionment
rate(s) for each state and local jurisdiction in which GT LLC files income or franchise Tax Returns for the relevant Taxable Year
and (ii) the highest corporate income and franchise tax rate(s) for each such state and local jurisdiction in which GT LLC files
income or franchise Tax Returns for each relevant Taxable Year, in each case, applicable to taxes payable on a pass-through basis;
provided, that the Assumed State and Local Tax Rate calculated pursuant to the foregoing shall be reduced by the assumed U.S.
federal income tax benefit received by PubCo with respect to state and local jurisdiction income and franchise taxes (with such
benefit calculated as the product of (a) PubCo&rsquo;s marginal U.S. federal income tax rate for the relevant Taxable Year and (b)
the Assumed State and Local Tax Rate (without regard to this proviso)). At PubCo&rsquo;s election, PubCo shall be entitled to
determine the Assumed State and Local Tax Rate for a given Taxable Year as of January 1 of the relevant Taxable Year based on good
faith estimates of its expected apportionment rates for such Taxable Year and on the tax rates in effect in relevant jurisdictions
as of January 1 of the relevant Taxable Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 273; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Attributable</U>&rdquo; is defined in
Section 3.01(b)(i) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Bankruptcy Code</U>&rdquo; means Title
11 of the United States Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Basis Adjustment</U>&rdquo; means the
increase or decrease to, or PubCo&rsquo;s share of, the tax basis of the Reference Property under Section 732, 734(b), 743(b), 754, 755,
or 1012 of the Code (or in each case, any similar provisions of state, local or foreign tax law) as a result of any Basis Transaction
or payment made under this Agreement in respect of such Basis Transaction. Notwithstanding any other provision of this Agreement, the
amount of any Basis Adjustment resulting from a Basis Transaction is to be determined without regard to any Pre-Redemption Transaction
and as if any Pre-Redemption Transaction had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Basis Schedule</U>&rdquo; is defined
in Section 2.02 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Basis Transaction</U>&rdquo; means any
(i) Redemption, (ii) transaction characterized under Section 707(a)(2)(B) of the Code as a sale by a TRA Party of Units or Reference Property
or (iii) distribution (including a deemed distribution) by a member of the GT LLC Group to a TRA Party or another member of the GT LLC
Group that results in a basis adjustment to a Reference Property under Section 734(b) or 732 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Basis Transaction Date</U>&rdquo; means
the date of any Basis Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>BCA</U>&rdquo; is defined in the recitals
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Board</U>&rdquo; means the board of directors
of PubCo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo; means any day
other than a Saturday, Sunday or a legal holiday on which commercial banking institutions in New York, New York are authorized to close
for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Caritas-PubCo Combination</U>&rdquo;
is defined in the recitals to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Change of Control</U>&rdquo; means any
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
consummation of a reorganization, merger, share exchange or consolidation (a &ldquo;<U>Business Combination</U>&rdquo;) in which (a)
PubCo is a constituent party or (b) a Subsidiary of PubCo is a constituent party, except any such Business Combination involving
PubCo or a Subsidiary of PubCo in which the holders of shares of capital stock of PubCo outstanding immediately prior to such
Business Combination continue to hold, or whose shares of capital stock of PubCo are converted into or exchanged for shares of
capital stock that represent, immediately following such Business Combination, more than 50% of the combined voting power of the
capital stock entitled to vote generally in the election of directors or other governing body, as the case may be, of (x) the
surviving or resulting corporation or other entity or (y) if the surviving or resulting corporation or other entity is a
wholly-owned subsidiary of another corporation or other entity immediately following such Business Combination, the parent
corporation or other entity of such surviving or resulting corporation or other entity;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 274; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
sale, assignment, conveyance, transfer, lease or other disposition, in one transaction or a series of transactions, by PubCo or any Subsidiary
of PubCo of all or substantially all of the assets of PubCo and its Subsidiaries taken as a whole, or the sale or disposition (whether
by merger, consolidation or otherwise) of one or more Subsidiaries of PubCo if substantially all of the assets of PubCo and its Subsidiaries
taken as a whole are held by such Subsidiary or Subsidiaries, except where such sale, assignment, conveyance, transfer, lease or other
disposition is to a directly or indirectly wholly-owned Subsidiary of PubCo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
Person or group of Persons acting together which would constitute a &ldquo;group&rdquo; for purposes of Section 13(d) or 14(d) of the
Securities and Exchange Act of 1934, as amended, or any successor provisions thereto (a &ldquo;<U>Securities Group</U>&rdquo;), other
than Amber GT or any Affiliate thereof, acquiring, holding or otherwise controlling more than 50% of the combined voting power of the
capital stock of PubCo entitled to vote generally in the election of directors (including, for avoidance of doubt, acquiring, holding
or otherwise controlling the right to cast all or a portion of the votes to which the Class B Common Stock is entitled pursuant to proxies,
voting agreements or other voting arrangements from or with Amber GT or any of its Affiliates in accordance with the LLC Agreement)&#894;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>the
approval by the stockholders of PubCo of any plan or proposal for the liquidation or dissolution of PubCo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the foregoing, a &ldquo;Change
of Control&rdquo; shall not be deemed to have occurred by virtue of (a) any indirect Change of Control of PubCo resulting from a change
of control of Amber GT as a result of Amber GT or any of its Affiliates acting together with any Person or Persons constituting a Securities
Group, (b) the consummation of any transaction or series of integrated transactions immediately following which the record holders of
the Class A Common Stock and the Class B Common Stock immediately prior to such transaction or series of transactions continue to have
substantially the same proportionate ownership in and voting control over, and own substantially all of the shares of, an entity which
owns all or substantially all of the assets of PubCo immediately following such transaction or series of transactions, (c) the consummation
of any transaction or series of integrated transactions in which a TRA Party or an Affiliate of such TRA Party merges with PubCo or a
Subsidiary of PubCo or (d) the direct or indirect distribution by Amber GT Parent of its retained beneficial interest in GT LLC by means
of a spin-off or split-off to its shareholders (however evidenced or structured) or (e) a direct or indirect sale by Amber GT Parent of
Units to any Person or Persons acting together to constitute a Securities Group to the extent such sale would cause a Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Class A Common Stock</U>&rdquo; means
shares of Class A common stock of PubCo, par value $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 275; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Class B Common Stock</U>&rdquo; means
the Class B common stock of PubCo, par value $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Code</U>&rdquo; means the Internal Revenue
Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Control</U>&rdquo; means the possession,
direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership
of voting securities, by contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Cumulative Net Realized Tax Benefit</U>&rdquo;
is defined in Section 3.01(b)(iii) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Default Rate</U>&rdquo; means LIBOR plus
500 basis points.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Default Rate Interest</U>&rdquo; is defined
in Section 3.01(b)(viii) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Determination</U>&rdquo; shall have the
meaning ascribed to such term in Section 1313(a) of the Code or any other event (including the execution of IRS Form 870-AD) that finally
and conclusively establishes the amount of any liability for tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Early Complete Termination</U>&rdquo;
is defined in Section 4.01(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Early Termination Effective Date</U>&rdquo;
means (i) with respect to an early termination pursuant to Section 4.01(b), the date an Early Termination Notice is delivered, (ii) with
respect to an early termination pursuant to Section 4.01(c), the date of the applicable Material Breach and (iii) with respect to an early
termination pursuant to Section 4.01(d), the date of the applicable Change of Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Early Termination Reference Date</U>&rdquo;
is defined in Section 4.02 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Early Termination Event</U>&rdquo; means
(i) an Early Complete Termination to which Section 4.01(b) applies, (ii) a breach of this Agreement to which Section 4.01(c) applies and
(iii) a Change of Control to which Section 4.01(d) applies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Early Termination Notice</U>&rdquo; is
defined in Section 4.01(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Early Termination Payment</U>&rdquo;
is defined in Section 4.03(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Early Termination Rate</U>&rdquo; means
the lesser of (i) 6.5% per annum, compounded annually, and (ii) LIBOR plus 300 basis points.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Early Termination Schedule</U>&rdquo;
is defined in Section 4.02 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Expert</U>&rdquo; is defined in Section
7.08 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Extension Rate Interest</U>&rdquo; is
defined in Section 3.01(b)(vii) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 276; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Final Payment Date</U>&rdquo; means any
date on which a payment is required to be made pursuant to this Agreement. The Final Payment Date in respect of (i) a Tax Benefit Payment
is determined pursuant to Section 3.01(a) of this Agreement and (ii) an Early Termination Payment is determined pursuant to Section 4.03(a)
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>GT LLC</U>&rdquo; is defined in the preamble
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>GT LLC Group</U>&rdquo; means GT LLC,
each of its direct or indirect Subsidiaries, and each of their predecessors, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Hypothetical Tax Liability</U>&rdquo;
means, with respect to any Taxable Year, the sum of (i) (A) the liability for U.S. federal income taxes of PubCo that would have been
reported on its IRS Form 1120 (or any successor form) for such Taxable Year and (B) without duplication, the portion of any liability
for U.S. federal income taxes that would have been imposed directly on GT LLC (and GT LLC&rsquo;s applicable Subsidiaries) under Section
6225 or any similar provision of the Code that is allocable to PubCo under Section 704 of the Code and/or the Partnership Audit Rules
(in each case using the same methods, elections, conventions and similar practices used on the relevant PubCo Return, but (a) calculating
depreciation, amortization, or other similar deductions, or otherwise calculating any items of income, gain, or loss, using PubCo&rsquo;s
allocable share of such items determined by reference to the Non-Adjusted Tax Basis as reflected on the Basis Schedule including amendments
thereto for the Taxable Year, and (b) excluding any deduction attributable to Imputed Interest for such Taxable Year) (provided, that
such amounts will be calculated excluding deductions of (and other effects of) state and local income taxes) and (ii) the product of (x)
the amount of the U.S. federal taxable income or gain calculated pursuant to clause (i)(A) for such Taxable Year multiplied by (y) the
Assumed State and Local Tax Rate. For the avoidance of doubt, (1)&nbsp;Hypothetical Tax Liability shall be determined without taking into
account the carryover or carryback of any tax item (or portions thereof) that is attributable to or (without duplication) available for
use because of the prior use of any Basis Adjustments or any Imputed Interest&nbsp;and (2) <FONT STYLE="background-color: white">the basis
of the Reference Property in the aggregate for purposes of determining the Hypothetical Tax Liability can never be less than zero</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Imputed Interest</U>&rdquo; is defined
in Section 3.01(b)(vi) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Joinder</U>&rdquo; means a joinder to
this Agreement, in form and substance substantially similar to <U>Exhibit A</U> to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Joinder Requirement</U>&rdquo; is defined
in Section 7.06(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>LIBOR</U>&rdquo; means for each
month (or portion thereof) during any period, an interest rate per annum equal to the rate per annum reported, on the date two
Business Days prior to the first day of such month, as published on the applicable Bloomberg screen page (or other commercially
available source providing quotations of LIBOR) for London interbank offered rates for U.S. dollar deposits for such month (or
portion thereof); <U>provided</U>, that at no time shall LIBOR be less than 0%. At the earliest of (i) the date that LIBOR is no
longer a widely recognized benchmark rate for newly originated loans in the U.S. loan market in U.S. dollars, (ii) June 30, 2023 and
(iii) the date on which the TRA Parties and PubCo mutually agree that it is appropriate to establish a replacement interest rate (a
 &ldquo;<U>Replacement Rate</U>&rdquo;), then PubCo and the TRA Parties shall establish a Replacement Rate, after giving due
consideration to any evolving or then prevailing conventions in the U.S. loan market for loans in U.S. dollars for such alternative
benchmark, and including any mathematical or other adjustments to such benchmark, including spread adjustments, giving due
consideration to any evolving or then prevailing convention for similar loans in the U.S. loan market in U.S. dollars for such
benchmark, which adjustment, method for calculating such adjustment and benchmark shall be published on an information service as
mutually selected from time to time by PubCo and the TRA Parties. The Replacement Rate shall, subject to the next two sentences,
replace LIBOR for all purposes under this Agreement. In connection with the establishment and application of the Replacement Rate,
this Agreement shall be amended, with the consent of PubCo and the TRA Parties (in each case, which consent shall not be
unreasonably withheld, conditioned or delayed), as necessary or appropriate, in the reasonable judgment of PubCo and the TRA Parties
to replace the definition of LIBOR and otherwise to effect the provisions of this definition. The Replacement Rate shall be applied
in a manner consistent with market practice, as mutually determined by PubCo and the TRA Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 277; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>LLC Agreement</U>&rdquo; means that certain
Amended and Restated Limited Liability Company Agreement of GT LLC, dated as of the date hereof, as such agreement may be further amended,
restated, supplemented and/or otherwise modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Market Value</U>&rdquo; means the Value
of a Class A Share, as defined in the LLC Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Material Breach</U>&rdquo; is defined
in Section 4.01(c) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Maximum Rate</U>&rdquo; is defined in
Section 7.12 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Net Tax Benefit</U>&rdquo; is defined
in Section 3.01(b)(ii) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Non-Adjusted Tax Basis</U>&rdquo; means,
with respect to any Reference Property at any time, the tax basis that such asset would have had at such time if no Basis Adjustments
had been made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Non-TRA Portion</U>&rdquo; is defined
in Section 2.03(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Objection Notice</U>&rdquo; is defined
in Section 2.04(a)(i) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Parties</U>&rdquo; is defined in the
preamble to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Partnership Audit Rules</U>&rdquo; means
Sections 6221 through 6241 of the Code, as such provisions were amended by the Bipartisan Budget Act of 2015, and Treasury Regulations
promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo; means an individual
or a corporation, partnership, limited partnership, limited liability partnership, trust, unincorporated organization, association, limited
liability company or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Pre-Redemption Transaction</U>&rdquo;
means any transfer of one or more Units (including from the exercise of an option to acquire such Units) that occurs after the Caritas-PubCo
Combination but prior to a Redemption of such Units and to which Section 743(b) of the Code applies.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 278; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>PubCo Return</U>&rdquo; means the U.S.
federal income Tax Return of PubCo filed with respect to any Taxable Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Realized Tax Benefit</U>&rdquo; is defined
in Section 3.01(b)(iv) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Realized Tax Detriment</U>&rdquo; is
defined in Section 3.01(b)(v) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Reconciliation Dispute</U>&rdquo; is
defined in Section 7.08 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Reconciliation Procedures</U>&rdquo;
means those procedures set forth in Section 7.08 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Redemption</U>&rdquo; is defined in the
recitals to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Reference Property</U>&rdquo; means an
asset (i) that is held by GT LLC, or by any of its direct or indirect Subsidiaries treated as a partnership or disregarded entity for
purposes of the applicable tax, at the time of, or immediately prior to, a Basis Transaction or (ii) the tax basis of which is determined,
in whole or in part, by reference to the tax basis of an asset that is described in <U>clause (i)</U>, including &ldquo;substituted basis
property&rdquo; within the meaning of Section 7701(a)(42) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Schedule</U>&rdquo; means any Tax Benefit
Schedule and any Early Termination Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Senior Obligations</U>&rdquo; is defined
in Section 5.02 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Subsidiaries</U>&rdquo; means, (i) one
or more entities of which at least fifty percent (50%) of the capital stock or share capital or other equity or voting securities are
Controlled or owned, directly or indirectly, by the respective Person, (ii) any partnership, limited liability company, joint venture
or other entity of which the respective Person or any Subsidiary is a general partner, manager, managing member or the equivalent and
(iii) in the case of GT LLC, any partnership (for U.S. federal and applicable state income tax purposes) resulting from the Co-Development
and Commercialization Agreement, dated as of [&#9679;], 2021, by and between GT LLC and Amber GT Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Tax Benefit Payment</U>&rdquo; is defined
in Section 3.01(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Tax Benefit Schedule</U>&rdquo; is defined
in Section 2.03(a) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Tax Return</U>&rdquo; means any return,
declaration, report or similar statement filed or required to be filed with respect to taxes (including any attached schedules), including,
without limitation, any information return, claim for refund, amended return and declaration of estimated tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Taxable Year</U>&rdquo; means a taxable
year as defined in Section 441(b) of the Code or comparable section of U.S. state or local tax law (and, therefore, for the avoidance
of doubt, may include a period of less than 12 months for which a Tax Return is made) ending on or after the date of hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 279; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Taxing Authority</U>&rdquo; means any
domestic, foreign, federal, national, state, county or municipal or other local government, any subdivision, agency, commission or authority
thereof, or any quasi-governmental body exercising any regulatory or other authority with respect to tax matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Termination Objection Notice</U>&rdquo;
is defined in Section 4.02 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Transfer</U>&rdquo; means to, directly
or indirectly, sell, transfer, assign, pledge, encumber, hypothecate or similarly dispose of, either voluntarily or involuntarily, by
operation of law or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>TRA Party</U>&rdquo; is defined in the
recitals of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>TRA Portion</U>&rdquo; is defined in
Section 2.03(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Treasury Regulations</U>&rdquo; means
the final, temporary and proposed regulations under the Code promulgated from time to time (including corresponding provisions and succeeding
provisions) as in effect for the relevant taxable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Units</U>&rdquo; is defined in the recitals
of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Valuation Assumptions</U>&rdquo; means,
as of an Early Termination Effective Date, the assumptions that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
in each Taxable Year ending on or after such Early Termination Effective Date other than an Early Termination Effective Date due to a
Change in Control, PubCo will have taxable income sufficient to use fully the deductions or other tax benefits available to it arising
from any tax basis in any Reference Property and the Imputed Interest during such Taxable Year or future Taxable Years (including, for
the avoidance of doubt, any tax basis in any Reference Property and Imputed Interest that would result from future Tax Benefit Payments
that would be paid in accordance with the Valuation Assumptions) in which such deductions would become available and (b) in each Taxable
year ending on or after such Early Termination Effective Date that is due to a Change in Control, PubCo will have taxable income in accordance
with PubCo management&rsquo;s preexisting projections (or, in the absence of such projections, as projected in good faith by PubCo&rsquo;s
management in a manner consistent with its projections for other purposes);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
income tax rates that will be in effect for each such Taxable Year will be those specified for each such Taxable Year by the Code and
other applicable law as in effect on the Early Termination Effective Date, except to the extent any change to such tax rates for such
Taxable Year have already been enacted into law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
taxable income of PubCo will be subject to the sum of (a) the maximum applicable federal corporate tax rates plus (b) the Assumed State
and Local Tax Rate for the Taxable Year in which the Early Termination Effective Date occurs for all relevant future Taxable Years;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 280; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
loss carryovers or carrybacks generated by any tax basis made available to PubCo in any Reference Property and Imputed Interest (including
any such tax basis in any Reference Property and Imputed Interest generated as a result of payments made under this Agreement) and available
as of the date of the Early Termination Schedule will be used by PubCo (a) with respect to an Early Termination Effective Date other than
an Early Termination Effective Date due to a Change of Control, ratably in each Taxable Year from the date of the Early Termination Schedule
through the scheduled expiration date of such loss carryovers or, if such carryovers or carrybacks do not have an expiration date, over
the fifteen (15)-year period after such carryovers or carrybacks were generated and (b) with respect to an Early Termination Effective
Date that is due to a Change of Control, to the extent there is sufficient taxable income in such Taxable Year after taking into account
any amortization pursuant to clause (i) above in accordance with PubCo management&rsquo;s preexisting projections (or, in the absence
of such projections, as projected in good faith by PubCo&rsquo;s management in a manner consistent with its projections for other purposes);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(v) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with
respect to an Early Termination Effective Date other than an Early Termination Effective Date due to a Change of Control, any non-amortizable
assets will be disposed of for book value on the fifteenth (15<SUP>th</SUP>) anniversary of the earlier of (i) the applicable Basis Adjustment
and (ii) the Early Termination Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if,
on the Early Termination Effective Date, any TRA Party has Units that have not been Redeemed, then such Units shall be deemed to be Redeemed
for the Market Value of the shares of Class A Common Stock that would be received by such TRA Party had such Units actually been Redeemed
on the Early Termination Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any
future payment obligations pursuant to this Agreement that are used to calculate the Early Termination Payment will be satisfied on the
date that any Tax Return to which any such payment obligation relates is required to be filed excluding any extensions; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with
respect to Taxable Years ending prior to the Early Termination Effective Date, any unpaid Tax Benefit Payments and any applicable Default
Rate Interest will be paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rules of Construction. Unless otherwise specified herein:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The meanings of defined terms are equally applicable to both (i) the singular and plural forms and (ii) the active and passive
forms of the defined terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of interpretation of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The words &ldquo;herein,&rdquo; &ldquo;hereto,&rdquo; &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo; and words of similar import
when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 281; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> References in this Agreement to a Schedule, Article, Section, clause or sub-clause refer to the appropriate Schedule to, or Article,
Section, clause or subclause in, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>References in this Agreement to dollars or &ldquo;$&rdquo; refer to the lawful currency of the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The term &ldquo;including&rdquo; is by way of example and not limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The term &ldquo;documents&rdquo; includes any and all instruments, documents, agreements, certificates, notices, reports, financial
statements and other writings, however evidenced, whether in physical or electronic form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the computation of periods of time from a specified date to a later specified date, the word &ldquo;from&rdquo; means &ldquo;from
and including;&rdquo; the words &ldquo;to&rdquo; and &ldquo;until&rdquo; each mean &ldquo;to but excluding;&rdquo; and the word &ldquo;through&rdquo;
means &ldquo;to and including.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section (and subsection) headings, titles and subtitles herein are included for convenience of reference only and are not to be
considered in construing this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Unless otherwise expressly provided herein, (i) references to organization documents (including the LLC Agreement), agreements
(including this Agreement) and other contractual instruments shall be deemed to include all subsequent amendments, restatements, extensions,
supplements and other modifications thereto; and (ii) references to any law (including the Code and the Treasury Regulations) shall include
all statutory and regulatory provisions consolidating, amending, replacing, supplementing or interpreting such law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
II </B></FONT><B><BR>
DETERMINATION OF REALIZED TAX BENEFIT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Basis Adjustments; 754 Election.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Basis Adjustments</U>. The Parties acknowledge and agree that, except as otherwise required by applicable law, the Parties shall
treat (i) each Redemption as a direct purchase of Units by PubCo from the applicable TRA Party pursuant to Section 707(a)(2)(B) of the
Code (or any similar provisions of applicable state, local or foreign tax law) and (ii) each Basis Transaction as a transaction that gives
rise to Basis Adjustments. For the avoidance of doubt, payments made under this Agreement shall not be treated as resulting in a Basis
Adjustment to the extent such payments are treated as Imputed Interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>754 Election</U>. PubCo shall cause GT LLC and any of its Subsidiaries that is treated as a partnership for U.S. federal income
tax purposes to have in effect an election under Section 754 of the Code (or any similar provisions of applicable state, local or foreign
tax law) for each Taxable Year. PubCo shall take commercially reasonable efforts to cause each Person in which GT LLC owns a direct or
indirect equity interest (other than a Subsidiary) that is so treated as a partnership to have in effect any such election for each Taxable
Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 282; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Basis Schedules</U>. Within one hundred twenty (120) calendar days after the filing of the U.S. federal income Tax Return of
PubCo for each relevant Taxable Year, PubCo shall prepare and deliver to the TRA Parties a schedule showing, in reasonable detail, (a)
the Non-Adjusted Tax Basis of the Reference Property as of each applicable Basis Transaction Date, (b) the Basis Adjustments to the Reference
Property for such Taxable Year, calculated (i) in the aggregate and (ii) solely with respect to each applicable TRA Party, (c) the periods
over which the Reference Property are amortizable or depreciable and (d) the period over which each Basis Adjustment is amortizable or
depreciable (such schedule, a &ldquo;<U>Basis Schedule</U>&rdquo;). For the avoidance of doubt, the Basis Schedule shall reflect all
changes in the bases of Reference Property arising other than from a Basis Adjustment (e.g., as the result of an audit). A Basis Schedule
will become final and binding on the Parties pursuant to the procedures set forth in Section 2.04(a) and may be amended by the Parties
pursuant to the procedures set forth in Section 2.04(b). All costs and expenses incurred in connection with the provision of the Basis
Schedules or Tax Benefit Schedules under this Agreement shall be borne by GT LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Benefit Schedules.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Benefit Schedule</U>. Within one hundred twenty (120) calendar days after the filing of the PubCo Return for any Taxable
Year for which there is a Realized Tax Benefit or Realized Tax Detriment, PubCo shall provide to the TRA Parties a schedule showing, in
reasonable detail, (i) the calculation of the Realized Tax Benefit or Realized Tax Detriment for such Taxable Year, (ii) the calculation
of any payment to be made to the TRA Parties pursuant to Article III with respect to such Taxable Year and (iii) all requested supporting
information pursuant to Section 2.04(a) of this Agreement reasonably necessary to support the calculation of such payment (a &ldquo;<U>Tax
Benefit Schedule</U>&rdquo;). The Tax Benefit Schedule will become final as provided in Section 2.04(a) and may be amended as provided
in Section 2.04(b) (subject to the procedures set forth in Section 2.04(a)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Applicable
Principles.</U> Subject to the provisions hereunder, the Realized Tax Benefit or Realized Tax Detriment for each Taxable Year is
intended to measure the decrease or increase in the Actual Tax Liability of PubCo for such Taxable Year attributable to the Basis
Adjustments and Imputed Interest, as determined using a &ldquo;with and without&rdquo; methodology. Carryovers or carrybacks of any
tax item attributable to any Basis Adjustment or Imputed Interest shall be considered to be subject to the rules of the Code and the
Treasury Regulations, and the appropriate provisions of state, local and foreign tax law, governing the use, limitation or
expiration of carryovers or carrybacks of the relevant type. If a carryover or carryback of any tax item includes a portion that is
attributable to a Basis Adjustment or Imputed Interest (a &ldquo;<U>TRA Portion</U>&rdquo;) and another portion that is not
attributable to a Basis Adjustment or Imputed Interest (a &ldquo;<U>Non-TRA Portion</U>&rdquo;), such portions shall be considered
to be used in accordance with the &ldquo;with and without&rdquo; methodology so that (i) the amount of any Non-TRA Portion is deemed
utilized first, followed by the amount of any TRA Portion (with the TRA Portion being applied on a proportionate basis consistent
with the provisions of Section 3.03(a)) and (ii) in the case of a carryback of a Non-TRA Portion, such carryback shall not affect
the original &ldquo;with and without&rdquo; calculation made in the prior Taxable Year. Except with respect to the portion of any
payment attributable to Imputed Interest, all Tax Benefit Payments and payments of Default Rate Interest (and including Extension
Rate Interest) will be treated as subsequent upward purchase price adjustments that give rise to further Basis Adjustments for PubCo
beginning in the Taxable Year of payment, and as a result, such additional Basis Adjustments will be incorporated into such Taxable
Year and into future Taxable Years, as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 283; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Procedures, Amendments.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Procedure</U>. Whenever PubCo delivers to the TRA Parties an applicable Schedule under this Agreement, including any Amended
Schedule delivered pursuant to Section 2.04(b), Early Termination Schedule or amended Early Termination Schedule, PubCo shall also (x)
deliver to the TRA Parties, at their request (and upon reasonable notice), any schedules, valuation reports and work papers providing
reasonable detail regarding the preparation of the Schedule and (y) allow the TRA Parties and their respective advisors reasonable access
at no cost to the appropriate representatives of each of PubCo and/or the Advisory Firm in connection with a review of such Schedule.
Without limiting the generality of the preceding sentence, PubCo shall ensure that any Tax Benefit Schedule that is delivered to the TRA
Parties, along with any supporting schedules and work papers, provides a reasonably detailed presentation of the calculation of the Actual
Tax Liability of PubCo for the relevant Taxable Year and the Hypothetical Tax Liability of PubCo for such Taxable Year, and identifies
any material assumptions or operating procedures or principles that were used for purposes of such calculations. The applicable Schedule
shall become final and binding on all Parties on the thirtieth (30th) calendar day after the TRA Parties receive such Schedule, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a TRA Party provides PubCo with notice prior to such thirtieth (30th) calendar day after receipt of such Schedule of a material
objection, made in good faith, to such Schedule (&ldquo;<U>Objection Notice</U>&rdquo;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>each TRA Party provides a written waiver of its right to deliver an Objection Notice within the time period described in clause
(i) above, in which case such Schedule or amendment thereto becomes binding on the date the waiver from all TRA Parties is received by
PubCo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the Parties, for any reason, are unable to successfully resolve
the issues raised in any Objection Notice within thirty (30) calendar days of receipt by PubCo of such Objection Notice, PubCo and the
TRA Parties shall employ the Reconciliation Procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Amended
Schedule</U>. The applicable Schedule for any Taxable Year may be amended from time to time by PubCo (i) in connection with a
Determination affecting such Schedule, (ii) to correct material inaccuracies in the Schedule identified as a result of the receipt
of additional factual information relating to a Taxable Year after the date the Schedule was provided to the TRA Parties, (iii) to
comply with the Expert&rsquo;s determination under the Reconciliation Procedures, (iv) to reflect a material change (relative to the
amounts in the original Schedule) in the Realized Tax Benefit or Realized Tax Detriment for such Taxable Year attributable to an
amended Tax Return filed for such Taxable Year, (v) to reflect a change in the Realized Tax Benefit or Realized Tax Detriment for
such Taxable Year attributable to a carryback or carryforward of a loss or other tax item to such Taxable Year; or (vi) to adjust a
Basis Schedule to take into account any Tax Benefit Payments made pursuant to this Agreement (such amended Schedule, an
 &ldquo;<U>Amended Schedule</U>&rdquo;). PubCo shall provide any Amended Schedule to the TRA Parties within thirty (30) calendar days
of the occurrence of an event referred to in clauses (i) through (vi) of the preceding sentence, and any such Amended Schedule shall
be subject to the procedures set forth in Section 2.04(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>LLC Agreement</U>. This Agreement shall be treated as part of the partnership agreement of GT LLC as described in Section 761(c)
of the Code and Sections 1.704-1(b)(2)(ii)(h) and 1.761-1(c) of the Treasury Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 284; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
III </B></FONT><B><BR>
TAX BENEFIT PAYMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payments.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as provided in Section 3.02 and Section 3.03, within ten (10) Business Days of a Tax Benefit Schedule with respect to a
Taxable Year becoming final in accordance with Section 2.04(a) (such date, the &ldquo;<U>Final Payment Date</U>&rdquo; in respect of any
Tax Benefit Payment), PubCo shall pay to each relevant TRA Party the Tax Benefit Payment for such Taxable Year determined pursuant to
Section 3.01(b). Each such Tax Benefit Payment shall be made by wire transfer of immediately available funds to a bank account previously
designated by the applicable TRA Party to PubCo or as otherwise agreed by PubCo and the applicable TRA Party. For the avoidance of doubt,
no Tax Benefit Payment shall be made in respect of estimated tax payments, including, without limitation, estimated U.S. federal income
tax payments. The TRA Parties shall not be required under any circumstances to return any portion of any Tax Benefit Payment, Early Termination
Payment or Default Rate Interest previously paid by PubCo to the TRA Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 10pt"></FONT><U>Amount of Payments</U>. A &ldquo;<U>Tax Benefit Payment</U>&rdquo; with respect to
any TRA Party shall be an amount equal to the sum of the Net Tax Benefit that is Attributable to such TRA Party and the Extension Rate
Interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Attributable</U>. A Net Tax Benefit is &ldquo;<U>Attributable</U>&rdquo; to a TRA Party to the extent that it is derived from
any Basis Adjustment or Imputed Interest that is attributable to a Basis Transaction undertaken by or with respect to such TRA Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Net
Tax Benefit</U>. The &ldquo;<U>Net Tax Benefit</U>&rdquo; with respect to a TRA Party for a Taxable Year equals the amount of the
excess, if any, of (A) 85% of the Cumulative Net Realized Tax Benefit Attributable to such TRA Party as of the end of such Taxable
Year over (B) the aggregate amount of all Tax Benefit Payments previously made to such TRA Party under this Section 3.01 (excluding
payments attributable to Extension Rate Interest). For the avoidance of doubt, if the Cumulative Net Realized Tax Benefit that is
Attributable to a TRA Party as of the end of any Taxable Year is less than the aggregate amount of all Tax Benefit Payments
previously made to such TRA Party, such TRA Party shall not be required to return any portion of any Tax Benefit Payment previously
made by PubCo to such TRA Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 285; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cumulative Net Realized Tax Benefit</U>. The &ldquo;<U>Cumulative Net Realized Tax Benefit</U>&rdquo; for a Taxable Year equals
the cumulative amount of Realized Tax Benefits for all Taxable Years of PubCo, up to and including such Taxable Year, net of the cumulative
amount of Realized Tax Detriments for the same period. The Realized Tax Benefit and Realized Tax Detriment for each Taxable Year shall
be determined based on the most recent Tax Benefit Schedule or Amended Schedule, if any, in existence at the time of such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Realized Tax Benefit</U>. The &ldquo;<U>Realized Tax Benefit</U>&rdquo; for a Taxable Year equals the excess, if any, of the
Hypothetical Tax Liability over the Actual Tax Liability for such Taxable Year. If all or a portion of the Actual Tax Liability for such
Taxable Year arises as a result of an audit or similar proceeding by a Taxing Authority of any Taxable Year, such liability shall not
be included in determining the Realized Tax Benefit unless and until there has been a Determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Realized Tax Detriment</U>. The &ldquo;<U>Realized Tax Detriment</U>&rdquo; for a Taxable Year equals the excess, if any, of
the Actual Tax Liability over the Hypothetical Tax Liability for such Taxable Year. If all or a portion of the Actual Tax Liability for
such Taxable Year arises as a result of an audit or similar proceeding by a Taxing Authority of any Taxable Year, such liability shall
not be included in determining the Realized Tax Detriment unless and until there has been a Determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Imputed Interest</U>. The principles of Sections 1272, 1274 or 483 of the Code, as applicable, and the principles of any similar
provision of U.S. state, local or foreign law, will apply to cause a portion of any Net Tax Benefit payable by PubCo to a TRA Party under
this Agreement to be treated as imputed interest (&ldquo;<U>Imputed Interest</U>&rdquo;). For the avoidance of doubt, the deduction for
the amount of Imputed Interest as determined with respect to any Net Tax Benefit payable by PubCo to a TRA Party shall be excluded in
determining the Hypothetical Tax Liability of PubCo for purposes of calculating Realized Tax Benefits and Realized Tax Detriments pursuant
to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Extension Rate Interest</U>. The &ldquo;<U>Extension Rate Interest</U>&rdquo; calculated in respect of the Net Tax Benefit (including
previously accrued Imputed Interest for a Taxable Year) will equal interest calculated at the Agreed Rate from the due date (without extensions)
for filing the U.S. federal income Tax Return of PubCo for such Taxable Year until the date on which PubCo makes a timely Tax Benefit
Payment to the TRA Party on or before the Final Payment Date as determined pursuant to Section 3.01(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Default
Rate Interest</U>. In the event that PubCo does not make timely payment of all or any portion of a Tax Benefit Payment to a TRA
Party on or before the Final Payment Date as determined pursuant to Section 3.01(a), the amount of &ldquo;<U>Default Rate
Interest</U>&rdquo; calculated in respect of the Net Tax Benefit (including previously accrued Imputed Interest and the Extension
Rate Interest) for a Taxable Year will equal interest calculated at the Default Rate from the Final Payment Date for a Tax Benefit
Payment as determined pursuant to Section 3.01(a) until the date on which PubCo makes such Tax Benefit Payment to such TRA Party.
For the avoidance of doubt, the amount of any Default Rate Interest as determined with respect to any Net Tax Benefit payable by
PubCo to a TRA Party shall be included in determining the Hypothetical Tax Liability of PubCo for purposes of calculating Realized
Tax Benefits and Realized Tax Detriments pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 286; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Interest</U>. The provisions of Section 3.01(b) are intended to operate so that interest will effectively accrue for any Taxable
Year as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>first, at the applicable rate used to determine the amount of Imputed Interest under the Code (from the relevant Basis Transaction
Date until the due date (without extensions) for filing the U.S. federal income Tax Return of PubCo for such Taxable Year);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>second, at the Agreed Rate in respect of any Extension Rate Interest (from the due date (without extensions) for filing the U.S.
federal income Tax Return of PubCo for such Taxable Year until the Final Payment Date for a Tax Benefit Payment as determined pursuant
to Section 3.01(a)); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>third, at the Default Rate in respect of any Default Rate Interest (from the Final Payment Date for a Tax Benefit Payment as determined
pursuant to Section 3.01(a) until the date on which PubCo makes the relevant Tax Benefit Payment to a TRA Party).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Parties acknowledge and agree that, as of the date of this Agreement and as of the date of any future Basis Transaction that
may be subject to this Agreement, the timing, amount and aggregate value of the Tax Benefit Payments cannot be reasonably ascertained
for U.S. federal income or other applicable tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Duplicative Payments</U>. It is intended that the provisions of this Agreement will not result in duplicative payment of
any amount (including interest) required under this Agreement. The provisions of this Agreement shall be construed in the appropriate
manner to ensure such intentions are realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pro-Ration of Payments as Among the TRA Parties.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Insufficient
Taxable Income</U>. Notwithstanding anything in Section 3.01(b) to the contrary, if the aggregate potential tax benefit of PubCo as
calculated with respect to the Basis Adjustments and Imputed Interest (in each case, without regard to the Taxable Year of
origination) is limited in a particular Taxable Year because PubCo does not have sufficient actual taxable income to utilize
available deductions fully in such Taxable Year, then the tax benefit for PubCo actually utilized in such Taxable Year shall be
allocated among the relevant TRA Parties in proportion to the respective Tax Benefit Payment that would have been payable if PubCo
had sufficient taxable income such that there was no limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 287; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Late Payments</U>. If for any reason PubCo is not able to timely and fully satisfy its payment obligations under this Agreement
in respect of a particular Taxable Year, then Default Rate Interest will begin to accrue pursuant to Section 5.01 and PubCo and other
Parties agree that (i) PubCo shall pay the Tax Benefit Payments (and any applicable Default Rate Interest) due in respect of such Taxable
Year to each relevant TRA Party pro rata in accordance with the principles of Section 3.03(a) and (ii) no Tax Benefit Payment shall be
made in respect of any Taxable Year until all Tax Benefit Payments (and any applicable Default Rate Interest) to all relevant TRA Parties
in respect of all prior Taxable Years have been made in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Excess Payment</U>. To the extent PubCo makes a payment to a TRA Party in respect of a particular Taxable Year under Section
3.01(a) of this Agreement (taking into account Section 3.02 and Section 3.03) in an amount in excess of the amount of such payment that
should have been made to such TRA Party in respect of such Taxable Year, then (a)&nbsp;such TRA Party shall not receive further payments
under Section 3.01(a) until such TRA Party has foregone an amount of payments equal to such excess and (b) PubCo will pay the amount of
such TRA Party&rsquo;s foregone payments to the other Persons to whom a payment is due under this Agreement in a manner such that each
such Person to whom a payment is due under this Agreement, to the maximum extent possible, receives aggregate payments under Section 3.01(a)&nbsp;(taking
into account Section 3.02 and Section 3.03) in the amount it would have received if there had been no excess payment to such TRA Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
IV </B></FONT><B><BR>
TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination, Breach of Agreement, Change of Control.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General</U>. This Agreement shall terminate at the time that there is no potential for any future Tax Benefit Payments to be
made to the TRA Parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Early Complete Termination</U>. PubCo may elect to terminate this Agreement (an &ldquo;<U>Early Complete Termination</U>&rdquo;)
by (i) delivering to the TRA Parties notice of its intention to exercise such right (&ldquo;<U>Early Termination Notice</U>&rdquo;) and
(ii) paying to the TRA Parties (1) the Early Termination Payment, (2) any Tax Benefit Payment and Default Rate Interest agreed to by PubCo
and the TRA Parties as due and payable but unpaid as of the Early Termination Notice and (3) any Tax Benefit Payment due for the Taxable
Year ending prior to, with or including the date of the Early Termination Effective Date (except to the extent that any amounts described
in clauses (2) or (3) are included in the Early Termination Payment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 288; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Material Breach</U>. In the event that PubCo breaches any of its material obligations under this Agreement, whether as a result
of failure to make any payment when due (as described below), failure to honor any other material obligation required hereunder or by
operation of law as a result of the rejection of this Agreement in a case commenced under the Bankruptcy Code or otherwise (&ldquo;<U>Material
Breach</U>&rdquo;), then all obligations hereunder shall be accelerated and PubCo shall pay to the TRA Parties (i) the Early Termination
Payment, (ii) any Tax Benefit Payment and Default Rate Interest agreed to by PubCo and the TRA Parties as due and payable, but unpaid
as of the Early Termination Notice and (iii) any Tax Benefit Payment due for the Taxable Year ending prior to, with or including the date
of the Early Termination Effective Date (except to the extent that any amounts described in clauses (ii) or (iii) are included in the
Early Termination Payment). Notwithstanding the foregoing, in the event that PubCo breaches this Agreement and such breach is a Material
Breach, the TRA Parties shall be entitled to elect to receive the amounts set forth in (i), (ii) and (iii) above or to seek specific performance
of the terms hereof. The Parties agree that the failure to make any payment pursuant to this Agreement within three (3) months of the
date such payment is due shall be deemed a Material Breach for all purposes of this Agreement, and that it will not be considered to be
a Material Breach to make a payment due pursuant to this Agreement within three (3) months of the date such payment is due, <U>provided</U>
that the interest provisions of Section 5.01 shall apply to such late payment (unless PubCo does not have sufficient funds to make such
payment as a result of limitations imposed by any Senior Obligations, in which case Section 5.01 shall apply, but the Default Rate shall
be replaced by the Agreed Rate), <U>provided further </U>that in the event that payment is not made within three (3) months of the date
such payment is due, a TRA Party shall be required to give written notice to PubCo that PubCo has breached its material obligations, and
so long as such payment is made within ten (10) Business Days of the delivery of such notice to PubCo, PubCo shall no longer be deemed
to be in Material Breach of its obligations under this Agreement. Notwithstanding anything in this Agreement to the contrary, it shall
not be a breach of a material obligation of this Agreement if PubCo fails to make any Tax Benefit Payment when due to the extent that
PubCo has insufficient funds to make such payment; <U>provided</U>, (x) PubCo has used reasonable efforts to obtain such funds and (y)
the interest provisions of Section 5.01 shall apply to such late payment (unless PubCo does not have sufficient funds to make such payment
as a result of limitations imposed by any Senior Obligations, in which case Section 5.02 shall apply); <U>provided</U>, <U>further</U>,
that PubCo shall promptly (and in any event, within ten (10) Business Days), pay all such unpaid payments, together with accrued and unpaid
interest thereon, immediately following such time that PubCo has, and to the extent PubCo has, sufficient funds to make such payment,
and the failure of PubCo to do so shall constitute a breach of this Agreement. For the avoidance of doubt, (i) all cash and cash equivalents
used or to be used to pay dividends by, or repurchase equity securities of, PubCo shall be deemed to be funds sufficient and available
to pay such unpaid payments, together with any accrued and unpaid interest thereon and (ii) the immediately preceding sentence of this
Section 4.01(c) shall not apply to any payments due pursuant to an election by a TRA Party for the acceleration upon a Change of Control
contemplated by Section 4.01(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Change
of Control</U>. In the event of a Change of Control, then all obligations hereunder shall be accelerated and PubCo shall pay to the
TRA Parties (i) the Early Termination Payment, (ii) any Tax Benefit Payment and Default Rate Interest agreed to by PubCo and the TRA
Parties as due and payable but unpaid as of the Early Termination Notice and (iii) any Tax Benefit Payment due for the Taxable Year
ending prior to, with or including the date of the Early Termination Effective Date (except to the extent that any amounts described
in clauses (ii) or (iii) are included in the Early Termination Payment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 289; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Early Termination Schedule</U>. In the event of a Change of Control or a Material Breach, PubCo shall deliver to the TRA Parties,
as soon as reasonably practical, and in the case of an Early Complete Termination, contemporaneously with the Early Termination Notice,
a Schedule (the &ldquo;<U>Early Termination Schedule</U>&rdquo;) showing in reasonable detail the information required or requested pursuant
to the first sentence of Section 2.03 and the calculation of the Early Termination Payment. The Early Termination Schedule shall become
final and binding on all Parties unless a TRA Party, within thirty (30) calendar days after receiving the Early Termination Schedule,
provides PubCo with notice of a material objection to such Schedule made in good faith (&ldquo;<U>Termination Objection Notice</U>&rdquo;).
If the Parties for any reason are unable to successfully resolve the issues raised in such notice within thirty (30) calendar days after
receipt by PubCo of the Termination Objection Notice, PubCo and the TRA Parties shall employ the Reconciliation Procedures. The date on
which such Early Termination Schedule becomes final shall be the &ldquo;<U>Early Termination Reference Date</U>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment upon Early Termination.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Timing of Payment</U>. Within ten (10) Business Days after the Early Termination Reference Date (such date, the &ldquo;<U>Final
Payment Date</U>&rdquo; in respect of any Early Termination Payment), PubCo shall pay to each relevant TRA Party an amount equal to the
Early Termination Payment for such TRA Party and any other payment required to be made pursuant to Section 4.01(b), Section 4.01(c) and
Section 4.01(d). Such payment shall be made by wire transfer of immediately available funds to a bank account designated in writing by
the applicable TRA Party to PubCo or as otherwise agreed by PubCo and the TRA Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amount of Payment</U>. The &ldquo;<U>Early Termination Payment</U>,&rdquo; as of the Early Termination Effective Date, shall
equal with respect to the relevant TRA Party the present value, discounted at the Early Termination Rate as of the applicable Early Termination
Reference Date, of all Tax Benefit Payments that would be required to be paid by PubCo to such TRA Party beginning from the Early Termination
Effective Date, applying the Valuation Assumptions. For purposes of calculating the present value pursuant to this Section 4.03(b) of
all Tax Benefit Payments that would be required to be paid, it shall be assumed that absent the Early Termination Event all Tax Benefit
Payments would be paid on the due date (without extensions) for filing the PubCo Return with respect to Taxes for each Taxable Year. The
computation of the Early Termination Payment is subject to the Reconciliation Procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
V </B></FONT><B><BR>
LATE PAYMENTS, ETC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Late Payments by PubCo</U>. The amount of all or any portion of any Tax Benefit Payment or Early Termination Payment that is
required to be made by PubCo to the TRA Parties under this Agreement but is not made by the applicable Final Payment Date shall be payable
together with any interest thereon, computed at the Default Rate and commencing from the applicable Final Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subordination</U>. Notwithstanding any other provision of this Agreement to the contrary, any payment required to be made by
PubCo to the TRA Parties under this Agreement shall rank subordinate and junior in right of payment to any principal, interest or other
amounts due and payable in respect of any obligations owed in respect of indebtedness for borrowed money (whether secured or unsecured,
whether senior or subordinated and whether evidenced by bonds, notes or other debt instruments) of PubCo and any of its Subsidiaries (&ldquo;<U>Senior
Obligations</U>&rdquo;) and shall rank <I>pari passu </I>in right of payment with all current or future obligations of PubCo that are
not Senior Obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 290; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
VI </B></FONT><B><BR>
CONSISTENCY&#894; COOPERATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>The TRA Parties&rsquo; Participation in PubCo Tax Matters</U>. Except as otherwise provided herein or in the LLC Agreement,
PubCo shall have full responsibility for, and sole discretion over, all tax matters concerning PubCo, including without limitation the
preparation, filing or amending of any Tax Return and defending, contesting or settling any issue pertaining to Taxes, and certain tax
matters concerning GT LLC. Notwithstanding the foregoing, (i) PubCo shall promptly notify the TRA Parties of, and keep the TRA Parties
reasonably informed with respect to, the portion of any audit of PubCo or GT LLC by a Taxing Authority the outcome of which is reasonably
expected to materially affect any TRA Party&rsquo;s rights and obligations under this Agreement and (ii) for so long as Amber GT (or any
of its Affiliates) is a party to this Agreement, Amber GT (or such Affiliate) shall have the right to participate in and to monitor at
its own expense (but not to control) any portion of any audit of PubCo or GT LLC by a Taxing Authority the outcome of which is reasonably
expected to materially affect Amber GT&rsquo;s (or such Affiliate&rsquo;s) rights and obligations under this Agreement and PubCo shall
(A) provide to Amber GT (or such Affiliate) reasonable opportunity to provide information and other input to PubCo and its advisors concerning
the conduct of any such portion of such audit and (B) not settle or fail to contest any issue in any such portion of such audit without
the prior written consent of Amber GT (or such Affiliate), which consent shall not be unreasonably withheld, conditioned or delayed; provided,
however, that PubCo shall not be required to take any action in connection with such audit that is inconsistent with any provision of
this Agreement or the LLC Agreement. For the avoidance of doubt, to the extent a TRA Party became a party to this Agreement pursuant to
Section 7.06, such TRA Party shall not have any right to participate in any audit under this Section 6.01.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Consistency</U>. PubCo and each TRA Party agrees to report and cause to be reported for all purposes, including U.S. federal,
state and local tax purposes and financial reporting purposes, all tax-related items (including, without limitation, the Basis Adjustments
and each Tax Benefit Payment) in a manner consistent with that contemplated by this Agreement or specified by PubCo in any Schedule required
to be provided by or on behalf of PubCo under this Agreement unless otherwise required by law. PubCo shall (and shall cause GT LLC and
its Subsidiaries to) use commercially reasonable efforts (for the avoidance of doubt, taking into account the interests and entitlements
of all TRA Parties under this Agreement) to defend the tax treatment contemplated by this Agreement and any Schedule in any audit, contest
or similar proceeding with any Taxing Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cooperation</U>. Each of PubCo, GT LLC and the TRA Parties shall (i) furnish to the other Parties in a timely manner such information,
documents and other materials as (A) the other Parties may reasonably request for purposes of making or approving any determination or
computation necessary or appropriate under this Agreement, preparing any Tax Return or contesting or defending any audit, examination
or controversy with any Taxing Authority in respect of the matters covered by this Agreement or (B) in the case of any proposed assignment
by Amber GT (or any of its Affiliates that is a party to this Agreement) in accordance with Section 7.06(a), the applicable TRA Party
may reasonably request in connection with such assignment (<U>provided</U> that Amber GT and its Affiliates, collectively, may only make
one request pursuant to this clause (B) within a given calendar year), (ii) make itself reasonably available to the other Parties and
their respective representatives to provide explanations of documents and materials and such other information as the requesting Parties
or their respective representatives may reasonably request in connection with any of the matters described in clause (i) above, and (iii)
reasonably cooperate in connection with any such matter, and the requesting Party shall reimburse the other Parties for any reasonable
and documented third party costs and expenses incurred pursuant to this Section 6.03.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 291; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Article
VII </B></FONT><B><BR>
MISCELLANEOUS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.01<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any notice, requests, claims, demands and other communications hereunder shall be sent in writing and shall be deemed to have been
duly given by delivery in person, by email (having obtained electronic delivery confirmation thereof (<I>i.e.,</I> an electronic record
of the sender that the email was sent to the intended recipient thereof without an &ldquo;error&rdquo; or similar message that such email
was not received by such intended recipient)), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt
thereof) to the other Parties as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to PubCo or GT LLC, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">[[<FONT STYLE="font-family: Symbol">&middot;</FONT>]<BR>
Email:]<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Kirkland &amp; Ellis LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">601 Lexington Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: &nbsp;&nbsp;Jonathan L. Davis, P.C., Sara B. Zablotney, P.C.
 &amp; Ryan Brissette</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Email: &nbsp;jonathan.davis@kirkland.com; szablotney@kirkland.com;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">ryan.brissette@kirkland.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to Amber GT, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">c/o [Amber], Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">3675 Market Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Philadelphia, PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: &nbsp;Chief Legal Officer<BR>
Email: gcoffice@amicusrx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Skadden, Arps, Slate, Meagher &amp; Flom LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1440 New York Avenue, N.W.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Washington, D.C. 20005</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn:&nbsp;&nbsp;Graham Robinson, Katherine D. Ashley &amp; David
Rievman<BR>
Email:&nbsp;&nbsp;graham.robinson@skadden.com; katherine.ashley@skadden.com;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">david.rievman@skadden.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD><B>Note to Draft</B>: Parties to confirm notice information.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 292; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If to any other TRA Party, to the address or e-mail address specified
on such TRA Party&rsquo;s signature page to the applicable Joinder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Party may change its contact information by giving the other Parties
written notice of its new contact information in the manner set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.02<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts; Electronic Signatures</U>. This Agreement may be executed in several counterparts, each of which shall be deemed
an original and all of which shall constitute one and the same instrument. Delivery of an executed counterpart hereof in .pdf format via
email shall be effective as delivery of an original counterpart hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.03<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Entire
Agreement&#894; Third Party Beneficiaries</U>. This Agreement, together with any exhibits and schedules attached hereto, sets forth
the entire agreement of the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous
understandings and agreements related thereto (whether written or oral), all of which are merged herein. This Agreement shall be
binding upon and inure solely to the benefit of each Party hereto and its respective successors and permitted assigns. Nothing in
this Agreement, express or implied, is intended to or shall confer upon any other Person any rights, benefits or remedies of any
nature whatsoever under or by reason of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.04<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement, and all claims or causes of action (whether in contract, tort or statute) that may be based
upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement (including any claim or
cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement or
as inducement to enter into this Agreement), shall be governed by, and construed and enforced in accordance with, the laws (both substantive
and procedural) of the State of Delaware, without giving effect to the conflict of laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.05<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Whenever possible, each provision of this Agreement will be interpreted in such a manner as to be effective
and valid under applicable law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under
applicable law, all other provisions of this Agreement shall remain in full force and effect so long as the economic or legal substance
of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any
term or other provision of this Agreement is invalid, illegal or unenforceable under applicable law, the Parties shall negotiate in good
faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order
that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.06<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Assignment; Amendments; Successors; Waivers. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Assignment</U>.
No TRA Party may assign, sell, pledge or otherwise alienate or transfer any interest in this Agreement, including the right to
receive any payment under this Agreement, to any Person without the prior written consent of PubCo, which consent may be withheld in
PubCo&rsquo;s reasonable discretion, and without such Person executing and delivering a Joinder agreeing to succeed to the
applicable portion of such TRA Party&rsquo;s interest in this Agreement and to become a Party for all purposes of this Agreement
(the &ldquo;<U>Joinder Requirement</U>&rdquo;); <U>provided</U>, <U>however</U>, that to the extent any TRA Party sells, exchanges,
distributes or otherwise transfers Units to any Person (other than PubCo or GT LLC) in accordance with the terms of the LLC
Agreement, such TRA Party shall have the option to assign (which assignment shall not, for the avoidance of doubt, be subject to
PubCo&rsquo;s consent) to the transferee of such Units its rights under this Agreement with respect to such transferred Units.
Notwithstanding the immediately preceding sentence, from and after such time as a TRA Party has transferred Units to PubCo or GT LLC
in accordance with the terms of the LLC Agreement, such TRA Party may assign (which assignment shall not, for the avoidance of
doubt, be subject to PubCo&rsquo;s consent) its rights hereunder to any Person that satisfies the Joinder Requirement, provided that
such TRA Party has first offered to assign such rights to PubCo and PubCo has declined such offer (provided, that if PubCo fails to
affirmatively accept or decline such offer within ten (10) Business Days, PubCo shall be deemed to have declined such offer). PubCo
may not assign any of its rights or obligations under this Agreement to any Person without the prior written consent of the TRA
Parties (which consent may be withheld in their reasonable discretion), and any purported assignment without such consent shall be
null and void. The transferee and transferor of any Transfer permitted pursuant to the terms and conditions of this Section 7.06
shall ensure that PubCo is provided with a copy (which may be by PDF) of the fully executed instrument of Transfer, which instrument
must clearly identify the name of the transferor and transferee and the number of Units being transferred, within five (5) days of
the effective date of such Transfer. Any Transfer, or attempted Transfer in violation of this Agreement, including any failure of a
purported transferee to enter into a Joinder to this Agreement or to provide any forms or other information to the extent required
hereunder, shall be null and void, and shall not bind or be recognized by PubCo or the TRA Parties. PubCo shall be entitled to treat
the record owner of any rights under this Agreement as the absolute owner thereof and shall incur no liability for payments made in
good faith to such owner until such time as a written assignment of such rights is permitted pursuant to the terms and conditions of
this Section 7.06 and has been recorded on the books of PubCo.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 293; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendments</U>. This Agreement cannot be amended, supplemented or modified, except by a writing signed by each of PubCo and
the TRA Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors</U>. All of the terms and provisions of this Agreement shall be binding upon, shall inure to the benefit of and shall
be enforceable by the Parties and their respective successors, assigns, heirs, executors, administrators and legal representatives. PubCo
shall require and cause any direct or indirect successor (whether by purchase, merger, consolidation or otherwise) to all or substantially
all of the business or assets of PubCo, by written agreement, expressly to assume and agree to perform this Agreement in the same manner
and to the same extent that PubCo would be required to perform if no such succession had taken place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver</U>. No provision of this Agreement may be waived unless such waiver is in writing and signed by the Party against whom
the waiver is to be enforced, and any such waiver shall apply only in the particular instance in which such waiver shall have be given.
Neither any failure or delay in exercising any right or remedy hereunder or in requiring satisfaction of any condition herein nor any
course of dealing shall constitute a waiver of or prevent any Party from enforcing any right or remedy or from requiring satisfaction
of any condition. No notice to or demand on a Party waives or otherwise affects any obligation of that Party or impairs any right of the
Party giving such notice or making such demand, including any right to take any action without notice or demand not otherwise required
by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 294; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.07<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exclusive Jurisdiction; Waiver of Jury Trial.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Except for Reconciliation Disputes subject to Section 7.08, each Party irrevocably and unconditionally submits to the exclusive
jurisdiction of the Chancery Court of the State of Delaware (or if the Chancery Court of the State of Delaware declines to accept jurisdiction,
any federal court within the State of Delaware). Each Party hereby irrevocably and unconditionally waives, and agrees not to assert, by
way of motion or as a defense, counterclaim or otherwise, in any Action or cause thereof against such Party (i) arising under this Agreement
or (ii) in any way connected with or related or incidental to the dealings of the Parties in respect of this Agreement or any of the transactions
contemplated hereby, (1) any claim that such Party is not personally subject to the jurisdiction of the courts as described in this Section
7.07 for any reason, (2) that such Party or such Party&rsquo;s property is exempt or immune from the jurisdiction of any such court or
from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of
execution of judgment, execution of judgment or otherwise) and (iii) that (1) the Action or cause thereof in any such court is brought
against such Party in an inconvenient forum, (2) the venue of such Action or cause thereof against such Party is improper or (3) this
Agreement, or the subject matter hereof, may not be enforced against such Party in or by such courts. Each Party agrees that service of
any process, summons, notice or document by registered mail to such Party&rsquo;s respective address set forth in Section 7.01 shall be
effective service of process for any such Action, demand, or cause thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY PROCEEDING, CLAIM, DEMAND,
ACTION, OR CAUSE OF ACTION (I) ARISING UNDER THIS AGREEMENT OR (II) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS
OF THE PARTIES IN RESPECT OF THIS AGREEMENT, IN EACH CASE, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY,
OR OTHERWISE. EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH PROCEEDING, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED
BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN
EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT
(A) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT,
IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (B) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS
OF THIS WAIVER, (C) EACH SUCH PARTY MAKES THIS WAIVER VOLUNTARILY AND (D) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION&nbsp; <FONT STYLE="text-transform: uppercase">7.07(</FONT>b<FONT STYLE="text-transform: uppercase">).</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 295; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.08<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Reconciliation</U>.
In the event that PubCo and any of the TRA Parties are unable to resolve a disagreement with respect to a Schedule prepared in
accordance with the procedures set forth in Section 2.04 or Section 4.02 within the relevant period designated in this Agreement, or
any other disagreement regarding the calculation of Tax Benefit Payments, the treatment of transactions for tax purposes or any
similar matter the resolution of which requires substantial tax expertise (a &ldquo;<U>Reconciliation Dispute</U>&rdquo;), the
Reconciliation Dispute shall be submitted by the applicable Parties for determination to a nationally recognized expert (the
 &ldquo;<U>Expert</U>&rdquo;) in the particular area of disagreement mutually acceptable to the applicable Parties. The Expert shall
be a partner in a nationally recognized accounting firm or a law firm (other than the Advisory Firm), and the Expert shall not, and
the firm that employs the Expert shall not, have any material relationship with PubCo or the TRA Parties or other actual or
potential conflict of interest. If the applicable Parties are unable to agree on an Expert within fifteen (15) calendar days after
any of the applicable Parties have provided the other applicable Parties with written notice of a Reconciliation Dispute, the Expert
shall be appointed by the International Chamber of Commerce Centre for Expertise. The Expert shall resolve any matter relating to
the Early Termination Schedule or an amendment thereto within thirty (30) calendar days, and shall resolve any matter relating to a
Tax Benefit Schedule or an amendment thereto within fifteen (15) calendar days, or as soon thereafter as is reasonably practicable,
in each case after the matter has been submitted to the Expert for resolution. Notwithstanding the preceding sentence, if the matter
is not resolved before any payment that is the subject of a disagreement is due or any Tax Return reflecting the subject of a
disagreement is due, such payment shall be made on the date prescribed by this Agreement and such Tax Return may be filed as
prepared by PubCo, subject to adjustment or amendment upon resolution. The costs and expenses related to the engagement of such
Expert or amending any Tax Return shall be borne by PubCo, except as provided in the next sentence. Each of PubCo and the applicable
TRA Parties shall bear their own costs and expenses of such proceeding. Any dispute as to whether a dispute is a Reconciliation
Dispute within the meaning of this Section 7.08 shall be decided by the Expert. The Expert shall finally determine any
Reconciliation Dispute and the determinations of the Expert pursuant to this Section 7.08 shall be binding on PubCo and the
applicable TRA Parties and may be entered and enforced in any court having jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.09<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Withholding</U>. PubCo shall be entitled to deduct and withhold from any payment payable pursuant to this Agreement such amounts
as PubCo reasonably believes it is required to deduct and withhold as a result of the execution of this Agreement or with respect to the
making of such payment, in each case, under the Code, or any provision of state, local or foreign tax law, provided that PubCo shall have
first notified the applicable TRA Party of its intent to deduct or withhold, and PubCo and the applicable TRA Party shall have discussed
in good faith whether such taxes can be mitigated to the extent permitted under applicable law. To the extent that amounts are so withheld
and paid over to the appropriate Taxing Authority by PubCo, such withheld amounts shall be treated for all purposes of this Agreement
as having been paid to the relevant TRA Party in respect of whom the deduction and withholding was made. PubCo shall provide evidence
of such payment to the TRA Parties to the extent that such evidence is available. Each TRA Party shall promptly provide PubCo with any
applicable tax forms and certifications reasonably requested by PubCo in connection with determining whether any such deductions and withholdings
are required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 296; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Affiliated Corporations; Admission of PubCo into a Consolidated Group; Transfers of Corporate Assets.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> If PubCo is or becomes a member of an affiliated or consolidated group of corporations that files a consolidated income Tax Return
pursuant to Sections 1501 et seq. of the Code or a similar provision of state or local law (other than if PubCo becomes a member of such
a group as a result of a Change of Control, in which case the provisions of Article IV shall control), then: (i) the provisions of this
Agreement shall be applied with respect to the group as a whole and (ii) Tax Benefit Payments and Early Termination Payments shall be
computed with reference to the consolidated taxable income of the group as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If any Person, the income of which is included in the income of PubCo&rsquo;s affiliated or consolidated group, transfers one or
more assets to a corporation or any Person treated as such for tax purposes with which such entity does not file a consolidated Tax Return
pursuant to Section 1501 et seq. of the Code, for purposes of calculating the amount of any Tax Benefit Payment (e.g., calculating the
gross income of PubCo&rsquo;s affiliated or consolidated group and determining the Realized Tax Benefit) due hereunder, such Person shall
be treated as having disposed of such asset in a fully taxable transaction on the date of such contribution. The consideration deemed
to be received by such entity shall be determined as if such transfer occurred on an arm&rsquo;s-length basis with an unrelated third
party. For purposes of this Section 7.10, a transfer of a partnership interest shall be treated as a transfer of the transferring partner&rsquo;s
applicable share of each of the assets and liabilities of that partnership. Notwithstanding anything to the contrary set forth herein,
if PubCo or any other entity that is obligated to make a Tax Benefit Payment or Early Termination Payment hereunder transfers its assets
pursuant to a transaction that qualifies as a &ldquo;reorganization&rdquo; (within the meaning of Section 368(a) of the Code) in which
such entity does not survive or pursuant to any other transaction to which Section 381(a) of the Code applies, the transfer will not cause
such entity to be treated as having transferred any assets to a corporation (or a Person classified as a corporation for U.S. income tax
purposes) pursuant to this Section 7.10(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Change in Law</U>. Notwithstanding anything herein to the contrary, if, in connection with an actual or proposed change in law,
a TRA Party reasonably believes that the existence of this Agreement could cause material adverse tax consequences to such TRA Party or
any direct or indirect owner of such TRA Party, then at the written election of such TRA Party in its sole discretion (in an instrument
signed by such TRA Party and delivered to PubCo) and to the extent specified therein by such TRA Party, this Agreement shall cease to
have further effect and shall not apply to any Basis Transactions occurring after a date specified by such TRA Party, or may be amended
in a manner reasonably determined by such TRA Party, provided that such amendment shall not result in an increase in any payments owed
by PubCo under this Agreement at any time as compared to the amounts and times of payments that would have been due in the absence of
such amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 297; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Interest
Rate Limitation</U>. Notwithstanding anything to the contrary contained herein, the interest paid or agreed to be paid hereunder
with respect to amounts due to any TRA Party hereunder shall not exceed the maximum rate of non-usurious interest permitted by
applicable law (the &ldquo;<U>Maximum Rate</U>&rdquo;). If any TRA Party shall receive interest in an amount that exceeds the
Maximum Rate, the excess interest shall be applied to the Tax Benefit Payment or Early Termination Payment, as applicable (but in
each case exclusive of any component thereof comprising interest) or, if it exceeds such unpaid non-interest amount, refunded to
PubCo. In determining whether the interest contracted for, charged or received by any TRA Party exceeds the Maximum Rate, such TRA
Party may, to the extent permitted by applicable law, (a) characterize any payment that is not principal as an expense, fee or
premium rather than interest, (b) exclude voluntary prepayments and the effects thereof and (c) amortize, prorate, allocate, and
spread in equal or unequal parts the total amount of interest throughout the contemplated term of the payment obligations owed by
PubCo to such TRA Party hereunder. Notwithstanding the foregoing, it is the intention of the Parties to conform strictly to any
applicable usury laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Independent Nature of Rights and Obligations</U>. The rights and obligations of each TRA Party hereunder are several and not
joint with the rights and obligations of any other Person. A TRA Party shall not be responsible in any way for the performance of the
obligations of any other Person hereunder, nor shall a TRA Party have the right to enforce the rights or obligations of any other Person
hereunder (other than PubCo). The obligations of a TRA Party hereunder are solely for the benefit of, and shall be enforceable solely
by, PubCo. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any TRA Party
pursuant hereto or thereto, shall be deemed to constitute the TRA Parties acting as a partnership, an association, a joint venture or
any other kind of entity, or create a presumption that the TRA Parties are in any way acting in concert or as a group with respect to
such rights or obligations or the transactions contemplated hereby, and PubCo acknowledges that the TRA Parties are not acting in concert
or as a group and will not assert any such claim with respect to such rights or obligations or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signatures pages follow]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 298; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PUBCO:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[CARITAS], INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>GT LLC:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CARITAS THERAPEUTICS, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>[AMBER GT]:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">[GT HOLDINGS,] LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature page to Tax Receivable Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 299 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF JOINDER AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This JOINDER AGREEMENT, dated as of [&bull;], 20__
(this &ldquo;<U>Joinder</U>&rdquo;), is delivered pursuant to that certain Tax Receivable Agreement, dated as of [<FONT STYLE="font-family: Symbol">&middot;</FONT>], 2021 (as amended,
restated, amended and restated, supplemented or otherwise modified from time to time, the &ldquo;<U>Tax Receivable Agreement</U>&rdquo;)
by and among [Caritas], Inc., (f/k/a ARYA Sciences Acquisition Corp IV), a Delaware corporation (&ldquo;<U>PubCo</U>&rdquo;), [Amber GT
Holdings], LLC, a Delaware limited liability company, Caritas Therapeutics, LLC, a Delaware limited liability company and each of the
TRA Parties from time to time party thereto. Capitalized terms used but not otherwise defined herein have the respective meanings set
forth in the Tax Receivable Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Joinder
to the Tax Receivable Agreement</U>. The undersigned hereby represents and warrants to PubCo that, as of the date hereof, the undersigned
has been assigned an interest in the Tax Receivable Agreement from a TRA Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Joinder
to the Tax Receivable Agreement</U>. Upon the execution of this Joinder by the undersigned and delivery hereof to PubCo, the undersigned
hereby is and hereafter will be a TRA Party under the Tax Receivable Agreement and a Party thereto, with all of the rights, privileges
and responsibilities of a TRA Party thereunder. The undersigned hereby agrees that it shall comply with and be fully bound by the terms
of the Tax Receivable Agreement as if it had been a signatory thereto as of the date thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Incorporation
by Reference</U>. All terms and conditions of the Tax Receivable Agreement are hereby incorporated by reference in this Joinder as if
set forth herein in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Address</U>.
All notices under the Tax Receivable Agreement to the undersigned shall be directed to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">[Name]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">[Address]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">[City, State, Zip Code]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">E-mail:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned has duly executed
and delivered this Joinder as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Exhibit A]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 300 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%"><B>[NAME OF NEW PARTY]</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acknowledged and agreed<BR>
as of the date first set forth above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[Amber GT Holdings, LLC]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>Name:</TD>
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>Title:</TD>
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Exhibit A]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 301 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;D</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Director Nomination Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 302 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit D</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Final Form</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CARITAS THERAPEUTICS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM OF DIRECTOR NOMINATION AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Director Nomination Agreement (this &ldquo;<B><I>Agreement</I></B>&rdquo;)
is made and entered into as of [&bull;], 202[&bull;], by and among Caritas Therapeutics, Inc., a Delaware corporation (formerly known
as ARYA Sciences Acquisition Corp IV) (the &ldquo;<B><I>Company</I></B>&rdquo;), ARYA Sciences Holdings IV, a Cayman Islands exempted
company (&ldquo;<B><I>ARYA Sponsor</I></B>&rdquo;), and Amicus Therapeutics, Inc., a Delaware corporation (&ldquo;<B><I>Amber GT Parent</I></B>&rdquo;).
Each of Amber GT Parent, ARYA Sponsor, and any of their respective permitted assigns, are referred to herein as a &ldquo;<B><I>Stockholder</I></B>&rdquo;.
Any capitalized term used but not defined herein shall have the meaning ascribed to it in the Business Combination Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, (i) pursuant to the Business Combination
Agreement, Amber GT Parent is entitled to designate two (2) individuals, one of whom will be a Class I director and the other a Class
II director, to serve as members of the board of directors of the Company (the &ldquo;<B>Board</B>&rdquo;) at the Effective Time (the
 &ldquo;<U>Initial Amber GT Parent Designees</U>&rdquo;) and (ii) from and after the Effective Time, the parties hereto desire to provide
Amber GT Parent certain ongoing director nomination rights, in each case, on the terms and conditions set forth herein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>WHEREAS</B>, (i) pursuant to the Business Combination
Agreement, ARYA Sponsor is entitled to designate one (1) individual to serve as a Class III director of the Board at the Effective Time
(the &ldquo;<U>Initial ARYA Sponsor Designee</U>&rdquo;) and (ii) from and after the Effective Time, the parties hereto desire to provide
ARYA Sponsor certain ongoing director nomination rights, in each case, on the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in consideration of the
mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Board of Directors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>(i) From and after the Effective Time and&#8239;until the Amber 15% Stockholder Termination Event shall have occurred, Amber
GT Parent shall have the right to designate one (1) Designee to be appointed or nominated, as the case may be, as a Class I director of
the Board and one (1) Designee to be appointed or nominated, as the case may be, as a Class II director of the Board (or, if the Board
does not contain classes, two (2) individuals to be appointed or nominated, as the case may be, to the Board), in connection with any
meeting of the stockholders of the Company called (or written consent of the stockholders) with respect to the election of such Directors
classes, and the Company shall, as promptly as practicable, take all necessary and reasonably desirable actions within its control (including,
without limitation, nominating such Designee as a Director, calling special meetings of the Board and the stockholders of the Company
and recommending, supporting and soliciting proxies in favor of such Designees), such that there is one (1) Amber GT Parent Designee serving
as a Class I director on the Board and one (1) Amber GT Parent Designee serving as a Class II director on the Board (or, if the Board
does not contain classes, two (2) Amber GT Parent Designees serving as members of the Board) at all times prior to the occurrence of the
Amber 15% Stockholder Termination Event and (ii)&#8239;from and after the time that an Amber 15% Stockholder Termination Event has occurred
and until the Amber 5% Stockholder Termination Event shall have occurred, Amber GT Parent shall have the right to designate one (1) Designee
to be appointed or nominated, as the case may be, as a Class II director of the Board (or, if the Board does not contain classes, one
(1) Amber GT Parent Designee serving as a member of the Board), in connection with any meeting of the stockholders of the Company called
(or written consent of the stockholders) with respect to the election of Directors, and the Company shall, as promptly as practicable,
take all necessary and reasonably desirable actions within its control (including, without limitation, nominating such Designee as a Director,
calling special meetings of the Board and the stockholders of the Company and recommending, supporting and soliciting proxies in favor
of such Designee), such that there is one (1) Amber GT Parent Designee serving as a Class II director on the Board (or, if the Board does
not contain classes, one (1) Amber GT Parent Designee serving as member of the Board) at all times prior to the occurrence of the Amber
5% Stockholder Termination Event. If (A) a vacancy on the Board occurs because of the death, disability, disqualification, resignation
or removal of an Amber GT Parent Director and (B) Amber GT Parent has the right to designate such Director seat pursuant to this Agreement,
then Amber GT Parent shall be entitled to designate a Designee to replace the Amber GT Parent Director that vacated the Board due to death,
disability, disqualification, resignation or removal, and the Company will, within ten (10) Business Days of such designation of such
Designee, take all necessary and reasonably desirable actions within its control such that such vacancy shall be filled with such replacement
Designee. Notwithstanding anything to the contrary, any Director position vacated by an Amber GT Parent Director because of such Director&rsquo;s
death, disability, disqualification, resignation or removal shall not be filled pending any such designation and appointment by Amber
GT Parent unless Amber GT Parent fails to designate a Designee within thirty (30) days after receipt of written notice from the Company
notifying it that such vacancy has occurred, in which case after such thirty- (30-) day period, the Company may nominate or appoint a
designee who may serve as a Director only until, subject to no Amber 15% Stockholder Termination Event or Amber 5% Stockholder Termination
Event, as applicable, having occurred as of such time, Amber GT Parent designates a Designee in accordance with the terms hereof (provided
that the Company may, in its discretion, fill such vacant Director seat and instead increase the size of the Board and appoint such Designee
to fill the vacant Director resulting from such increase in the size of the Board, with, if the Board has classes as of such time, such
Designee being in the same class of Directors that he or she would have been entitled to fill).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 303 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>From
and after the Effective Time and until the ARYA Stockholder Termination Event shall have occurred, ARYA Sponsor shall have the right
to designate one (1) Designee to be appointed or nominated, as the case may be, as a Class III director of the Board (or, if the Board
does not contain classes, one individual to be appointed or nominated, as the case may be, to the Board), in connection with any meeting
of the stockholders of the Company called (or written consent of the stockholders) with respect to the election of such Director class,
and the Company shall, as promptly as practicable, take all necessary and reasonably desirable actions within its control (including,
without limitation, nominating such Designee as a Director, calling special meetings of the Board and the stockholders of the Company
and recommending, supporting and soliciting proxies in favor of such Designees), such that there is one (1) ARYA Sponsor Designee serving
as a Class III director on the Board (or, if the Board does not contain classes, one (1) ARYA Sponsor Designee serving as member of the
Board) at all times prior to the occurrence of the ARYA Stockholder Termination Event. If (i) a vacancy on the Board occurs because of
the death, disability, disqualification, resignation or removal of the ARYA Sponsor Director and (ii) ARYA Sponsor has the right to designate
such Director seat pursuant to this Agreement, then ARYA Sponsor shall be entitled to designate a Designee to replace the ARYA Sponsor
Director that vacated the Board due to death, disability, disqualification, resignation or removal, and the Company will, within ten
(10) Business Days of such designation of such Designee, take all necessary and reasonably desirable actions within its control such
that such vacancy shall be filled with such replacement Designee. Notwithstanding anything to the contrary, the Director position vacated
by the ARYA Sponsor Director because of such Director&rsquo;s death, disability, disqualification, resignation or removal, shall not
be filled pending such any such designation and appointment by ARYA Sponsor unless ARYA Sponsor fails to designate a Designee within
thirty (30) days after receipt of written notice from the Company notifying it that such vacancy has occurred, in which case after such
thirty- (30-) day period, the Company may nominate or appoint a designee who may serve as a Director only until, subject to no ARYA Stockholder
Termination Event having occurred as of such time, ARYA Sponsor designates a Designee in accordance with the terms hereof (provided that
the Company may, in its discretion, fill such vacant Director seat and instead increase the size of the Board and appoint such Designee
to fill the vacant Director resulting from such increase in the size of the Board, with, if the Board has classes as of such time, such
Designee being in the same class of Directors that he or she would have been entitled to fill).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>If a Designee is entitled to serve on the Board pursuant to <U>Section 1(a)</U> or <U>Section 1(b)</U>, the Company shall
take all necessary and reasonably desirable actions within its control in connection with the nomination, appointment, election or re-election
of such Designee, as the case may be, to ensure that (i) the Designee is included in the Board&rsquo;s slate of nominees to the stockholders
of the Company for the applicable election of Directors and (ii)&#8239;the Designee is included in the proxy statement prepared by management
of the Company in connection with soliciting proxies for the applicable meeting of the stockholders of the Company called with respect
to the election of the applicable class of Directors, and at every adjournment or postponement thereof, and on every action or approval
by written consent of the stockholders of the Company with respect to the applicable election of the applicable class of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>If a Designee entitled to serve on the Board pursuant to <U>Section 1(a)</U> or <U>Section 1(b)</U> is not elected or appointed
because of such Designee&rsquo;s death, disability, disqualification, withdrawal as a nominee for election to the Board or for any other
reason (and such Designee is not replaced as a Designee pursuant to the applicable terms of <U>Section 1(a) or Section 1(b)</U> above),
(i) the applicable Stockholder(s) shall, for so long as such Stockholder is entitled to appoint or nominate such Designee pursuant to
<U>Section 1(a)</U> or <U>Section 1(b)</U>, be entitled to promptly designate a replacement Designee, and (ii) the Company will, within
ten (10) Business Days of such designation, take all necessary and reasonably desirable actions within its control such that such replacement
Designee is elected or appointed as a Director the Company. Notwithstanding anything to the contrary, the Director position for which
such original Designee was designated shall not be filled pending such designation and appointment or election, as applicable, unless
the applicable Stockholder(s) shall fail to designate such replacement Designee within thirty (30) days after receipt of written notice
from the Company notifying such Stockholder that such Designee was not elected, and after such thirty- (30-) day period, the Company may
appoint or nominate, as the case may be, a successor designee who may serve as a Director only, subject to no applicable Stockholder Termination
Event having occurred, until the applicable Stockholder(s) shall designate a replacement Designee in accordance with the terms hereof
(provided that the Company may, in its discretion, fill such vacant Director seat and instead increase the size of the Board and appoint
such Designee to fill the vacant Director resulting from such increase in the size of the Board, with, if the Board has classes as of
such time, such Designee being in the same class of Directors that he or she would have been entitled to fill).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 304 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>In accordance with the Bylaws, the Company may from time to time by resolution establish and maintain one or more committees
of the Board, with each committee to consist of one (1) or more Directors. To the extent feasible, the Company shall notify ARYA Sponsor
and Amber GT Parent in writing of any new committee of the Board to be established at least fifteen (15) days prior to the effective establishment
of such committee. If requested by ARYA Sponsor or Amber GT Parent, the Company shall take all necessary steps to cause at least one (1)
Stockholder Director as requested by Amber GT Parent and one (1) Stockholder Director as requested by ARYA Sponsor to each be appointed
as a member of each such committee of the Board unless such designation would violate any legal restriction on such committee&rsquo;s
composition or the rules and regulations of any applicable exchange on which the Company&rsquo;s securities may be listed; <U>provided</U>,
that the foregoing sentence shall not apply, with respect to any Stockholder, to any special committee of the Board established specifically
for the purpose of evaluating a transaction or other corporate action involving such Stockholder or to the extent the appointment of such
individual to such committee would, as reasonably determined by the Company, result in any other conflict or potential conflict of interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>From and after the Effective Time, (i)&#8239;until the Amber 5% Stockholder Termination Event occurs, the Company shall take
all necessary and reasonably desirable actions within its control to cause one (1) Amber GT Parent Director as requested in writing by
Amber GT Parent to be appointed as a member of the compensation committee, the audit committee or the nominating committee of the Board
and (ii) until the ARYA Stockholder Termination Event occurs the Company shall take all necessary or reasonably desirable actions within
its control to cause one (1) ARYA Sponsor Director as requested in writing by ARYA Sponsor to be appointed as a member the compensation
committee, the audit committee or the nominating committee of the Board, unless in the case of any request made pursuant to clause (i)
or (ii) above, such designation would violate any legal restriction on such committee&rsquo;s composition or the rules and regulations
of Nasdaq or any other any applicable exchange on which the Company&rsquo;s securities may be listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>The
Company shall pay all reasonable, documented and out-of-pocket expenses incurred by each Stockholder Director in connection with his
or her service as a Director or as a member of the board of directors (or other similar governing body) of any Subsidiary of the Company,
including, but not limited to, attending meetings or events attended on behalf of the Company at the Company&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>The Company shall, for so long as any Designee serves as a Director, maintain directors&rsquo; and officers&rsquo; liability
insurance in an amount determined by the Board to be reasonable and customary; <U>provided,</U> that upon such Stockholder Director ceasing
to serve as a Director for any reason, the Company shall take all actions reasonably necessary to extend such directors&rsquo; and officers&rsquo;
liability insurance coverage with respect to such Stockholder Director for a period of not less than six (6) years from the time at which
such director ceases to serve as a Director in respect of any act or omission of such Stockholder Director occurring at or prior to such
cessation of service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 305 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>For
so long as any Stockholder Director serves as a Director, the Company (i) shall provide such Stockholder Director with the same expense
reimbursement, benefits, indemnity, exculpation and other arrangements provided to the other Directors; <U>provided</U>, that any Stockholder
Director who is also an employee of the applicable Stockholder (or its Affiliates) may elect not to receive any standard director fees
paid by the Company to Directors, and (ii) shall not amend, alter or repeal any right to indemnification or exculpation covering or benefiting
any Stockholder Director as and to the extent consistent with applicable law, including, but not limited to, Article VII of the Certificate
of Incorporation and Article VII of the Bylaws (whether such right is contained in the Certificate of Incorporation, the Bylaws or another
document), (except to the extent such amendment or alteration permits the Company to provide broader indemnification or exculpation rights
on a retroactive basis than permitted prior thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>Any
Designee will be subject to the Company&rsquo;s customary due diligence process, including its review of a completed questionnaire and
a background check, consistent with the Company&rsquo;s corporate governance policies as in effect at the applicable time. Based on the
foregoing and to the extent consistent with the Company&rsquo;s corporate governance policies as in effect at the applicable time, the
Company may reasonably object to any Designee (i) provided it does so in good faith and (ii) solely to the extent such objection is based
upon any of the following: (1) such Designee was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding
(excluding traffic violations and other minor offenses); (2) such Designee was the subject of any order, judgment, or decree not subsequently
reversed, suspended or vacated of any court of competent jurisdiction, permanently or temporarily enjoining such proposed director from,
or otherwise limiting, the following activities: (A) engaging in any type of business practice, or (B) engaging in any activity in connection
with the purchase or sale of any security or in connection with any violation of federal or state securities laws; (3) such Designee
was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any federal or state authority
barring, suspending or otherwise limiting for more than sixty (60) days the right of such person to engage in any activity described
in clause (2)(B), or to be associated with persons engaged in such activity; (4) such Designee was found by a court of competent jurisdiction
in a civil action or by the SEC to have violated any federal or state securities law, and the judgment in such civil action or finding
by the SEC has not been subsequently reversed, suspended or vacated; or (5) such Designee was the subject of, or a party to any federal
or state judicial or administrative order, judgment, decree or finding, not subsequently reversed, suspended or vacated, relating to
a violation of any federal or state securities laws or regulations. In the event the Board reasonably finds the Designee to be unsuitable
based upon one or more of the foregoing clauses (1) through (5) and reasonably objects to the identified director, the applicable Stockholder
shall be entitled to propose a different Designee to the Board within thirty (30) days of the Company&rsquo;s notice to such Stockholder
of its objection to the Designee and such replacement Designee shall be subject to the review process outlined above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 306 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Definitions</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Action</I></B>&rdquo; has the meaning
set forth in <U>Section 11(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Affiliate</I></B>&rdquo; means, with
respect to any Person, any other Person directly or indirectly Controlling, Controlled by, or under common Control with such Person. Notwithstanding
anything to the contrary herein, the Affiliates of the ARYA Sponsor shall be deemed to include Perceptive Advisors LLC, a Delaware limited
liability company, and its Affiliates (including, for the avoidance of doubt, the Perceptive PIPE Investor).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Agreement</I></B>&rdquo; has the meaning
set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Amber 5% Stockholder Termination Event</I></B>&rdquo;
means the first time following the Effective Time at which Amber GT Parent and its Affiliates Beneficially Own less than five percent
(5%) of the total number of Voting Interests issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Amber 15% Stockholder Termination
Event</I></B>&rdquo; means the first time following the Effective Time at which Amber GT Parent and its Affiliates Beneficially Own less
than fifteen percent (15%) of the total number of Voting Interests issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Amber GT Parent</I></B>&rdquo; has
the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Amber GT Parent Designee</I></B>&rdquo;
means a Designee of the Amber GT Parent for the purpose of nomination to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Amber GT Parent Director</I></B>&rdquo;
means a Designee of Amber GT Parent that has been elected, appointed or is otherwise serving as a Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>ARYA Sponsor</I></B>&rdquo; has the
meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>ARYA Sponsor Designee</I></B>&rdquo;
means a Designee of ARYA Sponsor for the purpose of nomination to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>ARYA Sponsor Director</I></B>&rdquo;
means a Designee of the ARYA Sponsor that has been elected, appointed or is otherwise serving as a Director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>ARYA Stockholder Termination Event</I></B>&rdquo;
means the first time following the Effective Time at which ARYA Sponsor and its Affiliates Beneficially Own less than five percent (5%)
of the total number of Voting Interests issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Beneficially Own</I></B>&rdquo; has
the meaning ascribed to it in Section 13(d) of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Board</I></B>&rdquo; has the meaning
set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Business Combination Agreement</I></B>&rdquo;
means that certain Business Combination Agreement, dated as of September 29, 2021, by and among the Company, Amber GT Parent, Amicus GT
Holdings, LLC, a Delaware limited liability company, and Caritas Therapeutics, LLC, a Delaware limited liability company, as amended,
amended and restated, supplemented or otherwise modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 307 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Business Day</I></B>&rdquo; means
any day other than a Saturday, Sunday or a legal holiday on which commercial banking institutions in New York, New York are authorized
to close for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Bylaws</I></B>&rdquo; means the Amended
and Restated Bylaws of the Company, as in effect at the Effective Time, as the same may be amended, amended and restated, supplemented
or otherwise modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Certificate of Incorporation</I></B>&rdquo;
means the Certificate of Incorporation of the Company, as in effect immediately following the Effective Time, as the same may be amended
and restated, supplemented or otherwise modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Company</I></B>&rdquo; has the meaning
set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Control</I></B>&rdquo; means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the
ownership of voting securities, by Contract or otherwise; and the terms &ldquo;Controlled&rdquo; and &ldquo;Controlling&rdquo; have meanings
correlative to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Designee</I></B>&rdquo; means an individual
designated by a Stockholder for the purpose of nomination to the Board by the Company pursuant to the Business Combination Agreement prior
to the Effective Time or this Agreement at or after the Effective Time. For the avoidance of doubt, the Initial Amber GT Parent Designees
and the Initial ARYA Designees shall constitute Designees of Amber GT Parent and ARYA Sponsor, respectively, at the Effective Time for
all purposes under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Director</I></B>&rdquo; means any
individual then serving as a member of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Effective Time</I></B>&rdquo; means
the time immediately after the Closing on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Exchange Act</I></B>&rdquo; means
the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Initial Amber GT Parent Designees</I></B>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Initial ARYA Sponsor Designee</I></B>&rdquo;
has the meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Nasdaq</I></B>&rdquo; means the The
Nasdaq Stock Market LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Person</I></B>&rdquo; means an individual,
a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust, a joint venture, an unincorporated
organization and a governmental entity or any department, agency or political subdivision thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>SEC</I></B>&rdquo; means the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Stockholder</I></B>&rdquo; has the
meaning set forth in the preamble.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 308 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Stockholder Director</I></B>&rdquo;
means an Amber GT Parent Director or the ARYA Sponsor Director, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Stockholder Termination Event</I></B>&rdquo;
means the occurrence of any of the Amber 5% Stockholder Termination Event, the Amber 15% Stockholder Termination Event or the ARYA Stockholder
Termination Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Transfer</I></B>&rdquo; means any
sale, transfer, assignment or other disposition of (whether with or without consideration and whether voluntary or involuntary or by operation
of law) of Voting Interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Voting Interests</I></B>&rdquo; means
the Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share, all considered together
as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Assignment; Binding Effect</U>. This Agreement and the rights and obligations hereunder shall not be assignable or transferable
by any of the parties hereto, in whole or in part (including by operation of law), without the prior written consent of the other parties
hereto; <U>provided</U>, that Amber GT Parent or ARYA Sponsor may assign, in whole, but not in part, this Agreement without the prior
written consent of any other parties hereto to any of its Affiliates that Beneficially Own Voting Interests, so long as the applicable
assignee executes a joinder to this Agreement, in form and substance reasonably satisfactory to the Company, pursuant to which such assignee
agrees to be bound by the terms hereof as though such assignee were Amber GT Parent or the ARYA Sponsor, as the case may be. This Agreement
and all of the provisions hereof shall be binding upon and inure to the benefit of the parties hereto and their respective permitted
successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Specific Performance</U>. Except as otherwise expressly provided herein, any and all remedies provided herein will be deemed
cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party
of any one remedy will not preclude the exercise of any other remedy. The parties hereto agree that irreparable damage for which monetary
damages, even if available, would not be an adequate remedy, would occur in the event that the parties hereto do not perform their respective
obligations under the provisions of this Agreement in accordance with their specific terms or otherwise breach such provisions. It is
accordingly agreed that the parties hereto shall be entitled to seek an injunction or injunctions, specific performance and other equitable
relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case, without
posting a bond or undertaking and without proof of damages and this being in addition to any other remedy to which they are entitled
at law or in equity. Each of the parties hereto agrees that it will not oppose the granting of an injunction, specific performance and
other equitable relief when expressly available pursuant to the terms of this Agreement on the basis that the other parties hereto have
an adequate remedy at law or an award of specific performance is not an appropriate remedy for any reason at law or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 309 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notices</U>. Any notice, requests, claims, demands and other communications hereunder shall be sent in writing and shall be
deemed to have been duly given by delivery in person, by email (having obtained electronic delivery confirmation thereof (i.e., an electronic
record of the sender that the email was sent to the intended recipient thereof without an &ldquo;error&rdquo; or similar message that
such email was not received by such intended recipient)), or by registered or certified mail (postage prepaid, return receipt requested)
(upon receipt thereof) to the other parties hereto as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company, to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&#8239;</TD>
    <TD STYLE="width: 5%">&#8239;</TD>
    <TD STYLE="width: 5%">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3675 Market Street,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19104</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John F. Crowley</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy (which shall not constitute notice) to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirkland&#8239;&amp; Ellis LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">601 Lexington Avenue</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan L. Davis, P.C.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan Brissette</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jonathan.davis@kirkland.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ryan.brissette@kirkland.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to Amber GT Parent, to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amicus Therapeutics, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3675 Market Street,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19104</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: Chief Legal Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: gcoffice@amicusrx.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy (which shall not constitute notice) to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Skadden, Arps, Slate, Meagher &amp; Flom LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1440 New York Avenue, N.W.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington, D.C. 20005</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Graham Robinson</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Katherine D. Ashley</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">graham.robinson@skadden.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">katherine.ashley@skadden.com</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 1.5in"></P>

<!-- Field: Page; Sequence: 310 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 1.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">I<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f to ARYA Sponsor, to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&#8239;</TD>
    <TD STYLE="width: 5%">&#8239;</TD>
    <TD STYLE="width: 5%">&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o ARYA Science Acquisition Corp IV</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51 Astor Place, 10th Floor</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10003</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam Stone</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Altman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug Giordano</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Konstantin Poukalov</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adam@perceptivelife.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">michael@perceptivelife.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doug@perceptivelife.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Konstantin@perceptivelife.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy (which shall not constitute notice) to:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kirkland&#8239;&amp; Ellis LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">601 Lexington Avenue</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10022</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan L. Davis, P.C.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan Brissette</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jonathan.davis@kirkland.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ryan.brissette@kirkland.com</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustments</U>. If, and as often as, there are any changes in the Voting Interests by way of stock split, stock dividend,
combination or reclassification, or through merger, consolidation, reorganization or recapitalization, or by any other similar means,
appropriate adjustment shall be made in the provisions of this Agreement, as may be required, so that the rights, privileges, duties
and obligations hereunder shall continue with respect to the Voting Interests as so changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Presumption Against Drafting Party</U>. This Agreement has been negotiated at arm&rsquo;s-length by parties of equal bargaining
strength, each represented by counsel in connection with this Agreement and the transactions contemplated hereby. This Agreement creates
no fiduciary or other special relationship between the parties hereto, and no such relationship otherwise exists. No presumption in favor
of or against any party hereto in the construction or interpretation of this Agreement or any provision hereof shall be made based upon
which Person might have drafted this Agreement or such provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Third-Party Beneficiaries</U>. This Agreement shall be binding upon and inure solely to the benefit of each party and its
successors and permitted assigns and nothing in this Agreement, express or implied, is intended to or shall confer upon any other Person
any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement; <U>provided</U>, that, each Stockholder
Director shall be an express third-party beneficiary of the provisions in <U>Sections 1(g)&ndash;(i)</U> and shall be entitled to enforce
such provisions as though such Stockholder Director was a party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 311 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">Section
9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT><U>Execution
of Agreement</U><FONT STYLE="text-decoration: none">. This Agreement may be executed in one or more counterparts, each of which shall
be deemed to be an original, but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of a signature
page to this Agreement (including any of the closing deliverables contemplated hereby) by email or scanned pages shall be effective as
delivery of a manually executed counterpart to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Governing Law</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>This
Agreement, and all claims or causes of action (whether in contract, tort or statute) that may be based upon, arise out of or relate to
this Agreement or any of the transactions contemplated hereby, or the negotiation, execution or performance of this Agreement or any
of the transactions contemplated hereby (including any claim or cause of action based upon, arising out of related to any of the transactions
contemplated hereby or any of the transactions contemplated thereby or as inducement to enter into this Agreement), shall be construed
and enforced in accordance with and governed by the Laws (both substantive and procedural) of the State of Delaware, without giving effect
to the conflict of Laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="color: #010000">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT>Each
of the parties hereto irrevocably and unconditionally submits to the exclusive jurisdiction of the Chancery Court of the State of Delaware
(or, if the Chancery Court of the State of Delaware declines to accept jurisdiction, any federal court within the State of Delaware,
and then, if such federal court declines to accept jurisdiction, any state or federal court within New York, New York), for the purposes
of any Action (a) arising under this Agreement or (b) in any way connected with or related or incidental to the dealings of the parties
hereto in respect of this Agreement or any of the transactions contemplated hereby, and irrevocably and unconditionally waives any objection
to the laying of venue of any such Action in any such court, and further irrevocably and unconditionally waives and agrees not to plead
or claim in any such court that any such Action has been brought in an inconvenient forum. Each party hereby irrevocably and unconditionally
waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any Action or cause thereof against
such party (x) arising under this Agreement or (y) in any way connected with or related or incidental to the dealings of the parties
hereto in respect of this Agreement or any of the transactions contemplated hereby, (i)&#8239;any claim that such party is not personally
subject to the jurisdiction of the courts as described in this <U>Section&#8239;10(a)</U> for any reason, (ii)&#8239;that such party or
such party&rsquo;s property is exempt or immune from the jurisdiction of any such court or from any legal process commenced in such courts
(whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or
otherwise) and (iii)&#8239;that (x)&#8239;the Action or cause thereof in any such court is brought against such party in an inconvenient
forum, (y)&#8239;the venue of such Action or cause thereof against such party is improper; or (z)&#8239;this Agreement, or the subject
matter hereof, may not be enforced against such party in or by such courts. Each party agrees that service of any process, summons, notice
or document by registered mail to such party&rsquo;s respective address set forth in <U>Section&#8239;5</U> shall be effective service
of process for any such Action, demand, or cause thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 312 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Waiver
of Jury Trial</U>. EACH OF THE PARTIES HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY
PROCEEDING, CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (I) ARISING UNDER THIS AGREEMENT OR (II) IN ANY WAY CONNECTED WITH OR RELATED OR
INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS RELATED HERETO, IN EACH CASE,
WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. THE PARTIES HERETO EACH HEREBY AGREES
AND CONSENTS THAT ANY SUCH PROCEEDING, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT
THE PARTIES HERETO MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF
THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (A) NO REPRESENTATIVE, AGENT
OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION,
SEEK TO ENFORCE THE FOREGOING WAIVER, (B) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (C) EACH SUCH
PARTY MAKES THIS WAIVER VOLUNTARILY AND (D) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE
MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <U>SECTION&#8239;11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&#8239;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">Section
12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT><U>Entire
Agreement</U><FONT STYLE="text-decoration: none">. This Agreement sets forth the entire agreement of the parties hereto with respect
to the subject matter hereof and thereof and supersedes all prior and contemporaneous understandings and agreements related thereto (whether
written or oral), all of which are merged herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&#8239;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">Section
13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT><U>Severability</U><FONT STYLE="text-decoration: none">.
Whenever possible, each provision of this Agreement will be interpreted in such a manner as to be effective and valid under applicable
Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under applicable Law, all other
provisions of this Agreement shall remain in full force and effect so long as the economic or legal substance of the transactions contemplated
hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision of this
Agreement is invalid, illegal or unenforceable under applicable Law, the parties hereto shall negotiate in good faith to modify this
Agreement so as to effect the original intent of the parties hereto as closely as possible in an acceptable manner in order that the
transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&#8239;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">Section
14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT><U>Amendment
and Waiver</U><FONT STYLE="text-decoration: none">. Except as otherwise provided herein, no modification, amendment or waiver of any
provision of this Agreement shall be effective against a party, unless such modification is approved in writing by such party. Neither
any failure or delay in exercising any right or remedy hereunder or in requiring satisfaction of any condition herein nor any course
of dealing shall constitute a waiver of or prevent any party from enforcing any right or remedy or from requiring satisfaction of any
condition. No notice to or demand on a party waives or otherwise affects any obligation of that party or impairs any right of the party
giving such notice or making such demand, including any right to take any action without notice or demand not otherwise required by this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&#8239;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">Section
15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT></FONT><U>Termination</U><FONT STYLE="text-decoration: none">.
Notwithstanding anything to the contrary contained herein, (a)&#8239;following the occurrence of the Amber 5% Stockholder Termination
Event, this Agreement shall expire and automatically terminate solely with respect to Amber GT Parent, (b)&#8239;following the occurrence
of the ARYA Stockholder Termination Event, this Agreement shall expire and automatically terminate solely with respect to ARYA Sponsor
and (c) this Agreement shall expire and automatically terminate with respect to all parties hereto upon the consummation of a Change
of Control Transaction of the Company; </FONT><U>provided</U><FONT STYLE="text-decoration: none">, however, in either case, </FONT><U>Section&#8239;1(g)-(i)</U><FONT STYLE="text-decoration: none">,
this </FONT><U>Section 15</U> <FONT STYLE="text-decoration: none">and </FONT><U>Sections&#8239;2-5, 7-14</U> <FONT STYLE="text-decoration: none">(to
the extent related to any of the foregoing) shall survive any termination of this Agreement with respect to such terminated Stockholder
or any termination of this Agreement in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&#8239;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[SIGNATURE PAGES FOLLOW]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 313 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties have executed
this Agreement on the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company: </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 3%">&#8239;</TD>
    <TD STYLE="width: 47%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CARITAS THERAPEUTICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#8239;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 314 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders: </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 3%">&#8239;</TD>
    <TD STYLE="width: 47%">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMBER GT PARENT</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARYA SCIENCES HOLDINGS IV</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD>&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"><B></B></P>

<!-- Field: Page; Sequence: 315; Options: NewSection; Value: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;E</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Co-Development and Commercialization
Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 316 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;F</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Transition Services Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 317 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit F</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>TRANSITION SERVICES AGREEMENT</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This TRANSITION SERVICES
AGREEMENT (the &ldquo;<B><U>Agreement</U></B>&rdquo;), dated as of [&#9679;], 202[&#9679;] (the &ldquo;<B><U>Effective Date</U></B>&rdquo;),
is entered into by and between Amicus Therapeutics, Inc., a Delaware corporation (&ldquo;<B><U>Amber</U></B>&rdquo;) and Caritas Therapeutics,
LLC, a Delaware limited liability company (the &ldquo;<B><U>Company</U></B>&rdquo;). Each of Amber and the Company are referred to herein
individually as a &ldquo;<B><U>Party</U></B>&rdquo; and together as the &ldquo;<B><U>Parties</U>.</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to that
certain Business Combination Agreement, dated as of September 29, 2021 (as amended, restated, amended and restated, supplemented, waived
or otherwise modified from time to time in accordance with the terms thereof, the &ldquo;<B><U>Combination Agreement</U></B>&rdquo;),
Amber and its Affiliates sold, transferred, contributed, assigned, conveyed and delivered to the Company all of the assets, properties
and rights related to the Business, as described therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to the Combination
Agreement and in connection with the transactions contemplated thereby, Amber and the Company shall enter into this Agreement in order
to provide for the provision (i) from Amber and/or one or more of its Affiliates to the Company and/or one or more of its Affiliates and
(ii) from the Company and/or one or more of its Affiliates to Amber and/or one or more of its Affiliates of certain transitional services
in order to facilitate the orderly transition of the Business from Amber and/or one or more of its Affiliates to the Company and/or one
or more of its Affiliates, upon the terms and subject to the conditions hereinafter set forth; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Party providing
an applicable Service (as defined below) hereunder, as set forth in the Schedules to this Agreement, is referred to as &ldquo;<U>Provider</U>&rdquo;
and the Party receiving an applicable Service hereunder, as set forth in the Services Schedules, is referred to as &ldquo;<B><U>Recipient</U></B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing promises and the mutual covenants, agreements, representations and warranties hereinafter set forth, and intending to
be legally bound hereby, the Parties hereto hereby agree as follows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Definitions<FONT STYLE="font-weight: normal">. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Capitalized Terms</U>. Capitalized terms used in this Agreement and not otherwise defined herein shall have the meanings ascribed
to such terms in the Combination Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Services and Associated Fees.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Services</U>. From and after the Closing Date, Provider shall, or shall cause its Affiliates to, provide to Recipient and its
Affiliates (i) the services set forth on <U>Schedule A</U> (where Amber is the Provider) or <U>Schedule B</U> (where the Company is the
Provider), as applicable, including any other activities or tasks that are not specifically described on <U>Schedule A</U> or <U>Schedule&#8239;B</U>,
as applicable, but which are required for or are a necessary or inherent part of the proper performance or delivery of such services,
and (ii) all services reasonably required to transition or migrate from the provision of the services set forth on <U>Schedule A</U> or
<U>Schedule B</U>, as applicable, to Recipient, including data extraction and migration, knowledge transfer, and reasonable access to
personnel and facilities (clauses (i) and (ii), collectively, the &ldquo;<B><U>Services</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 318 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Omitted Services</U>. Notwithstanding anything in this Agreement to the contrary, if during the ninety (90) day period immediately
following the date of this Agreement (or promptly after a Recipient becomes aware of the need for an omitted service, to the extent a
Recipient does not become aware of the need for a periodic service until after such first ninety (90) day period), (i) Company as Recipient
identifies a service that was historically provided by Amber or its Affiliates in connection with the Business and such service was inadvertently
omitted from <U>Schedule A</U>, then the Company may provide notice thereof to Amber and (ii) if Amber as Recipient identifies a service
that was historically provided by the Company or its Affiliates and reasonably anticipated as of the date hereof to be necessary to continue
to support any portion of the Retained Business and such service was inadvertently omitted from <U>Schedule B</U>, then Amber may provide
notice thereof to the Company (any such omitted service as described in subclause (i) or (ii), an &ldquo;<B><U>Omitted Service</U></B>&rdquo;).
Upon receipt of such notice from either Party, (x) where the Company is the Recipient, upon Amber&rsquo;s prior written consent (such
consent not to be unreasonably withheld, conditioned or delayed), such Omitted Service shall be deemed to be a Service for purposes of
this Agreement and Amber shall provide such Omitted Service to the Company, and (y) where Amber is the Recipient, upon the Company&rsquo;s
prior written consent (such consent not to be unreasonably withheld, conditioned or delayed), such Omitted Service shall be deemed to
be a Service for purposes of this Agreement and the Company shall provide such Omitted Service to Amber; and in each of (x) and (y) the
Company and Amber shall use commercially reasonable efforts to promptly meet to identify and document the scope and pricing for such
Omitted Service and amend <U>Schedule A</U> or <U>Schedule B</U>, as applicable, to add such Omitted Service as a Service; <U>provided
</U>that the pricing for such Omitted Services shall be no greater than the cost allocation to the Business or the Retained Business,
as applicable, for such Omitted Service as provided immediately prior to the consummation of the transactions contemplated by the Combination
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Additional Services</U>. The provision of any services not expressly set out in <U>Schedule&#8239;A</U> or <U>Schedule B</U>
or contemplated by <U>Sections 2(a)</U> or <U>2(b)</U>, as applicable, or outside the scope, nature frequency or volume of the Services
as provided prior to the date of execution of the Combination Agreement (&ldquo;<B><U>Additional Services</U></B>&rdquo;) shall require
the consent of Provider, such consent not to be unreasonably withheld, conditioned or delayed. If such consent is given, then the Parties
shall promptly meet to identify and negotiate in good faith the scope and pricing for such Additional Service; <U>provided</U>, <U>however</U>,
that the pricing for such Additional Service shall be no greater than Provider&rsquo;s cost to provide such Additional Services, provided
that the term for such Additional Service shall not extend beyond the longest term for the other Services on <U>Schedule&#8239;A</U>
or <U>Schedule B</U>, as applicable, as of the Effective Date. If the Parties agree on such terms, then they shall amend <U>Schedule&#8239;A
</U>or <U>Schedule B</U>, as applicable, to include such Additional Service as a Service hereunder. Except as set forth herein, the Parties
acknowledge and agree that no services other than those specifically described in this Agreement will be provided by or on behalf of
a Party unless otherwise agreed in writing by the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Change Requests</U>. If Recipient wishes to make any material change to the scope, nature, frequency, amount or volume of the
Services provided under this Agreement (including any increases in staffing levels, equipment acquisitions, investments, or capital or
other expenditures), Recipient shall make a request to Provider, setting out in reasonable detail the change requested and the reason
therefor. Provider shall promptly consider such request in good faith and to the extent it consents to such change or changes (such consent
not to be unreasonably withheld, conditioned or delayed), <U>Schedule&#8239;A</U> or <U>Schedule B</U>, as applicable, shall be amended
accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 319; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Performance Standards</U>. Provider and its Affiliates shall perform the Services in all cases in a professional and workmanlike
manner with appropriate and qualified personnel. Without limiting the foregoing, Provider shall, or shall cause the its Affiliates to,
use commercially reasonable efforts to provide the Services in a manner, and at a level of service (including with respect to quality,
skill, performance, diligence and timeliness) in a manner generally consistent with how the services that are the same as such Services
were provided to the Business during the 12-month period prior to the date of execution of the Combination Agreement and with (i) at least
the same (and no less than a reasonable) standard of service (including with respect to quality, skill, performance, diligence, and timeliness)
that Provider and its Affiliates provide their own respective businesses and (ii) substantially equal priority; <U>provided</U> that to
the extent the manner, quality, or availability of the services have been adversely affected by restrictions or modifications put in place
due to the COVID Event (as defined in <U>Section 11(g)</U>) pandemic and governmental and public health measures adopted in response thereto,
then Provider shall resume performing to the pre-COVID Event service standards as promptly as reasonably feasible after any public health
measures permit the same to occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Services Fees</U>. Recipient shall pay to Provider in arrears the actual costs directly incurred by Provider in connection with
the Services, with no margin or markup (&ldquo;<B><U>Service Fees</U></B>&rdquo;), which costs shall be no greater than the cost allocation
of each Service for the applicable period in which such Service was provided. Within 30 days following the completion of each calendar
month, Provider shall provide to Recipient an invoice setting forth the amounts due with respect to the Services provided to Recipient
during the preceding month. All undisputed amounts invoiced shall be paid within 30 days of receipt. In addition, Recipient shall pay
reasonable and documented third-party costs and expenses actually incurred by Provider in connection with the Services provided hereunder,
including reasonable travel expenses and costs, solely to the extent such third-party costs and expenses are specifically identified in
<U>Schedule A</U> or <U>Schedule B</U>, as applicable, for a given Service and subject to Recipient&rsquo;s prior written consent to pay
such costs and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>All charges and fees to be paid to Provider under this Agreement are exclusive of any and all sales, use, transfer, value-added,
goods or services Taxes or similar gross-receipts-based Taxes, in each case, imposed with respect to the provision of the Services hereunder
(&ldquo;<B><U>Sales and Services Taxes</U></B>&rdquo;); <U>provided</U>, that Sales and Services Taxes shall not include, and Provider
(rather than Recipient) shall pay and be liable for, (x) any Taxes that are imposed on or measured by Provider&rsquo;s net income or
gain, profits or assets (including franchise Taxes) or (y) any value-added or similar Tax to the extent that such Tax is recoverable
by Provider or another Person who is a member of the same group as Provider for purposes of the relevant Tax. Recipient shall pay and
be responsible for any Sales and Services Taxes, and, to the extent Provider is the Party required by applicable Law to remit any Sales
and Services Taxes to the applicable Tax Authority, (A) Provider will deliver to Recipient an invoice (or other valid and customary documentation)
reflecting such Sales and Services Taxes in accordance with applicable Law, (B) Recipient will pay to Provider the amount shown as due
on such invoice and (C) Provider will remit such amount to the applicable Tax Authority in accordance with applicable Law. Provider shall
be responsible for any Sales and Services Taxes (including any deficiency, interest and penalties) imposed as a result of (x) a failure
to timely remit any Sales and Services Taxes to the applicable Tax Authority to the extent Recipient timely remits such Sales and Services
Taxes to Provider or Recipient&rsquo;s failure to do so results from Provider&rsquo;s failure to timely charge or provide notice of such
Sales and Services Taxes to Recipient or (y) any assignment by Provider pursuant to <U>Section 11(f)</U> or subcontracting by Provider
pursuant to <U>Section 2(j)</U>. For the avoidance of doubt, in no event shall Recipient be obligated to pay any past due Taxes of Provider
or its Affiliates arising in connection with and inuring to tax periods ending on or before the date hereof or activities not included
within the scope of the Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 320; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Notwithstanding any other provision in this Agreement, Recipient and its Affiliates shall have the right to deduct and withhold
from any payments to be made hereunder such amounts as are required to be deducted and withheld by them with respect to the making of
such payment under applicable Law. To the extent that amounts are so deducted and withheld, Recipient shall timely remit such amounts
to the appropriate Tax Authority and shall submit to Provider evidence of payment of any such amounts to such Tax Authority, and any such
amounts that are timely remitted to the appropriate Tax Authority shall be treated for all purposes of this Agreement as having been paid
to the Person in respect of which the deduction and withholding was made. For the avoidance of doubt, Recipient and its Affiliates shall
not be responsible for any payments or provisions of wages, bonuses, commissions, employee benefits or withholding or payment of any applicable
withholding or applicable Taxes made to employees of the Provider or any of its Affiliates. Provider shall be responsible for, and shall
withhold or pay or both (or cause to be withheld or paid or both), as may be required by applicable Law, all Taxes pertaining to the employment
of the personnel, agents, servants or designees of Provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In the event that a Party or any of its Affiliates (the &ldquo;<B><U>Transferor Party</U></B>&rdquo;) receives any credit, reduction
or refund of any Sales and Services Taxes (a &ldquo;<B><U>Tax Benefit</U></B>&rdquo;) for which the other Party or any of its Affiliates
(the &ldquo;<B><U>Transferee Party</U></B>&rdquo;) is economically responsible pursuant to this Agreement, the Transferor Party shall
(A) promptly provide to the Transferee Party a copy of the certificate or other documentation from the Tax Authority showing the receipt
of such Tax Benefit, and (B) provide the Transferee Party with an amount equal to such Tax Benefit, as and when actually realized and
net of any additional Taxes or reasonable out-of-pocket expenses incurred in connection therewith by the Transferor Party, it being understood
that the Transferee Party shall be liable for any subsequent disallowance of any such Tax Benefit and any related interest, penalties
and additions thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Each Party agrees to provide the other Party such information and data as reasonably requested from time to time, and to reasonably
cooperate with the other Party, in connection with (A) the reporting of any Sales and Services Taxes, (B) any audit relating to any Sales
and Services Taxes, or (C) any assessment, refund, claim or legal proceeding relating to any Sales and Services Taxes. Each Party shall
promptly notify the other Party of any deficiency claim or similar notice by a Tax Authority with respect to any Sales and Services Taxes.
Each Party shall reasonably cooperate with the other Party, and take any reasonably requested action which does not cause such Party to
incur any material cost or inconvenience, in order to minimize any Sales and Services Taxes, including providing sales and use Tax exemption
certificates or other documentation necessary to support Tax exemptions. Each of the Parties agrees to use its reasonable best efforts
to mitigate the imposition of any withholding Taxes in connection with payments pursuant to this Agreement (including, in the case of
Provider, by providing such Tax forms as Recipient shall reasonably request so as to minimize or eliminate any withholding Taxes that
might otherwise apply to the payments by Recipient to Provider under this Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 321; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Third-Party Consents</U>. If the use or provision of all or a portion of the Services pursuant to this Agreement requires the
approval, consent, permission, waiver or agreement (including any Permit) (each a &ldquo;<B><U>Consent</U></B>&rdquo;) of a third party
that has not been obtained prior to the date hereof<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>,
Amber shall, at its sole cost and expense, use its commercially reasonable efforts to obtain any necessary consents from such third party
or to modify such existing Contract to enable Amber to provide or receive the applicable Services. If any such consent cannot be obtained
as a result of such efforts, to the extent permitted by applicable Law, the Parties shall work together in good faith to identify and
implement a workaround or alternative means of providing or receiving the affected Service in such a manner as to give Recipient the full
benefit of such Service to the greatest extent possible, at no incremental costs or expense to the Company. For the avoidance of doubt,
any failure by Amber to obtain any applicable Consent shall not relieve Amber of any obligation to provide the Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Service Failure</U>. In the event that Provider becomes aware of any actual or anticipated failure in the provision of the Services
which impacts, or is reasonably likely to impact provision of any Service (an &ldquo;<B><U>Incident</U></B>&rdquo;), it shall notify Recipient
as soon as reasonably practicable but in any event within one (1) Business Day. Provider shall, as soon as reasonably practicable: (i)&#8239;investigate
the underlying cause(s) of the Incident and use commercially reasonable efforts to preserve any data indicating the cause of failure;
(ii) use commercially reasonable efforts to take actions to minimize the impact of the failure and to prevent it from recurring; (iii)
use commercially reasonable efforts to correct the failure and resume performance of the Services in accordance with this Agreement; and
(iv) advise Recipient of the status of the Incident and the remedial efforts being undertaken with respect thereto. Without limiting any
other term or condition of this Agreement, Provider shall cooperate in good faith to resolve such Incident and use commercially reasonable
efforts to minimize the impact of such Incident on Recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Subcontracting</U>. Provider may use contractors, subcontractors, vendors or other third parties to provide a Service (i) without
the prior written consent of Recipient, if such contractors, subcontractors, vendors or other third parties are being used to provide
such Service to the Business immediately prior to the date of execution of the Combination Agreement or (ii)&#8239;with the prior written
consent of Recipient, not to be unreasonably withheld, conditioned or delayed (and Provider shall bear any incremental cost increase).
Provider shall remain responsible for all Services furnished by its contractors, subcontractors, vendors or other third parties and Provider
shall be liable for the acts and omissions of its contractors, subcontractors, vendors or other third parties with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><SUP>1</SUP> &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; List
of any consents that will be required in connection with any Service to be confirmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 322; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Data Matters</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Recipient Data</U>. Provider acknowledges and agrees that Recipient shall own all right, title, and interest in and to all
data or information to the extent (i) where the Company is the Recipient, (A)&#8239;related to the Business and is collected, processed,
generated, calculated, derived, or stored by, or transmitted to, Amber, any of its Affiliates or any third parties in connection with
the Services, or (B) otherwise used in, or related to the Business, except in each case ((A) and (B)), to the extent related to the Retained
Business or Excluded Assets (&ldquo;<B><U>Company Data</U></B>&rdquo;); or (ii)&#8239;where Amber is the Recipient, (A) related to the
Retained Business or Excluded Assets and is collected, processed, generated, calculated, derived, or stored by, or transmitted to, the
Company, any of its Affiliates or any third parties in connection with the Services, or (B) otherwise used in, or related to, the Retained
Business or Excluded Assets (&ldquo;<B><U>Amber Data</U></B>&rdquo; and, together with the Company Data, &ldquo;<B><U>Recipient Data</U></B>&rdquo;).
Notwithstanding any other provision in this Agreement, Provider shall make all of the Recipient Data available to Recipient and its authorized
agents during the Term of this Agreement, in accordance with the terms hereof. As soon as reasonably practicable following expiration
or termination of this Agreement with respect to a Service, or receipt of a written request by Recipient at any time during the Term
with respect to particular Recipient Data, Provider shall provide to Recipient all Recipient Data (and copies of Recipient Data) that
is in Provider&rsquo;s possession or control in the form and manner maintained by Provider. Provider shall access and use the Recipient
Data only in connection with the performance of its obligations under this Agreement. Provider shall not use (other than in the performance
of Services), sell, assign, license, or otherwise dispose of, market, or transfer any of the Recipient Data to any Person, and Provider
shall not commercially exploit any part of the Recipient Data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Data Security</U>. Provider shall (i) maintain appropriate technical and organizational security measures to ensure that the
Recipient Data is protected against any and all loss, destruction, damage, and unauthorized access, use, modification, disclosure, and
other misuse of the Recipient Data, including such measures required by Provider&rsquo;s privacy policies and applicable data privacy
Law; and (ii) use commercially reasonable efforts to ensure that only Persons with a specific need and authorized by Recipient have access
to the Recipient Data. With respect to Recipient Data stored on Provider&rsquo;s networks or systems, promptly upon discovery and confirmation
of (A) any breach of the privacy or security of the Recipient Data, (B) any violation of any applicable Law with respect to the Recipient
Data, or (C) any loss, destruction, damage, unauthorized activity or disclosure (except as required by Law) of the Recipient Data, Provider
shall provide notice to Recipient explaining the nature and scope of the incident and fully assist and cooperate in any investigation
Recipient deems necessary (including any forensic investigation), and Provider shall reasonably support Recipient, at Provider&rsquo;s
sole expense, with respect to any breach notification, breach remediation, and identity protection services that Recipient reasonably
determines need to be furnished to affected Persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Intellectual Property Rights<FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Licenses</U>. Subject to the terms hereof, each Party, on behalf of itself and its Affiliates, hereby grants to the other Party,
a non-exclusive, fully paid-up, royalty-free, non-transferable (except in accordance with <U>Section 11(f)</U>), worldwide license under
the Intellectual Property owned or licensable (without further payment or obligation) by such granting Party and such Party&rsquo;s Affiliates,
solely to the extent necessary for the purpose of, as applicable, providing or receiving the Services, in each case, as set forth in and
in accordance with this Agreement. The rights granted to Provider under this <U>Section 4(a)</U> will be sublicensable to its Affiliates
and any contractors, subcontractors, vendors or other third parties engaged to provide Services in accordance with <U>Section 2(j)</U>.
The rights granted to Recipient under this <U>Section 4(a)</U> will be sublicensable only to such Recipient&rsquo;s Affiliates in connection
with their receipt of the Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 323; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Ownership</U>. Unless otherwise agreed in writing by the Parties, as between the Parties, each Party shall remain the sole and
exclusive owner of all right, title and interest in and to all Intellectual Property (including all derivative works, modifications and
enhancements thereof) owned by such Party that is made available to the other Party in connection with the Services. As between the Parties,
any Intellectual Property created or developed in connection with the provision of the Services, other than reports or deliverables created
for Recipient at its request or otherwise relating solely to the business of Recipient, shall be owned by Provider, <U>provided</U>, <U>however</U>,
that if Provider creates reports or deliverables for Recipient at its request or that otherwise relate solely to the business of Recipient,
the Intellectual Property therein shall be owned by, and Provider shall assign such Intellectual Property to, Recipient. The Parties acknowledge
and understand that Provider may use the Intellectual Property of third parties in providing the Services and Recipient shall comply with
all applicable terms, conditions and restrictions imposed by such third parties on the use of their Intellectual Property of which such
Recipient is aware or is made aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>All Other Rights Reserved</U>. Except as expressly set forth herein or in the Combination Agreement, neither Party nor any of
its Affiliates shall have any right or license, express or implied, with respect to any Intellectual Property of the other Party and all
rights and licenses not expressly granted by a Party under this Agreement are reserved by such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Term; Termination.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Term of Services</U>. The Services to be provided under this Agreement shall commence as of the Effective Date and, with respect
to each Service, shall continue until the date of expiration for such Service as set forth on <U>Schedule A</U> or <U>Schedule B</U>,
as applicable (each, a &ldquo;<B><U>Service Term</U></B>&rdquo;); <U>provided</U>, <U>however</U>, that, notwithstanding anything to
the contrary herein, Recipient may in its sole discretion elect to extend any Service Term for up to two&#8239;(2) additional extension
terms of three (3) months each, upon at least 30 days&rsquo; advance written notice to Provider. Except as set forth in this <U>Article
5</U>, neither Party shall have the right to suspend or terminate any Service or this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Term of the Agreement</U>. This Agreement shall remain in full force and effect until the earlier of (i)&#8239;the expiration
or termination of all of the Services provided hereunder and (ii)&#8239;the termination of this Agreement in accordance with <U>Section
5(c)</U> (the &ldquo;<B><U>Term</U></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Recipient may terminate this Agreement or one or more of the Services, in whole or in part, upon at least 30 days&rsquo; advance
written notice to Provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Provider may terminate this Agreement if Recipient fails to pay any undisputed Service Fees in any invoice within 30 days&rsquo;
after such Services Fees become due and payable in accordance with the terms hereof, upon at least 30 days&rsquo; advance written notice
to Recipient of such termination, unless Recipient pays such undisputed Services Fees within such 30-day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 324; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In the event that any Service (or portion thereof) is provided for less than an entire month (e.g., the effective date of termination
of a Service is a day other than at the end of a month), the Service Fee associated with such Service (or portion thereof) for that month
shall be pro-rated appropriately. In the event that any Service is terminated (A) in whole, Recipient shall have no further obligation
to pay the Service Fee associated with such Service, or (B) in part, the Service Managers shall determine in good faith the amount by
which the Service Fee associated with such Service shall be reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Agreement or any Service may be terminated by the mutual written agreement of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Survival</U>. A Party&rsquo;s obligations to another Party under <U>Section 2(g)</U>, <U>Article 3</U>, <U>Article 6</U>, <U>Article&#8239;8</U>,
<U>Article 9</U>, <U>Article 10</U> and <U>Article 11</U> shall survive termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Indemnity</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Indemnification by Provider</U>. Each Party as Provider hereby agrees to release, discharge, defend, indemnify and hold Recipient
and its Affiliates, and its and their respective shareholders, directors, officers, employees, representatives, and agents (the &ldquo;<B><U>Recipient
Indemnitees</U></B>&rdquo;) harmless from and against any and all claims, actions, suits, losses, demands, damages, Taxes, costs and
expenses (including reasonable attorneys&rsquo; fees) of every kind, nature, or description brought by a third party arising out of or
related to the provision or use of Services received hereunder (each, a &ldquo;<B><U>Claim</U></B>&rdquo;) suffered or incurred by a
Recipient Indemnitee arising from Provider&rsquo;s (i) material breach of this Agreement, (ii)&#8239;violation of Law, (iii) breach of
<U>Article 9</U>, or (iv) willful misconduct, gross negligence or fraud in connection with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Indemnification by Recipient</U>. Each Party as Recipient hereby agrees to release, discharge, defend, indemnify and hold Provider
and its Affiliates, and its and their respective shareholders, directors, officers, employees, representatives, and agents (the &ldquo;<B><U>Provider
Indemnitees</U></B>&rdquo;) harmless from and against any and all Claims suffered or incurred by a Provider Indemnitee arising from Recipient&rsquo;s
(i) material breach of this Agreement, (ii)&#8239;violation of Law, (iii) breach of <U>Article 9</U>, or (iv) willful misconduct, gross
negligence or fraud in connection with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>No Liability for Inherited Issues.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Notwithstanding
anything in this Agreement, the Company shall not be in breach of this Agreement as a result of, and the Company shall not be liable to
Amber for, any Losses to the extent arising out of any defects, imperfections, conditions, circumstances, or characteristics that, in
each case, existed as of or prior to the Effective Date with respect to the Business. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 325; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Representations and Warranties</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Representations</U>. Each Party hereby represents and warrants: (i) it has the requisite power and authority to execute and
deliver this Agreement and to perform the transactions contemplated hereby; (ii) all corporate action on the part of such Party necessary
to approve or to authorize the execution and delivery of this Agreement and the performance of the transactions contemplated hereby to
be performed by it has been duly taken; (iii) this Agreement is a valid and binding obligation of such Party, enforceable in accordance
with its terms, subject to the effect of principles of equity and the applicable bankruptcy, insolvency or other similar Laws, now or
hereafter in effect, affecting creditors&rsquo; rights generally and other customary qualifications; (iv) its execution and delivery of
this Agreement and its performance of its obligations hereunder does not and shall not conflict with, result in a breach of, constitute
a default under any license, sublicense, lease, contract, agreement, or instrument to which it is bound; and (v) it has obtained all Consents
from any third-party licensor or contractual counterparty or any other third party that is necessary to perform its obligations hereunder.
Provider represents and warrants that it will perform the Services in compliance with all applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Disclaimers</U>. <FONT STYLE="text-transform: uppercase">Without limiting any representations or warranties set forth in the
Combination Agreement,</FONT> EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, THE SERVICES ARE PROVIDED ON AN &ldquo;AS IS&rdquo;
BASIS, WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, NON-INFRINGEMENT OR OTHER WARRANTIES, CONDITIONS, GUARANTEES OR REPRESENTATIONS, WHETHER EXPRESS OR IMPLIED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Confidential Information</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Confidential Information</U>. As it is used in this Agreement, the term &ldquo;<B><U>Confidential Information</U></B>&rdquo;
shall mean, with respect to any Party, all information of such Party and its Affiliates (including information that might reasonably
be considered confidential (including information that is subject to confidentiality obligations to third parties), secret, sensitive,
proprietary or private), in written, oral, electronic or other tangible or intangible forms, stored in any medium, including studies,
reports, books and records, contracts, instruments, surveys, discoveries, ideas, concepts, know-how, techniques, designs, specifications,
drawings, blueprints, diagrams, models, prototypes, samples, flow charts, data, computer data, disks, diskettes, tapes, computer programs
or other software, marketing plans, customer names, memos, personally identifiable information and other technical, financial, employee
or business information or data. Notwithstanding the foregoing, the term &ldquo;<B><U>Confidential Information</U></B>&rdquo; shall not
include, with respect to the information of any Party or its Affiliates, any information that (i)&#8239;is or becomes available to the
general public, other than as a result of a disclosure by a member of the other Party or any of its Affiliates or any of its or their
directors, officers, employees, agents, accountants, counsel or other advisors or representatives (collectively, &ldquo;<B><U>Representatives</U></B>&rdquo;)
in violation of this Agreement; (ii)&#8239;becomes available to the other Party or any of its Affiliates on a non-confidential basis
from a third party; <U>provided</U>, that the source of such information was not bound by a confidentiality obligation with respect to
such information or otherwise prohibited from transmitting such information by a contractual, fiduciary or other legal obligation; or
(iii) is independently developed by any Party, its Affiliates or its Representatives without reference to any otherwise Confidential
Information; <U>provided</U>, <U>further</U>, that Recipient Data shall at all times be considered Confidential Information of Recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 326; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Nondisclosure Obligations</U>. Except as otherwise permitted by this <U>Article 9</U>, each Party shall, and shall cause its
Affiliates and its and their respective Representatives to, (i) not disclose such Confidential Information to third Persons (other than
to such Party&rsquo;s Representatives on a need-to-know basis), (ii) advise each of its Representatives of their obligations to keep such
information confidential, and (iii) use the same degree of care it uses to protect such Confidential Information as it uses for its own
confidential information of like kind, but in no event less than a reasonable degree of care. The terms and conditions of this Agreement
shall constitute the Confidential Information of each Party to the extent not publicly disclosed by agreement of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Permitted Disclosure</U>. In the event that a Party (i) is required to disclose any Confidential Information of the other Party
or any of its Affiliates pursuant to applicable Law or (ii) receives any demand under lawful process or from any Authority to disclose
or provide Confidential Information of the other Party or any of its Affiliates, such Party shall notify the other Party prior to disclosing
or providing such Confidential Information and shall cooperate, at the sole expense of the other Party, in seeking any reasonable protective
arrangements requested by such other Party. Subject to the foregoing, the Party that is required to so disclose or receive such demand,
as applicable, may thereafter only disclose or provide Confidential Information which is legally required to be disclosed or provided
and shall exercise its commercially reasonable efforts to obtain protective treatment of such Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Destruction of Confidential Information</U>. Each Party shall, at the request of the other Party or upon termination or expiration
of this Agreement, as soon as practicable and (with respect to destruction) except as required to be maintained to comply with provisions
of the Combination Agreement, applicable Law or applicable document retention policies, at such other Party&rsquo;s option (i)&#8239;return
to the other Party originals and all copies of all Confidential Information of such other Party or any of its Affiliates in a tangible
form (and electronically) or (ii)&#8239;destroy all originals and copies thereof and all notes, extracts or summaries based thereon. Each
Party shall, at the other Party&rsquo;s request, confirm compliance with this <U>Article 9</U> in a writing signed by one of such Party&rsquo;s
authorized officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Cooperation</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>General</U>. The Parties hereto acknowledge the transitional nature of the Services. Accordingly, as promptly as practicable
following the execution of this Agreement, Recipient agrees to use commercially reasonable efforts to transition each Service to its own
internal organization or to obtain alternate third party sources to provide the Services. Provider shall cooperate and assist Recipient
in all matters reasonably necessary for the provision and receipt of the Services. Provider shall provide to Recipient assistance reasonably
necessary for Recipient to transition the Services (including any terminated or expired Services) and segregate and migrate Recipient&rsquo;s
systems, environments, and data (including Recipient Data), from Provider&rsquo;s systems, facilities, or environments to Recipient&rsquo;s
(or its providers&rsquo;) systems, facilities, and environments. Such transition assistance includes (i)&#8239;making available relevant
management and employees for meetings or telephone conferences with Recipient as reasonably requested by Recipient, including for the
purpose of knowledge transfer, (ii) providing information, assistance and data (including data for operation and testing of Recipients&rsquo;
replacement or successor systems) regarding the specific Services being provided and the systems, software and data formats and data organization
being used for the Services, (iii)&#8239;coordination and other reasonable assistance with test runs of replacement systems and processes
(but not development of such systems and processes), and (iv)&#8239;other reasonable access to relevant information. Amber will bear all
start-up, one-time or non-recurring costs incurred in connection with the separation and migration of the Company&rsquo;s systems, environments,
assets and data (including Company Data), from Amber&rsquo;s systems, facilities, or environments to the Company&rsquo;s (or its providers&rsquo;)
systems, facilities, and environments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 327; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Coordinators</U>. The Parties shall each promptly appoint (i) one or more managers who shall have primary responsibility for
the coordination and performance of the Services by functional area (collectively, the &ldquo;<B><U>Service Managers</U></B>&rdquo;),
and (ii) one lead transition manager (&ldquo;<B><U>Transition Manager</U></B>&rdquo;), who shall act as the primary liaison to the other
Party (through its Transition Manager), have overall responsibility for directing all of such Party&rsquo;s activities hereunder, and
manage and coordinate such Party&rsquo;s Service Managers. Each Party may treat an act of a Transition Manager or a Service Manager of
the other Party as being authorized by such other Party without inquiring behind such act or ascertaining whether such Transition Manager
or Service Manager had authority to so act; <U>provided</U>, <U>however</U>, that no Transition Manager or Service Manager has authority
to amend this Agreement in their role as Transition Manager or Service Manager, respectively. Each Party shall promptly (and in any event
within ten (10) business days) advise the other in writing of any change in its Transition Manager or Service Managers. Provider and
Recipient agree that all communications relating to the provision of the Services shall be directed to the Transition Managers or the
respective Service Manager for such Transition Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Miscellaneous</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Dispute Resolution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Disputes</U>. For all controversies, claims and matters of difference (each a &ldquo;<B><U>Dispute</U></B>&rdquo;) arising
out of or relating to this Agreement, the Parties agree to promptly address the Dispute internally through upper-management personnel
(and shall cause such upper-management personnel to use good faith efforts to address any such Dispute). If the upper-management personnel
for both Parties cannot resolve the Dispute within 30 days following written notice of the Dispute, then the Dispute shall be elevated
to the Chief Executive Officer (or designee) of both Parties. If the Chief Executive Officers (or designees) are unable to resolve the
Dispute, <U>Section 11(a)(iii)</U> shall apply; <U>provided</U>, <U>however</U>, that a Party may file earlier to avoid the expiration
of any applicable limitations period, to preserve a superior position with respect to other creditors, or to apply for interim or equitable
relief, including for any breach of confidentiality or intentional breach or threat of intentional breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Continuation of Services</U>. Except where clearly prevented by the nature of the Dispute and without limiting either Party&rsquo;s
rights of termination under <U>Section 5(c)</U>, each of the Parties shall continue performing their respective obligations under this
Agreement (including payment of any charges in the case of Recipient and performance of the Services in the case of Provider) while the
dispute is being resolved, unless and until such obligations are terminated or expire in accordance with the provisions of this Agreement.
For the avoidance of doubt, a dispute regarding invoiced fees will not be deemed to prevent or preclude Provider from performing the Services
hereunder or prevent or preclude Recipient from paying any undisputed fees and other undisputed amounts owed hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 328; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Submission to Jurisdiction</U>. Each of the Parties irrevocably and unconditionally submits to the exclusive jurisdiction of
the Chancery Court of the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept jurisdiction, any state
or federal court within the State of Delaware), for the purposes of any Action arising under this Agreement or in any way connected with
or related or incidental to the dealings of the Parties in respect of this Agreement or any of the transactions contemplated hereby, and
irrevocably and unconditionally waives any objection to the laying of venue of any such Action in any such court, and further irrevocably
and unconditionally waives and agrees not to plead or claim in any such court that any such Action has been brought in an inconvenient
forum. Each Party hereby irrevocably and unconditionally waives, and agrees not to assert, by way of motion or as a defense, counterclaim
or otherwise, in any Action or cause thereof against such Party arising under this Agreement or in any way connected with or related or
incidental to the dealings of the Parties in respect of this Agreement or any of the transactions contemplated hereby, (A)&#8239;any claim
that such Party is not personally subject to the jurisdiction of the courts as described in this <U>Section&#8239;11(a)(iii)</U> for any
reason, (B)&#8239;that such Party is exempt or immune from the jurisdiction of any such court or from any legal process commenced in such
courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment
or otherwise) and (C)&#8239;that (x)&#8239;the Action or cause thereof in any such court is brought against such Party in an inconvenient
forum, (y)&#8239;the venue of such Action or cause thereof against such Party is improper or (z)&#8239;this Agreement, or the subject matter
hereof, may not be enforced against such Party in or by such courts. Each Party agrees that service of any process, summons, notice or
document by registered mail to such Party&rsquo;s respective address set forth in <U>Section&#8239;11(d)</U> shall be effective service
of process for any such Action, demand, or cause thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Governing Law</U>. This Agreement, and all claims or causes of action (whether in contract, tort or statute) that may be based
upon, arise out of or relate to this Agreement, or the negotiation, execution or performance of this Agreement (including any claim or
cause of action based upon, arising out of related to any representation or warranty made in or in connection with this Agreement or as
inducement to enter into this Agreement), shall be construed and enforced in accordance with and governed by the Laws (both substantive
and procedural) of the State of Delaware, including its statute of limitations, without giving effect to the conflict of Laws principles
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Enforcement</U>. Except as otherwise expressly provided herein, any and all remedies provided herein will be deemed cumulative
with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one
remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even
if available, would not be an adequate remedy, would occur in the event that the Parties do not perform their respective obligations under
the provisions of this Agreement (including failing to take such actions as are required of them hereunder to consummate the transactions
contemplated by this Agreement) in accordance with their specific terms or otherwise breach such provisions. It is accordingly agreed
that the Parties shall be entitled to seek an injunction or injunctions, specific performance and other equitable relief to prevent breaches
of this Agreement and to enforce specifically the terms and provisions of this Agreement, in each case, without posting a bond or undertaking
and without proof of damages and this being in addition to any other remedy to which they are entitled at law or in equity. Each Party
agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief when expressly available
pursuant to the terms of this Agreement on the basis that the other Party has an adequate remedy at law or an award of specific performance
is not an appropriate remedy for any reason at law or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 329; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>WAIVER OF JURY TRIAL</U>. THE PARTIES EACH HEREBY WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY
OF ANY PROCEEDING, CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (A)&#8239;ARISING UNDER THIS AGREEMENT OR UNDER ANY ADDITIONAL AGREEMENT OR
(B) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES IN RESPECT OF THIS AGREEMENT OR ANY ADDITIONAL AGREEMENT
OR ANY OF THE TRANSACTIONS RELATED HERETO OR THERETO OR ANY FINANCING IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED THEREBY, IN EACH
CASE, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. THE PARTIES EACH HEREBY AGREE AND
CONSENT THAT ANY SUCH PROCEEDING, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE
PARTIES MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES
HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (1) NO REPRESENTATIVE, AGENT OR ATTORNEY
OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE
THE FOREGOING WAIVER, (2) EACH SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (3) EACH SUCH PARTY MAKES THIS
WAIVER VOLUNTARILY AND (4) EACH SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS <U>SECTION&#8239;11(A)(VI)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Records; Audit</U>. Notwithstanding <U>Section 5(d)</U>, during the Term of this Agreement and for one (1) year thereafter,
or for so long as required by applicable Law, Provider and Recipient shall keep, or cause to be kept, complete and accurate books and
records concerning the Services in accordance with generally accepted accounting practices and applicable Law and consistent with such
Provider&rsquo;s or Recipient&rsquo;s internal document retention policies. Upon receipt of reasonable notice, each Party shall, to the
extent permitted by Law, give the other Party and/or the other Party&rsquo;s duly authorized representatives access, during normal business
hours, to such records as the requesting Party may reasonably require to fulfil any legal, regulatory or other compliance obligations
of the requesting Party or its Affiliates; <U>provided</U> that nothing in this <U>Section 11(b)</U> shall require any Party to provide
to the other Party access to its Tax returns or related workpapers. Each Party, when exercising its rights pursuant to this <U>Section
11(b)</U>, shall use its, and shall ensure that its representatives shall use their, reasonable best efforts not to cause any material
disruption to the business of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 330; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Entire Agreement</U>. This Agreement, including any exhibits and schedules attached hereto, the Combination Agreement and the
other Additional Agreements constitute the entire agreement of the Parties with respect to the subject matter hereof and supersedes all
prior and contemporaneous understandings and agreements related thereto (whether written or oral), all of which are merged herein. To
the extent that any provision in this Agreement (or any exhibit or schedule) is inconsistent or conflicts with any provision of the Combination
Agreement or any other Additional Agreement, the provisions of the Combination Agreement shall control in the case of a conflict with
this Agreement, and this Agreement shall control in the case of a conflict with any Additional Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notices</U>. Any notice, requests, claims, demands and other communications hereunder shall be sent in writing and shall be
deemed to have been duly given by delivery in person, by e-mail (having obtained electronic delivery confirmation thereof (i.e.<I>,</I>
an electronic record of the sender that the e-mail was sent to the intended recipient thereof without an &ldquo;error&rdquo; or similar
message that such e-mail was not received by such intended recipient)), or by registered or certified mail (postage prepaid, return receipt
requested) (upon receipt thereof) to the other Party as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If to Company:&#9;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 28%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 72%">c/o ARYA Science Acquisition Corp IV</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 28%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 72%">51 Astor Place, 10th Floor</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 28%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 72%">New York, New York 10003</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 28%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-size: 10pt">Attn: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Adam Stone</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Michael Altman</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Doug Giordano</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Konstantin Poukalov</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">adam@perceptivelife.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">michael@perceptivelife.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">doug@perceptivelife.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">konstantin@perceptivelife.com</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 2in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 28%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 72%">with a copy to (which shall not constitute notice):</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 1in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 28%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 72%">Kirkland&#8239;&amp; Ellis LLP<BR>
601 Lexington Avenue<BR>
New York, NY 10022</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 28%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-size: 10pt">Attn: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Jonathan L. Davis, P.C.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Ryan Brissette</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">jonathan.davis@kirkland.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#8239;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ryan.brissette@kirkland.com</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"></P>

<!-- Field: Page; Sequence: 331; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If to Amber:&#9;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 28%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 72%">Amber Therapeutics, Inc.</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 28%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 72%">3675 Market Street</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 28%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 72%">Philadelphia, PA 19104</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 28%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-size: 10pt">Attn:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Legal Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">gcoffice@Amberrx.com</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 2in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 28%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 72%">with copies (which shall not constitute notice) to:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 2in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 28%">&nbsp;</TD>
  <TD STYLE="width: 72%">Skadden, Arps, Slate, Meagher &amp; Flom LLP<BR>
 &#9;1440 New York Avenue, N.W.<BR>
 &#9;Washington, DC 20005</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 28%"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Graham Robinson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Katherine Ashley</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">graham.robinson@skadden.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#8239;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">katherine.ashley@skadden.com</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Counterparts; Electronic Signatures</U>. This Agreement may be executed in one or more counterparts, each of which shall be
deemed to be an original, but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of a signature
page to this Agreement by e-mail or scanned pages shall be effective as delivery of a manually executed counterpart to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Binding Effect; Assignment</U>. Subject to the provisions set forth in this Agreement, this Agreement shall be binding upon
and inure to the benefit of the Parties hereto and upon their respective successors and assigns. This Agreement and the rights and obligations
hereunder shall not be assignable or transferable by any Party without the prior written consent of the other Parties hereto, except that
either Party may assign this Agreement without the other Party&rsquo;s consent (i) in connection with a merger, acquisition, or sale of
all or any portion of the equity or assets of such Party or its Affiliates, provided the assigning Party remains liable for the assignee&rsquo;s
performance of this Agreement, (ii) to any of its Affiliates, provided the assigning Party remains liable for such Affiliate&rsquo;s performance
of this Agreement, and (iii) as collateral to any lender providing financing to such Party. Any assignment in violation of the foregoing
will be null and void at the outset and of no force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Force Majeure</U>. Subject to, and without limiting, <U>Section 2(i)</U>, each Party shall be excused for any failure or delay
in performing any of its obligations under this Agreement to the extent and only for such period of time such failure or delay is caused
by Force Majeure, except to the extent that such failure or delay cannot reasonably be circumvented through the use of alternate sources,
workaround plans or other means (including by invoking any business continuity or disaster recovery plans in place). For purposes of
this Agreement, &ldquo;<B><U>Force Majeure</U></B>&rdquo; means any circumstance or event beyond the reasonable control of the Party
relying upon such event or circumstance, including: any act of God; any accident, explosion, fire, ice, earthquake, lightning, tornado,
hurricane, or other severe weather condition or calamity; any third-party telecommunications, networks or Internet service interruptions;
any civil disturbance; any sabotage or acts of terrorism; any acts of a public enemy, uprising, insurrection, civil unrest, war, or rebellion;
or any action or restraint by court order or public or Authority or lawfully established civilian authorities. Notwithstanding anything
to the contrary contained in this <U>Section 11(g)</U> or elsewhere in this Agreement, the Parties acknowledge and agree that a COVID-19
pandemic and business disruptions related thereto or resulting from responses thereto (including COVID-19 Measures and any related non-performance
or delay in performance of any third-party vendor, service provider, or subcontractor upon which a Party relies) (such pandemic, disruptions,
or any other pandemic that is of a similar nature or as similar disruptions or effects as such pandemic, a &ldquo;<B><U>COVID Event</U></B>&rdquo;)
is and has been occurring as of the Effective Date. The Parties further acknowledge and agree that no COVID Event, nor any recurrence
of a COVID Event that results in effects or business disruptions that are similar to those effects and disruptions experienced prior
to and as of the Effective Date, shall be considered to be a Force Majeure event or otherwise excuse any failure or delay in performance
by a Party under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 332; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Independent Contractor Status</U>. Provider will provide the Services as an independent contractor and shall have no authority
to make binding contracts or commitments on behalf of Recipient in any way without the prior written approval of a duly authorized representative
of Recipient. Provider shall be solely responsible for the salary and benefits for all of its employees providing the Services. Nothing
in this Agreement shall create any employer-employee, agency, partnership, joint venture, fiduciary or other relationship between the
Parties or between a Party and the employees of the other.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Third-Party Beneficiaries</U>. This Agreement shall be binding upon and inure solely to the benefit of each Party and its
successors and permitted assigns and, except as provided in <U>Section 6</U>, nothing in this Agreement, express or implied, is intended
to or shall confer upon any other Person any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Amendments; Waivers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This Agreement cannot be amended, supplemented or modified, except by a writing signed by both Parties, and cannot be amended,
supplemented or modified orally or by course of conduct. No provision hereof may be waived, except by a writing signed by the Party against
whom such waiver is to be enforced, and any such waiver shall apply only in the particular instance in which such waiver shall have been
given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither any failure or delay in exercising any right or remedy hereunder or in requiring satisfaction of any condition herein nor
any course of dealing shall constitute a waiver of or prevent any Party from enforcing any right or remedy or from requiring satisfaction
of any condition. No notice to or demand on a Party waives or otherwise affects any obligation of that Party or impairs any right of the
Party giving such notice or making such demand, including any right to take any action without notice or demand not otherwise required
by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Severability</U>. Whenever possible, each provision of this Agreement will be interpreted in such a manner as to be effective
and valid under applicable Law, but if any term or other provision of this Agreement is held to be invalid, illegal or unenforceable under
applicable Law, all other provisions of this Agreement shall remain in full force and effect so long as the economic or legal substance
of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any
term or other provision of this Agreement is invalid, illegal or unenforceable under applicable Law, the Parties shall negotiate in good
faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order
that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 333; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Construction; Interpretation</U>. Each of the Parties, and their respective counsel, have reviewed, negotiated and adopted this
Agreement as the joint agreement and understanding of the Parties. The terms of this Agreement shall be deemed to be the language chosen
by the Parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any Party, but rather
this Agreement shall be construed and interpreted in accordance with the fair meaning thereof, having due regard to the benefits and rights
intended to be conferred upon the Parties hereto and the limitations and restrictions upon such rights and benefits intended to be provided.
The term &ldquo;this Agreement&rdquo; means this Transition Services Agreement together with the Schedules and Exhibits hereto, as the
same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. The headings set forth
in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. Unless
otherwise indicated to the contrary herein by the context or use thereof: (a) the words, &ldquo;herein,&rdquo; &ldquo;hereto,&rdquo; &ldquo;hereof&rdquo;
and words of similar import refer to this Agreement as a whole, including the Schedules and Exhibits, and not to any particular section,
subsection, paragraph, subparagraph or clause set forth in this Agreement; (b) masculine gender shall also include the feminine and neutral
genders, and vice versa; (c) words importing the singular shall also include the plural, and vice versa; (d) the words &ldquo;include,&rdquo;
 &ldquo;includes&rdquo; or &ldquo;including&rdquo; shall be deemed to be followed by the words &ldquo;without limitation&rdquo;; (e) references
to &ldquo;$&rdquo; or &ldquo;dollar&rdquo; or &ldquo;US$&rdquo; shall be references to United States dollars; (f) the word &ldquo;or&rdquo;
is disjunctive but not necessarily exclusive; (g) the words &ldquo;writing,&rdquo; &ldquo;written&rdquo; and comparable terms refer to
printing, typing and other means of reproducing words (including electronic media) in a visible form; (h) the word &ldquo;day&rdquo; means
calendar day unless Business Day is expressly specified; (i) the word &ldquo;extent&rdquo; in the phrase &ldquo;to the extent&rdquo; means
the degree to which a subject or other thing extends, and such phrase shall not mean simply &ldquo;if&rdquo;; (j) all references to Articles,
Sections, Exhibits or Schedules are to Articles, Sections, Exhibits and Schedules of this Agreement; and (k)&#8239;all references to any
Law will be to such Law as amended, supplemented or otherwise modified or re-enacted from time to time. If any action under this Agreement
is required to be done or taken on a day that is not a Business Day, then such action shall be required to be done or taken not on such
day but on the first succeeding Business Day thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Non-Recourse</U>. This Agreement may only be enforced against, and any action for breach of this Agreement may only be made
against, the Parties, and without limiting the generality of the foregoing, none of the Representatives of either Party shall have any
Liability arising out of or relating to this Agreement, the negotiation hereof or its subject matter or the transactions contemplated
hereby or the transactions contemplated hereby, including with respect to any claim (whether in tort, contract or otherwise) for breach
of this Agreement or in respect of any written or oral representations made or alleged to be made in connection herewith, except as expressly
provided herein or, for the avoidance of doubt, for claims pursuant to any Additional Agreement by any party(ies) thereto against any
other party(ies) thereto on the terms and subject to the conditions therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Signature page follows.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 334; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">INTENDING TO BE LEGALLY BOUND,
the undersigned Parties have executed this Agreement as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE COMPANY:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CARITAS THERAPEUTICS, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&#8239;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%; text-align: justify">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMBER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMBER THERAPEUTICS, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#8239;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Signature Page to Transition Services
Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"></P>

<!-- Field: Page; Sequence: 335 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE A</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Transition Services Provided by Amber to
the Company</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">[attached]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 336; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Schedule A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>SCHEDULE B</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Transition Services Provided by the Company
to Amber</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">[attached]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 337; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Schedule B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;G</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of ARYA Post-Closing Certificate
of Incorporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 338 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit G</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF INCORPORATION OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[CARITAS THERAPEUTICS, INC.]<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>a Delaware corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE I. NAME OF CORPORATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name of this corporation
is Caritas Therapeutics, Inc. (the &ldquo;<U>Corporation</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE II. REGISTERED OFFICE AND AGENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The address of the Corporation&rsquo;s
registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware 19801. The
name of its registered agent at such address is The Corporation Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE III. PURPOSE; EFFECTIVENESS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The nature of the business
or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which corporations may be organized
under the General Corporation Law of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;). The Corporation is being incorporated in connection
with the domestication of ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (&ldquo;<U>ARYA</U>&rdquo;), as a Delaware
corporation in accordance with Section 388 of the DGCL and Part XII of the Cayman Islands Companies Act (2021 Revision) (the &ldquo;<U>Domestication</U>&rdquo;).
This Certificate of Incorporation is being filed simultaneously with the Certificate of Corporate Domestication of ARYA, and shall be
effective upon the effectiveness of the Domestication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE IV. CAPITAL STOCK</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A. <U>Authorized Shares</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The total number of shares of all classes of capital stock which the Corporation shall have the authority to issue is [&#9679;]
shares, consisting of (i) [&#9679;] shares of Class A Common Stock, par value $0.0001 per share (the &ldquo;<U>Class A Common Stock</U>&rdquo;),
(ii) [&#9679;] shares of Class B Common Stock, par value $0.0001 per share (the &ldquo;<U>Class B Common Stock</U>&rdquo; and, together
with the Class A Common Stock, the &ldquo;<U>Common Stock</U>&rdquo;), and (iii) [&#9679;] shares of Preferred Stock, par value $0.0001
per share (the &ldquo;<U>Preferred Stock</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The number of authorized shares of Common Stock or Preferred Stock may be increased or decreased by the affirmative vote of the
holders of a majority of the voting power of all the then-outstanding shares of capital stock of the Corporation entitled to vote thereon,
without a separate vote of the holders of any of the Class A Common Stock, Class B Common Stock or Preferred Stock,, irrespective of the
provisions of Section 242(b)(2) of the DGCL (or any successor provision thereto), provided that the number of authorized shares of Class
A Common Stock shall not be decreased below the sum of (a) the number of Class A Common Shares then outstanding and (b) the number of
Class A Shares to be issued upon the exchange of Caritas LLC Common Units (as defined below) for Class A Common Shares as set forth in
Clause B(v) of this Article IV. Upon the effectiveness of the Domestication and this Certificate of Incorporation, each Class A ordinary
share, par value $0.0001 per share, of ARYA and each Class B ordinary share, par value $0.0001 per share, of ARYA that is issued and outstanding
immediately prior to the Domestication will, for all purposes, be converted into one (1) fully paid and non-assessable share of Class
A Common Stock issued and outstanding, without any action required on the part of the Corporation or the holders thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&#8239;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
ARYA and Amber GT shall mutually agree on a name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 339; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">B. <U>Common Stock</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Voting Rights</U>. Each share of Common Stock outstanding as of the applicable record date shall entitle the holder thereof
to one (1) vote on any matter submitted to a vote at a meeting of stockholders. Except as otherwise required by the DGCL or as provided
in this Certificate of Incorporation, the holders of Class A Common Stock and Class B Common Stock shall vote together as a single class
on all matters on which stockholders are generally entitled to vote (or, if any holders of any series of Preferred Stock are entitled
to vote together with the holders of Common Stock, as a single class with such holders of Preferred Stock). In addition to any other vote
required in this Certificate of Incorporation or by the DGCL, the holders of Class A Common Stock and Class B Common Stock shall each
be entitled to vote separately as a class only with respect to amendments to this Certificate of Incorporation that increase or decrease
the par value of the shares of such class or alter or change the powers, preferences or special rights of the shares of such class so
as to affect them adversely. Notwithstanding the foregoing, except as otherwise required by the DGCL, holders of Common Stock shall not
be entitled to vote on any amendment to this Certificate of Incorporation (including any certificate of designation relating to any series
of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected
series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon pursuant
to the DGCL or this Certificate of Incorporation (including any certificate of designation relating to any series of Preferred Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Dividends and Distributions</U>. Subject to any other provisions of this Certificate of Incorporation, as it may be amended
from time to time, holders of shares of Class A Common Stock shall be entitled to receive ratably, in proportion to the number of shares
of Class A Common Stock held by them, such dividends and other distributions in cash, stock or property of the Corporation when, as and
if declared thereon by the board of directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo;) from time to time out of
assets or funds of the Corporation legally available therefor. Except (I)&#8239;in connection with a dividend declared by the Board in
connection with a &ldquo;poison pill&rdquo; or similar stockholder rights plan, or (II)&#8239;as provided in Clause (B)(iv) of this Article
IV, dividends and other distributions shall not be declared or paid on the Class B Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Liquidation, Dissolution or Winding Up</U>. In the event of any liquidation, dissolution or winding up (either voluntary or
involuntary) of the Corporation, after payments to creditors of the Corporation that may at the time be outstanding, and subject to the
rights of any holders of any series of Preferred Stock that may then be outstanding, holders of shares of Class A Common Stock shall be
entitled to receive ratably, in proportion to the number of shares held by them, all remaining assets and funds of the Corporation available
for distribution. The holders of shares of Class B Common Stock shall not be entitled to receive any assets of the Corporation in the
event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Reclassification</U>. None of the Class A Common Stock or Class B Common Stock may be subdivided, consolidated, reclassified
or otherwise changed unless contemporaneously therewith the other class of Common Stock and the Caritas Therapeutics, LLC Membership Interests
(as defined below) are subdivided, consolidated, reclassified or otherwise changed in the same proportion and in the same manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 340; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Exchange</U>. The holder of each membership interest (&ldquo;<U>Caritas LLC Membership Interest</U>&rdquo;) of Caritas Therapeutics,
LLC, a Delaware limited liability company (&ldquo;<U>Caritas LLC</U>&rdquo;), designated as a &ldquo;Common Unit&rdquo; (a &ldquo;<U>Caritas
LLC Common Unit</U>&rdquo; and such holder, a &ldquo;<U>Caritas LLC Member</U>&rdquo;), other than the Corporation, shall, pursuant to
the terms and subject to the conditions of the amended and restated limited liability company agreement of Caritas Therapeutics, LLC (as
amended, supplemented or otherwise modified from time to time in accordance with its terms, the &ldquo;<U>Caritas LLC Agreement</U>&rdquo;),
have the right (the &ldquo;<U>Redemption Right</U>&rdquo;) to tender to Caritas LLC for redemption each such Caritas LLC Common Unit for
the applicable Cash Amount (as defined in the Caritas LLC Agreement), subject to the Corporation&rsquo;s right, in its sole and absolute
discretion, to elect to acquire some or all of such Caritas LLC Common Units that such Caritas LLC Member has tendered pursuant to the
Redemption Right for a number of shares of Class A Common Stock, the Cash Amount (as defined in the LLC Agreement) or a combination of
Class A Common Stock and a portion of the Cash Amount (the &ldquo;<U>Exchange Option</U>&rdquo;), in the case of each of the Redemption
Right and the Exchange Option, on and subject to the terms and conditions set forth in this Certificate of Incorporation and in the Caritas
LLC Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In connection with the Corporation&rsquo;s exercise of the Exchange Option under the Caritas LLC Agreement, the Corporation shall
issue to such Caritas LLC Member a number of shares of Class&#8239;A Common Stock as determined by the terms and provisions of the Caritas
LLC Agreement in exchange for the Caritas LLC Common Units that the Corporation has elected to acquire pursuant to the Exchange Option,
subject, at all times, to the Corporation&rsquo;s right, in accordance with the terms and provisions of the Caritas LLC Agreement, to
elect to deliver the applicable Cash Amount in lieu of issuing shares of Class&#8239;A Common Stock, or to elect to deliver a combination
of shares of Class&#8239;A Common Stock and a portion of the Cash Amount, with the form and allocation of consideration determined in accordance
with the Caritas LLC Agreement. No fractional shares of Class&#8239;A Common Stock shall be issued upon the Corporation&rsquo;s exercise
of the Exchange Option. In lieu of any fractional shares to which the Caritas LLC Member would otherwise be entitled, the Corporation
shall pay to the Caritas LLC Member cash equal to the value of the fractional shares of Class&#8239;A Common Stock (as determined in accordance
with the Caritas LLC Agreement). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Concurrently with any redemption of Caritas LLC Common Units pursuant to the Redemption Right or exchange of Caritas LLC Common
Units pursuant to the Exchange Option, a number of shares of Class&#8239;B Common Stock held by such Caritas LLC Member equal to the number
of Caritas LLC Common Units redeemed or exchanged, in each case shall be automatically, without further action by such Caritas LLC Member
or the Corporation, transferred to the Corporation for no additional consideration and shall be retired and resume the status of authorized
and unissued shares of Class&#8239;B Common Stock, and all rights of such Caritas LLC Member with respect to such shares, including the
rights, if any, to receive notices and to vote, shall thereupon cease and terminate. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Such number of shares of Class A Common Stock as may from time to time be required for exchange pursuant to the terms of Clause
(B)(v)(1) of this Article IV shall be reserved for issuance upon exchange of outstanding Caritas LLC Common Units. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Transfers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Without limiting any Caritas LLC Member&rsquo;s ability to effect their Redemption Right or the Corporation&rsquo;s ability to
effect the Exchange Option in compliance with Clause (B)(v) of this Article IV, no holder of Class&#8239;B Common Stock shall be permitted
to consummate a sale, pledge, conveyance, hypothecation, assignment or other transfer (&ldquo;<U>Transfer</U>&rdquo;) of Class&#8239;B
Common Stock other than with a concurrent Transfer of an equal number of Caritas LLC Common Units, in each case made to the same transferee
in compliance with the restrictions on transfer contained in the Caritas LLC Agreement (for the avoidance of doubt, whether pursuant to
a Permitted Transfer (as defined in the Caritas LLC Agreement) or otherwise in compliance with Section 10.3 of the Caritas LLC Agreement).
Any purported Transfer of Class&#8239;B Common Stock not in accordance with the terms of this Clause (B)(vi) of this Article IV&#8239;shall
be void <I>ab initio</I>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 341; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation may, as a condition to the Transfer or the registration of Transfer of shares of Class&#8239;B Common Stock, require
the furnishing of such affidavits or other proof as it deems necessary to establish whether such Transfer is permitted pursuant to the
terms of this Clause (B)(vi)(1) of this Article IV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Adjustments to Relevant Securities</U>. In the event of any split or reverse split of any of the Relevant Securities (as defined
below), or a distribution of any Relevant Securities to the holders of such Relevant Securities, unless a similar transaction is effected
with respect to the other types of Relevant Securities, references herein to a number of shares or units of any type of Relevant Securities,
or a ratio of one type of Relevant Securities to another, shall be adjusted as appropriate to reflect such split, reverse split or distribution.
For example, if there is a one-for-two reverse split of Caritas LLC Common Units, but no similar reverse split of shares of Class&#8239;B
Common Stock, and a holder of Caritas LLC Common Units and shares of Class&#8239;B Common Stock subsequently tenders Caritas LLC Common
Units for redemption pursuant to the Redemption Right or the Exchange Option, then the number of such holder&rsquo;s shares of Class&#8239;B
Common Stock that will be automatically transferred to the Corporation and retired pursuant to Clause (B)(v)(2) of this Article IV will
be equal to twice the number of Caritas LLC Common Units tendered for redemption. &ldquo;<U>Relevant Securities</U>&rdquo; means Class&#8239;A
Common Stock, Class&#8239;B Common Stock and Caritas LLC Common Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Retirement of Class B Common Stock</U>. In the event that (1)&#8239;any Caritas LLC Membership Interest is consolidated or otherwise
cancelled or retired or (2)&#8239;any outstanding share of Class&#8239;B Common Stock held by a holder of a corresponding Caritas LLC Membership
Interest otherwise shall cease to be held by such holder, in each case, whether as a result of exchange, reclassification, redemption
or otherwise, then the corresponding share(s) of Class&#8239;B Common Stock (in the case of (1)) or such share of Class&#8239;B Common Stock
(in the case of (2)) shall automatically and without further action on the part of the Corporation or any holder of Class&#8239;B Common
Stock be transferred to the Corporation for no consideration and thereupon shall be retired and restored to the status of authorized but
unissued shares of Class&#8239;B Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">C. <U>Preferred Stock</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Preferred Stock may be
issued from time to time in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board
of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized,
subject to limitations prescribed by law, to fix by resolution or resolutions the designations, powers, preferences and rights, and the
qualifications, limitations or restrictions thereof, of any series of Preferred Stock, including, without limitation, authority to fix
by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including
sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting
any such series and the designation thereof, or any of the foregoing. The Board of Directors is further authorized to increase (but not
above the total number of authorized shares of the class) or decrease (but not below the number of shares of any such series then outstanding)
the number of shares of any series, subject to the powers, preferences and rights, and the qualifications, limitations and restrictions
thereof stated in this Certificate of Incorporation or the resolution of the Board of Directors originally fixing the number of shares
of such series. Except as may be otherwise specified by the terms of any series of Preferred Stock, if the number of shares of any series
of Preferred Stock is so decreased, then the Corporation shall take all such steps as are necessary to cause the shares constituting such
decrease to resume the status which they had prior to the adoption of the resolution originally fixing the number of shares of such series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 342; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE V. STOCKHOLDER ACTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A. <U>Action Without a Meeting</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From and after the effectiveness
of this Certificate of Incorporation, and subject to the rights of holders of Preferred Stock, any action required or permitted to be
taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Company
and may not be effected by any consent in writing by such stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">B. <U>Special Meetings</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise required
by the DGCL, and subject to the rights of the holders of any series of Preferred Stock, special meetings of the stockholders of the Corporation,
for any purpose or purposes, may be called only by a majority of the Board of Directors or the Chief Executive Officer of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VI. DIRECTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following provisions are
inserted for the management of the business and for the conduct of the affairs of the Corporation, and for further definition, limitation
and regulation of the powers of the Corporation and of its directors and stockholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A. <U>Powers of the Board of Directors</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The directors in their discretion may submit any contract or act for approval or ratification at any annual meeting of the stockholders
or at any meeting of the stockholders called for the purpose of considering any such act or contract, and, to the fullest extent permitted
by law, any contract or act that shall be approved or be ratified by the affirmative vote of the holders of a majority of the total voting
power of all of the then-outstanding shares of stock of the Corporation, which is represented in person or by proxy at such meeting and
entitled to vote thereon (provided that a lawful quorum of stockholders be there represented in person or by proxy), shall be as valid
and binding upon the Corporation and upon all the stockholders as though it had been approved or ratified by every stockholder of the
Corporation, whether or not the contract or act would otherwise be open to legal attack because of directors&rsquo; interests, or for
any other reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In addition to the powers and authorities hereinbefore or by statute expressly conferred upon them, the directors are hereby empowered
to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation, subject, nevertheless, to
the provisions of the DGCL, this Certificate of Incorporation and to any Bylaws adopted from time to time by the stockholders; <U>provided</U>,
<U>however</U>, that no Bylaw so adopted shall invalidate any prior act of the directors which would have been valid if such Bylaw had
not been adopted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">B. <U>Election of Directors</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At each annual meeting of
stockholders, directors of the Corporation shall be elected to hold office until the expiration of the term for which they are elected
and until their successors have been duly elected and qualified or until their earlier resignation or removal; except that if any such
meeting shall not be so held, such election shall take place at a stockholders&rsquo; meeting called and held in accordance with the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 343; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">C. <U>Number and Class of Directors; Term
of Office</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subject to the rights of holders of Preferred Stock, the number of directors that constitutes the entire Board of Directors of
the Corporation shall be fixed only by resolution of the Board of Directors acting pursuant to a resolution adopted by a majority of the
Whole Board. For the purposes of this Certificate of Incorporation, the term &ldquo;<U>Whole Board</U>&rdquo; shall mean the total number
of authorized directorships whether or not there exist any vacancies or other unfilled seats in previously authorized directorships. At
each annual meeting of stockholders, directors of the Corporation shall be elected to hold office until the expiration of the term for
which they are elected and until their successors have been duly elected and qualified or until their earlier resignation or removal;
except that if any such meeting shall not be so held, such election shall take place at a stockholders&rsquo; meeting called and held
in accordance with the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Effective immediately following the Domestication, the directors of the Company (other than any who may be elected by holders of
Preferred Stock under specified circumstances) shall be divided into three classes as nearly equal in size as is practicable, hereby designated
Class I, Class II and Class III. Directors already in office shall be assigned to each class at the time such classification becomes effective
in accordance with a resolution or resolutions adopted by the Board of Directors. At the first annual meeting of stockholders following
the date hereof, the term of office of the Class I directors shall expire and Class I directors shall be elected for a full term of three
years. At the second annual meeting of stockholders following the date hereof, the term of office of the Class II directors shall expire
and Class II directors shall be elected for a full term of three years. At the third annual meeting of stockholders following the date
hereof, the term of office of the Class III directors shall expire and Class III directors shall be elected for a full term of three years.
At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors
of the class whose terms expire at such annual meeting. If the number of directors is changed, any newly created directorships or decrease
in directorships shall be so apportioned hereafter among the classes as to make all classes as nearly equal in number as is practicable,
provided that no decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The initial Class I Directors of the Corporation shall be [[Amber GT Parent Designee] and [Agreed Designee #1]]; the initial Class
II Directors of the Corporation shall be [[Amber GT Parent Designee] and [Agreed Designee #2]]; and the initial Class III Directors of
the Corporation shall be [[ARYA Designee], [Agreed Designee #3] and [Agreed Designee #4]].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Notwithstanding the foregoing, the directors elected to each class shall hold office until their successors are duly elected and
qualified or until their earlier resignation, death or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">D. <U>Removal</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any director may be removed
from office (i) only with cause and (ii) only by the affirmative vote of the holders of a majority of the outstanding voting stock (as
defined below) of the Corporation. At least forty-five (45) days prior to any annual or special meeting of stockholders at which it is
proposed that any director be removed from office, written notice of such proposed removal and the alleged grounds thereof shall be sent
to the director whose removal will be considered at the meeting. In case that any one or more directors should be so removed, new directors
may be elected at the same time for the unexpired portion of the full term of the director or directors so removed.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 344; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">E. <U>Vacancies</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as the DGCL may otherwise
require, in the interim between annual meetings of stockholders or special meetings of stockholders called for the election of directors
and/or the removal of one or more directors and the filling of any vacancy in that connection, any and all vacancies in the Board of Directors
(however occurring, including, without limitation, by reason of newly created directorships, death, resignation or removal) may be filled
only by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum, or by the sole remaining
director. Any director appointed in accordance with the preceding sentence shall hold office for the remainder of the full term of the
class of directors in which the new directorship was created or the vacancy occurred and until such director&rsquo;s successor shall have
been duly elected and qualified. When the number of directors is increased or decreased, the Board of Directors shall, subject to Clause
(C) of this Article VI, determine the class or classes to which the increased or decreased number of directors shall be apportioned&#894;
<U>provided</U>, <U>however</U>, that no decrease in the number of directors shall shorten the term of any incumbent director. In the
event of a vacancy in the Board of Directors, the remaining directors, except as otherwise provided by law, shall exercise the powers
of the full Board of Directors until the vacancy is filled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VII. LIMITATION OF LIABILITY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>To the fullest extent permitted by the DGCL, a person who serves as a director of the Corporation shall not be personally liable
to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the DGCL is amended to authorize
corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation
shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. Any repeal or modification of this Article
VII by the stockholders of the Corporation or by amendment to the DGCL, shall not adversely affect any right or protection with respect
to events occurring prior to the time of such amendment, repeal or modification, of a person serving as a director of the Corporation
at the time of such amendment, repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Subject to any provisions in the Bylaws of the Corporation related to indemnification of directors of the Corporation, the Corporation
shall indemnify, to the fullest extent permitted by the DGCL, any director of the Corporation who was or is a party or is threatened to
be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(a &ldquo;<U>Proceeding</U>&rdquo;) by reason of the fact that he or she is or was a director of the Corporation or is or was serving
at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&rsquo; fees), judgments,
fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding. The Corporation
shall be required to indemnify a person in connection with a Proceeding (or part thereof) initiated by such person only if the Proceeding
(or part thereof) was authorized by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Corporation shall have the power to indemnify, to the extent permitted by the DGCL, any officer, employee or agent of the Corporation
who was or is a party or is threatened to be made a party to any Proceeding by reason of the fact that he or she is or was a director,
officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit
plans, against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred
by such person in connection with any such Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Neither any amendment, repeal nor elimination of any clause of this <U>Article VII</U>, nor the adoption of any provision of this
Certificate of Incorporation or the Bylaws of the Corporation inconsistent with this <U>Article VII</U>, shall eliminate or reduce the
effect of this <U>Article VII</U> in respect of any matter occurring, or any Proceeding accruing or arising or that, but for this <U>Article
VII</U>, would accrue or arise, prior to such amendment, repeal, elimination or adoption of an inconsistent provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 345; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE VIII. EXCLUSIVE FORUM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the Corporation consents
in writing to the selection of an alternative forum (an &ldquo;<U>Alternative Forum Consent</U>&rdquo;), the Court of Chancery of the
State of Delaware shall be the sole and exclusive forum for (A) any derivative action or proceeding brought on behalf of the Corporation,
(B) any action asserting a claim of breach of a duty (including any fiduciary duty) owed by any current or former director, officer, stockholder,
employee or agent of the Corporation to the Corporation or the Corporation&rsquo;s stockholders, (C) any action asserting a claim against
the Corporation or any current or former director, officer, stockholder, employee or agent of the Corporation arising out of or relating
to any provision of the DGCL, this Certificate of Incorporation or the Bylaws (each, as in effect from time to time), or (D) any action
asserting a claim against the Corporation or any current or former director, officer, stockholder, employee or agent of the Corporation
governed by the internal affairs doctrine of the State of Delaware; <U>provided</U><I>, </I><U>however</U>,&#8239;that, in the event that
the Court of Chancery of the State of Delaware lacks subject matter jurisdiction over any such action or proceeding,&#8239;the sole and
exclusive forum for such action or proceeding shall be another state or federal court located within the State of Delaware, in each such
case, unless the Court of Chancery (or such other state or federal court located within the State of Delaware, as applicable) has dismissed
a prior action by the same plaintiff asserting the same claims because such court lacked personal jurisdiction over an indispensable party
named as a defendant therein. Unless the Corporation gives an Alternative Forum Consent, the federal district courts of the United States
of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting
a cause of action arising under the Securities Act of 1933, as amended. Failure to enforce the foregoing provisions would cause the Corporation
irreparable harm and the Corporation shall be entitled to equitable relief, including injunctive relief and specific performance, to enforce
the foregoing provisions. Any person or entity purchasing, otherwise acquiring or holding any interest in shares of capital stock of the
Corporation shall be deemed to have notice of and consented to the provisions of this Article VIII. The existence of any prior Alternative
Forum Consent shall not act as a waiver of the Corporation&rsquo;s ongoing consent right as set forth above in this Article VIII with
respect to any current or future actions or claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE IX. BUSINESS COMBINATIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A. <U>Opt-Out</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation elects to
not be governed by Section 203 of the DGCL.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">B. <U>Limitations on Business Combinations</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
the Corporation shall not engage in any business combination (as defined below) with any interested stockholder (as defined below) for
a period of three (3) years following the time that such stockholder became an interested stockholder, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>prior to such time, the Board of Directors approved either the business combination or the transaction which resulted in the stockholder
becoming an interested stockholder,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 346; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder
owned at least eighty-five percent (85%) of the voting stock (as defined below) of the Corporation outstanding at the time the transaction
commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested
stockholder) those shares owned by (1) persons (as defined below) who are directors and also officers of the Corporation and (2) employee
stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will
be tendered in a tender or exchange offer, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>at or subsequent to such time, the business combination is approved by the Board of Directors and authorized at an annual or special
meeting of stockholders, by the affirmative vote of at least sixty-six and two-thirds percent (66-2/3%) of the outstanding voting stock
which is not owned by the interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">C. <U>Definitions</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Solely for the purposes of
this Article IX, unless otherwise indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>affiliate</U>&rdquo; means, whenever used in this Certificate of Incorporation (whether in this Article IX or otherwise),
a person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with,
another person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Affiliated Company</U>&rdquo; or &ldquo;<U>Affiliated Companies</U>&rdquo; means, whenever used in this Certificate of
Incorporation (whether in this Article IX or otherwise), any affiliate or associate of the ARYA Sponsor or Amber GT Parent, any funds
advised by the ARYA Sponsor or Perceptive Advisors LLC or Amber GT Parent (other than the Corporation and any direct or indirect majority-owned
subsidiary of the Corporation), and any affiliate or associate of, or funds managed by any affiliate of ARYA Sponsor or Amber GT Parent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 347; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>Amber GT Parent</U>&rdquo; means Amicus Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>ARYA Sponsor</U>&rdquo; means ARYA Sciences Holdings IV, a Cayman Islands exempted limited liability company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>associate</U>&rdquo; means, when used to indicate a relationship with any person,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any corporation, partnership, unincorporated association or other entity of which such person is a director, officer or partner
or is, directly or indirectly, the owner of twenty percent (20%) or more of any class of voting stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any trust or other estate in which such person has at least a twenty percent (20%) beneficial interest or as to which such person
serves as trustee or in a similar fiduciary capacity; and </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any relative or spouse of such person, or any relative of such spouse, who has the same residence as such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>business combination</U>&rdquo; means, when used in reference to the Corporation and any interested stockholder of the
Corporation,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any merger or consolidation of the Corporation (other than a merger effected pursuant to Sections 253 or 267 of the DGCL) or any
direct or indirect majority-owned subsidiary of the Corporation with (a) the interested stockholder or (b) any other corporation, partnership,
unincorporated association or other entity if the merger or consolidation is caused by the interested stockholder and, as a result of
such merger or consolidation, Clause (B) of this Article IX is not applicable to the surviving entity;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions), except
proportionately as a stockholder of the Corporation, to or with the interested stockholder, whether as part of a dissolution or otherwise,
of assets of the Corporation or of any direct or indirect majority-owned subsidiary of the Corporation which assets have an aggregate
market value equal to ten percent (10%) or more of either the aggregate market value of all of the assets of the Corporation determined
on a consolidated basis or the aggregate market value of all of the outstanding stock (as defined below) of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any transaction which results in the issuance or transfer by the Corporation or by any direct or indirect majority-owned subsidiary
of the Corporation of any stock of the Corporation or of such subsidiary to the interested stockholder, except pursuant to (a) the exercise,
exchange or conversion of securities exercisable for, exchangeable for or convertible into stock of the Corporation or any such subsidiary
which securities were outstanding prior to the time that the interested stockholder became such, (b) a merger under Section 251(g), 253
or 267 of the DGCL, (c) a dividend or distribution paid or made, or the exercise, exchange or conversion of securities exercisable for,
exchangeable for or convertible into stock of the Corporation or any such subsidiary which security is distributed, pro rata to all holders
of a class or series of stock of the Corporation subsequent to the time the interested stockholder became such, (d) an exchange offer
by the Corporation to purchase stock made on the same terms to all stockholders of said stock or (e) any issuance or transfer of stock
by the Corporation; <U>provided</U>, <U>however</U>, that in no case under subclauses (c)-(e) of this Clause (C)(iv)(3) of this Article
IX shall there be an increase in the interested stockholder&rsquo;s proportionate share of the stock of any class or series of the Corporation
or of the voting stock of the Corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 348; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any transaction involving the Corporation or any direct or indirect majority-owned subsidiary of the Corporation which has the
effect, directly or indirectly, of increasing the proportionate share of the stock of any class or series, or securities convertible into
the stock of any class or series, of the Corporation or of any such subsidiary which is owned by the interested stockholder, except as
a result of immaterial changes due to fractional share adjustments or as a result of any purchase or redemption of any shares of stock
not caused, directly or indirectly, by the interested stockholder; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of the
Corporation), of any loans, advances, guarantees or pledges (other than those expressly permitted in clauses (1)-(4) above) provided by
or through the Corporation or any direct or indirect majority-owned subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>control</U>&rdquo; (including the terms &ldquo;<U>controlling</U>,&rdquo; &ldquo;<U>controlled by</U>&rdquo; and &ldquo;<U>under
common control with</U>&rdquo;) means, whenever used in this Certificate of Incorporation (whether in this Article IX or otherwise), the
possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether
through the ownership of voting stock, by contract, or otherwise. A person who is the owner of twenty percent (20%) or more of the outstanding
voting stock of any corporation, partnership, unincorporated association or other entity shall be presumed to have control of such entity,
in the absence of proof by a preponderance of the evidence to the contrary. Notwithstanding the foregoing, a presumption of control shall
not apply where such person holds voting stock, in good faith and not for the purpose of circumventing this Article IX, as an agent, bank,
broker, nominee, custodian or trustee for one or more owners who do not individually or as a group have control of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> &ldquo;<U>interested stockholder</U>&rdquo; means any person (other than the Corporation and any direct or indirect majority-owned
subsidiary of the Corporation) that is (1) the owner of fifteen percent (15%) or more of the outstanding voting stock of the Corporation
or (2) an affiliate or associate of the Corporation and was the owner of fifteen percent (15%) or more of the outstanding voting stock
of the Corporation at any time within the three (3) year period immediately prior to the date on which it is sought to be determined whether
such person is an interested stockholder; and the affiliates and associates of such person; <U>provided</U>, <U>however</U>, that the
term &ldquo;interested stockholder&rdquo; shall not include any person whose ownership of shares in excess of the fifteen percent (15%)
limitation set forth herein is the result of any action taken solely by the Corporation; <U>provided</U>, <U>further</U>, that such person
shall be an interested stockholder if thereafter such person acquires additional shares of voting stock of the Corporation, except as
a result of further corporate action not caused, directly or indirectly, by such person. For the purpose of determining whether a person
is an interested stockholder, the voting stock of the Corporation deemed to be outstanding shall include stock deemed to be owned by the
person through application of the definition of &ldquo;owner&rdquo; below but shall not include any other unissued stock of the Corporation
which may be issuable pursuant to any agreement, arrangement or understanding, or upon exercise of conversion rights, warrants or options,
or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>owner</U>&rdquo; (including the terms &ldquo;<U>own</U>&rdquo; and &ldquo;<U>owned</U>&rdquo;) means, when used with
respect to any stock, a person that individually or with or through any of its affiliates or associates: (1) beneficially owns such stock,
directly or indirectly; (2) has (a) the right to acquire such stock (whether such right is exercisable immediately or only after the passage
of time) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants
or options, or otherwise; <U>provided</U>, <U>however</U>, that a person shall not be deemed the owner of stock tendered pursuant to a
tender or exchange offer made by such person or any of such person&rsquo;s affiliates or associates until such tendered stock is accepted
for purchase or exchange; or (b) the right to vote such stock pursuant to any agreement, arrangement or understanding; <U>provided</U>,
<U>however</U>, that a person shall not be deemed the owner of any stock because of such person&rsquo;s right to vote such stock if the
agreement, arrangement or understanding to vote such stock arises solely from a revocable proxy or consent given in response to a proxy
or consent solicitation made to ten (10) or more persons; or (3) has any agreement, arrangement or understanding for the purpose of acquiring,
holding, voting (except voting pursuant to a revocable proxy or consent as described in item (b) of clause (2) above), or disposing of
such stock with any other person that beneficially owns, or whose affiliates or associates beneficially own, directly or indirectly, such
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 349; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>person</U>&rdquo; means any individual, corporation, partnership, unincorporated association or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>stock</U>&rdquo; means, with respect to any corporation, capital stock and, with respect to any other entity, any equity
interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>&ldquo;<U>voting stock</U>&rdquo; means, whenever used in this Certificate of Incorporation (whether in this Article IX or otherwise),
with respect to any corporation, stock of any class or series entitled to vote generally in the election of directors and, with respect
to any entity that is not a corporation, any equity interest entitled to vote generally in the election of the governing body of such
entity. Every reference to a percentage of voting stock in this Certificate of Incorporation shall refer to such percentage of the votes
of such voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">D. <U>Exceptions to Limitations on Business
Combinations</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The limitations contained in this Article IX shall
not apply if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>a stockholder becomes an interested stockholder inadvertently and (1) as soon as practicable divests itself of ownership of sufficient
shares so that the stockholder ceases to be an interested stockholder and (2) would not, at any time within the three-year period immediately
prior to a business combination between the Corporation and such stockholder, have been an interested stockholder but for the inadvertent
acquisition of ownership;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the business combination is proposed prior to the consummation or abandonment of and subsequent to the earlier of the public announcement
or the notice required hereunder of a proposed transaction which (1) constitutes one of the transactions described in the second sentence
of this Clause (D)(ii) of this Article IX, (2) is with or by a person who either was not an interested stockholder during the previous
three years or who became an interested stockholder with the approval of the Board of Directors and (3) is approved or not opposed by
a majority of the members of the Board of Directors then in office (but not less than one) who were directors prior to any person becoming
an interested stockholder during the previous three years or were recommended for election or elected to succeed such directors by a majority
of such directors. The proposed transactions referred to in the preceding sentence are limited to a (a) merger or consolidation of the
Corporation (except for a merger in respect of which, pursuant to Section 251(f) of the DGCL, no vote of the stockholders of the Corporation
is required), (b) sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions),
whether as part of a dissolution or otherwise, of assets of the Corporation or of any direct or indirect majority-owned subsidiary of
the Corporation (other than to any direct or indirect wholly-owned subsidiary or to the Corporation) having an aggregate market value
equal to fifty percent (50%) or more of either that aggregate market value of all of the assets of the Corporation determined on a consolidated
basis or the aggregate market value of all the outstanding stock of the Corporation or (c) proposed tender or exchange offer for fifty
percent (50%) or more of the outstanding voting stock of the Corporation. The Corporation shall give not less than twenty (20) days&rsquo;
notice to all interested stockholders prior to the consummation of any of the transactions described in subclauses (a) or (b) of the second
sentence of this Clause (D)(ii) of this Article IX; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the Corporation does not have a class of voting stock that is (1) listed on a national securities exchange or (2) held of record
by more than 2,000 stockholders, unless any of the foregoing results from action taken, directly or indirectly, by an interested stockholder
or from a transaction in which a person becomes an interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 350; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE XII. AMENDMENTS TO CERTIFICATE OF
INCORPORATION AND BYLAWS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A. <U>Amendment to Certificate of Incorporation</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation reserves the
right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation (including any certificate of designation
relating to any series of Preferred Stock), in the manner now or hereafter prescribed by this Certificate of Incorporation and the DGCL,
and all rights, preferences and privileges herein conferred upon stockholders, directors or any other persons by and pursuant to this
Certificate of Incorporation (including any certificate of designation relating to any series of) in its present form or as hereafter
amended are granted subject to the right reserved in this Article XII; <U>provided</U>, <U>however</U>, that the following provisions
may be amended, altered, repealed or rescinded, in whole or in part, or any provision inconsistent therewith or herewith may be adopted,
only by the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the outstanding voting stock of
the Corporation, voting together as a single class: Articles V, VI, VII, IX and XII; <U>provided</U>, <U>further</U>, that Article X may
only be amended as set forth therein; <U>provided</U>, <U>further</U>, that, as long as there are any shares of Class B Common Stock issued
and outstanding, the existence of the Class A Common Stock and the Class B Common Stock, and the rights, preferences and privileges conferred
upon the holders of Class A Common Stock and Class B Common Stock in Article IV, including those related to the Redemption Right and the
Exchange Option, may not be amended, altered, repealed or rescinded, in whole or in part, or any provision inconstant therewith or herewith
may be adopted, only by the unanimous affirmative vote of all of the holders of the Class B Common Stock.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">B. <U>Amendment to Bylaws</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bylaws may be amended,
modified or repealed, in whole or in part, either (i) by the affirmative vote of a majority of the entire Board of Directors (subject
to any bylaw requiring the affirmative vote of a larger percentage of the members of the Board of Directors) or (ii) without the approval
of the Board of Directors, by the affirmative vote of the holders of a majority of the outstanding voting stock of the Corporation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE XIII. MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When the terms of this Certificate
of Incorporation or the Bylaws refer to a specific agreement or other document (including, for the avoidance of doubt, the Bylaws) or
a decision by anybody or person that determines the meaning or operation of a provision hereof or thereof, the Secretary of the Corporation
shall maintain a copy of such agreement, document or decision at the principal executive offices of the Corporation and a copy thereof
shall be provided free of charge to any shareholder who makes a request therefor. If any provision or provisions of this Certificate of
Incorporation shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason
whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance
and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any sentence of Article
VIII containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable)
and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE XIV. SOLE INCORPORATOR</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name and mailing address
of the sole incorporator of this Corporation is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 351; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Final Form</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, the undersigned, as the sole incorporator of
the Corporation, have signed this Certificate of Incorporation on this [&#9679;] day of [&#9679;] 202[&#9679;].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 3%; text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&#8239;</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: left">&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: left">&#8239;</TD><TD STYLE="text-align: justify">Name:</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: left">&#8239;</TD><TD STYLE="text-align: justify">&#8239;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&#8239;</TD><TD STYLE="text-align: left">&#8239;</TD><TD STYLE="text-align: justify">Sole Incorporator</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature Page to Caritas Therapeutics,
Inc. Certificate of Incorporation]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 352 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Final Form</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BYLAWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CARITAS
THERAPEUTICS</B></FONT><B>,&#8239;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #010000"><FONT STYLE="text-transform: uppercase">Article&#8239;I</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OFFICES</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">1.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registered
Office</U>. The registered office of Caritas Therapeutics,&#8239;Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;) in
the State of Delaware shall be established and maintained at 1209 Orange Street, Wilmington, Delaware 19801, and The Corporation Trust
Company shall be the registered agent of the corporation in charge thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">1.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Offices</U>. The Corporation may also have offices at such other places both within and without the State of Delaware as the board of
directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo;) may from time to time determine or the business of the Corporation
may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #010000"><FONT STYLE="text-transform: uppercase">Article&#8239;II</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>MEETINGS OF STOCKHOLDERS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Place
of Meetings</U>. All meetings of the stockholders shall be held at such time and place, either within or without the State of Delaware,
as shall be designated from time to time by the Board of Directors and stated in the notice of the meeting or in a duly executed waiver
of notice thereof; <U>provided</U> that the Board of Directors may, in its sole discretion, determine that the meeting shall not be held
at any place, but may instead be held solely by means of remote communication pursuant to <U>Section&#8239;2.12</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Annual
Meetings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
annual meeting of stockholders shall be held on such date and at such time as may be fixed by the Board of Directors and stated in the
notice of the meeting, for the purpose of electing directors and for the transaction of only such other business as is properly brought
before the meeting in accordance with these Bylaws (the &ldquo;<U>Bylaws</U>&rdquo;). Except as otherwise required by law, written notice
of an annual meeting stating the place, date and hour of the meeting, shall be given to each stockholder entitled to vote at such meeting
not less than ten (10)&#8239;nor more than sixty (60) days before the date of the annual meeting. The Board of Directors acting pursuant
to a resolution adopted by a majority of the entire Board of Directors may cancel, postpone or reschedule any previously scheduled annual
meeting at any time, before or after the notice for such meeting has been sent to the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 353 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
be properly brought before the annual meeting, business must be either (i)&#8239;specified in the notice of annual meeting (or any supplement
or amendment thereto) given by or at the direction of the Board of Directors, (ii)&#8239;otherwise brought before the annual meeting by
or at the direction of the Board of Directors or (iii)&#8239;otherwise properly brought before the annual meeting by a stockholder who
is a stockholder of record on the date of the giving of the notice required by this <U>Section&#8239;2.2</U> and on the record date for
the determination of stockholders entitled to vote at such annual meeting and who complies with the notice procedures in this <U>Section&#8239;2.2</U>.
In addition to any other applicable requirements, for business to be properly brought before an annual meeting by a stockholder, the
stockholder must have given timely notice thereof in writing to the Secretary of the Corporation. To be timely, a stockholder&rsquo;s
notice must be delivered to or mailed and received at the principal executive offices of the Corporation not less than ninety (90) days
nor more than one hundred twenty (120) days prior to the anniversary date of the immediately preceding annual meeting; <U>provided</U>,
<U>however</U>, that in the event that the annual meeting is called for a date that is not within twenty-five (25) days before or after
such anniversary date, or if no annual meeting was held in the preceding year, notice by the stockholder in order to be timely must be
so received not later than the close of business on the tenth (10th) day following the day on which notice of the date of the annual
meeting was mailed or public disclosure of the date of the annual meeting was made, whichever first occurs. In no event shall any adjournment
or postponement of an annual meeting or the announcement thereof commence a new time period for the giving of a stockholder&rsquo;s notice
as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
be in proper written form, a stockholder&rsquo;s notice to the Secretary shall set forth (i)&#8239;as to each matter the stockholder proposes
to bring before the annual meeting (1)&#8239;a brief description of the business desired to be brought before the annual meeting (including
the text of any resolutions proposed for consideration and in the event such business includes a proposal to amend these Bylaws, the
language of the proposed amendment) and the reasons for conducting such business at the annual meeting, (2)&#8239;any material interest
of the stockholder in such business, (3)&#8239;a description of all arrangements or understandings between or among the stockholder or
any Stockholder Associated Person (as defined below) and any other person or entity (including their names) in connection with the proposal
of such business by the stockholder and any material interest of the stockholder, any Stockholder Associated Person or such other person
or entity in such business, and (4)&#8239;a representation as to whether the stockholder or any Stockholder Associated Person intends
or is part of a group which intends to deliver a proxy statement and/or form of proxy to the holders of at least the percentage of the
Corporation&rsquo;s outstanding capital stock required to approve the proposal or otherwise to solicit proxies or votes from stockholders
in support of the proposal; and (ii)&#8239;as to the stockholder giving the notice (1)&#8239;the name and address of the stockholder as
they appear on the Corporation&rsquo;s books, (2)&#8239;the name and address (if different from the Corporation&rsquo;s books) of the
stockholder, (3)&#8239;the name and address of any Stockholder Associated Person, (4)&#8239;the class, series and number of shares of capital
stock of the Corporation which are directly or indirectly held of record or beneficially owned by the stockholder or by any Stockholder
Associated Person, (5)&#8239;a description of any Derivative Positions (as defined below) directly or indirectly held or beneficially
held by the stockholder or any Stockholder Associated Person, (6)&#8239;whether and to the extent to which a Hedging Transaction (as defined
below) has been entered into by or on behalf of such stockholder or any Stockholder Associated Person, (7)&#8239;a representation that
the stockholder is a stockholder of record of the Corporation entitled to vote at such meeting and intends to appear in person or by
proxy at the annual meeting to bring such business before the meeting and (8)&#8239;any other information related to the stockholder or
any Stockholder Associated Person that would be required to be disclosed in a proxy statement or other filing required to be made in
connection with the solicitation of proxies or consents (even if a solicitation is not involved) by such stockholder or Stockholder Associated
Person in support of the business proposed to be brought before the meeting pursuant to Section&#8239;14 of the Securities Exchange Act
of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), and the rules, regulations and schedules promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>A
stockholder providing notice of business proposed to be brought before an annual meeting shall further update and supplement such notice,
if necessary, so that the information provided or required to be provided in such notice pursuant to this <U>Section&#8239;2.2</U> shall
be true and correct as of the record date for determining the stockholders entitled to receive notice of the annual meeting and such
update and supplement shall be delivered to or be mailed and received by the Secretary at the principal executive offices of the Corporation
not later than five (5)&#8239;business days after the record date for determining the stockholders entitled to receive notice of the annual
meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 354; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
anything in these Bylaws to the contrary, no business shall be conducted at the annual meeting except in accordance with the procedures
set forth in this <U>Section&#8239;2.2</U>. The Chairman of the Board of Directors or person presiding at an annual meeting, as applicable,
shall, if the facts warrant, determine and declare to the annual meeting that business was not properly brought before the annual meeting
in accordance with the provisions of this <U>Section&#8239;2.2</U>, and if such person should so determine, such person shall so declare
to the annual meeting and any such business not properly brought before the meeting shall not be transacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
used in these Bylaws: &ldquo;<U>Stockholder Associated Person</U>&rdquo; means, with respect to any stockholder, (i)&#8239;any person
controlling, directly or indirectly, such stockholder, (ii)&#8239;any beneficial owner of shares of stock of the Corporation owned of
record or beneficially by such stockholder, (iii)&#8239;any person directly or indirectly controlling, controlled by or under common control
with such Stockholder Associated Person or (iv)&#8239;any person who is an &ldquo;associate&rdquo; (as such term is defined in Rule&#8239;12b-2
under the Exchange Act) of such stockholder; &ldquo;<U>Derivative Positions</U>&rdquo; means, with respect to any stockholder or any
Stockholder Associated Person, any derivative positions including, without limitation, any short position, profits interest, option,
warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment
or mechanism at a price related to any class or series of shares of the Corporation or with a value derived in whole or in part from
the value of any class or series of shares of the Corporation, whether or not such instrument or right shall be subject to settlement
in the underlying class or series of capital stock of the Corporation or otherwise and any performance-related fees to which such stockholder
or any Stockholder Associated Person is entitled, based, directly or indirectly, on any increase or decrease in the value of shares of
capital stock of the Corporation; and &ldquo;<U>Hedging Transaction</U>&rdquo; means, with respect to any stockholder or any Stockholder
Associated Person, any hedging or other transaction (such as borrowed or loaned shares) or series of transactions, or any other agreement,
arrangement or understanding, the effect or intent of which is to increase or decrease the voting power or economic or pecuniary interest
of such stockholder or any Stockholder Associated Person with respect to the Corporation&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Special
Meetings</U>. Special meetings of the stockholders, for any purpose or purposes, may only be called in accordance with, and by the person
or persons set forth in, the Certificate of Incorporation of the Corporation (the &ldquo;<U>Certificate of Incorporation</U>&rdquo;).
Unless otherwise required by law, written notice of a special meeting of stockholders, stating the time, place and purpose or purposes
thereof, shall be given to each stockholder entitled to vote at such meeting, not less than ten (10)&#8239;or more than sixty (60) days
before the date fixed for the meeting. Business transacted at any special meeting of stockholders shall be limited to the purposes stated
in the notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Quorum</U>.
The holders of a majority of the voting power of the capital stock issued and outstanding and entitled to vote thereat, present in person
or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise
required by law or provided by the Certificate of Incorporation. If, however, such quorum shall not be present or represented at any
meeting of the stockholders, the holders of a majority of the voting power present in person or represented by proxy, shall have power
to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present or represented.
At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted
at the meeting as originally noticed. If the adjournment is for more than thirty (30) days, or if after the adjournment a new record
date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder entitled to vote at such
adjourned meeting as of the record date fixed for notice of such adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 355; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization</U>.
The Chairman of the Board of Directors shall act as chairman of meetings of the stockholders. The Board of Directors may designate any
other officer or director of the Corporation to act as chairman of any meeting in the absence of the Chairman of the Board of Directors,
and the Board of Directors may further provide for determining who shall act as chairman of any stockholders meeting in the absence of
the Chairman of the Board of Directors and such designee. The Chairman of the Board of Directors may be removed as Chairman at any time
by the affirmative vote of a majority of the Board of Directors. The Secretary of the Corporation or an Assistant Secretary shall act
as secretary of all meetings of the stockholders, but in the absence of the Secretary the person presiding at the meeting may appoint
any other person to act as secretary of any meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Voting</U>.
Unless otherwise required by law, the Certificate of Incorporation or these Bylaws, any matter (other than the election of directors)
brought before any meeting of stockholders shall be decided by the affirmative vote of the holders of a majority of the voting power
of the capital stock present in person or represented by proxy and entitled to vote thereon. At all meetings of stockholders for the
election of directors, a plurality of the votes cast shall be sufficient to elect. Each stockholder represented at a meeting of stockholders
shall be entitled to cast one vote for each share of the capital stock entitled to vote thereat held by such stockholder, unless otherwise
provided by the Certificate of Incorporation. Each stockholder entitled to vote at a meeting of stockholders may authorize any person
or persons to act for him or her by proxy. No proxy shall be voted or acted upon after three (3)&#8239;years from its date, unless the
proxy provides for a longer period. The Board of Directors, in its discretion, or the Chairman of the Board or such other person presiding
at a meeting of stockholders, in the Chairman&rsquo;s or such other person&rsquo;s discretion, as applicable, may require that any votes
cast at such meeting shall be cast by written ballot.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Voting
List</U>. The officer of the Corporation who has charge of the stock ledger of the Corporation shall, at least ten (10)&#8239;days before
every meeting of stockholders, prepare and make a complete list of stockholders entitled to vote at any meeting of stockholders; <U>provided</U>,
<U>however</U>, if the record date for determining the stockholders entitled to vote is less than ten (10)&#8239;days before the meeting
date, the list shall reflect the stockholders entitled to vote as of the tenth (10<SUP>th</SUP>) day before the meeting date, arranged
in alphabetical order and showing the address of each such stockholder and the number of shares registered in his or her name. Such list
shall be open to the examination of any stockholder for a period of at least ten (10)&#8239;days prior to the meeting in the manner provided
by law. A stock list shall also be open to the examination of any stockholder during the whole time of the meeting as provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Stock
Ledger</U>. The stock ledger of the Corporation shall be the only evidence as to who are the stockholders entitled to examine the list
required by <U>Section&#8239;2.8</U>, or to vote in person or by proxy at any meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 356; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Adjournment</U>.
Any meeting of the stockholders (whether or not a quorum is present), including one at which directors are to be elected, may be adjourned
or postponed from time to time by the Chairman of the Board of Directors or person presiding at the meeting or the stockholders, without
the need for approval thereof by stockholders to reconvene or convene, respectively at the same or some other place. Notice need not
be given of any such adjourned or postponed meeting if the time and place, if any, thereof, and the means of remote communications, if
any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned or postponed meeting are
announced at the meeting at which the adjournment is taken or, with respect to a postponed meeting, are publicly announced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Ratification</U>.
The directors in their discretion may submit any contract or act for approval or ratification at any annual meeting of the stockholders
or at any meeting of the stockholders called for the purpose of considering any such act or contract, and, to the fullest extent permitted
by law, any contract or act that shall be approved or be ratified by the affirmative vote of the holders of a majority of the voting
power of the stock of the Corporation which is represented in person or by proxy at such meeting and entitled to vote thereon (provided
that a lawful quorum of stockholders be there represented in person or by proxy) shall be as valid and binding upon the Corporation and
upon all the stockholders as though it had been approved or ratified by every stockholder of the Corporation, whether or not the contract
or act would otherwise be open to legal attack because of directors&rsquo; interests, or for any other reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Inspectors</U>.
In advance of any meeting of the stockholders, the Corporation shall appoint one or more inspectors to act at the meeting and make a
written report thereof, and the election of directors and any vote by ballot at any meeting of the stockholders shall be supervised by
at least one such appointed inspector. If the inspector so appointed shall refuse to serve or shall not be present, a replacement appointment
shall be made by the Chairman of the Board of Directors or person presiding at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">2.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Meetings
by Means of Conference Telephone</U>. To the fullest extent permitted by law, stockholders may participate in a meeting of the stockholders
by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear
each other, and participation in a meeting pursuant to this <U>Section&#8239;2.12</U> shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #010000"><FONT STYLE="text-transform: uppercase">Article&#8239;III</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>DIRECTORS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Powers;
Number; Qualifications</U>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors,
except as may be otherwise provided by law or in the Certificate of Incorporation. The number of directors which shall constitute the
Board of Directors shall be set in the manner provided in the Certificate of Incorporate. Directors need not be stockholders of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Election;
Term of Office; Resignation; Removal; Vacancies</U>. Each director shall hold office in the manner provided in the Certificate of Incorporation.
Unless otherwise provided in the Certificate of Incorporation or the Director Nomination Agreement, vacancies shall be filled, and directors
may be removed, in the manner provided in the Certificate of Incorporation. A director may resign at any time by electronic transmission
or by giving written notice to the Chairman of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 357; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Advance
Notification of Nomination of Directors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to the Director Nomination Agreement, nominations of persons for election to the Board of Directors of the Corporation at a meeting of
stockholders of the Corporation may be made at such meeting (i)&#8239;by or at the direction of the Board of Directors (or any duly authorized
committee or persons thereof) or (ii)&#8239;by any stockholder of the Corporation entitled to vote for the election of directors at the
meeting who is a stockholder of record on the date of the giving of the notice required by this <U>Section&#8239;3.3</U> and on the record
date for the determination of stockholders entitled to vote at such meeting and who complies with the notice procedures set forth in
this <U>Section&#8239;3.3</U>; <U>provided</U>, that, for the avoidance of doubt, the foregoing clause (iii)&#8239;shall be the exclusive
means for a stockholder to make nominations (other than nominees included in the Corporation&rsquo;s proxy materials pursuant to the
Director Nomination Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
addition to any other applicable requirements, such nominations by any stockholder (other than any stockholder entitled to nominate a
director pursuant to a Director Nomination Agreement) shall be made pursuant to timely notice in writing to the Secretary of the Corporation.
To be timely, a stockholder&rsquo;s notice shall be delivered to or mailed and received at the principal executive offices of the Corporation
(i)&#8239;in the case of an annual meeting, not less than ninety (90) days nor more than one hundred twenty (120) days prior to the anniversary
date of the immediately preceding annual meeting; <U>provided</U>, <U>however</U>, that in the event that the annual meeting is called
for a date that is not within twenty-five (25) days before or after such anniversary date, or if no annual meeting was held in the preceding
year, notice by the stockholder in order to be timely must be so received not later than the close of business on the tenth (10th) day
following the day on which notice of the date of the annual meeting was mailed or public disclosure of the date of the annual meeting
was made, whichever first occurs; and (ii)&#8239;in the case of a special meeting of stockholders called for the purpose of electing directors,
not later than the close of business on the tenth (10th) day following the day on which notice of the date of the special meeting was
mailed or public disclosure of the date of the special meeting was made, whichever first occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Such
stockholder&rsquo;s notice to the Secretary shall set forth (i)&#8239;as to each person whom the stockholder proposes to nominate for
election or reelection as a director, (1)&#8239;the name, age, business address and residence address of the person, (2)&#8239;the principal
occupation or employment of the person, (3)&#8239;the class, series and number of shares of capital stock of the Corporation which are
directly or indirectly held of record or beneficially owned by the person, (4)&#8239;the date such shares were acquired and the investment
intent of such acquisition, and (5)&#8239;any other information relating to the person that is required to be disclosed in solicitations
for proxies for election of directors pursuant to the Rules&#8239;and Regulations of the Securities and Exchange Commission under Section&#8239;14
of the Exchange Act; and (ii)&#8239;as to the stockholder giving the notice (1)&#8239;the name and address of the stockholder as they appear
on the Corporation&rsquo;s books, (2)&#8239;the name and address (if different from the Corporation&rsquo;s books) of the stockholder,
(3)&#8239;the name and address of any Stockholder Associated Person, (4)&#8239;the class or series and number of shares of stock of the
Corporation which are directly or indirectly held of record or beneficially owned by such stockholder or by any Stockholder Associated
Person, (5)&#8239;a description of any Derivative Positions directly or indirectly held or beneficially held by the stockholder or any
Stockholder Associated Person, (6)&#8239;whether and the extent to which a Hedging Transaction has been entered into by or on behalf of
such stockholder or any Stockholder Associated Person, (7)&#8239;a description of all arrangements or understandings (including financial
transactions and direct or indirect compensation) between or among such stockholder or any Stockholder Associated Person and each proposed
nominee and any other person or entity (including their names) pursuant to which the nomination(s)&#8239;are to be made by such stockholder,
(8)&#8239;a representation that such stockholder is a holder of record of the Corporation entitled to vote at such meeting and intends
to appear in person or by proxy at the meeting to nominate the persons named in its notice, (9)&#8239;any other information relating to
such stockholder or any Stockholder Associated Person that would be required to be disclosed in a proxy statement or other filings required
to be made in connection with the solicitation of proxies or consents for a contested election of directors (even if an election contest
or proxy solicitation is not involved), or otherwise required, pursuant to Section&#8239;14 of the Exchange Act, and the rules, regulations
and schedules promulgated thereunder and (10)&#8239;a representation as to whether such stockholder or any Stockholder Associated Person
intends or is part of a group which intends to deliver a proxy statement and/or form of proxy to the holders of a sufficient number of
the Corporation&rsquo;s outstanding shares reasonably believed by the stockholder or any Stockholder Associated Person, as the case may
be, to elect each proposed nominee or otherwise to solicit proxies or votes from stockholders in support of the nomination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 358; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
stockholder providing notice of nomination to be made at an annual meeting or special meeting shall further update and supplement such
notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this <U>Section&#8239;3.3
</U>shall be true and correct as of the record date for determining the stockholders entitled to receive notice of the annual meeting
or special meeting and such update and supplement shall be delivered to or be mailed and received by the Secretary at the principal executive
offices of the Corporation not later than five (5)&#8239;business days after the record date for determining the stockholders entitled
to receive notice of the annual meeting or special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Corporation may require any proposed nominee (other than nominees included in the Corporation&rsquo;s proxy materials pursuant to the
Director Nomination Agreement) to furnish such other information as may reasonably be required by the Corporation to determine the eligibility
of such proposed nominee to serve as a director of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the Director Nomination Agreement, no person shall be eligible for election as a director of the Corporation unless nominated in accordance
with the procedures set forth herein. The Chairman of the Board or other person presiding at an annual meeting or a special meeting,
as applicable, shall, if the facts warrant, determine and declare to the meeting that a nomination was not made in accordance with the
foregoing procedure, and if he or she should so determine, he or she shall so declare to the meeting and the defective nomination shall
be disregarded. In no event shall any adjournment or postponement of an annual meeting or special meeting, or the announcement thereof,
commence a new time period for the giving of a stockholder&rsquo;s notice as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Meetings</U>.
The Board of Directors of the Corporation may hold meetings, both regular and special, either within or without the State of Delaware,
or solely by means of electronic communication in accordance with Section&#8239;141(i)&#8239;of the Delaware General Corporation Law (the
 &ldquo;<U>DGCL</U>&rdquo;). The first meeting of each newly elected Board of Directors shall be held immediately after and at the same
place as the meeting of the stockholders at which it is elected and no notice of such meeting shall be necessary to the directors in
order to legally constitute the meeting, provided a quorum shall be present. Regular meetings of the Board of Directors may be held without
notice at such time and place as shall from time to time be determined by the Board of Directors. At all meetings of the Board of Directors,
a majority of the entire Board of Directors shall constitute a quorum for the transaction of business. Unless by express provision of
an applicable law, the Certificate of Incorporation or these Bylaws a different vote is required, the vote of a majority of directors
present at a meeting at which a quorum is present shall be the act of the Board of Directors. At any meeting of the Board of Directors,
business shall be transacted in such order and manner as the Board of Directors may from time to time determine. If a quorum shall not
be present at any meeting of the Board of Directors, the directors present thereat may, to the fullest extent permitted by law, adjourn
the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 359; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization
of Meetings</U>. Subject to the Director Nomination Agreement, the Board of Directors shall elect one of its members to be Chairman of
the Board of Directors. The Chairman of the Board of Directors shall lead the Board of Directors in fulfilling its responsibilities as
set forth in these Bylaws, including its responsibility to oversee the performance of the Corporation, and shall determine the agenda
and perform all other duties and exercise all other powers which are or from time to time may be delegated to him or her by the Board
of Directors. Meetings of the Board of Directors shall be presided over by the Chairman of the Board of Directors, or in his or her absence,
by the Chief Executive Officer, or in the absence of the Chairman of the Board of Directors and the Chief Executive Officer by such other
person as the Board of Directors may designate or the members present may select.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Actions
of Board of Directors Without Meeting</U>. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action
required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting,
if all members of the Board of Directors or of such committee, as the case may be, consent thereto in writing or by electronic transmission,
and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors
or committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Removal
of Directors by Stockholders</U>. Any director may be removed by the stockholders only in accordance with the Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Resignations</U>.
Any director may resign at any time by submitting his or her written resignation to the Board of Directors or Secretary of the Corporation.
Such resignation shall take effect at the time of its receipt by the Corporation unless another time be fixed in the resignation, in
which case it shall become effective at the time so fixed. The acceptance of a resignation shall not be required to make it effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Committees</U>.
Subject to the Director Nomination Agreement, the Board of Directors may designate one or more committees, each committee to consist
of one or more of the directors of the Corporation. Subject to the Director Nomination Agreement, in the absence or disqualification
of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he
or she or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place
of any such absent or disqualified member. Any such committee, to the extent provided by law and in the resolution of the Board of Directors
establishing such committee, shall have and may exercise all the powers and authority of the Board of Directors in the management of
the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require
it. Each committee shall keep regular minutes of its meetings and report the same to the Board of Directors when required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compensation</U>.
The directors may be paid their reasonable, documented out-of-pocket expenses, if any, of attendance at each meeting of the Board of
Directors and may be paid a fixed amount (in cash or other form of consideration) for attendance at each meeting of the Board of Directors
and any other meetings or events attended on behalf of the Corporation at the Corporation&rsquo;s request or a stated salary as a director.
No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. Members
of special or standing committees may be allowed like compensation for attending committee meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 360; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interested
Directors</U>. No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation
and any other corporation, partnership, association, or other organization in which one or more of its directors or officers are directors
or officers or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer
is present at or participates in the meeting of the Board of Directors or committee thereof which authorizes the contract or transaction,
or solely because his, her or their votes are counted for such purpose, if (a)&#8239;the material facts as to his, her or their relationship
or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board
of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested
directors, even though the disinterested directors be less than a quorum, (b)&#8239;the material facts as to his, her or their relationship
or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract
or transaction is specifically approved in good faith by vote of the stockholders or (c)&#8239;the contract or transaction is fair as
to the Corporation as of the time it is authorized, approved or ratified, by the Board of Directors, a committee thereof or the stockholders.
Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a
committee which authorizes the contract or transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">3.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Meetings
by Means of Conference Telephone</U>. Members of the Board of Directors or any committee designed by the Board of Directors may participate
in a meeting of the Board of Directors or of a committee of the Board of Directors by means of conference telephone or similar communications
equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to
this <U>Section&#8239;3.12</U> shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #010000"><FONT STYLE="text-transform: uppercase">Article&#8239;IV</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OFFICERS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>General</U>.
The officers of the Corporation shall be elected by the Board of Directors and may consist of: a Chief Executive Officer, Chief Financial
Officer, Chief Innovation and Administration Officer, Chief Science Officer, Chief Development Officer, Chief Medical Officer, Chief
Business Officer, Chief Patient Advocate, Chief Technical Operations Officer, Secretary and Treasurer. The Board of Directors, in its
discretion, may also elect a Chairman of the Board (who must be a director), one or more Vice Presidents (including Executive Vice Presidents
and Senior Vice Presidents), Assistant Secretaries, Assistant Treasurers, a Controller and such other officers as in the judgment of
the Board of Directors may be necessary or desirable. Any number of offices may be held by the same person and more than one person may
hold the same office, unless otherwise prohibited by law, the Certificate of Incorporation or these Bylaws. The officers of the Corporation
need not be stockholders of the Corporation, nor need such officers be directors of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Election</U>.
The Board of Directors at its first meeting held after each annual meeting of stockholders shall elect the officers of the Corporation
who shall hold their offices for such terms and shall exercise such powers and perform such duties as shall be determined from time to
time by the Board of Directors; and all officers of the Corporation shall hold office until their successors are chosen and qualified,
or until their earlier resignation or removal. The salaries of all officers who are directors of the Corporation shall be fixed by the
Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 361; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Voting
Securities Owned by the Corporation</U>. Powers of attorney, proxies, waivers of notice of meeting, consents and other instruments relating
to securities owned by the Corporation may be executed in the name of and on behalf of the Corporation by the Chief Executive Officer
or any other officer authorized to do so by the Board of Directors and such officer may, in the name and on behalf of the Corporation,
take all such action as any such officer may deem advisable to vote in person or by proxy at any meeting of security holders of any entity
in which the Corporation may own securities and at any such meeting shall possess and may exercise any and all rights and powers incident
to the ownership of such securities and which, as the owner thereof, the Corporation might have exercised and possessed if present. The
Board of Directors may, by resolution, from time to time confer like powers upon any other person or persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Chief
Executive Officer</U>. Subject to the provisions of these Bylaws and to the direction of the Board of Directors, the Chief Executive
Officer shall have ultimate authority for decisions relating to the general management and control of the affairs and business of the
Corporation and shall perform such other duties and exercise such other powers which are or from time to time may be delegated to him
or her by the Board of Directors or these Bylaws, all in accordance with basic policies as established by and subject to the oversight
of the Board of Directors. In the absence or disability of the Chairman of the Board, or if there be none, the Chief Executive Officer
shall preside at all meetings of the stockholders and, provided the Chief Executive Officer is also a director, at all meetings of the
Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Chief
Financial Officer</U>. The Chief Financial Officer shall have general supervision, direction and control of the financial affairs of
the Corporation and shall perform such other duties and exercise such other powers which are or from time to time may be delegated to
him or her by the Board of Directors or these Bylaws, all in accordance with basic policies as established by and subject to the oversight
of the Board of Directors. In the absence of a named Treasurer or Assistant Treasurer, the Chief Financial Officer shall also have the
powers and duties of the Treasurer as hereinafter set forth and shall be authorized and empowered to sign as Treasurer in any case where
such officer&rsquo;s signature is required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Chief Officers</U>. Each of the Chief Innovation and Administration Officer, Chief Science Officer, Chief Development Officer, Chief
Medical Officer, Chief Business Officer, Chief Patient Advocate and Chief Technical Operations Officer shall perform such duties and
exercise such other powers which are or from time to time may be delegated to him or her by the Board of Directors or these Bylaws, all
in accordance with basic policies as established by and subject to the oversight of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vice
Presidents</U>. At the request of the Chief Executive Officer or in the absence of the Chief Executive Officer, or in the event of his
or her inability or refusal to act, the Vice President or the Vice Presidents if there is more than one (in the order designated by the
Board of Directors) shall perform the duties of the Chief Executive Officer, and when so acting, shall have all the powers of and be
subject to all the restrictions upon such office. Each Vice President shall perform such other duties and have such other powers as the
Board of Directors from time to time may prescribe. If there be no Vice President, the Board of Directors shall designate the officer
of the Corporation who, in the absence of the Chief Executive Officer or in the event of the inability or refusal of such officer to
act, shall perform the duties of such office, and when so acting, shall have all the powers of and be subject to all the restrictions
upon such office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 362; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Secretary</U>.
The Secretary shall attend all meetings of the Board of Directors and all meetings of stockholders and record all the proceedings thereat
in a book or books to be kept for that purpose. The Secretary shall also perform like duties for the standing committees when required.
The Secretary (or any Assistant Secretary) shall give, or cause to be given, notice of all meetings of the stockholders and special meetings
of the Board of Directors, and shall perform such other duties and have such other powers as may be prescribed by the Board of Directors
or the Chief Executive Officer, under whose supervision the Secretary shall be. If the Secretary shall be unable or shall refuse to cause
to be given notice of all meetings of the stockholders and special meetings of the Board of Directors, then any Assistant Secretary shall
perform such actions. If there be no Assistant Secretary, then the Board of Directors or the Chief Executive Officer may choose another
officer to cause such notice to be given. The Secretary shall have custody of the seal of the Corporation and the Secretary or any Assistant
Secretary, if there be one, shall have authority to affix the same to any instrument requiring it and when so affixed, it may be attested
by the signature of the Secretary or by the signature of any such Assistant Secretary. The Board of Directors may give general authority
to any other officer to affix the seal of the Corporation and to attest the affixing by his or her signature. The Secretary shall see
that all books, reports, statements, certificates and other documents and records required by law to be kept or filed are properly kept
or filed, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Treasurer</U>.
The Treasurer shall have the custody of the corporate funds and securities and shall keep full and accurate accounts of receipts and
disbursements in books belonging to the Corporation and shall deposit all moneys and other valuable effects in the name and to the credit
of the Corporation in such depositories as may be designated by the Board of Directors. The Treasurer shall disburse the funds of the
Corporation as may be ordered by the Board of Directors, taking proper vouchers for such disbursements, and shall render to the Chief
Executive Officer and the Board of Directors, at its regular meetings, or when the Board of Directors so requires, an account of all
his or her transactions as Treasurer and of the financial condition of the Corporation. The Treasurer shall perform such other duties
and have such other powers as the Board of Directors from time to time may prescribe. If required by the Board of Directors, the Treasurer
shall give the Corporation a bond in such sum and with such surety or sureties as shall be satisfactory to the Board of Directors for
the faithful performance of the duties of his or her office and for the restoration to the Corporation, in case of his or her death,
resignation, retirement or removal from office, of all books, papers, vouchers, money and other property of whatever kind in his or her
possession or under his or her control belonging to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Assistant
Secretaries</U>. Except as may be otherwise provided in these Bylaws, Assistant Secretaries, if there be any, shall perform such duties
and have such powers as from time to time may be assigned to them by the Board of Directors, the Chief Executive Officer, any Vice President,
if there be one, or the Secretary, and in the absence of the Secretary or in the event of his or her disability or refusal to act, shall
perform the duties of the Secretary, and when so acting, shall have all the powers of and be subject to all the restrictions upon the
Secretary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Assistant
Treasurers</U>. Assistant Treasurers, if there be any, shall perform such duties and have such powers as from time to time may be assigned
to them by the Board of Directors, the Chief Executive Officer, any Vice President, if there be one, or the Treasurer, and in the absence
of the Treasurer or in the event of his or her disability or refusal to act, shall perform the duties of the Treasurer, and when so acting,
shall have all the powers of and be subject to all the restrictions upon the Treasurer. If required by the Board of Directors, an Assistant
Treasurer shall give the Corporation a bond in such sum and with such surety or sureties as shall be satisfactory to the Board of Directors
for the faithful performance of the duties of his or her office and for the restoration to the Corporation, in case of his or her death,
resignation, retirement or removal from office, of all books, papers, vouchers, money and other property of whatever kind in his or her
possession or under his or her control belonging to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 363; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Controller</U>.
The Controller shall establish and maintain the accounting records of the Corporation in accordance with generally accepted accounting
principles applied on a consistent basis, maintain proper internal control of the assets of the Corporation and shall perform such other
duties as the Board of Directors, the Chief Executive Officer or any Vice President of the Corporation may prescribe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Officers</U>. Such other officers as the Board of Directors may choose shall perform such duties and have such powers as from time to
time may be assigned to them by the Board of Directors. The Board of Directors may delegate to any other officer of the Corporation the
power to choose such other officers and to prescribe their respective duties and powers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Vacancies</U>.
The Board of Directors shall have the power to fill any vacancies in any office occurring from whatever reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Resignations</U>.
Any officer may resign at any time by submitting his or her written resignation to the Corporation. Such resignation shall take effect
at the time of its receipt by the Corporation, unless another time be fixed in the resignation, in which case it shall become effective
at the time so fixed. The acceptance of a resignation shall not be required to make it effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">4.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Removal</U>.
Subject to the provisions of any employment agreement approved by the Board of Directors, any officer of the Corporation may be removed
at any time, with or without cause, by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #010000"><FONT STYLE="text-transform: uppercase">Article&#8239;V</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CAPITAL STOCK</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Shares
of Stock</U>. Except as otherwise provided in a resolution approved by the Board of Directors, all shares of capital stock of the Corporation
shall be uncertificated shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Signatures</U>.
To the extent any shares are represented by certificates, any or all of the signatures on a stock certificate may be a facsimile, including,
but not limited to, signatures of officers of the Corporation and countersignatures of a transfer agent or registrar. In case an officer,
transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such
officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if
such person were such officer, transfer agent or registrar at the date of issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Lost
Certificates</U>. The Board of Directors may direct a new stock certificate or certificates or uncertificated shares to be issued in
place of any stock certificate or certificates theretofore issued by the Corporation alleged to have been lost, stolen or destroyed,
upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed. When authorizing
such issuance of a new stock certificate or uncertificated shares, the Board of Directors may, in its discretion and as a condition precedent
to the issuance thereof, require the owner of such lost, stolen or destroyed certificate, or his or her legal representative, to give
the Corporation a bond in such sum as it may direct as indemnity against any claim that may be made against the Corporation with respect
to the certificate alleged to have been lost, stolen or destroyed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 364; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fixing
Record Date</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
order that the Corporation may determine the stockholders entitled to notice of any meeting of stockholders or any adjournment thereof,
the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted
by the Board, and which record date shall not be more than sixty (60) nor less than ten (10)&#8239;days before the date of such meeting.
If the Board so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting
unless the Board determines, at the time it fixes such record date, that a later date on or before the date of the meeting shall be the
date for making such determination. If the Board does not fix a record date for any meeting of the stockholders, the record date for
determining stockholders entitled to notice and to vote at a meeting of stockholders shall be the close of business on the day next preceding
the day on which notice of such meeting is given, or, if notice is waived, the close of business on the day next preceding the day on
which the meeting is held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment
of any rights, or the stockholders entitled to exercise any rights in connection with any change, conversion or exchange of stock, or
for the purpose of any other lawful action, the Board may fix a record date, which record date shall not precede the date upon which
the resolution fixing the record date is adopted, and which record date shall not be more than sixty (60) days prior to such action.
If no record date is fixed, the record date for determining stockholders for any such purpose shall be the close of business on the day
on which the Board of Directors adopts the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>A
determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment
of the meeting; <U>provided</U>, <U>however</U>, that the Board of Directors may fix a new record date for the adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registered
Stockholders</U>. Prior to due presentment for transfer of any share or shares, the Corporation shall treat the registered owner thereof
as the person exclusively entitled to vote, to receive notifications and to all other benefits of ownership with respect to such share
or shares, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any
other person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of the State of
Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer
and Registry Agents</U>. The Corporation may from time to time maintain one or more transfer offices or agencies and registry offices
or agencies at such place or places as may be determined from time to time by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #010000"><FONT STYLE="text-transform: uppercase">Article&#8239;VI</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>NOTICES</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Form&#8239;of
Notice</U>. If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder
at such stockholder&rsquo;s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise
may be given effectively to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in
Section&#8239;232 of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 365; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Waiver
of Notice</U>. Whenever any notice is required to be given under the provisions of law or the Certificate of Incorporation or by these
Bylaws of the Corporation, a written waiver, signed by the person or persons entitled to notice, whether before or after the time stated
therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting,
except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of
any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any
regular, or special meeting of the stockholders, Directors, or members of a committee of Directors need be specified in any written waiver
of notice unless so required by the Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #010000"><FONT STYLE="text-transform: uppercase">Article&#8239;VII</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>INDEMNIFICATION OF DIRECTORS AND OFFICERS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a person who serves as a director of the
Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as
a director. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors,
then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so
amended. Any repeal or modification of this <U>Section&#8239;7.1</U> shall not adversely affect any right or protection of a director
of the Corporation with respect to events occurring prior to the time of such repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To
the fullest extent permitted by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only
to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation
to provide prior to such amendment), the Corporation shall indemnify any person who was or is a party or is threatened to be made a party
to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative by reason
of the fact that he or she is or was a director or officer of the Corporation, or while serving as a director or officer of the Corporation,
is or was serving at the request of the Corporation as an employee or agent of the Corporation or as a director, officer, employee or
agent of another corporation, partnership, joint venture, trust or other enterprise (including a subsidiary of the Corporation) (any
person in such a position, an &ldquo;<U>Indemnified Person</U>&rdquo;), whether the basis of such action, suit or proceeding is alleged
action in an official capacity as a director or officer of the Corporation or in any other capacity while serving as a director or officer
of the Corporation, against expenses (including attorneys&rsquo; fees), judgments, fines, losses and amounts paid in settlement actually
and reasonably incurred by him or her in connection with such action, suit or proceeding if such Indemnified Person acted in good faith
and in a manner such Indemnified Person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with
respect to any criminal action or proceeding, had no reasonable cause to believe such Indemnified Person&rsquo;s conduct was unlawful;
<U>provided</U>, <U>however</U>, that, except as provided in <U>Section&#8239;7.9</U> of these Bylaws with respect to proceedings to enforce
rights to indemnification or advancement, the Corporation shall indemnify any such Indemnified Person in connection with a proceeding
(or part thereof) initiated by such Indemnified Person only if such proceeding (or part thereof) was authorized by the Board of Directors.
The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its
equivalent, shall not, of itself, create a presumption that the Indemnified Person did not act in good faith and in a manner which he
or she reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action
or proceeding, had reasonable cause to believe that his or her conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 366; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Corporation hereby acknowledges that an Indemnified Person may have certain rights to other indemnification, advancement of expenses
and/or insurance from persons other than the Corporation (collectively, the &ldquo;<U>Other Indemnitors</U>&rdquo;). The Corporation
hereby agrees that with respect to any and all expenses (including attorneys&rsquo; fees), judgments, fines, losses and amounts paid
in settlement arising by reason of the fact that such Indemnified Person is or was an Indemnified Person, (a)&#8239;that the Corporation
is the indemnitor of first resort (i.e., its obligations to an Indemnified Person are primary and any obligation of the Other Indemnitors
to advance expenses, provide indemnification or otherwise pay for the same amounts incurred by such Indemnified Person are secondary),
(b)&#8239;that the Corporation shall be required to advance the full amount of expenses incurred by an Indemnified Person in accordance
with this <U>Article&#8239;VII</U> and shall be liable for the full amount of all amounts to the extent legally permitted and as required
by the terms of these Bylaws (or any other agreement between the Corporation and an Indemnified Person), without regard to any rights
an Indemnified Person may have against the Other Indemnitors, and (c)&#8239;that the Corporation irrevocably waives, relinquishes and
releases the Other Indemnitors from any and all claims against the Other Indemnitors for contribution, subrogation or any other recovery
of any kind in respect thereof. The Corporation further agrees that no advancement or payment by the Other Indemnitors on behalf of an
Indemnified Person with respect to any claim for which such Indemnified Person has sought indemnification or advancement from the Corporation
shall affect the foregoing and the Other Indemnitors shall have a right of contribution and/or to be subrogated to the extent of such
advancement or payment to all of the rights of recovery of such Indemnified Person against the Corporation. The Corporation and each
Indemnified Person agree that the Other Indemnitors are express third party beneficiaries of the terms of this <U>Article&#8239;VII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Expenses
(including attorneys&rsquo; fees) incurred by an Indemnified Person in defending any civil, criminal, administrative or investigative
action, suit or proceeding referenced in <U>Section&#8239;7.12</U> shall be paid by the Corporation in advance of the final disposition
of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such Indemnified Person to repay such amount if
it shall ultimately be determined that he or she is not entitled to be indemnified by the Corporation. The rights to indemnification
and advancement of expenses conferred by this <U>Section&#8239;7.4</U> shall be contract rights and such rights shall continue as to an
Indemnified Person who has ceased to be a director or officer of the Corporation and shall inure to the benefit of his or her heirs,
executors and administrators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>For
purposes of any determination under this <U>Article&#8239;VII</U>, a person shall be deemed to have acted in good faith and in a manner
such person reasonably believed to be in or not opposed to the best interests of the Corporation, or, with respect to any criminal action
or proceeding, to have had no reasonable cause to believe such person&rsquo;s conduct was unlawful, if such person&rsquo;s action is
based on the records or books of account of the Corporation or another enterprise, or on information supplied to such person by the officers
of the Corporation or another enterprise in the course of their duties, or on the advice of legal counsel for the Corporation or another
enterprise or on information or records given or reports made to the Corporation or another enterprise by an independent certified public
accountant or by an appraiser or other expert selected with reasonable care by the Corporation or another enterprise. The provisions
of this <U>Section&#8239;7.5</U> not be deemed to be exclusive or to limit in any way the circumstances in which a person may be deemed
to have met the applicable standard of conduct set forth in this <U>Article&#8239;VII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 367; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
repeal or amendment of this <U>Article&#8239;VII</U> or by changes in the DGCL, or the adoption of any other provision of the Certificate
of Incorporation or these Bylaws inconsistent with this <U>Article&#8239;VII</U>, shall, unless otherwise required by the DGCL, be prospective
only (except to the extent such amendment or change in law permits the Corporation to provide broader indemnification or advancement
rights on a retroactive basis than permitted prior thereto), and shall not in any way diminish or adversely affect any right or protection
existing at the time of such repeal or amendment or adoption of such inconsistent provision in respect of any proceeding (regardless
of when such proceeding is first threatened, commenced or completed) arising out of or related to any act or omission occurring prior
to such repeal or amendment or adoption of such inconsistent provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
indemnification and advancement of expenses provided by, or granted pursuant to this <U>Article&#8239;VII</U> shall not be deemed exclusive
of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote
of stockholders or disinterested directors or otherwise, both as to action in his or her official capacity and as to action in another
capacity while holding such office.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Corporation shall have power to purchase and maintain insurance on behalf of any person who is or was an Indemnified Person against any
liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether
or not the Corporation would have the power to indemnify him or her against such liability under the provisions of this <U>Article&#8239;VII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
a claim under <U>Section&#8239;7.2</U> or <U>7.4</U> of these Bylaws is not paid in full by the Corporation within sixty (60) days after
a written claim has been received by the Corporation, except in the case of a claim for an advancement of expenses, in which case the
applicable period shall be twenty (20) days, the Indemnified Person may at any time thereafter bring suit against the Corporation to
recover the unpaid amount of the claim. To the fullest extent permitted by the DGCL, if successful in whole or in part in any such suit,
or in a suit brought by the Corporation to recover an advancement of expenses, the Indemnified Person shall be entitled to be paid also
the expense of prosecuting or defending such suit. In (a)&#8239;any suit brought by the Indemnified Person to enforce a right to indemnification
hereunder (but not in a suit brought by the Indemnified Person to enforce a right to an advancement of expenses) it shall be a defense
that, and (b)&#8239;in any suit brought by the Corporation to recover an advancement of expenses, the Corporation shall be entitled to
recover such expenses only upon a final adjudication that, the Indemnified Person has not met any applicable standard for indemnification
set forth in the DGCL. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee
of such directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such suit
that indemnification of the Indemnified Person is proper in the circumstances because the Indemnified Person has met the applicable standard
of conduct set forth in the DGCL, nor an actual determination by the Corporation (including its directors who are not parties to such
action, a committee of such directors, independent legal counsel, or its stockholders) that the Indemnified Person has not met such applicable
standard of conduct, shall create a presumption that the Indemnified Person has not met the applicable standard of conduct or, in the
case of such a suit brought by the Indemnified Person, be a defense to such suit. In any suit brought by the Indemnified Person to enforce
a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses,
the burden of proving that the Indemnified Person is not entitled to be indemnified, or to such advancement of expenses, under this <U>Article&#8239;VII
</U>or otherwise shall be on the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 368; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>For
purposes of this <U>Article&#8239;VII</U>, references to &ldquo;other enterprises&rdquo; shall include employee benefit plans; references
to &ldquo;fines&rdquo; shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references
to &ldquo;serving at the request of the Corporation&rdquo; shall include any service which imposes duties on, or involves services by,
the Indemnified Person with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith
and in a manner he or she reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan
shall be deemed to have acted in a manner &ldquo;not opposed to the best interests of the Corporation&rdquo; as referred to in this <U>Article&#8239;VII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
indemnification and advancement of expenses provided by, or granted pursuant to, this <U>Article&#8239;VII</U> shall continue as to a
person who has ceased to be an Indemnified Person and shall inure to the benefit of the heirs, executors and administrators of such a
person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">7.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification and to the advancement
of expenses to any employee or agent of the Corporation to the fullest extent of the provisions of this <U>Article&#8239;VII</U> with
respect to the indemnification and advancement of expenses of Indemnified Persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #010000"><FONT STYLE="text-transform: uppercase">Article&#8239;VIII</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>GENERAL PROVISIONS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reliance
on Books and Records</U>. Each Director, each member of any committee designated by the Board of Directors, and, to the fullest extent
permitted by law, each officer of the Corporation, shall, in the performance of his or her duties, be fully protected in relying in good
faith upon the books of account or other records of the Corporation, including reports made to the Corporation by any of its officers,
by an independent certified public accountant, or by an appraiser selected with reasonable care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Inspection
by Directors</U>. Any director shall have the right to examine the Corporation&rsquo;s stock ledger, a list of its stockholders, and
its other books and records for a purpose reasonably related to his or her position as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Dividends</U>.
Subject to the provisions of the Certificate of Incorporation, if any, dividends upon the capital stock of the Corporation may be declared
by the Board of Directors at any regular or special meeting, pursuant to law. Dividends may be paid in cash, in property, or in shares
of the capital stock, subject to the provisions of the Certificate of Incorporation. Before payment of any dividend, there may be set
aside out of any funds of the Corporation available for dividends such sum or sums as the Directors from time to time, in their absolute
discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining
any property of the Corporation, or for such other purpose as the Directors shall think conducive to the interest of the Corporation,
and the Directors may modify or abolish any such reserve in the manner in which it was created.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Checks</U>.
All checks or demands for money and notes of the Corporation shall be signed by such officer or officers or such other persons as the
Board of Directors may from time to time designate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 369; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fiscal
Year</U>. The fiscal year of the Corporation shall be as determined by the Board of Directors. If the Board of Directors shall fail to
do so, the Chief Executive Officer shall fix the fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Seal</U>.
The corporate seal shall have inscribed thereon the name of the Corporation, the year of its organization and the words &ldquo;Corporate
Seal, Delaware&rdquo;. The seal may be used by causing it or a facsimile thereof to be impressed or affixed or in any manner reproduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendments</U>.
The original or other Bylaws may be adopted, amended, modified or repealed by the affirmative vote of (a)&#8239;the holders of a majority
of the outstanding voting stock of the Corporation, or (b)&#8239;if the Certificate of Incorporation so provides, a majority of the entire
Board of Directors. The fact that such power has been so conferred upon the Board of Directors shall not divest the stockholders of the
power nor limit their power to adopt, amend, modify or repeal these Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">8.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Interpretation
of Bylaws</U>. All words, terms and provisions of these Bylaws shall be interpreted and defined by and in accordance with the DGCL, as
amended, and as amended from time to time hereafter. <U>Entire Board of Directors</U>. As used in this Article&#8239;VIII and in these
Bylaws generally, the term &ldquo;entire Board of Directors&rdquo; means the total number of directors which the Corporation would have
if there were no vacancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 370 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;H</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of ARYA Post-Closing Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 371 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;I-1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Post-Closing Incentive Equity
Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 372 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Execution Version</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SPONSOR LETTER AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This SPONSOR LETTER AGREEMENT
(this &ldquo;<B><U>Agreement</U></B>&rdquo;), dated as of September 29, 2021, is made by and among ARYA Sciences Holdings IV, an exempted
company incorporated in the Cayman Islands with limited liability (the &ldquo;<B>ARYA Sponsor</B>&rdquo;), ARYA Sciences Acquisition Corp
IV, an exempted company incorporated in the Cayman Islands with limited liability (&ldquo;<B>ARYA</B>&rdquo;), Amicus GT Holdings, LLC,
a Delaware limited liability company (&ldquo;<B>Amber GT</B>&rdquo;), each of Todd Wider, Leslie Trigg and Michael Henderson (collectively,
the &ldquo;<B>Other Class B Shareholders</B>&rdquo;, and together with the ARYA Sponsor, collectively, the &ldquo;<B>Class B Shareholders</B>&rdquo;)
and each of Joseph Edelman, Adam Stone, Michael Altman and Konstantin Poukalov (collectively, the &ldquo;<B>Other Insiders</B>&rdquo;,
and together with the Class B Shareholders, collectively, the &ldquo;<B>Insiders</B>&rdquo;). ARYA, Amber GT and the Insiders shall be
referred to herein from time to time collectively as the &ldquo;<B>Parties</B>&rdquo;. Capitalized terms used but not otherwise defined
herein shall have the meanings ascribed to such terms in the Business Combination Agreement (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, ARYA, Amber GT and
certain other Persons party thereto entered into that certain Business Combination Agreement, dated as of the date hereof (the &ldquo;<B>Business
Combination Agreement</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Business Combination
Agreement contemplates that the Parties will enter into this Agreement concurrently with the entry into the Business Combination Agreement
by the parties thereto, pursuant to which, among other things, the ARYA Sponsor and each Other Class B Shareholder will (a) vote in favor
of approval of the Business Combination Agreement and the transactions contemplated thereby, (b)&nbsp;agree to waive any adjustment to
the conversion ratio set forth in the Governing Documents of ARYA or any other anti-dilution or similar protection with respect to all
of the ARYA Class B Shares held by him, her or it, and (c) subject to, and conditioned upon the occurrence of and effective as of, the
Closing, terminate certain existing agreements or arrangements, including any existing ARYA Sponsor registration rights and lock-up arrangements,
in each case, on the terms and subject to the conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the premises and the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties, each intending to be legally bound, hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Consent to Business Combination; Agreement to Vote</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Pursuant to Section 3 of that certain Letter Agreement, dated as of February 25, 2021 (the &ldquo;<B>Insider Letter Agreement</B>&rdquo;),
by and among ARYA and the Insiders, the ARYA Sponsor hereby consents to the entry by ARYA into the Business Combination Agreement and
each other Additional Agreement to which ARYA is or will be a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each Class B Shareholder (in his, her or its capacity as a shareholder of ARYA and on behalf of himself, herself or itself and
not the other Class B Shareholders) hereby agrees to vote at any meeting of the shareholders of ARYA (however called and whether or not
adjourned, including at the ARYA Shareholders Meeting or otherwise), and in any action by written resolution of the shareholders of ARYA,
all ARYA Class B Shares held by him, her or it as of the relevant determination time in favor of the Transaction Proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Waiver of Anti-dilution Protection</U>. Each Class B Shareholder hereby (a)&#8239;waives, subject to, and conditioned upon, the
occurrence of the Closing (for himself, herself or itself and for his, her or its successors and assigns), to the fullest extent permitted
by Law and the Governing Documents of ARYA, and (b) agrees not to assert or perfect, any rights to adjustment or other anti-dilution protections
with respect to the rate that the ARYA Class B Shares held by him, her or it convert into ARYA Class A Shares in connection with the transactions
contemplated by the Business Combination Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 373; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Transfer of Shares</U>. Except as expressly contemplated by the Business Combination Agreement, with the prior written consent
of Amber GT or with respect to a Permitted Transferee (as defined in the last sentence of this <U>Section 3)</U>, from and after the date
hereof until the earlier of the date of the Closing or the termination of the Business Combination Agreement in accordance with its terms,
each Class B Shareholder hereby agrees that he, she or it shall not (a) sell, transfer or otherwise dispose of any of his, her or its
ARYA Class B Shares, (b) deposit any of his, her or its ARYA Class B Shares into a voting trust or enter into a voting agreement or arrangement
or grant any proxy or execute any power of attorney with respect to any of his, her or its ARYA Class B Shares, in each case, that conflicts
with any of the covenants or agreements set forth in this Agreement, or (c) enter into any Contract with respect to the sale, transfer
or other disposition of any of his, her or its ARYA Class B Shares. Notwithstanding the foregoing or anything to the contrary herein,
the foregoing restrictions shall not apply to any sale, transfer or other disposition (i) to a Permitted Transferee, (ii) pursuant to
a bona fide gift or charitable contribution, (iii) in the case of an individual, by virtue of laws of descent and distribution upon death
of the individual, (iv)&#8239;in the case of an individual, pursuant to a qualified domestic relations order or (v) in the case of ARYA
Sponsor, by virtue of ARYA Sponsor&rsquo;s organizational documents upon liquidation or dissolution of the ARYA Sponsor; <U>provided</U>,
that, the transferring holder shall, and shall cause any transferee of his, her or its ARYA Class B Shares of the type set forth in clauses
(i)&#8239;through (v), to enter into a written agreement agreeing to be bound by the applicable provisions of this Agreement that are applicable
to the transferring holder prior and as a condition to the occurrence of such sale, transfer or other disposition and, from and after
the entry into such written agreement, shall be deemed to be a Class B Shareholder for all purposes of this Agreement. For purposes of
this <U>Section 3</U>, &ldquo;<U>Permitted Transferee</U>&rdquo; means, with respect to any Person, (A) any direct or indirect members,
partners (whether general or limited partners) or equityholders or other holders of interests of such Person or any of its Affiliates
or any officers, directors or employees of such Person or any Affiliates of any of the foregoing, (B) such Person&rsquo;s immediate family
or family member of any of such Person&rsquo;s officers or directors, (C) any trust for the direct or indirect benefit of such Person
or the immediate family of such Person, (D) if such Person is a trust, to the trustee or beneficiary(ies) of such trust or to the estate
of a beneficiary of such trust, or (E) <FONT STYLE="background-color: white">by private sales or transfers made in connection with the
consummation of a Business Combination at prices no greater than the price at which the Founder Shares (as such term is defined in the
Insider Letter Agreement) or Private Placement Shares (as such term is defined in the Insider Letter Agreement), as applicable, were originally
purchased</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Covenants</U>. Each Class B Shareholder hereby agrees to be bound by and subject to (i) Sections 6.5 (Confidentiality; Access to Information)
and 11.4 (Publicity) of the Business Combination Agreement to the same extent as such provisions apply to the parties to the Business
Combination Agreement, as if such Class B Shareholder is directly a party thereto, and (ii) Section 6.4 (Exclusive Dealing) of the Business
Combination Agreement to the same extent as such provisions apply to ARYA, as if such Class B Shareholder is directly party thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination
of Existing Lock-Up</U>. Each of the Insiders and ARYA hereby agrees that, subject to, and conditioned upon and effective as of, the
occurrence of the Closing, Section 5 of the Insider Letter shall be amended and restated in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">&ldquo;5.</TD><TD STYLE="text-align: justify; padding-right: 0.5in">Reserved.&rdquo;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the Parties further acknowledges and agrees,
for the avoidance of doubt, that none of the Insiders shall be subject to any of the restrictions or obligations set forth in Section
5 of the Letter Agreement from and after the time of the amendment contemplated by this <U>Section 5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.
This Agreement shall automatically terminate, without any notice or other action by any Party, and be void ab initio upon the earlier
of (a) the Closing and (b) the termination of the Business Combination Agreement in accordance with its terms. Upon termination of this
Agreement as provided in the immediately preceding sentence, none of the Parties shall have any further obligations or Liabilities under,
or with respect to, this Agreement. Notwithstanding the foregoing or anything to the contrary in this Agreement, (i) the termination
of this Agreement pursuant to <U>Section&#8239;6(b)</U> shall not affect any Liability on the part of any Party for a willful and material
breach of any covenant or agreement set forth in this Agreement prior to such termination, (ii) <U>Sections 1(a)</U>, <U>2</U> and <U>5
</U>and <U>Sections 10</U>, <U>14</U> and <U>15</U> (in each case, solely to the extent related to the foregoing <U>Sections 1(a)</U>,
<U>2</U> or <U>5</U>) shall each survive the termination of this Agreement pursuant to <U>Section 6(a)</U>, and (iii) this <U>Section
6</U> and <U>Sections 7</U>, <U>8</U>, <U>9</U>, <U>11</U>, <U>12</U> and <U>13</U> and <U>Sections 10</U>, <U>14</U> and <U>15</U> (in
each case, solely to the extent related to this <U>Section 6</U> or <U>Sections 7</U>, <U>8</U>, <U>9</U>, <U>11</U>, <U>12</U> or <U>13</U>)
shall survive any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 374; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Non-Recourse</U>.
This Agreement may only be enforced against, and any action for breach of this Agreement may only be made against, the Parties, and without
limiting the generality of the foregoing, none of the Representatives of any Party shall have any Liability arising out of or relating
to this Agreement, the negotiation hereof or its subject matter or the transactions contemplated hereby, including with respect to any
claim (whether in tort, contract or otherwise) for breach of this Agreement or in respect of any written or oral representations made
or alleged to be made in connection herewith, except as expressly provided herein or, for the avoidance of doubt, for claims pursuant
to the Business Combination Agreement or any other Additional Agreement by any party(ies) thereto against any other party(ies) thereto
on the terms and subject to the conditions therein. Notwithstanding anything to the contrary in this Agreement, (i) in no event shall
any Insider have any obligations or Liabilities related to or arising out of the covenants, agreements or obligations of any other Insider
under this Agreement (including related to or arising out of the breach of any such covenant, agreement or obligation by any other Insider),
and (ii) in no event shall ARYA have any obligations or Liabilities related to or arising out of the covenants, agreements or obligations
of any Insider under this Agreement (including related to or arising out of any breach of any such covenant, agreement or obligation
by any such Insider).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fiduciary
Duties</U>. Notwithstanding anything in this Agreement to the contrary, (a) each Class B Shareholder makes no agreement or understanding
herein in any capacity other than in such Shareholder&rsquo;s capacity as a record holder and beneficial owner of ARYA Class B Shares,
and not, in the case of any Insider, in such Insider&rsquo;s capacity as a director, officer or employee of ARYA, and (b) nothing herein
will be construed to limit or affect any action or inaction by any Insider or any representative of the ARYA Sponsor serving as a member
of the board of directors (or other similar governing body) of ARYA or as an officer, employee or fiduciary of ARYA, in each case, acting
in such person&rsquo;s capacity as a director, officer, employee or fiduciary of ARYA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Third Party Beneficiaries</U>. Except as set forth in <U>Section 3</U> or <U>Section 7</U>, this Agreement shall be for the sole benefit
of the Parties and their respective successors and permitted assigns and is not intended, nor shall be construed, to give any Person,
other than the Parties and their respective successors and assigns, any legal or equitable right, benefit or remedy of any nature whatsoever
by reason this Agreement. Nothing in this Agreement, expressed or implied, is intended to or shall constitute the Parties, partners or
participants in a joint venture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Remedies</U>.
Except as otherwise expressly provided herein, any and all remedies provided herein will be deemed cumulative with and not exclusive
of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude
the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not
be an adequate remedy, would occur in the event that any Party does not perform his, her or its respective obligations under the provisions
of this Agreement (including failing to take such actions as are required of them hereunder to consummate the transactions contemplated
by this Agreement) in accordance with their specific terms or otherwise breach such provisions. It is accordingly agreed that each Party
shall be entitled to seek an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement
and to enforce specifically the terms and provisions of this Agreement, in each case, without posting a bond or undertaking and without
proof of damages and this being in addition to any other remedy to which they are entitled at law or in equity. Each of the Parties agrees
that it will not oppose the granting of an injunction, specific performance and other equitable relief when expressly available pursuant
to the terms of this Agreement on the basis that the other Parties have an adequate remedy at law or an award of specific performance
is not an appropriate remedy for any reason at law or equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 375; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fees
and Expenses</U>. Except, in the case of ARYA and Amber GT, as otherwise expressly set forth in the Business Combination Agreement, all
fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby, including the fees and disbursements
of counsel, financial advisors and accountants, shall be paid by the Party incurring such fees or expenses; <U>provided</U>, that, any
such fees and expenses incurred by the Insiders on or prior to the Closing shall, in the sole discretion of the ARYA Sponsor, be allocated
to ARYA and deemed to be ARYA Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Ownership Interest</U>. Nothing contained in this Agreement will be deemed to vest in Amber GT or any of its Affiliates or ARYA or any
its Affiliates any direct or indirect ownership or incidents of ownership of or with respect to the ARYA Shares held by any Class B Shareholder.
All rights, ownership and economic benefits of and relating to the applicable ARYA Shares shall remain vested in and belong to each applicable
Class B Shareholder, and Amber GT and ARYA (and each of their respective Affiliates) shall have no authority to exercise any power or
authority to direct any Insider in the voting of any of the ARYA Shares owned by him, her or it (if any), except as otherwise expressly
provided herein with respect to the ARYA Shares owned by him, her or it (if any). Except as otherwise set forth in <U>Section 1(b)</U>,
no Class B Shareholder shall be restricted from voting in favor of, against or abstaining with respect to any other matters presented
to the shareholders of ARYA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendments
and Waivers; Assignment</U>. Any provision of this Agreement may be amended or modified if, and only if, such amendment or modification
is in writing and signed by the Parties, and any provision of this Agreement may be waived if, and only if, such waiver is in writing
and signed by the Party(ies) against whom such waiver is sought. Notwithstanding the foregoing, no failure or delay by any Party in exercising
any right hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further
exercise of any other right hereunder. Subject to <U>Section 8</U>, none of this Agreement or any of the rights, interests or obligations
hereunder shall be assignable by (a) an Insider without the prior written consent of ARYA and Amber GT, (b) Amber GT without the prior
written consent of the ARYA Sponsor and ARYA or (c) ARYA without the prior written consent of the ARYA Sponsor and Amber GT. Any attempted
amendment or assignment of this Agreement not in accordance with the terms of this <U>Section 13</U> shall be null and void ab initio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Any notice, requests, claims, demands and other communications hereunder shall be sent in writing and shall be deemed to have been duly
given by delivery in person, by email (having obtained electronic delivery confirmation thereof (i.e., an electronic record of the sender
that the email was sent to the intended recipient thereof without an &ldquo;error&rdquo; or similar message that such email was not received
by such intended recipient)), or by registered or certified mail (postage prepaid, return receipt requested) (upon receipt thereof) to
the other Parties as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If to ARYA or any Insider, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">c/o
ARYA Science Acquisition Corp IV</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">51
Astor Place, 10th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">New
York, NY 10003</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">Attention:&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Adam Stone</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">Michael Altman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">Doug Giordano</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">Konstantin Poukalov</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">Email: &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;adam@perceptivelife.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">michael@perceptivelife.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">doug@perceptivelife.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">konstantin@perceptivelife.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 376; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">with a copy (which shall not constitute notice)
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Kirkland &amp; Ellis LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">601 Lexington Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">New York, NY 10022</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">Attention: &#8239;&#8239;&#8239;&#8239;Jonathan L. Davis, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">Ryan Brissette</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">Email: &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;jonathan.davis@kirkland.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 1in">ryan.brissette@kirkland.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If to Amber GT, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">c/o</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Amicus
Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">3675
Market Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Philadelphia,
PA 19104</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Attn:
Chief Legal Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Email:
gcoffice@amicusrx.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">with a copy (which shall not constitute notice) to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.75in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Skadden,
Arps, Slate, Meagher &amp; Flom LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">1440
New York Avenue, N.W.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Washington,
D.C. 20005</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: -0.5in; text-indent: 2in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Attn: &#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Graham Robinson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 2in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#8239;Katherine D. Ashley</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: -0.5in; text-indent: 2in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Email: &#8239;&#8239;&#8239;&#8239;graham.robinson@skadden.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 2in; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#8239;katherine.ashley@skadden.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Incorporation
by Reference</U>. <U>Sections 11.7</U> (Governing Law), <U>11.8</U> (Counterparts; Electronic Signatures), <U>11.10</U> (Entire Agreement),
<U>11.12</U> (Severability), <U>11.13</U> (Construction; Interpretation), <U>11.16</U> (Submission to Jurisdiction) and <U>11.18</U>
(Waiver of Jury Trial) of the Business Combination Agreement are incorporated herein and shall apply to this Agreement <I>mutatis mutandis</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[signature page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<!-- Field: Page; Sequence: 377; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>IN WITNESS WHEREOF</B>, each of the Parties has
caused this Agreement to be duly executed on its behalf as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%"><B>ARYA SCIENCES HOLDINGS IV</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 3%; text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">/s/  Michael Altman</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 53%"></TD><TD STYLE="width: 5%; text-align: left">Name:</TD><TD STYLE="text-align: justify; width: 42%"> Michael Altman</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">Title:</TD><TD STYLE="text-align: justify">Chief Financial Officer</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%"><B>ARYA SCIENCES ACQUISITION CORP IV</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 3%; text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">/s/ Michael Altman</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 53%"></TD><TD STYLE="width: 5%; text-align: left">Name:</TD><TD STYLE="text-align: justify; width: 42%"> Michael Altman</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">Title:</TD><TD STYLE="text-align: justify">Chief Financial Officer</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%"><B>AMICUS GT HOLDINGS, LLC</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 3%; text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">/s/ Bradley L. Campbell</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 53%"></TD><TD STYLE="width: 5%; text-align: left">Name:</TD><TD STYLE="text-align: justify; width: 42%">Bradley L. Campbell</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">Title:</TD><TD STYLE="text-align: justify">President</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[Signature Page to Sponsor Letter Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 378 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%"><B>OTHER CLASS B SHAREHOLDERS:</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">/s/ Todd Wider</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">Todd Wider</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261.35pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">/s/ Michael Henderson</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">Michael Henderson</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261.35pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&#8239;/s/ Leslie Trigg</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">Leslie Trigg</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261.35pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%"><B>OTHER INSIDERS:</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt">&#8239;/s/ Joseph
  Edelman</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt; width: 50%"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">&#8239;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt; width: 50%"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Joseph
  Edelman</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">/s/ Adam Stone</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">Adam Stone</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">/s/ Michael Altman</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">Michael Altman</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&#8239;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">/s/ Konstantin Poukalov</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">&#8239;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 50%">Konstantin Poukalov</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261.35pt; text-indent: -0.35pt">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[Signature Page to Sponsor Letter Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261.35pt; text-indent: -0.35pt">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261.35pt; text-indent: -0.35pt"></P>

<!-- Field: Page; Sequence: 379 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 261.35pt; text-indent: -0.35pt">&#8239;</P>



<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS SECURITIES PURCHASE AGREEMENT
(this &ldquo;<B><I>Agreement</I></B>&rdquo;) is made effective as of 12:01 a.m.&nbsp;on September&nbsp;29, 2021 (the &ldquo;<B><I>SPA
Effective Date</I></B>&rdquo;), by and among Amicus Therapeutics,&nbsp;Inc., a Delaware corporation with its principal place of business
at 3675 Market Street, Philadelphia, PA 19104 (&ldquo;<B><I>Amicus</I></B>&rdquo;), and each Purchaser identified on the signature pages&nbsp;hereto
(each, including its successors and assigns, a &ldquo;<B><I>Purchaser</I></B>&rdquo; and collectively the &ldquo;<B><I>Purchasers</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">BACKGROUND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amicus desires to sell to
each Purchaser and each Purchaser desires to purchase from Amicus such number of Shares and Warrants (as defined below) set forth opposite
such Purchaser&rsquo;s name on <U>Schedule A</U> attached hereto, at a price of $10.18 per Share (the &ldquo;<B><I>Per Share Price</I></B>&rdquo;)
and on the terms and subject to the conditions set forth in this Agreement (the &ldquo;<B><I>Offering</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">TERMS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing recitals and the mutual covenants and agreements contained herein, the Parties hereto, intending to be legally bound,
do hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Definitions</U></B>.
The capitalized terms used herein shall have the meanings ascribed to them below or at such other place in this Agreement as is indicated
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Affiliate</I></B>&rdquo;
means, with respect to any specified Person, at any time, a Person that, directly or indirectly, through one or more intermediaries, controls,
or is controlled by, or is under common control with, such specified Person at such time. For purposes of this definition, &ldquo;control,&rdquo;
when used with respect to any specified Person, shall mean (a)&nbsp;the direct or indirect ownership of more than 50% (or such lesser
percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the total voting power of
securities or other evidences of ownership interest in such Person or (b)&nbsp;the power to direct or cause the direction of the management
and policies of such Person, directly or indirectly, whether through ownership of voting securities, by contract or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Closing</I></B>&rdquo;
has the meaning ascribed to such term in <U>Section&nbsp;3.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Common
Stock</I></B>&rdquo; means the common stock of Amicus, par value $0.01 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed into.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Cut
Back Shares</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended, together with the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>FDA</I></B>&rdquo;
has the meaning ascribed to such term in <U>Section&nbsp;4.7</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 380 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>FDA
Documents</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;4.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>GAAP</I></B>&rdquo;
means generally accepted accounting principles in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Holder</I></B>&rdquo;
means each Person owning of record Registrable Securities that have not been sold to the public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Indemnified
Party</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.5(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Indemnifying
Party</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.5(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Knowledge</I></B>&rdquo;
means the knowledge of such Person, assuming that such Person engaged in reasonable inquiry or investigation with respect to the relative
subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Lock-Up
Period</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;7.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Material
Adverse Effect</I></B>&rdquo; on or with respect to an entity (or group of entities taken as a whole) means any state of facts, event,
change or effect that has had, or that would reasonably expected to have, (i)&nbsp;a material adverse effect on the business, properties,
prospects, results of operations or financial condition of such entity (or of such group of entities taken as a whole) or (ii)&nbsp;a
material adverse effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Nasdaq</I></B>&rdquo;
means the Nasdaq Stock Market,&nbsp;Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Offering</I></B>&rdquo;
has the meaning ascribed to such term in the Background.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Party</I></B>&rdquo;
means a party to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Per
Share Price</I></B>&rdquo; has the meaning ascribed to such term in the Background.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Person</I></B>&rdquo;
means any individual, firm, corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint
venture, joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind, and shall include
any successor (by merger or otherwise) of such entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Press
Release</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;9.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Purchase
Price</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Purchased
Securities</I></B>&rdquo; means, together, the Shares and the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Purchaser
Indemnitee</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Register</I></B>,&rdquo;
 &ldquo;<B><I>Registered</I></B>,&rdquo; and &ldquo;<B><I>Registration</I></B>&rdquo; refer to a registration effected by preparing and
filing a Registration Statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such Registration
Statement or document by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 381; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Registrable
Securities</I></B>&rdquo; means (a)&nbsp;the Shares, (b)&nbsp;any shares of Common Stock or other securities issued as (or issuable upon
the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to,
or in exchange for or in replacement of, the Shares by way of stock dividend, stock split or in connection with a combination of shares,
recapitalization or other reorganization or otherwise, and (c)&nbsp;the Warrant Shares. Notwithstanding the foregoing, as to any particular
Shares or other securities described above, once issued they shall cease to be Registrable Securities when (i)&nbsp;a registration statement
with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been disposed
of in accordance with such registration statement, (ii)&nbsp;they shall have been distributed pursuant to Rule&nbsp;144 (or any successor
provision) under the Securities Act, (iii)&nbsp;such securities may be sold without volume restrictions pursuant to Rule&nbsp;144, as
determined by the counsel to Amicus pursuant to a written opinion letter to such effect, addressed and acceptable to Amicus&rsquo; transfer
agent, or (iv)&nbsp;such securities shall have been otherwise transferred in a private transaction in which the rights under <U>Section&nbsp;6</U>
hereof have not been assigned in connection with such transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Registration
Period</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.3(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Registration
Statement</I></B>&rdquo; means a registration statement filed pursuant to the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Restriction
Termination Date</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Rule&nbsp;144</I></B>&rdquo;
means Rule&nbsp;144 promulgated under the Securities Act, or any successor rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.30</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Sanctions</I></B>&rdquo;
has the meaning ascribed to such term in <U>Section&nbsp;4.20</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Sanctioned
Country</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;4.20</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC</I></B>&rdquo;
means the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC
Documents</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;4.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.34</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC
Guidance</I></B>&rdquo; means (a)&nbsp;any publicly-available written guidance, or rule&nbsp;of general applicability of the SEC staff,
or (b)&nbsp;written comments, requirements or requests of the SEC staff to Amicus in connection with the review of a Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.35</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC
Restrictions</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.36</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Securities</I></B>&rdquo;
means the Shares, the Warrants and the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the Securities Act of 1933, as amended, together with the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.38</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Share
Purchase Price</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 382; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Shares</I></B>&rdquo;
means the shares of Common Stock to be issued to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Trading
Day</I></B>&rdquo; means a day on which the Common Stock is traded on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Transaction
Documents</I></B>&rdquo; means this Agreement, the Warrant and any other documents or agreements executed in connection with the transactions
contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.42</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Transfer
Agent</I></B>&rdquo; means American Stock Transfer&nbsp;&amp; Trust Company, LLC, the company&rsquo;s transfer agent and registrar for
Common Stock, and any successor appointed in such capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.43</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Warrant
Purchase Price</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;2.2</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Warrants</I></B>&rdquo;
means collectively the Common Stock pre-funded purchase warrants delivered to certain Purchasers at the Closing in accordance with <U>Section&nbsp;3</U>
hereof, which Warrants shall be exercisable beginning on September&nbsp;29, 2021, in the form of <U>Exhibit&nbsp;A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.45</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Warrant
Shares</I></B>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Purchase
and Sale</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">On
terms and conditions as set forth herein, Amicus hereby issues and sells to the Purchasers, and the Purchasers hereby purchase from Amicus,
an aggregate of zero (0) Shares at the Per Share Price for an aggregate purchase price of $0.00 (the &ldquo;<B><I>Share Purchase Price</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">On
terms and conditions as set forth herein, Amicus hereby issues and sells to certain Purchasers and such Purchasers hereby purchase from
Amicus, an aggregate of 8,349,705 Warrants at a per Warrant Price of $10.17 for an aggregate warrant purchase price of $84,916,499.85
(the &ldquo;<B><I>Warrant Purchase Price</I></B>&rdquo; and together with the Share Purchase Price, the &ldquo;<B><I>Purchase Price</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Schedule
A</U> hereto sets forth the number of Purchased Securities to be purchased by each Purchaser and the portion of the Purchase Price to
be paid by such Purchaser for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Closing</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
The completion of the sale and purchase of the Purchased Securities (the &ldquo;<B><I>Closing</I></B>&rdquo;) shall occur upon the execution
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 383; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Deliveries</U>.
Subject to the terms and conditions hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser shall deliver to Amicus the Purchase Price attributable to the Purchased Securities purchased by such Purchaser by wire transfer
of immediately available funds to the following account:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 1in; vertical-align: top; width: 95%; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 5%; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 1in; vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank Address:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 1in; vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 1in; vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary Address:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 1in; vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABA:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 1in; vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt 0.25pt 0.25pt 1in; vertical-align: top; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SWIFT Code:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
receipt of a Purchaser&rsquo;s share of the Purchase Price, Amicus shall deliver to such Purchaser, as applicable, (i)&nbsp;the applicable
Shares to be registered in book entry form in the name of such Purchaser on Amicus&rsquo;s share register and (ii)&nbsp;a Warrant, registered
in the name of such Purchaser, to purchase up to a number of Warrant Shares, with an exercise price of $0.01, subject to adjustment therein.
Within one (1)&nbsp;business day of the date hereof, Amicus will provide each Purchaser with written confirmation of the registration
contemplated by <U>Section&nbsp;3(b)(i)</U>. Each of the Parties shall also deliver such other documents as are required to be delivered
by the Parties pursuant to the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Representations
and Warranties of Amicus</U></B>. Except as disclosed in Amicus&rsquo; disclosure schedules provided to the Purchasers along with this
Agreement, Amicus hereby represents and warrants to the Purchasers as of the SPA Effective Date (except as set forth below), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.
As of September&nbsp;27, 2021, the authorized capital stock of Amicus consisted of (a)&nbsp;500,000,000 shares of Common Stock, of which
(i)&nbsp;267,287,163 shares were issued and outstanding, and (ii)&nbsp;40,298,907 shares have been reserved for issuance under Amicus&rsquo;
Amended and Restated 2007 Equity Incentive Plan; and (b)&nbsp;10,000,000 shares of preferred stock, none of which is issued and outstanding.
All issued and outstanding shares of Amicus&rsquo; capital stock have been duly authorized and validly issued, and are fully paid and
nonassessable, and were issued in compliance with all applicable federal and state securities laws. As of the SPA Effective Date, there
are no preemptive or similar rights on the part of any holder of any class or securities of Amicus. As of the SPA Effective Date, except
as set forth in the SEC Documents or as described or referred to above, there are no securities convertible into or exchangeable for,
or options, warrants, calls, subscriptions, rights, contracts, commitments, or understandings of any kind to which Amicus is a party or
by which it is bound obligating Amicus to issue, deliver or sell, or cause to be issued, delivered or sold additional shares of its capital
stock or other voting securities of Amicus. As of the SPA Effective Date, there are no outstanding agreements of Amicus to repurchase,
redeem or otherwise acquire any shares of its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Litigation</U>.
There are no actions, suits, proceedings or, to its Knowledge, any investigations, pending or currently threatened against Amicus that
questions the validity of this Agreement or the issuance of the Common Stock contemplated hereby, nor to its Knowledge, is there any basis
therefor. As of the SPA Effective Date, there is no other material action, suit, or proceeding pending or, to the Knowledge of Amicus,
currently threatened against Amicus. As of the SPA Effective Date, there are no material outstanding consents, orders, decrees or judgments
of any governmental entity naming Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 384; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Organization
and Good Standing</U>. Amicus is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware
and has all requisite corporate power and authority to own, lease and operate its properties and carry on its business as now conducted.
Amicus is duly qualified and is in good standing as a foreign corporation in each jurisdiction in which the properties owned, leased or
operated, or the business conducted, by it requires such qualification except where the failure to be so qualified or in good standing,
individually or in the aggregate, would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization</U>.
All corporate actions on the part of Amicus, its officers, directors and stockholders necessary for the authorization, execution and delivery
of each of the Transaction Documents and for the issuance of the Purchased Securities have been taken. Amicus has the requisite corporate
power to enter into each of the Transaction Documents and to carry out and perform its obligations thereunder. Each of the Transaction
Documents have been duly authorized, executed and delivered by Amicus and, upon due execution and delivery by the Purchasers, each of
the Transaction Documents will be a valid and binding agreement of Amicus, except as enforceability may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally or by equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsidiaries.</U>
Except as set forth in the disclosure schedules to this Agreement, Amicus does not currently own or control, directly or indirectly, any
interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity.
Amicus is not a participant in any joint venture, partnership or similar arrangement other than as has been disclosed in SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflict With Other Instruments</U>. Neither the execution, delivery nor performance of any of the Transaction Documents, nor the consummation
by Amicus of the transactions contemplated hereby will result in any violation of, be in conflict with, cause any acceleration or any
increased payments under, or constitute a default under, with or without the passage of time or the giving of notice: (a)&nbsp;any provision
of Amicus&rsquo; certificate of incorporation or bylaws as in effect at the Closing; (b)&nbsp;any provision of any law, regulation, judgment,
decree or order to which Amicus is a party or by which it or any of its assets is bound, (c)&nbsp;any note, mortgage, contract, agreement,
license, waiver, exemption, order or permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
Documents</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
the two years preceding the SPA Effective Date, Amicus has filed, on a timely basis or has received a valid extension as of such time
of filing and has thereafter made such filings prior to the expiration of any such extensions, all reports, schedules, forms, statements
and other documents required to be filed by Amicus with the SEC under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or
15(d)&nbsp;thereof, (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
referred to herein as the &ldquo;<B><I>SEC Documents</I></B>&rdquo;) and with the U.S. Food and Drug Administration (&ldquo;<B><I>FDA</I></B>&rdquo;)
under its applicable regulations (&ldquo;<B><I>FDA Documents</I></B>&rdquo;), and Amicus has paid all fees and assessments due and payable
in connection with the SEC Documents and the FDA Documents. As of their respective dates, the SEC Documents and the FDA Documents complied
in all material respects with all statutes and applicable rules&nbsp;and regulations of the SEC or FDA, as applicable, including the requirements
of the Securities Act or the Exchange Act, as applicable, and none of the SEC Documents or FDA Documents, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 385; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
audited financial statements of Amicus included in Amicus&rsquo; SEC Documents comply in all material respects with the published rules&nbsp;and
regulations of the SEC with respect thereto, and such audited financial statements (i)&nbsp;were prepared from the books and records of
Amicus, (ii)&nbsp;were prepared in accordance with GAAP applied on a consistent basis (except as may be indicated therein or in the notes
or schedules thereto) and (iii)&nbsp;present fairly the financial position of Amicus as of the dates thereof and the results of operations
and cash flows for the periods then ended. The unaudited financial statements included in the SEC Documents comply in all material respects
with the published rules&nbsp;and regulations of the SEC with respect thereto, and such unaudited financial statements (i)&nbsp;were prepared
from the books and records of Amicus, (ii)&nbsp;were prepared in accordance with GAAP, except as otherwise permitted under the Exchange
Act and the rules&nbsp;and regulations thereunder, applied on a consistent basis (except as may be indicated therein or in the notes or
schedules thereto) and (iii)&nbsp;present fairly the financial position of Amicus as of the dates thereof and the results of operations
and cash flows (or changes in financial condition) for the periods then ended, subject to normal year-end adjustments and any other adjustments
described therein or in the notes or schedules thereto. The interactive data in eXtensible Business Reporting Language included in the
SEC Documents fairly presents the information called for in all material respects and has been prepared in all material respects in accordance
with the SEC&rsquo;s rules&nbsp;and guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Certain Events and Changes</U>. Since the date of Amicus&rsquo; Quarterly Report on Form&nbsp;10-Q for the quarter ended on June&nbsp;30,
2021: (a)&nbsp;Amicus has conducted its business in the ordinary course consistent with past practice, (b)&nbsp;there has not been any
event, change or development which, individually or in the aggregate, would have a Material Adverse Effect, taken as a whole, (c)&nbsp;Amicus
has not incurred any material liabilities (contingent or otherwise) other than expenses incurred in the ordinary course of business consistent
with past practice, (d)&nbsp;Amicus has not altered its method of accounting in any material respect, and (e)&nbsp;Amicus has not declared
or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase
or redeem any shares of its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>. Amicus owns, or has an exclusive right pursuant to a valid, written license agreement to use and exploit, all material intellectual
property used in or necessary for the conduct of the business of Amicus as conducted as of the Closing and the conduct of its business
will not conflict in any material respect with any such rights of others. No claims have been asserted by a third party in writing (a)&nbsp;alleging
that the conduct of the business of Amicus has infringed or misappropriated any intellectual property rights of such third party, or (b)&nbsp;challenging
or questioning the validity or effectiveness of any intellectual property right of Amicus, and, to the Knowledge of Amicus, there is no
valid basis for any such claim (a)&nbsp;or (b). To the Knowledge of Amicus, no third party is misappropriating or infringing any intellectual
property right of Amicus. No loss or expiration of any of Amicus&rsquo; material intellectual property is pending, or, to the Knowledge
of Amicus, threatened. Amicus has taken reasonable steps in accordance with standard industry practices to protect its rights in its Intellectual
Property and at all times has maintained the confidentiality of all information used in connection with the business that constitutes
or constituted a trade secret of Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 386; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Applicable Law.</U> Amicus has all material permits, licenses, franchises, authorizations, orders and approvals of, and has made
all filings, applications and registrations with, governmental entities that are required in order to permit Amicus to own or lease properties
and assets and to carry on its business as presently conducted that are material to Amicus. Amicus has complied and is in compliance in
all material respects with all statutes, laws, regulations, rules, judgments, orders and decrees of all governmental entities applicable
to it that relate to its business. Except as set forth in the disclosure schedules to this Agreement, Amicus has not received any notice
alleging noncompliance, and, to the Knowledge of Amicus, Amicus is not under investigation with respect to, or threatened to be charged,
with any material violation of any applicable statutes, laws, regulations, rules, judgments, orders or decrees of any governmental entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Valid
Issuance of Securities</U>. The Warrants have been duly authorized by the Company and when executed and delivered by the Company will
be valid and binding agreements of the Company, enforceable against the Company in accordance with their terms, except as the enforcement
thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights
and remedies of creditors or by general equitable principles; the Warrant Shares have been duly authorized and validly reserved for issuance
upon exercise of the Warrants; the Warrant Shares, when issued and delivered upon exercise of the Warrants in accordance therewith, will
be validly issued, fully paid and nonassessable and the issuance of the Warrant Shares is not subject to any preemptive rights, rights
of first refusal or other similar rights to subscribe for or purchase the Warrants. The Warrants and the Shares, based in part on the
representations of the Purchasers in <U>Section&nbsp;5</U> of this Agreement, will be issued in compliance with all applicable federal
and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governmental
Consents</U>. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with,
any federal, state or local governmental authority on the part of Amicus is required in connection with the consummation of the transactions
contemplated by the Transaction Documents, except for notices required or permitted to be filed with certain state and federal securities
commissions, which notices will be filed on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Brokers</U>. No broker, finder or investment banker is entitled to any brokerage, finder&rsquo;s or other fee or commission in connection
with the transactions contemplated by the Transaction Documents based on arrangements made by Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Undisclosed Liabilities</U>. Amicus does not have any liabilities (contingent or otherwise), except for (a)&nbsp;liabilities reflected
or reserved against in financial statements of Amicus included in the SEC Documents filed with the SEC prior to the date of each of the
Transaction Documents, and (b)&nbsp;liabilities that have not been and would not reasonably be expected to be material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Internal
Controls</U>. Amicus maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability, and (iii)&nbsp;access
to assets or incurrence of liabilities is permitted only in accordance with management&rsquo;s general or specific authorization. Since
the end of Amicus&rsquo;s most recent audited fiscal year, to its Knowledge, there have been no significant deficiencies or material weakness
detected in Amicus&rsquo;s internal control over financial reporting (whether or not remediated) and no change in Amicus&rsquo;s internal
control over financial reporting that has materially affected, or is reasonably likely to materially affect, Amicus&rsquo;s internal control
over financial reporting. Amicus is not aware of any change in its internal controls over financial reporting that has occurred during
its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Amicus&rsquo;s internal control
over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 387; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
Controls</U>. Amicus and its subsidiaries maintain an effective system of &ldquo;disclosure controls and procedures&rdquo; (as defined
in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) that complies in all material respects with the requirements of the Exchange Act and
that has been designed to ensure that information required to be disclosed by Amicus in reports that it files or submits under the Exchange
Act is recorded, processed, summarized and reported within the time periods specified in the SEC&rsquo;s rules&nbsp;and forms, including
controls and procedures designed to ensure that such information is accumulated and communicated to Amicus&rsquo;s management as appropriate
to allow timely decisions regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance</U>.
Amicus is not (i)&nbsp;in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse
of time or both, would result in a default by Amicus under), nor has Amicus received notice of a claim that it is in default under or
that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by
which it or any of its properties is bound (whether or not such default or violation has been waived), (ii)&nbsp;in violation of any judgment,
decree or order of any court, arbitrator or governmental body or (iii)&nbsp;in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to environmental protection,
occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or
reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Unlawful Payments</U>. Neither Amicus nor any of its subsidiaries nor, to the knowledge of Amicus, any director, officer, employee, agent,
affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken
an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic
government official or employee, including of any government-owned or controlled entity or of a public international organization, or
any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate
for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended,
or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or
anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful
benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit.
Amicus and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed
to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 388; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Anti-Money Laundering Laws</U>. The operations of Amicus and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts
business, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or
enforced by any governmental agency (collectively, the &ldquo;Anti-Money Laundering Laws&rdquo;) and no action, suit or proceeding by
or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with
respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflicts with Sanctions Laws</U>. Neither Amicus nor any of its subsidiaries nor, to the knowledge of Amicus, any director, officer,
employee, agent, affiliate or other person associated with or acting on behalf of Amicus or any of its subsidiaries is currently the subject
or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign
Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation
as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;), the United Nations Security Council the European Union,
Her Majesty&rsquo;s Treasury or other relevant sanctions authority (collectively, &ldquo;<B><I>Sanctions</I></B>&rdquo;), nor is the Company,
any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including,
without limitation, Crimea, Cuba,&nbsp;Iran, North Korea and Syria (each, a &ldquo;<B><I>Sanctioned Country</I></B>&rdquo;); and Amicus
will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business
with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate
any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person
(including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the
past five years, Amicus and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions
with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Company</U>. Amicus is not required to be registered as, and immediately following the Closing will not be required to register as, an
 &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Bad
Actor Disqualification</U>. None of Amicus, any predecessor or affiliated issuer of Amicus nor, to Amicus&rsquo;s Knowledge, any director
or executive officer of Amicus or any promoter connected with Amicus in any capacity, is subject to any of the &ldquo;bad actor&rdquo;
disqualifications within the meaning of Rule&nbsp;506(d)&nbsp;under the Securities Act, except for a disqualification event covered by
Rule&nbsp;506(d)(2)&nbsp;or (d)(3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 389; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Matters</U>. Assuming the accuracy of each Purchaser&rsquo;s representations and warranties set forth in <U>Section&nbsp;5</U>, no registration
under the Securities Act is required for the offer and sale of the Purchased Securities to the Purchasers hereunder. The Purchased Securities
(i)&nbsp;were not offered to the Purchasers by any form of general solicitation or general advertising and (ii)&nbsp;are not being offered
to the Purchasers in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state
securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Representations
And Warranties Of Purchasers</U></B>. Each Purchaser hereby represents and warrants to Amicus as of the SPA Effective Date as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Legal
Power</U>. Purchaser has the requisite corporate power to enter into each of the Transaction Documents, and to carry out and perform its
obligations under the terms of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Due
Execution</U>. Each of the Transaction Documents have been duly authorized, executed and delivered by Purchaser, and, upon due execution
and delivery by Amicus, each of the Transaction Documents will be a valid and binding agreement of Purchaser, except as enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally or by
equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Representations</U>. In connection with the offer, purchase and sale of the Purchased Securities Purchaser makes the following representations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Purchaser
is acquiring the Purchased Securities for its own account, not as nominee or agent, for investment and not with a view to, or for resale
in connection with, any distribution or public offering thereof within the meaning of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Purchaser
understands that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Purchased Securities have not been registered under the Securities Act by reason of a specific exemption therefrom, that such securities
may be required to be held by it indefinitely under applicable securities laws, and that each Purchaser must, therefore, bear the economic
risk of such investment indefinitely, unless a subsequent disposition thereof is registered under the Securities Act or is exempt from
such registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Warrant and each book entry position representing Shares and Warrant Shares (unless a Registration Statement has become effective prior
to the issuance of the Warrant Shares) will be endorsed with the following legend:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">THE SECURITIES REPRESENTED HEREBY HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES.
THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY&nbsp;NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED
UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM OR UNLESS THE COMPANY HAS RECEIVED
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 390; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amicus
will instruct its transfer agent not to register the transfer of the Shares, Warrant Shares, or any portion thereof, unless the conditions
specified in the foregoing legend are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of
the investment in the Securities to be purchased hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser acknowledges and agrees that the Purchaser is purchasing the Purchased Securities from Amicus. Each Purchaser further acknowledges
that there have been no representations, warranties, covenants and agreements made to the Purchaser by or on behalf of Amicus or any of
its respective affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing
or any other person or entity, expressly or by implication, other than those representations, warranties, covenants and agreements of
Amicus expressly set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser is an &ldquo;accredited investor&rdquo; as such term is defined in Rule&nbsp;501(a)&nbsp;of the rules&nbsp;and regulations promulgated
under the Securities Act. Each Purchaser acknowledges that it is aware that there are substantial risks incident to the purchase and ownership
of the Securities, including, without limitation, those set forth in the SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser became aware of this offering of the Securities solely by means of direct contact between the Purchaser and Amicus or a representative
of Amicus, and the Securities were offered to the Purchaser solely by direct contact between the Purchaser and the Amicus or a representative
of Amicus. The Purchaser did not become aware of this offering of the Securities, nor were the Securities offered to the Purchaser, by
any other means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Registration
Rights</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Registration</U>.
As soon as reasonably practicable, but no event later than 50 days after the Closing, Amicus shall prepare and file with the SEC a Registration
Statement covering the resale of all, or such portion as permitted by SEC Guidance (provided that, Amicus shall use commercially reasonable
efforts to advocate with the SEC for the registration of the maximum number of the Registrable Securities permitted by SEC Guidance),
of the Registrable Securities and use commercially reasonable efforts to cause a Registration Statement to be declared effective (including,
without limitation, the execution of any required undertaking to file post-effective amendments) as promptly as possible after the filing
thereof, but in no event later than ten (10)&nbsp;business days after the SEC has notified that Amicus that it will not review, or has
completed its review, of the Registration Statement. The Registration Statement shall be on Form&nbsp;S-3 (except if Amicus fails to meet
one or more of the registrant requirements specified in General Instruction I.A. on Form&nbsp;S-3, such registration shall be on another
appropriate form in accordance herewith). In the event that, despite Amicus&rsquo;s commercially reasonable efforts and compliance with
the terms of this <U>Section&nbsp;6.1</U>, the SEC refuses to alter its position, the Company shall (i)&nbsp;remove from the Registration
Statement such portion of the Registrable Securities (the &ldquo;<B><I>Cut Back Shares</I></B>&rdquo;) and/or (ii)&nbsp;agree to such
restrictions and limitations on the registration and resale of the Registrable Securities as the staff of the SEC may require to assure
Amicus&rsquo;s compliance with the requirements of Rule&nbsp;415 (collectively, the &ldquo;<B><I>SEC Restrictions</I></B>&rdquo;); provided,
however, that Amicus shall not agree to name any Purchaser as an &ldquo;underwriter&rdquo; in such Registration Statement without the
prior written consent of such Purchaser. Any cutback imposed on the Purchasers pursuant to this <U>Section&nbsp;6.1</U> shall be allocated
among the Purchasers on a pro rata basis, unless the SEC Restrictions otherwise require or provide or the Purchasers holding a majority
of the Registrable Shares otherwise agree. From and after the such date as the Company is able to effect the registration of such Cut
Back Shares in accordance with any SEC Restrictions (such date, the &ldquo;<B><I>Restriction Termination Date</I></B>&rdquo; of such Cut
Back Shares) applicable to any Cut Back Shares, all of the provisions of this <U>Section&nbsp;6</U> shall again be applicable to such
Cut Back Shares; provided, however, that (x)&nbsp;the Filing Deadline for the Registration Statement including such Cut Back Shares shall
be 10 business days after such Restriction Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 391; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Expenses
Of Registration</U>. Amicus shall pay all fees and expenses incurred in connection with any registration, qualification, exemption or
compliance by Amicus in the performance of its obligations pursuant to this <U>Section&nbsp;6</U>, whether or not any Registrable Securities
are sold pursuant to a Registration Statement, and including all registration and filing fees, exchange listing fees, and the fees and
expenses of counsel and accountants for Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Obligations
Of Amicus</U>. In the case of registration, qualification, exemption or compliance effected by Amicus pursuant to the Transaction Documents,
Amicus will, upon request of any Purchaser, inform such Purchaser as to the status of such registration, qualification, exemption and
compliance. Amicus shall, at its expense and in addition to its obligations under <U>Section&nbsp;6.1</U>, as expeditiously as reasonably
possible:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to keep such registration, and any required qualification, exemption or compliance under state securities
laws, continuously effective with respect to the Purchasers and its permitted assignees, until the date all Shares and Warrant Shares
registered by such Registration Statement shall have been sold or may be sold pursuant to Rule&nbsp;144 without regard to volume limitations.
The period of time during which Amicus is required hereunder to keep the Registration Statement effective is referred to herein as the
 &ldquo;<B><I>Registration Period</I></B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">advise
Purchasers promptly (and, in any event, within five business days):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">when
the Registration Statement or any amendment thereto has been filed with the SEC and when the Registration Statement or any post-effective
amendment thereto has become effective;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">of
the receipt by Amicus of any notification from the SEC of any stop order suspending the effectiveness of the Registration Statement or
the initiation of any proceedings for such purpose;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 392; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">of
the receipt by Amicus of any notification with respect to the suspension of the qualification of the Registrable Securities included therein
for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">of
the occurrence of any event that requires the making of any changes in the Registration Statement or the prospectus so that, as of such
date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to
make the statements therein (in the case of the prospectus, in the light of the circumstances under which they were made) not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement as
soon as reasonably practicable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
any Purchaser so requests in writing, promptly furnish to such Purchaser, without charge, at least one copy of such Registration Statement
and any post-effective amendment thereto, including financial statements and schedules, and, if explicitly requested, all exhibits in
the form filed with the SEC;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">during
the Registration Period, promptly deliver to each Purchaser, without charge, at least one copy of the prospectus included in such Registration
Statement and any amendment or supplement thereto and as many additional copies as each Purchaser may reasonably request; and Amicus consents
to the use, consistent with the provisions hereof, of the prospectus or any amendment or supplement thereto by each Purchaser in connection
with the offering and sale of the Registrable Securities covered by the prospectus or any amendment or supplement thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">during
the Registration Period, if a Purchaser so requests in writing, deliver to such Purchaser, without charge, (i)&nbsp;one copy of the following
documents, other than those documents available via EDGAR (and excluding, in each case, exhibits thereto): (A)&nbsp;its annual report
to its stockholders, if any (which annual report will contain financial statements audited in accordance with GAAP by a firm of certified
public accountants of recognized standing), (B)&nbsp;if not included in substance in its annual report to stockholders, its annual report
on Form&nbsp;10-K (or similar form), (C)&nbsp;its definitive proxy statement with respect to its annual meeting of stockholders, (D)&nbsp;each
of its quarterly reports to its stockholders, and, if not included in substance in its quarterly reports to stockholders, its quarterly
report on Form&nbsp;10-Q (or similar form), and (E)&nbsp;a copy of the Registration Statement; and (ii)&nbsp;if explicitly requested,
any exhibits filed with respect to the foregoing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">upon
the occurrence of any event contemplated by <U>Section&nbsp;6.3(b)(iv)</U>, Amicus will use its commercially reasonable efforts to as
soon as reasonably practicable prepare a post-effective amendment to the Registration Statement or a supplement to the related prospectus,
or file any other required document so that, as thereafter delivered to the Purchasers, the prospectus will not include any untrue statement
of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 393; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">comply
in all material respects with all applicable rules&nbsp;and regulations of the SEC which could affect the sale of the Registrable Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to cause all Registrable Securities to be listed on each securities exchange or market, if any, on
which equity securities issued by Amicus have been listed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to take all other steps necessary to effect the registration of the Registrable Securities contemplated
hereby and to enable the Purchasers to sell Registrable Securities under Rule&nbsp;144; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">permit
counsel for the Purchasers to review the Registration Statement and all amendments and supplements thereto, within two business days prior
to the filing thereof with the SEC;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>provided</I></FONT>
that, in the case of clause (k)&nbsp;above, Amicus will not be required to delay the filing of the Registration Statement or any amendment
or supplement thereto to incorporate any comments to the Registration Statement or any amendment or supplement thereto by or on behalf
of any Purchaser if such comments would require a delay in the filing of such Registration Statement, amendment or supplement, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Furnishing
Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">It shall be a condition precedent
to the obligations of Amicus to take any action pursuant to <U>Section&nbsp;6.1</U> that each of the selling Holders shall furnish to
Amicus such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities
as shall be legally required under the Securities Act or otherwise required by the SEC to effect the registration of their Registrable
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Indemnification;
Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amicus
shall indemnify and hold harmless each Holder (including the employees, agents, representatives, officers and directors of each Purchaser
and its Affiliates) (each a &ldquo;<B><I>Purchaser Indemnitee</I></B>&rdquo;) from and against any and all losses, claims, damages, liabilities
and expenses (including reasonable costs of investigation) arising out of or based upon any untrue, or allegedly untrue, statement of
a material fact contained in any Registration Statement, prospectus or preliminary prospectus or notification or offering circular prepared
by Amicus in connection with the registration and/or offering of the Registrable Securities (as amended or supplemented if Amicus shall
have furnished any amendments or supplements thereto) or arising out of or based upon any omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as the same are
caused by or contained in any information concerning such Holder furnished in writing to Amicus by such Holder specifically and expressly
for inclusion in such document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Holder shall indemnify and hold harmless Amicus, and its respective directors, officers, employees and each Person who controls Amicus
(within the meaning of the Securities Act and the Exchange Act) from and against any and all losses, claims, damages, liabilities and
expenses (including reasonable costs of investigation) arising out of or based upon any untrue, or allegedly untrue, statement of a material
fact contained in any Registration Statement, prospectus or preliminary prospectus or notification or offering circular prepared by Amicus
in connection with the registration and/or offering of the Registrable Securities (as amended or supplemented if Amicus shall have furnished
any amendments or supplements thereto) or arising out of or based upon any omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, if such statement or omission was made in reliance
upon and in conformity with any information concerning such Holder furnished in writing to Amicus by such Holder specifically and expressly
for use in the preparation of such document; <I>provided, however,</I> that in no event shall any indemnity under this <U>Section&nbsp;6.5(b)</U>&nbsp;be
greater in amount than the aggregate dollar amount of the proceeds received by all of the Purchasers upon the sale of such Registrable
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 394; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Person entitled to indemnification hereunder (the &ldquo;<B><I>Indemnified Party</I></B>&rdquo;) agrees to give prompt written notice
to the indemnifying party (the &ldquo;<B><I>Indemnifying Party</I></B>&rdquo;) after the receipt by the Indemnified Party of any written
notice of the commencement of any action, suit, proceeding or investigation or threat thereof made in writing for which the Indemnified
Party intends to claim indemnification or contribution pursuant to the Transaction Documents; <I>provided, however</I>, that the failure
to so notify the Indemnifying Party shall not relieve the Indemnifying Party of any liability that it may have to the Indemnified Party
hereunder unless, and only to the extent that, such failure results in the Indemnifying Party&rsquo;s forfeiture of substantive rights
or defenses. If notice of commencement of any such action is given to the Indemnifying Party as above provided, the Indemnifying Party
shall be entitled to participate in and, to the extent it may wish, jointly with any other Indemnifying Party similarly notified, to assume
the defense of such action at its own expense, with counsel chosen by it and reasonably satisfactory to such Indemnified Party. The Indemnified
Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses
of such counsel (other than reasonable costs of investigation) shall be paid by the Indemnified Party unless (i)&nbsp;the Indemnifying
Party agrees to pay the same, (ii)&nbsp;the Indemnifying Party fails to assume the defense of such action with counsel reasonably satisfactory
to the Indemnified Party in its reasonable judgment or (iii)&nbsp;the named parties to any such action (including any impleaded parties)
have been advised by such counsel that either (x)&nbsp;representation of such Indemnified Party and the Indemnifying Party by the same
counsel would be inappropriate under applicable standards of professional conduct or (y)&nbsp;there may be one or more legal defenses
available to it which are different from or additional to those available to the Indemnifying Party. In either of such cases, the Indemnifying
Party shall not have the right to assume the defense of such action on behalf of such Indemnified Party. No Indemnifying Party shall be
liable for any settlement entered into without its written consent (other than in the case where the Indemnifying Party is unconditionally
released from liability and its rights are not adversely effected), which consent shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the indemnification provided for in this <U>Section&nbsp;6.5</U> from the Indemnifying Party pursuant to applicable law is unavailable
to an Indemnified Party hereunder in respect of any losses, claims, damages, liabilities or expenses referred to therein, then the Indemnifying
Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result
of such losses, claims, damages, liabilities or expenses in such proportion as is appropriate to reflect the relative fault of the Indemnifying
Party and Indemnified Party in connection with the actions which resulted in such losses, claims, damages, liabilities or expenses, as
well as any other relevant equitable considerations. The relative faults of such Indemnifying Party and Indemnified Party shall be determined
by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact
or omission or alleged omission to state a material fact, has been made by, or relates to information supplied by, such Indemnifying Party
or Indemnified Party, and the parties&rsquo; relative intent, Knowledge, access to information and opportunity to correct or prevent such
action. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall
be deemed to include, subject to the limitations set forth in <U>Sections 6.5(a)</U>, <U>(b)</U>&nbsp;and <U>(c)</U>, any legal or other
fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree
that it would not be just and equitable if contribution pursuant to this <U>Section&nbsp;6.5(d)</U>&nbsp;were determined by pro rata allocation
or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding
paragraph. No Person guilty of an intentional or fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities
Act) shall be entitled to contribution from any Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 395; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rule&nbsp;144
Reporting</U>. In order to make the benefits of the rules&nbsp;and regulations of the SEC that may permit the sale of the Registrable
Securities to the public without registration available to the Holders, Amicus agrees to use commercially reasonable efforts to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">make
and keep public information available, as those terms are understood and defined in Rule&nbsp;144(c)(1)&nbsp;or any similar or analogous
rule&nbsp;promulgated under the Securities Act, at all times after the SPA Effective Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">file
with the SEC, in a timely manner, all reports and other documents required of Amicus under the Exchange Act; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">so
long as any Holder owns any Registrable Securities, furnish such Holders forthwith upon request: (i)&nbsp;a written statement by Amicus
as to its compliance with the reporting requirements of Rule&nbsp;144 under the Securities Act, and of the Exchange Act; (ii)&nbsp;a copy
of the most recent annual or quarterly report of Amicus; and (iii)&nbsp;such other reports and documents as a Holder may reasonably request
in availing itself of any rule&nbsp;of regulation of the SEC allowing it to sell any such securities without registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Assignment
of Registration Rights</U>. The rights and obligations under this <U>Section&nbsp;6</U> may only be assigned by a Holder to a transferee
or assignee of Registrable Securities that is (a)&nbsp;an Affiliate or (b)&nbsp;a successor (by operation of law or otherwise) to substantially
all the business or assets of such Holder; <I>provided, however</I>, that such attempted assignment shall be void unless (i)&nbsp;such
Holder, within 30 days after such transfer, furnishes to Amicus written notice of the name and address of such transferee or assignee
and the securities with respect to which such registration rights are being assigned, and (ii)&nbsp;such transferee agrees to be subject
to all obligations and restrictions with respect to the Registrable Securities set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Stock
Ownership Governance</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Lock-Up
Period</U>. Excluding any transfers or intra-company disposal of the Shares, Warrants and Warrant Shares between a Purchaser and any of
its Affiliates, for a period of nine (9)&nbsp;months following the SPA Effective Date (the &ldquo;<B><I>Lock-Up Period</I></B>&rdquo;),
each Purchaser shall not, and shall cause any other Holder not to, without the prior written consent of Amicus, sell, contract to sell,
pledge or otherwise dispose of, directly or indirectly, any Shares, Warrants or Warrant Shares or enter into a transaction which would
have the same effect; provided, however, that the foregoing shall not prohibit a Purchaser from (i)&nbsp;distributions of Shares, Warrants
or Warrant Shares to general or limited partners, members, shareholders, Affiliates or wholly-owned subsidiaries of such Purchaser or
any investment fund or other entity controlled or managed by such Purchaser; provided, in each case, that following any such transfer
such Shares, Warrants or Warrant Shares will remain subject to the provisions of this <U>Section&nbsp;7.1</U>; or (ii)&nbsp;disposing
of any Shares, Warrants or Warrant Shares pursuant to a bona fide third party tender offer, merger, consolidation or other similar transaction.
Any discretionary waiver or termination of the restrictions of any or all of this <U>Section&nbsp;7.1</U> by Amicus shall apply pro rata
to all Purchasers, based on the number of Purchased Securities. For the avoidance of doubt, this <U>Section&nbsp;7.1</U> shall only apply
to Shares, Warrants and Warrant Shares purchased pursuant to this Agreement and shall not impose any restrictions on any other securities
of Amicus owned by the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 396; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
Without prejudice to the rights and remedies otherwise available to the parties, Amicus shall be entitled to equitable relief by way of
injunction if any Purchaser or any other Holder breaches or threatens to breach any of the provisions of this <U>Section&nbsp;7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Covenants</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Covenant
of Amicus</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amicus
hereby covenants and agrees that it shall take all necessary and appropriate actions to ensure that it shall have available under its
certificate of incorporation as in effect at the Closing sufficient authorized but unissued shares of its Common Stock to issue and sell
to Purchasers all of the Shares. As of the date hereof, Amicus has reserved and Amicus shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling Amicus to issue the Warrant
Shares pursuant to any exercise of the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
the date hereof until such time as the Purchased Securities have been sold pursuant to Rule&nbsp;144 or are eligible for resale under
Rule&nbsp;144(b)(1)&nbsp;or any successor provision, Amicus will use commercially reasonable efforts to continue the listing and trading
of its Common Stock on Nasdaq and, in accordance, therewith, will use commercially reasonable efforts to comply in all respects with Amicus&rsquo;s
reporting, filing and other obligations under the bylaws or rules&nbsp;of such market or exchange, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amicus
shall not, and shall use its commercially reasonable efforts to ensure that no controlled Affiliate of Amicus shall, sell, offer for sale
or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that will
be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the
sale of the Purchased Securities to the Investors. Amicus shall not take any action or steps that would adversely affect reliance by Amicus
in any material respect on Section&nbsp;4(a)(2)&nbsp;for the exemption from registration for the transactions contemplated hereby or require
registration of the Securities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 397; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Removal
of Legends</U>. In connection with any sale or disposition of the Warrants or Shares by a Purchaser pursuant to Rule&nbsp;144 or pursuant
to any other exemption under the Securities Act such that the Purchaser acquires freely tradable shares and upon compliance by the Purchaser
with the requirements of this Agreement, if requested in writing by the Purchaser, Amicus shall use its commercially reasonable efforts
to request that the transfer agent for the Common Stock (the &ldquo;<B><I>Transfer Agent</I></B>&rdquo;) remove any restrictive legends
related to the book entry account holding such Warrants or Shares and make a new, unlegended entry for such book entry Warrants or Shares
sold or disposed of without restrictive legends within two (2)&nbsp;Trading Days of receipt of such request from the Purchaser. Upon the
earliest of such time as the Warrants or Shares (i)&nbsp;have been registered for resale pursuant to an effective registration statement,
(ii)&nbsp;have been sold pursuant to Rule&nbsp;144 or (iii)&nbsp;are eligible for resale under Rule&nbsp;144(b)(1)&nbsp;or any successor
provision, Amicus shall (A)&nbsp;deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended
entry for such book entry Warrants or Shares, and (B)&nbsp;cause its counsel to deliver to the Transfer Agent one or more opinions to
the effect that the removal of such legends in such circumstances may be effected under the Securities Act. Amicus shall be responsible
for the fees of its Transfer Agent and all DTC fees associated with such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Miscellaneous</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts
of law thereof. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
Party at the address in effect for notices to it under the Transaction Documents and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by the Parties and delivered to the other Parties, it being understood that
the Parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page&nbsp;were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Public
Statements</U>. Amicus shall no later than the close of business on the date immediately following the date hereof, either issue a press
release or file a Current Report on Form&nbsp;8-K disclosing the material terms of the transactions contemplated hereby and any other
material, nonpublic information that Amicus may have provided to any Purchaser at any time prior thereto promptly following the execution
and delivery hereof, which shall have been previously reviewed by counsel for the Purchasers (the &ldquo;<B><I>Press Release</I></B>&rdquo;).
Amicus shall not include the name of any Purchaser in the Press Release or any other public announcement without the prior written consent
of such Purchaser. Subject to the foregoing, any statement to the public regarding this the Transaction Documents shall be approved in
advance by Amicus and the Purchasers, except as otherwise required by law, rule, regulation, legal process or applicable SEC Guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 398; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the Parties and their successors and permitted assigns.
Amicus may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Purchasers purchasing
at least 85% of the Securities issuable hereunder. Subject to <U>Section&nbsp;6.7</U>, any Purchaser may assign any or all of its rights
under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided such transferee agrees in writing
to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules hereto, contain the entire understanding of the Parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters (other than confidentiality agreements to which Amicus is a party to with the Purchasers), which the Parties acknowledge
have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Separability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the Parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the Parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of
the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
Amicus does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw,
in its sole discretion from time to time upon written notice to Amicus, any relevant notice, demand or election in whole or in part without
prejudice to its future actions and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, Amicus shall issue
or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to Amicus of such loss, theft or
destruction. The applicant for a new certificate or instrument under such circumstances may also be required to pay a customary bond and
any reasonable third-party costs associated with the issuance of such replacement Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and Amicus will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be
adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agrees
to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 399; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto, shall be deemed to constitute the Purchasers as a partnership, an association, a
joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights, including without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in their review and negotiation of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendment
and Waiver</U>. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment,
by Amicus and Purchasers purchasing at least 85% of the Securities issuable hereunder or, in the case of a waiver, by the Party against
whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement
of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a)&nbsp;the date of transmission, if such notice or communication is delivered via email
at the email address set forth on the signature pages&nbsp;attached hereto prior to 5:30 p.m.&nbsp;(New York City time) on a Trading Day,
(b)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via email at the email address
set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time)
on any Trading Day, (c)&nbsp;the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier
service, or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages&nbsp;attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each Party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. Amicus shall pay all transfer agent fees, stamp taxes and other taxes
and duties levied in connection with the delivery of any Securities to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 400; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Titles
and Subtitles</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Counterparts;
Effectiveness</U>. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of
which together shall constitute one instrument. This Agreement shall become effective when each Party hereto shall have received counterparts
thereof signed and delivered (by telecopy or other electronic means) by the other Parties hereto. Counterparts may be delivered via facsimile,
electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act,
the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Construction</U>.
The Parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the Parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
<U>Section&nbsp;6.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 401; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Securities Purchase Agreement is hereby executed
as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMICUS:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amicus Therapeutics,&nbsp;Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Daphne Quimi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 4%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-top: 0.5pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daphne Quimi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3675 Market Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19104</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>gcoffice@amicusrx.com</U></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 402 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Redmile Capital Offshore Fund (ERISA),&nbsp;Ltd.<BR>
</B>By: Redmile Group, LLC, its investment manager</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Joshua Garcia</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 4%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-top: 0.5pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Joshua Garcia</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Redmile Group, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Letterman Drive, Suite&nbsp;D3-300</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Francisco, CA 94129</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 403 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Redmile Capital Fund, LP</B><BR>
By: Redmile Group, LLC, its investment manager</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Joshua Garcia</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 4%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-top: 0.5pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua Garcia</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Redmile Group, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One Letterman Drive, Suite&nbsp;D3-300</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Francisco, CA 94129</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 404 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RedCo II Master Fund, L.P.<BR>
</B>By: RedCo II (GP), LLC, its general partner</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Joshua Garcia</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 4%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-top: 0.5pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joshua
Garcia</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; width: 43%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o Redmile Group, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One Letterman Drive, Suite&nbsp;D3-300</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Francisco, CA 94129</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 405 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Schedule A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Purchaser Share and Warrant Amounts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Purchaser</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares <BR>
Purchased</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Warrants<BR>
 Purchased</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Purchase Price<BR>
 (in $)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Redmile Capital Offshore Fund (ERISA),&nbsp;Ltd.</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,220,100</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">12,408,417.00</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Redmile Capital Fund, LP</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">506,300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,149,071.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">RedCo II Master Fund, L.P.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6,623,305</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">67,359,011.85</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 406 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;OF PRE-FUNDED WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 407 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.4</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS SECURITIES PURCHASE AGREEMENT
(this &ldquo;<B><I>Agreement</I></B>&rdquo;) is made effective as of 12:01 a.m.&nbsp;on September&nbsp;29, 2021 (the &ldquo;<B><I>SPA
Effective Date</I></B>&rdquo;), by and among Amicus Therapeutics,&nbsp;Inc., a Delaware corporation with its principal place of business
at 3675 Market Street, Philadelphia, PA 19104 (&ldquo;<B><I>Amicus</I></B>&rdquo;), and each Purchaser identified on the signature pages&nbsp;hereto
(each, including its successors and assigns, a &ldquo;<B><I>Purchaser</I></B>&rdquo; and collectively the &ldquo;<B><I>Purchasers</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">BACKGROUND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amicus desires to sell to
each Purchaser and each Purchaser desires to purchase from Amicus such number of Shares (as defined below) set forth opposite such Purchaser&rsquo;s
name on <U>Schedule A</U> attached hereto, at a price of $10.18 per Share (the &ldquo;<B><I>Per Share Price</I></B>&rdquo;) and on the
terms and subject to the conditions set forth in this Agreement (the &ldquo;<B><I>Offering</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">TERMS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing recitals and the mutual covenants and agreements contained herein, the Parties hereto, intending to be legally bound,
do hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Definitions</U></B>.
The capitalized terms used herein shall have the meanings ascribed to them below or at such other place in this Agreement as is indicated
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Affiliate</I></B>&rdquo;
means, with respect to any specified Person, at any time, a Person that, directly or indirectly, through one or more intermediaries, controls,
or is controlled by, or is under common control with, such specified Person at such time. For purposes of this definition, &ldquo;control,&rdquo;
when used with respect to any specified Person, shall mean (a)&nbsp;the direct or indirect ownership of more than 50% (or such lesser
percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the total voting power of
securities or other evidences of ownership interest in such Person or (b)&nbsp;the power to direct or cause the direction of the management
and policies of such Person, directly or indirectly, whether through ownership of voting securities, by contract or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Closing</I></B>&rdquo;
has the meaning ascribed to such term in <U>Section&nbsp;3.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Common
Stock</I></B>&rdquo; means the common stock of Amicus, par value $0.01 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed into.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Cut
Back Shares</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended, together with the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>FDA</I></B>&rdquo;
has the meaning ascribed to such term in <U>Section&nbsp;4.7</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 408 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>FDA
Documents</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;4.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>GAAP</I></B>&rdquo;
means generally accepted accounting principles in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Holder</I></B>&rdquo;
means each Person owning of record Registrable Securities that have not been sold to the public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Indemnified
Party</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.5(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Indemnifying
Party</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.5(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Knowledge</I></B>&rdquo;
means the knowledge of such Person, assuming that such Person engaged in reasonable inquiry or investigation with respect to the relative
subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Lock-Up
Period</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;7.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Material
Adverse Effect</I></B>&rdquo; on or with respect to an entity (or group of entities taken as a whole) means any state of facts, event,
change or effect that has had, or that would reasonably expected to have, (i)&nbsp;a material adverse effect on the business, properties,
prospects, results of operations or financial condition of such entity (or of such group of entities taken as a whole) or (ii)&nbsp;a
material adverse effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Nasdaq</I></B>&rdquo;
means the Nasdaq Stock Market,&nbsp;Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Offering</I></B>&rdquo;
has the meaning ascribed to such term in the Background.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Party</I></B>&rdquo;
means a party to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Per
Share Price</I></B>&rdquo; has the meaning ascribed to such term in the Background.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Person</I></B>&rdquo;
means any individual, firm, corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint
venture, joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind, and shall include
any successor (by merger or otherwise) of such entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Press
Release</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;9.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Purchase
Price</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Purchaser
Indemnitee</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Register</I></B>,&rdquo;
 &ldquo;<B><I>Registered</I></B>,&rdquo; and &ldquo;<B><I>Registration</I></B>&rdquo; refer to a registration effected by preparing and
filing a Registration Statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such Registration
Statement or document by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 409; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Registrable
Securities</I></B>&rdquo; means (a)&nbsp;the Shares and (b)&nbsp;any shares of Common Stock or other securities issued as (or issuable
upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect
to, or in exchange for or in replacement of, the Shares by way of stock dividend, stock split or in connection with a combination of
shares, recapitalization or other reorganization or otherwise. Notwithstanding the foregoing, as to any particular Shares or other securities
described above, once issued they shall cease to be Registrable Securities when (i)&nbsp;a registration statement with respect to the
sale of such securities shall have become effective under the Securities Act and such securities shall have been disposed of in accordance
with such registration statement, (ii)&nbsp;they shall have been distributed pursuant to Rule&nbsp;144 (or any successor provision) under
the Securities Act, (iii)&nbsp;such securities may be sold without volume restrictions pursuant to Rule&nbsp;144, as determined by the
counsel to Amicus pursuant to a written opinion letter to such effect, addressed and acceptable to Amicus&rsquo; transfer agent, or (iv)&nbsp;such
securities shall have been otherwise transferred in a private transaction in which the rights under <U>Section&nbsp;6</U> hereof have
not been assigned in connection with such transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Registration
Period</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.3(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Registration
Statement</I></B>&rdquo; means a registration statement filed pursuant to the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Restriction
Termination Date</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Rule&nbsp;144</I></B>&rdquo;
means Rule&nbsp;144 promulgated under the Securities Act, or any successor rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Sanctions</I></B>&rdquo;
has the meaning ascribed to such term in <U>Section&nbsp;4.20</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.30</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Sanctioned
Country</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;4.20</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC</I></B>&rdquo;
means the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC
Documents</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;4.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC
Guidance</I></B>&rdquo; means (a)&nbsp;any publicly-available written guidance, or rule&nbsp;of general applicability of the SEC staff,
or (b)&nbsp;written comments, requirements or requests of the SEC staff to Amicus in connection with the review of a Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.34</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC
Restrictions</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.35</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the Securities Act of 1933, as amended, together with the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.36</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Purchase
Price</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Shares</I></B>&rdquo;
means the shares of Common Stock to be issued to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.38</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Trading
Day</I></B>&rdquo; means a day on which the Common Stock is traded on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 410; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Transaction
Documents</I></B>&rdquo; means this Agreement and any other documents or agreements executed in connection with the transactions contemplated
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Transfer
Agent</I></B>&rdquo; means American Stock Transfer&nbsp;&amp; Trust Company, LLC, the company&rsquo;s transfer agent and registrar for
Common Stock, and any successor appointed in such capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Purchase
and Sale</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">On
terms and conditions as set forth herein, Amicus hereby issues and sells to the Purchasers, and the Purchasers hereby purchase from Amicus,
an aggregate of 3,438,114 Shares at the Per Share Price for an aggregate purchase price of $35,000,000.52 (the &ldquo;<B><I>Purchase Price</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Schedule
A</U> hereto sets forth the number of Shares to be purchased by each Purchaser and the portion of the Purchase Price to be paid by such
Purchaser for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Closing</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
The completion of the sale and purchase of the Shares (the &ldquo;<B><I>Closing</I></B>&rdquo;) shall occur upon the execution of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Deliveries</U>.
Subject to the terms and conditions hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Purchaser shall deliver to Amicus the Purchase Price attributable to the Shares purchased by such Purchaser by wire transfer of immediately
available funds to the following account:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-indent: 1in; vertical-align: top; width: 100%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-indent: 1in; vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank Address:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-indent: 1in; vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-indent: 1in; vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary Address:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-indent: 1in; vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABA:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-indent: 1in; vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="text-indent: 1in; vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SWIFT Code:</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Upon
receipt of a Purchaser&rsquo;s share of the Purchase Price, Amicus shall deliver to such Purchaser the applicable Shares to be registered
in book entry form in the name of such Purchaser on Amicus&rsquo;s share register. Within one (1)&nbsp;business day of the date hereof,
Amicus will provide each Purchaser with written confirmation of the registration contemplated by <U>Section&nbsp;3(b)(i)</U>. Each of
the Parties shall also deliver such other documents as are required to be delivered by the Parties pursuant to the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 411; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Representations
and Warranties of Amicus</U></B>. Except as disclosed in Amicus&rsquo; disclosure schedules provided to the Purchasers along with this
Agreement, Amicus hereby represents and warrants to the Purchasers as of the SPA Effective Date (except as set forth below), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.
As of September&nbsp;27, 2021, the authorized capital stock of Amicus consisted of (a)&nbsp;500,000,000 shares of Common Stock, of which
(i)&nbsp;267,287,163 shares were issued and outstanding, and (ii)&nbsp;40,298,907 shares have been reserved for issuance under Amicus&rsquo;
Amended and Restated 2007 Equity Incentive Plan; and (b)&nbsp;10,000,000 shares of preferred stock, none of which is issued and outstanding.
All issued and outstanding shares of Amicus&rsquo; capital stock have been duly authorized and validly issued, and are fully paid and
nonassessable, and were issued in compliance with all applicable federal and state securities laws. As of the SPA Effective Date, there
are no preemptive or similar rights on the part of any holder of any class or securities of Amicus. As of the SPA Effective Date, except
as set forth in the SEC Documents or as described or referred to above, there are no securities convertible into or exchangeable for,
or options, warrants, calls, subscriptions, rights, contracts, commitments, or understandings of any kind to which Amicus is a party
or by which it is bound obligating Amicus to issue, deliver or sell, or cause to be issued, delivered or sold additional shares of its
capital stock or other voting securities of Amicus. As of the SPA Effective Date, there are no outstanding agreements of Amicus to repurchase,
redeem or otherwise acquire any shares of its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Litigation</U>.
There are no actions, suits, proceedings or, to its Knowledge, any investigations, pending or currently threatened against Amicus that
questions the validity of this Agreement or the issuance of the Common Stock contemplated hereby, nor to its Knowledge, is there any basis
therefor. As of the SPA Effective Date, there is no other material action, suit, or proceeding pending or, to the Knowledge of Amicus,
currently threatened against Amicus. As of the SPA Effective Date, there are no material outstanding consents, orders, decrees or judgments
of any governmental entity naming Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Organization
and Good Standing</U>. Amicus is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware
and has all requisite corporate power and authority to own, lease and operate its properties and carry on its business as now conducted.
Amicus is duly qualified and is in good standing as a foreign corporation in each jurisdiction in which the properties owned, leased or
operated, or the business conducted, by it requires such qualification except where the failure to be so qualified or in good standing,
individually or in the aggregate, would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Authorization</U>.
All corporate actions on the part of Amicus, its officers, directors and stockholders necessary for the authorization, execution and delivery
of each of the Transaction Documents and for the issuance of the Shares have been taken. Amicus has the requisite corporate power to enter
into each of the Transaction Documents and to carry out and perform its obligations thereunder. Each of the Transaction Documents have
been duly authorized, executed and delivered by Amicus and, upon due execution and delivery by the Purchasers, each of the Transaction
Documents will be a valid and binding agreement of Amicus, except as enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors&rsquo; rights generally or by equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Subsidiaries.</U>
Except as set forth in the disclosure schedules to this Agreement, Amicus does not currently own or control, directly or indirectly, any
interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity.
Amicus is not a participant in any joint venture, partnership or similar arrangement other than as has been disclosed in SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 412; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Conflict With Other Instruments</U>. Neither the execution, delivery nor performance of any of the Transaction Documents, nor the consummation
by Amicus of the transactions contemplated hereby will result in any violation of, be in conflict with, cause any acceleration or any
increased payments under, or constitute a default under, with or without the passage of time or the giving of notice: (a)&nbsp;any provision
of Amicus&rsquo; certificate of incorporation or bylaws as in effect at the Closing; (b)&nbsp;any provision of any law, regulation, judgment,
decree or order to which Amicus is a party or by which it or any of its assets is bound, (c)&nbsp;any note, mortgage, contract, agreement,
license, waiver, exemption, order or permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Disclosure
Documents</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">For
the two years preceding the SPA Effective Date, Amicus has filed, on a timely basis or has received a valid extension as of such time
of filing and has thereafter made such filings prior to the expiration of any such extensions, all reports, schedules, forms, statements
and other documents required to be filed by Amicus with the SEC under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or
15(d)&nbsp;thereof, (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
referred to herein as the &ldquo;<B><I>SEC Documents</I></B>&rdquo;) and with the U.S. Food and Drug Administration (&ldquo;<B><I>FDA</I></B>&rdquo;)
under its applicable regulations (&ldquo;<B><I>FDA Documents</I></B>&rdquo;), and Amicus has paid all fees and assessments due and payable
in connection with the SEC Documents and the FDA Documents. As of their respective dates, the SEC Documents and the FDA Documents complied
in all material respects with all statutes and applicable rules&nbsp;and regulations of the SEC or FDA, as applicable, including the requirements
of the Securities Act or the Exchange Act, as applicable, and none of the SEC Documents or FDA Documents, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
audited financial statements of Amicus included in Amicus&rsquo; SEC Documents comply in all material respects with the published rules&nbsp;and
regulations of the SEC with respect thereto, and such audited financial statements (i)&nbsp;were prepared from the books and records of
Amicus, (ii)&nbsp;were prepared in accordance with GAAP applied on a consistent basis (except as may be indicated therein or in the notes
or schedules thereto) and (iii)&nbsp;present fairly the financial position of Amicus as of the dates thereof and the results of operations
and cash flows for the periods then ended. The unaudited financial statements included in the SEC Documents comply in all material respects
with the published rules&nbsp;and regulations of the SEC with respect thereto, and such unaudited financial statements (i)&nbsp;were prepared
from the books and records of Amicus, (ii)&nbsp;were prepared in accordance with GAAP, except as otherwise permitted under the Exchange
Act and the rules&nbsp;and regulations thereunder, applied on a consistent basis (except as may be indicated therein or in the notes or
schedules thereto) and (iii)&nbsp;present fairly the financial position of Amicus as of the dates thereof and the results of operations
and cash flows (or changes in financial condition) for the periods then ended, subject to normal year-end adjustments and any other adjustments
described therein or in the notes or schedules thereto. The interactive data in eXtensible Business Reporting Language included in the
SEC Documents fairly presents the information called for in all material respects and has been prepared in all material respects in accordance
with the SEC&rsquo;s rules&nbsp;and guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 413; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Absence
of Certain Events and Changes</U>. Since the date of Amicus&rsquo; Quarterly Report on Form&nbsp;10-Q for the quarter ended on June&nbsp;30,
2021: (a)&nbsp;Amicus has conducted its business in the ordinary course consistent with past practice, (b)&nbsp;there has not been any
event, change or development which, individually or in the aggregate, would have a Material Adverse Effect, taken as a whole, (c)&nbsp;Amicus
has not incurred any material liabilities (contingent or otherwise) other than expenses incurred in the ordinary course of business consistent
with past practice, (d)&nbsp;Amicus has not altered its method of accounting in any material respect, and (e)&nbsp;Amicus has not declared
or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase
or redeem any shares of its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>. Amicus owns, or has an exclusive right pursuant to a valid, written license agreement to use and exploit, all material intellectual
property used in or necessary for the conduct of the business of Amicus as conducted as of the Closing and the conduct of its business
will not conflict in any material respect with any such rights of others. No claims have been asserted by a third party in writing (a)&nbsp;alleging
that the conduct of the business of Amicus has infringed or misappropriated any intellectual property rights of such third party, or (b)&nbsp;challenging
or questioning the validity or effectiveness of any intellectual property right of Amicus, and, to the Knowledge of Amicus, there is no
valid basis for any such claim (a)&nbsp;or (b). To the Knowledge of Amicus, no third party is misappropriating or infringing any intellectual
property right of Amicus. No loss or expiration of any of Amicus&rsquo; material intellectual property is pending, or, to the Knowledge
of Amicus, threatened. Amicus has taken reasonable steps in accordance with standard industry practices to protect its rights in its Intellectual
Property and at all times has maintained the confidentiality of all information used in connection with the business that constitutes
or constituted a trade secret of Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compliance
with Applicable Law.</U> Amicus has all material permits, licenses, franchises, authorizations, orders and approvals of, and has made
all filings, applications and registrations with, governmental entities that are required in order to permit Amicus to own or lease properties
and assets and to carry on its business as presently conducted that are material to Amicus. Amicus has complied and is in compliance in
all material respects with all statutes, laws, regulations, rules, judgments, orders and decrees of all governmental entities applicable
to it that relate to its business. Except as set forth in the disclosure schedules to this Agreement, Amicus has not received any notice
alleging noncompliance, and, to the Knowledge of Amicus, Amicus is not under investigation with respect to, or threatened to be charged,
with any material violation of any applicable statutes, laws, regulations, rules, judgments, orders or decrees of any governmental entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Valid
Issuance of Shares</U>. When issued, sold and delivered in accordance with the terms hereof for the consideration expressed herein, the
Shares will be duly and validly authorized and issued, fully paid and non-assessable, free and clear of all liens, and, based in part
on the representations of the Purchasers in <U>Section&nbsp;5</U> of this Agreement, will be issued in compliance with all applicable
federal and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governmental
Consents</U>. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with,
any federal, state or local governmental authority on the part of Amicus is required in connection with the consummation of the transactions
contemplated by the Transaction Documents, except for notices required or permitted to be filed with certain state and federal securities
commissions, which notices will be filed on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 414; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Brokers</U>. No broker, finder or investment banker is entitled to any brokerage, finder&rsquo;s or other fee or commission in connection
with the transactions contemplated by the Transaction Documents based on arrangements made by Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Undisclosed Liabilities</U>. Amicus does not have any liabilities (contingent or otherwise), except for (a)&nbsp;liabilities reflected
or reserved against in financial statements of Amicus included in the SEC Documents filed with the SEC prior to the date of each of the
Transaction Documents, and (b)&nbsp;liabilities that have not been and would not reasonably be expected to be material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Internal
Controls</U>. Amicus maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability, and (iii)&nbsp;access
to assets or incurrence of liabilities is permitted only in accordance with management&rsquo;s general or specific authorization. Since
the end of Amicus&rsquo;s most recent audited fiscal year, to its Knowledge, there have been no significant deficiencies or material weakness
detected in Amicus&rsquo;s internal control over financial reporting (whether or not remediated) and no change in Amicus&rsquo;s internal
control over financial reporting that has materially affected, or is reasonably likely to materially affect, Amicus&rsquo;s internal control
over financial reporting. Amicus is not aware of any change in its internal controls over financial reporting that has occurred during
its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Amicus&rsquo;s internal control
over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Disclosure
Controls</U>. Amicus and its subsidiaries maintain an effective system of &ldquo;disclosure controls and procedures&rdquo; (as defined
in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) that complies in all material respects with the requirements of the Exchange Act and
that has been designed to ensure that information required to be disclosed by Amicus in reports that it files or submits under the Exchange
Act is recorded, processed, summarized and reported within the time periods specified in the SEC&rsquo;s rules&nbsp;and forms, including
controls and procedures designed to ensure that such information is accumulated and communicated to Amicus&rsquo;s management as appropriate
to allow timely decisions regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compliance</U>.
Amicus is not (i)&nbsp;in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse
of time or both, would result in a default by Amicus under), nor has Amicus received notice of a claim that it is in default under or
that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by
which it or any of its properties is bound (whether or not such default or violation has been waived), (ii)&nbsp;in violation of any judgment,
decree or order of any court, arbitrator or governmental body or (iii)&nbsp;in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to environmental protection,
occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or
reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 415; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Unlawful Payments</U>. Neither Amicus nor any of its subsidiaries nor, to the knowledge of Amicus, any director, officer, employee, agent,
affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken
an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic
government official or employee, including of any government-owned or controlled entity or of a public international organization, or
any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate
for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended,
or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or
anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful
benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit.
Amicus and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed
to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Compliance
with Anti-Money Laundering Laws</U>. The operations of Amicus and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts
business, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or
enforced by any governmental agency (collectively, the &ldquo;<B><I>Anti-Money Laundering Laws</I></B>&rdquo;) and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries
with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Conflicts with Sanctions Laws</U>. Neither Amicus nor any of its subsidiaries nor, to the knowledge of Amicus, any director, officer,
employee, agent, affiliate or other person associated with or acting on behalf of Amicus or any of its subsidiaries is currently the subject
or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign
Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation
as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;), the United Nations Security Council the European Union,
Her Majesty&rsquo;s Treasury or other relevant sanctions authority (collectively, &ldquo;<B><I>Sanctions</I></B>&rdquo;), nor is the Company,
any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including,
without limitation, Crimea, Cuba,&nbsp;Iran, North Korea and Syria (each, a &ldquo;<B><I>Sanctioned Country</I></B>&rdquo;); and Amicus
will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business
with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate
any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person
(including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the
past five years, Amicus and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions
with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 416; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Investment
Company</U>. Amicus is not required to be registered as, and immediately following the Closing will not be required to register as, an
 &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Bad
Actor Disqualification</U>. None of Amicus, any predecessor or affiliated issuer of Amicus nor, to Amicus&rsquo;s Knowledge, any director
or executive officer of Amicus or any promoter connected with Amicus in any capacity, is subject to any of the &ldquo;bad actor&rdquo;
disqualifications within the meaning of Rule&nbsp;506(d)&nbsp;under the Securities Act, except for a disqualification event covered by
Rule&nbsp;506(d)(2)&nbsp;or (d)(3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Investment
Matters</U>. Assuming the accuracy of each Purchaser&rsquo;s representations and warranties set forth in <U>Section&nbsp;5</U>, no registration
under the Securities Act is required for the offer and sale of the Shares to the Purchasers hereunder. The Shares (i)&nbsp;were not offered
to the Purchasers by any form of general solicitation or general advertising and (ii)&nbsp;are not being offered to the Purchasers in
a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Representations
And Warranties Of Purchasers</U></B>. Each Purchaser hereby represents and warrants to Amicus as of the SPA Effective Date as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Legal
Power</U>. Purchaser has the requisite corporate power to enter into each of the Transaction Documents, and to carry out and perform its
obligations under the terms of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Due
Execution</U>. Each of the Transaction Documents have been duly authorized, executed and delivered by Purchaser, and, upon due execution
and delivery by Amicus, each of the Transaction Documents will be a valid and binding agreement of Purchaser, except as enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally or by
equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Investment
Representations</U>. In connection with the offer, purchase and sale of the Shares Purchaser makes the following representations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Purchaser
is acquiring the Shares for its own account, not as nominee or agent, for investment and not with a view to, or for resale in connection
with, any distribution or public offering thereof within the meaning of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 417; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Purchaser
understands that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">The
Shares have not been registered under the Securities Act by reason of a specific exemption therefrom, that such securities may be required
to be held by it indefinitely under applicable securities laws, and that each Purchaser must, therefore, bear the economic risk of such
investment indefinitely, unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
book entry position representing Shares will be endorsed with the following legend:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">THE SECURITIES REPRESENTED HEREBY HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES.
THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY&nbsp;NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED
UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM OR UNLESS THE COMPANY HAS RECEIVED
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Amicus
will instruct its transfer agent not to register the transfer of the Shares or any portion thereof, unless the conditions specified in
the foregoing legend are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Purchaser has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of
the investment in the Shares to be purchased hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Purchaser acknowledges and agrees that the Purchaser is purchasing the Shares from Amicus. Each Purchaser further acknowledges that there
have been no representations, warranties, covenants and agreements made to the Purchaser by or on behalf of Amicus or any of its respective
affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing or any
other person or entity, expressly or by implication, other than those representations, warranties, covenants and agreements of Amicus
expressly set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Purchaser is an &ldquo;accredited investor&rdquo; as such term is defined in Rule&nbsp;501(a)&nbsp;of the rules&nbsp;and regulations promulgated
under the Securities Act. Each Purchaser acknowledges that it is aware that there are substantial risks incident to the purchase and ownership
of the Shares, including, without limitation, those set forth in the SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Purchaser became aware of this offering of the Shares solely by means of direct contact between the Purchaser and Amicus or a representative
of Amicus, and the Shares were offered to the Purchaser solely by direct contact between the Purchaser and the Amicus or a representative
of Amicus. The Purchaser did not become aware of this offering of the Shares, nor were the Shares offered to the Purchaser, by any other
means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 418; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Registration
Rights</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Registration</U>.
As soon as reasonably practicable, but no event later than 50 days after the Closing, Amicus shall prepare and file with the SEC a Registration
Statement covering the resale of all, or such portion as permitted by SEC Guidance (provided that, Amicus shall use commercially reasonable
efforts to advocate with the SEC for the registration of the maximum number of the Registrable Securities permitted by SEC Guidance),
of the Registrable Securities and use commercially reasonable efforts to cause a Registration Statement to be declared effective (including,
without limitation, the execution of any required undertaking to file post-effective amendments) as promptly as possible after the filing
thereof, but in no event later than ten (10)&nbsp;business days after the SEC has notified that Amicus that it will not review, or has
completed its review, of the Registration Statement. The Registration Statement shall be on Form&nbsp;S-3 (except if Amicus fails to meet
one or more of the registrant requirements specified in General Instruction I.A. on Form&nbsp;S-3, such registration shall be on another
appropriate form in accordance herewith). In the event that, despite Amicus&rsquo;s commercially reasonable efforts and compliance with
the terms of this <U>Section&nbsp;6.1</U>, the SEC refuses to alter its position, the Company shall (i)&nbsp;remove from the Registration
Statement such portion of the Registrable Securities (the &ldquo;<B><I>Cut Back Shares</I></B>&rdquo;) and/or (ii)&nbsp;agree to such
restrictions and limitations on the registration and resale of the Registrable Securities as the staff of the SEC may require to assure
Amicus&rsquo;s compliance with the requirements of Rule&nbsp;415 (collectively, the &ldquo;<B><I>SEC Restrictions</I></B>&rdquo;); provided,
however, that Amicus shall not agree to name any Purchaser as an &ldquo;underwriter&rdquo; in such Registration Statement without the
prior written consent of such Purchaser. Any cutback imposed on the Purchasers pursuant to this <U>Section&nbsp;6.1</U> shall be allocated
among the Purchasers on a pro rata basis, unless the SEC Restrictions otherwise require or provide or the Purchasers holding a majority
of the Registrable Shares otherwise agree. From and after the such date as the Company is able to effect the registration of such Cut
Back Shares in accordance with any SEC Restrictions (such date, the &ldquo;<B><I>Restriction Termination Date</I></B>&rdquo; of such Cut
Back Shares) applicable to any Cut Back Shares, all of the provisions of this <U>Section&nbsp;6</U> shall again be applicable to such
Cut Back Shares; provided, however, that (x)&nbsp;the Filing Deadline for the Registration Statement including such Cut Back Shares shall
be 10 business days after such Restriction Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Expenses
Of Registration</U>. Amicus shall pay all fees and expenses incurred in connection with any registration, qualification, exemption or
compliance by Amicus in the performance of its obligations pursuant to this <U>Section&nbsp;6</U>, whether or not any Registrable Securities
are sold pursuant to a Registration Statement, and including all registration and filing fees, exchange listing fees, and the fees and
expenses of counsel and accountants for Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Obligations
Of Amicus</U>. In the case of registration, qualification, exemption or compliance effected by Amicus pursuant to the Transaction Documents,
Amicus will, upon request of any Purchaser, inform such Purchaser as to the status of such registration, qualification, exemption and
compliance. Amicus shall, at its expense and in addition to its obligations under <U>Section&nbsp;6.1</U>, as expeditiously as reasonably
possible:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to keep such registration, and any required qualification, exemption or compliance under state securities
laws, continuously effective with respect to the Purchasers and its permitted assignees, until the date all Shares registered by such
Registration Statement shall have been sold or may be sold pursuant to Rule&nbsp;144 without regard to volume limitations. The period
of time during which Amicus is required hereunder to keep the Registration Statement effective is referred to herein as the &ldquo;<B><I>Registration
Period</I></B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 419; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">advise
Purchasers promptly (and, in any event, within five business days):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">when
the Registration Statement or any amendment thereto has been filed with the SEC and when the Registration Statement or any post-effective
amendment thereto has become effective;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">of
the receipt by Amicus of any notification from the SEC of any stop order suspending the effectiveness of the Registration Statement or
the initiation of any proceedings for such purpose;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">of
the receipt by Amicus of any notification with respect to the suspension of the qualification of the Registrable Securities included therein
for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">of
the occurrence of any event that requires the making of any changes in the Registration Statement or the prospectus so that, as of such
date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to
make the statements therein (in the case of the prospectus, in the light of the circumstances under which they were made) not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement as
soon as reasonably practicable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">if
any Purchaser so requests in writing, promptly furnish to such Purchaser, without charge, at least one copy of such Registration Statement
and any post-effective amendment thereto, including financial statements and schedules, and, if explicitly requested, all exhibits in
the form filed with the SEC;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">during
the Registration Period, promptly deliver to each Purchaser, without charge, at least one copy of the prospectus included in such Registration
Statement and any amendment or supplement thereto and as many additional copies as each Purchaser may reasonably request; and Amicus consents
to the use, consistent with the provisions hereof, of the prospectus or any amendment or supplement thereto by each Purchaser in connection
with the offering and sale of the Registrable Securities covered by the prospectus or any amendment or supplement thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">during
the Registration Period, if a Purchaser so requests in writing, deliver to such Purchaser, without charge, (i)&nbsp;one copy of the following
documents, other than those documents available via EDGAR (and excluding, in each case, exhibits thereto): (A)&nbsp;its annual report
to its stockholders, if any (which annual report will contain financial statements audited in accordance with GAAP by a firm of certified
public accountants of recognized standing), (B)&nbsp;if not included in substance in its annual report to stockholders, its annual report
on Form&nbsp;10-K (or similar form), (C)&nbsp;its definitive proxy statement with respect to its annual meeting of stockholders, (D)&nbsp;each
of its quarterly reports to its stockholders, and, if not included in substance in its quarterly reports to stockholders, its quarterly
report on Form&nbsp;10-Q (or similar form), and (E)&nbsp;a copy of the Registration Statement; and (ii)&nbsp;if explicitly requested,
any exhibits filed with respect to the foregoing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 420; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">upon
the occurrence of any event contemplated by <U>Section&nbsp;6.3(b)(iv)</U>, Amicus will use its commercially reasonable efforts to as
soon as reasonably practicable prepare a post-effective amendment to the Registration Statement or a supplement to the related prospectus,
or file any other required document so that, as thereafter delivered to the Purchasers, the prospectus will not include any untrue statement
of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">comply
in all material respects with all applicable rules&nbsp;and regulations of the SEC which could affect the sale of the Registrable Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to cause all Registrable Securities to be listed on each securities exchange or market, if any, on
which equity securities issued by Amicus have been listed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to take all other steps necessary to effect the registration of the Registrable Securities contemplated
hereby and to enable the Purchasers to sell Registrable Securities under Rule&nbsp;144; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">permit
counsel for the Purchasers to review the Registration Statement and all amendments and supplements thereto, within two business days prior
to the filing thereof with the SEC;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>provided</I></FONT>
that, in the case of clause (k)&nbsp;above, Amicus will not be required to delay the filing of the Registration Statement or any amendment
or supplement thereto to incorporate any comments to the Registration Statement or any amendment or supplement thereto by or on behalf
of any Purchaser if such comments would require a delay in the filing of such Registration Statement, amendment or supplement, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Furnishing
Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">It shall be a condition precedent
to the obligations of Amicus to take any action pursuant to <U>Section&nbsp;6.1</U> that each of the selling Holders shall furnish to
Amicus such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities
as shall be legally required under the Securities Act or otherwise required by the SEC to effect the registration of their Registrable
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 421; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Indemnification;
Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Amicus
shall indemnify and hold harmless each Holder (including the employees, agents, representatives, officers and directors of each Purchaser
and its Affiliates) (each a &ldquo;<B><I>Purchaser Indemnitee</I></B>&rdquo;) from and against any and all losses, claims, damages, liabilities
and expenses (including reasonable costs of investigation) arising out of or based upon any untrue, or allegedly untrue, statement of
a material fact contained in any Registration Statement, prospectus or preliminary prospectus or notification or offering circular prepared
by Amicus in connection with the registration and/or offering of the Registrable Securities (as amended or supplemented if Amicus shall
have furnished any amendments or supplements thereto) or arising out of or based upon any omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as the same are
caused by or contained in any information concerning such Holder furnished in writing to Amicus by such Holder specifically and expressly
for inclusion in such document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Holder shall indemnify and hold harmless Amicus, and its respective directors, officers, employees and each Person who controls Amicus
(within the meaning of the Securities Act and the Exchange Act) from and against any and all losses, claims, damages, liabilities and
expenses (including reasonable costs of investigation) arising out of or based upon any untrue, or allegedly untrue, statement of a material
fact contained in any Registration Statement, prospectus or preliminary prospectus or notification or offering circular prepared by Amicus
in connection with the registration and/or offering of the Registrable Securities (as amended or supplemented if Amicus shall have furnished
any amendments or supplements thereto) or arising out of or based upon any omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, if such statement or omission was made in reliance
upon and in conformity with any information concerning such Holder furnished in writing to Amicus by such Holder specifically and expressly
for use in the preparation of such document; <I>provided, however,</I> that in no event shall any indemnity under this <U>Section&nbsp;6.5(b)</U>&nbsp;be
greater in amount than the aggregate dollar amount of the proceeds received by all of the Purchasers upon the sale of such Registrable
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Each
Person entitled to indemnification hereunder (the &ldquo;<B><I>Indemnified Party</I></B>&rdquo;) agrees to give prompt written notice
to the indemnifying party (the &ldquo;<B><I>Indemnifying Party</I></B>&rdquo;) after the receipt by the Indemnified Party of any written
notice of the commencement of any action, suit, proceeding or investigation or threat thereof made in writing for which the Indemnified
Party intends to claim indemnification or contribution pursuant to the Transaction Documents; <I>provided, however</I>, that the failure
to so notify the Indemnifying Party shall not relieve the Indemnifying Party of any liability that it may have to the Indemnified Party
hereunder unless, and only to the extent that, such failure results in the Indemnifying Party&rsquo;s forfeiture of substantive rights
or defenses. If notice of commencement of any such action is given to the Indemnifying Party as above provided, the Indemnifying Party
shall be entitled to participate in and, to the extent it may wish, jointly with any other Indemnifying Party similarly notified, to assume
the defense of such action at its own expense, with counsel chosen by it and reasonably satisfactory to such Indemnified Party. The Indemnified
Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses
of such counsel (other than reasonable costs of investigation) shall be paid by the Indemnified Party unless (i)&nbsp;the Indemnifying
Party agrees to pay the same, (ii)&nbsp;the Indemnifying Party fails to assume the defense of such action with counsel reasonably satisfactory
to the Indemnified Party in its reasonable judgment or (iii)&nbsp;the named parties to any such action (including any impleaded parties)
have been advised by such counsel that either (x)&nbsp;representation of such Indemnified Party and the Indemnifying Party by the same
counsel would be inappropriate under applicable standards of professional conduct or (y)&nbsp;there may be one or more legal defenses
available to it which are different from or additional to those available to the Indemnifying Party. In either of such cases, the Indemnifying
Party shall not have the right to assume the defense of such action on behalf of such Indemnified Party. No Indemnifying Party shall be
liable for any settlement entered into without its written consent (other than in the case where the Indemnifying Party is unconditionally
released from liability and its rights are not adversely effected), which consent shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 422; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">If
the indemnification provided for in this <U>Section&nbsp;6.5</U> from the Indemnifying Party pursuant to applicable law is unavailable
to an Indemnified Party hereunder in respect of any losses, claims, damages, liabilities or expenses referred to therein, then the Indemnifying
Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result
of such losses, claims, damages, liabilities or expenses in such proportion as is appropriate to reflect the relative fault of the Indemnifying
Party and Indemnified Party in connection with the actions which resulted in such losses, claims, damages, liabilities or expenses, as
well as any other relevant equitable considerations. The relative faults of such Indemnifying Party and Indemnified Party shall be determined
by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact
or omission or alleged omission to state a material fact, has been made by, or relates to information supplied by, such Indemnifying Party
or Indemnified Party, and the parties&rsquo; relative intent, Knowledge, access to information and opportunity to correct or prevent such
action. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall
be deemed to include, subject to the limitations set forth in <U>Sections 6.5(a)</U>, <U>(b)</U>&nbsp;and <U>(c)</U>, any legal or other
fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree
that it would not be just and equitable if contribution pursuant to this <U>Section&nbsp;6.5(d)</U>&nbsp;were determined by pro rata allocation
or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding
paragraph. No Person guilty of an intentional or fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities
Act) shall be entitled to contribution from any Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rule&nbsp;144
Reporting</U>. In order to make the benefits of the rules&nbsp;and regulations of the SEC that may permit the sale of the Registrable
Securities to the public without registration available to the Holders, Amicus agrees to use commercially reasonable efforts to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">make
and keep public information available, as those terms are understood and defined in Rule&nbsp;144(c)(1)&nbsp;or any similar or analogous
rule&nbsp;promulgated under the Securities Act, at all times after the SPA Effective Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">file
with the SEC, in a timely manner, all reports and other documents required of Amicus under the Exchange Act; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 423; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">so
long as any Holder owns any Registrable Securities, furnish such Holders forthwith upon request: (i)&nbsp;a written statement by Amicus
as to its compliance with the reporting requirements of Rule&nbsp;144 under the Securities Act, and of the Exchange Act; (ii)&nbsp;a copy
of the most recent annual or quarterly report of Amicus; and (iii)&nbsp;such other reports and documents as a Holder may reasonably request
in availing itself of any rule&nbsp;of regulation of the SEC allowing it to sell any such securities without registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Assignment
of Registration Rights</U>. The rights and obligations under this <U>Section&nbsp;6</U> may only be assigned by a Holder to a transferee
or assignee of Registrable Securities that is (a)&nbsp;an Affiliate or (b)&nbsp;a successor (by operation of law or otherwise) to substantially
all the business or assets of such Holder; <I>provided, however</I>, that such attempted assignment shall be void unless (i)&nbsp;such
Holder, within 30 days after such transfer, furnishes to Amicus written notice of the name and address of such transferee or assignee
and the securities with respect to which such registration rights are being assigned, and (ii)&nbsp;such transferee agrees to be subject
to all obligations and restrictions with respect to the Registrable Securities set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Stock
Ownership Governance</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Lock-Up
Period</U>. Excluding any transfers or intra-company disposal of the Shares between a Purchaser and any of its Affiliates, for a period
of nine (9)&nbsp;months following the SPA Effective Date (the &ldquo;<B><I>Lock-Up Period</I></B>&rdquo;), each Purchaser shall not, and
shall cause any other Holder not to, without the prior written consent of Amicus, sell, contract to sell, pledge or otherwise dispose
of, directly or indirectly, any Shares or enter into a transaction which would have the same effect; provided, however, that the foregoing
shall not prohibit a Purchaser from distributions of Shares to general or limited partners, members, shareholders, Affiliates or wholly-owned
subsidiaries of such Purchaser or any investment fund or other entity controlled or managed by such Purchaser; provided, in each case,
that following any such transfer such Shares will remain subject to the provisions of this <U>Section&nbsp;7.1</U>. Any discretionary
waiver or termination of the restrictions of any or all of this <U>Section&nbsp;7.1</U> by Amicus shall apply pro rata to all Purchasers,
based on the number of Shares. For the avoidance of doubt, this <U>Section&nbsp;7.1</U> shall only apply to Shares purchased pursuant
to this Agreement and shall not impose any restrictions on any other securities of Amicus owned by the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
Without prejudice to the rights and remedies otherwise available to the parties, Amicus shall be entitled to equitable relief by way of
injunction if any Purchaser or any other Holder breaches or threatens to breach any of the provisions of this <U>Section&nbsp;7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Covenants</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Covenant
of Amicus</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Amicus
hereby covenants and agrees that it shall take all necessary and appropriate actions to ensure that it shall have available under its
certificate of incorporation as in effect at the Closing sufficient authorized but unissued shares of its Common Stock to issue and sell
to Purchasers all of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">From
the date hereof until such time as the Shares have been sold pursuant to Rule&nbsp;144 or are eligible for resale under Rule&nbsp;144(b)(1)&nbsp;or
any successor provision, Amicus will use commercially reasonable efforts to continue the listing and trading of its Common Stock on Nasdaq
and, in accordance, therewith, will use commercially reasonable efforts to comply in all respects with Amicus&rsquo;s reporting, filing
and other obligations under the bylaws or rules&nbsp;of such market or exchange, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 424; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Amicus
shall not, and shall use its commercially reasonable efforts to ensure that no controlled Affiliate of Amicus shall, sell, offer for sale
or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that will
be integrated with the offer or sale of the Shares in a manner that would require the registration under the Securities Act of the sale
of the Shares to the Investors. Amicus shall not take any action or steps that would adversely affect reliance by Amicus in any material
respect on Section&nbsp;4(a)(2)&nbsp;for the exemption from registration for the transactions contemplated hereby or require registration
of the Shares under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Removal
of Legends</U>. In connection with any sale or disposition of the Shares by a Purchaser pursuant to Rule&nbsp;144 or pursuant to any other
exemption under the Securities Act such that the Purchaser acquires freely tradable shares and upon compliance by the Purchaser with the
requirements of this Agreement, if requested in writing by the Purchaser, Amicus shall use its commercially reasonable efforts to request
that the transfer agent for the Common Stock (the &ldquo;<B><I>Transfer Agent</I></B>&rdquo;) remove any restrictive legends related to
the book entry account holding such Shares and make a new, unlegended entry for such book entry Shares sold or disposed of without restrictive
legends within two (2)&nbsp;Trading Days of receipt of such request from the Purchaser. Upon the earliest of such time as the Shares (i)&nbsp;have
been registered for resale pursuant to an effective registration statement, (ii)&nbsp;have been sold pursuant to Rule&nbsp;144 or (iii)&nbsp;are
eligible for resale under Rule&nbsp;144(b)(1)&nbsp;or any successor provision, Amicus shall (A)&nbsp;deliver to the Transfer Agent irrevocable
instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Shares, and (B)&nbsp;cause its counsel to
deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected
under the Securities Act. Amicus shall be responsible for the fees of its Transfer Agent and all DTC fees associated with such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><B><U>Miscellaneous</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts
of law thereof. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
Party at the address in effect for notices to it under the Transaction Documents and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by the Parties and delivered to the other Parties, it being understood that
the Parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page&nbsp;were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 425; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Public
Statements</U>. Amicus shall no later than the close of business on the date immediately following the date hereof, either issue a press
release or file a Current Report on Form&nbsp;8-K disclosing the material terms of the transactions contemplated hereby and any other
material, nonpublic information that Amicus may have provided to any Purchaser at any time prior thereto promptly following the execution
and delivery hereof, which shall have been previously reviewed by counsel for the Purchasers (the &ldquo;<B><I>Press Release</I></B>&rdquo;).
Amicus shall not include the name of any Purchaser in the Press Release or any other public announcement without the prior written consent
of such Purchaser. Subject to the foregoing, any statement to the public regarding this the Transaction Documents shall be approved in
advance by Amicus and the Purchasers, except as otherwise required by law, rule, regulation, legal process or applicable SEC Guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the Parties and their successors and permitted assigns.
Amicus may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Purchasers purchasing
at least 85% of the Shares issuable hereunder. Subject to <U>Section&nbsp;6.7</U>, any Purchaser may assign any or all of its rights under
this Agreement to any Person to whom such Purchaser assigns or transfers any Shares, provided such transferee agrees in writing to be
bound, with respect to the transferred Shares, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules hereto, contain the entire understanding of the Parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters (other than confidentiality agreements to which Amicus is a party to with the Purchasers), which the Parties acknowledge
have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Separability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the Parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the Parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of
the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
Amicus does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw,
in its sole discretion from time to time upon written notice to Amicus, any relevant notice, demand or election in whole or in part without
prejudice to its future actions and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 426; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Replacement
of Shares</U>. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, Amicus shall issue or cause
to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to Amicus of such loss, theft or
destruction. The applicant for a new certificate or instrument under such circumstances may also be required to pay a customary bond and
any reasonable third-party costs associated with the issuance of such replacement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and Amicus will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be
adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agrees
to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.10</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto, shall be deemed to constitute the Purchasers as a partnership, an association, a
joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights, including without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in their review and negotiation of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.11</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Amendment
and Waiver</U>. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment,
by Amicus and Purchasers purchasing at least 85% of the Shares issuable hereunder or, in the case of a waiver, by the Party against whom
enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.12</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a)&nbsp;the date of transmission, if such notice or communication is delivered via email
at the email address set forth on the signature pages&nbsp;attached hereto prior to 5:30 p.m.&nbsp;(New York City time) on a Trading Day,
(b)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via email at the email address
set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time)
on any Trading Day, (c)&nbsp;the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier
service, or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages&nbsp;attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 427; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.13</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each Party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. Amicus shall pay all transfer agent fees, stamp taxes and other taxes
and duties levied in connection with the delivery of any Shares to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.14</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Titles
and Subtitles</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.15</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Counterparts;
Effectiveness</U>. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of
which together shall constitute one instrument. This Agreement shall become effective when each Party hereto shall have received counterparts
thereof signed and delivered (by telecopy or other electronic means) by the other Parties hereto. Counterparts may be delivered via facsimile,
electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act,
the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.16</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>Construction</U>.
The Parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.17</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt"><U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the Parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
<U>Section&nbsp;6.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 428; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> -<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Securities Purchase Agreement is hereby executed
as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMICUS:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amicus Therapeutics,&nbsp;Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Daphne Quimi&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0.5pt 0.25pt 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daphne Quimi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3675 Market Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19104</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><I>[Signature
Page&nbsp;to Securities Purchase Agreement]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 429 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Perceptive Life Sciences Master Fund,&nbsp;Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ James Mannix</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0.5pt 0.25pt 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">James Mannix</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51 Astor Place, 10th Floor,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10003</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><I>[Signature
Page&nbsp;to Securities Purchase Agreement]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 430 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Schedule A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Purchaser Share Amounts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Purchaser</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares <BR> Purchased</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Purchase Price(in <BR>
$)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Perceptive Life Sciences Master Fund,&nbsp;Ltd.</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,438,114</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">35,000,000.52</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 431 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.5<FONT STYLE="text-transform: uppercase">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS SECURITIES PURCHASE AGREEMENT
(this &ldquo;<B><I>Agreement</I></B>&rdquo;) is made effective as of 12:01 a.m.&nbsp;on September&nbsp;29, 2021 (the &ldquo;<B><I>SPA
Effective Date</I></B>&rdquo;), by and among Amicus Therapeutics,&nbsp;Inc., a Delaware corporation with its principal place of business
at 3675 Market Street, Philadelphia, PA 19104 (&ldquo;<B><I>Amicus</I></B>&rdquo;), and each Purchaser identified on the signature pages&nbsp;hereto
(each, including its successors and assigns, a &ldquo;<B><I>Purchaser</I></B>&rdquo; and collectively the &ldquo;<B><I>Purchasers</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">BACKGROUND</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amicus desires to sell to
each Purchaser and each Purchaser desires to purchase from Amicus such number of Shares (as defined below) set forth opposite such Purchaser&rsquo;s
name on <U>Schedule A</U> attached hereto, at a price of $10.18 per Share (the &ldquo;<B><I>Per Share Price</I></B>&rdquo;) and on the
terms and subject to the conditions set forth in this Agreement (the &ldquo;<B><I>Offering</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">TERMS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing recitals and the mutual covenants and agreements contained herein, the Parties hereto, intending to be legally bound,
do hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Definitions</U></B>.
The capitalized terms used herein shall have the meanings ascribed to them below or at such other place in this Agreement as is indicated
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Affiliate</I></B>&rdquo;
means, with respect to any specified Person, at any time, a Person that, directly or indirectly, through one or more intermediaries, controls,
or is controlled by, or is under common control with, such specified Person at such time. For purposes of this definition, &ldquo;control,&rdquo;
when used with respect to any specified Person, shall mean (a)&nbsp;the direct or indirect ownership of more than 50% (or such lesser
percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the total voting power of
securities or other evidences of ownership interest in such Person or (b)&nbsp;the power to direct or cause the direction of the management
and policies of such Person, directly or indirectly, whether through ownership of voting securities, by contract or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Closing</I></B>&rdquo;
has the meaning ascribed to such term in <U>Section&nbsp;3.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Common
Stock</I></B>&rdquo; means the common stock of Amicus, par value $0.01 per share, and any other class of securities into which such securities
may hereafter be reclassified or changed into.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Cut
Back Shares</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended, together with the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>FDA</I></B>&rdquo;
has the meaning ascribed to such term in <U>Section&nbsp;4.7</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 432 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>FDA
Documents</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;4.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>GAAP</I></B>&rdquo;
means generally accepted accounting principles in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Holder</I></B>&rdquo;
means each Person owning of record Registrable Securities that have not been sold to the public.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Indemnified
Party</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.5(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Indemnifying
Party</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.5(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Knowledge</I></B>&rdquo;
means the knowledge of such Person, assuming that such Person engaged in reasonable inquiry or investigation with respect to the relative
subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Lock-Up
Period</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;7.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Material
Adverse Effect</I></B>&rdquo; on or with respect to an entity (or group of entities taken as a whole) means any state of facts, event,
change or effect that has had, or that would reasonably expected to have, (i)&nbsp;a material adverse effect on the business, properties,
prospects, results of operations or financial condition of such entity (or of such group of entities taken as a whole) or (ii)&nbsp;a
material adverse effect on the performance of this Agreement or the consummation of any of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Nasdaq</I></B>&rdquo;
means the Nasdaq Stock Market,&nbsp;Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Offering</I></B>&rdquo;
has the meaning ascribed to such term in the Background.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Party</I></B>&rdquo;
means a party to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Per
Share Price</I></B>&rdquo; has the meaning ascribed to such term in the Background.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Person</I></B>&rdquo;
means any individual, firm, corporation, partnership, limited liability company, trust, incorporated or unincorporated association, joint
venture, joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind, and shall include
any successor (by merger or otherwise) of such entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Press
Release</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;9.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Purchase
Price</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Purchaser
Indemnitee</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Register</I></B>,&rdquo;
 &ldquo;<B><I>Registered</I></B>,&rdquo; and &ldquo;<B><I>Registration</I></B>&rdquo; refer to a registration effected by preparing and
filing a Registration Statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such Registration
Statement or document by the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Registrable
Securities</I></B>&rdquo; means (a)&nbsp;the Shares and (b)&nbsp;any shares of Common Stock or other securities issued as (or issuable
upon the conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect
to, or in exchange for or in replacement of, the Shares by way of stock dividend, stock split or in connection with a combination of shares,
recapitalization or other reorganization or otherwise. Notwithstanding the foregoing, as to any particular Shares or other securities
described above, once issued they shall cease to be Registrable Securities when (i)&nbsp;a registration statement with respect to the
sale of such securities shall have become effective under the Securities Act and such securities shall have been disposed of in accordance
with such registration statement, (ii)&nbsp;they shall have been distributed pursuant to Rule&nbsp;144 (or any successor provision) under
the Securities Act, (iii)&nbsp;such securities may be sold without volume restrictions pursuant to Rule&nbsp;144, as determined by the
counsel to Amicus pursuant to a written opinion letter to such effect, addressed and acceptable to Amicus&rsquo; transfer agent, or (iv)&nbsp;such
securities shall have been otherwise transferred in a private transaction in which the rights under <U>Section&nbsp;6</U> hereof have
not been assigned in connection with such transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 433; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.25</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Registration
Period</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.3(a)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Registration
Statement</I></B>&rdquo; means a registration statement filed pursuant to the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Restriction
Termination Date</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Rule&nbsp;144</I></B>&rdquo;
means Rule&nbsp;144 promulgated under the Securities Act, or any successor rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Sanctions</I></B>&rdquo;
has the meaning ascribed to such term in <U>Section&nbsp;4.20</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.30</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Sanctioned
Country</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;4.20</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC</I></B>&rdquo;
means the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC
Documents</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;4.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC
Guidance</I></B>&rdquo; means (a)&nbsp;any publicly-available written guidance, or rule&nbsp;of general applicability of the SEC staff,
or (b)&nbsp;written comments, requirements or requests of the SEC staff to Amicus in connection with the review of a Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.34</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>SEC
Restrictions</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;6.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.35</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the Securities Act of 1933, as amended, together with the rules&nbsp;and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.36</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Purchase
Price</I></B>&rdquo; has the meaning ascribed to such term in <U>Section&nbsp;2.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Shares</I></B>&rdquo;
means the shares of Common Stock to be issued to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.38</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Trading
Day</I></B>&rdquo; means a day on which the Common Stock is traded on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 434; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Transaction
Documents</I></B>&rdquo; means this Agreement and any other documents or agreements executed in connection with the transactions contemplated
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B><I>Transfer
Agent</I></B>&rdquo; means American Stock Transfer&nbsp;&amp; Trust Company, LLC, the company&rsquo;s transfer agent and registrar for
Common Stock, and any successor appointed in such capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Purchase
and Sale</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">On
terms and conditions as set forth herein, Amicus hereby issues and sells to the Purchasers, and the Purchasers hereby purchase from Amicus,
an aggregate of 7,858,546 Shares at the Per Share Price for an aggregate purchase price of $79,999,998.66 (the &ldquo;<B><I>Purchase Price</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Schedule
A</U> hereto sets forth the number of Shares to be purchased by each Purchaser and the portion of the Purchase Price to be paid by such
Purchaser for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Closing</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Closing</U>.
The completion of the sale and purchase of the Shares (the &ldquo;<B><I>Closing</I></B>&rdquo;) shall occur upon the execution of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Deliveries</U>.
Subject to the terms and conditions hereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser shall deliver to Amicus the Purchase Price attributable to the Shares purchased by such Purchaser by wire transfer of immediately
available funds to the following account:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; border-collapse: collapse; margin-left: 1in">
  <TR>
    <TD STYLE="vertical-align: top; width: 100%; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bank Address:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficiary Address:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABA:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account:</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SWIFT Code:</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Upon
receipt of a Purchaser&rsquo;s share of the Purchase Price, Amicus shall deliver to such Purchaser the applicable Shares to be registered
in book entry form in the name of such Purchaser on Amicus&rsquo;s share register. Within one (1)&nbsp;business day of the date hereof,
Amicus will provide each Purchaser with written confirmation of the registration contemplated by <U>Section&nbsp;3(b)(i)</U>. Each of
the Parties shall also deliver such other documents as are required to be delivered by the Parties pursuant to the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 435; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Representations
and Warranties of Amicus</U></B>. Except as disclosed in Amicus&rsquo; disclosure schedules provided to the Purchasers along with this
Agreement, Amicus hereby represents and warrants to the Purchasers as of the SPA Effective Date (except as set forth below), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Capitalization</U>.
As of September&nbsp;27, 2021, the authorized capital stock of Amicus consisted of (a)&nbsp;500,000,000 shares of Common Stock, of which
(i)&nbsp;267,287,163 shares were issued and outstanding, and (ii)&nbsp;40,298,907 shares have been reserved for issuance under Amicus&rsquo;
Amended and Restated 2007 Equity Incentive Plan; and (b)&nbsp;10,000,000 shares of preferred stock, none of which is issued and outstanding.
All issued and outstanding shares of Amicus&rsquo; capital stock have been duly authorized and validly issued, and are fully paid and
nonassessable, and were issued in compliance with all applicable federal and state securities laws. As of the SPA Effective Date, there
are no preemptive or similar rights on the part of any holder of any class or securities of Amicus. As of the SPA Effective Date, except
as set forth in the SEC Documents or as described or referred to above, there are no securities convertible into or exchangeable for,
or options, warrants, calls, subscriptions, rights, contracts, commitments, or understandings of any kind to which Amicus is a party or
by which it is bound obligating Amicus to issue, deliver or sell, or cause to be issued, delivered or sold additional shares of its capital
stock or other voting securities of Amicus. As of the SPA Effective Date, there are no outstanding agreements of Amicus to repurchase,
redeem or otherwise acquire any shares of its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Litigation</U>.
There are no actions, suits, proceedings or, to its Knowledge, any investigations, pending or currently threatened against Amicus that
questions the validity of this Agreement or the issuance of the Common Stock contemplated hereby, nor to its Knowledge, is there any basis
therefor. As of the SPA Effective Date, there is no other material action, suit, or proceeding pending or, to the Knowledge of Amicus,
currently threatened against Amicus. As of the SPA Effective Date, there are no material outstanding consents, orders, decrees or judgments
of any governmental entity naming Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Organization
and Good Standing</U>. Amicus is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware
and has all requisite corporate power and authority to own, lease and operate its properties and carry on its business as now conducted.
Amicus is duly qualified and is in good standing as a foreign corporation in each jurisdiction in which the properties owned, leased or
operated, or the business conducted, by it requires such qualification except where the failure to be so qualified or in good standing,
individually or in the aggregate, would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Authorization</U>.
All corporate actions on the part of Amicus, its officers, directors and stockholders necessary for the authorization, execution and delivery
of each of the Transaction Documents and for the issuance of the Shares have been taken. Amicus has the requisite corporate power to enter
into each of the Transaction Documents and to carry out and perform its obligations thereunder. Each of the Transaction Documents have
been duly authorized, executed and delivered by Amicus and, upon due execution and delivery by the Purchasers, each of the Transaction
Documents will be a valid and binding agreement of Amicus, except as enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors&rsquo; rights generally or by equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Subsidiaries.</U>
Except as set forth in the disclosure schedules to this Agreement, Amicus does not currently own or control, directly or indirectly, any
interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity.
Amicus is not a participant in any joint venture, partnership or similar arrangement other than as has been disclosed in SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 436; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflict With Other Instruments</U>. Neither the execution, delivery nor performance of any of the Transaction Documents, nor the consummation
by Amicus of the transactions contemplated hereby will result in any violation of, be in conflict with, cause any acceleration or any
increased payments under, or constitute a default under, with or without the passage of time or the giving of notice: (a)&nbsp;any provision
of Amicus&rsquo; certificate of incorporation or bylaws as in effect at the Closing; (b)&nbsp;any provision of any law, regulation, judgment,
decree or order to which Amicus is a party or by which it or any of its assets is bound, (c)&nbsp;any note, mortgage, contract, agreement,
license, waiver, exemption, order or permit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
Documents</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">For
the two years preceding the SPA Effective Date, Amicus has filed, on a timely basis or has received a valid extension as of such time
of filing and has thereafter made such filings prior to the expiration of any such extensions, all reports, schedules, forms, statements
and other documents required to be filed by Amicus with the SEC under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)&nbsp;or
15(d)&nbsp;thereof, (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively
referred to herein as the &ldquo;<B><I>SEC Documents</I></B>&rdquo;) and with the U.S. Food and Drug Administration (&ldquo;<B><I>FDA</I></B>&rdquo;)
under its applicable regulations (&ldquo;<B><I>FDA Documents</I></B>&rdquo;), and Amicus has paid all fees and assessments due and payable
in connection with the SEC Documents and the FDA Documents. As of their respective dates, the SEC Documents and the FDA Documents complied
in all material respects with all statutes and applicable rules&nbsp;and regulations of the SEC or FDA, as applicable, including the requirements
of the Securities Act or the Exchange Act, as applicable, and none of the SEC Documents or FDA Documents, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
audited financial statements of Amicus included in Amicus&rsquo; SEC Documents comply in all material respects with the published rules&nbsp;and
regulations of the SEC with respect thereto, and such audited financial statements (i)&nbsp;were prepared from the books and records of
Amicus, (ii)&nbsp;were prepared in accordance with GAAP applied on a consistent basis (except as may be indicated therein or in the notes
or schedules thereto) and (iii)&nbsp;present fairly the financial position of Amicus as of the dates thereof and the results of operations
and cash flows for the periods then ended. The unaudited financial statements included in the SEC Documents comply in all material respects
with the published rules&nbsp;and regulations of the SEC with respect thereto, and such unaudited financial statements (i)&nbsp;were prepared
from the books and records of Amicus, (ii)&nbsp;were prepared in accordance with GAAP, except as otherwise permitted under the Exchange
Act and the rules&nbsp;and regulations thereunder, applied on a consistent basis (except as may be indicated therein or in the notes or
schedules thereto) and (iii)&nbsp;present fairly the financial position of Amicus as of the dates thereof and the results of operations
and cash flows (or changes in financial condition) for the periods then ended, subject to normal year-end adjustments and any other adjustments
described therein or in the notes or schedules thereto. The interactive data in eXtensible Business Reporting Language included in the
SEC Documents fairly presents the information called for in all material respects and has been prepared in all material respects in accordance
with the SEC&rsquo;s rules&nbsp;and guidelines applicable thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 437; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Absence
of Certain Events and Changes</U>. Since the date of Amicus&rsquo; Quarterly Report on Form&nbsp;10-Q for the quarter ended on June&nbsp;30,
2021: (a)&nbsp;Amicus has conducted its business in the ordinary course consistent with past practice, (b)&nbsp;there has not been any
event, change or development which, individually or in the aggregate, would have a Material Adverse Effect, taken as a whole, (c)&nbsp;Amicus
has not incurred any material liabilities (contingent or otherwise) other than expenses incurred in the ordinary course of business consistent
with past practice, (d)&nbsp;Amicus has not altered its method of accounting in any material respect, and (e)&nbsp;Amicus has not declared
or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase
or redeem any shares of its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Intellectual
Property</U>. Amicus owns, or has an exclusive right pursuant to a valid, written license agreement to use and exploit, all material intellectual
property used in or necessary for the conduct of the business of Amicus as conducted as of the Closing and the conduct of its business
will not conflict in any material respect with any such rights of others. No claims have been asserted by a third party in writing (a)&nbsp;alleging
that the conduct of the business of Amicus has infringed or misappropriated any intellectual property rights of such third party, or (b)&nbsp;challenging
or questioning the validity or effectiveness of any intellectual property right of Amicus, and, to the Knowledge of Amicus, there is no
valid basis for any such claim (a)&nbsp;or (b). To the Knowledge of Amicus, no third party is misappropriating or infringing any intellectual
property right of Amicus. No loss or expiration of any of Amicus&rsquo; material intellectual property is pending, or, to the Knowledge
of Amicus, threatened. Amicus has taken reasonable steps in accordance with standard industry practices to protect its rights in its Intellectual
Property and at all times has maintained the confidentiality of all information used in connection with the business that constitutes
or constituted a trade secret of Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Applicable Law.</U> Amicus has all material permits, licenses, franchises, authorizations, orders and approvals of, and has made
all filings, applications and registrations with, governmental entities that are required in order to permit Amicus to own or lease properties
and assets and to carry on its business as presently conducted that are material to Amicus. Amicus has complied and is in compliance in
all material respects with all statutes, laws, regulations, rules, judgments, orders and decrees of all governmental entities applicable
to it that relate to its business. Except as set forth in the disclosure schedules to this Agreement, Amicus has not received any notice
alleging noncompliance, and, to the Knowledge of Amicus, Amicus is not under investigation with respect to, or threatened to be charged,
with any material violation of any applicable statutes, laws, regulations, rules, judgments, orders or decrees of any governmental entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Valid
Issuance of Shares</U>. When issued, sold and delivered in accordance with the terms hereof for the consideration expressed herein, the
Shares will be duly and validly authorized and issued, fully paid and non-assessable, free and clear of all liens, and, based in part
on the representations of the Purchasers in <U>Section&nbsp;5</U> of this Agreement, will be issued in compliance with all applicable
federal and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governmental
Consents</U>. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with,
any federal, state or local governmental authority on the part of Amicus is required in connection with the consummation of the transactions
contemplated by the Transaction Documents, except for notices required or permitted to be filed with certain state and federal securities
commissions, which notices will be filed on a timely basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 438; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Brokers</U>. No broker, finder or investment banker is entitled to any brokerage, finder&rsquo;s or other fee or commission in connection
with the transactions contemplated by the Transaction Documents based on arrangements made by Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Undisclosed Liabilities</U>. Amicus does not have any liabilities (contingent or otherwise), except for (a)&nbsp;liabilities reflected
or reserved against in financial statements of Amicus included in the SEC Documents filed with the SEC prior to the date of each of the
Transaction Documents, and (b)&nbsp;liabilities that have not been and would not reasonably be expected to be material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Internal
Controls</U>. Amicus maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions
are executed in accordance with management&rsquo;s general or specific authorizations, (ii)&nbsp;transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability, and (iii)&nbsp;access
to assets or incurrence of liabilities is permitted only in accordance with management&rsquo;s general or specific authorization. Since
the end of Amicus&rsquo;s most recent audited fiscal year, to its Knowledge, there have been no significant deficiencies or material weakness
detected in Amicus&rsquo;s internal control over financial reporting (whether or not remediated) and no change in Amicus&rsquo;s internal
control over financial reporting that has materially affected, or is reasonably likely to materially affect, Amicus&rsquo;s internal control
over financial reporting. Amicus is not aware of any change in its internal controls over financial reporting that has occurred during
its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Amicus&rsquo;s internal control
over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Disclosure
Controls</U>. Amicus and its subsidiaries maintain an effective system of &ldquo;disclosure controls and procedures&rdquo; (as defined
in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) that complies in all material respects with the requirements of the Exchange Act and
that has been designed to ensure that information required to be disclosed by Amicus in reports that it files or submits under the Exchange
Act is recorded, processed, summarized and reported within the time periods specified in the SEC&rsquo;s rules&nbsp;and forms, including
controls and procedures designed to ensure that such information is accumulated and communicated to Amicus&rsquo;s management as appropriate
to allow timely decisions regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance</U>.
Amicus is not (i)&nbsp;in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse
of time or both, would result in a default by Amicus under), nor has Amicus received notice of a claim that it is in default under or
that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by
which it or any of its properties is bound (whether or not such default or violation has been waived), (ii)&nbsp;in violation of any judgment,
decree or order of any court, arbitrator or governmental body or (iii)&nbsp;in violation of any statute, rule, ordinance or regulation
of any governmental authority, including without limitation all foreign, federal, state and local laws relating to environmental protection,
occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or
reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 439; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Unlawful Payments</U>. Neither Amicus nor any of its subsidiaries nor, to the knowledge of Amicus, any director, officer, employee, agent,
affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken
an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic
government official or employee, including of any government-owned or controlled entity or of a public international organization, or
any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate
for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended,
or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or
anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful
benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit.
Amicus and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed
to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance
with Anti-Money Laundering Laws</U>. The operations of Amicus and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts
business, the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or
enforced by any governmental agency (collectively, the &ldquo;<B><I>Anti-Money Laundering Laws</I></B>&rdquo;) and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries
with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Conflicts with Sanctions Laws</U>. Neither Amicus nor any of its subsidiaries nor, to the knowledge of Amicus, any director, officer,
employee, agent, affiliate or other person associated with or acting on behalf of Amicus or any of its subsidiaries is currently the subject
or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign
Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation
as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;), the United Nations Security Council the European Union,
Her Majesty&rsquo;s Treasury or other relevant sanctions authority (collectively, &ldquo;<B><I>Sanctions</I></B>&rdquo;), nor is the Company,
any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, including,
without limitation, Crimea, Cuba,&nbsp;Iran, North Korea and Syria (each, a &ldquo;<B><I>Sanctioned Country</I></B>&rdquo;); and Amicus
will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business
with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate
any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person
(including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the
past five years, Amicus and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions
with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned
Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 440; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Company</U>. Amicus is not required to be registered as, and immediately following the Closing will not be required to register as, an
 &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Bad
Actor Disqualification</U>. None of Amicus, any predecessor or affiliated issuer of Amicus nor, to Amicus&rsquo;s Knowledge, any director
or executive officer of Amicus or any promoter connected with Amicus in any capacity, is subject to any of the &ldquo;bad actor&rdquo;
disqualifications within the meaning of Rule&nbsp;506(d)&nbsp;under the Securities Act, except for a disqualification event covered by
Rule&nbsp;506(d)(2)&nbsp;or (d)(3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.23</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Matters</U>. Assuming the accuracy of each Purchaser&rsquo;s representations and warranties set forth in <U>Section&nbsp;5</U>, no registration
under the Securities Act is required for the offer and sale of the Shares to the Purchasers hereunder. The Shares (i)&nbsp;were not offered
to the Purchasers by any form of general solicitation or general advertising and (ii)&nbsp;are not being offered to the Purchasers in
a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Representations
And Warranties Of Purchasers</U></B>. Each Purchaser hereby represents and warrants to Amicus as of the SPA Effective Date as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Legal
Power</U>. Purchaser has the requisite corporate power to enter into each of the Transaction Documents, and to carry out and perform its
obligations under the terms of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Due
Execution</U>. Each of the Transaction Documents have been duly authorized, executed and delivered by Purchaser, and, upon due execution
and delivery by Amicus, each of the Transaction Documents will be a valid and binding agreement of Purchaser, except as enforceability
may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally or by
equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investment
Representations</U>. In connection with the offer, purchase and sale of the Shares Purchaser makes the following representations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Purchaser
is acquiring the Shares for its own account, not as nominee or agent, for investment and not with a view to, or for resale in connection
with, any distribution or public offering thereof within the meaning of the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 441; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Purchaser
understands that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
Shares have not been registered under the Securities Act by reason of a specific exemption therefrom, that such securities may be required
to be held by it indefinitely under applicable securities laws, and that each Purchaser must, therefore, bear the economic risk of such
investment indefinitely, unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
book entry position representing Shares will be endorsed with the following legend:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">THE SECURITIES REPRESENTED HEREBY HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;ACT&rdquo;), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES.
THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY&nbsp;NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED
UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM OR UNLESS THE COMPANY HAS RECEIVED
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amicus
will instruct its transfer agent not to register the transfer of the Shares or any portion thereof, unless the conditions specified in
the foregoing legend are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of
the investment in the Shares to be purchased hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser acknowledges and agrees that the Purchaser is purchasing the Shares from Amicus. Each Purchaser further acknowledges that there
have been no representations, warranties, covenants and agreements made to the Purchaser by or on behalf of Amicus or any of its respective
affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing or any
other person or entity, expressly or by implication, other than those representations, warranties, covenants and agreements of Amicus
expressly set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser is an &ldquo;accredited investor&rdquo; as such term is defined in Rule&nbsp;501(a)&nbsp;of the rules&nbsp;and regulations promulgated
under the Securities Act. Each Purchaser acknowledges that it is aware that there are substantial risks incident to the purchase and ownership
of the Shares, including, without limitation, those set forth in the SEC Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Purchaser became aware of this offering of the Shares solely by means of direct contact between the Purchaser and Amicus or a representative
of Amicus, and the Shares were offered to the Purchaser solely by direct contact between the Purchaser and the Amicus or a representative
of Amicus. The Purchaser did not become aware of this offering of the Shares, nor were the Shares offered to the Purchaser, by any other
means.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 442; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Registration
Rights</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Registration</U>.
As soon as reasonably practicable, but no event later than 50 days after the Closing, Amicus shall prepare and file with the SEC a Registration
Statement covering the resale of all, or such portion as permitted by SEC Guidance (provided that, Amicus shall use commercially reasonable
efforts to advocate with the SEC for the registration of the maximum number of the Registrable Securities permitted by SEC Guidance),
of the Registrable Securities and use commercially reasonable efforts to cause a Registration Statement to be declared effective (including,
without limitation, the execution of any required undertaking to file post-effective amendments) as promptly as possible after the filing
thereof, but in no event later than ten (10)&nbsp;business days after the SEC has notified that Amicus that it will not review, or has
completed its review, of the Registration Statement. The Registration Statement shall be on Form&nbsp;S-3 (except if Amicus fails to meet
one or more of the registrant requirements specified in General Instruction I.A. on Form&nbsp;S-3, such registration shall be on another
appropriate form in accordance herewith). In the event that, despite Amicus&rsquo;s commercially reasonable efforts and compliance with
the terms of this <U>Section&nbsp;6.1</U>, the SEC refuses to alter its position, the Company shall (i)&nbsp;remove from the Registration
Statement such portion of the Registrable Securities (the &ldquo;<B><I>Cut Back Shares</I></B>&rdquo;) and/or (ii)&nbsp;agree to such
restrictions and limitations on the registration and resale of the Registrable Securities as the staff of the SEC may require to assure
Amicus&rsquo;s compliance with the requirements of Rule&nbsp;415 (collectively, the &ldquo;<B><I>SEC Restrictions</I></B>&rdquo;); provided,
however, that Amicus shall not agree to name any Purchaser as an &ldquo;underwriter&rdquo; in such Registration Statement without the
prior written consent of such Purchaser. Any cutback imposed on the Purchasers pursuant to this <U>Section&nbsp;6.1</U> shall be allocated
among the Purchasers on a pro rata basis, unless the SEC Restrictions otherwise require or provide or the Purchasers holding a majority
of the Registrable Shares otherwise agree. From and after the such date as the Company is able to effect the registration of such Cut
Back Shares in accordance with any SEC Restrictions (such date, the &ldquo;<B><I>Restriction Termination Date</I></B>&rdquo; of such Cut
Back Shares) applicable to any Cut Back Shares, all of the provisions of this <U>Section&nbsp;6</U> shall again be applicable to such
Cut Back Shares; provided, however, that (x)&nbsp;the Filing Deadline for the Registration Statement including such Cut Back Shares shall
be 10 business days after such Restriction Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Expenses
Of Registration</U>. Amicus shall pay all fees and expenses incurred in connection with any registration, qualification, exemption or
compliance by Amicus in the performance of its obligations pursuant to this <U>Section&nbsp;6</U>, whether or not any Registrable Securities
are sold pursuant to a Registration Statement, and including all registration and filing fees, exchange listing fees, and the fees and
expenses of counsel and accountants for Amicus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 443; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Obligations
Of Amicus</U>. In the case of registration, qualification, exemption or compliance effected by Amicus pursuant to the Transaction Documents,
Amicus will, upon request of any Purchaser, inform such Purchaser as to the status of such registration, qualification, exemption and
compliance. Amicus shall, at its expense and in addition to its obligations under <U>Section&nbsp;6.1</U>, as expeditiously as reasonably
possible:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to keep such registration, and any required qualification, exemption or compliance under state securities
laws, continuously effective with respect to the Purchasers and its permitted assignees, until the date all Shares registered by such
Registration Statement shall have been sold or may be sold pursuant to Rule&nbsp;144 without regard to volume limitations. The period
of time during which Amicus is required hereunder to keep the Registration Statement effective is referred to herein as the &ldquo;<B><I>Registration
Period</I></B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">advise
Purchasers promptly (and, in any event, within five business days):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">when
the Registration Statement or any amendment thereto has been filed with the SEC and when the Registration Statement or any post-effective
amendment thereto has become effective;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">of
the receipt by Amicus of any notification from the SEC of any stop order suspending the effectiveness of the Registration Statement or
the initiation of any proceedings for such purpose;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">of
the receipt by Amicus of any notification with respect to the suspension of the qualification of the Registrable Securities included therein
for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">of
the occurrence of any event that requires the making of any changes in the Registration Statement or the prospectus so that, as of such
date, the statements therein are not misleading and do not omit to state a material fact required to be stated therein or necessary to
make the statements therein (in the case of the prospectus, in the light of the circumstances under which they were made) not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement as
soon as reasonably practicable;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">if
any Purchaser so requests in writing, promptly furnish to such Purchaser, without charge, at least one copy of such Registration Statement
and any post-effective amendment thereto, including financial statements and schedules, and, if explicitly requested, all exhibits in
the form filed with the SEC;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">during
the Registration Period, promptly deliver to each Purchaser, without charge, at least one copy of the prospectus included in such Registration
Statement and any amendment or supplement thereto and as many additional copies as each Purchaser may reasonably request; and Amicus consents
to the use, consistent with the provisions hereof, of the prospectus or any amendment or supplement thereto by each Purchaser in connection
with the offering and sale of the Registrable Securities covered by the prospectus or any amendment or supplement thereto;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">during
the Registration Period, if a Purchaser so requests in writing, deliver to such Purchaser, without charge, (i)&nbsp;one copy of the following
documents, other than those documents available via EDGAR (and excluding, in each case, exhibits thereto): (A)&nbsp;its annual report
to its stockholders, if any (which annual report will contain financial statements audited in accordance with GAAP by a firm of certified
public accountants of recognized standing), (B)&nbsp;if not included in substance in its annual report to stockholders, its annual report
on Form&nbsp;10-K (or similar form), (C)&nbsp;its definitive proxy statement with respect to its annual meeting of stockholders, (D)&nbsp;each
of its quarterly reports to its stockholders, and, if not included in substance in its quarterly reports to stockholders, its quarterly
report on Form&nbsp;10-Q (or similar form), and (E)&nbsp;a copy of the Registration Statement; and (ii)&nbsp;if explicitly requested,
any exhibits filed with respect to the foregoing;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 444; Options: NewSection; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">upon
the occurrence of any event contemplated by <U>Section&nbsp;6.3(b)(iv)</U>, Amicus will use its commercially reasonable efforts to as
soon as reasonably practicable prepare a post-effective amendment to the Registration Statement or a supplement to the related prospectus,
or file any other required document so that, as thereafter delivered to the Purchasers, the prospectus will not include any untrue statement
of a material fact or omit to state any material fact necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">comply
in all material respects with all applicable rules&nbsp;and regulations of the SEC which could affect the sale of the Registrable Securities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to cause all Registrable Securities to be listed on each securities exchange or market, if any, on
which equity securities issued by Amicus have been listed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">use
its commercially reasonable efforts to take all other steps necessary to effect the registration of the Registrable Securities contemplated
hereby and to enable the Purchasers to sell Registrable Securities under Rule&nbsp;144; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">permit
counsel for the Purchasers to review the Registration Statement and all amendments and supplements thereto, within two business days prior
to the filing thereof with the SEC;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>provided</I></FONT>
that, in the case of clause (k)&nbsp;above, Amicus will not be required to delay the filing of the Registration Statement or any amendment
or supplement thereto to incorporate any comments to the Registration Statement or any amendment or supplement thereto by or on behalf
of any Purchaser if such comments would require a delay in the filing of such Registration Statement, amendment or supplement, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Furnishing
Information</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">It shall be a condition precedent
to the obligations of Amicus to take any action pursuant to <U>Section&nbsp;6.1</U> that each of the selling Holders shall furnish to
Amicus such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities
as shall be legally required under the Securities Act or otherwise required by the SEC to effect the registration of their Registrable
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 445; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Indemnification;
Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amicus
shall indemnify and hold harmless each Holder (including the employees, agents, representatives, officers and directors of each Purchaser
and its Affiliates) (each a &ldquo;<B><I>Purchaser Indemnitee</I></B>&rdquo;) from and against any and all losses, claims, damages, liabilities
and expenses (including reasonable costs of investigation) arising out of or based upon any untrue, or allegedly untrue, statement of
a material fact contained in any Registration Statement, prospectus or preliminary prospectus or notification or offering circular prepared
by Amicus in connection with the registration and/or offering of the Registrable Securities (as amended or supplemented if Amicus shall
have furnished any amendments or supplements thereto) or arising out of or based upon any omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as the same are
caused by or contained in any information concerning such Holder furnished in writing to Amicus by such Holder specifically and expressly
for inclusion in such document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Holder shall indemnify and hold harmless Amicus, and its respective directors, officers, employees and each Person who controls Amicus
(within the meaning of the Securities Act and the Exchange Act) from and against any and all losses, claims, damages, liabilities and
expenses (including reasonable costs of investigation) arising out of or based upon any untrue, or allegedly untrue, statement of a material
fact contained in any Registration Statement, prospectus or preliminary prospectus or notification or offering circular prepared by Amicus
in connection with the registration and/or offering of the Registrable Securities (as amended or supplemented if Amicus shall have furnished
any amendments or supplements thereto) or arising out of or based upon any omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein not misleading, if such statement or omission was made in reliance
upon and in conformity with any information concerning such Holder furnished in writing to Amicus by such Holder specifically and expressly
for use in the preparation of such document; <I>provided, however,</I> that in no event shall any indemnity under this <U>Section&nbsp;6.5(b)</U>&nbsp;be
greater in amount than the aggregate dollar amount of the proceeds received by all of the Purchasers upon the sale of such Registrable
Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Each
Person entitled to indemnification hereunder (the &ldquo;<B><I>Indemnified Party</I></B>&rdquo;) agrees to give prompt written notice
to the indemnifying party (the &ldquo;<B><I>Indemnifying Party</I></B>&rdquo;) after the receipt by the Indemnified Party of any written
notice of the commencement of any action, suit, proceeding or investigation or threat thereof made in writing for which the Indemnified
Party intends to claim indemnification or contribution pursuant to the Transaction Documents; <I>provided, however</I>, that the failure
to so notify the Indemnifying Party shall not relieve the Indemnifying Party of any liability that it may have to the Indemnified Party
hereunder unless, and only to the extent that, such failure results in the Indemnifying Party&rsquo;s forfeiture of substantive rights
or defenses. If notice of commencement of any such action is given to the Indemnifying Party as above provided, the Indemnifying Party
shall be entitled to participate in and, to the extent it may wish, jointly with any other Indemnifying Party similarly notified, to assume
the defense of such action at its own expense, with counsel chosen by it and reasonably satisfactory to such Indemnified Party. The Indemnified
Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses
of such counsel (other than reasonable costs of investigation) shall be paid by the Indemnified Party unless (i)&nbsp;the Indemnifying
Party agrees to pay the same, (ii)&nbsp;the Indemnifying Party fails to assume the defense of such action with counsel reasonably satisfactory
to the Indemnified Party in its reasonable judgment or (iii)&nbsp;the named parties to any such action (including any impleaded parties)
have been advised by such counsel that either (x)&nbsp;representation of such Indemnified Party and the Indemnifying Party by the same
counsel would be inappropriate under applicable standards of professional conduct or (y)&nbsp;there may be one or more legal defenses
available to it which are different from or additional to those available to the Indemnifying Party. In either of such cases, the Indemnifying
Party shall not have the right to assume the defense of such action on behalf of such Indemnified Party. No Indemnifying Party shall be
liable for any settlement entered into without its written consent (other than in the case where the Indemnifying Party is unconditionally
released from liability and its rights are not adversely effected), which consent shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 446; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
the indemnification provided for in this <U>Section&nbsp;6.5</U> from the Indemnifying Party pursuant to applicable law is unavailable
to an Indemnified Party hereunder in respect of any losses, claims, damages, liabilities or expenses referred to therein, then the Indemnifying
Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result
of such losses, claims, damages, liabilities or expenses in such proportion as is appropriate to reflect the relative fault of the Indemnifying
Party and Indemnified Party in connection with the actions which resulted in such losses, claims, damages, liabilities or expenses, as
well as any other relevant equitable considerations. The relative faults of such Indemnifying Party and Indemnified Party shall be determined
by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact
or omission or alleged omission to state a material fact, has been made by, or relates to information supplied by, such Indemnifying Party
or Indemnified Party, and the parties&rsquo; relative intent, Knowledge, access to information and opportunity to correct or prevent such
action. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall
be deemed to include, subject to the limitations set forth in <U>Sections 6.5(a)</U>, <U>(b)</U>&nbsp;and <U>(c)</U>, any legal or other
fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The parties hereto agree
that it would not be just and equitable if contribution pursuant to this <U>Section&nbsp;6.5(d)</U>&nbsp;were determined by pro rata allocation
or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding
paragraph. No Person guilty of an intentional or fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the Securities
Act) shall be entitled to contribution from any Person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rule&nbsp;144
Reporting</U>. In order to make the benefits of the rules&nbsp;and regulations of the SEC that may permit the sale of the Registrable
Securities to the public without registration available to the Holders, Amicus agrees to use commercially reasonable efforts to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">make
and keep public information available, as those terms are understood and defined in Rule&nbsp;144(c)(1)&nbsp;or any similar or analogous
rule&nbsp;promulgated under the Securities Act, at all times after the SPA Effective Date;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">file
with the SEC, in a timely manner, all reports and other documents required of Amicus under the Exchange Act; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 447; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">so
long as any Holder owns any Registrable Securities, furnish such Holders forthwith upon request: (i)&nbsp;a written statement by Amicus
as to its compliance with the reporting requirements of Rule&nbsp;144 under the Securities Act, and of the Exchange Act; (ii)&nbsp;a copy
of the most recent annual or quarterly report of Amicus; and (iii)&nbsp;such other reports and documents as a Holder may reasonably request
in availing itself of any rule&nbsp;of regulation of the SEC allowing it to sell any such securities without registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Assignment
of Registration Rights</U>. The rights and obligations under this <U>Section&nbsp;6</U> may only be assigned by a Holder to a transferee
or assignee of Registrable Securities that is (a)&nbsp;an Affiliate or (b)&nbsp;a successor (by operation of law or otherwise) to substantially
all the business or assets of such Holder; <I>provided, however</I>, that such attempted assignment shall be void unless (i)&nbsp;such
Holder, within 30 days after such transfer, furnishes to Amicus written notice of the name and address of such transferee or assignee
and the securities with respect to which such registration rights are being assigned, and (ii)&nbsp;such transferee agrees to be subject
to all obligations and restrictions with respect to the Registrable Securities set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Stock
Ownership Governance</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Lock-Up
Period</U>. Excluding any transfers or intra-company disposal of the Shares between a Purchaser and any of its Affiliates, for a period
of sixty (60) days following the SPA Effective Date (the &ldquo;<B><I>Lock-Up Period</I></B>&rdquo;), each Purchaser shall not, and shall
cause any other Holder not to, without the prior written consent of Amicus, sell, contract to sell, pledge or otherwise dispose of, directly
or indirectly, any Shares or enter into a transaction which would have the same effect. For the avoidance of doubt, this <U>Section&nbsp;7.1</U>
shall only apply to Shares purchased pursuant to this Agreement and shall not impose any restrictions on any other securities of Amicus
owned by the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
Without prejudice to the rights and remedies otherwise available to the parties, Amicus shall be entitled to equitable relief by way of
injunction if any Purchaser or any other Holder breaches or threatens to breach any of the provisions of this <U>Section&nbsp;7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Covenants</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Covenant
of Amicus</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amicus
hereby covenants and agrees that it shall take all necessary and appropriate actions to ensure that it shall have available under its
certificate of incorporation as in effect at the Closing sufficient authorized but unissued shares of its Common Stock to issue and sell
to Purchasers all of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">From
the date hereof until such time as the Shares have been sold pursuant to Rule&nbsp;144 or are eligible for resale under Rule&nbsp;144(b)(1)&nbsp;or
any successor provision, Amicus will use commercially reasonable efforts to continue the listing and trading of its Common Stock on Nasdaq
and, in accordance, therewith, will use commercially reasonable efforts to comply in all respects with Amicus&rsquo;s reporting, filing
and other obligations under the bylaws or rules&nbsp;of such market or exchange, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 448; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Amicus
shall not, and shall use its commercially reasonable efforts to ensure that no controlled Affiliate of Amicus shall, sell, offer for sale
or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act) that will
be integrated with the offer or sale of the Shares in a manner that would require the registration under the Securities Act of the sale
of the Shares to the Investors. Amicus shall not take any action or steps that would adversely affect reliance by Amicus in any material
respect on Section&nbsp;4(a)(2)&nbsp;for the exemption from registration for the transactions contemplated hereby or require registration
of the Shares under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Removal
of Legends</U>. In connection with any sale or disposition of the Shares by a Purchaser pursuant to Rule&nbsp;144 or pursuant to any other
exemption under the Securities Act such that the Purchaser acquires freely tradable shares and upon compliance by the Purchaser with the
requirements of this Agreement, if requested in writing by the Purchaser, Amicus shall use its commercially reasonable efforts to request
that the transfer agent for the Common Stock (the &ldquo;<B><I>Transfer Agent</I></B>&rdquo;) remove any restrictive legends related to
the book entry account holding such Shares and make a new, unlegended entry for such book entry Shares sold or disposed of without restrictive
legends within two (2)&nbsp;Trading Days of receipt of such request from the Purchaser. Upon the earliest of such time as the Shares (i)&nbsp;have
been registered for resale pursuant to an effective registration statement, (ii)&nbsp;have been sold pursuant to Rule&nbsp;144 or (iii)&nbsp;are
eligible for resale under Rule&nbsp;144(b)(1)&nbsp;or any successor provision, Amicus shall (A)&nbsp;deliver to the Transfer Agent irrevocable
instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Shares, and (B)&nbsp;cause its counsel to
deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected
under the Securities Act. Amicus shall be responsible for the fees of its Transfer Agent and all DTC fees associated with such issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><B><U>Miscellaneous</U></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts
of law thereof. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
Party at the address in effect for notices to it under the Transaction Documents and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by the Parties and delivered to the other Parties, it being understood that
the Parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page&nbsp;were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 449; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Public
Statements</U>. Amicus shall no later than the close of business on the date immediately following the date hereof, either issue a press
release or file a Current Report on Form&nbsp;8-K disclosing the material terms of the transactions contemplated hereby and any other
material, nonpublic information that Amicus may have provided to any Purchaser at any time prior thereto promptly following the execution
and delivery hereof, which shall have been previously reviewed by counsel for the Purchasers (the &ldquo;<B><I>Press Release</I></B>&rdquo;).
Amicus shall not include the name of any Purchaser in the Press Release or any other public announcement without the prior written consent
of such Purchaser. Subject to the foregoing, any statement to the public regarding this the Transaction Documents shall be approved in
advance by Amicus and the Purchasers, except as otherwise required by law, rule, regulation, legal process or applicable SEC Guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the Parties and their successors and permitted assigns.
Amicus may not assign this Agreement or any rights or obligations hereunder without the prior written consent of Purchasers purchasing
at least 85% of the Shares issuable hereunder. Subject to <U>Section&nbsp;6.7</U>, any Purchaser may assign any or all of its rights under
this Agreement to any Person to whom such Purchaser assigns or transfers any Shares, provided such transferee agrees in writing to be
bound, with respect to the transferred Shares, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules hereto, contain the entire understanding of the Parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters (other than confidentiality agreements to which Amicus is a party to with the Purchasers), which the Parties acknowledge
have been merged into such documents, exhibits and schedules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Separability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the Parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the Parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of
the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
Amicus does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw,
in its sole discretion from time to time upon written notice to Amicus, any relevant notice, demand or election in whole or in part without
prejudice to its future actions and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Replacement
of Shares</U>. If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, Amicus shall issue or cause
to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to Amicus of such loss, theft or
destruction. The applicant for a new certificate or instrument under such circumstances may also be required to pay a customary bond and
any reasonable third-party costs associated with the issuance of such replacement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 450; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and Amicus will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be
adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agrees
to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.10</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto, shall be deemed to constitute the Purchasers as a partnership, an association, a
joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights, including without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in their review and negotiation of the Transaction Documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.11</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendment
and Waiver</U>. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment,
by Amicus and Purchasers purchasing at least 85% of the Shares issuable hereunder or, in the case of a waiver, by the Party against whom
enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.12</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of (a)&nbsp;the date of transmission, if such notice or communication is delivered via email
at the email address set forth on the signature pages&nbsp;attached hereto prior to 5:30 p.m.&nbsp;(New York City time) on a Trading Day,
(b)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via email at the email address
set forth on the signature pages&nbsp;attached hereto on a day that is not a Trading Day or later than 5:30 p.m.&nbsp;(New York City time)
on any Trading Day, (c)&nbsp;the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier
service, or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages&nbsp;attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 451; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.13</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Fees
and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each Party shall pay the fees and expenses
of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. Amicus shall pay all transfer agent fees, stamp taxes and other taxes
and duties levied in connection with the delivery of any Shares to the Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.14</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Titles
and Subtitles</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.15</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Counterparts;
Effectiveness</U>. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of
which together shall constitute one instrument. This Agreement shall become effective when each Party hereto shall have received counterparts
thereof signed and delivered (by telecopy or other electronic means) by the other Parties hereto. Counterparts may be delivered via facsimile,
electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act,
the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.16</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Construction</U>.
The Parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule&nbsp;of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.17</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the Parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
<U>Section&nbsp;6.5</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 452; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Securities Purchase Agreement is hereby executed
as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMICUS:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amicus Therapeutics,&nbsp;Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Daphne Quimi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daphne Quimi</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3675 Market Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19104</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>gcoffice@amicusrx.com</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature
Page&nbsp;to Securities Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 453 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Avoro Life Sciences Fund LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;/s/ Scott Epstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
Epstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner, CFO&nbsp;&amp;COO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110 Greene Street, Suite&nbsp;800</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, New York 10012</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature
Page&nbsp;to Securities Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 454 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Invus Public Equities, L.P.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Khalil Barrage</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Khalil
Barrage</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President of the General Partner</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">750 Lexington Ave, 30<SUP>th</SUP> FL</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature
Page&nbsp;to Securities Purchase Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 455 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">JANUS HENDERSON BIOTECH INNOVATION MASTER FUND LIMITED</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By: Janus Capital Management LLC, its investment advisor</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Andrew Acker</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Andrew
Acker</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized Signatory</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">151 Detroit Street</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denver, CO 80206</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Securities Purchase
Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 456 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sphera Biotech Master Fund LP</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Michelle Ross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michelle
Ross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portfolio Manager&nbsp;&amp; Partner</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PO Box 309, Ugland House, Grand</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman, KY1-1104, Cayman Islands</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Securities Purchase
Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 457 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sphera Global Healthcare Master Fund</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding: 0.25pt 0.25pt 0.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Michelle Ross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0.5pt 0.25pt 0.25pt; font-size: 10pt; width: 41%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michelle
Ross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portfolio Manager&nbsp;&amp; Partner</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PO Box 309, Ugland House, Grand</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman, KY1-1104, Cayman Islands</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;to Securities Purchase
Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 458 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Schedule A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Purchaser Share Amounts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Purchaser</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares<BR>
 Purchased</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Purchase Price<BR>
 (in $)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Avoro Life Sciences Fund LLC</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,929,273</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">39,999,999.14</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Invus Public Equities, L.P.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,946,955</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000,001.90</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Janus Henderson Biotech Innovation Master Fund Limited</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">491,159</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,999,998.62</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Sphera Biotech Master Fund LP</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">211,198</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,149,996</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25pt">Sphera Global Healthcare Master Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">279,961</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,850,003</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 459 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.6</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><U>Execution Version</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Investor Rights Agreement</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Investor Rights Agreement
(this &ldquo;<B>Agreement</B>&rdquo;), dated as of September 29, 2021, is among ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted
company (the &ldquo;<B>Company</B>&rdquo;) and the other parties hereto identified as a &ldquo;Holder&rdquo; on the signature pages hereto
(each, a &ldquo;<B>Holder</B>&rdquo; and collectively, the &ldquo;<B>Holders</B>&rdquo;). Capitalized terms used but not defined herein
have the meanings assigned to them in the Business Combination Agreement dated as of the date hereof (the &ldquo;<B>Business Combination
Agreement</B>&rdquo;), among the Company, Amicus Therapeutics, Inc., a Delaware corporation (&ldquo;<B>Parent</B>&rdquo;), Amicus GT Holdings,
LLC, a Delaware limited liability company (&ldquo;<B>Amber GT</B>&rdquo;), and Caritas Therapeutics, LLC, a Delaware limited liability
company (&ldquo;<B>Caritas</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to the Business
Combination Agreement, among other things, on the Closing Date, (i) the Company will redomesticate as a Delaware corporation and change
its name from &ldquo;ARYA Sciences Acquisition Corp IV to &ldquo;Caritas Therapeutics, Inc.&rdquo;, (ii) the Company will receive the
number of Common Units (as defined in the LLC Agreement (as defined below)) equal to the Net Outstanding ARYA Class A Shares determined
pursuant to the Business Combination Agreement, (iii) the Company will issue to Amber GT the number of ARYA Class B Shares equal to the
Transaction Equity Security Amount determined pursuant to the Business Combination Agreement and (iv) Amber GT will receive a number of
Common Units equal to the number of ARYA Class B Shares it receives on the Closing Date (the &ldquo;<B>Amber GT Units</B>&rdquo;), and
such Amber GT Units will be exchangeable for Common Stock (as defined below) from time to time pursuant to the terms of the LLC Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, in connection with
the consummation of the transactions contemplated by the Business Combination Agreement, Perceptive Life Sciences Master Fund Ltd., a
Cayman Islands exempted company (&ldquo;<B>Perceptive</B>&rdquo;), will be issued shares of Common Stock in a private placement transaction
pursuant to that certain Subscription Agreement, dated as of September 29, 2021;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company, ARYA
Sciences Holdings IV, a Cayman Islands exempted limited company (the &ldquo;<B>Sponsor</B>&rdquo;), and the Independent Directors (as
defined herein, and, together with the Sponsor, the &ldquo;<B>Original Holders</B>&rdquo;) are parties to the Registration and Shareholder
Rights Agreement, dated as of March 2, 2021 (the &ldquo;<B>Prior Agreement</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the parties to the
Prior Agreement desire to terminate the Prior Agreement and to provide for certain rights and obligations included herein and to include
Amber GT and Perceptive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing, the parties hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase; color: #010000">Article
I </FONT><BR>
DEFINITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 1.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Definitions</B>. For purposes of this Agreement, the following terms and variations thereof have the meanings set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Adverse Disclosure</B>&rdquo;
shall mean any public disclosure of material non-public information, which disclosure, in the good faith judgment of the Board, after
consultation with outside counsel to the Company, (i) would be required to be made in any Registration Statement or Prospectus in order
for the applicable Registration Statement or Prospectus not to contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements contained therein (in the case of any prospectus and any preliminary prospectus, in the light of
the circumstances under which they were made) not misleading, (ii) would not be required to be made at such time if the Registration Statement
were not being filed, and (iii) the Company has a bona fide business purpose for not making such information public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 460 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agreement</B>&rdquo;
shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Amber GT</B>&rdquo;
shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Amber GT Units</B>&rdquo;
shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Block Trade</B>&rdquo;
means any non-marketed underwritten offering taking the form of a block trade to a financial institution, &ldquo;qualified institutional
buyer&rdquo; (as defined in Rule 144A under the Securities Act) or institutional &ldquo;accredited&rdquo; investor (as defined in Rule
501(a) of Regulation D under the Securities Act), bought deal, over-night deal or similar transaction through a broker, sales agent or
distribution agent, whether as agent or principal, that does not include &ldquo;road show&rdquo; presentations to potential investors
requiring substantial marketing effort from management over multiple days, the issuance of a &ldquo;comfort letter&rdquo; by the Company&rsquo;s
auditors, or the issuance of a legal opinion by the Company&rsquo;s legal counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Board</B>&rdquo;
shall mean the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Combination
Agreement</B>&rdquo; shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
means a day other than Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by law
to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Caritas</B>&rdquo;
shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Change in Control</B>&rdquo;
means the transfer (whether by tender offer, merger, stock purchase, consolidation or other similar transaction), in one transaction or
a series of related transactions, to a person or group of affiliated persons of the Company&rsquo;s voting securities if, after such transfer,
such person or group of affiliated persons would hold more than 50% of outstanding voting securities of the Company (or surviving entity)
or would otherwise have the power to control the board of directors of the Company or to direct the operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commission</B>&rdquo;
means the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common Stock</B>&rdquo;
means, after giving effect to the Domestication, the Company&rsquo;s Class A common stock, par value $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company</B>&rdquo;
shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 461; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Demand Registration</B>&rdquo;
shall have the meaning given in&#8239;<U>subsection 2.1.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Demand Requesting
Holder</B>&rdquo; shall have the meaning given in&#8239;<U>subsection 2.1.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Demanding Holders</B>&rdquo;
shall have the meaning given in&#8239;<U>subsection 2.1.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange Act</B>&rdquo;
shall mean the Securities Exchange Act of 1934, as it may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Form S-1</B>&rdquo;
means a Registration Statement on Form S-1 or any comparable successor form or forms thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Form S-3</B>&rdquo;
means a Registration Statement on Form S-3 or any comparable successor form or forms thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Holders</B>&rdquo;
shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Independent Directors</B>&rdquo;
means Todd Wider, Michael Henderson and Leslie Trigg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Insider Letter</B>&rdquo;
shall mean that certain letter agreement, dated as of February 25, 2021, by and among the Company, the Sponsor and each of the other parties
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Liquidation Event</B>&rdquo;
shall mean any of the following : (i) the acquisition of the Company by another entity by means of any transaction or series of related
transactions to which the Company is party (including, without limitation, any stock acquisition, reorganization, sale of voting control,
merger or consolidation but excluding any sale of stock for capital raising purposes) other than a transaction or series of related transactions
in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions
retain, immediately after such transaction or series of related transactions, as a result of shares in the Company held by such holders
prior to such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding
voting securities of the Company or such other surviving or resulting entity (or if the Company or such other surviving or resulting entity
is a wholly-owned subsidiary immediately following such acquisition, its parent); (ii) a sale, lease, transfer, exclusive license or other
disposition of all or substantially all of the assets of the Company and its subsidiaries taken as a whole by means of any transaction
or series of related transactions, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly-owned
subsidiary of the Company; or (iii) any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>LLC Agreement</B>&rdquo;
shall mean the Amended and Restated Limited Liability Agreement of Caritas, as in effect following the consummation of the transactions
contemplated by the Business Combination Agreement, and as the same may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Maximum Number of
Securities</B>&rdquo; shall have the meaning given in&#8239;<U>subsection 2.1.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Misstatement</B>&rdquo;
shall mean an untrue statement of a material fact or an omission to state a material fact required to be stated in a Registration Statement
or Prospectus, or necessary to make the statements in a Registration Statement or Prospectus in the light of the circumstances under which
they were made not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 462; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>New Registration
Statement</B>&rdquo; shall have the meaning given in&#8239;<U>subsection 2.3.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Original Holders</B>&rdquo;
shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Parent</B>&rdquo;
shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Perceptive Holders</B>&rdquo;
means the Sponsor and Perceptive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&ldquo;Permitted Transferee</B>&rdquo;
shall have the meaning given in <U>subsection 7.3.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Piggyback Registration</B>&rdquo;
shall have the meaning given in&#8239;<U>subsection 2.3.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>PIPE Shares</B>&rdquo;
means shares of Common Stock purchased pursuant to those certain Subscription Agreements between certain Holders and the Company dated
on or about September 29, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prior Agreement</B>&rdquo;
shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Private Placement
Shares Purchase Agreement</B>&rdquo; shall mean that certain Private Placement Shares Purchase Agreement, dated as of February 25, 2021,
by and between the Company and the Sponsor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Pro Rata</B>&rdquo;
shall have the meaning given in&#8239;<U>subsection 2.1.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Prospectus</B>&rdquo;
shall mean the prospectus included in any Registration Statement, as supplemented by any and all prospectus supplements and as amended
by any and all post-effective amendments and including all material incorporated by reference in such prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registrable Security</B>&rdquo;,
 &ldquo;<B>Registrable Securities</B>&rdquo; shall mean (a) any outstanding share of Common Stock (including the shares of Common Stock
issued or issuable upon the exchange of any Amber GT Units pursuant to and in accordance with the LLC Agreement or the exercise of any
other equity security) held by a Holder as of the closing of the transactions contemplated by the Business Combination Agreement (including,
without limitation, the PIPE Shares and any shares of Common Stock issued pursuant to the Business Combination Agreement) and (b) any
other equity security of the Company issued or issuable with respect to any such share of Common Stock by way of a stock dividend or stock
split or in connection with a combination of shares, recapitalization, merger, consolidation or reorganization;&#8239;<U>provided</U>,&#8239;<U>however</U>,
that, as to any particular Registrable Security, such securities shall cease to be Registrable Securities when: (A) a Registration Statement
with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been sold,
transferred, disposed of or exchanged in accordance with such Registration Statement; (B) such securities shall have been otherwise transferred,
new certificates for such securities not bearing a legend restricting further transfer shall have been delivered by the Company to the
transferee, and subsequent public distribution of such securities shall not require registration under the Securities Act; (C) such securities
shall have ceased to be outstanding; or (D) such securities have been sold to, or through, a broker, dealer or underwriter in a public
distribution or other public securities transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 463; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registration</B>&rdquo;
shall mean a registration effected by preparing and filing a registration statement or similar document in compliance with the requirements
of the Securities Act, and the applicable rules and regulations promulgated thereunder, and such registration statement becoming effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registration Expenses</B>&rdquo;
shall mean the out-of-pocket expenses of a Registration or Underwritten Offering, including, without limitation, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(A)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
registration and filing fees (including fees with respect to filings required to be made with the Financial Industry Regulatory Authority,
Inc.) and any securities exchange on which the Common Stock is then listed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(B)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;fees
and expenses of compliance with securities or Blue Sky laws (including reasonable fees and disbursements of counsel for the Underwriters
in connection with Blue Sky qualifications of Registrable Securities);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(C)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;printing,
messenger, telephone and delivery expenses;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(D)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;fees
and disbursements of counsel for the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(E)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;reasonable
fees and disbursements of all independent registered public accountants of the Company incurred specifically in connection with such Registration
or Underwritten Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(F)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;reasonable
fees and expenses of one (1) legal counsel selected by the majority-in-interest of the Demanding Holders or the majority-in interest of
the Takedown Requesting Holders (including if such Underwritten Takedown is in the form of a Block Trade), as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registration Statement</B>&rdquo;
shall mean any registration statement that covers the Registrable Securities pursuant to the provisions of this Agreement, including the
Prospectus included in such registration statement, amendments (including post-effective amendments) and supplements to such registration
statement, and all exhibits to and all material incorporated by reference in such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Requesting Holder</B>&rdquo;
shall have the meaning given in&#8239;<U>subsection 2.3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Resale Shelf Registration
Statement</B>&rdquo; shall have the meaning given in&#8239;<U>subsection 2.3.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities Act</B>&rdquo;
shall mean the Securities Act of 1933, as amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Selling Holders</B>&rdquo;
means any Holder electing to sell any of its Registrable Securities in a Registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 464; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SEC Guidance</B>&rdquo;
shall have the meaning given in&#8239;<U>subsection 2.3.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Sponsor</B>&rdquo;
shall have the meaning given in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Takedown Requesting
Holder</B>&rdquo; shall have the meaning given in&#8239;<U>subsection 2.3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer</B>&rdquo;
means to, directly or indirectly, sell, transfer, assign, pledge, encumber, hypothecate or similarly dispose of, either voluntarily or
involuntarily, or to enter into any contract, option or other arrangement or understanding with respect to the sale, transfer, assignment,
pledge, encumbrance, hypothecation or similar disposition of, any interest owned by a person or any interest (including a beneficial interest)
in, or the ownership, control or possession of, any interest owned by a person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Underwriter</B>&rdquo;
shall mean a securities dealer who purchases any Registrable Securities as principal in an Underwritten Offering and not as part of such
dealer&rsquo;s market-making activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Underwritten Registration</B>&rdquo;
or &ldquo;<B>Underwritten Offering</B>&rdquo; shall mean a Registration in which securities of the Company are sold to an Underwriter
in a firm commitment underwriting for distribution to the public, including for the avoidance of doubt an Underwritten Shelf Takedown.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Underwritten Shelf
Takedown</B>&rdquo; shall have the meaning given in&#8239;<U>subsection 2.3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase; color: #010000">Article
II </FONT><BR>
REGISTRATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Demand Registration</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Request for Registration</U>. Subject to the provisions of&#8239;<U>subsection 2.1.4</U>&#8239;and&#8239;<U>Section 2.4&#8239;</U>hereof,
at any time and from time to time (but subject to Article V), (i) Amber GT or (ii) the Perceptive Holders holding at least a majority
in interest of the then-outstanding number of Registrable Securities held by all Perceptive Holders (as the case may be, the &ldquo;<B>Demanding
Holders</B>&rdquo;), may make a written demand for Registration of all or part of their Registrable Securities on Form S-3 (or, if Form
S-3 is not available to be used by the Company at such time, on Form S-1 or another appropriate form permitting Registration of such Registrable
Securities for resale by such Demanding Holders), which written demand shall describe the amount and type of securities to be included
in such Registration and the intended method(s) of distribution thereof (such written demand a &ldquo;<B>Demand Registration</B>&rdquo;).
The Company shall, within ten (10) days of the Company&rsquo;s receipt of the Demand Registration, notify, in writing, all other Holders
of Registrable Securities of such demand, and each Holder of Registrable Securities who thereafter wishes to include all or a portion
of such Holder&rsquo;s Registrable Securities in a Registration pursuant to a Demand Registration (each such Holder that includes all
or a portion of such Holder&rsquo;s Registrable Securities in such Registration, a &ldquo;<B>Demand Requesting Holder</B>&rdquo;) shall
so notify the Company, in writing, within five (5) days after the receipt by the Holder of the notice from the Company. Upon receipt by
the Company of any such written notification from a Demand Requesting Holder(s) to the Company, such Demand Requesting Holder(s) shall
be entitled to have their Registrable Securities included in a Registration pursuant to a Demand Registration and the Company shall effect,
as soon thereafter as practicable, but not more than thirty (30) days immediately after the Company&rsquo;s receipt of the Demand Registration,
the Registration of all Registrable Securities requested by the Demanding Holders and Demand Requesting Holders pursuant to such Demand
Registration;&#8239;<U>provided,</U> that&#8239;the Company shall not be obligated to effect any Registration under this&#8239;<U>subsection
2.1.1</U>&#8239;if the Demanding Holders and Demand Requesting Holders propose to sell Registrable Securities with aggregate proceeds of
less than $25,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 465; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Effective Registration</U>. Notwithstanding the provisions of&#8239;<U>subsection 2.1.1</U>&#8239;above or any other part of this
Agreement, a Registration pursuant to a Demand Registration shall not count as a Registration unless and until (i) the Registration Statement
filed with the Commission with respect to a Registration pursuant to a Demand Registration has been declared effective by the Commission
and (ii) the Company has complied with all of its obligations under this Agreement with respect thereto;&#8239;<U>provided</U>,&#8239;<U>however</U>,
that if, after such Registration Statement has been declared effective, an offering of Registrable Securities in a Registration pursuant
to a Demand Registration is subsequently interfered with by any stop order or injunction of the Commission, federal or state court or
any other governmental agency, the Registration Statement with respect to such Registration shall be deemed not to have been declared
effective for purposes of counting Registrations under&#8239;<U>subsection 2.1.1</U>&#8239;above unless and until (i) such stop order or
injunction is removed, rescinded or otherwise terminated, and (ii) a majority-in-interest of the Demanding Holders initiating such Demand
Registration thereafter affirmatively elect to continue with such Registration and accordingly notify the Company in writing, but in no
event later than five (5) days, of such election;&#8239;<U>provided</U>,&#8239;<U>further</U>,&#8239;<U>however</U>, that the Company shall
not be obligated or required to file another Registration Statement until the Registration Statement that has been previously filed with
respect to a Registration pursuant to a Demand Registration becomes effective or has been terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Underwritten Offering</U>. Subject to the provisions of&#8239;<U>subsection 2.1.4</U>&#8239;and&#8239;<U>Section 2.4</U>&#8239;hereof,
if a majority-in-interest of the Demanding Holders advise the Company as part of their Demand Registration that the offering of the Registrable
Securities pursuant to such Demand Registration shall be in the form of an Underwritten Offering, then the right of such Demanding Holder
or Demand Requesting Holder (if any) to include its Registrable Securities in such Registration shall be conditioned upon such Holder&rsquo;s
participation in such Underwritten Offering and the inclusion of such Holder&rsquo;s Registrable Securities in such Underwritten Offering
to the extent provided herein. All such Holders proposing to distribute their Registrable Securities through an Underwritten Offering
under this&#8239;<U>subsection 2.1.3</U>&#8239;shall enter into an underwriting agreement in customary form with the Underwriter(s) selected
for such Underwritten Offering by a majority-in-interest of the Demanding Holders, such Underwriter(s) to be reasonably acceptable to
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Reduction of Underwritten Offering</U>. If the managing Underwriter or Underwriters in an Underwritten Registration pursuant
to a Demand Registration, in good faith, advises the Company, the Demanding Holders and the Demand Requesting Holders (if any) in writing
that the dollar amount or number of Registrable Securities that the Demanding Holders and the Demand Requesting Holders (if any) desire
to sell, taken together with all other Common Stock or other equity securities that the Company desires to sell and the Common Stock,
if any, as to which a Registration has been requested pursuant to separate written contractual piggy-back registration rights held by
any other stockholders who desire to sell, exceeds the maximum dollar amount or maximum number of equity securities that can be sold in
the Underwritten Offering without adversely affecting the proposed offering price, the timing, the distribution method, or the probability
of success of such offering (such maximum dollar amount or maximum number of such securities, as applicable, the &ldquo;<B>Maximum Number
of Securities</B>&rdquo;), then the Company shall include in such Underwritten Offering, as follows: (i) first, the Registrable Securities
of the Demanding Holders and the Demand Requesting Holders (if any) (pro rata based on the respective number of Registrable Securities
that each Demanding Holder and Demand Requesting Holder (if any) has requested be included in such Underwritten Registration and the aggregate
number of Registrable Securities that the Demanding Holders and Demand Requesting Holders have requested be included in such Underwritten
Registration (such proportion is referred to herein as &ldquo;<B>Pro Rata</B>&rdquo;)) that can be sold without exceeding the Maximum
Number of Securities; (ii) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause
(i), Common Stock or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum Number
of Securities; and (iii) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses (i)
and (ii), Common Stock or other equity securities of other persons or entities that the Company is obligated to register in a Registration
pursuant to separate written contractual arrangements with such persons and that can be sold without exceeding the Maximum Number of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 466; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Demand Registration Withdrawal</U>. Amber GT or a majority-in-interest of the Perceptive Holders, as the case may be, in the
case of a Registration under&#8239;<U>subsection 2.1.1</U>&#8239;initiated by Amber GT or the Perceptive Holders, as the case may be, or
any Demand Requesting Holders (if any) shall have the right to withdraw from a Registration pursuant to such Demand Registration for any
or no reason whatsoever upon written notification to the Company and the Underwriter(s) (if any) of their intention to withdraw from such
Registration prior to the effectiveness of the Registration Statement filed with the Commission with respect to the Registration of their
Registrable Securities pursuant to such Demand Registration (or after such Registration Statement has been declared effective and is subsequently
interfered with by any stop order or injunction of the Commission, federal or state court or any other governmental agency).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Piggyback Registration</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Piggyback Rights</U>. If the Company proposes to file a Registration Statement under the Securities Act with respect to an offering
of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into equity securities, for its
own account or for the account of stockholders of the Company (other than pursuant to&#8239;<U>Sections 2.1</U>&#8239;and&#8239;<U>2.3</U>&#8239;of
this Agreement), other than a Registration Statement (i)&#8239;filed in connection with any employee stock option or other benefit plan,
(ii) for an exchange offer or offering of securities solely to the Company&rsquo;s existing stockholders, (iii) for an offering of debt
that is convertible into equity securities of the Company, (iv) filed on Form S-4 related to any merger, acquisition or business combination,
or (v) for a dividend reinvestment plan, then the Company shall give written notice of such proposed filing to all of the Holders of Registrable
Securities as soon as practicable but not less than ten (10) days before the anticipated filing date of such Registration Statement or
applicable Prospectus, which notice shall (A) describe the amount and type of securities to be included in such offering, the intended
method(s) of distribution, and the name of the proposed managing Underwriter(s), if any, in such offering, and (B) offer to all of the
Holders of Registrable Securities the opportunity to register the sale of such number of Registrable Securities as such Holders may request
in writing within five (5) days after receipt of such written notice (such Registration a &ldquo;<B>Piggyback Registration</B>&rdquo;).
The Company shall, in good faith, cause such Registrable Securities to be included in such Piggyback Registration and shall use its commercially
reasonable efforts to cause the managing Underwriter(s) of a proposed Underwritten Offering to permit the Registrable Securities requested
by the Holders pursuant to this&#8239;<U>subsection 2.2.1</U>&#8239;to be included in a Piggyback Registration on the same terms and conditions
as any similar securities of the Company included in such Registration and to permit the sale or other disposition of such Registrable
Securities in accordance with the intended method(s) of distribution thereof. All such Holders proposing to distribute their Registrable
Securities through an Underwritten Offering under this&#8239;<U>subsection 2.2.1</U>&#8239;shall enter into an underwriting agreement in
customary form with the Underwriter(s) selected for such Underwritten Offering by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 467; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Reduction of Piggyback Registration</U>. If the managing Underwriter(s) in an Underwritten Registration that is to be a Piggyback
Registration, in good faith, advises the Company and the Holders of Registrable Securities participating in the Piggyback Registration
in writing that the dollar amount or number of shares of Common Stock that the Company desires to sell, taken together with (i) the shares
of Common Stock, if any, as to which Registration has been demanded pursuant to separate written contractual arrangements with persons
or entities other than the Holders of Registrable Securities hereunder, (ii) the Registrable Securities as to which registration has been
requested pursuant to&#8239;<U>Section 2.2.1</U>&#8239;hereof, and (iii) the shares of Common Stock, if any, as to which Registration has
been requested pursuant to separate written contractual piggy-back registration rights of other stockholders of the Company, exceeds the
Maximum Number of Securities, then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">If the Registration is undertaken for the Company&rsquo;s account (which, for the avoidance of doubt,
shall not include an offering of securities by the Company for the purpose of delivering cash to Amber GT or its transferee in connection
with an exchange of Amber GT Units pursuant to the LLC Agreement, such a Registration being considered to be a Registration by Amber GT
or its transferee, such Registration to be subject to the reduction procedures set forth in subsection 2.1.4 or subsection 2.3.6, as applicable),
the Company shall include in any such Registration (A) first, Common Stock or other equity securities, if any, that the Company desires
to sell, which can be sold without exceeding the Maximum Number of Securities; (B) second, to the extent that the Maximum Number of Securities
has not been reached under the foregoing clause (A), the Registrable Securities of Holders exercising their rights to register their Registrable
Securities pursuant to subsection 2.2.1 hereof, Pro Rata, based on the respective number of Registrable Securities that each Holder has
so requested, which can be sold without exceeding the Maximum Number of Securities; and (C) third, to the extent that the Maximum Number
of Securities has not been reached under the foregoing clauses (A) and (B), Common Stock or other equity securities, if any, for the account
of other persons or entities that the Company is obligated to register pursuant to separate written contractual arrangements with such
persons or entities, which can be sold without exceeding the Maximum Number of Securities; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 468; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">If the Registration is pursuant to a request by persons or entities other than the Holders of Registrable
Securities, then the Company shall include in any such Registration (A) first, Common Stock or other equity securities, if any, of such
requesting persons or entities, other than the Holders of Registrable Securities, which can be sold without exceeding the Maximum Number
of Securities; (B) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing clause (A), the
Registrable Securities of Holders exercising their rights to register their Registrable Securities pursuant to subsection 2.2.1, Pro Rata
based on the respective number of Registrable Securities that each Holder has requested, which can be sold without exceeding the Maximum
Number of Securities; (C) third, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses
(A) and (B), Common Stock or other equity securities that the Company desires to sell, which can be sold without exceeding the Maximum
Number of Securities; and (D) fourth, to the extent that the Maximum Number of Securities has not been reached under the foregoing clauses
(A), (B) and (C), Common Stock or other equity securities, if any, for the account of other persons or entities that the Company is obligated
to register pursuant to separate written contractual arrangements with such persons or entities, which can be sold without exceeding the
Maximum Number of Securities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Piggyback Registration Withdrawal</U>. Any Holder of Registrable Securities shall have the right to withdraw from a Piggyback
Registration for any or no reason whatsoever upon written notification to the Company and the Underwriter or Underwriters (if any) of
his, her or its intention to withdraw from such Piggyback Registration prior to the effectiveness of the Registration Statement filed
with the Commission with respect to such Piggyback Registration, or, if such Piggyback Registration is in connection with an underwritten
offering pursuant to an effective shelf registration statement, then prior to the public announcement of such offering. The Company (whether
on its own good faith determination or as the result of a request for withdrawal by persons pursuant to separate written contractual obligations)
may withdraw a Registration Statement filed with the Commission in connection with a Piggyback Registration at any time prior to the effectiveness
of such Registration Statement. Notwithstanding anything to the contrary in this Agreement, the Company shall be responsible for the Registration
Expenses incurred in connection with the Piggyback Registration prior to its withdrawal under this&#8239;<U>subsection 2.2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Right to Terminate Registration</U>. The Company shall have the right to terminate or withdraw any registration initiated by
it under this&#8239;<U>Section 2.2</U>&#8239;prior to the effectiveness of such registration whether or not any Holder of Registrable Securities
has elected to include securities in such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 469; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Resale Shelf Registration Rights</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Registration Statement Covering Resale of Registrable Securities</U>. The Company shall prepare and file or cause to be prepared
and filed with the Commission, no later than fifteen (15) days following the Closing Date (the &ldquo;<B>Filing Deadline</B>&rdquo;),
a Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415 of the Securities Act or any successor
thereto registering the resale from time to time by Holders of all of the Registrable Securities held by the Holders (the &ldquo;<B>Resale
Shelf Registration Statement</B>&rdquo;). The Resale Shelf Registration Statement shall be on Form S-3 (or, if Form S-3 is not available
to be used by the Company at such time, on Form S-1 or another appropriate form permitting Registration of such Registrable Securities
for resale). If the Resale Shelf Registration Statement is initially filed on Form S-1 and thereafter the Company becomes eligible to
use Form S-3 for secondary sales, the Company shall, as promptly as practicable, cause such Resale Shelf Registration Statement to be
amended, or shall file a new replacement Resale Shelf Registration Statement, such that the Resale Shelf Registration Statement is on
Form S-3. The Company shall use commercially reasonable efforts to cause the Resale Shelf Registration Statement to be declared effective
as soon as possible after filing;&#8239;<U>provided</U>,&#8239;<U>however</U>, that the Company&rsquo;s obligations to include the Registrable
Securities held by a Holder in the Resale Shelf Registration Statement are contingent upon such Holder furnishing in writing to the Company
such information regarding the Holder, the securities of the Company held by the Holder and the intended method of disposition of the
Registrable Securities as shall be reasonably requested by the Company to effect the registration of the Registrable Securities, and the
Holder shall execute such documents in connection with such registration as the Company may reasonably request that are customary of a
selling stockholder in similar situations. Once effective, the Company shall use commercially reasonable efforts to keep the Resale Shelf
Registration Statement and Prospectus included therein continuously effective and to be supplemented and amended to the extent necessary
to ensure that such Registration Statement is available or, if not available, to ensure that another Registration Statement is available,
under the Securities Act at all times until the earliest of (i) the date on which all Registrable Securities and other securities covered
by such Registration Statement have been disposed of in accordance with the intended method(s) of distribution set forth in such Registration
Statement and (ii) the date on which all Registrable Securities and other securities covered by such Registration Statement have ceased
to be Registrable Securities. The Registration Statement filed with the Commission pursuant to this&#8239;<U>subsection 2.3.1</U>&#8239;shall
contain a prospectus in such form as to permit any Holder to sell such Registrable Securities pursuant to Rule 415 under the Securities
Act (or any successor or similar provision adopted by the Commission then in effect) at any time beginning on the effective date for such
Registration Statement (subject to lock-up restrictions provided in&#8239;<U>Section 5.1</U>&#8239;of this Agreement), and shall provide
that such Registrable Securities may be sold pursuant to any method or combination of methods legally available to, and requested by,
Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Notification and Distribution of Materials</U>. The Company shall notify the Holders in writing of the effectiveness of the
Resale Shelf Registration Statement as soon as practicable, and in any event within one (1) Business Day after the Resale Shelf Registration
Statement becomes effective, and shall furnish to them, without charge, such number of copies of the Resale Shelf Registration Statement
(including any amendments, supplements and exhibits), the Prospectus contained therein (including each preliminary prospectus and all
related amendments and supplements) and any documents incorporated by reference in the Resale Shelf Registration Statement or such other
documents as the Holders may reasonably request in order to facilitate the sale of the Registrable Securities in the manner described
in the Resale Shelf Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 470; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Amendments and Supplements</U>. Subject to the provisions of&#8239;<U>Section 2.3.1</U>&#8239;above, the Company shall promptly
prepare and file with the Commission from time to time such amendments and supplements to the Resale Shelf Registration Statement and
Prospectus used in connection therewith as may be necessary to keep the Resale Shelf Registration Statement effective and to comply with
the provisions of the Securities Act with respect to the disposition of all the Registrable Securities. If any Resale Shelf Registration
Statement filed pursuant to&#8239;<U>Section 2.3.1</U>&#8239;is filed on Form S-3 and thereafter the Company becomes ineligible to use Form
S-3 for secondary sales, the Company shall promptly notify the Holders of such ineligibility and use its commercially reasonable efforts
to file a shelf registration on an appropriate form as promptly as practicable to replace the shelf registration statement on Form S-3
and have such replacement Resale Shelf Registration Statement declared effective as promptly as practicable and to cause such replacement
Resale Shelf Registration Statement to remain effective, and to be supplemented and amended to the extent necessary to ensure that such
Resale Shelf Registration Statement is available or, if not available, that another Resale Shelf Registration Statement is available,
for the resale of all the Registrable Securities held by the Holders until all such Registrable Securities have ceased to be Registrable
Securities;&#8239;<U>provided</U>,&#8239;<U>however</U>, that at any time the Company once again becomes eligible to use Form S-3, the Company
shall cause such replacement Resale Shelf Registration Statement to be amended, or shall file a new replacement Resale Shelf Registration
Statement, such that the Resale Shelf Registration Statement is once again on Form S-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>SEC Cutback</U>. Notwithstanding the registration obligations set forth in this&#8239;<U>Section 2.3</U>, in the event the Commission
informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale
as a secondary offering on a single registration statement, the Company agrees to promptly (i) inform each of the Holders thereof and
use its commercially reasonable efforts to file amendments to the Resale Shelf Registration Statement as required by the Commission and/or
(ii) withdraw the Resale Shelf Registration Statement and file a new registration statement (a &ldquo;<B>New Registration Statement</B>&rdquo;)
on Form S-3, or if Form S-3 is not then available to the Company for such registration statement, on such other form available to register
for resale the Registrable Securities as a secondary offering;&#8239;<U>provided</U>,&#8239;<U>however</U>, that prior to filing such amendment
or New Registration Statement, the Company shall use its commercially reasonable efforts to advocate with the Commission for the registration
of all of the Registrable Securities in accordance with any publicly -available written or oral guidance, comments, requirements or requests
of the Commission staff (the &ldquo;<B>SEC Guidance</B>&rdquo;). Notwithstanding any other provision of this Agreement, if any SEC Guidance
sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement as a
secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of
all or a greater number of Registrable Securities), unless otherwise directed in writing by a Holder as to further limit its Registrable
Securities to be included on the Registration Statement, the number of Registrable Securities to be registered on such Registration Statement
will be reduced on a Pro Rata basis based on the total number of Registrable Securities held by the Holders, subject to a determination
by the Commission that certain Holders must be reduced first based on the number of Registrable Securities held by such Holders. In the
event the Company amends the Resale Shelf Registration Statement or files a New Registration Statement, as the case may be, under clauses
(i) or (ii) above, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as allowed by Commission
or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or
such other form available to register for resale those Registrable Securities that were not registered for resale on the Resale Shelf
Registration Statement, as amended, or the New Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Underwritten Shelf Takedown</U>. At any time and from time to time after a Resale Shelf Registration Statement has been declared
effective by the Commission, the Holders may request to sell all or any portion of the Registrable Securities in an underwritten offering
that is registered pursuant to the Resale Shelf Registration Statement (each, an &ldquo;<B>Underwritten Shelf Takedown</B>&rdquo;);&#8239;<U>provided</U>,&#8239;<U>however</U>,
that the Company shall only be obligated to effect an Underwritten Shelf Takedown if such offering shall include securities with a total
offering price (including piggyback securities and before deduction of underwriting discounts or commissions) reasonably expected to exceed,
in the aggregate, $15,000,000. All requests for Underwritten Shelf Takedowns shall be made by giving written notice to the Company at
least seven (7) days prior to the public announcement of such Underwritten Shelf Takedown, which shall specify the approximate number
of Registrable Securities proposed to be sold in the Underwritten Shelf Takedown and the expected price range (net of underwriting discounts
and commissions) of such Underwritten Shelf Takedown. Except in the case of a requested Underwritten Shelf Takedown in the form of a Block
Trade, following receipt of a request for an Underwritten Shelf Takedown, the Company shall promptly notify the other Holders of the request
and of their right to participate in the Underwritten Shelf Takedown, which shall specify the anticipated public announcement date. The
Company shall include in any Underwritten Shelf Takedown the securities requested to be included by any Holder (each a &ldquo;<B>Takedown
Requesting Holder</B>&rdquo;) at least 48 hours prior to the anticipated public announcement date of such Underwritten Shelf Takedown
set forth in the Company notice pursuant to written contractual piggyback registration rights of such Holder (including those set forth
herein). All such Holders proposing to distribute their Registrable Securities through an Underwritten Shelf Takedown under this&#8239;<U>subsection
2.3.5</U>&#8239;shall enter into an underwriting agreement in customary form with the Underwriter(s) selected for such Underwritten Offering
by the majority-in-interest of the Takedown Requesting Holders initiating the Underwritten Shelf Takedown.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 471; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Reduction of Underwritten Shelf Takedown</U>. If the managing Underwriter(s) in an Underwritten Shelf Takedown, in good faith,
advise(s) the Company and the Takedown Requesting Holders in writing that the dollar amount or number of Registrable Securities that the
Takedown Requesting Holders desire to sell, taken together with all other shares of the Common Stock or other equity securities that the
Company desires to sell, exceeds the Maximum Number of Securities, then the Company shall include in such Underwritten Shelf Takedown,
as follows: (i) first, the Registrable Securities of the Takedown Requesting Holders, on a Pro Rata basis, that can be sold without exceeding
the Maximum Number of Securities; (ii) second, to the extent that the Maximum Number of Securities has not been reached under the foregoing
clause (i), the Common Stock or other equity securities, if any, that the Company desires to sell, which can be sold without exceeding
the Maximum Number of Securities; and (iii) third, to the extent that the Maximum Number of Securities has not been reached under the
foregoing clause (ii) and (iii) the Common Stock or other equity securities, if any, for the account of other persons or entities that
the Company is obligated to register pursuant to separate written contractual arrangements with such persons or entities, which can be
sold without exceeding the Maximum Number of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Block Trades</U>. If the Company shall receive a request from a Holder or Holders of Registrable Securities with an estimated
market value of at least $15,000,000 that the Company effect the sale of all or any portion of such Registrable Securities in an Underwritten
Shelf Takedown in the form of a Block Trade, then the Company shall, as expeditiously as possible, cooperate and effect the offering in
such Block Trade of the Registrable Securities for which such requesting Holder has requested such offering, without giving any effect
to any required notice periods or delivery of notices to any other Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase; color: #010000">Article
III </FONT><BR>
COMPANY PROCEDURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>General Procedures</B>. If at any time the Company is required to effect the Registration of Registrable Securities, the Company
shall use its commercially reasonable efforts to effect such Registration to permit the sale of such Registrable Securities in accordance
with the intended plan of distribution thereof, and pursuant thereto the Company shall, as expeditiously as possible:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>prepare and file with the Commission as soon as practicable a Registration Statement with respect to such Registrable Securities
and use its commercially reasonable efforts to cause such Registration Statement to become effective and remain effective until all Registrable
Securities covered by such Registration Statement have been sold;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>prepare and file with the Commission such amendments and post-effective amendments to the Registration Statement, and such supplements
to the Prospectus, as may be reasonably requested by the Holders or any Underwriter of Registrable Securities or as may be required by
the rules, regulations or instructions applicable to the registration form used by the Company or by the Securities Act or rules and regulations
thereunder to keep the Registration Statement effective until all Registrable Securities covered by such Registration Statement are sold
in accordance with the intended plan of distribution set forth in such Registration Statement or supplement to the Prospectus;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>prior to filing a Registration Statement or Prospectus, or any amendment or supplement thereto, furnish without charge to the Underwriter(s),
if any, and the Holders of Registrable Securities included in such Registration, and such Holders&rsquo; legal counsel, copies of such
Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case including all
exhibits thereto and documents incorporated by reference therein), the Prospectus included in such Registration Statement (including each
preliminary Prospectus), and such other documents as the Underwriters and the Holders of Registrable Securities included in such Registration
or the legal counsel for any such Holders may request in order to facilitate the disposition of the Registrable Securities owned by such
Holders;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 472; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>prior to any public offering of Registrable Securities, use its commercially reasonable efforts to (i) register or qualify the
Registrable Securities covered by the Registration Statement under such securities or &ldquo;Blue Sky&rdquo; laws of such jurisdictions
in the United States as the Holders of Registrable Securities included in such Registration Statement (in light of their intended plan
of distribution) may request and (ii) take such action necessary to cause such Registrable Securities covered by the Registration Statement
to be registered with or approved by such other governmental authorities as may be necessary by virtue of the business and operations
of the Company and do any and all other acts and things that may be necessary or advisable to enable the Holders of Registrable Securities
included in such Registration Statement to consummate the disposition of such Registrable Securities in such jurisdictions;&#8239;<U>provided</U>,&#8239;<U>however</U>,
that the Company shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required
to qualify or take any action to which it would be subject to general service of process or taxation in any such jurisdiction where it
is not then otherwise so subject;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>cause all such Registrable Securities to be listed on each securities exchange or automated quotation system on which similar securities
issued by the Company are then listed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>provide a transfer agent and registrar for all such Registrable Securities no later than the effective date of such Registration
Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>advise each seller of such Registrable Securities, promptly after it shall receive notice or obtain knowledge thereof, of the issuance
of any stop order by the Commission suspending the effectiveness of such Registration Statement or the initiation or threatening of any
proceeding for such purpose and promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain
its withdrawal if such stop order should be issued;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>advise each Holder of Registrable Securities covered by such Registration Statement, promptly after the Company receives notice
thereof, of the time when such registration statement has been declared effective or a supplement to any Prospectus forming a part of
such registration statement has been filed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>at least five (5) days prior to the filing of any Registration Statement or Prospectus or any amendment or supplement to such Registration
Statement or Prospectus, furnish a draft copy thereof to each seller of such Registrable Securities or its counsel;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>notify the Holders at any time when a Prospectus relating to such Registration Statement is required to be delivered under the
Securities Act, of the happening of any event as a result of which the Prospectus included in such Registration Statement, as then in
effect, includes a Misstatement, and then to correct such Misstatement as set forth in&#8239;<U>Section 3.4</U>&#8239;hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>permit a representative of the Holders, the Underwriter(s), if any, and any attorney or accountant retained by such Holders or
Underwriter(s) to participate, at each such person&rsquo;s own expense (except as otherwise set forth herein), in the preparation of the
Registration Statement, and cause the Company&rsquo;s officers, directors and employees to supply all information reasonably requested
by any such representative, Underwriter(s), attorney or accountant in connection with the Registration;&#8239;<U>provided</U>,&#8239;<U>however</U>,
that such representatives or Underwriter(s) enter into a confidentiality agreement, in form and substance reasonably satisfactory to the
Company, prior to the release or disclosure of any such information;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 473; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>obtain a &ldquo;cold comfort&rdquo; letter from the Company&rsquo;s independent registered public accountants in the event of an
Underwritten Registration, in customary form and covering such matters of the type customarily covered by &ldquo;cold comfort&rdquo; letters
as the managing Underwriter(s) may reasonably request, and reasonably satisfactory to a majority-in-interest of the participating Holders
and such managing Underwriter;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>on the date the Registrable Securities are delivered for sale pursuant to such Registration, if requested by the Underwriter(s),
if any, obtain an opinion and negative assurance letter, dated such date, of counsel representing the Company for the purposes of such
Registration addressed to the Underwriter(s) covering such legal matters with respect to the Registration in respect of which such opinion
and negative assurance letter are being given as are customarily included in such opinions and negative assurance letters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>in the event of any Underwritten Offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing Underwriter(s) of such offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period of at least
twelve (12) months beginning with the first day of the Company&rsquo;s first full calendar quarter after the effective date of the Registration
Statement which satisfies the provisions of&#8239;<U>Section 11(a)</U>&#8239;of the Securities Act and Rule 158 thereunder (or any successor
rule promulgated thereafter by the Commission);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>if a Registration, including an Underwritten Offering, involves the Registration of Registrable Securities involving gross proceeds
in excess of $35,000,000, use its commercially reasonable efforts to make available senior executives of the Company to participate in
customary &ldquo;road show&rdquo; presentations that may be reasonably requested by the Underwriter(s) in any Underwritten Offering; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>otherwise, in good faith, cooperate reasonably with, and take such customary actions as may reasonably be requested by the Holders,
in connection with such Registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Registration Expenses</B>. All Registration Expenses shall be borne by the Company. It is acknowledged by the Holders that the
Holders shall bear all incremental selling expenses relating to the sale of Registrable Securities, such as Underwriters&rsquo; commissions
and discounts, brokerage fees, Underwriter marketing costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Requirements for Participation in Underwritten Offerings</B>. No person may participate in any Underwritten Offering for equity
securities of the Company pursuant to a Registration initiated by the Company hereunder unless such person (i) agrees to sell such person&rsquo;s
securities on the basis provided in any underwriting arrangements approved by the Company and (ii) completes and executes all customary
questionnaires, powers of attorney, indemnities, lock-up agreements, underwriting agreements and other customary documents as may be reasonably
required under the terms of such underwriting arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 474; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Suspension of Sales; Adverse Disclosure</B>. Upon receipt of written notice from the Company that a Registration Statement or Prospectus
contains a Misstatement, each of the Holders shall forthwith discontinue disposition of Registrable Securities until he, she or it has
received copies of a supplemented or amended Prospectus correcting the Misstatement or until he, she, or it is advised in writing by the
Company that the use of the Prospectus may be resumed, provided that the Company hereby covenants to prepare and file any required supplement
or amendment correcting any Misstatement promptly after the time of such notice and, if necessary, to request the immediate effectiveness
thereof. If the filing, initial effectiveness or continued use of a Registration Statement or Prospectus included in any Registration
Statement at any time (a) would require the Company to make an Adverse Disclosure, (b) would require the inclusion in such Registration
Statement of financial statements that are unavailable to the Company for reasons beyond the Company&rsquo;s control, or (c) in the good
faith judgment of the Board, would be materially detrimental to the Company, the Company shall have the right to defer the filing, initial
effectiveness or continued use of any Registration Statement pursuant to (a), (b) or (c) for a period of not more than ninety (90) consecutive
days or more than one hundred and twenty (120) total calendar days in any 12-month period. In the event the Company exercises its rights
under the preceding sentence, the Holders agree to suspend, immediately upon their receipt of the notice referred to above, their use
of the Prospectus relating to any Registration in connection with any sale or offer to sell Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Reporting Obligation</B>s. As long as any Holder shall own Registrable Securities, the Company, at all times while it shall be
a reporting company under the Exchange Act, covenants to file timely (or obtain extensions in respect thereof and file within the applicable
grace period) all reports required to be filed by the Company after the date hereof pursuant to Sections 13(a) or&#8239;15(d) of the Exchange
Act and to promptly furnish the Holders with true and complete copies of all such filings. The Company further covenants that it shall
take such further action as any Holder may reasonably request, all to the extent required from time to time to enable such Holder to sell
shares of Common Stock held by such Holder without registration under the Securities Act within the limitation of the exemptions provided
by Rule 144 promulgated under the Securities Act (or any successor rule promulgated thereafter by the Commission), including providing
any customary legal opinions as reasonably requested. Upon the request of any Holder, the Company shall deliver to such Holder a written
certification of a duly authorized officer as to whether it has complied with such requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Limitations on Registration Rights</B>. Other than the registration rights granted to the purchasers under the Subscription Agreements
to be entered into on about the date hereof with certain investors relating to the private placement of shares of Common Stock as provided
for in the Business Combination Agreement, the Company represents and warrants that no person or entity, other than a Holder of Registrable
Securities, has any right to require the Company to register any securities of the Company for sale or to include such securities of the
Company in any Registration Statement filed by the Company for the sale of securities for its own account or for the account of any other
person or entity. The Company hereby agrees and covenants that it will not grant rights to register any Common Stock (or securities convertible
into or exchangeable for Common Stock) pursuant to the Securities Act that are more favorable, pari passu or senior to those granted to
the Holders hereunder without (a) the prior written consent of (i) Perceptive Holders holding at least a majority in interest of the then-outstanding
number of Registrable Securities held by all Perceptive Holders in their capacity as Perceptive Holders (provided the Perceptive Holders
or their Permitted Transferees hold Registrable Securities at such time) and (ii) Amber GT (provided Amber GT or its Permitted Transferees
hold Registrable Securities at such time); or (b) granting economically and legally equivalent rights to the Holders hereunder such that
the Holders shall receive the benefit of such more favorable or senior terms and/or conditions. Further, the Company represents and warrants
that this Agreement supersedes any other registration rights agreement or agreement with similar terms and conditions and in the event
of any conflict between any such agreement or agreements and this Agreement, the terms of this Agreement shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 475; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#8239;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<!-- Field: Split-Segment; Name: a -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase; color: #010000">Article
IV </FONT><BR>
INDEMNIFICATION AND CONTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Indemnification</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The Company agrees to indemnify, to the extent permitted by law, each Holder of Registrable Securities, its officers and directors
and agents and each person who controls such Holder (within the meaning of the Securities Act) against all losses, claims, damages, liabilities
and expenses (including attorneys&rsquo; fees) caused by any untrue or alleged untrue statement of material fact contained in any Registration
Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of
a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as the same are
caused by or contained in any information furnished in writing to the Company by such Holder expressly for use therein. The Company shall
indemnify the Underwriter(s), their officers and directors and each person who controls (within the meaning of the Securities Act) such
Underwriter(s) to the same extent as provided in the foregoing with respect to the indemnification of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>In connection with any Registration Statement in which a Holder of Registrable Securities is participating, such Holder shall furnish
to the Company in writing such information and affidavits as the Company reasonably requests for use in connection with any such Registration
Statement or Prospectus and, to the extent permitted by law, shall indemnify the Company, its directors and officers and agents and each
person who controls (within the meaning of the Securities Act) the Company against any losses, claims, damages, liabilities and expenses
(including without limitation reasonable attorneys&rsquo; fees) resulting from any untrue statement of material fact contained in the
Registration Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any omission of a material
fact required to be stated therein or necessary to make the statements therein not misleading, but only to the extent that such untrue
statement or omission is contained in any information or affidavit so furnished in writing by such Holder expressly for use therein;&#8239;<U>provided</U>,&#8239;<U>however</U>,
that the obligation to indemnify shall be several, not joint and several, among such Holders of Registrable Securities, and the liability
of each such Holder of Registrable Securities shall be in proportion to and limited to the net proceeds actually received by such Holder
from the sale of Registrable Securities pursuant to such Registration Statement. The Holders of Registrable Securities shall indemnify
the Underwriter(s), their officers, directors and each person who controls (within the meaning of the Securities Act) such Underwriter(s)
to the same extent as provided in the foregoing with respect to indemnification of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 476; Options: NewSection; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Any person entitled to indemnification herein shall (i) give prompt written notice to the indemnifying party of any claim with
respect to which it seeks indemnification (<U>provided</U>,&#8239;<U>however</U>, that the failure to give prompt notice shall not impair
any person&rsquo;s right to indemnification hereunder to the extent such failure has not materially prejudiced the indemnifying party)
and (ii) unless in such indemnified party&rsquo;s reasonable judgment a conflict of interest between such indemnified and indemnifying
parties may exist with respect to such claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably
satisfactory to the indemnified party. If such defense is assumed, the indemnifying party shall not be subject to any liability for any
settlement made by the indemnified party without its consent (but such consent shall not be unreasonably withheld, conditioned or delayed).
An indemnifying party who is not entitled to, or elects not to, assume the defense of a claim shall not be obligated to pay the fees and
expenses of more than one counsel for all parties indemnified by such indemnifying party with respect to such claim, unless in the reasonable
judgment of any indemnified party a conflict of interest may exist between such indemnified party and any other of such indemnified parties
with respect to such claim. No indemnifying party shall, without the consent of the indemnified party, consent to the entry of any judgment
or enter into any settlement which cannot be settled in all respects by the payment of money (and such money is so paid by the indemnifying
party pursuant to the terms of such settlement) or which settlement does not include as an unconditional term thereof the giving by the
claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>The indemnification provided for under this Agreement shall remain in full force and effect regardless of any investigation made
by or on behalf of the indemnified party or any officer, director or controlling person of such indemnified party and shall survive the
transfer of securities. The Company and each Holder of Registrable Securities participating in an offering also agrees to make such provisions
as are reasonably requested by any indemnified party for contribution (pursuant to&#8239;<U>subsection 4.1.5</U>) to such party in the
event the Company&rsquo;s or such Holder&rsquo;s indemnification is unavailable for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>If the indemnification provided under&#8239;<U>Section 4.1</U>&#8239;hereof from the indemnifying party is unavailable or insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the
indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by the indemnified party
as a result of such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect the relative fault
of the indemnifying party and the indemnified party, as well as any other relevant equitable considerations. The relative fault of the
indemnifying party and indemnified party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made by, or relates
to information supplied by, such indemnifying party or indemnified party, and the indemnifying party&rsquo;s and indemnified party&rsquo;s
relative intent, knowledge, access to information and opportunity to correct or prevent such action;&#8239;<U>provided</U>,&#8239;<U>however</U>,
that the liability of any Holder under this&#8239;<U>subsection 4.1.5</U>&#8239;shall be limited to the amount of the net proceeds actually
received by such Holder in such offering giving rise to such liability. The amount paid or payable by a party as a result of the losses
or other liabilities referred to above shall be deemed to include, subject to the limitations set forth in&#8239;<U>subsections 4.1.1</U>,&#8239;<U>4.1.2</U>&#8239;and&#8239;<U>4.1.3</U>&#8239;above,
any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. The
parties hereto agree that it would not be just and equitable if contribution pursuant to this&#8239;<U>subsection 4.1.5</U>&#8239;were determined
by pro rata allocation or by any other method of allocation, which does not take account of the equitable considerations referred to in
this&#8239;<U>subsection 4.1.5</U>. No person guilty of fraudulent misrepresentation (within the meaning of&#8239;<U>Section 11(f)</U>&#8239;of
the Securities Act) shall be entitled to contribution pursuant to this&#8239;<U>subsection 4.1.5</U>&#8239;from any person who was not guilty
of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 477; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in any underwriting
agreement entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions
in the underwriting agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase; color: #010000">Article
V </FONT><BR>
LOCK-UP</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Lock-Up</B>.
Except as permitted by&#8239;<U>Section 5.2</U>, each Holder shall not Transfer any shares of Common Stock (including, without limitation,
the PIPE Shares, any shares of Common Stock issued pursuant to the Business Combination Agreement, and any other shares of Common Stock),
beneficially owned or owned of record by such Holder until the date that is 365 days from the Closing Date (the &ldquo;<B>Lock-up Period</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Exceptions</B>. The provisions of&#8239;<U>Section 5.1</U>&#8239;shall not apply (i) to the Original Holders or the Perceptive Holders
in connection with any of the following, and (ii) to Amber GT in connection with <U>subsections 5.2.6(i)</U>, <U>5.2.10</U>, <U>5.2.11</U>
or <U>5.2.12</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>transactions
relating to shares of Common Stock acquired in open market transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
of shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock as a bona fide gift or charitable
contribution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers of shares of Common Stock to a trust, or other entity formed for estate planning purposes for the primary benefit of
the spouse, domestic partner, parent, sibling, child or grandchild of the undersigned or any other person with whom the undersigned has
a relationship by blood, marriage or adoption not more remote than first cousin;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers by will or intestate succession upon the death of the undersigned;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Transfer of shares of Common Stock pursuant to a qualified domestic order, court order or in connection with a divorce settlement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 478; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if the Holder is a corporation, partnership (whether general, limited or otherwise), limited liability company, trust or other
business entity, (i) Transfers to another corporation, partnership, limited liability company, trust or other business entity that controls,
is controlled by or is under common control or management with the Holder, or (ii)&#8239;distributions of shares of Common Stock to partners,
limited liability company members or stockholders of the Holder, including, for the avoidance of doubt, where the Holder is a partnership,
to its general partner or a successor partnership or fund, or any other funds managed by such partnership;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>if
the Holder is a trust, Transfers to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
to the Company&rsquo;s officers, directors or their affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under&#8239;<U>Sections
5.2.2</U>&#8239;through&#8239;<U>5.2.8</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;</FONT>pledges
of shares of Common Stock or other Registrable Securities as security or collateral in connection with any borrowing or the incurrence
of any indebtedness by any Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
pursuant to a bona fide third-party tender offer, merger, stock sale, recapitalization, consolidation or other transaction involving
a Change in Control of the Company;&#8239;<U>provided</U>,&#8239;<U>however</U>, that in the event that such tender offer, merger, recapitalization,
consolidation or other such transaction is not completed, the Common Stock subject to this Agreement shall remain subject to this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.2.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;</FONT>the
establishment of a trading plan pursuant to Rule 10b5-1 promulgated under the Exchange Act;&#8239;<U>provided</U>,&#8239;<U>however</U>,
that such plan does not provide for the Transfer of Common Stock or any securities convertible into or exercisable or exchangeable for
Common Stock during the Lock-Up Period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>provided</U>,&#8239;<U>however</U>, that in
the case of any Transfer pursuant to&#8239;<U>Sections 5.2.2</U>&#8239;through&#8239;<U>5.2.10</U>, each donee, distribute, pledgee or other
transferee shall agree in writing, in form and substance reasonably satisfactory to the Company, to be bound by the provisions of this
Agreement, <U>provided further</U>, <U>however</U>, that the foregoing requirement shall not apply with respect to pledges made by Amber
GT or any of its Permitted Transferees pursuant to requirements under agreements governing borrowings or the incurrence of any indebtedness
by Parent and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Termination
of Existing Lock-Up</B>. The lock-up provisions in this <U>ARTICLE V</U> shall supersede the lock-up provisions contained in Section
5 of the Sponsor Letter Agreement and Section 1.C.(i) of the Private Placement Shares Purchase Agreement, which provisions shall be of
no further force or effect as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Release
of Lock-Up Restrictions</B>. Notwithstanding the other provisions set forth herein, the Board may, in its sole discretion, determine
to waive, amend, or repeal the restrictions set forth in&#8239;<U>Section 5.1</U>&#8239;above, whether in whole or in part;&#8239;<U>provided</U>,
that any such waiver, amendment or repeal shall (i) not make such restrictions more restrictive or apply for a longer period of time,
(ii) apply to each Holder equally, and (iii) require the unanimous approval of the directors present at any duly called meeting at which
a quorum is present. Notwithstanding anything to the contrary herein or in the LLC Agreement, any amendment, modification or waiver of,
or consent, approval or agreement under, the LLC Agreement (whether by the Board of Managers (as defined in the LLC Agreement), the Company
or otherwise) or any agreement with a Non-Corporation Member (as defined in the LLC Agreement) that (A) shortens, or has the effect of
shortening, the &ldquo;Lock-up Period&rdquo; (as defined in the LLC Agreement (as in effect following the consummation of the transactions
contemplated by the Business Combination Agreement)) (the &ldquo;<B>LLC Lock-Up Period</B>&rdquo;) with respect to a Non-Corporation
Member or (B) prior to the end of the LLC Lock-up Period, that allows, or has the effect of allowing, a Non-Corporation Member to transfer
its Common Units to any Person other than to a Permitted Transferee (as defined in the LLC Agreement (as in effect following the consummation
of the transactions contemplated by the Business Combination Agreement), and on the terms and subject to the conditions set forth therein)
shall, in each case, automatically have the effect of shortening the Lock-up Period hereunder for an equivalent amount of time, with
respect to clause (A), or immediately releasing all Holders from the transfer restrictions set forth in <U>Section 5.1</U> hereunder,
with respect to clause (B).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 479; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase; color: #010000">Article
VI </FONT><BR>
TERMINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Termination</B>. This Agreement shall terminate upon the earliest to occur of: (i) the date on which neither the Holders nor any
of their Permitted Transferees hold any Registrable Securities and (ii) a Liquidation Event. The provisions of <U>Section&#8239;3.5</U>
and <U>Article&#8239;IV</U> shall survive any termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Effect of Business Combination Termination</B>. In the event of a termination of this Agreement as a result of the termination
of the Business Combination Agreement, this Agreement shall become void; this Agreement shall only become effective upon the consummation
of the transactions set forth in the Business Combination Agreement, and prior to such date this Agreement shall be of no force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase; color: #010000">Article
VII </FONT><BR>
GENERAL PROVISIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Notices</B>. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and
shall be deemed to have been duly given upon receipt) by delivery in person, by e-mail or by registered or certified mail (postage prepaid,
return receipt requested) to the respective parties at the following addresses or e-mail addresses (or at such other address or email
address for a party as shall be specified in a notice given in accordance with this&#8239;<U>Section 7.1</U>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">If to the Company, to it at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: left">3675 Market Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: left">Philadelphia, PA 19104<BR>
Attention: John F. Crowley<BR>&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">with a copy (which shall not constitute notice)
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: justify">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: left">Kirkland&#8239;&amp; Ellis LLP<BR>
601 Lexington Avenue<BR>
New York, NY 10022<BR>
Attn: &#8239;&#8239;&#8239;&#8239; Jonathan L. Davis, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 1.5in; text-align: left">Ryan Brissette</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: left">Email: &#8239;&#8239;&#8239;jonathan.davis@kirkland.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 1.5in; text-align: left">ryan.brissette@kirkland.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: left"></P>

<!-- Field: Page; Sequence: 480; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: left">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If to a Holder, to the address
or email address set forth for Holder on the signature page hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Severability</B>. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule
of law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long
as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party.
Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually
acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Entire Agreement; Assignment</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>This Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes all
prior agreements and undertakings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> This Agreement shall not be assigned (whether pursuant to a merger, by operation of law or otherwise), by any Holder without the
prior express written consent of the Company, except that (i) any Holder may, without consent, assign such Holder&rsquo;s rights under
this Agreement to any transferee of Common Stock permitted under&#8239;<U>Section 5.2</U> and (ii) after the expiration of the Lock-Up
Period, any Holder may, without consent, assign its rights, in whole and not in part, to any transferee of its Registrable Securities
provided that such transferee continues to hold Registrable Securities following such Transfer (any such transferees in each of clause
(i) and (ii), a &ldquo;<B>Permitted Transferee</B>&rdquo;). This Agreement and the rights, duties and obligations of the Company hereunder
may not be assigned or delegated by the Company in whole or in part. Any assignment made other than as provided in this Section 7.3 shall
be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Parties in Interest</B>. This Agreement shall be binding upon and inure solely to the benefit of each party hereto (and its respective
successors and permitted assigns), and nothing in this Agreement, express or implied, is intended to or shall confer upon any other person
any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 481; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Governing Law</B>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware applicable
to contracts executed in and to be performed in that State. All legal actions and proceedings arising out of or relating to this Agreement
shall be heard and determined exclusively in any Delaware Chancery Court;&#8239;<U>provided</U>,&#8239;<U>however</U>, that if jurisdiction
is not then available in the Delaware Chancery Court, then any such legal action may be brought in any federal court located in the State
of Delaware or any other Delaware state court. The parties hereto hereby (a) irrevocably submit to the exclusive jurisdiction of the aforesaid
courts for themselves and with respect to their respective properties for the purpose of any action arising out of or relating to this
Agreement brought by any party hereto, and (b) agree not to commence any action relating thereto except in the courts described above
in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court
in Delaware as described herein. Each of the parties further agrees that notice as provided herein shall constitute sufficient service
of process and the parties further waive any argument that such service is insufficient. Each of the parties hereby irrevocably and unconditionally
waives, and agrees not to assert, by way of motion or as a defense, counterclaim or otherwise, in any action arising out of or relating
to this Agreement or the transactions contemplated hereby, (x) any claim that it is not personally subject to the jurisdiction of the
courts in Delaware as described herein for any reason, (y) that it or its property is exempt or immune from jurisdiction of any such court
or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid
of execution of judgment, execution of judgment or otherwise) and (z) that (i) the action in any such court is brought in an inconvenient
forum, (ii) the venue of such action is improper or (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such
courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Waiver of Jury Trial</B>. EACH OF THE PARTIES HERETO HEREBY WAIVES TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW ANY RIGHT
IT MAY HAVE TO A TRIAL BY JURY WITH RESPECT TO ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS
AGREEMENT. EACH OF THE PARTIES HERETO (I) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THAT FOREGOING WAIVER AND (II) ACKNOWLEDGES
THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY, AS APPLICABLE,
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS&#8239;<U>SECTION&#8239;7.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Headings; Interpretation</B>. The descriptive headings contained in this Agreement are included for convenience of reference only
and shall not affect in any way the meaning or interpretation of this Agreement. The parties have participated jointly in the negotiation
and drafting of this Agreement. If any ambiguity or question of intent arises, this Agreement will be construed as if drafted jointly
by the parties and no presumption or burden of proof will arise favoring or disfavoring any party because of the authorship of any provision
of this Agreement. Unless the context of this Agreement clearly requires otherwise, use of the masculine gender shall include the feminine
and neutral genders and vice versa, and the definitions of terms contained in this Agreement are applicable to the singular as well as
the plural forms of such terms. The words &ldquo;includes&rdquo; or &ldquo;including&rdquo; shall mean &ldquo;including without limitation.&rdquo;
The words &ldquo;hereof,&rdquo; &ldquo;hereby,&rdquo; &ldquo;herein,&rdquo; &ldquo;hereunder&rdquo; and similar terms in this Agreement
shall refer to this Agreement as a whole and not any particular section or article in which such words appear, the word &ldquo;extent&rdquo;
in the phrase &ldquo;to the extent&rdquo; shall mean the degree to which a subject or other thing extends and such phrase shall not mean
simply &ldquo;if.&rdquo; Any reference to a law shall include any rules and regulations promulgated thereunder, and shall mean such law
as from time to time amended, modified or supplemented. References herein to any contract (including this Agreement) mean such contract
as amended, supplemented or modified from time to time in accordance with the terms thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 482; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Counterparts</B>. This Agreement may be executed and delivered (including by facsimile or portable document format (pdf) transmission)
in counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original
but all of which taken together shall constitute one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>Specific Performance</B>. The parties hereto agree that irreparable damage would occur in the event any provision of this Agreement
was not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof,
in addition to any other remedy at law or in equity. Each of the parties hereby further waives (a) any defense in any action for specific
performance that a remedy at law would be adequate and (b) any requirement under any law to post security or a bond as a prerequisite
to obtaining equitable relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;
</FONT>Amendment</B>. This Agreement may not be amended except by an instrument in writing signed by (i) the Company, (ii) Perceptive
Holders holding at least a majority in interest of the then-outstanding number of Registrable Securities held by all Perceptive Holders
in their capacity as Perceptive Holders (provided the Perceptive Holders or their Permitted Transferees hold Registrable Securities at
the time of such amendment), and (iii) Amber GT (provided Amber GT or its Permitted Transferees hold Registrable Securities at the time
of such amendment); <U>provided</U>, <U>however</U>, that notwithstanding the foregoing, any amendment hereto or waiver hereof that adversely
affects one Holder, solely in its capacity as a holder of Registrable Securities, in a manner that is materially different from the other
Holders (in such capacity) shall require the consent of the Holder so affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>Waiver</B>. At any time, (i) the Company may (a) extend the time for the performance of any obligation or other act of any Holder,
(b) waive any inaccuracy in the representations and warranties of any Holder contained herein or in any document delivered by such Holder
pursuant hereto and (c) waive compliance with any agreement of such Holder or any condition to its own obligations contained herein. At
any time, (i) the Holders may (a) extend the time for the performance of any obligation or other act of the Company, (b) waive any inaccuracy
in the representations and warranties of the Company contained herein or in any document delivered by the Company pursuant hereto and
(c) waive compliance with any agreement of the Company or any condition to their own obligations contained herein. Any such extension
or waiver shall be valid if set forth in an instrument in writing signed by the party or parties to be bound thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 483; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>Further Assurances</B>. At the request of the Company, in the case of any Holder, or at the request of any Holder, in the case
of the Company, and without further consideration, each party shall execute and deliver or cause to be executed and delivered such additional
documents and instruments and take such further action as may be reasonably necessary to consummate the transactions contemplated by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>Prior Agreement Superseded</B>. Pursuant to Section 5.6 of the Prior Agreement, the undersigned parties who are parties to such
Prior Agreement hereby terminate the Prior Agreement upon the consummation of the transactions set forth in the Business Combination Agreement,
with the intent and effect that the Prior Agreement shall hereby be replaced and superseded in its entirety by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;&#8239;&#8239;
</FONT>No Strict Construction</B>. The language used in this Agreement shall be deemed to be the language chosen by the parties to express
their mutual intent and no rule of strict construction shall be applied against any party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">(<I>Next Page is Signature
Page</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 484; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each of
the parties has executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><B>&#8239;</B></TD>
  <TD COLSPAN="2"><B>COMPANY: ARYA SCIENCES ACQUISITION CORP IV</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2">&#8239;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&#8239;</TD>
  <TD STYLE="width: 2%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 48%">/s/ Michael Altman</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2">Name: Michael Altman</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&#8239;</TD>
  <TD COLSPAN="2">Title: Authorized Signatory</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page to Investor
Rights Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 485 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each of
the undersigned has executed this Agreement as of the date first written&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">HOLDER:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: ARYA Sciences Holdings IV</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%"> <FONT STYLE="font-size: 10pt">/s/ Michael Altman</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Michael Altman</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Address for Notice:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">51 Astor Pl 10th floor, New York, NY</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Facsimile No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 486 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each of
the undersigned has executed this Agreement as of the date first written&#8239;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HOLDER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Perceptive Life Sciences Master Fund Ltd</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 5%; border-bottom: black 1pt solid">&#8239;</TD>
    <TD STYLE="width: 43%; border-bottom: black 1pt solid">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51 Astor Pl 10th floor, New York, NY 10003</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile No.:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&#8239;&#8239;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page to Investor
Rights Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 487 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each of
the undersigned has executed this Agreement as of the date first written&#8239;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HOLDER:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Amicus GT Holdings, LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 45%">&#8239; /s/ Bradley L. Campbell&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#8239; Bradley L. Campbell</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: President </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3675 Market Street, Philadelphia, PA 19104</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile No.:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2">&#8239;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&#8239;&#8239;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 40%">&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Investor
Rights Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 488 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each of
the undersigned has executed this Agreement as of the date first written&#8239;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HOLDER:</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Todd Wider</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Todd Wider</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Todd Wider</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:</FONT>&#8239;&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 4%">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Investor
Rights Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 489 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each of
the undersigned has executed this Agreement as of the date first written&#8239;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HOLDER:</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Michael Henderson</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Michael Henderson&#8239;&#8239;&#8239; &#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Michael Henderson</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&#8239;&#8239;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 4%">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Investor
Rights Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 490 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&#8239;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8239;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, each of
the undersigned has executed this Agreement as of the date first written&#8239;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HOLDER:</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Leslie Trigg</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ Leslie Trigg</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Leslie Trigg</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile No.:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&#8239;</TD>
    <TD COLSPAN="3">&#8239;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&#8239;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:&#8239;&#8239;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 4%">&#8239;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8239;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8239;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[<I>Signature Page to Investor
Rights Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&#8239;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<!-- Field: Page; Sequence: 491 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in">&#8239;</P>



<P STYLE="margin: 0pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.7</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><B><U>LIMITED CONSENT AND AMENDMENT NO.1 TO LOAN
AGREEMENT</U></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS LIMITED CONSENT AND
AMENDMENT NO.1 TO LOAN AGREEMENT (this &ldquo;<U>Amendment</U>&rdquo;) is entered into as of [__], 2021 by and among AMICUS THERAPEUTICS,
INC., a Delaware corporation (&ldquo;<U>Parent</U>&rdquo;), AMICUS THERAPEUTICS INTERNATIONAL HOLDING LTD, a private limited company
incorporated under the laws of England and Wales with registered number 10147996 (the &ldquo;<U>Borrower</U>&rdquo;), the other Lenders
signatory hereto (such Lenders constituting all of the Lenders), and <FONT STYLE="text-transform: uppercase">Hayfin Services LLP</FONT>,
a limited liability partnership organized under the laws of England and Wales with registered number OC365614 (the &ldquo;<U>Agent</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-decoration: none">RECITALS</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Parent, the Borrower,
the other Credit Parties from time to time party thereto, the lenders from time to time party thereto (the &ldquo;<U>Lenders</U>&rdquo;),
and Agent are parties to that certain Loan Agreement, dated as of July 17, 2020 (as amended, amended and restated, supplemented or otherwise
modified from time to time prior to the date hereof, the &ldquo;<U>Existing Loan Agreement</U>&rdquo;, and as amended by this Amendment,
the &ldquo;<U>Amended Loan Agreement</U>&rdquo;), pursuant to which the Lenders agreed to make certain Term Loans and other financial
accommodations to the Borrower;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Borrower desires
to enter into and consummate the Gene Therapy Portfolio Spin-Off Transaction (as defined in the Amended Loan Agreement); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Lenders have
agreed to amend and modify the Existing Loan Agreement to permit the Gene Therapy Portfolio Spin-Off Transaction and Gene Therapy Portfolio
Spin-Off Transaction Steps, subject to the terms and conditions set forth in the Amended Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Defined
Terms</U>. Capitalized terms used but not otherwise defined herein shall have the respective meanings given to such terms in the Amended
Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Amendment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>In
reliance upon the representation and warranties set forth in <U>Section 4</U> below and subject to the satisfaction of the conditions
precedent set forth in <U>Section 3 </U>below, the Lenders party hereto (constituting all of the Lenders) hereby (x) consent to the Gene
Therapy Portfolio Spin-Off Transaction and Gene Therapy Portfolio Spin-Off Transaction Steps, each as defined in, and in accordance with
the terms and conditions set forth in, the Amended Loan Agreement, <U>provided</U>, that the GT Spin-Off Conditions (as defined below)
shall have been satisfied (or waived by the Agent), and (y) each of the parties hereto agrees that, effective on the Effective Date,
the Existing Loan Agreement (excluding, all Schedules and Exhibits and Appendices thereto, each of which shall remain as in effect immediately
prior to the Effective Date) shall be and hereby is amended as reflected in the pages of the Amended Loan Agreement attached as <U>Exhibit
A</U> hereto to delete the stricken text (indicated textually in the same manner as the following example: <FONT STYLE="color: Red"><STRIKE>stricken
text</STRIKE></FONT>) and to add the double-underlined text (indicated textually in the same manner as the following example: <FONT STYLE="color: rgb(49,122,255)"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">double-underlined
text</U></FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 492 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
consents set forth in clause (x) above are subject to the satisfaction (or waiver by the Agent) of the following conditions (the &ldquo;<U>GT
Spin-Off Conditions</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
completion of the Gene Therapy Portfolio Spin-Off Transaction (the &ldquo;<U>GT Spin-Off Effective Date</U>&rdquo;) shall occur no later
than six (6) months after the Effective Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>On
or prior to the GT Spin-Off Effective Date, the Agent shall have received a duly executed pledge agreement by GT JV Holdco in respect
of its owned Equity Interests of GT JV;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Agent shall have received duly executed copies of (i) the GT Business Combination Agreement, (ii) the GT Transition Services
Agreement, (iii) the GT Tax Receivable Agreement, (iv) the Co-Development and Commercialisation Agreement, (vi) the GT JV Operating Agreement,
(vii) the GT JV Investor Agreement and (viii) all other material agreements, documents and instruments executed and delivered pursuant
to the foregoing or in connection therewith, in each case, in form and substance reasonably acceptable to the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All parties hereto hereby agree that if the GT
Spin-Off Conditions are not satisfied and the Gene Therapy Portfolio Spin-Off Transaction is not consummated within six (6) months after
the Effective Date, this Amendment shall immediately terminate <I>ab initio</I> without any further action required by any party hereto
and the Loan Agreement and all &ldquo;Loan Documents&rdquo; as defined therein shall continue in full force and effect in accordance
with their terms as if this Amendment and the transaction contemplated herein had not existed and the consents contained herein had not
been granted (such date, the &ldquo;<U>Amendment Termination Date</U>&rdquo;); <U>provided</U>, that the Agent and Lenders agree that
no Default or Event of Default shall arise from the failure of the Credit Parties to comply with the time periods set forth in Sections
5.12 and 5.13 of the Existing Loan Agreement with respect to GT JV Holdco (solely in respect of granting a pledge of the Equity Interests
of GT JV) or GT JV, in each case, so long as the Credit Parties comply with the time periods set forth in such Sections 5.12 and 5.13
commencing from the Amendment Termination Date.<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Each
of the Borrower and Parent hereby acknowledge and agree that the consent contained in this <U>Section 2</U> (a) is a limited consent,
(b)&nbsp;shall only be relied upon and used for the specific purpose set forth herein, (c) shall not constitute nor be deemed to constitute
a consent to or waiver of (i) any Default or Event of Default, or (ii) any term or condition of the Existing Loan Agreement or the other
Loan Documents, (d) shall not constitute nor be deemed to constitute a consent to or waiver by the Agent or any Lender of anything other
than for the specific purpose set forth herein, (e) shall not constitute a custom or course of dealing among the parties hereto, and
(f) shall not affect the rights of the Agent and the Lenders to demand compliance by the Credit Parties with all terms and conditions
of the Loan Documents (except as otherwise specifically modified or consented to by this Amendment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Conditions
Precedent</U>. The effectiveness of this Amendment is subject to the satisfaction (or waiver) of the following conditions (such date
such conditions are satisfied, the &ldquo;<U>Effective Date</U>&rdquo;) the receipt by the Agent of this Amendment executed by Parent,
the Borrower, the Agent and each of Lenders party to the Loan Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Representations
and Warranties</U>. In consideration of the consent granted hereunder, each of the Borrower and Parent hereby represents and warrants
to the Agent and the Lenders that (a) no Default or Event of Default has occurred and is continuing as of the date hereof, (b) the representations
and warranties made by the Borrower and Parent contained in the Loan Documents are true and correct in all material respects (without
duplication of any materiality qualifier contained therein) as of the date hereof, except to the extent such representation or warranty
expressly relates to an earlier date (in which case, such representations and warranties were true and correct in all material respects
as of such earlier date), (c) the execution, delivery and performance by the Borrower and Parent of this Amendment has been duly authorized
by all necessary action and (d) this Amendment constitutes the legal, valid and binding obligation of the Borrower and Parent, enforceable
against the Borrower and Parent in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 493; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing
Law and Jurisdiction; Waiver of Jury Trial</U>. Article 10 of the Loan Agreement is incorporated herein by reference and is made a part
hereof and is applicable to this Amendment as if fully set forth herein, <I>mutatis mutandis</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Counterparts;
Delivery by Facsimile or Electronic Mail</U>. This Amendment may be executed in any number of counterparts and by different parties in
separate counterparts, each of which when so executed and delivered, shall be deemed an original, and all of which, when taken together,
shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Amendment by facsimile
or electronic mail shall be as effective as delivery of a manually executed counterpart of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">[signatures on the following
page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 494; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Amendment to be executed as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>BORROWER</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">AMICUS THERAPEUTICS
    INTERNATIONAL HOLDING LTD</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><U>PARENT</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">AMICUS THERAPEUTICS,
    INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Signature Page to Limited
Consent and Amendment]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 495 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><U>AGENT</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; text-align: left"><FONT STYLE="font-size: 10pt">HAYFIN
    SERVICES LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 47%"><FONT STYLE="font-size: 10pt">&nbsp;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[Signature Page to Limited
Consent and Amendment]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 496 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><U>LENDERS</U>:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed for and on behalf of <B>HAYFIN DLF
    III LUXCO 1 SARL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Authorized
    Signatory</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed for and on behalf of <B>HAYFIN SAPPHIRE
    IV CO-INVEST LUXCO SCA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acting by its managing shareholder Hayfin
    Sapphire IV Luxco Sarl</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: &nbsp;&nbsp;&nbsp;&nbsp;Authorized
    Signatory</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[Signature Page to Limited
Consent and Amendment]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"></P>

<!-- Field: Page; Sequence: 497 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Signed
    for and on behalf of</FONT> <FONT STYLE="font-size: 10pt">HAYFIN OPAL III LP &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">acting by it general partner Hayfin Opal
    III GP Limited &nbsp; &nbsp; &nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; padding-bottom: 1pt; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;&nbsp; Authorized
    Signatory &nbsp; &nbsp; &nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[Signature Page to Limited
Consent and Amendment]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 498 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B><STRIKE>EXECUTION
VERSION</STRIKE></B></FONT><B><FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt "><I>E<FONT STYLE="font-size: 10pt">XHIBIT</FONT>&nbsp;A <FONT STYLE="font-size: 10pt">TO</FONT>
L<FONT STYLE="font-size: 10pt">IMITED</FONT> C<FONT STYLE="font-size: 10pt">ONSENT</FONT></I></U></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: blue"><FONT STYLE="text-underline-style: double; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><B><I><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">AND
AMENDMENT NO. 1 TO LOAN AGREEMENT</U></I></B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>LOAN AGREEMENT</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Dated as of July&nbsp;17, 2020</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">between</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AMICUS THERAPEUTICS INTERNATIONAL HOLDING LTD,</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(as <I>Borrower</I>),</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>AMICUS THERAPEUTICS,&nbsp;INC.,</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(<I>as Parent</I>),</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CERTAIN SUBSIDIARIES OF PARENT FROM TIME TO TIME PARTY HERETO,</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(<I>as other Credit Parties</I>),</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>HAYFIN SERVICES LLP,</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(<I>as Agent</I>)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">and</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>THE LENDERS FROM TIME TO TIME PARTY HERETO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 499 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(iii)&nbsp;</FONT>If
at any time any Credit Party or any Subsidiary of a Credit Party shall incur Indebtedness not constituting Permitted Indebtedness, then
(A)&nbsp;Borrower shall promptly notify the Agent in writing of such incurrence of Indebtedness (including the amount of the Net Issuance
Proceeds received by a Credit Party and/or such Subsidiary in respect thereof) (and upon receipt of any such written notice the Agent
shall promptly notify each relevant Lender thereof) and (B)&nbsp;promptly (and in any event, within five (5)&nbsp;Business Days (or such
later date as agreed by the Agent)) upon receipt by a Credit Party and/or such Subsidiary of the Net Issuance Proceeds of incurrence of
Indebtedness, the Borrower shall deliver, or cause to be delivered, one hundred percent (100%) of such Net Issuance Proceeds to the Agent
for distribution to the Lenders as a prepayment of the Term Loans, together with any and all accrued and unpaid interest with respect
to the Term Loans so prepaid, and the Prepayment Premium (if applicable).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(iv)</FONT></TD><TD STYLE="text-align: justify">If at any time any Credit Party or any Subsidiary of a Credit Party shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(1)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>make
an Asset Sale <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(other than a Gene Therapy Liquidation Event) </U></FONT>or suffer an Event of Loss, and the
aggregate amount of the Net Proceeds received by the Credit Parties and their Subsidiaries in connection with such Asset Sale or Event
of Loss and all other Asset Sales and Events of Loss occurring during the same fiscal year exceeds $50,000,000; <FONT STYLE="color: red"><STRIKE>or</STRIKE></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(2)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>make
a Gene Therapy Portfolio Asset Sale <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(other than a Gene Therapy Liquidation Event) </U></FONT>(I)&nbsp;prior
to first regulatory approval in the United States or Europe of any treatments of Pompe disease provided to Parent or any Subsidiary thereof
which, as of the Effective Date, are undergoing clinical trials, and the aggregate amount of Net Proceeds received by the Credit Parties
and their Subsidiaries in connection with such Gene Therapy Portfolio Asset Sale and all other Gene Therapy Portfolio Asset Sales which
occur prior to such first regulatory approval exceeds $50,000,000 or (II)&nbsp;following the receipt of regulatory approval in the United
States or Europe of any treatments of Pompe disease provided to Parent or any Subsidiary thereof which, as of the Effective Date, are
undergoing clinical trials, and the aggregate amount of Net Proceeds received by the Credit Parties and their Subsidiaries in connection
with such Gene Therapy Portfolio Asset Sale and all other Gene Therapy Portfolio Asset Sales exceeds $150,000,000; <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">or</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; color: blue"><FONT STYLE="text-underline-style: double; color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(3)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;receive
Net Proceeds of any Gene Therapy Liquidation Event in excess of $50,000,000; or</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; color: blue"><FONT STYLE="text-underline-style: double; color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(4)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;or
receive any GT Tax Receivables Agreement Payment in excess of $1,000,000;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 500; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">then (A)&nbsp;Borrower shall
promptly notify the Agent in writing of such Asset Sale, Gene Therapy Portfolio Asset Sale <FONT STYLE="color: red">or</FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">, </U></FONT>Event
of Loss<FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">, Gene Therapy
Liquidation Event or GT Tax Receivables Agreement Payment </U></FONT>(including the amount of the Net Proceeds received by a Credit
Party and/or such Subsidiary in respect thereof) (and upon receipt of any such written notice the Agent shall promptly notify each
relevant Lender thereof) and (B)&nbsp;promptly (and in any event, within five (5)&nbsp;Business Days (or such later date as agreed
by the Agent)) upon receipt by a Credit Party and/or such Subsidiary of the Net Proceeds of such Asset Sale, Gene Therapy Portfolio
Asset Sale <FONT STYLE="color: red">or</FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">, </U></FONT>Event
of Loss, <FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">Gene Therapy
Liquidation Event or GT Tax Receivables Agreement Payment,</U></FONT> the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrower
shall deliver, or cause to be delivered, one hundred percent (100%) of such Net Proceeds </FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(</U></FONT>in
excess of the thresholds set forth in subclauses (1)<FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">,
(2), (3)</U></FONT>&nbsp;and (<FONT STYLE="color: red"><STRIKE>2</STRIKE></FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">4</U></FONT>)
above<FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">)</U></FONT> to
the Agent for distribution to the Lenders as a prepayment of the Term Loans, together with any and all accrued and unpaid interest
with respect to the Term Loans so prepaid, and the Prepayment Premium (if applicable). Notwithstanding the foregoing, and provided
that no Default or Event of Default has occurred and is continuing, no prepayment of all (or a portion) of such Net Proceeds shall
be required to the extent (i)&nbsp;a Credit Party or such Subsidiary reinvests the Net Proceeds (or applicable portion thereof) of
any such Asset Sale or Event of Loss with respect to Collateral in assets or property of any Credit Party constituting Collateral of
a kind then used or usable in the business of such Credit Party or (ii)&nbsp;a Credit Party or such Subsidiary reinvests the Net
Proceeds (or applicable portion thereof) of any such Asset Sale or Event of Loss with respect to assets that are not Collateral or
any such Gene Therapy Portfolio Asset Sale <FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">or
Gene Therapy Liquidation Event or receipt of GT Tax Receivables Agreement Payment </U></FONT>in assets or property of any Credit
Party or Subsidiary of a kind then used or usable in the business of such Credit Party or Subsidiary, in each case within three
hundred sixty-five (365) days after the date of receipt of such Net Proceeds or enters into a binding commitment thereof within said
three hundred sixty-five (365) day period and subsequently makes such reinvestment within one hundred eighty (180) days after the
final day of such three hundred sixty-five (365) day period. Pending such reinvestment, the Net Proceeds shall be deposited, and
shall remain on deposit, in a deposit account subject to a Control Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Allocation
of Prepayments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(i)&nbsp;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to Section&nbsp;8.3, each partial voluntary prepayment of the Term Loan shall be applied to reduce the then remaining installments of
the Term Loan as directed by the Borrower (and absent such direction, in direct order of maturity (including with the payment due on the
Term Loan Maturity Date)). In the case of a Tax-Related Cancellation and Prepayment the amount or amounts prepaid shall be applied in
prepaying the outstanding principal balance of the Term Loan of the relevant Lender or Lenders as specified by the Borrower to the Agent
in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to Section&nbsp;8.3, each mandatory prepayment of the Term Loan made pursuant to Sections 2.2(c)(iii)&nbsp;and (iv)&nbsp;shall be applied
ratably to reduce the outstanding principal balance of the Term Loan to the installments thereof (including the payment due on the Term
Loan Maturity Date) pro rata.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
prepayment or repayment by the Borrower on account of principal of and interest on the Term Loan shall be applied by the Agent on a pro
rata basis according to the respective outstanding principal amounts of the Term Loan then held by the Lenders, except, for the avoidance
of doubt, in the event of a Tax-Related Cancelation and Prepayment in which case the outstanding principal balance of the Term Loan of
the relevant Lender or Lenders shall be prepaid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Declined
Amounts</U>. In the event of any mandatory prepayment of the Term Loan pursuant to Sections 2.3(c)(ii), (iii), or (iv)&nbsp;(an &ldquo;<B>Applicable
Mandatory Prepayment</B>&rdquo;), each Lender may reject all or a portion of its share of such Applicable Mandatory Prepayment by written
notice (each, a &ldquo;<B>Rejection Notice</B>&rdquo;) (each such Lender, a &ldquo;<B>Rejecting Lender</B>&rdquo;) to the Agent no later
than 2:00 p.m.&nbsp;Eastern Standard Time, two (2)&nbsp;Business Days after the date of such Lender&rsquo;s receipt of notice of such
Applicable Mandatory Prepayment as otherwise provided herein (the &ldquo;<B>Rejection Deadline</B>&rdquo;). If a Lender fails to deliver
a Rejection Notice to the Agent at or prior to the Rejection Deadline, such Lender will be deemed to have accepted its ratable share
of the Applicable Mandatory Prepayment. The</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 501; Value: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Other
Information</U>. As promptly as practicable (and in any event within fifteen (15) days of the request therefor), such additional information
regarding the business or financial affairs of Parent or any of its Subsidiaries, or compliance with the terms of this Agreement or any
other Loan Documents, as Agent or any Lender may from time to time reasonably request (subject to reasonable requirements of confidentiality,
including requirements imposed by Requirements of Law or contract; provided that Parent shall not be obligated to disclose any information
that is reasonably subject to the assertion of attorney-client privilege or attorney work-product).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Budget</U>.
As soon as available, and in any event within sixty (60) days after the end of each fiscal year of the Parent <FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(the
 &ldquo;<B>Budget Delivery Date</B>&rdquo;)</U></FONT>, commencing with the fiscal year ending December&nbsp;31, 2020, a consolidated
budget for the then-current fiscal year (collectively, the &ldquo;<B>Budget</B>&rdquo;), which Budget shall be accompanied by a certificate
of a Responsible Officer stating that such Budget have been prepared in good faith on the basis of the assumptions stated therein, which
assumptions were believed to be reasonable at the time of preparation of such Budget, it being understood that actual results may vary
from such Budget and that such variations may be material<FONT STYLE="color: red"><STRIKE>.</STRIKE></FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">;
provided, that, from and after the GT Spin-Off Effective Date, (i)&nbsp;each Budget shall specify the anticipated contributions by the
Credit Parties to GT JV and its Subsidiaries pursuant to the Co-Development and Commercialization Agreement during the then-current fiscal
year and (ii)&nbsp;with respect to any Budget, in the event that Liquidity of Parent and its Subsidiaries (exclusive of, for the avoidance
of doubt, GT JV and its Subsidiaries), as reported in the most recent publicly-available balance sheet thereof dated on or prior to the
Budget Delivery Date for such Budget, was less than $150,000,000, the Credit Parties shall deliver to Agent, together with such Budget,
a certification of a Responsible Officer stating that the Credit Parties reasonably project that at all times from the Budget Delivery
Date and prior to December&nbsp;31 of the then-current calendar year the Credit Parties will be in compliance with Section&nbsp;6.17
(which projections shall have been prepared in good faith on the basis of the assumptions stated therein, which assumptions were believed
to be reasonable at the time of preparation of such projections).</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Compliance
Certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Commencing
with the fiscal quarter ending March&nbsp;31, 2021, concurrently with the delivery of any financial statements pursuant to Sections 5.2(a)(i)&nbsp;and
(ii), a certification (the &ldquo; <B>Consolidated Revenue Compliance Certificate</B>&rdquo;) substantially in the form of Exhibit&nbsp;D
hereto as to (x)&nbsp;the absence of a Default or Event of Default (or to the extent a Default or Event of Default has occurred and is
continuing, a description and actions taken or proposed taken with respect thereto), (y)&nbsp;the calculation of Consolidated Revenue
and confirmation as to whether the Credit Parties are in compliance with Section&nbsp;6.16, and (z)&nbsp;to the extent not previously
disclosed to the Agent, (1)&nbsp;a description of any change in the jurisdiction of organization of any Credit Party, (2)&nbsp;a list
of any registered Intellectual Property acquired or developed by any Credit Party during the applicable period and (3)&nbsp;a description
of any Person that has become a Subsidiary, in each case since the date of the most recent Consolidated Revenue Compliance Certificate
delivered pursuant to this clause (i)&nbsp;(or, in the case of the first such report so delivered, since the Closing Date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>As
soon as available, but in any event within thirty (30) days after the end of each calendar month, a certification substantially in
the form of Exhibit&nbsp;E hereto as to (x)&nbsp;the absence of a Default or Event of Default (or to the extent a Default or Event
of Default has occurred and is continuing, a description and actions taken or proposed taken with respect thereto), and (y)&nbsp;the
calculation of Liquidity and confirmation as to whether the Credit Parties are (and have at all times since the date of the
previously delivered Compliance Certificate (or if any action under laws outside the United States or England and Wales to attach,
maintain, perfect, protect or enforce the Lien of Agent in favor and for the benefit of the Agent and the other Secured Parties on
any such Collateral.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 502; Options: NewSection; Value: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>5.12.</B></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Additional
Collateral; Guarantors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>From
and after the Closing Date, except as otherwise approved in writing by the Agent, each Credit Party shall cause each of its Subsidiaries
organized in the United States or England and Wales (other than Excluded Subsidiaries) to guarantee the Obligations and to cause each
such Subsidiary to grant to the Agent in favor and for the benefit of the Agent and the other Secured Parties a first priority security
interest in and Lien upon, and pledge to the Agent in favor and for the benefit of the Agent and the other Secured Parties, subject to
Permitted Liens, all of such Subsidiary&rsquo;s properties and assets constituting Collateral <FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(including,
for the avoidance of doubt, in the case of GT JV Holdco, any Equity Interests owned by GT JV Holdco in GT JV or Equity Interests constituting
Class&nbsp;A Shares (or other shares representing common stock) of ARYA (including, to the extent deemed necessary and advisable by the
Agent (in its good faith determination), pursuant to a Control Agreement in form and substance reasonably acceptable to the Agent and
the Borrower) and, in each case, proceeds thereof but specifically excluding the ARYA Non-Economic Shares))</U></FONT>, whether now existing
or hereafter acquired or existing, to secure such guaranty; provided, that such Credit Party&rsquo;s obligations to cause any Subsidiaries
formed or acquired after the Closing Date to take the foregoing actions shall be subject to the timing requirements of Section&nbsp;5.13.
Furthermore, except as otherwise approved in writing by Agent, each Credit Party, from and after the Closing Date, shall, and shall cause
each of its Subsidiaries to grant the Agent in favor and for the benefit of the Agent and the other Secured Parties a first priority
security interest in and Lien upon, and pledge to the Agent in favor and for the benefit of the Agent and the other Secured Parties,
subject to Permitted Liens, the limitations set forth herein and the limitations set forth in the other Loan Documents, all of the Equity
Interests (other than Excluded Equity Interests) of each first-tier Subsidiary owned by a Credit Party. In connection with each pledge
of certificated Equity Interests required under the Loan Documents, the Credit Parties shall deliver, or cause to be delivered, to the
Agent, such certificate(s)&nbsp;together with stock powers or assignments, as applicable, properly endorsed for transfer to the Agent
or duly executed in blank, in each case reasonably satisfactory to the Agent. In connection with each pledge of uncertificated Equity
Interests required under the Loan Documents, the Credit Parties shall deliver, or cause to be delivered, to the Agent an executed uncertificated
stock control agreement among the issuer, the registered owner and the Agent substantially in the form attached as an Annex to the Security
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
the event any Credit Party acquires any fee title to real estate in the U.S. with a fair market value (reasonably determined in good
faith by a Responsible Officer of Parent) in excess of $10,000,000, unless otherwise agreed by the Agent, such Person shall execute
or deliver, or cause to be executed or delivered, to the Agent, (i)&nbsp;within sixty (60) days after such acquisition, an appraisal
complying with the Financial Institutions Reform, Recovery and Enforcement Act of 1989, (ii)&nbsp;within forty-five (45) days after
receipt of notice from the Agent that such real estate is located in a Special Flood Hazard Area, Federal Flood Insurance,
(iii)&nbsp;within sixty (60) days after such acquisition, a fully executed Mortgage, in form and substance reasonably satisfactory
to the Agent, together with an A.L.T.A. lender&rsquo;s title insurance policy issued by a title insurer reasonably satisfactory to
the Agent, in form and substance (including any endorsements) and in an amount reasonably satisfactory to the Agent insuring that
the Mortgage is a valid and enforceable first priority Lien on the respective property, free and clear of all defects, encumbrances
and Liens (other than Permitted Liens), (iv)&nbsp;simultaneously with such acquisition, then-current A.L.T.A. surveys, certified to
the Agent by a licensed surveyor sufficient to allow the issuer of the lender&rsquo;s title insurance policy to issue such policy
without a survey exception and (v)&nbsp;within sixty (60) days after such acquisition, an environmental site assessment prepared by
a qualified firm reasonably acceptable to the Agent, in form and substance satisfactory to the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 503; Options: NewSection; Value: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Product to any Person, other
than entering into a license arrangement as expressly permitted pursuant to <U>clauses (j)&nbsp;</U>and (k)&nbsp;of the definition
of &ldquo;Permitted Transfer&rdquo; and (y)&nbsp;Transfers of the Gene Therapy Portfolio shall only be permitted to the extent made
pursuant to <FONT STYLE="color: red"><STRIKE>clause</STRIKE></FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">clauses </U></FONT>(a)&nbsp;<FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">and
(l)</U></FONT>&nbsp;of the definition of &ldquo;Permitted Transfer&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>6.2.</B></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>Fundamental
Changes</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Without
at least ten (10)&nbsp;Business Days prior written notice to the Agent, solely in the case of a Credit Party: (i)&nbsp;change its jurisdiction
of organization, incorporation or formation, (ii)&nbsp;change its organizational structure or type, (iii)&nbsp;change its legal name,
or (iv)&nbsp;change any organizational number (if any) assigned by its jurisdiction of organization, incorporation or formation; provided,
that in no event shall either the Parent or the Borrower change its jurisdiction of organization, incorporation or formation, or change
its organizational structure or type, without the prior written consent of the Agent<FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">;
provided, further, that, the conversion of each of MiaMed,&nbsp;Inc. and Amicus Biologics,&nbsp;Inc. into limited liability companies,
the change of the legal name of Amicus Biologics,&nbsp;Inc., and the conversion of Celenex,&nbsp;Inc., into a limited liability company,
to the extent each of such steps are consummated with the primary purpose of consummating the Gene Therapy Portfolio Spin-Off Transaction,
shall be permitted so long as Agent receives, within ten (10)&nbsp;Business Days after such conversion or change, certified copies of
the amended Organizational Documents</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Permit
a Credit Party to be a direct or indirect Wholly-Owned Subsidiary of a Subsidiary of the Parent that is not also a Credit Party <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(other
than, substantially concurrently with the GT Spin-Off Effective Date, each of the Transfers set forth in clauses (vi), (vii), (x)&nbsp;and
(xi)&nbsp;of the definition of &ldquo;Gene Therapy Portfolio Spin-Off Transaction Steps&rdquo;)</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Permit
any Subsidiary of the Parent to issue any Equity Interests (whether for value or otherwise) to any Person other than (i)&nbsp;with respect
to any Subsidiary of the Parent that is, as of the Closing Date, a Credit Party, the issuance of Equity Interests of such Credit Party
to the direct parent (as of the Closing Date) of such Credit Party, (ii)&nbsp;with respect to any Subsidiary of Parent that becomes a
Credit Party after the Effective Date, the issuance of Equity Interests to a Credit Party <FONT STYLE="color: red">and</FONT><FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">,</U></FONT>
(iii), with respect to any Subsidiary of the Parent that is not a Credit Party, to any other Subsidiary of the Parent, provided that no
such issuance shall cause a Subsidiary that is (A)&nbsp;a Wholly-Owned Subsidiary of a Credit Party to cease to be wholly-owned by such
Credit Party, or (B)&nbsp;majority-owned by a Credit Party to cease to be majority-owned by a Credit Party<FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">,
and (iv)&nbsp;upon consummation of each of the Pre-Closing Gene Therapy Portfolio Spin-Off Transaction Steps and concurrently with the
GT Spin-Off Effective Date, the issuance of Equity Interests in GT JV to ARYA in exchange for cash in accordance with the terms of the
GT Business Combination Agreement</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Permit
a Wholly-Owned Subsidiary of a Credit Party to cease to <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">be</U></FONT> a Wholly-Owned Subsidiary of such Credit
Party, other than <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(x)</U></FONT>&nbsp;in connection with a Permitted Transfer of all of the Equity Interests
of such Wholly-Owned Subsidiary to a Person that is not a Credit Party or Subsidiary thereof <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">and (y)&nbsp;upon
consummation of each of the Pre-Closing Gene Therapy Portfolio Spin-Off Transaction Steps and concurrently with the GT Spin-Off Effective
Date, the issuance of Equity Interests in GT JV to ARYA in exchange for cash in accordance with the terms of the GT Business Combination
Agreement</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Permit
Scioderm Limited to conduct, transact or engage in any business or operations, or otherwise hold any assets, other than to the extent
necessary for the purposes of dissolving such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 504; Options: NewSection; Value: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>6.3.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Mergers,
Acquisitions, Liquidations or Dissolutions</B>. that any Credit Party or any Subsidiary or Affiliate of any Credit Party is listed
on the OFAC Lists or (a)&nbsp;is convicted on, (b)&nbsp;pleads <I>nolo contendere</I> to, (c)&nbsp;is indicted on, or (d)&nbsp;is
arraigned and held over on charges involving money laundering or predicate crimes to money laundering. No Credit Party will, nor
will any Credit Party permit any of its Subsidiaries or Affiliates to, directly or indirectly, (i)&nbsp;conduct any business or
engage in any transaction or dealing with any Blocked Person, including the making or receiving of any contribution of funds, goods
or services to or for the benefit of any Blocked Person, (ii)&nbsp;deal in, or otherwise engage in any transaction relating to, any
property or interests in property blocked pursuant to Executive Order No.&nbsp;13224, any similar executive order or other
Anti-Terrorism Law, or (iii)&nbsp;engage in or conspire to engage in any transaction that evades or avoids or violates, or has the
purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No.&nbsp;13224 or other
Anti-Terrorism Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>6.14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Amendments
or Waivers of Material Contracts</B>. (a<FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">)&nbsp;(i</U></FONT>)&nbsp;Waive,
amend, cancel or terminate, exercise or fail to exercise, any material rights constituting or relating to any Material Contract or (<FONT STYLE="color: red"><STRIKE>b</STRIKE></FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">ii</U></FONT>)
breach, default under, or take any action or fail to take any action that, with the passage of time or the giving of notice or both,
would constitute a default or event of default under any Material Contract, in each case of this Section&nbsp;6.14, (<FONT STYLE="color: red"><STRIKE>i</STRIKE></FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">A</U></FONT>)
which could reasonably be expected to, individually or together with any other such waivers, amendments, cancellations, terminations,
exercises or failures, result in a Material Adverse Change or (<FONT STYLE="color: red"><STRIKE>ii</STRIKE></FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">B</U></FONT>)
would be materially adverse to the interests of the Agent and the Lenders <FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">or
(b)&nbsp;waive, amend or otherwise modify the GT Business Combination Agreement, the GT JV Investor Rights Agreement or any disclosure
schedules delivered in connection therewith in a manner which (A)&nbsp;could reasonably be expected to, individually or together with
any other such waivers, amendments or modifications, result in a Material Adverse Change or (B)&nbsp;would be materially adverse to the
interests of the Agent and the Lenders</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>6.15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Transactions
with Affiliates</B>. Enter into or permit to exist any arrangement, contract or transaction, including any purchase, sale, lease or exchange
of property, the rendering of any service or the payment of any management, advisory or similar fees, with any Affiliate that is not
a Credit Party or a Wholly-Owned Subsidiary of a Credit Party unless <FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(x)</U></FONT>&nbsp;such
transaction is in the ordinary course of business and pursuant to reasonable terms no less favorable to such Credit Party or such Subsidiary
than would be obtained in a comparable arm&rsquo;s length transaction with a Person not an Affiliate of the Parent or such Subsidiary<FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">,
and (y)&nbsp;with respect to any transaction contemplated under each of the GT Tax Receivables Agreement and GT Transition Services Agreement
following the occurrence of the GT Spin-Off Effective Date, such transaction is on reasonable terms no less favorable to such Credit
Party or such Subsidiary than would be obtained in a comparable arm&rsquo;s length transaction with a Person not an Affiliate of the
Parent or such Subsidiary</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>6.16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Minimum
Consolidated Revenue</B>. Permit Consolidated Revenue of the Parent and its Subsidiaries <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(other than, for
the avoidance of doubt, GT JV and its Subsidiaries)</U></FONT> as of the last day for any period of four consecutive fiscal quarters ending
on any date set forth below to be less than the minimum Consolidated Revenue amount set forth below opposite such date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 505; Options: NewSection; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 64%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">Minimum</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Quarter Ending</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Consolidated Revenue</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">March&nbsp;31, 2021</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">140,000,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">June&nbsp;30, 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">140,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">September&nbsp;30, 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">140,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">December&nbsp;31, 2021</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">175,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">March&nbsp;31, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">175,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">June&nbsp;30, 2022</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">175,000,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">September&nbsp;30, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">200,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">December&nbsp;31, 2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">200,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">March&nbsp;31, 2023</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">200,000,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">June&nbsp;30, 2023 and each fiscal quarter thereafter</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">225,000,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>6.17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Minimum
Liquidity</B>. Permit Liquidity of the Parent and its Subsidiaries <FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(exclusive
of, for the avoidance of doubt, GT JV and its Subsidiaries) </U></FONT>to be less than $75,000,000 at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>7.</B></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B>EVENTS
OF DEFAULT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any one of the following shall constitute an event
of default (an &ldquo;<B>Event of Default</B>&rdquo;) under this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>7.1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Payment
Default</B>. Any Credit Party fails to (a)&nbsp;make any payment of any principal of the Term Loan when and as the same shall become
due and payable, whether at the due date thereof or at a date fixed for prepayment (whether voluntary or mandatory) thereof or by acceleration
thereof or otherwise, or (b)&nbsp;within five (5)&nbsp;Business Days after the same becomes due, any payment of interest or premium pursuant
to Section&nbsp;2.2, including any applicable fees, the Prepayment Premium, or any other Obligations (which five (5)&nbsp;Business Day
cure period shall not apply to any payments due on the Term Loan Maturity Date or the date of acceleration pursuant to Section&nbsp;8.1(a)&nbsp;or
Section&nbsp;2.2(b)(ii)&nbsp;hereof). A failure to pay any such interest, premium or Obligations pursuant to the foregoing clause (b)&nbsp;prior
to the end of such five (5)&nbsp;Business Day-period shall not constitute an Event of Default (unless such payment is due on the Term
Loan Maturity Date or the date of acceleration pursuant to Section&nbsp;8.1(a)&nbsp;or Section&nbsp;2.2(b)(ii)&nbsp;hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>7.2.</B></FONT><B>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Covenant
Default</B>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Credit Parties: (i)&nbsp;fail or neglect to perform any obligation in Sections 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.10, 5.12, 5.13 or 5.14
or (ii)&nbsp;violate any covenant in Section&nbsp;6; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Credit Parties fail or neglect to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in
this Agreement or any Loan Documents on its part to be performed, kept or observed and such failure continues for ten (10)&nbsp;days,
after the earlier of the date on which (i)&nbsp;a Responsible Officer of any Credit Party becomes aware of such failure and (ii)&nbsp;written
notice thereof shall have been given to the Parent or Borrower by the Agent. Cure periods provided under this Section&nbsp;7.2(b)&nbsp;shall
not apply, among other things, to any of the covenants referenced in clause (a)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>7.3.</B></FONT></TD><TD STYLE="text-align: justify"><B>Material Adverse Change</B>. A Material Adverse Change occurs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 506; Value: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>7.4.</B></FONT></TD><TD STYLE="text-align: justify"><B>Attachment; Levy; Restraint on Business</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>(i)&nbsp;The
service of process seeking to attach, by trustee or similar process, any funds of any Credit Party or of any entity under the control
of any Credit Party (including a Subsidiary) in excess of $20,000,000 on deposit or otherwise maintained with the Agent, or (ii)&nbsp;a
notice of lien or levy is filed against any of material portion of Collateral by any Governmental Authority, and the same under sub-clauses
(i)&nbsp;and (ii)&nbsp;hereof are not, within thirty (30) days after the occurrence thereof, transaction expressly permitted hereunder
or under any other Loan Document<FONT STYLE="color: red"><STRIKE>.</STRIKE></FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">;
provided, that, upon the occurrence of the Transfer by GT JV Holdco of 100% of the Equity Interests of Celenex, LLC to GT JV and the
Transfer by Parent of 100% of the Equity Interests of MiaMed LLC and FL RE Holdings LLC to GT JV, in connection with the consummation
of the Gene Therapy Portfolio Spin-Off Transaction and substantially concurrently with the GT Spin-Off Effective Date, each of Celenex,
LLC (f.k.a. Celenex,&nbsp;Inc.), MiaMed, LLC (f.k.a. MiaMed,&nbsp;Inc.) and FL RE Holdings LLC (f.k.a. Amicus Biologics,&nbsp;Inc.) shall
be automatically released from its guaranty of the Obligations and the security interests and Liens created by the Collateral Documents
in favor of the Agent, for the benefit of itself and the Secured Parties on the assets of each of Celenex, LLC (f.k.a. Celenex,&nbsp;Inc.),
MiaMed, LLC (f.k.a. MiaMed,&nbsp;Inc.) and FL RE Holdings LLC (f.k.a. Amicus Biologics,&nbsp;Inc.) shall be automatically released; provided,
further, that, if GT JV ceases to be an Excluded Subsidiary in accordance with the proviso set forth in clause (vii)&nbsp;of the definition
of &ldquo;Excluded Subsidiary&rdquo;, than each of Celenex, LLC (f.k.a. Celenex,&nbsp;Inc.), MiaMed, LLC (f.k.a. MiaMed,&nbsp;Inc.) and
FL RE Holdings LLC (f.k.a. Amicus Biologics,&nbsp;Inc.) shall be required to comply with Sections 5.12 and 5.13 of this Agreement.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>11.10.&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Right
of Set-Off</B>. In addition to any rights now or hereafter granted under Requirements of Law and not by way of limitation of any such
rights, upon the occurrence of an Event of Default and at any time thereafter during the continuance of any Event of Default, the Agent
is hereby authorized by each Credit Party at any time or from time to time, without prior notice to any Credit Party, any such notice
being hereby expressly waived by Borrower (on its own behalf and on behalf of each other Credit Party), to set off and to appropriate
and to apply any and all deposits (general or special, including Indebtedness evidenced by certificates of deposit, whether matured or
unmatured, but not including trust accounts) and any other Indebtedness at any time held or owing by the Agent or any Lender to or for
the credit or the account of any Credit Party against and on account of the obligations and liabilities of any Credit Party to the Agent
or any Lender hereunder and under the other Loan Documents, including all claims of any nature or description arising out of or connected
hereto or with any other Loan Document, irrespective of whether or not (a)&nbsp;the Agent or any Lender shall have made any demand hereunder
or (b)&nbsp;the principal of or the interest on the Term Loan or any other amounts due hereunder shall have become due and payable pursuant
to Section&nbsp;2 and although such obligations and liabilities, or any of them, may be contingent or unmatured. The Agent agrees promptly
to notify Borrower after any such set off and application made by the Agent; provided that the failure to give such notice shall not
affect the validity of such set off and application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101"><B>11.11.&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B>Marshalling;
Payments Set Aside</B>. Neither the Agent nor any Lender shall be under any obligation to marshal any assets in favor of any Credit
Party or any other Person or against or in payment of any or all of the Obligations. To the extent that any Credit Party makes a
payment or payments to the Agent or any Lender, or the Agent or any Lender enforces any Liens or exercises its rights of setoff, and
such payment or payments or the proceeds of such enforcement or setoff or any part thereof are subsequently invalidated, declared to
be fraudulent or preferential, set aside or required to be repaid to a trustee, receiver or any other party under any bankruptcy
law, any other state or federal law, common law or any equitable cause, then, to the extent of such recovery, the obligation or part
thereof originally intended to be satisfied, and all Liens, rights and remedies therefor or related thereto, shall be revived and
continued in full force and effect as if such payment or payments had not been made or such enforcement or setoff had not occurred.
Each Lender severally agrees to pay to the Agent upon demand its applicable share (without duplication) of any amount so recovered
from or repaid by the Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum
equal to the Federal Funds Rate from time to time in effect, and Agent&rsquo;s Liens securing such obligation shall be effective,
revived, and remain in full force and effect, in each case, as fully as if such recovered payment had not been made. The provisions
of this Section&nbsp;11.11 shall survive the payment in full of the Obligations and the termination of this Agreement Authority,
domestic or foreign (including any Environmental Claims), whether pending or, to the Knowledge of the Credit Parties, threatened
against or adversely affecting any Credit Party or any of its Subsidiaries or any property of any Credit Party or any of its
Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 507; Options: NewSection; Value: 59 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to any Person, each other Person that owns or controls directly or indirectly the Person, any Person that controls
or is controlled by or is under common control with the Person, and each of that Person&rsquo;s senior executive officers, directors,
partners and, for any Person that is a limited liability company or limited liability partnership, that Person&rsquo;s managers and members.
As used in this definition, &ldquo;control&rdquo; means (a)&nbsp;direct or indirect beneficial ownership of at least ten percent (10%)
(or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting
share capital or other equity interest in a Person or (b)&nbsp;the power to direct or cause the direction of the management of such Person
by contract or otherwise. In no event shall the Agent or any Lender be deemed to be an Affiliate of Parent or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agent</B>&rdquo;
means Hayfin Services LLP, in its capacity as administrative agent and collateral agent under this Agreement and any other Loan Document,
or any successor administrative agent and collateral agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agent-Related Person</B>&rdquo;
means the Agent, together with each of its respective Affiliates, Approved Funds, officers, directors, employees, partners, agents, advisors
and other representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Agreement</B>&rdquo; is defined in the preamble
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt">&ldquo;<B>Amendment
No.&nbsp;1</B>&rdquo; means that certain Limited Consent and Amendment No.&nbsp;1 to Loan Agreement, dated as of the Amendment
No.&nbsp;1 Effective Date, by and among, Parent, the Borrower, the Lenders party thereto and the Agent.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: blue"><FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt">&ldquo;<B>Amendment No.&nbsp;1 Effective
Date</B>&rdquo; means the Effective Date as defined in Amendment No.&nbsp;1.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;</U></FONT><B>Anti-Money
Laundering Laws</B>&rdquo; is defined in Section&nbsp;4.18(b).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <B>Anti-Terrorism
Laws</B>&rdquo; means any Anti-Money Laundering Laws or other laws relating to terrorism or money laundering, including Executive Order
No.&nbsp;13224 (effective September&nbsp;24, 2001), the Patriot Act, the laws comprising or implementing the Bank Secrecy Act, and the
laws administered by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Applicable Accounting
Standards</B>&rdquo; means with respect to Parent and its Subsidiaries, generally accepted accounting principles in the United States
as set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants
and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may
be approved by a significant segment of the accounting profession, which are applicable to the circumstances as of the date of determination,
consistently applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Applicable Mandatory Prepayment</B>&rdquo; is
defined in Section&nbsp;2.2(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Applicable Margin</B>&rdquo;
means a percentage per annum equal to (a)&nbsp;for LIBOR Rate Loans, six and one-half percent (6.50%) and (b)&nbsp;for Base Rate Loans,
five and one-half percent (5.50%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Approved Fund</B>&rdquo;
means Person (other than a natural person) that is engaged in making, purchasing, holding or otherwise investing in commercial loans
and similar extensions of credit in the ordinary course that is administered, advised or managed by (a)&nbsp;a Lender, (b)&nbsp;an Affiliate
of a Lender or (c)&nbsp;an entity or an Affiliate of an entity that administers, advises or manages a Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 508; Options: NewSection; Value: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <B>Article&nbsp;55
BRRD</B>&rdquo; means Article&nbsp;55 of Directive 2014/59/EU establishing a framework for the recovery and resolution of credit institutions
and investment firms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>ARYA</B>&rdquo;
means ARYA Sciences Acquisition Corp IV.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: blue"><FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>ARYA
Non-Economic Shares</B>&rdquo; means the Class&nbsp;B Shares of ARYA to be issued to GT JV Holdco pursuant to the Gene Therapy Portfolio
Spin-Off Transactions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;</U></FONT><B>Asset
Acquisition</B>&rdquo; means, with respect to Parent or any of its Subsidiaries, any purchase, in-license or other acquisition of any
properties or assets of any other Person (including any purchase or other acquisition of any business unit, line of business or division
of such Person). For the avoidance of doubt, &ldquo;Asset Acquisition&rdquo; includes any co-promotion or co-marketing arrangement pursuant
to which Parent or any Subsidiary acquires rights to promote or market the products of another Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Asset Sale</B>&rdquo;
means any Transfer, other than Transfers expressly permitted under clauses (a), (b), (d), (e), (f), (g), (h), (i), (j)(i), (j)(ii)&nbsp;(solely
to the extent the terms of the exclusive license permitted by such clause (j)(ii)&nbsp;are consistent with a commercial transaction negotiated
at arm&rsquo;s-length), (j)(iii), (j)(iv)&nbsp;or (k)&nbsp;of the definition &ldquo;Permitted Transfer&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Assignment and Assumption</B>&rdquo;:
an Assignment and Assumption substantially in the form of Exhibit&nbsp;G hereto or any other form approved by the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Bail-In Action</B>&rdquo; means the exercise of
any Write-down and Conversion Powers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Bail-In Legislation</B>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
relation to an EEA Member Country which has implemented, or which at any time implements, Article&nbsp;55 BRRD, the relevant implementing
law or regulation as described in the EU Bail-In Legislation Schedule from time to time; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>in
relation to any state other than such an EEA Member Country or (to the extent that the United Kingdom is not such an EEA Member Country)
the United Kingdom, any analogous law or regulation from time to time which requires contractual recognition of any Write-down and Conversion
Powers contained in that law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Bankruptcy Code</B>&rdquo;
means Title 11 of the United States Code entitled &ldquo;Bankruptcy,&rdquo; as now and hereafter in effect, or any successor statute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <B>Base Rate</B>&rdquo;
means for any day, a rate per annum equal to the greatest of (a)&nbsp;the Prime Rate in effect on such day, (b)&nbsp;the Federal Funds
Rate in effect on such day plus &frac12; of 1% and (c)&nbsp;2.00%. Any change in the Base Rate due to a change in the Prime Rate or the
Federal Funds Rate shall be effective as of the opening of business on the day of such change in the Prime Rate or the Federal Funds Rate,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Base Rate Loan</B>&rdquo; means a Term Loan that
bears interest based on the Base Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Blocked
Person</B>&rdquo; means (a)&nbsp;any Person listed in the annex to, or is otherwise subject to the provisions of, Executive Order
No.&nbsp;13224, (b)&nbsp;a Person fifty percent (50%) or more owned by, or acting International Settlements, the Basel Committee on
Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case
pursuant to Basel III, shall be deemed to be a &ldquo;Change in Law&rdquo;, regardless of the date enacted, adopted or issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 509; Value: 73 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Charged
Company</B>&rdquo; is defined in <U>Section&nbsp;3.1(g)</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Cipaglucosidase
Alfa/Miglustat</B>&rdquo; means the Credit Parties&rsquo; therapy formerly known as AT-GAA, in clinical development as of the Effective
Date, that consists of a recombinant human acid alpha-glucosidase (rhGAA) enzyme with an optimized carbohydrate structure (designated
by Parent as ATB200) administered with a small molecule pharmacological chaperon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing Date</B>&rdquo;
means the date on which the Term Loans are advanced by the Lenders to the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt "><B>Co-Development
and Commercialization Agreement</B>&rdquo; means a Co-Development and Commercialization Agreement entered into between GT JV and
Parent substantially in the form of Exhibit&nbsp;E to the GT Business Combination Agreement.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;</U></FONT><B>Code</B>&rdquo;
means the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York; provided, that,
to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different
Articles of the Code, the definition of such term contained in Article&nbsp;9 of the Code shall govern; provided, further, that in the
event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect
to, the Agent&rsquo;s Lien in favor and for the benefit of the Agent and the other Secured Parties on any Collateral is governed by the
Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term &ldquo;Code&rdquo; shall mean the Uniform
Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment,
perfection, priority, or remedies and for purposes of definitions relating to such provisions.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral</B>&rdquo;
means all property of the Credit Parties, now owned or hereafter acquired, upon which a Lien is purported to be created by the Collateral
Documents, but in any event excluding all Excluded Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral Account</B>&rdquo;
means any Deposit Account of a Credit Party maintained with a bank or other depository or financial institution located in the United
States or England and Wales, any Securities Account of a Credit Party maintained with a securities intermediary located in the United
States or England and Wales, or any Commodity Account of a Credit Party maintained with a commodity intermediary located in the United
States or England and Wales, in each case, other than an Excluded Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Collateral Documents</B>&rdquo;
means the Security Agreement, the Non-US Security Agreement, the Control Agreements, the IP Agreements, any Mortgages and all other instruments,
documents and agreements delivered by any Credit Party pursuant to this Agreement or any of the other Loan Documents, in each case, in
order to grant to the Agent in favor and for the benefit of the Agent and the other Secured Parties or perfect a Lien on any Collateral
as security for the Obligations, and all amendments, restatements, modifications or supplements thereof or thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <B>Commodity Account</B>&rdquo;
means any &ldquo;commodity account&rdquo; as defined in the Code with such additions to such term as may hereafter be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 510; Options: NewSection; Value: 77 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Exchange Act</B>&rdquo; means the Securities Exchange
Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exchange
Act Documents</B>&rdquo; is defined in <U>Section&nbsp;4.8(a)</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Excluded Accounts</B>&rdquo; is defined in Section&nbsp;5.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded Assets</B>
 &rdquo; means, collectively: (i)&nbsp;leasehold interests in real property, (ii)&nbsp;fee interests in real property with a fair market
value (reasonably determined in good faith by a Responsible Officer of Parent) less than $10,000,000, (iii)&nbsp;with respect to any U.S.
Credit Party, Excluded Property (as defined in the Security Agreement), and (iv)&nbsp;with respect to any U.K. Credit Party, Excluded
Property (as defined in the English Debenture).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded Equity
Interests</B>&rdquo; means, collectively: (i)&nbsp;any Equity Interests in a Subsidiary of a U.K. Credit Party that is not organized in
the United States or under the laws of England and Wales; (ii)&nbsp;any Equity Interests of any Subsidiary with respect to which the grant
to the Agent in favor and for the benefit of the Agent and the other Secured Parties of a security interest in and Lien upon, and the
pledge to the Agent in favor and for the benefit of the Agent and the other Secured Parties of, such Equity Interests, to secure the Obligations
(and any guaranty thereof) are validly prohibited by Requirements of Law; (iii)&nbsp;any Equity Interests of any Subsidiary with respect
to which the grant to the Agent in favor and for the benefit of the Agent and the other Secured Parties of a security interest in and
Lien upon, and the pledge to the Agent in favor and for the benefit of the Agent and the other Secured Parties of, such Equity Interests,
to secure the Obligations (and any guaranty thereof) require the consent, approval or waiver of any Governmental Authority or other third
party and (x)&nbsp;with respect to a consent, approval or waiver of a third party, the requirement to obtain such consent, approval or
waiver shall have been in place at the Closing Date or at the time such Subsidiary is acquired (is not created in contemplation of or
in connection with such Person becoming a Subsidiary) and (y)&nbsp;such consent, approval or waiver has not been obtained by Parent following
Parent&rsquo;s commercially reasonable efforts to obtain the same; (iv)&nbsp;any Equity Interests of any Subsidiary that is a non-Wholly-Owned
Subsidiary that the grant to the Agent in favor and for the benefit of the Agent and the other Secured Parties of a security interest
in and Lien upon, and the pledge to the Agent of, such Equity Interests, to secure the Obligations (and any guaranty thereof) are validly
prohibited by, or would give any third party (other than Parent or an Affiliate of Parent) the right to terminate its obligations under,
the Operating Documents or the joint venture agreement or shareholder agreement with respect to, or any other contract with such third
party relating to such non-Wholly-Owned Subsidiary, including any contract evidencing Indebtedness of such non-Wholly-Owned Subsidiary
(other than customary non-assignment provisions which are ineffective under Article&nbsp;9 of the Code or other Requirements of Law),
but only (x)&nbsp;to the extent, and for so long as such Operating Document, joint venture agreement, shareholder agreement or other contract
is in effect and (y)&nbsp;to the extent such prohibition shall have been in place at the Closing Date or at the time such Subsidiary is
acquired and is not created in contemplation of or in connection with such Person becoming a non-Wholly-Owned Subsidiary; <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(v)&nbsp;the
ARYA Non-Economic Shares;</U></FONT> and (<FONT STYLE="color: red"><STRIKE>v</STRIKE></FONT><FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">vi</U></FONT>)
any Equity Interests of any other Subsidiary with respect to which, Parent and the Agent reasonably determine by mutual agreement that
the cost of granting the Agent in favor and for the benefit of the Agent and the other Secured Parties a security interest, in and Lien
upon, and pledging to the Agent in favor and for the benefit of the Agent and the other Secured Parties, such Equity Interests, to secure
the Obligations (and any guaranty thereof) are excessive, relative to the value to be afforded to the Secured Parties thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 511; Options: NewSection; Value: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Excluded
Subsidiaries</B>&rdquo; means, collectively, (i)&nbsp;any Subsidiary with respect to which the grant to the Agent in favor and for
the benefit of the Agent and the other Secured Parties of a security interest in and Lien upon, and the pledge to the Agent in favor
and for the benefit of the Agent and the other Secured Parties of, such Subsidiary&rsquo;s properties and assets subject or
purported to be subject from time to time to a Lien under any Collateral Document and the Equity Interests of such Subsidiary to
secure the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obligations (and any guaranty thereof) are
validly prohibited by Requirements of Law; (ii)&nbsp;any Subsidiary with respect to which the grant to the Agent in favor and for
the benefit of the Agent and the other Secured Parties of a security interest in and Lien upon, and the pledge to the Agent in favor
and for the benefit of the Agent and the other Secured Parties of, such Subsidiary&rsquo;s properties and assets subject or
purported to be subject from time to time to a Lien under any Collateral Document and the Equity Interests of such Subsidiary to
secure the Obligations (and any guaranty thereof) require the consent, approval or waiver of any Governmental Authority or other
third party (other than Parent or an Affiliate of Parent) and such consent, approval or waiver has not been obtained by Parent or
such Subsidiary following Parent&rsquo;s and such Subsidiary&rsquo;s commercially reasonable efforts to obtain the same;
(iii)&nbsp;any Subsidiary that is formed of acquired after the Closing Date that is a non-Wholly-Owned Subsidiary, with respect to
which, the grant to Lender in favor and for the benefit of Lender and the other Secured Parties of a security interest in and Lien
upon, and the pledge to Lender of, the properties and assets of such non-Wholly-Owned Subsidiary, to secure the Obligations (and any
guaranty thereof) are validly prohibited by, or would give any third party (other than Parent or an Affiliate of Parent) the right
to terminate its obligations under, such non-Wholly-Owned Subsidiary&rsquo;s Operating Documents or the joint venture agreement or
shareholder agreement with respect thereto or any other contract with such third party relating to such non-Wholly-Owned Subsidiary,
including any contract evidencing Indebtedness of such non-Wholly-Owned Subsidiary (other than customary non-assignment provisions
which are ineffective under Article&nbsp;9 of the Code or other Requirements of Law), but only, in each case, to the extent, and for
so long as such Operating Document, joint venture agreement, shareholder agreement or other contract is in effect; (iv)&nbsp;any
Subsidiary which as of the Closing Date is a non-Wholly-Owned Subsidiary; (v)&nbsp;any Immaterial Subsidiary; (vi)&nbsp;any
Subsidiary which is not organized or incorporated in the United States or England and Wales; </FONT><FONT STYLE="color: red"><STRIKE>and
(vii</STRIKE></FONT><FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(vii)&nbsp;GT
JV (provided, that, if the Gene Therapy Portfolio Spin-off Transaction is not consummated within six (6)&nbsp;months following the
Amendment No.&nbsp;1 Effective Date, then GT JV shall immediately, upon six (6)&nbsp;month anniversary, no longer deemed to be an
Excluded Subsidiary), and (viii</U></FONT>)&nbsp;any other Subsidiary with respect to which, Borrower and Lender reasonably
determine by mutual agreement that the cost of granting the Agent in favor and for the benefit of the Agent and the other Secured
Parties a security interest in and Lien upon, and pledging to the Agent in favor and for the benefit of the Agent and the other
Secured Parties, such Subsidiary&rsquo;s properties and assets subject or purported to be subject from time to time to a Lien under
any Collateral Document and the Equity Interests of such Subsidiary to secure the Obligations (and any guaranty thereof) are
excessive relative to the value to be afforded to the Secured Parties thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <B>Excluded Taxes</B>&rdquo;
means any of the following Taxes imposed on or with respect to the Agent or a Lender or required to be withheld or deducted from a payment
to the Agent or a Lender, (a)&nbsp;Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits
Taxes, in each case, (i)&nbsp;imposed as a result of the Agent or such Lender being organized under the laws of, or having its principal
office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision
thereof) or (ii)&nbsp;that are otherwise Other Connection Taxes, (b)&nbsp;in the case of Lender, U.S. federal withholding Taxes imposed
on amounts payable to or for the account of such Lender with respect to any Obligation pursuant to a law in effect on the date on which
(i)&nbsp;Lender acquires an interest in any Obligation or (ii)&nbsp;Lender changes its lending office, except in each case to the extent
that, pursuant to Section&nbsp;2.6, amounts with respect to such Taxes were payable either to Lender&rsquo;s assignor immediately before
Lender became a party hereto or to Lender immediately before it changed its lending office, (c)&nbsp;Taxes attributable to Lender&rsquo;s
failure to comply with Section&nbsp;2.6(e), (d)&nbsp;any U.S. federal withholding Taxes imposed under FATCA and (e)&nbsp;any U.K. Excluded
Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <B>Existing Indebtedness</B>&rdquo;
means Indebtedness incurred by Parent and the U.S. Credit Parties pursuant to that certain Loan Agreement, dated as of September&nbsp;19,
2018, by and between Parent, the U.S. Credit Parties, and BPCR Limited Partnership (as successor to Biopharma Credit PLC), as Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 512; Value: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Facility</B>&rdquo;
means, with respect to any Credit Party, any real property (including all buildings, fixtures or other improvements located thereon) now,
hereafter or heretofore owned, leased, operated or used by such Credit Party or any of its Subsidiaries or any of their respective predecessors
or Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FATCA</B>&rdquo;
means Sections 1471 through 1474 of the IRC, as of the date of this Agreement (or any amended or successor version that is substantively
comparable and not materially more onerous to comply with), any current or future regulations promulgated thereunder or official interpretations
thereof, any agreements entered into pursuant to Section&nbsp;1471(b)(1)&nbsp;of the IRC, and any fiscal or regulatory legislation, regulations,
rules&nbsp;or practices adopted pursuant to any intergovernmental agreement, treaty, or convention among Governmental Authorities and
implementing such sections of the IRC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>FCPA</B>&rdquo;
is defined in <U>Section&nbsp;4.18(a)</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA</B>&rdquo; means
the United States Food and Drug Administration (and any foreign equivalent, including the European Agency for the Evaluation of Medicinal
Products).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA Good Manufacturing
Practices</B>&rdquo; means the standards set forth in 21 C.F.R. Parts 210, 211 and 600 (and any foreign equivalents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>FDA Laws</B>&rdquo;
means all applicable statutes, rules, regulations and orders administered or issued by FDA (and any foreign equivalent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>FDCA</B>&rdquo; is defined in Section&nbsp;13.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <B>Federal Funds Rate</B>&rdquo;
means for any day, the rate per annum equal to the weighted average of the rates on overnight Federal funds transactions with members
of the Federal Reserve System, as published on the next succeeding Business Day by the Federal Reserve Bank of New York, or, if such rate
is not so published for any day which is a Business Day, the average of the quotations for such day on such transactions received by Agent
from three Federal funds brokers of recognized standing selected by it (and, if any such rate is below zero, then the rate determined
pursuant to this definition shall be deemed to be zero).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Federal Reserve Board</B>&rdquo; means the Board
of Governors of the Federal Reserve System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Fee Letter</B>&rdquo;
means that certain fee letter, dated the date hereof, by and among Parent, Borrower and the Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<FONT STYLE="color: blue"><B><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">FL
RE Holdings LLC</U></B><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&rdquo; means the limited liability company resulting from the conversion of Amicus Biologics,&nbsp;Inc. to
a limited liability company and change of its name to a name to be determined.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;</U></FONT><B>Fraudulent
Transfer Laws</B>&rdquo; is defined in Section&nbsp;13.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <FONT STYLE="color: blue"><B><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">Gene
Therapy Liquidation Event</U></B><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&rdquo; means any of (i)&nbsp;a sale of Equity Interests of GT JV, or (ii)&nbsp;a sale of Equity Interests
of ARYA (including, without limitation, Equity Interests of ARYA received upon conversion of Equity Interests in GT JV), whether made
directly or indirectly (including, for the avoidance of doubt, by way of a sale of any Equity Interests of GT JV Holdco).</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;</U></FONT><B>Gene
Therapy Portfolio Asset Sale</B>&rdquo; means any Transfer of all or any portion of the Gene Therapy Portfolio pursuant to clause
(a)&nbsp;of the definition of &ldquo;Permitted Transfer&rdquo;, but excluding (i)&nbsp;any exclusive license of (or grant of a
covenant not to sue with respect to) all or any portion of the Gene Therapy Portfolio or an exclusive grant of development,
manufacturing, production, commercialization, marketing, co-promotion, distribution, sale or similar commercial rights with respect
to the Gene Therapy Portfolio, to third parties, in each case, outside the United States, the United Kingdom, France, Germany, Spain
or Italy, solely to the extent the terms of the exclusive license are consistent with a commercial transaction negotiated at
arm&rsquo;s-length and (ii)&nbsp;any non-exclusive license of (or grant of a covenant not to sue with respect to) all or any portion
of the Gene Therapy Portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 513; Value: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;
<B>Gene Therapy Portfolio</B>&rdquo; means any Intellectual Property and other tangible or intangible assets or rights subject to or derived
directly from the licenses described in <U>Schedule</U></FONT><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt "> 1(a)</U>&nbsp;of the Disclosure Letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <FONT STYLE="color: blue"><B><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">Gene
Therapy Portfolio Spin-Off Transaction&rdquo;</U></B><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt "> means (w)&nbsp;the transfer of the Contributed Business Assets (as defined in
the GT Business Combination Agreement) to the GT JV, (x)&nbsp;the transfer of the Equity Interests of Celenex LLC (formerly Celenex,&nbsp;Inc.),
MiaMed LLC (formerly MiaMed Inc.) and FL RE Holdco LLC (formerly Amicus Biologics Inc.) to the GT JV, (y)&nbsp;the issuance by the GT
JV of its Equity Interests to ARYA such that ARYA holds a majority of the outstanding Equity Interests of the GT JV, and (z)&nbsp;the
issuance by ARYA of non-economic voting Equity Interests in ARYA to GT JV Holdco, in each case, in accordance with the terms set forth
in the GT Business Combination Agreement.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>Gene
Therapy Portfolio Spin-Off Transaction Steps</B>&rdquo; means each of the following transactions, which are taken for the primary purpose
of consummating the Gene Therapy Portfolio Spin-Off Transaction: (i)&nbsp;the contribution by Parent of the intercompany receivables owed
to Parent by each of MiaMed,&nbsp;Inc., Amicus Biologics Inc, and Celenex,&nbsp;Inc. to MiaMed,&nbsp;Inc., Amicus Biologics Inc, and Celenex,&nbsp;Inc.,
respectively; (ii)&nbsp;the formation of GT Intermediate HoldCo, (iii)&nbsp;the contribution of Amicus Biologics,&nbsp;Inc . to GT Intermediate
Holdco and subsequent conversion of Amicus Biologics,&nbsp;Inc. to an LLC and change of its legal name to a name that does not include
 &ldquo;Amicus&rdquo;; (iv)&nbsp;the conversion of MiaMed,&nbsp;Inc. into a limited liability company, (v)&nbsp;the formation of GT JV
Holdco (and the corresponding investments by Parent and GT Intermediate Holdco expressly described in this definition) (provided that
Parent shall at all times own, directly or indirectly, 100% of the Equity Interests in GT JV Holdco unless otherwise agreed to by the
Required Lenders), (vi)&nbsp;the contribution by GT Intermediate Holdco of 100% of the Equity Interests of FL RE Holdco LLC to GT JV Holdco,
(vii)&nbsp;the contribution by Parent of 100% of the Equity Interests of Celenex,&nbsp;Inc . to GT JV Holdco, (viii)&nbsp;the conversion
of Celenex,&nbsp;Inc., into a limited liability company, (ix)&nbsp;the formation of GT JV (and the corresponding investment by GT JV Holdco
expressly described in this definition), (x)&nbsp;the Transfer by GT JV Holdco of 100% of the Equity Interests of Celenex, LLC to GT JV,
(xi)&nbsp;the Transfer by Parent of 100% of the Equity Interests of MiaMed LLC to GT JV Holdco, (xii)&nbsp;the Transfer by GT JV Holdco
of 100% of the Equity Interests of FL RE Holdings LLC and MiaMed LLC to GT JV, (xiii)&nbsp;the Transfer of the Contributed Business Assets
(as defined in the GT Business Combination Agreement) by Parent and its Subsidiaries owning such Contributed Business Assets to GT JV
(via GT JV Holdco) (the foregoing clauses (i)-(xiii), the &ldquo;<B>Pre -Closing Gene Therapy Portfolio Spin -Off Transaction Steps</B>&rdquo;),
and (xiv)&nbsp;the issuance of (A)&nbsp;Equity Interests in GT JV to ARYA and GT JV Holdco in exchange for cash and (B)&nbsp;non-economic
voting Equity Interests in ARYA to GT JV Holdco.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;</U></FONT><B>Governmental
Approval</B>&rdquo; means any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration,
filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Authority</B>&rdquo;
means any nation or government, any state or other political subdivision thereof, any agency, government department, authority, instrumentality,
regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative
functions of or pertaining to government, any securities exchange and any self-regulatory organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 514; Value: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Payor
Programs</B>&rdquo; means all governmental third party payor programs in which any Credit Party or its Subsidiaries participates, including
Medicare, Medicaid, TRICARE or any other federal or state health care programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GSK Agreement</B>&rdquo;
means the Second Restated Agreement, dated November&nbsp;19, 2013, by and between Borrower and Glaxo Group Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;</FONT><FONT STYLE="color: blue"><B><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">GT
Business Combination Agreement</U></B><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&rdquo; means the Business Combination Agreement dated the date hereof among ARYA, Parent, GT
JV Holdco and GT JV (as amended, restated, amended and restated, or otherwise modified from time to time, as permitted hereunder).</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>GT
Intermediate Holdco</B>&rdquo; means a Delaware limited liability company that will be a wholly-owned Subsidiary of Parent and which,
together with Parent, will directly hold 100% of the Equity Interests in GT JV Holdco.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>GT JV</B>&rdquo; means Caritas
Therapeutics, LLC, a Delaware limited liability company.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>GT
JV Investor Rights Agreement</B>&rdquo; means an Investor Rights Agreement entered into by GT JV Holdco and certain other direct and indirect
investors in GT JV substantially in the form of Exhibit&nbsp;C to the GT Business Combination Agreement (as amended, restated, amended
and restated, or otherwise modified from time to time, as permitted hereunder).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>GT JV Holdco</B>&rdquo; means Amicus
GT Holdings, LLC, a Delaware limited liability company.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>GT Spin-Off Effective Date</B>&rdquo;
has the meaning assigned to such term in the Amendment No.&nbsp;1.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>GT
Tax Receivable Agreement</B>&rdquo; means that certain Tax Receivable Agreement to be entered into by and among GT JV, GT JV Holdco and
the other members of GT JV from time to time substantially in the form of Exhibit&nbsp;D to the GT Business Combination Agreement (as
amended, restated, amended and restated, modified from time to time, as permitted hereunder).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>GT
Tax Receivable Agreement Payment</B>&rdquo; means any payment received by GT JV Holdco or any other Credit Party or Subsidiary pursuant
to the GT Tax Receivables Agreement.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;<B>GT
Transition Services Agreement</B>&rdquo; means that certain Transition Services Agreement to be entered into by and among Parent and GT
JV substantially in the form of Exhibit&nbsp;H to the GT Business Combination Agreement (as amended, restated, amended and restated, modified
from time to time, as permitted hereunder).</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&ldquo;</U></FONT><B>Guaranteed
Obligations</B>&rdquo; is defined in Section&nbsp;13.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Guarantor</B>&rdquo;
means Parent and each Subsidiary of Parent that is a present or future guarantor of the Obligations, other than (i)&nbsp;the Borrower
and (ii)&nbsp;any Excluded Subsidiary; provided, that in no event shall a Subsidiary that is not organized in the United States or England
and Wales constitute a Guarantor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Guaranty</B>&rdquo;
means the guaranty of the Guaranteed Obligations made by Guarantors as set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Hazardous
Materials</B>&rdquo; means any chemical, material or substance, exposure to which is prohibited, limited or regulated by any
Governmental Authority or which may or could pose a hazard to development, manufacture, production, use, commercialization, marketing, importing, storage, transport, offer for sale, distribution or
sale of the Product in the Territory, for which the breach of, default or nonperformance under, cancellation or termination of or the
failure to renew could reasonably be expected to result in a Material Adverse Change. For the avoidance of doubt, the GSK Agreement is
a Material Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 515; Value: 83 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: 3 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Maximum Guaranteed Amount</B>&rdquo; is defined
in <U>Section&nbsp;13.2</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <B>Medicaid</B>&rdquo;
means, collectively, the health care assistance program established by Title XIX of the SSA (42 U.S.C. 1396 et seq.) and all laws, rules,
regulations, manuals, orders, or requirements pertaining to such program, including (a)&nbsp;all federal statutes affecting such program;
(b)&nbsp;all state statutes and plans for medical assistance enacted in connection with such program and federal rules&nbsp;and regulations
promulgated in connection with such program; and (c)&nbsp;all applicable provisions of all rules, regulations, manuals, orders and administrative,
reimbursement, and requirements of all Government Authorities promulgated in connection with such program (whether or not having the force
of law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Medicare</B>&rdquo;
means, collectively, the health insurance program for the aged and disabled established by Title XVIII of the SSA (42 U.S.C. 1395 et seq.)
and all laws, rules, regulations, manuals, or orders pertaining to such program including (a)&nbsp;all federal statutes (whether set forth
in Title XVIII of the SSA or elsewhere) affecting such program; and (b)&nbsp;all applicable provisions of all rules, regulations, manuals,
orders and administrative, reimbursement and requirements of all Governmental Authorities promulgated in connection with such program
(whether or not having the force of law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Mortgage</B>&rdquo;
means any deed of trust, leasehold deed of trust, mortgage, leasehold mortgage, deed to secure debt, leasehold deed to secure debt or
other document creating a Lien on real estate or any interest in real estate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Multiemployer Plan</B>&rdquo;
means a multiemployer plan within the meaning of Section&nbsp;4001(a)(3)&nbsp;or Section&nbsp;3(37) of ERISA (a)&nbsp;to which Parent
or its Subsidiaries or any of their respective ERISA Affiliates is then making or accruing an obligation to make contributions; (b)&nbsp;to
which Parent or its Subsidiaries or any of their respective ERISA Affiliates has within the preceding five (5)&nbsp;plan years made contributions;
or (c)&nbsp;with respect to which Parent or its Subsidiaries could incur material liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo; <B>Net Issuance Proceeds</B>&rdquo;
means, in respect of any issuance of Indebtedness, the excess of: (a)&nbsp;the gross cash proceeds received by the issuer of such Indebtedness
from such incurrence or issuance, over (b)&nbsp;all underwriting discounts, fees, commissions and reasonable out-of-pocket costs and expenses
actually paid in connection therewith in favor of any Person not an Affiliate of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Net Proceeds</B>&rdquo;
means proceeds in cash, checks or other cash equivalent financial instruments (including Cash Equivalents) as and when received by the
Person making a Transfer <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(including, for the avoidance of doubt, in connection with any Gene Therapy Liquidation
Event) </U></FONT>and insurance proceeds received on account of an Event of Loss, net of: (a)&nbsp;in the event of a Transfer (i)&nbsp;the
transaction costs, fees and expenses relating to such Transfer excluding amounts payable to the Borrower or any Affiliate of the Borrower,
(ii)&nbsp;sale, use, income, withholding or other Taxes paid or reasonably estimated to be payable as a result thereof, (iii)&nbsp;amounts
required to be applied to repay principal, interest and prepayment premiums and penalties on Indebtedness secured by a superior Lien on
the asset which is the subject of such Transfer, (iv)&nbsp;any reserve reasonably established by the Parent and its Subsidiaries in respect
of any liabilities or other obligations associated with such asset or assets and retained by the Parent or any of its Subsidiaries after
such sale or other Transfer thereof, including pension and other post employment benefit liabilities and liabilities related to any indemnification
obligations and/or purchase price adjustments associated with such transaction or commitments or undertakings of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 516; Options: NewSection; Value: 93 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(s)&nbsp;Permitted Refinancings
of Indebtedness permitted in <U>clauses (b)</U>&nbsp;through (q)&nbsp;above; provided, that for purposes of clarity, the consummation
of Permitted Refinancings referred to in this clause (s)&nbsp;shall not result in Permitted Indebtedness described in clauses (b)&nbsp;through
(q)&nbsp;being reallocated to this clause (s)&nbsp;and otherwise providing additional capacity for Permitted Indebtedness under the current
dollar-based baskets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
(x)&nbsp;&ldquo;Permitted Indebtedness&rdquo; shall not include any Hedging Agreements other than those described in Section&nbsp;4.22(b)&nbsp;hereof
and those entered into in connection with a Permitted Bond Hedge Transaction and foreign exchange or interest rate hedging transactions
not for speculative purposes and (y)&nbsp;the aggregate principal balance of Indebtedness incurred by Subsidiaries of Parent that are
not Credit Parties at any time outstanding shall not exceed $20,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Permitted Investments</B>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
(including Investments in Subsidiaries) existing on the Effective Date and shown on Schedule 12.2 of the Disclosure Letter;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Investments consisting of cash and Cash Equivalents;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business
consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">subject to Section&nbsp;5.5,&nbsp;Investments consisting of deposit accounts or securities accounts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="color: red"><STRIKE>[reserved];</STRIKE></FONT><FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">upon
the occurrence of the GT Spin-Off Effective Date, the issuance by ARYA of non-economic voting Equity Interests in ARYA to GT JV Holdco
in accordance with the terms of the GT Business Combination Agreement;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Investments which are Permitted Transfers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of (i)&nbsp;travel advances and employee relocation loans and other employee advances in the ordinary course of business consistent
with past practice, and (ii)&nbsp;loans to employees, officers or directors relating to the purchase of equity securities of Parent pursuant
to employee stock purchase plans or agreements approved by Parent&rsquo;s Board of Directors in an aggregate principal amount not to exceed
$20,000,000 at any one time outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
(including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement
of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business consistent with
past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates,
in the ordinary course of business consistent with past practice; provided that this clause (i)&nbsp;shall not apply to Investments of
any Credit Party in any of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 517; Options: NewSection; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;joint
ventures or strategic alliances consisting of the non-exclusive licensing of technology, the development of technology or the providing
of technical support;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
in a Subsidiary of the Parent which is not a Credit Party that is required in order to consummate a Permitted Acquisition (including
the formation of any Subsidiary for the purpose of effectuating such Permitted Acquisition, the capitalization of such Subsidiary whether
by capital <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">contribution or intercompany loans, in each case,
to the extent otherwise permitted by the terms of this Agreement, related Investments in Subsidiaries necessary to consummate such Permitted
Acquisition, and the receipt of any non-cash consideration in a Permitted Acquisition), so long as (i)&nbsp;both before and after giving
effect to such Investment, the Credit Parties are in compliance, on a pro forma basis, with the financial covenants set forth in <U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">Section</U></FONT><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">&nbsp;6.16
</U>and Section&nbsp;6.17 and (ii)&nbsp;the aggregate Investments made pursuant to this clause (k), together with the Acquisition Consideration
paid for Permitted Acquisitions described in clauses (c)(ii)&nbsp;and (d)(ii)(B)&nbsp;and (C)&nbsp;of the definition thereof, and amounts
paid pursuant to clause (p)&nbsp;of the definition &ldquo;Permitted Investment&rdquo;, does not exceed $50,000,000 at any time outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments constituting
the formation of any Subsidiary for the purpose of consummating a merger or acquisition transaction permitted by Section&nbsp;6.3(a)(i)&nbsp;through
(iv)&nbsp;hereof, which such transaction is otherwise a Permitted Investment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
of any Person that (i)&nbsp;becomes a Subsidiary of Parent (or of any Person not previously a Subsidiary of Parent that is merged or consolidated
with or into a Subsidiary of Parent in a transaction permitted hereunder) after the Closing Date, or (ii)&nbsp;are assumed after the Closing
Date by any Subsidiary of Parent in connection with an acquisition of assets from such Person by such Subsidiary, in either case, in a
Permitted Acquisition; provided, that in each case, any such Investment (x)&nbsp;exists at the time such Person becomes a Subsidiary of
Parent (or is merged or consolidated with or into a Subsidiary of Parent) or such assets are acquired, (y)&nbsp;was not made in contemplation
of or in connection with such Person becoming a Subsidiary of Parent (or merging or consolidating with or into a Subsidiary of Parent)
or such acquisition of assets, and (z)&nbsp;such Investment would not otherwise result in a Default or Event of Default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
arising as a result of the licensing of Intellectual Property in the ordinary course of business consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Investments
by (i)&nbsp;any Credit Party in any other Credit Party, (ii)&nbsp;any Subsidiary of Parent which is not a Credit Party in another Subsidiary
of Parent which is not a Credit Party, (iii)&nbsp;any Subsidiary of Parent which is not a Credit Party in any Credit Party and (iv)&nbsp;any
Credit Party in any Subsidiary of Parent which is not a Credit Party, provided, that the aggregate consideration provided by Credit Parties
for Investments pursuant to this clause (iv)&nbsp;(net of all dividends, distributions, returns of capital and payments on Indebtedness
received by the Credit Parties from non-Credit Parties) shall not exceed $50,000,000; <FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">provided, further,
that no subclause of this clause (o)&nbsp;shall be utilized to make an Investment in GT Intermediate Holdco, GT JV Holdco, GT JV or any
of their respective Subsidiaries, except to the extent expressly contemplated in the definition of &ldquo;Gene Therapy Portfolio Spin-Off
Transaction Steps&rdquo;.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
limiting the generality of clause (k)&nbsp;above,&nbsp;Investments consisting of earnest money deposits required in connection with a
Permitted Acquisition or other acquisition of properties or assets not otherwise prohibited hereunder; so long as (i)&nbsp;both before
and after giving effect to such Investment, the Credit Parties are in compliance, on a pro forma basis, with the financial covenants set
forth in Section&nbsp;6.16 and Section&nbsp;6.17 and (ii)&nbsp;the aggregate Investments made pursuant to this clause (p), together with
the Acquisition Consideration paid for Permitted Acquisitions described in clauses (c)(ii), and (d)(ii)(B)&nbsp;and (C)&nbsp;of the definition
thereof, does not exceed $50,000,000 at any time outstanding; <FONT STYLE="color: red"><STRIKE>and</STRIKE></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(i)&nbsp;</U></FONT>other
Investments <FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(excluding any
Investments, directly, or indirectly, in GT Intermediate Holdco, GT JV Holdco, GT JV or any of their respective Subsidiaries) </U></FONT>in
an aggregate amount at any time not to exceed $20,000,000, so long as both immediately before and after giving effect to such Investment,
no Default or Event of Default has occurred and is continuing; <FONT STYLE="color: blue; border-bottom-style: double; border-bottom-width: 0.5pt; padding-bottom: 0.5pt"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(ii)&nbsp;other
Investments directly or indirectly in GT JV
Holdco to fund transaction costs associated with the Gene Therapy Portfolio Spin Off Transaction Steps, maintain existence and cover other
incidental overhead expenses; (iii)&nbsp;following the occurrence of the GT Spin-Off Effective Date, to the extent constituting Investments
in GT JV, payments by Parent in accordance with the Co-Commercialization and Development Agreement; and (iv)&nbsp;on the GT Spin-Off Effective
Date, a one-time investment of $50,000,000 in GT JV with the proceeds of equity contributed to Parent on or around the Amendment No.&nbsp;1
Effective Date; and</U></Font></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 518; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">(r)</U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">each
of (i)&nbsp;the formation of GT JV Holdco (and (substantially concurrently with the GT Spin-Off Effective Date) any corresponding investment
expressly contemplated in the definition of &ldquo;Gene Therapy Portfolio Spin-Off Transaction Steps&rdquo;) (ii)&nbsp;the formation
of GT Intermediate Holdco (and (substantially concurrently with the GT Spin-Off Effective Date) any corresponding investment expressly
contemplated in the definition of &ldquo;Gene Therapy Portfolio Spin-Off Transaction Steps&rdquo;) and (iii)&nbsp;the formation of GT
JV (and (substantially concurrently with the GT Spin-Off Effective Date) any corresponding investment expressly contemplated in the definition
of &ldquo;Gene Therapy Portfolio Spin-Off Transaction Steps&rdquo;); provided, that Parent, GT Intermediate Holdco and GT JV Holdco will
comply with Sections 5.12 and 5.13 in all respects and GT JV Holdco will become a Credit Party in accordance with Sections 5.12 and 5.13;
provided, further, that, all any and all other Investments in GT JV must be made pursuant to clause (q)&nbsp;above.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">provided, however, that, none of the foregoing
Investments shall be a &ldquo;Permitted Investment&rdquo; if&nbsp; (x)&nbsp;any Indebtedness or Liens assumed in connection with
such Investment are not otherwise permitted under Section&nbsp;6.4 or 6.5, respectively or (y)&nbsp;to the extent also constituting
a Transfer, such Investment is not otherwise permitted under Section&nbsp;6.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
 &ldquo;Permitted Investments&rdquo; shall not include any Hedging Agreements other than those described in Section&nbsp;4.22(b)&nbsp;hereof
and those entered into in connection with a Permitted Bond Hedge Transaction and foreign exchange hedging transactions not for speculative
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Permitted Liens</B>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
in favor and for the benefit of the Agent and the other Secured Parties pursuant to any Loan Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
existing on the Effective Date and set forth on Schedule 12.3 of the Disclosure Letter;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Liens
for Taxes, assessments or governmental charges (i)&nbsp;which are not yet delinquent or
(ii) which are being contested in good faith and by
appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the
applicable Person to the extent required in accordance with Applicable Accounting Standards;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;pledges,
deposits or Liens arising as a matter of law in the ordinary course of business (other than Liens imposed by ERISA) in connection with
workers&rsquo; compensation, payroll taxes, unemployment insurance and other social security legislation, (ii)&nbsp;pledges and deposits
in the ordinary course of business securing liability for reimbursement or indemnification obligations of (including obligations in respect
of letters of credit or bank guarantees for the benefit of) insurance carriers providing property, casualty or liability insurance to
Parent or any of its Subsidiaries, (iii)&nbsp;pledges and deposits in the ordinary course of business securing liability to landlords
(including obligations in respect of letters of credit or bank guarantees for the benefit of landlords) or other contractual obligations
and (iv)&nbsp;pledges or deposits to secure performance of tenders, statutory obligations, bids, leases or other</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 519; Value: 100 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;prohibitions or limitations
imposed by any amendments, modifications, restatements, renewals, extensions, supplements or replacements of any of the agreements referred
to in clauses (a)&nbsp;through (p)&nbsp;above, except to the extent that any such amendment, modification, restatement, renewal, extension,
supplement or replacement expands the scope of any such prohibition or limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Permitted Transfers</B>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
of all or any portion of the Gene Therapy Portfolio; <U>provided</U>, that (x)&nbsp;both immediately before and after giving effect to
any such Transfer, no Default or Event of Default has occurred and is continuing, (y)&nbsp;in no event shall the Gene Therapy Portfolio
be Transferred to a Subsidiary that is not a Credit Party other than pursuant to (i)&nbsp;a non-exclusive license<FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">,</U></FONT>
or (ii)&nbsp;an exclusive license that is exclusive only with respect to a territory outside of the United States, the United Kingdom,
France, Germany, Spain or Italy; provided, further, that no such license described in clause (i)&nbsp;or (ii)&nbsp;shall prohibit or otherwise
restrict the licensee from granting a security interest to the Agent in such licensee&rsquo;s interest in such license in a manner enforceable
under Requirements of Law, except to the extent the licensor of such license is otherwise prohibited from permitting such security interest;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #010101">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Transfers of Inventory in the ordinary course of business consistent with past practice;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
of surplus, damaged, worn out or obsolete equipment that is, in the reasonable judgment of Parent exercised in good faith, no longer economically
practicable to maintain or useful in the ordinary course of business consistent with past practice, and Transfers of other properties
or assets in lieu of any pending or threatened institution of any proceedings for the condemnation or seizure of such properties or assets
or for the exercise of any right of eminent domain;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: #010101">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Transfers which are Permitted Liens, Permitted Investments or Permitted Distributions;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
of cash and Cash Equivalents in a manner that is not prohibited by the terms of this Agreement or the other Loan Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
(i)&nbsp;between or among Credit Parties, provided that, with respect to any properties or assets constituting Collateral under the Loan
Documents, any and all steps as may be required to be taken in order to create and maintain a first priority security interest in and
Lien upon such properties and assets in favor and for the benefit of the Agent and the other Secured Parties are taken contemporaneously
with the completion of any such transfer, and (ii)&nbsp;between or among non-Credit Parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
sale or issuance of Equity Interests of any Subsidiary of Parent to any Credit Party or Subsidiary, provided, that (x)&nbsp;any such sale
or issuance by a Credit Party (other than the Borrower) shall be to another Credit Party and (y)&nbsp;any such sale or issuance by the
Borrower shall be to Parent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
sale or discount without recourse of accounts receivable arising in the ordinary course of business consistent with past practice in connection
with the compromise or collection thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
abandonment, cancellation, non-renewal or discontinuance of use or maintenance of Intellectual Property (other than in relation to the
Product) that Parent reasonably determines in good faith (i)&nbsp;is no longer economically practicable to maintain or useful in the ordinary
course of business consistent with past practice and that (ii)&nbsp;would not reasonably be expected to be adverse to the rights, remedies
and benefits available to, or conferred upon, the Secured Parties under any Loan Document in any material respect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Transfers
by Parent or any of its Subsidiaries pursuant to: (i)&nbsp;a non-exclusive license of (or grant of a covenant not to sue with respect
to) Intellectual Property or a non-exclusive grant of development, manufacturing, production, commercialization, marketing, co-promotion,
distribution, sale or similar commercial rights to third parties; (ii)&nbsp;an exclusive license of (or grant of a covenant not to sue
with respect to) Intellectual Property or an exclusive grant of development, manufacturing, production, commercialization, marketing,
co-promotion, distribution, sale or similar commercial rights, to third parties, in each case, solely with respect to portions of the
Territory outside the United States, the United Kingdom, France, Germany, Spain or Italy; (iii)&nbsp;a non-exclusive license of (or grant
of a covenant not to sue with respect to) technology or Intellectual Property to third parties for developing technology or providing
technical support; and (iv)&nbsp;a non-exclusive or an exclusive manufacturing license to third parties in the ordinary course of business
consistent with past practice;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 520; Options: NewSection; Value: 108 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to Section&nbsp;11.20, intercompany licenses or grants of rights of distribution, co-promotion or similar commercial rights (i)&nbsp;between
or among the Credit Parties, or (ii)&nbsp;between or among the Credit Parties and Subsidiaries that are not Credit Parties entered into
prior to the Effective Date, and renewals, replacements and extensions thereof (including additional licenses or grants in relation to
new territories outside the United States, the United Kingdom, France, Germany, Spain or Italy) that are on comparable terms and entered
into in the ordinary course of business consistent with past practice); provided, that with respect to any such intercompany license or
grant of rights pursuant to clause (ii), such license may only be exclusive with respect to territory;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="color: red"><STRIKE>[reserved];
and</STRIKE></FONT><FONT STYLE="color: blue"><U STYLE="border-bottom:.5pt double; padding-bottom:.5pt ">each of the Transfers set forth in the definition of &ldquo;Gene Therapy Portfolio Spin-off
Transaction Steps&rdquo;; and</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010101">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>other
Transfers, provided that (x)&nbsp;the aggregate fair market value (reasonably determined in good faith by a Responsible Officer of Parent)
of the properties or assets Transferred pursuant to this clause (m)&nbsp;shall not exceed $20,000,000 in the aggregate; and (y)&nbsp;both
immediately before and after giving effect to any such Transfer, no Default or Event of Default has occurred and is continuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Permitted Warrant
Transaction</B>&rdquo; means any call option, warrant or right to purchase (or substantively equivalent derivative transaction) relating
to Parent&rsquo;s common stock (or other securities or property following a merger event or other change of the common stock of Parent)
sold by Parent substantially contemporaneously with any purchase by Parent of a related Permitted Bond Hedge Transaction, with a strike
price higher than the strike price of the Permitted Bond Hedge Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization,
association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Plan</B>&rdquo;
means any employee pension benefit plan subject to the provisions of Title IV of ERISA or Section&nbsp;412 of the IRC or Section&nbsp;302
of ERISA which is maintained or contributed to by Parent or its Subsidiaries or any of their respective ERISA Affiliates or with respect
to which Parent or its Subsidiaries are subject to liability (including under Section&nbsp;4069 of ERISA).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&ldquo;<B>Prepayment Premium</B>&rdquo; means:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;during the period of
time from and after the Closing Date up to (and including) the date that is the second anniversary of the Closing Date, an amount equal
to the greater of (i)&nbsp;the Make Whole Premium and (ii)&nbsp;three percent (3.00%) of the principal amount of the Term Loan prepaid
(or in the case of a Prepayment Premium Trigger Event occurring under clauses (a)(ii), (b), (c)&nbsp;or (d)&nbsp;of the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 521 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.8</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT TO EMPLOYMENT AND CONFIDENTIALITY
AGREEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This <B>AMENDMENT TO EMPLOYMENT AND CONFIDENTIALITY
AGREEMENTS</B>(this <B><U>&quot;Amendment&quot;)</U></B> is
made and entered into this 28th day of September&nbsp;2021 (the <B><U>&quot;Amendment Effective Date&quot;)</U></B> by and between Hung
Do (the <B><U>&quot;Employee&quot;)</U></B> and AMICUS THERAPEUTICS,&nbsp;INC. (the <B><U>&quot;Company&quot;).</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>W I T N E SS E T H:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>the
Company and Employee are parties to an Employment Agreement, dated February&nbsp;18, 2020 (the <B><U>&quot;Employment
Agreement&quot;)</U></B> pursuant to which Employee currently serves as the Chief Science Officer for the Company and a
Confidentiality, Non- Disclosure and Non-Competition Agreement, dated February&nbsp;18, 2020 (the <B><U>&quot;Confidentiality
Agreement&quot;);</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>the Company
and Employee want to amend the Employment Agreement and Confidentiality Agreement to reflect Employee becoming a part-time employee of
the Company and taking on a different, more limited role with the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE, </B>in
consideration of the foregoing and of the mutual covenants and obligations hereinafter set forth, the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>Al. Part-Time
Employment; Change in Role. </B>Effective September&nbsp; 28, 2021 (the <B><U>&quot;Transition Date&quot;)</U>, </B>Employee will no longer
be employed as the Company's Chief Science Officer, but rather will take on the more limited role of &quot;Chief Scientific Advisor&quot;,
the duties of which are described on Exhibit&nbsp;C-1 attached hereto. In light of the reduced duties and responsibilities of the Employee
as &quot;Chief Scientific Advisor&quot;, the parties acknowledge and agree that the Employee is no longer a senior vice-president of the
Company in charge of a principal business unit, division or function, any other officer who performs a policy-making function, or any
other person who performs similar policy-making functions for the Company, and as such is no longer subject to Section&nbsp;16 of the
Securities Exchange Act of 1934 and the rules&nbsp;and regulations thereunder. In the role of Senior Scientific Advisor, the Employee
will be employed by the Company on a part-time basis, devoting up to 80 hours/calendar month, or such time as needed during a deadline,
to his duties with the Company. As such, the terms of the Employment Agreement requiring full-time employment, including without limitation
those set forth in Section&nbsp;2 of the Employment Agreement will, as of the Transition Date, be of no further force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>A2. Salary
and Benefits. </B>Effective as of the Transition Date, the reference in Section&nbsp;3.1 of the Employment Agreement to Employee's
gross base salary shall be changed to one-half of the current base salary of the Employee as of the Effective Date. Employee will
continue to participate in any benefit plans (including health and medical insurance) as may be in effect with respect to senior
management personnel of the Company at the current levels, without any reduction in benefits. For purposes of the Company's Amended
and Restated 2007 Equity Incentive Plan (and any other equity plans as the Company may adopt from time to time), Employee remains an
employee of the Company entitled to participate in those plans, and any grants made to the Employee under those plans, and Award
Agreements between the Employee and Company, remain in full force and effect and will continue to vest without interruption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 522 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>A3. Outside
Activities. </B>When not performing his duties as Chief Scientific Advisor, Employee shall have the right to be employed by, or provide
consulting or advisory services to, any third parties, such as other biotechnology and biopharmaceutical companies (including, without
limitation, M6P Therapeutics, a Cayman exempted company, and its affiliates (collectively, <B><U>&quot;M6P&quot;)),</U></B> either directly
or indirectly, and such outside activities shall not be deemed to be a breach of any duty of loyalty Employee has to the Company; provided
that Employee will comply with Section&nbsp;18 of the Confidentiality Agreement, as modified herein. Notwithstanding anything in the Confidentiality
Agreement to the contrary, Employee shall be permitted to serve as an employee, consultant, advisor, director, and/or owner (without any
ownership level restrictions) of and to M6P so long as Employee does not participate in any Competitive Activities (as defined below)
during the course of Employee's employment with Company and for a period of twelve (12) months thereafter (the <B><U>&quot;Restriction
Period&quot;)</U></B><U>,i.e., </U>by recusing himself from, or otherwise not participating in, discussions regarding, or other efforts
at M6P that are, Competitive Activities. Further, Section&nbsp;20 of the Confidentiality Agreement shall not prohibit Employee from (a)&nbsp;soliciting
business of or performing services for an actual or prospective Customer of the Company or (b)&nbsp;encouraging or assisting M6P to solicit
or service any actual or prospective Customer of the Company, so long as such efforts by the Employee are not directly related to a Competitive
Activity. Finally, the notice provisions of Section&nbsp;29 of the Confidentiality Agreement shall not apply to any employment relationship
Employee may establish in the future with M6P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>A4. </B>The
second sentence of Section&nbsp;18 of the Confidentiality Agreement is hereby deleted and replaced in its entirety with the following:
 &quot;For purposes of this Agreement, &quot;Competitive Business&quot; shall mean any person or entity who engages in the business of
researching, developing and/or commercializing gene therapies (in any therapeutic construct) for the treatment of Fabry disease or Pompe
disease in humans <B><U>(&quot;Competitive Activities&quot;).&quot;</U></B> For the avoidance of doubt, Employee may engage in any activities
of any kind, including with M6P, as long as Employee does not engage in any Competitive Activities during the Restriction Period, and
Employee acknowledges that information regarding the Company's AT-GAA Pompe ERT program, Galafold Fabry program, gene therapy programs
and other research efforts Employee oversaw as Chief Scientific Officer are Confidential Information (as that term is defined in the Confidentiality
Agreement). Further, the definition of in Section&nbsp;21 of Company Personnel is hereby deleted and replaced as follows: &quot;Company
Personnel&quot; means any employee, independent contractor or other personnel employed, retained or engaged by the Company, its wholly
owned affiliates, and any company in which it has a greater than 10% ownership, including without limitation Caritas Therapeutics LLC,
at any time during the twenty-four (24) months prior to the termination of your employment: ( l) with whom you interacted within the scope
of your employment with the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 523; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(2)&nbsp;whom you directly or indirectly
supervised during your employment with the Company; or (3)&nbsp;regarding whom you received non-public information about his or her job
responsibilities, compensation or job performance by virtue of your employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>AS. Intellectual
Property. </B>Notwithstanding anything to the contrary in Sections 11 through and including 15 of the Confidentiality Agreement, as of
the Transition Date the Company shall only have rights to Intellectual Property that the Employee conceives or develops that directly
relates to the Company's AT-GAA Pompe ERT program, Galafold Fabry program and gene therapy programs or that otherwise requires the use
or incorporation of Confidential Information <B><U>(&quot;Covered IP&quot;)</U></B> and not to any other Intellectual Property that Employee
may develop, conceive or reduce to practice, either alone or with others, in the future. Consequently, as of the Transition Date, the
Employee will only be obligated to disclose and assign to the Company Covered IP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>A6. Full Force
and Effect. </B>Except as modified by this Amendment, the Employment Agreement and the Confidentiality Agreement remain in full force
and effect in accordance with their respective terms. From and after the Amendment Effective Date, references in the Employment Agreement
to the &quot;Agreement&quot; shall mean the Employment Agreement as modified by this Amendment and references in the Confidentiality Agreement
to the &quot;Agreement&quot; shall mean the Confidentiality Agreement as modified by this Amendment. In the event of a conflict between
this Amendment and the Employment Agreement or the Confidentiality Agreement, the Amendment shall govern and control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>A7. Counterparts.
</B>This Amendment may be executed in counterparts, each of which shall be deemed an original but all of which shall together constitute
on and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IN WITNESS WHEREOF, </B>the parties have duly executed this Amendment
to be binding and effective as of the Amendment Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%">EMPLOYEE</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">/s/ Hung Do</P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Name:
Hung Do&nbsp;</P>

</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 50%">AMICUS THERAPEUTICS,&nbsp;INC.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"> /s/ David Clark</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 0.5pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 0.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 0.5pt">&nbsp;</FONT></TD></TR>
  </TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #525252; width: 50%"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #525252; width: 50%"><FONT STYLE="color: Black">Name: David Clark</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #525252"><FONT STYLE="color: Black">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; color: #525252"><FONT STYLE="color: Black">Title: Chief People Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 524; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT&nbsp;C-1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JOB DESCRIPTION FOR CHIEF SCIENTIFIC ADVISOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the Company's Chief Scientific Advisor, Employee
shall advise the Company on developing sound strategies for overcoming technical challenges to advance therapeutic programs and to support
filings with respective regulatory agencies around the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the Company's Chief Scientific Advisor, Employee
shall participate in external meetings on behalf of the Company, including those with potential investors, researchers, clinicians, contract
research organizations and contract manufacturing organizations to provide his perspective and advice for proper assessment and development
of various therapeutic approaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Chief Scientific Advisor will not oversee
the activities of any Company personnel and no Company personnel shall report into the Chief Scientific Advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 525 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1<FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="tm2128727d1_ex99-1img002.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2128727d1_ex99-1img001.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amicus Therapeutics and ARYA Sciences Acquisition
Corp IV&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Announce Formation of a Next-Generation Genetic
Medicine <BR>
Company: &ldquo;Caritas Therapeutics&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Business Combination of Amicus Gene Therapy
Business with ARYA IV to Result<BR>
in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>with Expected ~$400M in Initial Funding</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><I>Will Transform
Amicus into a </I></B></FONT><B><I>Premier Global Commercialization and Late Stage Product Development <BR>
Biotechnology Company in Rare
Diseases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I></I></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Transaction Advances Amicus Path to Profitability
- Expected as of 2023</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 1in"><B><I>Amicus Balance Sheet Further
Strengthened with a ~$200M Private Investment&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>from Leading Biotechnology Investors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B><I>Separation
will </I></B></FONT><B><I>Sharpen the Strategic Focus, Financial Profile, and Operational Execution<BR>
of Both Companies to Address the Needs of People Living with Rare Diseases &ndash;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Amicus to Retain Ownership of 36% of Caritas</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Conference Call and Webcast Today at 8:00
a.m.&nbsp;ET</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>PHILADELPHIA&nbsp;&amp;
NEW YORK, Sept. 29, 2021</B></FONT> &ndash; Amicus Therapeutics,&nbsp;Inc. (Nasdaq: FOLD) (&ldquo;Amicus&rdquo;) today announced its intent
to launch a next-generation genetic medicine company, Caritas Therapeutics,&nbsp;Inc., (&ldquo;Caritas&rdquo;) through a definitive business
combination agreement pursuant to which the Amicus gene therapy business will be acquired by ARYA Sciences Acquisition Corp IV (Nasdaq:
ARYD) (&ldquo;ARYA IV&rdquo;), a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors. The transaction will result
in two independent publicly traded companies with attractive stand-alone investment profiles. Amicus will become the largest shareholder
in Caritas with a ~36% ownership stake (assuming no redemptions by ARYA&rsquo;s shareholders) and retain co-development and commercialization
rights to the Fabry and Pompe gene therapy programs as well as negotiation rights on select future muscular dystrophy programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon consummation of the business combination,
current Amicus Chairman and Chief Executive Officer John F. Crowley will lead Caritas as Chairman and Chief Executive Officer and will
become the Chairman Emeritus and Chief Strategic Advisor for Amicus. Current Amicus President and Chief Operating Officer Bradley Campbell
will be named as Chief Executive Officer of Amicus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&ldquo;This is a big, bold vision
and a massive step forward for next generation biotechnologies for people worldwide living with some of the most devastating rare diseases.
In a single stroke with the formation and funding of Caritas we will create what will be one of the world&rsquo;s preeminent next-generation
genetic medicines companies. We strongly believe that separating our business into two highly focused, stand-alone companies is the best
way to unlock significant value for Amicus shareholders and to advance our medicines and technologies to people living with rare diseases
around the world,&rdquo; stated John F. Crowley, Chairman and Chief Executive Officer of Amicus. &ldquo;This transaction will serve patients
and shareholders well by accelerating funding for our next generation gene therapy pipeline, and strengthening the financial profiles
of both companies. We are immensely excited for what the future of science and biotechnology holds as we accelerate and recommit to our
mission.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">&quot;This transaction will transform
Amicus into a premier rare disease global commercialization and late stage product development company that we believe will benefit all
of our stakeholders,&quot; said Bradley Campbell, President and Chief Operating Officer of Amicus. &quot;The separation strengthens the
financial profile of Amicus and accelerates our path to profitability, while preserving significant equity ownership in the gene therapy
pipeline and commercial rights to the innovative and important Fabry and Pompe gene therapy programs. We will be laser focused on maintaining
the growth of Galafold and executing on the anticipated global launch of AT-GAA, as we build Amicus into a leading global rare disease
biotechnology company and bring our medicines to as many patients as quickly as possible.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 526 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="tm2128727d1_ex99-1img002.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2128727d1_ex99-1img001.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">Amicus expects the separation
to create value for all stakeholders and result in material benefits to the stand-alone companies, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Enhancing the ability of both companies to meet
the unmet needs of many individuals and families affected by rare diseases,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accelerating the development and broadening the
scope of one of the largest rare disease gene therapy portfolios in the industry,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Funding the gene therapy next generation scientific
platform technologies as well as manufacturing capabilities of the new company,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Strengthening the financial profile of each company,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reinforcing management focus on key strategic
and financial goals,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unlocking value while creating a more targeted
investment thesis for shareholders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Amicus Therapeutics&rsquo;
</B></FONT><B>focus as a rare disease global commercialization and late stage development company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the transaction, Amicus will remain
a global, patient-dedicated biotechnology company developing and delivering novel high-quality medicines for people living with rare diseases.
Amicus&rsquo; focus will be to grow its leadership position across Amicus&rsquo; two lead indications of Fabry disease and Pompe disease.
In addition, it is expected the transaction will strengthen the Amicus financial outlook and enable it to achieve profitability in 2023.<SUP>1</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Upon completion
of the transaction, Amicus will become the largest shareholder in Caritas and retain co-development and commercialization rights to the
Fabry and Pompe gene therapy programs</FONT>, as well as negotiation rights on future muscular dystrophy programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amicus plans to continue investing in the global
commercialization of Galafold for Fabry disease through geographic and label expansion, as well as support for diagnostic initiatives.
In Pompe disease, Amicus will focus on securing global approvals, executing the anticipated global launch of AT-GAA, and providing access
for patients as quickly as possible. Amicus continues to believe that AT-GAA has the potential upon approval to become the next standard
of care for all people living with Pompe disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amicus also announced today that a syndicate of
leading healthcare biotechnology investors, including Redmile Group, Avoro Capital Advisors, Perceptive Advisors,&nbsp;Invus, Sphera Healthcare,
and Janus Henderson Investors have agreed to a private investment in Amicus of approximately $200 million. Amicus expects to use the net
proceeds to further fund initiatives in the global commercialization of Galafold and the anticipated global launch of AT-GAA and, in connection
with the business combination, to invest $50 million in cash in Caritas in exchange for additional equity in Caritas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>1 </SUP>Based on projections of Amicus non-GAAP
Net Income under current operating plans, which includes successful AT-GAA regulatory approvals and continued Galafold growth. We define
non-GAAP Net Income as GAAP Net Income excluding the after tax impact of share-based compensation expense, changes in fair value of contingent
consideration and depreciation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Caritas&rsquo; focus as a clinical stage, rare
disease discovery and development next-generation genetic medicines company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The mission of Caritas, the Latin word for compassion,
will be to transform the lives of children and adults living with rare genetic diseases by harnessing the power of next-generation genetic
medicine and gene therapy technologies through advanced protein engineering and innovative gene therapy vector technologies. Through its
60+ bench scientists and experienced development and leadership teams, Caritas will develop and advance a series of novel platform technologies
to address the key challenges to the safe and efficient gene transfer necessary for next-generation gene therapies. These include proprietary
technologies designed to address delivery, safety, durability, and manufacturability of gene therapies. The gene therapy pipeline is founded
on deep expertise and platform technologies in protein engineering and rare disease biology, the broad research collaboration with the
Perelman School of Medicine at the University of Pennsylvania (Penn) for best-in-class gene therapies, and a new co-development collaboration
with Amicus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 527 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="tm2128727d1_ex99-1img002.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2128727d1_ex99-1img001.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pipeline is led by two Batten disease programs
with clinical proof of concept in CLN6 and CLN3, six active preclinical programs, including Fabry disease, Pompe disease, and CDKL5 Deficiency
Disorder (CDD), as well as multiple discovery programs. Caritas will have exclusive, global rights to gene therapy programs for nearly
50 rare genetic diseases through its broad collaboration with Dr.&nbsp;Jim Wilson and the Penn team, including a majority of next-generation
lysosomal disease programs as well as 11 more prevalent rare diseases. Among these are Angelman Syndrome, Duchenne Muscular Dystrophy,
Rett Syndrome, Myotonic Dystrophy and select other muscular dystrophies. Dr.&nbsp;Jim Wilson will become a senior scientific and strategic
advisor to Caritas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amicus management expects that, as a new, independent
entity with approximately 115 employees, Caritas will be better positioned to pursue its strategic priorities, accelerate its programs
and discovery work, as well as adequately fund its manufacturing capabilities. Amicus believes that this transaction will harness those
opportunities to the benefit of patients and shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;When ARYA IV was formed, our objective
was to identify a company with the potential to successfully address a significant, unmet need in biomedical science,&rdquo; said Adam
Stone, Chief Investment Officer of Perceptive Advisors and CEO of ARYA IV. &ldquo;Through Caritas, we are combining with a business we
believe has the potential to transform the field of genetic medicine through advanced protein engineering and innovative vector technologies.
Over the course of our long-standing relationship with Amicus, we've come to believe in the company&rsquo;s innovative science and experienced
leadership team. We are excited to see the next phase of growth for Amicus and Caritas, respectively.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Caritas Transaction and Timing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amicus is separating its gene therapy business
into a new entity that will be acquired by ARYA IV, a special purpose acquisition company or SPAC. At closing of the transaction, ARYA
IV will be named Caritas Therapeutics,&nbsp;Inc. As part of the transaction, Amicus will receive the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">~36% pro forma ownership in Caritas (depending
on the level of redemptions at ARYA IV)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Co-development rights and exclusive global commercialization
rights to existing Fabry and Pompe gene therapies including a 50/50 cost and profit share</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Right of first negotiation to certain multiple
muscular dystrophy programs being developed by Caritas</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amicus expects to incur charges related to the
transaction during the reporting periods preceding the separation and does not otherwise expect this to impact Amicus&rsquo; financial
guidance for 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the closing of the transaction,
in addition to its renaming, ARYA IV will redomicile as a Delaware corporation and its common stock is expected to be listed on Nasdaq
under the ticker symbol &ldquo;SPES&rdquo;, the Latin word for hope.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the approximately $150 million
held in ARYA IV&rsquo;s trust account, assuming no redemptions are effected, a group of leading global investors has committed to participate
in the transaction through a common stock private investment in public equity (PIPE) of approximately $200 million at $10 per share. Investors
in the PIPE include Perceptive Advisors, Redmile Group, Bain Capital Life Sciences,&nbsp;Invus, Avoro Capital Advisors, Surveyor Capital
(a Citadel company), Deerfield Management Company, Wellington Management and Sphera Healthcare. In connection with the business combination,
Amicus will also invest $50 million in cash in Caritas in exchange for additional equity in Caritas. Together, Caritas is expected to
receive proceeds of approximately $400 million at the closing of the transactions, assuming no redemptions are effected. Proceeds of the
business combination and the PIPE are expected to be used to advance development of the Caritas gene therapy pipeline, discovery work,
growth across its scientific teams and to support general corporate activities (including payment of certain transaction expenses). A
condition to closing of the business combination transaction is that these cash proceeds are no less than $300 million in total.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 528 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="tm2128727d1_ex99-1img002.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2128727d1_ex99-1img001.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The boards of directors of both Amicus and ARYA
IV have approved the proposed transaction. Completion of the transaction, which is expected in the fourth quarter of 2021 or early 2022,
is subject to approval of ARYA IV&rsquo;s shareholders, delivery of the minimum $300 million in cash proceeds, and the satisfaction or
waiver of certain other customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Advisors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goldman Sachs&nbsp;&amp; Co. LLC is acting as
financial and capital markets advisor to Amicus Therapeutics. Jefferies LLC is acting as financial advisor and private placement agent
to ARYA IV. Skadden, Arps, Slate, Meagher&nbsp;&amp; Flom LLP, Wilson Sonsini Goodrich&nbsp;&amp; Rosati and Troutman Pepper Hamilton
Sanders LLP are acting as legal counsel to Amicus Therapeutics. Kirkland&nbsp;&amp; Ellis LLP is acting as legal counsel to ARYA IV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Amicus Conference Call and Webcast</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amicus Therapeutics will host a conference call
and audio webcast today, September&nbsp;29, 2021 at 8:00 a.m.&nbsp;ET to discuss the transaction. Interested participants and investors
may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 4688658.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A live audio webcast and related presentation
materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants
are encouraged to register on the website 15 minutes prior to the start of the call. A replay of the call will be available for seven
days beginning at 7:30 p.m.&nbsp;ET on September&nbsp;29, 2021. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406
(international); conference ID: 4688658.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Caritas </U></B></FONT><B><U>Deal
Roadshow Webcast</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A webcast of the Caritas
Therapeutics presentation materials will also be available on Deal Roadshow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Recorded Deal Roadshow
Investor Login Details:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Wednesday, September&nbsp;29,
2021 at 9:00 a.m.&nbsp;ET&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">URL:
</FONT><U>https://dealroadshow.com</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Entry Code: <B>CARITAS2021</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">Direct
Link: </FONT><U>https://dealroadshow.com/e/CARITAS2021</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>A replay of the call
will be available today starting at 10:00 a.m.&nbsp;ET through the same Deal Roadshow link shown above.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About Amicus Therapeutics</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Amicus Therapeutics
(Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality
medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding
a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the
company&rsquo;s website at </FONT><U>www.amicusrx.com</U>, and follow us on <U>Twitter</U> and <U>LinkedIn</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About ARYA IV</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ARYA IV is a blank check company newly incorporated
as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization
or similar business combination with one or more businesses or entities. ARYA IV is led by Chairman Joseph Edelman; Chief Executive Officer
Adam Stone; Chief Financial Officer Michael Altman; and Chief Business Officer Konstantin Poukalov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Participants in the Solicitation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">ARYA IV and its
directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation
of proxies of ARYA IV&rsquo;s shareholders in connection with the business combination. <B>Investors and securityholders may obtain more
detailed information regarding the names and interests in the business combination of ARYA IV&rsquo;s directors and officers in ARYA
IV&rsquo;s filings with the SEC, including ARYA IV&rsquo;s final prospectus which was filed with the SEC pursuant to Rule&nbsp;424(b)&nbsp;of
the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) on February&nbsp;19, 2021, as well as in the Registration Statement,
which includes the proxy statement of ARYA IV for the business combination.</B> Shareholders can obtain copies of ARYA IV&rsquo;s filings
with the SEC, without charge, at the SEC&rsquo;s website at </FONT><U>www.sec.gov.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 529 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="tm2128727d1_ex99-1img002.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2128727d1_ex99-1img001.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B><U>Forward Looking Statement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529"><FONT STYLE="background-color: white">This
press release contains &ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation Reform Act of
1995 relating to the business combination, development of Caritas&rsquo; product candidates, preclinical and clinical development of our
product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the
potential regulatory approval of our product candidates, commercialization plans, manufacturing plans and financing plans. The inclusion
of forward-looking statements should not be regarded as a representation by us that any of our plans or Caritas&rsquo; plans will be achieved.
Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions
we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing,
and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical
studies and clinical trials, and revenue goals, including as they are impacted by COVID-19 related disruption, are based on current information.
The potential impact on operations and/or revenue from the COVID-19 pandemic is inherently unknown and cannot be predicted with confidence
and may cause actual results and performance to differ materially from the statements in this release, including without limitation, because
of the impact on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID-19,
such as travel bans, shelter in place orders and third-party business closures and resource allocations, manufacturing and supply chain
disruptions and limitations on patient access to commercial or clinical product or to treatment sites. In addition to the impact of the
COVID-19 pandemic, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent
in our business, including, without limitation: the potential that the transaction may not be completed in a timely manner or at all,
which may adversely affect the price of our securities; the potential that the proposed transaction disrupts our current plans and operations
and potential difficulties in our employee retention as a result of the transaction; the potential that results of clinical or preclinical
studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in clinical
trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product
candidates; the potential that Caritas may not be successful in maintaining or establishing collaborations, which could adversely affect
its ability to develop products; substantial competition in the rapidly evolving field of gene therapy, which may result in others discovering,
developing or commercializing products before or more successfully than Caritas; the potential that regulatory authorities approve biosimilar
products with claims that compete with any of Caritas&rsquo; product candidates; the potential that preclinical and clinical studies could
be delayed due to the identification of serious side effects or other safety issues; the potential that we or Caritas may not be able
to manufacture or supply sufficient clinical or commercial products; the potential that Caritas may become involved in product liability
lawsuits and in lawsuits to protect or enforce intellectual property rights, which could be expensive and time-consuming, and could result
in substantial liabilities and the impairment of commercialization efforts of product candidates; and the potential that we or Caritas
will need additional funding to complete all of our respective studies, commercialization and manufacturing. In addition, all forward-looking
statements are subject to other risks detailed in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2020 and Quarterly
Report 10-Q for the quarter ended June&nbsp;30, 2021. You are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and
we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 530 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><IMG SRC="tm2128727d1_ex99-1img002.jpg" ALT="">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2128727d1_ex99-1img001.jpg" ALT="">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>No Offer or Solicitation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release is for informational purposes
only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation
of any vote in any jurisdiction pursuant to the business combination or otherwise, nor shall there be any sale, issuance or transfer or
securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus
meeting the requirements of the Securities Act and otherwise in accordance with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt"><B>Amicus
Investors</B></FONT>:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Andrew Faughnan&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Executive Director,&nbsp;Investor
Relations&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>afaughnan@amicusrx.com&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(609) 662-3809</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt"><B>Amicus
Media</B></FONT>:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Diana Moore&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Head of Global Corporate
Communications&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>dmoore@amicusrx.com&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(609) 662-5079</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>ARYA
IV:<BR> </B></FONT><FONT STYLE="background-color: #FEFEFE">Michael Altman<BR> Chief Financial Officer of ARYA Sciences Acquisition Corp
IV<BR> <U>Arya4@perceptivelife.com</U></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOLD&ndash;G</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 531 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">Amicus Launches Next - Generation  Genetic Medicine Company  Conference Call &amp; Webcast September 29, 2021</P>

<!-- Field: Page; Sequence: 532 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img002.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">2 Forward - Looking Statements This p resentation contains &#8220;forward - looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business combination, development of Caritas&#8217; product candidates, preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing plans and financing plans . The inclusion of forward - looking statements should not be regarded as a representation by us that any of our plans or Caritas&#8217; plans will be achieved . Any or all of the forward - looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties . For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, and revenue goals, including as they are impacted by COVID - 19 related disruption, are based on current information . The potential impact on operations and/or revenue from the COVID - 19 pandemic is inherently unknown and cannot be predicted with confidence and may cause actual results and performance to differ materially from the statements in this release, including without limitation, because of the impact on general political and economic conditions, including as a result of efforts by governmental authorities to mitigate COVID - 19 , such as travel bans, shelter in place orders and third - party business closures and resource allocations, manufacturing and supply chain disruptions and limitations on patient access to commercial or clinical product or to treatment sites . In addition to the impact of the COVID - 19 pandemic, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation : the potential that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of our securities ; the potential that the proposed transaction disrupts our current plans and operations and potential difficulties in our employee retention as a result of the transaction ; the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective ; the potential that it may be difficult to enroll patients in clinical trials ; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates ; the potential that Caritas may not be successful in maintaining or establishing collaborations, which could adversely affect its ability to develop products ; substantial competition in the rapidly evolving field of gene therapy, which may result in others discovering, developing or commercializing products before or more successfully than Caritas ; the potential that regulatory authorities approve biosimilar products with claims that compete with any of Caritas&#8217; product candidates ; the potential that preclinical and clinical studies could be delayed due to the identification of serious side effects or other safety issues ; the potential that we or Caritas may not be able to manufacture or supply sufficient clinical or commercial products ; the potential that Caritas may become involved in product liability lawsuits and in lawsuits to protect or enforce intellectual property rights, which could be expensive and time - consuming, and could result in substantial liabilities and the impairment of commercialization efforts of product candidates ; and the potential that we or Caritas will need additional funding to complete all of our respective studies, commercialization and manufacturing . In addition, all forward - looking statements are subject to other risks detailed in our Annual Report on Form 10 - K for the year ended December 31 , 2020 and Quarterly Report 10 - Q for the quarter ended June 30 , 2021 . You are cautioned not to place undue reliance on these forward - looking statements, which speak only as of the date hereof . All forward - looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof .</P>

<!-- Field: Page; Sequence: 533 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img003.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">3 Disclaimer  Participants in the Solicitation ARYA IV and its directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of ARYA IV&#8217;s shareholders in connection with the business combination . Investors and securityholders may obtain more detailed information regarding the names and interests in the business combination of ARYA IV&#8217;s directors and officers in ARYA IV&#8217;s filings with the SEC, including ARYA IV&#8217;s final prospectus which was filed with the SEC pursuant to Rule 424 (b) of the Securities Act of 1933 , as amended (the &#8220;Securities Act&#8221;) on February 19 , 2021 , as well as in the Registration Statement, which includes the proxy statement of ARYA IV for the business combination . Shareholders can obtain copies of ARYA IV&#8217;s filings with the SEC, without charge, at the SEC&#8217;s website at www . sec . gov . No Offer or Solicitation This presentation is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the business combination or otherwise, nor shall there be any sale, issuance or transfer or securities in any jurisdiction in contravention of applicable law . No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act and otherwise in accordance with applicable law .</P>

<!-- Field: Page; Sequence: 534 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img004.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">4 Executive Summary &#9642; AT - GAA NDA/BLA accepted for review: respective PDUFA action dates of May 29,  2022 and July 29, 2022 &#9642; Amicus gene therapy programs, technologies, IP, and relationships to form new  company: Caritas Therapeutics &#9642; Caritas to be acquired by ARYA IV, a special purpose acquisition company, and  launch with ~$400M in capital (through SPAC, PIPE and Amicus funding) &#9642; Caritas immediately to become one of the world&#8217;s preeminent next - generation  gene therapy and genetic medicines company &#9642; John Crowley will lead Caritas as Chairman and CEO and to remain with Amicus  as Chairman Emeritus and Chief Strategic Advisor  &#9642; Bradley Campbell to succeed John Crowley as Amicus Chief Executive Officer  upon transaction closing &#9642; Amicus expects to become profitable as of 2023 &#9642; Amicus further funded through completed $200M private investment</P>

<!-- Field: Page; Sequence: 535 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img005.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White"> 5 Amicus has built a leading fully integrated, global rare disease biotechnology company Gene Therapy  PLATFORM Protein Engineering  &amp; Glycobiology $383M Cash as of 6 /30/21 Two Clinical - Stage Gene  Therapies AT - GAA Registration  in  Pompe Disease GLOBAL  COMMERCIAL  ORGANIZATION World Class  BIOLOGICS Capabilities Robust R&amp;D  Engine 50+ Lysosomal Disorders  and More Prevalent  Rare Diseases EMPLOYEES in 27 Countries</P>

<!-- Field: Page; Sequence: 536 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img006.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White"> 6 Operating from Position of Strength Galafold &#174; continues to exceed expectations  in Fabry disease FY16 FY17 FY18 FY19 FY20 FY21 $37M $91M $261M FY21 Rev.  Guidance  $300M - $315M $182M $5M Two lead programs each with potential $500M  - $1B peak sales opportunity AT - GAA submissions in Pompe disease  are on track to kick off launch next year &#8226; NDA &amp; BLA accepted for review &#8226; PDUFA action dates of May 29,  2022 and July 29, 2022 &#8226; EU MAA submissions to be  completed in Q4 2021 &#8226; UK submission via recognition  procedure based on CHMP  opinion</P>

<!-- Field: Page; Sequence: 537 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img007.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">7 Poised to Unlock Value Significant but unrecognized value created across Amicus' leading rare disease gene therapy pipeline  and cutting - edge next - generation platform technologies and partnerships DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY Batten Franchise CLN6 Batten Disease CLN3 Batten Disease CLN1 Batten Disease Other forms of Batten Disease LSD Franchise Fabry Disease Pompe Disease MPS IIIA MPS IIIB Broader CNS/Neuromuscular Franchise CDKL5 Deficiency Disorder (CDD) Angelman Syndrome Others*  *Caritas Therapeutics will have rights to gene therapy technologies for the majority of LSDs, plus 11 additional larger Rare  Dis eases, including Angelman Syndrome, Duchenne Muscular Dystrophy (DMD), Rett Syndrome, Myotonic Dystrophy and select other muscular d yst rophies Harnessing the power of  genetic  medicine </P>

<!-- Field: Page; Sequence: 538 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img008.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">8 Simplified Transaction Structure (1)  Amicus intends to launch Caritas as a next - generation genetic medicine company &#8226; Combining Amicus's gene therapy  business with ARYA IV, a special purpose  acquisition company (SPAC) &#8226; Caritas is carved out of Amicus, retaining a  collaboration with the Perelman School of  Medicine at the University of Pennsylvania  (Penn) as well as forming a new  collaboration with Amicus &#8226; Amicus retains an interest in the combined  entity (~36% pro forma ownership) (2) &#8226; The combined entity, renamed Caritas, is  capitalized with $400M to execute on its  R&amp;D plan: up to $150M from ARYA IV&#8217;s  trust, as well as an expected $200M from  leading PIPE investors, and a $50M Amicus  cash investment $400M  in Capital (3) PIPE Investors ARYA IV Penn  Relationship Amicus Technologies, Gene Therapy  Assets, Management and R&amp;D $200M  PIPE Proceeds $150M Cash in Trust ~36% OS ~24% OS (4) Shareholders Transaction Structure: Carving out Caritas and Combining with ARYA IV (2) ARYA Shareholders ~24% OS ARYA IV Sponsor  &amp; Perceptive ~15% OS (1) Assumes no shareholder redemptions and based on implied share price of $10 per share; (2) OS percentages show indirect ow ner ship in Caritas without regard to equity incentive and other awards and includes a $50M investment from Amicus as  contemplated by BCA (assuming no shareholder redemptions investment may increase to serve as backstop against redemptions); ( 3)  Excludes transaction fees and expenses; (4) Excludes PIPE commitment from Perceptive $50M Investment</P>

<!-- Field: Page; Sequence: 539 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img009.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">9 Strategic Rationale We believe this transaction will generate greater value for all stakeholders, significant therapeutic  advancement, and result in benefits to the stand - alone companies 1 2 3 4 6 Enhancing the ability of both Amicus and Caritas to meet the unmet needs of patients  living with  r are diseases Accelerating Amicus path to profitability, expected in 2023 Significantly strengthening the financial profile of each company Accelerating the development and broadening the scope of our gene therapy portfolio Reinforcing management focus on key strategic and financial goals 5 Unlocking value while creating a more targeted investment thesis for shareholders</P>

<!-- Field: Page; Sequence: 540 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img010.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">10 Transforming for the Future &#8226; Amicus remains a global, patient - dedicated biotechnology company  developing and delivering novel high - quality medicines for people  living with rare diseases &#8226; Focus will be to grow its leadership position across the Company&#8217;s two  lead indications of Fabry disease and Pompe disease: &#8211; Continue investing in the global commercialization of  Galafold in  Fabry disease through continued geographic and label  expansion, as well as support for diagnostic initiatives &#8211; F ocus on securing global approvals and executing the anticipated  global launch of  AT - GAA in Pompe disease &#8211; Prepare for co - development of gene therapy  programs  with Caritas in  Fabry and Pompe diseases Transaction transforms Amicus into a premier later stage development and commercialization  company and builds upon its leadership in Fabry and Pompe diseases</P>

<!-- Field: Page; Sequence: 541 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img011.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">11 Strengthening the Financial Profile of Amicus &#8226; Increases focus on commercial success of Galafold and AT - GAA  &#8211; Aims at maximizing patient access to Galafold and AT - GAA, each with $500M  - $1B peak sales  opportunity &#8226; Strengthens the financial outlook of Amicus &#8211; Reiterating financial guidance for 2021 &#8211; Transferring significant R&amp;D expenses into Caritas &#8211; Cash position increased through private investment of leading healthcare investors &#8211; Amicus becomes profitable in 2023 &#8226; Preserves upside in gene therapy programs and platform technologies &#8211; Secures 36%  pro forma  equity ownership in the new entity, Caritas &#8211; Joint development and exclusive global commercial rights to both the Fabry and Pompe gene therapies,  including 50/50 profit share &#8211; Right of first negotiation to multiple muscular dystrophy programs being developed by Caritas Dramatically strengthens Amicus financial profile while preserving upside in gene therapy portfolio  of programs and platform technologies 1 2 3</P>

<!-- Field: Page; Sequence: 542 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img012.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">12 Harnessing the Power of Genetic Medicine The mission of Caritas is to transform the lives of children and adults living with rare genetic diseases  through advanced protein engineering and innovative vector technologies Diversified portfolio of clinical and preclinical rare disease development programs with pivotal study start in CLN3, three  INDs, and two IND candidates targeted through end of 2023 1 Proprietary platform technologies and protein engineering capabilities enabling innovative, clinically  differentiated gene therapies 2 Exclusive relationship with Penn to develop gene therapies for rare genetic disorders 3 Fully designed, ready - to - build, state - of - the - art clinical manufacturing facility with commercial expansion  capabilities 4 Attractive risk and cost - sharing partnership with Amicus provides access to an established orphan disease  commercial platform 5 Experienced public company leadership coupled with fully built out gene therapy discovery, research and development  team 6</P>

<!-- Field: Page; Sequence: 543 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img013.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">13 Three Strategic Value Drivers Deep science in protein engineering driving a robust pipeline supported by industry - leading partnerships &#9642; Modern protein engineering platforms generating bespoke solutions &#9642; Engineered proteins and transgenes for enhanced expression, cross correction,  targeting and immune protection Science Pipeline Partnerships &#9642; 2 Batten disease programs with clinical proof of concept &#9642; 6 active preclinical programs, including Fabry disease, Pompe disease, CDD &#9642; Multiple discovery programs, including Angelman Syndrome &#9642; Penn collaboration with exclusive rights to next - generation AAV technologies  for  named indications &#9642; Strategic relationship with Thermo Fisher for manufacturing &#9642; Amicus co - development and commercialization agreement (Fabry &amp; Pompe GTx)</P>

<!-- Field: Page; Sequence: 544 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img014.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">14 Co - Development and Commercialization Agreement  New Amicus and Caritas collaboration around genetic medicine for Fabry and Pompe diseases &#8226; Differentiated gene therapy approach for greater potency and  optimized cross correction through transgene engineering for  stability and targeting &#8211; Fabry disease: IND expected in 2H2022 &#8211; Pompe disease: IND enabling work underway &#8226; Partnering with experts in the Fabry and Pompe field and securing  key long - term relationship &#8226; De - risks funding for Fabry and Pompe gene therapy programs with  50% funding split to commercialization and a net profit split on sales &#8226; Potential for other disease collaborations given Amicus&#8217; right  of first negotiation for muscular dystrophies</P>

<!-- Field: Page; Sequence: 545 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img015.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">15 Planning for a Seamless Evolution in Leadership &#8226; Amicus Chairman &amp; CEO for 15+ years &#8226; Co - founder, President and CEO of Novazyme Pharmaceuticals  (acquired by Genzyme in 2001) &#8226; Member of the Intellia and Entrada Therapeutics Board of  Directors &#8226; B.S. from Georgetown University, J.D. from the University of  Notre Dame Law School and an M.B.A. from Harvard Business  School   Upon completion of the separation, John F. Crowley  will lead Caritas as Chairman and CEO   John F. Crowley will be  Chairman Emeritus of Amicus  and employed as Chief Strategic Advisor to Amicus &#8226; Amicus Executive for 15+ years, President &amp; COO since 2014,  Director since 2019 &#8226; Member of the Board of the Association for Regenerative  Medicine (ARM) and the Corporate Advisory Board for NTSAD &#8226; Served on the Board of Progenics Pharmaceuticals from 2016 until  its successful acquisition by Lantheus Holdings in 2020 &#8226; B.A. in Public Policy from Duke University and an M.B.A. from  Harvard Business School   Upon completion of the separation, Bradley Campbell  will be named CEO of Amicus John F. Crowley CHAIRMAN &amp; CHIEF EXECUTIVE OFFICER Bradley Campbell PRESIDENT  &amp; CHIEF OPERATING OFFICER</P>

<!-- Field: Page; Sequence: 546 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img016.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White">16 Transaction Summary Unlocking value by allowing two stand - alone companies to realize their full potential Transaction  Details &#8226; Business combination of the Amicus Gene Therapy Business with ARYA IV, a SPAC, resulting in the launch of Caritas Therapeutic s,  an  independent, publicly traded  c ompany &#8226; Amicus to own  ~36% in Caritas, retain co - development and commercial rights to the Fabry and Pompe gene therapies  including 50/50 profit share, and right of first negotiation to multiple muscular dystrophy programs being developed at Carit as Strategic  Rationale &#8226; Enhancing the ability of both companies to meet the unmet needs of many individuals and families affected by rare diseases &#8226; Accelerating the development and broadening the scope of the gene therapy portfolio &#8226; Strengthening the financial profile of each company &#8226; Reinforcing management focus on key strategic and financial goals &#8226; Unlocking value while creating a more targeted investment thesis for shareholders Leadership &#8226; John F. Crowley, current Chairman and CEO of Amicus, to be Chairman and CEO of Caritas; will be Chairman Emeritus of Amicus a nd  employed as Chief Strategic Advisor to Amicus &#8226; Bradley Campbell, current President and COO of Amicus, to be CEO of Amicus Financial  Details &#8226; Balance sheet strengthened with $200M private investment; profitability expected as of 2023 &#8226; 2021 financial guidance unchanged &#8226; SPAC Trust, PIPE and Amicus investment to provide $400M of proceeds funding  Caritas through multiple value - creating milestones Timing &#8226; Completion of the transaction is expected in late 2021/early 2022, subject to approval of ARYA IV&#8217;s shareholders and the satisfaction or waiver of certain other customary closing conditions</P>

<!-- Field: Page; Sequence: 547 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="margin-top: 0; margin-bottom: 0"><IMG SRC="tm2128727d1_ex99-2img017.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 1px; color: White"> Thank You &#8220;Our passion for making a difference unites us&#8221; - Amicus Belief Statement</P>

<!-- Field: Page; Sequence: 548 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>



<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: right"><B>Exhibit 99.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Operator:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Thank
you for joining our call today. In this call we&rsquo;ll be discussing information contained in our press release issued today.
Before we discuss what we believe is a very exciting announcement and a significant milestone for both Caritas Therapeutics and Arya
IV &nbsp;I will make some important disclaimers. Please note that today&rsquo;s presentation is neither an offering of securities
nor a solicitation of a proxy vote. The information discussed today is qualified in its entirety by the registration statement on
Form&nbsp;S-4, containing a prospectus/proxy statement, that Arya IV and Caritas will file with the SEC in the future. The
shareholders of Arya IV are urged to read those filings carefully when they become available because they will contain important
information about the proposed transaction. Additionally, during the presentation we will make certain forward-looking statements
that reflect our current views related to our future financial performance, future events, and industry and market conditions, as
well as forward-looking statements related to the business combination, including the timing, proceeds and benefits of the
transaction, as well as statements about the potential of Caritas&rsquo; technology and timing of Caritas&rsquo; milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">These forward-looking statements are
subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. We strongly
encourage you to review the information that Arya IV files with the SEC regarding specific risks and uncertainties - in particular, those
that are described in the risk factors section of Arya IV&rsquo;s most recent filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">And with that,&nbsp;I&rsquo;ll turn the
call over to Adam Stone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Adam S:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Good morning everyone and thank you for
joining us today. I&rsquo;m Adam Stone, CEO of ARYA IV and CIO of Perceptive Advisors. We are extremely pleased to have announced the
proposed business combination of ARYA IV and Caritas Therapeutics. The combined company will be well capitalized with a $200mm PIPE financing,
up to $150m cash in trust from ARYA IV and $50m being contributed by Amicus, totaling up to $400m of capital. The $200m PIPE was led by
us at Perceptive Advisors with strong support from existing ARYA IV shareholders and leading biotech investors and mutual funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 549 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">When ARYA IV was formed, we set out to
find a company with differentiated technology and disruptive potential, which is what I believe we have found in Caritas&rsquo; gene therapy
pipeline and platform. We have been working diligently with the Amicus team over the past months as Caritas Therapeutics was carved out,
and believe this is a first-in-its-class transaction in the biotechnology space that epitomizes the potential of the ARYA platform in
facilitating access to the public capital markets. As John will explain, we believe Caritas will be at the forefront of the next generation
of science which will aim to deliver potentially curative therapies in devastating rare diseases. We believe that this transaction will
adequately capitalize Caritas to allow them to continue to execute on what we believe is a very exciting clinical development plan, and
expect significant value creation for both patients and shareholders in the years to come.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">We look forward to our relationships
with the newly formed Caritas team as well as with the team at Amicus. With that,&nbsp;I&rsquo;d like to hand over to John Crowley, from
Amicus, who is joining as Caritas&rsquo; new CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">John C:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Great, thank you, Adam. I&rsquo;m John
Crowley, the Chairman and CEO of Amicus Therapeutics, and I&rsquo;m very exciting that we&rsquo;re going to be launching a new company
that&rsquo;s been incubated within Amicus for the last 3 years &ndash; Caritas Therapeutics. Our intention is that Caritas will immediately
become one of the pre-eminent gene therapy companies in the world, focused on next-generation gene therapy technologies to advance the
next generation of science, of treatment and we believe ultimately of cures. So, something that we&rsquo;re very excited about.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">I&rsquo;m particularly grateful for the
partnership with our long-time colleagues at Perceptive which have been very supportive of Amicus, as we&rsquo;ve built our company, along
this journey, and now supportive of our initiative in gene therapy through Caritas Therapeutics. So, thank you to the Perceptive team,
and thank you all for listening.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Let me begin over the next couple of
slides, if you'd be kind enough to flip forward just with some of the disclaimers and forward looking notices, and then we'll come to
the 1st slide where we can talk about really the presenters for today beginning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 550 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">I will be the Chairman and Chief Executive
Officer of Caritas Therapeutics. I'm pleased to be joined today by Jill Weimer, who will be the Chief Science Officer of Caritas Therapeutics.
Jeff Castelli, Chief Development Officer. And also Jim Wilson, who currently leads the Orphan Disease Center at the University of Pennsylvania,
who will also be an important senior strategic and scientific advisor for Caritas Therapeutics. Each of us from Jill, myself and Jeff
come from the Amicus team. And Jim has been a partner, somebody I've known for a long time in my working career, and somebody who's been
a very important partner for us as we develop through Amicus, the Caritas Technologies now ready to be spun out into a new company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">On
the next slide, we'll talk a little bit more about what is Caritas in the vision. We'll begin with the name Caritas, the Latin word
for compassion, which means &ldquo;in the service to others&rdquo;. We see this as a dual mission for shareholders and for patients
to develop the best gene therapies for as many patients as quickly as possible. We've considered this spin from some time. It's been
proposed and the idea brought to us by several investors. We think this is important from an Amicus standpoint, because this unlocks
and allows us to build value in the gene therapy programs. We think it's important, too, that it will properly fund the gene therapy
programs going forward. Also too, within the walls of Caritas we will now have a dedicated leadership and scientific team focused
organization focused on bringing these programs forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So that makes sense for Amicus. For Caritas,
again we have a very big vision. We believe that this is the next generation of science, the next generation of gene therapies and ultimately,
we believe, has the potential to be the next generation of cures in many, many rare diseases. Our goal is to safely deliver enough vector
to target cells. We'll talk a lot about our technologies at Caritas. We'll talk about the important collaborations with both Amicus and
UPenn and other key partners going forward. But at the end of the day, we believe that we are at the dawn of the next iteration of gene
therapy programs and technologies. There are many problems still to be solved: problems of delivery, of safety, of durability, of manufacturability.
And we believe at the core, Caritas is a team of problem solvers with the programs, the technologies, the capabilities and the experience
to tackle these most important problems. And, again, to bring what we think is now the next generation of gene therapies forward. While
many companies have discrete aspects of next generation gene therapy technologies, we believe no other company puts it together with the
experienced team, the breadth and depth of technologies and programs as we have here now with Caritas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 551 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Turning to slide 7, we&rsquo;ll outline
the terms of the deal here. Again, we are spinning out all the gene therapy assets out of Amicus Therapeutics into this new company, into
Caritas Therapeutics. Amicus will own approximately 36% of the outstanding shares of Caritas at the end of the transaction. Caritas will
be merged into the ARYA IV SPAC, that platform sponsored by Perceptive. That SPAC contains $150M in cash. In addition, we will raise approximately
$200M through a PIPE. That, combined with the cash Amicus will provide as an asset in Caritas will have us launch Caritas with $400M in
cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So simplifying the transaction, on the
next slide here. We'll talk about kind of, the key investment highlights here, and again, what you have is a unique opportunity where
you have a diverse portfolio of both clinical and pre-clinical rare disease gene therapy programs. Including 2 programs, CLN6/CLN3, moving
into pivotal studies, 3 INDs, multiple IND candidates targeted over just the next few years. But again, these programs have been developed
and incubated within Amicus for now 3 years and they're ready to be spun out, they're ready to be mature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">These incorporate a series of platform
technologies, protein engineering capabilities, a number of key relationships with Penn, with Amicus on the manufacturing side, with ThermoFisher.
And again, you'll see we have developed, in fact are at the permitting stage, ready to build a state of the art, world class, clinical
gene therapy manufacturing facility in Florida with the vision to develop a large scale commercial manufacturing facility. We are firmly
of the belief that if we are going to be among the world's leading gene therapy companies, if not the leading gene therapy company in
the world, that we also need to be at the forefront of gene therapy manufacturing technologies. We believe in gene therapies, process
is the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 552 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">We also again see a partnership, or risk
sharing, in our core important programs of Fabry and Pompe gene therapy. Again, programs that were nurtured within Amicus, that will be
part of Caritas through a 50:50 joint venture and we'll describe that more fully later in the presentation. And again, this is a turnkey
team of about 115 people. So myself, Jill, Jeff and many other people who will be pivoting over from the Amicus side, are important to
lead. We see this as a decade of genetic medicine ahead and we're very, very happy to be a part of that R&amp;D effort going forward to
take Caritas to the next level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">On the next slide, you'll see 3 of the
4 pillars of how we're building this: science, the pipeline and partnerships. Science,&nbsp;I'll turn it over in a moment to Jill Weimer
to discuss more. The key platform technologies that we've been developing and incubating now within Caritas ready to launch forward, are
technologies that we've not discussed before. This is something that our 60+ scientists under Jill's leadership have been working on.
Again, looking at solving key problems of gene therapy. We combine that with the pipeline that we already have and the partnerships, again,
we think presents a very unique opportunity from an investment standpoint and a chance to build very significant value in the quarters
and years ahead.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">On the next slide, we'll look at the
pipeline. We see the pipeline and 3 discrete areas. We see a Batten franchise with the most advanced program, CLN6 Batten Disease, a small
fatal genetic disease in children. We see that as an opportunity to help children with the disease, to build a product, but also importantly,
to lay the path forward for CLN3 Batten disease. As Jeff Castelli will describe, the largest of the Batten disease programs. Other programs,
in CLN1 and others. We have our lysosomal disease franchise, which includes, very importantly, the Fabry and Pompe gene therapy programs
there that have products,&nbsp;IND candidates, already designated that we've worked on for several years, combining the technologies of
Amicus and UPenn. But we also see those as proof of principle for important aspects of our protein engineering. And again, we're very
excited about the potential to bring forward programs in other larger rare diseases where we have ongoing advance preclinical efforts
such as CDKL5 deficiency disorder and Angelman Syndrome. I'll also note that through our relationship with Penn, we have the rights all-in
to about 50 rare disease programs generated with our work with Jim Wilson and UPenn. Those include, for instance, Duchenne Muscular Dystrophy,
Rett Syndrome and Myotonic Dystrophy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 553 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So, a very robust pipeline, and again,
one that will be sharply focused on. And also one, too, is we continue to learn, advance the programs quarter by quarter, year by year.
We'll continually reassess the pipeline to prioritize programs where there is the most unmet need, where the technology is advanced and
where there&rsquo;s the most likelihood of helping patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Just a little bit on the organization
and the capabilities, again, we're targeting launching Caritas with 115 FTEs, the vast majority coming over from Amicus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">We see the vast majority, again, about
80% of all the employees of Caritas, a very efficient organization, who will be focused on technology and science and development, taking
these programs forward. We are going to operate this very efficiently, the business. Where appropriate we will have transition services
agreements with our partners at Amicus to take these programs forward and enable us to, again, operate the company in a very efficient
manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Let me go ahead now, and in the next
section, we'll dig more deeply into the core science and again, the science that Jill will now describe is science that we have developed
within Amicus, now Caritas going forward. This is science that we've not discussed outside of Amicus. Again, incubated over the last several
years. We see this as an important part of the solution for the challenges of gene therapy going forward and important drivers of value
ahead. So, Jill, with that,&nbsp;I'll turn it to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Jill W:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">Thank you, John. I just want to reiterate some of the points
that you made really driving home the principles on which Caritas is being formed. And that is in leveraging the proprietary protein engineering
platforms that have been developed over the past several years and learnings from Amicus and will be carried forward to help us develop
new and more effective gene therapy treatments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"></P>

<!-- Field: Page; Sequence: 554 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So, as John mentioned, we really like
to step back and think about the problems that face the gene therapy community today. I think it's very timely that we're discussing this
now on the heels of the FDA's workshop last week, looking at a number of different challenges that we face currently. And these are really,
in our minds, bucketed into a number of key areas. And so these are challenges around delivery, challenges around safety, the durability
of the gene therapy product and manufacturing and analytics, as John mentioned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">And so the way that we really approach
this with our partners at Penn is really to draw on their expertise in capsid development, gene therapy delivery, and to bring the Caritas
engineering approach to really focus on what's inside of those gene therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So how do we actually engineer something
that's much more durable, something that's much more safe and will really stand the test of time? So just to illustrate some of the areas
that we've really focused on. In the delivery approaches, we're focused on technologies that will allow us to cross-correct. Knowing that
a number of gene therapies, depending on the target tissues, usually target approximately 10% of the cells. How do we actually ensure
that we can double that, triple that to get more expression throughout the target tissue? By adding engineering strategies that allow
the cells to decrease the gene product and be taken up in neighboring cells, and then subsequently be targeted to the organelles that
they need to be maximally efficient inside of the cells and allow us to deliver these transgenes to where they need to be. We think that
this will help with our delivery strategies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">From the safety perspective, how do we
enhance the stability of the transgene itself? How do we make sure that enzymes are maximally effective? And also, how do we actually
ensure that the gene therapy that is getting into the cell is being turned on effectively and expressed long term?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">When we think about durability, how do
we make sure that we're getting immune modulation correct? And so, this was something that we've heard a lot about over the last couple
of months. That may be one of the driving factors that's contributing to some of those challenges within the gene therapy field. So how
do we take approaches like immunomodulation, engineering our transgenes to be less immuno-impactful? And how do we actually then engineer
our gene therapy so that we can redose or dose patients that have previously been exposed to AAVs in their environment?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 555 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So, if you go to the next slide,&nbsp;I'll
go through some of these and just a little bit more detail. So here thinking about our programs Fabry, Pompe and CLN3,&nbsp;I'll talk
you through some of our strategies for lysosomal targeting. And in addition to bringing the expertise in engineering, molecular biology,
computational biology and neuroscience,&nbsp;I will also point out that the Amicus team will be over at Caritas has over fifty five years
of experience in leadership between Jeff, John and myself and working in Fabry, Pompe and Batten Disease. And so, we bring a lot of rich
history of understanding these diseases and how we need to develop maximally effective gene therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So, when we think about this from an
engineering perspective, in the context of Fabry, what we've done is actually stabilize our enzyme, our GLA enzyme, by fusing the dimer
together. This allows for a more effective enzyme that can be secreted out of a cell, cross-correct, and have much more impact than just
the wild-type transgene alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">In terms of our Pompe programs and our
CLN1 Batten Disease program, we're using similar approaches where we've added secretory tags and uptake tags that allow for the transduced
cell to secrete the lysosomal enzyme, whether it be GAA or CLN1 out of the cells, and then this gets taken up and targeted back to the
lysosomal neighboring cells. So, this really helps us overcome that inefficiency that we might see in transduction from the gene therapy
itself and target more cells effectively. And I really think that this gives us a leg up over a number of other technologies that might
be liver-directed in the Fabry or Pompe space, where you would get possible liver-targeted toxicity or limited transduction outside of
the liver. It really allows us to maximally impact the systems within these diseases and get more targeting throughout the body. I will
also say, too, that by using these engineered approaches and cross-correction or a targeting to tissues such as the central nervous system
and crossing of the blood brain barrier through systemic delivery, which you would not see with a number of the existing programs that
are on the market today.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 556 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">To go to the next slide,&nbsp;I'll introduce
you to one of our novel concepts that we've not yet talked about and using Exosomal Targeting as a therapeutic approach. So, there is
a number of folks that are currently using exosomes as a way to encapsulate their gene therapy itself and help to evade their immune system.
We're not doing that in our particular engineering approach. Instead, what we're doing is transducing the cells with the normal capsid,
but then engineering the transgene or gene product to actually have an exosomal targeting motif that then would allow for release and
targeting to neighboring cells. And so, we think that this approach will be much more efficient in targeting tissues long distance. And
so we have evidence in the upper right hand side where you can see a producer cell that's producing a mCherry transgene that then when
collected in the media and put on to a recipient cell you can see it's very effectively taken up into target tissues. We can deliver these
targeted transfusions into the central nervous system and see very efficient targeting to peripheral organs. So, we're currently using
this to test in our CDKL5 programs with our Pompe GAA gene therapy programs and even starting to look at targeting to transmembrane proteins,
such as CLN3 is an effective way of delivering these proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So, this just gives you a little bit
of flavor and insight into some of our programs. Jeff Castelli will tell us a little bit more about some of the approaches that we're
using, Fabry and Pompe, that we really think will give us a leg up over the competition moving forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">But now on the next slide,&nbsp;I'd like
to turn it over to my colleague, Jim Wilson at UPenn, and he will talk through the similar and same challenges about how we actually are
tackling these from the capsid and gene therapy side of things. Jim?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Jim W:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Well, thank you, Jill. And it's a pleasure
to be here with my colleagues in Amicus and now Caritas to talk about what I think is an incredibly exciting opportunity for Penn and
for patients with rare diseases. What drew us to Amicus was their commitment to patients who are living with rare diseases. And in fact,
one of the few successful commercial companies in the space of orphan diseases. When I first began to talk to John about working together,
we reached a moment where it became very clear that this made a lot of sense, not only in terms of our culture and our mission, but our
science and it is a unique opportunity for us where the partner brings to the collaboration, a platform of science that complements what
we do here in the gene therapy program, and as Jill had discussed, we focus on delivery, immune responses, manufacturability, ability
to readminister vector.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 557 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">But at the end of the day, it really
comes down to potency of the product. And we have a long way to go to improve potency, and one way to do that and many but not all but
at least some important diseases, is to improve the activity of the protein that's being expressed. And as Jill has described, Amicus
has distinguished itself as a company capable of doing that, and that core expertise will be transferred to Caritas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">An
important part of our collaboration with Caritas is a discovery effort at the gene therapy program in which we derive generous
support from Caritas. And there are four major pillars that we're investigating as illustrated on this slide. They all relate to
developing improvements in the AAV platform with respect to efficacy and safety. The first is delivery, in that there are a lot of
programs across the country, both in the academy and in industry, trying to improve delivery for capsid engineering. We have been in
the game much longer than others and know what some of the limitations are but are making some significant progress, especially for
the targets important to Caritas such as skeletal muscle and the CNS. But an area where we've got an increasingly amount of energy
is around safety. And there have been important and unfortunate serious adverse events that have emerged over the years as AAV has
evolved in its development as a drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">We've been on top of many of these important
areas, at least with respect to attempting to identify them in advance through preclinical models, sorting out mechanisms and putting
together mitigation strategies. Early on, it related to systemic delivery of AAV and some of the concerns that we saw about, that emerging
new approach, and then more recently, neurologic toxicity on a cell type that&rsquo;s found in the dorsal root ganglion. But that's only
the beginning of our work and an important part of what we hope to bring to this collaboration are ways to improve the safety profile
of AAV products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Another area that has been identified,
at least with respect to some liver programs, is the durability of expression. I think we're not in bad shape in terms of some initial
distribution of the vector in its genome, but we have evidence initially in liver and more recently in the central nervous system that
the expression itself may decrease while the genome is retained. This is fascinating because it no longer becomes a delivery or distribution
problem, it becomes an expression problem and we're trying to identify ways to overcome that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 558 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">And then finally, in the process of all
of this research, we need to develop products that can be manufactured not only in terms of scale, but also in terms of quality. And the
whole professionalism of CMC and gene therapy is something that is emerging and that we're a part of, and we know that our partners at
Caritas believe the same, that manufacturing is going to be critical to be successful clinically and commercially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">So with that,&nbsp;I'll pass it over to Jeff to
talk more about pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Jeff C:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Thank you, Jim and hi everyone. Here
on slide 19, we're now going to go into a deeper dive on our different programs. Our lead programs in the clinic are in Batten Disease.
These are from technologies that came out of Nationwide Children&rsquo;s Hospital and Stanford Research Center and are focused around
Intrathecal AAV delivery. We see robust expression on target transgenes throughout the CNS and announcing proof of concept across other
programs in the space, as well as with our Amicus CLN programs. These all rely on wild type transgenes and are not part of our engineering
approach. And here we're really trying to leverage first-day class gene therapies for these very severe pediatric diseases that cause
early mortality, loss of vision, ability to walk and think, and an early mortality in childhood.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Take a first look into our CLN6 program.
This was our first gene therapy program into the clinic. We now have followed these 13 kids that we treated for two years. As you can
see here up in the disease overview, it's a very early onset; around two to four years of age, these kids begin to start showing symptoms.
And by the age of 10, they've lost all their ability to walk, think, talk, see and have early mortality. You can see there's somewhere
between 500 or 1000 patients worldwide. This is one of the smaller subtypes but we're really excited by the data we've seen so far. Here
you can see in the table and then in the survival plot on the right that we've seen a significant stabilization in the expected progression
of these kids&rsquo; loss of function here is measured on the Hamburg Motor Language Score that is really the main efficacy endpoint that's
been used in Batten Disease studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 559 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">As well we've seen pretty good tolerability
and nothing that we would would be unexpected with this gene therapy that's delivered intrathecally and anecdotally in addition to this
hard clinical data. We're really excited to hear that some of these kids have even been able to do things that would be unprecedented
for kids of their age with CLN6, going to school and being able to participate in sports. So we're really excited now to move into the
next registration study as soon as possible on CLN6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Moving on to Slide 21, as John mentioned,
we feel there's really good read through from CLN6 over to CLN3 given very similar approaches in terms of the capsid in the transgene
and the disease biology. CLN3 is a little bit later onset, it&rsquo;s pediatric or juvenile Batten Disease. Instead of two to four age
of onset, four to eight. But again, very serious progressive loss of function in the teen years and in earlier mortality. This is one
of the most or the most common cause of genetic blindness and neurodegeneration in kids. It's estimated to up to 5000 patients addressable
in worldwide markets and similar to CLN6, there are no current treatments in development and really here there's a potential for a first
treatment and a first-in-class AAV treatment for these kids.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">We just shared this data in the plot
on the right earlier this year at the World LDN conference. In what you can see in yellow is the expected worsening that's seen in natural
history in this disease and you can see in blue for the first three treated children at the low dose, we saw over the first year that
they had very stable scores on the main efficacy end point, which is the UBDRS physical domain in CLN3 and similar to CLN6, we saw that
the gene therapy was very well tolerated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">For both CLN6 and CLN3 we're now in the
stage of finalizing the clinical and registration patents and discussions with regulators and also working very diligently on our commercial,
material, and process for Thermo Fisher and look to start our next registration studies as soon as possible to move these programs towards
registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 560 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Jeff C:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Now, moving off of the Batten programs,
moving over to our lysosomal disease platform, our lead program here is Fabry disease. As Jill mentioned, Fabry leverages our platform
where we actually engineer stability into the enzyme itself. We&rsquo;ve learned over the years studying the enzymes and Galafold in particular,
and how it stabilizes endogenous enzymes with Amicus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">That stability is a very important property
for the GLA enzyme, especially when it's in the circulation at neutral pH. On the Amicus transgene in animal models has been shown to
be significantly more potent than the wild type transgene where we hold the capsid and everything else identical and just compare the
wild type transgene to the engineered transgene.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">And we see that that Caritas engineered
transgene leads to significantly better substrate reduction. Here we're showing in kidney, but we've seen similar results in DRGs, which
we're very excited about for potentially helping address pain. Fabry is obviously a disease that Amicus and Caritas know well, and we're
very excited to be partnered in a co-development collaboration with Amicus here on all of the development for into the foreseeable future
throughout the clinic. And we know Fabry is a very significant market and growing at $1.8B in 2020. And we think from an unmet need perspective,
remember, over half of the patients out there have mutations that are not amenable to Galafold, or migalastat, and really only have currently
an IV every other week, ERT, available to them. And we think of one time gene therapy could especially be attractive to those patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Moving on now to slide twenty-three in
Pompe here, the approach we've taken is to create a transgene, as John mentioned, that is actually a fusion protein that has a targeting
moiety for uptakes through the CIMPR receptor. This is very similar to how we addressed the limitations while at Amicus and binding to
the receptor for the ATGA enzyme. Here you can see on the right in the figure that that targeting leads to significantly better glycogen
reduction again at the same dose, same capsid as the wild type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">We see in that third panel over pretty
much clear glycogen in muscle and then down below in the spinal cord. With that engineered transgene, whereas with the wild type transgene
just right next to that on the left, we still see significant glycogen in those tissues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 561 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Pompe, again, is also, as we know, a
very large and growing market that was $1.1B in 2020 and the only approved treatments currently are standard care ERT, again, with biweekly
infusions. So again, a one time gene therapy could be very attractive for Pompe patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">We move on to slide 24. This is our lead
program in our broader CNS neuromuscular franchise. As Jill mentioned, we have several platforms that are not just for lysosomal storage
diseases, but for other diseases where we can help enable cross correction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">In CDKL5 We're looking at both cell penetrating
peptides, as well as the exosomal platform that Jill mentioned to create engineered transgenes that can create a cross-corrective CDKL5
gene therapy. And we have some really exciting preclinical data to date here shown in this slide, showing that cross correction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">They're now looking at several second
or third iterations of engineering to look for definitive proof of concept here. Soon, we hope. CDKL5 is a devastating pediatric seizure
disorder. It's increasingly being found that it's much more common than thought. It&rsquo;s now, recent newborn screening suggests it
could be up to 1 in 40,000 females, actually, are born with CDKL5 . And this is, again, a potential for a first and/or best-in-class gene
therapy for these children.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">And then finally moving on to slide twenty-five:
Our Angelman program, this is one we're very excited about. We just started up discovery efforts on this one recently, together with Penn.
This is one where we're trying to take the full armament of Caritas engineering approaches to create what we hope to be a cross-corrective
UBE3A gene therapy for Angelman. We think that this is one where you could get significant improvement in disease outcomes if you can
create some cross-correction and not just be able to treat that small percentage of cells that can be directly transduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Angelman is very large, relatively speaking,
for a rare disease. More than 30,000 patients estimated in commercial markets. And with some of the recent proof of concept data from
some of the ASO studies, it looks like you could potentially see significant clinical benefit even in those older patients with Angelmen,
if you can help restore some of that underlying UB3 reactivity. So this is one that's early, but we're really excited about the potential
and what we could bring to bear here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 562 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">And finally, the last two programs that
I'll talk about also leverage our lysosomal platform claim one is our first Batten program, where we're using engineering to create, again,
a targeted transgene here with our same fusion protein approach that we use in Pompe. And we've seen similar to Pompe that we were able
to create transgenes, with significantly better potency than the wild type CLN1 transgene. And now we're working on iterations of this,
combining it with Penn technologies and have mouse studies planned and ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">And
then finally on the last slide here, slide 27 on the pipeline. We also have active programs that we've been working on with Jim and his
team at Penn, in MPS IIIA and MPS IIIB. MPS or Sanfilippo is a very severe progressive pediatric neurodegenerative lysosomal storage
disease. There's currently no treatments available. We have now created a number of different targeted and restabilized transgenes for
both of these diseases. Those are now in ongoing animal studies at Penn with Jim and his team and we look to hopefully have some lead
candidates soon with some proof of concept.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So that was just the highlight of our
pipeline programs. And at this point,&nbsp;I will turn it back over to John to talk about our manufacturing strategy and capabilities.
John?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">John C:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Great, thank you, Jeff, and again, thank
you, Jill and Jim, and hopefully you'll see the core of an incredibly strong leadership for Caritas going forward. Let me talk for just
a moment about the manufacturing here. Again, we're firmly of the belief that the process is the product and that we want to be among
the world's leaders in manufacturing science, as well as biology and science of what we do in gene therapy. So we have set about over
the last year and a half to design a state of the art manufacturing facility to be based in Orlando, Florida, at the Lake Nona Medical
Innovation Center.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 563 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">We are ready now to begin construction
over the next several months. It's about a 12 to 18 month build, staffing and validation of the process. We think this will be an incredibly
important strategic asset for the company going forward, will give us maximum flexibility to ensure that we can manufacture product of
the highest quality, but also in the most timely fashion possible. This will also continue with our relationship with the manufacturing
and process science out of Jim's labs at UPenn. Together with our relationship with ThermoFisher Scientific. That'll be the first facility,
and we expect that to be operational again in about 18 months time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">And the vision, together with the land
that's already been purchased and that will also transfer to Caritas, is a larger scale manufacturing facility. Again, part of our long
term vision of building excellence in gene therapy and genetic medicine manufacturing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">On the next slide, just some more specifics
about what we envision, this is the actual building, the entire top third floor, more than 30,000 square feet of largely manufacturing
space, processed science, validation work includes fill and finish as well. And again, we think this will be an incredibly important capability
to develop within the company, that also gives us the capacity moving forward that we will need together with Thermal Fisher to advance
the pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">And the next slide,&nbsp;I'll talk a
little bit more here on Slide 32 about the strategic collaboration with Amicus. Again, we are to the point now where these programs are
ready to be spun out of Amicus. Amicus is able to do this from a position of strength as we now have one approved product, Galafold. But
then also moving toward the second approved product in Pompe disease, the enzyme replacement therapy ATGAA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So, again, Amicus does this from a position
of strength - select members of the senior leadership team move forward. I move over with the long term commitment to build, grow Caritas
together with Jeff, Jill, other members of senior management from Amicus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 564 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Amicus will be under the very capable
hands of Bradley Campbell. It's part of the planned evolution for Bradley to become the chief executive officer. I will remain with an
important role as senior strategic advisor at Amicus, charged with mentoring Bradley charged with ensuring that the programs, particularly
ATGAA, move forward through approval and launch and also continue to be engaged in ways to maximize shareholder value at Amicus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">The relationship with Amicus, this is
going to be an incredibly important one. If you even look at the logo with Caritas that we developed. You can see on the cover slide the
kind of clever representation of the double stranded helix with the color blue in the middle. So the notion is that Caritas is infused
with the culture of Amicus: the patient focus, the dedication to extraordinary science, and the relentless focus on moving these programs
forward at the fastest pace possible and at the highest quality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So all of that will continue to be part
of the Caritas culture, if you will. Again, we are going to take the top two floors in Philadelphia, already built out that have for the
last two years been the Global Research Center and Gene Therapy Center of Excellence for Amicus. That will become the corporate headquarters
for Caritas, together with the facility in Florida. And again, we will continue to maintain a strong relationship as we co-develop with
our team and partners at Amicus, the Pompe and Fabry gene therapy programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So a strong collaboration with Amicus.
Again, a little bit more on that co-development: we believe that this will be operated through a joint steering committee. Both companies
maintaining operational control. We think this de-risks the funding for both companies for both the Fabry and Pompe programs with the
split toward commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">We envision with the strong global reach
of Amicus&rsquo; commercial and medical affairs and patient advocacy operations, that the commercialization of these two gene therapies
will rest with Amicus. And we envision a full split on profits with Amicus going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">There is also the potential for continued
collaboration, as Amicus will remain to have a right of first negotiation in certain muscular dystrophies going forward as well.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 565 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Again, just a little bit more about the
structure here, we had a number of different options for funding of this spin out. We chose this merger with the ARYA entity and the deep
SPACing process ahead, together with the funding through the PIPE. We think this provides maximal funding. We think it provides certainty.
We think it provides a partnership with leading investors in biotechnology and importantly with this quantum of capital, about $400m into
this company. This fully capitalizes the company for several years ahead, well into the 2024, advancing all of the programs, building
the manufacturing and building the team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">And here on slide 36 you see the terms
of the transaction, the pro forma valuation, the sources of funds and the uses of funds. Again, with the Amicus assets being spun into
Caritas, having a pre-money valuation of $175M, that&rsquo;ll be combined with the cash held in trust in the ARYA IV trust of approximately
$150M, combined then also with the PIPE proceeds of approximately $200M, together with the additional cash to be provided by Amicus, leading
to total sources of funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Again, use of funds: This is highly efficient.
Most of our funding going toward research and development of these programs going forward. This will be sufficient to generate, in addition
to advancing the current pipeline, making sure that we can generate one to two additional INDs per year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Multiple milestones ahead for the programs
as well. Our registration pivotal studies to begin. Importantly for CLN3, and also, we believe for CLN6. We can generate initial proof
of concept data in Fabry patients with this funding. Again, we can build our manufacturing facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 566 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">And also, very importantly, we think
we can continue to advance a lot of the science that Jill talked about in the beginning part. And this is very unique and something I
want to emphasize here, that by advancing these programs over the next several years, we think we can actually accomplish three things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">First, with these medicines, we can dramatically
change people's lives. Secondly, we'll be able to deploy, refine and validate next generation gene therapy technologies. By doing that,
thirdly, we think that this could create the value to open up options on new programs, new indications. So, again, success building on
success here while we're solving some of the key problems in gene therapy, manufacturability, safety, targeting and durability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">Next slide on slide 38, you'll see many
of the milestones over just the next couple of years. We really think throughout 2022 being able to have regulatory clarity on what it
will take to get particularly the CLN3 Batten program into its pivotal study and what it will take to get that approved for patients,
multiple INDs moving forward, including importantly the IND for Fabry disease, being able to treat Fabry patients, further proof of concept
across the pipeline programs. And again,&nbsp;I think you'll expect to see month to month, quarter by quarter we&rsquo;ll have through
Caritas events, we&rsquo;ll have through scientific exchanges and symposia, publications, patents issued, advancing all of these core
problem-solving technologies. So something we and something I'm looking forward to, again, with the notion that this will be the next
decade of genetic medicine in gene therapy, and we intend for Caritas to be at the forefront of that.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">We'll end where we began, and that's
reminding everybody the very unique nature of Caritas: the pipeline, the programs, the advanced stage of several of the programs, including
importantly CLN3 Batten Disease, the platform technologies that we are developing, that we have developed and that will continue to develop
within the walls of Caritas in partnership with Jim Wilson and his team at UPenn, in other key partnerships ahead, especially on the manufacturing
side with the ThermoFisher team, and again, an experienced team to lead this going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">So it's something we're excited about,
something I'm deeply engaged in. And as I think about the ability to really transform lives and to build one of the next great companies
in biotechnology, building off the success we've had at Amicus. To think about Caritas as the future of harnessing genetic medicine is
something we're all excited about and certainly very much looking forward to. So thank you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 567 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-indent: 0.5in"></P>



<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2128727d1_ex99-4img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>U.S. FDA Accepts Filings
for Amicus&rsquo; AT-GAA for the Treatment of Pompe Disease</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>FDA Sets PDUFA Target
Action Date of May&nbsp;29, 2022 for the New Drug Application and</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>July&nbsp;29, 2022
for the Biologics License Application</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>On Track for MAA
Submission in the Fourth Quarter of this Year</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>PHILADELPHIA, PA,
Sept. 29, 2021</B> &ndash; Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has accepted
for review the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat for AT-GAA,
the Company&rsquo;s investigational two-component therapy for the treatment of Pompe disease. Pompe disease is a rare genetic disease
that causes premature death and has a debilitating effect on people&rsquo;s lives. <FONT STYLE="color: #212529">The U.S. represents the
single largest geography for Amicus to positively impact the lives of people with Pompe disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has set a Prescription Drug User Fee Act
(PDUFA) action date of May&nbsp;29, 2022 for the NDA and July&nbsp;29, 2022 for the BLA. <FONT STYLE="color: #212529">The BLA and NDA
are based on the evaluation of the effects of AT-GAA in Pompe disease patients and its safety profile, which include data from the Phase
1/2 and Phase 3 PROPEL studies as well as data from the open-label extension study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #212529">John F. Crowley, Chairman and
Chief Executive Officer of Amicus Therapeutics Inc., stated, &ldquo;The FDA&rsquo;s acceptance of these filings is an immensely important
step forward for people living with Pompe disease and their families in the United States. Patients need new medicines as soon as possible.
We will work with great urgency with the FDA as they review the applications over the course of the coming months. In parallel, we are
diligently working towards additional regulatory submissions outside of the U.S. With today&rsquo;s announcement, we remain confident
in the potential of this medicine to become the next standard of care in Pompe disease.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529">Previously,
the U.S. FDA granted Breakthrough Therapy Designation to AT-GAA for the treatment of late-onset Pompe disease based on clinical efficacy
results from the Phase 1/2 clinical study. The Marketing Authorization Application for AT-GAA is expected to be submitted in the EU in
the fourth quarter of 2021. In June&nbsp;2021, the U.K.&rsquo;s Medicines and Healthcare Products Regulatory Agency (MHRA) granted AT-GAA
a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><B><U>About
AT-GAA</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>AT-GAA</U><FONT STYLE="color: #212529">&nbsp;is
an investigational two-component therapy that consists of cipaglucosidase alfa (ATB200), a recombinant human acid alpha-glucosidase (rhGAA)
enzyme with optimized carbohydrate structures, particularly bis-phosphorylated mannose-6 phosphate (bis-M6P) glycans, to enhance uptake
into cells, administered in conjunction with miglustat (AT2221), a stabilizer of cipaglucosidase alfa. In preclinical studies, AT-GAA
was associated with increased levels of the mature lysosomal form of GAA and reduced glycogen levels in muscle, alleviation of the autophagic
defect and improvements in muscle strength.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><B><U>About
Pompe Disease</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><U>Pompe disease</U><FONT STYLE="color: #212529">&nbsp;is
an inherited lysosomal disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA levels
lead to accumulation of glycogen in cells, which is believed to result in the clinical manifestations of Pompe disease. The disease can
be debilitating and is characterized by severe muscle weakness that worsens over time. Pompe disease ranges from a rapidly fatal infantile
form with significant impacts to heart function to a more slowly progressive, late-onset form primarily affecting skeletal muscle. It
is estimated that Pompe disease affects approximately 5,000 to 10,000 people worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 568 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2128727d1_ex99-4img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>About Amicus Therapeutics</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amicus Therapeutics (Nasdaq: FOLD) is a global,
patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living
with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust
pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company&rsquo;s
website at <U>www.amicusrx.com</U>, and follow us on <U>Twitter</U> and <U>LinkedIn</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><B><U>Forward-Looking Statement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; color: #212529"><FONT STYLE="background-color: white">This
press release contains &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to top-line data from a global Phase 3 study to investigate AT-GAA for the treatment of Pompe Disease, the
potential implications on these data for the future advancement and development of AT-GAA, and anticipated regulatory submissions. There
can be no assurance that the FDA will grant approval for AT-GAA. Words such as, but not limited to, &ldquo;look forward to,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;intend,&rdquo; &quot;confidence,&quot; &quot;encouraged,&quot;
 &ldquo;potential,&rdquo; &ldquo;plan,&rdquo; &ldquo;targets,&rdquo; &ldquo;likely,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo;
 &ldquo;should&rdquo; and &ldquo;could,&rdquo; and similar expressions or words identify forward-looking statements. The forward-looking
statements included in this press release are based on management's current expectations and belief's which are subject to a number of
risks, uncertainties and factors, including that the Company will not be able to successfully complete the development of, obtain regulatory
approval for, or successfully manufacture and commercialize AT-GAA. In addition, all forward looking statements are subject to the other
risks and uncertainties detailed in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2020 and Quarterly Report
10-Q for the quarter ended June&nbsp;30, 2021. As a consequence, actual results may differ materially from those set forth in this press
release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only of the date hereof. All forward
looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise this press release
to reflect events or circumstances after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CONTACT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Investors</B>:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Andrew Faughnan&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Executive Director,&nbsp;Investor
Relations&nbsp;</P>

<P STYLE="text-decoration: underline; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">afaughnan@amicusrx.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(609) 662-3809</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Media</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Diana Moore&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Head of Global Corporate
Communications&nbsp;</P>

<P STYLE="text-decoration: underline; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">dmoore@amicusrx.com&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(609) 662-5079</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FOLD&ndash;G</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 569; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2128727d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !- *T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_***0G H
M 6BO)]7_ &Q/#$^MW&D^$[37?B'K%JYBFM_#EG]H@@<<$27;E+5"#P0TN1Z4
MZ/XG_%?4UWVGPJTBS0_P:OXPC@E'U%O;7"_^/5YO]K85NT&Y?X8RDO2\4U?R
M/1_LK$I7FE'_ !2C%_=)IV\SU:BO)[CXV?$+PTOFZU\(]1N+9.9)/#VNVNI.
M@]1'*+=V^BJ3[5N_"W]I#PG\7=5GTS3KZXLM?LUWW.BZI:R:?J5NO]XP2A7*
M_P"VH*^]73S/#3FJ?-:3V4DXM^G,E?Y$5,MQ$(.I:\5NXM22]>5NWS.[HHHK
MO.$**** "BBB@ HHHH **** "BBB@ HHHH **** &3SI;0O)(RQQQJ69F. H
M'))/I7S\M[JG[<FJ:I#I^LWFB?""QF;3VN=.;9<^-&'$P2?K%9JV8]T?S2D/
MA@*Z+]KN:X\;:?X;^&EC-+;S_$6_-K?RQL5:#2H%$U\01_?0+!];@>E>)_\
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MG);.3<K/NDW9/S21G4S2O*+A"T8O=12C==FTKM>3;"BBBO1//"BBB@ HHHH
M**** ."\9_LL?#+XC_$2U\7^(?AYX(UWQ78K&MMK.H:';7-_ (R2@29T+KM)
8)&#QDXKO:** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2128727d1_ex99-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !( *@# 2(  A$! Q$!_\0
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M!<_A7T7\3_A1X/\ V<?V>O$TMAI\(N+JP>Q6XF >::253&,$]\MGCTK]"/\
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M8I#&K=5!_"BB@!# A/W%_*G 8HHI62V 6CK113 3;[48HHH  H'8?E1BBB@
MQFD\M2?NCUZ444 *4#=0#^%((E4\*OY444K(!=@W9P,^N*3RU_NCKGI113L@
2#RE_NC\J7%%%%D M%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2128727d1_ex99-2img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
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M>R5>M901<65-V^XA/-IPY;6,<L$=*I;4'"6^Z%GF)?+<Y'S\5]*2IE7K)_\
MM7UATY8678X2ML$X!'*ME>.'=IU1#=C7"WL2F5C!2M//\]:&#:]1$+$W"Z.K
MV+02N-@6NY^\+Y$IMXALJ2Z[N94G:I#BMP3GQ!ZX]1K\T9B=>&H*I*FE)7M&
M%<B/+UUV?QT[ S=U@2;EH>68LQ(*A;92ON3OJ2O[T^WE7!LVV731.J5P+E%?
MMMSB/=V]'?!2MM6?U>OH:ZW9U5'4-)#L^7%<!M;9[Z9P!:"W@=1Z^U7[=.'C
M,U33;*UJ6#A1SCF?,UD2N%3UIMJ)C>Q12G("LDUO>&+OPOM:7G6G)+NW!0DG
MT5#ET%2B<Q.A!;)VK8QC:1G9[:Z."B@=#O71V!T[^:X2IK*B*8Q1R7(&84>T
MMI2-?6F%!*%K0D)+83CGYYKUZIX<+@W-]]*PA&X$(\0,"MQ:;['L;B%LX"]V
M-G@1XUZ-1WR5>+O(?#A2PZ04I\A@#'Z*J[4FC,09%:X.=E7IHIXW;V8DAPRN
MO"W-QXT$-D@N#S\:CE^F*@*2>A6<)YUNXL5I3P"G<>=0;BE/$&:XI! :CQTA
M)\UJSS_-BN:A!<^Q6XAB#W@76"J[H3+4MLI=<"2DO*&<9Z@>0\_S5Z#JMZ.A
MIN/_ )UT%:3G!Y??'U^50Y5Y;8CAH*YK6$$@]0!D_P"-32VL1(%@<N[Z$^ZW
M@EJ(@\\>7YASK?,<!D%OV0XA9;'1SJ9$U+C[_>NG&5KQS]7^/MJ82YR67G&&
MSNS@G)R%'P%5^%IM=Q#39 7M!QY''.LJ'=%2IJ7E+&5+ "0>O0#'_P U6#(R
MV96.Y<397II)5WMDH+BMQ7_=10AYQ]&]/4$C\WYJ]NL-)B\QF998[EHI[Q8"
M<=V<\\>KER'E5O\ ##0Z;^F- 9;]"UM)=E+2K_/2W0"EHGP#;>%J]:DU$N,V
MH'^&\TVUQLEB4G:%D ;L^'MJJZ1AS5S<%@L55\6,EUB0TT>];;.U+RDX"O\
M[5CJE*C M%.3XUDN2E0H[4E#K2DJ(< WX/3F#X>)KT.WF)*DG>E*4CD""":U
MDS /1*TE53D^<M/L=;=*PGT<Y%>3LIU9&[XOE67)>;2XKN@=IY8-93+L26T&
MU$!>,8-080M0XL#O.6H$]25@)'*O5)G*6H!*MR?56SDVN*V<;@,^)KR5;(4>
M*K8XE3N,X!I8+ 1N](#);SAKK=_0UZ%XC(*WFF'FDX..:T[?\:P=5ZNNNLIZ
MY-QDK=R<AO/HIK00IIWJC)!&X$CY*SFV=PY]:FC:/272[/)W-NU>M "1@5DM
M,]">=>2(Z0K.*\G'$1FE.+6$(2"HD^&*G6RT1Z2U$CN/NN);9;05J6H\@/.J
MAU7K[WZ</<!QF,DX[M2]I41S!P.G/]'+E6LOFJ'+]>9<=B4]'M_4L;\IR5?&
MQGD3_)%>NS6C<$+> :4M2V=A3DC("L^K(W<ZE:+**]\EB!5TNC;!:*VDK'()
M7MR!G) \A@Y-8-NT_,O:D,0XKLM;A)"4[L;?Y1(\ZD<QIZ\RHUIM"#[C9_Z.
MN2DX4ZM9W; 3T"00#\M=_=EC@!%TYHI<V7';,^2A.UUP EM(')(\AUYU%-+N
MAD,U/!3B9_G')<9Z<[+6H)T$2Y+!84L;D\@D 8\<\_EK7:EX 7S3T5]]LM2
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MVU#&C08Y/<G>\ZL#NVR<9]7M)\J^B\ZY0N&6C(\=M"I[B4I9882DE<AP]/1
M/+/JK3\#.#T'AKHF)#:9;]VE <DOE(RXZ>?R@= *W.K471D.2;8B'[\, ".9
M[_<M@9YG(!.<<OEK322F1V(K?Q0MB:&\>*X\XO\ %KBE;Y\EQ[1[<")N."Z5
M$]<CD#R^6JSM7'J;?9[<>[0E1))]#(SM/KJ1\:-=ZYFZGN$6\V*-#0TI10]$
MDN.A\?\ :*AD^VHKPWT3(XB7Y#+<5Q#H2I?-)2>7/QZ5GA8&DN 4H?(7# X]
MQ4R9U#;Y#+J9+0PHXW U6O$[33$K2-TDQS@1P)*?^R?^5?G$B-<['?7+2PV8
M[S+8W;S@#/C4/ES-5V>SW&/=&Q,MDV.IHN!6XMY')0QX5)''F' JO4RBSFEI
M[UF\*7'1I,*</H+D.*1[.0_6*EKS^.=0[0!][])0^^4$A04L#R](_P"%9LW4
M;2,AOTC6Q(N5SXL %NW9('50 ]M:Z9>&(P/IA1'@#45=>G3).X**$$YK77F2
M;9A2SN/C7N!,5E)_A+_1%*@WPG1^#I4F$<EAC7](=*4JPJ24I2B+0:\UG;>'
MNCKQJ2[N]S;;7%7*?5GF4I&=H]9. !YD5\1^(6M[OQ;X@W?4EQ2M^ZWF67 P
MC*BG)VMM)]24[4#V5W#]DVXSF/ LW#.W/X7*VW.Z[%=&TDAAH^U04LC^@GSJ
MKOL=7!+X>\4']9W&/WEFTP I@+3E+LU8.P>O8G*_:45WVR(V;.HGUTHS.G=P
M'K/Z+EJ][JNI;31Z#V_]!5GKNZ.\(="6O1EL=[B[S6C*N<IHX4G=R*4GPSC;
MG^2GUU5>E=(W76=S$"T1#)>QN6K.UMI/\I:CR _7X9JV.VII=6D>TAJBW-H7
M[EQ'=B)//[DMI)"1Y@**A\E7APDX1W#26E(UO8M3YFJ;]TSWRT4C?MRHK4>0
M2@<N9P #74-J&"%LH/I"_BN;?&Z)Q9:[KV7-'$7@TOAQI&/<Y=U1+GO2 S[G
M9:VMI&Q2B0HG)Q@> ZUWEI+['#PINFE[3,FNZA7+DQ&7G5)N*4@+4A*E8 1R
M&2:X2XIZ]/%?5UMM=M2OWK;D)C1LCTGW'%A!<QZ^02/+VU]J+;$3 @1XR/BL
MMI:&/)( _P *YS;M744S(A&\M)O>WJ6]V1 R;&96WM;]5SMPS[#.D^#G$&VZ
MLTEJ/44&5%*D.Q9#[3S,EE0PII8[L'!Y'KR(!'2M7VN')?$_7_#7@[#8E.6Z
M\W%%SOS[;2N[3#9)4&U+ P"K:LX)^]3YUU-56<8N,-XX2PI=U.B)M[T_%;:4
M]<HUPC-;5K<#81W:U!9PI2>>,<_4:Y."JGFJ&R.\]X%A<@9\.^Q-P%T,L$4<
M)8WS6G6POWK2W[L<<(+M8I\*/H&Q6^1)CK9;EQX@2ZPI22$K2H<P02#GU5RG
M]CSU'?N%W%?4?#R_V^?%A7-2TMNNQ7$LHG1R4J 61M]- 5X\]B:[+N?%^XZ5
MTW"NFJ=)2-/+E7F):4QW;A'>VI?6E ?4M"BD)22<@G.$FIOIW5EDU=!7-L=X
M@7F&A9;5(M\I#[84.J2I)(R/*IFUD\=/)%."]K^-[V(Y'/L49IXGRL?&<);P
MMJ#X+@G['U!G1NT3Q,>E6^7$:EQ)+C3DB.MM"Q[M!]%2@ >2@>5?O""#.3]D
MCU7.<M\MN$]+NC:)*XZPTHAH#DLC:<[3XUWCIW6NG]7*E"QWVVWDQ5[) M\Q
MM_N5>2MA.T\CU\J_;?K*P78RQ!O=NF&(TEZ0(\MMSN6SG:M>#Z(.U6"?Y)\J
MEDVF]\DKS';&W#KIVZ*-E$UK(VA_HNOW_BN#.,<"9*^R1:4F(MTQV%'FVIM<
ME$=PM)5W1/-8&WEN'C3C%;Y[WV2+2<U%OEN06)=J;5)1&66DGNSU6!M&-P\:
M[PT_KC3FK8DF59+_ &R\18QP^] FMOH:.,^D4DA/(9Y^%>-EUYIG4ER=M]IU
M#:KG/:;#SD6%-:><0@XPHI2HD Y'/UBO6[2>RUXO19@_[T0T;77L_5V+_K5<
M)=M/A?JGASVA;'QHL=GD7NSMOPY4L1FRLQWXY2"E8 )2E:$C"\8!SG'+/3&@
M.V%H7BE/L]KTNW>;K>;@XE#L%%M=1[@3U6Y(<4.[2E(SS"CDX SFK8<UMIUO
M4:=/+OMM3?E)WIM9F-B24XSD-9W8QSZ=*R!=;1!5<4B9"CF"D/30'4)]SI*2
MH*=_D@@$Y5CD":JRU8G@9'-&2Y@L"#;+A<6-_40IV0&.1SXWY..8M?/C;-?.
M?C)=;AV<^WH>(-XM$V5IZ6^F4V]':)[YER,&7 @GD5H5GT20>0\P:U/:'UI=
M>+G:6X=:MC:6OEMTZ/>\0')T%:'7F$S"5/K0,]VDJ*@G<02$YZ$5]#+WQ2TM
M;==:?T?-F,+NU[CNS(:"XV4*2V4XSE6=RMWH8!W;58^*:V<#649R/?I5R[BT
M0K3+7'<E2)K);*$H2HNJ*5$-CTL;5X4,9(P16P9M,LW<CH?.#<-[ZC3(6UOW
MJFZB#L;!)D77M;0ZZKF3M':EX,ZRXC7G1W&"R2; Y;H[*[/JI##Z52$K1N<0
MAU"#\11QM.Y)Y]#FL'['5PWNVC8NO[H$W!O1]SGMHLCER8,=V8TT7![I+1YI
MW)4@9\2#Y5U9#UCIB_Z>7?8MZM5PL;.Y:[BW*:<C-[?C$N9VIQXY/*M/+XSZ
M/8MMNN,:]QKM!G2O<;,FUN)DM]X!E04I!(& 1G//F.54NER&F-*QAL; W-P"
M,\A;(G4YJSN&"83N<,KVRL<^9OG;N4XI7X#D5^UHULTKA?M._P =5\_U4;^X
M17=%<+]IW^.J^?ZJ-_<(KIO)_P#JG?=/M"Y[;G],W[P]A564I2OH2X5*4I1$
MI2E$2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$
M2IYP1;+O$".D=?<S_P#NBH'5C=G]LN\2XJ1^*R#_ /**K5)M"\]A4D8N\!=-
M0(Y0CGGGXUD.QTE)/+E64EK:G J':YXA6_1L5QR6X&T)',JKC&XI'6:MH\LA
M;B>;!<O]N[3<*?I5;@2$R$^DA8Z@^%<[<+^U$G2?#F7;9<@=^B.M(0KIN"3@
M?GJQ.U?Q5A:NM[K5NDB4G85;$'.,>/*OG]>WG>]?2"IL;25(Z$&L-HU,](&%
MG'(_HJVQJ2EVC-,7WR-QX9^*P[S=%W;4\J:H[U$+(/\ V?\ S-3#@\TE&MHC
MRAA,9*0/^Z/^=5[9P'9+RE$X[M?ZJM/A%;C/OMS:;.'.[24>8( !_5^FN#VA
M+D\NY+[/L6 !\3&#*_Z+Z!<(KDS?VFN\2%H5R 5SS5JO\*K4VHS&[5&W'GDI
M&/DJA^##CEFM[2G4':D#TB.6*L7B1<[KJG3$V#!NK]O?>9*&UM#F@'K_ .O(
MU\P>]F(MLOLKX)"YN!UN:KG7$5K4G$"TQ62V[*BOI4TVUC:VE*N>/\:N?66@
MV-;VY%KGI#K2HR0D$X&021^FN4]&\0-4<,>(T!G5]E:F6Y66HMRAM* 4D?>*
M'4*_775<+BA\(+Q&7!TW/8:2RI7>.@):QC.#D[LGPY5=<UC&82?6%!(V1S@8
MFZ?/'FJ!N_9(B/N3VE6<NKF)6'7@Z5)2M6W<ZEL^BAPA(!4GP&*T?:)T0_PS
M[+]YM[\QV?L9:B-.R1]UPI:1M)\<"NVK%J&V7FUB:U]R41S;..1KE?MH<2(-
MBL=L1)9;FP_?!$AZ.I((6VVDDC'K)2!ZZE@D>]["7%UB+!:Q[0YDC< 9<$$]
M_%?/6&GO+(\@<REM.,_T<'_"NP>&%Z5==&6Z4%NA:FMQ?2KFDCD1ZZY%M3Z7
M%R"X $N.*R,],C_SJ]N"5\=7:(]M;4LH;>*2$'G@GE7TS95289BT_67Q7RAH
MNDTX<WZOL6UUA='7-0I=+9<4@'T@G!/K-1^7?9-PO$GT" 2,$<\^B*Z=F\)(
MERL*K@.]]T@#.Y'JY5R?JZ[KL&N+O%;0%EEW80D8\!5FMHY,9>XZK2;.G@J(
MA#:V%;AJ3(#BE'( Y>C52\2(:DZZ6I2N4CNEC< 2I(',#RZ5,VM32E.AQ)+>
M?O348UC$?OTA$X.8=904@^(2.9Q6N9%NS<KH(8V1NN%;O9BMZ/=5]<6T$N*<
M2GTAUY?KQBK8UEV>+YKCN9:KQ*7!#>UJ*P-J6/2SN&/C*]N14(X)0S!D7160
MH/J:?21_)*.1_-BNP>&MW+;!:61CUBK\1%K+I!#C9=41IWA8_HB/"8;E25*0
M%-O"0!M>Y[@L^13T &!C\]=7:?TN;GP^9;;"$O\ =8[SS]&JXXJ2&8X9E.)V
M1V05K*.6>60/T5*N'G'"QSM/VE+T*XQXDO:VASW(X=AQC[H /0R?$X%>2.8T
MV6#87X<30J7/8XA7;5<>XW+WP6\@@K)PI+Y!)W.#&TGG^8"NIN&_#J!P[TLU
M:84B:_$;RIIN<^7BWGJE*CS SX>%;%N2ZP$*4%%L_%5C&1X9K8":)C>4GT@/
MDK!Q &2@+7.7#O:C#<?4>L+=W9=3<51'BD<DY2>:O7T'YZY]CQEF3'BQ\MH6
ML [1@<_$5T_V@[8PSQ21+GDH:?8V(WC*%;0"?ESRJLG+=9);I4C[FM*L[D<@
M*UXD#;@\U%6.PO MP6PMW9E;GV%,MRX$ESTMI^]SY57'$/@4YI>#WL.0'%!0
MSN^^!JTF]7W"#$3'9F*4UT ]5:JZ7&5<MONATK3UP:G-4 ,@M"7XE1MMT'=&
MW$NDE*AXBMJ_H)RY+(>R7".JJL]R4F.DX3D8Y<JT:I[CTHK2G STJN:EQ-^*
M]!!&JKQ>ESH)3EW#/?!I)1LW8SNY=:US?%APR@ER$TAG./162JK/U#:I.I;3
M(AM,K>=4C*6VTE2B1SP .=5RYV<.(5VMT=V#I>6RZIU:E.R\,)"<#;S41ZS5
MAC]X,3U8B+@+!25G7%E>&3(6R0/2;7L*A[0%9_QK3F^:3U+JFPVZ1-;7$D7*
M.W+2I@Y4T74A8"L<L@X/JS7IMG8^US*N\6-=[K9K,EY]#+JU34O.(R0,A"3Z
M9Y] >=6%I_L?:$AZEU/IC4>LKJSJ*S+;*;E;DMIBNI<R&UA"@5 I4.8)\?50
MAMC8JXTO!!*L7B_+:X:Z%A1'X+$N]:A4[)DLMC:MU06I#2-V,AI&.2 0#CG6
M;V?>$TBVZR=NUV9PM#(6RB0/2"E<PHCESY#VUM>$_$'ACQ_U@OAWKV-+L^IV
M-T:TWI2L)]U!7W1"3]Z%K"E@*Y'=C.<58/'*^6_@+>K?;;TQ*DP'HR([=T0H
M+RXTG&Q8SN!VE)Z\QS&0*TS896##S745%73S'$#HNA;--;?C!:@ K9G!Z9Q5
M:\1US%.//%*D)R G>K(QY"HIHSM'Z*NC;2(=];5++>XM2&U@Y R?#&!CJ:E[
M-W9XCMK+4MB+92DYN3:N][PY&4MI!^,.77IX^5&T\DW\-C<UB*NGIQOI'#"N
M:]5</X$J6Y*N-T3&2H\PE1VD>L<ABKEX3<-K1I"PLW>VNE");.[W7);[I*D'
MH?2\#X>=9.L^SMI2[O,I>FW&7$FMGNY33Y;<3YC9S3D'P(QX5RQVA]+ZIDZ[
MNEQO.K)3EMM3>&H,&4[%:4A*?1*4#(!Q@D#D*LS;+G@:#(<BH:?;M%6N<V >
M>W@>7,+U=J?1D:_70WBTW5H2XJ>[<90,[D;LA?+K@\B.H!S5&/#43>D+E%D-
MB6E<=2!(2  V2H  D?&&,GF,@BMM#UK<+]JETRT(:M;:-C;0)4M:2G )5XYY
MU,[\W#A:(N:HPPRM#:U#EG(4.M1MO%:,YK*:TP=-'EDJE8C.I8994HI;;0$
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MISJ4*"B[''(]V-@2[L03DC!"0:O; IBO'5A,;HP->TGE[AV=FE@IP'A]]/\
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M8( 5RY]*]%AX@:DXR:[M6D[,S=;]<+DZHK>N5Q+4:*VV,N2'N[ VMH3E1/L
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M?\X?!P@@)2.?/<KR.:_/\^U):C71?9:+8--19L&?,KUC3T538[AI"&2G>"A
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M7W/N0KXJRK=G(\\559*&NNOK'DL9MDU^^G:0PBQ^0O&V61<"9(;9<P'3E*/
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M-YRS5&NAZ12R0]8$>*E_$.\*<>#"%$<^>*CUL90E"=PR3RS2ZR3.G..*.>9
MK8V6.A\I2HX KXCM&K-1.^9YOFNWH(&;/I&1-RL%L+!I5=^E@;,-@]<=:O\
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MSO=PK'RGK4^E:-D6Q"RAHK<:<4T4#KMP02/414+N2E-7M;;;*VV4)2C:4]2
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MQ2ET>PD9J==TAQM134 E6=-DUO:VXY#D9Y[+9 P4G!R#_A5GVRW*6PI>/"K
M%@J#P7%:=B0XV48) 2KPJ3AMN5#<"AE13CE4?64-91_)->^!<AE8*L#R-8E&
MJV->WI]S2^B[-#:7)>NB$)2A'QG"6TH _176O9Q[+<7AK99L^[%,Z]7(H4Z
MGT&4)'HMI]AR2?$UR1P<QJ#C1P=84E3L=,LM$'F,MJ6>GLKO?B;Q)O.EH,E-
MEMK#C3 ].5*>"$D^21_C5?",R\Y+8QN( #!F5%.*O#*VWY 6^G8MGTF5).-A
M_P#.J)OG#)JQPULQ$@I4=SCF>:CSR*TFI.U7J3W>Y%N%MB+W*PDL3D94/96V
MAZ\?U-95.O1WHO+("QGV\Q6DJ T&[5T-,YV0>JUNNF&FG%%2$A7/ QTJK-:Z
M9B):.UI 7@^EM&:E>LN*46V3WFU**U))'JJIM1<4'[Q+VPXV[/+:M>*EABD.
M:CJ9HF^:<U&9>CPXVH D*Y^%0ZXZ,FP0^0WWJ%>DDH/,'V5.%WZ]-.;G8K>T
M^&16<Q-%T:)6T6G4CFD^/KK9M<]FIR6E=%'+PLJ90HA1!Y*'4&LQ(*E;?Y2,
M"LK5D 0;XO:,)<&[EYU^V2&9]UCM>:TC)\JOAP+<2T[FEKRU74J<E6DK8M)Y
M&,C]51EJX9=YGQK;W"$Y9["W$=(RV5%('@"<X_34=@6R3(07D)RG/AUJD67%
MU:#L) 4@$OE2M3L<'+G^:E5=VK6\"V=66G^"3?\ 8>3_ ,755:59:?X)-_V'
MD_\ %U5^@IOJ]Z^8LXJ-\4?XS-6_UM*_OE5&*D_%'^,S5O\ 6TK^^548P3R2
MDK4>B4]2? "I(_0;W+%WI%?N"1G'*OROK-PN[(?"&QZ#T;H?5^E;1,U]=;"]
M-DS7V 97>)[OOE!6<@MJD)"?4CU5\N]1Z!N^F>(-QT6Y&<D7R%<U6D,-IRMY
MX.=VD)'B5G;C_2%:^DVA%6.>U@MAY\1F+CLR5F:F?" 7<5':59B>S-Q67J=G
M3HX?7[WZ=C^ZTPS%PH,[MO>*).U*=P(RHC)K#C]G[B5+UP_HYK0][7J9AL/N
MVWW*0MMH]'"HG8$$\@K=@\\'E5W?PGZXYZC3FH-V_JE5^3BOQ*TK&4J"AYI.
M:L>T:'U1PIXRZ6MNIM"2Y=W:N,5Y&F;DSM-R!= 2T.J5A9&T$9&>1SS%6)VX
M]4R-5\3[1+E<,)'"YU%J2CW'-:;;?F)[Q6'E!L!.$X* >9P#GP CW]Y6QM%P
MX$WN/9J5EN_,+CJ."YUI5K67LJ<8=0V5N[6_AQJ"1 <0'&W3&#96DC(*4+4%
MD$>0J-#@]K@Z'D:R^"MS^"L<K#UW+.([92YW:@59Y87Z)Y=:D$\1-@\<M1KR
M6)C>-05#J5,-/<'M;ZMTG/U19M+7.YZ=@=[[JN<9G<PQW:=[FY6>6U)!/JK,
MX>\!N(G%:$Y-TCHV[7Z"VHH5+C,@,[AU2'%E*21X@'(KTS1M!)<!;7/1>!CC
M:P4#K] S6ZUCHJ_</;^_8]2VB58[NPE*W(<Q&QQ*5#*3CR(Z$5<W84T-8.(W
M:-L]CU-:(E\M#L&8XY"FM[VU*0UE)(\P:QEG;%"Z;4 7R7K&%[PS0G)<_=*5
M<7:_TI9]#]I#6]BL%MCVBSPY#*(\*(C8TT#':40D>&22?EJ): X*:^XJ-.O:
M1TA=]01VE]VY(AQB64+_ ))<.$@\QRSFC)V.B;,38$ Y]J%C@\L&9"A5*E.O
MN%VK^%MR9@:NTW<=/2WT[V43V2@.IS@E"AE*L'R)Q7MUWPDUIPPC0)&K=,7+
M3S$_=[E<GM; ]M *MO/G@*!^6I!*PVLX9Z9Z]RQ+7"]QHHC2IEJ/@WKG2&G+
M9J"]:4N=KLES4TB%/DL[6I"G$[FP@YY[D@D>JMT_V9N*\;4%OL;O#Z_MW:>A
MQV-%5%])Q"-H6O.<!*2I.2H@>D/.L=_$!?&/$<-?!>X'\BJSI4DUYPXU3POO
M(M.K;!.T_<5-]ZAB<UM*T9QN21E*AD8R":DNBNS9Q2XBV5N[Z<T'>KK:W!N;
MF-L!MIT>:"X4[QZTYH9HVM#RX 'C<60,<3A S5:*<0@@*6E)/0*4!FO*OHKV
M =(.V3@YQNMVH+.(EVMTMQEZ//CI[V.L0<E)"AE)!KBI[L\\3;?H5O5TG0E\
M8TYW D&X+BD)2U@'O"G.\(P<[BG&.>:J15T<DLD1L,) !OK<7R4SX'-8UPSO
MV:*OZ5OM%Z#U'Q'O:;1I:QS[_<U)*_<T!DN*2D=5*QR2GUD@5M^(O!37G"7W
M,=8Z3N>GFY*BEEZ6T.Z<4!DI2XDE)..>,YJZ9&!V N%^5\_!0876Q6R4*I5E
M:,[-?%/B'8V[SIW05ZNEJ=3N:F-L!#;H\T%:D[QZTYJ!7NR7#35XFVF[0GK=
M<X3JF),22C:XRXGD4J'@11LL;W%K7 D=J]+7 7(R6&!GISH>5=/_ &/#AQIC
MBCQQN-HU98H6H;:BQOR$19[7>(2X'60%@>>%*'RFI?\ 9 >RE:N%\FWZ]T';
MV(NCIJA"G0H ^XP90)2E20/BH7@I(\%I_I50=M")E6*1V1(UX=RG%.\Q;X:+
MC'!QG'*ORNV[OP>T2Q]C2MVO&],6Q.L7"T%7L,?]*.;GW1]/_0]'V5RUP[X)
M:]XM)D+T=I*Z:@9CJV//Q&0&FU8SM+BBE.['AG/JJ6&LCE:]Q\T-<6F_8L7P
MN86C6XNH32IG(X,:[AZZ9T9(TE=8^JWTE;-H>8V/NI"2K<@$X6,)4<I)'(UC
M:@X5ZQTIJZ%I:\:9N=NU'-+0BVM]@A]_O%%+>Q/WVY0(&/$&K(EC)L'#GKPY
M]RBP.Y**TJ_>%?8UX@ZQXJV;2VI=,7W3-OD$.3IRHR"N(P0L)=*2KD%+04@G
MEG/7%9/:X[*T_@!K"0;+:KU)T,TQ%;1?K@$J0[)<22M.Y( SN&  .55Q6P&8
M0!P+B+_/;V*3<2!A>1DN>:4KNSLW]D[AYH_@B>-'&[=(M+L<3(=G<*PTEA1P
MTI:$D*=<=)&UOI@ISDDX]JJJ.D8'/N;FP U)Y!(HG3.LU<)@Y.!S-*[S;[47
M92O[RK5<N!RK;:E'8F<BUQBI*<8"B&G X/D)-<3:=TE>-<ZC39],VB;>[@^M
M98AP&%.N*0#UP.@ QDGD/$UC!4NE#C)&66YV^>])(PRV%P=?DM+2I[Q"X#<1
M.%$-B9J[1MUL,-Y8;1*DM!3)4>B=Z"I(4?(D&O!O@7Q#>T[:+\UHN\O6>[K:
M;M\QJ*5HE*=_S8;QDJ*L<N56!-$0'!PL>T*/ X&UBH+2IOQ#X(:^X3QHDC6&
MDKIIZ-+5L8?F-#NUJQG;O22 K'/:2#UY<J\^'G OB#Q8C/R=(:/NM_B,**')
M,5D!E*O%/>+*4E7J!S3?18-YB&'G<6\4P.OAMFH+2I1<.%^K[5K=C1TW35SA
MZID.I99M+\<HD.J5\4)2?C9P<$'!\ZWSW9RXH1YUTANZ#OC4BUQ!/G(<C;1'
M8(40M9)P 0A9 SD[3RY4,T8M=PS[4P..@5<TJS-)]F;BOKFS,W>Q</K]<+8^
MV'69:8W=MO(/,*05E.\'P*<YK7Z.X)ZOU;Q.9T,G3UU9OB'T)G0O<I$B(SO0
MEQU2%8Y)"P?(\O.O-_%GYXRUST7N[?EEJH'7X%I42 I*B.H!SBNK^U[V)9/
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M2MCP@GH<TY'G,)+!=<<4IE1R6E;CZ.?$>1]=6!"URF-+;:DNJ2A2PV#GJHG
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M$CP.%?HKIWC%P^U'K:>TMB0Q MD/<7774I=(R1Z:&E#:I8P0-^0,YP3BN/\
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MP\TY;>+2."=K6S'_ /;$:-O=G++'>*2%[T[5+42XH@Y5C'3-<><9>W[=^-G
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MRZ>8S\HJ?>^B(%M;4PT2/C+;/0GESQ_C4)U)=I$Z;WQ<SWAYYY8%2@FZKN:
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MR1A LS!MR LH:9;&Y2U8YJ6M7-2O-1P,9P ,"HI>M2OWB0M22N+%8P6&$K4
MP2 H@GEE93\8^:B/"O5;[RW)O$H/-*!899>;<4\=Y"^2NO3*TX\NF?#'V38&
MQV[(I&LE.*7B>WD.P+I*6DW+1?,K?S=,-W&0FX3U"3);&UM80-C8\<>*O:HG
MV"H1(;AP=>-6Z3LC2IZ%-I2<!+SB>:=A\24E0VGR%3YBZOI2-H25D$I"AR4/
M7_Y9QY5"^)_#V%QBTRW+M[GN>6E1[L+.-JTJ.6U$=.8]%0\P?&ND!LMJ&Y+%
MNNDW&$@H)2A/-.P94WZT^8SX>%:6[\/FM5V=YEIQ*;G'"GXA"<AQP<RD'PW
M$%/L(Z5#V[GQ4MZ%VI>IDJDM^@V+E!;<>!'+ <."3CEZ6?;5*:XA<086I8M\
ME:EN"KC ?$F*M*^[0PZD\E(0G"1SY=/4>M8O >VQ7K7.8X.;P4V?U_9!%CF)
M*;EN)YE"4J&/E(%1KB!>HNO56V)EU$2 ][M<24XWJ2DX2#X"M_>X^G^)-H;U
M39%PK1?4)*K]8DJ"5=Z!E<B.UD92KFHI3T'/&0JH=<(K;MGD+;N.4.1W0 E
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MT,.G*5AEDI4/DJG==<'I\9T&(PIU!2<*2@C::LA_8M9)3N'&ZK&R-MS&2T5
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M]D>6\UM7(C/)W+43E0#N#CE7S@L/%K7.E;4+99=9Z@M%M'(0X-T?9:'L0E8
M^2M3"U7?+9='[G#O5RB7)\%+LUB8XA]P$@D*<"MQ!(!YGP%1LV,6QNC)&A -
MC?UYV\ LG5H+@X ZWME;V+M#@0I1^RB:FW%1/OM?,Y_U3E=)\'M=V>T=M;CQ
MI28^S&N]X%KEP4/$#W0&H82XA.?C$!Q*MHYD;CX&ODQ&U'=X5X7=X]UG1[JM
M2E*GM25ID**OC$N [B3XG/.O"7?+E/NWOI)N,R1<]R5^[G9"U/[@,)5WA.[(
MP,'/+%6)]E=()N^WF!NG$$&_X:*..KW8%A]:_B++ZCKU/VB.'%POLF!P0X<6
MBW0&'G7KW!?##;T=L%>1L7WAR$Y"2GK4*^QQ7%/$+A5QGM+#D>-=[M.=DB,%
M82TF3&4E) Z[ O<,_P!&N#;UQ?UYJ2VFW7;6VHKG;R-IBR[L^ZT1Y%)7@_+6
METYJF]:.N2;C8+Q/LD]*2@2K=)7'<VGJ-R"#CU=*P_93G0/C) <;9@'ASN2L
MNE@2-=F0+Z]OJ7T/^QR\)]2\%>+W$K2VK(C4.\Q[/:W7&F'TOI"5N/E)W)Y<
MP,XK-[$U\M.ON%/&?A.S<6[5JB9=;LX@DX6IF2DM!Y(ZJ"%)(5CH-OG7SR7Q
M)U<Y>)5V5JN^&ZRTI1(G>^3W?O)3\4+7NW* \ 3R\*T\&[S[7<F[C"G2H=Q;
M67$2X[RFWDK/506D@@^O-92[+?.9'O?YSL.@T+?7HL6538PUK6Y"_@5='%7L
M7<3^"FCKEJ75<"W1+- >:C!Z//2\7U.+"$EM*1D#GGTMO+UU13W^9<_T3^JI
M/JCB;K'7$9N/J/5E\OT=LA2&;E<7I"$D>(2M1&?74:(R,5NH!,UO\<@GL%@J
M4F G^&+#M7TI[;VOY7"H=FK5\4*[VS/*E*2,C>V&(X<1_P!I!6GY:LWM::FL
M7";@?Q!XAV![_P!M<0H<"UL2D_\ 6!32D(6D^IE;BL^H5\G+QJB\ZA9CM76\
M7"YM1AAAN;*<>2T, 82%$[>0 Y>0I<-3WF[6Z+ G7>X38$7'N>+)E..-,X&T
M;$*)"<#ER Y<JT3=C@"(%WHDW[1BQ6\5?-9F\@:Z=F5EW_QL!3]BTT,$HSAF
MT821R/W;I5_:TU??N)W!+1>K.%.C-)<2T.-)+MOO^TKC@MI"@V5$)2M*T[5I
M)!Y#RKY"2-5WR79F[0_>KB_:6MNR Y+<5'1M.4X;*MHQX8'*LO2O$+56A2]\
M&]37C3_?'+HMD]V.'#TRH(4 ?EKQ^R"YHLX7#G.S!MYULC8WX+UM8 =,K >"
M^A5\X[:^TIQHX'VWC%HW2^A;2+D\_#3:Y)<5%!CN1$[_ $BAM&Z0CH>0&>6*
M\.U'V-=<<2^U%$UW!E6YC1LE5O=FW&7,2T;>F/M"P4'FK(1E.WEE?/'6OG3?
M]27?5<Y4V]W6=>9BAM,BX25R'"/+<LDXK:3.)NL;C8&+%*U9?)-D8*2U;GKD
M\N.C:<IPV58&" 1RY>%2-V9)$YLD+@TV(.1M8F^6>OK6!JFO!:\$B]QG_P!+
MZ3]L'EVPNS/R/[ZJ\/\ X[5>>OM?V7A[]DATX]?WVX,2Z:13:VI<@[4-/..K
M+>XGH%%&S/FH5\R9^M-172?#G3;_ '69-AJW1I,B<ZXZP<YRA142DY\B*Q+S
M?;EJ.4)5VN,NZR0@-AZ=(6^O:.B=RR3CF>7KK!FR+,:QS\@TMTYDFZR=67)<
M!J0? +N;M-]@;BGK[CWJ34FFT6^Z6._2A,$N5.#*HN4I2IMQ!!40G;R*0K(Q
MT-26QMEG[$Q=&SS*424Y Y'%W(_PKA5OC#KUFR"S-ZXU(BT!'=B"F[R R$8Q
MMV[\8]72M*G5=\19#9DWJXILYSFW"8X(QRK<?N6[;\;GTZ\ZFZ!4/CCCE>"&
M.:18<&WUSXK#I$;7.<QI\X$:\UWYV@E*3]C&X98W %JS ^L;%'_E65;U%/V)
M*4K;OQ&60DCD<77I7SYE:KO<ZSLVF3>KC(M3.T-0'I;BV&]OQ=K95M&/# Y4
M&K+XFQFRB]7(6<C!MPF.>YB-V[_-;MO7GTZ\Z#9C@QK,6DF/3\$Z4,1-OJX5
M]?\ B'J_4'$WA!HW5O"C16DN)K#S84[!O^TK82IM((:*B$I6E22E:"0>0\JX
MK[<W$7BC<],:+TMQ(T5IS1X"W+A;XUED*=<;0A/<[% **$)PL8"3]Z.E<P:5
MXB:KT*'AIO4UXT^EXY=3;)[L<.'S4$* )]9K7WW4=VU1/5.O5UG7B:H8,FX2
M5ON$?Z2R36%)LKHLH=<$ DC(WS]=OP7LU7O66S!/A[+K9<.-9.\.N(6F=4L-
M=^Y9;E'GAG\(&W HI^4 CY:^F?:8[/=K[=&C=+:^X;:DMYN46.IEHRU*[F0P
MLA99<*0HM.H5GD4GF2#CD:^5-;O2^M]1Z(DKD:<U!=+ ^Y\=RV37(Y7_ *6Q
M0S\M7*NC?-(R>%^%[>RX(/ J&&8,:8WB[2NG#V5-4]D&\:(XJ:^GVE5KMFJ+
M>VY MRW'W2@K*EN%12D#:E!.!DGU5>_;@[*NM.TOK72VM.'3UMOUGD6E,)2U
MST-H;3WBUI>2H\EH4'.>W)]'H:^=VI]>:FULXAS46H[O?EM_$-SGNR-OLWJ.
M/DK+TWQ3UIHVWK@6#5]^L<%>2J+;KD\PT2>IVI4 /S5 ZCJG/9/O!O&W&F5C
MZ[Y*031!ICPG">W.Z^E/:(U):M&73LS\)??!FY:EMNI;&[)#1RIMJ.$LAQ0Z
MI[Q2O1!YD!1\*J'[(JM?VW?"\95@1+>4C_\ .*NGYJX75=YZ[K[Z*GRE7/O0
M_P"[5/J+_> Y"^\SNW XYYS7ONNI;Q?9S,VYW:?<9K( :DS)3CKC8!R-JE$D
M8/,8/6L*?9>X>Q^.]@Z^6I=Q7LE5O&N%M2/P7<OV5M:AQ*X:C*@D0)) ]?NA
MK_D/T5=G; !^V![*Q(.?A&YU'KC5\K[WJ:\ZE>9=O%WGW9UD%+;DZ4X^I )R
M0DK)QSY\JL7@?Q%F'CYPTNFK-2RW[7:[[&D.2;O.<=;BMA0WJRM1VC &3ZA4
M1V:Z*&(8K[L/X:X@5F*H.>[+TBWU67;7;>['NNNT#QFL=YTF];Y-N-N9ML_W
M3+2VJWX<6KO"CJI*DK) 3DDI/+GFI3VF&=":^X]<">#^HI34]B,^]-N$9Q>-
MX$8HC,.$'(+JTGT>I '\H5S!VYN/)F\?6+WPSUX^(CMACQ7YNG+FMM*U)<>)
M0M3:AD@*!P>F:Y,E7*9.N#D^3+D2)[CG>KE.NJ4ZI><[BLG<5>O.:@I*">:&
M)TC[!K3;*Q!(MGW*2:H8Q[PUM[D7SRR7V,TO9>(^ENT:BU0=)Z0T?P<CH4W%
MD08[+<NXJ,<E+: E6X+"PI1&P (;/,YJ$\%!C[(KQYY']Z;>>G_PX]?,BY\5
M-:WJ5!DW#6-_G28((B/2+H^M<?*=I[LE>4Y!(..H.*PH^M]1P[K)NC&H;LQ<
MY20E^:U/=2^\!C 6L*W* P.1/@*];L9^%V)XNYN'(=H-SGF<EX:UMQ8'(WU[
M-%V+V*U+7V^=;E14I1-\SG))_P"E)ZULM#\7QPG^R5:V8E/=S9M27=5GE[CA
M*5K2V8ZS[' !GR<-</6_4=VM%S<N,"ZSH5Q<W;Y<:2MMY>XY5E:2%')YGGSK
MI'LK\.>%>NG?AYQ4XHM6>Y6F\=^[9KE)1WEQ;;2VXVXIQ9+A!7D' )(1C(JS
M54K(\<LINTLPV N;\U%%*YV%C<B#?5=)=KB);>ROV:=7Z8LCJ&KCQ$U+,>2&
MN2FX[R^\>2/4EI*6O_RE?,NNA>VWVC8W:)XKHDV93ITI96##MA=24%\E6YU\
MI/-.\A( //:A.<$XKGJK6RZ=\%.#+Z;LS\]RBJI&R2>9H,@E*4K;JFE*4HB4
MI2B)2E*(E*4HB4I2B)6;9V7I$X(8&YS8HX]0K"K=:1GLVV]!]_\ S8:6GEYD
M<JJ5;<5.]M[9%9-):00+K9R+P_WK++J<+) KH?AI#$/3Q<( .RN;IMWCS+VP
MIH>@%9YUT?I6>E>EMB",[/#V5^9O+&9T+F,#KBZV%2W%&T6M=>R5HGX2(6L)
M"B<G)%8VG8"K!"<96D)]SJ*UY'(O* ./7L;[L>UT^-2;A/J)N0)$&6 '6E[1
MD]036DN+B;A/FEK!C@NJ"L\EK4\<J^7 ^0#RKIJ3 *6(-Y+?T,8#0LZ#)6F*
M$.N92@!US/WQ(W*_.<5HE3D1=1VZ0MST9K+L%TN X;!RI'J&#GG[3Y5FN24Q
MVY8/I@AS=CQ2 D'%177CKT)AYM2D.>YH[4V,^A.2X@*!P1XG!/YJL$K;@*P4
MZF:LVIA'E*(@OJ2-P.0 <85M\/C=1X$5Y</KPJU:PU-8)&Y32Y)6A(/-#@Z[
M?:#R]OKJ"\3;B).EK-=&5X=<RE:TG/,MI"A[.21\@K-LEV$WB&].2H)5(APY
M&[/4EM)Z^W<*\NLE;NI]+V_6%M47DI4\@#[LV=IQ]ZH'JDCIGPZ<Q5/ZDTPI
MAP6G4"4J2Z=L6Z;?1=Y?$<'1*\?(15N(NA@W9/=*2E#J2^T@XVK!'IH\CSS@
M>JMM>=/V_4UD4VM'?0GAZ0QE<<^"A_*2#\H'LHE@N#.)/#Z3P^U%$N*$%,8N
M#TL9V9/G[!^CVUA7#WO?LUQ-O4WO8;<+L8+PME9'B/Y).,*Z'IR-=0:LT*N]
M6ZXZ+NXW27F5+MLQ7,%P<TC/D>5<N?!QFW7:4J<PN-*P8R]R2G*2,+0?#GC]
M%9@V4;AFKTX/W]NWZ<L4)]0]Q/,MKD*5TP0EM"$^(])8&?,<^E75:=+6R5#U
M%>6VFS++26F%$>FAM*O3'M)V9]GKKFSA\M4:,7VRATVSN8S25_>E"2$G(4,D
MJ7G!!Z9\*Z?L["K#I^%%66]TJW;$@+ZN'"L9(YG&.?FD^VA0*<1(PGZ(LK"D
MI4IR.ZQ@^.4DC])JP^$=L3-X>0^^23O>D!85C\*JH-:GFV;!:]JMRX[ARD<S
MN !4/SU:G"D,L:9[AH@M^[)>W \._61CY#6!S"FI[AY/9[E26M^!K=OU0F]-
M)48R'BIQG&<I]593_#>%?+?WT'O&"#T;40!Y5T9=X*)D$$I"L'GFH;%LB(MQ
M?92@I84 4XY8/E5-\8!71QU+BVW$*KH6I;S8%,6NZAB="(VH$T;DXQX*'-)_
M17M;MD6]LE%DF!B3S0(=P7OSSZ-O>/L4,U:3VB8TQIWO64K\/2&<U![MIA&F
M5.DQG)$!U6YQIKJG'B/.I(WRPFX.2AEC@J19PL55>LR(TAZURK8N4J/')EQF
MV_36E61M0#R)P#7"/%SA.S9$N7^Q,OL6F0ZK="=!)B\^1SY?JKZK772,;45J
MAOS&G);#8[R/. S(B$CES^_3SZ&J2U]P_7852&7[7'E6R2RX I.%I>2>N <
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M)),3M J4T.\WQ$UL]-.Y#;TQ0*CU[M"MJ4^TA.:Z=F1TL1$J6XEB,TD(3O4
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M(LLJ,I.]*T*(4GF/;5A:FF-PM+,VY4E+2DMA"T XW$C*OTFH RMEA:%' "5
MGV \ZKSBGJVY+U--"%KV(>5A*>>1X8^2M[L%Y.\)/);/9[0]QNJ^U[V:XDR_
M.7&V2T0PXK<H-+*,G.>8'(UKK5P?7;'R69"G@E'-2O$_)7Y/XC/SI_N%Z688
M2,'O/1*CZJF.DN*5JL]O<B7",6]@PE2/2W^OY:[;'B;9RV98T')4KK^/?K.M
MQR"RMQAL@$)5@J]8S6@L&LYTV7'BJ;N'>N*"4M+B[CGVBNB8.HK5=+O(2\TV
MJ'( VMNIY^OY*WB;)IV UO@Q&&5]1M'ZJ]\VRPW;CF"JWG:?D2M-MQ^X+DN2
M4CNPC8<9Z8\*V>G--IC1QWZMZTD GP]@]0J3N)6^[W:$!3CK12%J!^Y)W#TL
M^?45EKMC+$<,,G "=I/GRKGMH5+1_!;JJ%1+9N[&O%:H-1=BTD#(R#BM2]%:
M[W*59P<UO(T-AE"T%>X^ \36(IJ,S(*"OF>8)K5Q-8W.1RUK T:JS^RHGW/Q
MWTXXA.5;)2>74YC.5]$HL8):'H[2>9/KK@;LHQ&6N.FFR%))(E'_ /UG*[\,
MI+:U!(4X?("NVV.\.IC;F?8%A;,V7HNJVX<!YYQ6U#2=Q)]5?)/M37AI;=W@
M1$$-&0LY!YK6IS<H^OKBOI]Q0NTAG25Q7W2F4I;/I'QKY4<>[>X[>E/(.41V
MRM6X=3C=GU\Z5L@WS&'AFNCV;$3"]_/)8/9F4F-J2Q-.[%)DM.!2]N#TS@_(
M#746J>%&F+]'2M2!$=/I%3!"3GUXKCG@U<VH]YA3&G TJ.M0#(Y8RD\A[*N&
M]<9G(KBD;BIPX"4YZFM9*/XILNGI0-SB)4]L_#W3=AN:&HVYV0/34Z^LJ"$C
MQ)/("IE>H]JN"F@RMF=M0<LMJ2H[0,DXKGG55P?O.FE-NZF;L;LK!<2V\$K6
M <@8YFHE:38K=<69-SUDZWW/Q51WW$CU[@,9^6O PD$J4\+!=*:>TSHA^9[H
M9AL(<!R1T /LK=:XN$)NRO1X_=I'=G:$^'E7-.H-<0(<MJ;IF]L7)"L)<CH7
MZ>?,#K7G(XAS'7(_NHJ0UU6#R./*L2UULUZ"QW'15CK725_OEYF38UI7)AMN
M;VG"H#)^^P,^LU+-",)2AVV/M+;;>;(2E?)2".J3ZQGD?$8\JD=]XM1(ELD-
M08R ^&R0K^0.I/M\*@'#B[R9^M($YQPN07TN[>IZC!)]>14@>Y[+D6 6I=&U
MDF1N2ISPWN\C2%Z7+[OW/-@NA7?-\N\0.9!_3_Z-?5+A)KZ/KO1-KNS+B%]Z
MV O!Y!0Z_P#.OEUK*T.1VFY<,*^Z[D/*3_( \?S=:O7L8\59^E;7<+/,W/PV
MW@\AL'F6U  J3ZP14]/4B-V-QR*I5=,9686C,+Z&M/@]",>KG1UQ*4DD@"M!
M9;]&N5L;ELOI4VH;ACE^CSJM^+O&IC2\-<:$0_-6,)0D\AZS708FAN(G)<QA
M<3AMFK25?XB5$%U.0<=:5Q(YQ*NCSBG%7925*)40", FE5^E-Y*?HSE\[*LM
M/\$F_P"P\G_BZJK2K+3_  2;_L/)_P"+JK[E-]7O7S]G%1OBC_&9JW^MI7]\
MJHQ4GXH_QF:M_K:5_?*J,5)'Z#>Y8N](I2E*D6*4I2B)2E*(E*4HB4I2B)2E
M*(E*4HB4I2B)2E*(E*4HB4I2B)2E*(E*4HB4I2B)2E*(E*4HB4I2B)2E*(E*
M4HB4I2B)2E*(E*4HB4I2B)2E*(E*4HB4I2B)2E*(E8=W7LM[I]59E:^_';:W
M3[*UNTOZ*;[I]BM4O\]G>%?G9<AE=L2O'+KFNGF(V8VS&21@50W95@ :;97M
MZIKI2UH0J0EO;D\JX'&*>EWAX!?1*.$U$K8QQ6WT+IA32%.J'QNE:'BO>5:1
M>C2%(^Y%U )QTYU/_?Z)9HZ!O2D#D<FM/K9N!K.R!K8E[F#GUYKY[2SO%6)6
MZDKZ9607I71'2RZHX<OBXZ.A.IYA3*5#\U4QVF.&J5VA&KK1 0)EM6I5R3';
MPM^.K&75 ?&*".?J)JX^$B0WI* T.B64I_14BD,A$A04D*2H$%*AD$'J"/&N
MCJX6U ?$[0KY7!.ZFE$C>"^8&K]!L:SEQY$6Z2(S&0\N-'=VM2?Z#G\I!]52
MFW-R+#9VH5NB0[4E/>#$5I.05\E!+G-1R/S5>'&3LIS;;.]_>'+"7(ZEJ<F:
M?4[A0R<E44GD!U^YD^/(CI5;66\VNRPWS*(+R5J0IMU/ILK3R4A8^](/(BN(
MFBGI"(WZ<"NXIIX:L%[->(*HJ]Z9=LDQQQ()6!R6H8]>T#P%4)K?5(0I:''2
MMQ!(.3T)/2KVXX\5(,&(ZMA\EYPDH;'-1]@KDN5#FW62N5)0I*2HJ2@^'K-6
M:9I=Y\BIUCP'86&Y7T0^Q+PN^T]Q4NB\%QV;!CY]0;6K_&NRN($7O]/S$_RD
M$?HKC#[$Q>F6K;Q1L:W4)?0_"N"4*4 =A2MLGGX9Q787$#6-BB6R1$7=8QEJ
M94X&6U%:BG.,\O#/*NRHW!K6FZY-]Q*5\XIO"-4+7MPN>#AUY2CY=:W=VM(5
M'6G;X8JX;8;-=%..S9C+*'7%(07U]WN()R.?CR-0[4\.#&NHC1WDNH4>1"MP
MQ[:WX=$6.+2%(Q@+@&\5H;5;Q9=+/N*]'*2:UVAII<TM$?2!Z;CO/_\ *K_Y
M5L>),_WNTLXRUR)1T%1C@_)3)T';DO*VJ"GLY_URZ^/[:_IS(=,8_5;_ &\=
MW!%'\Z*5NS5.(.!S/ACG7@);B6%)4@I]=>U;3:"HH/3PKPW>Z&RGD/77'N+
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M2I1W@C)Y^-1PZ!:8(]SSY<7!YI R![,U<EX+4]4N[Z;1&5;5R"$Q([G>!H$
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M^*?=L+MU$ADLE7NH);V$Y*4IVG!)ZUY:'XANZDT3$>M+L)]L(VE2G5!PN=%
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M)2BL-N1Y*>Z)&%;2E?0C'+H,"I92JGTSVY]O^5GPK([$V>?]K\3[UJK=*U1
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K22B,TDX(P>83D<B16'2F_FZY\2F[9U1X+\2D)&  !Y"OVE*@4B4I2B+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2128727d1_ex99-2img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
M'0   @(# 0$!              <%!@,$" $""?_$ % 0  (" 0,$  0"!0H%
M P$ $P$" P0%!A$2  <3(0@4(C$501<C,E%6%AA"4V&2E)71TB125Y'4,W&!
M8@DE-$-&<B9S@K(U-D1CH;$XL\'_Q  = 0$!  ,!  ,!             0(#
M! 4&" D'_\0 1!$!  $# 0,)!08$ P8'      $"$2$#$E)3!!,5%C%1D:'A
M0:*CTM,%(F%Q@<$&%#+1(T+P!Q=SL;+Q,S548G*2PO_:  P# 0 "$0,1 #\
MF.CHZ.O[0_D@Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ
MZ.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ
MZ.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ
MZ.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ
MZ.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ Z.CHZ
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MZ/YSN._A^[_B8_\ 3ILR<QJ=QT]'26_G.X[^'[O^)C_TZ/YSN._A^[_B8_\
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MZ/YSN._A^[_B8_\ 3ILR<QJ=QT]'26_G.X[^'[O^)C_TZ/YSN._A^[_B8_\
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MZ/YSN._A^[_B8_\ 3ILR<QJ=QT]'26_G.X[^'[O^)C_TZ/YSN._A^[_B8_\
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MZ/YSN._A^[_B8_\ 3ILR<QJ=QT]'26_G.X[^'[O^)C_TZ/YSN._A^[_B8_\
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M_@O3W^4U_P#9UX.S^A#_ /@7I[_*:_\ LZ=9=/A3X^AT95O>3\!OF(?ZZ/\
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MOT$%HONOJS,ZATXV3J8=<'GLEE<9!%569;4!JO/XY79F*L'2NP9  5+ AC[
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M+B*1EYQ@G^BQ5-Q^>PZK^&[8:%PN.:IC=.X:M26SYS%#7CX"559 =OL"JEE
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M]%@LO\@R.\EYI:Q1IB&_6"-5M-Y#OLO( _4 69W+[HP]NIL'7;'M=LY>RU:
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MH85#$?#QG;^A;M?4&GHKF:KZ%3$8PV;44K5[Z3W'C$;@@(ZAZY64!=O6Q&Q
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MA0,K\R 5,G*7CXSLJ_<GIAZV['6(+^HL=AM$U+U;(4:M;3N3@EAA33DB<B[
M,P>/:5C8YPAFD8D-[ ):>7URV@]!XB_+I.S5L6;=7'1X&E)7,D,D\PB1>081
M[ L"=FV W_=U74^(*5LUCL"='Y+^4,U^Q0MTA9K\*1AB@G:5I2P5HS#81P5]
M[_3QY>NK>4+K5G9/46H,DU5='Q29=M1WKT^L9;4'ZZG/7M1P#]KRGQB:*(Q%
M=E$>Z[^NOJ_V^UOJ?+8W(Y'0TJ8O'XC#TKN%L9"J[945YYVGA'&0H4!>*11(
M563AQ;COMTPXOB.HUL>F6RVG<GB\'>QTV4Q%UFBE:_#&%;B(E;E&[JZ,BO\
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M9*XZSCS+5FCF"EMV4<GC4N0"X4$[[>F@>\-->SUW7S8J\L%*K8FGQ9X?,+)
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MX%G;GL6.[*N3%T+1[)87'M%%%D<M^%5LC%DZ>*:T#6IS)+Y1XAQY!2Q/TEB
M#LO$>NL='L+IC'Z:RV$B:]\EDZM>I.6L[OPA9V3B=O1W=MS^?KI:ZOCU%I-M
M18U-79N/&^/#WDL926RWFED>RMFNMF")I*ZN(HCN@(C;T  ^W5IUSJ^_!V9T
ME;-#.XJ3)M3AM&Q:GCL8]3&7)M2P1O-[9%C)4*2TB[L@)(BK,G97#TLY^+XS
M)Y?#Y&2S8L6)J5M5^96:<SM%(K(P*!V8KZ#*&8!AN=ZQF^Q&AL0]6/*9K*P5
M+=JQ3QU&;(;00RW)1-)%"O'[LZ$CD6(]@';UTKL'=[@YS0NH<O;SNJJV4P.G
MH;.-ACCEA$]J.Y?4-)$Z<I6:.*!61P>0(+#D0>I?4EG(YGN1AX\C;U'-G:NO
M(?\ [6+!-^'0XU?+\O* $\84IP8R\N1D9E)V'$5#6[S)I'.5X=/ZGU-:Q5>W
M4M26,;5F %VH%'F\J^-SP _I#B03]+;GK//V.PLLL\U7*9C'RME3FJKU+8!I
M6&C9)?#R0[)(KOS1N0/(D;';9?\ >'#Y6AK[6&H,-+FH<A'H=EJR4IIC&)A8
M< *@^DN![ VW][[?GU&9/(:PTQC_ .54=W5N:M2YS/TY<- Y*FDBW6KK%&8R
M$96AA*2[$G?;Z@0O44P/YM>F(L#!BJF2SM&NM&SC;,E?),);M:>625XYG();
M9Y9"K#9AR8<MB=]R7L#@([$5S'Y+,8;*1F-8\CC[@298UK15C'[0J49((B0R
MGZD##8@=)S1V5UCJ*U%ATSN?7!S:EQX6]5>VS-5DQ]AYT6Q819&C,L:;ML K
M'9>)V G=*97+0:OJXC6.>U36PU&U8J8.>/SJ<A*F0GC M2QIO(1"M8*'(5U9
MV/([D4-3%:$PFHM18O5"YK)YA<5+(E&"S8#0UYTC:K*Z[H'+$"0-NQ4DEMM]
MCUCR'9#!Y'5TF=>]E8FDRE?,R8^&YQJO<A1$25DX[DE(T!4MQ^D$ 'WTF)GU
MUEL3K?(OG=4T[>%P]B_C(*Y=$DMIDLEX]UXGRCQQ0)X_:E"OH[J>MW4&KLS7
M[ATEMYO4='.R:VJ4AC(EE3'-B6/ZOUQ\95U]EPW,R;H3L.(@:U[L)I>]IS"8
M:5KZUL-4FJTI8[926+F\;B0.!OY$>&-E8?8C\^MWMKI/!:>OZILXS,W<YDK=
MY$RUF_:$T@LQ01H%.RJ%/C\?TJ /?H#?I=][]2?(]R*N-O:AU+B,7)IFU9BA
MT[YB\MP6(EB)\2,W/ZB%4_2VY!W^W2_.:U=B]*V:F7@R^*S>6S$]BW?HM:KQ
M+:7&T_U>U:-G=GD:0HH*QEHG!)V"D'[C>RN'QF-7%1Y++RX:"W6MTL9-;#PT
M3!.)HTBW7D$Y*!Q9FV4!1L.BIV.TW3TWD<'&UWY*]AJN#FWL;O\ +P"01[';
MTWZU]V_/UZ]=*+2%S7.7Q-?5>1S&I$RT.9T_",;Q:*LT,]:@MP-!QV8$S3DD
M_P#IL"1QXGJW=DM86(L_F\=EK^5SCSVEC@SDOS1JV)&:PWA$$D2BK(B1CDJ;
MQ[&,\@6VZ#-EL7VRTOJ6G2/<&#2VIJL]C>),Y7AMRI:L&R\$D<F_)#))R4<>
M2\OI8;G?)I[L-HG-828X[,9;)866G?Q%6'\0Y05()IU,\40X^B)(=N3<F'$@
MDC;:P:KQ7S'>K05H4S+$E'*B6<0\E0D5>(9MM@3L=M_OL=OMTBVJ:\T-H'&Y
M/2MK/S9?('/Q28R2-Y:\2">>6)XX./TR*%)0CZI"=CRY* '2>LM'XW/6L/F;
MENU0L8&=[D-FI+P/$QLLJ.""&1D)W&V_H$$$=5+]!ND-2Z.TK5JVL@*&*QJ0
M8FY!9XRQH9*\\4P)7VX:O$P+#;[@J=^HCM=9S+=NM7W(]2V<] RRMC28+@EK
M,*_U*LEG]9+N^S#[A22H^VPI%.76]C$9'/R9O4R7\5'IMZ=+>00R-)%7^;\D
M?']:&YN'!WXD$CBP)Z!DW.SVF-)0+D9M19G&W7O2NN6DO@S_ #5QH(CLS(1N
MS11*J\>(Y$ ;$ 67MWVZ7MY^)5:N1FL8F9Q)7JR[;QR,SR3RL0 "\DLK,>("
M@!0 -NDW5L6]0:,(OWL_>UL,YB7S&-NK.(*3#*0DB&(J(UC4#TZ;\D')B?;=
M:5/N!J3,8;#8P9O/87)4-(9*/-9"UC;+)5R*2U$5I/H_62#]=MPW/%BXW&QZ
M!PX[MYIFAKIVAR%YLC%??4D>.>?E#!)-'+7D=!Q]*Y>0E2Q^KV-AZZ^*/8S"
MX;,KD\3E,UB)Y)'>X*5[@EX&S)8"S J=PKS2 %>+<6*DD=)NCJ[5]S$VFK?R
MFQN*CITX[,T<UB_*M?\ %)DM6JLDD8D?>#8J2GD5/84D*3-X9<[J;4&'Q5#4
M&J_Y$V<]:2MD&EFCLSU!C>;(T[J)/&+7()(Q#'CLK$;'H&1W,[<7]<:TT=?J
MY&WB:N*%YIKN/M"&Q&TL2HG$,K*P.S;A@0/1^X&VAD>W';K0V,_#,F_@I9ZE
M7TRE2S9=S9"O-(H4CZS*6GE=I-]]_J)&V_4&N:U</A[QD\UO+G(QW$J9/(0U
MR<BE!+QBFG5 FYE\"\N2J3[+*"=NJSIW$V]1]T=(78K^I<EIG'YNZ<1>NSV5
M9X#CU:02,P5I(Q8YHK2;\AR4%EVZ"_S:$T[C,RN FUKG#JW,Q*XLRW4ENS5(
M%<"(@Q%!"#+(3N@Y,Q.Y;J*Q7PXT8]2Y>&:Q>J:0^3Q5&MBZM\B*W!4C8".P
MI4D@';[,"X],2OKJ,[IX;/X_N7K#/Z;_ !DY(:3II&:CR2(!\Y,)C%"=XWF2
M'DZ+L3R(.Q+>X&67.9^_4Q6F=3:P;1ES/8^!<K(\PM -6N&Y&DTJ>3Q;I6^H
M^E=F"D$;"AL0=B,'7QE_%+D\W^#3,9*F.&0*PXV03"=9*Q #(R2*&3=F";;*
M OKJ0F[5P6;&'N2ZBSKY7&P6JRY$6T6>>&QQ+I)QC"D!DC9=E4J8U]_?=-ZO
MU-W!TGJ#/+0DS>1Q^E[DDX7Q/*,G%D$"58P>)+BM*SD[;\0J[[#J$;4^M,?K
M)L?5O:B>>G#DL7>2P]N=I/!CI3#9V,8@B\DL*21LC,[>3VQW*K ]#VQTQIG0
M>L*67N6;>-S<4]C.Y#(3@2SJ8!%([-&JJNT4:C=5'[.YW.Y,/2[7:0T^*.I+
M^H<GD9+-[&6(LEDKP?S3('AJ* J!0&^9(XJ "2#]]R5#K"#-4- MC-0:AUK9
M-W1#W*+P+/+)>RLL4GS$4HCC(W4>'A P"@/(=B02K+U-CM22Z)TG#+%4?"I=
MTZ5@@@F-R-EMU#(7]E>*@.3Z&P'L^CT1.YKX>=.9F7+.F0S6..76W%DA0O\
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MM3E]2UM5S9K.4AD<]IO\ DDI47CAAV:R1*%>5B?5@ J6^ZGV-]A<)EO7.\>
MP%C,)ELJLQJW98%AQN/M32P1QPPR2-*J*Q(02AFE " .@WWWWWY>\.CHL:]]
M\Y M-+QQS3%7XB<1>8C?;]GQ?K.?[/#ZM]NEWJ#X9OQ/55G4$5[#7K=B6<-5
MSN&^=K"&6.LNP3RJ1(K5N0;?8ARI7T#UOZL^&K&ZJRF;>?)FGA<CA#COPVM5
M5$@MF$5_G$]\=Q J1"/CMLOW][=,&5K3OAH]Z$MD7K:RQV(JGR$F-M+=>612
M\2I6,8E;FBLP(4CBK'?96VV.T>OF[E:4FS92)(OQ._4A,2NH:*"U)"C%7]AB
MJ D$#8[^AU3<;V+R6)@QF0Q]O3&)U+C<@+L5C%Z?->K.I@D@=)HA.78E97(8
M..!V !&_*W]L]"9?06-^0MYJOEX9;-^]9E%$P223V+33@KM(0JJ'=2NQ).QW
M&Q!#6O\ =44NZE32WR'/&R**TV5\I AO/&TT-<KMM]4,;MRW]%HQL>?6"#XA
M] V8)ITS<@JQ5YK?S#T+*Q/'#((YRCF,!_$Q <*25'L[#<]5Z_\ #/C<DM_+
MS92S_+6QF/QN+-++.(8ITF5H!\KY?&RI$D<)!&[*I^Q/K+;[.T].Z4T^F3LV
M,OCL!4R<-FG1H22RW8[8965(T+-N Q&P#$_V=,&3/I:FQF0RN5QU>UY+6*,8
MN*58+"73R*"Q'$G@0Q )V##?;<=4Y?B"T%^'7\A)FWKT*=0Y!K5BE8BCEJAU
M0SPLR 31!F4%X^0')3]F!.#LYV]NX7M3'C=3O)8S66B>;+2,0)&>1!&$)&XY
M)$L<>X)&Z;CJLWOAXS&=TU#ALMJJO8AQN(;"8J2#&&-DA:2!FDG_ %I$DA6M
M&OTA%_:.WL  SYNX&(ATQ6SVV1DHVB%ACBQEIK+DD[ 5Q'Y1]B?:CU[^W26S
MFL<+D^Z^F<IC%?/T+KXZY3ENY"VT%>2Q/-5>2.JS!(Y%6,@;H"K,_H$GIK=T
M] 7=?XS&5J>2AIK4O+:FJW89)JMV,(Z^*9$DC9E!<./JVY1KN"/75"TO\,[Z
M:_DW_P#E#',N'^6])0$2R^&[8M>E#[(#Y^.PWVX[^]]@%TUEJO1NAM65<QF)
M;"9TXV6-13KV+3QTED1Y)'CA5N$88+O(P _+?K7T%W/GUYW"U;C:B1C 845X
M89_E9PUJ22%)O*LQVC,?&0!57<D /OQ8=9M8]O,QE-3-G]-YZMB+UO%G$7/G
M:)MQM#S9XY(P)$XR(9)-MRRL&]CT.MOMKVP@[:C*0U+CV:=GY-((Y$V>)*].
M&LH9M_J)$(;?8?M;;=!1XOB<QDVHZ%9L9DJ6.DL9>I-Y\9:>U)+3>-08(D0L
MX(9V8!25X['8[]7:SWJT;57&2',>6MD*]>W%;@KS2P1PSGC!)-*JE85<^E,A
M7<[_ +CU$Z7[/W<!KU<Y+FH;5"O<RMJK56F4E47I(I75Y.9#<'1MB%&ZL ?8
MW-4POPO183)XBQ\Q@LPD6/H4+OXS@Q9<_*\@LE<F4>(LK;$,' *JP][@L&5T
MUWW-L::[BZ1TS7C2&#)Q6KUW(6JD\D,-> )R4.FR(QY[EW;B@7V#R7H7X@]!
MKB+N3GS,M.E3A@LO+<H68.<$T@BBFC5XP98V=E4.@(]CW['4AKOMC7U[EJLU
MVV\5%<3DL3/7C7ZY$MK$K,K[_25$1_([\O[/=-O=B\UJ:M"V?U54NVZ5>I1I
M34\:84$,-VO9D:53*W*20U8UW4JJ[$A?>W3 N</>/2+I6+Y1ZKV,A6Q<<-NI
M/!+\U8B$L$11T#*61@?J V]@[$$=?-;O-I*W?Q]2*_8;Y^?Y6O9-"R*SS<W1
M8_.8_&&9HW"@L.6PVWY+O7=?]BCK;564SM?.'&O;Q/R]>):WD$&01B:]_?D.
M31J2O'UN/Z0ZKP^&2Q'J'"6EU!6EQ^)M8RW72SCWELP_*",/#%(9N$<<K(TA
M(3ESD?=F!V#!E8[7Q*:'FP5N]B<G/D72&Q)$(L9;96\*_K'.T?\ Z2-LKR?L
MJWTDAO76_D.Y=^GV &O%JUCDCIZ/+_+$MX?(T"R%?OOQW.WWWVZK6-^'[+Z;
MP^,KX+5%:K<CPUC!7+-K&&99(9)6E22-1*O"1&=ON65@WL>AU-W>P^(L=LFT
M\HI0YPZ>CP#:A^3'F*+"L7(^]]CQ!X\O[-^F#*P/W;TM'J@:?;(N+_S0H&05
M9C66T4YBN;''Q"4J=^!;E]AMN=NJMJWXA\!5T=J/(:;LC(Y/'XRQD:26JMB*
MO>2$A7:&1E59D5B 3&Q^X/V(/663LO?DRL]0YZ+^2,^=_E$^/^2/S?S'D$QB
M$_DX^(S#R?L<ONO+;V("_P##EE,UI*/362U3!8QF,P=G!8=H\:4EBBFC6+G8
M(EVE98D"#@(P=RQ][;,"V9OOAIC$638EU!3KXBBUQ,C-)5G<%JZ(9?%*HX$1
MEP'(Y>]U],K ;R][M'FA<L_B%D/5N1T'I-C[(N-/(O.-$KF/ROS3ZE*J05!.
M^RDBC9/X:K%O P8"'4@CP>.AN5,3#+2YRU:TZQ[0NX<>01M&W%B Q5@&)*EF
MW^Y&@;.)U+/K:EE+$60&0I6:L<&$FR2QF.M8KNLD4+>1D=+#_4NQ0A3[]CI@
M7W$=S=,YS2-_4]3**<%1-A;5R>*2$0F!F68,KJ&'!E8'U^74'6[V8>WK+$Z?
MCQN=C?(4K-T6;6(M5TB$+QJ0XDC!4'R;\CZ]#\V7>)[1:2S8[2Y>KEDCCRF;
MO92\$R] %>%FQ*\?GK!_0*,I:+GN >).X/47A.P>;PL57Y36/RDR5<ECV%>M
M(12KVUA*+39YF>(PO KKS+CZV "CCQ8$WE/B)TS3L8R"K6S-ZQ<R4&.>NN)M
M130>:.1XY6C>,-XV$;<2!LVS;?LMM)93OSH?"2WQ?S+58J2RM)9DJ3^!_$ZI
M,(I>'"4QLP#",L5][_8[4#!?#5D\!8;*1:@Q,&62UC+:>#$R+6+U/F58R!K#
M2.95LMNQ?=64?<>NOJM\+,-.CE\;7M8..I/+++3R'X(/Q.+R6A.5DL>79P/K
M3<*I(*[D\3R8,K[C._&BLOFXL1#D[$>0>Z<<T-G'V8/#:X\E@E+Q@1NZCDBN
M0778KN"-R?OUH:K7R5BQFFKU*%=[<EJ:I.D4D"2+$\L+E-ID5W56:,L!R&_H
MCK!DNT+W\MDKOXJ$%O4U'4/C-??B*\,,?BWY>^7AWY?ER^QVZI6!^%V/!:3R
M&G(;>#CKFJM*GDX,$(\AXA/'+M8F$NTAVC53Q5.1 8^QMTP97&7O]IML_A<3
M2@RUZSD,G)BY43&64>E(M=IP98VC#*K(%*G;8JQ;?BK$6O2&NL/KJO-8PTMF
MS5C*\;,E2:&&=3OL\+NH65#L?J0D?V^QU4LQVBOV.X/\K,?FH*]H92M?6O9I
MM*AC2G+4DC)$BG=EF+*P_991N&&_6YVK[97>W]W.6+&2JO!D7C=,9BZTE:C7
M=2Y>5(GEDX/)S'((53Z%/'<DD-"G\0&D<?B<:V8ST4MN?'U\C-/1Q]KY=*\S
MND<[;JQAB+(PY2$!=O9'7UW9S&'FU+H_3&4CU('SEB>**? V;==$"Q%F$KP$
M;J?7W/T^V] $]16/^'V2CHG-8#\=5SD=+5M-_,?*$<#$;/Z[CS][_,?L[^N/
MW._JZ:MT1;SFH-(YBAD(:=G W'E>.Q7,J6(9(6BD3TRE6V;=6W(!'M2#T"X[
M>=]M.V>V&#KTIZ.GLE'CJ[Q5#CK7R*1">.NR0, /*$9TC/!CP9E+>NFMIW76
M(U7>OU<9)9L?)2/%)8-.9*[NDC1N(YF4)(5=65N#'8@[]+F[\.[V]*:.PPSR
MI_)^@](S?*']?RL59N0'/Z?_ +FVVW/[>_Y;&Q:)[97M*:XU%J";*54J9/F?
MPO&5I*]=G,I?YB56E=3/Q/%G0(&]E@21Q&66UWWT12R5RE-EY8Y*=F>E/,U*
MQX$L0QF22 R\.'DX*S!.6[ >@>L<??\ T-+BZ>2CRMEZ%N,V$L#&VN"0!@OS
M$GZO]7 2?4K[(WLAB 2%S7[+ZCU]4U9B\KE$Q6G9M39+(UZLF-;YAW(98'$O
MD :'FWE])R;;B& ZL.;^'6+(YO#9)9<)D#7PU3"7(<[AA=1XX&8K)#^L7QN?
M)("#R4[KN/I]L&5P_31I-J-RZEVW+4KV%J)/'CK+):F:1HQ'6(CVL'FK+M%R
M]C]WOJ5SW<+ Z6T>-49>Y)C<+M"6GLUI4=/*ZH@:,KS4EG4;%=P3[VZ6LG8+
M(<-3<LC@35R\D3#$'%SKCE996<V#$+.Z66Y*/)$R#= VQ)]6N]VNM7^V&&TE
M;U%8OVZ,U"9\M=0R2V#6LQSGD"V^[>/CN6)&X)+'?<98;_?733T;8QMJ>3("
MI/+52W0LP123QUVG-<NZ*HE"*2T6X=0&W *G;/I/O1@<VF"I6[9KYC(P0!U2
MM-\JMJ2N)S7$Y7Q^3B2PC+<MORZK%7X=8J.HM1VXI<))5RT]^Y'9L84/DZTU
MM'#A;/D *!I7(^@-Q/#?;WUJ:3^&=-*9>6:*YAYX9=[ OR88'*5K)K+"7@LF
M0A%#+Y%W0LNY7<C;9@RN@[ZZ/VD4VL@MI6B2.B^)N+:L>02-&T,!B\DJL(I2
M&12-HV]C;J0M=V=+TLU3Q<]^:.U9," M3G$4+S[>&.:3APAD?<<4D*L20-MR
M-U)C_A9R5*M;:;,X&]<M4ZE.62;#V%+- \SBUY!:\OS),H;R!_14@??JQ8?X
M=SA]:0YN:]BM0>8TIKMK/8=;.0:Q7@CA\L4XD 0N(8V.Z-Q;D5/U>F#*\ZV[
MLZ7[>64KYW(2U9FJ2WRD52>?A6C9%EF;QHW%$,BEF.P .Y];]:='O;I+*5+M
MBC;NWC4>%'KU<7:DG<2JS1/'$L?.2-U5BLB@H0I]^CU[K7MDVKLQ?O#(BJ+6
MG+V!\9@Y\389&\N_(;\>'[/Y[_<=5/4_8*]F,G5N5=00(D5;'59\?=IR25;B
M5DLJ1,J3(S FP'5=]@T0W# ^F!<:_>?1MS$7,G#F5DI5:E:[)(()=_%89DA*
MKQW8LZ,G$ L&4J0"-NL>I>[N)TGKB+3V1K9"-3B+.8ER,=262M##"RAN3*I
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M<\0[*3MU.Z[[K5]!:VP&*OQ2-0R5"]9)JU)[5DO U<!4CB5F(XRNS>O7$?\
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M7A>1/UP\TH7]66]NH'[2[S6/[K:?R>4JXZ Y/YZ>,2M!)B;:-65F=5-CE&/
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M:&--E7<L[_8$ $D;*6OWVUUJ+1DVI,=/@J,.-T;5U/9KR57G%J8RVEDB5Q*
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M2-\NU.9%6,?KAS6595Y$[%2IX[\O3T%+1[ZS$HKX1M5U:XV?A";T4.VP]_\
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MNKPSJ5(!XSN0=R0UNLOJ+N)KS5.+J:IO:3Q&GI(*:KB(:[V;4\E=)VD=YXY
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ME XL^+GKKL=O?ZR11_[;GK%VO[23Z"U+I^U!C:..J5](U<1<%,JI>S%(I&X
M', <]G/_ #']_5;K=],A2S&;R;UFC6[7Q#TL%G;34WK/-6FDD3BL4DADW104
M5&/YG8 GKY/Q+Y)+!SAPD+:5L:=Q>1J5_._SIMW+,D$<;*L1]>0*IV)V"E@&
M)XAE5.Q?;K4VL,+>?36G,#CKE#4FH<A#G[4L;FZ[378!6DBX%OK,@#\R4XQK
MZ;?82^A_A_SC]QL=F\_A*KX>+(G(+6R-JO9EC?\ #A75RD421<PZC8(NP 4[
M[CU>]/\ ?#*:@>EC,5HJ09V>:V[U[-EZE4UX/"7L12RP*\@9K$2J#$N[<]R
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M20Q*[&X:4[T2Y_*5\7<P38[)!<JMN-+8FCAEI2P(RHW <U<6%96(4C;8KO\
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MZM-;D-F>K#D9A3EF90K3& -XRY4#<[>R.7[7OJL=Q.U5'5&N6U)G+\E/3]3
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M]=+OMM\/^B\AVVTZ)+D^9L5\=5K092GF+,BU)("I8TG+ PKYH]_I WX@$;
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MEX#DS*S[D^R-@N*W\/N=FFI5CG<+>P>+DRST<?D,3)()EN\SPLD3#F$,CK]
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M NXWVW&]>E[/9[4&<ASVHL]0GRT=S&/MCZ#PP?+TYI9@H5Y6;F[S.2V^R@*
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M_P!E/VW/N%[&9.MIZQ0R.<J6++Z/_DDL]>FT:\5,@CF*F0G?BZ\E!VW!V(!
M# NEONWI.CJ9,#+EA^(/-#6)2"5X$FE4-%$\X4Q)(X*E49@QY+L/J&].R_Q*
MZ5AIY;*XK('-8[$XV[<LUJM"T;$SP/&C")R@0JC,5?[\21OL W1%V1RU>>?&
MQYZH-,7LG3S%VLU%OFC8@\!*1R^3BL;O6C8\E+*"P!]@KK0_#O-_)9,-+GD
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MX7>I7@2U%#]@/I'(+[V_=[Z\O1Z'RWGU#=3 7? %J392?P/XPDBNL;2G[<9
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M56F*C8.A/+=O8/O^WK)FL3H)Z3:RR6.P$T%)6R/XW+7AD\855+3"78_E&GU
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M.)4:4F54,8*'DA8N%.WWZ:$FE]!5LS+,^(T[%ELHS"21JU<3VS*A#;G;DY=
MP/WY#?[CKV_7TWJ!*,*X;%Y['99#CY9E%:6+P1J[A&#']8@92 BAMBQ.P )
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MBNO-. &S@@@^C:J^*[8Z?U^,U;OZ>LY',7(:V(62.NQI2UJO$QPN-^&R)O\
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M&O(  _TN.QN6A^VFBNVVB422'#3P3U!5N9BQ6@C^?B=CLLK_ &=3RVV)(/\
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MZ6+>0>E WZ"M2?#IDL=I*"EB,%C:5XX[5%&P8)$CYI<:0U(RP'M-O'Z/I H
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MI'$]7\+>LJ[+'YY)0Y17+OPV4%00 %O^:[;9NYV*T9I_Y2M>R.%AQ4E[#SS
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MI(UX@R#>11(/IX>^)DZA\)WGS5?-4HXJ,$NFQB\UD+-G+Y9$L+)6O^$#FR!
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M\G[DD]<R9O):FQ';K*WZ5O6U/*0Z4LMJ2;(R64,>4Y0>,U3+^K$G+YC;Y?\
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M2ETG:M5*%!KBV5O'(6!7,JQG=9./C"^3]7L"&] =$/#'?#OH>.-X(7R=GY2
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M4U4D&%2TE[$I)C%>:C*EM;2*[^0":-74KQXJW$[%B1OUF;LKD*.:ESV'U/\
M(9Y[]RUYIL>L]<Q68ZZRPM%S4D<JL3JP<$$;'<$@ADK?$-H1'KUZ=FU)25:8
M>S7QLWRU2.S]-<ROQVB!8<-FVXD$,%V.T_K3N3%I#MGF=8_A&2MQXZM-8_#S
M7:*P_C)&Q5ANH.V_(C]GZO8ZJ%#X=JF*TIJ#"PYJS*F72EY)I(5YAX'YN_H@
M$R.6)] +RV'H=6G):?LZU[9W-+ZFR%:MF,OC9*EQZ'':&25&W\:L??'WMO\
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MR'TF5=OSVJ*/ION?J?\ E[I"EJ?*8Z*'*4ZT:U]/-7MP2W'KRRR"5BWFC4A
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MHQ(]#Z3^[J)PW=/1^IJ-'/P7<*=.V<;'D1E;-R&-HPLH5%=&]J%9S]1/TO\
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M#[;?G^75,UAV'UU>TG:TYBY,:N,M5LU"L$=]J:P2VKDTT+N4A9I(_&\8,2E
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MOM(3Q.Y'3$U]W2NZ-UIA<0<=5AQMZ/FV5R4\D,,DG(J*T3+&R^8@ A9&3ER
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M]">G>FKM!$,0;9:=>(61-MR0Q(#-O]HU)90Q=*?B><T;-!EJ28Z^_GJ2,L?
M3E28OF/&0"JR<>:J=R%9??2<QW8+4-S06I<=E*&%CS-K26.TY4D2P9E\E7SC
MR%S&"BL7C<  D'^U0>LLW?+*:QC%!:PQ,T.4P%N&[C9K/AM5+.1$3(&EAB+C
M:-@60,CJ_H_<=-+5VM\O3U=C=+Z<QE2_EK52;(S2Y*T]>O!7C=(S[1'9G9I
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M')5V #>&1=B>09>+!21O5M0]^^VN<EP'XO4DMP"6KD89+4406GY9#'5G>-I
MQ#GZUX*Y52KL%]'K?S/8VGJBME<;GM:9'(:EO5:Z09)16@MU*\$Q=6BC1 -R
M[L&D(._+;T-AU,MV0Q]'64.<PF0DPL30U:]K'QU*\\4J5QQAX-(C-$0GT$H?
M:@?8CETP,_<W7]_1.I-$UZ=.QDH,K=LUIZ5*N)9YN-261 A9E5?J0$LQ V'L
MC?J&A[]8*:<Y(6,E\E^&QN,0<9_Q'S377J"$>^7G\RF+Q[<=QORV]]6/N)I"
M+5>9TR]?4TNG,[C9K%RAX!#(T^\#0R Q2 \T"S G;[$K['55K]@]/[RT(-1W
MVRM>I S3K+"UJ*Q\])=2XPX[!FG,AXE>! *@;;CH)2OW[Q-G,082/!9P:C>>
M2&;"O6B6S7"+&S2-O+P9.,T;#QNY()V!XMM%6OB'PNE6S4=^+-9<8Z2];M3T
M\6O"E4@MM!(S;/NRQE3[ +LH+!3[ ,Y\.D6IJTB9;4MRY8NVUN9*T:5999I$
M6-(3 P3>LT:1\5:/ZOK8DDD$;.0[)8&NVH(;6=L5GU37OXP+(T2GE:GFLL(@
M1]3KS?8>_I3<@[$],&6RO>;'YJ]3HPIE<!D$S=7'S4K^/7R2K-"\L1_;(6.1
M4)Y@EE*E2H.X$9H;OW7? :!CU)7M+D=1U:8_$8H(TJ-9G4E$"\^?LC;=495+
M %AUOU-$:4U?K$YS&:HBR%I+='(-!1LPS*#46>NH/'<\2TD@8_\ ,FPVV(ZA
M,+\*^*P>1Q$\.?OO!CY\=:$<E:LTDDM145 9O'Y%B81J3&I"ABS#;D06 PNV
MG<RAW3P;YC%X_)U,;Y#'#/D:PA%C;TS1CD25# KN=MR/6XV/5-B^)_2PP!S=
MK&9W'XM\5/F*EBU0"_.00\?-XE#DEE#*>+!>0.Z\@">KMH73V,[;:<PFDHLD
M)I(8I%K"TZ+/.JL6<A1MOQYC?8>@1O\ ?I3:)^&^WD^V6)Q>KLYE/FX<%)BX
M*16OMC?/P\W%D7]:VR*BEB0J[CV23T%SL_$#AZ0E:S@=0P14HHYLK(]!=L3'
M(Q"-9'/<;J/(50.RH0S!0>H+7_Q"1X3)XD8NAD3AXLY-0OY5J0:K.D%:S)8B
MA;EOS5X./(J%+(R@D[]6;5W9>OJC,Y>S'G,AC,=GHXHLWC:RQ-'>6->(V9E+
M1%DVC8H?:@?8CEU!:D[$XGA--EM67JFD*F0M9HXN8UXJT#3Q3K8Y3%0XC_XB
M5QNWTD_<@  +)G.]F P-N&D]?(6LA9I5+M6G5K!Y;/S+R)%%&.0'/]5(3N0J
MJI8L "1#93OVFGM2Y*KF=,97%8G'X!,Y8O3K$SP[R2)XV1)&.^\>P(W&Y^X4
M<NH[&_#Y'=-3-'7>5RF3AI48L5EEBJ[5TKF9HG553A)S2Q(K\MPX;<<?6UGO
M]JK]S*)EEU7;BRTF&;#VY_DJSQV%YLZ2&-D*J59W'$?2P;8CT#TP93\>MHUT
M3<U+:Q&1HPU:TUIZ4T<;62D8+'B$=D;D%W79MCN.JAG/B!TO7J9Z"K/=:U0A
MIMS@IB3D;<320M&&8!^*J68;C8#W]^I[MUHG#]M,)'I:#()8FL/8O?*R>.+=
M7<&7Q0+L$B5G4<5'%>0_,^Z=C?A?P6,HX6M'E\DYQE?(U_)(8RTXM*R(9/I]
MF%&*Q[?8???H*_D_B*RT&0K4:N'NRUJU[!PMDS6C8Y".Y'R8)$KDH[;C;\A]
M6Y '3AT3KS'ZWP=C(P06<<U6Q-4N5,C&(IJLT3;.D@#%?7H[JQ!!!!(/5/B[
M T:^?Q]^+-WTKUOPR1Z92(K++14I%)RX\EY(=F4';T"-COO<].:(IZ=BST0E
MDMQ9C(3WYDG"[*90H9!L/V=E_/W[Z"E#O'-J')Z+EPV-R%/"YC+_ "ZW\C55
M(\A6-2U*LD YEP"848%U4E2-AL>JUF=8Z%[CZVP\.2PD];4%+(TJX@RE&*=F
MCD,[Q;JLK*@YP.=W'-&4?0-P>IW%=J<;_)G&)-KBSDM+X%I&Q\G.N@JP)6L5
M61K" %N"2L.9/)3$-SOR)U-$_#7BM.W</DX]0V;YHBD:_BJU8(GCK^<Q[B*-
M0Q86&+/[+; C8>N@^JOQ1Z;?'+;AT[J?Y:3&'.QLN+4"2B&_761]?V0D<E.S
MGD"JN#OU>L%W+QVIM69+"8RE=MKC^*V<DD:"LDC1)*J;E^>Y212#PXGV VX(
MZ@*?8C&4L%5Q:Y.ZT4&EY]+B0B/D89.&\I];<QP&WY>_MU'+I#2VENY$>H\M
MK.G!<PE!*Z5)WJ57KUY56%!/( ))(V924$AVYL=MR!L&AW%[YY33MO6]"K@[
M-1-/'$NN3:-)X["V;*)(JQJW,L4+!?I]D'?;8;SMWO\ 8G'83*9"Q@,[#+BK
M;U+]*6O#'-5*PK,'8M*(RK1NK+Q<EM]@.0(&YJ;LW6U+J#,Y YBY5KY>*@MJ
MG&D;(9*E@312*Q')3L"C#?8@[^B-^HC6OP[X_6&J;V>_&KE*W==_*@K5[$:H
M]:&!O&LJ,$DV@0B0?4.3CVK$=,&4SHKNRNN-<9G#U,-9&(J4*-^KF24\5E+"
M,Z_3RYKN -MU_)M]O6^&/N5IC"YK5MR'%VX:%!Y)<WJ..LHJ">"%0R,W+G(Z
MHB)]",-P%WY @;FB.U$.A,S%<H9:W)6_!J>(GISI&RRFJI2*;EMR5N+," >)
M]'8;=:EKLM6M/J:BV:N_R7U#\Q)=PGCBXK-.-I)(IN/D3=OKVW(#$D>O708)
M._F(IP3KD,#J#%Y".6E&N,M45%F5;<OA@=%5R"IDW4[D%"#R"]5C3>O^WN6U
MVF<&CLIC\_--=J')9#'A1%=KQ,;%<-S8++XHF^M!P95($A]CJSP]D_F[J9'.
M:FR.<RR6*$BW)H8(B(JDYGCBX1H%^IR2[?<^MN( '67(]GZT-62:K;LSVH<K
MD<W#"P0+)-9KSQ&(G8?0/.=OSW W/WZ8$4GQ.Z43%UKUZEF,1%?I0WL6N2JI
M <G'*R(HAY/L&#21@B0IL'#'Z?JZUH_B;PUK)XAZV,MM@9:F3L9/)L\/'&-2
M:,2K)QD(8*'W+(6!!3CRW.T#H_X=X]5: TI9SVJ+V0RN,Q-*'%3H*DJ8N2,1
M,W'BACG)>,(S/R#*NPV)+&YY_L16U3A\71R><M2^"I>Q]QH:M>%;E6VJB:+@
MB 1[>.,JZ?4.'LMN=V#*;[<=W<'W/DR<.-6>O;QPA>Q5LF)G6.4,8GWC=UV;
M@XVWY J0P'6G/WUTO4RM3'V6MUK-BWD:7ZROZB>DA>8N02%4J 5/]+DO[^IG
MM_HJSHS'V*]O-29N65E(FDI5JI"A=AN(44,3]R3^9] #UU4-9?#Q@]5W=77K
M64OU'SYIO(860"IX-O(8MQZ\R*%D)WW ];=,"L6_B*M_+5_PC%Y')KE&RC)9
MLUH:YQOR]9941T\GU@<P2WW(W];C;J\=H^[T&OZ>/HVZ5^AFGP]3*DW*@ACN
M12J 9H=F/T\P058*PW7UL0>H<]F<%J^A%E,'JB9Z]K(7\A'<H&">&6*W%X9H
M5.Q4KL!Q8'<%?N?8ZN.GNVU/3V;QF2AN6)9*&#BP2)(%V:-&#"0[#?D>/_M_
M9T&AJOO-AM&:HKX7*TLA ;&ZPW?''X99!"\O!09 Y)6-AR"<.7TE@>HG$_$7
MIS*)5>3&YK'17(Z%FL]ZD(Q-6MRK%%8'UDA!(R*W+9EY*2NQ!ZBM5]@,'>UC
M8S=[4T]!<IE([<=:2.L&>U\NT B69T\C(4W98@VP8$CUZZV-==I$JZ2D3&U;
MV?OKII=,5:JO#&/NICLN[%>)1U5B1OL!N%)V'3!E?\9KS$9/%9S)\WJXW#V;
M-:S;LIPCWK^IG4[G=%8.I/KVC?N]JS7WQ$31:.MM@<!FZ.=LQU),>N0QT8,M
M:>S' ;4:-,H;@94_5N58-)'R4*20RM.]O:>+[;5M(7W.2K-0:E>E<E6MM(I$
M\C$>P9&9V.WYMU4X^P<=J%5R^J,KFIJT5:I2GL1P(U>O#:AL<#P0!V=J\0=V
M]D*-@IW)8$QK+5^8P$.EL%B8ZUG4^<D,$=C*(5@@$4)DFGE2(_40%V$:L-V<
M#DJ[D1.N]3-HOM_97N+6CU14G\IM2X3'_*UXZZ /]:S62>0V) 5RS;?2OH]6
MW7>@X=:UZ$D>1MX7+XV<VL?E*' RUY"C(WTNK(Z,K%61@00?R(!%!UAV+BUI
M-BH,[KB[:S8I7JIEFJ4N<M>;QB0PQ&/C&R;1@2*"PYD$GD-@T\9W-TCIG+5=
M(:0QN0QE2+*5$GMT\6KU+$EJ)+"1F5W!+RI(I+^V&WO;UOCTMW\PNG^W5?56
M3T=DM-TLC:MV[C1) T<9$W&2=V\HY$_<JH9SQ8A2 ";70[%8S'R1.N3N,8\I
MC\J P3]NI4CK(OV_998@Q_/<G;UU3\I\)>/R56>HVJ<DM.2I:QR(]2K*\%66
M5Y0D3O&2C*TC@R#9F7B&]JK!@ROB]RK&ILIE\1I;%SVK.+O1TK.0N(BTT998
MQ.O_ *@D++&[,-U 8CT2.I76_<.GH>SAJLV.R.5OYB>2M3JXRN)7D=(FE(/)
ME51Q1OJ8@;_<CJ-P_:F'']RK6LK&3EM77KR4X8DJPP!87,9X2O&H:?AXU"&0
MGB"VWW)ZTNZNC<[JK5.A;.$NSXK\-O6IY\C L4G@5J<L:\HY-PZLS@; ;^P=
MQMOT&C%\2>E)+%9/ELND;8Z;*79WHE8\;##)+%-\R2WT,DD#H5 8EMN/(;D;
M?Z>L-7K7!?PN=Q.3B6LU?$7:2K;NBPYCA\*ARI+."I#,I38\PH]]8<7\/6!H
MT\C4L7;^1@R6&EQ%WYAU#S^6Q-8FG+*HVD:2Q(?6RCUL!MUJ9#LS7M3(^<UM
M?MZJL/7CQ.4G2M%-":S-.@CB"!)6)YM)N#R7?]D#TP9?/;?O=_*#/ZNQN7J7
M*5BC<NRUJTU01O#5KPU.:2;,07YV"002&4@@[;;RN+[Y8[4M62S@,#FLU7CH
MI<ELP5XTA@=ZXL)7=GD7]:4:/<*&"EU#$;]5^;L%!CKTUP:\RE+.9FU<2>ZZ
M50]I+,,(E@C1DX@K\HCH5')>+;\AOU.:/[.P]MXQ%1U+<BT[\K&M_'VHH3'.
M\=5*YG\O$-&62)&8 [;KN-MSNP)/3'=6K>[0X_7>>HS:>JS8V/(6()P)&0,@
M;Z A8OR+ *!]3;@; G;K7SG>2'36DUS^4TKJ"C#R?G7GAKK+$BIS,C$S\ "/
M07ES)! 7<=9,1VNQ]KM!7T3<S%G-8CY)*M;(H8XYA NQ@960<2R!4(?;V5!(
M._4)JCL19UK#BWS>KKEW(4H[5;YLXZH>4,ZH&VC:,HDH\8*RJ.0Y./LVW0;M
M+X@=.9+,PTZU/+34)+]?&?C"TO\ @EL3PQS0*7Y<OK6:, A2 S -QW'50U1\
M0[V,ICY,1%D<9IN?#YK(_BUC&JZVHZT*LD]8%_J )+!7"<QL1]/OJY83L;C<
M'IZ'$Q9*[)%%EJ&7$CA.1>K'71$^W[+"LI/Y_4VQ^W4$WPTUIJ4..L:KR]C$
MTL7D<-CJ3QP 5*UN(1D<@@9VC50$9C]AL=_9+!E]ZR[WO2O8K&8.G>L,-0XS
M#WLLU)6IJ\TL?FAY<MQ)XW_:"E59@O+EZZ^-2?$I3QF*S9H:<RMK-8MZ1?%6
M/#'*T-BSX%E]2GCLP8<'XN#QW4 [C>S?P^P9F].HU/EJ>&L92#-2XNNL(4VX
M^(9A+P\BJ_ ,5!]/NP(^W41AOA8QV)PE^@-1WVDGQE;&03PU*L!KBO8\\$O%
M(PKR!]BQ<'GM[VWZ8,IIOB6T=7SMK&67LU7K?-)),RQR*)ZT32V(."2-)S18
MY=SPX$QL%9CMO;](:X_E?7IV(\#E<?6MPO/'/<2'QE1PXGE'*X/,/R7;?TK;
M[$;&IX7M$-$7,OD(-634ZMLV;+"6E3'@M6"6DE$K1\N)E=I!&Q*@MM[791L]
MJ>VMGM]:M"EEZ]S 7E:X\4->*%7MN5#/''&H2*,1QK]*?M/)(Q]G?H95O5_?
M3*XO*ZAIP8"Y4BP>HL3C#:,26/G8K+P<UC17+<R)CQ]?8@D@[@3%WXCM-8_%
M1S6J>2K91KMB@V$LI##;26!5>7?R2K%L$DB8$2$,)$VW)VZW,UVOQMS6UJU+
MJ*:O)E[M',#$GP[O/1:+]9'N.94JD2N/8&X(V+=:FH.P5/*YB;,T\U:Q^8;(
MV;T=AJT%B-%GA@BEA,4J%64_+1,#^T&7[[;@C*R9/NOI_'=LX]>K)/>T_+5A
MMQ24X#)+)'*5"%8_1)W<?3]__GJ&_3MAU>>D^&S::A2\E!-/M43YV9WB:9'0
M>3Q^,QI(W,N .# [,-NLW>+1F2U)V@R.G<2T]G(2)5BCEB,44OT3Q%I!Z"!@
M%9MMMMQZ'Y=1Y[%E[4F:?5.1?6!O+=CSA@@!C"PO L(@X>,Q>.1P01N68MN"
M!L&G8^(W%U\OC3)A\A6P#XO(9#(9.TB1G&O4FCBFBEC+\MT9R&XAO93CR#$C
M-1^)73&1@5:]#*V,DV1BQ@Q=>&*>QY98))XCO'*T85DAD]E_I*D-QV/7SE_A
MRQ.9Q56C8S.1=7@R-?)RD1<\BMUTEG9OHVC?RQQNI0 +QX[$>NIK"]I7IKA'
MR6>GREG%Y3\3CE6C6JAS\O+!P9844$$2LQ/WW^VP]=,&51O?$9'DI,M%2PV6
MQV-KZ<MY:7+RUHFDI302RPRQ/7:0%FC>)EV]@L/1XGEU*:V[X4<-'GL$M:W5
MSD6(O6Z%B[!'X+<D%?RMQ02%]MCO]2JK -Q)VZ^K_P /5*T<BL.>OUHLE2RE
M"Y&(XF$L5RQ)8];K])C>5^)'W'I@?OU&_P UW%_BEVRV>OF&8Y(QQ"M6#J;L
M3QREY1'Y)2OD/#FQX@!?8 V8,I2_K"/M-VUT6^%TL;L.1MT:9I8L1Q+$;+ N
MX#N-R68D;GVQ]G[GK6T=WS^8S=_%9O'Y$LVH,CB*>0@H_P#"EX2[QURP;DTA
MCC;V%XE@5Y<O75JUMH.GE-!T\;+F9<*F&:K=@ROZO]0]4JZNX<<"OT?4#ZV)
M^WWZB,UV*Q.I--3XB?+9!*UC,6\RT]9T23G8CF1E5@/0 G8@CWZ'W]]!#Y+X
MDZ9I;XK365O9.',8_&7,9(:ZS0):;9)=Q,4.X# +RW##9@OWZO\ K77]+0M+
M$S6Z-^[+E+J8^K5H0"65YFC=PI&X &T;;L3L/S(&Y% QGPV5L;C,BD>H[<>3
MLRXVQ%;K4:E>.M+2=GA*01QB/8\CR4@[^]B/6TWWFTWD=0C0L&.R38VU7U%%
M.;J/"'0+5LC<))ZDW) * $D$[;;;A@:$_P 3&EJWR@GHYF%WBN3W4>D/_M9'
M4E6.TUDA]D$9=22"W($%>6XWR8OXD-+YBG9^4J9*;+1V8*L>&@BBFMV'F1WB
MX>.1H]BD4K'DZ\!$_/CMUK0=@]-3O>QF2S-K*W,AB,A5R:2R1)-9%Z=));)5
M%' \X0J<1Q4+M[VZD(^RUDX:K'+JNXV:H7EOT,M!CZ<#0.(FB(:-(@D@=))
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MK.-L9?"9_)92&&Z9$@M0VC,FTDBJ6658Y5^L*WM2-B&W$=+V+U=CJV3FQMW
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M2OL\88AQY4D78@C==_W'H'QD^WVF\QC\S1NX:I9J9F=;-^*2/<6)0J*LC?\
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MW EAC=%D(#+^878= ])>RVAK&83*R::H27D\168H3LT2>-& WVY! $Y;<N(
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M9G?D5"H/4W_.3Q-J/)VZ&G\UD,1C<75S%O)QQPK%'!83R(.+2!RX4.64*>/
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MDK+9W%5\1=L23H96CA\O%P>&P<^9R3MM]M@-NF!33\1%O&9O-8W*:5GCDBU
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M5A\S7KVT=$D>-8)V9(I7=5*I&S*R\V(4$;$@]!0OAIU#J74L]RYF-3IE4>A
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M_72$U)H_*Z2U7K67$V[T6%P+4[^)K5*?E.)&1G(R=B!>)$CQQ),T:A3X_-*
M"& ZO&H/B&_D[C]39*>&E)!AY\FL52(SR3WHZU:&5&C*(P&YE'(GT%((_/J<
MT[WBKU\>TNI<A1^:$53_ (7$TKKS^66%I2H@:,RGZ1R "[A02P7H*!A>X-[
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M)&X.H9E9=RK %6V/$G;I=4OB?P-XZ9O^"U1PN6CR?-K=.Q\RLE5X@!'"J%I
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MZJZL/ML00>6XIN [O=R:M&M@J#5M59]US&2^;EIQHK1U\A)76 A[<8 Y#ZI
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M1W@<'\--O#:%R.$CFTY6R<=6G5H9BIBY4EE%::.5#9WF/TL8H^21E1OR(/V
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M H'KD:9JS1.?PUG^1.&NR9!<MD,'<MQK@;/ZMJWR:2R"V3X%B\=-6^HEPP*
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MAZ-A9[ MRB6JK"28($$C;CVW !=S[V&WVZYX_0-H[_I9+_D=3_R>C] VCO\
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M_P GI>K@ZGPOK&U3OT^_\CI[D/[?^W1R']O_ &ZYA_0-H[_I9+_D=3_R>C]
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M;5._3[_R.GN0_M_[='(?V_\ ;KF'] VCO^EDO^1U/_)Z/T#:._Z62_Y'4_\
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M9+_D=3_R>C] VCO^EDO^1U/_ ">EZN#J?"^L;5._3[_R.GN0_M_[='(?V_\
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)<[:.CHZ.@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tm2128727d1_ex99-2img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
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M,7-2Z:52WY3MN^[\W^9;_I3\IVW?=^;_ #+?]*9,F8N:ETTJEORG;=]WYO\
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M'L?VUJCCOC4M-DM3<1>*7%U2%*/),QH [._LK)?EU6?[H7+^=:_MKTE^TGV
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M-FFK)B:M-48]7Y_V:2O8Y=XUJ;NCUIGLVQSZ$YR(XEA?V:<*>)_?6/2"I02
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M]O:3=JG''MPX-R^A$G _"CF$G,5]<;5EME$)]O\ TOCL9\NW92T%*$.MJ^!
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MWX3'_LI\SV"?<O'OPF/_ &4Z2V]U/?\ !S95M<'@+ZAG],W_ !BGJ&?TS?\
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MWX3'_LI\SV"?<O'OPF/_ &4Z2V]U/?\ !S95M<'@+ZAG],W_ !BGJ&?TS?\
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MWX3'_LI\SV"?<O'OPF/_ &4Z2V]U/?\ !S95M<'@+ZAG],W_ !BGJ&?TS?\
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MI0"D^8L!: E6E:WV&@Q$SQ!RVGY+\/#IMPLS%Y;L?K6IC2'''WD-%A26EZ/
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MSR\J-Z4K5 <3O1DE0YC[6>:M;3WM&_\ 33%,IO4:[W?'K;<KE' 2W*DQDK6
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MKH*ZRIN_/]=;PBPWJUV%]&)Q'W)-PB^IV$RY6APYHTCN>2M[';6M[K#0^O\
M>[ETFSS*>%O@S;59X5PAQUIY(;6_";>TK:@5I+BCQ]MC0]ZFW6V+TVL5C7E>
M?V6#-BL*CPC*?@&2X M[BVWH J*2MSN/;N2:D-_Z3X9E4T3+OC%JN,D1_2>9
M(B)42SWT@]NX&SK[-G6J"L.JO43),<FYHQ=4Q(EG%GG*LL*5:?51+L6X*W2E
MQ_S-)<Y(>Y,*0 IMLZ)V2/S,ZC9I$CY3=X<NSLV3&KO!@)M9MZN<EAV/#4X"
MZ'--E/J%%)"3[ 'M5IR^E>(3KO<[I)QRW/W"Y,.1I<AR.%*>;6C@M*M_^2/A
M/VCL:Q@FX1*S.\8!\GM+NTN(U>YT-4%?DOM@H90XISCP4H>2V-;V A/V4$$Q
M#JQG.49DQ(8LDAW''[K*MSD=5M2TW&9:<=:#YEE\E2^;0*D>4!I9 [IV>DSU
M'ZC.6:=&>2IO)X\AAVZ6QBQ>8_:XJTNCS8S?GZG-J=;" M*N6DK/ J^$6\UT
MQQ)G*'<C1CUM1?'2I2YPCI#BE*3Q4HG_ ,BGL5>Y';=8T=#< 3:E6T8E:1"4
M^)"F1&&BL)*0=^_9*B-;UHD:[T'2RCJ.[;NF=AO5EG0;D_>G8$2+=7F5(B;D
MK0@2%HY!01\6PCD"24IV-[K%SKKFT?)+-A2,FM:;I+B2[DY>G;3HJ;;6TA++
M<?SN)7^=VI15V2!\/Q;%DSL;M5SL3EEE6V)(L[C(CJ@.,)+!; T$<-:T !VU
MVU4?>Z.81(Q^-9'<7MCEKC/*D,QU1P0VXKLI:3[A1'8G?<=CVH*[M747-\TE
MV6TVZXV:V2G8=X,NXIA*DLN.PIK4=+C*/,'P.<E'14=;T"=;J'Y;U'RW(.D,
MJ5?7+4[!RS"+K<DPH<=;7H'68[:@GS5+)<2L.JWM(*2D:V*V0A8I9;8["<AV
MN)$5"BKA1O(92@,L**2IM  TE)*$'0_\174=Z?8T_:XEN<L<%<"+#=M[$=3
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M ^_:LY?;OTGZH=16,*O3=CR++K(@71JUW"('78@(2?,3S3H'2D$C>_;8[4%
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M@].,CP>S2X$J8]E=U^2H[C"DA+"_+*^2]D'CVUVV:A2?%=8OF7N>?KLES;7
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M#MQY>8XT DJ'<)!4D$@&KF@WVVW.9*BQ)\:5*B*XR&&7TK6RK[%I!VD_\ZJ
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MN.SV)J,>%SHS?LLM'1:^V7"(.*1;-ZN=-SAF8T9%S;6EUM$?RD_G.RB-I7\
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M!Q( 4GXAWT/KH* 7X'+_ "HUY,K*+$F1=&;,AU,*TN,LI5"E!Y9XEU2EEQ(
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ME*=:!)X@4$VR3I9E&<>'N^X+?+M947VY6]ZWIFVJW+CPF4J[-\6"M2@$IT"
MKZNVJRN(PLRL.7VK'UQHW^B;7C4=E5QXCS95P"@@I1\?)*$MHY':>Y6-'L:P
M]MZ^OY%)A*LF*3+C <L3.027C(2AUIE:GT^4AKB2Z[R8(2D$!6]\AH<I5TJZ
M@N]2,9^6%Q;?%:6L);3;[F)H'P@E+A"$>6XDDI4@C8(]Z"N/$#X=+[UCR>-.
MA9/#@VKY&DVI^UW2 J6TA;FRF2RD.)2EX=D\U!6@.PW43Q'PAY)CV=85>1E=
MKMT?'X\%F0_9;<]&GW%##*6RQ(<\[RW6E$$_&V5 '6^PJX+1U5N%[C7&]1[#
M'8Q",F46KO,NK;"WBP5)*RTI.D-*4A0"U+!T HI -1.V>)AZZJ1#BXTW.NSE
MWBVM#<.Y<HRP_'>>0Z'G&4$@>0L*'#]J2KV(9KQ'=%YW6G#8$"SWAK'K];;@
MB="N;C)=\D\%MN#B"#\3;BA[^^JJ]WP,095SS>(N_"+B]XM"K?:8$:,?,MCK
MB8P?>V3Q5R5%:/'0[%0WWW5_=/LUD9E N?KK6;/=+7<'+=,BID!]L.)2A84V
MX$IY)4AQ!!*4GN00"*BELZV3+@Y9[DYC*V,0N]Q3;H=V]<E3Y4MPMLN+C<?A
M:<6  0LJ 4DE(!.@IZ!X++R;*TB?><=%Y9NMIDIN$"VRD+<BPWBX6W"[(<)4
MLD:X\4IT=#O5V](.E,KIK>.H4V3<69R<GR)^]LH::4@L(6A"0VHDGD1Q]QH=
MZA72KJK?[9A^+)NMD>E6ZYSY-M8N\BY<WE2"^_Y7F-%)*6E%' +Y$C:=H ]O
MACWB"R*S]++9>\BMMHD766]-\MDW?REOM,NK!X(1'*BH:"=!)3H!2E)Y:H([
MDOA"R7(NHSV0OYE;I<9&4LY#%];;%NS&FA[Q?.+A2&D]N*$H /<JW[5+/#UX
M=;[T?RN^WBXY#;UPK@P&&[#C\)Z';D+YE:I'DN/.!+JO8^7Q3W/:NTQUZ0AV
MXW"VV6XW-4VY66#'B2)Z4)_ZV*VZA24E.FPD.#D-G9!._JJQ,"S>9E2[W#NE
MH%EO%GF"))C-RA):5R:0ZVMMSBGDDH<3[I!!!&OK(4[U*\*UTSK-LQOC-_AQ
M6;[=L?N+;+D5:RTFWDE:5$*T2O?8CV^O=6/@72F5B'5KJ1E[MP9DQLJ<@K9B
MH:4E<?R&/+/)1.E<CW&@-5TI?6V:Q;;GD#.+KD8E%>=B,3DSD"5,?0]Y"0W'
M*=<%O? E2G ?]Q2!WKK7[KK<\-AWM&0XB8]VA06[C%AV^XIDHF,J?0RI*7"V
MCBXE;B-I4G1Y)TH]]!\L_P"BE]R#K/;<XLN00X#"K$]CUS@38:G2['6LN M+
M2L<%<M>X(T/VU5\CP/2KUAO3S&[ID[ AX[C=RL,QV)%4%O+D@<76P5:2$J2"
M4JWOVV*L^_\ 5V?#O46QWZPR+-</E*UK9-ONP<;>COR2UR4L-CZ*DZ<:UHA0
MTH[.NEBWBGM>47)IN+;FY<2;&E28#=MN")4]P,MJ<XO1DI!9+B$*X#DKOQ2K
MB2!0?GP[^'B?TAN=PN5[EV.YW)R$U;6)EL@R&7BP@\CYJGI#N]GB>* E((.A
MWK']2O"/:>K757)<FR-Z+)M]RQUFTPFTQSZJW2FW"M,MITG25#?;0!^H]B15
MH=*^H+O4C&?EA<:WQFEK"6TV^YB: .()2X0A'EN))*5((V"/>HXSUKN,L1+H
MSBQ.)S;D+5&NBK@D/*<4]Z=IQ4?@>+*WM)"N94 H**-;T%-7_P &N79/=8]]
MN^6V&\WR;:F;/?%7.URG(\Q#)*4/I0W(;/F*00%I65(*@2 -ZJI^JF'O6*Z9
M?TGP&_2;JW?<DB358FWC4@/1G0XRI:C.5^:$5*6PK8VKL!L#EO;KPWR[Q><(
MF7R_-J3=;C<YBG7#<W):5A$AQM(2E24I:2D)X!*  0D*/<FHAB77!F[>("5#
M.4QI-IN<N38(MC$A!7%>B)Y"1Q'Q#S5)E))/8A#.O?N$9S+P>Y!D+63(A9!C
M[;EXR>;?VI,VV/KDP \VVA)CO-O-K;=1P5\0/%6QM/:LYF/A>RBYW:)-M6<,
MO+?PES"[L]>X2WWYC9"B)"5I6.*RL@G>_8^Y.ZZG3K*;I>L^M<2%D.3R+O(N
M]V-UBW0K3;%6UJ1(:!C%:0%+0KTR1Y*B4[5R[;K-6;/;_;)4JTY#<)K<3IRS
M)GW^Z'23=&@A1@CE_NYLE3C@'^]M(^N@Q^8>%>_Y%C_3NTQ<M@LP<>L*K)-@
M3;>N3$?46D(]2VUYB0'4E'PE?()!WK?OT[?X3LDL$+I<NTY9;FKABMCDX_/]
M3 <<:EQW]<U-@. H7V[$['_^JE?AGZG/98;W9KEDT;)KHTEB\!^.^AT,MR@2
MJ-\/8!EU#B /?B6]^]?CJ-DV1VW*<_F6ZYS!'QB'8[T(#:_@=92Y+5,;UK_[
MC*#_ .Z$?901?'?"KE_3VVX#<,0S6V0,LQW'E8U*>N%J5)ARHY>+H6E <2M"
MTJ/_ )$'Z_;OD>FGA(7TRR6QS8N0HGQ8&,3K*]Y\8I=?DR91D+?&CQ2C:B.
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M(7(FMQNX6#MS:]\U*[CMV]Z##WOPB9YE&-X[:KMGEFE-6W'7L=7'<LSJXR4
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MW3V2D^R4@#1J.Y;;<N?R/I@I_+[7<KC.O+KT:9'MB0Q%2JURRLMI#A\U)!^
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M 65<.2D_4GXB1,>HF:R,6Q>T9'$EQC9VIT1=R?<1M)@ND(6XD[^$)+B'"?\
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MBJUML; &CR 3L>QJ:])NCMAZ-V.;;K&J9(5/F+GS9MQD%^1*?4 "XM6@"=)
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MB1XK=JAMQH\HSF6DL)"6Y!6I9=2-=EE2U*Y>^U$_772L_3?%<?N<VXVS'+5
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MM!N3V(!5Y2?;EV#LQ/#\S @SHS-[=6)>-2;"XZ_'"EJ=?><><DG1 [K=4>
M'V&L==_#3$F7T7)E=BEJD0XD6:+Y84SU$L-AH.,*+B?+Y(2 4J"T[ .O??R?
MZU2SDU_DPL:DW1<"U3GX342<ZKUC;$U,??D %.U+2M06 I?%.AO>JZ<_Q+O1
MHEGC1_\ 3DRZ38[LY<EJ?*5 2REWRTH"D1E.>:5;!2I "."MDG0(6UA&&IPR
M'=(Z9(DB;<Y=Q!#?#RP\Z5\/<[X[UOZ]>PJ&WCHQ=).27:[6W)6[>M^ZLWV"
ME=O\TQIB8PC.!P^8 ZRMH*!1I*@5$A?85/,.R5.7XG:;XF'(@"?%;D^EE(*7
M6N202A0/UCVJN)'6?(&KG>Y"<<@KQRRY$U894CY04)3@<5'0'FVO+X_"J0-I
M4H;"3K]H3/!L'DXU,O5TNES1=KW>'FW94AB-Z=E"6VPAMMMODHA*0"=J4HDJ
M)WK0%?9#X;/]67*]S;E=K<TN:I#K;4"S^4R\\V^AUIZ8TIU29*TA'E[ 1M*U
M[.R..4MG6.]S#9KX]C\1O#;Q<DVR+(1/4J<CS'BRR^MKR^'!:P/A"RI(6DG>
ME 9_I%G5ZZBX^J^7&T1+1 ?4I,)#,M3[S@0XXVM3@*$A /!)2 5'1.]>U!$6
M_#HDP8;?JK):GF7YCJQ8;'Z-EP/P78B04^:HDI\TKY%1WKB !WJ==.[!>L9B
M.VJX26G[9;V(<&W%#82IQ#4="7'5:)(*G.6DDG02/MJG<TZL7O+;/*:3;H=N
MG6W)[0TU9O7N-7#_ />;:$^H2IM*4-N) (6@K20HCXJFC_66\6B#D<.\VZT0
M,@M4V-#;2B:^[%E>>WYC?E\&"\I>N0\L-DDIV#KN ZDOP_7";<[Q=/\ 44*V
MW*4]'E,&U6@L,*D,24OMR)+1>4'G/@#94GRR4J5]9!3])70F]7!Z[W"3F#0O
M5PO-NO(DL6H):87$;2@-);+IVA7'W*MC9[GL14?4;J+/SB,Y=E-R+/(&/2XS
M\5IUU"4O,WN&RI20I*%C>B1R2E0"M$#O5[]=L@R3&\2M\C&7(;4QV\V^,XJ8
MXM"2VY*;04@I2HZ5R"5'6PDJ([@4&!OG0:ZY) NRKG?K//NUX?0Y,D2;&I33
M"6VO+8](@2 IE;>UJ#A6HE2S[#0$DL/36^8GD#LFTY2'+5.<COW*-<X'J)#S
MS;+;*W&WDK1P+B&D<N25CD"1K>JKO",\R?%9>52W[5#G6(9LNWS'UW%?J&B^
MN.T"RV4$%M"W!L*4DD;( ^O)8GXESE>1,,QK7'<M4XR41%-.OJE-!I#BTN2$
MED-H;7Y1&TN**2M .]GB&>A]"!$M6)POEGD+#;+C;N?I=>?ZI*4\]<_AX\?;
MOO?N*Q$CPXR\CQN#8<JRE-XMMKM*K9;A%MB8ZTK*$(]0]M:TN* ; "0$IT5;
M"M]L.KQ,WMNWV$R[%9[5<;S;&KVPS,N$A;;<1:4!"5J:CK(=4LK[ <4I3LJ)
M/&I=U2RM>1^&G(,ABQIEO=F6!<Q$9S;4AHJ;Y<#[:4#V^J@S72_I>.GZK@ZX
MSCR9,I+:.=AL@MP*4[/Q_G7"HDJWK8 ^H=S6.G=&I0N4^[VN_)@7M5_7?8;[
ML/SF6N<1N*XPZWS'F(4A!.PI!!((]N^%RWKS=^G,F3#R?'X4>;*9:>M7HY[C
MS*RM]#!;?5Y7)!07$*4I"5@IY<02-&5=(^IKW4:!<_4PVF)-OD)85(AEY422
M%("PII3K;:CK92H%/923W((H.M9ND4F+?[=?KE?$W"\(N[MWFN-PPRT\I4)4
M-#3:.1+:$-E.ME9)!V>_;,9S@\[(;I9+S9;LBSWNTEY#3DF+ZF.\R\E(=:<;
M"T$@E#:@I*@04#W!(-=9%XDI%AO-[:;M<*Z6Z/"NC\25"?D%*G8;*W5-N.*8
M2T>7!0(:6LH(T=]R.W<>N.18R^DW[&84>*N#'O'.%<%OEF$7VFI!6"VG\XT'
MD.=MI4D+[C7<)#C71LV+(;3>Y%Y5/N3#]PESG#%#:93TI+224)"CY:4)90D)
M^(D ;).R<EG."WB_Y/8+_8[['L\^TQYD<-RX'JV7P_Y.^8#B" GR0?A4#LCO
MK8.1Q/+W<IN^2-MQ4-VRUS?D]B4%DJD.H0"^>.NR4+5Y>]G90OVU4%7UREL7
M?,(\V/9K.FR\T,1+I.>9F/'S4MM/*;#!!9<WM*FBX?B0G7)6@'$;H5=K(Z)-
MHR\,3IL&3#NTF9;$O>I6\^Y(4^TD+2&EAQYS0/-/$I!!*=G XYTV0CJ7B-GA
MO2Y%LQ&RQ8MZD.0U,QYTN*@"!HJ^DI'FONGB5 ?FP3L"NI<.K[^1#$KI=8KE
MI58LLDQYZ(_GI0\VW9Y4CDE#J&W-%"D_"M(^).QL:-2GI-UW?ZB9"S;W[9'9
M:F053X[D%R0\8R04?FI)<90E+A#@(X*4DE"QOL"H+B T*YI2@4I2@4I2@5P?
M:N:_*SI)H*R8Z)87<[G+EL/3)26I<Q0B-W5U<:&_(;<1*"&@HI;4L/N$C6P5
M;&MUE,BPN/9+);I-FL2K[<+-;%VF!;W9@:0MASRD+2XI?8C32"2=G0.MDZ-1
M77J7D=L-[N"KR;7CUMR"[-7!ZTQX1F-M-+9#2RT\G\ZTD%P.% +I)1K?M78S
MWJOD^(7+,5R;^IA:(\F1968;41^#Y#):*U.'1?0^VDK*PY^;.SQ]M +?Z1]/
MV^F/3NR8X'1(>A, 2) 43YSRCR<7L]R"HG6^^M#ZJZ$OHCCETF3I5R<NMT?D
M)4AER9<WUJ@I4ZAT^F/(%D\VVE!23L>6C1 &J@V?=:7(&;WNT6R_I7&^3K2W
M#%M,5:VYDF3*2=N.[;1R;93W7L  $)45 '"8!U!S7J%>['8?]6"W;^7FY,^&
MQ$DO/^DDQ&V5!?E^5R ?4%*2CB?_ !!T0%LO='K-,QX6J=.O5Q4W*3-8N$NZ
MOKF1GDC25M.\MMZ!(TG0(4K8/([Z%XZ XU?6%MS9-[>,BWJMDYP7B0E=PCGF
M0F00K\YQ+KG$GV"B/;M4!QOJ=D>:HQNUS\NC8BZY97IS]U8C,!=P>;DKCJ#8
M?"FT)0&TN+2 3^=0 0!W_.)]4,XR3.&7&W-0/EYZUR+:^_;FXS<9M:V^0'F>
MJ+Y"$N@:XD*T$\2%4%K2>D>.R\=O=D<8?,"\+87+2)"@I1::9:1I7NGX6&_;
MWT3]9KYN='<><NL^:4S1ZVZ1KTY&$QSR$S&%)4EU*-Z25%">0'96N]8'/<GN
M;W4:)C#65(PN$;0NY"<EEA;LMP.\"A!?2I 2V-*6 .1\Q'< '<:Z<Y[F'47*
M<8:=OC5OMPL8N<M,.&V1<5)FN,I6DN!1;:>;0%_#W 4GBH>Y">VWHW9K*9C5
MON-^@PWVG&FH$>\R$1X@6>Y8;"M-D'Z.NR=_"!6>P_";=A,&4Q!5)?=ER#*E
MRYLA3[\ETI2CFM:NY(0A"1]0"0 *J?.GI]GZ]2[DQD4B)Y&&2I+%O*6"VXI#
MOT1R05'OQ6='>P!OCV,*RGJWF.,X*Q,_U@Y*R!G'&<FE^8S;XD-*74? R M!
M<=25-.#BV.?Q]W!M":"\+#T5QK';Q&G1$3E,PGER(-M?GNN0H+JPH*6RP5<4
M'2U@=M)Y'CQW4CL-DM>!8K$ML50B6BUQ@VA<AW8;:0/=2U?4 -DFJ6>SG,^&
M49&C)0F#9<MCVINS>A9+3T5Q<1"T+<X^9R'J%E*DD:(&^0J,]8<GOUPQGJC8
MKSD<J,XY:[C)MT>WMPG8+L-EQ"2 L)4\AP)6E#B7=;*E<#V[!<6#].\.=E6[
M*<?EOW"+ZB7/MZT3UO16S)_[_E))T$*5R5H=@HDBOO-Z)8_(+3L5^[6B8VY)
M7ZRUW)V,\M+[RGG6U*2?B1YBU* /T2?AUWJK;KU$SV)F-ZM5MG/258_+B06V
MICMKCLSTJ0TM;TGFI#HY^8I*"PE*04#06>0JQ^E5TR+([QE=QNU\,FW1KS.M
MD*V-1FD(:;:>XI6I8'-2] I]P-:V">]!.IMD9F6-RU^?+896QY >9DK0^@:T
M%!W?(*'ORWO?>H0>@N-^4VZB1>&;PE]<A5\:NCR;@ZI:$-J"W@=J24--)X'X
M0&T: (!J"Q.I=_D)B9 <MC"4]D_R*O#/3,#BV9GIBWO7GA]+?Y\JY<= _#Q[
MU.NB]PR'(;-/OM\OWRBW(G3(T:&W%:::C-L3'VDGDD<E+4E*=DG7PC0!V2'T
M?Z"8<];I4$07VXTFUJM#J4RW-K84\I]9*B22M3BE**R>1).S7</1^Q)O-TGL
M.W**U=/.5,MT>X.HAO..H*''2R#QYJ!)) ^E\6N7>J4N/63,+!%DVZ9=WI.1
MRYT9I:HJ;>J#$B.NO)2_$=)2GXBA+03*5L+4#I6]*S\'J%F#C=CL5UOC>/BY
M7B5%1D$@P7Y7DM,(=0RKRBJ,B0M2G$C8[H:)X!2NP3Z3T$Q22TZSY<]IAZV1
MK4ZRS/=0E:(Y!CN$ _\ =;(!2X-*!KX3>B^(P+'<F)LRX-&Y38DMZZ2KLZ)1
MF-<$,.)>4K:5[2A( ['L-=]5!<HZQ7+$<+ZI[R^)+N=ABQ%6J:\B.E;OF16U
M!S@D!*^;I7K0*=@@:UH?7,<JRI5_R>3_ *@;;LULRRSV6-;/01W$E#ZX!<6M
M:TE7(%Y?#6M$[.])XA-[CT<Q*.J*H39]GN+D^4XQ/B75R-)<=DJ\Q]H+"@5)
M64<O+[]T; !&ZS=AZ4XWC4A;MLA+B\[8FTE(?6H%@...]^1)*RMYQ1625$JV
M2:HS%+]=<-QRUJ9O3N22'<[NT=V'*9C*<'EIN3G!/%L*0MQ;2#OW&])TDZK]
M8QU-ZEY#CHN$*XQ5KN=G,Q*[E)M;;49\K:XIB):<4KB4K<0/4;TL-\CW4DA?
MLK#+ S@'^EY\=MW&F+>(+C,MP\?3H0$_$LD$:2D'EL$:WL&HW%Z)8K/LT]N0
M_<;Z+K':87<9]T=E/F.E8=;;;=4H\4<@%?#](]R3VK&V[.';ET)R6\1[E,GW
M"WP[DVX]=XT8/-OLI<VAQ+(\E?%2=;1M*@/KV:K\=0<V5C&9W^+DS<2-B[-K
M>CVQ%OCEE\+M\5]YMU7'D$J+J]<"DIW[D ) 7[F&'6[.+&Y:[D'@R76WVW8S
MZF7F76UA;;C:TD%*DJ2""/LK!8YT9QO&+Q%NL1N:Y<&)4B9ZB5-<>6X\^RTT
MZM943R)2RCW[ [UJOSU@R]S$L9C>GER(<^XSF;?$=C!@*\U?)6N3_P";0.*%
M?$H']B5*(!JCI]G^:]1KS9;&,N%M!8O@DSH4>)*=?5$FQV65!9;\K82ZH**4
M<5?4D=B FM]Z2)NV88K 8M/D8Y9;F_D3MQ=E\EOR75.K,=*-\N/FN)<5R^'3
M: -GVLC)(5KNUI>LUW4R8MU0N$677 @O\T*Y(3WV5<0H]N_8GZJH*S]9\O7C
MT./*EQWKYE-LCMX^\F.A#:9X>,:40G1Y)0/+E<5;T"X/9(JQ^K%^N>//X0U!
M>2Z])N,AE:W8[;BUE%LF.I*=I^%7F-H.TZ^L>Q(H.X[T1QOY"Q^VP_E"U*L3
M"H\&?;Y[K,M#:M>8E3H/)864A2N6]J 5[C=<.=*<.+V/VMD+C2+(EY^/'9G+
M#KK3RM/AX%14\AU7=?/?)0[G=5U,ZX7&19L+<MM_AR9<[";E>IJ60RM1D,QH
MRFW" #P 6XY\/8'N".W;&_ZISZ+,#",ABW&]2\7@74/.18<539=EA+K3"UI"
M=\ H-ATE)605?L"Z\,Z:V[!7EFWSKP]&\H,,0YUT>D1XS8.PAI"U$) T -[(
M T"!6-_TCAF>7L7V/*;N,M\6RX!<6;M*D1G'EQ7 E)^B5..]_96M=]57MIZE
MSLLG6>WL9V]C\!JT/7!RYW.'#3*FOHEN,.-K!3Y(2R6]+\K7+F@A0!V8;TZZ
MDW3'>G4),2;!B,IQK%D(N;T9);@B8_):=E+)T5(2E*2$K5Q2??0*MAL[;<;@
M6>[W>XQT+3*NSS;TDJ<)"EH:2TG0/M\*$^W_ #4!B=",'O*#.C.3)L!_UCD9
MMJZNN1&4RVW&Y'D("BE(7YJSV]B>VO:HEDL*<CJ5TNY]19=R0)]P;,KRX*>:
MO3<@TK@T$E1&T]@#Q5V[_%4=PKJ;?\DP]IR1G$+"E6S&(5U0!!BI1,6ZVM:W
MEI6G7D)4CR^+7 @A>U E.@N;+L.;M]H9EV:Q?+MTA6MRRQ(4B6&FE1W2V%AP
MJ.BD>4@D]U:! !)U7XP_'V^C/2RRV&,!=9\..EAMI4I#3EPED%:PE;J@"I:N
M:AL^W_%50KJ;G=TQS,LL%[%F%@^3)"+"8+2FSYL&)(?8>6I/F:*GE@$%*DD]
MR1H"U^JM^EV2X8&B,MI*9N0B,]YC*'"4>BEN?"5 \5<FTGD-'0(]B:#!8CT3
M9DV*VR[^9=MR!,NX35JL]R<9+;<R4J0Y%4XV4^8@$H!^KDC:=5(;1T4Q:QV=
M-LB19#<--C./)09*U$0R5'CLG?+XC\7O4!Z5YEF$A72N=>\E3>V,PLJY,J(J
M"RPAAY,=MY*V2V KOM04%%0.P1QUJI)F^3W*5U(3C+.6-X7#8M";FF4&6%O3
M5EU:%)27PI 0T$)*P!R_.H[I'N&9D]%L=GS;>Y--PGP8#33;%JE3G'(22VWY
M:%EDGB5!.^Y]R=ZWWKI6_H!BMO4DE5UE^7;Y-I8];='W_3PWTH2MEODH\4Z;
M3KZQH=S4&MG4V_RT6O(#ET94F7DHLSF'",P ALRS'*-Z\\/(;'GE15QT#\/$
M@C\=.,OS6\6SIK<[GEQFHRYN5&?81 CMIC*$=YUIYDA.^8\H A?)"N1^$:H+
M+MG1VP6>]Q+I;'KG;ULH80ZQ%N3R&)99;2VTIYL*XN*"$)3L]R$@*WH5\K5T
M.Q:TR>:8\J3'2)R&X<N4MZ.TW,*#(:2VHZ"%% /'V&SKWJF.E=XR*)@_2VS6
M[-7VHMQC7&3<)1BQI#[2& VH--CAH$$JV5!2OB5]?'7YM_6O,I\^1,M5V5<K
M>NRC*&(4GT2Y"XK4EGS&DH822T'&'7 $K4M84A/Q A0(6ZCP^8H;9-@257:X
MQWX2[:V)]U??,6*HI*FF2I1\L'@C9'Q$(2"2!4V3C,%O)WL@2A?RD[#1!4OS
M#Q\I#BUI''VWR6KO5 WSK+D]\NUM?L4]Y&,Y#-EIM4NW>A2ZN/%;;3R:7*(;
M)?=6ZL;Y'RV1Q2-J4/M:LNZB90]/B/Y.UC\FW8JU=#Z&-$EAZ09,QM+BE?&C
MBI$=LK0@Z"MA*DZ.PE%TZ06VZYCG5[RI]^'8I[T1Q2&[JN/&EQVHK:%)DH2H
M)4@+"AI7N"0=@ZJ13NA6+W&^.W-:;@@.W%B\&$S<'41/6-+0M+_D@\>1+:=]
MM'[-G=49F67WA,S),O3D'IIDGIY;KFW:G&(SD7DXM[D AQ!4I"5$J]SW5HD@
M ":W#J7?TKN=\:RR.U)@Y.+,WAPC,?GFO5)82A1(\[SG&U><E25!("D_"4@D
MA:LKIK;G+'(MD29=+4V_<'KDM^W3W&'O.=<4XY\:3OB5+5\/M[?8*C5R\-V%
M7&W.6],>X0;<_;1:I42#<GV6Y;"0O@'@E7YQ22XLA1[_ !'>QVJ)8;FN8NL8
M9?Y^3BY0[SD<VRO6PP6&V@RER8EI:5I3S\Q/IT;.^)!/P[[U*<]RBYO=1HN,
M,Y4C"X/R0NY"<&6%NRW [P*$%]*D!+8 4L <CYB.X .P3NF6!6C-+89=PD1K
MI.N"KE;[4[=G TN6&U!UUJ/RXE12M14=:VHGL5'<KMG3.PVJ)BL=AAWR<:B*
MA6]*WE*XM*:#1"M_3^!(&S5,](KM>,VZPVC([C>'"X_B 4N/'8:1&D($UUI+
MJ-I*TH<X)> "O]P&RD 5W^K/5^[X[F[S-ENJFF+3/MD*="DJB-L/*DN-[2$J
M2J0ZHMN@@H*$I(]U:4 %QX1A<# ,?8LML=EKM\<D1VYDE;Y9;_VMI4HDA"0
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ML:ME^:N+2)RF6):[A&M;D]U4"-)45*4\W'*N"5<EK4.V@5$@ ]ZS./6ZQX#
MM.-0WT14K\T0XS[_ "<=T2XYQWW5KD2?L%4PKK1?!U0B"WSW+C8Y4^Z6]-KD
M*B)6M<1A]1\EIM)?3IV/QYN+^(+^@-I-1*\]1;O!5@^8'*HN7W9>/W>^-VAI
MAE#;#HA)7P;\O2PVDJXD.%2CQ^D#N@O5/0_'7+BJ?,=NMTF!]A]I^X7)U]3
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MIHL*4ET<VT%05^<(".0.SN@V+ON,6;*&&F+S:H5V9:7YC;<Z,AY*%:UR 4"
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..;=-,XP4I2M=:4I2@_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2128727d1_ex99-2img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
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MLNS8;C*7/_:5) /D?*MVNE/7^^Y;\DW/LOS)N-F65]/KDR]CEUO3"7W8KTE
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ME,J'JK;6F*""?9\#[QL>511/E7V-DF8XKD(E3+QCW3J[Q471ULZN<5;C9C2
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M%>H5LI5O9<0AUE:AKLEU/?SJ+>CG63"<.QW)+3=<EM\6[1;_ 'V0NW+> DE
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M-E1 [G7?O7NQJ=<[C8XDB\VQ%GN;B27X+<D24M'9T/$"4A7;1\AYU%_RMK!
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MTI$,$^D"3OMZ)X7()WZIVWQ];5='2R-?)^58_(-VQFW=1FIBW;JT^]/%[EJ
M7XL>0VH</".QQ[>&D)04'030;I7N]0L<LT^[7%\1;? CN2I+ZDDAMI"2I:B
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MW[37*!@F-VJ:W,A6"UQ)39VA]B$TA:3K7902".Q-7VE I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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MV^XUYUA:.FHQ>S]'IV'V46O*Y5IE1)%Q:8*7W5JL[JT"4X1M0\=#1'B'LI(
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M&M@#?F>P\C6O> (:Z0Y1AE[O,N3<,>EV.XVZ)<X-DF-M,+<N#<AF-X)\1UM
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M#Y\4)"O,!MD()'M+PWY"K]E^:1<,@LR)$.YW%Q]PMLQ+3 <EON* Y'2$ Z
MV22!\=D5'O2.'D.&RX-COD./*R"^-S<CR.XQG%*8:DJ<;;:::5Q 4./JC>M)
M9WKO5QZQ8AD64S,<<M4=F\6B*X_]TK%(NSMM1+YI2&G%.-I45ALA1\-0T>6_
M-(J#,<?SVRY)B R>)+X6<-NN.O2FU,J8\(J2ZEQ"@%(4@H6% C8*36+M=?\
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M*RE 44=PK1!KUM]46\DZ@X"SCUR8G8S?+?=9#RD-=UN1RPE(VH!2"E2W I)
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M>^JCX$_77,I /<$;]]<>"3[?\J!R4/;7(.'VG_*N!0=]CO\ QKCQ4=Z&]>9
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M[?A3)B&!6[KWE5P<Q)KYO$-NY?;_ $RRA=Z1I*DM)=<3+(:_ I"%<@I'B$Z
M(!.AV0^OMTN\JQ6F#A8<R.X2[K;I4-VZ)1'AR(/#F2\&SS:5S!"@GEW'J[WK
M,X'25F#+Z<OBYN+.&P782$ED#TL+C(8Y*[^IH(Y:&_/56^P=#X]BS6-D(N[K
MZV;G=[EZ.6$@$S_#VCER\D>'V/MWWU3*XABMN^4!>)4"/=I>#*M]DCWI&/76
M0J[(6]&F&0(Q4RV&]/LI<4D%94A1!)".U=!^5%:_NZGBS:#CINPLPE&_L"XE
MPO\ H_C"#KEX/B]M\^?'U^&JS!_H<P]AMTL O#J$SLE.1^D>CI)0KTY$OP@G
M?<;1PY>>CO7LKP63H(<8R3TBV7:$BP>G.3Q;9-BC/R&U+<4ZMM$LZ4$<U*(V
ME2D@Z"NPU<IA@_4'J9?<XPRV7&)C'HF(R\EM;4.[&XCTIQ*+FTD/+C<!Q:64
M'B0X5:*24@$ZR&%U9CXKC5UF66Q6:VMKR:ZQ'C>L@$*,IYM]7B/%Q:%K*G%;
M(;0@A/?R KO/R?)[5MAV!O,YC>)6ZZ1[G;[3Z T5L^%*$@,+?Y<G&@00D:!
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M )V  D[V,23U^O,F;:+)%PKQ,KEW.=9Y5N=NB4,19$:.E\+\<-GDRM"T*"N
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M'X+PW6B--\R7 GAV.LKL71]RW7/%;C,NS#\NR.S'5"%;&H;+Y?:#>@A!]7B
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MC,Q"3.(RC?D5DJ4=J4=D_&E*5Z+C*4I0*4I0*5Q2ZE:E)2H$I.E 'R.MZ/\
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M^Q4Q*Q,, OO4_J594=1%-KQ:6U@T:/+E..0I#9N0,02'FVTAX^ =;XK45]R
M1YFKE\[V4XS=6DY4O&XEONN.R[]"=0'F46Y3'@[9DN%2O%20^C\(A*3M) 1W
M%9]<>EMDNK&;MO*E<,P8$>Y%#P&DB/Z./"[>H>'Z>_?X5X\OZ.8SFX@QKKZ2
MYZ):7[2RTW)\-7@.%DJ7V&^:5,-%*QK1'QH(G<^47EMMB97&<B6^[7*W1+;/
MM\I5HF6EA]$F:(RFRW(45D#S#J3KOW3M.C)F)9?E,?J;<,0R@VB856M-XA3+
M0PZP$(\<M+9<0XM?(@\2' 1L$[2*\:/DZX^X_<94^[Y!>9]QC1(LF;<;@'77
M$1I/I#0&D!*=+['B "-]MDFLU.)0O[;#*3XQNGW/-LT%_@O"+OB_BZ_&Y>W?
MEVU3$C'NK.<3<3:M$2UW.W6^YW)YQ#29=MDW)]U*$;5X,6.4K<()&R5!*01W
M)(%8#A76G-^I)Q&%:8EEL\VZVNY29LBXQ7UIC/1)J8VT,<T+THDGPU*24[[G
MU=&3<VZ;P,VN5JN*[C=K+=;:'6V)UGE^CNEISCXK*B4J"D**$'6M@I!!!KPX
M)T?QKI],MAL[DPN6N)+BLMR97BD-2I/I#A7L<B?$3V43Y;'<]Z#"L=ZNYGG4
MBTXY;&K%:<F2BXKN]PELO28;8B3/1/P#*7$+5XJP5#DL<$@[Y'57[Y.9F+QO
M*#<D1V[@<LNXD)B**FN?I)!*"='1\QON-Z.]5ZIO0S'^<1R%=;S8KHU,G2F;
MC;9Z69)$MXOR&>Z2E317I024DIX@@@C=9/@> VKIS9Y-LM'I)BR)K\]?I;Y>
M7XKR^:SR5W(*B3ZVSW\Z",NEV#8]U21DN59C:+?DM[?O=PMQ;NS"9*+?'CR%
MLM1FT+!2V E 6H@ J4LDGN*QJ)CEO^^ SN,CI= RZ+'79F6YKH@@6UL1$@)2
M'SSTD#EI&_Q>W>I2O?1*U7'(;A>K5>\@Q.=<U!RX?V?N'H[<UP)"0XMM25IY
M\0 5H 40!LG0KHF=#HR\CGWNWY?EEDE3FXS<M,"X-\'RPV&T*5XC2R5%([DG
MN>]16+=+\&QSJF,MR?,+1 R:]/7ZXVTINL=,A,"/'?4RU':2L$-C@D+.@"I3
MA)/<5D'0!2X-LR_'VGWI-IQ[(Y5KM:WW2ZI$8(;<#/,DJ4&E.+;&R2 D#V5<
MK[T5M=SO\V\6Z\Y!BTVX\3</N!<#&1.4E(2%N(*5#GQ 'B(XJ( V>PK*L3Q2
MU818(MFLD1,&W1M\&PHJ)425*6M:B2M:E$J*E=R22351$%[ZZW>U=1K?!BO6
MN\8_(R)K'WF8-JF%493BN'-<\GP/$2O04T$^\<N0U779>K>>2,>Q[+)[&/#'
MYU_397[>PR\)7AN3E1&Y"72YQ!"N!+90=@'UP3H94?D]8Z;Q&E_=&_>B1+PF
M_0[1]T3Z%%EATNJ6AKCOBI:EDI)4!R/'CNKXUTHLC&'6_&DKF?<Z#<F[HRKQ
MQXGC(E^E)VK6BGQ/9H=NV_;00SGN7Y=U!Z7L9*4V2/B,^_V]$:W!IWT]#"+J
MTA#ZGN?!2E%&RT$#05^/L=Y#^4[,OMKZ/9!,Q^YMVF:RIHKD*;6M?AEY"2$%
M*TE*CL>MW[;&N^QSE?)UQN4MUE5POS=H^Z"+JQ9&[B1!BR4OA\K;;X[ +@)X
MDJ2.2N(2=$9QF6)6[/,7N=ANR''+?<&BT[X+A;6.X(4E0\E @$'WCRJHC2/D
MG46_WV_V6SR\73*QLLQYLV; D!NX2W&@]X;3:7]QVPA;:>:E.$DJ(&AWS'!\
MV&<=.;5E+,4PC/M_I?HSBN?A+XGDC8UR 4DC?M'>K-+Z$6V2\9",ERF)/D1D
M1;G-B7,,O71" 0@R"EO16$J*0M 0OCH;[#6;V_'H%GL,>S0(R(5MC1A$8CL]
MDM-!/$)'Z!5A)PU[1\H'+;?@6$7F].6"W3,R:2[$+5MER6K<TADN/.NI:6I;
MZE;0$MI" GD>2R!NO;8>NV697-QVT6IBSF;.NTZV/7:5 EL17FF8:9")++#A
M2Y_>XJ;*B.22 L#O4DO=&[)_8_&\?CR+G 3CC:$6JYPI9:FQ>*"V2' -'D@E
M*@I)2H'N*],/II!CSL?FR[K>;Q/LCTE^-*N<P.K6I]KPEA>D@<0GR2D) /?W
MTWFY%QZQ]0H&-WG()\;&E0<8OHL=TCQVI'B7'4AMI;["BO3&@\@AM8<V4J]8
M#57*Z=<KM;.I5L@1G[9>,?E9$C'G6X%KF;C*45("U3R? +B5@!303[P%$BLY
MF=([#.QS(;(XJ:(5]NBKQ+*7P%A\NMNG@>/JIY-([:/;??O5I3T QY-WAS/N
MC?C%@W@7V%:3<3Z#%E>(IQ2D-<?Q5*6LE*B0.1X\=TWI$PQ#!NIN6Y.UB%HQ
MZ%C=D-V@7:8\\N$X6(ICS_!24,H<3SY!1*AR'K$JW[#)W2;,KAFF)>E7EB-&
MNT2X3+7,]"Y> MV.^IE3C85ZP2KB% $DC>MG5=&)])[%ADNT2+>J87+7%EPX
M_CO!8X29 D.\O5&SS T?8.W?SJ]8MBL'$(4R+ +Q:E3Y-Q<\9?(^*^Z77-'0
MTGDHZ'L'OI$&45QNO=\0,-CRH$#TQ=UD0,I4CDE$%MN6(2'&P5;')YUE7K;T
MCD?C6,Y5U5R7)K3D;]M;M%IDO8I?KG;KKZ&M4MN(Q+#30"PXD@N-@N;!T%%"
MM'CHRQ/Z*XQ<7LX==:E!W,&D-7%:'^);XHXA3';\&K?KD]_7 57J3TAQH^BH
M5'?4Q'Q]W&1'+WX-4)SCS"M#96> ];8\S4Q*Q,(MQUK/I'4RRMQ[M87;\_A#
M#CMTE0'BPALR]MI\ /<UK.]*7X@'8G7?52[TGS.5U Z?VF^3HC,.?(#K4EB.
MHJ:#S3RV5\">_$J;)&^^B-UTX5TMMV$SXL]FY7>ZS8]N%J;?NLE+RO1TNEU*
M3I"=E)[ GOKSV>]7?%,/@X7C*+';')"(C:GUH<<<"G4J==6ZHA6O8IQ6NW;0
M\]4A9:Q9%U:L#76"7GJ[@\F79;ZUC[38A2%-.6C18EK\4(\+7I#A>V5>4<>W
MM4B9GU=SFS'J?=+7&Q]=EP:4V51Y;;QD7!GT5I]QL+2L):6.9XK*5 ]@4@ D
MR9;>FMCMG348(AEU['ON>NVK:><Y+=:6DI65JUW6KDHE6O,[JUM=%K"G$\IQ
MYV3<Y,3)64,7%]^2%/K"(S<8*2OCV44-)).CM6SVWJF),PC[/>J^88A:LG@9
M);\:NZ'L3DY#"C-Q72RT6G6VUQI"5K(>3^&0>:>&]*VD=JSVS9GE^<Y5=VL>
M78[7CUAN+=LDFX1G7Y$YQ+;;CX;X.(2RE(="4DAS9!) &M^S-.D-ASQ;ZKFJ
M8DO65^P*]'?"/^&>6VM>O5/K[:3I7L[]N]<9'26W?VJ<OUON]\L4B4XT]/BV
MJ=X4>>MM*4I6\@I/K<4I25(*2H) .]4F%B5DM'66\W#I-C&4.1X*)USR%BU/
M(#:_#2RNY&*5)'+?+PQO>R.7LUVKOZ;=3[_E.?7.TWR3:;(\PJ3QQ=^ ^U<4
M-(=*&GTR%N>'(;4D)42VC2?$2.6QWYM?)_QLW)MXW"^(M[%V1>XMG%P/H,66
ME_QRMMOCV"EE1*22D<E<0G=9#9>D<"VY>WDDR\WN_3HP?$!%UF!UJ"'M>(&D
MA*?, )VLJ( T#Y[QX,HG+/*4I44I2E K >HDOG,B1@>R$%P_I)T/]*ST^511
MDTOTV_3'-[2E?AI_0GM^^MUJ,U9:KD[ELI2E=KG*4I044H(!)( '<D^RHFE=
M6;CG=\?L73Z.W(2ROPYF1RT[B1O?X:?_ (J_</(^XCO63]9FKD_TMR5FT-N/
M7!V(6VVV02M04I(4$@=]\2KRJ \-N3T)_&NG.+R'I][$N+.O;S#JS$M+33B7
M74'UE)+I4GB2G0T>/F="6[-[2KVRM[J8C-4\T?GR?YYGS?E'2KU.D4:-1F*9
MC,S'&<SB*:>:9Y9C?$<W%-TRVY7@\;TBS.1LCMS*?%D0)2"W.D+\W'4O E*G
M%'9XE('8)'D*S#'K]$R>R0KK 67(<MH.ME0XJ /L(]A!V"/>*N'8_ ;[42D)
M   2![ -5A31JSNG=S/9M6)LU?@JG5YIWXGLGC$=G#AC&_-?*HVROJ;)L><Q
M8;+*7,?@%IJ^3#_][+D'BQ^J0%*]P6*S#,,GBX;C5QO,SUF8;1<X>UQ7DA ^
M*E$#_&L3Q''+:G Y=MR"="D3[X'9-W/I*-J=>'K)'?\ N#BD>[@*UW)F9U*9
MQ/']N_\ QER:9<N5UQ8L5:M7]TS^7")_U3Q[(JA(OP]H[4-8-TFR)ZXV239Y
M\E$F\6%[[GRG4+"@\D#;+P(/<+1H_I!K.36VBJ*Z8JAW6+U.D6J;M/+X<\?G
M$[I1A8KAFF83\B7#R&W6R+ NK\!IARTAY7%&M$JYC9];W>RO9)R#)\%GP%9'
M(M]ZL<R2W#5/AQE1GHCJSQ05HY*2I!5H;!!&ZQ[!<GNEFN6:,0L4N=[:.12U
MF3#=82@'2/5TM8.Q^CVUZI%WN/5B_*QN1:EXY"M4F--N+4YY"I;Z4JYM);0C
M8X%0&U[/EKSKBBK\,3$SK>W'[/FK=Z)M4U45U[69G&=?5F<SNW_AQB-^.$9Q
MO2UW'GYUB609)-MO4'$K.R6Q"N;<U4@*1M1+3:5(XGV=R=^^LMV3LGS/>H^R
M_P#_ 'O=/?\ \5<__P!2BNNY,Q$8YX_S#WM-KJHMTS3./Q41[)KIB>^$@>RL
M1NMDS%Z=)=A97"AQ%**FHZ[,EU3:?8DK*QR_3JLO'E7%S_EJ_0?]*SJIBKBZ
M+MJF]&*IF/RF8_Q,(JP)[.\UQ&W7M66P(AEH4KP19$*X:6I/GS&_Q:E1A*T,
MMI=6'' D!2PGB%'7<Z]FS[*P+H4L(Z2X\2=#PW?_ -<NLV<F ?BC?Q-:K$?@
MIJY9B.5P>3:?_*VKM54S5533,YJF=^,\LSCV/!F&31\/QN?=Y*2XB*WR2TG\
M9UPG2&Q\5*('^-6+IKEEQNUJE0,B2VQDUJ>]'GM-?BJY#FVXG7]U23]:36.9
M)?(F3]28-HE3HS%KQX)N,M+SR4!V6H'P&]$C? ;6?B4UT9AD%LQG+;1E,:Y0
MW([O&U75MJ2A1+*U?@GM ]_#6>__ *5&L)K_ !:^=T;OWGV?I+DN:9,7IOQ5
M_NZ)U9CGZ57_ "SB.R(JYTJKF?\ 2G_$UB.<99<[=)LUIM'@)NUX?6RT]*25
M-,(0CFXX4CNH@:TG8V362<OZ%8_E^(,9=&BA4F1;YT)X2(<^(0'8[FM;&^Q!
M'8I/8BNFY3.K.KQ>EI6UJM3%K^[=V;L[XB>29C,1/)*U/XUF<9HR(>:";,2.
M0C3[:TF,X?\ I)1I20?>"=5D.+7B3?;#$FS+>]:I;B2'H;X]9M8)20#[1L;!
M]H(K&%#J)8T<@;+E3*/- 2J#*6/AW4V5?4*R/$LFBYA8F+G$0ZTA:E-N,/CB
MXRXA7%;:A[P1JM=N8BK$9CLG^3X2XM&FB+NK&M3./[:IF>;?$S,QNY<3R[^1
M>>54Y54 56NEZRFS[J:._*JZ^-5U45[6A^"1^@4HW_RT_H%*P;$UFN(!7Y=A
M[ZY!!4>_8>ZNP#5>:[<*)2$CM7*E*BE1OUDZES.G\6WIM[^/L2Y9<*?N[-=;
M*@CCM+3++;CCI];N0-) [[V!4D5@F9=+3DV5VW([?D-SQNZQ8KEO=>MZ65^D
M17%H6MLAU"^!Y(20M.E#OYT$;6KY2]SR]6%BTVZRV--^MK-P#N23W6&I#BG5
MMN18JTMD+=1X>]*XDAQ&D^>LWZ]7RYV[&[):[7/=M+V0WR'97+C'5Q>BLO+/
MB+:)_%<*4E"5>Q2P1W JRGY-K1P6U81_:^\G$8L81I-M6S%6J6 ZISDIY316
MA1*@"I!!]4$:/>I&SG!;5U#Q>78;PTXN'(X*"V'2T\RXA06VZVL=T+0I*5)4
M/(@4$-]9.C6'=/>B^=72Q63T>Y*LKS+D@R'77I"24DAQ3BSXBB4CUE[._:-F
MLG1U5RC',FEVK*;)9;>V_995ZMK[-U4&T)CJ;2XS*<<;"6R/&;/B)VG7+MV&
M_3+Z+7:^8]>;'?NH5^OMKGPEPDLR8T-M3044_A"IME)6L!.@5=NY[5=.I71F
MT]4)"7+G+F,)%JE6KC%4E.DON,.>("0?62J,@@=TG9V"*"'KG\H=&2X[EUJO
MUCQ[)#;4VN<V(+S[L"0V_.2TD*+S2"5MJ2' I(4D^KH@@BLCR/KYEUJM74&]
MP\9M;]FQ.YO6S\+.<2_.<!8X<$A'% _#$**CYZT/,U>IWR<47YZ[S+]F%[O5
MSND.%"?E/HCMA*(TOTEOPVT-I2C:NQ '?9/G5\N71"VW+$\RL*[C,0QDUU5=
M9#J0CFRLED\$=M<?P*?/9[GX4&-O=3>I:\WGX:QB^."]B"F\1I3EU>]$3%+B
MF_"<TSS\;FG6TCAK9V-:-@RKY4\J!@5ARBVQ+"P)EG%X?M5TN3OIJ@.06TTV
MRRLZ!00'EZ021V\]3,C!HR.H[F8>DO>F+M2;28_J^$$)>4[S\M\MJ(\]:J,X
M_P EJ';;(NT6S,+]:H,NRHL=R1%$?E-9;#H:45J;*FU#QU@^&4@C6^_>@XR.
MMV7W^1DBL3QJU28=FM\&Z%RZSW&52&WXI?+*0A"M. #7(^KW'GWU+F)9$SE^
M*6:^QFULQ[I#8G-MN?C)2ZA*P#\0%5C&+='[?BL:^,L3I3R;M;XEO<+@0."6
M(WHZ5)T/,I[G?;?EVK)\0QMG#\3LMACO./Q[7"8@MNNZYK2TVE 4K7;9"=G5
M!KAT+ME@5?[G=GNGMSD7YB_7MQ&6NLH,4<)4@)'B%[GV2/#[-^?;R[UD-CZ]
MY_=K9@,XX=9DM9O'X6UM-U<YQ9'@*>YR/P>O"*$+5ZG)8TD:V>V98QT8NN)S
MY"(6=W3[@2)\J<Y9EP(90?2'%N.(\7PO$UR<.CRWV'>KE9^C5NL]LZ<PF[A+
M<1A/_P!R*6$;D?\ "KC_ (30_P"EPGU==P/901S=OE0RL?M:;9>(]@LF6B\R
M[,Z]<KHIFTH+#+;RG_%*.9"D/-!+?'ER41O22:K9OE+7K,4X_;\;M%CNMWN%
MRN%H>DM712[<EV/&2^E]MU*"I;2DK3L<>0.T^8W6:W#H+">N%PNMOOMRM%^>
MO+]YCW*,&5*C+>CM,.L\%H4AQI264DI6"=@$$$"KM%Z7+7><4N]UR&X7FYV!
M<MQ#[[3#8?+[7AD*2VA(2$CR"1Y^9-!#,S.<P1?+9&P^UXY8G'\]FVRYH+CZ
M$7"0F$MPN.%"">*N))/XW)MKV%52&.M=P3TIO65+M<7TNW7UVSB,EY?AK2BX
MB)SY:V"02K6O/M7LN70>+(BRE0+_ '*U7-62.Y/&N#"&5KC2'&RTI 0M!0I!
M0I8TH$^MO?85X+K\G-BY)NL%.6WN+C]PN2+RNS,B/X*98?0^M066_$X*<1R+
M?+CM1(]@H/1AO5B[9?U/O5@5'LEMA6R3(C.6Z7,=3=UI;)")*62@(4RYV*5)
M4?54.^]I&0]6,V>P+'&ID5^S1Y3\A,=M=\FJCL@E*CZH0A2W%GCH-H&SLGL
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MHN*4IAU060$A/$D;5H6>V_*"AJ-LS"_8G%BST8O=)RW8KGBRF@S<&X_HC:B
M"'%\"3L#D![*OG43'IF*9-:KE;7L\DWEVWHA3;CC]OB2DW%M#BE);>"T\&7
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M$](:]*X>+X',<^&]<N/GK?;==W(>\4%:50D#S.J;'OH*TJA4![138WK8W0"
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MBEJ"/7(2/[H56S*.E&&-WR5>48I9DW:4^W)>G" V'G'4+"T+*];*@I(5OSV
M:[;ITSQ.]V5=HN&-VJ;;%R5S#$?AH6WXZU%:W>)'XY4I1*O,DGWT$'V;J'F/
M2URV7[/WIZ+"^S<K8MB7*CON(<84I^$XM3!+?CN,I>95Q_&6AOL">\S]+(-]
MA8%:3DTIV5?Y"#+FET[\%UU1<+*?_0WR#8^"!6/93T?&12,=L,=NSVGI[:9$
M>XKM,2#IY^0RX7&VP=\$-<^"U:25**2-@*-2>!VH(8^3!=+;'Z3B(_*::O\
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M%$M4!;AY\TJ*D)/;PSH>>]]M;"9#TRQ+++O$NMZQFTW:YQ->!+FPFW76]'8
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M*AH*3Y'0]PH(E1U4S;(,NMU@MD^V03.OV06Q4I^'XO@L1./A*2@+')8WH@D
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M!1) ![T$77'JUF-LM74)[(+A&M%^M]GNDN%BTNR*2TI#'+PGV9164RD<0@K
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MB"I'C-EIQ"DJ*5H6D]TJ2I*DD'R*35Z\N_E\?+_,=JJ*?BCW?Y?[4_%^&_\
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MX4J1D<?P)B75M*:9==/AMN*;6ZH)02AH+2H>(H!'8^M5RF&;\5I_NJ'Z-_\
M@UQ/Q'U_[BL9N?6/#K5?(=H=O3;T^6AIQMN(T[)2$N#;:EK:2I* L=TE1'+V
M;K$\2^5)@^2VV7,E3UV5MFZ/6MOTZ-(;#RTN.I;*5*:2.2TLJ5P_&3L).E=J
M93"400/(C_#_ &-<NY]Y^O\ WJ/Q\I#ILY&BOG*8J6WWC'/B,NI,=86$:D H
MW']8@ N\ ?95VR'K!A.+9(BQ76^18ES);#C:D+4A@N'38><2DH9Y;''Q%)WL
M:W5R893KOY?Y?[4T!_\ 1_M6%W?KGT_L5V>MD[((T>6Q,$&0DM.E$9X\=)>6
M$\6@>:=*60D[[$Z->?$.ME@S'J1DV&QF935PLKP:\1R,^$/Z;2I9"BV$IXE7
M$;5ZVMIV-&F3#/>P/E3?P->KP4^[_,T\!'_2*9,/)Q^'^7^U-?#^OJKU^"C_
M *1]55#:1Y #_"F3#Q^W]W_TU4(4H>1->W5-5,F'D#"]^6O\JY",3YD?ZUZ=
M56F3#H$5/M)-=4YQ$"$_((&FD*7W^ KV5CF=R_1[$ML'2GUI;_P\S_I5IWS$
M$[HRC?942I7XQ.S^FE*5Z+D*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*
M4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0375%#D"*K2O,=K',9P2VXG*D2(1?+
MCZ0E?BN<AK>^W:LCI2N31=$L:%:BSHU$4TQR1PWMMV[<O5:]R<R5$_4[IW>>
MIG4'&8ZIERL6-65AZY?=.URFVWW+@K\"T@!040$-*?))3H^(G1V#4L535=;4
MUL=Z)95C^1?<F'Z9D6-*RJTY.BX7*4RM]#@4I,U*_P 4G7ALNC2>_,ZV163W
MKIK?)<_KL^U;4*.3VAB);%^(V#*6F XT4$[VD!Q>O7T.Y/E4V4H-8V^CF9PY
M[]X;LS,MZVW''[HQ;WI3:?3_ $6WF.^VE6R$+0M94@KTDJ;3W /(9ED/]L;E
MEF&YQ'P2X<[4FX6Z38G+A#$WP9"6"A]*O%+)TMG13XF]*WY]JFK5-4&LRNG.
M5-6:3<9.)7IK*W,ANUPM\W&KQ$;=MS<A2"D*4\M*'&W E(4DI5W;!X^1K8#$
M$7I&)V9.1KCNW\1&1<%Q.S2G^(\0H^'+>JO.JK0:Y6;IUF.'V;IU>6\?<O%Q
MQZYWI4RSQYC"'UQYCKQ0XVM:PV2-MJ*2L=E'VC5<[%TTR^=E-JN]VL#4-(SZ
M3?W61*:>#$55L++:]@]U>)H$#N#LCMWK8G5-4&O_ %4P+++I=^I\6VX^Y=H6
M6XU'A1IC<MA"&7V4R06G4.+2KU_&3Q4D*'GRXU<NMW2*\]0Y,"':6VX;"L5O
M%H7++B4)8=?$7P4$#UN"O!6#Q!  /O&YNU5:#56Y='LJRO%<G,RTYBJ_#&[A
M;(+60WZ!*BK=D(0E;37@Z)2>"?7<" .(]4'RV=M,0P;3$C>&&O"90WX:=:3I
M(&AKMH:]E>S55H->9737+;9 7=(MF-PG6WJ%*R1FV)EM(7,AN)=:VVI2N"5\
M7BH)64_BZ)&Z\\CIYF659=<[W/Q@6V/,RJPW-N(],8>6B+&;"75.<5%/-*AO
MBDGV<2K6ZV-IJ@@+J/TPR>X]1;QD]JM+=P;BOV"X1HBY#;?W15$<F>,T"H^J
MM*7VU(4O22I*>XT2+'G'37.NIMVRN\C'WL97(B6-R!&5<F$RI"X4UY]QIQQ'
MB(;<(6GBKUT@\"3Y@;,ZIJ@UA/2')INLH:M642[_ &V?;9*;?EUYA/KN#$9Y
MQPM-E@E#:DEU2T*6KNK7XH[U(V 6K)KAU>R+*[QC2L<M\ZR08,9I^4R](4MI
MZ2I8=\)2DA6G4ZTI0T1WWL"6-4U01KG5HOS'5;"\BMEG>O-NC0Y]LF)C2&FE
MQO2%QE(>(<4D*0/ 5R"25=QH&L/L_2O(('2CI!9?N6AJX8_>8,RX,)=; 80@
M.^*L$'2CZXWQV3R/GWJ>M4H->+!TKRK'.E73OPK*S*O>+7R1=9%C7(;1Z4EQ
M<I/J.;\,.A,@.)*B 2""4D['5D_3_,\PN]SSAO&/N9<&9UD?AX](G,>E3&X+
M[KKBG'4*4TA:P^I*!S(TV.1'+0V,U35!K;D>%YQE>2W[*G<61;BF5C\ZWV:;
M<6/$F^AO2%.,+6A2D(<_"I4GN4\@CUO/5DS"VY!U;SG/X3>,B#/5C]D85:Y$
MN.Z^D"Y.O$2%(4IM*BV%J".:O5T?[P%;-Y%C5JRVT2+5>;?&NEND !V+*;#C
M:M'8V#[B 0?817FQ+!\?P.VF!CMFA66&I?B*:A,);"U?]2M?C'6AL[.@*#&G
M,4N1Z[Q\C$4&TIQMVWKD\T[\8RVW$HX[Y?BA1WK0_P :MW4"QW^T]3+#FUGL
M2\K8B6R5:G[8Q(:9DL^*XTX'V2\I*#_RN"@5).BD@G1!E&E!"<1K-<1S?)<D
MCX(_?&\ICPW?1H]RBMOV]]EDM%A]3BPE3?DH+:*]%;GJGL3XND?1N^8!='VY
ML=AYIO#H=I1+86G@J2E^6ZZT@'U@A/C( ) ! 'N[3SJJT&N3'3"^V'ICT;BN
MVM$5>*VV2+LVVXW_ ,*3:)#)UHZ5MU:1ZN_/?EWKR],[+E.:8)T9M;N)IL=H
MQ]NWW=V\"8RMF0EN(H-HC-I/B!3A<'/Q$H"1S&U;!K9*3&:F1W6'VTNLNH*%
MH6-A22-$'X$5U6RV1;-;HL"#';B0HK2&&&&D\4-MI 2E*1[    /A0:I6/HG
MG.*0L/G^BY('&L9C6:;#Q:\0XTF,\R\\YZWC_@W&U![S0L$%/DH':<A7T3OM
ME1"L]GM-P3:+IALK&W)3MP8=?M3[KRW0X^=H\1 \0C;04?5T!KO6RNJ4&L.'
M]$\ANZ(L._1\OMTVW6B7!C3+E?(4JW,.O1E1R6$,@.J3I6QS2C02-C8U5\LV
M.YQ=7>DMMFX.FQQ<0G-^G3#/CN-J2B"]'"HR4**O")4G\<(4 0.)[D;!:IJ@
MM]^E3H-EER+; 3<Y[314S#4^&?&4!V1S((3ORV>U:O=/\>SZQ-=0\BPS%'\?
M5+>E,-8_(E1U>--5.[R6VO$\!LM,%:?QPEU03OL 3MC35!KP,%O%SPN5;[3@
MEXLE]A7"'D*+CDUQAO+O$R.^A92\ZR\XH*6A!2"4A" 4A(  35<JP',>H=^=
MSI6-_<6[6=5N-HL5PFLJ>D^CR5/R/$<:4MMOQ O@CUCHHY*UO0V&U35!KUE.
M!YCU"GW#)G\><L\IZ;88L2TR9;"Y#42)<!)?><4VM38)*U:2E2CIOWJT/2WT
M5OS.<9*"&G,0ALSKACD9+@"A<)[:DR$D;TE+9\7@>P_XM7_34^:I08STTL\O
M'NFV)VJ>UX$Z#:8<60UR"N#B&4)4G8V#H@C8[5KSTVM&49MT:QS$8N*IBVMV
M\^G.Y)Z8SX#;#5S5(4I+>_%]();XZX<=JY<]=JVL(W7BLMCM^.6UFWVR&S @
ML\BW'CH"4)Y**E: ]Y)/^-!!PZ69(CI4;4BU):NJ\Y^[:V4/-C<;[L>D^*5<
MM$^#I6M\NVM;[5;[STASJ+DF6)L"8[-LMXN%ZQ=Y]Y''[IS4<5I*#OCX1,DI
M*AQW*'8\2*V.U5:#4J=T9SC*9&:R4V.\0#=,+7:(RLEO[<Z0[,\?GQ44+6AI
M*AY</5[DD)/:KSD> YM=<[NF5IM&908N108K;MKL5[M[$B$XR%H+<@.*+:T*
M"N:5-N*US4"G?>MF]4U06'!,:9P["K%8HR'FV+="8BMMR'@\XA*$ !*E@ *(
MUK>AO51'TOZ6Y#8,APJ7<[6EENUMY&'G"\VLLJE7!+K&M$GUVP3V\O(Z\JGN
MJ:H-;;QTFSFW6^;><;AH9RAK*+RN*E<A"4JM]P44J=WRUZBO!?XGN2SK6SJO
M/?>A^0X9E[CF.IRJ9CK]G@6QEK&+M#ANL&*A;82\B2 %(4%\@I"MA2E[3WW6
MS5-4&NL/IED.#W['6,%L-\LST=FVQ9USDW6*];9D5H(0M$EHJ\1;J&N;:5MM
MI)(1ZW$:'.#T]RTWBU6R3CCOH-JZ@2LA%S7+86R_$?,QQ*TIY\PM!>0% I!W
MW3L=QL/JFJ"!<LZ5W^Y8W\H%B+:D+F96-6K\*V#+ MK+(!)/JZ<2L>OKW^1W
M6)7WHCE#E]S&VRV,ON=@R:6J4?N%?84:*&W66VW&Y+;P\0%/ CDWS!2$ZT1J
MMIZ:H(+N_2V^/]+^MEH:MB7;ED<J:NVH4ZWRE)5"9::4I1.@2I!'K$:UOM61
MX/8K_C75G,'95F><LM\1#E,75J2T6VEM14,K9<;*@YR*D;!2DI(/<@]JE&FJ
M"M*4H%*4H%*4H%*4H%8#U$E^),B1@=AM!<(^).A_I6>U9[CB=ONDM4F0AQ3J
M@ 2'"!H?"ME$Q35F6%43,8A%M*DG^P=I_)._]U5/[!VG\D[_ -U5=&VI:=G*
M-J5)/]@[3^2=_P"ZJG]@[3^2=_[JJ;:DV<HVI4D_V#M/Y)W_ +JJ?V#M/Y)W
M_NJIMJ39RC:E23_8.T_DG?\ NJI_8.T_DG?^ZJFVI-G*-J5)/]@[3^2=_P"Z
MJG]@[3^2=_[JJ;:DV<HVI4D_V#M/Y)W_ +JJ?V#M/Y)W_NJIMJ39RC:E23_8
M.T_DG?\ NJI_8.T_DG?^ZJFVI-G*-J5)/]@[3^2=_P"ZJG]@[3^2=_[JJ;:D
MV<HVI4D_V#M/Y)W_ +JJ?V#M/Y)W_NJIMJ39RC:E23_8.T_DG?\ NJI_8.T_
MDG?^ZJFVI-G*-J5)/]@[3^2=_P"ZJG]@[3^2=_[JJ;:DV<HVI4D_V#M/Y)W_
M +JJ'!+2/_AN_P#=53;4FSE&U*D)G$K!)D/L-+\5]@@.M(D;4WL;'( [&_C7
M?_8.T_DW?^ZJKM:8-G*-J5)/]@[3^2=_[JJ?V#M/Y)W_ +JJFVI-G*-J5)/]
M@[3^2=_[JJ?V#M/Y)W_NJIMJ39RC:E23_8.T_DG?^ZJG]@[3^2=_[JJ;:DV<
MHVI4D_V#M/Y)W_NJI_8.T_DG?^ZJFVI-G*-J5)/]@[3^2=_[JJ4VU)LY9%5"
M=56L+ZMXO;\NQ!RWW.R*R"*7VG##3&;D$E)V%<%K0.WOWVKC]DSV1C/LS,1W
MS$=KHG\_Y[(F?!F?(?'ZJ<A\?JK6'YAL._-8[]AQ/YFGS#8=^:QW[#B?S-3-
M74W/A?68ZU/3I]_Y&SW(?'ZJ<A\?JK6'YAL._-8[]AQ/YFGS#8=^:QW[#B?S
M-,U=3<^%]8UJ>G3[_P C9[D/C]5.0^/U5K#\PV'?FL=^PXG\S3YAL._-8[]A
MQ/YFF:NIN?"^L:U/3I]_Y&SW(?'ZJ<A\?JK6'YAL._-8[]AQ/YFGS#8=^:QW
M[#B?S-,U=3<^%]8UJ>G3[_R-GN0^/U4Y#X_56L/S#8=^:QW[#B?S-/F&P[\U
MCOV'$_F:9JZFY\+ZQK4].GW_ )&SW(?'ZJ<A\?JK6'YAL._-8[]AQ/YFGS#8
M=^:QW[#B?S-,U=3<^%]8UJ>G3[_R-GN0^/U4Y#X_56L/S#8=^:QW[#B?S-/F
M&P[\UCOV'$_F:9JZFY\+ZQK4].GW_D;/<A\?JIR'Q^JM8?F&P[\UCOV'$_F:
M?,-AWYK'?L.)_,TS5U-SX7UC6IZ=/O\ R-GN0^/U4Y#X_56L/S#8=^:QW[#B
M?S-/F&P[\UCOV'$_F:9JZFY\+ZQK4].GW_D;/<A\?JIR'Q^JM8?F&P[\UCOV
M'$_F:?,-AWYK'?L.)_,TS5U-SX7UC6IZ=/O_ "-GN0^/U4Y#X_56L/S#8=^:
MQW[#B?S-/F&P[\UCOV'$_F:9JZFY\+ZQK4].GW_D;/<A\?JIR'Q^JM8?F&P[
M\UCOV'$_F:?,-AWYK'?L.)_,TS5U-SX7UC6IZ=/O_(V>Y#X_53D/C]5:P_,-
MAWYK'?L.)_,T^8;#OS6._8<3^9IFKJ;GPOK&M3TZ??\ D;/<A\?JIR'Q^JM8
M?F&P[\UCOV'$_F:?,-AWYK'?L.)_,TS5U-SX7UC6IZ=/O_(V>Y#X_53D/C]5
M:P_,-AWYK'?L.)_,T^8;#OS6._8<3^9IFKJ;GPOK&M3TZ??^1L]R'Q^JG(?'
MZJUA^8;#OS6._8<3^9I\PV'?FL=^PXG\S3-74W/A?6-:GIT^_P#(V>Y#X_53
MD/C]5:P_,-AWYK'?L.)_,T^8;#OS6._8<3^9IFKJ;GPOK&M3TZ??^1L]R'Q^
MJG(?'ZJUA^8;#OS6._8<3^9I\PV'?FL=^PXG\S3-74W/A?6-:GIT^_\ (V>Y
M#X_53D/C]5:P_,-AWYK'?L.)_,T^8;#OS6._8<3^9IFKJ;GPOK&M3TZ??^1L
M]R'Q^JG(?'ZJUA^8;#OS6._8<3^9I\PV'?FL=^PXG\S3-74W/A?6-:GIT^_\
MC9[D/C]5.0^/U5K#\PV'?FL=^PXG\S3YAL._-8[]AQ/YFF:NIN?"^L:U/3I]
M_P"1L]R'Q^JG(?'ZJUA^8;#OS6._8<3^9I\PV'?FL=^PXG\S3-74W/A?6-:G
MIT^_\C9[D/C]5.0^/U5K#\PV'?FL=^PXG\S3YAL._-8[]AQ/YFF:NIN?"^L:
MU/3I]_Y&SW(?'ZJ<A\?JK6'YAL._-8[]AQ/YFGS#8=^:QW[#B?S-,U=3<^%]
M8UJ>G3[_ ,C9[D/C]5.0^/U5K#\PV'?FL=^PXG\S3YAL._-8[]AQ/YFF:NIN
M?"^L:U/3I]_Y&SW(?'ZJ<A\?JK6'YAL._-8[]AQ/YFGS#8=^:QW[#B?S-,U=
M3<^%]8UJ>G3[_P C9[D/C]5.0^/U5K#\PV'?FL=^PXG\S3YAL._-8[]AQ/YF
MF:NIN?"^L:U/3I]_Y&SW(?'ZJ<A\?JK6'YAL._-8[]AQ/YFGS#8=^:QW[#B?
MS-,U=3<^%]8UJ>G3[_R-GN0^/U4Y#X_56L/S#8=^:QW[#B?S-/F&P[\UCOV'
M$_F:9JZFY\+ZQK4].GW_ )&SW(?'ZJ<A\?JK6'YAL._-8[]AQ/YFGS#8=^:Q
MW[#B?S-,U=3<^%]8UJ>G3[_R-GN0^/U4Y#X_56L/S#8=^:QW[#B?S-/F&P[\
MUCOV'$_F:9JZFY\+ZQK4].GW_D;/<A\?JIR'Q^JM8?F&P[\UCOV'$_F:?,-A
MWYK'?L.)_,TS5U-SX7UC6IZ=/O\ R-GN0^/U4Y#X_56L/S#8=^:QW[#B?S-/
MF&P[\UCOV'$_F:9JZFY\+ZQK4].GW_D;/<A\?JIR'Q^JM8?F&P[\UCOV'$_F
M:?,-AWYK'?L.)_,TS5U-SX7UC6IZ=/O_ "-GN0^/U4Y#X_56L/S#8=^:QW[#
MB?S-/F&P[\UCOV'$_F:9JZFY\+ZQK4].GW_D;/<A\?JIR'Q^JM8?F&P[\UCO
MV'$_F:?,-AWYK'?L.)_,TS5U-SX7UC6IZ=/O_(V>Y#X_53D/C]5:P_,-AWYK
M'?L.)_,T^8;#OS6._8<3^9IFKJ;GPOK&M3TZ??\ D;/<A\?JIR'Q^JM8?F&P
M[\UCOV'$_F:?,-AWYK'?L.)_,TS5U-SX7UC6IZ=/O_(V>Y#X_53D/C]5:P_,
M-AWYK'?L.)_,T^8;#OS6._8<3^9IFKJ;GPOK&M3TZ??^1L]R'Q^JG(?'ZJUA
M^8;#OS6._8<3^9I\PV'?FL=^PXG\S3-74W/A?6-:GIT^_P#(V>Y#X_53D/C]
M5:P_,-AWYK'?L.)_,T^8;#OS6._8<3^9IFKJ;GPOK&M3TZ??^1L]R'Q^JG(?
M'ZJUA^8;#OS6._8<3^9I\PV'?FL=^PXG\S3-74W/A?6-:GIT^_\ (V>Y#X_5
M3D/C]5:P_,-AWYK'?L.)_,T^8;#OS6._8<3^9IFKJ;GPOK&M3TZ??^1L]R'Q
M^JG(?'ZJUA^8;#OS6._8<3^9I\PV'?FL=^PXG\S3-74W/A?6-:GIT^_\C9[D
M/C]5.0^/U5K#\PV'?FL=^PXG\S3YAL._-8[]AQ/YFF:NIN?"^L:U/3I]_P"1
ML]O?O^JJUK]@?1W%[!F-IN,+IVY:I4=[FW--HC-!D\2.7-+ZBGSUL ^=; #R
M%7,SQHFG_5J__FJJ/'/8RB8GA,3^6?UB%:U[^6E\H=?07I>3:G4IRJ]*5$MF
MQLLZ&W)''V\ 1KWJ4FM@G%AM"E*(2D#9).@*^3W73J/*ZZ=6\NZC",J=@^%>
M'"@)5V:<47"E@'_\:Z%.'_TI2/=7N^1]#ITK2,W/[*=\]L\D>V7F>4=)G1[,
MZG]T\/UE(6%=-+_\E?!,>ZT7:^S'LNO%\A1[I;52.;7H,A1\5N0>Y<>(*5[)
M]10&MZ)/T?2K8KXPSK)E^;8JW?LDR-V+;ITN.F);0HZ>6MT(0I+0(2-!2BDD
M$Z!]^Z^D70WY,]\Z)9&N>CJCD&36EUA3+]GO"0XTH_W5H45GPU [[CS!(/LU
MZWEO1J:8BY=NQK[\;IWQNQ&[AAY_DO2)KS3;H_#&,[^$[]_;EFLGKG98O76'
MTP6R]]U)5K7<$2P1X7B)._1_?XGA[<_]NO>*R1_J9B$6Z"VO9596KB75L>B+
MN+(>\1">2T<"K?)(()'F 1NM<LMZ%9Q=K/9\[L\Y,WJ/!R89(;(J5'$5(<*6
MG(P?"0K0BI;1W64GAY=Q7DO/R:<BNMVODU_&K?+5.ZI0\E*GGF2IVU(;2%\B
M?<0K\&?/9]]>/YKHM6/]YC=B=_+GCOY-^[VO2VU^,_@SS?E^Z>;QU59ENX@_
MB=PQR_6F[W;T"1,-Z:0 @(45>CZV'G0H >&#O6ZR%WJ-BL:YRK:]DMH:N$1"
MUR(JYS0<92A/-96DJVGBGUCOR'<]JUEMGR<\RM^<19K=HBLVMCJM(RA*42F@
ME%N7'+:7$H'DHJ\T#O5VZ?\ 1;,+#T;S;IO=<<8D7&8J].0LI,IAQE]<M+G!
MP@GQ4N$.<%;3Y ]R.U2O1M&BF-6Y'?&=\SOX\F[="TWKV=]'\^[8K^WF-$((
MR&U$+A?=))]-:]:)O7I ];NUL@<_Q?C7NLE^MN26]$^TSXURA+)2F1$=2Z@D
M'2AR22-@@@CV$:K3N!T#S;)!;&\BPUVV6ZW]/6,46Q:[W&],]*:F1W0XTK?%
M.@WXB>1T>.E:W6QG03',LQ; A!S&9]T+J)LE;<IUMI$AV.7#X2I'A>H7BG14
M4D]SW).S6C2-&LVJ-:BY$SGAF/TS_.?DVVKURY5BJG$)'I2E>8["E*4"J:W5
M:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5
M:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5
M:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5
M:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5
M:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5
M:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5
M:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5
M:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5
M:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5:4%-#W"FA[A5
M:4%-#W56E*"/NO\ 9,GR3HUE]KPY;:,BF6]QB+XB^'+D-+2E7L64<@DGL%$;
M[5$G1CY)5L@_).<Z=Y)&7#N&11S+NSC83XT>4OBIOB?>SQ; 'EM)]];-TU7;
M;TN[:M;*B<1F*L\N8X.>JQ177M*M^[#0NW?)*ZL9;UJPY691\<@X-BLAMYE^
MP!+#<I+12I/X$[7XBRA 45G20" ??OGQ!3H@'?F*KJJUEI6FW=,FG:8_#&(Q
M_.,L;&C4:-$Q1RHNB=&$VUZ([ E,VU4:X39Z?06U1^7CR$.)2K@1R"4)*"%;
M!V.VAJNRV].LH87(<D90^XYZ7(?9'CO*0>32T-%0V-:4H*+8V@<!KO4FTK3Y
MQ<GC+9LJ.1#5KZ<9\S(MC,C)O!:C-N\YC4M]U22IQQ24AM9TYH*2DJ<\@!Q[
MU[[-TYS&$FR-RLG+[#>TW%M4A]PK2' L>&HD$E0!2>7D%$#MJI6I64Z37/-W
M)%FF$4V+I?D5E=LP3>T.1XZ&&WV0_(0$EN.RUS!"MNDEI?JN;&G"3LCOD_3;
M%;IB]D4S>IXN=Q4XK;_BN.:;WZJ2I9V2.YWH>>O9NLOI6%=^NN,2RIMTTSF"
*E*5SMI2E*#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2128727d1_ex99-2img005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
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MS2I-YUFC4MA1P%K#9ZME/EV-J^"(%>A5:-]:]<FIL^QP3FC4M2QV\%3#@_\
MIHS_ *XA^.EWT?-3M<;JLB>LRX*+0Y&V'O3)H5!UY+BYX+!2O"$*&U*4@#CG
MQU1P-[UF6NVBS/?A:T&3UQ_\'>NAL;'4:!J@23^"9WT5/1SPVB6[J9(,9=D5
M"DU-21S962IA9_U5E2,_]X(K=B_/4C3Z7U7TNK=I5U#245BGJE7RT2I#3JD\
M%H)P3L6 H$_8B*'KEMRH6?<=4H-69+%3IDT[)S39^M<;44J][(R/(1&KP?M6
MULYH..;/P/O^"J7C2P5!4&A_%<I_]P=_U%?DB_>T)]5+TCHTXA 6N7H;#R4J
MY$IETD _!%!#_P"X._ZBOR1?[8;4N_I=;[<V$&571Y=+O6'"=A83NR>[&8J\
M)/)HSRG\E+=FK_,J^J#Z+1<HJ$JNM:?TM=-*DE_P">=2\$=I1O24D@<@<9[Q
M$XND%9E&U1T(NVF55A*Y-^E/3+2W4X4PZALN-.C/L5)4 ?A$)'3_ *,/1ZF9
MEBNVE:-K554D\.KFI)T3K;3J<*'UZT[AD'CQ' PT_HA72Q.F%M3^F]&D9UJX
M:[('KJF\T6Y=B3<RE9:4?W19 4GAP3DDG.!&,X4;7:J;+!3+' YSYL]3HKH+
MZ-)SK0Z0H(]$;0EWI#:Q4>A/MJ](99(J%9=3P"99)&6\]A<40@>0J/9%H/2S
MN^NVKI@+5L28E*/7:JUX*W-J66Q3Y0#:M;82"0K&$(QRR3]:(2_04T9D^C[T
M?C<=?2W3JM6V/3FJ//\ B^"RJ4%3+:CV!#>5'N4M7=#EZ>6K*:BU%^_ZW+IF
M_#E_]%RKXW(8EDG"%%/(J.">/+.>9BY;;8RT6LUJF=.ED!RN]QW#K5)E*I3H
MBE2R>_?R#W]95=_1UZ+>H%KZY6I5'J&]4Z$E<QUE4D4+6RWEAP#>5 $9) !X
M@D\X56I_1GU 8Z7]$N.E675YRWEU6E3TQ4):7W--E*V^M*B#PV[,DXB>U\Z[
MT2SZB*5)LKK-32L-*9EU!+;2B<;5*X\?( ?+B&)UIZ;=PZ9])F@Z8R%N4N;D
MIQVFM3,Y,O.AYLS*P%!(3XOB@@C,.%JMMHM&W;2 EA$$[@9G=RHIML[*9HFI
M):1) W^X4@>D#J7.:/:-77>4A),5"<H\IX0U*S*E);<.]*<**>./&[(B#HEZ
M)M6K^U1MRUKALB1E96M3S5/;FZ9-N*6RXXH)0HH6G"DY(S@@@<>.,1-W46CV
MQ<-DU>GWFB27;$PSLGTU%X-,%O<#XZRH8&0.T0@M+NCKHQ:L[)W98]IV^'\*
M5*U:1(F0.:26W"I0!YC*>/,1B6:K9&6=XKTBYQT/)EV_DM2JRLZHTTW0-X2
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MUZE06ZMC?LVZ-1!!!'2+,1!!! A$$$$"$0000(1!!! A$$$$"$0000(1!!!
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M3S*%1%(@'F ?=@"0.0 ]P1)1NNG9K4;31, _1W>\YIK[4ZK2V3Q/6OA\$L.
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M000(1!!! A$$$$"$0000(1!!! A$$$$"$0000(1!!! A$$$$"$0000(1!!!
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M[QKM9L:U-SCLR1+@6-JL-1KG2P" UKIPEQ$:&0K#N$-G878V. &*# S+7!I
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M[!7=:+91-4\3"T5*;&# 26C"&$ 29XFS(SSXQ6?;/BFT,%.C4#!QI.%Q<<4
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M7]T(])OZH^/[OY_J*X>B7\+9G^AK_/1#Y0B++T[D[3JKDY+U%R;6MDM%"PC
M!(.>'N0MX]OX(W9:KINP6:UMPOQ$Q(.1[%Q-[6JE:[2:M$R("(((([18R(35
M> ],.7U@_P 84L)JO?O_ /V!_C A<[ [A!@=P@@@0C [A!@=P@@@0C [A'A
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M+L\DY\DXZ/\ ")*7E%0U/)59^KR?^M>]OP[/_P!Y<A(%,+36!&-6+V_#D_\
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MH>><ZM7:%%K"0?( <=L-=<5LV9-:M4&EVM-N3]MU!V52M1=)6DK<VK1D@%)
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MLQ-./#N%W^3/U0OJGX.O\$WZ[OR1!!!'%KT]$)JO?O\ _P!@?XPI835>_?\
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M *:;,C;-RW=JS(6II[84Y>-M5 R5N4.=9;;8FY8O'KWUI<<2AYP8X<0$ @
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MP=&A;;+8O!&V<XP<W@@2,69!#FNDC=(Y)7K=IM=UV^\Q>+[:!3<,J9:3A(;
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MVO&H_!<$QQ+B'#(KIT6?2ZVCCAM[*DY[%_7#W^)'OQU"(;ZVIP%2Y)TX:>P
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ME]BT+(N"S)]RHN7U<M:FFTU"FS'7.>*A:G$K9"?%V[$G(P>&=Q@&6D)! 0D
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M#]<3@+>'8ID#DN/J@56NW%-T^AMRE>?DJ;;E(?99H=49D%O*=EP5/K4I25K
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M5T41+E2FOM2TI4MLIXGQ1@^[P/P&)/:CVN*C;=U2[:,O2C,K.HQS*4+VK_\
M2L?!$?;@2@LLN# < 4VKOX$$#\<<[1=R+H*D.":&_),2YD"V0I26TE)/#O/Y
M,"' L:L)JU&0RZKZ8A.,GNA+:GLIZUII&$K2A)3W =GXP8Y]CU%;#J6U I[
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M5F10:!N)_);<$$$3K.1! >4<28J$\NI/2TLELA SA0]SM]^&N<&ZJ:E2=6)
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M54=7UT-E]U2^1_\ %'GKH++/94OD?^^&NNRV.:1LSW)[+PLS'!V,&.M0-F-
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M.3A=1M5E!0!GAWQ)&0R/?[55!S/&'=^&67J6"VO^S_\ Q#^01UXY%M?]G_\
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M*4I&2HG@ !WQVKCL2Y;/:8<K]NU:AMOJ*&EU*1=EPXH<2$E:1DC/9 F#$02
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MR3V^GU/_ +TU%U6OIQHU=G9_D2_SA&4\1;[-]9O^P4]I,W7:_J._U*KW/."
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M30U/U(J$JUUR#UFT95Q!P/?C%=FF-RV/(LSE9IIE)9USJDN!U"QNP3@[2<<
M?@AQJ-2+OHFM%F2UWU!4_,*6XXP3,=<$H*5 \<#'$0ZNHLJC4"UKTMY WU"E
MEMYE/;GJTNMX]WQTQ1J7E5I5*;3A+2))$[W1(S[%:98:=1CR)#@8 ,<DYJ*=
MK6E5KTJ:J?1I0SDTELNJ1N"0$@@$DD@=HCH5;3*Y*'7J;1IV0#-1J)Q+,]<A
M6_CCF#@<>^'4T'819]@5F['@$S$_,M4^4*N9&\)X>ZM?_HA2:K_5TTY_U_\
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M;=SEO()3C&>.'PZ,6CVHG1SFIU.H&I5(J5@2=-$M3)/PM3;4L0XE0<PXE(0
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M+1#YQZ?P>OJI?]A%MJMPF2(F=.M<[;K!3NVMX/2TB=(U1!!!'2K/1$1^D_\
M5.3^#F/SG(EQ$1^D_P#5.3^#F/SG(Z&XOG?F/Y+%O;YMYPFD/*)>3=M5VZM%
M+7D;?G_2RH"5E'"\7EM>(&N(W)&>.1PB(<;;=:J#3:$-U&<0A(PE*)E8  [
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M].[V4[*:#8#B()A1.MCGUQ5=, S$J0^I?1ZN.\KWJU8DYJG-RLVM)0EYQ86
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MAFL4K;DC;]PV,66U-3\T.MF4J63QV#L/+B3'S>FH=;MN]IUF6F@N39*")9Q
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MILF3QG9G3LG>44:SVV9SWQ XHR&OL":JW:%,W-7*?2), S,XZEE!5R&>:CY
M,D^Y$AZXUIYH-)R<C,49-P5IYO>I3S:''%#EO45^*A).< #L[><-)H3/R].U
M8H#LR0EM;CC*2>Q:VU)3\)('OPI^DY;=0E+Z%96RXNFS<NVA#X22A"T @H)[
M#V^7)B6U_P!>V,LSW$,B<C$F=%'9_P"E9G5V"73'+ Y4E-9=3+3N&E4V9IE
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MR<9X$QR=2;3EJ32Z95&) 4I]\]7,R:%A:4+QG((..P\O)&/7X+VZS6$VVI$
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MY.4+7776:?URU#J%TSLDBDJG&Y="I"6?6XRDM,I:"ANQDD)YX[80"@8QJYQ
M0-5,U[L)9.1_+_ZLSLX^\RVRX\ZXTWP0VMPE*/<!.![T9U5:<=E^H<FYEQC
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M2++?1>T[J!IC_39_^R9BM<-X'"*%F_MA9%ZN_P"J<.S\%X.!C*D'E@@@\01
M@;-JTE0=2K((Y#N(\N8S.3#LU-./O+4X\XHJ6M7$J)YDQ?"Q21"]3GA&QSC
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M$ .8E-T-[#F;2Z73]MUF4#SE+8J4FZ'FPI"E(P KB,<1@@^6&OZ25"<;U\U
M$LQM:].I@(;2WM2!D<L<,1;;: ZMLAR3*@-(BGC/+":F",CK#C!PXVML\O&2
M1&/,6E B"""!"(((($)5:4?53LO\.2']Y;BY;4;^ U9_F%?E$4TZ4?53LO\
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MUZ=JW'K&W0@2^3@#;CQB.V.DK3NA2?I5)33DVN>GGGY9+K*QLR@GQR#RP .
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M)(4 >2CW8AV*4D+!,!2Y4O,3:)5E)X-!&WCY>TQS92J3")U'63CB6MV"H#(
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M;R;AJB)TSB:E-)FBCJR^'3O*?L<]T:"E%:E*42I2B22>9,8%\WK1O(4VT68
MPO@0(ASBX:<DQ&F66JT+%97V8N+W23&>>X0O((((YA::(((($(@@@@0G!T2_
MA;,_T-?YZ(?*&-T2_A;,_P!#7^>B'RCZ;^#_ /PH^L[\EYE?_P ]/8$0001Z
M0N<1%5WHDG^<>W^ 9/\ M'XM1BJ[T23_ #CV_P  R?\ :/QNW-\Z\Q63>?\
M8\X46(((([M<DB)H]$+HOVTY)65J)?M5:4BNSKLO0[=7*H?:G2&GL]=N2H'Q
M6W%@8 &Q))R0(A=$U^@]TE9ANIVCI)<= 9JL@J8=>H=25A+TB=CJS@*'C)_=
M$A22"-Y'$<LR\=KL":7G[(5ZQ;/;#:>;ME,/K#8NEM$NJUTV%?$S6[?JCJDU
M%Z=:"'J9AU"5%2=B#[%2E#*?K.V'WT^Z,O1ZUMF*I;-AWW<KMTR<LJ81,SC
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M&$.*R4@#FHXX<H:V)!=/?_.HN[^9D?[HU$?8Z.RN+Z#'..9 _!8E=H;5>T:
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M6ZL8'9%DOHL8S0M-OZ9/?V;,5N/#&<"-6SF&!><7P?\ KGCL_ +64OCCL\L
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M2;GO[-F*WWD9)BQKT6E\L6_IL0.<Y/?V;,5PIF0OB8TJ!A@"\VOEI\.>>S\
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M4PE*-CC>Y)&>(/#A$?\ 5+0V6NZ[)!NBU"FTZ==E4E]@(*6\_6JRG@"H>3@
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M>(:VLY@(*C==E*L]E4&(W*4VBM?WTTL23[:9I7!*73A(/>?)#N2#%2FI:?\
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MAPX<Q A6#:E](:N4WHM=(2ZZ J5L&\'[ZEY-UBBU5N:<9<ZFGLON,OI"=Q4
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M@DD @@8\GPYB'NH&KTU<U??F*8R)"76TEHE2!UBCQRKR=T3FE@/%*IT+>^W
MMJLRA.=>^JBZ7:KDG/.,/U%T!V7;(*B3G&2>P8S[L1L=:+F21SXF-IQY^=<*
MWG')A8'LEDJ.!_A'H2,8QF)ADG,:VC(8N',LD'OC!G ).#CL,=:<9/,".0Z@
MI41@XA(6G2=B"^8NL]#>.>AY9/\ /3_]^>BE7JSMSVQ=5Z&^,=#VR1_WT_\
MWYZ*E<$-7075_?/9^85;&KGU6+W_  ]/_P!Y<A)'E"JU</\ UL7O^'JAV?\
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MWQP'"_\ K6*JVEQB6/&6><=2Z>XP:=9I?EQFZ]JC4><=.F3[,E*.!U!65.C
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M&X!61GRQF]3:Y_N.]\='Z4)\37F/_P!K4]!WZ)?#;*?^ZWTA^J3\F0)M@DX
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M'=^*#Q>[\41B]0:SOO6._,<I^TP>H-9WWK'?F.4_:8)=T-3[K^9&)O/;]O\
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MP[OQ0<.[\41B]0:SOO6._,<I^TP>H-9WWK'?F.4_:8)=T-3[K^9&)O/;]O\
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-0B"""*ZE1!!! A?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2128727d1_ex99-2img006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
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MD@9;AB+U:G^Z+?-A+?8= W24E!Z1U$'@1U$5@VS0^E='TZ=:UTW,:\@ D[2
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MRP^_V'(%05SX%KFMHYRX(2DJW&B#IOD Z ]8/'A6<_T9T]3%1SZ#@&$@R1L
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M6BB$E0X:GAJ!K6#V_;Y?<LE[3K;D-COT2QQ&'$#V-2U'D6A"4+)2ZYK^-5H
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M);+G?_9^W]WV]5M;"U/:DA+80?"WR1IV#CKT5B-WY0N5-[9<<LL?$KPU:I,
M2';08[9ER%*23OI43P0V3HH<.*%5>LGHEIVU NY.X+CWB^X-D,F] )F9!&(
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MF+RI&2JL4(WY$?N5,_N@<X&O>=.FG'LJBQ6C3#=)6O2=NL#WNK4WL@,==EP
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MG#=_!U.FNNO#HKSWSDZYC?<"RZ3+%O<S')[W&N+\5F1HQ&9:6HA <(XGPOZ
M*W7[T>3?!&?.$T[T>3?!&?.$UL!I_P!,;XK.LI=4#@Z\:3I(%0U0PQ N!YO0
M #LF!"QSH_0]TL%6&Q$7A$W;L]MW#\)6I61<GJYW;;[;<C:4RG$GW(MQNL<N
M@*<EQT*"/ _*!.Z=?&JLIV&;.+Y@5^VA2[PVPAJ]W@S8A9>#A4V2OBH#\$^$
M.%;&=Z/)O@C/G":=Z/)O@C/G":U%KMGI3;;%J^M97%EQE/\ [;IAC@YIGI8
M$[6@#9*S*-#15"OZPRJ+UXN^4,W"#W9GM)45YGL\QS:)$C1<DM#%WCQG"ZRV
M^5 (41H2-".JKK9;-"QVTP[9;8Z8EOB-)988;UW6T#H2->/"L_[T>3?!&?.$
MT[T>3?!&?.$UR[M$Z??0;974:IIM,AL/N@G,@9 G> MH+5H]KS5#V7CF9$GO
M6C^T79;M*VKYPQ9L@B8XR4P-$7V,'3S3"92%;Z!IX+_Y.[KINE1X5*?*!V:W
MO:'8L5AV1+3[MMO#$Q]4EX-GFD)T)U/2KQ5L;WI,GTT[D9T_UE-.]'DWP1GS
MA-=E4TCZ2FK8ZM*PE@LUZXT4W79<(<8SQ & ( C 8E:5MFT:&5FOKWN5B27"
M8&0^.:U8VM[/,UG[;\=S?%[3:[NS;+<Y&5'N4L,I4M9=!U&A.@#@.O;5PV$;
M)+]A.19=D^1JMT6Y9"\E9MEGU[FC@$GI(&IU.G#H&O'C6R_>CR;X(SYPFG>C
MR;X(SYPFL2K:?26KHT:+]2(9<;3+A3?>+&OOAI))'RC,@ [)A7FTM&MM/K7+
M F2Z+P@$BZ3ORPQ*T[V\KO#?*-V7+L#<5Z[HBRE,-35%++A!5JA2@"4ZC4:Z
M<"0:\,SDW97M!MNT*\Y*_;[3D^1JCF'$BNEUB.&5)4E*U@<=[=2GAKIIKXJV
MYN')RF77(;;?9EBA2+Q;4J3#F+D#?8"M=X)XZ<=35X[T>3? V?.$UN:>E=/V
M"R62CHVQ/94I,#7/-,EQNUG50!LN$W9!$D@C(XX3K)8+15K/M-<%KG$@!PC%
M@9)ZXF,?-:66C8+DKMFN*&,.L>'Y"W:W8\.^P[W(?>7(4 D[J22&TK27 3Q(
MWAI7FPWD]99;,TPV].8Y9+(S;HLAB?W'<%//R'5,J0'G5*_"4HJZ$G1(UX\>
M&[O>CR;X(SYPFG>CR;X(SYPFI=Z0>EQ95I^INBH' RVJZ YI:0"YY,8D@&0U
MV+0),AH[1 +'<L.;!S8,B",@-T$B"1G."T=P#DZYQLRCXCDEG8@KRJ _(CW2
MWN3!S,J&M6HT<TT"@"1P_P!$]1UV*VAP)UXPBXQ(-E@7V3(;2@VNZ.[C#Z"H
M;Z%+'0=-=#V@5+'>CR;X(SYPFG>CR;X(SYPFM)I:T>DNFK92MULL1-2F200Q
MXD%U\-)!FZTDAL$. ,7L!&;9*6C;%1=0HU@&N$?*:=D3VD9["=BT4;Y.FT-G
M&<M:LO,8G"N2XQCXNQ>7'VU)0K5T%X@;F]V=>NA.FE>J)R=,K;O&53(^/6*P
M1;KC#MNCV^VSBM#<A13P6M8U43NDJ7T= XZ:G>'O1Y-\$9\X33O1Y-\$9\X3
M70N])?3!U[_HOE9_PZFY@Q-Z7'F-YS[S\^=!(6O&B]#B/XV7^IO7EAA\HX"!
MEA@M(+GR:LCC)PF[)LULR61;[(W:[G8Y=Q7&25H*MU;;R--?PNCQ=!UKVY#L
M(NDK$(=LC;+,:YQ[GGU&-?7FW;=(4=$K2ZK4K&XE!4.C>'16Z7>CR;X(SYPF
MG>CR;X(SYPFK/M!Z7N=3<^R.)821A6;F7$"&/:,+Q@Q>@ $D8&O5VAP' 51S
MAO8=V]I.,=FT %0[LBQB\X7LZL=FOUR]E;M$9W7I.^5C7>)"0H\5!((3J>G2
MHB7LMVC[/KQGD7#X=FO%ERQYR0F1<)99>@K<"@K5.GA@!9TZ>@>,5M_WH\F^
M",^<)IWH\F^",^<)KGK(_P!(K+:+1:#82\5S+VNINNDAU\$!MV(=B(,;""%L
M:S='5:=.GR\<G@"'"8B#B9F0M"LHV?7795E6PK'+,_$GWR#W6M#DK>1'=?4O
M?4DD<4I.I2#IJ.!TKU[0]F^41<+VM[0,Q;@P;K=[<S#8MMO>YY#+*76N*E]9
MT0D>4GITK=&Z\G*9>[Y:[Q/L4*5=+65*A2G) WV"KIW>/77IO^P.ZY39Y5IN
MUHB3[=*2$/1GI"=U8U!T.A[0*[6GI_3C:EDJOL+R]I_C/Y,WW#U@UW-9C !P
MS Q! (!QTCM'6$MK-%=L'Y O8#^&& G;(QVY=:T[L.S?/-J5NV71[XS:(6(V
M!,6Y)FQ7U*D3 $)+:2V1X"M $GJXDZG@*]"-D&TS"K3FN(8U%LESQW))3SS=
MSF2RT]$2\-U84C3PB$\.&O1KUZ5N';=B5]M%OC085MC1XD9M+++*)"=U"$C1
M*1QZ !7I[T>3?!&?.$UJ:NF?23E"REH_^#,AAI/NS?-0/,&;]XR<;NR[&"RV
MV'1MT%UHY^1<'"8NAL991U3MF5JA8-@MWQ/:/LPF1%,3++C-G=A2I2W0AQ3R
MN<)4E'205.?H%7+:=L_S$[9\4SS%(=ONO<$-<&3#FR>8T"E*U6#U\%GHXZIZ
M.-;.]Z/)O@C/G":=Z/)O@C/G":U1MOI14M3;76L9>X4WTR#3=#FU"\NO1!DE
MYQ:1L64*&BVTC196#1>#A#A(+0 (^J,Y6D,C85M+M>&[0,)MD:R2;'>IRY[%
MP>EE+RP5I/-A&FB20E.I5P&ATUU%9SLWV29%C6V*U9%/9C)MD?%HMI<4W("E
MB0VA 4 G3BG5)XUM+WH\F^",^<)IWH\F^",^<)K-M6E_2JUT*M!]A@50X.(I
MO!)<UC2[.)(8W(1G@K-*QZ*HO94;7^21$N&$$D#LYQ6CEEY.6:P;-CD9V-!#
ML',G;T\!,20(R@V 0=.*O 5X-2%C^"Y5@>WC+<B$>UR<,R-:'I<V1*#;D1*4
MGAN'I\+AV:'7JK:'O1Y-\$9\X37CN^PR]7^UR[;<;7%F0);2F7X[LA)2X@\"
MD\>@U5:=+>D^D"]ELL1+*C7,<!3?D][7DC$<YKF@MQC"#(5-.QZ,L]UU&MSF
MD$<X9@%L'#(@P?):2;"L$;F;>+W&ART7'#\+FRY%M4V=YI,B3N@)!Z"4!*NC
MWH[:VUJ]8KR<Y>$6I-ML%@@6F"%%?,1G4)!4>E1XZD^,U>.]'DWP1GSA-:KT
MG9ICT@MPM LE6XQH:V6&3&+G.@1>>\N>8VNB3FLS19L>CZ!IFJV223!PZ@)Q
M@  #L6&TK,N]'DWP1GSA-.]'DWP1GSA-<C[/Z7_I*GU'?DMOK"R<5OB%AM*S
M+O1Y-\$9\X33O1Y-\$9\X33V?TO_ $E3ZCOR36%DXK?$+#:5F7>CR;X(SYPF
MG>CR;X(SYPFGL_I?^DJ?4=^2:PLG%;XA8;2LR[T>3?!&?.$T[T>3?!&?.$T]
MG]+_ -)4^H[\DUA9.*WQ"PVE9EWH\F^",^<)IWH\F^",^<)I[/Z7_I*GU'?D
MFL+)Q6^(6&TK,N]'DWP1GSA-.]'DWP1GSA-/9_2_])4^H[\DUA9.*WQ"]^Q+
M^%LG_4U_VT5.519LPP6\8SD#\JX,-M,JC*;!2\E1WBI)Z!]!J4Z^A?0BRU['
MH@4K2PL=>=@00? KSW3=6G6M9?3<"(&24I2N^6A2L/VMYE+P#9]=K]"89DRH
M8;*&I&NXK><2@ZZ$'H4:S"HQY2O\2F2?R6/]NW659&-?:*;'"07 >:QK2XLH
M/<TX@'W*#O=CY5\26;]MZ]/=CY5\26;]MZ]0'2O2=56+ACS7G^LK7Q"I\]V/
ME7Q)9OVWKT]V/E7Q)9OVWKU =*:JL7#'FFLK7Q"I\]V/E7Q)9OVWKT]V/E7Q
M)9OVWKU =*:JL7#'FFLK7Q"I\]V/E7Q)9OVWKT]V/E7Q)9OVWKU =4!!Z"#]
M%-56+ACS365KXA4^^['RKXDLW[;UZ>['RKXDLW[;UZ@.J!05T$'Z#355BX8\
MTUE:^(5/ONQ\J^)+-^V]>GNQ\J^)+-^V]>H") Z2!]-5UIJJQ<,>::RM?$*G
MSW8^5?$EF_;>O3W8^5?$EF_;>O4!;Z=-=X:=NM5!!'#C355BX8\TUE:^(5/G
MNQ\J^)+-^V]>GNQ\J^)+-^V]>H#I355BX8\TUE:^(5/GNQ\J^)+-^V]>GNQ\
MJ^)+-^V]>H#I355BX8\TUE:^(5/GNQ\J^)+-^V]>GNQ\J^)+-^V]>H#U ZZ4
MU58N&/--96OB%3Y[L?*OB2S?MO7I[L?*OB2S?MO7J Z4U58N&/--96OB%3Y[
ML?*OB2S?MO7I[L?*OB2S?MO7J Z4U58N&/--96OB%3Y[L?*OB2S?MO7I[L?*
MOB2S?MO7J Z4U58N&/--96OB%3Y[L?*OB2S?MO7I[L?*OB2S?MO7J Z4U58N
M&/--96OB%3Y[L?*OB2S?MO7I[L?*OB2S?MO7J Z4U58N&/--96OB%3Y[L?*O
MB2S?MO7I[L?*OB2S?MO7J Z4U58N&/--96OB%3Y[L?*OB2S?MO7I[L?*OB2S
M?MO7J R=.F@(/0=::JL7#'FFLK7Q"I\]V/E7Q)9OVWKT]V/E7Q)9OVWKU =*
M:JL7#'FFLK7Q"I\]V/E7Q)9OVWKT]V/E7Q)9OVWKU =*:JL7#'FFLK7Q"I\]
MV/E7Q)9OVWKT]V/E7Q)9OVWKU =*:JL7#'FFLK7Q"I\]V/E7Q)9OVWKT]V/E
M7Q)9OVWKU =*:JL7#'FFLK7Q"I\]V/E7Q)9OVWKT]V/E7Q)9OVWKU >H[:4U
M58N&/--96OB%3Y[L?*OB2S?MO7I[L?*OB2S?MO7J Z4U58N&/--96OB%3Y[L
M?*OB2S?MO7I[L?*OB2S?MO7J Z4U58N&/--96OB%3Y[L?*OB2S?MO7I[L?*O
MB2S?MO7J Z4U58N&/--96OB%;A;$.4'==I613;==;?!B(:82XTJ)OZE15H0=
MY1X:5<MOVVN[[)YMD9ML"%,3.;>6X9>_JDH* --TCWQJ%N2E_#V;_JR?[=9-
MRT?\ZXG_ -1*_M-5S1LE#6PH7>9&7_YE="+56U8:U[G3G_\ J%:O=CY5\26;
M]MZ]/=CY5\26;]MZ]0'2NEU58N&/-<]K*U\0J?/=CY5\26;]MZ]/=CY5\26;
M]MZ]0'2FJK%PQYIK*U\0J?/=CY5\26;]MZ]/=CY5\26;]MZ]0'2FJK%PQYIK
M*U\0J?/=CY5\26;]MZ]/=CY5\26;]MZ]0'5-X=H\M-56+ACS365KXA4^^['R
MKXDLW[;UZ>['RKXDLW[;UZ@+>3[X>6JTU58N&/--96OB%3Y[L?*OB2S?MO7I
M[L?*OB2S?MO7J BH#I(!\9JNH[::JL7#'FFLK7Q"I\]V/E7Q)9OVWKT]V/E7
MQ)9OVWKU >M-1VTU58N&/--96OB%3Y[L?*OB2S?MO7I[L?*OB2S?MO7J Z4U
M58N&/--96OB%3Y[L?*OB2S?MO7I[L?*OB2S?MO7J Z4U58N&/--96OB%3Y[L
M?*OB2S?MO7I[L?*OB2S?MO7J Z4U58N&/--96OB%3Y[L?*OB2S?MO7I[L?*O
MB2S?MO7J @0>@@_15::JL7#'FFLK7Q"I\]V/E7Q)9OVWKT]V/E7Q)9OVWKU
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MOSD#JRCLA6*].S"FXTSCAM'5E!/7G/:KO#V.V21L0&4JOL)J[./ZAQU]090
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M5J1D!A&X#'R^>["P.O33=WO]'6LVS[;S"O5ONDNRY3>8KTUC<18W;5'YI"B
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M1'F>C,_6P5[RK9!>LSRJ,U<+G:H<>!8&9CTJ!;EH"6B5A*>:22IQ?@J.HZN
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M@I)4DD'0C@1PZ:Z*V'N$'&\/V7S+\O%+7=9K.428C29+9"0V'7 $G=XE(2-
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M';Q/EJW4I4!H;D%423F4I2E2J4I2E$2E*41*4I1$I2E$2E*4135R4OX?3?\
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M%#3EN8FF0B. ^%>&-P+Z0CCKN]M8-*U6FI7##@TN=X-[O\ZEF5+-9Z=$N&)
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MOTY%W<0&US$NZ.+0.A*NH@=A%4N&T');LBY(F7R9)1<@A,Q+CFH?"?P0H:=
MZJQ_0]A\E-#V'R4Y*E,W1X)RM2(O'Q5QN617.\08$.=/>E18""W%9=5JEE)T
MX)[!P'DJKN2W5^T0K4Y<'UVZ$X7H\4J\!I9))4D=1U)\M6W0]A\E-#V'R57<
M9 $#!4WW9RLB;VBY0U?W+VB_SD7=QL-+F!W1:T#H2KJ('8179(VFY9*E3)+V
M0SW)$Q@1I#A=\)QH:Z(UTX)\)7 :=)K&=#V'R4T/8?)5OD:71'@%7RM3I'Q5
MY3F5]1;[;!3=Y:8EL<#T)H.:",L:Z*0>E/2>@UU9'E-WR^X(FWNX/W.4EL-!
MU\@J" 20D:#HU)/Z:M>A[#Y*:'L/DJL4V W@!*I-1Y$$F%*65;0L?MNS1.$X
M@JYO0Y4KNR?,N0"%*/ AM*4\--4IU/\ H]>M8AC^T?*<5@*A6B_SK?#42HL,
MNZ)!/20#KH?HTK'-#V'R4T/8?)5EEFI,86$3)DSC)WJZ^T5'.#@8@0(P@+(K
M;M&RFSV]<&%D%PBQ%/&0IIM\@%PJWBKMXJXGM/371,S>_P!PBW*-)N\I]BY.
MAZ8VM>H?6--%*[2-U/D%630]A\E-#V'R5<Y*F#-T3V*WRM0B+QCM2E-#V'R4
MT/8?)5Y6DI30]A\E-#V'R41*4T/8?)30]A\E$6XG)+_@#_WSO]LU.PZ*@GDE
M_P  >S[\[_;-3L.BO)K?\[J_W'WKTZQ?-J?]H]RK2E*P%FI7BNT-B? >CR66
MWV5@;S;J M)^D'A7MKIE?B55(P*@XA8"=GU@))]BHGF[?HIWO;!\5Q/-V_16
M2=M*NWW[U:N-W+&^][8/BN)YNWZ*=[VP?%<3S=OT5DE*7W[TN-W+&^][8/BN
M)YNWZ*=[VP?%<3S=OT5DE*7W[TN-W+&^][8/BN)YNWZ*=[VP?%<3S=OT5DE4
MI??O2XW<L<[WM@^*XGF[?HIWO;!\5Q/-V_161ZU0J [/+2^_>EQNY8[WO;!\
M5Q/-V_13O>V#XKB>;M^BLA+J1^4*XF0@?E?T4OOWI<;N5@[WM@^*XGF[?HIW
MO;!\5Q/-V_15^,E'C\E4,I([?)2^_>EUFY6+O>V#XKB>;M^BG>]L'Q7$\W;]
M%7SNM/8KR4[K3_I>2IOOWE+K-RL?>]L'Q7$\W;]%.][8/BN)YNWZ*OHEH\?D
MH939Z_Z*7W[REUFY6'O?V#XKB>;-^BN*L!L _P#E</S=OT5?2^D_E"J<XGWP
MI??O476[E83@-A^*X?FZ/15/:!8?BN'YNCT5?M\4W_\ SK4WW;U%UNY6#V@V
M'XKB>;H]%/:!8?BN'YNCT5?N<T_*JG.#MI?=O2ZW<K%[0;#\5P_-T>BGM L)
M_P#E</S='HJ_<X.VN7."E]V]+C=RQ_V@6'XKA^;H]%5& 6'XKA^;H]%7_>%5
MWJ7W;TNMW+'_ &@6'XKA^;H]%/:!8?BN'YNCT5D&]XZ BE]V]+C=RQ_V@6'X
MKA^;H]%/:!8?BN)YNCT5D&M*7W;TN-W+'_:!8?BN'YNCT4]H%A^*XGFZ/160
MTJ+[MZ76[ECWM L/Q7$\W1Z*>T"P_%<3S='HK(:4ONWI<;N6/>T"P_%</S='
MHI[0+#\5P_-T>BLBI2^[>EQNY8[[0+#\5Q/-T>BGM L/Q7#\W1Z*R+KI2^[>
MEQNY8[[0+#\5Q/-T>BJC ;"/_E</S='HK(>D4I?=O4W&[E8!@6/]=KB#_P#K
MM^BN7>_L'Q7$\V;]%=V6Y=9\$QZ;?K_<&K7:(:4JD2W@HI;!4$C4)!/%2@.@
M\36*P>4#L\GP%S6,LAAA$M,%?.-/-N)?4TIY*"VM 7J6D*7KNZ;J2=:B^[>I
MN-W+)>][8/BN)YNWZ*=[VP?%<3S=OT59K+MTP*_ILO<.66U]V\S%V^WQ^<4A
M^1(0-5M!E0#@4D:$[R1IJ->D:^F[[9L)L&;P\/N.1Q(>22^9#,!U+@4HO;P9
M&_N[@*RE02"H$D:#C3E';TN-W*X=[VP?%<3S=OT4[WM@^*XGF[?HK(]X4!UI
M??O2XW<L<[WM@^*XGF[?HIWO;!\5Q/-V_1624I??O2XW<K58\0M5JN*'HD)F
M.X/RFFDH)^G05D-\ALRXP0ZV%I\8KIA_Y0FO;<_Q(JV229*K  $!8U[7H'P=
M/D%/:_ ^#H\@JY4J45M]K\#X.CR"GM?@?!T>05<J416WVOP/@Z/(*>U^!\'1
MY!5RI1%;?:_ ^#H\@I[7X'P='D%7*E$5M]K\#X.CR"GM?@?!T>05<J416WVO
MP/@Z/(*>U^!\'1Y!5RI1%;?:_ ^#H\@I[7X'P='D%7*E$5M]K\#X.CR"GM?@
M?!T>05<J416WVOP/@Z/(*>U^!\'1Y!5RI1%;?:_ ^#H\@I[7X'P='D%7*E$5
MM]K\#X.CR"GM?@?!T>05<J416WVOP/@Z/(*>U^!\'1Y!5RI1%;?:_ ^#H\@I
M[7X'P='D%7*E$5M]K\#X.CR"GM?@?!T>05<J416WVOP/@Z/(*>U^!\'1Y!5R
MI1%;?:_ ^#H\@I[7X'P='D%7*E$5M]K\#X.CR"GM?@?!T>05<J416WVOP/@Z
M/(*>U^!\'1Y!5RI1%;?:_ ^#H\@I[7X'P='D%7*E$5M]K\#X.CR"GM?@?!T>
M05<J416WVOP/@Z/(*>U^!\'1Y!5RI1%;?:_ ^#H\@I[7X'P='D%7*E$5M]K\
M#X.CR"GM?@?!T>05<J416WVOP/@Z/(*>U^!\'1Y!5RI1%;?:_ ^#H\@I[7X'
MP='D%7*E$79C]M8@ETLMA&]TZ5>ZMUK_ "ZN54*M*4I1$KIE?B55W5TROQ*J
M*"K+VTJFM44L"JU2N54UKJ4\-.'&NM3JCXJ0HE>@J K@7@.O7Z*Z.GIXTTJ8
M25V%_7H'EKB75'KT^@5QII4PH0DGI)\M4(JM4THHA-VFE5TII1(7'=INURTH
M:(N.[K5"D"N1-<-2L^"":(J$"N)TZJ[DL$\5'] KL2A*>@:5,HO,EI:N@:"N
M8C]I\E>@U2HE(75S"1VU0QQU&N[2FE)4PO.6#7$H4.D5ZM*II25$+R@:5R%=
MY2#U5P+0ZN%3,HN -5"J%L_37'\$\112N>M5UKAK5=:A1"YZ_HJNI%<-:KK1
M1BJZU7>JFM.!HIE<M:K7#2FI%%*YZTKCO54'6B*HI2E0BK5.NE63+LVQ[9_:
M/97)KW L%MYQ+/==RD)9;WU'1*=5=9])Z :(L:V_8@UG>R'(;-(O<;'(SJ67
MGKK,<+;49MI]MU2RL$;O!L@*U&A(-1[C^SJS9UEZMHFS++X%YEP<<D8["ND]
MQ^Y+;N)5O-27UJ.KJD,N*1X6JBE>FN[5^VXW+#MJ&S;*\=:S_&[7*M3D29,>
MES&76(:VGVWFDS&]\$-+4A*2">(5PX\*@O*<+RF\2\@E77;1A!FW:R3G%0IN
M0/O(M=K?7&>1(8<W4*4@*9<T4M("4NC12@.-*D+.\:P>WV3!\+R"\WZSAVPY
MUW7<+ZS#FN.W.4M2X:T.+>3SG.N274\1HT E.Z D C)=J7)CO&>;2;AET'(E
MVV246L18+B'U1]Z-W0E;CS:2$K<'/A;+FFK;C8/$$U$-TY.5ZOF3PX;>T'$K
MI<[FZF^VAJ?/E.R(L5%S7,4Y%92K=>;<0MM*U*&@+:0#H01C<;8? MDC([;E
M.UG"F(UK9?\ 9.V-7I^.U!G282H[;RQX ;"GRTYN]13IQ4.)2LXQGD'Y#8+
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MWQ]UA7WM]7;SK*F7=>O?-8[E6Q2X;:L[QRY[0[?&CX_9K,X6;3:[N_O"ZON
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M65I0"LN K47=4D>#609A<59;!M]BL<?+;C=,?Q&#+G&TY/[!6ZV<ZP5-/..
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M EP* !TZ*\/)PVAR]J6QNPY!<)+4VX+,B'(F,-\VW*6Q(<9YY*>A(<#87H.
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MZTOO:#7BYQTK;Y+J5>(]AK3$_=1]E_5C66^;Q?\ CU3_ )4C9C\FLM\WC?\
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M/&9W8EY"),MU"'%M[HWE--%7'7FU#J-;$VZ\P+J[,1!FL2W(4@Q9*6'0HL/
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M:M+4&6A04E2)"WT+5OO)*$D%*4#4:E)JDA5 K@,[VA8%F&&0\[1C,ZT91/\
M8@+Q]F0R[;)JFENMI475J#[:N;6C? 00=T[NAX8"YRBMI3&S [1Q8\;DV*+?
MWK,[94%]$R8CN]<-MYM\K*&CO\WJA2%:@+.HX"I-L>R&^S,FQR[YKG+F9-8X
MZ95KB(M+4!/=);4V),@H6KG7$H6L#0(2"LG=UTT\QY/44[&E[/\ V;?YA5X-
MW[O[G3O[QN7=W-[F]IIKX&NO1Q\50JEY+=M,S;&\ZR+%,O;Q^;+8Q=W)K?,L
MK#[+:>;<4VY'=2XM15HO=(<24[PUU2DUB]MVX[2(FS3"=IE_MF-M8I>O8U,^
MSPT/]WQ&I:FVTR$/%90K1QU*BUN<$'3?)%23M V?)DY-?LZ3+<,E.(3[&FWA
MH%*@M:G^<WM===1N[NG'6HOV,[#KUDVQ[97$R/,IDW$8%NM=T3C;MM;:>4\V
MTVZTS(D[V\MIMP!01N)5X*0I1THB\L/:NUL:Q[;;?^88D2W=I#ENAMRG%-L&
M0^S#;0IU205!M/%:BD$Z)( U(KRRMON39AB^TG';=?\ &;I=8.+/WJ)D=CA3
M&(Z&TA2'V%-K<WD/I\%3:TK(.NI2-W0RG<^3W!NMAS2WN7N;&D7_ "495%N$
M5M"7K7,0&.94WKJ%[BF ?"&B@I0(J]VS LFN-BR&U9MF:<HC7: NWAJ%:&[<
MAA"T+0XL:+<4IQ07TE6Z-!HD<:(HIE;;,@V4['=FC5\N5@=R+)T,,0[G+9DH
MA1(R8:'EO24A:W'7 !IHE20M:QQ2 37&R\J:ZS\=O4.-'LV2Y4S?H&/VF?;D
M/QK7<')J2IIU0<U<;#80[SB$E7XL;I\+AF2-@UY5A.(VY[.7?;1B$A+ECR./
M:FVRTT&.Y^9>CE92\E;6H6=Y.IT(W=!5RR+8]>\YPA=KR;-WYE_8N;%WM=[M
MUL:B"V26""R6F-Y86G7>W@XI6\%J&H&FA%A5E3E['*TQIC+G;+.>1A5S5&GV
M1AV.AQ)F1-Y*F7%K*2D@:$+(4#T)(TK*;_GSEEVKYW$8L]K[HLV#M7INY*8_
MYT\KGI.C#BQQ+(+04$CK4H]=>O%]CMY@[4(6>9'F;N17B/9Y%F$=FVMPHB6W
M'6G=YMM*U%)U;XDJ45;W2 D"KG>MDC-YS+*\@5<W6EW_ !A.-+8#((92%O*Y
MX'7PC]_(W3H/!''C10H]QG;-M![DV39#D=NQUG'L[>B05V^ E_NVWO2(JGF7
M2ZI90XE1;4%(" 4A0\)6A)R+E/7:>Q@5FLL">_:1E&16W'I5PBK*'H\:2[H\
M6UCBA:D)* H<05\.-7A_8RP_BFS*Q^RKJ481-MTUI_F1K+,2.M@)4-? W@O>
M)&NFFG&LCVA[/K1M/P^?C=\;=7 EA"N<CN<V\PZA06V\TL<4.(6E*DJ'01]-
M$4,[;]@^";/]BV19%AV.6S#<CQ2VO7>T7JU,!B4P]'07 %NCPG4KW2E:7"H*
M"CKQK!.5'M-C[7=D>8XQ%ND2W0;5C2KID8[J0VX]-5%#T>UMI*MY6BBEQW37
M1*6T=*R!FVTW87M8R?$V;8[M'A9M;(TIA^1CMTM+=L%Z8;6%&/)F,J41O: D
MI0E*B-%#0FLZSSD_XAM5PJ^Q;CB-DL5_OL%UEZY-VZ-(E0WG$:%Q+H2-]22=
M0H$:Z#HHI6?8C.CW#%;-)BR&I+"H;&Z\PL+0=&T@Z$:@Z$$?HJ!<CP3#WMJ^
M%6'9QC\&'DN.7UN[W^_6U@)5;XA2LO,29/X3KTG?">94I2M/#4$@ U/N.8Y"
MQ/'8-FM,:/;X<)A+++45E+3:"!Q4$)T U5JHCM)J)-F^PO.=F=IM]HM^U%E^
MT,2529#+V+QR]+4MS?>4X]SN\7'"3JYQ/'7JHH6#C +#M7Q/;SDN26]B9?VK
MQ=K?;[D^@&3:68#"1%$9P^$R4K27=4$:J62=:R:Z3\"O6R3"LVVC8S!RK)KY
MCT.-%MLB"F;,GO.L)<5'BLJUT4M2R5*2!NCBI02GA?\ *.3],O%TRUJT9G,Q
M[%\P=+]^LS$%MU;KBFTM/*CR%$*CEYM"4K\%?6I.Z3K7/)=B%\?VC1\KQ7-&
M<7,6RLV.+!=L34]N*PA2E*YHK<3N;^J K0<0V@'HHI71B6QV5)Y.>*X=F\VX
M+EVVW(,]F#<W6^>*4+*8SKJ"%.M)"DH(U 7S8U)'3[^2> CDS;+P  !CT70
M='@UG5@M=U@8PF#?[XB^W(H<0[<6X2(@<"M=W1I*B$Z @<#QTUZZM.S+$$;,
MMG.-8C'F+N#5D@-04S'6PA3P0--XI!(!/9J:D!4DPLQ6XE U)TKS.2R?P!IX
MS70=5'4G6E50J24)*CJHDFJ:4)KD&U*Z!Y:E4KC5"=:[PP.LZ_17-+:4] HI
MA><)*N@:UR#2CXJ] JM1*F%TA@]M5# [:[:4E2N',I%.:2.VN=*A%[+8PDE9
MXBO?S">HFO):_P NO?5,JI=B/!2!KT#2E521H*52JH7.NJ5^)57=73*_$JHA
M5E[:4[:56J4I2E$2E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4JE$5:4I1$I
M2E$5"D&OF!]U8&FV/#/^SI_O;U?4"OF!]U9_CCPO_LZ?[V]6]T+\\;V'W+4Z
M4^;'N6DU*4KT5<0E*4HB4I2B+ZG?<R_XB#_.LS^M%0E]U;_C/P+^8GO[TJIM
M^YE\=A!Z_P#TK,_K14)?=6_XS\"_F)[^]*KB;+]+N[7?BNMM'T>.P+1ZE*5V
MRY)*4I1$I2E$7T;^Y9K"<*RP$Z?^ET_[!%;$<I+\3CW\M_\ J16NGW+<?^I>
M6'3A[+)X_P#<(K8;E%_B,?\ Y;_]2*XNG]-=Y_VKIJ_T5W#WA0M2E*[=<2E*
M4HB4I2B*4=@G^?I?\E'^]6PFO'Z*UYV#*TO\O^2G_>K80*KS73'SZIW>X+T3
M17S-G?[RO1$_RA'77MN!^\@ZUX(BASZ/IKW3SJS6E6W5MIKU_P!-*5*(:II5
M:414TJFFM<CH!459SM*O4:_R;+;HQL,>/H'+Q<&0MQ_4 _\ -62=TI&NG.N<
M-=0E"M-:NTZ9J& J3@I2YLJZ 3]%4YM7#@?)47X>_;Y]GR=<V1,O:NY6^?7=
M9:W]X<YT!'!"!KU(2FN^U-8^WCV3JBVUB"!#3SBX2E,+(WQIHI!!!UZP0:MO
MYE44EG4[-RE!U:<NK#QG\"I'UIK4'Q]H5ZQE8<M\]S(X23X5KN[P+Y'8S*T!
MWNQ+H4#T;R>FIDLUU:OEO9DH9?B.+0A;L.8@-R(RE)"@VZWJ=Q>A' _3Q'&K
MU2D:>)6  2O;5-*KNFJ<15E%4*[:Y UPUUIT44KG36N(55=:*56JU3>IJ.GJ
MJ$7)*BCB#I7>W)!_"X'MKS:]5-:)*N 5KQU_352=3J3J3UFO AQ2.@UZ$2 >
MGP340JI7?2J:\ >H]!JM0I2E*I1%6E*41*4JFHHBK2J%0%=2I"$_E#]%$7=5
M-:\JYGO4^6NE;JU])X=@J842%ZUR$HZ3J>P5T+E*5^"-VNGHJFM3"HDJI)4=
M2=3XZ:Z536N2&RHZ] J5"XZUS2T5=/ 5VI;"?IKE42JH7%+:4] XUSI2H4H*
M4I1%6J56E$2E4-5HB4UI5*(KA:_RZN%6^UG\.O<5:52JEWIUT%*HCBD'Q4JE
M5+MKIE?B55W5TROQ*J(59>VE.VE5JE*4I1$I2E$2E*41*4I1$I2E$2E*41*4
MI1$I2J:T1#T5KSGVVW,,5Y1EKQ9UNWV7%7H95!]D8KJE9$^4H)8CR H-M/I5
MJVE"M=222#O(TV&J-\KV"8QFFT&VY9=W+I*?@^&BV*N+W<"GDELMO<QO;H6@
MM)4-!H5!*B"4BH10IA/*SSG)+)ER5X[9'\@M>+HR=N*XW-MS4$!;B)$.1SR2
MMUUDH'A-A*5DD>#IK7NC<KB[VS:+L\AY!!M</#K[B]NNMUN;:7$N0I<MI];8
M!*RD-%3"D\03JH<:FBR[$,5LD+)&0W<KE(R**8-SN-VNC\V:_'W%(#//NJ*D
MH2%KW4I( *B>FK3>^3+L[R.QO6>Y69Z5;WK/!L*VE370>XX;G.1T@@ZA25$Z
MK'A*!T)THI5GY+NVO(MMEERN=D=IAV9ZW79,>)&BI6%"*[&:D,\[O*/WS<=3
MKIH->JILK'L7P2RX9/O\RT1E1GKY,3/G:NJ4E;R6D,@I2>" $-H&Z.'#6L@U
MJ5"K7S ^ZL_QQX7_ -G3_>WJ^GVM?,'[JS_''A?_ &=/][>K>Z%^>-[#[EJ=
M*?-CW+2:E*5Z*N(2E*41*4I1%]3ON9G\0Y_G69_6BH2^ZM_QGX%_,3W]Z54V
M_<S/XAS_ #K,_K14)?=6_P",_ OYB>_O2JXFR_2[NUWXKK;1]'CL"T>I2E=L
MN22E*41*4I1%]'ON6'\"<M_G<?W=%;#<I-(#6/$ #PW^KQ(K7G[EAPPG+3__
M "Z?[NBMAN4I^)QW^6__ %(KBJ?TUWG_ &KIZ_T3W#WA0A2E*[A<0E*4HB4I
M2B*4-@J0J_2]1U(_WJV"+>G0?+6ONP503?Y6HZ4I_P#&MA H'H/Z*\UTQ\^J
M=WN"]$T5\S9W^\JL8*2^C@3QZJ]LUS5G2O/$'_.$:]M>RX@%GB*TRVRM855=
M:H6QU5Q*5#QT1=FM-:Z]XCIKD@[ZDIZ-X@5*2H)VP;;F4[4+3LPQ?*6+3G+2
M&;W(@O-#2=%!5I$0ZH[J75G=)0H J0= H$BLGLV8XWMPMKU@NS1M.1Q=X*B*
M\!]E8X*6SO<2!UH/$=8TXUJIE'+3V9#:E?%W'8_;KA<FY+D)R]2#'4\^&E;B
M5*462K0[@T!)TT'963N<NW"9=R;N;VSMAVX(*5(F+FL%X%(T20OF]> \=8!M
MEG-0.H/,C,'?U;EZ)2]%]+NLW)5K&=[7 L!QV''$=N(4J0\6ONS2S;1&[I]_
MA>QK*XEP:'WM\<]Q&GY*AJ-4GMX:CC5EP*]3LFQ7/(=M8=G3U6UI+$=D:K6H
MO  "H^S_ )==DS?";Q8F["N [<&.9$A5P0X&SO ZE(0->CMZZP78SRGK/LLN
M%Y?F0Q>VKC&1'+*9 :W0%$G4E)U!!TTJNI;&OM#:QV1Y+;V3T5TDS1->C4HD
M5"<!(RYNV8WYE3YC"SCMV:M%EYK)\[7KSCS!#D.U>^W5'@M:>MP^"GH&IK)\
MMRW!>2C8Y.:YO>E)NMW6Q$EOM%2W)2@LA&XUJ-X(WE:NJX[O#7\%-1%:N7EA
MF/AT6G9^Q;P[ISG<<UAK?TZ-=UL:Z5BFT3ER[.,D1O7S9+!R20L);/=[T>00
MA)U )4RK0 ] J#;:!J\M:GSV?@M96]&=-<EZO9+*6M(Q)<V7;<>=E.0[UONP
M^U*9;>8<0\PZD.-NMG5*TD:A0/6""#^FN>FM1WR?=IMOVO;)+%DMKM/L%"=2
MY&;MH6E0CAI9;"4E( TT2"  - 0.JI%Z:RVN:\!S<BO/Z]"I9:KZ%80YI((W
M$8%<=T&J%%<]*5*QUY>ZV#,,3GV3+#?.F.'$\X$:Z;VYKKNZ\-=--:[:P1K8
M?B[6VMW:JEN9[;';8+2I1DGN?F1IQYO3\+0 :ZZ=>FO&L_(!ZJ*(6";<KS/Q
MW8KGMUMDMV#<H5AFR8TI@Z.,NH84I*TGJ((!%8IMRRV\X[R6;]D%LN4F!?&+
M#&DM7!E>CR'5<SO+![3O*\IJ2LVQ2/F^&W['93BFHUWM\BWN.(&I0EUM2"H#
MM&]K^BH/NF#[5\[V;0]F60V*Q6ZVJ;BP+IE<6[\^),1E;94IB)S86EUU+0&B
MU;J"HG4Z"BD+GF>VB]XKR@,BQ"U+5>;W=;%:4XW89+F[%3+6J6J1)</Y+:&V
MTK<(XJ"$I2-34TX'CT_&<9@VVZ7^9D]U&JI-TG$!3[JSJHI2.#;8)T0@<$I
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M //)"SS:$JU;T;5J#J:F5,*5-GN:V[:3BD7(;4A]$"2Z^TA,EL(<U:>6RO4
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M\M-Y7OCY:<O9N /K._-.2K<7R"L.%Y&]EF)6B\2+7*LLB=$:DNVZ:DAZ*I:
MHM+U \)).AX#B.BOE;RU-CN?9-RHL^N=GPC([M;9$EA3,R#:GWF70(S()2M*
M"#Q!' ](-?6_IH%$=!(_34V*VFQ5348V9$1WJ+591:J8IN,0OA)W@-J'S;Y;
M]AR?4IW@-J'S;Y;]AR?4K[N;RO?'RTWE>^/EK=>T%7ACQ6JU-3Z97PC[P&U#
MYM\M^PY/J4[P&U#YM\M^PY/J5]W-Y7OCY:;RO?'RT]H*O#'BFIJ?3*^$?> V
MH?-OEOV')]2@V ;4-1_[-\M^PY/J5]W-Y7OCY:;RO?'RT]H*O#'BIU-3Z94
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MJ6%-Q2V 9###:U%PK*AOM@;Y\(#:Z7AMNGWRW7J3:HS]VMK;K4*:ML%V.AT
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CI*EG4D<3KH.G3JUK+Z50^N]X@JIM-K3(2E*5CJZE*4HB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2128727d1_ex99-2img007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
M'0 !  $$ P$               @"!08' 0,$"?_$ & 0  $# P$#! T'" 4)
M!@0%!0$" P0 !1$&!Q(A"!,Q4Q05%R)!4556D9*5T=(6&#)ADY2B(T)25%=Q
MH=0S<H&QX0DD-F)T@K+!TR4T-3=#LV-S=;0F1$5&@\+P.66C_\0 '0$!  (#
M 0$! 0            0% @,&!P$("?_$ $H1  $# 00$"@<' P(% P4   $
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M!*1-?2E(& /RJ@ !4[-$:/MNAO\ *J2+7:(S<.WJ<DRVX[*=U#9>@%Q82!P
MWE*.!P&<"M9<FVWVS0^FMN&V69;(MXN^CG.QK''FM\XRU,D/+2'RGH)3E&/%
ME6,$Y'P6L"HZN!,L9 [W%T?FAH]$,)T%W@ HS3](WZUV],^;8[I"@*XB5)@N
MMM'_ 'U) _C5I)P./#'CJ36R/EK[41M2M"=5ZF?U;IR[3FH5TLUS::<C/,/.
M!"PE&YA! 5D8X<,$$&MFZ:V&:0V2<I/;G?YMI9NNG-FUN[=VNS/#>94\^WSK
M"% YREOO@,]'>G\VI#[8^@2VLW.)$&9S C,#.2-ZUMHBI!8<I@SO4+UZ/O[5
MK%S78;JBVD9[-5 >#./'O[N[CZ\XK?NV^SP(?(YY/,YB%&8FRG+J)$EME*7'
MMUWO=]0&58\&2:Q6]\LS;)J.7=')VMI:HES9=C2+6EIL0@TXDH4VEK=PD;JB
M <[W0<YJ2VG-@G=PY*W)_P"V$U5NTEIV/>+I?),<<Y*[&2Z>\8;&5*6K!&0#
MN]/$X!TVFL^B:52T0 ':B3]EW</FLZ3&OQMIYY:_>% @VV8( G&')["*MP2N
M97S6]T8W\;N>GAFO*H$I(!P2.!\5;AY0/*!=VO2K=9+#!^3.S>PHYBQ:=8.Z
MAM &.>> .%O*XDDYQDC))43I^K:DY[V!SVP=GUK41X:##3*D1RC]F>EH^R39
M+M-T/:&[-9]0V]4&ZQ&'%N(:N37TR=]1(WB'1C.,-CQ\<4Y*.R:-MGVZZ>L%
MS;#E@:*[A=MY12GL1E.\M)4.("CN(SG\ZMF<G91VP<F':SLG<//76TH3JZPM
MJZ=]K'/H3^_ &/\ XIKHV,O=QODB;2=HF2S>]9/(TC9',X6&<%4EQ/U8W^/C
M;%5!JU*=&I0!Z8.$'7TM!^ /@IF!KGMJ1E$GX:=_ZK2&LK?&UIM%U*]H+3<I
M.GS.=[7P+:P])YF,"0WDC>.2D;W$_G&L47%>A3Q&DL.QGVW$I<9>;*%H.1P*
M2 1_:*E/L?C\HJ;L@L+.C[M%V>;/XJG.Q[O)FQK0B:M3BE*<6\O\H]C.Z".]
MPD#CBK[RY[))E;.MB.K+[<K+?]8SH\JW72^V%U+L:X<RM&XL.) "R.^!('25
M < *W,M>&LV@8()(R,D0)SRUQMTK6:,L-3/;H@9[%@O+UT_'@\I>3;K-;&V$
MKM%N+<2WQ@G>46B3NH0.)/U"HWN-K9<6VXA3;B"4J0L$*21T@@]!J?NT7_\
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M3W+8*T 2T$C0I,\GO;[;'^6HG:CKB>Q8;?/D3Y,AYS>6W'#C"D--]Z"3@;B
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M7P&[(9ZYOUQ3LAGKF_7%??GN0:$\R]/>R8_P4[D&A/,O3WLF/\%.<M/LCO\
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MV[4-H<6Y;YS?.-\XG=6D@D*2H> @@@U1VNZ;TL%G;:K33+6.@ R-<D2 9&(
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M.V?F$%WF0,J=4H'=0$C&0>/?#&:6?@U?MJI"O1H.+<\Y T.P'208#LG'0-<
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M-8_I;7MCUI+O$:SS>RWK1)[#FIYI2.:=X][D@9Z#Q'"O1:/]0.$+G.MK6AV
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MKCMGV:WC2>G]MU_F-,IL]Y3!$%3;P4XI*'4 [R?S>%2FT_IZVZ5L\6U6B&W
MMT9)2S&9SNH!)) S]9)JG4>FK7J^S2+3>835QMLC =C/9W%X((S@CP@&NG']
M0:S;UX]E(-LW&EY:!TB#695)]:,9XMH.>'* !I57S>8;+@+B:F&))RD,<P#1
MZHQ'O4?+/LVUYM.G;,W-2,VB#I;3;;$]N5"?4IZ<>;;* 4$=X<)2#X!Q(SPJ
MPVODQWK3EPN5J?T98-86R3-4['N\V[OQ5M,J.2E;*#WQ \7A\)&,2NA0V+=#
M8B1FDLQF&TM--IZ$(2,) ^H  5W56#A]>= NIV5K64B(#6XVQTG/Q2UX=B)<
M9Z6$S&&  )/-^ROAU4ES]I@Z@(@@B( C*>^5%S5?)XU7/M^UN+;XL(-:AF0G
M+4E4L#+32SG?S]'"<=/36>:&V6W^P[;KGJ>8U'3:9&GHMM0M#X4OGFVVDJ!3
MTXRA7']U;GI5?:.&EYVJSOLU0-PO:6G(S!;29UM,46?'%M$2*=R66E4;5;,@
MSI[WG9M>?!0^A\E75D?0^GE/0[9.O%GNTN0Y:)$U26)D9[F^'.HP4J!0?%T]
M/#%;RV(;/5:,C7:7)TC;-(S9SB$F/;KB[-+C: <%Q:SC>WE*X#P5L^E97OPU
MO6^[,^RVHC"XD]'&-+L9$8\)&+,8FEPU&(2QW)9+#5%6E,@ 9P= B9B1EL('
M<M@[$O\ 2V3_ +&O_C16\JT;L2_TMD_[&O\ XT5O*O7?Z?\ _91_J=^BY&__
M /K3[@E*4KTA<XE:3VY?Z16__93_ ,9K=E:3VY?Z16__ &4_\9KSOA]_V.I_
MJ;^870W#_P!<WW'\EKBE*5^8%Z>E*4HB4I2B)2E*(E*4HB4I2B)73-E-PH<B
M0ZZAAIEM3BW73A"  25*/B&,FNZO)=K7&O=JF6Z8@N1);*X[R <;R%)*5#/@
MX&ME/!C'&>K.<:8UK%TX3ATJ+MDV\ZIAZYT:?E,O5M@OMQ3;WU'3AM\0%2@G
M,9Y7?.8)\/@''IKRJVN;5+MH/7NIX>HK;#BZ6NCC(:5;4+=D-A83N9Z $@@Y
MQE63Q&*V=:.2O8+2K3A5J+44Y&GYJ9EN9ERDK:8 4%<TE&[@))&21Q/C%7J%
MR?K#!T1J_2Z)]Q5!U-*7+ENJ4CG&U*4"0WWN,=Z.D&O=JW"#@E2J-?0H-<0Y
M@)=19FP527'"&M;B-(P2&@D]X!7!,N^]WM(J/(R<<GG26B,Y)C%GI_.%KZT[
M6->[6M?V[3^EKG;]+HBV*+=YTB1#$GGWG4-JYL)/$(RL#A@])ST5Z>18'4Z+
MU>)&YSXU$_SG-_1WN;1O8^K.<5E,[DS:>D7&RW"%>+[99]OM[5K<DVR6&7)D
M=M(2$N$#I*1@E..&/$",GV4;)+3L?LT^V6>1+D1IDM4Q79BDJ4A12$[H( X8
M2.G)^NJ:]K\N)URU[!=@PXQ2AO%P98YQ>75-+ID%H/JC(1FIMDL%O%M97M1G
M#BSQ2(($ -U1KC3IS6!:NUWK76&VJ7L^T==H>F6+7 3-G7.1$$EUPJ"2$H0K
MA@;Z1Z3GH%=^@]=ZN5MNU%HN^W2/<6+386)1<8B):"Y!#>\X,#(!WCWO0,UD
M>OMA%GUQJB/J9BZW;36HF6@P;C99 :6ZV. 2L$$' X9\6 <X%6V?R:[%.OUO
MNZ;[J*+.8@HMTI^/.W'+@RD8P\O&\21P41C( Z.FHU*\>#K[$VSO#631P_\
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MDE).3T>,XQ7.I.3E8-0ZPEZB;NU\L\FX,"/<F;9,YI$Y 2$_E#C/$ 9P>./
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M(Z!.3BT XA!,:8&K6K19]5C2NTG;S=DWN+IQ8>A!JX38RI"6BI70&D\5J(R
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MYX;I#F1GQ9\/"ZQ=J^T;3UZV572^7FW3[)J_<:>ML:"$*9!2C*]_I*B%A7#
MSD8Q6>*Y,-@>=U$_)OE^G2K];4VV;*F24O.K2%(47-XI^D2V/]4#@!5^N.Q"
MRW)G0+;DV<E.C'$.0=U2/RQ2$ !WO>([P=&.DUU]>_N"A(%.SM(?BQGBFS_R
M,(PY##_> =T0V,R )(513N^]HEU0R(CIGM)SSSZ&6<[%'C6&M-?[6]AVN-7O
M7>W0])\^J(FP]A@N<TAUOOP]TA8)3TY!X]'"I/;'QG95HL>.T1/_ &DUKR=R
M1]*RF;S#9O6H(-FN3ID*M$:8!%:=SG?2@IXX\ 5D#Z\#&W],6)C2U@M5GC+<
M<C6^.U%;6Z1OJ2A(2"K'#.!5%PJONZ+;=K+'=4!HJEX:*89A86-: 2/7<"#+
MC).TB%/NFPVRA:36M>9+0"<6*3B)D;!GD-2B]:MJ&UC4^SG6FJXFIK7 C::G
M2$AI=M0MR4AO!*">A( (QPRHD\1PJ\:DVX7W4-DT[+LNJ%V6[3+&BXN6.U:?
M5<WR[E65N*/!ID[HQX<$D\*LFQSD\#6VG-3-ZBE:DT\R_?'N>@,.F.U/9!"D
M%:%)XX).%#_D,;?NW)PTY/U$U=(-PO%@3VN1:I$.TR^9:DQD)"4MK.-[& ,X
M/' \/&NRO2W\%;#>#Z%1C)8YQ;@HT\(&!L,=+7!\NQ.#H);D 6R<-+9;/>M>
MSBHUQAP ,O=,R>D,P6P($3GL.O4['* U_JJ#LH397[=#N>I>RXLL/1@IA3K;
MFX'?"4@#OMU/21CHKS[1K!KQO;KLOA3-80WKX[&=$6>BVIYJ.X$D.++? +WC
MDCHQG%;=T[R;=.Z:>T6Y&N-S<.E77WH8=4WATNJWE!S">@'HQBKOM0V*VO:A
M/LMQ?N=SLEVM"E&)/M3H;=0%8R.(/A&01Q''QU6,X47!8[Q8+OI,IT2VT-<[
MB6EP+S5%.9!):&N8"!I$M,C)2777>%:S'TAQ<\&F0,9 Z(9BT9 DAT';F(6E
MW=IVU*]0MJDFVZCMT&+HZ4LI+EN0MUY"-[+8\ &$DY())P.'&NFX\I34NHI.
MD+7$GG32I=C;NERN,&SJN3JG5;P"&V1G=1WN2?!O8SPX[GM.PBR6BU:Y@-S[
M@ZWJ\K,Y;BT%;94E23S9W?\ 6/3FK4_R:;$W$TX;7>[Y8;O8H?8$>\6V0EN0
MXQE1W'.]W5?2/@'32G?_  3=4<*MG:((P$4FB)H@$O&$APXT$@.:^)D C)?7
MW?>P:"RH<_6!<>N2 ,Q'1C01LE:J:V][3+P=GMMC(C6N]W:;*MTD7"WEIJ04
M%'-O[JAO)&ZO)">DI(KU:TVG;0]$ZQCV#56L$Z7MS4-OF=1LZ?3)BW%\\5*<
M./R:1G&$CAN\1QS6X3L.MKUVT=<YE\O5SGZ8==?CR)TA+KDE3BMY7.J*<D#P
M!.,"O-KG8)#V@W.<NZ:JU(+).=0](L+,M*8:U) Q@%)*0=T' /3QK&EPAX,>
ME4VFS4V4L+\1%(.<'&JXMP%S' Q3(PA[</V3!#2WZ^[KTXIQXQQ?+8Z9 @-$
MS!!];209UYR0=+05ZK=VS[9Y>D;W!M;T>*S-=FO1A(YU*&@I*6P>] 5Q.\0<
M#&!QJ]0]M5^U1:MA=RD-P.R+[=G(T\KAMKSN.)1OME0):403Q21TUN"R[%;)
M8+]JVZ1)$M"]214PY#!*>;8;2C<'-<,C \9-6FU<G'3UJM^A83=QN2FM(S5S
M82EJ;RZM:PHASO>(R/!BL:O";@_:2TUZ8)8UC6GBQB@65]-P<=)BK@B20(D:
MU]9=EX4@>+=&(N)&++.J'"!JZ.*=Q6JK7M*VK:MTCM!OL#4UKMT72TZ2$(<M
MJ%NR$-Y/-YZ$@)'3@E1.,@"NW5^WW6,G3>S^\H>>TGIR\6\OW.^P[3V?S,@+
M4@H"5<$I.Z%>/"O#C%>/9/R?5:WB:X1?Y6I-.,R+\\'(L9TQVKA'SO)WD*20
MH9)PH>/PUN74^PF%?842WV_4M_TS9F8";8NU6F2E,=YA.>"DJ2>^(405>'PU
M;7C>'!B[[Q%GJ4J9PNG*DV&L-( B0'"H[&<;2YKVM(@@ P(=FL]Z6BS&HU[A
M(UO,DAVG2"T1D8()_/+M W3MWHRS3C>&-0%^,E9ND9KFFY)\*PC\W/Z/@((J
M_P!6C26E;=HC3=NL5I:4S;H+0990M6\K'222>DDDDGZZN]>"VUU%]JJOL\X"
MXX9 !B3$AN0,:AD- R7?T ]M)HJ>M G2<XSS.9^.:4I2H:W)2E*(E*4HB4I2
MB)2E*(E*4HBV#L2_TMD_[&O_ (T5O*M&[$O]+9/^QK_XT5O*OTW_ $__ .RC
M_4[]%YE?_P#UI]P2E*5Z0N<2L2U?LZAZQG,2I,J0PMIOFPEG=P1DGP@^.LMI
M4&VV&SWA1-GM3,3#J/<M]&O4L[^,I&"M:]PRU>49WX/AIW#+5Y1G?@^&ME4K
MGN:-Q^S#>?-6'*UN[4^'DM:]PRU>49WX/AIW#+5Y1G?@^&ME4IS1N/V8;SYI
MRM;NU/AY+6O<,M7E&=^#X:=PRU>49WX/AK95*<T;C]F&\^:<K6[M3X>2UKW#
M+5Y1G?@^&G<,M7E&=^#X:V52G-&X_9AO/FG*UN[4^'DM:]PRU>49WX/AIW#+
M5Y1G?@^&ME4IS1N/V8;SYIRM;NU/AY+6O<,M7E&=^#X:=PRU>49WX/AK95*<
MT;C]F&\^:<K6[M3X>2UKW#+5Y1G?@^&G<,M7E&=^#X:V52G-&X_9AO/FG*UN
M[4^'DM:]PRU>49WX/AIW#+5Y1G?@^&ME4IS1N/V8;SYIRM;NU/AY+6O<,M7E
M&=^#X:=PRU>49WX/AK95*<T;C]F&\^:<K6[M3X>2UKW#+5Y1G?@^&G<,M7E&
M=^#X:V52G-&X_9AO/FG*UN[4^'DM:]PRU>49WX/AIW#+5Y1G?@^&ME4IS1N/
MV8;SYIRM;NU/AY+6O<,M7E&=^#X:=PRU>49WX/AK95*<T;C]F&\^:<K6[M3X
M>2UJ=AMK/3<IQ_?N?#3N&6KRC._!\-;*I3FC<?LPWGS3E>W=J?#R6M>X9:O*
M,[\'PT[AEJ\HSOP?#6RJ4YHW'[,-Y\TY6MW:GP\EK4;#;6#PN,X'ZMSX:=PR
MU>49WX/AK95*<T;C]F&\^:<KV[M3X>2UKW#+5Y1G?@^&G<,M7E&=^#X:V52G
M-&X_9AO/FG*UN[4^'DM:]PRU>49WX/AIW#+5Y1G?@^&MDJ4$)*E$)2!DDG %
M64:WT\?_ -=MGWQKXJ<T;C]F&\^:<K6[M3X>2Q#N&6KRC._!\-.X9:O*,[\'
MPUE_RWT]Y=MGWQKXJ?+?3WEVV??&OBIS1N/V8;SYIRM;NU/AY+$.X9:O*,[\
M'PT[AMK(QVQG8\7>?#67_+?3WEVV??&OBI\M]/>7;9]\:^*G-&X_9AO/FG*U
MN[4^'DL0[AEJ\HSOP?#3N&6KRC._!\-9?\M]/>7;9]\:^*GRWT]Y=MGWQKXJ
M<T;C]F&\^:<K6[M3X>2Q#N&6KRC._!\-.X9:O*,[\'PUE_RWT]Y=MGWQKXJ?
M+?3WEVV??&OBIS1N/V8;SYIRM;NU/AY+$.X9:O*,[\'PT[AEJ\HSOP?#67_+
M?3WEVV??&OBI\M]/>7;9]\:^*G-&X_9AO/FG*UN[4^'DL0[AEJ\HSOP?#3N&
M6KRC._!\-9FQJ^Q2GD,LWFWNNK.ZA");:E*/B "N-=?RVT]Y=MOWQKXJ<T;C
M]F&\^:<K6[M3X>2Q#N&6KRC._!\-.X9:O*,[\'PUE_RWT]Y=MGWQKXJ?+?3W
MEVV??&OBIS1N/V8;SYIRM;NU/AY+$.X9:_*,[\'PT.PRUGIN,X^I\-9?\M]/
M>7;9]\:^*GRWT]Y=MGWQKXJ<T;C]F&\^:<KV[M3X>2Q#N&6KRC._!\-.X9:O
M*,[\'PUE_P M]/>7;9]\:^*GRWT]Y=MGWQKXJ<T;C]F&\^:<K6[M3X>2Q#N&
M6KRC._!\-.X9:O*,[\'PUE_RWT]Y=MGWQKXJ?+?3WEVV??&OBIS1N/V8;SYI
MRM;NU/AY+$.X9:O*,[\'PT[AEJ\HSOP?#67_ "WT]Y=MGWQKXJ?+?3WEVV??
M&OBIS1N/V8;SYIRM;NU/AY+$.X9:O*,[\'PT[AEJ\HSOP?#69L:OL<E>XS>;
M>ZO=*MU$MLG &2>"N@ $UU_+?3WEVV??&OBIS1N/V8;SYIRM;NU/AY+$.X9:
MO*,[\'PT[AEJ\HSOP?#67_+?3WEVV??&OBI\M]/>7;9]\:^*G-&X_9AO/FG*
MUN[4^'DL0[AEJ\HSOP?#3N&6KRC._!\-9?\ +?3WEVV??&OBI\M]/>7;9]\:
M^*G-&X_9AO/FG*UN[4^'DL0[AEJ\HSOP?#3N&6KRC._!\-9?\M]/>7;9]\:^
M*GRWT]Y=MGWQKXJ<T;C]F&\^:<K6[M3X>2Q#N&6KRC._!\-.X9:O*,[\'PUE
M_P M]/>7;9]\:^*GRWT]Y=MGWQKXJ<T;C]F&\^:<K6[M3X>2Q#N&6KRC._!\
M-#L-M9.3<9Q_?N?#67_+?3WEVV??&OBI\M]/>7;9]\:^*G-&X_9AO/FG*]N[
M4^'DL0[AEJ\HSOP?#3N&6KRC._!\-9FUJ^Q/APMWFWN!M!<64RVSNI'23WW
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M]\:^*G-&X_9AO/FG*UN[4^'DL0[AEJ\HSOP?#3N&6KRC._!\-9[;;U;[P'#
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M%%$2V0&@TT@?25XUJ/A4HY)/A)KB[FNQUNJ&TVG,3GWGR7 6"ROOVTFTU_\
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MSWU2LQ3%$4=-J')EM&UC5]ROMSO6I[<B[6INQW:V6F2VQ&N,)#JW>9=):4X
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MY*5H=0H$*2I)&"""00>D&NFRV2TZ;M$.U6BWLVNUPV@S&A0FD-,LMCH2A"0
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MA*CCR_X@D<FJ]N$<6)D-P?;I3_\ U5(ZHW_Y0&8(W)LO#9.#(G0VA]>'@O\
M_IK3>$>AU9ZI_):+UCT"O/5/Y*'/).>4(.IT9X(<CK'[]USW"OJ;;EE<&.H]
M);23Z!7RSY)T=1@:F7CO7'8[8_>$K]XKZFV]!;@QT'I2VD'T"N,X+3QUH_\
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M.;DI4J,K)5C#J4+4@_G!*B,@&N_NQ:#.HY&G_EE8.WL>2S#>MHN3/9#;[O\
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M*>=;5?KNAH'_ /+6Y)6L_5O* 'H!KZ":8V(6%Q:U379<THQWJG VD_OW>/\
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MKT]OH_D"T>H__P!:G;Z/Y M'J/\ _6JSTJYPA>5<:[NW#R5X[?1_(%H]1_\
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MG'?O_'KG_M;W_N*JXNX27?!>8<-W%K+/$:7:@>KM7H[9V?R ?:+ONIVSL_D
M^T7?=5HI5WA"\IXUVP?XM\E=^V=G\@'VB[[J=L[/Y /M%WW5:*4PA.-=L'^+
M?)7?MG9_(!]HN^ZG;.S^0#[1=]U6BE,(3C7;!_BWR5W[9V?R ?:+ONIVSL_D
M ^T7?=5HI3"$XUVP?XM\E=^V=G\@'VB[[J=L[/Y /M%WW5:*4PA.-=L'^+?)
M9SLYN-J7M!TRENQEI9N<8)7V>XK=/.)XX(XU/,J1O'\EX?TS7SXV:?\ F-I;
M_P"J1O\ W4U]!%?2/[ZHKQ$.:O7.!+BZA6G:-0&KN56\CJOQFF\CJOQFJ*54
M+TE5[R.J_&:;R.J_&:HI1%7O(ZK\9IO(ZK\9JBE$5>\CJOQFF\CJOQFJ*415
M[R.J_&:;R.J_&:HI1%W,J1OG\G^:K\X^(U0%(Q_1?C-<L_3/]57]QKK'11%7
MO(ZK\9IO(ZK\9JBE$5>\CJOQFF\CJOQFJ*415[R.J_&:;R.J_&:HI1%7O(ZK
M\9IO(ZK\9JBE$5>\CJOQFF\CJOQFJ*41=S:D?E/R?YA_//C%4;R.J_&:-?\
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G.8;SWJ2I9R2.)S@=./!FLOI6#Z[WB"LFTVM,A*4I4=;4I2E$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2128727d1_ex99-2img008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
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ME;+\&F\^S/*K]B7%?B[AV<P+U9YK,G#V+@W.E-.);*DN-AIH-M%L@ZZ*Y?A
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MBT\7^D#D6<8ZW)1;)KD1R.W<&0AS5IAI!WI!(TW-GS\Q42TKEIV=E.Z6_=!
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MTRFTL+0H$I2E6LAWF$ DI2$J43J=*U-I5'V)E0$.<<1!QS&.?CZJ6UW-,@#
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M%.T,^[-_EBO?GQ08)[R\>^:8_P!"GB@P3WEX]\TQ_H4Y2T^R/C]$XK=UO)>
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MX]\TQ_H4Y2T^R/C]$XK=UO)> W:&?=F_RQ3M#/NS?Y8KWY\4&">\O'OFF/\
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M9CXK,A]PC?*D>NGBLR'W"-\J1ZZ^?THSA%I>SV>S5[&X-H@AL,>3C$XN+C&
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MFZ]8W;C<VLH=O,2&_*/4RXZT@*0M:>:%'0?IYBKG=^C3<LKPF](CXC9<)O\
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MJA=/%')78V!3$2[0J5DSK#C6.M1'%RUQ'7=7'MX<\E,=A;:U**-JE)*=4EQ
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M2G1Q"@M*3MT*3WZBIJLO#N7:.)>,WMF'#C6VW8:JPN]04I4E[KX[B$)2!S;
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M:T:<4\Z-Z"XHA*=R]"LJ"M,MP?-3ERKY%DP%6J[66X*M\V$IT.A)*$.M+2L
M!25M.(4.7(E0\VI@-!VJ;Q"B3.<.XG<058U/MV-63![Q8F;JS&)NC4UE#C]L
M<CL*2E+0'5I=4E(202$\RG0;3C-@X$9T_G,3(9]N[$T;SC<YQJY9*;K+#<%4
MWM"E.E(3K^Z&]C;8"="=-#J!M32K7 JWBH3XZFX,\2N#+]KL\6_7&-=+H\U
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M2E6H'(UL=2IN!1?*UEM?!G.'<*PS!Y6/V6VQ<-<>>:R.+<4J5<B(LEE'5L!
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M:%((*2E:M>4W@H@J8;?_  YC\;_*KM-_AEN_XJ_\-=6F!_#F/QJNLS^&6_\
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M@4DH0H$;5 I[]"08^Z17$ZY<*<\CWZ"TY<8UKQ&^W%=G,E33$IUN5 0WOTU
M(ZQ0"B#IN/I-<69\7LCL]VD8UD^-VZ/<4W"P/0G+1>Y(94S,N791UJPA"PMI
MQ&JD %MQ)T/(D5,MR40<UG%ZX"XMD5FL=KN*9LB%9[&Y8(Z!(V*+"A' 65)
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M@:J%:BN,&J@UBM5RZU;[GD$"SN-HF24L+<3N2"DG4=WF%=S7X:C[B=_&%O\
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M2IHO/ [&+S.DW >%;9=GKBY=/"EINCT26T\XRTRZ$.(((;6AEH*;YI)0#IJ
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ME:NK=D!T.E6OLP0^YH#W:C3N%6.Y='/![LQ*9DP9BD26)4=P)G.#5$B>BX/
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M:DBE3="24YDDGF2=32E*E52E*41*4I1$I2E$78@?PYC\;_*KK-_AEN_XJO\
M#75JM_\ #F/QJNTW^&6_T=:O_#77'6Z0752R*[=4-5(YTK!;+Y(]-<:F]:Y=
M.=4(UJ4764@CN-?&XCES%=LC6N-;8-3*K"X@HU4*/IJBFR.ZOC4COJ5"Y=WP
MTW'TGXZXPJJZT16N:Z!E=G278:5*CRR&W$:R%:=3S;5YDC7RQY]4>BL=XD<2
M[M@LZV,6W \BS%J4E9>D65#11$.J4-!>]0)WK4-=NNQ(4M7D@UD$R0$Y59VC
M(CH*X\M0CK:U><TZGRD+T\D)U\H>?<GOTJZ2&&Y3#C+R0MIQ)0M)Y:I(T(Y?
M 34N& _FU <2M:+UT],8L2,A;E61UF7;K\+!%+UX@MQ9;P:4ZX522YU; ;0D
M;PX=4J<;3S).F?X[TE+=?\]>Q!5DF0+P):&&D2Y#2 XUY8<>!)&H!;.T)W%P
M+0I/+<4<#O1%X628G42+%.EJ7(5(?E2;W.=DR@64L%E]Y3Q6ZP6DI;ZE:BWM
M2!MTK+'>"F&OY';K\[:2[=H$E<QF0Y(<)4ZHI(*QNT6$;$=6D\FPA(2 !5(*
MM*Q;+.DNQCF:2;5%Q*\7BQ6R\0;#>,BC.L(8A3I:F4LLI:6L./D=H8*RV#M#
M@]D00,@X'\9T<;++=[JQ89MBBPKB[ ;1/D,K>64'176-(45,. CFTX$J&J3S
M!!KK7/HX\/KSFDS*9ME>?NDM_MCS9N4H1%2@SU(E=F#@:$@-@)#P3O&@(((!
MK).'?#3'N%MLF0;!&DMIFR3,ERITU^;*E/;$HWNOO+6XX0A"$#<HZ)2D#D*0
M5,K+=35->ZFNM4UHBKK5#^W[?M^&JU3S_M^W[=U%"?M^W[:_AH#S&E/-\'[?
MMZ/P4HBYVY'F5\=<X.M=#]OV_;^ROMMXM_"GT5$*P*[M6K*_Y,W;^J/?X:JN
M2' L:@U;<K_DQ=OZH]_AJHWI!2<BNO@G\BK!_P"GQ_\ "35]JQ8)_(JP?^GQ
M_P#"35]H[I%0WHA*4I559*4I1$I2E$2E*41*4I1$I2E$2L-Q+^7&;?UB)_[5
M%9E6&XE_+C-OZQ$_]JBM&9.]GZA9NS;_ #85F5*4K-:)2E*(E*4HB4I2B)2E
M*(E*4HB4I2B*Q94V'$VO5J$[MN#"AVU>W:0H^4CTN#[4><U@'29B0YO#IIN?
M?(=EB=M:*VKJP\[;KAY*P(DH-$*#2R1Y_9I0-%Z[%9_E6W;:]W8/XP8T[?W:
M[C^]_P#F>U^&NIGF:PL)MUN=EP)=S<GSF8,6)!:0XXX\K52=-ZDI &PG4D::
M5<Y!5&94&IR!G(<FX3QDVNZ85D:(T2?,3,DRU(CQ@%MH@!1\EU;RCHH+ 4EM
M)4YM7U8K![<]D'9,>=0,B[(J%#1Q#ZX2MPD=N;#W(\]=.T!?5<NIT^UV5/8Z
M2&)/6==PC(N<H(@1Y_9VHA#OV:8J&EK:I0'6!]"D*!.@TUUTYUV+3QXM-^O4
M2S6VRWN9=G3+3)AI8:0N$8SS;+P=*W0GDIYLC85[@K4:BJ*R@!F[9=A61VW,
MH,3)KKCV/M7-R+9V42'53[2]<>J:0&U:[EH26W6]WEAIL>8U-/1ELN06"S9I
M#R:7-G73ZI'GW)$Q;BTJ4[%C.N!@K[F4NK=2@)\D!.@\]9'=>-=CLN;JQN5%
MN2%(E18#ER$<&(W(DH*F&U*W;M5: :[=H*@"1K5V;XL82[$ARF\NL;D68Z6(
MSZ+BT6WUC;JE"MVBB-Z>[VP](HBRRE8[*XBXK!>N;4G([4P[:]O;D.3&TF-N
M("0X"?)))  /G(](KF:SK&W[A @M7^V.3;@P)4..B8V7)+)!4'&T@ZJ20E1!
M'(A)/F-$5\I4?6SCMA=UN=[CM7ZWIA6D1>MN:IC/95K?#A2A*PKFH!I1(.G(
M@C45GZ%I<2%)(4DC4$'4&B+ZKH7;V$;^L-_WJ[]="[>PC?UAO^]1%WAW"JU0
M=PJM$2E*41<5="]_P$_CBN_70O?\!/XR:TI],+-_1*L%*4KT5P+',YP"T<0[
M7'A79$E!BR438<R!)7&E0Y" 0EUEU!"D* 4H<N1"B"""16)W#H[8K="5OS<E
M#\B&+?<9#602FW;M'"ED-S%I4"\!UCB03H0E92"$\JD^E06@YJ9(4:W+H[8'
M=WI2I5F4MB3(7(<B)D+3')5;?!A0$#0!'9?("1R!\H<ZMQZ+V$OM/=L=R*YR
MGC!+D^??Y+LL]C=6[%T>*MR>K4XHC:1KRUU.I,MTI="F2HR^MWQ'L.TKO:KO
MX0\*?5&;P^;OVGJNIW]KUW:=3]BV>PV<MM=ZT\"\.L^WJ[>_)4J'/@R5SI;D
MA<U$U3:I:I"EDJ=6X6D K)U &@T&@&?TJ+HW*)*B1KHO8.+;<(4@WVX";:VK
M,N1/ODA]]J*T\EYA#3BE:MEMQ*5(4GF".>O.K@_T>\4?#CP=O;%V5<?"R;W'
MN[S=Q;DF,U%6M+Z=" MIE"5I(*5::D:]TETI=;N4WBL*Q/@]C&$WFVW6TQ9#
M=P@19<5$A^6X^MX27VWY#CREDEUU;C*%%Q1UY$#0<JOF(8C;<&QF!8+0VXU;
M82%-L(==+B@"M2SJH\SS4:O-*F %$J-[YT>L'R)G+FIUL>6C*KA%N=TV2EH+
MC\?;U901[!/D^4D<E;UZ^R-=N[<$<7N]PEW!2+A#N$B^M9'VR!/<8=:FMQDQ
M0IM2?8H+* A2/8D%7IK/:5%T;DDK#+1PCQJQV;&;7$C2$0L=N+EUMR%25**)
M"R^5%1/LQ^Z7?)/+F/0*O4;$[?#S&7E#27A>I,!JVJ>+RMJ([;BW$H0GN3JM
MQ141[+1.OL15YI4P$DK [3P1Q.QS;])AQ)+*[U%EPY2.U++8:DON2'DMI[F]
M777%#3NW'2N&^\!\0R.TPK;.B2UQ8=E;L#*6YBT*$-#S#R4DCO5OBLG?WZ C
MSFI"I2Z-RF2HXF]'_$+@_D"7D74VF_=I5<+"BZOIMCKD@'KW1&"MJ7%$E6Y.
MFBB5 !7.NO!Z/./6Z5.GQ[WEZ+S-C1H;]Z5D<E4Y33#BW&D=:3J "ZL$::*!
MY@GG4GTJ+HW)>*LN'8?:L"QN%8K+'5&MT0+V)<=4ZM2EK4XXM:U$E2U+6M2E
M'F2HFKU2E64)2E**$I2E$2E*41*4I1$I2E$78M_\.8_&_P JNTT_NRW_ /%7
M_AKJTP/X<Q^-_E5UF?PRW?\ %7_AKKCK=(+JI9%=S_E3S_#^W]M/V_;_ %I\
M'Z/V_P JP6R>;X/T53S_  U7NY]WI/[?YU3S?\OV]5$5-.[T4JOG_;]OCJFG
M(?H_;U41?)3K7&IL$5S>GT5\D?M^W^M2HA=93>WNKXYBNV4ZUQJ;U\U6E5A6
M*;*",IM#':VV^LCRU=F+.Y;NWJ?*"_M0G=S'VV\>UJ\:ZU:)SW5Y3:&!,4WU
MD>6KLH9W![;U/E%?VNW=W?;;_P"C5U[O@JYR"J,ROL&J@UQZU4*JJM*Y-?-5
M0:X]:J#4(N0*TKZ"]?PUQ:TUI"E<]4UU_;]OV]%<85I\(K[W:U6%*^C5/V_;
M]O[*MN2Y';\0QVZ7R[/]FM=LC.3)3VTJZMI"2I9T U/('D!S]%89.XT0\>P=
MO)<DL%[L3:YJ(8AJBB2Z MQ*6W265*0&RE:5%15HG4IUW#0D4BT[OV_;]O36
M(*XEV].3W^T&'/2S8$A5SNJFVQ#BZQP_Y2BO>?L:@=0@C4Z$UBERZ36'V*"S
M*NS-WM2'9,!E*)< I4&9F_L\I0"CM8/5.;E'FC8K<E)%$4M)44G4'3]OV_TJ
MP\2,KM>*8!?KK>YS%KMT>(YUTJ2K:VC<-HU/FU4H#^VNA XFV2Y\3[K@<=R0
MN_6R"S<)6C)ZA"'%[0GK-="X 4DI[P%I//6O(/C5_M0>,+F09QA<F)BLNPF5
M-M*V7[05%<<.+:T)ZSOVCO\ 34M+0X%V2$&#"]B.#^46G,.&F.72R7!BYVYR
M$TA$J,K<VI2$A"P#Y]%)4#\(-9C7A%B'^U;XT8+BUIQVS1,3B6JUQ6X<9D6A
M7DMH2$C4];S/+4GSDDU=_P#?#<>O:8I\T*_ZM0\M+B6Y*S 0T YKW&I7AS_O
MAN/7M,4^:%?]6G^^&X]>TQ3YH5_U:HK+W&I7AS_OAN/7M,4^:%?]6G^^&X]>
MTQ3YH5_U:(O<:E>'/^^&X]>TQ3YH5_U:?[X;CU[3%/FA7_5HB]QJ5X<_[X;C
MU[3%/FA7_5I_OAN/7M,4^:%?]6B+W&I7AS_OAN/7M,4^:%?]6G^^&X]>TQ3Y
MH5_U:(O<:E>'/^^&X]>TQ3YH5_U:?[X;CU[3%/FA7_5HB]Q2=!4/<+.+>+9?
MQAXD8W:;DJ5>K:^P9<4Q74%G8TAI6Y2DA/LP0.?/34:CG7DW_OA>/7M,4^:%
M?]6K'9_]J?Q?L&17Z_6^UX=%NU]6RNXRD6907(+2.K;W?9?,GE6S',#7!V9&
M'B,UFX.):1L7O%2O-S_9U]/GB?TGN.=SQ/,DV,6J/8)%R1X.@%ASK4/,(3JH
MK5RT=5RT]%>D=8K1*4I1$I2E$2E*41*4I1$I2E$2E*416+*G$MIM>YV"UK<&
M$CMJ-VX[CR;]#A^U/IJT<3.&L7B= LD.:\$1(%T8N3K10HA\-A8ZO4*24ZE8
M.NOF[C5WRM\,)M6LF+&WW%A [4UUF\E1\A'+DL^97FJ^)]B*N>B%49E0_F71
MSMN3/3FH<F/9[3(M-OM"+='AZ-M-Q9QE<MJDZ!0.S0::=^I[JY;OP%B-9OC5
M]L$7'XL6SPY$5%ON-J,A*5O2&GE2&E!Q)0[N:.JCJ25:D^F7*5164=-\%K0O
MB)D&83$,3KE<!'[&MUDE4$M,%K<@[M"H[E'< "-2->=8<_T:7V,4L]DMU_C,
M-LXDG#IRWK;O#D71.YUE(< :<.BN1W)YI)!V#6=J410?<.CS<95A59&LD:;M
MT.^+O]L6(SR)(>6^MY;;[S;Z%+3JZL!2-BN2"22GG;XW1,MS%P)%P";8]%:;
M<B-JEI[,\VRZT'8^LDI[G5$=:EQ0)5H?*Y; 4HBU]7T9KP];II<R> B\.M0&
M8=QA6UZ(Y;S%COQT/LJ;DA76E+ZM=24;24%)2:GFW1G(<&.PZ^J4ZTVE"GUI
M"5.$  J(2  3WZ  <^5=FE$2NA=O81OZPW_>KOUT+M["-_6&_P"]1%WAW"JU
M0=PIK1%6E4UI1%QUT+W_   _C)JX5;[W_ 3^,FM*?3"S?T2K!KI2L)XKV#,L
MBL4-C"<B8QJY-S6G7Y,AGK XP-=R!R/P'33GIIJ-=:S5((',ZGTZ:5ZA: T.
MG/9N7G DDB%P7&X1K3 E3ICZ(T.*TM]]YPZ);;0DJ4HGT  G^RNGB^3VK-,<
MME^L<UNY6>Y1T2H<QG78\TL:I4-0"-?00#Z14;=)55YOF'VW"L=89D7C+;@W
M (EK6W'3#;!D3"ZXA"BA*FFBUJ$DZO#0&HDLD7++5D]HX:WE3^,MG-C<@WB<
MY],9=HG09SYCHD;&UA")33J3R24[F]NGDFL2Z#"U#9"VXU]5=*RWF)D-IBW*
M XMV'*;#K2ULK:44GSE"TI4G\"@#6LN'0,AL;V-W7ZJ,KN$B-Q)DXOU-RN+S
M[*[.%R&T-.-GR7- E"A(6"YJD:K(Y59>#>8.7B'A">*>6Y5:G';!97["$S9D
M=-SDK*NU+=6T-9#X="$*:=) ;*3MT6HU%]3=6X-*U!M?%FXW#'N$V.'*+U:L
MLA2;Q&R=]V+(=<@+;MT_8N4"G:YM<2TXA))W]6DIUT!J4^BM?_#6+W:.I^9=
ME09C+*[\J[R[E"NBRR@J>C.2@'$#7DXUIM0LD GOJ0\$PH+2%-==5=UAM7-F
MW+E,IN#S*Y#<4K'6K:04I6L)[RD%203W J'IK3N^2<OLV+VN_P G(KTNU7;+
M+U"O<BZ7J?$BPXC,N2(+ 7'0MR,TI0 +J$@KT;0IP((%=%N8]BN18EF]\NMX
MRJ:G%+^FRNV:Y7$IGK;E-.1(:''$)+SO5;_+<;^R]6E9"RD&HO\ <IN+<^Z7
MF)9A%,QQ;8E26XC6UI;FYUPZ(!VI.T'3V1T2/.17<UY:UI3@.;Y(YF$&);,I
MN%WQ]_)L6<2]"EW*3'4A]<U,MH/RR7'6R&FNL VM[A[!)U%73"QDMIX6\)LD
M<SK*H-WR*V72->;C=)+\YF,GL,EUE\Q5:I2IEQIM22D!2@"%%6ZH#YV(60MP
M^ZE0WT7;\+YB%R9"YDT0K@F.J\NW>7<X=Q5U+94]%>E .!&IT6WIHAP+ )[Z
MUNRCBGE=R^JVYV.[WRU29V-9,J7:$2[E(DVN4PV#&#A=T98?202A$="2 2-5
MC11L7@!1=QA;Z$Z#6NG;+S$O"I@B.+<,.2N&]N:6C:ZC3<D;DC<.8\I.J3YB
M=#45X5:9^'<:)-G9O5^NEGN&*-7-Y%YG.S$IFIEEM3C:EZ]65H5Y3:-$^2"$
MC2HYL:;_ )SQMBV&ZY!E$>P+R3,&W685QD10XPSX/[,UUB"%);3UCA0$D=ZM
M#H5 P7P@;*V=5=8:+FW;52F1<'&52412L=:II*@E3@3W[0I203W:D"NUK6C0
M5D-ON]DR)N??KAG2<.R*UX^_-E22)\^)<U(BM+0/L;KA80%[5IT=*0LA1YUV
MK)=\FOEK2U8N($IRWR[E88<T6N\W2X3F'W+BVEYY3LMAOLZELEU"V4^2" K8
MG;SB_P!RFXMVZZMPNL.TMLN393,1MYYN,TI]80%NK5M0A.O>I1Y #F36H35R
MRZU<7Y6/KRMRRW.VY"Q%LT:[WJZR'9-G04;0(H96S+#S76[GW7"L.$E2T=6!
M6,W.1"R+%=EYR"_9/#L.3V*X7+,[=?+F83S*YCB7%J9.TPWVT[5+;:U0VE3:
MDE.G)?[DN+>"XWF):G8#<IQ:%SI(B,!+2U[G2E2@"4@A(T0KRE:)Y::ZD ]W
M6HGXOW6X6Y[A8+).G-1)61)9D*C.N?9XW@R:M*72.:D%2&E>5WJ"2>>E1YP/
MBWZSM\!KI)R+)[K*RG&7U7]N\SWI+3KJ(3+S2RVOR65I65)!2$E0)"MQYU8N
M@J+N"G;*^(N/X5;[C,NEP0VBW&*);3"2Z\SVEY++!4A/,!:U  ^@$]P-9*H%
M"E)/)0.A'PUI9T@L9@Q\]XPMB7>8M[O,#&'[>A$J2M#R!<$HD.--G<T2T0@@
M$'JR=0 %'6^\7I&6<.,CRJQV*^WUW$!,LLJY2[M=IKBH4=Y,Y,DIF(0Z^RTX
MXS%"RWKL"R1U842*WSM4W5MM3T?#W5 W#BZY>C@!F=PLEWC97>&_"#F-=FD2
M9P1HR.J8Z^6A#DG:[OVJ4"""E&Y6W6L$7EF+]BQARV9_F<O$),H)S.ZR+C<.
MT17NS.&,V^H@+A)<?W!T,A 24M)5M21K8OA1=6VE6W),AA8GCMTOER<4U;;9
M$>FR7$(*U)::05K(2.:B$I/(<S6LN$P[MGF>6&Q+R?,5\/7EY";7,\(RHLJ?
M"0FV]0IR1Y+JTH><E!IQ1"E(2.:DDE6)3?JJ3P3QR[3,AR:]W+*L(R=B]LW-
M]Q]M];,!:HR@QH$,N)*  4)25[E;MQ.M5+^Y2&XK<:?DEOM=A\,RG5MV[JFW
MNL2PXXK:O:$G8A)4?9I[@=->?(&KF>1(/F.E:3Y)ETV'C#[G#K+LPNC;6.13
MD#LI^6HPY_;H"& CK$CL[ZD*EI6RT GJQS2  3FT1C(HK3V6M9#DSUX;XJR[
M0U"?N#RH)MJKFXQV<QCY'5;""%D:IT!2H  4OI=6T6M6CZJ[=]5WU,]:OPQX
M/\*=5U2MO9^MZK=N[M=_+;W^?NK2K&\TXGR;!<I\')G3GS%GG.7ZQHF7&;/2
M]H 2W!>CIC17&%$EL-'182$CK=P-2WP8?QN;T@I\G#[]?<FL'U%MH%PN\J5+
M1UWA#524/2!NWD;5+0#HDGD$DD4OSDA;"V8@?PUC\:KK-/[KM_\ Q5_X:ZM4
M'^&L_C5<Y:M9=O\ @=7_ (:ZQK9A;4LEWM>8IW#X*IK2N=;+Z\]4UJGP>:J^
M?X:(GG_!YOV_RI_R\Y_;_.J:ZCX/T>JJ^?X?V_MHBI^W[?Z4 W=WE#X.8K%>
M*G6'AOD89R$8FXJ$X$7PC40E$:!TZ$<@>\@@@:G4::C7!5\9B<.+7.@OQ+/;
M[%,N2&[0QD5P5"R,AEM:50)2"'5I*UJ"4$*'6%P)"M HE*VX()\Q_;]OAJA&
MIK5;(,PO[]ZN+[<R\P,N%XEARR&2\E,:R^"EN(460>K 2X6SUP&[KM4A1.J:
ML6/Y5G<J+PZQ>3=;^5XG>;,JZW5Q3R7+TS,<;[*AUSO=2EAQ[K@21O:05<S2
M5$+:R<_LRJTL]J?;#D>4HQD-:M.[>I\I:_M2G7R1Y]RO15T6W5MF.J3E-H;Z
M^6A*XTH]2VC6.O3J>;BO,H:^2!W[E^BKN>[]'[?L*T.05!M754V1W5\ZD=]=
MHIKC4WK4 I"X0:KKI13>E?/,5*A?>ZJZU\:_!5@X@Y%)Q' <EOL**)TRUVR3
M-9C$$AU;;2EI2=.>A*1W<].ZB2LC!JH5I4*Y9Q/D\)\"CWA[)&<SN$Z&9[$>
M2@)#R6XRGW3'$1DD-E*=0IS5*!S*S5DSOCO>G;-=X]OAIL$Y7@^79E/NK#D^
M.J7!0ZX' VIK9^ZBTM(/6(\Z?*!$2K*>KTQ(G6:=&B+BHE/,+;:5-8+S&XC0
M!QL$;D'N*=1J#4,,]'^])X2WC%HMSLUB?O5Q9N3\&+$><MEL"2TM3$-OK4J"
M2XSN)U"2IQ9"4Z@5=I/%*;,PZ--E13!N#&9QL:E-VZ80VI7;T,%:5*026U)4
M"6R 3J4[A[*N;A#QCN7$A]IFXVB+:#-L4>^Q%0IBI!2TZZXUL7N0G18+84"
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M;??L[S?";)=,WN\_%)<'()#:\=O<]*%LHD6],=IR:XAIYXM%Q_:Z="4G;N4
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MN\YC='\!9D8%G68W6Z.X>'<GDRY$ITP)I5#$9Q*7$A,>05K?'5M@!3845)(
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MXC7UAVYS7IJVD6Y@I07'%+(!W<P-VE>@P5I7(%Z]_?40K KS?_W*.&??+O\
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MLN>(R\6?9920^D/O!:G4J[M D::'SZ>:K N(D*I !73=Z2^ Q;-/NLR?<K;
MB,,R^MN%FEQNTQG7T,-R(Z5M@OM%QUL;T Z!:2= H$W.#QOQFY1+NY&:OKLR
MU2&8TNTBPS/""%.I*FB(W5]84+2%*"]-NB5:D:&HDMO1+N#>/2X,EW%8UQ"8
M#,>[6^-/4^XVQ.C27.L#[ZTM]8F*D;&QINT)5HD"LNXJ<"+SG&;W+(;?=K68
MTMZVK=LEX8?<AS6XS<M"FI/5+2I2=TI#B0-1N:&X$'E$OW*8:KQ)Z36 1H<:
M2F?<I0?MSMVZF)9I;[S49IY3#[CK:6RIOJG$*2X% %.G.NW;>D3@-T:N+S=[
M6Q$A6X7?M<N$^PS*A%80),9:T 2&RM24@M[M5+0 #N3KA_#+HW3^'\.:PY>;
M:_U^/7*R($*"J.VVJ5<'Y:5I1J0E" \$; 2?)Y&OC,.C YF>*XW99=[CM"T8
M@WCW7)CK5ODMR(3[;V@4D]5NA:*1N"B%\E C6IEZ0U9H>D#AZ+<\^\N[PYS<
MMF"+++LDIFZ./.H4MI*(:FPZO>A#B@0DC1M9)&Q6GQP?XH*XA0,WNDA[9;;5
MD4R!&+T1<9UF,RPPLI=;6 L+2I;F[< >6FG*L#L?1OOF/2+?D-K7B-FS"VSQ
M(95$CSWH<M@QWF'&9"GGU/=SZU(*- @^96Y523PMX?77$(.5IR*YP[Y-R"]R
MKN\J'&4PRA+S3399"5*4=$AHC4DD@C7GK4 N)$H0T9*R8!E7$3B)$LN7,G&K
M%AUS");%GEQ)#]R<@JYH=7(2ZEMMU2"E?5AM83J$E1.I':F=(_!K5%N3UTEW
M.S)@",XZBZ6:7%<6T^^([3S2%MA3C:G2$;D@Z$C4#45;L;X:<1,/LD?#[7EU
ME.'Q(ZH4.X2;>^;U%C;5);;"DN!A:VP4I2Z4@D(!4DGOC_'.B->;=.B3)EVQ
MIF0U&M49Y5KMTA"YBX=R9F*D/N.N*6XZZ&BDDG1)([QJ:2[8$@;5E4OI/0H>
M26>#'MMXN[-UR(68L-8[-CRK6/!Z96Q]"@2MX[DJTT1HA:M1JVHG+YO2!PRT
MR;FQ<Y5RM*H$9<S?<;1*CHEM(=0TI44K;':/LCC:=&]22XC0$*!K';QP.OJL
MPG9-:;U;&[@K-$93'9G1G5-=5X,1 <964*!WZ!3B5#EKM!'?6#V#HFW^TS$S
M)TW#+]+:M$ZTO.7*TR7%WKKW6%]HN#A=*UKT:.J4':E2@4\@$A+@D-*V+QC)
M(^5VANXQHMQA-K6MLL76 ["D(4DZ$*:= 4GX"1H1S%8KEW%JSX/E;\&[W5#3
M+5J8F"W,6U]^6ZX]+[,SU:D$APK7HVEE*"LJ\K73E5LX+8AF. F58+W<&[G8
MHS >AOA3KG5NNO.*,5I;SBW2PPTEI*2Z2HEP\]$@#K<2^#,[-,MNE[8\ 3V)
MF/,6,VN_QGW&%%$Y4DN%32DJ2=%#8I/E)6D*J271("B!*DO'[XSDEHC7&.Q-
MBM/@D,W&(Y$D(T)!"VG %(.H/(CX?/5QK%>%V*7/",&MEEO%Y<O]PC!S?-<+
MBO)4XI2&DJ<4IQ2&TJ2VE3BE+*4 J).M956@RQ52NQ;_ .',?C?Y5=IO\,MY
M_P#-7S_^FNK3;_X<Q^-_E5VF_P +MYU_[U7/_P"FOSUQUND%TTLBNY\'Z*?M
M^WGI_G^G_*G[?MYZYUNN-;"'.9&A](KKKB*2?)\KX.XUW/A_3_KZZH?1^BK2
MJP%;BD@]VA%?2'UH\^OX:[RD!?(C7X/VYUP+B @[3I^'F/CJ958.Q41(2KD?
M)-<FNO=SU_;]N^NJME3?>-!Z1W5\)44=QTJ825W3_P OV_;NKC4T#W>2:^$R
M3W*&OPBN5+B5]RN9\W[?ZU"G JR3HJSE-HD=CZWJH\M/:@]IU.[J?)V?;;MO
M?]KL_I5=@YKZJLU^#L2\P+DW9W;EV2+*!=C+!?;*BSHA""H!6_:>9(TZOX:Y
M9-^=;$H^ [J\66D.CJV6R72KO0C5P:J3KS!T T.A-:1('\VJN1*NX750JK'*
MO;T;MI19;L]V<-E(;9;)?W=X;U<&I3KY6NFG/36DF_R(IEZ6.[/B.M"4EEEM
M0>W=ZF]7!J$_;:Z:>8&HNE+ROH/[?M_K37NJQO9$ZRJ2!9;J]U+R&06V6R'0
MKO<1JX-4#SDZ'X#7TYD#R%.@66ZKZN2(X*&6]%I/_>I^R<VQYSR/]&HNE3(5
MZ\Y'G/F_;U4U[C^W[?VU9O#[V[;X%NA':^S:]2WIM]V_?/WOX>_^C56\@>6I
MH&R75&^48VY3+8"$C_OE?9.39\Q[_P"C2Z4D*\>D>GS?MZJ=W/\ 35G8O[SZ
MHX-DNK0=?6R2XRV V$]SBM'#H@^8@$_ *1L@>D&'NLEU8,A;B%%UEL=0$]RG
M-'#H%>;37X0*72DA7?3S?HII5GC9 ](['NL=U8[0'"KK66QU.WNZS1PZ;OM=
M-VOGTI'R%Y],0FQW9DOM..$.,M@LE.NB%Z.'12M.0&HYC4BETI(5WVU\E.M6
MIK(7G0QK8[LWUL=;Y"V6QU93K]B5]D]F=.0&HYCF*)R!Y2$J\!W8;HADZ%EO
M4*'_ ')^R?OA\P[OZ5+I20KJA +B//Y0Y?VUY29OQ/S*-FF0,M9=?FFF[E)0
MAM%S?"4I#RP  %<@!YJW]XL](&5PKOV$PD</\DR1.0OEI:+6PA<B,0D*]@%$
M**?M@2D <PH]U>;6<.%W-LA64+;*KE*5L<&BDZO+Y$>8CSU\[IQM2FRD[(&=
MOL7YIPSKN93HBFX@R9B1L"[WC5S;WXY!\ZO_ $Z>-7-O?CD'SJ_].L6KZ;""
MX@.$I;*AN([P->?Z*^1UC^L5^6?::_:'Q*DG&KQQ0RJ&_-AY/D*;>RL,JF/7
M9YMHO*]@RE2E@*<4>02#KWDZ $U:+MG_ !$L-Q?M]RR;)X$Y@[78\BXR$+0=
M->8*O00?A!UJ6NE4;'%AVZVQ5*@)C]2W9<>0LCL<$-J*I#[7<VX^HH(21O(2
M5*TU J"+])O4N'95W<OK83"#=O<D)YJC)<6$A*N]2 K>!KKIIH.0%=-::3BR
M\21WKUK<'V1YHBHXN;F9P\-G=GWYX7ZV9_Q%O2Y"(.3Y-+5'CN2G@S<I"BVT
M@;EK/E\DI',FNIXU\W]^60_.K_TZS[!+%D.'83;+S9(\5=VO,I,IP29T=C]P
M,K\EI27%I)0^X%%7+0I;3Z:P3BCAR<)S&1$CITMDE"9L!0<2X.SN<TIWI)2H
MH.YM1!/E-FJN%1K Z3_SDLZS+32H-JE[N_$QCB(]V?N646E7&*^6N+<85ZR1
MZ'*25L.&]J1UH"BDE(4Z"?*21W=XK%KQGV=,/2K9=,DR)#K:BU(AS)[X*5 \
MTK0I7>".XBLMN&,8]D..<.47;*H^/R';461VFW.O(2DS9 "U.)Y!/,Z^C36L
M8XM2G'L[EQG8TJ,Y;6F+:KMVG:'>H:2UUKFA(W*V[N1(T*=">\R\N:V0X[-O
M=/N]ZO:!4IT0\/=]W[TS(G(8CWY^Y?5PXA\0[7V4R\KR1CM3"93)7='_ +(T
MK7:L>7W'0_%63VECC+?+<B?!O>0R(BV0^'$W_31LD *4"\"D:D#F!WBL;XH?
MO>%__NS"_O.UQ\/FT&Q<0-4))^I\]X__ %R-503>NDGQ[E5KW-M!I/>XB-CH
MV3N*Y;QQ XB8[<GH$[+L@CRVM-Z$WEU>FHU'E)<(/(CN-'>(/$EBSQKJYE64
M(MLEYR.S*5=)&QQQ 25I!W]X"TZ_AK$[+9I607B%:K>SUTV:\B.PV.0*U'0?
M@'/G\%3Y,PV??I-RPF,NVN8XW#1%LCR;M$4HS&-RD/!"72K60M;R2 -?LR/:
M"IIBI4D@GZI9FVBTASF/=&0Q)QV _E.\A1/&XIY_,D-1X^89*^^ZL-MM-W20
MI2U$Z!( 7J22=-*R.\S^+UAM\F;,R3(1'BD"26+^I]48DZ#K4MO*4WSY>4!S
M.G?6$X1<[EC^9VFX6R"J;<X4E+S4,M*67%(U)24IY]P.NG,=_FK)K;;<<R!J
MZJQ&==\?NHMTE]5MFJ0\S(CH;*WF4R&]JO8)40%HT5MT)UTUJQQ<,S/M_DJE
M!]2HPS4=>V"]'YY^R0=TRK1XV\Z]^N1?.TCZ=/&WG7OUR+YVD?3K$Z5EK'[R
MO/\ M5?M#XE;<=!'.LER7C+<8EXR*[7:*FR/N!B=.=>0%!Y@!02I1&NA(U^$
MUOUKI7G3_L]O^W"Y_P#H+_\ CL5LSTN\ZSW!L5L\G$%/VRT&0X[?L@@VOPK*
MM45I(<2XF&'$%QM2D['%))4A!)"23J/LM%$FS2=Y7[AP1>ZIHP.>9-XYJ?J5
MI/EO3^3;N+C-JLDJQW3&HEDG276]CR)=SEM6WMR%QR>2(ZM4-I40HJ5UG<$
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M-T!)$-U3K'$A]E9:0P5MV@)5L04E(U#W]%/X=*YE] V4XVPA7$11ZF093:O
MJ=4N%6\G]^TTW<]-*V.CK6[I-/B/5=[^#NEJC;KV./\ \F_-N6F-];O=]NJW
M;B@RI;,-!U2$%*([2 E&W;Y.U*4@<O1Z=:^W6+]=;-982TJ?@,K6B"WJC['U
MJBHIU[P%%"E *Y:A1'>:W0:Z#%Q9EN2D\2W#)<2A#CJ[(VI2PCV(5JZ=?A].
M@U[JZS/0(E1UP%)XD/:0=.SMFS@H1S)]CUVGG//OJO%EJF;IQ[QZJAX,Z3))
M--V.?.9O_P!6/JM,9_ABY1H<>1ND,6UI<5@)VE+:$E3RD@COTWJ5KS[ZY+\Y
M>KJ83MR7VI;%O0&7-Z%*$9')&XIYG:#M&[GH .X#3<M/0(>0W)0.(.@D%2E?
M_!$DI*D[5;27M1JGD:ZJO]GX6VU;N(BDH$?LQ)LZ0 UKKIKUWZ:'1EKZOF/5
M4/!G2I!&K./_ +F[,OO+4*YP[_=W[7&F)+[S49,.*WN1N;:;!4$* /DZ!1/E
M<]#5NCW&?8A<HC+Q8$MDQ)2$[5!QO>E>W7GRW(2=1Z*W8=Z!#CTUJ6O/&C);
M45EP6! 4XK30J60]J3\/+GS[^==&?_L]3<);TI_/E*>=45K*+.D D_ 'J@Z,
MM>89YCU4/X,Z5F\VF9_U-RCV_P "TSL][G8_.[9;I"HLH-N-!Y &Y*5H*%::
M]Q*5*&HYC7E748<5%>:=946G6E!:%HY*2H'4$'S$$5N=_N[&??\ .?- _P"M
M3_=V,^_YSYH'_6JO%=LZGF/58<F=,0!JOB;ZK4!W([F]D*[[VQQJ\+DF89C!
MZI8>*MV\;=-IW<^6E7NY<4,@ND*9&6]#CB:CJY;T.W1X[TE)()2XXV@*4"0"
M1KH?/K6TO^[L9]_SGS0/^M5/]W:S[_7/F@?]:K#1UM&3?,>JU;P=TXV0&''/
MGMQ^):7TK=#_ '=K/O\ G/F@?]:G^[M9]_SGS0/^M5>*[7U/,>JPY+:7['XF
M^JPK_9\*".-]S)( \ O]_P#QF*W7XJ\&<'XT-69O,;2Q>&K3+[7&0XH@:Z:*
M0K3V3:AIN0?)5M3J#I42\!>B@WP/S.3D",G5>2]!<A=G5!#&FY:%;MW6*[MF
MFFGGK8#6OJ-'6=]"A<J"#)7ZMP<LEHT?8!0M#8=).8/Y+IW'#\8N<RT2I=HA
MR7[0T\Q *V 1&;=;#;B$)[@E2 $D:::<JPI/1NX1L8?+Q9KA[8D6&5+3.=@H
MAI2A3Z1M0X".8*4ZI3H1HDD#0$BI"UY^BJ:UZET+ZB\5B4O@]@,N*[&<PVSJ
MC.H@-+8,5/5E$)15#3M'(!DJ5L Y#4U<&<"QJ,T\VU8H+3;MU5?%I2UH%3U'
M54D\_P!\)YZU?=?[*I4P%$E6NS8O:,=6VJUVUB"IJ$Q;D*93MVQF=W4M#^BC
M>K0>;<:L;G"##5I?3]3T1"77TR=K:G$!MT+*PMH)4.J5O)42WMU).NNIK,*J
M$ZT42H^M' K#++DZ+W%L[*'F(\2-#BA.C$)$;K.JZI Y<BZH^5NT.A3H>==Y
M7!C"5-,(3C4)I$>/'BL]3O;ZIMA14P$E*@06R3M4/* ) .A(K- -*J 5G0#6
MB*QXS@^/X6VM%BM$2TH6RS'4F*C8"VT%!I'X$A:M!\)J^H0I?(=P_17,B.!S
M4=?@KF'(:#NJ)5@%QML!/,\S7+5*5"LJBJU2E$5:52E0BK\-*IK376B*O?2E
M-:(FM-:IK5"L"B+ZUKI7-6B8O]9:_O5SK> UU-=&X+6XF-M&H[2US/=[*IA1
M*[Y< '?7&DK>.C:=1[8]U<[4$<BX=Y] [J[24A( '(#S"HD!3!.:^$-E*$@G
M4@:$TKEI559*MU]_@!_&35QJW7W^ '\9-:4^F%5_1*QVE*5Z*\]1SQPSN[X)
M9,>799=FMTN[7Z):%3K\VMR+&;=2ZI3BDI<;)(ZL >6!SJ/+ATB[W9N%\N]7
M)['(KT/*_J;>R9IJ0]:%LA(49S;*5]:M.X]44)<4 L*.\I234I<4^&S/$V-C
M4.6F$_ ME^BW:5$GQP^U*::0ZDM;"""27 1N&GD_@J/(W +)L/O%HE8E>[*+
M?C4V8YCEGO,5Y;$*'+:0'HVYLA2.J6E74+2#M;<4VH::&LG7I,+01M75O'24
MNEOX)*OAM\5O-7,=7?HS:V'%6YQ@3416WCY8<2EP.(=2V3N"205:I-9C#S#.
M,,SK'<?S86&\0,B??AP;OC\9^(8\IME;P:>8=<=U2MMMS:XE?)2="GF#49R>
MBMEC5FSR!"OV,-HS&(.O9%NDM,VI]+Q>2S"2'5;8JG%+6M) 45K6H:;MJ94L
M^"9;D&8VC(\\NUF=-D6\];+1CL=Y$=,AULMJD/./**UK2VI:$H 2E.]1.XZ:
M0+TXJ3=C!7#,>-F*X-?G;)<G[@]=VK>FZN0[;:I,UQ$0K6@OD,H5H@*;4%$]
MW+TBL9QSCFQ.RG.U..O7K'(#EG\"FP6QZ<_(1+@]H4H)92I3@)\H*T 2GSU:
MLF@9G(Z1E]7ATZS0)"L,M[+KE[B//-#6=-VK06E))6@\]A\E6HU*>\XXUT2K
MK86VHUGOUKN%I8=M85:;Y'?[-<&8EM,0B4EE2=QZP]<E(U1J-%#D"))=." -
MVJ1I72:X?1F8[C=RN$\OVKPV&[?9Y<EQ$,.N-+=6A#9* A;3B5A0!04\Q6:X
MOG%FS1R:+-*5-;B%C>^&%I9<#S*'VE-.* 2ZE3:TG<@D#70Z$$5%/!SH[7'A
M>'4OWF!,2K&'+ D0XBV$!:KA,E!P(U(2@)E)1L!)!0>>FE9]PDQ._P"!XE;L
M?O%RMUQB6F%"@V]4&.XTI*&8S;;O6%:B%%3J5J3M"=$D @D$U9I=M53&Q=E'
M%3&G+;;9Z9ZS%N-[..QE]G<U7.#SC):TTU ZQIP;SY/+770BK+AO2$P?/9UG
MC6:Y2W1>4.*MLJ3;),>--4V"IQIEYQ 0MQ(2HE .ODJ[]ITP]K@1EZ+I9+<G
M(K']25JS?ZKF$JA/>$'4JD//JC+5NZL;5OKVK U4 D$#F3CW1SX?95D/#?@_
M+OETM2<9QQI-U@Q(L)UN<\_U3[327U*44)0V'W#Y U60G7;SUK>=,0IAL9J0
MKKTA;+CO%#)<5O469:K;8K-'N\B^R(;_ &0!Q3H(+@1L"0&TA*M3O6HH2"I.
ME91AG%*PYW.N$"W*GQ;G!;;>?MUWMLBWRDM.:AMT-/H2I3:BE0"AJ-4D'0C2
ML&XG\#+SG67WFXV^^P;9!NUG@P72_%6[(C2H4M<N*\V H(<;+B@'$+T)2GR3
MJ>61X=A&3'.I699C<+._>%6M-GC1+#'>1&99Z[KW'%*>45K6M83RY!*4Z>42
M34RZ840(6(V?BKEF3=)>[8=%E66U6.QL*,FTSX[JI\UG[ 1-:6%!(0HO*2C1
M*TZ-.;B%$;>W)XSY-;I7%A%TQR%9T8G847FVM*E]I=E!29>U3^S1* HQDD(0
M20E7-6IT'7SK@_EF>\;\8O\ -EV"-C6/N"5"FQF'A=VBEYMPQPHKV)#FU2%K
M T+94DHU(-9NO"+K#SG+\FMTV"F3=K/"M\-F6RM;;+T=4E6]T)(*D*+Z>22#
MHD\^Z@E,%'-BXTY)<,)LDB)DN#9?D.27:+9K>Y8FG40K>\MA;\CM([0XIPMM
MM.*"$J05%('+746"_=*+)\(RVRV.^VNT/H@7^9:\IGP4NI0W#;CQ'F9K"%+)
M; 3-:4XA97H$.:'D#61S. F57G(I6<3+SC\'.D2[=*@,VZ"\+6@1$26]K^Y0
M==4ZB8\A3G(H&P)!VG7M6_H[2;CE,>_93/MUT?N"[PYD$2*PXAB0)L./$0RQ
MN)(0VS&2DE?E*))Y=PKSE;FJY9MQHN%BX]X)P_M<*+*AW)QP7R:[N*HFZ-(=
MBM-;3IO7V5U9W:^0!IS4#77XO\8IF&<3,(Q>,Y*MT*X,3;M<[BW9'9Z>S14M
MJ+*5#R4;MZBMSF6P$\AO!KI8-T<[CB2<*D3LF%^O%GR!Z\W.Z2F2EV>WV!V#
M&:&A\DM,J83J>1V+/>JLKXE\*Y>=Y':[E'N$>(W#L5ZM*FWFU**ESFFFT+&G
MVJ"T21WG4:58WH*@79"Z47I.8%<8,:5 DWFY(E,JF,-0<?G/O.10$GM:6TM%
M1CZK"0]IM4H*2DDI.G+=>DQPYLX6X]?UNPVHD.X/SXL"0_$C1)0)8DNO(04-
MM*VGRU$!/GTYZ6Z+PJS##+I9;KAUZL2)K6-P,=N,>]Q7UQU]D"BS(8+2@I)"
MG'-6U>2H%/-)'.PP>B_)LW#G/,4A7YAQ.0X[ LK$R1'4DH=80^''G$I.FU:W
MU*"4^Q'+G42_<D-4IX3Q1Q[B!+ND2T2)0F6WJE28L^"]#=#;H467DH=2DJ:<
M"5;7 "D[3SU%8BKC)<4\>V<2\'1_J.419UWG576)O:F.UIC=^W9V8>C=UA ^
M"LKM.$O6_BI>\L<DM.Q[A9K?:Q&"2'$JCNR7%**NXA0D  =XVGTU%:^B;!=Q
M]RZKF-CBDJ[_ %1#)DORNSBXB5UR5=GZS9U8; 8TV;M@[]:DWMB@1M71QKCM
MG-]O-I9:FX9</#M[NMCBVF(R^)]K,94I+4N3H^H.,@QD=8-K7)Y.U6N@/:B]
M*23<<>9N;%J9:>LMAD7#*X+@4IR%< LQ8]M;T/[ZY*0[IN!^QH2=/+2:O.,]
M'9>%R['?;%(M5MRV)>9\BXSV890BZVV9,=>=AOE("UJ0E;1;6K7:XR#[%1%?
M-_Z-R,GNN1LW&9#7C619<QDMT@,H<9>E-,0VVV6%.(((/:&D/%0(Y) ',FJ\
MY6YJS;@UF]USC"4/Y%#C6W*[=*?M=[@Q"HLL365Z+#>XE75J24.().I2XFL,
ME<;[W;N-$G'9,* ,68R&)CSDM*5B0T[*M:)49:CNVZ*?W-'R?MV_/J3DG#3@
MS#X399D\C'G>S8S?&XTA=K=>>?<:GMA3;CX<=4HE+C09203J"T#W&K3E/ J3
MDD;BNGPI'8?RV3 GVM_JE$VV5#C,H8=7S\K1]A#GD_:\N^K<Z JX25\N\9+J
MC)\KGN-VN%PXQBX*@7*]2-Y=268A<DE("O*(D.L,I"4DZH=UU)34D8IE,7,+
M5V^)%N<)OK%-*8N]N>@2$J3IKJT\E*P.8T.FA\U8?8>%DG'^":L.4;1?+M(B
M/&>]=XRUP+A,?<4[*<=;!W=6XXXX= =0"GT5WN#6!W;AUB+EJNUV3<UF6Z_'
M8:=?=8M["@D(BM./J4ZM"=I4"LZZK( "0D"1,XJ#$+.Z4I5U5=FV_P 8,?C?
MY5>9Z/W9;M.1+JO\-=6:V_Q@Q^-_E5[G_P ,MO\ Q5?X:ZXZ_2"ZZ.178*"!
MIIJ/@]5?/?\ #I^WX178TKY4V%=]<\K>%P_#K_;K_GZZ=WP:_P!FO^1K[4V1
MS!U_0:XR-"1W?!W?Z&BA/@_1_IZJ#G\.G]NG^8I\'Z-/\J=_PZ?VZ?YU*A._
MG^G_ %JGP]WP_P"HJO?S[_A[_P!/?37SZ_V_ZC_.B*G</0#_ &?Z53NY?H[O
MT'E5>[GW#T]WZ>ZG=\ ^+_2B*A]!^+_0_P"1H3J=//\ #_KSH>0T[AZ.[_GR
MIIH-#\7^AY4144D.'0C=\!YGUUPJC))\DE)]'?\ ZUS$>8_$?4?\C0^8'XCZ
MCZZE1"ZICK'< O\ !ZJXB-#H1I\!KO'S _\ Y?Z^NJJ[M#W>@_Z^NIE1=71"
ME)[B0/17V'R.\ _HKF5'1Z-OX#I_SY5\&*1S"N7](:?IJ9"B"%0/(/?J/[*^
MTJ"NY0-<)96!KM)'I3SKX(]-%$KLD:GF-:^2TD^;0UP@D=Q-6B9F5O@7!V"M
MU]V4TE"G&X\1U[JPOV.XH20->_0^8$]PJ0"<D) S5[+'H-?/5K'PU8OJ]MP1
MN+-Q(TW?Q7*UTT)]S^#_ "[S7V,YMF[:6KCKKI_%DDCO(]S](_S[JM<?N47F
M[U>M5#O2:IUA'?RJSC.K60#LN.A&O.U2AYDGW/\ I#]/H.E?JVM9!^QW Z:]
MUKD_TO\ R_Z)_1Z1JNNW)>;O5Y#GPU7K*LIS"U[PGJKAJ3I_%<GT@>Y_"/TG
MN!KX^K"U;=P;N8&F[E:Y7HU]S]'Z>7?2X[<EX;U?@NJ[A5A.6VT*TVW+773^
M*Y/I(]S_ *)_1Z1K\C,+?RT3<>?_ /BI7]'_ ,O^D/T^@Z+CMR7AO60;J!58
M\<RMX3KLN)&FO\5RO03[G_1/Z/2-?KZKX&[;U=PUUV_Q9)T[]._J_3Z^ZEQV
MY+PWJ_[JAWI<XA=<ZX Y3:;7?OJ>"V0[+DAK>IR.@[E,I.].S<0D%6O<"-.=
M2#]6EOV[NJN.A&O\5RO0#[GZ"/TCO!K&>*%_;O'#O)($&)=)$V1"<:9;;MDK
M<M9)  (;_HGS^CF-0:VHA[*C7 9$+.H6N8YO<LPQ&VW.R8M:;=>KFF]7:)%;
M8E7%+/5=J<2D)+NS4[2K34C4\R:NQ-6%>90-ZOL5Q]D>ZV2?2O\ \O\ H*__
M !]LG6GU9V\D#J[AJ2!SMLD>=(]S_II_3[4Z9%KB9A7#F@1*OYT5W\Q7R4 Z
MZ'2L?.<6T(W[+CIMW?Q7*UTVE7=U?H!Y>G0=Y KZ.9VX+V;;ANW;>5LDZ:[B
MGOZONU'?Z.?<=:BX[<IO-WJ^%!'PU0_"*L(S>W*2%;+EH0#_ !7*]"3[G_3'
MZ1]J=!S6V@$E%RY:G^*Y/]+_ ,O^@K_\?;)U7';E6\W>K]I5-*L8S*W%03U=
MPUW;?XLDZ:[DI[^K]*A_9J>X'3Y&;VSJ]_5W+;MW?Q5*UTV[N[J^_3S>GEW\
MJ7';DO#>K]I32K&<RMP64]7<=0=O*V2=.]0]S]*3_9H>XC4,UMIT^QW'GIWV
MN2/:_P#E_P!-/_Y>U5HN.W)>&]7W2E6$YO; @JZNY: ;OXKE:]RC[GZ$'] [
MR-:_5C;BO9LN&N[;_%DG37=M[^K]/G]'/NYTN.W)>&]7R@&O?5IM646Z\RUQ
M8ZWDR4M)?+,B,ZPOJSIHH!:1J-2 =.X\CH:NW,U!!&!5@9R7UW54 J.@YFOD
M"OM+A2 !W5"E<B6?;'^RN8 )&@&E< ?](UKZ#X^$57%6$+FI7&'4^FJA8/GJ
M%:5R:TKX"JJ#1%]U36OG=3<!YZ(OJJU\%8 [Q7R7DC[841<FM-?AKA,A(\QK
MX[0I1T2/BJ842%V"H#SU\J> KC2P^YYMH^'E7,BW \UK*O@'*HP3$K@5(YZ=
MY^"OI##SOFV#TFN\VPAH>2D"OO2HO;E-W>NLW!0GFK59^'NKANJ0EN* -/W0
MU_>JX5T+M["-_6&_[U1,JP$+O#N%5J@[A5:A2E*4HB5;K[_ #^,FKC5NOO\
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M7G;DAJS"?TFN&UN>0A>1E]*K>Q=>OAP9,AE,5Y*BR\IQMLI2E904)U()64H
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MKJHJY$!N<TZ'D@A75NMSE!)2=Z"G=STT,RY3#5,%FXNXU?6+JXP_-C+M5O\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2128727d1_ex99-2img009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
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MQJ4F'4H*YC:>J@'$X/\  (XW&(NN?M/ZJWK0:U1;@O>IUFD5A ;FY*=*%M*
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M?;6_;$'?M?;6_;$?<,:6VA]Q] _F>7_NXP=+K0^XZ@$__1Y?^[@^D+?9'O\
MV1ZN=]M?#WOVOMK?MB#OVOMK?MB/N&G2ZS\G_@=0/YGE_P"[CT=+K/\ N/H'
M\SR_]W!](F>R/?\ LCU<[[2^'7?M?;6_;$9[YO[8CVA'VVG=+[2"#BT* /\
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M;6_;$?8Y5A6@ATH^*U#(''-*E_U(Z9>P[/4ZD*M2@!)\329?]2$^D3?9'O\
MV5HV:XB<_@OC/WS7VUOVQ!WS?VU'M"/M:=-[,5_[I4#^:9?]2$^=T\LT)< M
M2A#'B*5+_J1/TA9[(]_[)/5SOM+XQAQ!Z+2?F4("X@=5I'SJ$?3;433:V7'=
MTO0*6R4@JPW(M)''S)CSI9IM0*HC+E!I;H3QY\@TK_5BP;?:6YN:/?\ LJS@
MB'Y"Y?,KOF_MJ/:$'?M?;6_;$?:2F:16JED?\%:&LJYYI3!_U(5_V)+52G'Q
M/H/\T2_ZD5?2)GLCW_LK?5SOM^"^(G?M?;6_;$'?M?;6_;$?;)_3&TV0<6A0
M!ZC29?\ 4CHD=+;1<VH-HT G'/\ O1+G_P#'!](F>R/?^RGU:[[?@OB+W[7V
MUOVQ!Y0U]N;]L1]R9?22S&YQH.VA04IW#(-'E\'^A#G.D5C!.?B7;P'KI$OC
M_0A3RD8/Z1[_ -E/JQWV_!?!#OF_MK?MB#OF_MJ/;$?::LZ:6BU//[+0H(9*
MSMQ29?I[$)+FFUIGE-K4//H^"I?]2#Z1L]D>_P#93ZL=]OP7QN[YO[:CVA&>
M^;^VM^V(^Q)T\M4'_DM0_P":I?\ 4CH3IS:KC8/Q5H8V\'_>J7_ ?D0?2-GL
MCW_LCU8[[?@OC;WS7VUOVQ!W[7VUOVQ'V:E[$M&7X<M.@J!ZYI4O^I'>BQ[.
M*-OQ1M]25=%"D2_ZD3](F>R/?^R@[-</Y_!?%;OF_MJ/;$'?-_;4>T(^TCNE
MEI.C*;3H7X*3+_J1P/:76HUG_@K0_P":F/U(GZ1,]D>_]DOJX_;\%\:N_:^V
MM^V(._:^VM^V(^RM,L6SI6=2'K3H*FU'!W4J7./Z$*]7L*RGI8H1:5OH21PI
M-)EP0?8A3RC8/Z1[_P!DWJUWV_!?%/OF_MJ/:$'?M?;6_;$?8V5L"UFG0%VG
M0R ?&E2_ZD.VE6!9CJ1NL^WB?71Y8_\ XXD<HV'^D>_]DAV>1JY?$7OVOMK?
MMB#OVOMK?MB/NLWIK99 _P"!EN_S-+?W<>E:967X69;WK_WFEO[N#Z1,]D>_
M]D>KS]M?"?OVOMK?MB#OVOMK?MB/NR-,+,QGXF6]_,TM_=QY5II98_\ <RW?
MYFEO[N#Z1L]D>_\ 93ZN/VU\*._:^VM^V(._:^VM^V(^XL_IY9LN,BSK>Q_]
M'EO[N$6;LRS6P3\4;>'_ )1+?J1/TB;[(]_[(]7'[:^*G?M?;6_;$'?-?;4>
MT(^Q\W;=FHRDVI;X]'^],M^I"#.4"U 3_P %J"D#Q^"Y<?ZD,.4#3_2/?^R7
MU>?MKY'=\W]L1[0C/?-_;$>T(^K<S1K3 .+:H73K\&2X_P!2&].4VUDDE-NT
M3^;F/U(;U^WV1[_V4' $?S+YB]ZC[-'M"#O$?9I_&(^CL]0K?>^IT"D _P &
MGL_JPCSEJV]*/;WZ12TI6-R6TR315_H\0XVZT_TSW_LJC@R/YE\^N\1]FGVA
M!WB/LT^T(OT]3Z"<);H5)0CT"29)/SG;"O1[<H#Y&:%25?/(L_JQ)VX!_2/?
M^R@86?YE\[N]1]FCVA!WS?VU'MB/IHFRK=:*5BWZ0I6<X^#V?U8<S1M:6E4H
M>LV@K= ^5\%2_P"I%)Y0,'](]_[*T8$G^;P7RD[YO[:CVA!'T_<;HRG%$6K0
M0"20/@J7_4@@^D+?9'O_ &4^@'[7@KHEO_\ 6(B?6!YV7KD@EMUQL&6)PA9'
MUY]$2^6XB#6D8KU/_P#E3_IF/SYR]<6[#J%I_F;\0OHNP0#CFSP/P3#\MF?W
MR]^55[XQY9,?OA[\HKWQJ@C\P\[4^T5]/R-X+;Y4_P#;W?RA]\'E3_V]WVS$
M!U&YZI9W:PEI"?JTVJV:]17'V91UXEAEUM)*RE)X!^E$\?9Q'NB.L=Q#42K5
M.XZE-OT*OTJ?K%,EIATJ:90P\L@(2>$^:A0X]4?1*7([:%?!NQE&L"T4F51K
M+LV:6#_N;S;Y_P#%>;=MG#TZPHO9!SN:=+1%SU',V.U6^\J?^WN_E#[X/*G_
M +>[[9]\5@T=UFJ%MZ?VZW56:U>MXW6_,U"3IC#H6XW*I44I.YP@(1YBB!X\
MQ-NFNI5-U1MYVIT]F8DW)>87*3<E.)"7I9Y'RD*P2/'J(Y&V.3NT]C.JNJ2Z
MFQQ;G!L2"6S$Y@TN:X!Q$$@@&5MP6T<+C0T-LXB8]P,3I,$$C42GEY3,8SWS
MV/3O5!Y4_P#;W?RA]\58D-1YNRNT7JL6Z16KG7W+!9IM,!<[M*4I*UG<=J$@
M$>LDX ,2$CM.VU-V30Z[3Y&HU&>K4VJ0DZ)+H3Y4N83C>@Y.T ;DG=G'G#TQ
MMQG)+;% TCAVFJVHVF01 @OI\Y!&:0 ,W2,-.4F1!BBCM?!U \5"&EI<(/\
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M/B!G&1'K\?R'VS@,.ZJ3G<QSPX-(,!C6/+ID$V=<1(#2=%Q\/MS!8BH& 0"
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MM4ME;*9^CO*:+V'%!*5)6#M(R>?_ %B/HSMW.ZF*)+FEK2 YI(+BT"0'2+N
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M,];EQM>JVNT. %4-!N]Q;ES?4+WN+9#G W(@D !6,V%@V&F8^I/ 3,:P #$
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M>8G_ *@56M9ZN9_%<XNJ.+<N<N8&1#'DS:<S7,,P6M;>>!2Y/-EWI+N@  T
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M2"HG'S QVV\O=K.JN>:;'.<9%G2":8I'*X/SR6@2XN+I$YIF<)Y/X0,#<S@
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MCG>!3G[9N.#STCHU%O6IT?M!V71982GD4U29R86IR4;6\E:4.$;'"-R1YHR
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M"0GG<GDC"B<X!](B1)GLX6]-:=VY9JJA4A3J'."=EW@IOOEK"E'"SMQCSCT
MCBUETAE)]%YWK**GYJOS5N/4M$BR IM:2GC:D#<5?A_!'6I[<Y,XS%B@,-3#
M7NJ@?PFBQJL-"\6AN8..\6=(B,KL!M2C2YSG7$@-/UR?Y#GMOO$=X4:S^KVJ
M%KZ?V/J%4:W2YZDU289EWZ*U()0MQ"]WGESKO(0>$X"21P>8Z-7=<[EMBJW'
M4;;N[X4EZ-.!IRE2UNER281N"2V_.'HYD_6^/ YA;TA[.%,J5H6-5;AFJ\M<
MBRB<%NSLP1*,3.XDJ[I0RG) )3G&?4<0XJQV4[:K N-@URX)6F5N8,X]3)>;
M2)9M\J"BX$%/G'J!NR!GU#&NIM7DCA=I9,13:>;<\'+19D<TU1#(RNES& P\
M03/U[7I;A-L5<---Q&8-(E[I!RZS(L3'1,@1HFVK4;4.^=5Z_;-M5J0HDDU0
MY:J,KFI)+ZF"MIM92D^)*EXRK( R<$XAL6QKM<MV2ND$U4?(')FH5Z9D)YY4
MBVM2TMEO"T9![M6U9!*,9Q$\VSH[2+5O:=N>5FYUV=FZ8S2EM.J26PVTA"$J
M&!G<0@9YQR8;=O\ 9BMNW&K4;EZE5'!;E3=JDJ7%MY<=<V92O">4CNQC&#R8
MXU';W)AK.:=0: UC TBF,Q=S%5E271)FH:9O(D9A>2MK\!M0NS"H;DR,UHSM
M+8&@Z(=IV*&_HE[YK?PC<-)F'2S+U'N96V6* Y,-/RR5 **YM(.US'. ?Q9$
M.:0UHNN:U=<IER7"NPY-<^TFFTJ;HH<8GY=1& 9D\I6H$ 'ID^'2)%E>SI3:
M/6YN;H5T7-;E-G)KRR8HU+G@W*N.9!.!MRD''(!Z<=,1[G.SS3JS<,M/UJY[
MCKE/E)XU&5HT]-I5*LN[BH8PG=M!/ STXC96V[R0?F;2P[6L+" >;:7MD-@0
M6%A<"#+G9G$.)YT& J&8#; @OJ$G,)Z1RG639P<!?00+#HE2L>I\.>D$!.23
MXGF"/@Z]\B"""!"(((($(@@@@0B"""!"(((($(@@@@0B"""!"(((($)?LI?=
MUA1SCZ4?ZQ$CL3?FQ%MN.]S4"KIYA'Z1#UEY_P T#,?J3_IXV=A-_P#-WY+Y
M1RC=&T#V!.3RH>G],$(7EO\ ^L01]+RKS6<+N<;*%$0A5BWF:P^AQUUQM2$[
M0$8P><^,.5YO?S^".9U@IY',<W&X'#;1HG#XIF9AW'JTT6FC7JX9_.4C!317
M9DJGI,/_ (=ONCBF+:89!PZ[^'$.YX8SF$F=^28\\.2&P?NK>]WFM_KG:'M3
MX>2:C]/0T3A2C\^(Y2TD*QDPHU \F$]!W$^GUQ:.1^P8_P#2M[W>:I.V]H3_
M ,I\/)=#%/0[U4H?-B.]%OLK'#CGZ(U2',(6HEW7)94A\)4JB2M9IS:<S 4Z
MXEYG^$4@<I]8Z>/IBRCR)V'B*HI4\*V3I)(\24E7;^.H4S4?5,#@)^ 3G3;+
M*OVUW]$;T6BPH?5G?T>Z( 3VLZJ.1;5//_BG/=&Y/:YJZ?\ W9IQ_P#%.^Z.
M_P#_ $KPGW%O_N__ -+B?3G_ /<G_P!O[*?$V;+G]O>_1[H\JL^73^WO?B'N
MB*K![5\A5+A9D[KIC=%ICWF_"$DXIWN59ZN)4,[/21R.N,1:J5LF0J4JU,RM
M2,Q+/(#C;S6U2%I/(4"."#Z8Y.-Y [)V>X-Q." G2Y([P5U,'REQ6/:78?$$
MQV ]Q"B)RV6$?MKOZ(YET1I/1Q?Z(F5S3&7<_=SP_B)C0K2>55_E![\FF.;]
M$N3_ -U;^+S6_P!:[4]J?#R40)HC2C]47^B.A%MLJ'+KGZ(E=.E$JD_X^\?X
MB8W)TQED_NU[V$Q/T3Y/_=6_B\U VKM3VI\/)1-\6&/MSOZ(T+M]E)^JN?HB
M8CII+G]VN^PF-2M+)91SY>\/XB8/HER?^ZM[W>:;UKM/VI\/)1&BWF%$#O7?
MT1L%M2Y/U9W]$2PG2R62<^7O>PF,ITNET_N][V$P?1+D]]U;^+S1ZUVG[4^'
MDHG^+,OCZJ[^B#XLL9^K._B$2X-,Y<?NY[V$QG]C26_?KWL)@^B7)_[JW\7F
MI]:[3]J?#R41_%=@_MKOZ(]IM274?JSOZ/=$M?L;2_[]=]A, TWEQ^[7O83$
M?1+D_P#=6_B\U/K7:7M3X>2BDVA*A.>_>_H^Z.5^VV&DJPZZ2/3B)B.G+!&/
M+7?83&AS2^7<ZS[P_B)B?HER?^ZM_%YJ?6VTO:GP\E"BJ6-^ I1CVJB*"<@D
MQ, TCE4JS\(O_DTQN_8LEOW^\?Y-,1]$N3_W5OXO-+ZVVG[4^'DH053G$DY!
M_%&!(+XSGGU1."M*Y50QY<]["8TKTBE%*!$^\G'3#:8/HGR?^ZM[W>:/6NTO
M:GP\E#R*/N2"5*R8W(H"5#)<7^ ")=3I/+  ?"#QQ_V:8V)TMEDC_'WO83!]
M$^3_ -U;WN\T>M=I^U/AY*(V[;;41EQS]$*$K9DN^!N?>'S8]T2>G3"73^[G
MO83'6S8##/2;=/\ $$*>26P/NK>]WFK!M;:.^J?#R4:MZ=2:QS-3']'W1Z.G
M$B/W5,_T?=$IHM%M _QEP_Q1 JTFE?NASV1"_1+8/W5O>[S5OK;'^U/AY**C
MIW)9QY5,_P!'W1S3ECR4LG/E,Q^';[HEPV>T?W2Y[(CCG-/6IP$&>>1\R$P?
M1+8/W5O>[S1ZVQ_M3X>2KS<CS-$2>[45JSA(7X_BC=;<H[6&T*F &MW/TOP'
MX8E&K]GJ3K$ZA]VMS:0CHVEE&(7*7I!)TM&U$^^KC'+:1#?1+8$?^E;^+S58
MVMM"?^4Q[O)1VS9<NXD%3[P^;'NC>BQ951_QE_\ H^Z)338+*1@3;OLB-B;&
M92?\:</\40OT2V#]U;WN\U9ZVQWM3X>2BY&GTFKK,S']'W1[.G<CC(FIG/H\
MWW1*0LUH?NESV1&?B<UG_&7#ZMH@^B6P?NK>]WFH.UL?NJGP\E&+>FLBI.3-
M3.?F3[HT3>GTC+=)N8/&3G;Q^B):%JMI&!,+]D1R3ECMSB"DSCJ,]2$")')+
M8&_"M_%YI#M;:&ZJ?#R4)+H$MY1W:7G<#DYQD"-HMAC9RZ[O\1QQ$W-65)MT
M,TXG=E)!?V +W9SN^>$M.E\JE&WRY['WB8M')/D]]U;^+S2>M=I>U/AY**6[
M4EUI'T]T'\'NCNEK%DU J?F9AM &2H!/NB36]-Y9M6?+'3Z,H3&]RQ&G&@WY
M8Z!U/F#F(^B7)[[JW\7F@;5VE[4^'DHF59<IN(3,/D>'R?=&_P"(<HEO<J9?
M!]'F^Z)-9T[896")UTC[$H3B-KMAM.?NQT?Q1##DGR>^ZM_%YJL[5VG[4^'D
MHF39\@3A4S, ^GS?='.[:<OWFUIYY9SC!Q[HE=6FK"E9\O>]A,;I?3N6ER2)
MIU2CXE(Z0_T3Y.?=6_B\U(VKM/VI\/)1A+V#+. ;IEX'QQMQ_5&F:L^09WE$
MS,*2GC)V\_HB6G;%:6@)$XZ@>.$#F.16FDNOA4\\4YR1L3S%?T2Y/?=6_B\T
MWK;:7M3X>2A]JVFWEY2XX&AQN.,GYHT.4>6"U):==<VG!5Q@'T9Q$QS^E[,V
MR&FZB_+HZ'NVTY(]'JCR-*I5J3$LU.NMMCKAM))AOHGR=C_TK?Q>:@;5VG/_
M "GP\E"3U/*%822H^OTPL4:TQ4VR5..(6#T3CD1)PTAE=^XU!\G_ +M,+5-L
M66IH&Q]Q1'B4B*/HEL'[JWO=YJ\;6Q_M3X>2CN7TMDW$A3DY,I'J"?='B;TV
MILN 4SDVH9YSM]T2LNWD*&.^6/P".9RSVW"<S+@S_!$1]$M@_=6][O-2=K8_
M=5/AY**QIU)*(Q-3.#][[H\JT\DVU87-3'X-ONB5D6@TA('E#AQ_!$>)FRVI
MDY,TXGYDB)^B6P/NK>]WFD];;0]J?#R48'3RG)&3.3./5M]T>1I_32"?*YK'
M\7W1)[%CL-'SYEUT> ( C+UD2[GR)AQL>@ &#Z);!^ZM[W>:/6NT/:GP\E%:
M[%IB3@3<U_1]T=4OIS2WAS.S8^;9[HD Z>-*.3//>PF.IBRVF!@33A^=(@^B
M6P?NK>]WFCUKM#VI\/)1^WI?2%'SIZ< _B>Z-PTJH@&349W\&SW0_P!5HMG]
MTN#^*(U.V8'$[1/.H'J0(CZ);!^[#O=YH];;0W53X>28*=*J0\3W52FCCTA'
MNC1,Z5RC*<IG)@_.$^Z']+6)Y,?-J3Q&<_4TPHIMO"<&:<5\Z1#?1+8'W9OX
MO-5C:VTM]4^'DHC1INTI7,P]CU!/NCI.F,F$;C-3/XD^Z)6;MQM!R75*_BB/
M3E ;<&.\4/P"%^B6P?NK>]WFK&[6VA%ZI\/)0Q,V+),' F9@_/M]T<HL^44?
M-F'R/XONB7INPV)H\S3B?F2(YD:;L(.1//9^\3$_1+8/W9OXO-/ZVQ_M3X>2
MBYFRY1:\*F'PGQ4 GC]$=DQIY)M)"T3;ZT'[W/\ 5$GR]BM,!2?*W%(5U24)
MCR+#;2KS9UT)'1.T<0?1+8/W5O>[S4>ML?[4^'DHP:L*GN=9N8'S;?='2G3*
M5*.\$W,!'@?-S_5$B&P&=^Y,ZZGTC:,1VREJ)EDE)FG'$'ZTI$'T2V!]U;WN
M\U'K;:'M3X>2AMZRI:7=4EV8?XYR,<C\49%F2+SC9:FG^Z5P5+VY!_%$MSMB
MR\ZD@S+B#G((2.(Y&=-F&E?X\ZI)ZI*$\P?1+8/W5OXO-'K;:'M3X>2C,V'+
M)*DF8?"AXG;@_HCC?M&7940'GCCTX]T3&Y9#;C:$&;<\WQV#)CF>TZ8>',ZZ
M#Z0A,3]$M@?=6][O-1ZVVA[4^'DHA1:TNL</.Y_!&%VNPG&'G"",^$2O^Q<Q
MG_C%\#Q&Q/,9.E\NI.TS[V,Y'F)XB/HEL#[JWO=YJ1M;:'M3X>2AF9HR&<[5
MK5\^(Y6I(+5@E0'IB:G-)I9S.:@_S_V:8TC1V4'^4'_R:8CZ);!^ZM[W>:GU
MMC_:GP\E%#%%86<+=<3ZQB%Z@V/3:I.I9?G9AEM23A8VCGP'(A]#2"5R":D^
M<>EM,=\MILS+E)\O>5CP+:8/HEL'[JWO=YI/6VT)_P"4^'DFDYI12/*^Y:J4
MVLA.5$;#CU=(W?L/4O&?+YS^A[H?#-HI8=[Q$VX">HVCF.TT/(QY0O\ $(/H
MCL'[L/Q>:;UOM#VA\/)1+,Z:R##JD"<F2!XG;[H\-:<R"U8,W,@?Q?=$IN6D
MVZHDS+G/\$1K39S:3D33GLB&^B6P/NK?Q>:K.UMI>U/AY*-SIA3\$IG)H^S[
MHXIG3V49!*9F8./2$^Z)=%LM@8[]?LB-+UH-/)(\H6,^.T1'T2V#]U;WN\T>
MMMI>U/AY*$INU&F#YKKJ@1GG$);])+6<$GYXG-_3J7? S..C QPA,<;FE$HX
M<F>>]A,3]$M@?=6][O-2-K;1]J?#R4$3##[1\U 5\^8XG9A]I))0@JSC',3X
M[H[*.@CX0?&?0VF.![0B2>SFJS(SCHTB)^B6P/NK>]WFI];;1]J?#R4#.5:9
M;&2TW^,QI%=FE* #+>#X\^^)W7V?)!8P:M,_DD1K3V=J>DY^%YK\DB#Z)[ ^
MZM[W>:CUMM'VI\/)0:Y6YMM6.Y;/X_?'1*U1][Y;: /5F)J5V=I @YK$U^21
M$5URB-V_<4_34.%Y,JZ6PXL %0P.3CYXM;R1Y/NL,*WO=YK-4VQM)ES5/AY+
MJIA*7PKU0YVIC8@9/XH;D@C+8QU'!A=;1N1TCTN!V?A=FT?1\(P,9K XGM7)
MK8FKBG\Y6=+N*Z/+QZ_QP1R]UZA!'0LJKJ0E$ $1H6/_ .T>)A:I-\MN$$IZ
MD>,<[DWX '/IC&M<K1- !2L0C3OR3"F^[G)/,)<XH%)\(8*HIMSXY/2$Q/"H
M\Z@U"JT:U*M/T*E_#=888*Y2G[]OE#F0 G/AU)_!%=- -1M0+HUUO.@7O--,
MN4V02OX)DPGR>5<*V^$D9).U6"2H\YC=3H.JTW5 1T>_N66H\,>UI&JM'(CS
M086)<Y,)$H=OS0J-' C"5I"A35[L]"=[^MVG+A$QRM^EHX2YZ5->A7\#H?#T
M171:%-K4A:5(6DE*DJ&"".H(\#'T#:=QCF(OU=T1D;^0Y4Z9W<A< &2L^:W-
M8\'/0KT+_'GP]_L7E&:48;&F6[G;QV\1U[OAXG:^P15FOA!#M[>/9U]6_P"-
M2HF?0+M)U;1Z;;IT\':K:CB_IDGNRY+9ZK9ST])1T/A@\Q$55I4Y0ZB_(5"6
M<E)QA6UQET84D_VCUC@QRQ]%Q&'H8ZB:=4!S3\R#^:\)0Q%;!5A4I'*X?,'R
M7UEM.[J3>]"EJQ1)YJH4Z83E#S1\?%)'5*AX@\B%F/E]I#K/<&C==\MI+O?R
M#RAY93'E'N9@#Q_@K'@L<^G(XCZ&Z5ZLT#5RW4U2B3.5HPF9DG2 _++^Q6G^
MI0X/@8^-;8V%6V6[.WI4SH>'4?/0^"^N;)VU2VDW([HU!J./6/FWBGI$==H3
M4F?TAT;NB\*9*R\[/4J72\U+S94&EDN(1A6T@]%'I$BQ"/;5EW9KLO:@-,-.
M/O*DFPEMI!6I7T]OH!R8X&':'UF-=H2/BN]6);2<1K!2-HSJYJW<DO*7-?\
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MQL.RZ)V>;;4ZV>BT@G)2?LND44I&F]-K.FG:OJE1MMN;J\O6)LTZ:F)(J>;
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MV_.KI*Z@P6TH2%LH 2H(7QCPP03D;LGETL.RK5>UI) TC4WC]UNJ5GTZ;7$
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MXQX8 8W7W:;^OS5HM<.U-:6B35N";=;JTS7'VDL-2DVT B76<&:6HGZD.?.
M.3Q#)M[M5,/]HN\Z-5+EH,OIM3J'+5*1JBEH0E:W>Z /?E6%@E:L #^J*R7;
MI77[-[)^D-6N>W'W7Z7<8?FVG)/O9F4IJW%+0RX,;@@G)V'@%8! )B2M-+3L
M[53M<7K446NQ.V>_:$L_2F)REEEAM*FV4C8TI("% ;@!@$9.,1(PF'ITW'6
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M2!GP),/WLQ5!%E:V6[:U@.-7_9LZ],3DS,U*V5R51H&Y)R5S*T#)^MQD@Y(
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MWC/ VC&(<%R4>R;%[1.MU OBA3M)I5PR"$T6;I-$4^I@*;^F.L;$$(."HDC
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M:TA9-:JTP9NZ)IGNW$LK/<2S9P2VG[,Y RH^C@#J7/HAH%0M&*1_@Z1/UU]
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M0JI//SD[;5:FIM]16Z\\R5*6KTDYCG_8AO?[DZK^;_\ K#I7VF[\W$*>IJ5
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M"4N F.ARX*:TH!<ZPDGG!7"5*:>TB2=#J$.ET?7J=),;W;*IK[I<6'BK_O3
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M\YWSA+CC:,D!L@ )5\KKGDQ833#7#6&L=J2_J+.6\JITVG(2AZAIJK26Z4R
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MCX8:S]XO]6$-W1"ENY_WRJ"<]0%-_JQQJ[/M'4K<*I4QZ@IO]2& I[RH)J\
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MF2RMR7YDGUE/NAB*&XE*'8G>!\^]+B+PHZQE,ZDC[Q7N@-WTA/6<2/XJO='
MBP9)L8#\Q^-/NC*K"DE'/?S'XT^Z*B*>XJ\&KO 2JU<=.>3E$TA0^8^Z..=O
MJA4[_&*@VW_%4?ZA'*+!E "$S4RD'T%/NA.G-):;.JW.3DYGU*1^K$ 4]Y03
M5W +H>U>M"7)#E::21Z6G/U8YU:W62GK7FOR+OZL),UH#1)M14J>GP?4IO\
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MHOQN>'7.[BJ Z$Z(U37=W7"J3-7JZ*%=[$O3I.Y:Q(!M^>4AP../I8\T!&4
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MMNTE"R-JDX.,==W,0Y*=@J7MBU[-^*E[S]"O6V9B8F6+@\D0XAXO*W.(4QG
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M,]8].K@NNG>5VK<M1H5:83YK#,XMN7FA]BH X2KT*'X?2.E@'AF):2X-ZR)
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M+EK4=Y)2Y2Y18/@IE)_LCF%A6V%9^ J=GT^2H]T6--,?6"1P=N*;\KJ_3YI
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M]V]<]F.@34'=V";'M]^Y7BM'5RUKYNRY[;HM3\KK%M/(EZG+EEQ'<K5G "E
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MU"N4R;NJB,4Z=8?996M#K:&\@M'8<;QU\.,G-ZOJ$$APTG?<0#PZ^U7>F,$
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M'LB#R9G[4CV1 A)BKD82,]VY^CWQJ-V2P_:G?Z/OA8\E9^U(]D1CR-C[2W[
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MYU!-:F?XO^B(?IZ1'=W.[:Y,CI\G_1$"@I'>=XX,<3KO,#SQYQS'*7-RN8%
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M8HB*-,OU$-?3PG;]-.U.=QV =<1-4$2<76<"TNU_-0,/2:00W15R8[%%N,:
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M#300P"D[4H;2!D[$Y)R?-^>%S770VFZ\4"C4JIU*<IK5,JK-5;<D@@J6ML*
M2=P/FG=X<Q)<$(:]0U!4FX3"BP,+(L5!NIO9:E+TU!<OBW;OKU@71,RHDIZ=
MH;B,3C0P %I4/E  #</L4^(!A(F>Q)9QTYMNT)*I522EZ16DU]V=W-N3$]-
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M?O3$'-Z1V2?\WB2?_D&_[Z.A&C]DJ_S=#^;FO[Z*L[_85/[/^9-+!_4;W/\
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AMI-:9"\K7@=8YUDJ5'I:B28\$<_@C,KH6<01F"!$+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2128727d1_ex99-2img010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
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M_-_B6_JH^Z=MWP?F_P 2W]5+2G$5.I3314+?=.V[X/S?XEOZJ/NG;=\'YO\
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MI06TV^D='$I4 1OT[]>J>=5@^[JL_P $+E_&M?9H^[JL_P $+E_&M?9KB5^
M7#7$M:ROA7.#9@%[#$ZQT]\#R'4%TZ?"+85$EU.J 3K#79^BL_158/NZK/\
M!"Y?QK7V:*T__IKPL^1/_P J?ZUGYT['[_T=[*GU%%%?T%7YQ1116=418HHH
MHB****(BBBBB(HHK"7$KWRJ2K7?RG>J(LT4441%%%%$11111$44;HHB****(
MBBBBB(HH)UW]*PE:5C:5)4/6D[HBS1111$44441%%%8"@HD @D=X![J(LT44
M41%%%%$116=5BB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBB
MBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****
M(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB
M****(BBBBB(HHHHB****(BBBBB*4N$O$CA[A5FF1<PX41<_G.R.U9G/W9^&6
M6^4#LPEL:/4$[/KJQG&>X<#.$V,\-KJC@';[D<PL+=Z+1OTMOQ4J"/O>]GG]
M]W].[NJD-6@\,G_^FO@Y?_V(Q_Z6JX^(HM.(IYGI$STG#0>!R^Y;E-Y%-V0R
MC<.O[% V5QO[S9E*DX]B4NQ0+FX7[;9(Z'I!;:T/-;44\SH'4\P![Z1H%BN=
MTGK@PK;-F3D$A<6/&<<=20=':$@D=>G45=KCWQRO?!O@OP(1AKZ;-D]TQ%A,
MB^(:0Y(:AMALAAHK!" MQ7,H@;/9I'HJ/."MR\(G+L'O<O!Y[>.6";=G[C=L
MKDOQK;XU*<(YPJ4YU(203RMC0*COU5-/%/-'C" T:"7=1CJ\/M*.I-OMDDZY
M#ZJL=QMLRT2UQ9\21!E(ZJ8E,J:<3\:5 $?)6YFP721+C16K9.=E2D\\=A$5
MPN/)_&0D)VH>T;%7-\+&QWB\>"'AF0YID-AS+-+3?W;4<@L<M$L.QEMN*#+K
MR4@*6DI3OIZ >\G?7X4?'+(N%."<%H&'R!8+W<<)A+FWZ,A/CJHR4I#<=MP@
MEM'/SK5RZ*CR[.A4,QSZH8&-!)+AKEEOTT^Y2Z@&R7'( '3K5(;C;9EGEKB3
MXDB!*1[]B4RIIQ/QI4 1\E=5IQ>]7]IUVUV:XW-IK_>+A0W7TH^,H20*M#QL
MRF?QN\";"\_RA3<_,;/DK]@5=RA*7Y4<MJ4 X0 "00C]J2>]1W*?$67Q0R/#
M<2O_ (-.1<_#VUV=AIW',7=:;FP9(![7QB.1S.J)UO>SL$Z.]D<<X  M ,D$
MD]$$>,;]VB"@"3!D0#IGGX>"KKX%O">!Q*X\VN+DMF?N./V^/*GRHSC"^R><
M9;VAE9UKWRDDH/?K1[Z:/'3C%E/%BY0#DMEM]A9MY?,")!M @!IE:AYAZ K2
MGD !/=YWKJQ/@(\;L^O/'K(+/<K[)3"ND>[7RX0.P;;0NX<B.9TIY-I5L=4@
M@#7=2%X.&57'CEQ%R?B)Q7FKSAOAUC,BZQ(EP:;"'' HJ;0I*$ %((6KJ#UY
M3Z-5@?5?3Q%2K5:"&M$9YYSIEO.1^Y7#&NIM8TZD^D?V56U8??TVKRF;#=1;
M=<WCI@/!C7KY^7EU[=ZI,C1W9C[;,=IR0\X>5#;*"M2SZ@!LG]E3Y;?#QXS0
MLR;R*5ECTV+VO:/V);38MZV?PF UR^:GEVD$'F'0[-3#DW#ZR8%_:+\.',<B
M(MUFR!^#?683(Y41U/(="TI [@5(*M#H.8@=*W'8JK1)%9HFTD09TU&@6$4F
MOS8=X&G6J5IL=R7&ER$VZ8J/$5R27A&<*&%;URN*UI!WZ%:-;XF*WN?<%P(U
MEN4B<A <5%:A.K=2D]RB@)Y@/:1JK#^$QX0^42^)^;\/[%/%FP%J\OPG+/%:
M;Y)C@D\SS[RRGG4XMX*7O8T- =W63?#H\(S,^&W'I^R8/=G,3[.!"EW"7;T(
M#]PD*:\PO+4DE2$("4I1[WJHZV:J,57<6-#!+P2,] (UR\=RDTJ8#C<<LM/M
M\?!4CB6>X3[EY.BP)<FX<Q1XFS'6M[F'>.0#FV/2-=*US[?+M,Q<6=$?A2F_
M?L2FE-.)^-*@"/DJ\OA2<>[OB&%<-LMP]EC%<WXA6%BY9#D%M:2B4^EI" EI
M"M'D25K4I1&B0E )T*C_ (_Y3,XQ^"/PLX@Y&43<PBWN;8)-U[-*'9;"4K4G
MM"D $CD3^WF/I-12QE1]CG,AKC&N<B?#201KXH^BUMP#I(ST_P"=:A+B#FT'
M(\%P2TQ\"@8M(L\-QIZ]16UI=O6RG[ZLJ2 K6B=@JZJ.B!H4T&,=NTJ>Q!9M
M,]Z:^CM&HS<1Q3KB?QDH"=D>T#56&\*S?W/7@V[)/_Y+RO\ U-5*?AB\>,DX
M6.\.+3A4PXY<YN'6]^XWN&D":^T H-1PX02AM)#BR$ZYE+Z]U5IXEP#&4F?$
M7:DY0?OU^BEU,=(O.D;NL*CDZ!*M<MR+-C/PI3?1;$EI33B?C2H C]HKJL^-
MW?(E.BTVF?="T-N"#$<?Y!_XN1)U^VK2<?+S-XY^"OPBSV^AJ1FRKU*QN3=0
MTE#DML%0;+G* "04)/QE6M<QI9\*?C%D7@V9-:^#G"^YN8?8\;MT9<R3; E$
MBXS'4!Q;KKA!)Z%/3TDG?30%VXQ[[:;6B\ETYY"TP3,?9&6]0:+6RXG++[<U
M3IRVS&8RI#D20W'0X65/+94$)<'>@J(T%?\ A[_97-5T>*G$ZY<7/[/FWWZ]
MM1O+@SE$6?-CLI:,]U$=>GW$I ':%!0E1 ZE&ZI=6UAJSJS7%S8()&LZ+%48
M&$09D2K)>!7P_@7C(<SS"^8X;_%Q+')-XMT&7&4Y%E3$'384-:<Y2#YHWU(]
M51/Q@XG9/Q4R2+<LMA0X%SC1$Q4-0[8( [/F4I.VP!L^<0">N@!Z*LKX#W&/
M-;=P^XM62-D,EJU8YA\JY6F*$-E,.25J47$[3LGF).E$CKW4G\ \RN-^QWBW
MX0><+;S3+L1MT2%9U75E"FT2724MNJ0E(2>3F3KITVKKO1'+-5]/$5:KV@Q:
M!GGGH-,IG/\ RMJQKJ;&M,3)/W>VY57G8A?K7;DSYMBND. H;$J1!=;:/_QJ
M2!_.D^)!DW!Q3<6,_*<2DK4AAI3A"1WDA(.@/75D>%'AL<4D<4;2<IR9_+,=
MNLYJ'=++<VFEQ7F'7 A82CDT@@*V-=.FB"#4U\$^'%DX1^'?Q8QF.R48Y&QV
M:^B,VLCLXSJ&'2T#W@)"U)'J %;%7&5,.'"JP2!<(.L$ C09YA8VT6U(L.4P
MJ#.6J<S;F;@Y!E-V]Y10U+4PL,N*'>$K(Y2?8#6EF,_+<#49AV2^H'D:905K
M40-Z  )-2-Q1\(G,^+UN;M-UN*6<4COI?MN/Q6&VHEO0A!0TAH)2#I+:N7J3
MOJ33,Q/,KUP^R")D..W%VTWJ!SN1IC(25M**%)) 4".Y1'4>FNBTU"R7 !W5
M/^8_PM8AMV1R4E\>_![D\&3APC.W*\HO..1[Y+?7 4AN(XZ5;:V 0 D ;*B#
M\5/+PD<=8'!CP;Q:K6@W"X8X^IP0HP+TE?.UHD(',M7?ZSWU)GAO\?N(5JAX
M!88F53&+1DF!PY%WB);:Y9CCP6EU2B4;',.AY2/9JM?&+C->.$G@S>#^G$UH
MM&2W/'G&UWYIM*I4>*DME3+*E ]GSK4DJ4GSB&P-ZK@TZV(J-H/< 7$G?X.U
MR]UON93::@!R@?W'BJ7W6SW"Q2S%N<"7;90&RQ,86RO7KY5 '7MKU:+'<L@E
M&-:K=,N<D#F+,*.MY8'KY4 D#VU:O.,[NO'7P$9639D\+SE&(Y4U!BWAY"1(
M<C.MI);6H <W^\UL]_(DGJ-U+>1<+^)/"OA+@.)\';O8<4$VU-7?(;R_>(\&
MXW"8Z 0G;FU!I V!K7H'H.]MVT"P!K@ Z2,SEEG,QU$;EB&'N,@R(G3/-?/&
M;"DVV6[%F1WHDIH\KC$AM3;B#ZBE0!'[16A1TDGV5='PL,>O-X\&W$<DXA7&
MPW'B?9[NJU/S;3/8D.SK>XE1;4\6O?*2I(&]=.I_"-4N7[Q7Q5O86O\ Q%._
MQ(ZQEU'J6"K3XMUJN=Q*'!K@5@_"@W'@M"RVY9)BT:[2YSEYDQCVI0@+\U)(
MZDD]-?%5<N*.4XMQ$OML."\.DX0VAE33MO@S'IZI3A5L+\X<P(2"- >VK:<>
MV.#+O#S@4>)DS,HUR&$Q!$3C3+"VBUR(YBOM.O-S=VNFJC/P;&\":\-GAH.'
M$B_2+!SN\Z\B;;1)[?Q63S@!OIR:Y->G>ZX^%JAE%U<AQ< XYET&)\8]%N56
M%SPP$ &-PG=]ZJRM"FUJ0I*DK2>4I4-$'U$>NG%B6"W/*,TM..F'-B/S9<>.
MXHPW%+80ZXE':J1H'E'-O9T#KOKUQ /_ .<[)O\ ]]R__F5U<'C_ ,2<FX<^
M'Y#<QN\OVE=U9L%NFEE*%=O'6IOF;/,D]#ZQH^VNG6Q#VPU@S+2?*/ ]:U64
MVF2XY @><^RJ]QWX02.#O%+),8CIN%PMMKE(BLW.1$4V'R6T*WL#EV2H@ $]
MU1_+AR+?(7'E1WHKZ/?-/MJ;6GXTJ (JU_AA<:LXOGA(9!@D[(Y4G$8&2051
MK2I#8;:*2RI)!"0KH5*/57III?V@)WX6^;]=_P#L?_RK58\+B*CQ295 ES9F
M>JWP&LJ]6FT7%AT,?W]E7YZ#)C-,.O17V6I YF7'&E)2Z/6@D:4/:-UU-8Y=
MWY;L5NT7!R4RWVSC"(;I<0C\=20G83[2-58_PCNO +P6^I__ $)*_P#YT>I1
M\.;PA\KX=<;)&+X'-&-NS+?#?O$R.RVM^X/.-<C:%K6DD-H;"0$#75:CWFJC
M&5'EC6,$NNU.EICJWIQ+6@EQTCU$JCUFQZ[9&ZMJTVJ==7&QS+1!BN/E(]9"
M =?MKC?CNQ'W&'VG&'FU%*VG4%"T$=X(/4'V&OH[Q8X8\5>%4#'.'W!J^V#"
M\;M,!ER=*\N1H4^YSE#;CKQ6"OE[M#N._4 !#GAKV&7<.&/#'+LKDV.1Q,47
M[1?G[+,8?3+0CF6P\OLNG-RI.SKO5KNT*I0VB*SV@ 0[3/,=4B-_VY9*U3#%
MC3,R/#+[E4&BBBNRM)%%%%$11111$44441%%%%$11111$44441%%%%$11111
M$44441%%%%$11111$44441%%%%$11111$44441%%%%$11111$44441%%%%$1
M1111$44441%%%%$11111$44441%%%%$11111$44441%%%%$11111$44441%%
M%%$14^^$[Q$QS.,&X(P;%=6;E+L.(M6ZY--!0,:0 WMM6P.OFGNV.E0%16%]
M(/>QYU;/J(60/+6EO6IZ\)GB'CN;X=P4AV*ZLW*38L31;[DVT% QI *-MJV!
MUZ'NV.E/5%RP'CQX-'#?#9O$>V</+]A:I+<FWWUESQ2<EQ7,'T*1T*@/C.U+
M'38)JC1W5K'!M#&L:X@M)(.6^?"-Y63CC<21,B/[>RM/Q=S7A=;_  /K7PVP
MC)57RZVW*%2GW'XZF%S@6E]I*0V1YC14H(0">;202.M-3PL.(N.<0(G"-&/7
M5FZ*LV&Q;;/#*5#Q>2D^<VKF ZCV;'MJ J*4L&RFX.N)().?6=4=6+@1'4/)
M3W)XB8ZOP'8>$INK)RI&9KN:K7I7:",62D.;URZWT[]^RGAP^X?<..%_$"S9
MM8/"/M4.S09+4I;;4*2U=7&DD*5'4RGHHJ&T'?3KW552L[/KH["2'-:\@.))
MTSG[04%7,$B8CKW?>K;\*O""PR1X:>9<1[A(1B^,W>'<4QURT$$J6TVA!6$
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M26P?7UU[2[..,3A+X3F41>)C/%JU8+,GP8Z+[8[Q"><E1WFTA!+"4#[[M(
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M]]$Q_L4YRT^Z/G]$Y+=VO1? ;QAG\LW\\4>,,_EF_GBOOS[D&"? O'OHF/\
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M"L]X]+UOQF1KU]JKZZQY0E?G4C]\KZZKQCW%#'+)Q'X@WZZJR6T2(5JBR[C
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MK3;;/8[SD+]VM:;I"3;FDJ4Z#S?>RDG:5#D5LGH-'K5!P8V\X!PH.@@GXFY
M"9/2R!'2$Q<WI"1FI.U, #!>.K0ZZ999YY&-#D<U-?E"5^=2/WROKK/CTO6_
M&9&O7VJOKJO/W85D<Q55]8Q/(I$6*]V%S*&D!%O45:2%K)THJ] '[=;%=,7B
M)BL+C3D=W=N5];1'QIFY/%Z2#;A&*6U)4AGWP<(4GIZR?76SS3VW2XS^)I/8
M6AQ R<2YI:"W)V7Q@CK!! (,K%RM@7V\4\&2/" 03.8ST/V9S$*?/*$K\ZD?
MOE?71Y0E?G4C]\KZZA;'O"4MUWN%L8GXS>K#'O$9Z3:)<\-]G.2VDJ('*HE!
M('3F[]CUBNWA1X0$'B[-8;M6.7F-#4RXX[<9+:?%VG$D:9*QT*R"%=.ZM+$<
M&]N86E4KUJ)#&"7&YL#XAJ'0<VN$"2' M.>2ST]I8&JYK&/!+M!!G=X>(/V&
M=%+HGRSW29!^)U7UUCRA*_.I'[Y7UU7_ ,+N;(@XWABH\AZ.I>1QDJ++A05)
MT>AT>H]E.+/N/ON>3ISERPK(/[O0I0C/7Q*6DL[) YD(*N9:=G6P.M9J'!['
MXS"87$8-U[JU\-D BQS6Y%SA<7%V0&?4"J/VCAZ-:K3K"T,MSUU!.X9 1J<E
M+WE"5^=2/WROKH\H2OSJ1^^5]=5SG\?\C3Q_CXY#L-PF8Z8?.B,PPWVLD*/F
MS LG?8 '?H/0[%+BO"DL?C*I:+#>'<23<1:U90E"/%.V)UL)WSE&_P +7[*S
MU."6W6"F64[[V->+7 P'3#3F.F8R:))SMD@Q1FU\ XN!=$$C,=6I^P;SNWZA
M3AY0E?G4C]\KZZ/*$K\ZD?OE?74.6GPC+??<[F8K;\:O4V9#N8M\F2PVE;#"
M.8I,A:A[U&QW'J>OJIW\4.)=KX48D[?KJV^^REU##<>, 7'7%[Y4C9 '<22>
M[5<BKL7:U#$T<'4I.%6K%K9!)NTT.4SOA;C,;A'TGUFN%K)D[A&J>GE"5^=2
M/WROKH\H2OSJ1^^5]=5PXO>$#EN.\-'KK PRZXQ<%R$,HF7%#,AAI"@"%[22
M#S;Y1WZ(.Z=SG&R\P\<MTX\-\GEON13)DIY66@PE)(YE*4K1*N4K"1UY2*ZC
MN"VV&X>GB>C#W.8/YK-6@$YW6QGETM=8ELZ@VK@S4=2SEH!^$Z'[I]/\Q,/E
M"5^=2/WROKH\H2OSJ1^^5]=0M/\ "?QQ&*XQ=K7;KG?)V1N+:@6:(VD22M"N
M585LZ&CTWUWZ/37NP^$Q8+G(RMJY6JZX[_=J&F7/%R;2%H)4$]F$)))5S$ >
M@[&N^M<\&=OBFZJ<.^ 2#I,A]AZ,W'I]&0(+LAH5DY4V?<&\8,\_#2[733/[
M%,WE"5^=2/WROKH\H2OSJ1^^5]=1'A7'^'E626FS3\;N^-/7J,J7:7;D&RB:
MVD;.N4DI.NNC]6W5Q-XE6CA3BCU^O':K82M++4>. 77W5;Y4)!Z;Z$[/0 &M
M&ML?:M#&4\ ^F[C:D6@$&Z21D02#F"#GD008(*V&8S"5*+L0UPL;J=(RG.<]
M,T\_'I>M^,R->OM5?76/*$K\ZD?OE?754T\19N6^%%@+LNT7C%$-VN27[==3
MR CLWEASH>52=>G70I(/=3[A^%)9IC\.4G'KRC%YL[R;%R-Q+8C.O]0!R\W.
M$DC7,1_R->@QG!#;&'XH4@:A=3#S!'1ESP&@W$/)#"1;)(F 8)7.H[8P=2XO
M-H#BT:YP&DF(R'2 ,Z;SFIQ\H2OSJ1^^5]='E"5^=2/WROKJ&&O"9L"N&-YS
M)ZV3XR+5/\FOVMPM^,E_F "1H\O79/?^":U7SPEH-KF7)B)BE[O";+&;DWMV
M'V7);>=(44+*E#G6G\()[B#ZC7.9P8V\][F"@Z6DM,EH$BV1)(']; ,X)< )
M)A;)VI@&@.+QF =#H9\/ _9!E3;X_+UOQF1KU]JKZZQY0E?G4C]\KZZK%:.(
MEM^Z4ON1KNC@Q=.'M7(.*4KLTME+9YN3\;T:UO?2G3:/"GM,V79W;CB]_L5A
MO+XCV^^3FD".\HG2=Z.T@^OK\@K>Q/!+;%*PX=CJDL8\[B"YI=8 3+G- ,AL
MF!,!:]+:^#=/&$-Z1 WR 8NTR!)U.7BIT\H2OSJ1^^5]='E"5^=2/WROKJ$K
MOX2\.%?\ILUOQ"_WR?CSI1*3 0A2.S3OF=*M^:D:[CU.^@Z&LR/"CQM-OPZ9
M$MEUN363]JB,W$;2IUIUM02II2-[*N8@#EZ==[U6D."^WR&$8=QNTS'8-0;\
MI8"X3$@&,P5GY5V?)'&#+P/7;U=<!39Y0E?G4C]\KZZ/*$K\ZD?OE?74 M^%
MC =A7P(PK)%7BRK5X_:PT@KC-)]\ZXO?*D ]-=_QCK2Y*\(^ROV_%56*SW3(
M[OD<94N':(:4)>0VDD+4XI1Y4Z4E0[^O*:M4X+<(*) ?0<),3<V,FWR3= %O
M2N)#2 2#DH;M79[P;:@\CUQI$DSE SE3%Y0E?G4C]\KZZ/*$K\ZD?OE?74)3
M_"EQN!A=MR)5LN:FY-T5:)$+D2)$.0D;4%IWYVA^+LFMMM\(MJZ77)+*,/O\
M+(+3",]FUR6T!^6UM(!2G?0Z4%:/HWUV*KS8V\&.J.H. :2#) B'!IU.@)$G
M0 @DQFIY4V?(:'@DQN.\2-V\ Y?=JIH\H2OSJ1^^5]='E"5^=2/WROKJ#?!D
MXN9#Q2QV6[?[=(+S;SBDW5#*&HC@Y@ R@ [YDCJ=_*:D?.<NEXC C.P<<NF3
M2I#I:3%M@1M&DE16M2R$H3TUL^D@5I8_8^/V=M-^R:I!JM,9.%O7\1( 'VQ&
M^%GP^,P^)PPQ;!T2)TS\A/I*=?E"5^=2/WROKH\H2OSJ1^^5]=0:]X5%AB81
M=;_*LMTC2;3<F[7/M3A;[=AU?-H\V^52?-5W=>AKOL?A(6>XYB]8+I9+OC2O
M$'+G&EW9I+:)$="2M2PD'F2.5*B-^HCH>E;C^#&WV,?4=AW0R9S!^$ F #)
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M95#@X-:1)>]CWOU/2<:;?_4 0&A6H[&P]%[*@+B6D1)W-! &F@#CX]959H/
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M<J'OHZ2 5@;UKT^DU;,#9 ]?2F]B6?6+.'+JW99OCBK7*,.6.R4CLW1O:?.
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M49MRZ)RTR^W7-0=:N$>00LWXP7)3,<0\E@^+VPB0"I2NS*0%C\'J1U--2X\
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M9D6[2YH,N&XE/*.R5K0&@-@[V0#W@5]2V)M/8&&P>&IXQC;FN?Q@-(/+B?\
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M==C3G<K?=W]:)_%CB;A]DX=9E=[S;+E9LB?CQ7[+'@)0L)<3L+#G>5D;)UH
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MB*<:=*5 Z)"M&OJ3X ,U4SP8[$Z5E9-PN VKKW2%5\DS(YFW$%7F^@"OJ_\
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M8_'E70N-E2Y#Q]^XI1(^4U5MQS68-"F^#D.,.NB.G);PXEQ/(M:6&VFU=/\
MQKW\E*666.0JRMR[9=%7:%'0.T;2DI=93^,1ON]9&Q[:@R;C,Q'G=D'-^D'=
M.'A]GESP:ZL,2^9%N<6$E1Z]D3TV#ZNO4=Q%6MA",DYL:XA7/&I8\7E+6US
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M3#.+<<+WD.4XC=,IL]RL\.%9YENLR[L(9;4Z9,932$J+1<4MM?.0$J T5#E
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M6Q^%TK)"D %.R-X1,)'$.=*;5?;UC<[$[5?+;;+5:7)4A*'G)!<D%I">9(Y
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MA"$A*4[/4Z  V>OKJ1.A4%9M%IA6&UP[;;HK4&WPV41XT5A/*VRV@!*4)'H
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M5=H" 3L:/4[I6PG"UXCPNLF(KF)E.6VS-6I4M+90EPH8#7/RD[ .MZ)W[:D
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MYM12$N().P % [UWZ^+T^JLEQ(4E)4 I6]#?4^O0^JJJ\'P/=!X<?_O;._\
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M2I6N_74>RM.HX!T%;E-I+<DNR&UO1G6SH\Z%)^4$5\;\V:=AW:>A3:D<CY"
M  E12I0/_+^5?8E#BTR6FR%D+5K9.P*^0/&1*8697N(LAI$>Y2&_.7UZ.KV
M/16O46>GD5*_@CX%)XI9+>;-&RFZ8F1!$I4JT.!#[H2XD=F2?P=JW5T^)US>
MX.\$'H?:2,B2U$,)^=.D:?(6"@.J.O/5M0V.E4Q_L^;Z+?QRCQ5*&I]LDQU;
M.]J3RK'7_P" U>KC=;+??N%.5.7*.W(:AP9#J.4]4K2V3OXP:AHZ)C50^+LU
M\I\D9<,X*5(*EMK WOH1KOW[-;I0M7A#Y.CAQ<>'MAN@AV)<CQA];30[:22H
M<VUGJ$'E3I([_3NFQF4KRC"D1FUE';(VAT#J-)]GKI%Q3'8EBN&.)\9<D7&Y
M*G>-M]S;;30:+7+Z222O9/LJM "!.JQ[1<X47V[@E.1=[VMM?CZ6Y:%#KV?F
MN:^+N-),F_6]B.5:Z\P'*K8*5>C?JI>O,I+;JQS ?%3'OS3<MM2B!S@:YP.\
M>H^L5T(7@</5;4=GE]B<]IOWC;2D+0 T1U2!W>RE.-&2XKS5;2>NB"-4T^'=
MJE3!'CQVW)$J40AIEI)<<<43T2D#TU9O$O!EODR&J5D$I%@;Y?,8Z/OD_P#B
M2#I(_:36%UE/I')=<#%8IYH4)<!Y#[RHA9B-[!*1ONIP09:>5MJ0I80C1:D(
MZN,$'8UZ2D'T>CT:]+IRK@M?,:2783L>]1QUU&VE[7K+:N_]A-,)4\QWELOM
MJ:=0=*;6DI4#[0>ZK->U_P )6K5;B<(Z*S2%<C%9BN)7!UZ/> AUU^(ZPXXD
M[2MUO?(ZD^TA*OEJ&\.NJHV/HV\H'OT@ZIZ8!D4;#N"T<O<R9#H<Y4- N;6Z
MLA!Z>C:D[]0[Z@Z+>GK1!7"?;6U)966W&UC12H'1!_:#2HT&%V#5<&M=X)W7
M3)G ZH=J2GU;_P"=)CV1F0CLU/J0GT:/2F+<<@*UDE7I[J27,@_\73UU$0%S
MWR\S*=4Z\K@W9:>U"DN +"M_L_PJ>_![\)6?PSE.6^>V[<\;E?[UAI8+D91_
M[UH$]_K2._XQ5/LBO:ELMR$*WV2N10W^"?3\NOEH@7M)1YC+04=??'21KY#5
M5M,N: YIS7U%C^#["S3';9<(N=7N5&=;[1A^//7V2T%15H#UC>COKL'?6I7X
M?8=_<3&8UG\=?N/8\W^TRE%3B]G?G'TU\Q^%WA!YQPX:["T90F%#4>94%3"7
M&2?7RJ! _9K=73X$>%Q:^(45R'E"HEHN;*=B<R2(D@>H[WV:_3RDZ/H/HHT
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M.+4XRT5J<!YP@)T 37I'@Z*G7:YW>^9K=[]=KB[9W7Y#\9AI"3;Y*WVTMMH
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M&W&P5 >^'*ZOH?6#Z*;6:\%L9SV]*NES3<V9+T+R;+3;KF]$;G1=J(9D(;4
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MDVXT.8H68KI!Y?3W:U[:H/+OMQLN4.ICN)6H\BT-J! 0KF!4DI[]:ZZJ^/\
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MCR'B UXPL/2%<IYUI"0- *JS[F/0),J=)7;&'9$R.F'+>+ 4I]E/-IIPZ\Y
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MI()[M"O-MX6X;9[/<[5;\1L<*U751,^%'MK*&)9/?VJ G2_V[J;5$JJ+V0Y
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M[\5/RUI5*<5^%JM/-1S$]!5H"K)*R23WG=:GCY[/_$'^-;-$^RO#B/.9V?\
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M!Z5;V?138<F/NZ2MU:@D )V>X5Y?D>..-EMCLTAM*5! .BH#JK]IK)$ZK$'
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M"2J[,(E(=EOM<Y2E0?C-1F1L@**7$DZ)K;#X9Q\HAY'>+\_FKL<6R)"5'@8
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MU)'0J_ZU\R5@MDH_%\T_LKZ(\',I@7.R7FR%UQ%KF2%%J1(*>5$A>]L@$G9
M2#W$>GTU1WBWP_G\-,WN%JFIYFRZMR-( TEULG8(]HWHC_ UW\&;I<>H#R45
MA(#@D"U6)ZY6R[W$ B-;FFU.+T>4J6L)2GXSU.O8:UFX!8UL?+JI"7$NEFX
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M3O>7R<8M]\8F7R-V@=C,H<4E"FSIQ/:\O9E23T*0K8Z['0U!_P#<?/+=A+.
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M[IO1-<6,<?X.1W6PI<QJ]6FQ9$X6K%?9H8["X*Y%.)'9I<+K/:(0I2"ZE/,
M.XD"FK=^!]UR3/;1=IS^.P8%N"6E3K5#?:N\Z+V!:5$?=*^S4TKF).PKH$Z
M/4)G";P98W#2^6=;EEP.7%LR>6)>8UB6S>7.5)2VMQ?/V:7-'SEI!YNO1/,=
M(,I<(5BC,:'4*W\0KR9R!W))KA&N[NHW62 J7%=2IQUYJ /CK6J4X=]>7XA6
MFL5,!1)*3\EQVUYE9I%IOEO8NUMD:[6+*3S(7H[!]A! ((Z@UQ8A@F.\/[<Y
M QNRPK)$<7VKC<-KE[1>M<RU=5*.NFU$G72EVL\NZ0HE8K/+L>RL@:K(!4=
M5*A8Y0/CKTE!7T Z5L0R![X[]E;:K*L O"&4IZGJ:V:HHJ%8(UT]E<-\L-NR
M6UO6VZPF;A ?Y2[&?3S(7RJ"T['L4E)^,"NZLT4H)V23WGJ31KT:K%%$6?;1
MJC=&Z(LT"L;[Z-T1&ZUO'SV/^(/\:V;K2\OSV?\ B#_&JNT4C5. 'H*"K5:5
M/ )ZFO*2X\=(3OV^BM>%FE;%. #OK6DK>.FT['XQ[JWMP1O;AYCZO174E(2
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MRU%EP78J6^>-#"'B#YIY"3TZ#?,3UU3.MK3./YI;NPDN/PA*2VMQ:0.4*VD
MJ[B=*H79TO AU96&/-2K13H;[SZ!U--RZ%:IB4\RDI;Z)Z^]T?166A2#9@JE
M0EL%3WPZARX7&5^U.1GEV?(6$H+B6SV:'N723O6O?)(/QBFZQP3=OO&R+AB@
MZAIZ3XT^ZI(TU$&RZ1\7*4_&4U-G"&9'XH6*%-F3%0&K,TV[!1%TV5R K;P<
M(\X^<  #W[%39.QZW67+I>1F./*USB-M-O#7F,+TZL<H[B5CY!6XTEPS69[
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M^4;DK]ADJ(_E7S @W)XWEMN7&A.0RQV+[L,-. =2D+V%'2QOH-@;'5(KZP>
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MYM]=I:A9+'EW!"D1W'VTS(B4_>.T0TKWBG.11"5:)I<$M*L&I(7T(YOCZ_\
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MR0=@[^/H:9*,UK[NO=[>[^8IMP,,1;N(EZRQ$UTNW.VQ+:J)R!*$!AQ]86%
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MO@ F/P_Q6P0,B=B7#&KJ[=X%S?M[4A!=<6^HI<CK/*M($A0'G @@*!!KUBW
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M.(,E2F24N<@)/*5[/-YW0]PZ=3T-5^R_Q=>5W-;LAPONK2WVGFGS4)Y$\V@
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MN0\[ETL\"ZK8@R7U)"3(4T ?OFDI)(/*2D%22:?F08Y#R;%[E8)O:FWW"$Y
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MCS=MVJP%K[0*VH C1 T][%:18;3&@)F3K@&$Z\:N4E4B0X=DDK<5U)Z^P#H
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M;#OU6._0<3_,TEW<U/ROWDN;VV_C_0K/<P]OR4<P]OR56'W!L._58[]!Q/\
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&***(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2128727d1_ex99-2img011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
M'0 !  $% 0$!              <!! 4&" ,""?_$ %H0  $#!  # P8'#@0"
M!P8$!P$" P0 !081!Q(A$Q0Q"!<B05%A%3)6<971TA@C4U155X&1DI.4HM3P
M%D)2H3/A)#9B<K&RP0DE-$-T\28X1'."@QFT165V_\0 '0$! 0 # 0$! 0$
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M."V/\6<@RFYY?(F-8EB-G=O5QCVXZD2DIWRM(/\ EWRJ)(Z]  1O8V.+Y0G
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M4HB4I2B)2E*(E*4HBDS@IA_#K-G[W;\\S=W Y'8MKM5R5$5(C*<VKM$/) Z
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M>&?PS?[8IWAG\,W^V*_?GS08)\B\>^B8_P!BGF@P3Y%X]]$Q_L4YRT^R/?\
M9.2W=;P7X#=X9_#-_MBG>&?PS?[8K]^?-!@GR+Q[Z)C_ &*>:#!/D7CWT3'^
MQ3G+3[(]_P!DY+=UO!?@-WAG\,W^V*=X9_#-_MBOWY\T&"?(O'OHF/\ 8IYH
M,$^1>/?1,?[%.<M/LCW_ &3DMW6\%^ W>&?PS?[8IWAG\,W^V*_?GS08)\B\
M>^B8_P!BGF@P3Y%X]]$Q_L4YRT^R/?\ 9.2W=;P7X#=X9_#-_MBG>&?PS?[8
MK]^?-!@GR+Q[Z)C_ &*>:#!/D7CWT3'^Q3G+3[(]_P!DY+=UO!?@-WAG\,W^
MV*=X9_#-_MBOWY\T&"?(O'OHF/\ 8IYH,$^1>/?1,?[%.<M/LCW_ &3DMW6\
M%^ W>&?PS?[8IWAG\,W^V*_?GS08)\B\>^B8_P!BGF@P3Y%X]]$Q_L4YRT^R
M/?\ 9.2W=;P7X#=X9_#-_MBG>&?PS?[8K]^?-!@GR+Q[Z)C_ &*>:#!/D7CW
MT3'^Q3G+3[(]_P!DY+=UO!?@-WAG\,W^V*=X9_#-_MBOWY\T&"?(O'OHF/\
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M2G.6GV1[_LG)CNMX+;ZACC;)>8R" &WG6P8I)"%E(^.?8:F>H3XY?]8K?_\
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M!H[<( V>7YAL@UH9P5X057%M.@YVFCFD&02,)#H=(:Z,,S!&N2V.O6[V"75
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M4!F&+XA;)4+#[KB\Z5<$QW7KBVR^@(&O0202"I>_1/7XJJY[IX.7M?+J/X<
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M7?[K8FW\<O5HLU_D*C6F]34MAB6X#H#E"BI&SX$UN_%:7%@\-<FD3G)S4-J
MZIY=M=#4D)UU[-1Z)5[S7S->Y[RL=KI62V-+'5" ,P?U83H8D&06R""(,%>G
M3MEFK47UJ)!#1.[9.T:$9@[M%N9GRP>LJ0#[W5?75/A"5^-2/WROKKGW&>/=
MFQ&R8+CT.T9+?Y%ULPF0>92)$MT K 0OJ-K)2>OQ0-=>E;_PDXO6_BY;+D_%
MM\RTS+;*,29!G =HTO6QU'0^!'M!!%=5X<'KWNZE4M-6F[BFF,4C3$6@D22
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M8Z\NVR"?8:M^$_!&Z6*]VEV]8#8;<_;&%ZOD:\OONNO!LI0I#)/*G9/7?3V
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MS$.U)W:+0IO$_BAAW$;)\4DR8&6W$X^N[6UB) [$-O#1"$I!YE@#GZ$DJT/
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M4,&O_&9.N]0!EMMRA?E?Q$QLD8BOFTN2HSRH <#$,%14QR[])1 5Z?CU'LK
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MI2B)2E*(E*4HB4I2B)2E*(E*4HB4I2B)2E*(E*4HB4I2B*0>"7_6V3_]&O\
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MNBDI42D^(%;97'?!#.LSX?\  S%(T)^RWFZ91?9-IL4-V(Y'1%>,N4Y)D27
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ME"@GF3O?6O17'+*^(&98+:<';M<"W93B:\@5,N["WEP/OC0^(A:>T(#G+R[
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MN9I$%YS65D5RL%GD6Q=K9@-1&F(LP("%=FV-)61'5Z0^-KH$@:*"DA;?Y/\
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M\1X"L%C? W([+:+U:)7$0W*W7H3%W(KL3"),IV0VI*G%.A>]IYDZ&M!+:4]
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M.%N=7Z^WK*<;R>+;FKW8'HX7(M*G.[2&7VNT;4$N>DA0TI)22?B@@]>F(L_
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MR@@DG>O$UKF!8-=8.5W[+<F<M[N07-MF"TU;4K+,2$R5J;;"U@*6I2W%K42
M-D #2=DD+=NZH]>R3ZZH8:3X$BKC5*2I 5H8JAX:-?!:4GQ35]JJ:JXD@*Q
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M\;X=N\#[UCMIC6N]?XG@P'[FPV!*E,R(SH?2^[\9WG(!/.3U&ZLK5C<?@MQ
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MS 5)WDPX/@U^X2XCE\NVVN]95-4W/N-^N#+;L[X4*_O@4ZH<Z%H<V@(V.4
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M=?-5A15*0H$$ @]""*TNQ\%L%QIMMNUXI:X#;=Q3=FVV& E+<M*5)2\D?Y5
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M5,EB[&JYS+5&7=8D:#<E(W(CQ))D--J]B7"A!4/#J4CYJR/9J;2= BKA*0D
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MK;-IU(FL+BJ B/?!COIN@CT%=J?%6CSD>NK3BEB%SO+G&-GX%F38]RO&.%E
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MH08$6$7VTNM\_.ZE:AV:T*);0K04-]=@1SP4XXO1,)Q=C(+;D$UBX763:O\
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MR52@@H2&&AS)V"5^DXD!7MGS)+<]=L:NT!@I#\J&\PV5G20I;:DC9]FSX_\
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MME#0<4D-)?22XE3IT .4;/6NG<0[\<:MQN5UB7N:60I=Q@,]BQ)WU#B$<RM
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M ,??_O\ \Q1%SGD]NR6;Y7-R>Q2\0;9<X^$Q2IFZ1E2(DEM4UT%+@0I*TD$
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M=CVIP7:.AMT.I:0Z7.1"MIY2ZE.RDGILU+J+M%5.5"[=KOJ&P\J.EP%Q+9)
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M/9K0M"TD=""002"/ CH?G(\0:\&8,-B=(FMQ6&YDA*$/2$-I#CJ4[Y0I6MJ
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MUH?YM_,*^%7! \ HU8;Z^RJ;JX0F(J\5<%?Y4#])KR7,=5_FY?F%>&_T52K
M4DKZ4XI?B2?G-?)I50G=514JNB:J!JJ@%9T!NB*@2!7TAM2SH>%>R(X'51W[
MJ]AT&AX5C*R 7FVP$]3U->M4I462J*K5*415I5*5$5??2J;IO=$5?&E*;HB;
MINJ;JA6!1%];JA5JO);P&]FOA)<>.D)W[_55A25Z*< 'C7FDK>.FT['^H^%>
M[<$;VX>8^SU5=)2$@ = /4*D@*P3JOA#92A()V0-$TKUI6*R2E*452E*41*4
MI1$I2E$5*T.7Q]X:6^6_%E<0,8CR6'%-.LNW=A*VUI.E)4"K8((((]U;[7@8
M,=1)+#1)ZDE HB\+)?+=DEJC7.TSHUSMTE':,2XCJ76G4^U*DD@CWBKT^%40
MA+:0E*0E(Z  : JI\*(N9VL;L> <2;C(XF8;%N_PQD'>;/GSS"9:&%..I,6*
M\5;<B*;5R-H(^]'2>H42*^8?E9R+CD;+\3X+>LKMY%J396X4U5S+7>.[F3VP
M3V(T=N%K1] ?\3FZ5(]ZX)3LGN"V+WG=]NN+*FHGFP/-14H4I#H=0TI]+0=4
MTE:4Z3O9"0"2-[NK!P>EXI?%*M&97F#C"ISEQ..I;84TEUQPNK0AU39=2TI9
M4HMA7^8@$ ZHBU1'%?/+Q@5[XAVUC'HF*1H4^;"MTQE]V:^TPAWLG5NI<2A'
M.IL*[,).DJUS[\,]D?%JZV=S $M182AD%OF2Y)6E?WM34'O"0C2O JZ'>^GO
MZUZ6K@8+*)EHC9/<Q@\I,E*\7<984RE+_/VC27BCM4M;6HA'-T\ ==*QUK\G
M9<:;C[]SS:^7Q-ABRH-O;F-QTAN.]'[#2^1M)<6E.OOBMDZ]YV1:3(\I#++/
MA>$7*^?X=M%PS.,B9")BRWV+<PEA+CJG@VI2GE*+C80A/($\Q"EGEV;D^4O?
M)&"0[FB/;+>1?';/.R:7#EJM,=M#/:HE%H\CH0X5(;])02A?-M9 !,B3."$<
MXGA=NME^N-GO&(QD1;9>XR6U.\@92TM+C:DEM:%I2DJ21XI21H@5?S.'^2N8
MY%@QN(5V9N275N2;DY"AO&0%#JCLE-<B$CU!(&O63NB+:,6F2KCCENDS95OG
M2GF$..2K428KI(WSM;)/(?$=3X^)\:@[RG<9@.6ZXW!. )>DK8;>?SYE#*G[
M*E"NKZ0E7>26DIY]-IY3Z^G-4S8#A%OX<8=:\;M1>5 MS/8M*?4%+5U)*B0
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MA3HTQ<1]462&'4N%EY(!4VO1VE8"DDI/4;'MKZGW.%;EQ439;$94MX1XZ7W
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M]S57J? $_HJ$;_Q=X@-VGB5D=K38&;+A<U9[E-B/&3/81%8D.-E8< 96$N*
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M(2 GQT*C[#XV*\=>(UQFW&SQ+KCD3%[2Y9;;<8R%M,,S.W6ZL-':4K(:;;)
MV WH'QK=?)LER)/!NQMOON2NZ.2X#+SJ^=2V6)3K+1)/4_>T)&S[*(KN)P2M
M$/!;#BR)TY4*SW1FZLO*4CM5N-RC)"5>CKE*CHZ .O7OK65Q[ARUC&;9!?X-
MWN"8M\6),NSN=DJ*)(0AOMT'D[1*BAM(*>?E\3K=10YQ;XD.87EV:,-8XFSX
MQ<KFTNV.QWNWN,6*^M*BEX.\K*^1! VA84H;/*#H>USXY93;E\1+[W>V.8QB
MLMJ-&AAA8EW%Q^+'6R@N%SE9 =D(YE%*M@D<HY=DBE/B)P\8S^+:_P#WG.LM
MRM4U-P@7&WELNL/!"VR>5Q*T*!0XM)2I)&C4=8CPZP2ZY+(5;L^7DU];OS.1
M2T"YQI,@R(\<1"%I0-I1I0VD !)( Y1H58\1,IXE8K";M%VN6./KR.'-8BSK
M=;GV_@V2U%7(*%)4^2\A3;3J0L%LI5RDI()%:!C]TR?'^%D*QP95@ASAPQ<O
M,6[1+.II]AI(9 9V'ME7*5>F"!S\J^7IRDBG/)^ UFRB[WN[.7*Z0;I<)$&:
MQ,ANH0Y D1$+0TXSM)!)2XL*2L*2H*(UHU?89PG9P[++GE$K(+M?KS<8+$*5
M)N:VN4H:6XM)2AM"$M_\10Y4@#UZV23<<&1>_-CCKE^N<>[3G8++HD1XRF/0
M4TDI2H*<65+'K7L<QZZ'A6F,<3[[<N+UUQB=/M&.1HSRVXEEN$!XS+O&# 49
M,>3VB6SZ14.S2A92&SS:WT(MDO?#Z%G5XA9EC.6W"Q3Y$),55SL+L=YF=%YB
MM"5I=;<;7RE2RE8',.=0!T:MK[P#M&3=^=NEVN\Z<Y C0(-P>?29%M[%0<2\
MPOEZ.J=2EQ2U [*$C7*.6HLX(9EE^&<-^#*YGP,]BU\$:RI@LL.B9'*V75-/
MEXKY%[+>E-]F.4*Z*.NN?LW'JZ+XGX_957[&\CMM\ERH(;LD"4.XK;9==0>]
MJ6II_?8E*D@(()V 0#1%OT/@^;/DDFZ6?*[W9HT^4F=<K7%[N8TR0 D+<TMI
M2FBYRCG#2DA74]"2:Q4'R=[?8XV-_ >27RQ7"R1WX2;A#4P7),5Y[M5LNI<:
M4@CGT4J"0I.NAZFHZC>43F,3AUA5]O+EEAS<RY40D1[5+DHM[;;:W'GW4M+4
MMXJ2$!+20@)*O260":E3@AQ*N'$.V7E-R9"WK7.[HBYLVZ3!8GMEM"TNH9D#
MG01S%"D[4 I!TH@T1>-OX&G'\+@8S8,RR"R0(SDM3CC/=GW9*9#JG5I<4\RO
MJ"M0"AI77J2:R.(\%,=PQNZ1H:'GK;<+3"LKD&2H+;3&C-.-(3X;)4EQ7-LG
M?NJ0*4117;O)XQ^V\-8>(-S[KN'-%RCWL/I3<&Y:5;0^%A/*5)3I&BD@H'*0
M1NMRP[%IN-1I N&273)I;ZPM4FY]BCE &@E#;+:$)'MTG9/4FMBI1%%G'&U6
MQP8_>)#V3VN[6V0X8-XQ:W+G/Q>=&G$.-):="FU@ $*;(VE)Z$ UIG"O@^]D
M;M[OUZ-^@M2LIAWV!\,E"9\GNK"&DNOHY=-I<4%D-A*2E 2-)\!T+JFM411,
MKR=;46'K0+_>TX4_*5,<Q,.,]R*U.]JI 7V?;!HKVHM!SEZD:Y3JOFY^3Q&G
M2\H[OE^1VVW91-7+O%MB/,AJ2%MH;4VE2FBMH%* "IM25$$[/0:ERE$40Y'Y
M-]JO;>2PH>07NP6+(HB8MQLUL<90PYRQTQT*2I39<1II"$E*5A*N4;!!(.XX
MEPY@X?>;[<HLF2\]=^ZEY+I3RH[".EA'+H#Q2@$[WU/30Z5MM*(M#S'A8C),
M@B9!;;[<\7R&/&5#^$;7V*B]'*N;LG6WFUMK 5M224[22='J:PLW@AR7.7/M
M>8Y)8)%S::;NZX3D<FXK;;#8>45-*[)XH 27&@@D)3_I%2M5-44A:%BW"JR8
M9?6KE9TNQ&6;+&L3,))!9:CLK6M!!US%6W#LDG?S[JPM_!>TV_%,)L#4V:N+
MB<YF?$=44%QY;:70$N:3X'M5;T!X#WU)2FDJ.R!OVUYKC[]?[0W54@J.+?P6
MM%NP_%<;:G3EQ<=N;5TC.J+9<<<;=6X$K]$>CMPCH = =:\\FX'63)[M?;F_
M/N46Y7-V!):E1'DMNP'X:5I9=8)3\;3B@H*Y@H$@C1-20IE?LYA\^_\ 8U\'
M:1H['N.Q]8JJ+0#PF5.C6L7W*KW?Y<"[Q[RB3-+#>W&0H(;#;;26TH/,=\H!
M)Z[KZNO"</Y3-OUDR:]XK(N79&YLVOL%LSBVD)2M276W.S<Y $%;?*2$IWX"
MM\ T.@_4/JJG0GU$_H)_]#1%&%QX#6]^Z.7:VW^\66^?#$F\LW&&6%K97(90
MR\T$.-J0ILH;3\9)4#U!KULW >S6-N(E-TNLE4?)593VLQY*W')2FBVI*U%'
M5!!)Z:._ @ "I+/O\/?_ ,Q0;_R_R_\ (TA%B,LQN/F&*7FP27768ETAO077
M&-<Z4.(*%%/B-@'IL:K6<FX56.[HMDBY(EW"/:;+,M'<&^4][COM-H<2H:!*
MBEH <I'51]VM\.M]=?IU_P"H%5!)'3>O=O\ ]":JBYFQ+%YF19_P^3;)N=WF
MT8Q+=F.2\N@*@LP61&<9;CI"F6UR7E%Q/WP\_*E"MJZ]98@\%[1;\*Q3&439
MQAXY<(]RC/**.T<<9=4ZE*_1 Y25D'0!T/&I 5U/I=?^]_S% =>!'Z_^=2%5
M'$3A!*LAO2+!G%_L,>XW!=S1&CHB/(BO.*4IX([5I1*%J43RK*N4_%UUK9\#
MP>#P^QQJS6]<B0VEYZ2[(E*"G7WG7%.NN*TD)!4M:CI( &] "MAZGVG]?_.J
M%/N_V_Y55%HM^X/VO(<LN5YDS)HBWBV"TWBSZ;5$N+"0X$!?,@K0I(=7U;4G
M?3>]5:X]P99M5TL\JZ91?LH9L9*[3$N[C);AK[,MAPEMM"GG A2DA;I41S$^
M)W4B:]W^W_*GKHBU+B)PVA\1V+(B5<KA:W;/<472+(MKJ6W$O);6A/504-#M
M"=:ZZT=@D'7QP#M$ZV7A-[O%XOU[NKL9YV_R'FV9C"XRBJ*6.R0E#79**E )
M3HE2BK?,:DXGYZIK^_[%%5'T#@U"<<NTG(KW=<NN-RMCMG<FW(M-*9AN;[1I
MI##:$(YCHJ5KF)2G9Z 5Z8?PE9Q2[6*Y/W^ZWR;9[6]9X[MP2R"8SCC2P%]F
MVG:D=BE(5XD$E6SUK?.G]_\ VI\U(4E8#"\-AX/;)D&&^\^W*N,NY+4^4\P<
MD/*=6D: ]$%9 ]>O'=:GE' NWY/-R]:K[=H4#*F&T7*W,=BIE3S:4)0^@J;*
MT+Y&TI("N4^)&ZDOPJE$6E9OPEL?$*[&;>>\/-JM$JS.16UA"%,ON-.*7S <
MR5I4R@I4"->/CJKK#<*N&+O..3\QOV4_>@PRB[*8"6D [WIII'.OIU6O9_6:
MVNJ?-1)6OWG"X=[R_',A>>?1+L:928[3?+V;@D(2A?/L;Z! UHCW[K5<MX'P
M\IN^22V\COEFC9)$3$O$"W.-):EA+1:0OF4V7&R$'1Y%)"M#?KJ2P@J/05Z)
MC+/CT^>F29J(V> +5KN$J=8\SR/'Y<JWPK6^Y!5'(<8C-%M'HN-*"5D*)YT@
M*!^*0.E9_%>$EAP>\0+A:$R(S<"R)L;,3FYT!E+Q>YR2.93A43LD]=DZV:D%
M,0#Q.Z]DM)3X "I(5@J$^%>)F^<4\RXA)MMQM4"X)9A6Z/<V%QG'"E"!)E=@
ML!3?:EMA'I %0CA6M*%2#GG#N)Q Q\6R7+EP'&I3$Z+-@J2EZ-(9<#C3B>8*
M22% =%)(/K%;;JJU)64*)1Y.]ND2KK-N.1WR[W*Z.VI^7,EK9YE+@/J>:Y4I
M;2E"5%6E)2 -#IHDDYC-^"=DSZ\72XW&5/:>G6Z-;P8CP:5',>2J2R^TH#:7
M4N*!!V1Z(Z>.Y"I454=XMP>38<V8RVXY/>LDOK=M=M9>N182@LK<;<Z-M-H2
MD@MCJ!UV>;?36P7G!X=[S/'<D>??1+LC4MEAI!3V:Q(#865[&]CLQK1'B=[K
M9*41:1FG"YG*;[ O]OO5RQC(X4=R(W<[7V2E+CK4E2F7&WD+;6GF2%#:=I/4
M$;.["R<#K)8;CC\]F7<'I]JN$NZNRI+J5N3Y,EE3+CCYY1UY5#00$@!*0!H:
MJ1J411[=>"]INV*Y]8G9LU$;,9#LF8X@HYV5.,MLD-;3K02TDCF!ZDUH-HX0
MW+*,WXJK=OV28M NEX::=1 +;;=PC"!'02A3C:B@[YT%QDI5TUO:1KH"E$48
MRN!,&%=$S<5O]XPCG@Q[;)CV93*FI$=A/(R"EYMP(6A'HAQ&E:T"3H:D>)&[
MG$98[1QT-(2CM'E\ZU:&MJ/K/M->]*(N3.)N"IO$#*,(Q/\ Q[_[XGK/P ];
ME,6:,\X^%NRN]K9'WC?,[V2'B%$Z".I FN9P9'^)+I=;-EE_QIB[O)DW.W6U
MQGL)3P0E': N-*6RM24)"BVI/-R@^/6I'U5:(M"F\'K7.QO/[*N9,$?,W7W9
MJTE'.R78Z&%!KT= !+8(Y@>I/JZ58.\$DQ;Y-GV3+<@QV/<EMNW.!;G&.QEN
MH;2WVH*VE*:6I*$!2FE)YN4'QZU)E*(OGEZ5&&,<!+?B[F/MM7V[2[?C]S>N
M5JA22R410ZTZVI@*#86ML=NLCF)4-)'-H:J4:411I?N!-JO=WN]W;NUUM=YF
M71F\1KA!=0AV#(;BIB_>]H(4A30*5H<"@H*4/9J]C<)PM_')=VR2\7VX66Y.
M71N7.+(+KBXZV.0I;;2E* E9(2@#KU).SO?J410[D_DV6W)&<E@G)[_!L5^F
M&YRK/%<8#(EE2%*="BT7-$M@ELK*-[Z5KF,\&)V5W+B>W/OF1X[:;QDTD2K=
M%*&F;E%,=A/,E3C:EH"@%(*V5)*@"-[&QT+2B*+[MY/>-W1R\N(?GVY<Y=N=
MC+@.I:5;782"B.Y'/+T(!((5S C8(T2*RT?AU>6;#+B*X@9&]=9#J'1=UIA]
MHT$] A#08[$)(\?0))Z[\*WJE$49XEPOGX3D5M3;KO,>M!7/N=X?DN([:YW!
M\MA*G$H0E(2E(<.DA(!".AZU)E*41*4I1$I2E$2E*41*4I1$I2E$2E*41*4I
M1$I2E$2J56E$4=6K@E:K1DT*]M3YRY$2]7&]H;64<A=F-%MQ!TG?*D*)3UWO
MQ)JWNW BUW&XW.Z,7:Z6R]2;Q\.1KG#6V'83YBMQE);"D%*FU-M@*0X% [/L
M&I($IDO=D'4%S_0%#?ZJ^&+C%E29,=F2RZ_&4$/M(<"E-$@* 4 =I)!!Z^HT
M11O*X#V^_*EN9)>[KDC\VQR+#*=EEEI3K+SJ7"H=DV@(4DI 3R@ >\]:LD>3
MI N4TR<FR:^Y<M5FE6!:;HXRE*HCY;*AIIM&ECLQ]\^,3U).AJ59T^-;(RY,
MR0U%CHT%.O+"$#9 &R3KJ2!^FO>B*+K+P+[EDN,WNZYED622\<6[\'IN;C'(
MEMQE3)2L-M([16E;[16UG7CHD&\QS@C:<:7AZF)\YTXR[<'8W:E'WTRRLN<^
MDCXO.>76O ;W4C4HBA?B'PRL-@LUSN;\K)FI<K)!?V+CC\0RI=MEEA+/,AMM
MM94T4(*5)4A8(<(/3PMN N.7(YSFV62OAYV%<V8$*--R1D1Y<XL!U2WA'"$=
M@UMY*4HY$[Y5'779F.1>K?%N<6W/3HS-PE)4J/%<>2EUX)&U%""=J 'CH=*7
M:]6^P0S+N<Z-;HH4E!?EO):1S*.DCF40-D] *(L9F6-W+(XD=%KR:XXQ)9<Y
MS(M[4=TN)T04*2^VM)'7?@""/&M35P&M"<::@,76[,7EJZ&]HR,/(5/[^4E!
M>)4@MG;9[,M\G)R>CR@ 5(L"X1;K$;E0I+,N,X"4/,.!:%:.CI0)!Z@U<411
M,QP07&R&PR7+J[=H[5S7?;Q,N1!EW&:AD-1>C:$MI:;!*@E( !;;T/$UL.:\
M.[EE\Q89S6_6*UOL=WDVZV",E+HZ[*75M*=;40=$H4/ :T>M;Q2B*-KMP0@&
M1:Y&-7FZ84_!MJ+-SV4LD/04';;2DO-N#:"5%+@ 6GF5UZUN6+8Q;\,QRW6.
MTL=WMT!E+#+945$)'K)/4D]22>I))/C67I1%SGP_X&R,IL&1Q+Y>,BMECN.2
MW5^=COH-QY[1FK4C:EM]JAMQ(22EM:4K!/\ J.Y1=X.V&;;LXM\\/SX&72>\
M3H[B@D(/8-,@-E(!3H-)4#O85U!\*WNJ;HBC"+P-;?E(DY!E=]RI^+$D0[<N
MYJCI[DEYLM+<2&FD=HZ4$I[1SF.BK_4=W4+@?9(H@H=DS)3$;%CB99<4D!V*
M>3:U%(!"R$ ;&AU/2M^@7&+=8J),.2S+CK)"7F' M"M$@Z()'0@CYQ7ONB+7
M.'^(O8+BL.QN7N=?FX:0RQ*N"60\EE("4-DM(0%<J0!S$<Q\22:P5UX2'(,O
MA7>[9/=[E;[?.^$H%E=3'3&C2 A2$K"TM!U02%J(2I9&SUWK5;S"N,6XH<7$
MDLR4-N*96IEP+"5I.E).CT(/0CQ!JXHBCF-P0M$;"\(QKOLU<+%)+$F,XHHY
MWRTVXV$N:3K1#BM\H!Z#6JP^.>3K#L$K$2O*\@N4'$WRNS6^6XP&8S7=W& T
M>1I)<TAPZ6LE0Y0-Z*MR]5-T11GYB+6S@>)X[#N]UMTK%N55IO<5QM,MA80I
M!)V@H6%(6I*D*24J!\/"MQQ''96-VQ4>;?;CD4IQTNN3;D6PLD@#24M(0A"1
MKHE*1XD^)K.4HB4I2B)2K>5/C0EL(D2&F%2' RR'%A)<7HGE3L]3H$Z'7H:I
M+N,6!V'>9+,?MW4LM=JX$=HXKXJ$[/51T= =31%<TJF^E>$6?&G*?$>0T^6'
M"RZ&EA79K !*5:\#HCH>O4417%*4HB4I2B)2E*(E*\9DQBWQ7I,IYN-&907'
M'GEA"$)'4DD] ![37HA:7$)4A04E0V% [!%$7U5-56E$7FIE"O%(W[=5\JC@
M^M7Z]_\ C7R[/C,2F(KLAIN3("BRRM8"W D JY1O9UL;UX;JXHBMN[%/Q5#_
M ''_ (5\%A?K2%?I!_\ $5>52K*D*SY5I_RJ'S;_ /0U\GWC]?\ S%7VA35)
M4A6 ('@1^C_D:^NI]I_7_P Z]84R+=(R9$1]F7'42$NLK2M!()!T1TZ$$?.*
M]>Q0?\B?U592%::Z^'^W_*F@/_M_RJ[[!'^D?JIV"/924A6O0'PIOW&KKL4^
MS_<T[!'^D4E(5IR^[_;_ )4U[O[_ %5=]BC_ $C]55#:1X #]%)2%9^OZO\
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MZI'H^ETQ6-\8L\78,!RR_P!GL;.-Y0Y;XKD.$XZ9D-<L)2T\5J)0M!6I(+8
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9K=;?2L'UWO$%9-IM:9"4I2N=;4I2E$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm2128727d1_ex99-2img012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
M'0   00# 0$               4&!P@! P0) O_$ &L0   % P$#!0L'!@<+
M"08!#0$" P0%  81!P@2(1,7,5:5%!88(D%159/1TM05,E-489&2(U=QE*+3
M,S9"15*!M DD-49B<G6%H:.R)4-S=':"@['P-#A$I,'A)F.SP\3"\1DW.61E
MA+7_Q  = 0$!  ,! 0$! 0           0(#! 4&!P@)_\0 2!$  0,!!0,(
M!@H" 0(& @,  0 "$0,$$A,A404Q008B4V&1H='P%18R4G'A%#-4@:*CL<'2
MTR-"8@=R-#5#@I+Q%R1$PN+_V@ , P$  A$#$0 _ %BBBBOVA?DB****(BBB
MBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****
M(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB
M****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(H
MHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBB
MBB(HHHHB****(BBBBB*5+"_BPW_SU/\ B&G#3>L+^+#?_/4_XAK5J5<TC9MD
MR\W&,$)%PQ;G<"DY7%(@$*43&,(@ B.,?-# CGI#IK_.[E-9ZEKY4VVSTHO/
MKO D@"2\@9F %_6NQ:K:.Q;-5?N%-I/'<T)S45&-X:E3EO1]LOVK6*<A*@T*
M6+,=47KM142\H5 "\ !,IMX3&R& XXZ1D\> CY>/37S5JV?7LE*G6JQ#[P&?
MND _KOW;Q,@@>S1M-.NYS&;VQ/W[O/[$+%%%%>:NI0514+>$['=7WOZRG[*/
M"=CNK[W]93]E?ZE72OXNP*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4
MT4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$[
M'=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\
M)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64
M_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^
MLI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4
MT4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$[
M'=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\
M)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64
M_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^
MLI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4
MT4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$[
M'=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\
M)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64
M_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^
MLI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4
MT4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$[
M'=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\
M)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64
M_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^
MLI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4
MT4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$[
M'=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\
M)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64
M_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^
MLI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4
MT4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$[
M'=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBFFBH6\
M)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^LI^RCPG8[J^]_64
M_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4T4TT5"WA.QW5][^
MLI^RCPG8[J^]_64_92Z4P*FBFFBH6\)V.ZOO?UE/V4>$['=7WOZRG[*72F!4
MT4TT5"WA.QW5][^LI^RCPG8[J^]_64_92Z4P*FBM[87\6&_^>I_Q#2E/PC6Y
M8.0B'Q3F9/FYVRY4S[IA(<! V!\@X'IJKMN[:D3"12;0]J2*IB&,.\5XD #D
M<^:E+PZH?JA)?KJ7NU_$_*'D'RIM.W;7;K'9"6NJO<UP<P9%Q((YP(UU7]&[
M)Y0;)H[,H6:O5$AC6D0[W0"-RFQYI3$.IMC+I/9=@^9,DXY([*0,D'($'($$
M,>40#>\^ S3SJL'AU0_5"2_74O=H\.J'ZH27ZZE[M>):.0/+2U!HKV1SKH@2
M^GD-/;7ITN46PJ))IU0)W\UW@K/T56#PZH?JA)?KJ7NT5Q__ (UY6?83_P#*
MG_-;_6G8_3]SO!4^HHHK_05?SBBBBBB(HHHHB****(BBBBB(HHHHB****(BB
MB@!S1$44441%%%%$11111$45@3  @ B "/0&>FLT1%%%%$11111$44441%%%
M%$11111$44441%%%%$11111$45@QRD#)C%*'G,.*R Y#AQHB***SNCC.!Q1%
MBBBBB(HHHHB****(BBBC-$11111$44441%%%%$11111$445@Q@*&3"!0\XCB
MB+-%&:*(BBBC.:(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB**
M**(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHH
MHB****(BBBBB*>]BW3>V]4=6I.(NF+3EXY*WG[PB"ASD JR?)[A\E$!X;P^7
M'&H#+Q*%6G_N<?(!K])=T@H+?O8D>4!(<&$OY+.,^7&:0BO]E'=#_DG5?]<9
M5Y6.ZG:JC;I<(;NSC>NO##J33(&9_9)]X:<6Y&[&>G]ZMHM-*YY*Y7;%W(@<
MXF50(5<2D$HCN@ ;A>(!GA4+1%O2UPG4+%13^4,G\\&+51<2>7CN%'']=6VV
MAU;,5V(=,S6"A--[;[['?(ISZB9W6_R3C?WA3\7&]G'V4GZ5MMI!YI-;9;9G
M&FF]@-2B#.1>/VT01Z83"8RQCGRHL(YQG&[@ QFM5*TN;1<\D"7.'.,1F<N/
M8LWT@7AHT&X*IJ[99JY.W6141<$-N'14()3E-YA*(9 ?L&NU.W)=9RX;)Q,@
MHX;I\JLB5HH)TB=.\<N[DI?M' 5;O;=AE5TM"KKEGT-,77*L>YI:9@3@HUD#
MHK([JI3E  /\\P9QY<= !2_MX[1=U:=ZY3UJ64][VT%VC=>:<-T4S+22RB %
M*50YBB/)D1W"E(&,")AZ1K.G;GUL,4V"7!W'(72 >'[+%U!K+Q<=T<-1*I"E
M"22ZS1%*.>*+/ WFR9&QQ,N'G3  R</M+FOB3BGT(\,TD63F/=%#)D':)D5
M#S[I@ :NIKOK5-Z2:#Z!-K04+"7#(VD0J\\B0HNTFA 2P@B<P#R8&..\82X$
M=PH9Q38U.O*1URV%&%Z7<H$M=]KW7\D(S"A"@NNU.EO;BA@ -[B<OX 'I$:M
M.V5'77N8 USKN_/>1,1ND:J.HM$M#LP)55H>!D[A<F;Q4:]E'!0WA28MCKG
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MX7..Z1)$@G.8?,!0R(C^BO1;5B-U\B=0UF.F-R6K8]C0"@-(6":SS-NGR2>
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MB B!"[IL 'D$H9  X_-K:A2VTYLQ:E!>[@LM>&G:2$[!W&JD0'94]XPG2.<
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M87'*^3D^Z-[>_1N\:MA>&U+:UK;=4SJ%%N"W18THR2BGYV91RLV.W3(KN 8
M$1(<@#@<9W1#/&J:T=-;*MEIUC+]"W[C'@L657,&6H/9_P#:L=,[/.B@S*DG
M&Z^6^WL]1054VRT8NI*))]/)<D >,< \4!'&1 ,A5?II*.0FI%.'567B".52
MLU7) (J= #CR9CE#@!A+NB(!T"(UQY'SUBME*F^G[3R[XQ^P"Q>YKMS0.U%%
M%%="UHHHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB(HHHHB*
M***(BBBBB(HHHHB****(BBBBB(HHHHB****(BBBBB+X[H1^F3_&%'="/TR?X
MPKWZYGK$ZEV]V2W]RL<S]B=2[>[);^Y7QGK+3Z(]OR7M^C'>]W+P&[H1^F3_
M !A1W0C],G^,*]^>:"Q.I=O=DM_<HYH+$ZEV]V2W]RGK+3Z(]OR3T6[WNY>
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M?XPH[H1^F3_&%>_/-!8G4NWNR6_N4<T%B=2[>[);^Y3UEI]$>WY)Z+=[W<O
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M6,2*<7)%"[Q2@7I 0+D1$0P&*CJ8U=-94;JQ*VLVN-W,(R*2;D\LJ1RTCCF
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M+R3L,9  $H^*(AT9\X><*3(;:IBI]21!C:L\NC&F<@^<E(046Q4B&, F. X
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M>\I9+.'FXVZS<L<)%T*"C);!@$<8\<H"<P_=T8XV!KY45(B03J'*F0.DQS
M!_6->79>4-JL]JM-I+&/^D$WVN!+3+P_<""(< 1!ZC(E=579U*I2I4@XMP_9
M(.8RNZ1F-^2K3)[-D_&Z0V1:\:JUD9*-G2RT@J97DD^.1,!,AD0#@ >? C5B
M+E@VMTP4I$/ ,+.005;*[@X'<.40$0^WCFD]*_8-:]EK1*\$9]%J#T[7DS<$
MAQ@V]C=\H<,YIP5LVOMK:MN=1?;A=<"ZJTP6DXK@Z\.$2.; B-5C8[#9* >*
M&8(#2)D<T1'QSSE5NLVS]<-)(<UK0*-M7%"H&.#!^_7,D= IA$?&( @.,B([
MO'CG XI"OS9]ORZYR]U7<;"SZLH!5(V8?OS@HQ* !E%%'YI!\F\/  #/'.*M
M=17MT>7>T+/:G6ZE0I-JN]IP:6EQO-=>,.&9+<P(:Z3>:97"_8%GJ4A0>]Y8
M-P)! $$0)&ARF2($%0-IMH]<=LZLP=P/T&I8YG:;>(4.FX QP<$(4I@ OE+P
M'QJ3U-!KDD([6QFKW(W[[')5XQ05]X#;IS&#E,!DF> ?U_95B:*XCRSVF:QM
M NAQ;3;N.ZE4%1O'?> G490MXV+90S#SB7'?[S;IX:%57<:0ZG7 %DEGK?@Y
M.+A6@QJD$XECD:GW2@!'2FY\X?\ )#/S #RURPVS]=<+I^XMZ3L> NI-:5=/
M"E&5%H=KO$3*FHB<H")0\4V2CY +G-6287[!R=XR5K-GG*3D<B5PZ;<F8.3(
M;&Z.\(8'YP= ^6G!7MUN76V;,&T7T&4VY/  J,WESVN$5 1-\F\T@N$22 %P
MLV#8JI+VU"XY@GFG= (,M(X;CNSR"C[0BR9[3[3=A#7'(A(R22BA\E5,J5 A
MAR5(#FXF OGZ./#A3(NW2NYW6L%V72SA8J<BY"!3CDF,DY B;D^\GOD. !DH
M;I38-YP"IXH$<!7R=#E';*%OM&T0UI?7D.$$#G.#C%T@C,#<9CKS7KOV;1J6
M>G9B3=9$9YY C.09WJ"- -(KBL&[;@E7;)"UX!ZB5-M;;63.^(FJ @(J[Q@P
M'0. Z?&\P4J[0&G5S7<_LN=M5%F\DK<D1=]QO%N2*L4=T>!NCI)@?L'AT5(-
MOW_!71/SD+&O>Z)*$4*D_1Y(Q>2,(B !D0P;YH]&:<-=UJY1;4I;:&UK33#:
MP:!=<'06NIW1>O&^Z\PS>+BXS-[<N>ELZROL1LE)Q+)W@C>'3E @0X;@(&Z%
M71KIWJ?85T79+6S&P<FG=R9'#I!V]%,8YT)1WP*./RA"F.? ^4,='EDS0S3-
M32;3>/MYPZ(\>D.HX<K) ($%4XY$"YXX# !GRXS3_HKEVERGMNU+-]%JM8T$
ML+BT$%^&TL9>))]EI($ 3O,G-;;+LNC9:N*PDD3 )R%XRZ,N)SX]4*O<UI5>
M\=JO?DG#,HZ0@;NCQ;*K+NN25:FY$2A@OE'>#'FP;/DKY7T:O5+9?B;*CUD6
M=PM5"G<H).Q(FX3Y4YC)<J7HW@,4?MQBK#45W>N>T;M 7&?XG4G W3SC1:6,
MO<Z#S3!@#<#D<UH]"V>:AO.YX<-^X/()C+43G*JBTV=+K3EKL=M[>@H!K+6R
MK'-X^-?"<B;@PDX',<,F$=T1,?HZ \F1=$_HK=+ZQ=&XQN@T%]:SU%>1 SD
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M"ZA4D$2&444-T%*4,B(_8  (TEVA>4-?L$C,P#].2C%C&(1PF!@ 1*.#!@P
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MTS>ONJ/<6AMY[FM;N#G>[),@$G)K>.G9>RZEAJNJ/=E=#6B9@ D[R!KD.\J
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M&7,N'<BB"P&4%,0.!LA_)'Q@Z:D"R;ZA-1(49: >"^8 L=#E13,GXY<;P8,
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M*FP;'4:&NG*8W<77N(C?J"(RA5JNO0*>=::V^2W;>AH">CIWY95B$'YU4%,
M!0_+*=)L%)GH#IQ2@UT6NB[KWOV6N1NSAV]TV\G'B+-SRW(.,$W@ .D2@)>G
MR_UU86BM7KOM44W,%V\;T.-XN <]M0@%SC(#F-(O7CP)*R]!V2\'&8RRR ,
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M$1(KOY^:4 $-SRYSY*LC30U2TPB=6K7&#EU'"")5B.4EVA@*HDH7.#!D! >
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MF"3U.16!7)<' <&QD1'?,(B(CQI.M79EM2UK*N.V2KR#]G/$(FY<.E2\L4A
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M-RWY$ '<,Y,DSE"LCM#7QIVQU+B)IXRGYN"=-6K"0!H5$F5A'B8A< ( 4,@
M^7@(B%.0EY:G63JIIM;=Q7+'S+*X3&4<&;QY$5  "Y,F(^8!Q@P  CQS3BU*
MT4MIM'Z@7"]83=Q&N'N<[N.C=PRR8IG*!3MPQG>+\X0$1R "'EJ-=--.)&Y-
M8+0FV3"[20%N)F.K*WB.XNN;=$$T$4_Y)"Y\GVB(]%?2V>MR?M^SZULIT:;
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M\G]H646IU"FVZT&L74F!I(H1#9BX<3/F-%\D 3!"\^UT]H6:KA![C)Y@#G2
M7[S[W-RS/-ZE<T0P80^W'^VJF:@[0%SVS)/9J#NP+BBV<KW,LP0MT2QR:0G$
M 3%Z/$RH!@.'2.<<*METCD0Z1SBH->;(]L/(N0BOEZXDHAR\[N2CB/"]SME1
M')C$()<"(]&39$ ^WC7YMR.MNQ+#7J5-MB\TW0 6->")-_>TEIB(+2T[^=D
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MY4WB!U! 3 !@+@2Y*'#'DZ:<^GFC$)IZ>8<D</IR5F W9"3EUN677+C&X(X
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MR6 #<, CG/'../#A7'$;.\8RMJ9@)&Y;BGXN19E8E;R+P#%:IE,!B\D !P,
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M?6U=N<E' -LU!K'7(8YU(/N._P >3V70'S#X<34(+IW$!ODLL.UA)JO+A>S
M>1>'.]DS+=XD"Z"!'QA6)"]6VJ>MCBW)IC%/V"23MX[6:<L*QDTQ,)$RCP(!
MA P[P@.. 8Z:6(O76_;P=Z3M(I]'QSJYV+GNPR[,%$@434.3E0+TAP)O;@"
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M94@F$ID1 ,E$-\>G/#AY:^[,V?8:T[D3GW<Q-7-+MVYFC1S-.05[D2$! 03
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M )<YX9 <8$>-.V4U>?VCJSJ\=9NT<L;>ADG;9(C8A%5#^)NE.J ;YBY-T"/
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M]SICG(% I0R/$>(^<:\?:FVN2]>A:Z=FHM:7-ACFTVATR\M$&F&M$$!Q;=?
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M;92K3DWL<Y2W0.@HD4394R<@ !1$!$P<>FHWN?;F9%T\OUW$V/=D1>T#;PW
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M!59V3=,W,(&X$+Y#=(YX@%:K=V,X6 F;:D.^-^\+!W5+72""C1,"N#OR 11
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M(6RB"K5,G=";I4RAE38-XIBB;  &0' 9&EACLJVN;9F8Z)S+MY,6^U: V*_
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MF$QC\DB4J9,B8>!2@ </TTYJW#=FM92#-\+NL?\ TFM_8W%2@%1?.?QNL?\
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MY0>5*. ((^*.\!@SPXV]MW3JSK1?B]A8.+BW8QZ$2*S8H%,+-$,(H=/S"!P
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MA7P3K)^II^I)[*BS538N:V^]+>E@LB2,JW#$C;3D0*A+H!TE3$0PDX#^28.
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M(B 3)<>V2]@'2L:72"[WUP1T2>X)R(2<- 5AX_E#%345.)]TZAR%Y0$2")@
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M4B#L3F H*$WB'34('27 \/T"+X=[;,,WNYTB6R;C4L5M<W>DK>X"B#(DCO\
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MZ8QA9)103E7Y(J8#D@C@ WL#@,Y'.80^9260HMT@U_O&<5TF2G+JE5W$Y?\
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M' 0X50'IS5$6KVVXXNK16_U;*65M6\;7DH5-9RPD6LF@=N[<E+O(N$P%,^0
MY#!C(#Y1Z:=#+:?F+ U9U=1N5.0N"UHZ^(>VV@HJ))DA$7:'!8V2@)D^5$H#
MQSD0I=/L%V>Y@;HC7UVW?*'N)&)1>OG[Q%9< CE-]#<$4L% >!1* 8 H!N@
MY$=&OFSU)=Y6K+>QK>/>4YJJ\1"23E9-%FUAS$2W4W9!$N\<$S%(;< 1.)L"
M' ,5(?O5ENY3#H]JVWUCB)V6813EA%L)M[#-73A4IRR!6RG)G<)@7H3$X&*
M#Q\4:?U,W1O39IH_I;:]F,E.71A6";4SC&!75^<JJ/VG4,<W_>IY5N$QFM1W
MY(HHHJJ(HHHHB****(BBBBB)!G/XW6/_ *36_L;BI0"HOG/XW6/_ *36_L;B
MI0"N2T>T/A^Y770W'X_L%FBBBN5="^.4+YZA';+5*;9\G2 .0.]C"F /*'R@
MWJ7S'$WEJ%ML$=[065)_3DHHF?-E^A7991_G9\1^JY:Y_P 3_@?T4Y"H.3
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M-)THW,J0R8"0#B!A3,.2B("(7!T4O9OJ/I/:ES-9-Q,H2C C@K]TR*S57XB
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MAC"F J#D1$1W0$V ''&GOK-;$?;5P1!8QBFS8R$*V?;J9EN354-OE4,1-?\
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M:%O9;51> N= EK65<,48MM"G#=UHS)SQIEE4SO@6RW6(<P "8I8$"CGIS5Q
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M\%VBC[U'.Q9/6^"[11]ZEPZ)>&J^C:76>=A<3$]KQ*C*XUS.IELHT(=.15,
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MQ_)#FM3;?O5_.0#>>TYB8Z*4OL^GLL^931USI2&3;IVZ8D 3) 4 $QCCD1R
M %3P\V:]/G\NO)KPRYGJ]T(WFHH#Y8 &52*)4UL ;&Z #_!_-'S5J)LQ:=)X
MW89<,7;W\ /=ZW^%^/Y?YWS>/\'\S[*L/U26Z*";5V_W]WS#]6.LHKBW%$IC
MN%RF#T5FYV**BB9WIQ0! J:XI&* )J&,3AO9I2M_:ZU)N2"TR;-=.K?"[]24
MCOK?8JSBA6B;%% JBZ[E3DQ,4PB8-Q,@&'='B.0P,N1FRCIC"S\Y+Q\"Y9+S
M*;M-VV;RCHC/^^2"FX,FV!3DDSG*8P;Q2@(9'&*WW-LOZ;7?8EJVA*0"BL/:
MR9$H4Z+Y=%VQ*4H%#DW!#@H&2@ #XW' 9Z*EU^J2W10VKK=*6+K/JH\N-1K"
MRD5:$"NNSD9IRO#(O%S[@II)II&/G?,( *91.I@ P F$08][[2EQ:HHZ<(JM
M75HS,)K''6Y*HQZKMJF]1%$Z@;R:Q4UBD, ^,DJ7I*&<YX62E=DO2Z;92S1]
M;RSE&4C&$0YWY%P)A;LQ 6NZ??WBG()0'E '>$<Y$<C6N)V1-*X)%HDPMU9L
MFUN!O=*10DG!L22*?)IK")CB)O%$<E$1 PB(CD1I=<EYJ9VTEM</-&=0&=EP
M%OMIN</"+7 L#X'@E41(H)"-D2M453"LH8I@ QP!,N WAXTW+IVU;CA-0+;L
MUO9+(DS?+**?V@22>'0 2N38<IR!1P9$Z.#X @>.(  !D<5.&J>SS8FLLE'2
M5T1+A:4CTSH-Y".D'#!R5(_$Z0JH'(8R8CQW1'&1'SC2-<6R9IA=3N6>2<"X
M<OI(S QWGRDX!=OW%_[*5NIO[R $\R8AO=)LC5(?.14!;&840W1MJ7G:\K>S
M\VG\2]LFT+R2M61DDY<Z;U4%3)E(=%N)! Q@WP,("8 P( '08P+ZNV&Z;:V,
M[0)%14S;\HZEH]C,10O<).F2)U135551*@J([@E,5 YA3$0R(^7;8^Q1;9-4
M+UO6^8]I/R+^[E+BA12>N.323W"<F#E'Q4U%"'*8P9 P!O#@>(A3TB]C[2>%
MO,EUL;8.VG$WKI^FN60<"1)5R0Y%]Q,3B0A3 H81*4 #(YZ0#$ ?JJ2U0_IQ
MMOWM<_>0XE]+VI6EYVY*S$&WA)4SAX[78D,<R/)F( $!3=W2!DQLB C_ $0;
MLQM226JECZ:2CH[2+E5M2(.+=Q%M2SYDZCQ6!43(/R+)%,? EP) #DU  1 W
M"K(-=ES3EC'6@Q;1#QLA:4>]C(8R,HX(HU0=E$JX <IP,)A 1P<1WBCQ*(8K
M2ELH::D!$ZT5(/WJ<ZUN0\G(3#IR]</VQ1*W46<**"=0"%,( 0P[N!Z*77\2
MDMT45LMM*Y'4Q&3Y["8IZ52=Z=Y#>6+*B,J#D512!P9MN;@)[X#XF]O@'']/
M/9VVE>$W=%I%E; BF-I3UYO+*)*-I8ZCD'21C@10$!)@">)XPB;(CG   !O2
MZRV3-*8_4D+[;VHFG<)7YI8O]]K"S(]'I=%:[_) KGCO@7.>/37:QV:M/8YE
M!-&\,L1"$N)2ZV)1?+"*4DH(B=41$WC (F'Q!\7CT4A^J2W12> Y *S0' **
MW+4BBBBB)M71_&>R<<1^5%?[&XI_@!OLI@W-_&BR/]**_P!C<5(.*YZV\?#]
MRM]+<?/ )01_@2?YH45A(/R9/T!17$NI?0U"&UIXUAVQYN_&"_MR=3>!!,/'
M@'FJ$]K8,6':_P#VQ@O[<G759?KF?%:*_P!4[X*;RE ,_I&OJL!T5FN5=***
M**(BBBBB(HHHHB****(BBBBB(HHHHBP/15;MJ./=69<]L:HLXX\LTAT5XR<C
MTB[QW,6N <KNAY3$$ . >7B%62KAEXIO,,%FCE,%$52B @-;J50TGAX6NHP5
M&EI7ES=>C\G:3<)FSV[B]]-G@BM%S,*07*C9(1R""Z9?'*8GS<X\G' \*1K9
ML:\M0)'N2VK3EG;I00 [R1:*-&J  & ,JJJ 8* >0,CPX!4Q1.E4O&ZHZE2=
MD.9F$MR)F"1@*6T^%JHJX*D4[D1(8ITC[IC@7!B=(#Q"GF2+M:ZB@UO_ %-U
M#EFG0I$39NXFRGG*<6B8 H7[-[C7Z%3Y05Z=(4KP) XCG#+L/<OAJFP:%2J:
MI!@G@<C^X7%HY8#&3FK7LZ =EF[5LF1/.7#<*8?D)6=$H@1!$>@Q$LB8PAD
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MJ/$.CB50?_V*R&N-@A@ NM@&.C@IP_1XE,)R8@5>-G_4^Y)#:CNRV)Z['-]
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M^=@=;(_[E/<K//G8'6R/^Y3W*73HDC5/FBF+SYV!ULC_ +E/<K//E8'6N/\
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MI3;(=,6F%8YJ;8Z/DM/_ -?97(:1O,.!I"##/D&,7#_]8K OKR H"+^# H]
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M.:JV/1:=<7=]X>D8+LU?XBCN^\?2,%V:O\33 .H3%"6HBQ(2"=@Y9,2(K &
M,%."F"A<]PQUQ0;237BG+2275;CW(T514(8J"BH" F5. _P>,8\O3PI^";%:
MGL+#!6;7!PD+>7. HK!.)0'[**U+8MM0?M;_ ,1+7_[8P7]N3J<*@_:W_B):
M_P#VQ@O[<G759?KF?%::_P!4[X*;PZ*S6 Z*S7*MZ****(BBBBB(HHHHB***
M*(BBBBB+X54*D0QC& I0#(F,.  /.-4,UWUF;:EL.^&?<R/-R9ZHSMBU8E<6
MSFYUDAPH[75#BFU*8!W<=(<>D0JU6TO,/('0#4-^P$Q'B,&[%,Y!P)1%,0R
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M-!=B =+M6F%]R[JU$5XI!TFQCK/A%&"*BS@H$4<+F55.81W.!4R8(7([H!Q
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MVJ!S1P55;6VC)756]MGN[)*#:L)QW$W<+E)L\<@W379I&(.ZF"FZ<AQ3 <*
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MX;JA@-OF(GT%4P(E$V*M@&T!9H&$0EGH&'I$(UYD?T_DJP.OMEB  ,H\$ Z
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M]CE_?5@5+J* B-S-0 .(B,.7]]3 .H[_  3&;HG%S>V]Z);?@"CF]M[T2V_
M%-M-Q="Q .G=#-0@\0,2(*8!_0(+U][]U]96O8Y?WU, ZCO\$QFZ)P\WMO>B
M6WX HYO;>]$MOP!3;5<W.@03JW2S3('28\24H!_6*]"KFYT""=2Z6:9 Z3'B
M2E#[Q7I@'4=_@F,-$Y.;VWO1+;\ 4<WMO>B6WX IN%7N@QC%"YV@F*.# $04
M1#R\?R_#A7UOW7UE:]CE_?4P#J._P3&;HG#S>V]Z);?@"CF]M[T2V_ %-[?N
MOK*U['+^^HW[KZRM>QR_OJ8!U'?X)C-T3AYO;>]$MOP!1S>V]Z);?@"F]OW7
MUE:]CE_?4;]U]96O8Y?WU, ZCO\ !,9NB</-[;WHEM^ *.;VWO1+;\ 4WM^Z
M^LK7L<O[ZC?NOK*U['+^^I@'4=_@F,W1.'F]M[T2V_ %'-[;WHEM^ *;IE;I
M* B-S-0 .(B,.4 #_?5A->Z%2 <ET-#D,&0,2(*(#^@07I@'4=_@F,W1./F]
MM[T2V_ %'-[;WHEM^ *;V_=?65KV.7]]7P=S<Z9B >Z69!.."@:)* F'S!E?
MB-, ZCO\$QFZ)R<WMO>B6WX K Z>6Z/3$-OP!3?W[JZRM>QR_OJ-^ZNLK7L<
MO[ZF =1W^"8S=$NCIS;ODBFX?8) $*^#:=V^'3$-_P &?_O2$1S<Z@G ETLS
MB0=TP%B2CNCYAPOP&LE6N@XF MSM#"4=T<1!1P/F'\OP&K@.U'?X)C-T2US?
M6\/'Y);#]NX _P"WIHYOK=Z?DEM^G<#_ ,PI&S=(CGOD:Y\_R,7]]6 [Z@$1
M[Y6V?/\ (Q<__GJ8!U'?X*8HT2US?6\''Y);_IW #_:'"L<WUN@&?DEN'V[@
M!_\ :D8 ND,__B5MD?+\C%S_ /GJP 72 #BY6H"/E"&+^^I@'4=_@IC#1+7-
M];H?S4V#/^0 ?_:CF^MTH?X);A_W #_[4AG5N9N3)[I9I (XWC1!"Y'S<5J^
M@"Z2@(!<K4,^4(8O[ZK@'4=_@F*-$LCI];H!_@EL ?Y@!_\ :@=/K= /\%-P
M#_,  _\ J%(8JW*D<J8W2S(H?.Z48@@&-CIP'+<:^RA=)0X7*UR/E^1B_OJ8
M)U'?X)BC1+'-];P!_@EOCS[F/:%8YOK> .$2WQYP)[.%(V]<Z0AO7.T 3#N@
M(PY $1'H /RW$?LH4/<S8.46NAFF4?Y:L.0H?>*P4P3J._P3%&B60T_M[R13
M<?T$#_Z>R@M@6Z(\(EMG["!_],#2.);I$V1N5J/Z88G[ZOD3W,HH*??2S$Y<
M"*?R.01 /)D.6R%,$ZCO\$Q1HEH=/[=SQBFV?M(&?_H-!M/K=QQB6V/M('_U
M#_ZTBJJW*D4H'NEFD!AW2[T00-X?( 96XC]E""ERG W)70R/NCNF$D00<#Y0
M'"W ?LI@G4=_@F*-$L#IQ;A@_P $-OT@3'_EFOCFWMT1X1B'X &DE4US(%%1
M6Z6:9 Z3*0Z90#^L5JV&[Z3A_&9MC_0Q?WU,%VH[_!,4:)0-IM !_-;;^LF*
M^!TZ@0_FAN/Z"@-<(GN9 N\:YF9 R ;QH<@!Q' ?\]6"GN=P<Q272T4.0<&*
M2'(82CYA#EN%7!.H[_!3$&A7:.GT '3$(!^DE8[P+>]%-OP!7*!;I#_&1J/^
MIB_OJP)+H-_C(U[&)^^I@G4=_@IB#K77W@6]Z*;_ ( H[P+>]%-_P!7&#>Z#
M9Q<;4?T0A/WU8Y"Y^LC7L4G[ZK@G4=_@IB#1=W>% >BV_P"$*.\* ]%H?A"N
M#N>Y^LK;L4G[VCN>Y^LK;L4G[VF"=1W^"8G4N_O"@/1;?\ 4=X4!Z+;_ ( K
MAY"Y^LK;L4G[V@&]T&' 7(V$?,$(0?\ ]+3!.H[_  3$ZEW=X4!Z+;_A"L=X
M%O\ HIO^ *3R!<:AS$+=+,QR8WBEATQ$N>C(<MP_KK[[GN?K*V[%)^]I@G4=
M_@F)U+N[P+>]%-_P!6.;^WA_FEM^ *XNY[GZRMNQ2?O:.Y[GZRM>Q2?O:8)U
M'?X)B=2[>;^W_13?\ 4<W]O>BF_X KBY"Z.LK7L4G[VL\C= ?XS-NQ2?O:8)
MU'?X*X@T7:&GUO\ HIO^ * T^M[/^"F_X I.,I<)1.4UU,0,0 $X&B$\E >C
M/Y;A_76T$[H#_&5J'^I2?OJ81U'?X)B#0KN#3N ]$M_P!60T[M_RQ3?\ 5P<
MG=/65KV*3]]6.3NCK*U[%)^^J8)U'?X)B#0^?O2ES>VZ'\U-Q_[@5GF_M[T2
MV_ %)G)W3UE:]BD_?4<E='65KV*3]]3!.H[_  5Q1HE$=/;='^:6WX KZ)IM
M *?-B4/TB0,4F@2Z _QD:#^F%+^^K[WKJ#_&5KV,7]]3!.H[_!,4:)3'2^!Q
MPC&HCYA)7P.F4('1$-A_04*X-^Z^LK7L<O[ZC?NOK*U['+^^J8+M1W^"N(W0
MKL'3B$+TPR'JPKYYOH$.F'0#_P .N7?NOK*U['+^^HW[KZRMNQR_OJN$[4=_
M@IB-ZUTC8-O!_-3?\%8[PK=]%-@_[@5R*N+G1()U;H9ID#I,I$%* ?I$5ZSO
M72/^,C7L8O[ZF$=1W^"8@Z_/WKK[P;>]%-OP!1WA6[Z*;?@"N3_\4]9&G8Q?
MWU9S=/61KV,7]]3".H[_  4Q!Y_^UU!8-O>BFWX K/>!;X]$2@/_ (=<(N+F
M(H5,;H9%4-D2D&((!A\^ Y?(U]'7NA(@G/=#0A"AD3&B"@ !]HBO3".H[_!7
M$'7Y^]=P:>08]$,B/_AU]!IM"C_,S</TE"N JMTG*!BW.U,40R A#E$!#UU9
MW[KZRM>QR_OJ83M1W^"8C>M*(:8P8],6U+_W<UM+I=;W\J.0']"8!2,HXN=$
M@G4NAFF0.(F/$%* ?I$5Z^@4NHP (7,U$!\H0Y?WU3!=J._P5Q&Z%+A-,K9)
M_,[<P_:6MH:=VX4,!#M@#["!3?W[KZRM>QR_OJ-^Z^LK7L<O[ZI@.U'?X++&
M;HG#S>V]Z);?@"CF]M[T2V_ %-[?NOK*U['+^^HW[KZRM>QR_OJF =1W^"8S
M=$X>;VWO1+;\ 4<WMO>B6WX IO :ZQ 1"Y&P@'2/R,'#_?4;]U]96W8Y?WU,
M ZCO\$QFZ)P\WMO>B6WX HYO;>]$MOP!3>W[KZRM>QR_OJ-^Z^LK7L<O[ZF
M=1W^"8S=$ZXZT(B)<@NTCT6ZP=!R% !I8"HX;3]P1-S0#5]+-I%I).%6QTRQ
MW(&*((**E,!@4-Y4\8$.@:D<.BM3V%A@K:QX>)"S1116M9HJ#]K?^(EK_P#;
M&"_MR=3A4'[6_P#$2U_^V,%_;DZZK+]<SXK17^J=\%-X=%9K =%9KE6]%%%%
M$1116!Z*(HMU]U0D; @(V,MELE(7Q<CKY,@VBW\&"HE$QUU/_P FD0!.;S\
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MZJ<IB@ @)B\!^RE^6L2W)ZXXB?DH./?SD054D=(N$"G7:%4+NJ F8>)0, B
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MR@4QE$2$-GQ!IJZ8[8VK!8W2VY;Q2MN7@+U@)^0)'Q#!1NZ15CDE52F,H)A
M>4Y/=W2A@ X\1XU;Q#1#3UK<BEPHV/;Z,\HZ,^/)IQR97!G!BF*945 #(F$I
MS (_Y0^<:Z8O2.R80+<"/M.'9A;95R0P(M"E".*MD%@1_H <!'>QTY'-+KM5
M;S=%2/2+4RZM6MJ?9[N>Z[@M67<2ML3,B@PMQ(R:D6FJED&[C)S9,&[@#<!R
M!P$!QD5_;1UONJ5<:U:>1LQ:]N6Y;MFIN7R4VF8SV9.[(/Y-J8#EW!( E ,
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MMX/M^ZC>#[?NJL/,-9WYK%>PVGQ-',-9WYK%>PVGQ-)=T-3\K^Y+S??;^/\
M@K/;P?;]U&\'V_=58>8:SOS6*]AM/B:.8:SOS6*]AM/B:2[H:GY7]R7F^^W\
M?\%9[>#[?NHW@^W[JK#S#6=^:Q7L-I\31S#6=^:Q7L-I\327=#4_*_N2\WWV
M_C_@K/;P?;]U&\'V_=58>8:SOS6*]AM/B:.8:SOS6*]AM/B:2[H:GY7]R7F^
M^W\?\%9[>#[?NHW@^W[JK#S#6=^:Q7L-I\31S#6=^:Q7L-I\327=#4_*_N2\
MWWV_C_@K/;P?;]U&\'V_=58>8:SOS6*]AM/B:.8:SOS6*]AM/B:2[H:GY7]R
M7F^^W\?\%9[>#[?NHW@^W[JK#S#6=^:Q7L-I\31S#6=^:Q7L-I\327=#4_*_
MN2\WWV_C_@K/;P?;]U&\'V_=58>8:SOS6*]AM/B:.8:SOS6*]AM/B:2[H:GY
M7]R7F^^W\?\ !6>W@^W[J-X/M^ZJP\PUG?FL5[#:?$T<PUG?FL5[#:?$TEW0
MU/RO[DO-]]OX_P""L]O!]OW4;P?;]U5AYAK._-8KV&T^)HYAK._-8KV&T^)I
M+NAJ?E?W)>;[[?Q_P5GMX/M^ZC>#[?NJL/,-9WYK%>PVGQ-',-9WYK%>PVGQ
M-)=T-3\K^Y+S??;^/^"L]O!]OW4;P?;]U5AYAK._-8KV&T^)HYAK._-8KV&T
M^)I+NAJ?E?W)>;[[?Q_P5GMX/M^ZC>#[?NJL/,-9WYK%>PVGQ-',-9WYK%>P
MVGQ-)=T-3\K^Y+S??;^/^"L]O!]OW4;P?;]U5AYAK._-8KV&T^)HYAK._-8K
MV&T^)I+NAJ?E?W)>;[[?Q_P5GMX/M^ZC>#[?NJL/,-9WYK%>PVGQ-',-9WYK
M%>PVGQ-)=T-3\K^Y+S??;^/^"L]O!]OW4;P?;]U5AYAK._-8KV&T^)HYAK._
M-8KV&T^)I+NAJ?E?W)>;[[?Q_P %9[>#[?NHW@^W[JK#S#6=^:Q7L-I\31S#
M6=^:Q7L-I\327=#4_*_N2\WWV_C_ (*SV\'V_=1O!]OW56'F&L[\UBO8;3XF
MCF&L[\UBO8;3XFDNZ&I^5_<EYOOM_'_!6>W@^W[J-X/M^ZJP\PUG?FL5[#:?
M$T<PUG?FL5[#:?$TEW0U/RO[DO-]]OX_X*SV\'V_=1O!]OW56'F&L[\UBO8;
M3XFCF&L[\UBO8;3XFDNZ&I^5_<EYOOM_'_!6>W@^W[J-X/M^ZJP\PUG?FL5[
M#:?$T<PUG?FL5[#:?$TEW0U/RO[DO-]]OX_X*SV\'V_=1O!]OW56'F&L[\UB
MO8;3XFCF&L[\UBO8;3XFDNZ&I^5_<EYOOM_'_!6>W@^W[J-X/M^ZJP\PUG?F
ML5[#:?$T<PUG?FL5[#:?$TEW0U/RO[DO-]]OX_X*SV\'V_=1O!]OW56'F&L[
M\UBO8;3XFCF&L[\UBO8;3XFDNZ&I^5_<EYOOM_'_  5GMX/M^ZC>#[?NJL/,
M-9WYK%>PVGQ-',-9WYK%>PVGQ-)=T-3\K^Y+S??;^/\ @K/;P?;]U&\'V_=5
M8>8:SOS6*]AM/B:.8:SOS6*]AM/B:2[H:GY7]R7F^^W\?\%9[>#[?NHW@^W[
MJK#S#6=^:Q7L-I\31S#6=^:Q7L-I\327=#4_*_N2\WWV_C_@K/;P?;]U&\'V
M_=58>8:SOS6*]AM/B:.8:SOS6*]AM/B:2[H:GY7]R7F^^W\?\%9[>#[?NHW@
M^W[JK#S#6=^:Q7L-I\31S#6=^:Q7L-I\327=#4_*_N2\WWV_C_@K/;P?;]U&
M\'V_=58>8:SOS6*]AM/B:.8:SOS6*]AM/B:2[H:GY7]R7F^^W\?\%9[>#[?N
MHW@^W[JK#S#6=^:Q7L-I\31S#6=^:Q7L-I\327=#4_*_N2\WWV_C_@K/;P?;
M]U&\'V_=58>8:SOS6*]AM/B:.8:SOS6*]AM/B:2[H:GY7]R7F^^W\?\ !6>W
M@^W[J-X/M^ZJP\PUG?FL5[#:?$T<PUG?FL5[#:?$TEW0U/RO[DO-]]OX_P""
ML]O!]OW4;P?;]U5AYAK._-8KV&T^)HYAK._-8KV&T^)I+NAJ?E?W)>;[[?Q_
MP5GMX/M^ZC>#[?NJL/,-9WYK%>PVGQ-',-9WYK%>PVGQ-)=T-3\K^Y+S??;^
M/^"L]O!]OW4;P?;]U5AYAK._-8KV&T^)HYAK._-8KV&T^)I+NAJ?E?W)>;[[
M?Q_P5GLY\_W5FJ_6'H[:\!>,3(LM.U(ITW6WTWHQ#9($1W1#>WRKF$O3C( /
M35@ Z JR3O86_P#==_\ ZN<.^>I9 @[B#\)_<!9JO>VEM#GT%TO$8I4I;JFC
M&:1F0R*. RHXW?+N (8\YC%JP2AP3(8QA I0#(B(X *\GM=-1W6NFK=W:C V
M,^L>RN39,"FX)*&%02H /_2J@90?\DI0\U>[L>QMM5HFI[#<SUG@/O*\S:-I
M-GHFY[1W?N5(5E::3^RO8EO:T2TZ\6NZ8G&3>4C3.-]+N%P8>53<#Q%180$I
M\B/B& ,9P(CZ/E-D*\87T)=][6JG/7)<:K6.?.VY6D:!APL<ZH$(8J0"!0P!
MC"41 1P ^?->D6ANS/.:)7&=^35&X+FB54#(KP\P4%$C#_).0PG'DS .>(=(
M"(#Y,>MMNS-:!4JU1?SC(YC*!ENA>?LNT%\MILYHB<]QSSZY3U<ZYPK775GI
M@=%;Y4=19Y CL!#DN4*.>Y_/RG)Y4_S<><*<B^IEH-90(U:ZH5*1%4Z'<AY%
M$%N4(7>.3<$V=XH" B'2 "&:KE=NA5\2T/#WW#OBO=1V-S!<@PAG3<&I04$J
M2C8%P*!L U*F3B<2CN='$*Y)G9IN*5EIQZO;4>[,^U29W*)EED1,K%$3*!]X
M1\P@;\F/3D?/7C_1;*Z/\D90<^,[\^&>7WKTL:N)YDZ?#Q4\S&JJ+M6T%[3D
M+<GHF7ENX'#P9I(@ 0"&$W<^,@LJ!@ .3 <XS3A5U&M5M)NHU:Y8A*0:$.=P
MU.^2!1$I"[YQ.439+NE\8<] <1X566,V<[RC[X:O4XAJC%H:K.+H*4CI("DC
MCMQ3*H4@=!A-TD#C2MI_HM>$#HW>VF\K;B#B1>&FE&5TBZ0417.[*IN*" CR
MI5!!3<-DO0 \1#A4?9K,&B[4':)S)SW\,L@JVM6G-GGYJQ7?Y;0@00N&*$#L
MOE(H]VI>,TSCN@/&XI9$ W_F_;7="3T;<D>1_$OVTDR.(E*X:*E5((@.#!O%
M$0R @("'D$,53MAH'>UR!&)W%9JL9'1^GJ%J'0BYMMW9W4D\;J@HD;.Z7 )\
MH7>' [N#8S5C-!+<NRUK"!C>+SY0E0>N3INE4TB.%6XJ#R1G')>(*PEP)A*(
M\1XB(Y&M%HLU&DR\RH"9W2/VGSKPVTJU2HZ'-@*1Z***\Q=B****(BL8S6:*
M(L8#S!1@/,%9HHBQ@/,%& \P5FBB+& \P48#S!6:*(L8#S!1@/,%9HHBQ@/,
M%& \P5FBB+& \P48#S!6:*(L8#S!1@/,%9HHBQ@/,%& \P5FBB+& \P48#S!
M6:*(L8#S!1@/,%9HHBQ@/,%& \P5FBB+& \P48#S!6:*(L8#S!1@/,%9HHBQ
M@/,%& \P5FBB+& \P48#S!6:*(L8#S!1@/,%9HHBQ@/,%& \P5FBB+& \P48
M#S!6:*(L8#S!1@/,%9HHBQ@/,%& \P5FBB+& \P48#S!6:*(L8#S!1@/,%9H
MHBQ@/,%& \P5FBB+& \P48#S!6:*(L8#S!1@/,%9HHBQ@/,%& \P5FBB+& \
MP48#S!6:*(L8#S!1@/,%9HHBQ@/,%& \P5FBB+& \P48#S!6:*(L8#S!1@/,
M%9HHBQ@/,%& \P5FBB+& \P48#S!6:*(L8#S!1@/,%9HHBQ@/,%& \P5FBB+
M& \P48#S!6:*(L8#S!1@/,%9HHBQ@/,%& \P5FBB+& \P48#S!6:*(L8#S!1
M@/,%9HHBQ@/,%& \P5FBB+& \P48#S!6:*(L8#S!1@/,%9HHBQ@/,%& \P5F
MBB+& \P48#S!6:*(L8#S5FBBB*/M?X2Y[DT:N^+LXZ9+B>1ZB#7E#[F]O!@Y
M2F\AQ)O 41X 80SPJ)-&-DJ,8[)RFG=R-CLY"XFXNY91,"\LW='W3)[H^='=
M3  Z,E'SU9NC%=M.UU:5+"88$AT\9&Y<[J#'OQ'9Y0J%QVR5JQ=NM5G&O)O;
MC&QK5<)K(KP %03=%2$IB_D1R?E#B0@&$XX* " #Y[Y[H"7 @ YZ0K.*S65J
MMM6V%N)'-$"/.\K&A9F68$,XJ+FFC!8U9HJP=(QIFT@]?E[A3,WWN7<$4*4V
MX(;P%(42"!L@.0X8#%;(W3JZ$#N%'%T+J*=UN%T0Y=8Q!WDCD2$P9#&#& PI
MAD@;@8XU)M%:?I%0[RMF$S@H:B].+^1<1B+BYN12;)J[[Q)VNJ8HF44,4H)G
M'"F ,4HF4Z  -WC7?#:<WBR+")NKG%=!/)9%,SA=03E!0#AR9A$!$3  E'>Z
M ,(!PQ4K45D;2\Z=B@HM"BF"TON*%5A@+-D4;MR()KH@NX(!13;HI;X"!LJB
M(I'\53(84$1R(<7/IM:LI:\(9&:?A)R)E#97Y513">?%*)CCD1#B.<!TX\F:
9=]%8/KO>(*R;3:TR$4445SK:BBBBB+__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm2128727d1_ex99-2img013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
M'0   04! 0$!              $"!@<(!00#"?_$ &(0  $#!  # @<)#@,$
M!P4"#P$" P0 !081!Q(A$S$(%!<B05'1%3)4559AD9*5%A@C0E-7<8&3E*32
MU.)$4J$D,T-B-$5R@H.QLB4V<W3!"28U8Z(W.':SM,+P.61UH^'_Q  = 0$!
M 0 # 0$! 0           @$#! 4&!P@)_\0 1!$  0,!! 0*"00!! $% 0$
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M_IW=U8AK4'AC_P#YM_!Q_P#U%8_\FJ\>T46FT4\3RB9Y3AD.HX=B[E-Y%-V
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MQ:]V6&S+N-EN5OB/:#4B7#=9;7ZN52D@&N<TTN0ZAII"W75D)0VVDJ4HGN
MZD_,*_1W@Y:^,]SS2;:N,N7XSEG#J_QGXMWA2L@A/]CS(5R.,(2!R$+T-)Z
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M7\(*YN8X(3=ON\./=%L6YY#K#+[@4'D)*.@'.@JU_P WJ(KBLUNU]0,(&(G
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M+4GF=?D<X*R22- ]#U/<0!E32%UUT "20"3 AL G+?@!VK6V>1/NRZ\O!?G
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M Q[ACX0UGR#*+HS9K,S"FM.3'PHI2I;)2@>:">IZ=U4317"^RL>VJTD\O/N
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M*>R2KFVAH%6N8G>AONKN\#<_P;.. UZX,<1;\,/0+B+WC^1*84ZQ'E%.EM/
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M[P=X;7W!>"XN=UN.1->*WW-[NUV#ST?KMB,UT*$$$@D@=Y]\=$<#&N(..P?
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M\89_+-_7%'C#/Y9OZXK]^?)!@GR+Q[[)C_R4>2#!/D7CWV3'_DIZRT^B/?\
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M4>,,_EF_KBOWY\D&"?(O'OLF/_)1Y(,$^1>/?9,?^2GK+3Z(]_X3T6[G>"_
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MCW0E?"I'[97MJ@HWA2(O3^'Q['BDFZRL@\::\5\=;;7'D,'E4@J(*5)]//L
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M 65D=$E*0.7KL*WU'H%=WB3G$_"($1^!9V+HI]Q2%.3;HS;X[  !VMUSTGN
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M;!\[OWZ*JSBA%@XM;^(6)XOG*)ONY.6LX>Q:U.S_ !M:QS-I<[DM$Z)5KJ
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M=J_/+CIPKE83PUO%YNM[]U\ER+(X#LN<S'##3825A"6T$G03O?4^@>JK-?\
M!XDY?>[U=,ZR07^3+M2K-%$&&(B8S).RYKF5MS?7U=3\VM@+X!AT:7>$K&]Z
M7#!'^JJ=Y!S\=_PO]]35/#-]EITJ="[4:7$O!HS!%,!K8BX&BF!#2 1 (@8T
MP:&;5<YSY:0,.7$B\23SB2Z<<BL@63@1?';KB1RK+FK[9\4<#MLAQ[<(SCBT
M@);4^OF/,4@#N WJN]PNX0*P'AU=,5FW)-P3/?EN+D,-%OE0^-$ $GJ/76H?
M(.?CO^%_OH\@Y^._X7^^O$M6CN&5LI&A5I"X2TPW4M$M+G @-@ R]Q,9DXS
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MV8T&_P!F3:9\6=#+SA"&.R0M#@4-'HE1V.O7UC6O?(.?CO\ A?[Z/(.?CO\
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MKKH_,>ZM2<'+H9N%M0UN%URU/KM_.KO4VD)6R3_X+C0_57P6FK,*-<56Y/\
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MD65]_P (3A_<H<NZ&:Q8+XXQ!8FJ:CON-B*I#:T#H4K4H!8_& 3OWHJ$89Q
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M3PD%05H%0&@==0/5OU4U-/34E4$H2-GH//.U=/?'UGUT_E&NX=VNZFCO%/\
M14JPE2D!:E  *5KF4!U.N[9]-.2A.ECE&EDE70><?3OUT@IZ>ZI6A"4) (Y1
MHC1&NA'ST\)'FC0TGHD:[OT>JD%.'?4E6%XW;% D7J)=W(K:[E%9>CL23OF;
M;=*"XD>CSBVWLZWYHZUT?2*:/13O2*@HGCT4\>BF#T4\>BI*H)U/3W4RGI[J
MDJ@GIIXIB:>*E6$\4M(*6I*H)Z:>*8FGBI*U.'?3Z8.^GU*I.'=2T@[J6I5(
MHHHHB****(BBBFK6$)*B0 .I)HB52@!5>\2^,]AX<6MZ5/FM-!'0J4?QCW)
M&RI1]"4@D^@5!^./A!,8@E%HM"#<;S+"DQXC*P%.:]\M2NY#:?QEGH.@ *B
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M(+C2$$=W*EI &OHJ UVLQ<6]>U..[[13:$KW_F2.4_\ IKBU_1-%@ITF,&0
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M&LNOWJKS,H7,N?%V\\/YJV\[MUKAL.6&;>6'K.\ZXDNQE@KB$N <SA:<9((
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M=*]SG!G%)EUN5PN$*5>7;@Q)BN,W:X2)D=IF009#;+3BRAE+G*GF" .B4@:
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M(.'V&2N(69VG'X8//->"7'/0TT.KBS\R4@G]5:-=G1\YXSN.VY.L<Q6&B%#
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M;L^=<+FZEZ=<KK,7+ER5)3R("W%?BI3YJ4@!(&]#J29$*>*R!,JI,0@]!K9
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M:]%M>E3O-.4$$YD9 R,0=FQ3:1P^LMWS.VY==;5;IF2VMAR+ N(C .Q6G/\
M>)2L^<=_/W;.M;.^;"X6P;3FMTRRWQ;7%R"XI[.3<A%69#S8/F(6KGTH)&M#
M73736ZY\?P@<1EK2F,[<914N.V.PMSJAVCP_!(WKWQ.QKU@TZ'Q_Q2>AH1S<
MG9$A+2HL86]SM97.5I'9I_&T6G ?5RF@MU'(5!NS6G0FD1BZSNP_VG;Y[E]Y
M?!^W7._R;],@V=V]26THD241'&Q*Y!^#[=*7 EX)]'.%:'2O&K@%C[MAO%D=
MM-E?L]YDB;<8#L)Q3,J1T*G7!V@YU*4.8D^H;WH:YT[C^TY?EL6F/"DVA-E1
M>Q.DNO(4XT0X5!*$-*T4]D=\Q'?KO&J]$OPA;:VU"1!@R;C,5/BPI33;+B0D
MN[YBUM.UD'N!">;O%1Z3I[*F7\;ES^KND,)HG''W3OW=JZK7!.SL>[I;MMG#
ME^83'NJU1GE&<VE/*E#I+VU@)\T;/O=CN.JFF(XW%Q#'(%E@1H\.#";[&/&B
M(4AIIL>]0E*B2 !H:WH:Z:'2H(/"1P8MAT7"06_%?&5*$5?F#D4OD4.\*Y4G
MIK736]D"K#L-Y9R&T1;C';?:8DH[1M,EI33G*>XE*NHV.O7T$5R-M3:_):^>
MU=&T:-M5B ?7HN8#O!"Z0[J6D'=2UJZ:****(BBBBB(HHHHB****(BBBBB(H
MHHHB****(BBBBB(HHHHB*:OT4ZFJ[J(OS0RFZ:X-0+3U#C-X#RTGO'X)2/\
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M>QEOA;9[-<GKK=+U"=BEE2XR6Q#2B2'70'DK!?;(3L(6DD'T^D4C15#15G
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M.P-#7.GH2"=]-Z->P$>NLMMYGE<7&H;:[_=GG(V(9F3(==4''7H<I#41]T@
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M1*3.B)DO1"\VE0276G5-.)3L#FTM*D['0D'1-4=PS\*K[IV\BN=[C6QNPVB
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M,6R6QWJ9<(4F4U&O2[@8K:VTF7<);,A78@[TTGLU)\X\QZ'74ZY4+@#-=PK
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BI9V2.IWH=^O1NI?14/KO>(*IM-K3(1111777*BBBBB+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm2128727d1_ex99-2img014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
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M=+'.#;]4@<\VGG(^Y8=Q#@)YSX1KY*-T.U3KC/$&)"DRIQ)2(K#"W'21XCD
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M53B4%202.ATKQWM'X9Q/R'C]V3N-MLSVY.Y/,Q5F'>;1<;@$JD15J<4E20X
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M#UE$  ^526[1N37C@QVUK+=<*N35@E95"M*KJNTH069/>OI2]KF21RK[M)V
M"?'Q)I$=O[C1F]UXQY_@,O(Y3^'1);"V+0I#8:04L-N)((1S=%$GJKSK'2Q5
M:O6IE@ :YLQ/B/#A-N?@K/I,IL=.H,?KXIE^,>;PLVFXZY"P&!@/H-I:B.,P
M6UH$Y0W_ +PH*2G>_ 'J?':C23M.*7R_QW'[79+G<V&_ENPH3KR$^W:D)(%3
M+X]\/HW%7M.]G[$YZUB!=,5M+,HH5I7<CO5N 'R)2A0WY;I!<=>UUG]AXI7G
M'L"OCN#8?C4URUVNT61IMEI+;*BCG6.4\Y44DZ/3J!KS,T,2Y[64Z#+D3<F
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M4.DEHGG?]X4N>*K7"GM87ECB!&XCVOAGETV,TB_6+(F'.Y+S: GOF'4]% I
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MBO?GXH,$^9>/?9,?]RCXH,$^9>/?9,?]RGK+3[H_'Z)Z+=VO)> WI#/Y9O\
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M<&*KX;#TS4W3BV6D02!F&4$@G,SK  20M5NUL#NF5:C@W,)@\+Q?E!L?%/\
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MVE 2=$DI4-'6M$^%;-O[2%G9<N[&3V6ZX=-MUN^%?1KDE"U/QB0 ILH)VK9
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MON83K)C>+7?)8UN?;8FW.$IH-,E9^4$*5SJ2.I) \C5ST9VZ&;UU$AL227-
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MOS1GZPFCXH\F_-&?K":C"[8Z5X.K5K4\&<U0,!_IOT93W8T(D93<.D9NL "
MIJX+9-9K&.K6;)]IO]SLQX<^4&+*'MYX09Y!S7BD+5!MD^P9HPX1*=E]T['7
MW:N1/(1YJ.B?#77W5K6G@AG6"OX!E%AC6RXWZS68VBXVF9**&W$DK(4VZ!K>
ME_W#QZU,OXH\F_-&?K":/BCR;\T9^L)J1MCI3NQ1.!EL!KANW]<"GNNM?BR
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M$)ULJ)) !IMY/:BS7%\;X\*R;$[-&OO#&TQ)Z$0)[KL6Y%Z.Z]S@J0%(0>[
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M!/A2\XG=H7(N%+6&XO>W<&MN>Y"B7*7.N5T>BV*#$8*07%+< ><<5WC:$M)
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MG59(55T%1G+YD-LDR$A7HL5Q:#Y=X?5YOIUNM;-'$6.P2'=<RTIY4I ZD_\
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M:'*ZEM[.6<8%D5^B89=L+5A]ZNS]X R/'W)=PM;DAPN2&V5H=0AU!6I:D!P
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M*<4ISE!T3U)'G2FPK%49!-[EYQ;,5">9Y;:M*Y?Z*3Y$^&_9ND[&9[QU2UJ
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M8';O(=;[ER4E#L=M"E%+3*DDA32-)(/44ZF-XS+[1O$OBR[D689798^+7_\
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M4C>PDE*@%:T2D^RHA%T0JJ\PK%S5IS[[;;2]&:G7")"=E+[MAN2^AM3JNG1
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M4T>9"2 @I UT%$2,R3#[#P[X^\,G</MT2P7"].3X=V@VME,=J9 ;BK<[UUI
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MO$X=[)AIQFV.I.Y%S![U0(UM+0Z_KU7N?CL+X.L-NBE7/W$9IKFUK?*@#?\
M=7+QO]JTJKVNLTRNC1117,6NBBBBB+D[6?!/ZZ.59\P*S%&JIRZ\JR2L4+'W
M9_I']%'=^\UDU1X>=3*+'W8HY/=639JFZA%9RCV530]FJR;WY"KN0Z_X:OT
MU*A82![:J/<3^NKM)/MJG(DGQ_NHI1S*'G5P</F?[JBCP]XQ9#%M_#6\W+B,
MSD[V1ON)O&/28T)!@14M/..2FU,(0MM+/=HYN]Y@0K711%.YCW'2)>Y^/"7C
M5\L5HR1P-66\W)ME+$Q:D%QM*D(<4XR5H2I2 ZE/-K70D"B)T5.GP'4^P5<A
MD[YE@D^SRIDXW:<MST6U3AAN4&V7:<_:8$U#+"DR9[;CB!'2GO>8<Y:7RNJ
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M.MG?A_'W^^O1-!7EGNE<.2XPI@"04%OEV2OPI)97/@8Q!<N*IZ6838*E@KV
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MCY]:RH>0OST??40IE<VRMW9B7=!<G8*XGI0-N1#96VMN.&T>JZ5$A2^<+ZI
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MR%Z\MKLUSM MT]<%"[BRE"9B4I2KOV-*/,T>;04=':5=*;KLS9!CE[PBZQ+
MQE%M>M-U=@W.S9?->ES[9+"$+4P7'''"6^52%H*5J00O:3UU3"9SF>7/\(N+
MAMV67:UW5GC'%LT"XLR5*=A1ES+<CNF]G0; <7^+^2>90(()%$4V_P!8^FN3
MD&66?%/@WX7N,>W?"<YJVPP^KE](DN;[MI'M4KE.A[C3!XOCTKA#VK;)C5JR
M/(;ECV2XK<;A.@WZ[OW$";%DQDIDMJ>4HMJ6E]84E&D'2?5&JUNVKA$#*Y/!
MAR7,N\8JSZVP"+;=I,-(0ZEXJ4 TM(#@Y!RN?+3LA)',=E*>JV\385SXL7S
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MM4['$3&IW9\N?#S+H.4Y'<[$UDAA94F\W9Z2T^S<0B.F2I*U<C:69*8ZDI2
MEM+CG* "14J%)+7A[/*C1\@>GNIF^SA=KIGC>:<09UQEOVK)+TZFPPG7U%B/
M:XO^[,K;;)(07U-NOD@>L'$;\!36]I*X?RZS',;;C4/-KM></LK;DZ5:\P./
MVJR.N-N/M.^JL%Y_DTL\R%H"4H!UL@D4M"C?EO=8UM[\1^BH981=\CX^99P+
MB7[+;[!ME\X5N7V^Q+/<'((N4@.PAS*4T4E!*G%$J04JUM.^52@=)G,\IL.'
M7#ARWF5Y8@KXP(P1G(GYA<N<.U.QT2@TF2O:N])46$.JVH!8T>8 U,I"E/<>
M(<.V\5[-@2XDDW&Z6>7>6Y(Y>Z0W'=9;4A0WS<Q+Z2-#6@=^5:G%KBY:.#5A
MM]UO$.[7 7"XL6F)#LL(RY+\ET*+:$M@@G?(JF8Q_ ('#?MN8G:;9?+S/AN8
M'=I";;>KH]<'(9,R&DK0X\I3H2X4_)*BG;9*0-FNWVU'KM$L7"IVQ1(L^])X
MB68PXLY]3##KNI'*EQQ*5%"3YD)41[#4RJPG$X9\<,;XI7&ZVJ W=K1?[4AM
MV=8\AMKMOG,-N;[MTM. <S:B" M)(V-;W3@G8UL$;\-BHA\78'$GA[CN;\9L
MCN%CQW+7;5;\3MC%@6Y*C62$]<6^^F.O/(1WKJ2\5CU A 0/'9-*G(\/>X \
M3N$R\9R;*+DG);\;#=[9?[W(N2+BPJ*\Z982\I7=NM*92KG;"4\JBDC6M2H4
ME!O7@>GG1U&M@@'P)J"&11\F>[/7%?B8G/,I9RO%<JO;U@6W=GA%AM1[AR)8
M7'WW;S:AS)(<"M)(2GE  IWK+CDSA'VE.&EK@Y/D5XB9?9[J;XS>[J],:D2H
MR8[K<E"'"4LKVXXDI:"4\I Y= 4123ZZ/0Z'B=>%"=J\ 2?8!NH'8[:+E=>R
M!DW%JX<3<L1F%@3>YELN";Z^(\!469([F,XQS=V\%%"4J#J5*4%A(( 2 I<I
MR7..,?&29CLC'\EGVRSXM:+E\"XSE"; I,J:EQ;LAU?>(<=Y%-AM"0KD04J*
M@2004J9H)V /$]-4TU@[03F4R[^_9\$R2[8]:[M\"-WF$(ZQ,E(DB/(+;)<#
M@:95S%3J@ 0VKE!Z;WN!UIS-S@S:+/Q*7(3E0:?A37T34JDK:[U:&7%/LD /
M%GNRI:""%@D:-15P.RN<..S<J[V"]9!%G3.*C=L>4[>Y3R3'3DRFE)"5N%*2
MX@D.* !=V><JW4(I\Z.SH$Z]E(^3Q+A1N+5NP!420JXS;)(OJ)8*>Y2TR^TR
MI!Z[YB7DD=-:!ZBHN9G(SWC)QEXM6R):LOGQ\5F,VBRHQC+F[(BV+5$:?$I;
M16DON+6Z2%.!;?*@)"?E;45GO.767C;@ESS"&R_F\'A!<WKG'C+2M#TQN7#+
M@24=/66DGU>GK=*A2I \6^)4+A!@,_++C#DSH<-V,TIB)H.*+TAMA)!40.BG
M03U\ ?&E@1HD>PD?Q_'Z*\_N(N'&^=BZQ<4;IG>17;*<D-CN,]3]X=7;YBY,
MZ,I4-$,J[EM#95I ;2E:2UU)VK<S^,^96CA_PORO(+[.GVVUPX+I>EVD S&^
M;U$EC>QWO,M(1OH%$;U1$L2"/$$?2*#L>1\?9_'\>VH6</+AE?#SM!P,=7;,
MHQ:RW_#;K<';9DN7F^R79$=3'=RBDK<]&<_&K2>192O?AM%<3%K?D6+]G3@7
MQ:5GF5W/,Y\_'6+@[/O#[L29"FR&V'(SD92NZ("' >\Y>\*T\Q4231%.B0]Z
M*P\_HE+2"LZ]@&_\O_R4F^$W$B%Q=X;8SF4"(_ AWV"W/8C2BDN-I6-A*BDD
M;^@TP%ALC_&R]<8\FR#-<CL<C%<@G6.TQK3>'846SL16&U!];*%!#RW2M3BB
M^%)*"E( 2#2Z[&*M]D_A(3UWCD0GRV.6FJG1/EY>'3VZJA5I).N@\]5$W%T7
M3AYQ^CGBH,O5<[]D4EG&<I@WU]=@ELN!Q4:W/0DK"&%I:! "VB%J;*PX2::N
MS2>,_&?';_GN,V?*WLU3?IS=HN#.8L1+/;T19JV4PG+:7 E390UISO4*6LJ*
M@H>KI,*=5Z A7>$@))/N%6: UL5&J#87>T)QTXJV7)[_ )#;;/AKMNM]NQVP
M7F1;0E3\-$E<UY<=25NJ4M90WS*Y$ADZ&R32BX776Z,]J/BYCTNZW"9:K;9L
M:=A1)LE;J6@IN4EYU()T"LMCG4 -E(W5I1/>MM)5X&N&S?W9.6W"QJLMTCM0
MXK,E-V>92(<DN*6"TTOFYBXCDVH%( "D]34,<)R/*>(W#7LT01F]_B*R?)\@
MBW.YP[BXF1+AH1<%!!=WL^HVD(5XHTE2=%((6V77&ZX/=^T-8;9?KU\'8SPL
MM\BU>DW)YYV,]W5R)>2XI15WI[M&W-\QY$DGH*G,HA2M+(WS'>CTWJK%!022
M-E/AO51&B6"\<-'^SKE[.99/>+[E5TM]GR,W6[O2(EQ9DV]QT_[LH]TT6UMI
M*"VE)'79422>$['N/$C@#Q8XOW/.\IL>5P'<B;M_P=>WHL.QMPG'V6(WHJ5!
MI14EI)67$E:E. @@A)%LRK"F>MGH5$UKCUO ZU2>X33)%SX281+EO.R)<BPP
M'GGGEE;BW%1FRI2E'J5$DDD]232E2P0>M9 ;+&=4*6H) %6B04;WU'AUK.&J
MQN,I"5*/E5A"E6J>2H:\#5%=0 /,5JI]9S?E61QP)Z@]*M"@+%*:(3H'QK0;
M;*%'9Z5M%XO.:*M"K'F4I&PJK!05H24CFZ'Z:QHF >J0.4=-UDD*2A!_G5SG
M76HS*GGW4,-)ZE;JPA(^DFA@"ZD FP66Y>CB.5.K4T#I!4@;402.@UU)\/#K
M1(>?N$1V#Z7W%X:0I49S0"GD #J1K7,/9UZ 'VTU(XH8_C?$FYN')&[DU-BH
M:8@L2._0PXE7RN5 )25))&QYBN[G$V9=,SQRVVU]46:VXB;)D(&BPRG1(ZCQ
M6=( /D5>RO,8RJRH3\%['"8:I3#6DZ"9_P ?NKF[DYGT.X6&6D0<FB-=]ME1
M0B0V#KOFCO:2DZ"D[Z$@^!%<NQ9"YDHDX1DJPJ]):4["EK U-;1KF22/_.1T
M)_I)(4/!6M_B':9U@N,/,[.REYRW/%]<9OHI;9&G6/?S)*M?^FD)Q1LOPW(A
MW_'YA*N=$VW3VU=$J_FJ _FD':3[BI*M]:\S5EAZWN/B.!7=I-%00P^(\#Q"
M:[)%JX'\19-X0>:UW=08NL9/\U9]5#^O('H%>\ ^9KKVI$N-?6'4/,N,1Y1D
M!EPG7J;Z*UUT.9*QY$BE3?8%FXDP5WI+0E"1^)D1T[YF'0 EYE8_FD'FZ'KT
M&NFJ;C#[TW$8N./75*D7F(\Y;UK.R7&]?BW/H4@I(/MW6E!8?<ND((]ZQ/SO
M2I,A]7@ZM;AWXJ))))_73)\:,VNT9A*,0O!A7^#(YT(9/*XTH(VE>SZN_6T!
MY>-.ID?+CEL?=?6>9E)YSO7AX_X5&F:U+N-U7+];O9;RG-D> )\*W\"X4:F]
M<)A<S: =6I[IIB4V6(1N*V,SQ(3'DRT*5SK](F(4I1)V3S%6R?IJ>W9GS3(,
MGQ67,FL*C*BOIBA'.%\R^7F5X;'0%/ZZ89O'TM,I2L**M=.;SJ5792Q]$/A*
M%);UW]VF+ZCR"DI'_P!->EH8XU'V"\GB, *+)E.'&S>^QD\B4,* \"IG?^=#
MG$;)5^J!%'771C_O2F8L:I)&SKW"NI&PR.Z "P"3YZZUV&5'ONN0YK ;)"L\
M2,FDS$1>]AQ%*'1UR)S)V3H ^L-?3X>W5*RT6S)[TK_>,IBQB#I3:;6E"TGV
M'9-=!>)MMR7HS"$IDMZ=9YQL.#0YD$&NY"@*N,!MR.KN9C:=#70+ _F'Z/*M
MUHMUEA/@JPN'LA0#DJ\RIG3^8&D _J3NLEPPB$\R4K3,7H>3ZTD_LZHB./=3
MS*2=]4^PUO-7-^.H?C"0?(FLD#@%BNF_G8[B;+C)?MQ3*9/,VY*6XM23[1S*
M-:,]<!"TJ'</,I\4I !5_P!Z=5]V)=4<LIA#F_Z0!I,W3#+2I948+2DD^73_
M  K4J4B3(*V&/ LD'(BX[)T=.,'WKT*YZ\<L;3OI$=1<5XGF5UI=+P:QN)V8
MJFB!XH6K5:4GAO;)0*6WW4#QY=C58RQT65PX)$3 W(0#%=4TZT0MMP'P(IS\
M3S^-=834>Z(0'= $JZC?M!I+GAU%95RAU1U[35[>&H8*>[44^?JFLM-^2Q"H
MX9DI<AQR%;#+N;$=+A<:*T.@DDC7A3[6Y7/ CJUK;:3_ /**8S& \AMRSS#W
MD>0#Z.M77D7KY/T*']]/M$1W<5I.M:0D?W5BJMATC0HTVA9J**INL*LJT53=
M%$6.BJU0T4(JE5JE%"*YN1V*WY5C]SLMUC"7:[E%=ARXZE%(=9<04+02D@C:
M5$;!!Z]*Z"E?_DI!<?<IN> \"^(>3V=Y$>\V?'I]PA.N-AQ+;S4=:T**3T5I
M21T/C4Z(E?8,=@X[8[?:($9,6V0(S<.+%!*@VRA 0A.U$DZ2 .I/OIK['V/>
M$6.7*W38&((:=MEQ1=;<VJ?*6S;Y"%]X%1FE.E# YCLH;2E*N@((  56*<4;
M-*1B-DN=YAC+KU9D75%N"@'G&@V@NO<@^2@*5K9T-]!UKG8KVEN&&<7^=9+#
MFUINMSAM.OK8C.E7>-M'3JVCK3R4^9;*M>=0K)78I@EBPCX8^ [>B!\+W)^[
MS>5:U=]+>(+KIYB=%7*.@T.G0"D;#[,W#>!;;];6,=*+9?+@Q=9L#T^28WI+
M4CTEM;31<Y6?QWXPAL)"C\H'PI2.\6,09P*)FJ\A@#%9B&%Q[MWNV'0\M+;/
M*?,K6M*0/$D@4D>U#Q!O?#+A(]?L>DMQ;DF\6B&''&DNCNW[C'8='*KIU;<6
M-^6]CPHB7D_!;%=,PM&4RH"7;_:8TF)"F%:P66GRV7DA(/*>8M-]2"1R]-;-
M(;&^RSPRQ#*&;]9\<7 EL2USV(K5RE^@,2%%14ZW#+O<(42I1VEL:))&C75X
MD]H#A[P?FQ(6897 LLZ4VI]F(Z5+>+23HNEM 4H-@].<@)\>M;UXXTX)8,9L
MN17#+K/$L%Z.K=='):/1I7XI;OJ.;Y3^+;6KQ_FFB+;MO"[%[1:LGML2TMLP
MLFER9UV:#CA$IZ0@(>625;3S)2!I.@-=-5BM/"7$['/Q>;!L[<>3C%I78[0X
M'7#Z+"4&@ID JTH$,-=5;5ZGCU.];A[QMP;BI:+G<\6R:#=H=L66YRDJ+:HA
MY>;\:A82I *02"H $ D'5<#%NU5PES6[Q+79,^LUPGS)28<2.V\0J4XH+(#.
MP.]20VOUD;3T\?"B+#Q4X46-&#9PW;N&\;.W<JELR[S8GK@(WPDL)::+B7'3
MR(6AMI!3HHZMC12?6IJN _ "X0.-4;/)&"O\/;3:;/)ML6)=[X;Q=[B_(6R5
M.OO]Z[R---LA#;?>*ZK6=)\Y539S%OA/RI#B6X[+:G7%GP2D#9/Z *9G@1VL
ML*X\-Y3\&3XL1RPSIK3B%ODA4-AWNTS"I2$I0A8];1.T@]?.B)RLYP>Q\2L1
MNF,9+;F[M8;HR8\N&ZI24NH)!UM)!'4 [!!!'2N9/X18=<[_ (?>I-@BNW/#
MT.-V)_UAZ EQH-+" #HCD2!ZP.M;&CUK1X<]H#ASQ=N4VWXAE]MOLZ&T)#K$
M9PA99)Y0Z@* YV]].\3M.R.O6N7$[4/">X1I$F-GUE?BQH;%P?DH?VTTP\ZA
MEI:EZY4\SCC:0"0?7!UH[J5$)4#A=BI=R]Q5ECNJR_0OJ72I:)X$<1P%I)(U
MW20C20 1X]>M<?%> 6#88UB[=KL[J?Y,/OR;.N7<94I<-;S)8<Y5.N*)26E%
M 2K:4CY(%<C\*[A$8][>&?V=2;.XVW+2EU1<!6HI1W:.7F>"BD@%L*!T>O2E
MWA&=X_Q)QB%D6+W>)?+),"BQ-AN<[:^4E*A[00H$$'1!!!%%"K:\(LEERJ^9
M+"@(8O=\;C,W"6%J)D(CI6ED$$\HY0XL>J!OFZ[Z5P>)7!'#>+<BUR<EM+DB
M?:RLPKC"FOP9D8+ "TH?86AP)5H<R=\IT-CH*&N.F /YJQB#65VY[)WYK]O1
M:VG"M\2&6PXZVI('JE*% ^MH== DUJXGVB.&N<YFYBE@S2TW6_MEP"''?V7>
M[.G0TK7*Z4?S@VI7+H[\*(MFS\#<(L*\47#L:4*Q94A=G+LEYWT9Q\$/.^NL
M\[J@I0+B^9?K*T1S';:<:>S3;,@@8?:<;QF*]97>(#.39%!<?_$J;6R^F2\$
M.*T"I:T**&P/6)4!O9KH\+./;+'#C,\JXB7^#;+?:,PO%F;FOH2RA++,Y;$=
MK21M:R E(T"I1]IK)G/;!X=XSP0R3B59[W#R2W6<N1Q%8<6TXY-2V5IBJ"D%
M32U =.9(Z$'PHB6?#[@9AO"U^XRL<M*H]PN24(F3YTQ^=*?0C?(VIZ0M:RA.
MSI'-RC?A7#Q7LR<.\"R./>K%CR[?(B/.2(D9NXRU0HCBPKG6S$4Z66B>97R4
M#6SK6S6:U<8;/GEZX>S,9S>SIM-Y<G(5;G(JW'[L66.92([BBDMEE7KJ)2KF
M2-=/&LU_[37"O%LQ7BMVSJSP;XT\B.]&=>/+'=7KD;=< Y&EJV-)6I)ZCI4R
MHA*3%L-LV$QYS%D@I@-3I\BZ2$H6I7>2GE\[KGK$Z*E==#H/("D(WV8N',>R
M7&T1K)+@VZ=<$W13$*\SHX8D@N$+C\CP]'ZNN$I:Y4DK.P:5/$#C=@'#*:J%
ME646^S7 14S4PWUDR'&5.=V%(;2"I?K@C203T/30W6K*XW\/8W#F'GIS"U'$
M)JDHBW5+W.V^M2BD-MA(*EN<R5#D *MI(UT-6D*L'@NQP]P+&^&%B79\<MHM
ML-Q]<IXEYQ]V0\O7.ZZZXI3CBSH;4M1.@!X 5J/\%L)F6RZP'+$TN%=;XWDD
MQKOG=/7%#C3B9!(7L$*8:/*"$^IX=3ML>)':'M<*V\*LEQK);?\ R1ON4FVW
M2Y/)"6O141)2W4DN %HI<93LZ!&B/.E,CCIB6<\-\QOF&9W:(YLD-XRKM)96
MMJU.!HK2[(85R+Y !SZ.@H Z-("24XDO";).S*WY4_ 2YD%OAOP(TTK5S-L/
M*;6ZCE!Y2%*:;.R"1R]"-FM'B+PSQOBOC:K%E%N^$K:7VI2$)><8<9>;5S-N
MMNMJ2MM:3U"DJ!%<&^<=,,X>PX+&6Y?:HEP<MK4_KS(7*:40WWS3("E*2I9Z
M)3L]?<32GP7B!CG$W'6+[BMYB7VTO*4A$J&YS)YTG2D*'BE23T*5 $>8J(5M
M5K6#AQCV+7U=ZMUN4S=G+9%L[DQR0Z\XN+&*RPVHK4=E)<6>8^LHJ/,37"NO
M9^X>WS"7<2FXTP]85W)V\B.'WDK:FN/*>7(:="PXTYWBUD*0H:YB!H=*<7PJ
MA2#[C[J(DIP[X78WPM@2XF.PWXZ9CPD27YDY^;(?<"0D*6\^M:U:2  "K0'@
M*Z$;"+)$S2=EK4!*,AG06;;(G<ZRIR.TM:VV^7?* E3KAV ">;J3H5V>H]_T
M54*W4(FYS3LZ\/.(.7?RFOV.B9>%QDPY#J)<AEN8PDDI;D--N)0^E))T'$J
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M[B_Q6;X66^RMQK/+R;(K_<$VNS6.$XAMR7(*%.*YG%GE;;0VVM:UJV $^!)
MHB<+?]]&_P#M3)XOVCG7<WR/%LTQ&5@TW'L=_E+<);\]J7$,7O5HYFG&P"M(
M#:B20D@@IY? G1Q+M12KQ?\ #TWW Y^+XSF;PC6&\2;C'?=<=6TIYA$J,CUX
MY=;0HIZKT=)5RDZHB?OR/]]&^H]O\?QYU&:X=LF?'QO*<KB<,+O-PS$KM.ME
M]NWPE';<:3%?+3KT9@CF?2E("U=4:V4@J4DZ6N;=H"9!S1S$\&Q%S.[W%M[-
MTN/_ +48MT:&P]S>CI+KH/.\[R+*4!/1(VI2=C92GC]OL_N_C]5&^OO_ (_C
MSI)<*^)5KXO</K-E]G1(CP;DTI08F(Y7X[B%J;=:< ) 4AQ"TG1(VGIL5'6T
M\6>(^=63M(6G(\:3!M%G1<H<:2F[1W/@[5I9<1&"&T!3G,75.][OIWG+XIHB
MEL""/(C^[[O\*#X^_P#C^/.HM\$NT)=K#@_!6W7_  *Y6O%<D@6VQVO)WI[2
MUN2S""FN^BC\8TVZ6EA"RHGY)4E/-7?RWM;&PG*+S:\'GW[A_BDQV#?,D8N,
M=I;;C! E*C1%>O(0P20M0*-E"P@*Y:*%(0^1_1NJ$>5,Y=>T),=XNR^'^+X7
M,RFX18%NNST]N>S&BHA25N)+I6OKS([L$-C97S=-!)-:65]HR\X%F]L@Y+P]
MD6?$KG?&[#$OJ[U%7(4XZ[W+#ZH2?72PXOETKFY@% J2.NB0GN*:L*-TQ<CM
M(Y+><GSNQ87PLN65R<.NAMUP>5=HT)I[\0V\GT<N EQU06?Q9  Y1S+'.!79
MX?\ :5L7$C*L.MMMM\QFW9?CCM_M%QE*2CO5LNI;DPE-^*7FN=*CU((YM?)J
M940G8*->%6]122X6\3(_%6VWVYP+>]%M<&\S+1$ENN)4FX",ONG'VP/!LNI=
M0-]3W9/@13;.=I3([W=\WA8?PINN4)PZ[R+7<WS=HT1+I;;0X/1@L$NN*2LG
MNSR@:&U;4 )E1"?;QHU3&7?M50)1X<MX=B]QS*3GUFE7>S--2&H8 9#2E-OJ
M<Z-:#JN91V$ELC2B4[W)W'C)+GD=YL>&<-I>63<>2RU?7%7F/"8BS'&4N^A,
MK6#W[R4K25$!*!S)VK9Z%$)YC5BCJF:E=IVUW7#<%NF)6"XY/>\U<?9M-@4M
MN&\A4<*]+])<7M+*6"E25GUO6T$@[%:47M,OL-<3V+[@UQL-WP"Q-7N=#<GL
MO(EI<0^M*8[R!I22EGHL@=5$%(*34A$]_,=^VJ[!%-)9>,&79+A2LDM/"VXO
ML3#%<M$>1>(K"Y49ULK5)>*O_#(0 .B@I9"TZ2#L!,O=K6):>'67Y#>,5F1K
MOB5ZAV6ZV2!.9F$KDK9#3K#Z!RNI*'TJ TE6TE) -7D*+I_R/"J^5,/+[1V6
M0L]<P1[A-<&\QE1#<[1$-[BJB28:5E#KK\E(*8ZFU<H*.59)<0$D]2*N=JR&
M>&=GR!&+SF\BN>2+Q!&-RIC+)8NJ%N(<:=E'\6EL=TI0< /,"D!))U20I3[%
M',.M6%L<M<;#;M?KU8VW<BQT8Q>"ZMM=M]/;F) !TE8=0 "E0Z]0"/,4SER[
M8./6?A7B&9SK)/CF^WM5CD6H/(4_;'&GW&93CJ@-%#!;*E$:Z*3X4E$^Q3S'
M205'W"JI?+7@=CV&F%XN<7<>D3,EQR[8]<+I;\<O^.0'I4.X&,E<Z9(;4TE)
M1I6F>9EQ8)TL+"=>-78GQ0X@7/M6YKA\S&TJQ2VPK:ZVZ+I''HB'5R_][Y C
MG<+W=('=<VV^3K\JKRJPGZ7)"T @[]U6(4D]3X&H7]G[CU=>'/9VPRX7'!KC
M)P>+-=MEPRCX192MAQVY.M!Y$4[<=82MQ"%+Y@?$I20-F9BW/1]H<&RDE)(J
MP*D^*JM(5X>%8U (!.JO#H4/5.Q6-_8'N/E5E5:3JTN$UGBIYE>LKI5OH)6.
M8=-U4-+8Z>(J94+))2.4@'K6BMI2/64="MM*3(YA[.E8GF5.J0R.JE'0'MJ%
M(U6>RQ4JDIE+/XM!Z;'B::G)\]=L&63[2^ZY'5(>!9=)]4;IR,JNJK/;.Y9*
M$%L>*CYTPO%%3.:X\Q>F?4E1%AIT!6] ^!K6J.(&8+I8=@)OHMO'+S'O7%*V
ML/14AYJ2M2'T'0)#:NI'TUV>)*DJ>#:CUZ*V#X4W7"-:VL[L[DA8YN^*-J5[
M4*I0<2+^PQD:D%2WCYH8;4X1^A(->7Q[BX2!JO4X/JON= FXRFWR8LP.*:5W
M+G1)IM>.4]U"<>M*9"F!RJG.=VLI.P>1'A[/6-/1DMZ?NT..W%L]TDE)T%)M
MS_3V>**97B5PUR"[9NQ/E VN&N.TAAN6PX'2E/11".FAS$^-<&AA:M6L6TVW
M76KXJE3I!U0IN[_DDN) :7+F/RTK24(0ZLD!1\"12'@NJB25%?J@J^4>@IW\
MFX02'+9W@NO,MD%:6Q'TE73PWS;IK+/C\F^REL+!9CLD=^\/(?T4_P#,?[J[
M?H_$TWL8YMW:+DC'X=['5&NL%Z/=AUNZ7GA0,AN[ID*D/N18"E]5^CMGE*B?
M/:@0#[$T^ET 3L[Z5%[LO=H6RV7'[1@]U::LR8+8C09&],/#?0*)^2O9\3T)
M\ZDW=GN]CE8Z[&]UZ]F'-!H:O(5:^_>7\TD[RE+JB.AI(7]QBU1%O+T3X)23
MKF-*"XW!##;KKA]5/D/$^X4WM[E-./+E2M2)(.FV0?40?)/OU6I5=UE=@E-)
MQ:X48[Q4QYQS(HSCDM2BW$FLZ0]'/CZI\.7?BD[!_OJ#?$O@[?>%5Y2B:PIV
MUE)[BYLH/<O ^&S_ #5>U)_1NO3"](8A6Z+WZ/2+AHJ:95\E*E>*B/=7!NUC
MC7:V^ARVT2FWFRAYIQ 6VX#XA23T-;V%Q;F=4Z+5Q&':^XU7E@[;1*6IQLK#
M@\1OIKWT]W!'"&K5B[B;L@Q'Y,U$A(<!3L)T4>MX$&G"XK=E'T9+TW#5!M)!
M)M#RM)/N:6?#_I5^@UDP7)"YBT2%=(SD*ZMI4T]">3I20R "%)5X'0_OKN![
M*@D%<4M=3,$)F<AG"^W*XW!EM*DIEN<W*0I"0A925*'LT>E<IV$),8L-A:BL
M+9"$'UWU#UDDCQ"?H]E3?[/O!O!LT[/EJNMPQV+,>O<F9/[Y22VZ@+?6 A*T
MZ.@$CI2>SCL:VFX+><QN_P BTRU\J@S<T]\D\O@E+HZI&NG@?*MZE4:YH!U6
ML^F^9 4)I<54GOFT-EQQ;29"(S.TM-J3X\W3J?#]=:[X7+<DM-M^GN+;3):2
MVGE9:4/'IKKKI^OV&G/XF\"LTX=MJD7.P.OV:.Z5-NVK<IM:%?*YEH3M.CUT
M130S'E1FVTR24-Q'N5,&..JFE=>I"?+?]WOJQ"-Y%;;RFKE(<:)]/<F,<R6V
MD\C32P.N_5Z]-?3XCJ:UVIJ1<;=+[UQV:M/=%N"2R6UCY.W$@>8/7P]OA6O+
M;,2,IF8@QVX;_>-064'G4TK9(*@GV;\/82/*L<J&Y'CS8^_@U@E,J/'2WS.N
M$^6^3QV/H.]>1JL2L@3G8CVE^(>!MN-IOYNGH[G(8%P;+QY1H[[S?,- ^!)_
MOJ1_#WM]P6"Q'R^Q.6I2T!?I,=?>-:WK9UU'Z1[>M0F94IIU#J6_@RW3V.KB
MTE2EA/7?5._/Q\1X^8K:AE"(+<AF,X%1E[=DK)]97\T$%) (!'71 &O,TW37
M*^\<W6Z]>,!XWX1G\-+ULO,9\*&B"L'1]FZD['908[1'4<B=:/NKY_8J?@>X
MNRH<R0J06R0_:U*9<+I'JIURCKKP0?:":]]\76I>-6E2^8K,-DJYSL[[M.]U
MQ-I4C2#3.L_X70PU05)LM_N$>_\ 71W"?(FLE%<25O+(CU4@;\!JBJI(T**J
MK0KZK1112DU.X:8G<\T@9?+QNU2<I@,J8BWEV&VJ6PV=[2ATCF ZGS_G'VFE
M+111$4D>+^+3,YX3YICEN+2;A>+)-M\<OJ*6PX['6VCF(!T-J&SH]*5U8)TY
MBV0GY<IU+,9AM3KKBO!"$@E1/T &B**MLX<<?\KX36KA?<V</P#'D6ABQW&_
MVNZ2+G<G8J64LN>C-*8:;:<6D$!:E*Y.8D D"L7$;LE-67B):<DQCAUB?$3'
MVL<AXTO&LEE>BK@IB%8C/1GU,NIUR.%"T%()Y$$'Q%/)PY[3G#3BW>VK3B63
MMWF<['5*;0W$D(2MH:VL+6VE)'K#SZ[Z5G8[27#.3Q$.#-9C;EY.)*H7H84K
ME,E*>94<.\O=EX#Q:"N?W41:6'\!L0E\.+)9,LX9X0T8JG9/P+$M[4R!#><4
M2KN2ZT-DCEYE\J>8[Z:U6&5P?D1>/F"Y/9XENMV*X]B]RL@A1P&BRIYZ(IE+
M324\H0$QUCH1KH *4*N.N"(SY.%G(XPR)4CT,1N1SN_2>[[WT?ON7NN^[OU^
MZYN?EZ\M*2VYA9[OD5WL4*>U)NUH2PJ?&;V3&[Y)4T%G6@I24E7+O>B"0 1L
MB95?"C+,>?XVSF,:QS-&,QOT6;'L-YFEJ/+AI@Q8SS;JBRX$KVRLI!2I)Z;U
MOHV[790S&Y<!\ZP\P[98[7?[_:I]IPE=X>GPK-#8D1ERF4R%H!T[W3J^Z0D(
M25!*2-DU*_-\ULO#G$[KDV13V[99+7'5*ERW 2&VT^)T 23Y  $DD  DUCP3
M,F<^QB)>X]MNUH:D\W+$O<!R%*0 HC:VE@*3O6QOQ!!HB9C#N%^?\';!E&$6
M"WV'-N'[<4KQ>#?YJF'8C:EZ<M4@]TX'& @J[IT@J2-(6E0'-67LO<',@X8W
MK,)\JS0<%Q>[&*;;@UKNSEQBVYU <[]]"U(0EKO>9 [IM(2.[WXGI('=&Q[:
M(FMN'#>[RNTU8L]0J-\!PL3G65U)=/?^D/3(KR-)UHIY65[._'73K4?;]V=>
M+[? 3(>"5GM^++QU-R=EV[)9-U=2\_$7<O31'7&#![MT<RD%SG4G21H$GI*_
M-N(EEX?? 7PR^XS\-7:/9(?=M*<YY3Y(;2=?)!Y3ZQZ"MG'LTM.47*^P+<\\
MY)LDP0)J78SK00\6T.:2I:0'!RK3ZR"1O8WL&B)$X9PVN]A[0'$[,I1BFSY%
M;[+&A!MTEX+BB4'>=/* D?CD:T3OKX:ZLOC'9PXA\-<6X5WZQMV6ZYCA4N_H
ME623.6S%N,&Y3''BE$GNE%MU #"@2@IWSI/D:EUL>VC8]M$439G ;BAFR.T'
M=<B:Q^W7'B%A\:R6BW0I[CS<%QMB8WW3SI:3S>M(2HN)3H\R@$Z2"IQ\7X0W
MZS\<L9RV0J'\%6[A^,:>"'B7?2_2F'=I3RZ*.5M7K;!WKI3UT;'MHBB3?.SK
MF%IBW:]VZ?8X^51>*<C-\?BSY:DQ;@R[&#!B/+"-MN+;4]HI2OE*4GJ-U=PV
MO679;VY'IF3V^TVB1:^'[D=ZSVB>;A\&EZX,J;$B1W: 770RXL("1RH;!VK9
M-23SKA_C/$W'W;'E=C@9#:'%I<5#N+"7F^=/R5@'P4/(CJ*;;AMDG"'ACB]Z
M3AMGC8W:(63'&YR+79W$ERYAQ#/KAM!4OUEI'>JV .I( HB[/&'AO=LZS3A/
M=+:J,F-B^2JNTX/N%*BR8,ICU  >97.^CH==-]:0L+!>*O!K,,\_D'9,;RW'
MLON[E_95>+N[;WK3-=:;0\EP)8<[]@J;2M/*4K&U)]A$A&Y\9Z8[$1(:7*92
ME;C"5@K0E1(22GQ /*K1/CH^RB5<(L$LB3(:CEYP,M=ZX$]XL^"4[/4G1Z#K
MTHBCCA'9AO'#^Y\ VX]PBW2+A)O<B]37"6ER),]E96MEO1]4ONKZ$CE3KJ33
M_P"66MZ]8M=[?'Y!(E0WF&^<Z3S*;4D;/LV:ZVQ[:K1$T'#KA;DF+=E:P\/?
MA9NT99!Q%JR)ND-:G$19:8O=)>0= D(6 H= >GE3"\+.RIF-DS[@Y?)6"8-A
MXPV3(-ZN-KN#DVY7M2X+K'I"GUL(64EQ846UJ425%15ZNC-C8]M&Q[:(H;V'
M@SQSQ[@C?N$D:#B*+=D#]V;&3FZO=Y:XDV6^MP&-W/X]T-O**"'$)VH!7R-J
M=S"^"LS"N.HR"(6#BT7!K=BT1*W"9(<C27E^LGEUR]VM'4'J=]*>P@&L90/(
MCZ/*I4*(V9\.493VVHMGMTMMS'I<*WYEEMO3M0$R MQFVE1\!WRE-J*3U(@)
M-22XDX_=LJX>9/9;%=E6&^7&V28D&ZHWS1'W&E);>&NNTJ(.QUZ=.M&&\-L6
MX=&ZG&L?M]B7=92YT]R$P&U2GU$DN.*\5'J?'PWTU2C]WM\O^U%"AQPJ[+^5
MV#BEPAR9[ L'P>+B(G-7AZS7!<VX75QV"ME,A;ZF$*4DK.^1:E*]8J*MC14S
MG9ORU78CE<*.>V?RI=4\4J]*7Z+ZUU5*'XSDW_PS_1^5T]]2BZ>W]-4_S_O_
M ,C1%']S!.)G#'C!G5[P>TX_D^/YQ)C7!U%WN;D%ZT36XZ(ZW"$LN=^RI#3:
M^5)2H*"@#H["J[+G#._<(.!]BQ7)I,.9?(;\YV3)@*)9=+TUYX*3L#6PX"4D
M="2-G6RZ^ZX8S*U'-%8J'W?AM-O%T+7H[G=^CEPM!7?<O)S<PUR<W-KKK76B
M)M<%X'BT\=.*N;WRU6>:C(+A;I-FDK:0]*80Q :8<V5(VV>\;) 2H['7IX5J
M9M@.<8CQJE\2<#M]JR9-YLT>S7FPW2XJM[@,=UU<>2P_W3@V ^XE;:DC8Y2#
ML$%\.F]>W^/HI X_QQQ')K#C%X@S93D')+D]:;:OT%XER2TMY"TK 2>Z2#'=
M]=>D]!UZBB)G9O9NR^\87=IEQDVDYKDN>6G+;HS&?7Z%#CQ7XP$9EQ2 IQ26
M(P]8I3SK4>B1JG/<X<7;\)-&= QS8TXFJR\O>'O_ $@S@_\ (UKDY!X[\>FO
M.G0WOJ#^G_O]]!]G]U3*@B5"?/\ AOE?#; L$M:';8C(9G&=5X@*=6MV-R2)
M$M]E+N@%#:#RJT"4D[&]=7(/"/+>,&=3LCXC0K;C%O:QB?C%ML]FN1N#P$[D
M$J4X^6FT@\K:$H0$]!LJ/75/M>K38,GDQV;G&A7.19I+5R9:= <<AOI"NZ>"
M?E(5KGY3].JP8CDEJSW%[?D%C>>=M4]KO8[DF.Y'4I.R.J'$I6GJ#T4!5I58
M(T4:>"'9TN&"W'$K9>^$'#3GQ\M)<SF%*)E2PRCE:D-Q#'"FY"B$*45.Z2>8
M@GH*='C_ (+?K]=>'V5XB_:G,LQ2[N3(5KO,DQX]T:>C.,2(X<"5%#A;45)4
M$JT4=1HFG66TIOJ1T]HZBDUG/#S%^)ME%HRRP6_(K:EU+Z(MQ8#J$.@$!Q.^
MJ5 $@*&CU-(2>:C98;'?N./:)XMV;+VK=:D2N'+&.RXMBF&<+09,B24MN/E"
M$KD%)4Z4A*0$E Z^)[W!+L^7/#KUB<:^\'^&\)ZP<O?9G;)97)EK:04MOL1O
M1TEIQ1Y5*YG"$[5KFZ4_F"X+C'#*S&TXKCMMQRVEPO*CVN,EA*W#XK5H>LH^
M:B=^^E,EQ"_DJ\?+^/\ O474R%';XA,G3V9N+&!<UO-\RB7D;T%0D'N F=(=
M<8[Q?+M)Y5CFZ'1WXTF\X[-,YGBB[F4?A_B'%"/=K-;[?/M>23/0WH$F*A2$
MO1WBRZE3:TJ 6@I!VVE0)V14K_\ +^[^/T4F\ZSNR\/;7#N-\><9BR[C$M;2
MVFE.$R)+R664D)Z@%:P"? >)J46OPQQA&%X%:+.FR6;&ULM$NVO'P1!CN*45
M+2UM*21LGJ4C9V=#=-+\5.<V_(..MIBV^T2\:S]N3<8-V7<E-R(TMRVM0Q'<
MC]T=IYFN;O0OH#\DFI J9*20%=0? ]:LVI/B-@>8ZTA1*9&]<%LAN/##@;8&
ME01/PR[V&=<RI\ALMPXY;>[H\OKGF/J@@;'LILV.RC-Q/),K@L\*.'G$*T7N
M\R;K#R#(I?H\F$B2Z776)#(CN%X-J4L(4A8YD\H.B-U+L.@U<' ?.D)*;/#N
M&$[&N/.:Y7W<-JP76PV:UP66%'O$*B*E%P%'+I*=/-A/4[T?#51J;[(N?RH%
MIA7#&,)DWZV9A#OL[B%*N#DFZWJ.W/#Y"0MGFC+[O0*>\*3R!"0 =B<04#6.
M-.CS2\&'VGRRX6G>Z6%=VL:)2K1Z$;&P>O4=*B%*B?PWN/%&U\1N/_\ (.QX
MY?HTO-G6D*O-S<A*M\H6Z'^.6$M.=^T04'D3R*!0>I"MC3XP\+9W ;LU\+8&
M,7EF5Q*Q6[Q8E@ENM\IN5PG*<8E-A ZA"Q)>=*?YH9!/R=U+&TXY:;!)NC]M
MM\: ]=)1G3G&&PDR7RA*"ZO^DKE0A._8D>RN?,X>8Q<<U@YA*L-OE91 CF)$
MN[S 7(CM$DE+:C\C?,KJ-'2B/ T18N&F P.%O#S'L1MA*X5F@M0D.*^4Z4IT
MIQ7M4M7,LGS*C4:N%TSBI#O?'5G!+-C=VC3L]N;3$J\W)R&JV2/1XR2ZM"6E
M^D-Z*5!*2A0*2-Z5L2[V->ZDM=9.)<'\:R;)I:86.6="WKW>)B&^4+<Y1WCZ
MPD$J60A(Z=3H "I1-/@'9OG<-LJX,B#,8GV7"L5N=EFRGE%#\B3(,50=0WH^
MJI33I/7U=@=:RM85Q,X2YWG4W!;-C^6V'+[G\-I:NUW<MSUKG*9;:=YM,NAY
MA7=(6 GE6#S#KL$.-A/%ZR9S+@08T2]6NY38+ER:@7FT2(;HCH=#16KG3RI)
M404I)YBD[ U2PB3(]P82_%D-2F5; =8<"TG1(.B-CH01](-$48&NS[E'"NU\
M*+EB]PL^19GB[EV5<+=<Y)@,7I-R7WTWN%\JRTI#O*I&TJ'*-*\=TE+!8<OX
MQYEVHX$I-G9O5SQ:WXZS'@2U/0X,I4:84Q5R>0=XX@/-J<4$#E+H 3TZREX@
M<+\0XIV^/!R_'+;D42,[WT=NX,!SN7-:*D'Q2==-@^%;>(X3CW#VPLV7&;);
M\>M#2E*1!ML9+#25*.U*Y4@;)/4D]34A0F8XT<(<ERK"N&\"WV^UY+%QR0PY
M><4N=P7#AWAM$0LA!=2A0/=N:<2E:2A12-CPIO(/9=RYG%N)<%FTXICJLERB
MP7N!:K&\6X<2/#7&4\V=-)]<!E?K!([Q1WI.^DGLOSBSX7*QZ/=7W&7;]=&[
M/ #;17SR5H6M*5$?)'*VOUCTZ>^L=KS:RW@W_N)G=(L4Q4"X.RVEQVV74H2L
MZ6X$I4GE6GUTDI\M[%7@*J3%SP6YS.T7:<X08_P)%QB;9W 7"'N_=F,O(TC7
M5/(VK9WXZ&J;R-P@R2P\/<QL<S"L8XA1,@S*Z7A^R7:Y=PTN#(<YVE!:F5I#
MR2$DI(Z==*V!4ABWLCW50]/?5H4)KNSQP^OW#+AVJRW^6%N*N,J5"MR)[LY%
MIAN+!9A(DN@+>2T ?6('RM#H!3?)[*TJ[<1>*2[S*B*P6_P;BFR0VU%3T67=
M&V4W!Q2=:3I<=)1HG?>+\/.13J]*]GTU5#G,?&IRJ)49[;V>LV>X$P[/?)5K
ME\0+AF-ORF_2FY"O1W"Q-86H(64[44QX[:0-#:M^&]TX+6&Y5CW:8NV8V^!;
MKGBN2VFWV^X//3RQ*MRXBY*DK0UW:@^E8? T%)*2#Y>+K*4$GQT36/F ^BD*
M)4<SV?,I/8T9X7!=M_E.GEVKTD^C=+IZ4?QG+O\ X?\ R_*Z>^I%RCSO.+'R
M5+41OV$UR,=SFSY/?,FL]O><<GXY+:A7%"VB@-NN,I?0$D]%#D<2=CPWKRKL
MN!*Q5@A6'HR@J'C6%=Q2L GU2?.LY(UR]"*T'F!O0ZUD%]50E=%J5T\>E8I+
MI6WL#K7.6M4=&QOZ*M3-4XWRD<NZ0IS2M^#)]8HUI1-9R\F"AR6O04$D()\A
M6&&SI"W-==!*3]/_ &I,YU>Q'AJ;21X<H%4<5L4VRDIG5]?>2]W+J5+&QR[\
M=^-,Y'O+UKDR$+/-%DI4TZV?#P(!_0:[=_E.&8>1:E#P'MI)3677GFXZ?6<=
M<"4@>.R=?YUSG.-1\-7=I,#&W4FNS[#@7/AXT^NVQO2&93K/I"F$E:P""#S$
M;.N;6_=2AN[:F7W5(24CEV4H]4=/"MSATE%OL"HB$I2U'Y4)"1H=$@'^^BXR
M \Y*V &V0>96O=LUF<S+9<QM3,XN/%)-$EYQPG?,D^.SY4S7:1MBC/QV9SJ2
MA1<CKY3]"@?\:=N+/<<0ITCN&@=;(%-5VBIT=FU65R1)0R?2E<I<\](\ *Y^
M%!WXE;N((W)A-I.9;>A++8 ( WS>!]HKBYMPV;Q>.YZ%&6W'0I2N5?590K1"
MR1XD[KKKNL*5"6AMXN$H\$-'[JD.O'H&>8#;%J*42G8+?([KS*!L']/ZJ]E3
M<QL%P^B\O4SF0"H.2(06/$$'QYAL4ZO##M17'AFY%L>0]_>;&O2&P#S28J?Z
M22?E(']$G?L/E2>SC$GL9F/,J:(>;4I);UYCS^@^--N;:A4P.+VX\H\[BCU/
MN'NK8J!K>J1*QTW9KJ;MRR2WY-:F+K8[@U/M;WK(6T?YWF"-;2H>P]1NDVA3
M8?2^])"%HWR!"=\OZ_\ &HW\+^([W#[(5)E/*%GN"@U)9'4(5X)= ]J?/V@G
MV5(2Y);90E]'KMN>L.4\R3OP(/F#7#Q- #K!=2E5)$+:])MA>WW+TQY73G<5
MXFMXQ;8GHZP&UD=0E1I-Q)X<? Y0@#PI7VR S+ 4!I1\=UH,87&RRN*XTVV6
MEY!Y>]U[ H^-(K/>&EMRRV.=X7(DM3*V6KC'2.^:V".O])/7Y)_1JGC_ ),H
M4>H -<:[6IR+S)_\OS(K:#G4[K$6AUBE%@<"T)X=V2V6N6R'[7":C/1D-A "
MDI 4L(\@2-['MK1N3"F'5!YH+'DI/44AS#<ASF9,=:VG$JVE:#HBEC&R9JZ,
MI1) 9E#H2>B5GVCV?173H5QQ6O4H@:)-W*,ZUS&(^MKKLI!_NU31YUP9PWB
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MC[,F%9B#)LRI.)SEI*5FVK/<]?'F:)UX^S5-7>NR-GV&0B<?BQ\C8:=[YJ7
M>=$A"1Y%HGF.@.4:WK=;5*HTV*P/ID:)HXT:6NTO]RRRT;>VMQ:D+2'%*Y5'
M0(6"0.I4KQ\!JO?+$EES%;,I7B83!.O_ -&FO"2_6UVTN-KOQ<5(>0M4N*]S
M,K;*4'2"%HZ)1TV>@4?'Q->[F*+"\7LZDG:3"8(/_P --<[;%FTQ[_\ "V<#
MJ[[O\KJT53=4*M5YE=99T[T**HCJD'W455666BBBBE%%%%$17 X@6"3E6"9'
M983Z(LRXVV3#9?=!*&UN-*0E1UUT"H'I[*[]<[(;.,AL5PMAF3+<)D=QCTNW
MO=S(8YDD<[:_YJQO8/D0*(HW<.<RXA\"[K@'";-+7CUSB7"RO6['+UC;SX)?
MM\,+[F2P\#KG:05!:%$;200-BFEEQ(S7^RRQ.Y05!R\ICV>]1Y7B[\+.71EQ
M3@/CWBGUK!/CZROHJ4>#=G:VXIF<3+;QE.3YYD<"*Y#MT[)YC3HM[3FN][AI
MEIMM*EA*0IPI*R!KFUTKD6OLCXE:LBARFKMD+F-0;LJ^P\,=G)-FC3BX70\A
MKDY])=4IU+9<+:5GF" 0-$37\7.'V1<+T.N-7&UW>PS<Z3DUCL[;"T76XWEY
MTNL6\KWW:61(VXM_Y26&U@ITDJKO=G7B;"Q1FR6239KM-8RR]3V%9^\6!'OM
M[0'525]T%EUII7HKZ&"I.N[CH3T'(5/O<>'%KN_$.SYC-<DR;C9XC\6WQW'
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M:%#0!&B 0KHW9HQ.)@?\E@Y='V';['R2;<Y$SO9\^X,R&WP\^\I)YB5-(20
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M!4H@J/*.M+9YP(5S)5XUE:("QDKH$!:2.A^FM=QQ#8UT K"W+/+[31'9,J2
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M=2S:)G)DE#A(\Q[*T6[@M@D'UT$^!I\7)MJ6@H^#(:FSY( !I)WS![->5*5
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MBZEH@$)<)+@V!L+"M=:E%/\ MN2VB\N7-NWW2%-7;)"HDY$>0E9BO)2%*:=
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MN,_B.,VLL2X.J<A36FT10F/*Y4\R$N!IY"N793S)5U\*[G"SA-<,7:R:]P.
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M9!YEQX8VZZ1Y$^"4^\UT\PN[=J=<6/E.=1H^?G347_(5ON%II.E.'8:1U_\
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MC]%6&V?_ 'P_LUOT5.8I 7.<M/>#7>D?^FL)L /_ )ZOV1]]=>BI#W!5R-7
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M %5&'XAL._JL=^PXG^IH^(;#OZK'?L.)_J:2[N:GY7\R9F]MOX_D4GN8>_\
M51S#W_JJ,/Q#8=_58[]AQ/\ 4T?$-AW]5COV'$_U-)=W-3\K^9,S>VW\?R*3
MV]^W]55J/V!\'<7L&8VFXPN';EJE1WN=N:;1&:#)Y2.;G2^HI\=; /C4@!X"
MIDG5A;_^V7_^7.'G/@K @Z$'W3_D!5J/?;2[0Z^ O"\FU.I3E5Z4J);-C99T
M-N2.7SY 1KVJ4FI!.+#:%*40E(&R2= 5Y/<=.(\KCIQ;R[B,(RIV#X5W<* E
M71IQ1<*6 ?\ ]*Z%.'_E2D>RN[L?!MQ6(FI[#;GQ/ ?>5S-HXDX>B<GM'3_)
M3A85PTO_ &5\$Q[C1=K[,>RZ\7R%'NEM5(YVO09"CWK<@]2X\04KV3ZB@-;T
M2?1]*MBO&&=9,OS;%6[]DF1NQ;=.EQTQ+:%'3RUNA"%):!"1H*44D@G0/MW7
MI%P-[,]\X)9&N>CBCD&36EUA3+]GO"0XTH_S5H45GNU [ZCQ!(/EKK;;PS6@
M5*M49[Q8W%H%M(7/V7B"^6TV=41-]#>_C*6LGCG98O'6'PP6R]\*2K6NX(E@
MCNN\2=^C^WO.[VY_TZ]HI2/\3,0BW06U[*K*U<2ZMCT1=Q9#W>(3S+1R%6^9
M(()'B 1NHY9;P*SB[6>SYW9YR9O$>#DPR0V14J.(J0X4M.1@^$A6A%2VCJLI
M/)X=16I>>S3D5UNU\FOXU;Y:IW%*'DI4\\R5.VI#:0OF)]A"OQ9\=GVUQ_LN
M%=']2+0;\9UOPO;[UTM]7$]2>7N_=/S>.*K,MW$'\3N&.7ZTW>[>@2)AO32
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7T51]=[Q!5FTVM,A%%%%:ZRHHHHHB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm2128727d1_ex99-2img015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
M'0 !  $$ P$               8!!0<( P0) O_$ %\0  $# P,! P4+"04&
M! (#$0$" P0 !08'$1(A"!,Q%!<B05$5,E-687&1DI25TA@9(U57@='3U!8S
M0E*A"31B<K'P)(+!X25#-F-SA+*S\28G*$9V@S4W1V5UH[3_Q  = 0$! 0$!
M 0$! 0$          0(#! 4&!P@)_\0 0Q$  @$" P0&" 4$  4#!0    $"
M Q$$$B$3,5&1%!9!4E.A!15A@:*CTN$B<;'3\ 8RP=$C,T*2\0=BPA<D5'*"
M_]H # ,!  (1 Q$ /P"\4I2O[0?R04I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%
M*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E*
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MK\E;C=J+5O(NS'=['HYIC<G,1M5AMD9^Y3;:E*)-RFNIYK<<<()\-CM_Q>P
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MMPG4/?;YH]9RONE^I&E>D&G^*Z.W:PXH9]J:O&17F1=X\&XSY;H!"=W-U!I
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M!MX%1Z ;J.P K/MQUJSC4?M;XO9,ER.5=[59L^";?%>0VE,<)F%L<2E()V0
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MB[ZVLDNQ-:O@M^AZG4664I6NU;2]W_HPK6?NR7J+CFGR-61D-V9M1O&%S+9
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ME*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E
M*4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*LF99,SB&-SKJ\@N]PC]&R#L77"0
ME"!\JE$#]]5*[LB-V5V0[5[4%^QV^5;+.[PN?DY=>DIZ^2H._';_ (U;'C[
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MJHU9V/5%YE="E*5#0I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E
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M!M:;M'8E.EV0C&\\@%9(C7-!@.@>'/JMH_2E:?\ ]Y6P8OT4CQ7]6M2[C)7
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M*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E*
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M)W'$@=2K< >O?< X"[,&JFE>I^0^YUW:D6^^K?VM]OO:D*C.]?1 <2 E;O\
MPJ W/@":O^:8)?\ 63,+YE.1J19K3;8CS%OMLAQ+K(:1N1Y0E7Z,H41R6#U/
M@"-@:U"MFFMHU.LS608E%F6:*J>8LVS*"G6TR&D=XKR)[?DXV#Q*D*])O=/I
M*!!KRT\-0J)SK1U6Y_S^?D>B>)KTELZ4K)[T>Q<*"VTUP4C@G;;9'3;;U?\
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M'<5R/0O\X7IS^I\F^RL?SJ?G"].?U/DWV5C^=7GI2G5W \'S'6''<5R/0O\
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MVZ^RIIB7;4T:P.U)MN.X?>K-!3_\F' CH"OE4>^W4?E)-:'%0'B=OGJNX_\
M2NG5[ [DGS.'6''=K7(]"_SA>G/ZGR;[*Q_.I^<+TY_4^3?96/YU:*IP6YJT
M\5F@,?W%3=!9R.\_3=^6B[[S;WO$>._CZJCI4 "=_"L1] >CY7RWTTWFY>GO
M2$;9K:Z[CT,_.%Z<_J?)OLK'\ZGYPO3G]3Y-]E8_G5IS=M!\GLV.S[U(-O\
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M\[#OT3$>&^3_ )VG:[-^6VG!-<L0O]]EB!:8,I;DB2I"EAM):6D$A()/50\
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MG:M3+OF+>.6M+MR@QX"X+#CK+;*&0V!W2TJY)2KN@%(ZI4E121M41\QNH_Q
MR?[H?_#3S&ZC_$#)_NA_\-%0]'J+BLMMV_C9\?8-OCVU)YK[]W#3A[2[/:X.
M3,VR&^2L7M+MNR"WMVZXV)MQYJ*MM ;X%I25<VN*F6RD).R=MO"K_:>U7D5D
MCP;?"MD1BP068C<:RIDO&*TJ/.$M+@!43R)2&R2?>_+4*\QNH_Q R?[H?_#3
MS&ZC_$#)_NA_\-:E2P$TE)II6[>&[MW^W>2-;'1;<4];]G'?V;O831OM27R-
M$L/DEL1$GV:W2;=%EM7&1LV'FEMEU#7+@AP<^7)(W)2-^E1C3K6FY8"<K4Y%
M7=W,D92U,?7/?C/;A:EE7>-$*/(J/('H?772\QNH_P 0,G^Z'_PT\QNH_P 0
M,G^Z'_PU52P*BXIJS]OMOQXZDVN.<E)IW7L]EN' F=@[3UQL#F.AK&[=W&/,
MNQ;6AF2^PY%8=C=R^@.(/(E:OTW+Q2O?;8':NFQVB7X]PLUS_LI:Y-YL<QR1
M:KE,E27G8S3D@OK97NO9X%2W!S7NH!Q77?8B,>8W4?X@9/\ =#_X:>8W4?X@
M9/\ =#_X:SL<!>]U_P!WY^WMN[\;NYK;X^UK/_M_+V>Q6X61W[SK*[<$S(L'
M'X%GM+F.NXW&@,/.N",PX_WZW M:BI:RYR/I';96WJ%7&Y]HJ]W.TY+;U6V"
MVU>G(J^:2LKB=TTRTXEHD^#R([07O[.E1_S':C_$#)_NA_\ #3S':C_$#)_N
MA_\ #6\F!TU7/\GQ]AC:8[56?+\UP]I>LUU]NN6ZL6G4%FWMV^\VYY$A#;DQ
M^8TI:'"L#9U1*$=2."=@ 3M7?8[25TQ^W2K=B5CA8=!=B2F&TVR2^IUEZ0ZR
MMV0EU:BHJVCH0$^]"=_7UJ+>8[4?X@9/]T/_ (:>8[4?X@9/]T/_ (:SLL#E
MC%M66[7[Z^\NUQR<I).[WZ?8EL;M3YA#N+$M'=.") M\&''?<6XS&\E<87S2
M@GQ=,<<QX>DK;U5UT:]QH.)9!C=IPN#8[3=WDR7&8-UF) ="2-U;K/>IZCT%
M>B.*>E1GS':C_$#)ONA_\-/,?J-\0<F^Z'_PU-C@%N:6[<[;MW;_ #WLNVQW
M:F_=QW]G\]QW-7M:;MK/+B3+W%91,BORE-2&W%J4&'7 XF/Z1VXMGD$GQV5L
M=]AMCVIMYC]1OB#DWW0_^&GF/U&^(.3?=#_X:]5*IAJ,%3IR22]J/+5AB:TW
M4J1;;]C(32IMYCM1_B!D_P!T/_AIYCM1_B!D_P!T/_AKKTFCWUS1RZ/6[CY,
MA-*FWF.U'^(&3_=#_P"&GF.U'^(&3_=#_P"&G2*/?7-#H];N/DR$TJ;>8[4?
MX@9/]T/_ (:>8[4?X@9-]T/_ (:=)H]]<T.CUNX^3(32IMYCM1_B!D_W0_\
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MX7S!CLD.]YOZ)!'$["+W?M"/VZ.W?H5L@9'/-@;D(3;+Q(1!=6N[-PRT$.(
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MJ\]G:7>KYE$\Y!#M;-Y4T3#M5M6RTZIN:S)0_)07U(=?2ECN@ZA+9(6HJY=
M,V4J61;F$)79SGW&1;K;+RMM>&V^ZW.Y,6IJV\)13.9EMNLKD]X00@S72A00
M#ML%;D;U\8GV:?[.8_ MBYV/MN0)EJ?:GVC'$09$AN$^ET"0H.JYK<X)!*>*
M0=U!/789RI2R%S%DC1B6WES>10+\TQ-1E#V0=U(@EUM33T%$-V.=G$GEQ1R2
MX#T.P*2/&\Y]I]<<DR.P9#9+K!MUWL[,N*VB[6XSHKK4D-AS= <;4E8[I.RT
MJ]Z5I((54ZI5LA<QAHIH[+T:1=H35]8NMIG/B:VT;:([T=\@!2$J2X4^3I"0
MEID)'=I''DH 5]XUI?D.'SEVVU91"_L*N6]*%EFV?OI3+;JU..QFY(>2.Z*E
MKVY-J6D**0H@#;)E*ED+F'+=H7?(UCM>(3,S;G:?6QU@L6TVH)N#D=A:7&(K
MTOO2E3:2AL%26DK6E !5U43]2]#[\FUWG%K;F;=OP&[OR7'[:;2')\=J2XIR
M3'CRN]"4-K4XYL5-*6@.$ ]$D9AI2R%R :KZ8KU#Q"-8(+MKMS+*P4.3H#D@
MQPELH;7'4V\TMEU!(*7$J]1'KJU6/0]RSY?;KZ[D;]R>B79JZK5*8!>D*1:!
M;CS6%;<E$%XJ \24[>NLJ4JV1#$6-Z)7C!KW%N^/9/$9FJ3)CST7"UJ?:D1W
M+@_-;X!+R%-N-JDN(Y;J2H'<I! IIKV?XFFV62;C&-BE0?*ILN*ZJQ(3=FU2
M7%.*0N;S/-*2XX 0A*BDI2HGCUR[2I9%N8QGZ:Y2]JVO+V,@L;\ )98C0;I9
MGI#\&.$@2&X[J9*4(4\>14ONRKJE)Y)2!7SIQHS(P6[V-V7?A=[9C4*1;;!$
M$+N7(T=YQ"E=^YS5WRPAIMM*@E X@D@J5N,H4I9$,+2^S!9[KA4*S7"\W47"
MWF[F'<K9->@]UY>\XZL*;;6 O8.)3U/4)(Z!1%3+2O%;Q@UD1C<R0)EFL\6'
M!MDMYQ3LJ2$,#OG75*4HC=P\4I_PI1ZP1M-Z5;%N*4I5(*4I0'-$_P!Y;^?_
M -*N@\*M<3_>6_G_ /2KH/"N$]YUAN*TI2N9L4I2@.*E*4(*4]=#0%MG?[P?
MF%<%=B=_O!^85U_WUZH[D>=[RF]4)H30)*SN?#V5HATKS98&2VF;:[K#8N%K
MF,J8DQ)386T\VH;*2I)Z$$5#HF@N#1K))MC=I>?AR%L/<I%TEONMJ9)+*F7E
MO*6R4$DI+:D[;GVU37QY3>EMS9+JH\:9(@P9;J%<2B*_,99?._J_1K6"?4":
MQ!=]?;U;]9UV?')8N4!F?<[.,7?5$;7WD6WO/-I:8;09"$EUA(2XXX M+@XM
M[<36&]3:1L3BV)VK"K0W;+-#3"AH<6]Q"U.+6XM14MQ:UDJ6M2B25*))/B:L
M5TT>Q"[VV-!?M!0U%F29\=V++?COLOR%*4^I#S:TN)[PK5R2%<3OMML!MB.-
MJK+7A6&3/.S$DM9%<(S-ZOS;,%+=BYQ7GNX0CAQ9+CJ$L#RGFI/7Q4:L^(]H
MFXP;6[-R/-(+]K7;LI\ANTB,S%;FR(,\-QB@  %88W/=I]^-U;'U+H69ER^Z
M%:99BA-IF6"#(;MUN;M+EOB2W64HA[]XTR\TTXGD@*W6CO =B5*3XDF4KT^Q
MYPNE5L02[>$7Y9YKZSD<0E_WWB.".GO>GA6N%LU/SC)WL>A0<C8LMQOLS&HL
MFYLVN,X\$2K-(DOD!2.)47&P4\@0CP X[I-8^N6HRY687./<;(\_9T7Q"\1D
MRFES&Q$"TQEIBML)?"B4-NK*G5(6A[T G=%1-"S,S0-!M,X-UD-,8]!<E>0R
M8JH+TIUY#4*6K],TEA;A2VRXI!]%*0G=)VVVKL,Z08BBV.VNU%Z--@.+=CS%
M7)^9*M\AR(N.AP%UU2@I++IXI4>.Q! ]=8]T1O$:]:]9>]%SIG4) Q&S[W9E
MJ.@ JDS%%&[ "".O(#;=(5L2?&HSF&>3,*U:U3?LV71XE^;O&/\ DF(F.RMR
M]%V-&:6WZ0+JMT%0!:*>[*2I6XZ4NB69LG(Q6W3L1<QJ:TN=:'H!MK[4AQ2E
M/,%KNU!:]^1*D[[JWWZD[[U\7C&++=F+1&N,9IQN!+8F04..E/!]G^Z4GJ.1
M3OX=?E!K&6EN<91D^>3<9N,\NN8>B9%OKWDJ&S.D./\ _P /5L!L@&*GOB$;
M EQ/JZ5BW4W(<5Q]_4N[9?:<4R+/K;=UO6^U9E([IURU)0A4--L!0LDJVZ=T
M.KI7R(4!2Z%C856CN)>[]SO*+6MF?<N]5++,V0TTZMQONG'2REP-AU2/1+H2
M%^OEOUKAA:+8=;T) LB):@I]:W9\AZ6X\7F!'=[U;JU*=Y,I2WLLD!( &U8<
M1K!G-RU#RMM%]LUKCVB;=HB\<ES&!+$:/&<6P^W'+'?%Q12T]WBG2T6UD<1T
MKY1JW?,+L+,K-\_D>17#"H&1>60X,./(8G+>;:\GC!3904O*<2A*70HA77D
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MDK8C<U;LQTKP/*;ZW<\CMD=VX35QHX[R<ZPF6XPI3L<*:2XE#KC9"E(W25
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M*'@"DNK4L[^)VW\!M\8[HU">7G,W*HENGS\PELNW%F!WJ& S'0AN.V%*(62
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MQ7RPM9,5W+RJ*];GDVE#4QUATMQVT.!QL-KC-JZDA?-S<)*@4V27V5+U_P#
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M&QW!(+4FACNW=HR[0WVEL8Y<\AQQG'+A?I,Y^5&3<#Y/.6RM(;0$H4E*4G8
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MOINK.YW/7QVVJ(6WM26&>[?8JK3*5<[>(OD\"!.B3ES5R9!C,LI6RZ6VW2Z
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M@7T [U<>X1\M=*)_O"/^_55QKC/>=8;CC[A'R_33N$^HFN2E<[FSD1Z*0-_
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M679,9Z*VMM]9V)4M!&RE>BGJ03T'L%5BV*WV]:'(<&)$6VE24*8CH04A1!4
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MC8W:HD.-"8M$)B(PE88C-0VTMMA0(6$("=@% D'8=03OON:LF;_V9QNTKO\
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MK4-Q'5;/+W8,-3?\\L&,R+]BZ\J-Z>M+2&">+($-M+C@24M\E.N+WYD+2$\
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M6G@@IV2=_#KW=9>TMK3B[FON2V')K'"QW3*_6YEJRS+(AY^8R^EH*84_R'
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M75Y(!4EMQIS@%%I6Q[Q/CMN9G1<K-\WWVXS+CSSB6F6TE:UK.R4I W)._@
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MT6DN*2E:%;>/1F&4WTV)/0;D^RK?#R&U7&>_!B72#*FQ]^^BL2FW'6MCL>2
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M9I6Q/5.QZU9[1BFFHR1^V6NT8M[OV:8;R[#B1H_E4&5(3_O2D)')MQU(_O"
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MVK?J+C78<RY4_.HS^20=GKI<[7:O(TS(RI(3Y.T@.$L;!;8+G)14&R"/3.T
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<AX[>K>I?2L3KSFK,U&G&+NA2E*\YU%*4H#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm2128727d1_ex99-2img016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
M'0 !  $% 0$!              <!! 4&" ,""?_$ %L0  $# P(# P0,"0<+
M P,#!0$" P0 !1$&$@<3(10B,0A!46$5%Q@R4U9QD9*4E=(6(T)25%>AT=0S
M-X&3L]/P)$-58G)T=;&RP>$T-G,E)D0)@O$U16-V@__$ !T! 0 " P$! 0$
M           ! @,$!0<&" G_Q !+$0 " 0(# P8)"@,( 00# 0   0(#$002
M(04Q408305)QDA46%R)389&AT10R,T*!HJ.QTM,C8G(')"4T5,'A\/$U0X*R
M8W/"XO_:  P# 0 "$0,1 #\ S%*4KV@\D%*4H!2E* 4I2@%*4H!2E* 4I2@%
M*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E*
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M:U)U\1#S7:.K?0]S2]>J3^PF$^;IRUU?_;^S3[2-J4I73-44I2@%*4H!2E*
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MO-4S-&<7](:AE7:9'@6N--B^S[+3<]D*>:!2YRR4X(4"!GICS9Q7UFSO[/\
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M[V#VA#&NHH1:<':SLGT]%[J]M+VN><2Z0I[TAF+,CR78R@A]MEU*U-*(R H
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MEZTP@\KER_9!ML,9.,@!\OH5C\EK/GJ6KS>46&TOSGV),I+0&68,=;[JR2
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MRRW*)*+SD&/'C/"; B2%2 PI1;6%K;*FE8602V1D!/0$9J6X8>$5H2%H7("
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M+UD=N"' X&$R.T25)0LH(<YC"2G)*PUE8ZXK+:9L3\KC;=K/#D(>TI9) U"
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MG+;;K-.@JEVQ3.]LN.1>6V$.H6"-K2\';W2D=?3ZQ^!6FX=EN5ICN3F(<V)
MB)#;X"XW8^L=QM>,\P*PLE6<J2,CQ!D@P&L^.\@1+;!L-MN<2^2;Y%M,J//M
MVYZ$AU*G Z6BXD*2M*%!*@HCWV>J"FLGH3C3^$VJ;3I]$.7<VYEH7=/9U$3L
M[!Q(6UL+96HIZHQXGKCT],BQP<MZKBU=+C=[G=KRFY1KDY<)!:0IQ4="T,M;
M$(2A+:0ZLX2 25$D]:^]*<'[9HRXV69;;C<$JML%VW*;=4VI,IE;I> <[F04
MK)(*"GQP<BH),1KSCG'M-JU(JRL29$BPSX<.7*7#4N.%KE1VW64X(4IP-OY
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MLJ4I).3GK0$A:CUQ!TIIQJ[7)F4USE-,M0D,\R2Z^X0$,I0DG<LDXP#@8))
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M/3& , >- 747CK89CMMB-0[N;M-F/PO8I4%29+*V.67BM). E*76E9!.4K!
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MZXJ-K;QFOW#TWZ;=X*+MI_V:U VVM,MQ<U*HJ'Y(2E"D[0WL86V!NRGNGP)
M Z/I4><)M?:@UM#N2[[IYVS%@M+CO\IYMJ2E:"HA(=2E1*"-I5C:<@CQ(&D3
M/*.N+>E;%<XUCAR)EST_'O'9C,4E*''9D:/R]VTG;^/4=V/%&,>- 3U2H.?X
MTZN3->LC5BLR[[%G7"&^ZJ:Z(I$>*Q*0M/XO?WD/I001W5 G)'C9+\HN_0K
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MGZ:_WL?]*JU"MRX-_P Z>F/]\'_0JM7%_P"7J?TO\C9PWT]/M7YG=\5EQ4=
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M!;Y1Z=4!!*<'P!(\*O7M.V&&6U.VZ PI<UJ4VIQI*=TL)#;;@SXN!*0E)\<
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MD %(+3B$J&4G:KU'!(](K0^*^C'[SQ TE?&+5.N0BP+I!+D1U>UAUYMLLEQ
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M5CQ4?.?/5WM'H%5I0%, ^:F!Z*K2@*8'HH !X#%5I0"E*4 I2E *4I0"E*4
MI2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I2E *4I0"E*4!B<K/@GYZ
MP.OTK_ /4F2!_P#3)7]BJMD*,5@.("<:"U)T_P#[9*_L55LTG_$CVHUJB\R7
M8?GDGWB?D%5JB?>)^056O7SRT517@:K3QH#KIA[28M_!MK449U<U<-)MLDN$
M,,OA#93S$@@G*MN/-GQ\:TZUV35CG$KB%?KS(AV^7;$(,I]NU]O6$'):[*RH
M^=*/?')QZ\X@FYZFNUZB6^+.N,B7'MZ.7$;=7D,)Z=$^CP'S"LN.*NL4W(W
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MY$U7:]6VG2[4O5,2^OZ@4SIYB#<V+MRVHBMT5$IAQ"'1N=6]SBH!"^:%I&<
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M#DP\-];*9ES+%I_4-DN1TVS"FR+A<TR'I<D3F'):6LR#WG&DNX6%MA>Y(RC
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M<O#+F5J 0#M_..+&X>4NFWOD*L8,=OG.OK,DA;+*HJ'X"BG;[Z07 UC\E84
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M5,ME1&2E2\'- 312H,O/E%7 6IB]V#3T:[6;V)M=V=4_/+#RDS7G&0TA/+4
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MQ5Y:;O?;DQQ9CW/3L:TV^!"D1X3[,+D%2 ES"-W^<&T)5GS;O76K5VG*5/\
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M"TQ;3'>4%K:BHVIZ#  'F '@!T'F%9ZE :>_P@T9)O,^ZN::MRI\]#K<I[D
M<\.H*'=X'0E22021D@]35S>.&>EM0.J=N-A@2W5+967'605;F@I+1SX]U+BT
MCU+4/ FMGI0&M0N&VEK:B*B+8+?'1%$8,):CI2&A'*RP$@>'+YB]OHW'%7K6
MD+*Q,9EMVN*B2S*=FMNAH;D/NI*7' ?SE)403YP368I0&H#A'HQ-Q@3QIFV"
M7 2PB,Z(R<LADY9V^@H/O3XCP'2LO:]'V6R+@K@6N+$7!C+AQBRT$EEA:DJ4
MVGT)*D()'I2*S%* U.1PKTG*OL^\.V*(NXSTK1+?*3E\*:Y2MXSA66P$G(\
M!615HNQ*=><-IB%;JHRG%<H948ZMS!/_ ,9&4^BLW2@-4C\*M(Q7[BZUIZWM
MJN+J7Y02R EUQ+@="B/#/, 7D 94,GK5Y<]!:>O)DF;9X<A4F6U/=4MH;E2&
MTI2VZ3X[DI0E(/H&/"L_2@-./![11F7&4-,6Q,FX)>3)=2P IP.J2IT9'AN4
MA*CC&5 'QZUG;;IFU6BQILT.WQF+4$*;[&EH<HI5G<"D^.XDDYSG)SG-92E
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M6O\ 3<2TW1YEUM$Z'-D!<8.-2"P\AU2"VHD!*RG&"58!\]6-YX5VNZW!*N[
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M=%)VR._ X91P+X@!"?\ [3N'@/,C[U5]HOB!\4[A\R/O5<I\H;B(4I/X3R/
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M%I4.FU14D!1(!) !STKZ5Q3TPB\7*U*U# %QMK+C\N.71N90VD*<)\W<!!4
M24@C(&:#0V?E*\-IZTY:_':?\?X]=8!_B'8(NEX.I'KY";L,T1S&N2G1R'@^
MI*6-JO/O*T!./'<*S_-<.0"3U\PH-!RE]1M_Q_R_Y4Y:_':?\?M_YU;7.\(M
M,%V9(YQ8;QN+#"WE=2!T2@%1ZD>&?V5<\UP$@DY!]%!H4Y2^HVG_ !^S_E0M
M+_-/^/\ 'KKS=N"6'V677T-O/$I:;6H!3A R0D'J< 9.,].M>BY"T(*E$X *
MO#S?]Z#0H65].Z<BJ%E?YIQ7E;[H+I;X\V/S>1(;2ZCG,K:7M(R-R%@*2?41
MD><5[\YP^<]/5_C_ +5.I&AYF.O\TU\F*L_D&O;FN]1WL^<8\/\ ']->46X)
MGLAZ,^B2RK(#C*@M)P2#U'3H01\H-+L61YF(Z/!"JIV9X?YM7S5<<]W(&3GY
M/&J%][!ZG \3BIU(LCP[,[\&KYJIV5WX-7S5],W+M7-Y,A#W*66W.6H*V+'B
MDX\",C(/7K7UVF0?!1(]0J=2+(\^S/?!J^:J]F=^#5\U?7:I'3JK!Z [?&L/
MJ+7$+2JH2+C)>0]-=4S'8CQ7'W7%)05JPAM*E82D$DXP!XGJ*:C0S 8='^;5
M\U??)<(]XJK*#?D7)*3'D;UEMMTM*3M=0E8RC>@@*02 >B@#T/H->:]3LMW]
MFR*DD71Z*N:B/L.2RA:4+5G&.BEI&,YZU&HT,CR'/S#\U.0Y^8:PDS7<"VW%
MF#*DNLR7I2(;05&<VNO+:6ZE*%;=JNXVLD@D C!P<"LA;-0,W=AIR,\HEQA$
MD-.-EMY#:\[%+;4 M&=JO? '*2/$&FI.A><AS\PT+#GAL-.TN].\>OATKZ[0
M]G&3XX\*:DZ'SR',^\)KT:YS7@DD>@U\F0Z!DD@>DBG/>W 95D^;%-1H7B%;
MAU!3ZC7W6+;N(>?>9;?0MYE02ZVD@J;)&0%#Q!(((!\QS7S<K_'L-JG7*Y.<
MF#!87)D/;2>6VA)4I1 &3@ GH,U2Q:YEJ5X0YC,^*S)87S&7D)<0H C*2,@_
M,:]LU!8K2J9K$1-6VR=?KE9V'UN3;:E"I>&5AIG>D*2DN[=F_:4JV;MP2I)(
M (- 9BE:A;^+FCKI:;I<XVH[>Y!M829C_.P&0KWBCG!PKP21D*/09KXE\8M%
MP+-;[M(U) :MT]2TL2%.]U10<.9Z=W8>BBK&T]#B@-RI6O*X@:>1JEO3BKM&
M1>G4[FXBE$*<[N_"21A1V][ .<=<8K8: 4I2@%*4H!2E* 4I2@%*53- 5I7P
MXZEL94H)'KJR>N!/1L8_UC4I-D-I%XX\EH940!5F[<">B!CUFK11*SE1)/I-
M4JZ2,;EP/I;A6<J))]=?.2:8SYJ]$,+7YNGI-6*GEBJ@5=HB >^.?4*]$-(3
MX)%5N39EFELJ\ 37HF.L^;%7=5I<FQ;"*?.JOH11Z:]Z5%R;'D(R?75>0@>G
MYZ]*5%R3SY"/7\].0GS$UZ4I<'HCNI SX#%*JDC I52UC[K7N(O\W^IO^%RO
M[)5;%6N\1?YO]3?\+E?V2JRT?I(]J,=7Z.78?G*CWB?D%?0!4H #))  KY1[
MQ/R"O6/_ .H9_P#D3_S%>QL\J1O$_@7KRUP)$V5IR0U%CM*>=<+K9"4)&2>B
ML] #6 U#HB\Z6MEFN%RBI8BW=GM$-:74K*T8!R0#E/10Z'TU/GE)IL*;S*7(
MU?=+==Q:T<FSQVW#'>]]MW*!P-W4'Y*L+?PTTU*U#P>BO6M#D>\6QUZ<VIU9
M#RPP%@^^[O>).$X%?/T=HS=*-6KN=WI%K=%O>W[]QVZN @JDJ=/HLM6NEI="
M]QSK2I]G:2T7J'0W$A-JTX;5<-,/K$>>9*W7'L*5[X> '=(V]>F.N:S^E>$F
MGKJV=/WO3UGLEU<M?:&TMW1QZZI6$C\<M &Q*2<]W/3H.M;$MITX1;E%JW1I
M?<G??P9@CL^I)I1DM>WBU;=Q1S'2IRMECT9IOA%HC4=VTP+U<;C.7%>_RE;2
M7!S'!N5C.<!(P!C)\:V*X<%])V7B)K69(@/2=/V&V-7%%H9=4"XM:5DIW9W;
M1RSTS^5Z!BK2VE3BVG%Z7X:M-+37BUOL0MGU))-26MN.EU?73@N@@G26A[SK
MF1-8LT5,IR''5*>"G4M[6P<$C<1D^JL"D[@"/ U.7#*)I+B;J+4+K6E(]FC0
MK ZX(L>6XM!>"^CF<@^](!!Z'%7W"3A]9)UGTLUJ33EE9%Z2KERKA='4SIF<
ME*F&4#"0!M\2,^/GJ)X]4G/G(O2VFE]S?'7=T$PP3JJ.22UOKK;>EPTW])#T
M/0]UGZ,N&J&4-&T07TQWEEP!86K;C"?..^FL"CWZ/]H?\ZGV596]-\">)UI9
M6IQF#J01VUK\2E*V@"?7C%0$CWZ/]H?\ZV<-7=?.^A.R[+)_[FMB**HN"6]J
M[[;M?['56OM3_@CI*=<4J;3) 2Q%YQP@ON*"&MWJW*!/^JE51WI7CT_+T1I5
M]^UJO.H;@_+MDIJ&ZVPVB7%;4MU1*_>H4E&X8\RQTJ2-3PWI"[*_'C,2'XUP
M:4A3Z%K#.[+:G0$J'5*5JZG(&?-XU'[,* F["YR.'C_LO)D29[K[+B]I?,?E
ME>#^6ML[#T]/B:^:I*FX6E&[_P"-W9TGU,\V;1F-F\?V;_9VU,V^\6(OLVFY
M17V'8ZW'H\J4&0"#D([P(4#UVG(.>E;'-XWM1],WO4S%AE2M.VV6]"$M$EM+
MCSK;Z658;/4)*U':2<G8<@9%8ART:9BSF+2K0+H#(B6QC:MW:IEA1>;2V<=0
MVX"H9P#D$JQTK[D6NS7&T7EM>@YB$WM,AV5;W77A'=7DJ6M2$]U"U%",J2 H
MJ(QGQ.9QHZ>9I?W:>LQIU.M_WV&1O''FW6:]RK;(MST<Q[PJS*ERGDM1RZEM
MI?\ *8(25!T!*5[<E*NHZ9ENU=+G''_^2H25IZQV]F<PC0\M;1EI=>:$B01,
M4I:4\QQ)R'4X;;.%$DE.<#Q,U64N&?$+P2'2H;]A)&?/@GS5HXI05/S%;1FS
M0<G/SGTHWRX0]4NZQTW(MMQMS&E66)(NT)^,I<J0X4I[.6G <("3N*@0<Y&*
MVD5X,O-H#+:EI2M:<I22 58QG \]7%?)'T)%G'>U7.<UI.3;D7X)A71QV0_I
MM#2YK*%0I+84@.@IP5K0D]#C.>GC46VW3/$2VR.'4!O3TVUJLR;0VX_ ?46#
M&[3B4AQ*9(90I+.-XY;I62=I 2".AM97&\6NU%^S1+;)=02MY=VFJBL,MA)*
MEE:6UGS >  R23TP8S7Y0DJ19VKY#TT%6B%:8%VO/:9>R1&;E9(0RD((=4A"
M2XK<I (*0.IZ 1^SI?B#:K?HVWP;#=8<BVN1GQ*8?6485=%*E-K2F0AI&(Y!
M)6VZ5I<(2!M-99S0O$.V6MJ59G+X+W.A7UF:9%T4H#,L+A! <64-KY16EM8
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MY/L>'7V7G!;9)5%4R</<] ;W,!&1N4X$@ @YP: BMKA[K&WW.9?+3'N-KO\
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M60$O[5+=5M4YDI VXW_3FAKS[G:S:;49%IU UIQB,-KNUZ/*0RG:-R3U(<2
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M*MN"1N4 K:<5Z<2>#3NOKC<7XNHG[*U=+:U:[BRW$;?YK33JG6B@J(+:@7'
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M@JO@L#S'%?.Q:?0: ]@:KG->&\CQ!JH<'IH+GMUIFO,+JH7UJ"3[I7SD57-
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M9(2 D(2&P/EO=?\ "JXVB?8;M#DZGO\ /<O9FW:Y6QR,W."!;WX[00DA#:4
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MO&WJ*$D^KXAZ;3JE>G%7>-[-(!S%[Q(4$<PHW8V[]G?V9W;>N,=:MCQ-T@=
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M6DXETL5[U##1IM#,F# NY1(9O)2C?(>6I])42!M#NY6PI5T[V:7%CH5*B05
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MHBHAEIY3*2XG&UQ0)!()PHC/G7%D3R6E#'0D'PZ>/R5;3IK%LBN2)CS<2.V
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M4]S[P^_6O _K(_\ >5S]@>@4P/0*?),3_J'[(_ ?*</Z!>U_$Z!]S[P^_6O
M_K(_]Y3W/O#[]:\#^LC_ -Y7/V!Z!3 ] I\DQ/\ J'[(_ ?*</Z!>U_$Z!]S
M[P^_6O _K(_]Y0>3]P_2I)]M>!T(/\I'^_7/V!Z!3 ] I\DQ/^H?LC\!\IP_
MH%[7\3O(:AT4 !^&UG^NL_>I^$.BOCM9_KK/WJX-P/0*8'H%</Q9H==F_P"&
M'Z->UG>7X0Z*^.UG^NL_>I^$.BOCM9_KK/WJX-P/0*8'H%/%FAUV/##]&O:S
MO+\(=%?':S_76?O5<0+MI*?-8CQ-76N5)<5AMEF4TI:SZ  K)K@7 ] K<^#
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ML GPZU!/!G4MQUMQ L=TNQ2_,19+S!5(;0D!U#-V::0O*0$Y4E"22D!).2
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M3+;POF\0F9<6UZFNC[UT:DW:2&V6&)3S*4(RL%"'!%98;05C:E?OA@JR!/\
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M3[4%%M"S>WG%.MO[ K*@$\M(VMG*"YN42G KL)/A0'U2E* 4I2@%*4H!2E*
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M3L93A/@$Y_A/P>?X<WFW2&F+=#BHTI;[1*1![I>EL*7N<(VC<,+P%GO=3T%
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M2@*8'H%,#T"JTH"F!Z!3 ] JM* I@>@4P/0*K2@*8'H%,#T"JTH"F!Z!3 ]
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=G.!XX\V:V^E4G7G-69:-.,7="E*5KF44I2@/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm2128727d1_ex99-2img017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-2img017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '> U(# 2(  A$! Q$!_\0
M'@ !  ,! 0$! 0$!          8'" 4!"00# @K_Q !A$  ! @0" P@*#0D&
M P8$!P   0(#! 4&!Q$2(90(%A<Q4516TA,U-D%3=9*SM-,)%!@B,C=A<7-V
MEM'4%55C=X&3E;*V(T)28G2U&20S)G*"D:'!)3FBL2<T.$-&@\+_Q  = 0$
M 00# 0              ! (#!0@!!@<)_\0 0Q$  0(# 0L(!P<% 0$!
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MGJG\!F!P??IZI_ 9@8DG^HG>9]0P^7ZR[G6$.!,>#[]/5/X#,#@^_3U3^ S
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M,6!'DGR[VJ]KG-7)RZ]3%."8R/+Q)9UY%2B[475G153.BH2X<5D5+YG^TX@
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MH
M                                                 F6&7;&>^A;_
M #%AE>89=L9[Z%O\Q89HI]JWYKF/AA^1ILWZ#?@<+:[S*  >1'?0
M                      =RT.V4WXOG/,/.&=RT.V4WXOG/,/)]S_O<+XDX
MD>9YE^Q3M7#W+/\ HJ3Z-%(23:X>Y9_T5)]&BD))]V>>9L7SO(TC[#MJ>5H
M!@3(E%)QEP2':67^I]._W9A3Z<9<$AVEE_J?3O\ =F'TXG,S-J&FTK^K8I ,
M1/C"NGQM-^?>1XD.(GQA73XVF_/O(\2X/-MV(18O..V@ %TM
M
M                                    $RPR[8SWT+?YBPRO,,NV,]]"
MW^8L,T4^U;\US'PP_(TV;]!OP.%M=YE  /(COH
M        .Y:';*;\7SGF'G#.Y:';*;\7SGF'D^Y_WN%\2<2/,\R_8IVKA[EG
M_14GT:*0DFUP]RS_ **D^C12$D^[//,V+YWD:1]AVU/*T  P)D2BDXRX)#M+
M+_4^G?[LPI].,N"0[2R_U/IW^[,/IQ.9F;4--I7]6Q2 8B?&%=/C:;\^\CQ(
M<1/C"NGQM-^?>1XEP>;;L0BQ><=M  +I:
M
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M+@\VW8A%B\X[:  72T
M
M      3+#+MC/?0M_F+#*\PR[8SWT+?YBPS13[5OS7,?##\C39OT&_ X6UWF
M4  \B.^@                              [EH=LIOQ?.>8><,[EH=LIO
MQ?.>8>3[G_>X7Q)Q(\SS+]BG:N'N6?\ 14GT:*0DFUP]RS_HJ3Z-%(23[L\\
MS8OG>1I'V';4\K0 # F1**3C+@D.TLO]3Z=_NS"GTXRX)#M++_4^G?[LP^G$
MYF9M0TVE?U;%(!B)\85T^-IOS[R/$AQ$^,*Z?&TWY]Y'B7!YMNQ"+%YQVT
MNEH
M                                                   F6&7;&>^A
M;_,6&5YAEVQGOH6_S%AFBGVK?FN8^&'Y&FS?H-^!PMKO,H !Y$=]
M                      !W+0[93?B^<\P\X9W+0[93?B^<\P\GW/\ O<+X
MDXD>9YE^Q3M7#W+/^BI/HT4A)-KA[EG_ $5)]&BD))]V>>9L7SO(TC[#MJ>5
MH !@3(E%)QEP2':67^I]._W9A3Z<9<$AVEE_J?3O]V8?3B<S,VH:;2OZMBD
MQ$^,*Z?&TWY]Y'B0XB?&%=/C:;\^\CQ+@\VW8A%B\X[:  72T
M
M                                     3+#+MC/?0M_F+#*\PR[8SWT
M+?YBPS13[5OS7,?##\C39OT&_ X6UWF4  \B.^@
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M_P!I0 "\4
M                                                         &E]
MPQW9W5XM@^>-DF-MPQW9W7XM@^>-DFAWVL?FR8^&'Y&FP?H=^$0]KO,H !Y
M=U                              !W+0[93?B^<\P\X9W+0[93?B^<\P
M\GW/^]POB3B1YGF7[%.U</<L_P"BI/HT4A)-KA[EG_14GT:*0DGW9YYFQ?.\
MC2/L.VIY6@ &!,B?*!OPD^<U31^Y&1_590?ZG@F5F_"3YS5-'[D9']5E!_J>
M"?3Z=S,VH:HP/U;"CL>/CSQ(^L]4],BD&)SCQ\>>)'UGJGID4@Q,@\TW8A8?
M[2@ %XH
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M_:4  O%
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M %XH
M                                                    -+[ACNSN
MOQ;!\\;),;;ACNSNOQ;!\\;)-#OM8_-DQ\,/R--@_0[\(A[7>90 #R [J
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M[.Z_%L'SQLDT.^UC\V3'PP_(TV#]#OPB'M=YE  /(#NH
M              .Y:';*;\7SGF'G#.Y:';*;\7SGF'D^Y_WN%\2<2/,\R_8I
MVKA[EG_14GT:*0DFUP]RS_HJ3Z-%(23[L\\S8OG>1I'V';4\K0 # F1/E WX
M2?.:IH_<C(_JLH/]3P3*S?A)\YJFC]R,C^JR@_U/!/I].YF;4-48'ZMA1V/'
MQYXD?6>J>F12#$YQX^//$CZSU3TR*08F0>:;L0L/]I0 "\4
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M\6P?/&R30[[6/S9,?##\C38/T._"(>UWF4  \@.Z@
M           [EH=LIOQ?.>8><,[EH=LIOQ?.>8>3[G_>X7Q)Q(\SS+]BG:N'
MN6?]%2?1HI"2;7#W+/\ HJ3Z-%(23[L\\S8OG>1I'V';4\K0 # F1/E WX2?
M.:IH_<C(_JLH/]3P3*S?A)\YJFC]R,C^JR@_U/!/I].YF;4-48'ZMA1V/'QY
MXD?6>J>F12#$YQX^//$CZSU3TR*08F0>:;L0L/\ :4  O%
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M51DQ"<BMB0GY?W7-54^34O>(<"+ E609=)=<K42F7I+CXKGQ%B9E/HOB!;V
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M#YXV2:'?:Q^;)CX8?D:;!^AWX1#VN\R@ 'D!W4
M        '<M#ME-^+YSS#SAG<M#ME-^+YSS#R?<_[W"^).)'F>9?L4[5P]RS
M_HJ3Z-%(23:X>Y9_T5)]&BD))]V>>9L7SO(TC[#MJ>5H !@3(GR@;\)/G-4T
M?N1D?U64'^IX)E9OPD^<U31^Y&1_590?ZG@GT^G<S-J&J,#]6PH['CX\\2/K
M/5/3(I!B<X\?'GB1]9ZIZ9%(,3(/--V(6'^TH !>*
M
M                             #2^X8[L[K\6P?/&R3&VX8[L[K\6P?/&
MR30[[6/S9,?##\C38/T._"(>UWF4  \@.Z@
M     [EH=LIOQ?.>8><,[EH=LIOQ?.>8>3[G_>X7Q)Q(\SS+]BG:N'N6?]%2
M?1HI"2;7#W+/^BI/HT4A)/NSSS-B^=Y&D?8=M3RM  ,"9$^4#?A)\YJFC]R,
MC^JR@_U/!,K-^$GSFJ:/W(R/ZK*#_4\$^GT[F9M0U1@?JV%'8\?'GB1]9ZIZ
M9%(,3G'CX\\2/K/5/3(I!B9!YINQ"P_VE  +Q0
M
M                          :7W#'=G=?BV#YXV28VW#'=G=?BV#YXV2:'
M?:Q^;)CX8?D:;!^AWX1#VN\R@ 'D!W4
M '<M#ME-^+YSS#SAG<M#ME-^+YSS#R?<_P"]POB3B1YGF7[%.U</<L_Z*D^C
M12$DVN'N6?\ 14GT:*0DGW9YYFQ?.\C2/L.VIY6@ &!,B?*!OPD^<U31^Y&1
M_590?ZG@F5F_"3YS5-'[D9']5E!_J>"?3Z=S,VH:HP/U;"CL>/CSQ(^L]4],
MBD&)SCQ\>>)'UGJGID4@Q,@\TW8A8?[2@ %XH
M
M                         -+[ACNSNOQ;!\\;),;;ACNSNOQ;!\\;)-#O
MM8_-DQ\,/R--@_0[\(A[7>90 #R [J
M#N6AVRF_%\YYAYPSN6AVRF_%\YYAY/N?][A?$G$CS/,OV*=JX>Y9_P!%2?1H
MI"2;7#W+/^BI/HT4A)/NSSS-B^=Y&D?8=M3RM  ,"9$^4#?A)\YJFC]R,C^J
MR@_U/!,K-^$GSFJ:/W(R/ZK*#_4\$^GT[F9M0U1@?JV%'8\?'GB1]9ZIZ9%(
M,3G'CX\\2/K/5/3(I!B9!YINQ"P_VE  +Q0
M
M                       :7W#'=G=?BV#YXV28VW#'=G=?BV#YXV2:'?:Q
M^;)CX8?D:;!^AWX1#VN\R@ 'D!W4                              '<
MM#ME-^+YSS#SAG<M#ME-^+YSS#R?<_[W"^).)'F>9?L4[5P]RS_HJ3Z-%(23
M:X>Y9_T5)]&BD))]V>>9L7SO(TC[#MJ>5H !@3(GR@;\)/G-4T?N1D?U64'^
MIX)E9OPD^<U31^Y&1_590?ZG@GT^G<S-J&J,#]6PH['CX\\2/K/5/3(I!B<X
M\?'GB1]9ZIZ9%(,3(/--V(6'^TH !>*        %5$3-=2  '^4B,7+)[5S3
M-,EXPZ*QBY.>UJ_YG(@!_H!%14147-%[Z            '^FPWO:]S6.<UB9
MO<UJJC4XLU7O?M /\@      _92Z-4:W%?"IM/FZC%8W2>R3EWQG-3E5&HN2
M?.?CXE5%145.\IQ7H.0 #DX       /[>U)A9;VQ[7C>UL]'L_8G=CSY-+++
M/]I_.'#?&B-APV.B1'+DUC&JYRK\B)K4 _R          ?V9)S$67?'9+QGP
M&:GQF0G*QOSN1,D_:H!_$'^GPWPT8KV/8CVZ35<U4TDY4SXT^5#];*+48E,?
M4F4Z<?36+HNG6R[U@-7/+)8F6CQZN,XJB')^('[(-%J,Q38M1A4Z<BT^$N42
M<9+O=!8N>6MZ)HIKY5/QBJ*  #DX             /\ 20WNANB(QRPV*B.>
MC55K57BS7B3,_P @          '^>S0_",X\OA)Q\A_H             TON
M&.[.Z_%L'SQLDQMN&.[.Z_%L'SQLDT.^UC\V3'PP_(TV#]#OPB'M=YE  /(#
MNH                              .Y:';*;\7SGF'G#.Y:';*;\7SGF'
MD^Y_WN%\2<2/,\R_8IVKA[EG_14GT:*0DFUP]RS_ **D^C12$D^[//,V+YWD
M:1]AVU/*T  P)D3Y0-^$GSFJ:/W(R/ZK*#_4\$RLWX2?.:IH_<C(_JLH/]3P
M3Z?3N9FU#5&!^K84=CQ\>>)'UGJGID4@Q.<>/CSQ(^L]4],BD&)D'FF[$+#_
M &E  +Q0      ":8,W+;=F8GV]7KMIDW6J%3)E)N+3Y)(>G,/9[Z&U=-4;H
MZ:-5R*NM$R[Y"P4/:CVJU>DJ1;U45#27"+*X_P A3<-J'28E.NV^KU=5*Y6(
M\*%V)&/<Y($&"C5TDAP8>3E143-6+REY8RX]V;N*+CE\,<.L.*#6HU-EH42M
MU2MLTXTT][4=H*]$S5ZM5'*YRZ+=-$1N2&+<&L0>"G%>T[P67=-PZ-4(<U%E
MV+DZ)#3-L1J+RJUSLOER-GXMX48#;H3$J)BM&QOI-$MZJ,@QJK1XRL9.:3(;
M6*QJ.<CH:N:Q$5%8Y47/+/-#KLU"APHS6Q47DJ*N2JU=KIJS&1A/<]BJQ4O\
MFC-^^O.<S=8;FV@8@WC@Q7; ITK:TQB8U(<>2;"T8$%ZP61TCJQG$J,<Y'Z*
M(BZ*+EFJYTI:^XVKUW;H>X\)J?<5-B3U!EEF)NKK!B^UDR;"56(WX6><5&_.
MUQHNB[K6P\0=V58;VSD&@X;VA39R0HTW/_V$)\S$A)#2*[2_Z;%8F@S2UZLU
MRTLCJV=>.%N#59W0=Y0L4Z-<U]5N'-QI5)9R0H;4>D6)!EX#E<O9HFEV-'*W
MWJ9,1->9$AS$Y+0DA*BUO<F2N579*KJ327G0X,5U_5*5RY="?[4S1A7N)[CQ
M<P_K=W4FY:+*4VFU:-2].?TX3(K(3V-B3/9%]ZV&C7J[7KR:J<:H4SB99T##
MV_*W;<O6I2X85,C]@_*<BF4".NBU55FM<T155,\USR-(8DXE6];6X%P[PZH-
MPR,_7:K.).UZ3DIA'Q(35=$CJR,U-:>_6$F2]]F1E2C4:-7ZM(4F59G,3\Q"
ME(36I_>B/1B?^KC.RCXT17Q(KO[4541*4R)TD",UC4:UB9:)6PTQ0]P37JA9
M]BW/5+YMFVZ1=,*#$AQ*M$=!= =%8CH,)$<J=EB/TLD:W+B557ECTYN(L1&8
M[SF%\FDC.STK*PZA%J^FZ')0Y1^I(SU5-)NM'-T<E55:N6::S9.ZCPULRI8@
MX8P;LQ.MRU;)L*3A/F*',S/_ ,0CN:K%;H0D_NN9!8W2R5<M+)%S([9^ZALG
M':X<?)*-=$G8<>XZ9!I= J59>D'2E8<"-#5ZN54R7LD5[]#-'(V(F6M%,'#N
MA-OA\JW*E.KD2KD1-N3*I/=+P6NO%R+MSY,NS*9PO+<4-M_"6Z,0*-BC;%UT
MFW-)D\E,AQ7-[*W1183(B*K5=F]J<FM#\\UN+9BV++H]9O7$BU;)J=9D'U&G
MT.I/>Z8C0VL1V2JF2([)6IDF>2N1-:ZBT;\K.&UH[BJ@856?B+1JS/5JXY>'
M6)UKNQ(QCH[G1IAT)5TFP&]BAHBKK5B-7ODHOZZ+8H^Y:N*U<5,0['Q/J<G)
M]@LR/;[^RU*'$2'HPEB.3X.BJ,S=_A1R.5VK.\DW-41+Y<KE3V<JID2M*4SY
M5KEH6U@PLN3HKGR5WU,^67N.YFKX9V[>]W8@VSAW2[C=E2(5;>]8DRF2JBKE
MDC$5$SXUU:URS))A52;XPRW(^+-VT>LVVEI5::?1)F%.R#XTW-:+VP.R2[\T
M:UKNRKEIHN6BKD1%+ML.KVCAW@16;2Q7Q/L#$K#R#3E2A2%,<L:JPHV2JV&Q
M-:IEFJ,7C:N6M&ZDK:X[AL^X/8W;9MJF7K19"NTB96?J=#CQ,YR<CI%C+V%K
M$5%S5T1CD=DK=%H68C1EO7Y6J]J>SDIE716N1$6N93E(;&)5N1;U>G+7,0G#
MK<)7%=5H6_7[DN^W</X5Q/;#HDE7(JI-3ZN1%9HLS3+2145$S5V2HN29H<RR
M]Q)>UTX[7#A9-SM/HU8HLE^4(T[%1\:6BP5<Q(;F:*(JH_LB*F>662HNM#3N
M(E5PDW0MV83XF36+%"MNV[3E83YVW)Q^A.-BPXC8J0VP\\T728UBY-7-&)HY
MYH?BH>ZNLZKUK=#XHPJU*4JJS5*A42UY&9C)#G9F'!@1%;%;#^%[^+$1V7&F
M62ZT*$G9US7*U,M,U[[*WR(B:\F53GD("*B+FVYTI5=AGFY=Q!<5N8.7)?B7
M;;=4?;L1S*G1Z;,+'BRJM<U',?$:JL2*U'-<L/O:TS53/-*D4J=5DI)TS DV
MS$>'!=,S+T9"@HYR-5[W+Q-;GFJ]Y$4U-3,0K:LCV.VI6M)U^GS-X757.R3M
M-A3".FH4#LS<W1&\:(K)=NM?")RF8K7M^-=MST>AR[5=,52=@2,-$XU=%B-9
M_P#Z,U*1(KFQ.67,Y41:4R)_-2#&:Q%;>)G1#Z6W';T[N3MR10*/8>(-M42[
M)M7U.)46PF1H]Q*J*YL*38Y%5[G+$@,:N2Y-RRRSS,ZTOV.F[9Y)*GU>^K4H
M=\U.5?/2UJ3DRY\X]J9J[25O?X\U:UR)KUKDI-]VOB52;(W7^%,G'@NC6_8,
M"G18\M#;I*C5C(]V3>^J0X<)43Y"Q*Q7<(J/NF9O=%U+&"B56D0J<U*70*>J
MQ9Y8WM;L.AH(N>63GJC=%%TG^^5,E5>MPHDQ A)$8N6(BNK>U55K_:W_ 'PH
M9-[8<1ZM7,VB4K2B=*F3<(-Q=>F+TM?J2\U)46I6A-+(34C4$<BQIA&N5T-K
MT]ZU$T4S<NK)R+Q%;XR89PL([YBVU"N2F74Z#+08T2H4AVE+:;VZ2L:[-=+1
MU:_EXD-2W)N@:&_<=8CS4I6Y"6OG$:Z9F=FJ/+3*.FY65BQD;HO:FM$[!!T5
M7B7LGRF(%1(4-58U$R151K4R.PRCYB,][XJT:BT1*:DJM=%:T,=&;#8U$9E7
M/4T39.XNN*\\&*-B4ZZ+?H-"J,TZ"]]:C++,E8217PUC1(KO>Y:3,D:F;E5S
M43CU32K>QP770K^I5!J%[VO(TNJ,:DC5YJ,L-9N87/\ Y:#+JNG$B(B:6I='
M15->:Y'4Q_O.SJKA;N<\):)=E+FZ1)NEXEP3$O-M=+RS_P"R:Y8KDU-R6+,.
MU\F9.KYQBL;$'V02R:I,W92&6':%,1\O4GS;4DUCI#>_)C\\M+3?"35X+Y#%
MK,SJU>U:(J/7V<R(O]O[J2DA0$R*F7^U,^G.9HEMQ[?E3Q\K>%-.;)3E5H^C
M%G*FL162<&7<UKVQGN5%5$5'MR;DKL\T[RJ2F[]Q.V@8471?U'Q1M>ZZ3;>D
MR?2F0XKF]E;HHL)D1%5JOS>U$SU:T+PPDQMLV_KLW3U-G[SIMI5.\XT2%1JW
M4(J0X3Y5D*+ 8K7JJ<2:+M'-%5'YIQ$4Q"KF'%E[B*C86V;B!2;AJ-9N& RK
M1X,3L*Z*QW+%C+#7WS(+>Q0T1SN-NBO?*EFYM8C&+5%JU%_MSU2KEKX)0XY&
M"C5=GS].O(A*+JPCN6X-Q_@+A!;$GIURZ9C\MSSGJJ0H$!$='?&C*GP6-=,0
MOE541$155$*]W-F!UQV/NE:U L&^;4K-4L^FQ8]1JDY(1XM.AN>[L;H"9*CG
M/1$55>U41-%4S76AI6I[JK#>>Q3J&&27?39*Q)FRVR,O<LG--8DM-9O8YC9A
MJ^]7L2L5$SU.8G*4#N*JG:%E69CO:-0OVWZ!<=1A+3)"L3LRU)6- ;"C0TCP
MG9IIMTGJ[)JYY*T@PXDPDO%OFTKEI2M;]V55V)DH7W-AK%91<V3/H3-^^DJ?
M#[<V7?NG[>O_ !,E*O1Y-9:I1HD>',,]JPIB*]$C/<UVID&&B1$55=J:F?(?
MGQGW'M?PEM*SKBD;AI%\4ZYYEDE)OM[3B(^.]JK#;#5?^JUV2HCDRUIK1,R>
MUO$"V; ]CT@6/0;HI]0N>OUQ\6H2,G&18S9=(SW(L1G&UKF0(*9+_C1"S+EQ
MSPYLBY]RO;L"XJ94[:M*'[8K$W)1DCP9:8662!#>]6\2MB/>]>^B:^\9%9F:
M;$JQ/[:N1$IT-;IUKF(Z0H*M_N7+1,M>E5LSE8T#V.VMSE9IUMUO$:U*#?$]
M*K.0[8TGS,TR&B*JJ_05$3++6J(J<>2J9BOFUHEBWI7K=C3DO/Q:1/1I&)-R
MN:0HKH;E:YS=+7EFB\?(?43#&VK.H>/F,V-T&_*;>G8*:Z:ALIR]DA4R7="1
M^A$C(JM5ZM@(UK&\34551-)#Y4SU3B5>IS%2G$6-%FYATU':JZWJ]ZO>G[<U
M+]SIF-,/??NJB(WHIE7*J)TY-9;F83(;4O4HJJO37(AH6Q-Q16J[9M"N:\+P
MH&',C<,1D.BRU:<YTW/J_+05L)N2HCLT5$S5<E151,T*^W0^!<]N=\0UM&I5
MF1K<VDI#G'1I%CV-8UZN1K7(_6CLFYZLTR5#=6(U?P;Q0QSP?Q*FL5Z%)6U1
MI1C92WE=_:LF&.=%8L77E 8BHQ'::(N<-K4XTRQ3NO;_ );$W=(7Q79"=@U"
MFOFV2TG,R[T?"B084)C&N8Y.-%5'+^U2B2F9F8C)RE42BJJ4I1:T1*TJN3.5
M1X4.&S^W/73JSG^,#-S+<N.,E5JU GJ=;%GT=%_*-R5J+V.5@*B(Y6)WW.R5
M%7B1,TS5,T1=2W_8<K@QN!).S;?N22NN-?\ <L"! JE-:YD&;;%BM^ BJJJB
M-EVM52+8:UNP\1=P6_#N<Q$I&']8I]8?/U3\I9J^8@I,.BHK8351T7-JLR1N
M?OH:)D2K&#%?"^4O_<PVQ1+GI\_8=IS#)F=FX49KVP%AMA,@K'1NIJYHKG<F
M;N\1)B-'CQT:J+1KE6E.AJ51:]-5S(A=ALALAU1<JHF6NE<N341[&G"N[L4<
M?<.<'+ZO*SY1]&HT-9>:I\F^42(Q\1K/:^3ES?'>V%FUK<FIK5$3-2V-UC2)
MR^+VMW!6V\4+2M*S9Z' IDQ:C$8DQ!?#RC,[)E[YJO7L+(<-%325<\EUG+HE
MMTK$KV2R4NBF732KOI<"EOK.=*B)$AR*0H+9:%">]%5JNTWJ_5EQH4ON>TX<
M_9$H]PNSBR<*LU"M([CRA0$<R!_ZK!(K:N1L15HD.'?4HF1RUZ%3/D+RT2K:
M>TZF?H0O+=GTNYYU+:P6PLN2B-IDY @4:-8,@V&D]DB.C>V8[U3.#!:R'#55
MS3/255TLS,-Y;B6I6[85XW%1[_MB[IJSD5:_2Z4Z)V235$TGM1Z^]<YJ(JY+
ME\%4XTR+,P>W1-JT+=_X@7?=<_#D:15(D[29.IQ\^Q2RLB0X<)SU_NM<V K=
M+B323/)%53^^Z#O6J+;\*U.%K#1EN7'6I>%-4:PY!LMV:5B1<XLS.1=)V@U&
MHBN3/WRKK5412_+K,RJPX#,B4156F=5]K,BYDR="Z5H6XG)14=$=K1,N;00.
M;]C_ +@HUGT>Z*U>]NT6CS])=5'OF]-D2$[L+8K)=K'*BQ8KD<[4WBT%Y41?
MSV=N"+AKJ4"G5V]+<M"\;@E'3M+M6HN?$GHL%K5<KHB,_P"GJ15RR7+)<]:*
MB=K=NXY6Y>.Z-LF+1I^6N*RK2@R+V,D(J18$1W9TBQT8J:E=H,AL_P##D:*Q
MFQVE*Q-S-]6#B[AC;]*B4Q(:3L>EI,7(U4:JK 9I.S7-5U-<U-%57-%*W3,^
MD.&JK17HJYLVA,RYZY<G1D.$A2ZN<G5UY]*F0K'W$-YWK95YW!^5:/2'6O5H
M]'FY:HQNQL6)!5B1HG9UR8V&W3S5R]YJZN)#\V,FXVN;"N2L2;IM:IE]0+QC
M-E::Z@HY4BQG-1S&L5VI[7(N:/1<M2YHA.\1<5*+3]P+:UG4^Z)6J7E<M7=4
M[@EX4VD288L2)%CN[.B:T57)!1<^^BEL7?NA<.K$QDW-U*EJ_3JO9]FTN+"G
MI^G1$F(,M'B2R2S'N5N>MNBKE[Z([,O+,SJ/OD2J5?DIG1J9,NM<W^RWR4"E
M,V1,M=*_Z0SYB1N,(V$MH5*>N?$RSY*Z9&06H/M.',+$G'MU9,;K15<N>K)N
M2\N6LZ5G;@FX:XEOT^OWK;=G7=<,N^;I5KU%SXD]&A-:KE<]K/\ IZD5<M:I
MDN>M%1/[[I^T[/MW%V8Q/E\3:#?<*KW++U)E!I;^S339732(_LCT<K4:QK$A
MM3OZ3>+)33^,>/$E79N+?=@XN88V_2G4Q(?MV;I:3%R,71<JP8:.=FN:KJ:Y
MJ:*JN:*6WS<VD.'>.JKJY;VE%R9,R].JJTR*5M@P;YU\F;HKGUYSYF77;,_9
M=T5>WZK#9"J=+FXLE,L8]'M2)#<K79.3C3--2\A8MZ[G2K6-@39N)D]5I-\"
MZ8R0I*C0X3_;2(J1'(]7+[U4R8G%_C;\I553J,Y69F<GYR/$FJC-O?'C1XSM
M)\2*]5<YSE[ZJY555/HSB#.8,XF6MN>%J.*5%IMK6U"EX<:A,5'S4>+H0&HV
M)K_L&M6&Y(CGIJ15RUJAE)N8B2ZPM"UK1*YDS?NI$A0VQ$?X9=9G>K[ABYJ/
MC#9&'$2Y*5$K=S4V-4]-L&+V.1A0VJY>R=]556N:F7?0Z[_8]+I2E7S%A7I;
M$S5[5;%BQJ-+QUB3+X36N<QT1$5>P+$:QRL:_7EEGEGJT'2,>L/IW=N7[B!4
MKPHZT*@6O!IM%F'SC=";B/1(L5(*_P!Y473:N7?7+OE'X%XO46S]S%C[<51N
M.0;B!>$:) EZ=&F$]NQ4B-T5>C%]\J:4S%7/D8O(8I)F><U%1:+1GZ<ZN7+N
M3.2^2ET7?T]")_M3DV_2;[L?<+QIM*K;<I9-]UF'+^UIV2=[?1SHG8E>D?-&
M-9E 5V;D56HU514S+"QRW(V'V%FY<H<=MRVO+WK$8^J1:Y&F(CHM<A,8YR0)
M&&KES1W9(*>]37DBKQG&W0]=LFZ]Q)A'3+=OBD:5NP8'MRW4?I3T>8=#2&]$
M8BYM6&KXSE5R9*G$O%G(-VC=UA5>IX-WI;][46X;<MUTG+,MF1BI%G'0FQ61
M(D141?>-2'!8Q4<B+I9(4H^,^(Q4JVKWJM$T9D7)T[MQRK6-:Y%RT1.G3GH5
MC:6X$N*LOH=*KMZVW:5Z5V4?.TVU)][XD[$@M:KE=$1G_3U(JY9+EDO?142/
MV3N-*Y6+7N&YKNNN@X>V[1:K%HL:?J\1T1(LU#B=C>UB,R31T_>HY5UKGDFH
MU]C5CK*U6:G;ZL'%[#&@4J+3$8V<B4Q(]R:2,5>P,TG9KFJIDUS4T576BY$"
MW*=?DK*L)T7$#%NP+@PSN"5B5*M6S6(O9ZE+3D9NF]J,7-7.T_AIKS=FK41=
M:\).SBP5B*M%R9*+7IJB9*5T5J<K @(]&IOKDU=/ PK>]MP+0O"K425K,E<,
MO(QU@LJE.55EYE,D73AJO&W7EG\BD^NW<[56S=S]:N*L]5Y)9.XYGL$G1V0W
M^V<O[7WZN7WN64+/5_B:5U><:DS%U5^+;D")+4*).S#Z;!C*NG#EUB.6"UV?
M?1NBFLW_ 'U,8-8FX8;G>5J&*-'I-M6VV69.T-BH^;F(RPX+%8],T[ UJMB(
M][TR1KG*FO+/,3,Q$@<E2M%7+DKF3-DS*JD*%#;$O]6;+K,]U[<,7E2L1[$L
M>5J]+J%?NFGQ*FL-$B0F4Z Q&Z3HSE1<\E<J)HIFJMR[Y"\:L"J)A'"E6P,2
MK?O.9_*#Z=4)"AH[VQ).8B]D5R.7+4J*U%7+WVKO+EJ'$Z_78J[LBI758.+E
MI6G&M>DR<K2:A69E%D:@D1'NF(37<3FHKU1R9+KRRR76E5[ORZ\/;MN^UIFU
M8]%J-WMDG[Z:G;B+[1F)A=#1T7<3W(J15TM:Z+FHY55-4*6F9F)%A,B+G;5:
M)F7/ER9J41*=.<OQ84)K'*WH7)EX'\;GW7=!FIF^)N@6M,4V9FK>E;4M9L9D
MNK*5)-__ #,6+E\*.]?@N;GEHMUZC+B(C41$U(B9( 9J#+PX"*D-,_\ K)_V
MNI"?$=$]H  D%H         TON&.[.Z_%L'SQLDQMN&.[.Z_%L'SQLDT.^UC
M\V3'PP_(TV#]#OPB'M=YE  /(#NH                              .Y
M:';*;\7SGF'G#.Y:';*;\7SGF'D^Y_WN%\2<2/,\R_8IVKA[EG_14GT:*0DF
MUP]RS_HJ3Z-%(23[L\\S8OG>1I'V';4\K0 # F1/E WX2?.:IH_<C(_JLH/]
M3P3*S?A)\YJFC]R,C^JR@_U/!/I].YF;4-48'ZMA1V/'QYXD?6>J>F12#$YQ
MX^//$CZSU3TR*08F0>:;L0L/]I0 "\4          =_/O\O?     !(L.KQ=
MAY?UO70R0@U2)1IZ%/,DYAZLAQ7PUTFHY4UHFDB+^PCH*7-1R*U<RG**J+5"
M=XWXN5+'3$^KWK592!(SE02$WVK+N5[(+(<-K&M:YVM?@Y_.JD$RS .&,;#:
MC&)1$R(<N57*KESJ B(F>2(F?'D 5E(R1%5<D15XU&2  #OY]].^   =BS[K
MJ5B772;CH\2'!JM+F63<K$C0DBL9$;K:JM74N2Z\E..#A41R*BYCE%HM4))B
M)B%7<5;SJ5U7+-MGJW4',=,1V0TAM718UC41K=2(C6HF2$;[^??7O@'#6HQ$
M:U*(@555:J  5'    RSX]8XP  ,D7O   FN$&)4/"B\FUV-;-(NZ LK%E(E
M,K<-7R[V1$1'+DG$Y$34JHO&NHA0*'L1[5:[,I4BJU:H7]B;NP*O>F',>P;8
MM&W\-[0FHG99V0MZ&J/FUS1<HCU1/>JK4S1&YKDB*N6HH$ HA08<!M[#2B%3
MWNB+5R@ %XMC(  $[PEQMN[ ^?JT[9\] ITU5)3VE,Q8DJR,Y86>EDW23WJY
MZ\TY$Y#_ #A!C5=N!5?G*U9T] D*G-2BR42/'E63"]B5R.5$1Z+DN;4U\>H@
MP++H,-U]?-1;[/DSTTE:/<E*+FS'^HD1T6(^(]RNB/<KG.5=:JJYJI_E$1.)
M,D^0 O% '?S[_+WSU$5>)"W-SO@9!QFKLPVK56)0:'#BP:="G(;$<^8J,PJM
ME99B.U*KE:Y[E[S&*NK-"U%B-@L5[UR(5M:KUO6E19 []N8?W-=T29A42@S]
M7BRL:'+1VR4!8G8XKW.:QJ\FDK'Y9_X5SR1%.G.8,W[3I*NSDU9M;EY2A/['
M5(\63>UDFY$152(O>R1S554S1$<BKJ5#E8C$6BN2NTX1KE2M"&Y(G>'?S[_%
MGWR:OPXGJG#M"G4.B7%/W/69.).OD72;70X\)8CD@Q97057.AJQCE<YZ(B*U
M<M6LY]Q8:W7:#:DM;MVHTIM-B0(4XLW!T$@/C-<Z"CE_SM:Y6Y9YHU5.$BL5
M:5R_S07JYZ$:!+Z-A!?%Q5IM(IEIU:?J:R<*H^U8$LKGI+141849>\C'HYJM
M553/-,C\%K67/W)B!2+2=!B2M3GJK!I3H41N3X41\9(3D5.\K55<T^0YY1F7
M+FRB]701\%TW]A78L.R+ON"RJO<$9EKU^%1(ZUR'+K!J"1716MB2SX*)DY.P
MJY8;D5=%R+F0FJ8,7S05H:UBU*O1H-:FH4G(QYZ4=#;%BQ%1&M3/B=[Y%T5R
M7(MLCPWI6M-N37P*W0W-4AF2<@R37JX^,M/%'#>A6O6;X@T6!<$Q)4VY$H%&
MFUAPXTK,OAHY)AD6(F3EBJJ(YC6-5%1VOO9_A@;GC$A]SV_0)JS*S3:A78O8
MI%DY*.A]DRR5ZZ_\#5TG(N2HB<02/#5M\JTV[*^'2<+#=6E"NN_GW^49)GGD
MF?+WRSL<\/:78>*<6RZ-3*K37R,=))TY79QCUGW.?HLFFL8QJ0(3_A(W-ZHU
M455[QU<1<)+;MN\*AAW;J7=7<19"H-INA&E):%)3L9%_M.Q0T7LK&Y:V*Y5T
MDR5<LSA)ABHU=*5_;3XG*PW94T%. L^]-SC?=H8G3EBPJ#.URLP&+%A_DZ6<
M]L>"FIT9O)#1VDW2=DF;?E0_9:6Y8Q)NNJW'3M[-0ILY0J:M0F8$W+JCW*K<
MX,%J(NM\7^[WM2KGJ&$P4;?WZ4SY^@<D^M*%2*B*F2HBIR*"62>$M[5"V)VX
MY6TZO,4&26(DQ4H4HYT"'V-<HBZ7?1JZG*F:)WU0_P!2F$5\3]#C5F6M*L3%
M)@R3:E$G84HYT)LJ[2RC:2?W51KES3O)GQ:RYRL/K)O*;UV@B()-<.&-WVE&
MI$*M6Q5J7&J[=*GPYJ4>U\WK1,H;<LW+FYJ:/'FJ:M9^VK8+W[0:[2:+4;.K
M,C5JMI>T)./*JV)-*U,W(Q.)53OIGFG?R.>5AY/[DWG%Z[00P$SX%[]2:MZ6
M?9]8@QKA?V.E-CRKH?MQR(BJC%7OHBHJHN2Y:\CS%S"JM8,WW4+7KL/_ )F5
M<O8YEK5;#F8>:IV6&BZ]!51R(JY9Y<1PD6&YR-1R57_1RK'(E50AH +I0
M   :7W#'=G=?BV#YXV28VW#'=G=?BV#YXV2:'?:Q^;)CX8?D:;!^AWX1#VN\
MR@ 'D!W4                              '<M#ME-^+YSS#SAG<M#ME-
M^+YSS#R?<_[W"^).)'F>9?L4[5P]RS_HJ3Z-%(23:X>Y9_T5)]&BD))]V>>9
ML7SO(TC[#MJ>5H !@3(GR@;\)/G-4T?N1D?U64'^IX)E9OPD^<U31^Y&1_59
M0?ZG@GT^G<S-J&J,#]6PH['CX\\2/K/5/3(I!B<X\?'GB1]9ZIZ9%(,3(/--
MV(6'^TH !>*
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M20/U;"CL>/CSQ(^L]4],BD&)SCQ\>>)'UGJGID4@Q,@\TW8A8?[2@ %XH
M
M                                             -T>Q-?&E?OB:7](
M4^GQ\P?8FOC2OWQ-+^D*?3X\PN]]^=L3@AVJ0^[I^X !UXR(    ([>&(=L8
M?RD.9N6OTV@P(BY0WU":9!TU_P NDNO]A4UKGK>M2JG"JC4JI(@<^AU^FW-2
MX%2I$_+5.GQTTH4U)QFQ83T^1S55%.@<*BHM%"+7*@ !P<@
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M YIFQ.  !$+P
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M5;\KE1=?(B<JFV]V_N;H^.^'L"=H<)K[MH*OCR4/4GMJ&Y$[) SY5T4<W/\
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M^M&(I[J<;!C"7ZW A )OO)D?!U3:9'UHWDR/@ZIM,CZT8BGNIQL&,)?K<"$
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M<KEJ[*JU7VETGEMWV-9/N:Q*)1,VQ  #OAUT
..               __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm2128727d1_ex99-4img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2128727d1_ex99-4img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  _ )\# 2(  A$! Q$!_\0
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MA+\./%^GWUQ?>,?%U]<:-!J=VYFEM7ENK^1ILG[S+' 57/0E?2M*O"V*C"6
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F6OD0:;80Z5IUO:V\:Q06T:Q11KT15   ^@%3T45AOJSM6FB/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
